{
  "evaluation_metadata": {
    "evaluator_name": "LLM-as-Judge Evaluator (Model: qwen3-235b-reasoning)",
    "evaluator_model": "qwen3-235b-reasoning",
    "model_evaluated": "nemotron-nano-30b-reasoning",
    "experiment": "e4_page_window_relevance_desc",
    "pattern": "qualitative_2hop_cross_year",
    "total_questions_in_experiment": 1000
  },
  "evaluation_results": [
    {
      "question_id": 77,
      "question": "How did the gross benefit obligation and the actuarial losses for LMT's nonqualified defined benefit pension plans evolve between 2023 and 2024?",
      "original_answer": "In 2023, the gross benefit obligation for LMT's nonqualified defined benefit pension plans was $1.0 billion with actuarial losses totaling $347 million. By 2024, the gross benefit obligation decreased to $905 million, and the actuarial losses declined to $303 million. This indicates a reduction in both the liability and the associated actuarial losses over the period.",
      "llm_answer": "\nBetween 2023 and 2024 the gross benefit obligation of LMT’s non‑qualified defined‑benefit pension plans stayed essentially unchanged at about **$1.0 billion** (the filing notes the same $1.0 billion figure for both 31 Dec 2023 and 31 Dec 2024).  At the same time, the actuarial‑loss balance recorded in accumulated other comprehensive loss fell from **$347 million** as of 31 Dec 2023 to **$303 million** as of 31 Dec 2024, indicating a modest reduction in unrecognized actuarial losses over the year.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "(1) The LLM answer is partially correct but contains a significant factual error regarding the gross benefit obligation. The ground truth states that the gross benefit obligation decreased from $1.0 billion in 2023 to $905 million in 2024. However, the LLM claims it 'stayed essentially unchanged at about $1.0 billion' for both years, which contradicts the documented decrease. This misrepresents a key part of the evolution. The actuarial losses are correctly reported: $347 million in 2023 and $303 million in 2024, showing a correct decline. (2) Quantitatively, the actuarial loss figures are accurate, but the gross benefit obligation for 2024 is wrong—the LLM repeats $1.0 billion instead of the correct $905 million. This is a material error in a core metric. (3) The reasoning is partially sound in noting a reduction in actuarial losses, but fails on the multi-hop synthesis for the gross benefit obligation, incorrectly asserting stability when there was a 9.5% decrease. The model may have misread or misinterpreted the data source. (4) Contextual relevance is high—the answer addresses both components of the question (gross benefit obligation and actuarial losses) and the correct time frame. However, due to the major inaccuracy in one of the two key metrics, the overall correctness is significantly compromised. A score of 5 reflects partial credit for correct actuarial loss data but major error in obligation trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1217,
        "completion_tokens": 394,
        "total_tokens": 1611
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did General Motors' long-term rate of return assumptions on U.S. pension plan assets evolve between 2022 and 2024, and what does this indicate about the company's strategic asset mix adjustments?",
      "original_answer": "In 2022, General Motors reported that the weighted-average long-term rate of return on U.S. pension plan assets decreased from 5.6% at December 31, 2020, to 5.4% at December 31, 2021. By contrast, in 2024, the company indicated that the weighted-average long-term rate of return on U.S. pension plan assets increased from 6.3% at December 31, 2023, to 6.5% at December 31, 2024. This indicates a notable shift in the company's strategic asset mix, moving from a more conservative assumption in 2022 to a more optimistic projection in 2024, likely reflecting changes in capital market assumptions and investment strategies aimed at improving funded status.",
      "llm_answer": "\nGM lifted its long‑term expected return on U.S. pension‑plan assets from roughly 6 % (the 2022‑2023 level) to **6.5 % at the end of 2024** (up from 6.3 % in 2023).  This upward adjustment is tied to a modest but intentional shift in the plan’s strategic mix: the allocation stays about **11 % equity**, **≈60 % debt**, but the “other” bucket (private‑equity, real‑estate, hedge‑fund and absolute‑return strategies) expands from roughly **15 % of non‑U.S. assets to 29 % of the U.S. portfolio**, while the overall debt weight is held steady.  The change signals that GM is tilting the portfolio toward higher‑return alternative assets to improve funded status while still using a liability‑driven, risk‑mitigated asset mix.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative details. The ground truth states that in 2022, GM was reporting on a decrease from 5.6% (2020) to 5.4% (2021), not a rate around 6% in 2022–2023. The LLM incorrectly retrojects the 2023–2024 rates (6.3% to 6.5%) back into 2022 as if GM had already assumed ~6%, which contradicts the original answer. This misrepresents the evolution of the rate of return assumption, making the comparison between 2022 and 2024 misleading. (2) The specific allocation percentages (11% equity, ≈60% debt, expansion of 'other' from 15% to 29%) are not present in the original answer and appear to be fabricated or misattributed. The original answer does not provide any breakdown of asset allocations, so these figures cannot be verified and likely stem from incorrect data synthesis. (3) The reasoning about strategic shift toward alternative assets to improve funded status aligns semantically with the original answer’s conclusion about a more optimistic projection reflecting changes in capital market assumptions and investment strategies. This shows sound qualitative reasoning, even if based on incorrect numbers. (4) The contextual relevance is high because the answer addresses both parts of the question—evolution of return assumptions and strategic implications—and attempts multi-hop synthesis. However, due to major quantitative errors and unsupported asset mix figures, the correctness score is reduced to 6, reflecting partial accuracy with significant factual flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 427,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Chevron's relationship with PDC Energy evolved between 2023 and 2024, and what specific operational and financial impacts were attributed to this change?",
      "original_answer": "In 2023, Chevron acquired PDC Energy, and as a result, PDC was excluded from Chevron’s internal control assessment due to the business combination. By 2024, the integration had progressed to the point where Chevron reported a $2.2 billion increase in U.S. upstream earnings attributed to legacy PDC assets, and a 19% increase in net oil-equivalent production driven by the full-year contribution from PDC. This reflects a shift from acquisition to operational integration and performance contribution.",
      "llm_answer": "\nChevron moved from acquiring PDC Energy in 2023 to fully integrating it as a wholly‑owned subsidiary by 2024, so that PDC’s upstream assets and production are now reported within Chevron’s own segments.  The integration added roughly **$3.5 billion to U.S. upstream earnings** and **boosted net oil‑equivalent production by about 250 k bbl/d**, contributing to higher segment earnings and revenue; it also caused the company to exclude PDC from its internal‑control assessment because the acquisition occurred during 2023.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the acquisition of PDC Energy by Chevron in 2023 and the integration into Chevron's operations by 2024, including the exclusion of PDC from internal control assessments due to the timing of the acquisition. It also captures the general idea that PDC's assets contributed significantly to U.S. upstream earnings and production growth. However, there are significant quantitative inaccuracies: the LLM states a $3.5 billion increase in U.S. upstream earnings, whereas the ground truth reports $2.2 billion. Similarly, it claims a production increase of 'about 250k bbl/d', but the original answer cites a 19% increase in net oil-equivalent production without specifying an absolute volume—this makes the LLM's figure unsupported and potentially misleading. The 19% growth is a relative metric that cannot be directly equated to 250k bbl/d without additional context or data, so this represents a factual overreach. While the qualitative reasoning about integration and reporting is sound, the incorrect figures undermine the reliability of the financial impact claims. The answer is contextually relevant and addresses both operational and financial aspects of the relationship evolution, but the numerical errors reduce its overall correctness, especially in a financial analysis context where precision matters. Multi-hop synthesis is partially correct—linking acquisition to integration to performance—but the financial attribution is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 405,
        "total_tokens": 1665
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did Southern Company's treatment and valuation of energy-related derivatives change between 2022 and 2024, particularly in terms of unrealized gains (losses) and their presentation in financial statements?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of unrealized derivative gains (losses) from energy-related derivatives that were designated as regulatory hedging instruments and deferred, specifically as of December 31, 2021, and 2020. By 2024, the company shifted its disclosure focus to the fair value of energy-related derivatives, interest rate derivatives, and foreign currency derivatives, which were presented as either assets or liabilities in the balance sheets, typically under 'Other' or separately as 'Risk Management Activities'. This indicates a change in both the valuation approach and the presentation of these instruments in financial disclosures.",
      "llm_answer": "\nSouthern Company continues to value its energy‑related derivatives at fair value, but the 2024 filing presents them with a far more detailed balance‑sheet breakdown—separate current and non‑current asset and liability lines, gross amounts, an offset‑collateral column, and a net‑amount line—whereas the 2022 filing aggregated the balances as a single regulatory‑hedge asset or liability. Consequently, the unrealized position moved from a modest net regulatory‑hedge asset of roughly $21 million in 2022 to a net liability of about $84 million in 2024, and the gains/losses are now shown net of $7 million of offsetting collateral.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several specific quantitative claims not supported by the original answer or ground truth. Notably, it states that in 2022 Southern Company had a 'net regulatory-hedge asset of roughly $21 million' and in 2024 a 'net liability of about $84 million', along with '$7 million of offsetting collateral'. These figures are absent from the ground truth and cannot be verified; the original answer does not provide any specific dollar amounts or changes in net position. Thus, the inclusion of precise numbers constitutes a significant factual overreach. (2) The quantitative accuracy is low because the LLM fabricates numerical data (e.g., $21M, $84M, $7M) that are not present in the original answer. There is no mention of actual balances or collateral in the ground truth, so these values cannot be considered accurate or semantically equivalent. (3) Qualitatively, the LLM captures a shift in presentation—from aggregated regulatory-hedge items in 2022 to a more detailed breakdown in 2024—which aligns with the original answer’s claim of changed disclosure focus. The mention of fair value and balance sheet presentation under risk management activities reflects the correct direction of change. However, the original answer emphasizes a shift from reporting *unrealized gains/losses under regulatory hedging deferrals* (as of prior years) to *fair value presentation in balance sheets*, which the LLM partially captures but misframes as a change in formatting rather than a conceptual shift in accounting treatment and regulatory deferral policy. (4) Contextual relevance is high because the response directly addresses the evolution in treatment and presentation of energy-related derivatives over time, focusing on unrealized gains and balance sheet disclosure. Despite incorrect specifics, the general trend described—increased disaggregation and transparency—is plausible and relevant. However, the invention of figures undermines factual correctness, warranting a low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 548,
        "total_tokens": 1890
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Chevron's financial relationship with Tengizchevroil evolve between 2022 and 2024, particularly in terms of its investment carrying value and equity earnings?",
      "original_answer": "In 2022, Chevron disclosed that its carrying value of its investment in Tengizchevroil (TCO) was about $100 higher than its underlying equity in TCO's net assets, with a significant portion of the investment tied to a $4,500 loan to fund the FGP/WPMP development. By 2024, Chevron's financial stake in Tengizchevroil had grown substantially, with its investment and advances reaching $27,368 million in 2024, compared to $26,954 million in 2023. Additionally, Chevron's equity in earnings from TCO declined from $4,386 million in 2022 to $3,033 million in 2024, indicating a reduction in profitability from the venture over this period.",
      "llm_answer": "\nChevron’s investment in Tengizchevroil expanded – the carrying value rose from roughly **$23–$24 billion at the end of 2022** to **about $27.4 billion at the end of 2024** (CVX 10‑K 2024, Note 15, p. 83).  At the same time, Chevron’s equity earnings from the affiliate fell from **≈ $4.4 billion in 2022** to **≈ $3.6 billion in 2024** (CVX 10‑K 2024, Segmented Income Statement, Upstream – Equity‑affiliate income, p. 84).  The higher carrying value reflects additional capital contributions and loan accruals, while the earnings decline is due to lower net income generated by TCO in those years.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies in key numbers compared to the ground truth. While it correctly identifies a rising trend in carrying value and declining equity earnings, the specific figures are incorrect. The ground truth states that by 2024, Chevron's investment and advances reached $27,368 million (i.e., $27.368 billion), which the LLM approximates reasonably well as $27.4 billion. However, the LLM claims a 2022 carrying value of $23–24 billion, which contradicts the ground truth — the original answer does not provide a total carrying value for 2022 but instead notes that Chevron's carrying value was about $100 million higher than its equity in net assets, with a $4.5 billion loan highlighted. There is no support for a $23–24 billion figure in 2022 in the ground truth. Additionally, the LLM reports equity earnings of ≈$3.6 billion in 2024, but the ground truth specifies $3,033 million ($3.033 billion), making the LLM's figure significantly off. The 2022 equity earnings are correctly approximated as ≈$4.4 billion (vs. $4,386 million). (2) Calculations and comparisons: The LLM implies a smaller drop in earnings ($4.4B to $3.6B = $0.8B decline) versus the actual $1.353B drop per ground truth, understating the reduction. Investment growth is partially accurate — from $26,954M in 2023 to $27,368M in 2024 — but the LLM fabricates a 2022 baseline. (3) Multi-hop reasoning: The LLM correctly infers that higher carrying value stems from capital contributions and loans (aligning with the $4.5B loan mentioned in ground truth), showing sound qualitative reasoning. It also correctly identifies declining earnings, though with inaccurate magnitude. (4) Justification: Correctness score is 6 due to partially accurate trends but significant numerical errors in both investment value and earnings. Quantitative accuracy is low (5) due to incorrect figures. Qualitative accuracy is 7 because reasoning and entity identification (Chevron, TCO, carrying value, equity earnings) are correct. Contextual relevance is high (9) as the answer directly addresses the evolution of the financial relationship with appropriate metrics and timeframes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 585,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Walmart's ownership stake in Alert Innovation evolve between fiscal 2023 and fiscal 2024, and what specific transaction occurred to change its relationship with the entity?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, which was previously consolidated as a variable interest entity, resulting in Walmart becoming a 100% owner. However, by fiscal 2024, Walmart had subsequently sold and deconsolidated Alert Innovation, indicating a complete exit from the entity. This marks a full transformation from full ownership to no ownership within a single fiscal year.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Walmart’s ownership of Alert Innovation stayed at 100 % – the stake was already fully consolidated after the prior year’s purchase. The change in relationship was triggered by the **fiscal 2023 $0.4 billion acquisition of Alert Innovation**, which moved the entity from being a variable‑interest entity to a 100 % owned subsidiary, after which no further ownership transactions occurred through fiscal 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim that Walmart maintained 100% ownership through fiscal 2024. The ground truth states that Walmart sold and deconsolidated Alert Innovation in fiscal 2024, resulting in a complete exit. The LLM incorrectly asserts no further transactions occurred, which contradicts the original answer. (2) Quantitatively, the $0.4 billion acquisition amount is correctly stated, and the fiscal 2023 timing of the acquisition is accurate. However, the failure to report the fiscal 2024 sale and deconsolidation — a critical quantitative and qualitative change (from 100% to 0% ownership) — represents a major omission. (3) The multi-hop reasoning is flawed: the question requires synthesizing ownership changes across two fiscal years and two transactions (acquisition in 2023, divestiture in 2024). The LLM only captures the first hop (acquisition) and misses the second (sale), failing to reflect the full evolution. (4) While the answer is relevant to the topic and correctly identifies the initial acquisition, its central inaccuracy — claiming continued ownership — severely undermines correctness. The contextual relevance is moderate because it addresses the right companies and timeframe but misses the key event in 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 359,
        "total_tokens": 1584
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did Starbucks' foreign currency - other derivative asset and liability positions change from fiscal year 2022 to 2023, and what does this indicate about the company's exposure management strategy?",
      "original_answer": "In fiscal year 2022, Starbucks reported a foreign currency - other derivative asset of $55.3 million in Accumulated Other Comprehensive Income (AOCI) with $32.5 million expected to be reclassified into earnings within 12 months. By fiscal year 2023, Starbucks had shifted its position significantly, reporting foreign currency - other derivative assets of $1.9 million in current assets and $1.7 million in long-term assets, while carrying derivative liabilities of $4.7 million in current liabilities and $4.1 million in long-term liabilities. This indicates a substantial reduction in overall foreign currency - other derivative exposure and a shift from unrealized gains in equity to more balanced short- and long-term asset and liability positions.",
      "llm_answer": "\nFrom fiscal 2022 to fiscal 2023 Starbucks cut the fair‑value of its foreign‑currency‑other derivatives.  The combined asset position fell from about **$115 million** (≈ $73 million of designated assets plus $42 million of non‑designated assets) in 2022 to roughly **$64 million** in 2023, while total liabilities dropped from roughly **$6.2 million** to **$4.3 million**.  The reduction in both the notional size and net fair‑value of these contracts shows that the company is scaling back its explicit currency‑hedge program and is managing foreign‑exchange exposure more conservatively—likely by relying more on natural hedges and operational adjustments rather than maintaining a large derivative book.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies in key numbers, which undermines its correctness. (1) Quantitative Accuracy: The original answer states that in 2022, Starbucks had a foreign currency - other derivative asset of $55.3 million in AOCI (with $32.5 million expected to be reclassified), not a combined asset position of $115 million as claimed. The LLM incorrectly inflates the 2022 asset value by nearly double, likely by conflating designated and non-designated assets not mentioned in the ground truth. In 2023, the correct figures are $1.9M (current) and $1.7M (long-term) in assets, and $4.7M (current) and $4.1M (long-term) in liabilities—totaling $3.6M in assets and $8.8M in liabilities. The LLM incorrectly reports total assets as $64M and liabilities as $4.3M, which is completely inconsistent with the source. (2) Completeness: The LLM addresses the change in positions and attempts to interpret strategy, so it covers both parts of the question. (3) Entity Accuracy: The company (Starbucks) and fiscal years (2022–2023) are correct, and the metric (foreign currency - other derivative) is correctly identified. (4) Reasoning: The LLM draws a reasonable conclusion about conservative exposure management, but this is based on fabricated numbers. The shift from AOCI to balance sheet asset/liability classification is misrepresented as a reduction in fair value, when the real story is a structural change in how derivatives are accounted for and disclosed. (5) Semantic Equivalence: The overall narrative of reduced exposure has some alignment, but the magnitude and nature of the change are misrepresented. Due to severe quantitative errors and flawed multi-hop synthesis, the correctness score is low despite relevant context and attempted reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 482,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Medtronic's treatment of A Preferred Shares evolve between fiscal years 2022 and 2024, and what specific action was taken regarding these shares in 2022?",
      "original_answer": "In fiscal year 2022, Medtronic redeemed 1,872 A Preferred Shares for $0.075 million during the third quarter, and no A Preferred Shares were outstanding by April 29, 2022. By fiscal year 2024, no A Preferred Shares remained outstanding, indicating that the company did not reissue or reintroduce this class of shares after the redemption in 2022. This shows a discontinuation of the A Preferred Shares following their redemption.",
      "llm_answer": "\nBetween fiscal 2022 and 2024 Medtronic eliminated any outstanding A Preferred Shares. In the third quarter of FY 2022 the company redeemed the 1,872 A Preferred Shares that had been outstanding (for a nominal $0.075 million), and by the end of FY 2022 — and consequently throughout FY 2023 and FY 2024 — no A Preferred Shares remained issued or outstanding. No further actions regarding these shares were taken in later years.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: Medtronic redeemed 1,872 A Preferred Shares in the third quarter of FY 2022 for $0.075 million, and no shares remained outstanding by the end of FY 2022. The answer correctly notes that no A Preferred Shares were outstanding in FY 2023 and FY 2024, confirming discontinuation. (2) Quantitative accuracy is perfect: the number of shares (1,872), dollar amount ($0.075 million), and fiscal timing (Q3 FY 2022) match the original. The phrasing 'nominal $0.075 million' is acceptable as interpretive commentary. (3) Multi-hop reasoning is sound: the model correctly infers that because no shares were outstanding after FY 2022 and none reappeared in FY 2024, no reintroduction occurred, supporting the conclusion of discontinuation. (4) The answer fully addresses both parts of the question: the specific 2022 action (redemption) and the evolution through 2024. Wording differs slightly but meaning is preserved. All entities (Medtronic, A Preferred Shares, fiscal years 2022–2024) are accurate. No irrelevant or extraneous information is included.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1217,
        "completion_tokens": 327,
        "total_tokens": 1545
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did Comcast's financial relationship with Atairos evolve between 2022 and 2023, particularly in terms of equity income (losses) driven by fair value adjustments on underlying investments?",
      "original_answer": "In 2022, Comcast's equity in net income (losses) from investees, particularly Atairos, showed a loss of $(434) million due to fair value adjustments on its underlying investments. In contrast, by 2023, Atairos generated income of $1.1 billion for Comcast, reflecting a significant turnaround. This change indicates a substantial improvement in the performance of Atairos's underlying investments over the period.",
      "llm_answer": "\nBetween 2022 and 2023 the equity income (loss) that Comcast records from its investment in Atairos flipped sign.  In 2022 the investment generated a **$434 million loss**, driven by fair‑value adjustments to Atairos’ underlying holdings, while in 2023 it produced a **$1.1 billion gain** from those same fair‑value adjustments.  This swing helped turn Comcast’s consolidated “Investment and other income (loss), net” from a negative $(861) million in 2022 to a positive $1.252 billion in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key financial figures are correct: the $434 million loss in 2022 and $1.1 billion gain in 2023 match the original answer exactly, with acceptable formatting (e.g., $434 million vs $(434) million). (2) The additional context about the impact on Comcast’s consolidated 'Investment and other income (loss), net'—changing from $(861) million to $1.252 billion—is factually consistent with the broader financial narrative and supports the main point, even though it was not part of the original answer. This does not introduce error but adds relevant context. (3) The multi-hop reasoning is sound: the model correctly identifies the shift in equity income from Atairos due to fair value adjustments and links it to a broader financial outcome, demonstrating proper synthesis across time periods and financial statements. (4) Entity accuracy is strong: Comcast, Atairos, equity income (loss), fair value adjustments, and the years 2022 and 2023 are all correctly referenced. (5) Semantic equivalence is maintained—the core message of a dramatic turnaround in equity income driven by fair value changes is preserved and clearly communicated. The only minor limitation is that the original answer emphasizes the 'substantial improvement in performance of underlying investments,' which is slightly more cautious in attribution than 'produced a $1.1 billion gain from those same fair-value adjustments,' which may oversimplify by attributing the entire gain directly to fair value moves without noting possible operational improvements. However, this is a nuance and does not constitute a factual error. Overall, the answer is factually excellent, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 476,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about the company's strategic positioning in that geographic area?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure slightly declined to 296 billion cubic feet. This minor decrease suggests limited growth or a strategic reallocation of resources in the region during that period.",
      "llm_answer": "\nBetween the end of 2023 and the end of 2024 the company’s **consolidated** natural‑gas reserves in the Asia‑Pacific/Middle‑East region slipped from about **312 billion cubic feet to 296 billion cubic feet** (≈ 5 % lower).  When the **equity‑affiliate** reserves are added, total regional reserves actually rose from roughly **5.6 trillion to 6.2 trillion cubic feet**, showing that ConocoPhillips is compensating for modest declines in its direct holdings with growth through partnerships, underscoring a continued strategic emphasis on the Asia‑Pacific/Middle‑East.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the decline in COP's consolidated natural gas reserves from 312 to 296 billion cubic feet between 2023 and 2024, matching the ground truth. However, it introduces new data—equity-affiliate reserves increasing from 5.6 to 6.2 trillion cubic feet—that is not present in the original answer and cannot be verified from the provided ground truth. This significantly undermines factual accuracy. (2) The quantitative values for consolidated reserves are accurate (312 → 296 Bcf), and the ≈5% decrease is a reasonable approximation (actual drop is ~5.1%). However, the trillion-cubic-foot figures for equity-affiliate reserves are not supported by the ground truth and appear fabricated or misattributed, failing the quantitative accuracy check for those numbers. (3) The multi-hop reasoning is flawed: while the model attempts to synthesize a strategic narrative, it does so using unsupported data. The original answer infers limited growth or reallocation based solely on the decline in direct reserves; the LLM instead posits a broader strategic emphasis via partnerships, which is not corroborated by the ground truth. (4) The contextual relevance is moderate—the answer addresses the evolution of reserves and strategic positioning as asked—but the inclusion of unverified affiliate data distorts the conclusion, reducing correctness. The core fact (decline in direct reserves) is right, but the expanded interpretation is not grounded in the source data, leading to a partial score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 419,
        "total_tokens": 1646
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did the revenue performance of ENBREL in Canada evolve between 2022 and 2024, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ENBREL in Canada generated $113 million in revenue, which declined to $47 million in 2023, and further dropped to $28 million in 2024. This indicates a consistent downward trend in revenue, suggesting a shrinking market presence or reduced demand for ENBREL in Canada over this period.",
      "llm_answer": "\nENBREL’s Canadian sales fell sharply—from $73 million in 2022 to $47 million in 2023 (a 36 % drop) and then to $28 million in 2024 (another 40 % decline). This consecutive year‑over‑year reduction indicates a weakening market position for ENBREL in Canada, likely driven by biosimilar competition and pricing pressure, pointing to a continued downward trajectory.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the revenue decline trend and reports accurate figures for 2023 ($47 million) and 2024 ($28 million), which match the ground truth. However, it incorrectly states the 2022 revenue as $73 million instead of the correct $113 million, a significant factual error. This affects the accuracy of the calculated percentage drops: the LLM claims a 36% drop from 2022 to 2023, but the actual decline from $113M to $47M is approximately 58.4%, not 36%. The second decline from $47M to $28M is correctly characterized as around a 40% drop, which is reasonably accurate (exact: ~40.4%). (2) The quantitative inaccuracies stem primarily from the incorrect 2022 baseline. While later figures are correct, the initial error undermines the validity of the trend analysis. (3) The qualitative reasoning is strong: the model correctly infers a weakening market position and attributes the decline to plausible factors like biosimilar competition and pricing pressure, which aligns with typical market dynamics for biologics post-patent expiry. It synthesizes the multi-hop trend across three years and draws a reasonable conclusion about market trajectory despite the flawed starting point. (4) Contextual relevance is excellent—the response directly addresses both parts of the question: revenue evolution and market trajectory implication. The explanation is well-structured and adds insightful context. However, due to the major error in the 2022 revenue figure, the correctness score is limited to 6, as the core financial data is partially incorrect, even though the overall trend direction and later data points are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1162,
        "completion_tokens": 455,
        "total_tokens": 1617
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Qualcomm's approach to linking human capital advancements with executive compensation evolved from fiscal 2023 to fiscal 2024, and what specific performance modifier range was applied in fiscal 2024?",
      "original_answer": "In fiscal 2023, Qualcomm indicated that human capital advancements would be considered in determining executives' fiscal 2024 bonus. By fiscal 2024, this approach evolved into a more defined structure where progress toward human capital advancements served as a non-financial performance modifier that could adjust executives' bonus payouts by a multiplier ranging from 0.9 to 1.1. This represents a shift from a general consideration to a quantified performance modifier in executive compensation.",
      "llm_answer": "\nFrom fiscal 2023 to fiscal 2024 Qualcomm tightened the way human‑capital progress influences executive bonuses – the 2023 bonus modifier was applied over a wider band (roughly 0.8 to 1.2), whereas for fiscal 2024 the HR & Compensation Committee limits the non‑financial performance modifier to a narrower 0.9 to 1.1 range. This tighter band reflects a more direct and stringent linkage of measurable human‑capital advancements to the final bonus payout.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly regarding fiscal 2023. The ground truth states that in fiscal 2023, human capital advancements were only 'considered' in determining fiscal 2024 bonuses, with no indication of a quantitative modifier range (e.g., 0.8 to 1.2). The LLM incorrectly asserts that a 0.8 to 1.2 band was used in fiscal 2023, which is not supported by the original answer and contradicts the evolution narrative. The only correct quantitative detail is the fiscal 2024 modifier range of 0.9 to 1.1, which matches the ground truth. (2) The calculation and number accuracy is partially correct—0.9 to 1.1 is accurate for fiscal 2024—but the unsupported claim about a 0.8 to 1.2 range in 2023 introduces a major quantitative error. No evidence in the ground truth supports any numerical modifier in fiscal 2023. (3) The multi-hop reasoning is flawed: the model incorrectly infers a narrowing of a pre-existing range, whereas the original answer describes an evolution from a qualitative consideration to a defined quantitative modifier. This misrepresents the nature of the change. (4) Despite the incorrect premise about fiscal 2023, the answer correctly identifies the 2024 modifier range and contextualizes it as a more structured linkage, which maintains some qualitative and contextual relevance. However, the core factual error in the comparative claim severely undermines correctness and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 407,
        "total_tokens": 1661
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has the therapeutic scope of Breyanzi evolved between 2022 and 2024, based on the specific indications and approvals documented in those years?",
      "original_answer": "In 2022, Breyanzi was associated with trials for 3L+ Chronic Lymphocytic Leukemia (TRANSCEND-CLL-004) and 3L+ Follicular Lymphoma (TRANSCEND-FL), both with expected timing in 2023/24. By 2024, Breyanzi received FDA accelerated approvals for two distinct indications: relapsed or refractory Follicular Lymphoma (FL) after at least two prior lines of therapy (approved in May 2024), and relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) after at least two prior lines of therapy, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor (approved in March 2024). This reflects a shift from being in late-stage trials to having concrete accelerated approvals in specific patient populations.",
      "llm_answer": "\nBetween 2022 and 2024 Breyanzi’s approved disease portfolio widened markedly. The 2022 filing shows that the CAR‑T was initially approved only for relapsed/refractory large‑B‑cell lymphoma; by 2024 the FDA had granted accelerated approvals for three additional B‑cell malignancies—relapsed/refractory CLL/SLL, relapsed/refractory follicular lymphoma and relapsed/refractory mantle‑cell lymphoma (with further Japanese approvals for FL)—thereby expanding the therapeutic scope from a single lymphoma indication to a broader set of refractory/relapsed B‑cell cancers【BMY_10k_2022.pdf pp. 18‑22】【BMY_10k_2024.pdf pp. 43‑46】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies despite addressing the general evolution of Breyanzi's therapeutic scope. (1) The claim that Breyanzi was approved for three additional indications by 2024 is incorrect. According to the ground truth, only two FDA accelerated approvals were granted: one for relapsed/refractory Follicular Lymphoma (FL) in May 2024 and another for relapsed/refractory CLL/SLL in March 2024. The LLM incorrectly adds 'mantle-cell lymphoma' as an approved indication in 2024, which is not supported by the original answer or knowledge graph. Additionally, it falsely claims Japanese approvals for FL were part of the 2024 expansion, which is not mentioned in the ground truth. (2) The assertion that Breyanzi was 'initially approved only for relapsed/refractory large-B-cell lymphoma' in 2022 is misleading—the original answer does not state this was its only approval, but rather focuses on the ongoing trials for CLL and FL. While Breyanzi did have prior approval in large B-cell lymphoma, the question specifically asks about evolution between 2022 and 2024 based on documented indications and approvals, so framing the starting point as a single indication oversimplifies and misrepresents the context. (3) Multi-hop reasoning is partially sound—the model attempts to compare 2022 trial status with 2024 approvals—but fails in synthesis by adding unverified indications. It also cites document pages plausibly but invents approvals not present in the ground truth. (4) Despite these errors, the answer is contextually relevant and captures the directional trend—expansion from trials to approvals in FL and CLL. However, the addition of a third non-existent indication (mantle-cell lymphoma) and extraneous international approvals severely undermines factual correctness. Minor formatting issues (e.g., use of em dashes) do not affect scoring, but the core quantitative and entity accuracy failures justify a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 529,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the financial performance of Disney's Resorts and Vacations segment evolved from 2023 to 2024, and how does this compare to the overall revenue growth of the Parks & Experiences segment?",
      "original_answer": "The Resorts and Vacations segment saw an increase in revenue from $7,949 million in 2023 to $8,375 million in 2024, representing a 5% growth. This growth was slightly below the overall Parks & Experiences revenue growth of 5%, which increased from $32,549 million in 2023 to $34,151 million in 2024. The Resorts and Vacations segment remained a significant contributor to the overall Parks & Experiences division, maintaining a consistent proportion of total revenue despite the modest growth difference.",
      "llm_answer": "\nIn fiscal 2024 the Resorts‑and‑Vacations business generated about **$8.38 billion in revenue**, up **5 %** from $7.95 billion in 2023.  That growth is essentially in step with the **overall Parks & Experiences segment**, whose revenue rose **5 %** to $34.15 billion, so the vacation‑club and resort operations contributed proportionally to the segment’s total top‑line expansion (the segment’s operating income also edged up 4 % to $9.27 billion).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures: Resorts and Vacations revenue increased from $7.95 billion in 2023 to $8.38 billion in 2024 (matching ground truth $7,949M to $8,375M, with acceptable rounding). The overall Parks & Experiences revenue rose from $32,549M to $34,151M, a 5% increase, which the LLM accurately reflects as $34.15 billion and 5% growth. The 5% growth rate for both segments is correctly stated. (2) All calculations are accurate: the percentage growth for both segments is correctly reported as 5%, and the dollar amounts are properly rounded (e.g., $7,949M ≈ $7.95B, $8,375M ≈ $8.38B). (3) The multi-hop reasoning is sound: the model correctly compares the segment-level performance (Resorts and Vacations) to the broader Parks & Experiences segment, noting proportional contribution, which aligns with the ground truth. (4) The only minor shortcoming is that the LLM adds unsolicited information about operating income ($9.27B, up 4%), which was not part of the original answer or question, slightly diluting qualitative accuracy. However, this does not detract from correctness. The core answer fully addresses both parts of the question: evolution of Resorts and Vacations revenue and comparison to overall segment growth. Wording differs but semantic meaning is equivalent. Contextual relevance is perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 380,
        "total_tokens": 1630
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has the structure and value of CVS's forward contracts associated with accelerated share repurchase (ASR) transactions evolved between 2023 and 2024?",
      "original_answer": "In 2023, CVS executed a $2.0 billion ASR with Citibank, N.A., which was accounted for as an initial treasury stock transaction of $1.6 billion and a forward contract of $0.4 billion. The forward contract was classified as an equity instrument and recorded within capital surplus, with the final 20% of shares received in February 2023. In 2024, CVS entered into a larger $3.0 billion ASR with Morgan Stanley, accounted for as an initial treasury stock transaction of $2.6 billion and a forward contract of $0.4 billion. The forward contract was similarly classified and recorded, but the remaining 15% of shares were received later, in March 2024. Despite the increase in the ASR size, the forward contract value remained constant at $0.4 billion, indicating a shift in the proportion of the ASR allocated to the forward contract component.",
      "llm_answer": "\nThe company’s forward contracts tied to accelerated share‑repurchase (ASR) transactions continued to be treated as equity instruments recorded in capital surplus, using the same two‑step structure: an initial treasury‑stock purchase for roughly 80 % of the ASR notional and a forward contract for the remaining portion. In 2023 the company entered a $2.0 bn ASR with Citibank, with a $0.4 bn forward contract that was settled in February 2023, and in 2024 it executed a larger $3.0 bn ASR with Morgan Stanley, again with a $0.4 bn forward that was settled in March 2024; the forward amount stayed close to 20 % of the notional (≈ $0.4 bn) even as the notional size grew, and the forward was re‑classified to treasury stock once the final shares were received. Thus, the contract’s structure was unchanged, but the absolute forward exposure increased in line with the larger 2024 ASR.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution of CVS's ASR forward contracts between 2023 and 2024. It correctly identifies the $2.0 billion 2023 ASR with Citibank and the $3.0 billion 2024 ASR with Morgan Stanley, as well as the $0.4 billion forward contract in both years, which aligns with the ground truth. The settlement dates (February 2023 and March 2024) are accurately reflected. The answer correctly notes the consistent $0.4 billion forward value despite the larger ASR size in 2024. However, there is a subtle but important error in interpretation: the LLM states the forward amount 'stayed close to 20%' and 'increased in line with the larger 2024 ASR', which is factually incorrect—the forward value remained exactly $0.4 billion, meaning its proportion decreased from 20% ($0.4B / $2.0B) to approximately 13.3% ($0.4B / $3.0B). Thus, the forward exposure did not increase in line with the ASR; it remained constant in absolute terms but decreased proportionally. This mischaracterization affects quantitative and qualitative accuracy. The structure, accounting treatment (equity instrument, capital surplus), and reclassification upon final share receipt are correctly described. The answer is contextually relevant and synthesizes multi-hop information across years and counterparties correctly. Minor wording differences (e.g., 'settled' vs. 'final shares received') are acceptable under semantic equivalence. The core facts are present and mostly accurate, warranting a score of 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1432,
        "completion_tokens": 416,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did Duke Energy's disclosure regarding the Master Retirement Trust's pension asset valuation methodology evolve from 2023 to 2024, particularly in terms of transparency around fair value categorization?",
      "original_answer": "In 2023, Duke Energy disclosed the allocation percentages of the Master Retirement Trust among its subsidiaries and noted that certain investments measured at fair value using the net asset value per share practical expedient were not categorized in the fair value hierarchy. In 2024, the company maintained the same allocation percentages but added a new disclosure element — a reconciliation of beginning and ending balances of the Master Retirement Trust's qualified pension and other post-retirement assets, specifically those valued using significant unobservable inputs (Level 3). This represents a significant increase in transparency regarding the fair value categorization of pension assets.",
      "llm_answer": "\nFrom 2023 to 2024 Duke Energy made the fair‑value hierarchy disclosure for the Master Retirement Trust more explicit and granular.  The 2024 tables separate Level 1, Level 2 and Level 3 amounts (with Level 3 now limited to partnership interests of $68 million) and show a reduced “Not Categorized (b)” balance of $14 million, while also providing a reconciliation of the Level 3 beginning‑ and ending‑balances.  This tighter segmentation and the accompanying reconciliation improve transparency about how each asset class is valued and where it falls in the fair‑value hierarchy.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies the key qualitative evolution in Duke Energy's disclosure from 2023 to 2024: increased transparency through the addition of a Level 3 fair value reconciliation and more granular categorization of assets within the fair value hierarchy. It accurately notes that in 2024, Duke Energy began providing a reconciliation of beginning and ending balances for Level 3 assets, which aligns with the ground truth and represents a significant improvement in transparency. However, the LLM introduces specific dollar amounts—$68 million for Level 3 partnership interests and $14 million for 'Not Categorized'—that are not present in the original answer and cannot be verified against the provided ground truth. Since the ground truth does not include any numerical values for asset levels or balances, the inclusion of these figures reduces quantitative accuracy, even if they reflect actual data in the filing. The reasoning is sound in terms of multi-hop synthesis—comparing disclosure practices across years and identifying enhanced transparency—and the entities (Duke Energy, Master Retirement Trust, Level 3 inputs) are correctly identified. The answer addresses the core of the question regarding evolution in transparency around fair value categorization, making it contextually highly relevant. While the conceptual progression is accurately captured, the unsupported numerical specifics prevent a higher correctness score due to potential factual overreach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 408,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did Pfizer's financial obligations and revenue recognition related to Paxlovid change between 2023 and 2024, particularly concerning the U.S. government's inventory return and the creation of the U.S. Strategic National Stockpile?",
      "original_answer": "In 2023, Pfizer recorded a non-cash revenue reversal of $3.5 billion related to the expected return of 6.5 million EUA-labeled Paxlovid treatment courses previously purchased by the U.S. government. In 2024, this estimate was adjusted based on the actual return of 5.1 million treatment courses, resulting in a favorable final adjustment of $771 million. Additionally, in 2024, Pfizer recognized $442 million of revenue in connection with the creation of the U.S. Strategic National Stockpile (SNS) of 1.0 million Paxlovid treatment courses for future pandemic preparedness. These developments reflect a shift from revenue reversal and inventory transition in 2023 to revenue recognition and strategic stockpile establishment in 2024.",
      "llm_answer": "\nIn 2023 Pfizer recorded a $3.5 bn non‑cash revenue reversal tied to the expected return of roughly 6.5 million EUA‑labeled Paxlovid courses bought by the U.S. government, which was reflected in a large deferred‑revenue balance of about $5.1 bn at year‑end 2023. In 2024 the company reversed $771 m of that estimate after 5.1 million courses were actually returned, recognized $442 m of revenue for the creation of a U.S. Strategic National Stockpile of 1 million courses (with no cash consideration), and reduced the deferred Paxlovid balance to $2.2 bn, leaving only about $1 bn of contracted revenue remaining for future Paxlovid deliveries under long‑term agreements.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all key aspects. (1) Quantitatively, all numbers are accurate: the $3.5 billion revenue reversal in 2023, the actual return of 5.1 million treatment courses in 2024 leading to a $771 million favorable adjustment (implying a per-unit value of ~$150, consistent across both years), and the $442 million revenue recognized for the 1.0 million-course U.S. Strategic National Stockpile in 2024. The mention of the deferred revenue balance decreasing from $5.1 billion to $2.2 billion and only ~$1 billion remaining in contracted revenue adds context not in the original answer but aligns with the financial logic and does not contradict the ground truth. (2) The answer is complete, addressing both the 2023 revenue reversal due to expected returns and the 2024 developments: final adjustment based on actual returns and new revenue from SNS creation. (3) Entity accuracy is perfect: Pfizer, Paxlovid, U.S. government, EUA-labeled courses, and the Strategic National Stockpile are all correctly identified and contextualized. (4) The multi-hop reasoning is sound—synthesizing changes in revenue recognition, inventory returns, and strategic stockpile formation across two years. The LLM even enhances the original answer with additional context (deferred revenue balances) that supports the narrative of transition from reversal to recognition. (5) Semantic equivalence is maintained: though the LLM provides more granular financial detail, the core facts and their interpretation match the ground truth exactly. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 443,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the financial performance of ERLEADA evolved between 2022 and 2023, and what does this indicate about its role in J&J's oncology portfolio?",
      "original_answer": "ERLEADA's sales increased from $1,881 million in 2022 to $2,387 million in 2023, representing a 26.9% growth. This indicates that ERLEADA has become a more prominent contributor to J&J's oncology segment, which saw overall growth of 10.5% in 2023. The strong performance of ERLEADA contrasts with the decline in other key oncology products like IMBRUVICA and ZYTIGA, suggesting that ERLEADA is playing an increasingly important role in sustaining J&J's oncology revenue.",
      "llm_answer": "\nERLEADA sales jumped from $1.88 billion in 2022 to $2.39 billion in 2023—a 26.9 % increase (≈27 % on an operational basis). This strong growth helped lift the overall Oncology segment up 10.5 % and underscores ERLEADA’s rising importance as a key growth driver within J&J’s oncology portfolio, particularly in the metastatic castration‑resistant prostate‑cancer market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports ERLEADA's sales growth from $1.88 billion (2022) to $2.39 billion (2023), which aligns with the ground truth values of $1,881 million and $2,387 million (rounded appropriately). The calculated growth rate of 26.9% is accurate and matches the ground truth. The mention of ≈27% on an operational basis is a minor addition not in the original but does not contradict it. 2) Quantitatively, all numbers are correct: $1.88B = $1,881M and $2.39B = $2,387M (rounded), and the 26.9% growth is precisely calculated: (2387 - 1881) / 1881 ≈ 0.269. The overall Oncology segment growth of 10.5% is also correctly cited. 3) The reasoning is sound: the LLM identifies ERLEADA as a key growth driver in J&J’s oncology portfolio and links its performance to the broader segment growth. However, it omits the contrast with declining products like IMBRUVICA and ZYTIGA, which is a key part of the original answer’s qualitative insight about ERLEADA’s increasing strategic importance. This partial omission reduces completeness in multi-hop synthesis. 4) Despite the omission, the answer is contextually relevant, accurately addressing the evolution of ERLEADA’s financial performance and its role in the oncology portfolio. The semantic meaning is largely equivalent, with only a minor gap in comparative product performance. Thus, high scores across all dimensions, with a 9 in correctness due to the missing comparative context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1210,
        "completion_tokens": 398,
        "total_tokens": 1608
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How did the global sales performance of ERLEADA evolve from 2022 to 2023, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ERLEADA reported worldwide sales of $1,291 million, with a significant growth rate of 70.0% compared to the previous year. By 2023, the product's global sales increased further to $2,387 million, reflecting a 26.9% growth from 2022. This indicates that ERLEADA continued to experience strong market adoption and revenue expansion, albeit at a slower growth rate compared to the prior year, suggesting a maturing growth phase in its lifecycle.",
      "llm_answer": "\nERLEADA’s worldwide sales jumped from **$1.88 billion in 2022 to $2.39 billion in 2023**, a **26.9 % increase** (see J&J 2023 10‑K, page 31).  This growth outpaces the overall oncology segment’s 10.5 % rise, indicating that ERLEADA is gaining strong market traction and is on a clear upward trajectory.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a major factual error in the 2022 sales figure. The ground truth states ERLEADA had $1,291 million (or $1.291 billion) in worldwide sales in 2022, but the LLM incorrectly reports $1.88 billion—a significant overstatement. The 2023 sales figure is approximately correct at $2.39 billion (vs. $2,387 million in the original), though slightly rounded up. The 26.9% growth rate from 2022 to 2023 is accurately reported. However, the LLM fails to mention the 70.0% growth in 2022, which is a key part of the question about evolution and market trajectory. (2) Calculations: The 26.9% increase from $1.291B to $2.387B is correct per the original data, but if one were to calculate growth from the LLM's stated $1.88B to $2.39B, it would be about 27.1%, so the percentage is close but based on an incorrect base. The core quantitative error undermines the accuracy. (3) Multi-hop reasoning: The model attempts to compare ERLEADA’s growth to the oncology segment (10.5%), which adds contextual insight not in the original answer, but this does not compensate for missing the prior-year growth context (70.0%) needed to assess trajectory change. The conclusion of 'upward trajectory' is reasonable but misses the nuance of slowing growth (from 70% to 26.9%), which the original answer correctly identifies as a sign of maturing growth phase. (4) Justification: Correctness score is 5 due to one major factual error (2022 sales) and omission of key prior-year growth context, though the 2023 figure and growth rate are close. Quantitative accuracy is low (4) because the foundational number is wrong. Qualitative accuracy is moderate (6) as reasoning is logical but incomplete. Contextual relevance is high (8) because the answer addresses market performance and trajectory with supporting data and comparison.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1184,
        "completion_tokens": 498,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did NVDA's debt management strategy evolve regarding the 0.584% Notes Due 2024 between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal year 2023, NVDA reported a balance of $1,250 million for the 0.584% Notes Due 2024, with an effective interest rate of 0.66%. By fiscal year 2024, NVDA disclosed in its 10-K filing that it repaid these notes in fiscal year 2025, resulting in no remaining balance for this instrument as of January 26, 2025. This indicates a shift in NVDA's debt management strategy, where it chose to retire the obligation before or shortly after the due date rather than rolling it over or extending it.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 NVIDIA kept the 0.584 % Notes Due 2024 on its balance sheet at roughly $1.25 billion (the same $1.25 billion carrying amount reported for both years).  The company did not refinance or retire the issue during that period; instead it continued to carry the notes as a short‑term obligation while beginning to plan their repayment, which was ultimately executed in fiscal 2025.  Thus, the evolution was a shift from simply maintaining the notes in FY 2023‑24 to actively preparing for and completing their payoff in the following year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that NVDA maintained a $1.25 billion balance on the 0.584% Notes Due 2024 in both fiscal years 2023 and 2024, matching the ground truth value of $1,250 million. It accurately notes that repayment occurred in fiscal year 2025, resulting in no remaining balance as of January 26, 2025. All numeric values—$1.25 billion (equivalent to $1,250 million), the 0.584% interest rate, and the fiscal 2025 repayment—are factually correct. (2) Quantitative accuracy is perfect: dollar amounts are correctly represented across formats, and the timeline (notes carried in FY2023–2024, repaid in FY2025) aligns with the original answer. There are no calculation errors. (3) The multi-hop reasoning is sound: the model synthesizes information across fiscal years and correctly infers a strategic shift—from maintaining the debt to preparing for repayment—based on the lack of refinancing and the eventual payoff. The only minor shortcoming is that the LLM does not explicitly mention the effective interest rate of 0.66%, which was included in the ground truth and could add precision to the characterization of the debt in FY2023. However, since the question focuses on debt management strategy (repayment vs. rollover), this omission does not undermine the core conclusion. (4) The answer is contextually relevant, directly addressing how the strategy evolved. The qualitative reasoning is strong, accurately interpreting the company’s actions as a strategic choice to retire rather than extend the debt. The slight deduction in qualitative accuracy accounts for the missing detail on the effective interest rate, though it does not affect the overall correctness of the strategic assessment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 470,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did Honeywell's investment in Mortgage/Asset-backed securities evolve between 2022 and 2023, and what was the magnitude of this change?",
      "original_answer": "In 2022, Honeywell reported $982 million invested in Mortgage/Asset-backed securities under U.S. Plans. By 2023, this amount had significantly decreased to $10 million under Non-U.S. Plans. This represents a reduction of $972 million, or over 98%, indicating a major shift in Honeywell's investment strategy concerning Mortgage/Asset-backed securities.",
      "llm_answer": "\nBetween the end of 2022 and the end of 2023 the company’s mortgage‑/asset‑backed‑security holdings in its non‑U.S. pension portfolio fell from **$31 million to $10 million**.  That is a **$21 million decline**—roughly a two‑thirds reduction—over the one‑year period.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Honeywell's investment in Mortgage/Asset-backed securities was $982 million in 2022 under U.S. Plans and dropped to $10 million in 2023 under Non-U.S. Plans. The LLM incorrectly states that the 2022 amount was $31 million in the non-U.S. pension portfolio, which contradicts both the amount and the plan type. (2) The calculated change is also wrong: the LLM reports a $21 million decline (from $31M to $10M), whereas the correct reduction is $972 million (from $982M to $10M), a drop of over 98%. The magnitude and percentage change are therefore severely understated. (3) The multi-hop reasoning is flawed—the model fails to correctly identify the correct plan (U.S. vs. Non-U.S.) and year-to-year transition, and does not reflect the major strategic shift indicated in the original answer. It appears to have synthesized incorrect or partial data, possibly from a different context or entity. (4) While the answer addresses the general question about change in investment and attempts a quantitative comparison, the core numbers, entities, and conclusions are incorrect, warranting a low correctness and quantitative accuracy score. Contextual relevance is moderate because the structure and intent align with the question, but factual foundation is unsound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1153,
        "completion_tokens": 380,
        "total_tokens": 1533
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Capital One's use of securitized debt obligations evolve between 2022 and 2023, particularly in terms of their role in the company's funding mix and their fair value classification?",
      "original_answer": "In 2022, securitized debt obligations were described as a key component of Capital One's diversified funding strategy, used alongside deposits, senior and subordinated notes, federal funds purchased, and FHLB advances to maintain access to wholesale funding sources. By 2023, the company disclosed that the carrying value of securitized debt obligations was $18,043 million, with an estimated fair value of $18,067 million, all classified under Level 2 of the fair value hierarchy. This indicates that while the company continued to rely on securitized debt obligations as a funding source, the 2023 data provides more specific transparency into their valuation and classification, showing a shift toward more detailed disclosure and potentially more structured risk management.",
      "llm_answer": "\nBetween 2022 and 2023 Capital One’s securitized‑debt balance rose from roughly **$16.97 billion** (carrying value on 12/31/22) to **$18.04 billion** (carrying value on 12/31/23), underscoring a modest expansion of securitization as a funding source to support loan‑portfolio growth and diversify the company’s wholesale funding mix. In both years the obligations are reported at carrying value with their **estimated fair values classified as Level 2** in the fair‑value hierarchy—i.e., they are measured using observable market inputs rather than unobservable inputs. The increase is reflected in both the reported carrying amounts and the corresponding fair‑value figures, indicating that securitized debt remained a Level 2‑valued component of Capital One’s funding structure from 2022 through 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the carrying value increase from $16.97 billion in 2022 to $18.04 billion in 2023 is consistent with the ground truth's 2023 carrying value of $18,043 million (i.e., $18.043 billion); the $16.97 billion figure for 2022 is not explicitly in the original answer but may be derived from external data and does not contradict it. The fair value of $18,067 million in 2023 is accurately implied as close to carrying value, and the Level 2 classification is correctly stated. (2) The answer correctly notes that securitized debt obligations remained classified under Level 2 of the fair value hierarchy in both years, which matches the ground truth's emphasis on Level 2 classification in 2023 and implies consistency with 2022. (3) The reasoning is sound: the LLM infers a modest expansion in the use of securitized debt as a funding source and links it to loan growth and funding diversification, which is a reasonable interpretation of the trend. (4) The original answer emphasizes increased transparency and structured risk management in 2023, a qualitative insight slightly underdeveloped in the LLM response, but the core multi-hop synthesis—comparing role in funding mix and fair value classification across years—is well executed. Minor deduction due to lack of explicit mention of enhanced disclosure in 2023, but factual and numerical content is excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 400,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How did JPMorgan's treatment of CECL capital transition provisions under U.S. capital rules evolve from 2023 to 2024, and what was the quantitative change in the CECL-related capital benefit during this period?",
      "original_answer": "In 2023, JPMorgan reported a $1.4 billion benefit from the CECL capital transition provisions included in its CET1 capital. By 2024, this benefit had decreased to $720 million, reflecting a phased reduction in the CECL-related capital benefit as the provisions were being phased in under U.S. capital rules. The capital metrics indicated that the CECL benefit was fully phased in by January 1, 2025.",
      "llm_answer": "\nFrom 2023 to 2024 the firm’s CECL‑related capital transition relief was phased down: the CET1 capital benefit that stemmed from the U.S. CECL transition provisions fell from **$1.4 billion at the end of 2023 to $0.72 billion at the end of 2024**, a net reduction of roughly **$0.68 billion**. This decline reflects the scheduled wind‑down of the transition provision, which was fully phased out as of January 1 2025.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values $1.4 billion (2023) and $720 million (2024) are accurately reported, with the latter correctly expressed as $0.72 billion. The net reduction of $0.68 billion is a correct calculation ($1.4B - $0.72B = $0.68B). (2) The timeline is accurate: the phase-down from 2023 to 2024 and full phase-out by January 1, 2025, is correctly stated. (3) The reasoning is sound—LLM correctly attributes the decline to the scheduled wind-down of the CECL capital transition provisions under U.S. capital rules, demonstrating proper multi-hop synthesis of regulatory treatment and its financial impact. (4) All entities—JPMorgan, CECL, CET1 capital, U.S. capital rules—are correctly identified and contextually used. (5) The answer addresses both parts of the question: the evolution of treatment (phase-down) and the quantitative change (reduction from $1.4B to $0.72B). Wording differs slightly but maintains full semantic equivalence. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1220,
        "completion_tokens": 306,
        "total_tokens": 1526
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How did the terms and capacity of Salesforce's Revolving Loan Credit Agreement evolve between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Salesforce had a $3.0 billion unsecured revolving credit facility under the Revolving Loan Credit Agreement, which was scheduled to mature in December 2025. By fiscal 2024, this agreement was replaced with a new $5.0 billion unsecured revolving credit facility that matures in October 2029. The increase in capacity and the extension of the maturity date reflect a strategic enhancement of the company’s credit resources.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Salesforce replaced its prior $3 billion unsecured revolving credit facility—originally set to mature on December 23 2025—with a new $5 billion revolving loan credit agreement that now matures in October 2029. The amendment increased borrowing capacity by $2 billion and extended the maturity date, while still providing an unsecured facility that had no outstanding borrowings as of the fiscal‑year‑end filings.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and fully aligned with the ground truth. (1) All key facts are correct: the $3.0 billion facility in fiscal 2023 maturing in December 2025 is accurately stated, as is the replacement with a $5.0 billion facility maturing in October 2029 in fiscal 2024. The increase in capacity ($2 billion) is correctly implied. (2) Quantitative accuracy is perfect: dollar amounts ($3 billion, $5 billion), maturity dates (December 2025, October 2029) match the original answer exactly, with only minor formatting differences (e.g., 'December 23 2025' likely a typo for 'December 2025' but does not affect correctness given context). (3) The reasoning is sound and captures the multi-hop evolution—comparing two fiscal years’ credit agreements, noting changes in size and maturity, and correctly identifying the facility as unsecured in both cases. (4) The answer is contextually relevant, directly addressing how terms and capacity evolved. It adds minor but accurate detail (no outstanding borrowings), which is consistent with typical 10-K disclosures and does not contradict the ground truth. Semantic equivalence is maintained with precise factual correspondence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1215,
        "completion_tokens": 334,
        "total_tokens": 1550
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did UPS's relationship with Coyote evolve between 2022 and 2024, and what financial impact did this change have on UPS in 2024?",
      "original_answer": "In 2022, UPS had an active business relationship with Coyote, operating it as a branded subsidiary that provided truckload brokerage services in the U.S. and Europe. Coyote was integrated into UPS’s broader supply chain offerings, leveraging the UPS fleet and third-party carrier networks to provide customized transportation solutions. However, by 2024, UPS had completed the divestiture of Coyote, recording a pre-tax gain of $156 million ($152 million after tax) as a result of the transaction. This change marks a full transition from a strategic business unit to a divested asset, reflecting a shift in UPS's supply chain strategy.",
      "llm_answer": "\nBetween 2022 and 2024 UPS moved from operating Coyote as an owned truck‑load brokerage business within its Supply Chain Solutions segment (see page 7 of the 2022 filing) to completing the sale of the unit in the third quarter of 2024 (see page 30 of the 2024 filing).  The divestiture generated a pre‑tax gain of **$156 million** (approximately **$152 million after tax**) that was recorded in “Other expenses” and excluded from GAAP operating profit but boosted the company’s reported net‑income adjustments for 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the pre-tax gain of $156 million and after-tax gain of $152 million are accurately reported, with acceptable formatting (bolded but numerically correct). The timeline is precise: Coyote was operated as a subsidiary in 2022 and divested in Q3 2024, consistent with the knowledge graph. (2) The answer addresses both parts of the question: the evolution of the relationship (from owned subsidiary to divestiture) and the financial impact in 2024 (the gain recognition). (3) Entities are correct—UPS, Coyote, proper segment (Supply Chain Solutions), and accurate citation of filing pages (though not required, they reflect source fidelity). (4) Multi-hop reasoning is sound: the model correctly synthesized information across 2022 and 2024 filings to show a strategic shift and its financial consequences. The mention of the gain being recorded in 'Other expenses' and excluded from GAAP operating profit adds contextual depth beyond the ground truth, without introducing error. Semantic equivalence is maintained throughout, with no factual discrepancies. All scores are 10 due to complete accuracy, proper synthesis, and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 343,
        "total_tokens": 1628
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has Union Pacific's relationship with chassis evolved between 2023 and 2024, particularly in terms of total units and ownership structure?",
      "original_answer": "In 2023, Union Pacific had a total of 48,340 chassis units, with 30,635 owned and 17,705 leased. By 2024, the total number of chassis dropped significantly to 5,553 units, with only 4,356 owned and 1,197 leased. This represents a transformation in Union Pacific's relationship with chassis, shifting from a heavy reliance on both owned and leased chassis to a much smaller, still mixed but significantly reduced footprint. The drastic reduction in total chassis units indicates a strategic shift in how the company manages this asset class.",
      "llm_answer": "\nBetween 2023 and 2024 Union Pacific cut its chassis fleet dramatically – total chassis units fell from roughly 48,300 (30,600 owned + 17,700 leased) to about 5,550 (4,350 owned + 1,200 leased), a decline of roughly 88 percent.  At the same time the proportion of owned chassis rose from roughly 63 percent of the fleet to about 78 percent, while leased chassis fell from ≈37 percent to ≈22 percent, reflecting a shift toward greater ownership and far less reliance on leased units.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the core evolution in Union Pacific's chassis relationship between 2023 and 2024, including the dramatic reduction in total units and the shift in ownership structure. All key numbers are accurately approximated: 2023 total (48,340 vs. 'roughly 48,300'), owned (30,635 vs. '30,600'), leased (17,705 vs. '17,700'); 2024 total (5,553 vs. 'about 5,550'), owned (4,356 vs. '4,350'), leased (1,197 vs. '1,200'). These minor rounding differences are acceptable under semantic equivalence. (2) The calculation of the approximate 88% decline is accurate: (48,340 - 5,553) / 48,340 ≈ 88.5%, correctly rounded to 'roughly 88 percent'. The proportional shift is also correctly calculated: 2023 ownership ~63.4% (30,635/48,340), reported as '63%'; 2024 ownership ~78.4% (4,356/5,553), reported as '78%'. Leased proportions also align. (3) The multi-hop reasoning is sound—LLM synthesizes data across two years, compares totals, ownership breakdowns, and infers a strategic shift toward greater ownership concentration despite overall fleet reduction. It correctly identifies the shift in reliance from leased to owned units in relative terms, even as absolute numbers drop. (4) The answer is contextually complete and relevant, addressing both total units and ownership structure as asked. The only reason for not scoring a 10 is the use of approximations rather than exact figures, which slightly reduces quantitative precision, though this does not impair factual correctness. Overall, the answer conveys the same meaning as the ground truth with high fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 439,
        "total_tokens": 1693
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Boeing's treatment and disclosure of aluminum agreements evolved between 2022 and 2024, particularly in terms of their classification as derivatives and the time horizon for these agreements?",
      "original_answer": "In 2022, Boeing disclosed that its aluminum agreements were classified as derivatives but were not designated for hedge accounting treatment, with changes in fair value recorded in earnings immediately. The agreements were described in the context of long-term strategic sourcing objectives and non-U.S. business requirements. By 2024, the disclosure evolved to indicate that these aluminum agreements were now part of a broader set of commodity contracts hedging forecasted transactions through 2028. This represents a shift from purely strategic sourcing to a more structured hedging strategy with a defined time horizon extending to 2028.",
      "llm_answer": "\nBetween 2022 and 2024 Boeing shifted from a largely implicit treatment of its aluminum supply contracts—where they were simply bundled with other commodity purchases and not singled out as distinct derivatives—to an explicit disclosure that these agreements are derivative instruments that **do not qualify for hedge accounting** and are therefore recorded at fair value with changes in fair value recognized immediately in earnings.  The 2024 filing also reveals that the aluminum‑related commodity contracts have notional amounts of roughly 129 million pounds (2024) and are intended to hedge forecasted aluminum needs **through 2028** (with certain contracts carrying original maturities of at least five years), a time horizon and detailed derivative‑accounting description that were not separately presented in the 2022 filing.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, Boeing treated aluminum agreements as derivatives not designated for hedge accounting, with fair value changes recorded in earnings—matching the original answer. By 2024, it notes the shift to a structured hedging strategy with a time horizon through 2028, which is factually correct and captures the evolution in disclosure. (2) The LLM introduces a specific quantitative detail—'129 million pounds' of notional amount in 2024—which is not present in the original answer. While this may be factually accurate based on actual filings, it goes beyond the ground truth provided and introduces a detail not confirmed by the knowledge graph. However, this does not contradict the truth and adds context, so it doesn't warrant a major penalty. (3) The reasoning is sound: it correctly synthesizes the shift from strategic sourcing to formal hedging, recognizes the change in disclosure specificity, and identifies the multi-year horizon (through 2028) as a new element. (4) The only minor deviation is the absence of explicit mention of 'non-U.S. business requirements' and 'long-term strategic sourcing objectives' from 2022, which were in the original answer. While the LLM implies this by contrasting later hedging with prior implicit treatment, it doesn't explicitly state the strategic rationale. Overall, the answer is semantically equivalent, factually correct, and contextually complete, meriting a high score with only slight deduction for minor incompleteness in contextual nuance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 437,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Procter & Gamble's exposure to currency rate risk evolved between the fiscal years ended June 30, 2023 and June 30, 2024, particularly in terms of its hedging instruments and confidence in mitigating near-term exchange rate fluctuations?",
      "original_answer": "Procter & Gamble's exposure to currency rate risk remained materially unchanged between the fiscal years ended June 30, 2023 and June 30, 2024. The company continued to use forward contracts and currency swaps with maturities of less than 18 months to manage exchange rate risk. Additionally, P&G maintained its assessment that, at a 95% confidence level based on historical currency rate movements, the impact of a near-term change in currency rates would not materially affect its financial statements in either reporting period.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 P&G’s currency‑risk exposure and hedging program showed essentially no material change.  The company continues to manage foreign‑exchange risk primarily through short‑term forward contracts and currency swaps (typically with maturities under 18 months) as part of a diversified, natural‑hedge approach, and its internal risk‑measurement models (a one‑year, 95 % confidence‑level VaR analysis) indicate that even significant near‑term exchange‑rate movements would not have a material effect on the financial statements.  Consequently, management remains confident that its existing hedging instruments can effectively mitigate short‑term currency fluctuations.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: P&G's currency risk exposure remained materially unchanged between FY2023 and FY2024; the company continues to use forward contracts and currency swaps with maturities under 18 months; and it maintains a 95% confidence level assessment that near-term exchange rate fluctuations will not materially affect financial statements. (2) Quantitative elements—'95%', 'under 18 months', and 'one-year' VaR horizon—are correctly reported and match the original. No calculations are required, but the risk assessment methodology (VaR at 95% confidence) is accurately described. (3) The multi-hop reasoning is sound: the answer synthesizes information about hedging instruments, risk assessment methodology, and management's confidence across two fiscal years, directly addressing the evolution (or lack thereof) in exposure and mitigation strategy. (4) The wording differs slightly (e.g., 'VaR analysis' is an acceptable interpretation of the confidence-level assessment based on historical movements), but the meaning is preserved and contextually appropriate. No omissions or inaccuracies are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 339,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 129,
      "question": "How has Adobe's positioning and integration of Frame.io evolved between 2022 and 2024, particularly in terms of its functional scope and integration with other Adobe products?",
      "original_answer": "In 2022, Frame.io was listed among Adobe's trademarks, indicating it was an established product within Adobe's portfolio but with no detailed description of its functionality or integration. By 2024, Frame.io was actively described as a 'cloud-native creative collaboration platform' with expanded capabilities such as real-time upload, review and approval, frame-accurate commenting, and Camera to Cloud functionality. It was also integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront, and positioned as part of Adobe GenStudio for large-scale content production. This reflects a significant evolution from a trademarked asset to a core collaborative tool deeply embedded in Adobe's creative workflow.",
      "llm_answer": "\nBetween 2022 and 2024 Adobe broadened Frame.io’s functional scope and deepened its integration with the rest of its portfolio.  The 2022 filing described Frame.io mainly as a cloud‑native collaboration hub for video review that linked to Premiere Pro, After Effects, Photoshop and Lightroom, but the 2024 filing adds capabilities such as Camera‑to‑Cloud ingest, AI‑enhanced frame‑accurate commenting, and native connectivity to Adobe Express and Firefly‑powered services, positioning Frame.io as a central, end‑to‑end workflow layer within Adobe’s Creative Cloud and GenStudio offerings.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Frame.io's functional scope and integration between 2022 and 2024. It accurately captures the expansion from a collaboration hub to a more comprehensive workflow layer and correctly identifies key integrations with Premiere Pro, After Effects, Photoshop, and Lightroom. The mention of 'cloud-native collaboration hub' and enhanced capabilities like Camera-to-Cloud and frame-accurate commenting matches the original answer. However, the LLM introduces 'AI-enhanced frame-accurate commenting' and 'Firefly-powered services' that are not present in the ground truth, which only specifies 'frame-accurate commenting' without AI enhancement. Additionally, the original answer notes integration with Workfront and positioning within Adobe GenStudio, which the LLM mentions but omits Workfront. The LLM also adds 'Adobe Express' connectivity, which is not in the original. These additions, while plausible, are not supported by the ground truth and represent minor factual overreach. There are no numeric values to evaluate, so quantitative accuracy is scored as 10 by default. The reasoning is sound and reflects multi-hop understanding across years and product integrations. The answer is highly relevant and addresses the core of the question about functional and integration evolution. Thus, the correctness score is 8 due to minor inaccuracies in added details not present in the source.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 408,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between the 2022 and 2023 fiscal years, particularly in terms of the carrying value of its investment and the nature of its financial disclosures?",
      "original_answer": "In the 2022 filing, AMD disclosed that the carrying value of its investment in the ATMP JV was $69 million as of December 25, 2021, and $63 million as of December 26, 2020. Additionally, AMD provided detailed figures regarding purchases from and resales to the ATMP JV, including purchases of $1.1 billion in 2021 and $831 million in 2020. In contrast, the 2023 filing omits any mention of the carrying value of the investment and specific transaction figures, only reiterating the structural details of the relationship, such as AMD's 15% equity interest and the accounting method used. This indicates a reduction in the level of financial disclosure regarding the ATMP JV, even though the nature of the relationship and AMD's equity stake remained unchanged.",
      "llm_answer": "\nBetween the 2022 and 2023 fiscal years AMD’s equity‑method investment in the ATMP joint venture grew from roughly **$83 million (as of Dec 31 2022)** to **about $99 million (as of Dec 30 2023)** – an increase of roughly **$16 million**.  This rise is disclosed in the “Investment in ATMP JV” line of other non‑current assets and is accompanied by detailed related‑party tables that show purchases, sales, payables, receivables and the **$14 million gain in 2022 and $16 million gain in 2023 recorded in “Equity income in investee.”**  AMD continues to account for the ATMP JV under the equity method (no consolidation, no funding obligation) and reports the investment, related‑party balances and resulting gains in its financial statements.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth in multiple critical ways. (1) Quantitatively, the LLM claims the carrying value of AMD's investment in ATMP JV increased from $83 million (Dec 31, 2022) to $99 million (Dec 30, 2023), but the original answer states that the 2022 filing reported values as of 2021 ($69M) and 2020 ($63M), with no carrying value disclosed in the 2023 filing at all. The LLM invents numbers not present in the source and misrepresents the timeline. (2) The LLM asserts that AMD recorded a $14 million gain in 2022 and $16 million gain in 2023 from equity income, but the original answer does not mention any such gains—this information is fabricated. (3) The LLM incorrectly states that detailed transaction data (purchases, sales, receivables, etc.) were included in the 2023 filing, while the ground truth explicitly says the 2023 filing omitted all such figures. (4) The qualitative reasoning is flawed: instead of identifying a reduction in disclosure, the LLM suggests continued detailed reporting, which is the opposite of the truth. The only correct element is that AMD maintains a 15% equity interest and uses the equity method—this is mentioned in both answers. However, this does not compensate for the extensive factual inaccuracies. The answer fails on multi-hop synthesis, incorrectly asserting trends and disclosures that are not supported by the data. While the response is framed around the right topic (AMD’s relationship with ATMP JV), its factual foundation is unsound, leading to a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 432,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How did Honeywell's revenue from Commercial Aviation Original Equipment evolve between 2023 and 2024, and what does this indicate about its position in the aerospace sector?",
      "original_answer": "Honeywell's revenue from Commercial Aviation Original Equipment decreased from $2,397 million in 2023 to $2,223 million in 2024. This decline suggests a contraction in this segment despite overall growth in the Aerospace Technologies division, indicating a potential weakening in original equipment demand or supply constraints in this specific product line.",
      "llm_answer": "\nHoneywell’s Commercial Aviation Original Equipment sales slipped from **$2.397 billion in 2023 to $2.223 billion in 2024** (a decline of roughly 7 %). This dip reflects the softer demand and slower aircraft‑production environment that have weighed on the commercial aerospace market, yet the company remains a leading OEM supplier, underscoring its strong overall position in the sector despite the recent contraction.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the revenue figures for Honeywell's Commercial Aviation Original Equipment: $2.397 billion in 2023 and $2.223 billion in 2024, matching the ground truth of $2,397 million and $2,223 million. The percentage decline is accurately calculated as approximately 7% ((2,397 - 2,223) / 2,397 ≈ 0.0726 or 7.26%, rounded to 'roughly 7%'), which is acceptable. (2) All numeric values are correct and properly formatted; $2.397 billion = $2,397 million, and $2.223 billion = $2,223 million. The calculation of the decline is sound and factually accurate. (3) The multi-hop reasoning is strong: the model correctly identifies the trend (decline), links it to broader market conditions (softer demand, slower aircraft production), and contextualizes Honeywell’s position as a leading OEM despite the contraction—this aligns with the ground truth’s implication of potential demand or supply issues. (4) The only minor difference is in emphasis: the original answer highlights 'contraction in this segment despite overall growth in the Aerospace Technologies division,' which the LLM omits mentioning the division’s overall growth. However, the core facts, numbers, and logical interpretation are correct and semantically equivalent. Thus, the answer is highly accurate with only a slight omission in contextual nuance, warranting a 9/10 on correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1201,
        "completion_tokens": 390,
        "total_tokens": 1591
      },
      "error": null
    },
    {
      "question_id": 140,
      "question": "How did the global revenue contribution from Heart Failure Devices evolve between 2023 and 2024, and what was the percentage change in this segment's total revenue?",
      "original_answer": "In 2023, the global revenue from Heart Failure Devices was $1,161 million, while in 2024, this figure increased to $1,279 million. This represents a 10.2% increase in total revenue for the Heart Failure Devices segment. The growth was consistent across both U.S. and international markets, with minimal impact from exchange rate fluctuations, indicating strong underlying demand and market expansion.",
      "llm_answer": "\nHeart‑Failure device sales rose from **$1.161 billion in 2023 to $1.279 billion in 2024**.  This reflects a **10.2 % increase in total revenue** (or **≈10.3 % when the foreign‑exchange effect is excluded**) between the two years.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reported the global revenue figures for Heart Failure Devices in 2023 ($1.161 billion = $1,161 million) and 2024 ($1.279 billion = $1,279 million), and accurately calculated the percentage increase as 10.2%, matching the ground truth. The minor discrepancy in mentioning '≈10.3% when the foreign-exchange effect is excluded' does not contradict the original answer, which notes minimal impact from exchange rates, and may reflect a nuanced interpretation consistent with the data. (2) All numeric values are factually correct and properly formatted; the percentage change is accurate: (1,279 - 1,161) / 1,161 ≈ 0.1016, or 10.2% when rounded. (3) The multi-hop reasoning is sound—revenue figures across two years are correctly compared, and the synthesis of growth trend is valid. The LLM adds slight interpretive detail about foreign exchange, which is contextually supported but not explicitly required. (4) The answer is semantically equivalent to the original, addresses both parts of the question (evolution of revenue and percentage change), and maintains high factual and contextual accuracy. The slight deduction in qualitative accuracy is due to the addition of an unverified ≈10.3% figure, which, while plausible, was not confirmed in the ground truth. Overall, the response is excellent and fully aligned with the question's requirements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1162,
        "completion_tokens": 384,
        "total_tokens": 1546
      },
      "error": null
    },
    {
      "question_id": 151,
      "question": "How has IBM's treatment of the 0.300% Notes due 2028 evolved between the 2022 and 2023 filings?",
      "original_answer": "In the 2022 filing, the 0.300% Notes due 2028 were referenced as part of a list of debt instruments, with their rights defined in Exhibit 4.1 to Form 8-K filed February 10, 2020, and incorporated by reference. By 2023, the 0.300% Notes due 2028 were formally listed in the table of registered securities with a specific trading symbol (IBM 28B) and explicitly called out as a distinct class of notes registered on the New York Stock Exchange. This reflects a shift from general incorporation by reference to explicit disclosure and formal registration.",
      "llm_answer": "\nBetween the 2022 and 2023 Form 10‑K filings IBM did not change the accounting classification or the substantive terms of the 0.300 % Notes due 2028.  In both filings the securities are listed under “Notes payable” (2022) and later under the same series identifier “IBM 28B” in the 2023 filing, continuing to be presented as long‑term debt (non‑current) with no re‑classification, amendment or change in measurement treatment.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim and fails to capture the key evolution in IBM's treatment of the 0.300% Notes due 2028 between the 2022 and 2023 filings. While it correctly identifies that the notes were classified as long-term debt in both years and retains the 'IBM 28B' identifier (which aligns with the ground truth), it incorrectly asserts there was no change in disclosure or registration treatment. The ground truth shows a significant shift: in 2022, the notes were only incorporated by reference via Exhibit 4.1 to a Form 8-K filed on February 10, 2020, without explicit listing in the securities table. In 2023, they were formally registered on the New York Stock Exchange and explicitly listed in the table of registered securities with the trading symbol IBM 28B. This evolution from passive incorporation to active, explicit registration and disclosure is the central point of the question, which the LLM answer misses entirely. The answer focuses narrowly on accounting classification (which indeed did not change) but ignores the critical regulatory and disclosure developments. Quantitative accuracy is acceptable—no numbers are misstated, and the use of '0.300%' and 'IBM 28B' matches the ground truth. However, the qualitative reasoning is flawed: the model fails the multi-hop synthesis required to compare the nature of disclosure across filings. Contextual relevance is partial—it addresses IBM and the correct instrument but misinterprets the nature of the question, which was about disclosure and registration treatment, not accounting classification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1231,
        "completion_tokens": 435,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 158,
      "question": "How has Apple's financial performance in the Rest of Asia Pacific region evolved from 2022 to 2023, based on changes in net sales and operating income?",
      "original_answer": "In 2022, Apple's Rest of Asia Pacific segment reported net sales of $29,375 million and operating income of $11,569 million. In 2023, these figures increased to $29,615 million in net sales and $12,066 million in operating income. This represents a moderate growth in both metrics, with net sales rising by $240 million (0.8%) and operating income increasing by $497 million (4.3%).",
      "llm_answer": "\nApple’s Rest of Asia Pacific net sales rose modestly, climbing from **$29.38 billion in 2022 to $29.62 billion in 2023** (≈ 0.8 % growth), and operating income increased more notably from **$11.57 billion to $12.07 billion** (≈ 4.3 % growth) over the same period, reflecting a small sales uptick but a stronger improvement in profitability for that region.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same information as the ground truth with minor formatting differences that do not affect correctness. (1) Quantitatively, the LLM reports net sales as $29.38 billion (vs. $29,375 million) and $29.62 billion (vs. $29,615 million), which are accurate when converted (29.375 ≈ 29.38 and 29.615 ≈ 29.62). Operating income is given as $11.57 billion (vs. $11,569 million) and $12.07 billion (vs. $12,066 million), again correctly rounded. The growth percentages (0.8% and 4.3%) match exactly. (2) Calculations are sound: the increase in net sales is ~$240M (0.8%) and operating income ~$497M (4.3%), consistent with ground truth. (3) The reasoning correctly synthesizes year-over-year performance across two financial metrics and draws a valid qualitative conclusion about modest sales growth and stronger profitability improvement. (4) All entities—Apple, Rest of Asia Pacific, 2022–2023, net sales, operating income—are correctly identified and contextualized. The answer is fully relevant and complete. The score is 9 instead of 10 due to slight rounding in the input numbers (e.g., $29.38B instead of $29.375B), but this is within acceptable formatting variation and does not constitute a factual error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1186,
        "completion_tokens": 349,
        "total_tokens": 1535
      },
      "error": null
    },
    {
      "question_id": 169,
      "question": "How has the vesting period for stock options issued under the 2007 Omnibus Incentive Plan evolved between grants made prior to 2022 and those made after December 31, 2021, based on disclosures in the 2022 and 2024 10-K filings?",
      "original_answer": "In the 2022 10-K filing, stock options granted prior to 2022 under the 2007 Omnibus Incentive Plan generally vested pro rata over a five-year period, while those granted after December 31, 2021, under the amended and restated plan, generally vested pro rata over a four-year period. The 2024 10-K confirms that stock options granted prior to 2022 continued to vest pro rata over a five-year period, and those granted after December 31, 2021, also continued to vest pro rata over a four-year period. This indicates a consistent reduction in the vesting period from five to four years for post-2021 grants, showing a structural change in the incentive plan's vesting terms over time.",
      "llm_answer": "\nThe 2022 10‑K notes that “stock options granted **prior to 2022** under the 2007 Omnibus Incentive Plan generally vest pro‑rata over a **five‑year** period,” whereas the 2024 10‑K states that “stock options granted **subsequent to December 31, 2021** … generally vest pro‑rata over a **four‑year** period.” Thus, the vesting schedule was shortened from a five‑year graded schedule for pre‑2022 grants to a four‑year graded schedule for grants made after that date (both still terminating after ten years).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the essential information from the ground truth. (1) Quantitatively, all numbers and dates are correct: 'prior to 2022' and 'after December 31, 2021' align with the original answer, and the vesting periods of five years (pre-2022) and four years (post-2021) are accurately reported. The use of 'subsequent to December 31, 2021' is semantically equivalent to 'after December 31, 2021'. (2) The answer correctly cites the 2022 and 2024 10-K disclosures, though it does not explicitly mention that the 2024 10-K confirms the continuation of the same vesting terms (i.e., no change between 2022 and 2024 filings), which is a minor omission in completeness. (3) The multi-hop reasoning is sound—correctly comparing pre- and post-2022 grants across filings and identifying the structural change from five- to four-year vesting. (4) The answer uses 'graded' instead of 'pro rata', but these are often used interchangeably in vesting contexts, so this does not constitute a factual error. The note about options terminating after ten years is a minor addition not in the original but is contextually reasonable and not incorrect. Overall, the answer is factually correct and well-aligned with the ground truth, missing only slight contextual reinforcement from the 2024 filing about continuity. Hence, a score of 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 402,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 170,
      "question": "How has CVS's approach to validating the fair value estimates for its Level 2 debt securities evolved from 2022 to 2023, particularly in terms of price adjustments and secondary source comparisons?",
      "original_answer": "In 2022, CVS obtained one price for each of its Level 2 debt securities and did not adjust any of those prices at December 31, 2021 or 2020. The company compared selected sample prices quarterly to secondary sources and reviewed variances over a specified threshold. In 2023, the company maintained the same validation methodology, obtaining one price per Level 2 debt security without any adjustments at December 31, 2023 or 2022, and continued to compare prices quarterly to secondary sources. Despite maintaining the same process, the emphasis on consistent internal validation by the investment team appears to have remained stable, indicating a sustained but unchanging approach to fair value estimation.",
      "llm_answer": "\nFrom 2022 to 2023 CVS continued to validate each Level 2 debt‑security fair‑value estimate by obtaining a single quoted price from a primary source, then selecting a sample of those prices for cross‑check against a secondary source and reviewing any variance that exceeds a preset threshold; importantly, the company **did not adjust any Level 2 fair‑value amounts in either 2022 or 2023**.  The same quarterly sampling and internal‑team comparison process that was used in 2022 was retained in 2023, indicating a consistent approach with no material changes to price adjustments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: CVS obtained one price per Level 2 debt security in both 2022 and 2023, made no price adjustments in either year (specifically at December 31, 2022 or 2023), and maintained a quarterly process of comparing sample prices to secondary sources with review of variances above a threshold. The statement that no adjustments were made in either year matches the original answer’s claim for both years. (2) Quantitative accuracy is perfect: no numerical errors, correct years (2022 and 2023), correct characterization of unchanged practices. Format variations (e.g., 'did not adjust any Level 2 fair-value amounts') are semantically equivalent to the original. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across years and validation steps (primary source pricing, secondary comparison, internal review), and correctly infers that the unchanged process indicates consistency in approach. (4) The only minor shortcoming is that the LLM omits the explicit mention of 2020 and 2021 data referenced in the 2022 description in the original answer, though this is not directly required by the question focusing on 2022–2023 evolution. It also does not mention the 'emphasis on consistent internal validation by the investment team' noted in the original, which adds slight contextual nuance. However, the core evolution (or lack thereof) is correctly conveyed. Thus, the answer is factually complete and contextually relevant, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 455,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 172,
      "question": "How did CVS's classification and valuation methodology for privately-placed equity securities evolve between 2022 and 2023, particularly in terms of fair value determination and unobservable inputs?",
      "original_answer": "CVS maintained a consistent classification of privately-placed equity securities as Level 3 in both 2022 and 2023, indicating no active market for these securities. However, the company emphasized in both years that it uses an internal analysis of financial statements and cash flow projections to determine fair value. In 2022, the significant unobservable inputs included earnings and revenue multiples, discount for lack of marketability, and comparability adjustments. In 2023, the same unobservable inputs were referenced, but with an added emphasis on the potential impact of changes in these inputs on fair value measurements, suggesting a more detailed sensitivity analysis or increased scrutiny of these inputs in the valuation process.",
      "llm_answer": "\nCVS continued to classify its privately‑placed equity securities as Level 3 in both 2022 and 2023.  Fair value is still derived from internal valuation models that use unobservable inputs—mainly earnings and revenue multiples, a discount for lack of marketability, and comparability adjustments—with the company explicitly stating that any change in those inputs would affect the measured fair value.  No material change in hierarchy or methodology was disclosed; the 2023 filing simply reiterated the same Level 3 approach.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly states that CVS classified privately-placed equity securities as Level 3 in both 2022 and 2023, which matches the original answer. The use of internal valuation models based on unobservable inputs—earnings and revenue multiples, discount for lack of marketability, and comparability adjustments—is accurately reported. (2) There are no numeric values requiring calculation, but all qualitative financial terms and classifications are used correctly. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years, noting consistency in classification and methodology. The LLM captures the key evolution—continued use of the same inputs with an increased emphasis on sensitivity to changes in those inputs—even if it phrases this as 'any change in those inputs would affect the measured fair value' rather than explicitly mentioning 'sensitivity analysis' or 'increased scrutiny.' This is semantically equivalent but slightly less precise in capturing the nuance of enhanced analytical focus in 2023. (4) The answer is fully contextually relevant, directly addressing classification, valuation methodology, fair value determination, and unobservable inputs over the two years. The only minor shortcoming is the lack of explicit mention of the 'added emphasis on the potential impact' in 2023 as a developmental shift, though the idea is implied. Hence, a score of 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 437,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 184,
      "question": "How did the total net revenue from Alphagan/Combigan change between 2023 and 2024, and what was the trend in its international revenue during this period?",
      "original_answer": "The total net revenue from Alphagan/Combigan decreased from $272 million in 2023 to $248 million in 2024, reflecting an 8.8% decline. During the same period, its international revenue slightly increased from $151 million in 2023 to $153 million in 2024, representing a 1.5% growth.",
      "llm_answer": "\nThe total net revenue for Alphagan/Combigan fell from **$272 million in 2023 to $248 million in 2024**, a decline of roughly **8‑9 %**.  During the same period its **international sales rose modestly**, increasing from **$151 million to $153 million** (about a **1‑2 % increase**).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same information as the ground truth with only minor, acceptable variations in precision. (1) All key numbers are correct: total net revenue decreased from $272 million in 2023 to $248 million in 2024, and international revenue increased from $151 million to $153 million. (2) The percentage decline is reported as 'roughly 8-9%' versus the exact 8.8% in the original; this is a negligible rounding difference and semantically equivalent. Similarly, the international growth is stated as 'about 1-2%' compared to the precise 1.5%, which is acceptable given the small range. (3) The multi-hop reasoning is sound—revenue trends for both total and international segments across two years are correctly synthesized and contrasted. (4) All entities (Alphagan/Combigan, revenue metrics, years) are accurately identified. The answer fully addresses both parts of the question. Minor imprecision in percentage ranges does not detract from overall correctness, warranting a high score but not perfect due to slight loss in quantitative fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1142,
        "completion_tokens": 307,
        "total_tokens": 1450
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Chevron's relationship with PDC Energy evolved from 2023 to 2024, and what specific operational impact did this change have on Chevron's overall production performance?",
      "original_answer": "In 2023, Chevron acquired PDC Energy, Inc. (PDC), and as a result, PDC was excluded from Chevron's internal control assessment over financial reporting due to the timing of the acquisition. By 2024, Chevron's relationship with PDC had evolved from a newly acquired entity to an integral operational component, as evidenced by the 7% increase in Chevron's worldwide oil-equivalent production, which was attributed in part to the full-year contribution from legacy PDC operations. This indicates that PDC Energy transitioned from being a recent acquisition in 2023 to a key contributor to Chevron's production growth in 2024.",
      "llm_answer": "\nChevron’s relationship with PDC Energy shifted from an independent producer to a fully‑owned subsidiary after the 2023 acquisition, so that by the 2024 filing PDC’s assets and production are fully integrated into Chevron’s operations.  This integration added the “full‑year of legacy PDC Energy production” to Chevron’s output, contributing to a roughly 7 percent year‑over‑year increase in worldwide oil‑equivalent production in 2024, especially through growth in the Permian Basin and other U.S. fields.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Chevron acquired PDC Energy in 2023, and by 2024, PDC was fully integrated, contributing a full year of production. The 7% year-over-year increase in worldwide oil-equivalent production is correctly cited, matching the original answer. (2) Quantitative accuracy is perfect: the 7% production increase is correctly reported, and the timing (2023 acquisition, 2024 full-year contribution) is accurate. No calculations are required beyond this, and the numbers match exactly. (3) The multi-hop reasoning is sound—linking the acquisition in 2023 to operational integration in 2024 and then to production impact shows proper synthesis across time and entities. The mention of the Permian Basin adds contextual detail not in the original but is plausible and consistent with PDC’s asset base, without contradicting the ground truth. (4) The only minor shortcoming is that the original answer notes PDC was excluded from internal control assessment in 2023 due to the acquisition timing—a detail omitted in the LLM response. While not critical to the operational impact, it was part of the original relationship evolution. However, since the question emphasizes operational impact on production, this omission does not significantly detract from correctness. Overall, the answer is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 395,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has UPS's investment in cold-chain logistics capabilities evolved from 2023 to 2024, and what specific acquisitions contributed to this change?",
      "original_answer": "In 2023, UPS expanded its cold-chain logistics capabilities through the acquisition of Bomi Group and MNX Global Logistics, aiming to enhance its healthcare logistics services. By 2024, this strategic focus intensified with the acquisition of Frigo-Trans and Biotech & Pharma Logistics in Germany for approximately $440 million, signaling a significant increase in international investment in complex cold-chain logistics. This represents a shift from general expansion to targeted, high-value international acquisitions in the cold-chain sector.",
      "llm_answer": "\nFrom 2023 to 2024 UPS deepened its cold‑chain platform by acquiring **Bomi Group** (2022) and **MNX Global Logistics** (2023), then in 2024 it completed the purchase‑accounting for those deals, integrated the businesses and divested its non‑cold‑chain Coyote brokerage unit, laying the groundwork for further expansion—highlighted by the announced 2025 purchase of **Frigo‑Trans** and **Biotech & Pharma Logistics** to boost its international cold‑chain capabilities.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains several critical factual errors that undermine its correctness. (1) It incorrectly states that Bomi Group was acquired in 2022, while the ground truth confirms it was part of 2023 activity. (2) It misrepresents the 2024 acquisitions of Frigo-Trans and Biotech & Pharma Logistics as 'announced for 2025', when they occurred in 2024 and were a key part of UPS's evolution during that year. (3) It introduces the divestiture of Coyote Logistics as contextually relevant, which is not mentioned in the ground truth and distracts from the core narrative of cold-chain expansion. (4) The answer omits the $440 million price tag, a key quantitative detail indicating the scale of international investment. (5) The reasoning is flawed: it suggests UPS 'completed purchase-accounting' in 2024 for prior deals, implying no new strategic movement, whereas the ground truth shows a clear escalation in 2024 via high-value German acquisitions. While the entities (Bomi, MNX, Frigo-Trans, Biotech & Pharma Logistics) are mostly correct in name, their timing and significance are misrepresented. The answer addresses the general theme of cold-chain evolution and mentions relevant companies, so it retains partial contextual relevance. However, due to major errors in dates, sequence, and omission of financial magnitude, the quantitative and qualitative accuracy scores are low. The core multi-hop synthesis—tracking evolution from 2023 to 2024 based on specific acquisitions—fails because the timeline is reversed and key facts are missing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 423,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Linde plc's non-employee director restricted stock unit award program evolved between 2022 and 2024, particularly in terms of governance structure and long-term shareholder alignment mechanisms?",
      "original_answer": "In 2022, Linde plc introduced the Non-Employee Director Restricted Stock Unit Award under the 2021 Linde plc Long Term Incentive Plan, establishing a framework for equity-based compensation tied to long-term performance metrics. This initiative was part of a broader suite of incentive programs aimed at aligning director interests with those of shareholders. By 2024, the company expanded this framework by introducing the Linde plc Non-employee Director Deferral Program, adopted by the Board of Directors on July 30, 2024. This deferral program enhances governance by allowing directors to defer receipt of stock units, thereby reinforcing long-term alignment with shareholder value creation. The evolution from a basic restricted stock unit award to a more sophisticated deferral mechanism indicates Linde’s strategic emphasis on strengthening board accountability and promoting sustained corporate governance standards.",
      "llm_answer": "\nBetween 2022 and 2024 Linde plc replaced the legacy non‑employee‑director RSU awards that had been issued under the 2009 Praxair Long‑Term Incentive Plan with a dedicated award under the 2021 Linde plc Long‑Term Incentive Plan (first filed as Exhibit 10.0e in the 2021 Form 10‑K and later amended in early 2024).  The Board formalized a **Non‑Employee Director Deferral Program** (adopted July 30 2024) that requires directors to defer receipt of vested RSUs and subjects a greater portion of the award to performance‑based clawback and equity‑holding rules, thereby tightening governance oversight and aligning director compensation with long‑term shareholder value.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution of Linde plc's non-employee director RSU program from 2022 to 2024 and correctly identifies the key development: the adoption of the Non-Employee Director Deferral Program on July 30, 2024. It accurately references the 2021 Linde plc Long-Term Incentive Plan as the governing framework, aligning with the original answer. However, there are notable discrepancies: (1) The claim that legacy RSU awards were issued under the '2009 Praxair Long-Term Incentive Plan' and that Linde 'replaced' them is not present in the ground truth and introduces unverified historical context; the original answer does not mention Praxair or a replacement narrative. (2) The statement that the deferral program 'requires' directors to defer receipt is incorrect—the original answer describes it as an option (allowing deferral), not a mandate. (3) The mention of 'performance-based clawback' and 'amended in early 2024' lacks support in the ground truth, which does not reference clawbacks or plan amendments. These additions introduce factual inaccuracies and overstate governance stringency. Quantitatively, dates (2022, 2024, July 30, 2024) are correct, and no numerical calculations are required. The reasoning partially reflects multi-hop synthesis (linking plan evolution to governance and alignment), but the unsupported details reduce qualitative accuracy. The answer remains contextually relevant and addresses both governance structure and shareholder alignment, albeit with embellishments. Thus, the correctness score is 7 for core accuracy with significant but not fundamental errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 441,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did General Motors' financial and legal relationship with Stellantis evolve between 2022 and 2024, particularly regarding indemnification obligations and investment gains?",
      "original_answer": "In 2022, General Motors reported a gain of $0.2 billion related to Stellantis N.V. (Stellantis) warrants, indicating a positive financial relationship. However, by 2024, the relationship had evolved into a more complex and potentially costly one. GM had agreed to indemnify Stellantis for certain liabilities tied to pre-sale emissions claims, product liabilities, and recalls related to the 2017 sale of the Opel/Vauxhall business. Additionally, GM faced potential future liabilities from ongoing investigations into Opel’s historical conduct in Europe. Unlike the earlier gains, GM's 2024 disclosures highlighted contingent liabilities and legal risks rather than financial benefits from its relationship with Stellantis.",
      "llm_answer": "\nBetween 2022 and 2024 the only lingering financial link to Stellantis is the indemnification provision built into the 2017 sale of Opel/Vauxhall; the 2024 filing notes that GM must cover certain post‑sale losses (e.g., emissions, product‑liability and recall claims) subject to time‑limited caps, and that it cannot quantify any reasonably possible material loss—effectively rendering the exposure immaterial.  At the same time, any equity stakes or other investments tied to that transaction generated only modest, non‑material gains that are recorded in other income and do not affect GM’s core automotive results, so the relationship has evolved into a largely passive indemnity arrangement with no significant investment upside.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures some correct elements but misses key facts and misrepresents the financial relationship. The ground truth states that GM reported a $0.2 billion gain in 2022 from Stellantis warrants, which is a specific, material financial event. However, the LLM answer downplays this by stating that 'any equity stakes or other investments...generated only modest, non-material gains,' which contradicts the $0.2 billion figure (i.e., $200 million, which is material). This is a significant factual inaccuracy. (2) Quantitatively, the $0.2 billion gain in 2022 is omitted entirely, and no correct dollar amount is mentioned. The LLM correctly references the indemnification obligations in 2024 but fails to specify that these stem from the 2017 Opel/Vauxhall sale, which is mentioned in both the original and LLM answers—partial credit for timeline alignment. (3) The multi-hop reasoning is partially sound: the model connects the Opel sale to indemnification and recognizes the shift from financial gain to liability risk. However, it incorrectly minimizes the 2022 gain, undermining the evolution narrative. The conclusion that the relationship is 'largely passive' with 'no significant investment upside' contradicts the documented $0.2 billion gain, indicating flawed synthesis. (4) Contextual relevance is strong—the answer addresses indemnification and investment aspects over time and focuses on the right companies and transaction. However, due to the omission and mischaracterization of a key financial figure and the resulting flawed narrative, the correctness and qualitative accuracy scores are reduced. The answer is not completely wrong but is significantly incomplete and partially misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 472,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did Southern Company's treatment and disclosure of energy-related derivatives evolved from 2022 to 2024, particularly in terms of their financial presentation and categorization?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of energy-related derivatives not designated as hedging instruments on the statements of income for prior years (2021, 2020, and 2019), indicating a focus on income statement impacts. By 2024, the company shifted its disclosure to emphasize the fair value of energy-related derivatives as either assets or liabilities on the balance sheets, specifically categorized under 'Other' or 'Risk Management Activities'. This represents a shift from income-focused reporting to balance sheet-oriented transparency.",
      "llm_answer": "\nFrom the 2022 filing Southern Company presented its energy‑related derivatives in a single, relatively coarse‑grained table that combined regulatory, cash‑flow and non‑designated contracts and gave only total asset/liability figures with minimal offset disclosure. In the 2024 filing the company separates those contracts into clearly labeled categories (regulatory hedges, cash‑flow/ fair‑value hedges, and non‑designated contracts), shows current versus non‑current balances, discloses gross amounts, offsetting (including cash collateral), and provides detailed breakdowns of interest‑rate and foreign‑currency derivatives—resulting in a far more granular and transparent presentation of how the derivatives are categorized and reported on the balance sheet.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of the evolution of Southern Company's derivative disclosures from 2022 to 2024, though it provides more granular detail than the original answer. It correctly identifies a shift in disclosure focus from a less detailed, aggregated presentation in 2022 to a more segmented, transparent balance sheet-oriented approach in 2024. The entities (Southern Company, energy-related derivatives, 2022 and 2024 timeframes) are accurate, and there are no numerical inaccuracies—no specific dollar amounts or percentages are cited in either answer, so quantitative accuracy is not compromised. The reasoning is sound: the LLM correctly infers a move toward greater transparency and improved categorization, aligning with the ground truth’s characterization of a shift from income statement to balance sheet emphasis. However, the original answer emphasizes the shift from 'pre-tax effects on income statements' (2022) to 'fair value on balance sheets' (2024), while the LLM focuses more on structural presentation improvements (e.g., gross vs net, current vs non-current) without explicitly mentioning the income statement impact in 2022. This omission of the pre-tax income effect—a key element in the ground truth—is a minor but notable gap in completeness. Still, the core evolution in financial presentation and categorization is accurately captured, warranting a high correctness score. Semantic equivalence is largely preserved, with the LLM offering a more detailed but not contradictory account.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 426,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did GILD's strategic relationship with Arcus evolve between 2023 and 2024, particularly in terms of equity ownership and governance influence?",
      "original_answer": "In 2023, GILD owned approximately 19.9% of Arcus' issued and outstanding voting stock and had two designees on Arcus' board of directors. In January 2024, GILD made an additional $320 million equity investment in Arcus, increasing its ownership to 33%, and expanded its board representation to three designees. This represents a significant increase in both financial commitment and governance influence over Arcus within a year.",
      "llm_answer": "\nBetween the end of 2023 and early 2024 Gilead lifted its ownership in Arcus from roughly 19.9 % (≈14.8 million shares) to about 33 % after a $320 million equity investment in January 2024, and it added a third designee to Arcus’s board (expanding from two seats).  The earlier three‑year standstill that had limited Gilead’s share purchases expired in Q2 2023, and the amended agreement now lets Gilead buy up to 35 % of Arcus’s outstanding voting shares over the next five years, giving it both a larger equity stake and stronger governance influence.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all key figures are correct: GILD's ownership increased from 19.9% to 33% following a $320 million investment in January 2024, and board representation expanded from two to three designees—this matches the original answer exactly. The mention of the standstill expiration in Q2 2023 and the new 35% purchase cap adds context not in the original answer but does not contradict it and is plausible supplemental detail. (2) Calculations and dates are precise: the $320M investment timing and ownership percentages are consistent. (3) Multi-hop reasoning is sound—LLM correctly links the equity investment to increased ownership and governance influence across 2023–2024. (4) The only minor deviation is the inclusion of forward-looking agreement terms (5-year, up to 35%) not present in the ground truth, which, while potentially accurate, slightly extends beyond the scope of the documented evolution. However, this does not undermine the core factual correctness. Overall, the answer is semantically equivalent, comprehensive, and contextually appropriate, warranting a high score with a small deduction in qualitative accuracy for the added detail without explicit confirmation in the source.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 358,
        "total_tokens": 1604
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the maturity date and borrowing capacity of the 2021 Multicurrency Credit Facility evolved between 2022 and 2023?",
      "original_answer": "In 2022, the 2021 Multicurrency Credit Facility had a maximum borrowing capacity of $6.0 billion with a maturity date of June 30, 2025. By 2023, the borrowing capacity remained at $6.0 billion, but the maturity date was extended to July 1, 2026. This reflects a one-year extension of the facility’s term without any increase in the total commitment amount, indicating a strategic move to maintain financial flexibility over a longer horizon.",
      "llm_answer": "\nBetween the end of 2022 and the 2023 amendment, the 2021 Multicurrency Credit Facility’s maturity was extended—from July 1, 2026 (the date in force at the close of 2022) to July 1, 2028 (after the June 29 2023 amendment).  The total commitment remained unchanged at $6.0 billion (including the $3.5 billion multicurrency sub‑limit), with the amendment only replacing the LIBOR benchmark with SOFR.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 the maturity date was June 30, 2025, not July 1, 2026 as stated by the LLM. The LLM incorrectly claims that by 2023 the maturity was extended to July 1, 2028, whereas the correct date is July 1, 2026. Additionally, the LLM implies the extension occurred via a June 29, 2023 amendment, which is not supported by the original answer. While the borrowing capacity of $6.0 billion is correctly stated, the additional detail about a $3.5 billion sub-limit and SOFR/LIBOR replacement is extraneous and not part of the original answer, suggesting potential hallucination or misattribution. (2) Quantitative accuracy is severely compromised: the 2022 maturity date is off by over a year (June 30, 2025 vs. July 1, 2026), and the 2023 maturity is wrong by two years (July 1, 2026 vs. July 1, 2028). These are critical errors in financial contexts. (3) The reasoning is flawed: the LLM reverses the timeline, suggesting the 2026 date was already in place in 2022, when in fact the extension from 2025 to 2026 occurred during the 2022–2023 period. It fails to correctly synthesize the evolution across years, misrepresenting the direction and magnitude of change. (4) Contextual relevance is moderate—the answer addresses the right facility and the general topic of maturity and capacity—but due to major factual and temporal inaccuracies, the core of the response is incorrect. The inclusion of irrelevant benchmark rate changes further distracts from the actual question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1203,
        "completion_tokens": 432,
        "total_tokens": 1635
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Chevron's utilization of imported crude oil in U.S. refining operations evolved between 2023 and 2024, and what changes in refinery capacity utilization accompanied this trend?",
      "original_answer": "Chevron's reliance on imported crude oil in U.S. refining operations remained consistent at approximately 60% of refinery inputs in both 2023 and 2024. However, the utilization of U.S. refineries changed: in 2023, crude unit distillation capacity utilization averaged 90.8%, while in 2024 it decreased to 86.6%. This indicates that while the company's dependency on imported crude oil remained stable, the overall operational intensity of its U.S. refineries declined slightly in 2024.",
      "llm_answer": "\nChevron’s mix of crude in its U.S. refineries was essentially unchanged – imported crude still made up roughly 60 percent of refinery inputs in both 2023 and 2024.  What did shift was the overall plant utilization: average crude‑unit distillation capacity utilisation fell from about **89.8 % in 2023 to 87.9 % in 2024**, indicating that the refineries were running slightly less full even though the share of imported versus domestic crude stayed steady.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "1) The LLM correctly identifies that Chevron's reliance on imported crude oil remained stable at approximately 60% in both 2023 and 2024, which matches the ground truth. However, the reported refinery capacity utilization figures are inaccurate: the LLM states 89.8% in 2023 and 87.9% in 2024, whereas the ground truth reports 90.8% in 2023 and 86.6% in 2024. These discrepancies affect the quantitative accuracy significantly. 2) The numbers are off by more than minor rounding differences—0.9 percentage points in 2023 and 1.3 points in 2024—which constitutes a material error in financial and operational reporting context. The direction of the trend (a decline in utilization) is correct, but the magnitude is misrepresented. 3) The reasoning is sound: the model correctly synthesizes that imported crude share remained constant while overall refinery utilization decreased, indicating a decline in operational intensity. This reflects proper multi-hop understanding of both crude sourcing and capacity metrics. 4) Contextually, the answer is well-structured and relevant, addressing both parts of the question. The qualitative interpretation aligns with the ground truth, even if the numbers are slightly off. Due to the importance of precise figures in financial and operational analysis, the correctness score is reduced to 6—partially correct but with significant numerical inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 384,
        "total_tokens": 1629
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did UPS's hedging position in British Pound Sterling evolve between 2023 and 2024, and what does this shift indicate about the company's currency risk management strategy?",
      "original_answer": "In 2023, UPS reported a British Pound Sterling (GBP) hedge position of 663 million units, which decreased to 536 million units in 2024. This represents a reduction of 127 million units, or approximately 19.15%. The decrease indicates a strategic move to reduce exposure to GBP, suggesting that UPS may have reassessed its currency risk related to the British Pound and opted for a more conservative hedging approach or a lower anticipated risk in that currency during the later year.",
      "llm_answer": "\nBetween 2023 and 2024 UPS trimmed its British‑Pound‑Sterling hedge book: the notional amount of GBP‑denominated contracts fell from **$663 million (2023)** to **$536 million (2024)**, and the AOCI balance on foreign‑currency debt designated as a net‑investment hedge swung from a **$119 million loss** to a **$127 million gain**.  This reduction in hedged notional and the reversal of the AOCI result reflect a deliberate scaling back of explicit GBP hedges—UPS is relying more on natural offsets and cash‑flow hedges for its GBP exposure, signaling a more measured approach to currency‑risk management.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the decrease in UPS's GBP hedge position from $663 million in 2023 to $536 million in 2024, which aligns with the ground truth. However, it introduces additional data not present in the original answer — specifically, the AOCI (Accumulated Other Comprehensive Income) balance shifting from a $119 million loss to a $127 million gain — which is not supported by the provided ground truth and appears to be either hallucinated or derived from external data. This undermines quantitative and qualitative accuracy. (2) The core numbers for the hedge position (663M to 536M) are accurate and correctly formatted; the implied reduction of 127M is correct, though the LLM does not compute the percentage decrease (~19.15%) mentioned in the ground truth. The inclusion of AOCI figures without verification makes the quantitative accuracy partially incorrect. (3) The reasoning about a strategic reduction in hedges is consistent with the original answer’s interpretation, but the LLM extends the conclusion to suggest a shift toward 'natural offsets and cash-flow hedges' — a plausible inference but one not supported by the provided ground truth, thus representing an unsupported leap in multi-hop reasoning. (4) While the answer addresses the evolution of the hedging position and offers an interpretation about risk management strategy, it adds unverified financial details and inferences, reducing factual reliability. The contextual relevance remains high as it directly responds to both parts of the question with coherent structure and relevant domain language.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 441,
        "total_tokens": 1720
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the fair value of money market investments held by Bank of America evolved between 2023 and 2024, and what does this shift indicate about the company's short-term investment strategy?",
      "original_answer": "The fair value of money market investments held by Bank of America increased from $1.2 billion at December 31, 2023, to $1.3 billion at December 31, 2024. This indicates a modest growth in the company's short-term investment holdings, suggesting a slight expansion in liquidity management or short-term capital deployment strategies over the year.",
      "llm_answer": "\nThe fair‑value of Bank of America’s money‑market investments edged up from **$1.2 billion at the end of 2023 to $1.3 billion at the end of 2024** (as disclosed in Note 4 – Securities, page 113).  This modest rise indicates that the company is modestly increasing its allocation to short‑term, highly liquid cash‑equivalents—likely to take advantage of higher yields in a rising‑rate environment while maintaining ample liquidity for funding and risk‑management purposes.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values '$1.2 billion at the end of 2023' and '$1.3 billion at the end of 2024' are accurate and match the original answer exactly; minor formatting differences (e.g., spacing, use of 'end of' vs 'December 31') do not affect correctness. (2) The answer addresses both parts of the question: the evolution of fair value (increase from $1.2B to $1.3B) and the implication for short-term investment strategy. (3) Entities—Bank of America, money market investments, years 2023 and 2024—are correctly identified. (4) The reasoning is sound: the modest increase is correctly interpreted as a strategic shift toward slightly higher short-term liquidity deployment, with plausible context about rising rates and liquidity management. The addition of a footnote reference (Note 4 – Securities, page 113) enhances credibility, even if not required. Semantic meaning and factual content are equivalent to the ground truth, with slightly more contextual interpretation that remains reasonable and supported. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1215,
        "completion_tokens": 326,
        "total_tokens": 1542
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the maximum expected volume of natural gas subject to physical supply contracts with sell-back options changed across Southern Company's subsidiaries between 2022 and 2024?",
      "original_answer": "In 2022, the maximum expected volume of natural gas subject to such contracts was 26 million mmBtu for Southern Company as a whole, with individual volumes of 6 million mmBtu for Alabama Power, 8 million mmBtu for Georgia Power, 4 million mmBtu for Mississippi Power, and 8 million mmBtu for Southern Power. By 2024, this volume had decreased to 15 million mmBtu company-wide, with corresponding reductions in each subsidiary's volume: 4 million mmBtu for Alabama Power, 6 million mmBtu for Georgia Power, 2 million mmBtu for Mississippi Power, and 3 million mmBtu for Southern Power. This represents a consistent reduction across all entities.",
      "llm_answer": "\nThe maximum expected volume of natural gas subject to physical‑supply contracts with sell‑back options fell sharply – from roughly **26 million mmBtu** (the level disclosed for the 2021/2022 reporting period) to about **15 million mmBtu** in 2024, a reduction of roughly **11 million mmBtu**.  At the subsidiary level this translates to a drop from **6 → 4 mmBtu** for Alabama Power, **8 → 6 mmBtu** for Georgia Power, **4 → 2 mmBtu** for Mississippi Power, and **8 → 3 mmBtu** for Southern Power.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) Quantitatively, all key numbers are correct: the total volume decreased from 26 million mmBtu in 2022 to 15 million mmBtu in 2024, and the subsidiary-level volumes (Alabama Power: 6→4, Georgia Power: 8→6, Mississippi Power: 4→2, Southern Power: 8→3) match exactly. The reduction of 11 million mmBtu is correctly calculated. (2) The only minor issue is the reference to '2021/2022 reporting period' instead of clearly stating 2022 as the baseline year; while this does not make the answer factually wrong (since the 2022 data is correctly used), it slightly muddies the temporal clarity. (3) The multi-hop reasoning is sound: the model correctly synthesized data across Southern Company and its four subsidiaries for two time points and accurately described the trend of consistent reduction across all entities. (4) All entities and metrics are correctly identified, and the answer fully addresses the question about changes between 2022 and 2024. Wording differs slightly but maintains semantic equivalence. Thus, the answer is excellent with only a minor lapse in temporal precision, warranting a 9/10 on correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 345,
        "total_tokens": 1639
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the integration and application of the Firefly Vector Model evolved across Adobe's product suite between 2023 and 2024?",
      "original_answer": "In 2023, the Firefly Vector Model was integrated into Adobe Express, enabling users to generate custom images and text effects from text prompts in over 100 languages. By 2024, the Firefly Vector Model had expanded its application beyond Adobe Express and was now also integrated into Adobe Illustrator, powering features like Generative Recolor, which allows users to create different color palettes using text prompts and apply them to vector graphics. This represents a significant expansion of the Firefly Vector Model’s functionality and reach within Adobe’s creative tools, moving from a single-app integration to becoming a core AI-driven feature across multiple professional-grade applications.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Adobe expanded the Firefly Vector Model from a newly‑launched feature limited to Illustrator and Adobe Express into a cross‑portfolio capability.  The model is now natively embedded in Photoshop, Illustrator, Express, Acrobat, Experience Cloud and other products, with a tiered‑access model that provides free monthly Generative Credits and a paid Firefly subscription for additional usage.  In addition, Adobe introduced enterprise‑focused Firefly Services and Custom‑Model APIs, allowing organizations to apply the vector‑generation technology at scale and with brand‑specific training while maintaining commercial‑use safety.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) It incorrectly states that the Firefly Vector Model was already integrated into Illustrator and Adobe Express in 2023, whereas the original answer specifies that in 2023 it was only in Adobe Express. The expansion to Illustrator occurred in 2024, not before. (2) The LLM claims integration into Photoshop, Acrobat, Experience Cloud, and other products, which is not supported by the original answer—only Adobe Express (2023) and Illustrator (2024) are mentioned as integrations. (3) The introduction of a tiered-access model with free Generative Credits, a paid Firefly subscription, enterprise Firefly Services, and Custom-Model APIs is not mentioned in the ground truth and represents fabricated details. (4) The original answer emphasizes a progression from Adobe Express in 2023 to Illustrator in 2024, specifically highlighting Generative Recolor as a new feature—this key evolution is missing in the LLM response. While the LLM captures the general idea of expansion across the product suite, the specific multi-hop synthesis of correct years, products, and features is flawed. The contextual relevance is moderate because the answer addresses the evolution theme and Adobe’s product suite, but the factual backbone is incorrect. Quantitative accuracy is low due to incorrect dates and unsupported product integrations. Qualitative accuracy suffers from incorrect entity relationships and invented features/services.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 415,
        "total_tokens": 1751
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the commercial significance of Biktarvy evolved for GILD from 2023 to 2024, and what implications does this have for the company's HIV business strategy?",
      "original_answer": "In 2023, Biktarvy was a major revenue driver for GILD, generating $11,850 million in total product sales globally, representing a growth from $10,390 million in 2022. By 2024, although Biktarvy remained central to GILD's HIV portfolio, the company highlighted increased risks around its reliance on HIV products, particularly those containing TAF like Biktarvy, due to potential shifts in treatment paradigms and growing generic competition. This indicates that while Biktarvy continued to be a key asset, GILD faced mounting pressure to diversify or innovate within its HIV pipeline to sustain revenue growth.",
      "llm_answer": "\nBetween 2022 and 2023 Biktarvy’s sales jumped ≈ 14 % to **$11.85 bn**, representing roughly **65 % of GILD’s $18.2 bn HIV franchise** and about **44 % of total company revenue**, underscoring its central commercial role.  The 2024 filing, however, flags intensified pricing pressure from Medicare‑Part D rebate reforms, Medicaid‑rebate caps and growing generic competition, meaning that future growth for Biktarvy will have to come from **label‑expansion, earlier‑line adoption and complementary pipeline assets rather than volume alone**, shaping a strategy that leans on lifecycle management and next‑generation HIV innovations to protect the franchise.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: $11.85 billion in 2023 sales matches the ground truth of $11,850 million. The 14% growth from $10.39 billion in 2022 is accurate (calculated as (11.85 - 10.39)/10.39 ≈ 14%). The contextual revenue percentages (65% of HIV franchise, 44% of total revenue) are not in the original answer but are plausible and do not contradict it; they add context without introducing error. (2) The 2024 risks—generic competition, pricing pressure from Medicare Part D and Medicaid rebate changes—are consistent with the original answer’s emphasis on increased risks due to treatment paradigm shifts and generics. (3) Multi-hop reasoning is sound: the model correctly infers that despite strong 2023 performance, 2024 challenges necessitate strategic shifts toward label expansion, earlier-line use, and pipeline innovation—this synthesizes the trajectory from financial performance to strategic implication. (4) The only minor gap is that the original answer specifically notes TAF-containing products as a risk category, which the LLM omits, but the broader risk context is preserved. Wording differs but semantic meaning and factual content are equivalent. No calculation or entity errors (GILD, Biktarvy, years correct). Thus, the answer is factually excellent with only slight omission of TAF-specific detail, warranting a 9/10 on correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 398,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did the status and financial structure of the Series 2018-1A Securities evolve between 2022 and 2023, particularly in terms of outstanding principal and interest rate?",
      "original_answer": "In 2022, the Series 2018-1A Securities had an aggregate principal amount of $500.0 million and an interest rate of 3.652%. By 2023, the outstanding principal had slightly decreased to $496.8 million, while the interest rate remained unchanged at 3.652%. This indicates a minor reduction in the principal amount over the year without any modification to the interest rate.",
      "llm_answer": "\nBetween 2022 and 2023 the Series 2018‑1A Securities remained part of the same securitization trust, with their outstanding carrying principal modestly rising from **$496.1 million (2022)** to **$496.8 million (2023)**.  The securities kept the **fixed coupon of 3.652 %** and the **anticipated repayment date of March 15 2028** (final legal maturity March 15 2048) unchanged; the slight increase in principal reflects routine accruals/adjustments within the trust rather than a new issuance or refinancing.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in key quantitative data. According to the ground truth, the outstanding principal in 2022 was $500.0 million, but the LLM incorrectly states it was $496.1 million. While the 2023 principal of $496.8 million matches the ground truth, the direction of change is wrong: the LLM claims a slight increase due to 'accruals/adjustments', whereas the correct trend is a decrease from $500.0M to $496.8M, indicating amortization or repayment. The interest rate (3.652%) is correctly reported. (2) Quantitative accuracy is severely compromised: the 2022 principal is off by $3.9 million, and the explanation for the change contradicts the expected behavior of a paying-down security. No calculation is required, but the comparison over time is incorrect. (3) The qualitative reasoning is partially sound—the securities are correctly identified as fixed-rate with unchanged terms—but the interpretation of the principal change is flawed. The mention of the repayment and maturity dates adds context not requested and does not compensate for the core factual error. (4) Contextual relevance is high as the answer addresses the evolution of principal and interest rate as asked, but the incorrect numbers undermine the validity. Due to major quantitative inaccuracies affecting the core of the question, the correctness score is low despite some accurate elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 393,
        "total_tokens": 1619
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did UPS's relationship with Coyote evolve from 2023 to 2024 in terms of financial impact and strategic direction?",
      "original_answer": "In 2023, UPS recorded a $111 million impairment charge related to the Coyote trade name due to declining market conditions and a strategic evaluation of the business. By 2024, this strategic evaluation culminated in the September 2024 divestiture of Coyote, which significantly impacted UPS's Supply Chain Solutions revenue, contributing to a decrease primarily driven by Coyote's exit. This marks a clear evolution from impairment and strategic review in 2023 to full divestiture in 2024.",
      "llm_answer": "\nFrom 2023 to 2024 UPS moved from treating Coyote as a core, indefinite‑lived trade name in its Supply‑Chain Solutions unit—where it recorded an $111 million goodwill/intangible‑asset impairment in late 2023 after testing for impairment and began exploring strategic alternatives—to completing a full divestiture in September 2024, which generated a $156 million gain on sale and eliminated Coyote’s revenue (down $976 million) and related expenses from the business.  The transaction reflects a strategic shift away from the Coyote brokerage platform and a focus on growing the remaining Logistics and Forwarding operations, while the 2023 impairment highlighted the unit’s weakening financial performance.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies that significantly undermine its correctness. While it correctly identifies the $111 million impairment charge in 2023 related to Coyote, it incorrectly states that this was a 'goodwill/intangible-asset impairment'—the original answer specifies it was specifically related to the Coyote trade name, not goodwill broadly. More critically, the LLM introduces a $156 million gain on sale from the September 2024 divestiture, which is not present in the ground truth and appears fabricated. Additionally, it claims Coyote’s revenue was 'down $976 million' due to the divestiture, but the original answer does not provide a specific revenue decline amount, only that Coyote's exit contributed to a decrease in Supply Chain Solutions revenue. (2) The date of the divestiture (September 2024) is correctly stated and aligns with the original answer. However, the two introduced financial figures—$156 million gain and $976 million revenue decline—are unsupported by the ground truth and represent major quantitative errors. The $111 million impairment is accurate and correctly attributed to 2023. (3) The reasoning partially captures the strategic evolution—from impairment and strategic review in 2023 to divestiture in 2024—but overreaches by implying financial outcomes (gain on sale, specific revenue drop) that are not in the source. The synthesis of strategic direction is plausible but not fully supported; the original answer does not mention a strategic shift toward Logistics and Forwarding operations. (4) The contextual relevance is high because the answer addresses both financial impact and strategic direction across 2023–2024 and focuses on the correct entities (UPS, Coyote, Supply Chain Solutions). However, the inclusion of unverified financial data severely reduces factual accuracy, warranting a low correctness and quantitative accuracy score despite some alignment in narrative structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 532,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did Linde plc's structure of Performance Share Unit Awards evolve between 2022 and 2024, particularly in terms of the performance metrics used for grants beginning in 2019?",
      "original_answer": "In 2022, Linde plc disclosed two forms of Performance Share Unit Awards under the Amended and Restated 2009 Praxair, Inc. Long Term Incentive Plan: one with Return on Capital performance metrics (Exhibit 10.11k) and another with Total Shareholder Return performance metrics (Exhibit 10.11l). By 2024, these same forms of Performance Share Unit Awards remained in place, as evidenced by Exhibits 10.10l and 10.10m, which correspond directly to the 2019 grants with the same performance metrics. This indicates that the company maintained the same dual structure for Performance Share Unit Awards tied to 2019 grants, without introducing new metrics or eliminating existing ones.",
      "llm_answer": "\nBetween 2019 and 2024 Linde’s Performance Share Unit (PSU) awards were governed first by the Amended & Restated 2009 Praxair Long‑Term Incentive Plan, which for grants beginning in 2019 introduced two distinct performance‑share designs—one tied to **Return on Capital** and another tied to **Total Shareholder Return**. When the 2021 Linde plc Long‑Term Incentive Plan replaced the older plan, it retained those same two metrics for its PSU grants, but the **January 2024 amendment** (effective January 29 2024) updated the award language and clarified the performance‑metric definitions, though the underlying metrics remained Return on Capital and Total Shareholder Return. Thus, the evolution reflects a continuity of the same performance metrics with only refinements to the award documentation and thresholds in the 2022‑2024 period.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the two performance metrics—Return on Capital and Total Shareholder Return—for Linde's Performance Share Unit (PSU) awards tied to grants beginning in 2019, which aligns with the ground truth. It also correctly notes that these metrics were maintained through 2024. However, the LLM introduces information not present in the original answer: specifically, the claim that the 2021 Linde plc Long-Term Incentive Plan replaced the Praxair plan and that a January 2024 amendment updated award language. While plausible, these details are not supported in the ground truth, which only confirms the continuity of the same PSU structures via exhibit numbers (e.g., 10.11k/l in 2022 → 10.10l/m in 2024) without discussing plan replacements or amendments. (2) Quantitatively, all dates and exhibit references in the LLM answer are either consistent with or reasonably aligned to the ground truth, though the January 29, 2024 date is not mentioned in the original and thus unverifiable. The absence of numeric calculations makes this dimension less critical, but the timeline (2019–2024) is handled accurately. (3) The multi-hop reasoning is partially sound—linking PSU structures across years and noting continuity—but overreaches by inferring plan succession and amendments not confirmed in the source. The core synthesis of metric continuity is correct. (4) Despite the addition of unsupported procedural details, the LLM captures the essential conclusion: Linde maintained the same dual PSU structure for 2019 grants through 2024. This justifies a score of 7 for correctness—core facts are right, but with minor factual overreach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 457,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the regulatory status of Trodelvy evolved between 2023 and 2024, and what does this indicate about its development trajectory?",
      "original_answer": "In 2023, Trodelvy was indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer, hormone receptor-positive/HER2-negative breast cancer, and urothelial cancer. By 2024, the FDA granted Trodelvy a Breakthrough Therapy designation for the treatment of extensive-stage small cell lung cancer in patients whose disease has progressed after platinum-based chemotherapy. This indicates a strategic expansion of Trodelvy’s development into new oncology indications with high unmet medical need.",
      "llm_answer": "\nBetween 2023 and 2024 Trodelvy shifted from a newly‑approved therapy in metastatic HR⁺/HER2⁻ breast cancer—where the FDA granted full approval and the European Commission followed suit—to receiving a Breakthrough Therapy designation from the FDA for a completely different indication, extensive‑stage small‑cell lung cancer, in 2024. This progression—from a first‑in‑class approval in breast cancer to a designated expedited‑review pathway in lung cancer—signals that Trodelvy’s development is expanding into additional oncology indications and that the company is leveraging regulatory incentives to accelerate its pipeline growth.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the key regulatory development in 2024—Breakthrough Therapy designation for extensive-stage small cell lung cancer—which aligns with the ground truth. It also accurately references Trodelvy’s approval in HR+/HER2-negative breast cancer, consistent with its 2023 indications. However, the LLM adds details not present in the ground truth, such as 'first-in-class approval' and actions by the European Commission, which are not mentioned or verifiable from the provided answer. These additions, while plausible, introduce unsupported claims. (2) There are no numerical values requiring calculation, but the years (2023, 2024) and regulatory milestones (FDA Breakthrough Therapy designation) are correctly cited. The mention of 'full approval' in 2023 for HR+/HER2-negative breast cancer is factually reasonable but not explicitly confirmed in the ground truth, which only lists indications without specifying approval type or timing nuances. (3) The multi-hop reasoning is sound: the model connects prior approvals with a new designation to infer a strategic expansion, which matches the ground truth’s conclusion about development trajectory. However, the inference is slightly overextended with unverified details (e.g., 'first-in-class', EU approval), weakening the qualitative accuracy. (4) The answer is contextually relevant and captures the core trajectory—expansion into new oncology indications via regulatory incentives. The conclusion about pipeline growth is semantically equivalent to the ground truth’s 'strategic expansion into new oncology indications with high unmet medical need.' Minor overstatement prevents a top score, but overall correctness is high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 467,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the role of the Vertex AI platform within Google Cloud evolved from 2023 to 2024, particularly in terms of its capabilities and integration with generative AI models?",
      "original_answer": "In 2023, the Vertex AI platform was described as a tool that allowed developers to train, tune, augment, and deploy applications using generative AI models and services such as Enterprise Search and Conversations. By 2024, the platform had evolved to specifically support Gemini and other leading generative AI models, offering developers the ability to train, tune, augment, test, and deploy applications with additional services like vector search, grounding, and distillation to improve model cost and quality. This reflects a shift toward more advanced and optimized generative AI integration.",
      "llm_answer": "\nFrom 2023 to 2024, Vertex AI grew from a generic generative‑AI development platform into the primary engine for Google’s Gemini family within Google Cloud. In 2024 Gemini 2.0—Google’s most capable multimodal model—is now natively available through Vertex AI, and the platform adds pre‑packaged AI agents for coding, testing, documentation and cybersecurity, while integrating tightly with Cloud infrastructure, data‑analytics and security services to enable end‑to‑end training, fine‑tuning, deployment and operation of Gemini‑powered applications.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly captures the evolution of Vertex AI from 2023 to 2024 with respect to enhanced generative AI integration, particularly around Gemini, and mentions expanded capabilities like training, tuning, and deployment. It accurately reflects the platform's growing role within Google Cloud. However, while the original answer emphasizes specific new services—vector search, grounding, and distillation—the LLM response substitutes these with 'pre-packaged AI agents for coding, testing, documentation and cybersecurity,' which are not mentioned in the ground truth and may represent speculative or inaccurate additions. Additionally, the mention of 'Gemini 2.0' and its characterization as 'Google’s most capable multimodal model' introduces specific details (version number, capabilities) not present in the original answer, potentially over-specifying beyond the source. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default. The reasoning is logically sound and contextually relevant, showing a clear understanding of the platform’s trajectory, but the substitution and addition of unverified features reduce qualitative accuracy. The core evolution—Vertex AI becoming more central to Gemini and advanced generative AI—is correctly conveyed, warranting a 7 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 374,
        "total_tokens": 1668
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the treatment and valuation of weather derivatives changed in SO's financial disclosures from 2022 to 2024, particularly in terms of the amounts considered immaterial and excluded from derivative valuations?",
      "original_answer": "In 2022, SO disclosed that the premium and intrinsic value associated with weather derivatives were immaterial for all periods presented, but did not specify exact amounts. By 2024, SO continued to exclude the premium and intrinsic value of weather derivatives as immaterial, but also provided more specific context by disclosing that cash collateral held in broker margin accounts was $17 million and $62 million at the end of 2024 and 2023, respectively. This suggests a more detailed and structured approach to derivative disclosures over time, even though the weather derivative component remained immaterial.",
      "llm_answer": "\nSouthern Company has continued the same accounting treatment for weather‑related contracts from 2022 through 2024—these instruments are carried at fair value as energy‑related derivatives and are presented in the balance‑sheet line items for “Energy‑related derivatives not designated as hedging instruments.”  The key change is that the 2024 filing makes the exclusion explicit: the reconciliation of gross to net derivative amounts (note (b)) states that “net amounts recognized in the Balance Sheets … exclude immaterial premium and intrinsic value associated with weather derivatives for all periods presented.”  Consequently, while weather derivatives are still valued at fair value, the amounts reported as assets or liabilities no longer include any premium or intrinsic value that the company deems immaterial, a clarification that was not separately highlighted in the 2022 disclosure.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Southern Company (SO) treated weather derivatives as immaterial in both 2022 and 2024, and that they were excluded from derivative valuations on that basis. It accurately notes that the 2024 filing explicitly stated the exclusion of immaterial premium and intrinsic value, which was not separately highlighted in 2022—this aligns with the ground truth’s observation of increased disclosure detail over time. However, the LLM answer omits the specific quantitative disclosures about cash collateral in broker margin accounts ($17 million at end of 2024 and $62 million at end of 2023), which are key new elements in the 2024 filing and directly relevant to the evolution of derivative-related disclosures. (2) No incorrect numbers are stated, but the absence of the $17M and $62M figures results in a partial failure to meet quantitative completeness. The years (2022, 2024) and entity (Southern Company) are correct. (3) The reasoning is sound in identifying a trend toward more explicit disclosure, but it does not fully synthesize the multi-hop aspect of how valuation treatment evolved—not just in terms of exclusion of weather derivative values, but also through the addition of collateral data that provides context around derivative arrangements. This limits the depth of the analysis. (4) The answer is contextually relevant and well-structured, with accurate terminology and proper focus on changes in disclosure practices. The correctness score is 7 because core facts about immateriality and exclusion are correct, but the omission of key numerical disclosures in 2024 reduces completeness and quantitative accuracy despite no factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 465,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the regulatory and market positioning of Biktarvy evolved between 2023 and 2024 based on GILD's disclosures?",
      "original_answer": "In 2023, Biktarvy was listed with a U.S. patent expiration year of 2033, indicating long-term market exclusivity protection in the U.S. In 2024, Biktarvy received an expanded regulatory indication from the FDA to treat people with HIV who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance. Additionally, the FDA approved an updated label with data reinforcing Biktarvy's safety and efficacy for use in pregnant people with HIV-1. This represents a shift from primarily patent protection in 2023 to expanded therapeutic application and broader patient eligibility in 2024.",
      "llm_answer": "\nBetween 2023 and 2024, Gilead’s disclosures show that Biktarvy remained under strong IP protection—its core U.S. and EU compound patents (and related extensions) are projected to expire in 2033, with U.S. regulatory exclusivity set to run through 2032 and pediatric exclusivity adding further protection.  In early 2024 the FDA granted an expanded indication for Biktarvy to treat HIV‑infected patients who have M184V/I resistance and to use the drug in pregnancy, thereby adding a new clinical claim that bolsters its premium market positioning and delays the onset of generic competition.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the key developments in Biktarvy's regulatory and market positioning between 2023 and 2024. (1) Quantitatively, all dates (2033 patent expiration, 2032 U.S. regulatory exclusivity) are correct and align with the ground truth, with acceptable elaboration (e.g., mention of EU and pediatric exclusivity not in original but not contradictory). (2) The FDA's 2024 expanded indication for M184V/I resistance and use in pregnancy is correctly reported, matching the original answer’s core claims. (3) The reasoning is sound: it contrasts continued IP protection (2023 focus) with new regulatory expansions (2024), demonstrating correct multi-hop synthesis across time and disclosures. (4) Minor deduction in qualitative accuracy because the original answer specifies that the pregnancy label update was based on safety/efficacy data, which the LLM omits, and the LLM incorrectly implies both indications were approved together as a single action. However, the overall semantic meaning and strategic implication—broadened eligibility enhancing market positioning—are preserved. Contextual relevance is perfect: the response directly addresses the evolution in regulatory and market positioning as requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 348,
        "total_tokens": 1646
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did AMT's utilization of the 2021 Multicurrency Credit Facility change between 2022 and 2023, particularly in terms of borrowing amounts and facility amendments?",
      "original_answer": "In 2022, AMT made additional net borrowings of $850.0 million under the 2021 Multicurrency Credit Facility, which were used to repay existing indebtedness and for general corporate purposes. By 2023, the company borrowed an aggregate of $3.0 billion and repaid $6.1 billion under the same facility, including a significant repayment of 842.6 million EUR ($919.1 million). Additionally, the facility underwent amendments in 2023 that extended its maturity date to July 1, 2026, maintained a total commitment of $6.0 billion, and replaced the LIBOR pricing benchmark with SOFR. This reflects a significant transformation in the usage and structure of the facility.",
      "llm_answer": "\nBetween 2022 and 2023 AMT moved from a modest net draw of roughly **$850 million** under the 2021 Multicurrency Credit Facility in 2022 (used for general corporate purposes and to repay existing debt) to a far larger gross borrowing of **$3.0 billion** in 2023, which was subsequently offset by **$6.1 billion of repayments**, leaving an outstanding balance of **$723.4 million** at year‑end 2023 (page 44 – 2022 borrowing; page 52 – 2023 borrowings/repayments and balance).  In June 2023 the facility was amended to extend its maturity to **July 1 2026**, increase the commitment levels and replace LIBOR with SOFR (page 52).",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the key changes in AMT's utilization of the 2021 Multicurrency Credit Facility between 2022 and 2023. (1) Quantitatively, it correctly states the $850 million net borrowing in 2022 and the $3.0 billion borrowed and $6.1 billion repaid in 2023. It also accurately notes the July 1, 2026 maturity extension and the replacement of LIBOR with SOFR. However, it incorrectly claims the commitment was 'increased' in the 2023 amendment, while the ground truth specifies the total commitment was 'maintained' at $6.0 billion — a significant factual discrepancy. (2) The mention of an outstanding balance of $723.4 million at year-end 2023 is not present in the original answer and appears to be an inference (possibly correct), but since it's not in the ground truth and not explicitly asked for, it doesn't add value and may reflect over-interpretation. (3) The reasoning is sound in comparing 2022 to 2023 usage and recognizing the structural changes in 2023, but the error regarding the commitment level indicates a flaw in multi-hop synthesis or source interpretation. (4) Despite this, the answer addresses both borrowing activity and facility amendments, is well-contextualized, and uses appropriate terminology. The core facts are correct, but the commitment level error prevents a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 371,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has the role of Google Ad Manager in Alphabet's advertising revenue recognition strategy evolved between 2023 and 2024, particularly in terms of its integration with revenue reporting models?",
      "original_answer": "In 2023, Google Ad Manager was directly tied to Alphabet's advertising revenue recognition on a gross basis, with the company reporting the full amount billed to customers as revenue for ads placed on Google Network properties. By 2024, the language around Google Ad Manager shifted, emphasizing a more nuanced control-based evaluation where Alphabet asserts its role as principal by controlling advertising inventory before transfer to customers, being primarily responsible to them, and having discretion over pricing. This reflects a strategic evolution from a transactional reporting model to a more control-driven justification for gross revenue recognition, reinforcing the centrality of Google Ad Manager in revenue operations.",
      "llm_answer": "\nBetween 2023 and 2024 Alphabet moved from a generic “Google Network” label to a more explicit treatment of Google Ad Manager as a distinct platform in its revenue‑recognition framework.  The 2024 filing clarifies that Ad Manager inventory is evaluated for principal‑versus‑agent status, and revenue is recorded gross when Alphabet controls the advertising inventory—consistent with the earlier gross‑basis rule—but now the gross amount is allocated to separate performance obligations (e.g., brand vs. performance ads) and variable‑consideration estimates are applied.  Consequently, Ad Manager’s proceeds are integrated more tightly into the revenue‑reporting model, with clearer segregation of gross revenue, cost‑of‑revenues to network partners, and allocations tied to the specific performance obligations delivered through Ad Manager.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) There are no numeric values in the question or original answer, so quantitative accuracy is not applicable—no errors present. (2) The LLM correctly identifies the evolution from 2023 to 2024 in how Google Ad Manager is treated in revenue recognition, noting the shift from a transactional gross-basis reporting model to a more detailed, control-based evaluation consistent with principal status. It accurately reflects that Alphabet maintains gross revenue recognition but now applies more granular accounting treatments, such as allocation to performance obligations and variable consideration estimates—details that align with a more sophisticated integration into the revenue reporting model. (3) The multi-hop reasoning is sound: the answer synthesizes changes over time (2023 vs 2024), connects Google Ad Manager to revenue recognition policy, and explains how its role evolved conceptually and operationally within Alphabet’s financial reporting framework. (4) Minor deduction in qualitative accuracy due to slightly different emphasis—the original answer highlights Alphabet's justification based on control (inventory control, responsibility, pricing discretion), which the LLM mentions implicitly via 'controls the advertising inventory' but doesn't fully enumerate. However, the core reasoning and factual content are semantically equivalent. The answer is fully contextually relevant, directly addressing the evolution of Ad Manager’s role in revenue recognition strategy and reporting integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 433,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has UPS's financial exposure and strategic positioning regarding Roadie evolved between 2023 and 2024, particularly in terms of goodwill impairment and risk assessment?",
      "original_answer": "In 2023, UPS recorded a $56 million goodwill impairment charge related to Roadie, indicating financial concerns about its value. By 2024, although no further impairment was recorded, Roadie was identified among the reporting units with limited excess of fair value over carrying value, signaling ongoing financial risk. This evolution reflects a shift from active impairment to a cautious monitoring stance due to Roadie's continued sensitivity to cost of capital and performance forecasts.",
      "llm_answer": "\nBetween 2023 and 2024 UPS moved from an outright goodwill write‑down of **$56 million** for Roadie in 2023 to **no impairment in 2024**, but the unit remains “high‑risk”: the 2024 annual test showed only a **limited excess of fair value** for Roadie (and two other units), representing about **$1.1 billion of the $4.3 billion consolidated goodwill** and flagged as especially sensitive to cost‑of‑capital and cash‑flow assumptions. Consequently, while UPS’s financial exposure to Roadie has been reduced (no new impairment charge), the company continues to monitor the reporting unit closely, noting that a further miss on forecasts could trigger future impairment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all key figures are correct: the $56 million goodwill impairment in 2023 is accurately reported; the absence of a 2024 impairment is correctly stated; and the mention of 'limited excess of fair value' for Roadie in 2024 matches the original. The additional detail about $1.1 billion of $4.3 billion consolidated goodwill is consistent with UPS's disclosures and adds context without contradicting the ground truth. (2) The entity identification (UPS, Roadie), time periods (2023 to 2024), and financial concepts (goodwill impairment, fair value vs. carrying value, sensitivity to cost of capital and cash flow) are all accurate. (3) The reasoning correctly synthesizes the evolution from active impairment to ongoing risk monitoring, capturing the multi-hop logic required: from past impairment to current risk status based on valuation sensitivity. (4) The only minor gap is that the original emphasizes a 'shift from active impairment to cautious monitoring' more explicitly, while the LLM focuses on risk sensitivity—semantically equivalent but slightly less emphasis on strategic positioning nuance. However, the core message about continued financial exposure through valuation risk is preserved. Wording differences do not affect factual correctness. All criteria for high accuracy are met, warranting a 9/10 due to slight compression of strategic context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 401,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Linde's relationship with helium evolved from 2022 to 2024, and what quantitative impact did this change have on the company's sales and operating profit?",
      "original_answer": "In 2022, helium was a supply component for Linde, indicating a positive or neutral role in operations. By 2024, helium had a negative impact on performance, with a 2% underlying sales decrease in the 'Other' segment primarily due to lower volumes in global helium and Linde Advanced Materials Technology (LAMT). Additionally, operating profit in the 'Other' segment saw increased costs related to helium, partially offset by an insurance recovery for LAMT. This reflects a shift from helium being a supply input to a source of cost pressure.",
      "llm_answer": "\nOver the 2022‑2024 period Linde’s helium business moved from a modest growth contributor to a cost‑pressured unit: helium‑related sales fell 2% in 2024, a decline of about $32 million, while the “Other” segment’s operating profit rose $19 million (44%), an increase driven largely by an insurance recovery that more than offset higher helium costs, leaving the net effect on consolidated sales essentially negligible (≈0.1% of total sales) and producing only a modest uplift in operating profit (well under 0.2% of total operating profit).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. The ground truth states that helium caused a 2% underlying sales decrease in the 'Other' segment due to lower volumes, but does not provide an absolute dollar decline of $32 million—this figure is fabricated or extrapolated without support. Similarly, the claim that operating profit in the 'Other' segment rose $19 million (44%) is not in the original answer; while the original mentions an insurance recovery partially offsetting higher helium costs, no specific dollar increase or percentage growth in operating profit is given. These unsupported numbers severely undermine factual correctness. (2) The calculation of $32 million as 2% of sales assumes a total segment size not provided in the ground truth, and there is no verification that this aligns with Linde’s actual 'Other' segment revenue. The net impact on consolidated sales (≈0.1%) and operating profit (<0.2%) are speculative additions not present in the original and cannot be verified. (3) Qualitatively, the LLM captures the directional shift—helium went from being a supply component in 2022 to a cost pressure in 2024—and correctly identifies the 'Other' segment and LAMT as relevant entities. It also notes the insurance recovery offsetting costs, which aligns with the original. However, it misrepresents the nature of the impact by implying net positive profit growth in the segment, whereas the original emphasizes increased costs (only partially offset), suggesting a drag, not a driver. (4) Contextually, the answer addresses the evolution of Linde's relationship with helium and attempts to quantify the impact on sales and profit, fulfilling the question’s intent. However, the inclusion of unsourced quantitative figures and incorrect inferences about profit growth reduce its reliability. The reasoning is partially sound but fails in precise multi-hop synthesis, especially in financial magnitude.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 528,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did the total value of loans covered under long-term credit protection agreements with FNMA and FHLMC evolve from 2023 to 2024, and what does this indicate about the Corporation's credit risk exposure on residential mortgage loans?",
      "original_answer": "In 2023, the Corporation had $8.7 billion in loans covered under credit protection agreements with FNMA and FHLMC, which decreased to $8.0 billion in 2024. This indicates a reduction in the Corporation's reliance on full credit protection for residential mortgage loans that become severely delinquent. Since these agreements provide full credit protection and the Corporation does not record an allowance for credit losses on these loans, the decline suggests a potential decrease in the volume of high-risk residential mortgage loans in their portfolio.",
      "llm_answer": "\nThe long‑term credit‑protection agreements with FNMA and FHLMC covered **$8.7 billion of loans at the end of 2023**, but that balance fell to **$8.0 billion at the end of 2024** – a reduction of about $0.7 billion (≈8 %). Because these residential‑mortgage loans are fully insured, the Corporation does **not record any allowance for credit losses** on them, so the decline signals a modest reduction in the protected loan portfolio while still leaving a sizable, but largely mitigated, credit‑risk exposure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and closely matches the ground truth. (1) Quantitatively, all numbers are correct: $8.7 billion in 2023 and $8.0 billion in 2024, with a correct difference of $0.7 billion (≈8%) noted. These match the original answer exactly, and formatting variations (e.g., $8.7 billion vs $8.7 billion) are acceptable. (2) The answer addresses both parts of the question: it describes the evolution of loan values from 2023 to 2024 and interprets the implications for credit risk exposure. (3) Entities are correctly identified: FNMA and FHLMC, the Corporation, residential mortgage loans, and the absence of allowance for credit losses are all accurately referenced. (4) The reasoning is sound: the LLM correctly infers that the decline indicates reduced volume in fully protected loans and notes the risk mitigation due to full credit protection. The only minor shortcoming is that it does not explicitly state that the reduction suggests a 'decrease in reliance on full credit protection' or a 'potential decrease in high-risk residential mortgage loans,' as in the original answer. While the implication is similar, the original answer links the decline more directly to risk profile changes. This slight omission in depth of interpretation prevents a perfect 10, but the core facts, calculations, and logic are fully correct and contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 380,
        "total_tokens": 1668
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Adobe's strategic positioning of Adobe Firefly evolved between 2023 and 2024, particularly in terms of competitive differentiation and associated regulatory risks?",
      "original_answer": "In 2023, Adobe positioned Adobe Firefly as a competitive differentiator by emphasizing its generative AI capabilities that are natively integrated into Adobe products and designed to be safe for commercial use. By 2024, Adobe continued to highlight Firefly's AI innovations but introduced new concerns around regulatory risks, particularly referencing the EU AI Act adopted in 2024, which could impose compliance costs, delay development, or require changes to AI development practices. This reflects a shift from purely competitive emphasis to a more risk-aware strategic positioning of the product.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Adobe deepened Firefly’s integration—moving it from a stand‑alone generative‑AI app into a native layer across Photoshop, Illustrator, Express and the broader Experience Cloud suite—and began coupling that technical breadth with enterprise‑level IP indemnification to stress “safe‑for‑commercial‑use” as its key competitive differentiator.  At the same time, the company highlighted the growing regulatory exposure of AI, noting that new AI‑specific rules such as the EU AI Act could impose stricter compliance, governance and liability requirements that may slow adoption or force costly redesigns.  Consequently, Firefly’s competitive edge now hinges on both its expanded AI‑enabled workflows and its ability to meet evolving regulatory standards, while the associated risk is that regulatory constraints could limit its rollout or increase compliance costs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures Adobe's strategic evolution of Firefly from 2023 to 2024: in 2023, Firefly was positioned as a competitive differentiator through native integration and commercial safety; by 2024, regulatory risks—especially from the EU AI Act—became a highlighted concern. The answer accurately reflects the shift from pure competitive emphasis to a risk-aware stance. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the LLM synthesizes Firefly’s technical integration (across Photoshop, Illustrator, etc.) with strategic positioning (IP indemnification, commercial use) and regulatory developments (EU AI Act implications), correctly linking competitive differentiation and emerging risks. (4) Minor deduction in qualitative accuracy due to slightly more detailed product integration description (e.g., naming specific apps) than in the original, which is not incorrect but adds granularity not in the ground truth—this does not affect correctness. Overall, the answer is semantically equivalent, contextually relevant, and factually sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 358,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did the financial performance and regulatory trajectory of Trodelvy evolve between 2023 and 2024?",
      "original_answer": "In 2023, Trodelvy generated total product sales of $1,063 million, reflecting a 56% increase compared to the previous year. By 2024, the regulatory landscape for Trodelvy advanced significantly with the FDA granting it a second Breakthrough Therapy designation, specifically for the treatment of adult patients with extensive-stage small cell lung cancer who have progressed after platinum-based chemotherapy. This indicates both strong financial growth and increased regulatory recognition of the drug's potential clinical impact.",
      "llm_answer": "\nBetween 2023 and 2024 Trodelvy’s top‑line performance accelerated sharply – its product sales jumped 56 % year‑over‑year to **$1.06 billion in 2023** and continued to rise in 2024 as the company added new indications and a Breakthrough‑Therapy designation for extensive‑stage small‑cell lung cancer, while its U.S. patent life (expiring **2028**) and EU exclusivity (until **2029**) remain protected by regulatory exclusivity that extends to **2032**.  This combination of expanding clinical approvals and a still‑protected IP position drove a **37 % increase in oncology sales** and helped lift overall product revenue, offsetting declines in Veklury and contributing to a modest rise in total revenues despite pricing pressures.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 56% year-over-year sales growth and $1.06 billion in product sales for Trodelvy in 2023, which aligns with the ground truth ($1,063 million ≈ $1.06 billion). However, the LLM introduces several pieces of information not present in the original answer and not supported by the provided context: specifically, the 37% increase in oncology sales, patent expiration dates (2028/2029), regulatory exclusivity until 2032, and claims about Veklury declines and pricing pressures. These additions are factually unverifiable from the ground truth and represent overreach. (2) The quantitative accuracy is partially correct: $1.06 billion is an acceptable rounding of $1,063 million, and 56% growth is accurate. However, the 37% increase in oncology sales and extended IP timelines are unsupported and likely incorrect in this context. (3) The qualitative reasoning correctly links regulatory advancement (Breakthrough Therapy designation for extensive-stage small cell lung cancer) to clinical and commercial momentum, which matches the original answer’s emphasis on increased regulatory recognition. However, the model extrapolates beyond the provided data, synthesizing additional financial and IP details that were not in the source, undermining the multi-hop integrity. (4) Contextual relevance is high—the response directly addresses both financial performance and regulatory trajectory as asked. However, the correctness score is reduced due to the inclusion of unsupported quantitative claims and peripheral details not grounded in the original answer, making the response partially accurate but misleading in scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 454,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has Chevron's financial involvement and strategic positioning in Angola LNG evolved from 2022 to 2024, based on specific disclosures regarding its equity investments and affiliate transactions?",
      "original_answer": "In 2022, Chevron reported improved income from equity affiliates, including upstream-related earnings from Angola LNG, which contributed to an overall increase in income from equity affiliates to $5,657 million. By 2024, Chevron's specific interest in Angola LNG Limited was disclosed as a 36.4% ownership stake, with Angola LNG Limited described as a key entity that processes and liquefies natural gas produced in Angola for delivery to international markets. This evolution reflects a continued strategic emphasis on LNG as part of Chevron’s broader upstream portfolio, with a clear quantification of its stake in 2024, suggesting a more defined and stable long-term positioning compared to the more general mention of earnings contribution in 2022.",
      "llm_answer": "\nChevron’s 36.4 % equity stake in Angola LNG Limited grew sharply – the investment’s carrying value rose from about **$405 million in 2022 to $1.66 billion in 2024**, and equity‑method earnings from the project surged from **$1.86 billion in 2022 to $3.38 billion in 2024** (as disclosed in the 2024 10‑K notes on investments and earnings).  This increase reflects both the higher market value of the LNG assets and Chevron’s deeper financial commitment, including financing arrangements that support the plant’s expansion, positioning Angola LNG as a key pillar of Chevron’s upstream growth strategy through 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly identifies Chevron's 36.4% ownership stake in Angola LNG Limited in 2024 (matching the ground truth), it fabricates specific financial figures not present in the original answer. The claim that the carrying value of the investment rose from $405 million in 2022 to $1.66 billion in 2024, and that equity-method earnings surged from $1.86 billion in 2022 to $3.38 billion in 2024, is unsupported by the ground truth. The original answer only states that Chevron reported improved income from equity affiliates in 2022, with total income from equity affiliates reaching $5,657 million — it does not break this down by affiliate or attribute specific dollar amounts to Angola LNG. (2) These fabricated numbers represent major quantitative errors. There is no verification of calculations because the inputs themselves are incorrect. The ground truth does not provide any carrying values or affiliate-specific earnings for Angola LNG in either year, so the LLM’s precise figures appear invented. (3) The multi-hop reasoning is partially sound in that the model attempts to connect Chevron’s strategic positioning with financial disclosures over time, and it correctly identifies Angola LNG as part of the upstream portfolio. However, it fails to accurately synthesize only what is disclosed — instead, it hallucinates granular data. The evolution described (from general mention in 2022 to specific stake in 2024) aligns with the ground truth, but the financial narrative built around it does not. (4) The correctness score is low due to major factual and quantitative errors. The qualitative accuracy is moderate because the conceptual framing and entity identification are correct. Contextual relevance is high since the response addresses the right topic, timeframe, and strategic implications, even if based on incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 518,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the value and issuance activity of META's Fixed-Rate Senior Unsecured Notes evolve from 2023 to 2024?",
      "original_answer": "In 2023, META issued $8.46 billion of net proceeds from Fixed-Rate Senior Unsecured Notes in May. By the end of 2024, the total value of these Notes had increased to $29.0 billion, up from $18.50 billion at the end of 2023, with an additional $10.50 billion issued in August 2024. This reflects both continued reliance on this form of debt financing and a significant increase in the total outstanding amount over the two-year period.",
      "llm_answer": "\nFrom the end of 2023 to the end of 2024 the balance of Meta’s fixed‑rate senior unsecured notes surged from **$18.5 billion to $29.0 billion**, an increase of roughly **$10.5 billion** that came from a new issuance in August 2024 (the August 2024 series, maturing 2029‑2064 at 4.30‑5.55% interest).  The 2024 portfolio therefore includes the older 2022‑2023 series (maturing 2027‑2063 at 3.5‑5.75% interest) plus the August 2024 notes, and interest expense on the notes rose to **$683 million in 2024** (up from $420 million in 2023).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key numbers are correct: the increase from $18.5 billion to $29.0 billion by end of 2024, the $10.5 billion issuance in August 2024, and the reference to the $8.46 billion net proceeds in May 2023 (implied in the context of prior balance). The interest expense figures ($683M in 2024 vs $420M in 2023) are factually consistent with filings and add useful context, even if not in the original answer. (2) Quantitative accuracy is perfect: the $10.5B increase matches the $29.0B - $18.5B difference, and all dates (May 2023, August 2024) are correct. Format variations (e.g., $10.5 billion) are acceptable. (3) Multi-hop reasoning is sound: the model correctly synthesizes data across years and issuances, identifying both the 2023 and 2024 activities and their impact on total debt. It adds value by including interest rate ranges and maturities, which enrich the response without contradicting the original. (4) The only minor shortcoming is that the LLM does not explicitly mention the 2023 issuance of $8.46 billion in net proceeds, though it is contextually implied by referencing the starting balance. This omission slightly affects completeness but not overall correctness. The answer remains semantically equivalent and highly relevant, with excellent contextual detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 376,
        "total_tokens": 1609
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did LIN's financial exposure to helium as a raw material change from 2023, when it was categorized as a supply, to 2024, when it became a dependency, based on specific cost or sourcing disclosures?",
      "original_answer": "In 2023, LIN categorized helium as a supply, indicating it was a standard input with manageable sourcing dynamics, and reported helium costs at 4.2% of total raw material expenses. By 2024, the relationship shifted to 'depends_on,' signaling increased strategic importance, and helium costs rose to 6.8% of raw material expenses, reflecting a more critical role in operations and a corresponding increase in cost exposure.",
      "llm_answer": "\nThe only quantitative reference to helium in the excerpts is the “Raw materials and supplies” line, which was $614 million at the end of 2023 and fell to $529 million at the end of 2024 (page 62). Neither the 2023 nor the 2024 filing includes a separate disclosure that re‑classifies helium from a generic supply to a “dependency,” nor does either period contain specific cost‑or‑sourcing language beyond this aggregate inventory figure. Thus, based on the provided pages, there is no explicit evidence of a change in financial exposure or a new dependency classification for helium.",
      "correctness_score": 1,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and fails to align with the ground truth. (1) It claims there is no evidence of helium being reclassified or of specific cost disclosures, but the original answer states that helium was explicitly categorized as a 'supply' in 2023 and shifted to 'depends_on' in 2024—this reclassification is central to the question. (2) The LLM incorrectly focuses on aggregate raw materials inventory ($614M to $529M) as the only quantitative data, while the ground truth provides specific percentages: helium costs were 4.2% of total raw material expenses in 2023 and rose to 6.8% in 2024. These percentages represent critical cost exposure metrics that the LLM failed to report or acknowledge. (3) The multi-hop reasoning required—linking the change in relationship label (supply → depends_on) with the increase in cost percentage to infer heightened financial exposure—was entirely missed. Instead, the LLM concluded no change occurred due to lack of 'explicit' evidence, contradicting the structured knowledge graph data. (4) The response is contextually relevant in that it attempts to address helium's financial exposure using disclosed figures, but it lacks the necessary depth and access to the correct disclosures, resulting in a factually incorrect conclusion. The model appears to have based its answer on incomplete or incorrect excerpts, leading to a severe factual deficit.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 389,
        "total_tokens": 1654
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did PayPal's utilization of European customer balances for credit activities evolve between 2022 and 2023, and what was the percentage change in the amount approved for such activities?",
      "original_answer": "In 2022, PayPal had $3.8 billion approved to fund credit activities, representing approximately 37% of European customer balances available for corporate use. In 2023, the approved amount decreased to $3.0 billion, representing approximately 39% of European customer balances. This indicates a reduction in the absolute amount approved for credit activities, even though the percentage slightly increased, signaling a more conservative approach to utilizing customer balances for credit funding.",
      "llm_answer": "\nBetween the end of 2022 and the end of 2023 the pool of European customer balances that PayPal could designate for credit activities was reduced from **$3.8 billion** (approved as of 31 Dec 2022) to **$3.0 billion** (approved as of 31 Dec 2023).  This is a **decline of about 21 %** (≈$0.8 billion) in the amount approved for such credit activities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the key numbers: $3.8 billion approved as of 31 Dec 2022 and $3.0 billion as of 31 Dec 2023, matching the ground truth. The calculated percentage change of approximately 21% (from $3.8B to $3.0B, a $0.8B decrease) is accurate: (0.8 / 3.8) ≈ 21.05%, so 'about 21%' is correct. (2) All numeric values and dates are factually accurate. The calculation of the percentage decline is correct and clearly explained. (3) The LLM captures the evolution in the absolute amount approved but omits the contextual nuance about the percentage of European customer balances increasing from 37% to 39%, which is part of the multi-hop reasoning in the original answer. This omission slightly weakens the qualitative analysis, as it misses the implication that despite a higher proportion of balances being used, the total approved amount decreased—indicating a more conservative approach. (4) Despite this omission, the LLM fully addresses the core question about the evolution and percentage change in approved amounts. The answer is factually sound, well-structured, and semantically aligned with the ground truth on the primary metrics. The missing detail reduces qualitative accuracy slightly but does not undermine correctness. Hence, high scores across all categories with a 9 on correctness due to partial omission of interpretive context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 382,
        "total_tokens": 1604
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did Starbucks' exposure to foreign currency - other instruments evolve between 2023 and 2024, particularly in terms of their fair value and the expected reclassification impact on earnings?",
      "original_answer": "In 2023, Starbucks reported a fair value of $1,164 million for foreign currency - other instruments, with a net gain of $39.6 million included in AOCI. By 2024, the fair value decreased to $920 million, and the net gain included in AOCI dropped to $11.5 million. Additionally, the amount expected to be reclassified from AOCI into earnings within 12 months declined from $55.3 million in 2023 to $9.5 million in 2024, indicating a reduced short-term earnings impact from these instruments.",
      "llm_answer": "\nBetween fiscal 2023 (ended Oct 1 2023) and fiscal 2024 (ended Sep 29 2024) the fair‑value of Starbucks’ foreign‑currency “other” derivatives contracted markedly – derivative assets fell from $32 million (current) and $22.9 million (long‑term) in 2023 to $1.9 million (current) and $1.7 million (long‑term) in 2024, while related liabilities rose from $2 million to $4.7 million (accrued) and from $0 to $4.1 million (long‑term).  Consequently, the amount of gains remaining in AOCI that is expected to be re‑classified into earnings over the next 12 months dropped sharply from $39.6 million in 2023 to $9.5 million in 2024, and the realized re‑classification impact on earnings moved from a $3.6 million loss in 2023 to a modest $0.1 million gain in 2024.  (See SBUX_10K_2023 pp. 69‑73 and SBUX_10K_2024 pp. 68‑73.)",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant quantitative inaccuracies despite addressing the correct topic and timeframe. (1) The fair value of foreign currency - other instruments is incorrectly reported: the ground truth states $1,164 million in 2023 and $920 million in 2024, but the LLM breaks down derivative assets and liabilities into much smaller figures (e.g., $32M, $22.9M), which do not sum to the correct total and misrepresent the scale. (2) The AOCI net gain included in equity is stated as $39.6M in 2023 and $11.5M in 2024 in the ground truth, but the LLM incorrectly uses $39.6M as the expected reclassification amount (confusing total AOCI gain with reclassification expectation). (3) The expected reclassification into earnings within 12 months is correctly reported as dropping from $55.3M to $9.5M in the ground truth, but the LLM states it dropped from $39.6M to $9.5M — the 2023 figure is wrong. (4) The LLM introduces additional details not in the original (e.g., realized reclassification impact: $3.6M loss to $0.1M gain), which are potentially derived but conflict with the known truth and are not supported by the provided ground truth. (5) While the LLM attempts multi-hop reasoning and cites correct documents, it fails to accurately synthesize the key metrics — particularly conflating AOCI gains with reclassification expectations and misreporting the fair value. (6) The answer is contextually relevant and structured well, but core financial facts are incorrect, undermining reliability. Minor formatting variations are acceptable, but magnitude and calculation errors are severe.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 437,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the fair value of energy-related derivatives held by Alabama Power and Georgia Power evolve from 2022 to 2023, and what was the directional change in their asset versus liability positions?",
      "original_answer": "In 2022, Alabama Power reported energy-related derivatives with a fair value of $55 million in assets and $11 million in liabilities, while Georgia Power reported $75 million in assets and $8 million in liabilities. By 2023, Alabama Power's energy-related derivatives decreased to $15 million in assets but increased significantly to $110 million in liabilities. Similarly, Georgia Power's derivatives were valued at $13 million in assets and $124 million in liabilities in 2023. This indicates a substantial shift toward liability exposure for both entities over the period.",
      "llm_answer": "\nThe fair‑value of Alabama Power’s energy‑related derivatives grew from roughly $15 million (recorded as an asset) in 2022 to about $55 million (also an asset) in 2023, with no liability recorded in either year – a clear strengthening of its asset position.  \nFor Georgia Power, the same line item rose from a $13 million asset and a $124 million liability in 2022 to a $358 million asset and a $358 million liability in 2023, so both its asset and liability exposures expanded, with the liability growing much more sharply.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains almost entirely incorrect information. It reverses the values for Alabama Power, claiming assets grew from $15M in 2022 to $55M in 2023, when in fact assets decreased from $55M to $15M. It also claims no liabilities were recorded, but Alabama Power's liabilities increased from $11M to $110M. For Georgia Power, the LLM incorrectly states that in 2022 it had a $13M asset and $124M liability, when the truth is $75M asset and $8M liability. The 2023 figures for Georgia Power are also wrong: LLM reports $358M in both assets and liabilities, but the correct values are $13M in assets and $124M in liabilities. (2) All numeric values are incorrect or swapped across years and entities. Calculations and directional changes are therefore also wrong. The LLM suggests asset growth for both companies when in reality both saw sharp declines in asset values and large increases in liabilities. (3) The multi-hop reasoning failed completely: the model did not correctly identify or synthesize data across the two companies and two years. It misrepresented trends and magnitudes. (4) The contextual relevance is low but not zero because the answer attempts to address the evolution of fair value and asset vs liability positions. However, due to pervasive factual and quantitative errors, the correctness score is near the minimum.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 379,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the asset allocation strategy for the U.S. Retiree Health Care Plan evolve from 2022 to 2023, particularly in terms of the percentage distribution between fixed income securities and equity securities?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan allocated 65% to fixed income securities and cash equivalents and 35% to equity securities. By 2023, the allocation to fixed income securities increased to 80%, while equity securities decreased to 20%. This represents a shift toward a more conservative investment strategy in 2023 compared to 2022.",
      "llm_answer": "\nFrom the 2022 disclosures the U.S. Retiree Health Care Plan was invested roughly 65 % in fixed‑income securities (cash and cash equivalents) and 35 % in equity securities. By the end of 2023 the allocation had shifted to about 80 % fixed‑income and 20 % equity, moving the portfolio toward the upper end of the plan’s target fixed‑income range (65‑80 %) and away from the higher‑equity weighting it held in 2022. This re‑balancing reflects the company’s strategy to better match the plan’s asset duration with its liability profile.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the percentages for both years are accurate: 65% fixed income and 35% equity in 2022, shifting to 80% fixed income and 20% equity in 2023. These values exactly match the original answer, with acceptable formatting variations (e.g., 'about 80%' vs 'increased to 80%'). (2) The answer is complete, addressing the evolution of asset allocation between the two years and the shift in distribution between fixed income and equity securities as required by the question. (3) Entity accuracy is correct—'U.S. Retiree Health Care Plan' is properly identified, and the years 2022 and 2023 are correctly referenced. (4) The reasoning is sound and adds contextual depth by noting the shift toward the upper end of the target fixed-income range (65–80%) and the strategic rationale (matching asset duration with liability profile), which aligns with and enhances the ground truth without introducing inaccuracies. The multi-hop synthesis—comparing allocations across years and interpreting the strategic shift—is logically and factually sound. Overall, the answer is semantically equivalent and factually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1234,
        "completion_tokens": 336,
        "total_tokens": 1571
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has the regulatory approval status of Trodelvy evolved between 2022 and 2023, and what new indications were granted in 2023?",
      "original_answer": "In 2022, Trodelvy was indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies and for metastatic urothelial cancer after platinum-based chemotherapy and a PD-1/PD-L1 inhibitor. By 2023, Trodelvy received additional approvals: it was granted EC approval and FDA approval for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. This represents a significant expansion of the drug’s therapeutic applications.",
      "llm_answer": "\nBetween 2022 and 2023 Trodelvy moved from being an investigational oncology product (still only being evaluated for HR⁺/HER2⁻ breast cancer and NSCLC in 2022) to receiving regulatory approval for a new indication. In 2023 the FDA granted full approval and the European Commission granted conditional marketing authorization for **monotherapy treatment of adults with unresectable or metastatic HR⁺/HER2⁻ breast cancer who have received endocrine‑based therapy and at least two additional systemic therapies**—a new breast‑cancer label that expands Trodelvy’s approved uses beyond its earlier metastatic triple‑negative breast‑cancer indication.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies the key regulatory approvals for Trodelvy in 2023: FDA full approval and European Commission (EC) conditional marketing authorization for the treatment of unresectable or metastatic HR+/HER2- breast cancer in patients who have received endocrine-based therapy and at least two additional systemic therapies. This matches the ground truth and addresses the new indications granted in 2023. However, the LLM incorrectly characterizes Trodelvy's status in 2022 as an 'investigational oncology product' still being evaluated for HR+/HER2- breast cancer and NSCLC. This is inaccurate because, in 2022, Trodelvy already had approved indications for metastatic triple-negative breast cancer (TNBC) and metastatic urothelial cancer, as stated in the original answer. The LLM omits the urothelial cancer indication entirely and misrepresents the 2022 status, undermining the multi-hop comparison between 2022 and 2023. While the new 2023 approvals are accurately described with correct regulatory bodies (FDA and EC), patient population, and prior treatment requirements, the failure to acknowledge the existing 2022 indications—especially beyond TNBC—constitutes a significant factual omission. Quantitative accuracy is high: all dates (2022, 2023), regulatory bodies, and treatment criteria are correct. The reasoning is partially sound but flawed in the baseline characterization, affecting qualitative accuracy. Contextually, the answer is highly relevant and focused on the question’s core about evolution and new indications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 425,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Meta's disclosure regarding user perception as a risk factor evolve between 2023 and 2024, particularly in terms of the nature of risks highlighted and their potential impact on business operations?",
      "original_answer": "In 2023, Meta emphasized user perception risks related to privacy, safety, content quality, and regulatory changes, specifically noting concerns around decreased user sentiment and engagement due to data practices and content policies. In 2024, while user perception was still acknowledged, the focus shifted toward broader operational and financial risks, such as integration challenges from acquisitions, tax liabilities, and investor sentiment. The explicit mention of user perception as a direct risk factor was notably reduced in 2024, indicating a strategic shift in how Meta communicated its risk profile.",
      "llm_answer": "\nIn the 2023 10‑K (pp. 15‑17) Meta warned explicitly that “if people do not perceive our products to be useful, reliable, and trustworthy, we may be unable to attract or retain users, which would reduce engagement and advertising revenue.” The 2024 filing (pp. 33‑36) no longer isolates “user perception” as a stand‑alone risk; instead it weaves the issue into broader concerns about adverse media coverage, regulatory and legislative actions (e.g., GDPR, DMA, EU‑U.S. DPF invalidations, digital‑services taxes), and litigation that can erode brand trust and limit data‑driven advertising. Consequently, the perceived risk has shifted from a direct user‑trust warning to an indirect risk that external legal and regulatory pressures could constrain Meta’s operational flexibility and revenue‑generating capabilities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the shift in Meta's risk disclosure between 2023 and 2024: in 2023, user perception was explicitly highlighted as a standalone risk related to trust, usefulness, and reliability, with direct consequences for user retention and ad revenue. In 2024, this was no longer a distinct risk factor but was instead embedded within broader regulatory, legal, and operational risks. (2) There are no numeric values (e.g., dollar amounts, percentages, user counts) in either the question or the original answer, so quantitative accuracy is not applicable in that sense—however, the citation of page numbers (pp. 15–17 for 2023, pp. 33–36 for 2024) is consistent with typical 10-K structures and does not contradict the ground truth; these are plausible and contextually appropriate. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly infers a strategic shift in risk communication, and connects indirect risks (regulatory actions, litigation, media coverage) to impacts on brand trust and advertising—a nuanced but valid interpretation. (4) The LLM uses different but semantically equivalent phrasing (e.g., 'weaves the issue into broader concerns' vs. 'focus shifted toward broader operational and financial risks') and accurately captures the reduced emphasis on user perception. The only minor shortcoming is that it does not explicitly mention 'acquisitions' or 'investor sentiment' as part of the 2024 risk focus, which are noted in the original answer—hence a slight deduction in qualitative accuracy. Overall, the response is factually correct, contextually precise, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 472,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How has the notional amount of Lockheed Martin's variable interest rate swaps evolved from 2021 to 2024, and what does this indicate about the company's interest rate risk management strategy?",
      "original_answer": "In 2021, the notional amount of Lockheed Martin's variable interest rate swaps was $500 million, while by 2024, it had increased to $1.3 billion. This indicates a significant shift in the company's interest rate risk management strategy, with a growing emphasis on converting fixed-rate borrowings to variable-rate borrowings, likely in response to changes in the interest rate environment and the company's borrowing profile over the period.",
      "llm_answer": "\nThe notional amount of Lockheed Martin’s outstanding variable‑rate interest‑rate swaps grew from roughly **$0.5 billion at the end of 2021** (as reported in the 2022 10‑K) to about **$1.3 billion at the end of 2024** (as disclosed in the 2024 10‑K).  This more than doubling shows that the company has expanded and intensified its use of interest‑rate swaps to hedge exposure to rising rates, reflecting a proactive and broader‑based interest‑rate risk‑management strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the notional amounts for Lockheed Martin's variable interest rate swaps in 2021 ($0.5 billion) and 2024 ($1.3 billion), matching the ground truth exactly in value (with acceptable format variation: $0.5 billion = $500 million). The statement that the amount 'more than doubled' is accurate (from $0.5B to $1.3B is a 160% increase). 2) Quantitatively, all numbers and comparisons are correct. The use of 'roughly' and 'about' is reasonable given typical reporting conventions and does not detract from accuracy. 3) The reasoning correctly infers that the increase reflects an intensified hedging strategy, which aligns with the ground truth's interpretation of a strategic shift in interest rate risk management. However, the LLM slightly reframes the strategy as hedging 'exposure to rising rates' and converting to variable-rate borrowings—while related, the emphasis differs subtly: the ground truth specifies the company is converting *fixed-rate borrowings to variable-rate*, which is a more precise characterization of the economic intent behind pay-fixed/receive-variable swaps. The LLM's interpretation is plausible but less precise in directional logic. 4) The answer is fully contextually relevant, addresses both parts of the question (evolution of notional amount and strategic implication), and synthesizes information across years correctly. The minor deduction in qualitative accuracy reflects the slightly less precise characterization of the hedging objective, but overall the answer is factually sound and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 430,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did PayPal's approach to its Seller Protection Programs evolve between 2022 and 2023, particularly in terms of financial provisions for transaction losses?",
      "original_answer": "In 2022, PayPal acknowledged the risk of losses from its Seller Protection Programs and noted that historical loss rates ranged between 0.09% and 0.15% of TPV, with the potential for increased losses due to macroeconomic conditions such as the ongoing impacts of the COVID-19 pandemic. By 2023, PayPal provided more structured financial disclosures, showing that the allowance for transaction losses was $64 million (down from $66 million in 2022), indicating a slight decrease in expected losses. This shift reflects a more defined and quantified approach to managing seller protection risk in 2023 compared to the more qualitative risk assessment in 2022.",
      "llm_answer": "\nBetween 2022 and 2023 PayPal continued to treat its Seller‑Protection Programs as assurance‑type warranties and to record the estimated cost of those protections as part of transaction and credit losses.  The company modestly raised the overall allowance for transaction losses (from $278 million to $282 million) and increased the provision for expected losses (from $1.170 billion to $1.192 billion), while the specific reserve for transaction losses slipped only slightly from $66 million to $64 million—indicating a refined, slightly more conservative estimate rather than a fundamental change in the program.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. While it correctly notes that the specific reserve for transaction losses decreased from $66 million in 2022 to $64 million in 2023—matching the ground truth—the additional figures about the 'overall allowance for transaction losses' increasing from $278 million to $282 million and the 'provision for expected losses' rising from $1.170 billion to $1.192 billion are not present in the original answer and contradict the ground truth, which makes no mention of such figures or trends. These numbers appear fabricated or misattributed, severely undermining factual correctness. (2) The ground truth emphasizes a shift from qualitative risk disclosure in 2022 (mentioning historical loss rates of 0.09%–0.15% of TPV and macroeconomic risks) to a more structured, quantified approach in 2023 with explicit allowance figures. The LLM answer fails to mention the 0.09%–0.15% TPV loss rate range or the macroeconomic context (e.g., COVID-19 impacts) from 2022, omitting key qualitative elements. Instead, it introduces unsupported claims about increasing overall allowances and provisions, which misrepresents the trend. (3) The multi-hop reasoning is flawed: while the model attempts to compare 2022 and 2023 disclosures, it synthesizes incorrect financial data and misses the core evolution described in the ground truth—i.e., a shift from qualitative risk discussion to specific, disclosed allowances. The mention of 'assurance-type warranties' and cost recording as part of transaction losses adds technical accounting context not present in the ground truth and may be contextually accurate in a broader sense, but it distracts from the specific evolution asked about. (4) The contextual relevance is moderate because the answer addresses the general topic of PayPal’s Seller Protection Programs and financial provisioning over time, but the inclusion of false quantitative data and omission of key qualitative disclosures from 2022 result in a largely incorrect portrayal. The correctness score is low due to major factual errors in numbers and incomplete synthesis of the actual evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 597,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Starbucks' derivative asset and liability positions in foreign currency - other change from fiscal year 2023 to fiscal year 2024, and what was the magnitude of this change on the balance sheet?",
      "original_answer": "In fiscal year 2023, Starbucks reported a derivative asset of $1,164 million under 'Foreign currency - other.' By fiscal year 2024, this amount significantly decreased to $1.9 million in derivative assets under the same category. Additionally, the derivative liability for 'Foreign currency - other' increased from $2.0 million in 2023 to $4.7 million in 2024. This indicates a major reduction in the company's foreign currency derivative assets and a moderate increase in liabilities tied to foreign currency over this period.",
      "llm_answer": "\nStarbucks’ “foreign‑currency – other” derivative **asset** fell sharply – from about **$62 million** ( $32.0 + $22.9 + $7.5 ) on the FY 2023 balance sheet to roughly **$5 million** ( $1.9 + $1.7 + $1.8 ) on the FY 2024 balance sheet, a decline of **≈ $57 million**.  \n\nAt the same time the **derivative liability** for the same category rose from roughly **$4 million** ( $2.0 + $0.5 + $1.8 ) to about **$11 million** ( $4.7 + $4.1 + $2.5 + $0.1 ), an increase of **≈ $7 million**.  \n\nThe net result is a swing of roughly **$64 million** from a net derivative asset position in FY 2023 to a net derivative liability position in FY 2024 on the consolidated balance sheet.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both asset and liability values for Starbucks' 'foreign currency - other' derivatives. According to the ground truth, the derivative asset decreased from $1,164 million in FY2023 to $1.9 million in FY2024, a massive drop of approximately $1,162.1 million. However, the LLM incorrectly reports the FY2023 asset as only $62 million (summing $32.0 + $22.9 + $7.5), which is not supported by the original answer or known data. Similarly, the FY2024 asset is stated as $5 million based on an erroneous sum of $1.9 + $1.7 + $1.8, while the ground truth reports only $1.9 million as the total asset. (2) For liabilities, the ground truth states an increase from $2.0 million in FY2023 to $4.7 million in FY2024. The LLM instead reports $4 million in FY2023 (summing $2.0 + $0.5 + $1.8) and $11 million in FY2024 (summing $4.7 + $4.1 + $2.5 + $0.1), introducing components not present in the original answer. These sums appear to conflate subcategories or unrelated line items not mentioned in the ground truth. (3) The multi-hop reasoning is flawed because the model fabricates component values and performs incorrect aggregations across unspecified derivative sub-types, failing to reflect the singular 'Foreign currency - other' category as reported. There is no evidence in the ground truth that these derivative positions are composed of multiple line items being summed. (4) While the LLM attempts to address the change in asset and liability positions and calculates net impact (a relevant approach), the core numbers are entirely incorrect, undermining the conclusion. The contextual relevance is moderate because the structure and intent align with the question, but factual correctness is severely compromised. Thus, the correctness score is low due to major quantitative errors, despite appropriate framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 510,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the financial impact of energy-related derivatives on natural gas cost and revenue hedging positions evolve from 2022 to 2023?",
      "original_answer": "In 2022, energy-related derivatives had a negative impact of $117 million on natural gas revenues and a $27 million negative impact on the cost of natural gas. In 2023, the impact shifted positively with a $59 million gain on the cost of natural gas, while the revenue impact remained neutral at $0. This indicates a transformation in the role and effectiveness of these derivatives in managing natural gas exposure.",
      "llm_answer": "\nIn 2022 the Registrants posted a $37 million gain (Southern Company) and modest positive impacts elsewhere from energy‑related cash‑flow hedges that offset natural‑gas cost and revenue, but in 2023 those gains flipped to a $44 million loss for Southern Company (and comparable negative swings for Alabama Power, Southern Power and Southern Company Gas), indicating a sharp deterioration of the hedging position from 2022 to 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both quantitative and qualitative aspects. (1) Quantitative Accuracy: The numbers provided do not match the ground truth. The original answer states a $117 million negative impact on natural gas revenues and $27 million negative impact on cost in 2022, whereas the LLM claims a $37 million gain for Southern Company and 'modest positive impacts elsewhere'—which contradicts the ground truth of significant losses. In 2023, the original answer reports a $59 million gain on cost and $0 impact on revenue, but the LLM reports a $44 million loss for Southern Company and negative swings across subsidiaries—again contradicting the positive shift in cost hedging. None of the figures align, and no mention is made of the neutral revenue impact in 2023. (2) Completeness: The LLM fails to capture the full scope of the financial impact across revenue and cost for both years as required by the multi-part question. It focuses narrowly on Southern Company and its subsidiaries rather than the broader financial impact described in the original answer. (3) Entity Accuracy: The LLM introduces specific entities (Southern Company, Alabama Power, etc.) not mentioned in the original answer, which presents aggregated or generalized impacts without attributing them to specific registrants. This misrepresents the source of the data. (4) Reasoning: The multi-hop synthesis is flawed—the LLM incorrectly infers a 'deterioration' in hedging positions, while the ground truth shows a clear improvement in cost hedging (from -$27M to +$59M) and stabilization in revenue (from -$117M to $0). The conclusion is therefore the opposite of what the data supports. (5) Semantic Equivalence: The overall message is not equivalent—the original describes a transformation toward more effective hedging, while the LLM describes a deterioration. Despite addressing the general topic of hedging impacts over time, the factual inaccuracies severely undermine correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1208,
        "completion_tokens": 531,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Walmart's treatment of its Deferred Compensation Matching Plan evolve between the 2023 and 2024 10-K filings, particularly in terms of its documentation status and effective date?",
      "original_answer": "In the 2023 10-K filing, the Deferred Compensation Matching Plan was newly introduced as 'Walmart Inc. Deferred Compensation Matching Plan, as amended and restated effective November 8, 2023.' By the 2024 10-K filing, the plan was no longer labeled as newly introduced but was instead referenced as being 'incorporated by reference' to the 2024 Annual Report on Form 10-K, indicating that it had become an established, ongoing plan. The effective date remained unchanged at November 8, 2023, suggesting no substantive changes to the plan’s implementation timeline, but its treatment shifted from being newly introduced to being formally integrated into the company's long-term compensation framework.",
      "llm_answer": "\nIn the 2023 Form 10‑K the Deferred Compensation Matching Plan was not presented as a separate, formally‑documented exhibit—it was only mentioned in passing in the narrative disclosures. By contrast, the 2024 filing lists the plan as **Exhibit 10.1** and explicitly states that it is “**amended and restated effective November 8, 2023**,” thereby formally documenting the plan and fixing its effective date for the first time. This marks a shift from an informal reference to a fully disclosed, dated amendment.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) It incorrectly states that the Deferred Compensation Matching Plan was 'not presented as a separate, formally-documented exhibit' and only 'mentioned in passing' in the 2023 10-K. However, the ground truth indicates that the plan was explicitly introduced in the 2023 filing as 'Walmart Inc. Deferred Compensation Matching Plan, as amended and restated effective November 8, 2023,' which contradicts the claim of informal or passing mention. (2) The LLM claims the plan was 'formally documented' for the first time in the 2024 filing as Exhibit 10.1, implying the effective date was 'fixed for the first time' then. This is incorrect—the effective date of November 8, 2023, was already established in the 2023 filing, not newly set in 2024. (3) The ground truth emphasizes that the plan transitioned from being 'newly introduced' in 2023 to being 'incorporated by reference' in 2024, indicating institutionalization, not first-time documentation. The LLM misrepresents the nature and timing of the plan's formalization. (4) While the effective date (November 8, 2023) is correctly cited, the reasoning around documentation status is fundamentally flawed, failing the multi-hop synthesis required to compare treatment across years. The answer misinterprets the evolution, reversing the timeline of formalization. Quantitative accuracy is partially preserved due to correct date mention, but qualitative and contextual reasoning is poor, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 427,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has the disclosure and treatment of LTIP Units evolved between 2023 and 2024, particularly in terms of their dilutive effect and accrual policy?",
      "original_answer": "In 2023, LTIP Units were described as potentially dilutive securities that are convertible into units and exchangeable for common stock, with no material dilutive effect reported for the years 2023, 2022, and 2021. The company stated it does not adjust net income attributable to common stockholders or weighted average shares outstanding due to no dilutive impact. In 2024, the disclosure simplified, stating that LTIP Units are potentially dilutive but again noting no material dilutive effect for the years 2024, 2023, and 2022. Additionally, the accrual policy remained consistent, stating that distributions are accrued when declared. The treatment of LTIP Units remained stable with no significant change in dilutive impact or accrual policy.",
      "llm_answer": "\nBetween 2023 and 2024 the company’s disclosure of LTIP Units was unchanged: they are still presented in the “potentially dilutive securities” column of the earnings‑per‑share/unit tables, and the filings explicitly note that LTIP Units had **no material dilutive effect** for either year, so no adjustment to net income or weighted‑average shares/units is made.  The accrual policy for dividends on those units also remains the same—dividends are accrued only when declared, with no separate treatment or impact on earnings per unit.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the original answer. (1) It correctly states that LTIP Units are treated as potentially dilutive securities with no material dilutive effect in both 2023 and 2024, and that no adjustments are made to net income or weighted-average shares due to this lack of dilutive impact—matching the ground truth. (2) The accrual policy is accurately described: distributions (or dividends) are accrued only when declared, which aligns with the original answer’s statement. (3) The multi-hop reasoning is sound—information is synthesized across two years (2023 and 2024) and two dimensions (dilutive effect and accrual policy), with correct comparison showing consistency over time. (4) All entities (LTIP Units, dilutive effect, accrual policy) and time periods (2023, 2024) are correctly referenced. Minor wording differences (e.g., 'dividends' vs 'distributions') do not affect meaning, as both refer to the same accrual treatment. No factual errors, omissions, or misinterpretations are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 300,
        "total_tokens": 1621
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Meta's compliance approach to the EU-U.S. Data Privacy Framework (EU-U.S. DPF) evolved between 2023 and 2024, particularly in response to regulatory actions and decisions?",
      "original_answer": "In 2023, Meta was in the process of implementing steps to comply with corrective orders from the Irish Data Protection Commission (IDPC) following a EUR €1.2 billion fine and a directive to suspend unlawful data transfers to the U.S. under Standard Contractual Clauses (SCCs). At that time, the EU-U.S. DPF had just been finalized, and Meta viewed its implementation as a key milestone to address data transfer compliance. By 2024, Meta had implemented compliance measures with the corrective orders and was actively engaging with regulators on new compliance models, such as the 'subscription for no ads' alternative introduced in November 2023. In 2024, the European Commission opened formal proceedings into the compliance of this model with the Digital Markets Act (DMA), issuing preliminary findings in July 2024 that suggested non-compliance. This reflects a shift from foundational compliance with the EU-U.S. DPF framework to navigating more complex regulatory scrutiny around specific business models under evolving EU laws.",
      "llm_answer": "\nBetween 2023 and 2024 Meta moved from defending its reliance on Standard Contractual Clauses—culminating in the Irish Data Protection Commission’s €1.2 billion fine and corrective orders (which it is appealing and which are currently on interim stay)—to fully embracing the newly‑adopted EU‑U.S. Data Privacy Framework. After the European Commission’s July 2023 adequacy decision, the company engaged with the IDPC, implemented concrete steps to bring its trans‑Atlantic data‑flows into compliance with the DPF, and adjusted its product‑level practices (e.g., the “subscription‑for‑no‑ads” model and consent‑based legal bases) to satisfy GDPR, the DMA and DSA requirements. This evolution reflects a shift from reactive litigation over SCCs to a proactive compliance program built around the DPF and related regulatory obligations.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in Meta's compliance approach between 2023 and 2024. It accurately references the €1.2 billion fine by the Irish Data Protection Commission (IDPC), the shift from reliance on Standard Contractual Clauses (SCCs) to the EU-U.S. Data Privacy Framework (DPF), and the July 2023 adequacy decision. The mention of Meta's implementation of compliance steps and adjustments to product-level practices like the 'subscription-for-no-ads' model aligns with the ground truth. However, the LLM omits key details about the European Commission opening formal proceedings in 2024 into the DMA compliance of the subscription model and the July 2024 preliminary findings of non-compliance, which are central to the 2024 regulatory evolution. While it correctly notes Meta’s shift to a proactive compliance posture, it does not fully convey the ongoing regulatory scrutiny in 2024 that challenges the adequacy of these new models. The quantitative accuracy is high: the €1.2 billion fine and July 2023 adequacy decision date are correct. The reasoning is sound in tracing a shift from reactive to proactive compliance, but it falls short in synthesizing the multi-hop element that the 2024 phase involves not just implementation but new regulatory pushback under the DMA. The answer remains contextually relevant and semantically close to the original, warranting a high score with minor deductions for incompleteness on 2024 developments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1474,
        "completion_tokens": 407,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Linde's approach to green hydrogen production evolved between 2023 and 2024, particularly in terms of production methods and emphasis on renewable energy sources?",
      "original_answer": "In 2023, Linde described green hydrogen as being produced primarily through electrolysis using renewable energy or from steam methane reforming of biomethane, and it was presented as one of the company's clean energy offerings alongside blue hydrogen. By 2024, the company had expanded its description to emphasize green hydrogen as 'renewable hydrogen' produced by electrolysis using renewable energy and water as feedstock, and it was clearly differentiated from low-carbon (blue) hydrogen. Additionally, in 2024, Linde placed more emphasis on the carbon intensity metric to differentiate production methods, indicating a more refined and strategic framing of green hydrogen within the broader context of clean energy solutions.",
      "llm_answer": "\nBetween 2023 and 2024 Linde’s wording on green hydrogen shifted from a broad reference to “hydrogen produced by electrolysis using renewable energy (or from SMR of biomethane)” to a clear emphasis on **renewable‑electricity‑driven electrolysis** and the use of a **carbon‑intensity label** to distinguish “green” hydrogen from “blue” or “low‑carbon” hydrogen. The 2024 filing expands the portfolio of clean‑hydrogen technologies, describing green hydrogen as a core element of its strategy and underscoring that it is produced from renewable energy sources, while also highlighting new low‑carbon production pathways and the role of engineering solutions that capture and utilize CO₂. This reflects a stronger, more detailed focus on renewable‑energy‑based production methods in Linde’s green‑hydrogen approach.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution in Linde's approach: in 2023, green hydrogen was described using both electrolysis with renewable energy and steam methane reforming (SMR) of biomethane; by 2024, the focus shifted to renewable-electricity-driven electrolysis, with clearer differentiation from blue hydrogen. The emphasis on carbon intensity as a distinguishing metric in 2024 is accurately noted. (2) There are no numerical values to verify, so quantitative accuracy is not applicable in a traditional sense, but all dates (2023, 2024) and technical terms (electrolysis, SMR, renewable energy, carbon intensity) are used correctly. (3) The multi-hop reasoning is sound—LLM synthesizes changes in terminology, production methods, and strategic framing across two years. It correctly infers a more refined and strategic positioning of green hydrogen in 2024. (4) The only minor shortcoming is that the LLM answer mentions 'new low-carbon production pathways' and 'engineering solutions that capture and utilize CO₂'—while consistent with Linde’s broader clean energy strategy, this detail slightly extends beyond the scope of the original answer, which focused specifically on the redefinition and sharpened framing of green hydrogen. However, this does not introduce factual error, only slight expansion. Overall, the answer is factually correct, contextually relevant, and semantically equivalent to the ground truth with excellent qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 421,
        "total_tokens": 1812
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did Southern Company's relationship with Sequent evolve between 2022 and 2023, and what were the financial implications of this change?",
      "original_answer": "Southern Company's relationship with Sequent evolved from a business ownership relationship in 2022 to a completed divestiture in 2023. In 2022, Southern Company Gas completed the sale of Sequent to Williams Field Services Group for $159 million, recognizing a pre-tax gain of $121 million. Additionally, the sale resulted in $85 million of additional tax expense due to changes in state apportionment rates. By 2023, Sequent was no longer part of Southern Company's portfolio, and the financial impact of the sale was fully reflected in the company's financial statements, with the gain from the sale reported as a $121 million pre-tax benefit. This marked a complete transformation in the relationship, shifting from operational integration to full separation.",
      "llm_answer": "\nSouthern Company completed the sale of Sequent in July 2021 and, by 2022, the business was fully divested, so in 2023 there were no ongoing operations with Sequent. The 2023 financial statements reflect only the residual effects of that transaction—a $85 million additional tax expense from state‑apportionment changes and an $84 million pre‑tax impairment charge on the PennEast pipeline investment—both of which reduced 2023 earnings, whereas the 2021 sale had generated a $92 million after‑tax gain.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple critical factual errors. It incorrectly states that the sale of Sequent occurred in July 2021, while the ground truth confirms the sale was completed in 2022. This misalignment in timing undermines the entire narrative of the relationship evolution between 2022 and 2023. Additionally, the LLM claims a $92 million after-tax gain from the 2021 sale, which contradicts the ground truth pre-tax gain of $121 million in 2022. The $84 million pre-tax impairment charge on the PennEast pipeline is mentioned but not part of the original question or answer, introducing irrelevant information. (2) Quantitative inaccuracies include: wrong sale year (2021 vs 2022), incorrect gain amount ($92M after-tax vs $121M pre-tax), and omission of the $159M sale price. The $85M tax expense is correctly mentioned but misattributed to 2023 earnings impact without context of the 2022 transaction that caused it. (3) The multi-hop reasoning fails because the model does not correctly trace the timeline or financial cause-effect: the divestiture occurred in 2022, not before, so 2022 should reflect the gain, not just residual effects in 2023. The answer incorrectly frames 2023 as the year of financial impact, while the gain was recognized in 2022. (4) Despite these errors, the answer is contextually relevant in discussing divestiture and tax implications, and it correctly notes that Sequent was no longer part of Southern Company in 2023. However, due to major factual and temporal inaccuracies, especially in key financial figures and dates, the overall correctness is very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 442,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Walmart's relationship with the Allswell brand evolved between 2023 and 2024, and what does this indicate about its strategic positioning within the company's private brand portfolio?",
      "original_answer": "In 2023, Walmart introduced the Allswell brand as part of its private brand offerings, indicating its initial entry into the market. By 2024, the brand was not only retained but explicitly listed among other mature private brands like 'bettergoods,' 'Equate,' and 'Great Value,' suggesting that Allswell has transitioned from a newly introduced brand to a more established part of Walmart's private label strategy. This evolution indicates that Allswell has likely gained traction and is being positioned as a core component of Walmart’s private brand portfolio.",
      "llm_answer": "\nWalmart’s SEC filings for fiscal 2023 and fiscal 2024 both list “Allswell” among the Company’s private‑brand portfolio (page 7 of the 2023 filing and the same list in the 2024 filing), with no disclosed change in its status or strategic treatment.  This continuity shows that Walmart is deliberately maintaining and supporting a stable of value‑focused private labels—such as Allswell—to reinforce its low‑price positioning and to grow margin within its broader private‑brand strategy.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in stating that Allswell was listed in Walmart's private-brand portfolio in both the 2023 and 2024 SEC filings, with no disclosed change in status. This aligns with the ground truth regarding the brand's continued presence. The quantitative and entity accuracy is correct—'Allswell' is properly identified, and the years (2023 and 2024) are accurate. However, the LLM answer misses a key nuance in the evolution of the brand: the original answer notes that Allswell was *introduced* in 2023 and then *retained and grouped with mature brands* in 2024, indicating a transition from new to established. The LLM interprets the continuity as stability but does not capture this developmental progression, which is central to the question about strategic positioning. While the conclusion about Walmart maintaining value-focused private labels is reasonable, it does not fully reflect the inference in the ground truth that Allswell has moved from a new initiative to a core component of the portfolio. Thus, the reasoning is sound but incomplete in its multi-hop synthesis—correctly identifying presence across years but underinterpreting the strategic implication of its repositioning among mature brands. Wording differences are acceptable, but the omission of the brand’s maturation trajectory reduces qualitative accuracy. Contextual relevance is high as the response directly addresses the question’s focus on brand evolution and strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 405,
        "total_tokens": 1678
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has the strategic importance of Embedded Processing products evolved from 2022 to 2023 based on TXN's revenue composition and strategic emphasis?",
      "original_answer": "In 2022, Embedded Processing products were described as one of two core segments, positioned alongside Analog as a key part of the business, though no specific revenue figures were disclosed. By 2023, Embedded Processing remained a strategic focus area, and notably, it partially offset a decline in Analog revenue, contributing to a $17.52 billion total revenue. This indicates that while Embedded Processing maintained its strategic importance, it also played a more pronounced compensatory role in the revenue mix during a year of overall revenue decline.",
      "llm_answer": "\nBetween 2022 and 2023 the Embedded‑Processing business grew its contribution to total sales from roughly 16 % of revenue ($3.26 bn of $20.03 bn) to about 19 % ($3.37 bn of $17.52 bn), and management continued to treat it as a core strategic pillar—highlighting its importance in the industrial and automotive end‑markets and directing capital spending to strengthen its manufacturing and technology base. This increased revenue share, coupled with the same strategic emphasis on analog and embedded‑processing products, shows that the strategic importance of Embedded Processing has risen from 2022 to 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific revenue figures and percentages not present in the original answer or ground truth. The original answer explicitly states that 'no specific revenue figures were disclosed' for Embedded Processing in 2022, yet the LLM claims 16% ($3.26B) of $20.03B in 2022 and 19% ($3.37B) of $17.52B in 2023. These numbers are unsupported by the ground truth and appear fabricated. The total revenue of $17.52B in 2023 is correct per the original answer, but the Embedded Processing segment revenue of $3.37B is not corroborated. (2) Calculations based on these figures (e.g., 16% to 19% increase in share) are therefore invalid. The $20.03B total revenue for 2022 is not mentioned in the original answer and contradicts the absence of disclosed segment-level data. (3) The qualitative reasoning about strategic emphasis is partially correct—both answers agree Embedded Processing remained a core strategic pillar and was emphasized in industrial and automotive markets. The LLM correctly identifies continued strategic focus and capital investment, which aligns with the idea of sustained importance. However, it incorrectly infers an increase in strategic importance due to rising revenue share, while the original answer frames Embedded Processing as playing a 'compensatory role' during Analog revenue decline, without asserting a rise in strategic importance—only continuity with added functional weight in revenue stabilization. (4) The contextual relevance is high because the LLM addresses revenue composition and strategic emphasis over the two years, but the quantitative inaccuracies severely undermine the correctness. The model fails the multi-hop synthesis by inventing numbers instead of acknowledging data limitations. Thus, while the direction of reasoning is relevant, the factual foundation is flawed, leading to a low correctness and quantitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 517,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has Chevron's involvement in Angola LNG evolved from 2022 to 2024, and what does this indicate about its strategic positioning in the LNG market?",
      "original_answer": "In 2022, Chevron's involvement in Angola LNG was referenced in the context of its production volumes, indicating operational participation. By 2024, Chevron's stake in Angola LNG Limited was explicitly stated as a 36.4% interest, highlighting a more defined and structured investment approach. This evolution suggests a strategic shift toward securing a stable position in the LNG market through formalized equity stakes.",
      "llm_answer": "\nFrom 2022 through 2024 Chevron’s equity stake in Angola LNG Limited stayed roughly at the 36 % level, but the recorded investment slipped modestly from about $1.76 bn (2023) to $1.66 bn (2024) while earnings from the project contributed roughly $0.5 bn to Chevron’s 2024 income.  This stability—despite a small decline in book value—shows that Chevron is treating Angola LNG as a core, long‑term source of low‑cost LNG to diversify its portfolio and meet rising global gas demand, reinforcing its strategic pivot toward expanding its LNG footprint.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Chevron's stake was not explicitly quantified in 2022 but was noted in terms of production involvement, while in 2024 it was explicitly stated as 36.4%. The LLM incorrectly claims the stake was 'roughly 36%' throughout 2022–2024, which misrepresents the evolution. Additionally, the LLM introduces specific financial figures—$1.76 bn (2023) and $1.66 bn (2024) book values and $0.5 bn earnings in 2024—that are not present in the original answer and cannot be verified from the provided ground truth. These numbers are therefore fabricated or hallucinated. (2) Quantitative accuracy is very low: while 36.4% is close to 'roughly 36%', the precise evolution from unspecified to defined stake is lost, and the introduced dollar amounts (investment values, earnings) have no basis in the ground truth and are incorrect. (3) The multi-hop reasoning is flawed. The original answer infers a strategic shift based on the increasing clarity and formalization of Chevron’s stake. The LLM instead assumes stable ownership and interprets a book value decline without any such data in the ground truth, leading to an unsupported conclusion about 'core, long-term source' based on financial metrics that weren’t provided. (4) Contextual relevance is moderate—the answer addresses Chevron’s strategic positioning in LNG and references Angola LNG across years, so the general direction is appropriate. However, due to major factual and quantitative errors, the qualitative and correctness scores are low. The answer creates a narrative unsupported by the source data, failing the core requirement of factual fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1243,
        "completion_tokens": 464,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has the financial contribution and production status of the CH-53K program evolved between 2021 and 2024, and what does this indicate about its role within Lockheed Martin's RMS division?",
      "original_answer": "In 2021, the CH-53K program contributed to a $540 million increase in RMS net sales, driven by higher production volume alongside the Black Hawk and CRH programs. Additionally, it contributed to a $140 million increase in operating profit due to higher risk retirements and production volume. By 2024, the CH-53K program was described as being in a 'production ramp-up' phase, contributing $1.1 billion to higher product sales within RMS, indicating a shift from early-stage production and risk retirement to a more mature, high-volume production phase. This evolution shows that the CH-53K has transitioned from a developing program with growing financial impact to a key growth driver within RMS.",
      "llm_answer": "\nBetween 2021 and 2024 the CH‑53K moved from early‑stage production to a clear ramp‑up phase: RMS reported that higher volume and production‑line ramp‑up on the CH‑53K added roughly $1 billion of product sales (and the corresponding rise in cost of sales) by 2024, helping lift the segment’s overall sales and margin.  This growth underscores the CH‑53K’s emergence as a strategic, high‑visibility program that now serves as a primary driver of RMS’s sales and backlog, positioning the heavy‑lift helicopter as a central growth engine within Lockheed Martin’s RMS division.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of the CH-53K program between 2021 and 2024. (1) Quantitatively, it correctly identifies the ~$1 billion contribution to product sales by 2024, aligning with the ground truth. However, it omits the specific 2021 figures: the $540 million increase in RMS net sales and $140 million increase in operating profit. While the 2024 number is correct, the absence of precise 2021 data reduces quantitative completeness. (2) The answer correctly characterizes the program’s shift to 'ramp-up' in 2024 and links it to higher volume and production-line maturity, which matches the ground truth. (3) The reasoning is sound: it infers the program’s growing strategic importance and role as a key driver within RMS, which is supported by the data. The synthesis across time (2021 to 2024) is logically presented, even if 2021 specifics are underdeveloped. (4) All entities—CH-53K, RMS, Lockheed Martin—are correct, and the answer stays fully focused on the question’s scope. The omission of exact 2021 financials prevents a perfect score, but the overall message about the program’s maturation and increasing financial impact is semantically equivalent and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 342,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did PayPal's use of macroeconomic factors in its loss curves for revolving consumer credit products evolve between 2022 and 2023?",
      "original_answer": "In 2022, PayPal applied macroeconomic factors such as forecasted trends in unemployment and benchmark credit card charge-off rates to its revolving consumer credit loss curves, using a single scenario deemed most appropriate for the economic conditions. By 2023, the company updated its expected credit loss models for revolving consumer receivables to include forecasted trends in household disposable income and retail e-commerce sales, replacing unemployment rates after the first quarter of 2023. This reflects a shift in the macroeconomic indicators used to inform loss curves for this segment.",
      "llm_answer": "\nBetween 2022 and 2023 PayPal lengthened the macro‑economic horizon used in its revolving‑credit loss curves—from a ≈ 2‑year forecast period in 2022 to roughly 5 years 7 months in 2023—and expanded the set of indicators (adding household‑disposable‑income and retail‑e‑commerce‑sales trends, whereas 2022 relied mainly on unemployment). The model was refreshed in the second quarter of 2023, but the update did not produce a material change to the credit‑loss provision.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core qualitative shift in PayPal's use of macroeconomic factors—correctly identifying the addition of household disposable income and retail e-commerce sales in 2023 and the reduced reliance on unemployment rates. It also correctly notes a model update in 2023. However, it introduces significant quantitative inaccuracies not present in the ground truth: (1) The claim that the macroeconomic forecast horizon expanded from ~2 years in 2022 to ~5 years 7 months in 2023 is not supported by the original answer, which makes no mention of forecast horizon length or any such change. This is a major factual addition with no basis in the source. (2) The statement that the model refresh in Q2 2023 did not produce a material change to the credit loss provision is also absent from the ground truth and cannot be verified from the provided information. While the original answer confirms a shift in indicators and timing (unemployment replaced after Q1 2023), the LLM incorrectly adds unsupported numerical and financial impact claims. The qualitative reasoning about evolving indicators is sound and contextually relevant, but the inclusion of unverified quantitative details reduces factual correctness. The answer is semantically aligned in direction but overreaches in specificity, particularly on timing and impact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 372,
        "total_tokens": 1636
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Starbucks' foreign currency debt-related gains or losses included in AOCI change from 2023 to 2024, and what does this indicate about the company's exposure to foreign currency fluctuations?",
      "original_answer": "In 2023, Starbucks reported a foreign currency debt-related loss of $6.3 million included in OCI before reclassifications, while in 2024, the company reported a gain of $135.2 million in AOCI related to foreign currency debt. This indicates a significant shift from a loss to a substantial gain, suggesting a reversal in the company's exposure to foreign currency fluctuations over this period.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 the foreign‑currency‑denominated debt gains recorded in AOCI slipped from **$140.2 million to $135.2 million**, a decline of roughly **$5 million**. This drop shows that the company’s net foreign‑currency hedge positions are producing fewer unrealized gains, indicating either a reduced level of foreign‑currency exposure or that recent currency movements have offset prior hedge benefits.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in its core quantitative claims. According to the ground truth, Starbucks reported a foreign currency debt-related **loss of $6.3 million in 2023** and a **gain of $135.2 million in 2024**. However, the LLM states that gains were $140.2 million in 2023 and $135.2 million in 2024, which misrepresents both the magnitude and direction of change. In reality, the company shifted from a loss to a large gain, whereas the LLM describes a decline in gains—this is factually wrong. (2) The calculation of a $5 million decline is based on incorrect input numbers and is therefore invalid. The actual change is from a $6.3 million loss to a $135.2 million gain—an improvement of $141.5 million—not a decrease. (3) The multi-hop reasoning fails because the model did not correctly retrieve or synthesize the data across years. It incorrectly assumes gains in both years, missing the critical shift from loss to gain, which undermines the qualitative interpretation. (4) The contextual relevance is moderate because the answer addresses foreign currency debt gains in AOCI and attempts to interpret exposure, but the flawed data leads to an incorrect conclusion about reduced exposure or offsetting hedges, when the truth suggests a significant reversal in currency impact. Thus, while the structure and intent are relevant, the factual foundation is unsound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1218,
        "completion_tokens": 388,
        "total_tokens": 1606
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the fair value of energy-related derivatives for Alabama Power and Georgia Power change between 2022 and 2023, and what was the overall trend in their combined liabilities related to these derivatives?",
      "original_answer": "In 2022, Alabama Power reported a net liability of $144 million related to derivatives in non-designated hedging relationships, including energy-related derivatives. In 2023, Alabama Power had $15 million in assets and $110 million in liabilities related to energy-related derivatives, resulting in a net liability of $95 million. Georgia Power had $13 million in assets and $124 million in liabilities related to energy-related derivatives in 2023, yielding a net liability of $111 million. Therefore, the combined net liability for energy-related derivatives across both entities decreased from $255 million in 2022 to $206 million in 2023, indicating a reduction in exposure.",
      "llm_answer": "\nAlabama Power’s energy‑related derivative liability grew from $32 million in 2022 to $61 million in 2023, while Georgia Power’s liability fell from $178 million to $124 million. As a result, the combined liability of the two declined from $210 million to $185 million, indicating a modest overall reduction in net liability exposure.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. According to the ground truth, Alabama Power had a net liability of $144 million in 2022, not $32 million as stated by the LLM. In 2023, Alabama Power had a net liability of $95 million (assets of $15M, liabilities of $110M), not $61 million. Georgia Power’s 2022 liability is not provided in the original answer, so the LLM’s claim of $178 million is unsupported and incorrect. The LLM incorrectly states Georgia Power’s 2022 liability, and misrepresents Alabama Power’s figures for both years. (2) Calculations are also wrong: the LLM claims combined liability was $210M in 2022 and $185M in 2023, but the correct combined net liability was $255M in 2022 (only Alabama Power reported in 2022) and $206M in 2023 (sum of both companies’ net liabilities). The LLM incorrectly assumes Georgia Power reported a liability in 2022, which is not stated in the original answer. (3) The multi-hop reasoning is flawed: the model fails to correctly identify that only Alabama Power reported a net liability in 2022, and incorrectly assigns a value to Georgia Power for that year. It also fails to compute net liabilities correctly by not accounting for assets in 2023 for Alabama Power. The synthesis across entities and years is therefore inaccurate. (4) Despite these major errors, the LLM does recognize that the trend is a reduction in combined liability, which aligns with the original answer’s conclusion, giving it partial credit for directional trend understanding. However, due to severe quantitative and qualitative inaccuracies, the correctness score is low. Contextual relevance is moderate because the answer addresses the right companies, time frame, and metric type, but with wrong data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 483,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Walmart's financial relationship with Alert Innovation evolve between fiscal 2023 and fiscal 2024, particularly in terms of acquisition and subsequent disposition activities?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, bringing its ownership to approximately 100%. However, in fiscal 2024, Walmart sold and deconsolidated the Alert Innovation entity, signaling a complete exit from the investment. This represents a full evolution from acquisition to divestiture within a one-year span.",
      "llm_answer": "\nIn fiscal 2023 Walmart closed a $0.4 billion transaction that brought its stake in Alert Innovation to 100 % ownership. The 2024 Form 10‑K does not report any additional acquisition or disposition of Alert Innovation, indicating that the company was simply held during FY 2024; the next step—selling the entity and de‑consolidating it—was disclosed only in the FY 2025 filing.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states the $0.4 billion acquisition in fiscal 2023 and Walmart achieving 100% ownership, which matches the ground truth. However, it incorrectly claims that no disposition occurred in fiscal 2024, stating that the sale was only disclosed in the FY 2025 filing. The ground truth explicitly states that Walmart sold and deconsolidated Alert Innovation in fiscal 2024, meaning the divestiture activity did occur during that period. The LLM's assertion contradicts this key fact. (2) Quantitatively, all numbers are accurate: $0.4 billion and 100% ownership are correctly reported with acceptable formatting. (3) The multi-hop reasoning fails because the model incorrectly infers that no action occurred in FY 2024 based on absence of reporting in the 10-K, but the ground truth confirms the disposition did happen in that fiscal year. This reflects a failure in synthesizing the correct timeline and events across fiscal years. (4) While the answer is relevant and begins correctly, the core error—denying the FY 2024 divestiture—undermines the factual accuracy. The answer should have reflected the full cycle of acquisition and divestiture within FY 2023–2024, not deferred the sale to FY 2025. Hence, correctness and qualitative accuracy are significantly penalized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1190,
        "completion_tokens": 365,
        "total_tokens": 1556
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the regulatory approval status of Trodelvy evolve between 2022 and 2023, and what does this indicate about Gilead's oncology strategy?",
      "original_answer": "In 2022, Trodelvy was part of Gilead's marketed product portfolio and contributed to growth in the oncology franchise, though no specific regulatory updates were mentioned. By 2023, Trodelvy received both FDA and EC approvals for the treatment of adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who had received prior endocrine-based therapy and at least two additional systemic therapies. This regulatory progress indicates a strategic focus by Gilead on expanding the therapeutic applications of Trodelvy and strengthening its position in the oncology market, particularly in breast cancer treatment.",
      "llm_answer": "\nBetween 2022 and 2023 Trodelvy moved from the accelerated‑approval milestones it received in 2021–2022 (full FDA approval for metastatic triple‑negative breast cancer and accelerated approval for urothelial cancer) to new regulatory wins in 2023, most notably the European Commission’s 2023 approval of Trodelvy as a monotherapy for HR⁺/HER2‑negative advanced breast cancer and continued global roll‑outs in additional markets.  This expansion of approvals across multiple tumor types and regions demonstrates Gilead’s oncology strategy of broadening the clinical utility of its antibody‑drug‑conjugate platform, diversifying its cancer‑focused pipeline, and driving growth through multiple, high‑impact indications.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2023 European Commission (EC) approval for HR+/HER2- advanced breast cancer, which aligns with the ground truth. However, it references prior accelerated approvals in 2021–2022 (e.g., for metastatic triple-negative breast cancer and urothelial cancer) that are not mentioned in the original answer and were not part of the 2022–2023 evolution specified in the question. While factually plausible, these details go beyond the provided ground truth and introduce unverified regulatory milestones. The core 2023 approval expansion is accurate and correctly tied to Gilead’s oncology strategy. (2) There are no explicit numerical values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not compromised; dates (2022–2023) are used appropriately. The mention of '2023' for EC approval matches the ground truth. (3) The multi-hop reasoning is strong: the model infers strategic intent (expanding clinical utility, diversifying pipeline) from regulatory developments across years and geographies. It synthesizes the significance of multiple approvals to reflect Gilead’s broader oncology strategy, which is consistent with the original answer’s conclusion. (4) The answer is contextually highly relevant, directly addressing both the regulatory evolution and strategic implications. The slight overextension into pre-2022 approvals reduces correctness slightly, but the core facts and strategic interpretation are sound and semantically aligned with the ground truth. Hence, a score of 8 is justified for correctness, with high marks for qualitative reasoning and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 452,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Simon Property Group's financial relationship with ABG evolved between 2023 and 2024, particularly in terms of capital transactions and strategic positioning?",
      "original_answer": "In 2023, Simon Property Group (SPG) engaged in multiple capital transactions with ABG, including recognizing a non-cash pre-tax gain of $36.4 million from a dilution of ownership in ABG during the second quarter and an additional $145.8 million gain in the third quarter due to further dilution from SPARC Group issuing equity. Additionally, SPG had a long-standing strategic partnership with ABG dating back to 2021, involving licensing ventures such as Forever 21, Brooks Brothers, and Eddie Bauer, which resulted in significant gains. In 2024, SPG no longer reported active capital transactions with ABG, such as gains from dilution or new equity investments. Instead, the 2024 filing only referenced historical transactions, such as the 2021 sale of a portion of SPG’s ABG interest for a pre-tax gain of $18.8 million and the 2022 acquisition of Reebok assets alongside a strategic partnership. This indicates a shift from active financial engagement and restructuring with ABG in 2023 to a more stable, historically referenced relationship in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 Simon Property Group moved from a series of incremental equity‑sale and dilution events with ABG to a full exit from the partnership.  In 2023 the company recorded several non‑cash gains as ABG’s capital transactions diluted Simon’s ownership (e.g., a $10.3 M gain when ABG’s stake fell to ~9.6 % and a $157.1 M gain on a partial 2023 sale), but by the first quarter of 2024 Simon sold its **remaining** ABG interest for **$1.2 billion in cash**, generating a **$414.8 M pretax gain** and eliminating its equity exposure to ABG.  This disposal gave Simon substantial cash that it could redeploy—supporting its share‑repurchase program, reducing debt and funding the $498 M of remaining development capital it expects to need—while repositioning the business away from the ABG joint‑venture toward its core retail‑property and development strategy.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and contains significant factual errors, particularly in quantitative details and overall narrative. (1) The key claim that Simon Property Group (SPG) sold its remaining ABG interest in Q1 2024 for $1.2 billion in cash, generating a $414.8 million pretax gain, is false according to the ground truth. The original answer states that SPG did not report any active capital transactions with ABG in 2024—only historical references. There is no mention of a $1.2B sale or $414.8M gain in 2024. (2) The LLM incorrectly reports a $10.3M gain tied to ABG stake falling to ~9.6% and a $157.1M gain from a partial sale in 2023. The ground truth specifies two non-cash gains: $36.4M in Q2 and $145.8M in Q3 2023 due to dilution from SPARC equity issuance—not from a direct sale by SPG. The numbers do not match: $36.4M + $145.8M = $182.2M total in 2023, not $10.3M + $157.1M. (3) The qualitative shift described—moving from incremental transactions to a full exit—is contradicted by the original answer, which states that SPG stopped reporting active transactions in 2024 but maintained a strategic relationship rooted in prior licensing ventures. The original does not support a full exit or cash sale in 2024. (4) The LLM invents strategic repositioning around share buybacks and development funding based on non-existent cash proceeds, which undermines reasoning accuracy. While the question asks about evolution in financial relationship and strategic positioning, the LLM fabricates a narrative not supported by the data. Contextual relevance is moderate because it addresses capital transactions and strategy, but the facts are invented. Thus, correctness and quantitative accuracy are very low; qualitative accuracy is poor due to flawed multi-hop reasoning; relevance is acceptable as it attempts the right topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1485,
        "completion_tokens": 497,
        "total_tokens": 1983
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Chevron's relationship with Chevron Phillips Chemical Company LLC evolve between 2022 and 2024, particularly in terms of financial reporting and investment value?",
      "original_answer": "In 2022, Chevron Phillips Chemical Company LLC was included in Chevron’s consolidated financial disclosures, specifically in Note 8 on page 70 of the 10-K filing, indicating it was a consolidated subsidiary. By 2024, the company was reported as an equity method investee under 'Downstream' in the Investments and Advances section, with a disclosed investment value of $8,571 million as of December 31, 2024, up from $7,765 million in 2023. This reflects a shift from full consolidation to an equity method investment, suggesting a structural or ownership change in Chevron’s relationship with the entity.",
      "llm_answer": "\nChevron’s 50 % stake in Chevron Phillips Chemical Company LLC remained unchanged, but the investment’s carrying value rose from roughly **$7.8 billion** in the 2022 10‑K (Note 8) to **$8.57 billion** in the 2024 filing (Note 15, p. 85), driven by additional capital contributions—including a **$669 million loan** for the Golden Triangle Polymers project.  At the same time, the equity earnings recognized from the joint venture fell from **$867 million** in 2023 to **$608 million** in 2024, reflecting weaker joint‑venture profitability despite the larger investment.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies and omissions compared to the ground truth. While it correctly identifies the increase in investment value from approximately $7.8 billion to $8.57 billion, it misrepresents the timeline and nature of the accounting change. The original answer states that Chevron Phillips Chemical Company LLC was consolidated in 2022 (per Note 8 of the 2022 10-K), but by 2024 it was reported as an equity method investee. The LLM answer fails to mention this critical shift from consolidation to equity method accounting, which is central to the evolution of the relationship. Instead, it assumes a constant 50% stake and frames the change purely as a valuation increase, missing the structural accounting implication. (2) Quantitatively, the LLM cites a 2022 value of 'roughly $7.8 billion' but the ground truth specifies $7,765 million in 2023 (not 2022), and $8,571 million in 2024. The LLM incorrectly attributes the $7.8 billion figure to 2022, when the knowledge graph does not provide a disclosed value for that year—only 2023 and 2024. The $669 million loan and equity earnings figures ($867M in 2023, $608M in 2024) are not present in the original answer and appear to be hallucinated or sourced incorrectly. (3) The multi-hop reasoning is flawed: the model fails to recognize that the change in reporting method (from consolidated subsidiary to equity investee) indicates a significant shift in control or ownership structure, which is the key insight in the ground truth. Instead, it assumes continuity in ownership and interprets changes as mere fluctuations in valuation and profitability. (4) Despite these issues, the answer is contextually relevant and correctly identifies Chevron Phillips Chemical Company LLC and its financial trajectory in broad terms. The investment increase is directionally correct, and the mention of capital contributions aligns with plausible reasoning, even if specific figures are unsupported. However, the omission of the accounting method shift and introduction of unverified numbers significantly reduce factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 567,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did the status and financial impact of Meta's Facilities Consolidation Strategy evolve between the end of 2023 and the end of 2024?",
      "original_answer": "At the end of 2023, Meta had 'substantially completed' its facilities consolidation initiatives as part of the 2022 Restructuring, indicating the process was still ongoing. By the end of 2024, the company reported that it had 'completed the 2022 restructuring initiatives,' which included the facilities consolidation strategy, showing the process had reached full completion. Additionally, the 2024 disclosure included a financial summary of the 2022 Restructuring pre-tax charges across three years (2022–2024), indicating a retrospective quantification of the financial impact that was not explicitly detailed in 2023.",
      "llm_answer": "\nBy the end of 2023 Meta had largely finished its 2022 facilities‑consolidation effort, with most of the related costs already recorded and only a small residual footprint remaining; the company had accumulated about $2.255 bn of total 2022 restructuring charges (the facilities‑consolidation portion being a part of that amount). In 2024 the consolidation generated $389 million of pre‑tax charges—all classified as facilities‑consolidation expenses—and cumulative spending on the initiative had risen to roughly $5.2 bn (≈ $7.25 bn when combined with other restructuring categories), showing that the financial impact had sharply tapered off and the strategy was now essentially completed.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual and quantitative errors that undermine its correctness. (1) Quantitative Accuracy: The financial figures provided are incorrect. The LLM claims $2.255 billion in restructuring charges by end of 2023 and $5.2 billion cumulative spending on facilities consolidation by 2024, with an additional $389 million in 2024 charges. However, the ground truth does not specify exact dollar amounts for facilities consolidation alone, nor does it state that $389 million in new charges were incurred in 2024 specifically for facilities consolidation. More critically, the total figure of $5.2 billion (or $7.25 billion including other categories) is not supported by the original answer, which only mentions that a retrospective summary of pre-tax charges across 2022–2024 was disclosed in 2024—without providing specific totals. These fabricated numbers represent major inaccuracies. (2) Completeness: While the answer attempts to address the evolution of the strategy, it misrepresents the financial impact by introducing unsupported figures and fails to mention the key qualitative shift from 'substantially completed' (2023) to 'completed' (2024) as stated in the original. (3) Entity Accuracy: The company (Meta) and timeframes (2023–2024) are correct, and the reference to the 2022 Restructuring is accurate. (4) Reasoning: The multi-hop synthesis is flawed. The LLM incorrectly infers ongoing financial charges in 2024 as evidence of completion, whereas the original emphasizes that completion was declared in 2024 and the 2024 filing included a retrospective summary—not new major charges. The logic is partially sound but based on incorrect data. (5) Semantic Equivalence: The overall message of 'nearing completion' is directionally plausible, but the specific financial claims make the answer factually misleading. The original does not support the level of financial detail provided, especially the itemized charges. Thus, while contextually relevant and attempting the right comparison, the answer is largely incorrect due to invented financial data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 559,
        "total_tokens": 1884
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Lockheed Martin's involvement in hypersonics programs evolved from 2022 to 2024, particularly in terms of strategic focus and program status?",
      "original_answer": "In 2022, Lockheed Martin's involvement in hypersonics programs was described as a key growth area that was dependent on U.S. Government authorization and funding, indicating that the programs were still in a development phase with uncertain future funding. By 2024, the company was actively producing hypersonic strike weapons under multiple programs with the U.S. Air Force and Army, showing a shift from a funding-dependent future initiative to an active production program. This evolution reflects a significant advancement in the maturity and strategic importance of hypersonics within Lockheed Martin's portfolio.",
      "llm_answer": "\nFrom 2022 through 2024 Lockheed Martin shifted hypersonics from a standalone R&D project to a core element of its multi‑domain “21st Century Security” strategy, embedding the effort in its Advanced Development Programs (Skunk Works) and linking it to CJADC2 and joint‑all‑domain initiatives.  The company is now actively designing and building several hypersonic strike weapons for the U.S. Air Force and Army, moving from prototype demonstrations toward program‑level development and production, while continuing to leverage rapid‑prototype and technology‑insertion pathways to accelerate fielding.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly captures the evolution of Lockheed Martin's hypersonics involvement from 2022 to 2024: starting as a development/funding-dependent effort and transitioning into active production. While the original answer emphasizes U.S. Government funding dependency in 2022 and active production by 2024, the LLM adds valuable context—positioning hypersonics within Lockheed’s broader '21st Century Security' strategy, Skunk Works, and integration with CJADC2 and joint-all-domain operations. These details are consistent with Lockheed Martin's public strategic framing and enhance the answer without introducing inaccuracies. The shift from prototype to production is correctly described, matching the ground truth’s emphasis on maturation. There are no numeric values to verify, so quantitative accuracy is scored as 10. The only minor gap is that the LLM does not explicitly mention the 'uncertain future funding' aspect in 2022, though the implication of R&D dependency covers it implicitly. This slight omission prevents a perfect 10 on qualitative accuracy. The reasoning is sound, multi-hop synthesis is appropriate, and the answer is fully contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 347,
        "total_tokens": 1652
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Southern Company's treatment and disclosure of energy-related derivatives evolve from 2022 to 2023, particularly in terms of their designation and financial impact?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of unrealized derivative gains (losses) from energy-related derivatives that were designated as regulatory hedging instruments and deferred. By 2023, the company expanded its disclosure to include the pre-tax effects of energy-related derivatives not designated as hedging instruments on its statements of income, covering the years 2023, 2022, and 2021. This indicates a shift from focusing only on regulatory hedging instruments to providing a broader view of its energy-related derivative activities.",
      "llm_answer": "\nFrom 2022 to 2023 Southern Company kept energy‑related derivatives in the same hedging categories—cash‑flow, fair‑value and regulatory—but the financial outcome changed dramatically: cash‑flow hedges went from a $37 million gain in 2022 to a $44 million loss in 2023, and the regulatory‑hedge portfolio shifted from a modest $9 million unrealized gain at the end of 2022 to a $257 million unrealized loss at the end of 2023, with the corresponding amounts reclassified from AOCI to earnings turning negative.  The 2023 disclosures also added detailed tables showing the cumulative fair‑value hedge adjustments to long‑term debt and the exact gains/losses reclassified from OCI, underscoring a larger impact on income and equity than was reflected in the 2022 filings.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in terms of quantitative accuracy and misrepresents the core evolution in Southern Company's derivative disclosures. (1) The ground truth states that in 2022, Southern Company reported pre-tax effects of unrealized gains (losses) from energy-related derivatives designated as regulatory hedging instruments and deferred. In 2023, it expanded disclosure to include derivatives not designated as hedging instruments, providing a broader view across 2023, 2022, and 2021. The LLM answer instead introduces specific dollar amounts (e.g., $37M gain, $44M loss, $257M loss) and changes in AOCI reclassifications that are not present in the original answer and cannot be verified from the provided ground truth. These figures are likely hallucinated. (2) There is no mention in the ground truth of cash-flow hedges, fair-value hedges, AOCI reclassifications, or cumulative hedge adjustments to long-term debt—these are all fabrications or misattributions. (3) While the LLM attempts multi-hop reasoning by comparing 2022 and 2023 disclosures, it fails to identify the actual evolution: a shift from reporting only regulatory hedging instruments to including non-designated derivatives in income statement disclosures. Instead, it invents a narrative around changing gains/losses and expanded tables on debt adjustments that are unsupported. (4) The contextual relevance is moderate because the answer addresses derivative disclosures and the 2022–2023 timeframe, but the qualitative and quantitative inaccuracies severely undermine correctness. The core factual claim about broadening disclosure scope is missed entirely, replaced with fabricated financials and hedge accounting details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 465,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Gilead's intellectual property strategy regarding Truvada evolve between 2022 and 2023, particularly in terms of patent disclosures?",
      "original_answer": "In 2022, Gilead highlighted the October 2020 loss of exclusivity of Truvada in the United States as a transitory headwind, indicating that the product was no longer protected under patent, which likely affected revenue. In 2023, Gilead provided structured disclosures regarding the patent expiration dates of its principal products, including Truvada, focusing on the actual or estimated expiration dates in the U.S. and the EU. This represents a shift from acknowledging a past loss of exclusivity to proactively disclosing future intellectual property timelines for key products.",
      "llm_answer": "\nBetween the 2022 and 2023 Form 10‑K filings, Gilead moved from openly flagging the October 2020 loss of U.S. exclusivity for Truvada and describing its reliance on patent‑term extensions and voluntary‑licensing tactics (see 2022 10‑K, pages 37‑38) to providing no fresh patent‑term‑extension, new filing, or exclusivity disclosures for Truvada in the 2023 report (pages 7‑9, which only reference prior TAF‑related settlement agreements and focus on other products).  This shift shows that, after the patent protection for Truvada expired, the company’s IP strategy for that product has effectively wound down—no new patent disclosures were made, and the emphasis turned to managing generic competition rather than pursuing additional exclusivity.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements but diverges significantly from the ground truth in key aspects, leading to a partially correct assessment. (1) Quantitatively, the mention of the October 2020 U.S. loss of exclusivity for Truvada is accurate and aligns with the original answer. However, the LLM incorrectly implies that Gilead made *no* new disclosures about Truvada’s patent status in 2023, when in fact the ground truth states that Gilead *did* provide structured disclosures on actual or estimated expiration dates for Truvada in the U.S. and EU in 2023—this is a critical factual discrepancy. (2) The LLM cites specific page numbers (e.g., 2022 10-K pages 37–38, 2023 pages 7–9) and references to TAF-related settlements, which may reflect real document content but are not verifiable from the knowledge graph and introduce unconfirmed detail. More importantly, these details are used to support a conclusion opposite to the ground truth: the original answer describes a shift toward *more* structured and forward-looking IP disclosures in 2023, while the LLM interprets the same period as a 'winding down' with 'no fresh' disclosures. (3) The multi-hop reasoning is flawed: the model correctly identifies the 2022 context (acknowledging past exclusivity loss) but fails to recognize the evolution in 2023 toward proactive, systematic disclosure of patent expirations. Instead, it infers absence of action, which contradicts the ground truth. (4) While the LLM stays focused on the topic and uses appropriate terminology (e.g., patent-term extensions, generic competition), its core conclusion about the evolution of strategy is incorrect. The original answer emphasizes increased transparency and forward-looking disclosure; the LLM claims strategic withdrawal. Thus, despite accurate dates and contextual framing, the central claim is factually wrong, warranting a mid-range correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 514,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did SPG's use of the Supplemental Facility evolve between 2022 and 2024, particularly in terms of borrowing and repayment activities?",
      "original_answer": "In 2022, SPG borrowed $1.05 billion under the Supplemental Facility in January 2022, which was used to fund the early extinguishment of nine mortgages with a principal balance of $1.16 billion. This borrowing was repaid shortly after issuance. By 2024, SPG again utilized the Supplemental Facility, borrowing €750.0 million ($815.4 million U.S. dollar equivalent) in November 2023, which was repaid on November 17, 2023. Additionally, in 2024, SPG issued new senior unsecured notes to redeem other outstanding notes at maturity, indicating a shift in financing strategy. The evolution shows a continued reliance on the Supplemental Facility for short-term financing needs but with a more structured approach to repayment and refinancing.",
      "llm_answer": "\nBetween 2022 and 2024 SPG’s use of the Supplemental Facility shifted from a single $1.05 bn draw in December 2021 – which it fully repaid with note proceeds on January 12 2022 – to a complete retirement of the borrowing.  In November 2023 the company used the proceeds of a €750 m euro‑denominated bond issuance to extinguish the remaining €750 m (≈ $815 m) outstanding under the Supplemental Facility, leaving the facility with no balance on its books; the 2024 filing therefore reports only the facility’s available capacity, not any outstanding borrowings.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains several factual inaccuracies that significantly affect correctness. It incorrectly states that the $1.05 billion borrowing occurred in December 2021 and was repaid on January 12, 2022, whereas the ground truth specifies the borrowing occurred in January 2022 and was repaid shortly thereafter—timing is reversed and misattributed. Additionally, the LLM claims the €750 million was used to 'extinguish the remaining €750 million outstanding,' implying prior drawdowns, but the ground truth states this was a new draw in November 2023 that was repaid on November 17, 2023—same day or very short-term use—not a retirement of accumulated debt. The LLM also mischaracterizes the 2024 situation by suggesting the facility was fully retired, while the original answer notes SPG again utilized the facility, indicating ongoing access and use for short-term needs. (2) Quantitative accuracy is partially correct: $1.05 billion and €750 million ($815.4 million) figures are accurate and properly converted, but the dates (December 2021 vs January 2022) are wrong, affecting temporal precision. (3) The reasoning is flawed in synthesis: the LLM implies a linear reduction of debt on the facility over time, while the ground truth shows two discrete, short-term borrowings—2022 and 2023 (for 2024 reporting)—with full repayments, not a continuous balance. It also fails to mention SPG’s issuance of new senior unsecured notes in 2024 to redeem maturing notes, a key part of the strategic shift noted in the original answer. (4) Contextual relevance is strong—the response addresses the evolution of SPG’s use of the Supplemental Facility and focuses on borrowing and repayment—but the factual and temporal errors reduce overall correctness. Minor wording differences are acceptable, but incorrect dates and misrepresentation of the nature of borrowings (e.g., 'remaining' balance) constitute significant errors. Thus, partial credit is given for correct dollar/euro amounts and general direction of use, but major deductions for timeline inaccuracies and missing strategic context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 560,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has the role of cash buffer needs in MetLife's capital management strategy evolved from 2022 to 2024, particularly in terms of liquidity levels and their impact on capital allocation decisions?",
      "original_answer": "In 2022, MetLife maintained a short-term liquidity position of $12.4 billion and a total liquid asset base of $223.0 billion, reflecting a strong buffer to meet business requirements under both normal and stress scenarios. The company emphasized its belief in having ample liquidity and highlighted active monitoring and adjustment of liquidity and capital plans. By 2024, the narrative shifted to a more cautious tone, noting that maintaining or increasing cash buffers could limit capital available for innovation, acquisitions, and shareholder returns. This indicates that while liquidity remained a strategic priority, the implications of holding larger cash buffers became more pronounced, potentially constraining other capital deployment opportunities.",
      "llm_answer": "\nFrom 2022 to 2024 MetLife shifted the cash‑buffer from a vague “capacity‑to‑pay‑dividends” constraint to a concrete, forward‑looking liquidity framework.  The 2024 disclosures tie the buffer size to daily cash‑flow forecasts, rolling‑12‑month stress tests and collateral‑call scenarios, so any rise in required buffer—driven by market volatility, rating‑agency expectations or securities‑lending collateral demands—directly limits capital‑allocation decisions such as dividend payouts, share‑repurchases and the scale of external financing.  In short, the buffer now explicitly governs how much capital can be deployed, rather than merely flagging a potential restriction.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct in describing a shift in MetLife's cash buffer strategy from 2022 to 2024, capturing the evolving impact on capital allocation. However, it fails to include any of the specific quantitative data present in the original answer—namely, the $12.4 billion short-term liquidity position and $223.0 billion total liquid asset base in 2022. These figures are critical for factual completeness and are entirely missing, which severely undermines quantitative accuracy. (2) There are no numbers in the LLM response to verify against the ground truth, and no mention of the actual liquidity levels in either year. This omission constitutes a major deficiency, especially since the question asks about 'liquidity levels' directly. (3) The qualitative reasoning is reasonably sound: the LLM correctly identifies a strategic evolution—cash buffers becoming a more active constraint on capital allocation by 2024. It introduces concepts like stress testing, collateral calls, and capital deployment trade-offs, which align with the cautious tone shift described in the original. However, these are presented as specific new frameworks (e.g., 'daily cash-flow forecasts', 'rolling-12-month stress tests') that are not explicitly confirmed in the ground truth, introducing potential overinterpretation. (4) Contextual relevance is high because the answer addresses the core theme—evolution of cash buffer role in capital management—and correctly infers increased trade-offs in 2024. But due to the absence of key financial figures and unverified procedural details, the correctness score is limited to 5: the central idea is directionally accurate, but lacks evidentiary support and precision required for full factual alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 479,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did Starbucks' exposure to 'Foreign currency - other' derivatives evolve between 2022 and 2023, particularly in terms of asset and liability classifications?",
      "original_answer": "In 2022, Starbucks reported 'Foreign currency - other' derivative liabilities of $0.3 million under accrued liabilities and no corresponding asset value. By 2023, the company had a derivative asset of $1.9 million under prepaid expenses and other current assets and a derivative liability of $4.7 million under accrued liabilities for the same category. This indicates a significant increase in exposure and a shift toward a more balanced treatment across asset and liability classifications.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 the “Foreign currency – other” designated derivatives moved from a sizable asset position to a liability position.  In 2022 (page 68) the company carried $39.9 million of such derivatives in prepaid expenses / other current assets and $33.5 million in other long‑term assets, with only a $0.3 million liability in accrued liabilities.  By 2023 (page 74) those assets had fallen to $1.9 million in current assets and $1.7 million in long‑term assets, while liabilities increased to $4.7 million in accrued liabilities and $4.1 million in other long‑term liabilities, shifting the exposure from a net asset to a net liability.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. According to the ground truth, in 2022 Starbucks had only a $0.3 million liability for 'Foreign currency - other' derivatives and no asset value. However, the LLM claims there was a $39.9 million asset in prepaid expenses and $33.5 million in long-term assets in 2022, which is not supported by the original answer and represents a major overstatement. Similarly, for 2023, the LLM reports $1.9 million in current assets (correct), $1.7 million in long-term assets, and $4.1 million in long-term liabilities—none of which are mentioned in the ground truth, which only reports a $1.9 million asset and $4.7 million liability, both current. The original answer does not mention any long-term asset or liability classifications for this derivative category in either year. The LLM also mischaracterizes the evolution as a shift from 'a sizable asset position to a liability position,' whereas the ground truth indicates a transition from a small liability-only position to a balanced asset-and-liability position. This reflects a fundamental misrepresentation of Starbucks' derivative exposure. While the LLM correctly identifies the $1.9 million 2023 current asset and $4.7 million 2023 liability, and references the correct trend of increasing exposure, the inclusion of unsupported long-term balances and incorrect 2022 asset values severely undermines the quantitative and qualitative accuracy. The reasoning is structured appropriately and addresses the question's focus on asset/liability classification changes, but the factual foundation is flawed. Contextual relevance is moderate as the response discusses the right topic and direction of change, but with incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 480,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has The Coca-Cola Company's relationship with Coca-Cola FEMSA evolved from 2023 to 2024, particularly in terms of its strategic engagement and financial stake?",
      "original_answer": "In 2023, Coca-Cola FEMSA was one of The Coca-Cola Company's five largest independent bottling partners, operating in multiple countries including Mexico, Brazil, and Argentina, and collectively these top five bottlers accounted for 42% of Coca-Cola's worldwide unit case volume. By 2024, the relationship had evolved significantly, as Coca-Cola FEMSA transitioned from being a key bottler to becoming an equity method investee in which The Coca-Cola Company held a 28% ownership stake. This shift indicates a deeper financial commitment and alignment beyond the traditional bottler-concentrate supplier model.",
      "llm_answer": "\nFrom 2023 to 2024 Coca‑Cola kept its 28 % equity stake in Coca‑Cola FEMSA and continued to treat the bottler as a core strategic partner, but the financial exposure changed only modestly: the carrying value of the FEMSA investment slipped from roughly $1.97 bn to $1.79 bn (page 87) while the fair‑value premium widened to $2.76 bn, and the overall Bottling‑Investments balance fell from $3.09 bn to $2.999 bn (page 88). This indicates a slight reduction in the company’s monetary stake yet continued deep‑ening of the partnership through shared pricing models, supply‑chain collaboration and the possibility of future equity adjustments or divestitures.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents the evolution of The Coca-Cola Company's relationship with Coca-Cola FEMSA from 2023 to 2024. (1) QUANTITATIVE INACCURACY: The claim that Coca-Cola 'kept its 28%' stake in 2023 is false according to the ground truth — in 2023, Coca-Cola FEMSA was a bottling partner, not an equity method investee; the 28% ownership stake is a 2024 development, not a pre-existing condition. The financial figures cited (e.g., $1.97B to $1.79B carrying value, $2.76B fair-value premium, Bottling-Investments balance) are not present in the ground truth and cannot be verified, suggesting fabrication or misattribution. (2) COMPLETENESS: The answer fails to correctly describe the core transformation — the shift from a traditional bottler relationship to an equity method investee model — instead implying only a minor financial adjustment. (3) ENTITY & TEMPORAL INACCURACY: The answer incorrectly assigns the 28% ownership stake to 2023, reversing the causal and chronological logic of the relationship evolution. (4) REASONING: The multi-hop synthesis is flawed — the model conflates financial metrics from unknown sources (e.g., 'page 87', 'page 88') with the strategic narrative, but these pages and figures are not part of the provided knowledge. The conclusion of 'slight reduction in monetary stake' contradicts the ground truth's emphasis on deeper financial commitment. (5) SEMANTIC EQUIVALENCE: The overall message is misleading — the ground truth describes a strategic transformation, while the LLM portrays a minor financial fluctuation. Despite addressing the general topic and using relevant terminology, the answer is factually incorrect on key points, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 476,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Intel's strategic positioning of FPGAs evolved between 2022 and 2024, particularly in terms of their role within adjacent products and their broader production focus?",
      "original_answer": "In 2022, Intel positioned FPGAs as part of its 'adjacent products' within the Client Computing Group (CCG), Data Center Group (DCG), and Internet of Things Group (IOTG), indicating a supporting role within comprehensive platform solutions. By 2024, FPGAs were explicitly listed under direct product definitions, signaling a shift toward a more central production focus. This reflects a transformation in the strategic importance of FPGAs, moving from a supplementary role to a core product offering.",
      "llm_answer": "\nBetween 2022 and 2024 Intel moved FPGAs from a discrete “Programmable Solutions” offering into the core of its **xPU** architecture, using them as the programmable networking and acceleration engine inside the **Infrastructure Processing Unit (IPU)** and other adjacent product families (e.g., modem, Ethernet, silicon‑photonic and AI‑accelerator blocks).  This integration lets FPGAs bind together platform CPUs, AI accelerators and Mobileye/NSG components into end‑to‑end platform solutions, while Intel’s “Smart Capital” and production‑capacity investments now target scalable fab capacity for these programmable devices to support its broader CCG‑DCG‑IOTG focus.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains no explicit numerical data, dates, or financial figures, so quantitative accuracy is not applicable in a traditional sense; however, since no numbers were misstated, it receives full credit by default (10). The contextual relevance is high (8) because the response addresses the evolution of Intel's FPGA strategy and connects it to broader architectural and production trends. However, the qualitative accuracy is low (5) due to significant factual and conceptual discrepancies. The ground truth states that in 2022, FPGAs were categorized as 'adjacent products' within CCG, DCG, and IOTG, and by 2024 were elevated to direct product definitions—marking a shift from supplementary to core. The LLM instead claims FPGAs were moved from a 'discrete Programmable Solutions' group into the xPU architecture and IPU, which is not supported by the original answer. It introduces unverified concepts like 'xPU' and specific integration into IPUs, modem blocks, silicon photonics, and Mobileye/NSG components—none of which appear in the ground truth. These additions reflect plausible-sounding but unsupported technical elaboration. While the LLM captures the directional shift (increased strategic importance), it fabricates the mechanism and context of that shift. Thus, the core correctness score is 6: it gets the high-level trend right (FPGAs becoming more central), but fails on the actual documented organizational and strategic framing, introducing speculative details not present in the source. The multi-hop reasoning is partially sound but based on incorrect entity mapping and unsupported synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 443,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did ConocoPhillips' financial activity related to the Lower 48 region evolve from 2022 to 2023, particularly in terms of asset acquisition and depreciation, depletion, and amortization expenses?",
      "original_answer": "In 2022, ConocoPhillips noted that purchases in the Lower 48 were driven by the Concho acquisition, indicating a strategic expansion in that region. The depreciation, depletion, amortization, and impairments expense for the Lower 48 was $4,854 million. In 2023, the company's expense for the same category in the Lower 48 increased to $5,729 million, showing a significant rise of $875 million. This increase suggests continued investment and asset utilization in the Lower 48 following the acquisition.",
      "llm_answer": "\nBetween 2022 and 2023 ConocoPhillips grew its Lower 48 position by spending more on capital projects—capital expenditures jumped from **$5.6 bn to $6.5 bn** (page 135)—and its depreciation, depletion and amortization expense rose from **$4.85 bn to $5.73 bn** (page 134).  This increase in DDA reflects the added acreage from the Concho acquisition and subsequent extensions and discoveries that expanded proved undeveloped reserves in the Lower 48 (pages 163, 165).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: DDA expense increased from $4.85 billion (matching $4,854 million in original) to $5.73 billion (matching $5,729 million), with a difference of $875 million—correctly implied. Capital expenditures cited as $5.6B to $6.5B are consistent with the context of increased investment, though not part of the original answer; these figures do not contradict but add supplementary detail. (2) The core financial metric—DDA—was accurately reported with correct year-over-year values and proper rounding ($4.854B → $4.85B and $5.729B → $5.73B is acceptable). (3) Qualitatively, the reasoning correctly links the DDA increase to the Concho acquisition and subsequent reserve expansions, demonstrating sound multi-hop synthesis across time and operational outcomes. The mention of capital expenditures, while not in the original answer, supports the narrative of continued investment and is contextually appropriate. (4) The only minor gap is that the original emphasizes the 2022 acquisition 'drive' and 2023 expense rise as evidence of ongoing utilization, while the LLM focuses more on capex and reserve growth—slightly shifting emphasis but not misrepresenting facts. Overall, the answer is factually correct, complete, and relevant, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 378,
        "total_tokens": 1633
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve between 2022 and 2024, particularly in terms of ownership structure and financial impact on gross margins?",
      "original_answer": "In 2022, Emerson completed the acquisition of AspenTech, contributing approximately $6.0 billion in cash, paying $87.69 per share to Heritage AspenTech stockholders, and retaining $168 million in AspenTech's balance sheet. The acquisition positively impacted gross margins by 0.6 percentage points in 2023. By 2024, Emerson owned 55% of AspenTech on a fully diluted basis, and AspenTech continued to operate under its former name and ticker symbol 'AZPN.' The acquisition's financial impact persisted, contributing to a gross margin increase of 1.8 percentage points to 50.8% in 2024, despite a negative impact from acquisition-related inventory step-up amortization of $231 million, which reduced margins by 1.3 percentage points.",
      "llm_answer": "\nBetween 2022 and 2024 Emerson’s stake in AspenTech grew from the ~55 % ownership it obtained after the May 2022 acquisition of Heritage AspenTech to about 57 % by late‑2024, and in November 2024 it announced a proposal to acquire the remaining shares—moving the relationship from a joint‑venture stake toward full control.  The added software and analytics businesses from AspenTech helped lift Emerson’s consolidated gross margin to **50.8 % in 2024** (up from 49.0 % in 2023), although a $231 million acquisition‑related inventory‑step‑up amortization in 2024 offset roughly **1.3 percentage‑points** of that improvement.  Thus, while the strategic partnership deepened and contributed to higher margins, the net margin effect was a modest increase tempered by the step‑up amortization.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in key quantitative details. The ground truth states that Emerson owned 55% of AspenTech by 2024 on a fully diluted basis, but the LLM claims ownership grew from ~55% in 2022 to ~57% by late-2024 and mentions a November 2024 proposal to acquire the remaining shares—information not present in the original answer and thus factually unsupported. Additionally, the original answer does not state Emerson’s ownership was ~55% in 2022; it only confirms 55% by 2024. The LLM incorrectly implies a progression of ownership that isn’t verified. (2) The gross margin data is partially correct: the LLM correctly identifies the 2024 gross margin of 50.8% and the $231 million inventory step-up amortization that reduced margins by 1.3 percentage points. However, it misstates the 2023 gross margin as 49.0%, which is not in the original answer. The original states the acquisition improved gross margins by 0.6 percentage points in 2023, but does not provide the overall margin for that year. The LLM fabricates a baseline (49.0%) to support a comparison. The 1.8 percentage point increase in gross margin contribution by the acquisition in 2024 is omitted. (3) The multi-hop reasoning is partially sound—linking the acquisition to margin impacts and adjusting for amortization is valid and shows understanding of financial cause-effect. However, the narrative of increasing ownership stake and pending full acquisition introduces unsupported strategic evolution. (4) Despite these issues, the answer captures the core financial impact on margins and correctly identifies the $231 million amortization effect and 50.8% margin in 2024, earning moderate scores. Contextual relevance is high as it directly addresses ownership evolution and margin impact as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 491,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has the treatment and availability of shares under the 2015 Director Stock Plan evolved between 2022 and 2024, particularly in terms of share recovery and issuance mechanics?",
      "original_answer": "In 2022, the 2015 Director Stock Plan specified that each share issued under the plan reduced the number of shares remaining for issuance by one, and shares recovered from expired, forfeited, or cash-settled awards were again available for issuance. By 2024, the plan had a total of 35,395,894 shares authorized for issuance as of January 1, 2015, with 37,608,213 shares recovered for issuance between 2015 and 2024. However, 42,343,146 shares were covered by new awards and reinvested dividends since 2015, leaving 30,660,961 shares available for future issuance. This reflects a net reduction in available shares over time despite ongoing share recovery, indicating a shift in the balance between new issuances and recovered shares.",
      "llm_answer": "\nBetween 2022 and 2024 the 2015 Director Stock Plan continued to treat forfeited, expired or cash‑settled awards—and the shares tendered for tax withholding—as newly available on a one‑for‑one basis, but the net pool of shares that can still be issued fell.  The 2022 filing showed about 31.5 million shares had been recovered since 2015, leaving roughly 34 million shares available for future grants; by the 2024 filing cumulative recoveries had risen to 37.6 million shares, yet after deducting shares used for new awards and imputed dividend credits the remaining authorized shares had dropped to 30.66 million.  Thus, while the recovery mechanism kept adding back shares, the volume of new grants outpaced those recoveries, tightening overall availability.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth with only minor discrepancies in rounding. (1) Quantitatively, the LLM correctly states that 37.6 million shares were recovered by 2024 (matching the ground truth of 37,608,213), and that 30.66 million shares remained available (matching 30,660,961). The 2022 figure of 'about 31.5 million' recovered shares is a reasonable approximation given the lack of explicit 2022 recovery data in the ground truth; however, the ground truth does not specify the 2022 recovery number, so this estimate cannot be fully verified but is contextually plausible. The '34 million available' in 2022 is not directly confirmed but aligns with the trend. (2) The key calculation — that new awards (42.34M) exceeded recoveries (37.61M), leading to a net reduction in available shares — is correctly inferred and matches the ground truth logic. (3) The reasoning is sound: the LLM correctly identifies the one-for-one recovery mechanism for forfeited, expired, or cash-settled awards and explains how share availability decreased despite ongoing recovery due to higher issuance volume. (4) All entities (2015 Director Stock Plan, time frame 2022–2024, share recovery and issuance mechanics) are accurately referenced. The answer addresses both parts of the question: treatment/availability evolution and share recovery/issuance mechanics. The only minor shortcoming is the use of approximated figures for 2022 not explicitly present in the ground truth, but these are reasonable interpolations. Overall, the answer is factually correct, well-reasoned, and contextually complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 448,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Starbucks' relationship with the Global Coffee Alliance evolved from fiscal year 2022 to fiscal year 2023 in terms of strategic emphasis and revenue contribution?",
      "original_answer": "In fiscal year 2022, the Global Coffee Alliance contributed to the growth of the Channel Development segment, which saw a $250 million increase in revenue driven by product sales and royalty income from the alliance. By fiscal year 2023, the strategic emphasis on the Global Coffee Alliance had evolved, with Starbucks explicitly highlighting its licensing relationship with Nestlé under the alliance as a core channel for product distribution, indicating a deeper integration and ongoing importance to Starbucks' global licensing and product expansion strategy. This evolution reflects a shift from viewing the alliance primarily as a revenue driver to positioning it as a strategic enabler of global product reach and brand extension.",
      "llm_answer": "\nFrom fiscal 2022 to fiscal 2023 Starbucks deepened the strategic role of the Global Coffee Alliance, moving it from a modest royalty‑ and product‑sales line (which generated about $216 million of “other” revenue in 2022) to a primary growth engine for the Channel Development segment; the partnership was highlighted as a key driver of the segment’s 16 % revenue increase and a larger share of total net revenue. This shift reflects a stronger strategic emphasis on co‑developed products, expanded licensing and joint marketing, and a higher overall contribution of the Alliance to Starbucks’ top‑line performance.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. The ground truth states that the Channel Development segment saw a $250 million increase in revenue in fiscal year 2022 due to the Global Coffee Alliance, but the LLM incorrectly reports 'about $216 million of “other” revenue in 2022'—a figure not supported by the original answer and potentially conflated with another data point. Additionally, the LLM claims the alliance drove a '16% revenue increase' in the segment, which is not mentioned or verifiable from the ground truth. (2) While the qualitative shift in strategic emphasis—from revenue contributor to strategic enabler—is correctly identified, the LLM overstates the evolution by calling it a 'primary growth engine' and introducing elements like 'co-developed products, expanded licensing and joint marketing' that are not present in the original answer. The ground truth emphasizes the licensing relationship with Nestlé as a core distribution channel and highlights deeper integration, but does not mention joint marketing or co-development. (3) The multi-hop reasoning is partially sound: the model correctly infers an increased strategic role from 2022 to 2023 and connects the alliance to Channel Development. However, it fabricates specific financial metrics and misattributes revenue figures, undermining the factual basis of the synthesis. (4) Contextual relevance is high because the response directly addresses both strategic emphasis and revenue contribution over the two fiscal years. Despite incorrect numbers and some invented details, the overall direction of the strategic evolution is plausibly interpreted, warranting a mid-range score for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 466,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has NEE's financial stake and involvement in the Mountain Valley Pipeline evolved between 2022 and 2023, and what does this indicate about its investment strategy?",
      "original_answer": "In 2022, NEE's equity method investments totaled $6,159 million, and the Mountain Valley Pipeline was listed among key equity method investees alongside NEP OpCo, Sabal Trail, and Silver State South Solar, with NEE's interest ranging from approximately 32% to 55%. By 2023, NEE's total equity method investments were $6,156 million, with its interest in the principal entities, including the Mountain Valley Pipeline, ranging from approximately 32.8% to 52.6%. The shift from a broader range (32%–55%) in 2022 to a narrower range (32.8%–52.6%) in 2023 suggests a slight adjustment in ownership stakes, potentially reflecting a more refined or strategic investment posture. Additionally, in 2023, the Mountain Valley Pipeline was specifically noted in the context of Nonrecurring Fair Value Measurements, indicating a possible revaluation or change in financial treatment.",
      "llm_answer": "\nBetween 2022 and 2023 NEE’s exposure to the Mountain Valley Pipeline was sharply reduced – the carrying amount of its equity‑method investment in the pipeline fell by roughly $1 billion and a $1.2 billion impairment charge was recorded in 2023, reflecting a write‑down of the asset. This decline signals that NEE is pulling back from long‑haul gas‑pipeline investments and reallocating capital toward renewable‑energy and clean‑energy projects.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth. (1) Quantitatively, the claim that NEE's carrying amount fell by $1 billion and that a $1.2 billion impairment charge was recorded in 2023 is false; the original answer states that total equity method investments were $6,159M in 2022 and $6,156M in 2023—a negligible decrease of $3M, not $1B. There is no mention of any impairment charge. (2) The original answer indicates NEE maintained its involvement in the Mountain Valley Pipeline as an equity method investee, with ownership stakes slightly adjusted from 32%–55% to 32.8%–52.6%, not a sharp reduction. (3) The LLM incorrectly infers that NEE is pulling back from gas pipelines and shifting to renewables based on non-existent impairment data—this conclusion is unsupported. The original answer notes only a minor narrowing of ownership ranges and a mention of the pipeline in Nonrecurring Fair Value Measurements, which does not imply divestment or strategic retreat. (4) The LLM fails on multi-hop reasoning: it fabricates financial figures, misrepresents trends, and draws strong strategic conclusions from false data. While the topic (investment strategy) is relevant, the factual foundation is entirely wrong, leading to a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 358,
        "total_tokens": 1692
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Medtronic's InterStim Therapy product line evolved between 2022 and 2024 in terms of neurostimulator offerings and therapeutic indications?",
      "original_answer": "In 2022, InterStim therapy was described with a range of neurostimulators including InterStim II, InterStim Micro, and InterStim X, targeting symptoms of overactive bladder, urinary retention, and bowel incontinence. By 2024, the product line continued to include InterStim II and InterStim X, now specifically labeled as 'recharge-free' neurostimulators, and retained its focus on overactive bladder and urinary retention, but expanded its therapeutic scope to include 'chronic fecal incontinence.' This reflects a refinement in product positioning and a broadening of clinical applications over the two-year period.",
      "llm_answer": "\nBetween 2022 and 2024 Medtronic expanded the InterStim portfolio with new recharge‑free (InterStim X and InterStim II) and rechargeable (InterStim Micro) neurostimulators, and broadened its approved therapeutic indications to include overactive bladder, non‑obstructive urinary retention and chronic fecal incontinence, while continuing to support pelvic‑health applications.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is mostly correct but contains a key inaccuracy regarding the rechargeable status of InterStim Micro. According to the ground truth, by 2024, InterStim II and InterStim X were specifically labeled as 'recharge-free,' implying a product positioning update. However, the LLM answer incorrectly states that InterStim Micro is rechargeable, which is not mentioned or implied in the original answer — the ground truth does not specify the power type of InterStim Micro, so asserting it is rechargeable introduces unsupported information. The therapeutic indications are correctly identified: overactive bladder, urinary retention (specified as non-obstructive, which aligns with standard terminology), and the expansion to include chronic fecal incontinence. The timeline (2022 to 2024) is handled appropriately, and the evolution in product lineup and indications is generally accurate. The answer is contextually relevant and captures the core developments. However, the unsupported claim about InterStim Micro's rechargeability affects qualitative accuracy, preventing a higher score. Quantitative accuracy receives full marks because there are no numerical errors (the years and product names are correct), and the answer correctly reflects the expansion in indications. Overall, the answer conveys much of the same information with sound reasoning but introduces a detail not present in the source, reducing its factual precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 397,
        "total_tokens": 1646
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Simon Property Group's financial stake and strategic relationship with Authentic Brands Group (ABG) evolve from 2022 to 2024?",
      "original_answer": "In 2022, Simon Property Group held a 1.37% interest in ABG and had merged Forever 21 operations into SPARC Group after increasing its stake to 50% alongside ABG. By 2024, Simon sold a portion of its ABG stake, realizing a pre-tax gain of $18.8 million, and later acquired additional interests in ABG for $100 million in cash, indicating a dynamic evolution in their financial relationship.",
      "llm_answer": "\nFrom 2022 through 2024 Simon Property Group steadily pared down its ownership in Authentic Brands Group (ABG).  In 2022 it sold a portion of its licensing‑venture interest to ABG and acquired additional ABG equity, generating a $159 million pre‑tax gain while its non‑controlling stake fell to roughly 10 %.  By the end of 2023 a further capital transaction diluted the holding to about 9.6 % and SPG recorded a $10.3 million non‑cash gain on the deemed disposal.  In the first quarter of 2024 SPG sold the remaining ABG interest for $1.2 billion, recognizing a $414.8 million pre‑tax gain and effectively ending the strategic relationship.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Simon Property Group (SPG) held a 1.37% interest in ABG in 2022 and later sold a portion (not all) of its stake, realizing a $18.8 million pre-tax gain, then reinvested $100 million in cash to acquire additional interests in ABG in 2024—indicating an ongoing strategic relationship. In contrast, the LLM claims SPG sold its entire stake in Q1 2024 for $1.2 billion, recognizing a $414.8 million gain, which contradicts the original answer. The LLM also states SPG had a roughly 10% stake in 2022 and was diluted to 9.6% by end-2023, but the ground truth specifies only a 1.37% interest in 2022—making the LLM's percentages grossly inaccurate. (2) Quantitative errors include: incorrect pre-tax gains ($159M vs. $18.8M; $414.8M vs. no such figure in truth), incorrect transaction amounts ($1.2B sale vs. $100M investment), incorrect ownership percentages (10%, 9.6% vs. 1.37%), and incorrect timing (2023 dilution not mentioned in truth). (3) The multi-hop reasoning is flawed: the LLM incorrectly infers a complete exit from ABG, whereas the truth shows a dynamic but continuing relationship with both divestment and reinvestment. It fails to mention the SPARC Group merger with Forever 21, a key strategic move. (4) Scores reflect major factual and numerical errors (correctness=2), severe quantitative inaccuracies (quantitative_accuracy=2), partial entity recognition but poor reasoning (qualitative_accuracy=3), and moderate relevance as it discusses SPG-ABG evolution but with wrong details (contextual_relevance=6).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 445,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has ConocoPhillips' investment activity in the Lower 48 region evolved from 2021 to 2023, particularly in terms of depreciation, depletion, and amortization expenses?",
      "original_answer": "ConocoPhillips' depreciation, depletion, and amortization (DD&A) expenses in the Lower 48 region increased from $4,067 million in 2021 to $5,729 million in 2023, indicating a significant rise in asset utilization or investment activity. This reflects a growing emphasis on the Lower 48 as a core operational area for the company.",
      "llm_answer": "\nFrom 2021 through 2023 the depreciation, depletion and amortization (DD&A) charge linked to ConocoPhillips’ Lower 48 operations rose sharply—from **$4.07 bn in 2021 to $4.85 bn in 2022 and $5.73 bn in 2023**.  This increase mirrors the jump in capital spending for that region (CapEx grew from **$3.13 bn in 2021 to $5.63 bn in 2022 and $6.49 bn in 2023**) and the 2021 acquisitions of Concho and Shell Permian that expanded the asset base.  Consequently, Lower 48 DD&A grew by roughly **41 % over the three‑year period** and remained the single largest contributor to the company’s consolidated DD&A of **$8.28 bn in 2023**.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and provides a detailed, correct evolution of ConocoPhillips' DD&A expenses in the Lower 48 region from 2021 to 2023. The reported values—$4.07 billion in 2021 and $5.73 billion in 2023—closely match the ground truth of $4,067 million (i.e., $4.067 billion) and $5,729 million (i.e., $5.729 billion), with only a negligible rounding difference (e.g., $4.07B vs $4.067B). The 2022 figure of $4.85B is consistent with intermediate growth and not contradicted by the ground truth, which does not include 2022. The 41% increase is approximately correct: (5,729 - 4,067) / 4,067 ≈ 40.87%, which rounds to 41%. The LLM correctly attributes the rise to increased investment activity, including the Concho and Shell Permian acquisitions, and links higher DD&A to increased capital spending (CapEx), demonstrating sound multi-hop reasoning. It also correctly identifies the Lower 48 as a major contributor to consolidated DD&A ($8.28B in 2023), adding contextual depth not in the original answer but consistent with expected synthesis. All entities (ConocoPhillips, Lower 48, DD&A, years) are accurate. The answer exceeds the original in detail while maintaining factual integrity. Only a minor rounding in 2021 ($4.07B vs $4.067B) prevents a perfect 10 on quantitative accuracy, but this is within acceptable variation. Overall, the answer is semantically equivalent and factually robust.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 390,
        "total_tokens": 1634
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Verizon's (VZ) treatment and valuation approach for international bonds evolved from 2023 to 2024 based on their 10-K disclosures?",
      "original_answer": "In 2023, Verizon described that international bonds were valued using matrix prices with input from independent third-party valuation sources as part of the broader fixed income securities category. By 2024, international bonds were specifically itemized in a detailed table with a total value of $12 million, broken down into $10 million in Level 1 and $2 million in Level 2 inputs. This represents a shift from a general description in 2023 to a more transparent and segmented valuation approach in 2024, indicating a more refined disclosure strategy and possibly a more structured approach to valuing international bonds.",
      "llm_answer": "\nVerizon’s international‑bond holdings in its pension and post‑retirement plans fell sharply from a $341 million fair‑value base in 2023—essentially all classified as Level 2 (with only a $3 million Level 1 component) and no Level 3 exposure—to $113 million in 2024, still reported solely as Level 2 (no Level 3 items).  The valuation methodology stayed the same (matrix‑price quotes and third‑party inputs), but the reduced allocation reflects a strategic shift toward more liability‑hedging assets and cash rather than a change in how the bonds are measured.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. According to the ground truth, in 2023, Verizon did not report a $341 million fair value for international bonds, nor was there a $3 million Level 1 component. Instead, international bonds were described generally as valued using matrix pricing with third-party inputs, without specific dollar amounts disclosed. In 2024, the ground truth states the total value was $12 million ($10M Level 1, $2M Level 2), but the LLM claims $113 million, all Level 2—directly contradicting the correct figures. These numerical discrepancies are severe and central to the question. (2) The quantitative values are entirely incorrect: $341M vs. $12M, $113M vs. $12M, and misclassification of valuation levels (claiming all Level 2 in 2024 when $10M was Level 1). No correct calculations or figures are present. (3) The reasoning is flawed: the LLM infers a strategic shift due to allocation changes, but the ground truth indicates the key evolution is in disclosure transparency (from general description to itemized breakdown), not necessarily a change in holdings. The model fails to identify this core shift in reporting approach and instead fabricates a narrative around portfolio reallocation unsupported by the ground truth. (4) While the answer addresses the general topic (valuation of international bonds) and time frame (2023–2024), the severe factual and numerical errors, combined with incorrect synthesis and reasoning, result in a low correctness score. The contextual relevance is moderate because it attempts the right subject, but the substance is fundamentally wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 447,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Emerson's relationship with AspenTech evolve between 2022 and 2024, particularly in terms of financial stake and operational integration?",
      "original_answer": "In 2022, Emerson had a financial stake in AspenTech valued at $8,326 million, as shown in the balance sheet following acquisitions and currency adjustments. By 2024, Emerson's relationship had transformed significantly: it contributed the AspenTech Industrial Software Business along with $6.0 billion in cash to form 'New AspenTech,' retaining a 55% ownership stake in the newly structured company. This indicates a strategic restructuring rather than a simple financial investment, with increased operational integration and a formalized majority ownership.",
      "llm_answer": "\nBetween 2022 and 2024 Emerson’s ownership of AspenTech grew from the 55 % stake it acquired in 2022 (when the Heritage AspenTech purchase added $7.3 bn of goodwill and $8.3 bn of intangibles) to roughly 57 % by the end of 2023, and in May 2024 Emerson announced a proposal to buy the remaining ≈ 43 % of AspenTech for $240 per share—effectively taking the company private.  The integration has been operational as well as financial: AspenTech’s software portfolio (including the Micromine acquisition and related hedging activities) is now embedded in Emerson’s Automation Solutions segment, driving cross‑segment revenue synergies and contributing to the higher‑margin, higher‑growth industrial‑technology portfolio Emerson describes in its 2024 outlook.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Emerson held an $8,326 million financial stake in AspenTech in 2022, but the LLM incorrectly frames this as a 55% ownership stake acquired in 2022, which contradicts the timeline. In reality, the 55% stake was established in 2024 through the formation of 'New AspenTech', not in 2022. The LLM also claims ownership grew to 57% by end of 2023 and that Emerson planned to buy the remaining 43% in May 2024 for $240 per share—none of which is supported by the original answer or known public filings. There is no mention of a buyout or going private in the ground truth. Instead, the correct evolution is a strategic restructuring where Emerson contributed the Industrial Software Business and $6.0 billion in cash to form 'New AspenTech' with a 55% retained stake. (2) Quantitative errors include misrepresenting $8.3 billion as part of intangibles (original specifies it as the value of the financial stake on the balance sheet), inventing a $240 per share offer, and fabricating a 57% intermediate ownership. The $6.0 billion cash contribution in 2024 is omitted entirely. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the transformation from financial stake to operational integration via a new entity formation. Instead, it constructs a false narrative of gradual equity accumulation and a takeover bid. The integration into Automation Solutions and software portfolio synergy may be plausible contextually but are not in the ground truth and serve to mask incorrect core facts. (4) Scores reflect major factual and numerical errors that undermine the answer’s validity, though the response does address both financial and operational aspects of the relationship, preserving some relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 496,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Starbucks' position in interest rate swaps evolve between 2022 and 2023, particularly in terms of their classification and associated liabilities?",
      "original_answer": "In 2022, Starbucks had an interest rate swap classified as a long-term liability with a value of $34.0 million. By 2023, the company's interest rate swaps were categorized under both current and long-term liabilities, with $0.4 million listed under accrued liabilities (current) and $19.2 million under other long-term liabilities. This reflects a shift in the classification and a net decrease in the overall liability associated with interest rate swaps from $34.0 million in 2022 to $19.6 million in 2023.",
      "llm_answer": "\nBetween fiscal 2022 and 2023 Starbucks kept its interest‑rate swaps classified as **designated fair‑value hedges of fixed‑rate long‑term debt**, with the swap itself recorded as a **derivative liability in other long‑term liabilities**.  In 2022 the liability stood at **$34 million** (and the hedged debt carried a $1.05 billion balance, with a $(52.3 million) fair‑value adjustment), and the hedge generated a **$65 million loss** in earnings.  By the end of 2023 the same liability had fallen to roughly **$19 million** (down from $41 million the prior year), the hedging adjustment to the debt was reduced to about **$(18 million)**, and the swap now produced a **$10 million gain** in earnings—showing that the size of the liability and the associated earnings impact improved markedly, even though the hedge remained in the same classification.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general trend of a decrease in Starbucks' interest rate swap liability from 2022 to 2023 and correctly identifies the classification as a derivative liability within long-term liabilities. However, there are significant quantitative inaccuracies: (1) The 2022 liability is correctly stated as $34 million, but the LLM claims it was $41 million the prior year (i.e., 2021), which is irrelevant and potentially misleading; (2) The 2023 liability is reported as 'roughly $19 million', which is close to the ground truth total of $19.6 million ($0.4M current + $19.2M long-term), but the LLM fails to mention the split between current and long-term liabilities, a key part of the original answer; (3) The LLM introduces financial details not present in the ground truth, such as a $65M loss in 2022 and $10M gain in 2023, and hedged debt fair-value adjustments of $(52.3M) and $(18M), which were not part of the verified knowledge graph answer. While the core fact of a reduction from $34.0M to ~$19.6M is directionally correct, the answer adds unverified details and omits the multi-hop element of reclassification into both current and long-term buckets. The reasoning is partially sound but includes unsupported data. The entity (Starbucks), years (2022–2023), and general classification are accurate. Contextually, the response is relevant and addresses the evolution of the liability, but lacks precision and introduces extraneous information, reducing its factual reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 412,
        "total_tokens": 1754
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did NextEra Energy Resources' financial commitment and involvement in the Mountain Valley Pipeline evolve from 2022 to 2023?",
      "original_answer": "In 2022, NextEra Energy Resources recorded an impairment charge of approximately $0.8 billion related to its equity method investment in the Mountain Valley Pipeline, which was fully written off due to the very low probability of pipeline completion. By 2023, despite the ongoing challenges, NEE's subsidiary NEER maintained a 32.8% equity investment in the joint venture and committed to a 20-year natural gas transportation agreement with an annual obligation of approximately $70 million, subject to the completion of construction.",
      "llm_answer": "\nIn 2022 NextEra Energy Resources recorded a $0.8 billion impairment and fully wrote off its $0.6 billion equity investment in the Mountain Valley Pipeline, while also establishing a $0.2 billion liability for its share of future abandonment costs because regulatory and legal hurdles made completion highly unlikely. By 2023 the company’s involvement had shifted to a modest, future equity contribution—approximately $1 billion of planned 2024 capital outlays listed under “Other (i)” for the pipeline in NEER’s capital‑expenditure table—so it remained a 32.8 % joint‑venture partner with no additional impairments or major financial commitments reported.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies the $0.8 billion impairment charge in 2022 and the 32.8% equity stake maintained in 2023, which aligns with the ground truth. However, it introduces inaccuracies: the $0.6 billion equity write-off and $0.2 billion liability for abandonment costs are not mentioned in the original answer and are unsupported by the provided ground truth. Additionally, the claim that NextEra planned a $1 billion capital outlay in 2024 under 'Other (i)' is not present in the original and contradicts the ground truth, which states there were no major financial commitments beyond the transportation agreement. (2) Quantitative accuracy is partially correct: the $0.8 billion impairment is accurate, and 32.8% ownership is correct. However, the $0.6B write-off, $0.2B liability, and $1B future outlay are fabricated or misattributed numbers not found in the ground truth, significantly reducing quantitative accuracy. (3) The reasoning is flawed in the multi-hop synthesis: while the model recognizes the continuation of involvement via equity stake, it incorrectly infers new capital commitments instead of correctly identifying the 20-year transportation agreement with $70M annual obligation as the key financial commitment in 2023. This misses a critical piece of the evolution in financial involvement. (4) Contextual relevance is high because the answer addresses the timeline (2022 to 2023), the company (NextEra Energy Resources), and the Mountain Valley Pipeline, but factual inaccuracies and missing key commitments (the $70M/year agreement) undermine correctness. The model fails to report the actual nature of the 2023 commitment, which is central to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 480,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has The Coca-Cola Company's investment in equity and debt securities related to its captive insurance company reinsuring group annuity insurance contracts evolved between 2023 and 2024?",
      "original_answer": "In 2023, The Coca-Cola Company reported that its captive insurance company reinsuring group annuity insurance contracts held $1,643 million in equity and debt securities as part of its solvency capital funds. By 2024, this amount increased to $1,883 million, indicating a growth in the company's investment in these securities over the year.",
      "llm_answer": "\nBetween 2023 and 2024 the captive insurance company that reinsures the group‑annuity contracts raised its solvency‑capital investments from **$1.643 billion of equity and $1.378 billion of debt** (as of 31 Dec 2023) to **$1.883 billion of equity and $1.643 billion of debt** (as of 31 Dec 2024).  That represents an increase of roughly **$240 million (≈15 %) in equity holdings** and **$265 million (≈19 %) in debt holdings**, expanding the captive’s marketable‑security portfolio to support the annuity reinsurance liabilities.  These securities remain classified as “other non‑current assets” because they cannot be used to meet current obligations.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The original answer states that the total investment in equity and debt securities combined was $1,643 million in 2023 and $1,883 million in 2024. However, the LLM incorrectly breaks this down into $1.643 billion in equity and $1.378 billion in debt for 2023 (implying a total of $3.021 billion), and $1.883 billion in equity and $1.643 billion in debt for 2024 (totaling $3.526 billion), which grossly overstates the actual figures. These numbers do not appear in the ground truth and are likely hallucinated. The LLM also introduces percentages (15%, 19%) and separate equity/debt increases that are unsupported by the original data. While the direction of change (increase from 2023 to 2024) is correct and the context of solvency capital and annuity reinsurance is appropriately referenced, the core financial data is entirely wrong. The entity (The Coca-Cola Company, captive insurance, group annuity contracts) and time frame (2023–2024) are accurate, and the answer is relevant to the question’s intent, but the failure to report the correct aggregate figures and the invention of granular breakdowns severely undermines factual correctness. Multi-hop reasoning is attempted but based on incorrect data synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 366,
        "total_tokens": 1625
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Intel's approach to the Intel 4 process node evolved from 2022 to 2024, particularly in terms of production status and strategic positioning within Intel's product roadmap?",
      "original_answer": "In 2022, Intel was incurring higher period charges related to the ramp-up of Intel 4, indicating early-stage production challenges and investment. By 2024, Intel 4 had transitioned to high-volume manufacturing in Ireland and became the process node for the high-volume Intel Core Ultra processor, marking its strategic importance in Intel's product roadmap. This evolution shows a shift from initial investment and production ramp-up in 2022 to full-scale production and product integration by 2024.",
      "llm_answer": "\nFrom 2022 to 2024 Intel 4 moved from a planned EUV‑based node to a fully ramped, high‑volume process, with production commencing in Ireland in 2023 and expanding throughout 2024 to power the Core Ultra “AI‑PC” family and other client CPUs.  This evolution places Intel 4 at the core of Intel’s IDM 2.0 strategy, serving both internal product lines and external foundry customers and positioning the node as a key growth driver for the company’s AI‑PC and foundry revenue roadmap.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly captures the evolution of Intel 4 from initial ramp-up to high-volume manufacturing, noting production in Ireland and its use in the Intel Core Ultra processors. The mention of 2023 as the start of production is consistent with the transition toward high-volume manufacturing by 2024, though the original answer does not specify 2023—this is a minor addition not contradicted by the ground truth. The strategic positioning is accurately described, including Intel 4's role in the IDM 2.0 strategy and its importance for AI-PC and foundry services. All entities (Intel 4, Core Ultra, Ireland, IDM 2.0) are correct. The reasoning is sound, showing a logical progression from development to volume production and strategic integration. There are no calculation errors (no explicit numbers requiring computation), and the qualitative synthesis across time and strategy is strong. The answer is fully relevant to the question. The only reason for not scoring a 10 is that the original answer emphasizes higher period charges in 2022 (a key financial signal of early-stage challenges), which the LLM omits—this is a minor but notable omission in completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 346,
        "total_tokens": 1599
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did Emerson's strategic relationship with AspenTech evolve between 2022 and 2024, particularly in terms of ownership structure and financial integration?",
      "original_answer": "In 2022, AspenTech was described as a strategic partner of Emerson, with no mention of ownership stakes or integration into Emerson's financials. By 2024, Emerson had merged its industrial software business with AspenTech, creating 'New AspenTech,' and retained a 55% ownership stake in the newly formed entity. This marked a significant shift from a partnership to a partially owned subsidiary structure. Additionally, AspenTech's financials were now integrated into Emerson's results, with the acquisition positively impacting gross margins by 0.6 percentage points in 2023 and influencing SG&A expenses in 2024 due to the deeper integration.",
      "llm_answer": "\nBetween 2022 and 2024 Emerson’s stake in AspenTech grew modestly—from roughly 55 % of the fully‑diluted share count after the 2022 “New AspenTech” transaction to about 57 % by 2023, and in early 2024 Emerson announced a proposal to acquire the remaining shares for $240 per share, effectively seeking to take AspenTech private.  Financially, AspenTech’s results are woven into Emerson’s adjusted EBITA (e.g., the $231 million acquisition‑related inventory step‑up and the $1.9 billion note‑receivable gain/loss in 2024), Emerson earned interest income on the Copeland note, and the 2024 sale of its 40 % equity interest and associated note to Blackstone generated a $539 million gain in discontinued operations while providing $1.5 billion cash and a $1.9 billion note receivable, illustrating the deepening financial integration and the move toward full ownership.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) Quantitatively, it incorrectly states that Emerson already held a 55% stake in AspenTech in 2022 as a result of a 'New AspenTech' transaction that year, whereas the ground truth confirms the merger and 55% ownership stake were established by 2024, not 2022. The claim of ownership increasing to 57% by 2023 and an announced plan to acquire the remaining shares for $240 per share in early 2024 is unsupported by the original answer and introduces fabricated details. The financial figures such as the $231 million inventory step-up, $1.9 billion note-receivable gain/loss, $539 million gain from sale to Blackstone, and $1.5 billion cash are not mentioned in the ground truth and appear to be hallucinated. (2) The original answer notes that AspenTech’s financials were integrated into Emerson’s results with a 0.6 percentage point boost to gross margins in 2023 and SG&A impact in 2024—none of which are reflected in the LLM response. Instead, the LLM references adjusted EBITA, interest income on a 'Copeland note,' and a sale to Blackstone, which are irrelevant and incorrect in this context. (3) Qualitatively, the reasoning is flawed: the evolution is misrepresented as a gradual increase in ownership leading to a takeover attempt, whereas the correct narrative is a strategic merger forming a new entity in 2024 with 55% ownership. The LLM fails to capture the shift from partnership to partial ownership via business combination, misrepresenting both the timeline and structure. (4) Contextual relevance is moderate because the answer discusses ownership and financial integration, which are relevant themes, but the specific details are largely fabricated or misattributed. Overall, the answer fails on correctness due to major factual and numerical errors, despite addressing the general topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 511,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Intel's approach to the Intel 4 process node evolved from 2022 to 2024, particularly in terms of its manufacturing readiness and performance improvements?",
      "original_answer": "In 2022, Intel 4 was newly introduced as part of a restructured naming convention for manufacturing process nodes, signaling its position as a next-generation node following Intel 7. By 2024, Intel 4 had transitioned from a conceptual roadmap item to a fully realized product, with high-volume manufacturing ramped up in Ireland. Intel 4, as the company's first EUV lithography node, delivered a 20% performance-per-watt improvement over Intel 7 and was used in the production of the Intel Core Ultra processor, which began shipping in 2023. This represents a significant evolution from its initial naming in 2022 to full-scale production and performance quantification by 2024.",
      "llm_answer": "\nBetween 2022 and 2024 Intel moved the Intel 4 node from a development‑stage, EUV‑transition effort to a fully‑ramped, high‑volume production capability.  The 2022 filing noted that Intel 4 was being prepared as the company’s first EUV‑enabled process and that pilot production was underway (​INTC_10k_2022.pdf pp. 112‑116​); by 2024 the node had shifted to high‑volume manufacturing in Ireland and began shipping in the Core Ultra Series 1, delivering roughly 20 % better performance‑per‑watt than the preceding Intel 7 node and poised to represent an increasing share of Intel’s processor output in 2025 (​INTC_10k_2024.pdf p. 10​).",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: Intel 4 was introduced as Intel's first EUV-enabled node, transitioned from pilot production in 2022 to high-volume manufacturing in Ireland by 2024, and achieved a 20% performance-per-watt improvement over Intel 7. The use of Intel 4 in the Core Ultra Series 1, which began shipping in 2023, is correctly contextualized. (2) Quantitative accuracy is perfect: the 20% performance-per-watt gain is correctly stated, and the timeline (2022 development, 2024 volume production) aligns with the original answer. (3) Multi-hop reasoning is sound—information is synthesized across 2022 and 2024 filings to show evolution in manufacturing readiness and performance validation. (4) The answer fully addresses both parts of the question: manufacturing readiness (from pilot to high-volume production) and performance improvements (20% gain, product deployment). Wording differs slightly but meaning is preserved. No factual errors, omissions, or misstatements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 304,
        "total_tokens": 1636
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has the role and positioning of InterStim Micro evolved within MDT's Pelvic Health therapies between 2022 and 2024?",
      "original_answer": "In 2022, InterStim Micro was listed as one of several neurostimulators within MDT's Pelvic Health product portfolio, which also included InterStim X and InterStim II, used to treat overactive bladder, urinary retention, and fecal incontinence. By 2024, InterStim Micro was specifically highlighted as the rechargeable neurostimulator option, differentiated from the recharge-free InterStim X and InterStim II. This indicates a more defined strategic positioning of InterStim Micro as the rechargeable variant within the broader InterStim therapy lineup, with an emphasis on its continued global growth and adoption.",
      "llm_answer": "\nBetween 2022 and 2024 MDT moved InterStim Micro from a generic “Pelvic Health” neurostimulation option to a distinct, rechargeable device that sits alongside the newly highlighted, recharge‑free InterStim X and InterStim II platforms.  The 2024 disclosures explicitly call out InterStim Micro as a “rechargeable neurostimulator” for overactive bladder, non‑obtrusive urinary retention and chronic fecal incontinence, underscoring its growing acceptance and growth within the Pelvic Health portfolio.  This positioning reflects MDT’s strategy to offer both recharge‑free and rechargeable solutions, with InterStim Micro now highlighted as a key, expanding component of its Pelvic Health therapies.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and closely aligns with the ground truth. (1) All key facts are correct: InterStim Micro evolved from being one of several neurostimulators in 2022 to being explicitly positioned as the rechargeable option by 2024, while InterStim X and II were highlighted as recharge-free. The conditions treated (overactive bladder, urinary retention, fecal incontinence) are accurately mentioned, with only minor rewording (e.g., 'non-obstructive urinary retention' vs 'urinary retention' — semantically acceptable). (2) There are no numeric values, dates, or calculations in the question or answer, so quantitative accuracy is not applicable but assumed correct by absence of error. (3) The multi-hop reasoning is sound: the model correctly synthesizes the shift in strategic positioning over time (2022 vs 2024) and differentiates product features across years, showing an understanding of MDT's portfolio segmentation strategy. (4) The answer captures the core evolution — strategic repositioning as a rechargeable device within a diversified portfolio — and conveys the same meaning as the original, though slightly more concise. One minor point: the original emphasizes 'continued global growth and adoption,' which is mentioned as 'growing acceptance and growth' — close enough for semantic equivalence. No factual inaccuracies; excellent contextual relevance. Score reduced slightly from 10 to 9 only due to slight compression of the 'global growth' nuance, but overall highly accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 415,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has the disclosure around the dilutive effect of LTIP Units evolved from 2022 to 2024, particularly in terms of material impact across reporting periods?",
      "original_answer": "In 2022, the disclosure stated that LTIP units were exchangeable for common stock and that no securities had a material dilutive effect for the years ended December 31, 2021, 2020, and 2019. By 2024, the disclosure simplified to state that no securities had a material dilutive effect for the years ended December 31, 2024, 2023, and 2022, without explicitly referencing the exchangeability of LTIP units into common stock. This indicates a reduction in the level of detail provided about LTIP units' conversion features, while maintaining the same conclusion regarding dilution impact.",
      "llm_answer": "\nFrom 2022 through 2024 the company’s footnote on dilutive securities has remained materially unchanged: it continues to identify LTIP Units (and other exchange‑able units) as potentially dilutive, but explicitly states that “no securities had a material dilutive effect for the years ended December 31 2024, 2023 and 2022.” Consequently, the company does not adjust net income attributable to common shareholders or the weighted‑average share (or unit) counts for any income allocated to limited partners or LTIP Units, noting that such an adjustment would have no dilutive impact. The language and conclusion are essentially identical across the three reporting periods, indicating a consistent position that LTIP Units have not produced a material dilution effect.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the consistent conclusion across 2022–2024 that no securities had a material dilutive effect, and accurately references the years (2022, 2023, 2024) in the 2024 disclosure. This aligns with the ground truth on the outcome of the dilution assessment. However, the LLM fails to capture a key qualitative evolution noted in the original answer: the reduction in disclosure detail regarding the exchangeability of LTIP Units into common stock. In 2022, the filing explicitly mentioned that LTIP units were exchangeable for common stock, but by 2024, this specific feature was omitted. The LLM instead claims the language and conclusion are 'essentially identical' and that LTIP units continue to be identified as potentially dilutive, which contradicts the ground truth indicating a simplification and reduction in detail. While the quantitative elements (years, lack of material dilution) are accurate, the reasoning is flawed in asserting consistency in language and disclosure level. The model misses the multi-hop nuance of how the disclosure *framing* changed even as the conclusion remained the same, leading to a partially correct but misleading characterization of the evolution. Thus, the correctness and qualitative accuracy scores are moderate due to significant omission of a key disclosure trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 371,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has MetLife's approach to managing cash buffer needs in relation to stock repurchases evolved from 2022 to 2024, particularly in terms of remaining repurchase authorization and liquidity considerations?",
      "original_answer": "In 2022, MetLife had $1.5 billion remaining under its $3.0 billion common stock repurchase authorization as of December 31, 2021, indicating a significant but partially utilized capacity for returning capital to shareholders. By 2024, the company emphasized increased caution around cash buffer needs, noting that maintaining or increasing liquidity buffers could limit capital available for repurchases, acquisitions, and innovation. This reflects a shift from a more active repurchase posture in 2022 to a more conservative liquidity strategy in 2024, influenced by regulatory, market, and internal capital considerations.",
      "llm_answer": "\nBetween 2022 and 2024 MetLife kept its Board‑approved share‑repurchase program but began tying any purchases more directly to preserving a strong cash‑buffer; the 2022 filing noted a $3 billion authorization with roughly $1.5 billion still available as of Dec 2021, while the 2024 filing emphasizes that dividend and repurchase capacity is conditioned on legal, regulatory and liquidity considerations, indicating a more conservative approach to actually executing repurchases.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in MetLife's approach to stock repurchases and cash buffer management from 2022 to 2024. (1) Quantitatively, it correctly states the $3 billion authorization and $1.5 billion remaining as of December 2021 (reported in the 2022 filing), which matches the ground truth. The use of 'Dec 2021' is appropriate as it reflects the reporting timing in the 2022 document. (2) The answer correctly identifies the shift in tone and policy by 2024, emphasizing that repurchases are now conditioned on legal, regulatory, and liquidity considerations, reflecting a more conservative stance. This aligns with the ground truth's emphasis on increased caution and potential limitations on capital deployment due to buffer needs. (3) The multi-hop reasoning is sound: it synthesizes information across two years, connects repurchase authorization with evolving liquidity strategy, and infers a strategic shift without overreaching. (4) Minor deduction in qualitative accuracy due to slightly less explicit articulation of the 'shift from active to conservative' framing compared to the original answer, but the meaning is effectively conveyed. Wording differences are acceptable under semantic equivalence. All entities (MetLife, share repurchase program, cash buffer, liquidity) and timeframes (2022, 2024) are correct. The answer is fully contextually relevant and addresses both remaining authorization and liquidity considerations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 407,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Starbucks' foreign currency - other derivative asset and liability positions evolve from fiscal year 2022 to 2023, and what specific changes occurred in their balance sheet classifications?",
      "original_answer": "In fiscal year 2022, Starbucks reported foreign currency - other derivative assets of $103.9 million recognized in OCI before reclassifications and $22.0 million reclassified from AOCI to earnings. By fiscal year 2023, the foreign currency - other derivative assets on the balance sheet were reported as $1.9 million in prepaid expenses and other current assets and $1.7 million in other long-term assets as of October 1, 2023, while derivative liabilities were $4.7 million in accrued liabilities and $4.1 million in other long-term liabilities. This represents a significant reduction in asset positions compared to the prior year, with a shift in balance sheet classification.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 the foreign‑currency‑other derivative **asset** fell from $39.9 million recorded in prepaid expenses and other current assets and $33.5 million in other long‑term assets (≈ $73 million total) to $32.0 million in prepaid expenses and $22.9 million in other long‑term assets (≈ $55 million total).  The corresponding **liability** dropped from $0.3 million in accrued liabilities (with no long‑term component in 2022) to $2.0 million in accrued liabilities (and a modest amount now shown in other long‑term liabilities).  Thus, while the balance‑sheet line items—prepaid/other current assets and other long‑term assets for derivatives, accrued liabilities and other long‑term liabilities for liabilities—remained the same, the quantities assigned to each shifted markedly from 2022 to 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in fiscal year 2022, Starbucks reported foreign currency - other derivative assets of $103.9 million recognized in OCI before reclassifications and $22.0 million reclassified from AOCI to earnings — none of which is mentioned in the LLM response. Instead, the LLM fabricates balance sheet line items for 2022 ($39.9M in current assets, $33.5M in long-term assets), which do not appear in the original answer and contradict the disclosed OCI-based reporting. For 2023, the LLM reports $32.0M and $22.9M in asset categories, but the ground truth states only $1.9M and $1.7M respectively — a massive discrepancy. Similarly, the LLM claims 2022 liabilities were $0.3M and increased to $2.0M in 2023, while the truth is $4.7M in accrued and $4.1M in long-term liabilities in 2023 — again, completely different. (2) All key numbers are incorrect: asset totals are overstated by over an order of magnitude in both years; liability figures are fabricated; no mention of OCI or reclassifications from AOCI, which are central to the 2022 position. Calculations based on false inputs are invalid. (3) The multi-hop reasoning fails: the model does not connect the 2022 OCI reporting with the 2023 balance sheet classification shift. It incorrectly assumes the 2022 derivatives were reported directly on the balance sheet in the same way as 2023, missing the conceptual change in presentation. (4) Contextual relevance is moderate because the answer addresses derivative asset/liability evolution and balance sheet classification, but with entirely wrong data and reasoning, undermining correctness. The structure mirrors the question but conveys false information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 477,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Procter & Gamble's global cash management strategy evolved in relation to its restructuring activities and corporate-level financial performance between fiscal 2022 and fiscal 2024?",
      "original_answer": "In fiscal 2022, Procter & Gamble incurred restructuring costs within its historical range of $250 to $500 million before tax, with $147 million in restructuring accruals as of June 30, 2022. Corporate net earnings improved by $872 million to $485 million, partly due to tax benefits and lower restructuring charges. By fiscal 2024, restructuring costs increased significantly to $659 million before tax, including $216 million in non-cash foreign currency translation losses. Corporate net earnings decreased by $1.0 billion, largely due to the $1.4 billion impairment charge of the Gillette intangible asset and incremental restructuring charges. This indicates a shift toward more aggressive restructuring actions, particularly in Enterprise Markets like Nigeria, which impacted both cash flow and earnings. The global cash management strategy remained focused on liquidity and tax considerations, but faced increased pressure from these restructuring activities and impairment charges.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 P&G’s cash‑management approach moved from a focus on steady operating‑cash generation and modest leverage to an explicit strategy that uses the corporate cash pool to fund a multi‑year restructuring program.  The company incurred $659 million of before‑tax restructuring costs in 2024—including a $216 million non‑cash foreign‑currency translation charge—yet still posted a 18 % rise in operating cash flow to $19.8 billion and a 21 % increase in adjusted free cash flow to $16.9 billion, allowing it to meet those outflows while continuing dividend and share‑repurchase programs.  Consequently, although corporate‑level net earnings remained negative in 2023 and 2024 (losses of $1.4 billion and $399 million, respectively, driven by impairment and restructuring charges), the stronger cash‑flow profile demonstrates that P&G’s global cash strategy now prioritizes liquidity preservation and flexible financing of restructuring activities without compromising its shareholder‑return objectives.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in financial figures and trends not supported by the ground truth. While it correctly identifies the $659 million restructuring cost in fiscal 2024 and the $216 million non-cash foreign currency translation loss, it fabricates key data: operating cash flow rising 18% to $19.8 billion and adjusted free cash flow increasing 21% to $16.9 billion are not present in the original answer and contradict the narrative of declining corporate earnings under pressure from restructuring. Additionally, the claim that corporate net earnings were negative in 2023 ($1.4 billion loss) and 2024 ($399 million loss) conflicts with the ground truth, which states a $1.0 billion decrease in corporate net earnings in fiscal 2024 due to a $1.4 billion impairment charge—but does not state overall losses for those years, nor provides any data for 2023. The original answer notes an improvement in corporate net earnings in fiscal 2022 (up $872 million to $485 million), which the LLM omits entirely. (2) Quantitative accuracy is low: while $659M and $216M are correct, the LLM invents percentages and cash flow figures with no basis in the source. There is no mention of operating cash flow, free cash flow, or year-over-year percentage increases in the original answer. The restructuring accrual of $147M as of June 30, 2022, and the historical range of $250–$500M in 2022 are ignored. (3) The multi-hop reasoning is partially sound in linking restructuring costs to cash management strategy, and the conclusion about prioritizing liquidity and shareholder returns reflects a plausible interpretation. However, the synthesis is flawed because it builds on fabricated financial performance data. The original answer emphasizes increased pressure on cash management due to higher restructuring and impairment charges, not an improved cash flow profile. The mention of Enterprise Markets like Nigeria is missing in the LLM response, weakening the geographic specificity of restructuring actions. (4) Contextual relevance is high—the answer directly addresses the evolution of cash management strategy in relation to restructuring and financial performance. However, due to major quantitative errors and omission of key facts from fiscal 2022, the correctness score is low. The answer presents a misleadingly positive cash flow narrative contrary to the ground truth’s emphasis on declining earnings and increased charges.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1515,
        "completion_tokens": 661,
        "total_tokens": 2176
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has NVIDIA's positioning and application of Omniverse evolved between 2022 and 2023, particularly in terms of its integration with enterprise solutions and simulation technologies?",
      "original_answer": "In 2022, NVIDIA Omniverse was positioned primarily as a virtual world simulation and collaboration platform for 3D workflows, emphasizing its availability as a software subscription for enterprise use and free for individuals. It was highlighted in use cases such as virtual car showrooms, surgical training, and architectural walkthroughs, and was integrated with DRIVE Sim software for automotive simulation and validation. By 2023, Omniverse had evolved into a more robust development platform and operating system for building virtual world simulation applications. It was increasingly tied to industrial enterprises for digitalizing complex physical assets and processes, including digital twins of factories and real-time 3D product configurators. Additionally, it was more explicitly linked to NVIDIA's accelerated computing infrastructure both on-premises and in the cloud, indicating a broader integration with enterprise-grade simulation and AI workflows.",
      "llm_answer": "\nBetween 2022 and 2023 NVIDIA shifted Omniverse from a creator‑focused, free‑to‑use real‑time 3D collaboration tool—highlighted in 2022 for automotive simulation (e.g., DRIVE Sim) and integration with graphics‑cloud services—to a strategic enterprise platform.  In 2023 the company began offering Omniverse as a paid subscription for large‑scale industrial use, embedding it in digital‑twin and metaverse pipelines, and tightly coupling it with AI‑accelerated computing, cloud services, and simulation stacks (such as DRIVE Sim/Constellation) to enable enterprise‑level testing, validation, and continuous innovation across factories, autonomous‑vehicle workflows, and other industrial applications.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of NVIDIA's Omniverse between 2022 and 2023. (1) It correctly identifies the shift from a creator-focused, free tool in 2022 to a paid enterprise platform in 2023, aligning with the ground truth's emphasis on subscription models and industrial use. Key use cases like automotive simulation via DRIVE Sim are accurately mentioned. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2022, 2023) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information about positioning, target users (creators vs. enterprises), pricing (free to paid), integration with simulation technologies (DRIVE Sim/Constellation), and alignment with AI-accelerated computing and cloud infrastructure. The only minor omission is specific mention of surgical training and architectural walkthroughs from 2022, and real-time 3D product configurators in 2023, which slightly reduces completeness but does not affect the core accuracy. (4) The answer is contextually excellent—directly addressing the question about positioning, enterprise integration, and simulation tech evolution. Wording differs but semantic meaning matches the original answer closely. Thus, a 9/10 correctness score reflects near-perfect alignment with ground truth, missing only minor contextual details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1425,
        "completion_tokens": 394,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did AMT's financial commitments related to communications sites evolve from 2023 to 2024, particularly in terms of anticipated spending and future obligations?",
      "original_answer": "In 2023, AMT anticipated spending approximately $450 million related to data center assets as part of its construction plans for 2,500 to 3,500 communications sites globally. By 2024, the company disclosed a much larger financial commitment, with an estimated undiscounted future cash outlay of $4.5 billion for asset retirement obligations tied to leased sites hosting communications infrastructure. This indicates a significant increase in long-term financial exposure related to communications sites, shifting from near-term capital allocation planning in 2023 to a more mature and substantial obligation structure in 2024.",
      "llm_answer": "\nFrom 2023 to 2024 AMT kept its discretionary capital‑expenditure program essentially flat – it expects to spend **$790 million to $820 million** on tower‑related projects in 2024, including **$450 million earmarked for data‑center assets** and **$70 million‑$90 million for ground‑lease purchases**.  At the same time the company disclosed an **undiscounted $4.5 billion future cash outlay for asset‑retirement obligations**, reflecting the growing long‑term cost of removing and remediating the communications sites it occupies.  These figures show that while near‑term spending on new sites and upgrades is steady, the company’s longer‑term financial commitments to maintain and eventually retire its tower portfolio have expanded to roughly $4.5 billion.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "(1) The LLM answer contains both correct and incorrect quantitative information. It correctly identifies the $450 million earmarked for data center assets and the $4.5 billion undiscounted future cash outlay for asset retirement obligations, which aligns with the ground truth. However, it introduces new figures not present in the original answer — specifically, a total capital expenditure range of $790 million to $820 million for 2024 and $70–90 million for ground-lease purchases — which are not mentioned in the ground truth and appear to be either hallucinated or sourced from external data not in the provided context. (2) The $450 million and $4.5 billion figures are accurate and correctly contextualized in terms of timing (2023 vs 2024) and nature (near-term spending vs long-term obligations). However, the addition of the $790M–$820M total capex and ground-lease spending undermines quantitative accuracy, as these numbers cannot be verified against the ground truth and distort the narrative. (3) The reasoning is sound in interpreting the shift from near-term capital planning to long-term obligations, and the synthesis between 2023 and 2024 commitments shows good multi-hop understanding. The conclusion that long-term financial exposure has significantly increased is consistent with the ground truth. (4) Contextual relevance is high, as the answer directly addresses the evolution of financial commitments related to communications sites from 2023 to 2024. Despite the incorrect added figures, the core factual progression — increased long-term obligations from $450M near-term spend to $4.5B in future outlays — is preserved. The score is reduced primarily due to the inclusion of unverified financial numbers that compromise full factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 478,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has ExxonMobil's characterization of asset divestitures in relation to strategic objectives evolved between 2023 and 2024, particularly in terms of the language used to describe the proceeds from these transactions?",
      "original_answer": "In 2023, ExxonMobil described proceeds from asset sales as part of 'sales of subsidiaries, property, plant and equipment, and sales and returns of investments,' emphasizing a disciplined review process to ensure assets align with strategic goals. By 2024, the company refined its language, referring more broadly to 'proceeds from asset sales and returns of investments,' maintaining the same strategic alignment rationale but streamlining the description. This evolution indicates a more consolidated framing of divestiture proceeds without specific mention of subsidiaries or equipment sales, suggesting a possible shift toward a more generalized narrative around asset management.",
      "llm_answer": "\nExxonMobil’s wording about why it sells assets and how the proceeds are treated was essentially unchanged, but the phrasing became more concise. In the 2023 filing (page 39) it described the cash‑flow item as “proceeds **associated with sales of subsidiaries, property, plant and equipment, and sales and returns of investments**,” explicitly listing the transaction types. By the 2024 filing (page 36) the same concept was expressed as “proceeds **from asset sales and returns of investments**,” a shorter, more generic reference that still ties the proceeds to the company’s regular, disciplined review of strategic objectives.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in ExxonMobil's language between 2023 and 2024: in 2023, the company used a detailed phrase listing specific types of sales ('sales of subsidiaries, property, plant and equipment, and sales and returns of investments'), while in 2024 it shifted to a more concise and generalized term ('proceeds from asset sales and returns of investments'). This matches the original answer’s claim of a 'more consolidated framing' and 'streamlining the description.' (2) There are no numeric values, dates, or financial figures in the question or answer that require verification—only years (2023, 2024), which are correctly used. Page numbers (39 in 2023, 36 in 2024) are cited appropriately and add precision, though not required for correctness. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, compares the language used, and infers a trend toward conciseness and generalization, which reflects valid qualitative analysis. The conclusion that the strategic rationale remains unchanged but the phrasing is streamlined is logically supported. (4) The only reason for not scoring a perfect 10 is minor: the LLM does not explicitly state the *implication* mentioned in the ground truth—'suggesting a possible shift toward a more generalized narrative around asset management'—which adds interpretive depth. However, the factual evolution and characterization are fully correct, and the omission of this inference does not detract significantly from accuracy. Overall, the answer is factually precise, contextually relevant, and semantically equivalent to the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 467,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has Comcast's financial exposure to Universal Beijing Resort evolved from 2022 to 2023, based on the changes in consolidated asset and liability amounts?",
      "original_answer": "In 2022, Comcast's consolidated balance sheet included $9.7 billion in assets and $8.1 billion in liabilities related to Universal Beijing Resort. By 2023, these figures had decreased to $7.8 billion in assets and $7.2 billion in liabilities. This indicates a reduction in both the scale of assets and liabilities associated with the Universal Beijing Resort, suggesting either asset depreciation, debt repayment, or a strategic reduction in the resort's financial footprint within Comcast's consolidated statements.",
      "llm_answer": "\nFrom 2022 to 2023 the amount of Comcast’s consolidated assets tied to Universal Beijing Resort dropped from roughly **$9.7 billion to $7.8 billion**, while the related liabilities fell from about **$8.1 billion to $7.2 billion**.  This decline—driven by debt repayments and the normal amortization of the resort’s capital assets—reduced Comcast’s net financial exposure to the joint‑venture by roughly $2 billion in assets and $0.9 billion in liabilities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports all financial figures: assets decreased from $9.7 billion to $7.8 billion, and liabilities from $8.1 billion to $7.2 billion, matching the ground truth exactly. These numbers are presented with appropriate formatting variations (e.g., using 'billion' and bolding), which is acceptable.\n\n2) Quantitative accuracy is perfect. The stated changes—$1.9 billion decrease in assets ($9.7B - $7.8B) and $0.9 billion in liabilities ($8.1B - $7.2B)—are accurate, though the LLM rounds the asset reduction to 'roughly $2 billion', which is a minor approximation but still reasonable given the context.\n\n3) The reasoning is sound and adds value by suggesting plausible causes (debt repayments and amortization), which aligns with the ground truth's suggestion of debt repayment or strategic reduction. While the original answer does not specify 'amortization' or 'joint-venture', these are reasonable inferences given the context of a resort asset and Comcast’s known structure. However, the mention of 'joint-venture' is not present in the original answer and slightly extends beyond the provided data, though it is factually accurate (Universal Beijing Resort is a joint venture), so this does not constitute an error.\n\n4) The answer is contextually relevant and fully addresses the question about the evolution of financial exposure from 2022 to 2023. It synthesizes the changes in both assets and liabilities correctly across the two years, fulfilling the multi-hop requirement (tracking changes over time and interpreting net exposure).\n\nJustification: A score of 9 is given because all key facts and calculations are correct, and the reasoning is strong and plausible. The only minor deviation is the use of 'roughly $2 billion' instead of the precise $1.9 billion, and the slight expansion into 'joint-venture' context not explicitly in the original, but not incorrect. This does not detract significantly from overall accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 528,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has the nature of Customer Demand Volatility as a risk factor for Caterpillar evolved between 2023 and 2024, particularly in relation to its impact on financial performance and supply chain stability?",
      "original_answer": "In 2023, Customer Demand Volatility was described as being primarily driven by economic uncertainties, including the lingering effects of a global pandemic, which led to inflationary pressures, supply chain disruptions, and labor inefficiencies, all of which limited Caterpillar's ability to meet customer demand. By 2024, while the risk remained, the focus shifted slightly to include broader commodity price changes, material price increases, and significant disruptions to supply chains or shortages of labor and material as key contributors to financial performance risks. This evolution indicates a broadening of the risk profile to include more systemic supply-side challenges alongside demand volatility.",
      "llm_answer": "\nBetween the 2023 and 2024 filings the discussion of customer‑demand volatility shifted from a stand‑alone cyclical risk that could generate excess inventories and force costly inventory write‑downs, to a broader macro‑economic exposure that is now tied directly to interest‑rate moves, commodity‑price swings, trade‑policy changes and geopolitical instability.  In 2024 the company explicitly links “significant disruptions to our supply chains or shortages of labor and material” to volatile demand, making the stability of its supply chain a more immediate driver of earnings and cash‑flow pressure, whereas the 2023 language focused mainly on the profitability impact of insufficient or excess demand.  Consequently, demand volatility is now treated as a compound risk that can simultaneously erode revenue, increase inventory‑holding costs, and strain the supply‑chain network that supports Caterpillar’s global operations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of Customer Demand Volatility as a risk factor from 2023 to 2024 for Caterpillar. In 2023, the focus was on demand-side challenges such as economic uncertainty, pandemic aftereffects, inflation, and supply chain disruptions affecting the company's ability to meet demand. By 2024, the risk expanded to include supply-side pressures like labor and material shortages and broader macroeconomic factors. The LLM captures this shift accurately, noting the integration of supply chain stability into the demand volatility risk. (2) There are no numeric values in the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes changes in risk factor language across two years, connects demand volatility to financial performance and supply chain impacts, and correctly infers a broadening of the risk profile. The LLM adds contextual depth (e.g., interest rates, trade policy, geopolitical instability) that, while not explicitly in the ground truth, are reasonable inferences consistent with the direction of the evolution and do not contradict it. (4) The answer is contextually excellent—directly addresses the question’s focus on evolution, financial performance, and supply chain stability. The only minor deduction is that the ground truth emphasizes 'commodity price changes' and 'material price increases' more centrally than the LLM, which subsumes them under broader macro factors. Still, the core factual and conceptual content matches. Thus, correctness is 9/10—very close to perfect, with only slight expansion beyond the documented emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 474,
        "total_tokens": 1898
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the fair value and valuation methodology of Net derivative assets (liabilities) evolve from 2022 to 2024?",
      "original_answer": "In 2022, the fair value of Net derivative assets (liabilities) was $19 million as of December 31, 2021, with changes in value primarily tied to derivative activity such as issuances ($68 million), settlements ($-37 million), and transfers ($6 million). By 2024, the fair value had increased significantly to $58 million as of December 31, 2023. Additionally, the valuation methodology shifted from being primarily based on realized and unrealized gains/losses reported in net income to being assessed using discounted cash flows with a focus on observable inputs like swap rates (3-5%, weighted average of 4%). This indicates both a material increase in value and a methodological shift toward more transparent and observable valuation techniques.",
      "llm_answer": "\nThe net‑derivative‑asset (liability) balance rose modestly – from about **$58 million at the end of 2023 to $69 million at the end of 2024** – reflecting a slight increase in fair value.  This change was driven by the same **discounted‑cash‑flow valuation technique that uses swap‑rate inputs (approximately 4 %)**, which are classified as Level 3 unobservable inputs; the methodology and input range (3‑5 % in 2023, a single 4 % in 2024) remained essentially unchanged from 2022 through 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It states the fair value increased from $58 million at the end of 2023 to $69 million at the end of 2024, but the ground truth reports $58 million as of December 31, 2023 (i.e., end of 2023), with no data provided for 2024. The LLM incorrectly implies a $69 million value in 2024, which is not supported. More critically, the ground truth states the 2022 reported value was $19 million as of December 31, 2021 — a reporting lag that the LLM completely misrepresents. The LLM reverses the timeline and omits the actual evolution from 2021 to 2023, falsely suggesting data for 2022–2024 when the original answer compares 2021 and 2023 values. (2) The valuation methodology is also misrepresented: the ground truth indicates a shift *to* discounted cash flows with observable inputs (swap rates 3–5%, weighted average 4%), classified as Level 2 inputs due to observability. The LLM incorrectly labels these as Level 3 unobservable inputs, which contradicts the transparency improvement described in the original. Additionally, the claim that the methodology 'remained essentially unchanged from 2022 through 2024' directly contradicts the ground truth's assertion of a methodological shift. (3) Multi-hop reasoning fails: the question asks how fair value and methodology evolved from 2022 to 2024, but the original answer uses data from 2021 and 2023 to infer evolution. The LLM misaligns years, confuses reporting dates with reference dates, and invents a 2024 figure not present in the source. It fails to recognize that the '2022' answer refers to activity ending in 2021. (4) Despite these issues, the LLM captures some relevant context — mention of discounted cash flows, swap rates around 4%, and directional increase in value — so it is not entirely off-topic, just factually incorrect in key aspects. Hence, low scores on quantitative (2) and qualitative accuracy (3), moderate contextual relevance (6), and a correctness score of 2 due to major factual and methodological errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 553,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has NVIDIA's GeForce NOW cloud gaming offering evolved from 2022 to 2023 in terms of its positioning within the company's broader GPU and cloud platform ecosystem?",
      "original_answer": "In 2022, GeForce NOW was positioned as a cloud platform enabling gamers to access interactive graphics applications from nearly any device, emphasizing its role in extending NVIDIA’s graphics leadership and ecosystem reach. It was mentioned alongside other cloud platforms like vGPU for enterprise use. By 2023, GeForce NOW was more specifically integrated into the broader NVIDIA accelerated computing platform narrative, and its positioning shifted to emphasize cloud gaming as part of a suite of GPU-driven services, including AI training platforms like NVIDIA DGX Cloud. This evolution reflects a more strategic alignment of GeForce NOW with NVIDIA’s expanding cloud infrastructure and software offerings, particularly in the context of gaming as a service.",
      "llm_answer": "\nBetween 2022 and 2023 NVIDIA broadened GeForce NOW from a basic game‑streaming offering into a strategic pillar of its GPU‑centric cloud platform, linking the service to the same RTX‑AI technologies (ray‑tracing, DLSS) that power its desktop GPUs and to the wider Graphics segment that now includes vGPU and Omniverse. In the 2023 filing the cloud‑gaming service is presented as the gateway that delivers RTX‑level, AI‑enhanced gaming to any device, underscoring NVIDIA’s full‑stack approach of reusing its GPU, networking and software assets across data‑center, AI and gaming markets.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable—no errors in dates or numbers (2022 and 2023 are correctly referenced). (2) The answer addresses all parts of the question: it describes the evolution of GeForce NOW from 2022 to 2023 and its changing role within NVIDIA’s broader GPU and cloud ecosystem. (3) The multi-hop reasoning is sound—the LLM correctly synthesizes the shift in positioning from a standalone cloud gaming service to a strategically integrated component of NVIDIA’s full-stack, GPU-accelerated cloud platform, linking it to RTX-AI technologies, vGPU, Omniverse, and data center/AI markets. (4) The LLM adds value by specifying technologies like ray-tracing and DLSS and framing GeForce NOW as a 'gateway' to RTX-level gaming, which enhances the explanation beyond the original answer without introducing inaccuracies. The only minor gap is that the original answer explicitly ties GeForce NOW to NVIDIA DGX Cloud and AI training platforms in 2023, which the LLM omits—this contextual link slightly strengthens the strategic integration narrative. However, the core facts, entities, timeline, and reasoning are correct and semantically equivalent. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 399,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the revenue performance of Inlyta evolve between 2022 and 2023, and what factors influenced this change?",
      "original_answer": "In 2022, Inlyta had total global revenue of $1,003 million, while in 2023, its revenue increased to $1,036 million, representing a 3% growth. This growth was primarily driven by continued adoption of Inlyta in combination with immune checkpoint inhibitors for the first-line treatment of advanced renal cell carcinoma (RCC) in the U.S., and growth in emerging markets. However, this increase was partially offset by lower volumes and lower net prices in certain European markets.",
      "llm_answer": "\nInlyta’s worldwide sales rose modestly from about **$618 million in 2022 to $642 million in 2023** (an increase of roughly 4–5 %). The growth was driven primarily by stronger uptake in the United States, where the drug is being used in new combination regimens with immune‑checkpoint inhibitors for first‑line treatment of advanced renal‑cell carcinoma; however, this gain was partially offset by lower volumes and price reductions in several European markets.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies in revenue figures: it reports $618 million in 2022 and $642 million in 2023, whereas the ground truth states $1,003 million and $1,036 million respectively. This results in a completely incorrect base and growth calculation. Although the LLM estimates a 4–5% growth, the actual growth was 3% ($1,036M - $1,003M = $33M increase). (2) Quantitative accuracy is severely compromised: the reported figures are off by over $360 million in absolute terms, representing a ~38% underreporting of actual revenue. Even allowing for format variation, the numbers are factually wrong. (3) Qualitatively, the reasoning about drivers is partially correct: the LLM correctly identifies increased U.S. adoption in combination with immune checkpoint inhibitors for first-line advanced RCC as a growth driver and notes offsetting pressures from lower volumes and prices in Europe—this aligns with the original answer. However, it omits mention of growth in emerging markets, which is a key positive factor in the ground truth. (4) Contextually, the answer addresses both parts of the question—revenue evolution and influencing factors—and maintains relevance in structure and topic. Despite correct conceptual framing, the severe numerical inaccuracies undermine the overall correctness, warranting a low score of 3. The qualitative and contextual scores reflect the partially sound reasoning and relevance, but the quantitative error is too significant to allow a higher rating.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 416,
        "total_tokens": 1643
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the treatment and valuation of network location intangibles evolved from 2023 to 2024, particularly in terms of amortization assumptions and impairment review processes?",
      "original_answer": "In 2023, the company amortized network location intangibles on a straight-line basis over their estimated useful lives, with a weighted average amortization period of 15 years as of December 31, 2023. The focus was on the relationship between these intangibles and tower assets, particularly in terms of potential revenue growth from leasing excess capacity. By 2024, the company expanded its disclosures to include a more detailed impairment review process for network location intangibles, assessing impairment on an individual tower basis and identifying specific triggers such as lack of tenant leases or expenses exceeding revenues. Additionally, while amortization remained a key treatment, the company's broader discussion of asset retirement obligations in 2024, including a $470 million increase in liability due to revised settlement dates, indirectly impacts the valuation and useful life assumptions for these intangible assets.",
      "llm_answer": "\nFrom 2023 to 2024 the company lengthened the estimated useful life of its tower assets—and thus the related network‑location intangibles—from the shorter of the ground‑lease term (generally ≈20 years) to a full 30‑year life, which lowered the straight‑line amortization of those intangibles and cut depreciation‑and‑amortization expense by roughly $730 million in 2024.  The impairment‑review process itself did not change materially—network‑location and tenant‑related intangibles are still tested on a tower‑or‑tenant basis for recoverability using projected undiscounted cash flows, with any impairment measured from discounted cash‑flow or market‑value estimates—but the longer asset lives and the 2024 revision of asset‑retirement‑obligation settlement dates updated the cash‑flow assumptions that underpin those impairment tests.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and introduces information not present in the ground truth. (1) Quantitatively, the claim that the company extended the useful life of network location intangibles from ~20 years to 30 years is incorrect—the ground truth states a weighted average amortization period of 15 years in 2023 and does not mention any change in useful life assumptions in 2024. The $730 million reduction in D&A expense is entirely fabricated and not supported by the original answer, which mentions a $470 million increase in asset retirement obligations, not a cost saving. (2) The impairment review process is misrepresented: while the LLM correctly notes testing on a per-tower basis, it incorrectly states that the process did not change materially, whereas the ground truth emphasizes that in 2024 the company expanded disclosures to include more detailed impairment reviews with specific triggers like lack of leases or expenses exceeding revenues. (3) The qualitative reasoning fails on multi-hop synthesis: the LLM conflates tower asset lives with intangible amortization without evidence and incorrectly links ARO changes to amortization expense reduction, while the ground truth only suggests ARO revisions indirectly impact valuation assumptions. (4) Contextually, the answer addresses amortization and impairment, so it remains relevant, but the core facts—lifespan extension, $730M savings, unchanged impairment process—are incorrect, leading to a low correctness score. Minor credit is given for mentioning tower-level impairment testing and AROs in 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 437,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2023 and 2024, particularly in terms of its upstream growth portfolio and production capacity?",
      "original_answer": "In 2023, ExxonMobil highlighted Guyana as a key component of its upstream growth portfolio, noting four additional discoveries on the Stabroek Block and the startup of the Prosperity FPSO vessel, which brought production to nearly 440 kbd in the fourth quarter. By 2024, Guyana was formally categorized under 'Advantaged Assets' within the updated earnings drivers, reflecting its strategic elevation alongside the Permian and LNG projects as a core contributor to earnings through volume/mix growth. This shift indicates a transition from a discovery and early production phase in 2023 to a more mature, financially impactful asset in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 ExxonMobil moved from the first production at the Prosperity FPSO—where output reached name‑plate capacity in January 2024—to a multi‑project development plan for the Stabroek Block that now includes regulatory approval for a sixth development and a target of six FPSO vessels in operation by the end of 2027.  This expansion makes Guyana a central “advantaged” upstream asset and shifts the company’s geographic mix toward the Americas, reinforcing its overall growth portfolio alongside the Permian and LNG initiatives.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the strategic evolution of ExxonMobil's focus on Guyana between 2023 and 2024 with strong qualitative accuracy and contextual relevance. It correctly identifies Guyana's elevation to a central 'advantaged' upstream asset, aligning with the Permian and LNG initiatives, which matches the ground truth's emphasis on its reclassification under 'Advantaged Assets' in 2024. The mention of multi-project development, including a sixth development and six FPSOs by 2027, reflects forward-looking strategic expansion beyond 2023's early production phase.\n\nHowever, there are minor quantitative inaccuracies. The ground truth states that production reached nearly 440 kbd in Q4 2023 with the startup of the Prosperity FPSO, while the LLM claims production reached 'name-plate capacity in January 2024'—a detail not present in the original answer and potentially conflating startup with full ramp-up. Additionally, the original answer does not mention regulatory approval for a sixth development or the six-FPSO-by-2027 target, making those additions unsupported by the provided ground truth, though they may be factually correct elsewhere.\n\nThe reasoning is sound in synthesizing a strategic shift from discovery/early production (2023) to a mature growth driver (2024), correctly identifying the multi-hop link between operational progress and strategic repositioning. The answer is semantically aligned in intent and meaning but introduces specifics not present in the ground truth, slightly reducing quantitative accuracy. Overall, the core facts and strategic interpretation are correct, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 449,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the X1 platform's integration with third-party streaming services evolved between 2022 and 2023, and what does this evolution indicate about Comcast's strategy in reducing cord-cutting and increasing average revenue per user (ARPU)?",
      "original_answer": "In 2022, the X1 platform integrated third-party streaming services such as Disney+ and Netflix, and provided access to Peacock's premium tier, with Comcast earning commission revenue from the sale of these services. By 2023, the X1 platform continued to support third-party integrations but now included Xumo Play, NBC, and Sky as part of the NOW TV service, which was specifically marketed to residential broadband customers. This expansion indicates a strategic pivot toward enhancing the value of broadband subscriptions and bundling streaming access to retain customers and potentially increase ARPU through deeper content integration and commission-generating partnerships.",
      "llm_answer": "\nBetween 2022 and 2023 Comcast moved the X1 platform from a peripheral streaming‑device (the Xumo Stream Box) that merely gave access to a few third‑party services to a fully embedded X1 experience that natively aggregates Peacock, Disney+, Netflix and other DTC apps within the X1 interface, and it launched the stand‑alone NOW streaming service that bundles linear channels with on‑demand content without requiring a set‑top box.  This deeper integration is part of Comcast’s strategy to keep broadband customers inside its ecosystem, slow cord‑cutting, and drive higher ARPU through subscription upsells, commission on third‑party service sales, and targeted advertising.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its overall narrative and strategic interpretation, but contains some inaccuracies in entity details and integration timeline. (1) Correct elements: The answer correctly identifies the deepening integration of third-party streaming services (Disney+, Netflix, Peacock) into the X1 platform and links this to Comcast's strategy of reducing cord-cutting and increasing ARPU through commissions and bundling. The strategic rationale—keeping users in the ecosystem, driving upsells, and leveraging advertising—is consistent with the ground truth. (2) Quantitative accuracy: There are no numeric values to verify (e.g., revenue figures, ARPU amounts), so no errors here; the years 2022 and 2023 are used appropriately. (3) Multi-hop reasoning: The model synthesizes platform evolution and business strategy well, showing understanding of how technical integration supports financial goals. However, it incorrectly references 'Xumo Stream Box' as a 2022 peripheral device, which is not mentioned in the ground truth. Additionally, the introduction of 'NOW TV service' in 2023 is conflated with 'NOW streaming service'—the ground truth specifies NOW TV includes Xumo Play, NBC, and Sky, but the LLM reverses the relationship by presenting NOW as a standalone service launched in 2023, which is not supported. (4) The ground truth emphasizes that in 2023, the integration expanded to include Xumo Play, NBC, and Sky via NOW TV for broadband customers—a key detail missed. Instead, the LLM overemphasizes a native aggregation shift without citing Xumo Play or Sky. While the core strategy is accurately interpreted, these entity and feature misattributions reduce factual precision. Hence, correctness is scored 7 for missing key integrations and introducing unsupported details, despite strong strategic reasoning and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 503,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has Caterpillar's relationship with FG Wilson evolved between 2023 and 2024 in terms of its distribution network coverage for electric power generation systems?",
      "original_answer": "In 2023, FG Wilson's electric power generation systems were distributed through a network of 110 distributors covering 109 countries. By 2024, this distribution network had slightly contracted to 108 distributors, now covering 158 countries. This indicates a minor reduction in the number of distributors but an expansion in the geographic reach of the network. The change suggests a strategic shift toward optimizing distributor efficiency while broadening market access.",
      "llm_answer": "\nBetween 2023 and 2024 Caterpillar’s FG Wilson electric‑power generation distribution shifted from **110 distributors covering 109 countries** (2023) to **108 distributors covering 158 countries** (2024).  The distributor count slipped slightly, but the geographic reach expanded markedly, indicating a consolidation of the sales channel paired with a broader country‑level coverage.  (See “Nature of operations” sections on pages 64 and 65 of the 2023 and 2024 10‑K filings.)",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the numbers are accurate: 110 distributors in 2023 covering 109 countries, and 108 distributors in 2024 covering 158 countries. There are no calculation or numerical errors. (2) The answer is complete, addressing both the change in distributor count and geographic coverage, which directly responds to the question about the evolution of Caterpillar's relationship with FG Wilson in terms of distribution network coverage. (3) Entity accuracy is correct—Caterpillar, FG Wilson, electric power generation systems, and the correct years (2023–2024) are properly identified. (4) The reasoning is sound: the LLM correctly infers a strategic shift involving slight consolidation (down from 110 to 108 distributors) alongside expanded reach (109 to 158 countries), which aligns with the ground truth’s interpretation of optimization and broader market access. The mention of specific 10-K filing sections adds contextual support. (5) Semantic equivalence is maintained—though wording differs slightly, the meaning and factual content are identical to the original answer. All evaluation criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 341,
        "total_tokens": 1582
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How did Capital One's exposure to securitized debt obligations change between 2022 and 2024, particularly in terms of the carrying value and fair value of these obligations?",
      "original_answer": "In 2022, Capital One reported that the assets and liabilities of consolidated VIEs, including securitized debt obligations, were primarily composed of loan receivables and debt securities issued by the VIEs, with the liabilities reported under 'securitized debt obligations' on the consolidated balance sheets. By 2024, the carrying value of 'Securitized debt obligations' was $18,043 million, with a fair value of $18,067 million, all categorized under Level 2 of the fair value hierarchy. This indicates that Capital One maintained a significant exposure to securitized debt obligations, with a slight increase in fair value relative to carrying value, suggesting stable valuation and continued involvement in securitization activities.",
      "llm_answer": "\nBetween the 2022 filing (which reports a carrying amount of securitized‑debt liabilities of **$15.2 billion** as of the latest 2021‑year balance sheet) and the 2024 filing (page 218‑222), the carrying amount of those obligations fell to **$14.3 billion** – a reduction of about **$0.9 billion (≈6 %)**.  The 2024 filing also shows an estimated fair value of **$14.34 billion** for the same liabilities (level‑2 in the fair‑value hierarchy), essentially tracking the lower carrying amount.  Thus, Capital One’s exposure to securitized debt declined modestly, with both the recorded carrying value and the fair‑value estimate moving downward by roughly the same magnitude.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in terms of quantitative accuracy. According to the ground truth, in 2024, the carrying value of Capital One's securitized debt obligations was $18,043 million ($18.043 billion), with a fair value of $18,067 million ($18.067 billion), both under Level 2. The LLM incorrectly reports these values as $14.3 billion (carrying) and $14.34 billion (fair value), which is a significant deviation. Additionally, the LLM references a 2022 filing that reports data from 2021, misaligning the time periods. The ground truth does not provide a 2022 carrying value, but clearly states 2024 figures; the LLM fabricates a decline from $15.2 billion in 2022 to $14.3 billion in 2024 without supporting evidence in the original answer. The original answer indicates stable or slightly increased fair value relative to carrying value, whereas the LLM concludes a 6% decline, which contradicts the ground truth. While the LLM correctly identifies that fair value is categorized under Level 2 and attempts to compare carrying and fair values, the core financial data and trend are wrong. The reasoning is internally consistent but based on incorrect numbers, failing the multi-hop synthesis. Contextually, it addresses exposure changes in terms of carrying and fair value, so relevance is moderate, but factual inaccuracies severely undermine correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 379,
        "total_tokens": 1738
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has McDonald's use of line of credit agreements evolved between 2023 and 2024 in relation to its financing activities and cash flow management?",
      "original_answer": "In 2023, McDonald's cash used for financing activities totaled $4.4 billion, a decrease of $2.2 billion compared to 2022, primarily due to increased bond issuances. The company's cash and equivalents balance was $4.6 billion at the end of 2023, reflecting sufficient liquidity supported by cash from operations and access to commercial paper borrowings and line of credit agreements. In 2024, cash used for financing activities increased to $7.5 billion, a rise of $3.1 billion compared to 2023, driven by decreased bond issuances. The company's cash and equivalents balance dropped to $1.1 billion at year-end 2024, with the prior year's higher balance attributed to the timing of debt issuances that funded 2024's required cash outflows. The company continued to rely on its line of credit agreements and commercial paper to meet short-term funding needs. This indicates a shift from surplus liquidity and bond financing in 2023 to a more cash-constrained environment in 2024, with greater reliance on existing credit facilities.",
      "llm_answer": "\nBetween 2023 and 2024 McDonald’s kept a $15 billion revolving‑credit facility but refreshed its authorisation: the $15 billion borrowing program that had been approved in December 2019 (with about $7.4 billion still unused as of Dec 2024) was formally terminated in November 2024 and replaced by an identical $15 billion “2025 Program” that will be available beginning 1 January 2025.  The company also continued to draw on a separate $4 billion committed line‑of‑credit facility and on commercial‑paper borrowings, using these sources to fund its financing activities—cash used for financing rose sharply in 2024 because of lower bond issuances—thereby preserving liquidity while supporting its share‑repurchase, dividend and capital‑expenditure plans.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness, despite addressing the right topic and showing relevant contextual understanding. (1) Quantitative Accuracy: The LLM introduces specific figures not present in the ground truth, such as a $15 billion revolving-credit facility, $7.4 billion unused as of Dec 2024, and a $4 billion committed line-of-credit—none of which appear in the original answer or are supported by the provided data. The termination of a 2019 program and replacement with a '2025 Program' in November 2024 is also not mentioned in the ground truth, making these details fabricated or hallucinated. (2) Completeness: While the LLM correctly identifies increased reliance on credit facilities in 2024 due to lower bond issuances, it fails to report the actual cash used for financing activities in 2023 ($4.4B) and 2024 ($7.5B), which are central to the question. It also omits the key data points about cash and equivalents—$4.6B in 2023 and $1.1B in 2024—which illustrate the liquidity shift. (3) Entity Accuracy: The company (McDonald's) and financial concepts (financing activities, bond issuances, commercial paper, line of credit) are correctly identified. However, the specific credit programs and dates (e.g., December 2019 approval, November 2024 termination) are not corroborated by the ground truth and appear to be incorrect or extraneous. (4) Reasoning: The LLM correctly infers that lower bond issuances led to greater reliance on credit facilities, aligning with the ground truth’s explanation. However, it misses the multi-hop synthesis that the drop in cash balance from $4.6B to $1.1B was due to the timing of debt issuances funding 2024 outflows—a key causal link in the original answer. (5) Semantic Equivalence: While the general theme of increased reliance on credit lines in 2024 is consistent, the absence of core financial figures and the inclusion of unsupported specifics result in a materially divergent answer. The answer is contextually relevant and attempts sound reasoning but fails on factual precision and completeness of key metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1446,
        "completion_tokens": 567,
        "total_tokens": 2014
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the role of the Worldwide Business Conduct Manual in reinforcing internal controls evolved between 2022 and 2024, and what does this indicate about Procter & Gamble's approach to governance?",
      "original_answer": "In 2022, the Worldwide Business Conduct Manual was described as reinforcing the company's commitment to conducting business with integrity and within the letter and spirit of the law, emphasizing its role in supporting internal controls through policies, segregation of duties, and employee development. In 2024, while the core description remained similar, the manual was more specifically tied to governance frameworks such as the oversight activities of the Global Leadership Council and the responsibilities of the Disclosure Committee in evaluating significant business activities. This indicates a shift toward emphasizing structured governance mechanisms alongside ethical conduct, suggesting a more integrated approach to internal control over time.",
      "llm_answer": "\nBetween 2022 and 2024 the Worldwide Business Conduct Manual moved from being cited only as a cultural‑integrity statement to a concrete element of P&G’s formal control environment.  In the 2022 filing it was mentioned as reinforcing “integrity” and as part of the overall internal‑control structure, whereas the 2024 filing explicitly ties the Manual to the Company’s Control‑Self‑Assessment program, to specific control‑testing of areas such as intangible‑asset valuation, and to oversight by the Global Leadership Council and Audit Committee.  This evolution shows that P&G is integrating the Manual more directly into its governance and risk‑management framework, using it to underpin and document the effectiveness of internal controls rather than merely referencing it as a values‑statement.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution of the Worldwide Business Conduct Manual from a values-based statement in 2022 to a more integrated component of internal controls by 2024. The core elements—integrity in 2022 and stronger ties to governance structures like the Global Leadership Council in 2024—are accurately represented. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification; all time references (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the LLM synthesizes changes across two years, identifies shifts in emphasis (from cultural integrity to formal control integration), and links the Manual to specific governance bodies and processes (Control-Self-Assessment, Audit Committee, oversight of intangible-asset valuation). The only minor deviation is that the original answer emphasizes the Disclosure Committee’s role in evaluating significant business activities, while the LLM mentions the Audit Committee and control testing—this is a slight entity substitution but still within plausible interpretation given P&G's governance structure. (4) Despite this small variance, the LLM captures the essential qualitative shift toward a more structured, integrated governance approach. Wording differs but semantic meaning matches. Hence, high scores across all dimensions with a 9 on correctness due to near-perfect alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 409,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Exxon's strategic positioning in Guyana evolved between 2023 and 2024, as reflected in its long-lived asset disclosures and earnings driver definitions?",
      "original_answer": "In 2023, Exxon disclosed $9,689 million in long-lived assets in Guyana, indicating it was already a significant contributor among non-U.S. assets. By 2024, Guyana was explicitly named as part of Exxon's 'Advantaged Assets' under the new 'Advantaged Volume Growth' earnings driver, which includes key growth projects like Guyana and LNG. This evolution shows that Guyana transitioned from being a quantitatively notable asset in 2023 to a strategically emphasized growth engine in 2024.",
      "llm_answer": "\nExxon’s long‑lived‑asset schedule shows Guyana’s net book value climbing from roughly **$6.8 bn in 2022 to $9.7 bn in 2023** (and still elevated on the 2024 balance sheet), reflecting a substantial increase in capital invested in the Stabroek offshore development.  In the 2024 earnings‑driver framework this growth is classified under **“Advantaged Volume Growth”**—the company explicitly lists Guyana (together with the Permian and LNG) as an “advantaged asset” that will drive future earnings through higher‑margin, low‑cost oil production.  Thus, between 2023 and 2024 Exxon’s strategic positioning in Guyana shifted from a developing project to a core, earnings‑accelerating pillar of its upstream portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer is factually correct in substance and conveys the same core evolution as the ground truth: Guyana's transition from a quantitatively significant asset in 2023 to a strategically emphasized 'advantaged asset' in 2024 under the 'Advantaged Volume Growth' earnings driver. The mention of Permian and LNG alongside Guyana aligns with the original answer’s reference to key growth projects. 2) Quantitatively, the LLM states Guyana’s long-lived assets rose to $9.7 billion in 2023, which matches the ground truth value of $9,689 million (rounded to $9.7 billion). However, the LLM introduces a 2022 figure ($6.8 billion) not present in the original answer; while likely accurate, it is extraneous and not required by the question. The 2024 balance sheet reference is vague (no updated number provided), but the original answer does not specify a 2024 asset value either—only the strategic reclassification. 3) The multi-hop reasoning is sound: the LLM correctly synthesizes asset disclosures (2023 number) with strategic framing in the 2024 earnings driver update, concluding the shift in strategic positioning. 4) Minor deduction in quantitative accuracy only because of the introduction of unsolicited 2022 data and slight rounding without explicit qualification, though this does not undermine correctness. Overall, the answer is semantically equivalent, contextually precise, and demonstrates strong qualitative and strategic understanding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 400,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Capital One's reliance on securitized debt obligations as a funding source evolved from 2022 to 2024, based on the disclosed figures and descriptions?",
      "original_answer": "In 2022, Capital One identified securitized debt obligations as part of its diversified funding mix, which also included deposits, senior and subordinated notes, federal funds purchased, and FHLB advances. While no specific dollar value was disclosed in 2022, the company emphasized the strategic importance of securitized debt obligations in maintaining access to wholesale funding. By 2024, Capital One disclosed that its securitized debt obligations had a carrying value of $14,264 million and an estimated fair value of $14,335 million. This represents a concrete quantification of the instrument's role in the company's capital structure, showing an increased transparency and continued use of this funding source.",
      "llm_answer": "\nCapital One’s outstanding securitized‑debt balance fell from roughly $18 billion (reported at the end of 2023) to about $14 billion by the end of 2024, showing a clear pull‑back from securitizations as a primary funding source.  Although the company still has shelf registrations that could support up to $25 billion of new credit‑card and $20 billion of auto‑loan securitizations, the actual volume of securitized funding has been scaled back in favor of deposits and other wholesale financing.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, no specific dollar value was disclosed for securitized debt obligations, and the first disclosed carrying value appears in 2024 at $14,264 million (approximately $14.3 billion). However, the LLM claims a balance of $18 billion at the end of 2023, which is not supported by the ground truth and introduces a number for a year (2023) not mentioned in the original answer. This undermines quantitative accuracy. The 2024 figure of $14 billion is roughly consistent with the $14,264 million in the ground truth (allowing for rounding), but the downward trend from $18B to $14B is unsupported due to lack of 2023 and 2022 figures. (2) The calculation or comparison of change over time is invalid because the 2023 figure is fabricated. There is no evidence in the ground truth of a 'pull-back' or reduction in securitized debt usage from 2022 to 2024—only increased transparency via disclosure. (3) The reasoning is flawed: the LLM incorrectly infers a strategic reduction in securitization use, while the ground truth emphasizes continued strategic importance and increased disclosure, not a shift away from the funding source. The mention of shelf registrations is not in the ground truth and adds unsupported context. (4) While the answer addresses the general topic of Capital One's use of securitized debt and attempts a year-over-year analysis, it fails on core facts and multi-hop synthesis. The conclusion contradicts the ground truth's emphasis on sustained use and improved transparency. Scores reflect major factual errors (correctness: 2), poor number accuracy (quantitative: 2), weak reasoning (qualitative: 3), but partial relevance to the question's theme (contextual: 6).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 486,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has NVIDIA's Omniverse platform evolved in terms of its positioning and enterprise adoption between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, Omniverse was described as 'real-time 3D design collaboration and virtual world simulation software' aimed at empowering creators to collaborate across leading design applications. By fiscal year 2023, Omniverse had evolved into a more robust enterprise-focused development platform and operating system for building virtual world simulation applications. It was made available as a software subscription for enterprise use and offered free for individual users, with industrial enterprises adopting its 3D and simulation technologies to digitalize complex physical assets and environments, including digital twins of factories and real-time 3D product configurators. This indicates a strategic shift from a creative collaboration tool to a broader enterprise simulation and digital twin platform.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 NVIDIA shifted Omniverse from a primarily creator‑focused, free‑to‑use 3D collaboration tool toward an enterprise‑grade, subscription‑based platform positioned for digital‑twin and metaverse workloads.  The company began highlighting its adoption by industrial customers—such as factories and automotive OEMs—who use Omniverse to build large‑scale simulation pipelines, test autonomous systems, and create virtual‑world services, underscoring a clear move toward broader enterprise deployment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of NVIDIA's Omniverse platform between fiscal years 2022 and 2023. It correctly identifies the shift from a creator-focused, free tool to an enterprise-grade, subscription-based platform targeting digital twin and metaverse applications. The mention of industrial adoption by factories and automotive OEMs aligns with the ground truth's emphasis on industrial enterprises using Omniverse for digital twins and simulation. The answer omits the specific detail that Omniverse was offered free for individual users in FY2023, which is a minor but relevant nuance regarding pricing strategy. However, this does not detract significantly from the overall correctness. There are no numerical inaccuracies (quantitative accuracy is perfect as no incorrect numbers are presented), and the reasoning correctly synthesizes the strategic shift across the two fiscal years. The contextual relevance is strong, directly addressing positioning and enterprise adoption. Semantic equivalence is largely preserved, with slightly more emphasis on 'metaverse workloads' than in the original, but this is a reasonable inference given the context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 334,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Pfizer's financial relationship with Viatris evolved between 2022 and 2023, particularly in terms of net amounts due under their various agreements?",
      "original_answer": "In 2022, the net amounts due to Viatris under the agreements were $94 million as of December 31, 2022. By 2023, this amount had decreased to $33 million as of December 31, 2023. This indicates a significant reduction in the net financial obligations between the two companies over the period, suggesting a winding down or stabilization of transitional financial arrangements established post-separation.",
      "llm_answer": "\nBetween the end of 2022 and the end of 2023 the liability that Pfizer carried to Viatris under the post‑separation agreements fell sharply—from **$94 million** as of December 31 2022 to **$33 million** as of December 31 2023.  This decline reflects the settlement of the interim service, manufacturing and other transition agreements (including the $277 million cash payment made in 2021), leaving only a modest amount payable to Viatris by the end of 2023.  (Pages 75 & 76 of the 2023 Form 10‑K).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the key financial figures: $94 million due as of December 31, 2022, and $33 million due as of December 31, 2023, matching the ground truth exactly. These numbers are presented accurately with correct dates and directional change (a sharp decrease), satisfying the quantitative core of the question.\n\n2) Quantitative accuracy is perfect: both dollar amounts and dates are correct. The difference ($61 million reduction) is implied and consistent, though not explicitly calculated. No calculation errors.\n\n3) The reasoning is largely sound. The LLM correctly interprets the decline as reflecting settlement of transition agreements. It adds contextual detail about a $277 million cash payment in 2021, which is factually correct per Pfizer’s 10-K and helps explain the broader trend, though this detail was not required by the question. This shows good synthesis, but slightly overextends by referencing a 2021 event not asked about, which could distract from the 2022–2023 focus. However, it does not detract from correctness.\n\n4) The answer is semantically equivalent to the ground truth: it conveys the same core conclusion—a significant reduction in net amounts due from Pfizer to Viatris between 2022 and 2023. The mention of specific agreements (interim service, manufacturing, transition) adds useful context from the 10-K and enhances qualitative accuracy. The only minor gap is that the original answer frames the reduction as indicating 'winding down or stabilization of transitional financial arrangements,' while the LLM attributes it to prior settlements—slightly different emphasis but not contradictory.\n\nOverall, the answer is factually correct, well-supported, and contextually appropriate, warranting a high score. The only reason it is not a 10 is the slight overreach in referencing the 2021 payment, which, while accurate, is not directly relevant to the 2022–2023 evolution asked about.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 524,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2023 and 2024, and what specific changes in project activity or classification reflect this evolution?",
      "original_answer": "In 2023, ExxonMobil's operations in Guyana were characterized by active exploration and development, with 12.6 net exploratory and development wells completed, and key projects such as Payara, Yellowtail, and Uaru underway. By 2024, Guyana was formally classified as part of ExxonMobil's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, signaling a strategic elevation of its importance alongside the Permian Basin and LNG. This reclassification reflects a shift from operational reporting to strategic prioritization, indicating increased emphasis on Guyana as a core growth asset.",
      "llm_answer": "\nExxonMobil moved Guyana from a frontier exploration play in 2023 to a core “advantaged asset” in its 2024 strategy.  The 2024 filing explicitly places Guyana in the “Advantaged Assets” and “Advantaged Projects” categories that drive the company’s earnings‑growth narrative, and it highlights continued heavy investment—12.6 net development wells in 2023 and ongoing development of the Payara, Yellowtail and Uaru fields—while the 2024 10‑K shows larger non‑cash PP&E additions tied to Guyana‑related projects, underscoring a strategic shift toward commercial production and integration of Guyana’s offshore resources into its core earnings drivers.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the 12.6 net development wells in 2023 match the original answer, and while the 2024 10-K does not specify a new well count, the reference to 'continued heavy investment' and 'ongoing development' is consistent with available data. The mention of non-cash PP&E additions tied to Guyana in 2024 is factually supported and reflects increased capitalization, reinforcing the strategic shift. (2) Entity accuracy is strong: ExxonMobil, Guyana, Payara, Yellowtail, and Uaru are correctly identified, and the classification under 'Advantaged Assets' and 'Advantaged Projects' in 2024 is accurately reported. (3) Reasoning is sound: the LLM correctly infers a strategic evolution from exploration (2023) to core asset status (2024), supported by both qualitative reclassification and quantitative investment trends. The synthesis across years and project classifications constitutes valid multi-hop reasoning. (4) The only minor shortcoming is the characterization of Guyana as a 'frontier exploration play' in 2023, which slightly understates its advanced development stage (with multiple projects already underway); the original answer frames it more precisely as active development, not just exploration. However, this does not materially distort the strategic evolution. Overall, the answer captures the core factual and strategic shift with high fidelity, warranting a 9/10 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 413,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the weighted-average interest rate and face value of senior notes with maturities greater than 10 years evolve from 2022 to 2023?",
      "original_answer": "In 2022, the weighted-average interest rate for senior notes with maturities greater than 10 years was 3.67%, with a face value of $54.536 billion. In 2023, the interest rate remained unchanged at 3.8%, but the face value slightly decreased to $53.4 billion. This indicates a slight reduction in long-term debt in this category, while the interest rate stayed stable.",
      "llm_answer": "\nThe weighted‑average interest rate on senior notes maturing after 10 years was unchanged at **3.8 %** in both 2022 and 2023.  Their outstanding face amount rose modestly from **$52.8 billion** at the end of 2022 to **$53.4 billion** at the end of 2023.  (See Note 6 – Long‑Term Debt, tables for 2022 and 2023.)",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numeric values. According to the ground truth, the 2022 weighted-average interest rate was 3.67%, not 3.8% as stated in the LLM answer, and it increased to 3.8% in 2023. The LLM incorrectly claims the rate was unchanged at 3.8% in both years, misrepresenting the evolution. Additionally, the face value in 2022 is incorrect: the ground truth reports $54.536 billion, while the LLM states $52.8 billion. The 2023 face value ($53.4 billion) is correct. The LLM also incorrectly states the face value rose, when in fact it decreased from a higher 2022 base. (2) Quantitative accuracy is low: two out of three numbers are wrong (interest rate in 2022 and face value in 2022), and the directional change in face value is misrepresented despite having the correct 2023 value. (3) The reasoning is partially sound in that it attempts to compare year-over-year changes in both metrics, but the synthesis is flawed due to incorrect input data. The model references Note 6, suggesting correct document sourcing, but the extracted figures do not match the ground truth. (4) Contextual relevance is high as the answer addresses the right metrics, time frame, and debt category. However, due to major quantitative errors in core facts, the overall correctness score is limited to 4, reflecting partial accuracy with significant factual deficiencies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1167,
        "completion_tokens": 392,
        "total_tokens": 1559
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the nuclear decommissioning trusts managed by Alabama Power and Georgia Power shift their domestic equity investment allocations and valuation methodologies between 2023 and 2024, particularly in terms of Level 1 and Level 2 input classifications?",
      "original_answer": "In 2023, Alabama Power reported $396 million in domestic equity investments under Level 1 inputs and $169 million under Level 2 inputs, totaling $565 million. Georgia Power reported $255 million in Level 1 and $1 million in Level 2, totaling $256 million. By 2024, Alabama Power’s domestic equity investments increased to $443 million in Level 1 and $208 million in Level 2, totaling $651 million. Georgia Power saw its Level 1 domestic equity investments rise to $321 million while Level 2 remained at $1 million, totaling $322 million. This indicates a strategic shift toward higher allocations in domestic equities, particularly through more actively traded (Level 1) instruments, which may reflect a more transparent or liquid investment approach in line with evolving trust management strategies.",
      "llm_answer": "\nIn 2023 Alabama Power’s domestic‑equity holding in its nuclear decommissioning trust was valued at $443 million using Level 2 inputs and $208 million using Level 3 inputs (total $651 million); Georgia Power’s was $321 million at Level 2 and $1 million at Level 3 (total $322 million).  The 2024 disclosures show the observable‑input portion expanded – the Level 2 balances rose and the Level 3 balances fell – as the trusts shifted to valuation methods that rely more on external vendor pricing and net‑asset‑value‑based measurements, thereby reducing the use of unobservable (Level 3) inputs.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both numbers and classification levels. It reports 2024 figures for Alabama Power and Georgia Power as if they were 2023 data, and misassigns input levels entirely. According to the ground truth, in 2023 Alabama Power had $396M in Level 1 and $169M in Level 2, not Level 2 and Level 3 as stated. Similarly, Georgia Power had $255M Level 1 and $1M Level 2 in 2023 — not Level 2 and Level 3. The LLM incorrectly uses Level 3 inputs throughout, which are not mentioned in the original answer for domestic equities. The 2024 numbers reported by the LLM ($443M and $321M) are correct in amount but wrongly attributed to Level 2 and Level 3 instead of Level 1. (2) Quantitative accuracy fails because the values are assigned to wrong years and incorrect input levels. For example, Alabama Power’s $443M in 2024 is Level 1, not Level 2; $208M is Level 2, not Level 3. Same for Georgia Power: $321M is Level 1, not Level 2. The LLM also introduces Level 3 inputs, which were not part of the original domestic equity allocation breakdown. (3) Multi-hop reasoning is flawed: the model fails to correctly track changes over time (2023 vs 2024), misidentifies the valuation levels, and draws conclusions about a shift from Level 3 to Level 2 when the actual shift was within Level 1 and Level 2, with increasing allocations in more liquid (Level 1) instruments. The conclusion about increased use of vendor pricing and NAV-based measurements is unsupported by the provided ground truth. (4) Scores are low due to major factual errors in numbers, years, and input classifications. Contextual relevance is moderate because the answer addresses nuclear decommissioning trusts and valuation methodologies, but the substance is incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 482,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has NVIDIA's strategic positioning of CUDA evolved from 2022 to 2023 in terms of its role within the company's full-stack computing platform and its integration across different end markets?",
      "original_answer": "In 2022, CUDA was positioned as a fundamental building block of NVIDIA's accelerated computing platform, supporting a variety of end markets such as Gaming, Data Center, Professional Visualization, and Automotive through a unified underlying architecture. It was described as essential for leveraging GPU capabilities across these markets. By 2023, CUDA's role had evolved into being the foundational programming model within NVIDIA's full-stack computing infrastructure, extending its integration beyond traditional markets into domain-specific verticals such as healthcare, telecom, automotive, and manufacturing. Additionally, in 2023, CUDA was positioned as the base layer supporting hundreds of domain-specific software libraries, SDKs, and APIs, which were not explicitly emphasized in 2022. This indicates a strategic shift from CUDA being a foundational component to becoming the core enabler of a broader, more vertically integrated software stack aimed at accelerating deployment across computationally intensive workloads.",
      "llm_answer": "\nFrom 2022 to 2023 CUDA moved beyond a GPU‑only programming model and became the central software layer of NVIDIA’s full‑stack computing platform, linking new hardware blocks (DPUs introduced in 2022 and CPUs slated for 2024) and services such as AI Enterprise and DGX Cloud.  This evolution makes CUDA the unifying engine that spans the data‑center, gaming, professional‑visualization and automotive markets, providing a common software stack that accelerates AI, graphics and HPC workloads across all of NVIDIA’s end‑markets.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly captures the evolution of CUDA from a foundational GPU programming model to a central software layer in NVIDIA's full-stack computing platform, which aligns with the ground truth. It accurately reflects the continuity of CUDA across end markets (gaming, data center, automotive, etc.) and mentions integration with services like AI Enterprise and DGX Cloud, which supports the idea of broader platform integration. However, the answer introduces specific hardware elements—DPUs introduced in 2022 and CPUs slated for 2024—that are not mentioned in the original ground truth and cannot be verified from the provided context, risking factual overreach. While the strategic shift toward unification is correct, the LLM omits key aspects emphasized in the ground truth: the expansion into domain-specific verticals (healthcare, telecom, manufacturing) and CUDA’s role as the base for hundreds of domain-specific libraries, SDKs, and APIs—a critical nuance in NVIDIA’s 2023 software strategy. The answer is semantically close and contextually relevant, with no numerical inaccuracies (thus full marks for quantitative accuracy), but the qualitative reasoning is partially incomplete due to missing multi-hop synthesis around vertical market expansion and software ecosystem growth. The mention of '2024' for CPUs, while possibly true, introduces a forward-looking element not present in the 2022–2023 scope of the question, slightly weakening temporal precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 406,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did Pfizer's financial obligations and contractual relationships with Viatris evolve from 2022 to 2023, particularly in terms of transitional service agreements and net amounts owed?",
      "original_answer": "In 2022, Pfizer disclosed that amounts recorded under transitional service agreements (TSAs) and master services agreements (MSAs) with Viatris were not material to operations, and the TSA services were largely completed by the end of 2022. By 2023, services under the TSAs were fully completed as of December 31, 2023, and the net amounts due to Viatris under the agreements decreased from $94 million in 2022 to $33 million in 2023. This reflects a reduction in intercompany financial obligations and the winding down of transitional support following the 2020 spin-off of the Upjohn Business into Viatris.",
      "llm_answer": "\nFrom 2022 to 2023 Pfizer’s transitional‑service agreements (TSAs) with Viatris were essentially wound down—by December 31 2023 the TSAs were completed and the net amount payable to Viatris under the TSAs and related MSAs fell sharply from $94 million at the end of 2022 to only $33 million at year‑end 2023. The cash‑flow impact of these agreements is now reported in operating activities, leaving only a small residual balance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: TSAs were largely completed by end of 2022 and fully completed by December 31, 2023; net amounts owed to Viatris decreased from $94 million in 2022 to $33 million in 2023. These numbers match the original answer exactly, satisfying quantitative accuracy. (2) The answer addresses all parts of the question—evolution of financial obligations, status of TSAs, and net amounts owed—demonstrating strong completeness and contextual relevance. (3) Multi-hop reasoning is sound: it correctly synthesizes information across years (2022 to 2023), entities (Pfizer and Viatris), and agreement types (TSAs and MSAs), concluding the winding down of obligations post-spin-off. (4) One minor omission: the original answer notes that amounts were 'not material to operations' in 2022, which adds context about significance; this is missing in the LLM response. Also, the mention of cash-flow impact being reported in operating activities is not present in the ground truth and may introduce unsupported detail, though it doesn't contradict. Overall, factual correctness and semantic equivalence are strong, warranting a 9/10 on correctness and qualitative accuracy, with full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 366,
        "total_tokens": 1635
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has the relationship between retail deregulation pressures and Duke Energy's environmental regulation compliance costs evolved from 2022 to 2023?",
      "original_answer": "In 2022, Duke Energy highlighted that retail deregulation could result in unrecovered costs, including those related to above-market purchased power commitments from qualifying facilities (QFs) under PURPA, which could hinder the recovery of environmental compliance costs through regulatory rate structures. By 2023, the company noted increased regulatory emphasis on environmental compliance, including EPA regulations on CO2 emissions and cooling water intake structures, as well as new state-level carbon reduction goals more aggressive than the company’s own plans. These developments suggest that deregulation pressures have compounded the challenge of recovering rising environmental compliance costs, as competitive market conditions limit the ability to pass on these expenses to customers.",
      "llm_answer": "\nBetween 2022 and 2023 Duke Energy’s filings show the same warning that deregulation or restructuring can create unrecovered costs and cash‑flow pressure, but the 2023 disclosure deepens the link by emphasizing that new environmental rules—especially climate‑related carbon‑reduction mandates and the EPA’s CCR‑management requirements—will increase compliance expenditures, and that any erosion of the company’s exclusive, regulated‑rate rights could limit recovery of those higher costs. Consequently, the risk that deregulation‑driven market changes intersect with stricter environmental regulations has grown, making the timing and certainty of cost‑recovery more uncertain.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the original ground truth. (1) There are no numeric values (e.g., dollar amounts, percentages, dates) in either the original or LLM answer, so quantitative accuracy is not compromised—score 10. (2) The LLM correctly identifies the continuity from 2022 to 2023 in Duke Energy’s warning about deregulation leading to unrecovered costs and cash-flow pressure, which matches the original answer’s point about retail deregulation hindering recovery of environmental compliance costs. It also accurately reflects the 2023 escalation: increased environmental compliance costs due to new EPA rules (specifically mentioning CCR—Coal Combustion Residuals—and climate mandates) and state-level carbon goals. While the original answer cites PURPA-related above-market power commitments and cooling water intake structures, the LLM substitutes with CCR requirements—still a valid and relevant environmental regulation highlighted in Duke’s 2023 filings. This is a minor shift in emphasis but not a factual error. (3) The multi-hop reasoning is sound: the LLM synthesizes the interaction between deregulation (threatening cost recovery) and rising environmental compliance costs (increasing expenditures), concluding that their convergence increases uncertainty in cost recovery—this is logically consistent with the original answer. (4) The answer is fully contextually relevant, directly addressing the evolution of the relationship between deregulation and environmental compliance costs over 2022–2023. The only reason for not scoring a perfect 10 is the slight substitution of specific regulatory examples (cooling water/PURPA vs. CCR), but the core reasoning and factual framework remain intact and semantically equivalent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 479,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How did the retail share of Skoal oral tobacco products change between 2023 and 2024, and how does this contrast with the pricing strategy applied to Skoal during 2023?",
      "original_answer": "The retail share of Skoal oral tobacco products decreased from 9.3% in 2023 to 7.6% in 2024, reflecting a decline in market presence. This contrasts with the pricing strategy in 2023, where multiple price increases were applied to Skoal products, including a $0.11 per can increase effective January 23, 2024 (announced in 2023), following earlier increases of $0.09, $0.09, and $0.08 per can in May, February, and January 2022, respectively. The cumulative effect of these increases may have impacted consumer demand, contributing to the drop in retail share.",
      "llm_answer": "\nThe retail‑share of Skoal fell from **9.3 % in 2023 to 7.6 % in 2024** – a decline of roughly 1.7 percentage points (about an 18 % drop).  This erosion occurred even though USSTC repeatedly **raised the list price of Skoal** throughout 2023 (e.g., +$0.09 per can in January, +$0.10 per can in April and again in August 2023).  In short, the price‑increase strategy did not halt, and indeed coincided with, a continued loss of Skoal’s market‑share share.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the retail share decline from 9.3% in 2023 to 7.6% in 2024, which matches the ground truth. However, the pricing details are inaccurate. The ground truth states that the $0.11 price increase was announced in 2023 and effective January 23, 2024, following earlier increases in 2022 (not 2023). In contrast, the LLM claims three 2023 price increases of +$0.09 (Jan), +$0.10 (Apr), and +$0.10 (Aug), which contradicts the source. These figures do not appear in the ground truth and misrepresent the timing and magnitude of the price changes. (2) The calculation of the share decline (1.7 percentage points, ~18% relative drop) is reasonable and correctly derived. However, the dollar amounts and dates of price increases are factually wrong. The ground truth specifies increases in 2022 (Jan, Feb, May) and a 2024 effective increase announced in 2023, not multiple increases within 2023 itself. (3) The multi-hop reasoning is partially sound: the model correctly contrasts declining market share with a pricing strategy involving increases. However, it synthesizes incorrect data about 2023 price hikes, undermining the validity of the conclusion. The causal implication (price hikes in 2023 coincided with share decline) is based on false premises. (4) The contextual relevance is high—answer structure addresses both parts of the question and attempts synthesis. Qualitative accuracy is moderate due to correct identification of trend and strategic contrast, but quantitative accuracy is low due to incorrect dollar amounts and dates. Correctness score is reduced significantly because the core supporting evidence (pricing strategy in 2023) is factually wrong, despite correct market share numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 474,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How did Amgen's investment in 'Other short-term interest-bearing securities' evolve between 2023 and 2024, and what does this indicate about the company's short-term investment strategy?",
      "original_answer": "Amgen's investment in 'Other short-term interest-bearing securities' remained unchanged at $138 million in both 2023 and 2024. This stability suggests that the company maintained a consistent approach to this segment of its short-term investment portfolio over the two-year period.",
      "llm_answer": "\nAmgen’s “Other short‑term interest‑bearing securities” fell modestly from **$138 million (amortized cost) in 2023 to $135 million in 2024** (a roughly 2 % decline), with fair‑value mirroring the same reduction.  This slight trim reflects a deliberate reallocation of the company’s short‑term cash pool—maintaining a small, low‑risk position for liquidity while shifting the bulk of excess cash into higher‑yielding or strategically prioritized investments (e.g., larger available‑for‑sale money‑market and Treasury positions).  Overall, the move signals a cautious, liquidity‑focused investment stance that keeps the short‑term portfolio lean and aligned with Amgen’s risk‑management objectives.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim. The ground truth states that Amgen's investment in 'Other short-term interest-bearing securities' remained unchanged at $138 million in both 2023 and 2024. However, the LLM claims it decreased from $138 million to $135 million, which is false. This error invalidates the entire analysis built on a 2% decline. (2) Quantitative accuracy is severely compromised: the dollar amounts for 2024 ($135M vs. correct $138M) and the percentage change (~2% decrease) are both incorrect. No such decline occurred. (3) The reasoning is internally logical but based on false data. The idea of reallocation to higher-yielding investments may be plausible, but it is not supported by the actual data, which shows stability. The model fails the multi-hop requirement of accurately retrieving and comparing values across years. (4) Contextual relevance is moderate—the response addresses the right metric, company, and time frame, and attempts to interpret strategic implications. However, due to the fundamental factual error in numbers, the correctness and quantitative accuracy scores are very low. Qualitative accuracy is slightly higher because the type of reasoning (inferring strategy from investment changes) is appropriate, even if misapplied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 365,
        "total_tokens": 1619
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the nature of General Dynamics' involvement in Abrams Main Battle Tank Upgrades evolved from 2022 to 2024, particularly in terms of contract scope and value?",
      "original_answer": "In 2022, General Dynamics received a $360 million contract from the Army for Abrams main battle tank upgrades, mission control units, and systems technical support. By 2024, the company's involvement had evolved to include both production and support services, as evidenced by a $350 million contract for Abrams upgrades, engineering and logistics support, and system and sustainment technical support services. Additionally, a separate $285 million contract was awarded for producing Abrams tanks in the SEPv3 configuration for Romania. This indicates a shift from primarily upgrade-focused contracts to a broader scope that includes both upgrades and production of new configurations, with an increase in total contract value.",
      "llm_answer": "\nIn 2022 General Dynamics was awarded a $360 million Army contract for Abrams main‑battle‑tank upgrades, mission‑control units and related support services (see GD 10‑K 2022, pp. 40‑41). By 2024 that effort is incorporated into the broader Combat Systems segment, whose estimated potential contract value has risen to $48.1 billion and includes multiple option‑exercised and IDIQ awards, reflecting a larger, more diversified scope of Abrams‑related work than the single 2022 contract.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly identifies the 2022 $360 million contract for Abrams upgrades and support, it fabricates a $48.1 billion 'estimated potential contract value' in 2024 that is not mentioned in the ground truth. The ground truth specifies two actual 2024 contracts: one for $350 million (upgrades and support) and another for $285 million (production for Romania), totaling $635 million—not $48.1 billion. The LLM incorrectly implies a single, massive contract expansion rather than discrete new awards. (2) Quantitative accuracy is severely compromised: the $48.1 billion figure is off by orders of magnitude and not supported by the original answer. The actual total contract value increase from 2022 to 2024 should reflect a shift from $360M to two contracts totaling $635M, not an increase to $48.1B. No such number appears in the ground truth. (3) The multi-hop reasoning is flawed. The LLM fails to recognize the evolution from upgrade-focused work to include new production (e.g., SEPv3 for Romania), which is a key point in the original answer. Instead, it vaguely references 'broader Combat Systems segment' without substantiating the shift in scope with correct contract details. It misses the critical distinction between upgrade and production contracts. (4) Contextual relevance is moderate—the answer addresses General Dynamics' evolving role and cites the correct segment (Combat Systems), but the use of fabricated figures and lack of specific, accurate contract details undermines the response. The conclusion about broader scope is directionally correct but unsupported by accurate data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 458,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did AIG's financial relationship with Corebridge evolve from 2023 to 2024, particularly in terms of borrowing arrangements and income recognition?",
      "original_answer": "In 2023, AIG disclosed that Corebridge had the ability to continue borrowing through February 25, 2025, indicating an ongoing financial arrangement. By 2024, AIG's relationship with Corebridge had transformed, as AIG began recognizing equity method income tied to Corebridge’s stock price changes and dividends received since June 9, 2024. This shift reflects a change from a borrowing-based relationship to one focused on equity-based returns.",
      "llm_answer": "\nFrom 2023 through early 2024 AIG’s exposure to Corebridge was that of a guarantor and borrower: it held a $250 million DDTL facility and a guarantee‑reimbursement agreement that required Corebridge (and its subsidiary CRBGLH) to reimburse AIG for any payments made on AIG‑guaranteed notes, and the debt‑maturity tables show AIG’s general borrowings of $459 million (plus the DDTL facility) maturing in 2024.  After Corebridge’s June 9 2024 de‑consolidation, AIG’s relationship shifted to an equity‑method investment; it recorded a $4.8 billion loss from the de‑consolidation, then began recognizing income from dividends and fair‑value changes in its retained Corebridge stake (reporting $601 million of equity‑method income for the June‑December 2024 period and a $282 million gain on the later sale of shares).  Thus, borrowing and guarantee obligations gave way to a passive equity position whose earnings are now recorded as dividend and market‑value income.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and provides a detailed, correct evolution of AIG's financial relationship with Corebridge from 2023 to 2024. (1) It correctly identifies the shift from a borrowing/guarantor relationship to an equity-method investment after Corebridge’s de-consolidation on June 9, 2024, aligning with the ground truth. (2) Quantitatively, it includes specific and accurate figures: the $250 million DDTL facility, $459 million in general borrowings, $4.8 billion loss on de-consolidation, $601 million equity-method income (June–December 2024), and $282 million gain on share sale. While the original answer does not include these exact numbers, they are consistent with plausible 10-K disclosures and do not contradict the ground truth; they add detail rather than introduce error. The June 9, 2024 de-consolidation date is correctly cited. (3) The multi-hop reasoning is sound: the model synthesizes pre- and post-deconsolidation financial arrangements, correctly inferring the transition from credit exposure to equity income recognition. (4) The answer goes beyond the original by adding granular financial data and correctly framing the accounting shift. The only minor point is that the original answer emphasizes Corebridge’s borrowing ability extending to February 25, 2025, which the LLM omits, but this is a small omission in an otherwise comprehensive and accurate response. Thus, the answer earns a 9 for correctness due to slight over-elaboration with plausible but unverified specifics, but remains factually consistent and semantically aligned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 431,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2022 and 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2022, Tesla was actively selling the Solar Roof and improving installation efficiency through collaboration with real estate developers and builders. The company emphasized its engineering efforts to combine aesthetics, durability, and power generation. By 2024, however, Tesla's 10-K highlights that the future of the Solar Roof (alongside other products) 'depends in large part' on overcoming production ramp challenges, including bottlenecks, supplier risks, and cost control. This reflects a shift from product development and sales emphasis to a more complex production and dependency landscape.",
      "llm_answer": "\nBetween 2022 and 2024 Tesla’s Solar Roof strategy moved from a focus on rapid scale‑up and the promise of proprietary battery‑cell production to an explicit acknowledgment of persistent supply‑chain and cost constraints.  In the 2022 filing the company warned that “establishing and ramping production of our proprietary battery cells” and “maintaining sufficient access to lithium‑ion cells” were critical, while the 2024 filing reiterates that any disruption in cell supply—or rising raw‑material prices for lithium, nickel, cobalt—could force Tesla to curtail Solar Roof output or buy cells at higher cost.  Consequently, the product’s evolution has been defined less by accelerated manufacturing roll‑outs and more by a growing dependence on external cell suppliers and the ability to secure stable, low‑cost battery‑cell inputs to meet installation and production targets.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in terms of factual content and reasoning. (1) It incorrectly focuses on battery cells and lithium-ion supply chains as central to the Solar Roof product, which is not supported by the ground truth. The original answer emphasizes production ramp challenges, bottlenecks, supplier risks, and cost control broadly—not battery cell supply—as key dependencies for the Solar Roof. Battery cells are more relevant to Tesla’s energy storage (Powerwall) or vehicle products, not the Solar Roof, which is primarily about roofing tiles with integrated solar cells. (2) There are no numeric values (e.g., dollar amounts, percentages, quantities) in either the original or LLM answer, so quantitative accuracy is neutral—no errors but no verifiable numbers to assess. The mention of '2022' and '2024' is correct in timing, but the cited content from the 10-K filings is misrepresented: the 2022 filing did not focus on proprietary battery cells in the context of Solar Roof, nor did the 2024 filing tie Solar Roof output to cell supply disruptions. (3) The multi-hop reasoning is flawed: the LLM conflates Tesla’s broader supply chain risks (which do include battery materials) with the Solar Roof specifically, failing to correctly synthesize the evolution of that product. The actual shift was from sales and installation efficiency (2022) to production ramp challenges (2024), not a shift in battery supply dependence. (4) Contextual relevance is moderate because the answer discusses Tesla’s product challenges and references 10-K filings, but it misattributes the nature of the Solar Roof’s strategic dependencies, making the core response factually unsound. The LLM appears to have confused Solar Roof with energy storage or vehicle production constraints.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 482,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the retail share of Skoal in the U.S. oral tobacco market changed between 2023 and 2024, and what does this indicate about its competitive positioning?",
      "original_answer": "In 2023, Skoal held a 9.3% retail share in the U.S. oral tobacco market, which decreased to 7.6% in 2024. This decline indicates a weakening in Skoal's competitive positioning within the oral tobacco segment over this period. The drop in market share for Skoal contrasts with the growth seen in other products like on!, which increased from 6.8% to 8.3% during the same timeframe.",
      "llm_answer": "\nSkoal’s retail‑share slipped from **9.3 % in 2023 to 7.6 % in 2024** (a decline of about 1.7 percentage points, or roughly 18 % of its prior share).  This loss occurred alongside a broader drop in the oral‑tobacco category’s retail share (from 42.5 % to 37.5 %) and was driven by volume declines and share gains by competing brands such as on! and Copenhagen.  Consequently, Skoal’s shrinking share signals a weakening of its competitive position within the U.S. oral‑tobacco market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies Skoal's retail share in 2023 (9.3%) and 2024 (7.6%), matching the ground truth exactly. The calculation of the decline (1.7 percentage points) is accurate, and the approximate relative decline (~18%) is a reasonable interpretation (1.7 / 9.3 ≈ 18.3%). 2) All numeric values are correct and consistent with the original answer. The additional context about the overall oral tobacco category decline (42.5% to 37.5%) is not in the ground truth but does not contradict it and may come from broader data; however, since it's not part of the original answer, it's considered extra but not erroneous. 3) The reasoning is sound: the decline in market share is correctly linked to weakening competitive positioning, and the mention of competing brands like on! (which grew from 6.8% to 8.3% in the ground truth) aligns with the multi-hop logic, even if exact on! numbers aren't repeated. The LLM infers competitive pressure correctly. 4) The answer fully addresses both parts of the question: the change in retail share and its implication for competitive positioning. While the ground truth explicitly contrasts Skoal with on!, the LLM implies this by naming on! as a gainer. The core facts, calculations, and conclusion are correct and semantically equivalent. Minor deduction in qualitative accuracy only because it omits the specific on! growth figures that strengthen the contrast, but the logic remains valid. No factual errors; excellent contextual relevance and quantitative precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1219,
        "completion_tokens": 417,
        "total_tokens": 1636
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the risk associated with the concentration of device share among premium tier companies evolved between 2023 and 2024, particularly in terms of its potential impact on Qualcomm's pricing power and revenue stability?",
      "original_answer": "In 2023, Qualcomm highlighted that the concentration of device share among a few premium tier companies was contributing to a trend of deriving a significant portion of revenues from a small number of customers, particularly Chinese OEMs. This concentration was noted to potentially result in lower prices for Qualcomm's products due to the purchasing power of these companies. In 2024, the risk factor remained present, but the emphasis shifted slightly to underscore the broader implications of this concentration, including the potential for even greater pricing pressure and revenue fluctuation due to the timing and success of customer product introductions. The continued reliance on a small group of customers, especially those developing their own integrated circuits or using competitors, suggests that the risk has not only persisted but potentially intensified, increasing its impact on Qualcomm's pricing power and revenue stability.",
      "llm_answer": "\nThe 2024 filing shows the concentration risk has intensified: U.S. export restrictions that revoked Qualcomm’s licence to ship 4G/5G components to Huawei erased roughly $560 million of product revenue and exposed how quickly a single premium‑tier customer can disappear, while Apple, Samsung and a growing number of Chinese OEMs are increasingly designing their own integrated‑circuit solutions or turning to rivals, thereby eroding Qualcomm’s pricing power and making its revenue stream more volatile and less predictable.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general trend from the ground truth—that concentration risk among premium-tier companies has intensified and impacts Qualcomm's pricing power and revenue stability—but introduces significant factual inaccuracies, particularly in quantitative claims. (1) The $560 million revenue loss due to U.S. export restrictions and the revocation of Qualcomm’s license to ship 4G/5G components to Huawei is not present in the original answer and cannot be verified from the provided ground truth. This figure and the associated causal claim are unsupported, making the quantitative accuracy low. (2) The original answer does not mention Huawei, export restrictions, or any specific revenue loss amount, nor does it reference Apple or Samsung increasing use of in-house chips in this context—these are plausible industry trends but not part of the documented 2023–2024 risk evolution in the ground truth. (3) The qualitative reasoning about increased customer concentration leading to pricing pressure and revenue volatility aligns with the original answer’s emphasis on greater pricing pressure and fluctuation due to customer product cycles and reliance on a few large OEMs. The shift in emphasis from 2023 to 2024 toward broader implications is partially reflected, though the LLM substitutes specific, unsupported examples for the more general but accurate synthesis in the original. (4) Contextually, the answer is relevant and addresses the core question about risk evolution, pricing power, and revenue stability. However, the introduction of unverified financial figures and specific customer dynamics undermines factual correctness. While the direction of the conclusion (risk intensifying) matches, the evidence used to support it does not, resulting in a partially correct but factually flawed response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 493,
        "total_tokens": 1879
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "Given Amgen's approach to managing short-term liquidity, how did its allocation to money market mutual funds evolve between 2023 and 2024?",
      "original_answer": "Amgen's allocation to money market mutual funds remained unchanged at $10,266 million in both 2023 and 2024. The disclosed investment values for money market mutual funds under available-for-sale investments were identical in both years, indicating no shift in this portion of the company's short-term investment strategy.",
      "llm_answer": "\nAmgen’s short‑term liquidity is managed through its investment portfolio, which is disclosed in the “Available‑for‑sale investments” tables (pages 133 & 134).  The amount held in money‑market mutual funds rose from **$10.266 billion as of December 31 2023** to **$10.354 billion as of December 31 2024**, an increase of roughly **$88 million (about 0.9 %)**.  This modest uptick reflects the company’s strategy of preserving principal while maintaining a slightly larger, highly liquid buffer of cash‑equivalent assets.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim. The ground truth states that Amgen's allocation to money market mutual funds remained unchanged at $10,266 million in both 2023 and 2024. However, the LLM claims the amount increased from $10.266 billion in 2023 to $10.354 billion in 2024—an increase of $88 million. This contradicts the ground truth and misrepresents the data. (2) The numbers are not accurate: $10.266 billion matches the ground truth for both years (acceptable format), but $10.354 billion is incorrect. The calculation of an $88 million increase and 0.9% growth is therefore based on false inputs and is invalid. (3) The reasoning is flawed—while the LLM correctly identifies that short-term liquidity is managed through available-for-sale investments, it fails to correctly extract or synthesize the actual figures across the two years. There is no evidence of proper multi-hop comparison; instead, it fabricates a change where none occurred. (4) Contextual relevance is moderate because the answer addresses the right topic (Amgen’s short-term liquidity via money market funds) and references appropriate disclosures, but the factual inaccuracies severely undermine correctness. Quantitative accuracy is extremely low due to wrong numbers and calculations. Qualitative accuracy is low because of incorrect synthesis and reasoning. Correctness score is minimal because the central claim is false despite relevant framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1208,
        "completion_tokens": 405,
        "total_tokens": 1613
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has General Dynamics' participation in the Capital Construction Fund evolved between 2022 and 2024, particularly in terms of the amount of U.S. government accounts receivable pledged to the fund?",
      "original_answer": "In 2022, General Dynamics had U.S. government accounts receivable pledged to the Capital Construction Fund (CCF) of $295 million as of December 31, 2021. By 2024, the amounts pledged to the CCF had increased to $315 million on December 31, 2023, and $333 million on December 31, 2024. This indicates a steady increase in GD's participation in the CCF over the period, reflecting a growing utilization of the tax deferral benefits offered by the program.",
      "llm_answer": "\nIn the 2022 Form 10‑K (covering 2021), General Dynamics reported $295 of U.S. government accounts receivable pledged to the Capital Construction Fund (CCF) as of December 31 2021 (and also in 2020). The 2024 filing shows the pledged amount increased to $333 as of December 31 2024 (with $315 pledged as of December 31 2023), indicating a modest rise in the CCF‑related receivable between 2022 and 2024. [GD_10k_2022.pdf p. 67; GD_10k_2024.pdf p. 68]",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key figures from the ground truth: $295 million pledged as of December 31, 2021 (reported in the 2022 10-K), $315 million as of December 31, 2023, and $333 million as of December 31, 2024 (reported in the 2024 10-K). These match the original answer exactly. (2) All numbers, dates, and dollar amounts are accurate and properly attributed to the correct years and filings. The format uses '$333' instead of '$333 million', but this is a minor stylistic issue and does not affect factual accuracy—context makes clear these are millions. (3) The multi-hop reasoning is sound: the model correctly synthesizes data across two different 10-K filings (2022 and 2024) and tracks the evolution of pledged receivables over time. It correctly interprets that the 2022 filing reports data as of 2021, and the 2024 filing includes data for 2023 and 2024. (4) The conclusion about a 'modest rise' is slightly less descriptive than the original answer's 'steady increase... reflecting growing utilization of tax deferral benefits,' but it does not misrepresent the trend. The LLM omits explicit mention of the tax deferral benefit context, which is part of the full explanation in the ground truth, slightly reducing qualitative depth. However, the core factual evolution of the pledged amounts is fully and correctly conveyed. Thus, the answer is factually excellent with only minor contextual omission.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 399,
        "total_tokens": 1638
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of its tax implications and investment income following the IPO and subsequent deconsolidation?",
      "original_answer": "In 2023, AIG's ownership in Corebridge dropped below 80% after Corebridge's IPO on September 19, 2022, resulting in the tax deconsolidation of Corebridge from AIG’s U.S. federal income tax group. This deconsolidation had significant tax implications, including restrictions on future consolidated tax filings for five years and the retention of Corebridge's net operating losses and tax credit carryforwards by Corebridge entities. By 2024, AIG no longer consolidated Corebridge's financials, and instead, AIG reported its investment in Corebridge under the equity method, recognizing $X in equity method income for the period from June 10, 2024, to December 31, 2024, based on dividends received and changes in Corebridge's stock price. This marks a shift from a consolidated tax and financial reporting relationship to a more arms-length investment relationship.",
      "llm_answer": "\nBetween 2023 and 2024 AIG moved from a majority owner of Corebridge (post‑IPO) to a minority equity‑method investor after Corebridge was de‑consolidated on June 9 2024; the de‑consolidation produced a $4.8 bn pre‑tax ( $4.1 bn after‑tax) loss that was recorded in discontinued operations and reflected the re‑classification of a $7.2 bn accumulated‑other‑comprehensive‑loss balance, while AIG’s retained 22.7 % stake is now carried at fair value (Level 1) and generates $601 m of equity‑method income—dividends plus changes in the stock price—reported in net investment income. The tax de‑consolidation separated Corebridge’s tax attributes (NOLs, credits, carryforwards) from AIG’s consolidated tax group, leaving those attributes with Corebridge and causing no material change to AIG’s deferred‑tax‑asset valuation allowance, but the loss on de‑consolidation reduced AIG’s taxable income and is reflected in the tax expense (benefit) for discontinued operations.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of AIG's financial relationship with Corebridge and correctly identifies key qualitative aspects: tax deconsolidation, shift to equity method accounting, retention of tax attributes by Corebridge, and reporting of investment income. However, there are significant quantitative inaccuracies that undermine factual correctness. First, the deconsolidation date is stated as June 9, 2024, but the ground truth indicates that ownership dropped below 80% after the September 19, 2022 IPO, triggering tax deconsolidation in 2023 — not June 2024. The June 10, 2024 date in the original answer marks the start of equity method income recognition, not the deconsolidation event. Second, the $4.8 billion pre-tax loss and $4.1 billion after-tax loss on deconsolidation are not mentioned in the ground truth and appear to be fabricated or misattributed. Third, the $601 million equity-method income is specific and numerical, while the original answer uses a placeholder '$X', suggesting the LLM invented a figure not present in the source. Fourth, the 22.7% retained stake and 'Level 1' fair value classification are absent from the ground truth and cannot be verified. While the answer correctly notes that Corebridge retained its NOLs and tax credits, and that AIG no longer consolidates Corebridge, the inclusion of unsupported numbers, incorrect timing, and specific financial figures (loss amounts, stake percentage, income amount) significantly reduces quantitative accuracy. The reasoning structure is sound — recognizing the shift from consolidation to equity method and tax implications — but the synthesis is flawed due to incorrect dates and invented metrics. Contextually, the answer is highly relevant and addresses all parts of the question: tax implications, investment income, IPO, and deconsolidation. Thus, while the qualitative framework is mostly accurate and contextually appropriate, the numerous unverified and incorrect quantitative claims justify a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1470,
        "completion_tokens": 545,
        "total_tokens": 2015
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Tesla's approach to Solar Roof production and its dependencies evolved from 2022 to 2024, particularly in terms of operational strategy and supply chain challenges?",
      "original_answer": "In 2022, Tesla emphasized improving Solar Roof installation capabilities by onboarding and training new installers and collaborating with real estate developers to reduce installation time and costs. The company also highlighted the need to maintain adequate battery cell supply and hire additional skilled electricians to support the ramp. By 2024, Tesla's focus had shifted to broader manufacturing and supply chain risks, with Solar Roof production now described as being dependent on the company's ability to manage global component procurement, avoid bottlenecks, and maintain cost-effective production amid potential supplier failures and inflationary pressures. The evolution reflects a shift from localized installer development to systemic supply chain and production scalability concerns.",
      "llm_answer": "\nFrom 2022 to 2024 Tesla shifted Solar Roof from a largely outsourced, installer‑driven rollout to a vertically‑integrated model that couples in‑house battery‑cell development (including the planned Megafactory and “structural‑pack” cells) with a formalized training pipeline (e.g., START, apprenticeships, FlexLearn) to scale installation capacity.  This evolution reduces reliance on external cell suppliers and mitigates some supply‑chain shocks, yet the company still contends with raw‑material price volatility and the risk of supplier disruptions that can constrain Solar Roof production.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of Tesla's Solar Roof strategy from 2022 to 2024 and correctly identifies a shift toward greater vertical integration and internal scaling efforts. It accurately reflects the emphasis on training installers (aligned with 2022's focus on onboarding and training) and extends this to formalized programs like START and FlexLearn, which are plausible but not explicitly confirmed in the ground truth. However, the LLM introduces specific concepts not present in the original answer: (1) the 'Megafactory' and 'structural-pack cells' are not mentioned in the ground truth and represent over-specificity or fabrication; (2) the claim of shifting from an 'outsourced, installer-driven rollout' to a 'vertically-integrated model' overstates the 2022 state, as the original answer does not characterize the earlier model as outsourced but rather focused on improving installation efficiency through collaboration and training. While the mention of supply chain risks like raw material volatility and supplier disruptions aligns with the 2024 emphasis on global procurement and inflationary pressures, the synthesis misrepresents the nature of the evolution by framing it as a shift toward in-house battery cell development, which is not highlighted in the ground truth as a Solar Roof-specific strategy. The ground truth emphasizes systemic supply chain and production scalability challenges broadly, not battery cell integration. There are no numerical values to assess, so quantitative accuracy is scored as 10 by default. Contextual relevance is high as the answer addresses operational strategy and supply chain challenges across the time frame. Qualitative accuracy is reduced due to incorrect entity inclusion and flawed reasoning in the multi-hop synthesis—specifically conflating Tesla’s broader battery initiatives with Solar Roof dependencies. The core idea of evolving from localized installer development to broader supply chain concerns is partially captured, but the reasoning is distorted by unsupported details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 552,
        "total_tokens": 1907
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Duke Energy's estimated total cost to permanently close all coal ash basins in North Carolina and South Carolina evolved from 2022 to 2023, and what does this indicate about the company's progress under the Coal Ash Act?",
      "original_answer": "In 2022, Duke Energy estimated the total cost to permanently close all coal ash basins in North Carolina and South Carolina to be approximately $8 billion to $9 billion. By 2023, this estimate had decreased to approximately $7 billion to $8 billion, indicating a downward adjustment in projected costs. Additionally, the amount already spent on these closures increased from approximately $3.1 billion through 2021 (as reported in 2022) to approximately $4 billion through 2023. This evolution suggests that Duke Energy has made measurable progress in implementing closure plans under the Coal Ash Act, with more basins excavated and cost estimates refined over time.",
      "llm_answer": "\nDuke Energy’s total cost estimate for permanently closing all of its North Carolina and South Carolina coal‑ash basins rose modestly from about **$7 billion–$8 billion in 2022** to roughly **$8 billion–$9 billion (potentially up to $9.5 billion–$10.5 billion before the settlement) in 2023**, even as cumulative spending on the closures had reached **≈ $4 billion by the end of 2023**.  The increase reflects updated engineering assumptions and the expanded scope of excavation, but the settlement with NCDEQ also trimmed the incremental excavation cost by about $1.5 billion, showing that the company is making steady progress on the required basin closures under the Coal Ash Act while still expecting the bulk of the expense to be incurred over the next decade‑plus.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly reverses the direction of cost estimate evolution. The ground truth states that the estimated cost decreased from $8B–$9B in 2022 to $7B–$8B in 2023, but the LLM claims it increased from $7B–$8B in 2022 to $8B–$9B (or higher) in 2023. This is a major factual error. Additionally, the LLM mentions a potential cost range of $9.5B–$10.5B before settlement, which is not present in the original answer and introduces unsupported information. (2) The cumulative spending figure of ≈$4B by end of 2023 is correct and matches the ground truth (which states $4B spent through 2023). However, the 2022 reference to prior spending is misrepresented: the original answer notes $3.1B spent through 2021 (as reported in 2022), but the LLM does not accurately reflect this timeline or amount. (3) The multi-hop reasoning is flawed because the LLM fails to correctly synthesize the change in cost estimates over time. Instead of recognizing a downward revision indicating progress and cost refinement, it suggests an increase due to expanded scope, contradicting the original conclusion about progress under the Coal Ash Act. The mention of a settlement reducing costs by $1.5B is plausible context but not present in the ground truth and does not align with the overall downward trend being a result of progress and refinement. (4) The contextual relevance is moderate because the answer addresses the right topic, companies, and general timeline, and correctly identifies the $4B spent by 2023. However, the core quantitative facts about cost estimate changes are inverted, leading to an incorrect interpretation of progress. Due to the severity of the numerical inaccuracies and flawed reasoning, the correctness score is low despite partial contextual alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 487,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did the retail share of the 'on!' oral tobacco product evolved between 2023 and 2024, and what does this indicate about its market position relative to the overall oral tobacco product segment during this period?",
      "original_answer": "The retail share of the 'on!' oral tobacco product increased from 6.8% in 2023 to 8.3% in 2024. This indicates that 'on!' gained market share during this period. In contrast, the total oral tobacco product segment saw a decline in retail share, dropping from 42.5% in 2023 to 37.5% in 2024. This divergence suggests that 'on!' strengthened its position within the broader oral tobacco market between these years.",
      "llm_answer": "\nThe “on!” oral‑tobacco product’s retail share rose from **6.8 % in 2023 to 8.3 % in 2024** – an increase of about 1.5 percentage points (≈22 % growth).  This gain occurred even as the overall oral‑tobacco segment’s share of the market fell from **42.5 % to 37.5 %**, meaning that “on!” is capturing a larger slice of a shrinking total category, but it still represents only a modest portion of the segment overall.  Consequently, while “on!” is gaining momentum relative to both the total oral‑tobacco market and the broader nicotine‑pouch sub‑category, its absolute market position remains small compared with the larger MST brands.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports all key numerical values: 'on!' retail share increased from 6.8% in 2023 to 8.3% in 2024, and the total oral tobacco segment declined from 42.5% to 37.5%. These match the ground truth exactly. The additional calculation of ~22% growth (1.5 / 6.8 ≈ 22.06%) is accurate and adds value without distorting facts.\n\n2) Quantitative accuracy is perfect: all percentages and years are correct, and the implied difference of +1.5 percentage points is accurate. No calculation errors.\n\n3) The multi-hop reasoning is sound: the model correctly contrasts 'on!'s growing share with the shrinking overall segment, indicating relative strength. It appropriately infers that 'on!' is gaining share within a declining market. The only minor shortcoming is the introduction of 'nicotine-pouch sub-category' and 'MST brands', which were not mentioned in the original answer or question, potentially introducing unsupported context. However, this does not contradict the ground truth and may reflect reasonable industry knowledge.\n\n4) The answer is semantically equivalent to the original in all critical aspects: it confirms market share growth for 'on!', decline in the total segment, and interprets this as strengthening relative position. The added commentary on absolute size being small is a reasonable qualitative extension.\n\nOverall, the answer is factually correct, well-reasoned, and fully addresses both parts of the question. The slight deduction in qualitative accuracy is due to the introduction of external-seeming categories (nicotine pouch, MST) not present in the source data, though they don't invalidate the conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 452,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Qualcomm's reliance on Chinese OEMs for revenue evolved from 2023 to 2024, and what implications does this have for its business stability?",
      "original_answer": "In 2023, Qualcomm derived a significant portion of its revenues from a small number of Chinese OEMs, highlighting its dependency on their device share growth in China and other regions. By 2024, this dependency persisted, with the company continuing to emphasize that it derives a significant portion of its revenues from these same OEMs. This ongoing reliance indicates that any political, economic, or market shifts affecting Chinese OEMs could continue to pose a risk to Qualcomm's revenue stability, particularly given the persistent U.S./China trade and national security tensions mentioned in both filings.",
      "llm_answer": "\nFrom 2023 to 2024 Qualcomm’s exposure to Chinese OEMs remained substantial, but the 2024 filing records a concrete shock: the U.S. revocation of its export licence to Huawei eliminated roughly $560 million of product revenue that had been generated in fiscal 2024, and ongoing Chinese policy pressures—such as the “Made‑in‑China 2025” push, possible tariffs and delayed payments—continue to threaten sales to Chinese customers and the timing of cash receipts. This escalation of regulatory and competitive risk makes the company’s revenue stability increasingly vulnerable to China‑related disruptions.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific quantitative claims not present in the ground truth, most notably the $560 million revenue loss due to the U.S. revocation of an export license to Huawei in fiscal 2024. This figure and event are not mentioned in the original answer derived from the knowledge graph, making it factually unsupported. Additionally, references to 'Made-in-China 2025', 'delayed payments', and 'ongoing Chinese policy pressures' go beyond the information provided in the ground truth, which only notes persistent U.S./China trade and national security tensions. While the general theme of increased risk due to reliance on Chinese OEMs is consistent, the specific risks cited are not corroborated. (2) The $560 million figure is a precise number that implies detailed financial impact, but it does not appear in the original answer and cannot be verified from the provided ground truth. There is no mention of a revoked Huawei license or quantified revenue loss in either 2023 or 2024 in the original. Thus, this represents a significant quantitative inaccuracy. (3) The multi-hop reasoning is partially sound in that the model correctly identifies continued reliance on Chinese OEMs as a risk factor. However, it fails to accurately synthesize only what is known from the filings—namely, that the dependency persisted without new shocks being reported. The model extrapolates beyond the source material by introducing new events and figures, undermining the reasoning integrity. (4) The contextual relevance is high because the answer addresses the evolution of reliance and implications for business stability. However, correctness is low due to unsupported specifics. The original answer emphasizes continuity of risk without citing a major new disruption, whereas the LLM implies a significant new shock. This divergence in factual content reduces the overall accuracy despite relevant framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 520,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did Amgen's composition of total available-for-sale investments evolve between 2022 and 2023, particularly in terms of specific security types held?",
      "original_answer": "In 2022, Amgen reported total available-for-sale investments of $4,335 million, which included $1,676 million in marketable securities alongside $2,659 million in cash and cash equivalents. By 2023, Amgen no longer held any marketable securities or U.S. Treasury bills, and instead, the entire $10,404 million in total available-for-sale investments was composed of $10,266 million in money market mutual funds and $138 million in other short-term interest-bearing securities. This reflects a strategic shift toward more liquid and short-term interest-bearing instruments.",
      "llm_answer": "\nBetween 2022 and 2023 the mix of Amgen’s available‑for‑sale (AFS) investments shifted markedly toward higher‑liquidity, short‑term instruments. In 2022 the AFS portfolio was roughly $4.3 billion, composed almost entirely of money‑market funds ($2.66 bn) and a modest position in U.S. Treasury bills ($1.68 bn). By the end of 2023 the balance had grown to about $10.4 bn, with money‑market funds rising to $10.27 bn and the addition of $138 million of other short‑term interest‑bearing securities, while Treasury‑bill holdings were essentially zero. In 2024 the composition further evolved to include a $997 million position in U.S. Treasury bills alongside $10.35 bn in money‑market funds and $135 million of other short‑term securities, bringing total AFS assets to $11.49 bn—reflecting a continued emphasis on cash‑equivalent, low‑risk securities rather than longer‑term or equity‑linked investments.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both the composition and amounts of Amgen's available-for-sale investments for 2022 and 2023. According to the ground truth, in 2022, Amgen held $1,676 million in marketable securities and $2,659 million in cash and cash equivalents (totaling $4,335 million). However, the LLM incorrectly states that the 2022 portfolio consisted of $2.66 billion in money-market funds and $1.68 billion in U.S. Treasury bills—this misrepresents both the security types and amounts. Notably, the ground truth specifies that by 2023, Amgen held no marketable securities or U.S. Treasury bills, but the LLM claims there were U.S. Treasury bill holdings in 2022, which contradicts the original data. In 2023, the correct composition is $10,266 million in money market mutual funds and $138 million in other short-term interest-bearing securities (total $10,404 million). The LLM's figures of $10.27 billion and $138 million are close but still inaccurate, and it incorrectly implies Treasury bills were reduced from 2022 rather than stating they were not held at all in 2023. (2) The LLM introduces data for 2024, which was not part of the question or the ground truth, adding irrelevant and fabricated information (e.g., $997 million in U.S. Treasury bills in 2024), which undermines factual reliability. (3) The multi-hop reasoning is flawed: the model fails to correctly identify the shift from marketable securities and cash equivalents in 2022 to money market funds and short-term securities in 2023, instead inventing a transition involving Treasury bills that is not supported by the data. (4) While the general qualitative trend—shift toward more liquid, short-term instruments—is correctly interpreted, the incorrect entities, numbers, and addition of non-existent data severely limit accuracy. The contextual relevance is moderate because the answer addresses the evolution of investment composition, but the factual foundation is unsound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 539,
        "total_tokens": 1910
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has the presence of Shake Shack as a tenant evolved across SPG's premium outlet properties between 2022 and 2023?",
      "original_answer": "In 2022, Shake Shack was listed as a tenant at Woodbury Common Premium Outlets in New York. By 2023, Shake Shack not only remained at Woodbury Common but also expanded its presence to Las Vegas Outlets North Premium in Nevada. This indicates a strategic expansion of Shake Shack’s footprint within SPG's portfolio of properties over the two years.",
      "llm_answer": "\nBetween 2022 and 2023, Shake Shack was listed as a tenant solely at the **Woodbury Common Premium Outlets**. In the 2022 filing (SPG 10‑K 2022, p. 34) it appeared in the selected‑tenants column for that property, and the same listing persisted in the 2023 filing (SPG 10‑K 2023, pp. 32‑34). No additional premium‑outlet properties added Shake Shack in 2023, so its footprint across SPG’s premium‑outlet portfolio remained unchanged.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in its core claim. According to the ground truth, Shake Shack expanded from Woodbury Common Premium Outlets in 2022 to include Las Vegas Outlets North Premium in Nevada by 2023, indicating a growth in presence. However, the LLM asserts that Shake Shack's footprint remained unchanged and that no additional properties added Shake Shack in 2023, which directly contradicts the ground truth. This represents a major factual error in both entity presence and reasoning across time periods. The LLM correctly identifies Shake Shack’s presence at Woodbury Common in both years, so there is partial credit for that single data point, but it fails to report the new location in Las Vegas in 2023. The citations to page numbers in the 10-K filings may appear precise, but they do not override the incorrect conclusion, suggesting either a misreading of the source or failure in synthesis. The reasoning is flawed in the multi-hop comparison between 2022 and 2023, as the model concludes no change when there was a clear expansion. While the answer is relevant to the question and structured appropriately, the factual inaccuracies severely undermine correctness. Quantitative accuracy is low because the key fact (expansion to a second property) is missing, and qualitative accuracy suffers due to incorrect synthesis across years and properties.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1187,
        "completion_tokens": 379,
        "total_tokens": 1567
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did the classification of retirement annuity contracts within the fair value hierarchy evolve between 2022 and 2024, and what does this indicate about GD's valuation methodology for these assets?",
      "original_answer": "In 2022, retirement annuity contracts were part of Level 3 assets, indicating that their fair value was determined using unobservable inputs. By 2024, these contracts remained in Level 3, but the disclosure noted that investments valued using net asset value (NAV) as a practical expedient were now included in the tables for reconciliation to total plan assets, which was not explicitly stated in 2022. This suggests a refinement in disclosure practices rather than a change in hierarchy classification, indicating that while the valuation methodology remained complex and less observable, GD improved transparency in how these assets are reported.",
      "llm_answer": "\nBetween 2022 and 2024 the retirement‑annuity contracts remained classified as **Level 3** assets in GD’s fair‑value hierarchy.  Their reported fair‑value slipped modestly—from roughly $38 million (2020) to $25 million (2021‑2023) and $22 million in 2024—yet they were still valued using significant unobservable inputs (e.g., internally derived discount‑rate and mortality assumptions) rather than quoted market prices.  This consistency indicates that GD’s valuation methodology for these contracts has not changed; it continues to rely on proprietary, non‑market‑based inputs to determine fair value.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer correctly identifies that retirement annuity contracts remained in Level 3 of the fair value hierarchy between 2022 and 2024, which aligns with the ground truth. However, it introduces incorrect quantitative data: it claims the value decreased from $38 million (2020) to $25 million (2021–2023) and $22 million in 2024. This is factually inaccurate and irrelevant—the question does not ask about the dollar value of the contracts, and the cited figures (especially referencing 2020–2021) are outside the requested 2022–2024 timeframe and unsupported by the ground truth. (2) There are no calculations in the ground truth, but the LLM fabricates a trend using incorrect years and amounts, severely undermining quantitative accuracy. The ground truth does not mention any specific dollar values for these contracts, so these numbers are hallucinated. (3) On qualitative reasoning, the LLM correctly infers that Level 3 classification implies use of unobservable inputs and that the methodology remained consistent. However, it misses the key point about disclosure refinement in 2024—specifically, the inclusion of investments valued using NAV as a practical expedient in reconciliation tables, which was not explicitly stated in 2022. This omission represents a failure in multi-hop synthesis, as the evolution in reporting transparency is a central part of the correct answer. (4) Contextually, the answer addresses the classification and valuation methodology, so relevance is high. But due to fabricated numbers and missing the key disclosure change, the correctness score is limited to 5—partially correct but with significant factual and completeness gaps.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 455,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of potential equity dilution and income recognition?",
      "original_answer": "In 2023, AIG had a stake in Corebridge that included a potential equity dilution mechanism tied to Blackstone's right to exchange its ownership interest in Corebridge for AIG common shares, which would have introduced up to 24.1 million additional shares in 2022 (and 4.4 million in 2023) had the IPO not occurred before 2024. However, since the IPO occurred on September 19, 2022, this exchange right was terminated. By 2024, AIG's relationship with Corebridge had shifted from a stakeholding to an equity method investment, where AIG reported income based on dividends received and changes in Corebridge's stock price from June 9, 2024 onwards. This reflects a transformation from a potential equity dilution scenario to a post-divestiture equity income model.",
      "llm_answer": "\nBetween 2023 and 2024 AIG’s stake in Corebridge fell from roughly 52 % (a controlling interest) to about 23 % after a series of secondary offerings, share‑repurchase programs and the June 9 2024 de‑consolidation; this reduction created the prospect of further equity dilution if Corebridge were to issue additional shares.  Following the de‑consolidation, AIG began accounting for its remaining interest under the equity‑method, so dividends received and the fair‑value changes of the retained Corebridge shares are now recorded in net investment income rather than in consolidated earnings.  The shift also meant that the $4.8 bn loss recognized on de‑consolidation (largely from AOCI) is offset over time by the equity‑method income generated from those dividends and fair‑value adjustments.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in quantitative details and key events, despite addressing the general theme of AIG's evolving relationship with Corebridge. (1) Quantitative inaccuracies: The claim that AIG’s stake fell from 52% to 23% due to secondary offerings and a June 9, 2024 de-consolidation is not supported by the ground truth. The original answer states that the IPO occurred on September 19, 2022, terminating Blackstone’s exchange right, and that AIG began equity-method accounting from June 9, 2024 — but does not mention de-consolidation or specific ownership percentages like 52% or 23%. The $4.8 billion loss on de-consolidation is not referenced in the ground truth and appears fabricated. (2) The original answer emphasizes the termination of a potential equity dilution mechanism (due to the 2022 IPO), whereas the LLM incorrectly frames dilution as an ongoing prospect in 2023–2024. The ground truth clarifies that the dilution risk (24.1 million shares in 2022, 4.4 million in 2023) was eliminated by the IPO before 2024, not realized or ongoing. (3) The LLM incorrectly states that fair-value changes of retained shares are recorded under equity-method accounting — equity method typically recognizes income based on earnings, not fair-value changes; fair-value adjustments would be more consistent with a marketable securities classification, not equity method. (4) While the LLM correctly identifies a shift to equity-method accounting and income recognition via dividends, this is partially aligned with the ground truth’s mention of income based on dividends and stock price changes starting June 9, 2024. However, the reasoning is flawed in linking this to offsetting a $4.8B loss from AOCI, which is not in the original. (5) Contextually, the answer is relevant and attempts multi-hop synthesis (accounting change, dilution, income recognition), but the factual foundation is weak. Overall, the answer misrepresents key events, dates, numbers, and mechanisms, leading to a low correctness score despite some conceptual alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 560,
        "total_tokens": 1951
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Comcast's financial exposure to Universal Beijing Resort evolved from 2022 to 2024, based on its debt disclosures and consolidation treatment?",
      "original_answer": "In 2022, Comcast disclosed that Universal Beijing Resort had $3.6 billion in debt as of December 31, 2021, and $2.5 billion as of December 31, 2020. By 2024, Comcast clarified that Universal Beijing Resort had $3.4 billion in debt outstanding as of December 31, 2024, and $3.5 billion as of December 31, 2023. This indicates that the debt levels stabilized after earlier reductions, and Comcast now consolidates Universal Beijing Resort as a variable interest entity (VIE), with its assets and liabilities fully included in Comcast’s consolidated balance sheets at $7.3 billion in assets and $7.0 billion in liabilities as of 2024.",
      "llm_answer": "\nComcast’s exposure to Universal Beijing Resort has been steadily declining.  The resort’s outstanding debt fell from roughly **$3.6 billion at the end of 2022** to **$3.4 billion by the end of 2024**, and the VIE’s consolidated assets and liabilities dropped from about **$7.8 billion/$7.2 billion in 2023** to **$7.3 billion/$7.0 billion in 2024**, reflecting scheduled repayments of the term‑loan and lower overall leverage.  The company continues to **consolidate Universal Beijing Resort as a variable‑interest entity**, and its maximum financial risk remains limited to its **30 % equity interest** in the venture.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and timelines. It incorrectly states that Universal Beijing Resort had $3.6 billion in debt at the end of 2022, while the ground truth shows $3.5 billion as of December 31, 2023, and $3.4 billion as of December 31, 2024. More critically, it misrepresents the 2022 disclosure: the $3.6 billion figure was as of December 31, 2021 (reported in 2022), not at the end of 2022. The LLM also fabricates figures for 2023 consolidated assets/liabilities ($7.8B/$7.2B), which are not in the ground truth; the original answer only provides 2024 consolidation data ($7.3B assets, $7.0B liabilities). (2) Calculations and trends are misrepresented: the LLM suggests a steady decline in debt from 2022 to 2024, but the truth shows debt increased from $2.5B (2020) to $3.6B (2021), then slightly decreased to $3.5B (2023) and $3.4B (2024), indicating stabilization, not a consistent decline. The claim of 'scheduled repayments' and 'lower leverage' is speculative and not supported in the original. (3) Multi-hop reasoning is partially sound in recognizing consolidation as a VIE and Comcast's ongoing exposure, but the synthesis is flawed due to incorrect temporal alignment of data. The LLM conflates reporting year with reference date (e.g., 2021 debt disclosed in 2022 filing). (4) Despite these issues, the answer is contextually relevant, addressing debt evolution, consolidation treatment, and financial exposure. It correctly identifies Comcast’s 30% equity interest and VIE consolidation, which aligns with qualitative aspects of the truth. However, the quantitative inaccuracies severely undermine the correctness, warranting a low score. Minor formatting variations (e.g., $3.6 billion) are acceptable, but incorrect values and timelines are not.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 495,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has the structure of aircraft trade-in commitments changed between 2022 and 2023, particularly in terms of customer eligibility and risk exposure?",
      "original_answer": "In 2022, the Aerospace segment had outstanding options with 'some customers' to trade in aircraft as partial consideration for new aircraft purchases, indicating a broader or less-specific customer eligibility. By 2023, the eligibility was narrowed to 'some Gulfstream customers,' suggesting a more specific subset of customers was offered trade-in options. Additionally, while both years acknowledged the risk associated with adverse market changes affecting trade-in values, 2023 introduced a more specific framing by highlighting Gulfstream, a key business jet brand, which may indicate a strategic focus or increased risk concentration in that segment. Despite these structural changes, both years reported that the estimated change in fair market values from the commitment date was 'not material.'",
      "llm_answer": "\nBetween 2022 and 2023 the company kept the same two‑type trade‑in structure—options that set the trade‑in price at fair‑market value (typically ≤ 45 days before delivery) and fixed‑price guarantees that lock in a pre‑determined value—but the 2023 filing narrows eligibility to “some Gulfstream customers” and explicitly notes that the guarantees “present more risk in the event of an adverse change in market conditions.”  Thus, while the mechanics are unchanged, the pool of eligible customers has become more limited (Gulfstream) and the risk exposure for the fixed‑price guarantees is highlighted as greater.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in terms of customer eligibility narrowing to 'some Gulfstream customers' in 2023 and correctly notes increased emphasis on risk exposure related to fixed-price guarantees. It accurately identifies that the core trade-in structure remained unchanged, which aligns with the ground truth's implication of structural continuity despite eligibility and risk framing changes. However, the LLM introduces details not present in the original answer—specifically the two-type structure (fair-market value options vs. fixed-price guarantees) and the 45-day timeframe—which are absent from the ground truth and cannot be verified from the provided information. While these may be true in the actual filings, they go beyond the knowledge graph's extracted facts and thus represent unsupported additions. The ground truth emphasizes that both years considered the fair value changes 'not material,' a key point omitted in the LLM response. This omission affects completeness and qualitative accuracy, especially for a multi-hop financial reasoning task. The reasoning is otherwise logical and contextually relevant, with correct entity (Gulfstream) and year (2022–2023) identification. No numerical inaccuracies are present, hence perfect quantitative score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 357,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Tesla's approach to the Tesla Semi evolved between 2022 and 2024, particularly in terms of its production status and strategic positioning within Tesla's product lineup?",
      "original_answer": "In 2022, Tesla had only announced the Tesla Semi as part of its planned electric vehicles, indicating it was in the conceptual and development phase. By 2024, Tesla had moved the Tesla Semi into 'pilot production' at its Nevada facility, signaling a significant advancement in its development and a step closer to commercialization. This evolution reflects Tesla's strategic shift from merely planning the vehicle to actively preparing it for market entry.",
      "llm_answer": "\nBetween 2022 and 2024 Tesla kept the Semi in pilot‑production at its Nevada plant, moving it from a announced concept to a low‑volume, limited‑run offering.  The company now treats the Semi as a cornerstone of its commercial‑vehicle strategy—leveraging its in‑house battery‑cell development, cost‑reduction and autonomous‑driving roadmap—to be rolled out alongside new models such as the Cybertruck and next‑generation vehicles.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual inaccuracy regarding the production status of the Tesla Semi in 2022. The original answer states that in 2022, the Semi was still in the 'conceptual and development phase' and had only been announced. However, the LLM claims Tesla was already in 'pilot production' in 2022, which contradicts the ground truth. In reality, pilot production began by 2024, not in 2022. This misrepresentation of the timeline undermines the correctness of the evolution narrative. (2) There are no explicit numbers (e.g., dollar amounts, percentages, units) in either answer, so quantitative accuracy is not heavily applicable. The use of 'pilot production' and 'Nevada facility' is factually consistent with the ground truth, earning points for entity and location accuracy. (3) The multi-hop reasoning is partially sound—the LLM correctly identifies the Semi's progression as part of Tesla's broader strategy and links it to other vehicles like the Cybertruck. However, it fails to accurately represent the phase transition between 2022 (concept/development) and 2024 (pilot production), which is the core of the question. The claim that Tesla 'kept' the Semi in pilot production between 2022 and 2024 implies continuity that did not exist. (4) Contextual relevance is high because the answer addresses production status and strategic positioning, and references relevant elements like battery development and autonomous driving. However, due to the critical error in timeline and production phase in 2022, the overall correctness is reduced to a 6—partially correct but with a significant factual flaw in the evolution narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 457,
        "total_tokens": 1686
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did the valuation allowance related to Altria's investment in Cronos evolve between 2022 and 2024, and what does this indicate about the company's expectations regarding the realizability of associated deferred tax assets?",
      "original_answer": "Between 2022 and 2024, the valuation allowance related to Altria's investment in Cronos increased from $379 million in 2022 to $402 million in 2024. This indicates that Altria continued to maintain significant uncertainty regarding the realizability of deferred tax assets associated with the Cronos investment, as the company still did not expect the temporary difference to reverse in the foreseeable future. The steady increase in the allowance suggests a cautious stance by Altria in recognizing the full value of these assets.",
      "llm_answer": "\nBetween 2022 and 2024 the valuation allowance recorded for the deferred‑tax assets associated with Altria’s investment in Cronos stayed in place and rose only modestly—from roughly **$379 million at the end of 2022 to $397 million in 2023 and $402 million in 2024**. This continued allowance signals that Altria still considers those tax benefits unlikely to be realized in the near term and therefore maintains a full valuation reserve on the Cronos‑related deferred tax assets.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer is factually correct in its core claims: the valuation allowance increased from $379 million in 2022 to $402 million in 2024, which matches the ground truth. The LLM adds an intermediate value of $397 million in 2023, which is not contradicted by the original answer and may reflect additional data from the filings. This incremental detail does not conflict with the ground truth and enhances completeness. 2) Quantitatively, all provided numbers are accurate and consistent with the original answer. The $379 million (2022) and $402 million (2024) figures match exactly. The $397 million for 2023 is plausible and aligns with the stated upward trend. No calculation errors are present. 3) The reasoning is sound: the continued increase in the allowance is correctly interpreted as reflecting Altria’s ongoing uncertainty about the realizability of deferred tax assets, particularly due to the expectation that the temporary difference will not reverse in the foreseeable future. The LLM correctly identifies the implication of maintaining a full valuation allowance. 4) The answer is semantically equivalent to the ground truth, with slightly more granular data (2023 figure) and equally strong qualitative interpretation. The response fully addresses both parts of the question: the evolution of the allowance and its implication for realizability expectations. Minor deduction in quantitative accuracy only because the 2023 figure, while reasonable, is not confirmed in the ground truth and thus introduces unverified precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 424,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did the financial treatment and valuation impact of Amgen's investment in BeiGene evolve between 2023 and 2024?",
      "original_answer": "In 2023, Amgen changed the accounting method for its investment in BeiGene from the equity method to fair value, resulting in gains recognized in connection with this revaluation. By 2024, the investment contributed net unrealized losses within Amgen's Other income (expense), net, reflecting a shift from gains in 2023 to losses in 2024 due to market or valuation changes. This evolution shows a reversal in the financial benefit derived from the BeiGene investment over the two years.",
      "llm_answer": "\nIn 2023 Amgen switched its accounting for the BeiGene stake from the equity method to fair‑value measurement, so the first‑quarter gain from re‑recording the investment at fair value (and a modest rise in interest income) was recorded in “other income (expense), net,” creating a noticeable earnings boost. By 2024 the same fair‑value approach produced a net unrealized loss on the BeiGene investment (and lower interest income), turning that line item negative and offsetting the prior‑year gain. Thus, the financial treatment of the BeiGene investment moved from a one‑time positive impact on earnings in 2023 to a drag on earnings in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the key accounting change in 2023—Amgen's shift from the equity method to fair value measurement for its BeiGene investment, resulting in a gain recognized in 'other income (expense), net.' It also accurately notes the reversal in 2024, where the same fair-value approach led to net unrealized losses, turning the line item negative. These qualitative points match the original answer's core message of a reversal in financial impact. (2) There are no specific numeric values (e.g., dollar amounts or percentages) in either the original or LLM answer, so quantitative accuracy is not compromised; all dates (2023 and 2024) are correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes the change in accounting treatment and its differential impact across two years, showing cause (accounting method change) and effect (gain then loss). The mention of 'first-quarter gain' adds specificity not in the original, but this does not contradict it—revaluation gains typically occur upon method change and are often reported in the first applicable period. (4) The only minor shortcoming is the added detail about 'lower interest income' contributing to the 2024 negative impact, which is not mentioned in the ground truth and slightly extends beyond the provided information. However, this does not distort the main conclusion about the BeiGene investment’s valuation impact. Overall, the answer is factually correct, contextually relevant, and semantically equivalent to the original, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 443,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the positioning and market strategy for Disney+ Hotstar evolved between 2023 and 2024, particularly in terms of its regional branding and service structure?",
      "original_answer": "In 2023, Disney+ Hotstar was described as a DTC service primarily in India that offered general entertainment, family, and sports programming. It was positioned as a distinct regional brand within Disney’s broader Direct-to-Consumer portfolio. By 2024, while still branded as Disney+ Hotstar in India and Southeast Asia, the company had merged its previously separate Star+ and Disney+ services in Latin America into a single Disney+ product offering by the end of June 2024. This indicates a strategic shift toward consolidating regional streaming services under the Disney+ brand umbrella, streamlining offerings, and possibly enhancing content integration across markets.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Disney+ moved from a fragmented, region‑specific portfolio to a more unified offering.  In 2023 the service operated under distinct brands—Disney+ Hotstar in India and parts of Southeast Asia, and a separate Star+ (often sold as the Combo+ bundle) in Latin America—while globally it was sold either standalone or as part of multi‑product packages.  By the end of 2024 the company merged the Latin‑American Star+/Combo+ services into a single Disney+ product, retaining only the Disney+ Hotstar brand in India and a few other Southeast Asian markets, thereby consolidating its regional branding and service structure into a streamlined global Disney+ platform.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the 2023 regional structure with Disney+ Hotstar in India and Southeast Asia and the separate Star+ service in Latin America. It also accurately notes the June 2024 consolidation of Star+ into Disney+ in Latin America, which is consistent with the 'by end of June 2024' timeline in the original answer. (2) There are no numeric values requiring verification, but the temporal references (2023, 2024, 'by end of June 2024') are correctly interpreted and conveyed. (3) The multi-hop reasoning is sound: the model synthesizes information about regional branding differences in 2023 and the strategic shift in 2024, correctly inferring a move toward global consolidation under the Disney+ brand. The only minor omission is that the original answer explicitly mentions the 'Combo+' bundle, which the LLM includes but does not emphasize as a key product structure—this does not detract significantly from accuracy. (4) The LLM answer conveys semantic equivalence: it captures the evolution in positioning and market strategy, correctly identifying which regions retained Disney+ Hotstar and which were consolidated. Wording differs slightly (e.g., 'fragmented, region-specific portfolio' vs 'distinct regional brand'), but meaning is preserved. The conclusion about streamlining and global platform alignment matches the original's implication. No factual errors; minor lack of specificity on 'Combo+' prevents a perfect 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 417,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did PayPal's approach to its Protection Programs evolve between 2023 and 2024, particularly in terms of risk exposure and loss recovery mechanisms?",
      "original_answer": "In 2023, PayPal disclosed that the costs associated with its protection programs were recorded in 'transaction and credit losses' during the period the payment transaction was completed, and it did not provide a separate service to customers under these programs. By 2024, PayPal introduced more detailed disclosures around its protection programs, highlighting that it incurs substantial losses from these programs due to customer disputes and faces challenges in recovering losses from merchants, especially in cases involving fraud or merchant insolvency. Additionally, PayPal noted that it may face increased exposure due to evolving fraud schemes and potential regulatory changes affecting chargeback requirements. This indicates a shift toward more explicit risk acknowledgment and a broader understanding of potential financial impact.",
      "llm_answer": "\nBetween 2023 and 2024 PayPal’s view of its Protection Programs shifted from a relatively passive cost‑center to a heightened risk focus.  In the 2023 filing the company noted that purchase‑ and seller‑protection programs were meant to curb fraud but that recoveries from merchants were often incomplete; by 2024 it warned that rising loss rates—driven by more sophisticated fraud, potential regulatory changes to charge‑back and error‑resolution rules, and the prospect of losing the ability to accept payment cards—could materially harm the business, emphasizing that loss‑recovery mechanisms remain limited and unreliable.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in PayPal's approach to its Protection Programs between 2023 and 2024. It correctly identifies that in 2023, PayPal treated protection programs as a cost without separate service recognition and faced incomplete recoveries from merchants—aligning with the ground truth. In 2024, the LLM accurately reflects the heightened risk focus, including increased exposure due to sophisticated fraud, regulatory changes affecting chargebacks, and unreliable loss recovery, especially in fraud or insolvency cases. The mention of potential loss of payment card acceptance is not explicitly in the original answer but is contextually plausible and does not contradict it; it may reflect an inference from 'regulatory changes affecting chargeback requirements' and 'increased exposure'. There are no numeric inaccuracies (quantitative accuracy is perfect as no specific numbers were in the original and none were fabricated). The reasoning is sound, showing a clear multi-hop synthesis across years and disclosures. The answer is semantically equivalent to the ground truth, with slightly more emphasis on business impact ('materially harm the business') but remains factually consistent. One minor point: the original emphasizes a shift in disclosure transparency, which the LLM does not explicitly mention, slightly reducing qualitative completeness. Overall, this is a strong, contextually relevant, and factually correct response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 408,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has NextEra Energy's relationship with solar generation facilities evolved from 2022 to 2024, particularly in terms of ownership structure and financial exposure?",
      "original_answer": "In 2022, NextEra Energy Resources was actively divesting ownership stakes in solar generation facilities, including the sale of a 100% ownership interest in a 100 MW solar facility in Arizona and the sale of a 90% ownership interest in a portfolio that included four solar facilities. These transactions resulted in significant cash proceeds and the recognition of gains. By 2024, the company's relationship had transformed into a more complex structure involving equity stakes and consolidated variable interest entities (VIEs). For example, NextEra consolidated eight VIEs owning solar generation facilities with approximately 765 MW of capacity and held a 10% direct ownership interest in additional solar facilities. This shift indicates a strategic move from outright ownership and divestiture to a more diversified and financially leveraged stake through VIEs, with increased financial exposure through guarantees and credit support.",
      "llm_answer": "\nFrom 2022 through 2024 NextEra moved many of its solar projects from wholly‑owned or jointly‑owned assets into a structure dominated by consolidated variable‑interest entities (VIEs) and “differential‑membership” arrangements in which it retains only a controlling stake while third‑party investors hold the economic upside.  This shift means that NEE’s direct ownership has been pared back and its financial exposure now includes large guarantees (≈ $1.3 bn), cash‑sweep and performance‑obligation liabilities, and contingent redemption rights tied to the VIE debt and power‑sale contracts that back the solar assets.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the strategic shift from direct ownership to VIEs and differential membership structures, aligning with the ground truth's description of a move toward consolidated VIEs and reduced direct ownership. It accurately reflects the evolution in financial exposure, including guarantees, performance obligations, and contingent redemption rights. However, specific quantitative details from the original answer are missing or altered: the 2022 divestitures (100% sale of a 100 MW Arizona facility and 90% sale of a portfolio) are not mentioned, and the 765 MW of solar capacity across eight VIEs consolidated by 2024 is omitted. Instead, the LLM introduces a $1.3B guarantee figure not present in the ground truth, which cannot be verified and appears to be an overreach or hallucination. (2) While the general trend of increasing financial exposure through guarantees is correct, the introduction of a specific dollar amount ($1.3B) without support in the original answer reduces quantitative accuracy. The original answer mentions 'significant cash proceeds' and 'gains' in 2022 but does not quantify them, nor does it specify the amount of guarantees—so the LLM's precision here is misleading. (3) The multi-hop reasoning is strong: the model synthesizes the shift in ownership structure and infers increased financial complexity and exposure, correctly identifying VIE consolidation and the separation of control from economic interest. This demonstrates sound qualitative understanding of the strategic evolution. (4) The answer is highly contextually relevant, directly addressing both ownership structure and financial exposure over the 2022–2024 period. Despite missing some specific facts and introducing an unsupported number, the core reasoning and direction of the transformation are accurate, warranting a high correctness score with a deduction for the unverified quantitative claim.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 524,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did ACN's investment in Mutual Fund Debt Securities evolve from 2022 to 2023, and what was the change in valuation methodology as reflected in the fair value hierarchy levels?",
      "original_answer": "In 2022, ACN reported Mutual Fund Debt Securities valued at $379,989 with the entire amount categorized under Level 2 of the fair value hierarchy. In 2023, this investment decreased to $253,025, and the valuation remained entirely under Level 2. The decrease in value indicates a reduction in exposure to Mutual Fund Debt Securities over the year, while the valuation methodology remained consistent, relying on observable market data.",
      "llm_answer": "\nBetween fiscal 2022 and 2023 the amount of mutual‑fund debt securities held in ACN’s defined‑benefit pension plans fell from **$379.9 million (classified as Level 2)** to a lower balance that reflects the reduced 2023 target allocation for non‑U.S. debt securities (the 2023 target is 48 % versus 50 % in 2022, indicating a modest decline; the exact 2023 figure is not disclosed). Throughout both years these securities remained **Level 2** in the fair‑value hierarchy, meaning the valuation methodology—quoted prices for comparable instruments in active markets—did not change.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2022 value of Mutual Fund Debt Securities as $379.9 million (matching the ground truth $379,989,000), and correctly states that the entire amount was classified under Level 2 in both years, indicating consistent valuation methodology. However, it fails to report the exact 2023 value of $253,025, instead stating that the 'exact 2023 figure is not disclosed'—which contradicts the ground truth that explicitly provides this number. This is a significant omission in quantitative accuracy. (2) The ground truth shows a clear decrease from $379,989 to $253,025, a reduction of $126,964. The LLM acknowledges a decrease but avoids citing the actual figure, undermining completeness and correctness. The mention of '48% vs 50%' allocation targets introduces unverified context not present in the original answer and may conflate allocation percentages with actual holdings, risking misinterpretation. (3) The reasoning correctly infers that Level 2 valuation methodology remained unchanged, relying on observable market data (consistent with fair value hierarchy definitions), which shows sound qualitative understanding. However, the failure to retrieve and report the precise 2023 value breaks the multi-hop synthesis required—comparing two years of data across time—making the answer incomplete. (4) Scores reflect partial correctness: quantitative accuracy penalized for missing key number; qualitative accuracy docked slightly for introducing speculative rationale (target allocations) not in source; contextual relevance remains high as the response stays focused on the question and interprets Level 2 correctly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 456,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has Chevron's financial stake and involvement in Tengizchevroil evolved between 2022 and 2023?",
      "original_answer": "In 2022, Chevron's carrying value of its investment in Tengizchevroil was $23,727 million with a reported equity in earnings of $1,238 million. By 2023, Chevron disclosed that its carrying value was approximately $80 million higher than its underlying equity in Tengizchevroil's net assets, indicating a more complex valuation approach. Additionally, Chevron highlighted that it provided a loan of $4,500 million to Tengizchevroil to fund the Future Growth Project and Wellhead Pressure Management Project (FGP/WPMP). This shows a significant deepening of Chevron's financial involvement and strategic commitment to the partnership in 2023 compared to 2022.",
      "llm_answer": "\nChevron’s equity stake in Tengizchevroil edged up modestly – the carrying value of the investment rose from **$26.5 bn at the end of 2022 to $26.95 bn at the end of 2023** (an increase of about $0.42 bn or 1.6 %).  At the same time, the company’s share of the joint‑venture’s earnings slipped from **$4.386 bn in 2022 to $3.375 bn in 2023**, indicating a lower contribution to earnings despite the slightly larger equity position, although Chevron continues to hold a **$4.5 bn loan to TCO for the FGP/WPMP development** that remains part of its ongoing involvement.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies in key financial figures. According to the ground truth, Chevron's carrying value in Tengizchevroil was $23,727 million ($23.727 billion) in 2022, not $26.5 billion as stated. The 2023 carrying value is misrepresented as $26.95 billion, whereas the original answer does not provide a total carrying value for 2023 but instead notes a $80 million difference between carrying value and underlying equity in net assets. The equity earnings figures are also incorrect: the ground truth reports $1,238 million ($1.238 billion) in 2022, while the LLM claims $4.386 billion in 2022 and $3.375 billion in 2023—over three times higher than reality. Only the $4.5 billion loan for the FGP/WPMP project is correctly reported. (2) Calculations are therefore invalid: the claimed 1.6% increase and $0.42 billion rise are based on false inputs. The actual ground truth does not support a direct comparison of total carrying values between years, but rather emphasizes a valuation discrepancy in 2023. (3) The multi-hop reasoning is flawed—the LLM appears to synthesize a trend (rising investment, falling earnings) that is not supported by the data. It fails to capture the key qualitative shift in 2023: the complexity in valuation methodology and the strategic significance of the loan as a deepening of involvement. Instead, it fabricates precise figures not present in the source. (4) Despite incorrect numbers, the answer is contextually relevant—it addresses the evolution of Chevron’s financial stake and mentions the correct project and loan, showing awareness of the strategic dimension. However, the severe quantitative errors undermine factual reliability, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 477,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has Disney's relationship with ABC Network evolved between 2023 and 2024, particularly in terms of its strategic positioning within Disney's broader entertainment ecosystem?",
      "original_answer": "In 2023, ABC Network was positioned as a core component of Disney's 'Linear Networks' within the Entertainment segment, specifically highlighting its domestic footprint through eight owned ABC television stations and its role in content distribution. By 2024, ABC Network's role had evolved, with its programming becoming more integrated into Disney's direct-to-consumer platforms, such as Hulu and Disney+. Specifically, content from ABC Network was made available on Hulu's SVOD service one day after its linear airing. This shift indicates a strategic move toward digital integration and away from traditional linear distribution. Additionally, while ABC Network was still referenced in the context of affiliate fees in 2023, 2024 emphasized its contribution to streaming services rather than standalone linear revenue.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Disney deepened the integration of ABC into its broader entertainment ecosystem, using the broadcast network as a conduit for its streaming strategy.  ABC’s primetime, news and sports programming now feeds directly into Hulu (with next‑day availability) and will soon be accessible via an ESPN‑branded tile on Disney+, while its carriage agreements continue to generate strong affiliate‑fee and advertising revenue that underpin Disney’s linear‑to‑DTC cross‑selling model.  This tighter linkage positions ABC not only as a traditional broadcast outlet but also as a key driver of Disney’s multi‑platform audience reach and monetisation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the strategic evolution of ABC Network between 2023 and 2024, emphasizing its integration into Disney's direct-to-consumer (DTC) platforms, particularly Hulu with next-day availability of content—this matches the original answer's key point. (2) There are no numeric values (e.g., dollar amounts, percentages, station counts) in the LLM answer that contradict the ground truth; while the original mentions 'eight owned ABC television stations' and 'affiliate fees', the LLM does not misstate these but omits the specific number of stations. This omission is minor and does not affect core accuracy. (3) The multi-hop reasoning is sound: the LLM synthesizes ABC’s role in linear networks with its growing function in streaming distribution, correctly linking it to Hulu and the future ESPN tile on Disney+, which reflects forward-looking integration. (4) The LLM adds a detail about an 'ESPN-branded tile on Disney+' that is not in the original answer; however, this is contextually plausible and consistent with Disney’s strategy, and does not introduce factual inaccuracy. The emphasis on ABC supporting cross-platform monetization via affiliate fees and advertising in 2023–2024 is consistent with the original. Overall, the answer captures the strategic shift accurately, with only minor omission of the specific count of owned stations. Hence, correctness is high but not perfect, warranting a 9. Quantitative accuracy is 10 as no numbers are incorrect. Qualitative accuracy is 9 due to the slight expansion beyond the original with unverified (but reasonable) details. Contextual relevance is perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 463,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has General Dynamics' positioning of the ASCOD vehicle within its Land Systems portfolio evolved between 2022 and 2023, and what does this indicate about potential shifts in production focus or investment allocation?",
      "original_answer": "In 2022, General Dynamics explicitly stated it was 'producing and upgrading' the ASCOD vehicle, indicating active development and enhancement of the platform. By 2023, the company's disclosure shifted to simply 'offering' the ASCOD, without specific mention of production or upgrades. This change in language suggests a potential shift in focus away from active investment or development of the ASCOD platform, possibly reallocating resources to other vehicle programs like the Piranha 5 and AJAX, which are explicitly called out in both years with continued production and international deployments.",
      "llm_answer": "\nBetween 2022 and 2023 General Dynamics raised the profile of the ASCOD within its Land Systems portfolio, explicitly noting expanded production and support for the vehicle across additional European customers (e.g., Luxembourg, Switzerland and Germany) and tying its development to new robotic‑and‑autonomous upgrades such as the MUTT and TRX prototypes.  This emphasis signals a strategic shift toward allocating greater production capacity and R&D investment to tracked combat‑vehicle platforms—particularly ASCOD and its variants—while scaling back relative focus on other legacy vehicle lines.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both factual content and reasoning. (1) It claims General Dynamics 'raised the profile' of ASCOD and expanded production to Luxembourg, Switzerland, and Germany with robotic upgrades like MUTT and TRX—none of which appears in the ground truth and directly contradicts it. The original answer states that in 2022, GD was 'producing and upgrading' ASCOD, but by 2023 shifted to merely 'offering' it, indicating a reduction in active development. The LLM instead asserts increased investment and production, which is the opposite of the truth. (2) There are no accurate numbers, dates, or financial metrics in the LLM response—no specific figures are mentioned, but the qualitative claims (e.g., new customers, R&D programs) are fabricated. (3) The multi-hop reasoning is flawed: the model fails to detect the linguistic shift from 'producing and upgrading' to 'offering' and instead invents a narrative of expansion. It also incorrectly ties ASCOD to MUTT and TRX, which are not mentioned in the ground truth and are unrelated to ASCOD in the context provided. (4) While the answer is framed around the question’s topic (ASCOD’s positioning and investment shifts), its content is factually inverted and hallucinated, resulting in very low correctness, quantitative, and qualitative accuracy. Contextual relevance is slightly higher only because it addresses the right company and vehicle platform, albeit incorrectly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 401,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has PayPal's utilization of European customer balances for credit activities evolved between 2023 and 2024, and what does this shift indicate about the company's credit funding strategy?",
      "original_answer": "In 2023, PayPal had approved $3.0 billion of European customer balances for credit activities, representing approximately 39% of balances made available for corporate use. By 2024, the approved amount had decreased to $2.0 billion, or 26% of European customer balances. This indicates a strategic shift toward reducing reliance on customer balances for credit funding, potentially in favor of external financing sources, as evidenced by PayPal's multi-year agreement to sell consumer installment receivables, which saw $20.8 billion in loans sold in 2024 compared to $5.5 billion in 2023.",
      "llm_answer": "\nBetween 2023 and 2024 the balance of European customer deposits that PayPal can earmark for credit‑funding fell from **$3.0 bn to $2.0 bn**, and the share of total European customer balances it represents dropped from **≈39 % to ≈26 %**.  This pull‑back shows the company is reducing its reliance on internal customer deposits as a funding source for credit products and is instead leaning more on external financing (e.g., debt issuances, credit‑facility borrowings) to support its loan and installment‑credit portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: the approved European customer balances decreased from $3.0 billion in 2023 to $2.0 billion in 2024, and the percentage of total balances used dropped from approximately 39% to 26%, which matches the original answer exactly. (2) Quantitative accuracy is perfect—both dollar amounts and percentages are correctly reported, with acceptable formatting (e.g., $3.0 bn = $3.0 billion). (3) The reasoning is sound: the LLM correctly infers a strategic shift away from using customer balances toward external financing. While it does not explicitly mention the multi-year receivables sale agreement or the specific figures of $20.8 billion in loans sold in 2024 versus $5.5 billion in 2023, it captures the essence of the shift by referencing external financing sources like debt issuances and credit facilities. This omission slightly affects completeness and qualitative accuracy but does not undermine the core correctness. (4) The answer is contextually relevant, directly addressing both parts of the question—evolution of utilization and strategic implication. The conclusion is logically supported by the data provided. Minor deduction from 10 to 9 due to incomplete synthesis of the receivables sale evidence, which is a key multi-hop element in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 378,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the valuation and categorization of equity securities within NEE's Special Use Funds evolve between 2022 and 2024, and what does this indicate about changes in transparency or investment composition?",
      "original_answer": "In 2022, NEE's Special Use Funds reported equity securities at a carrying amount of $906 million (with an estimated fair value of $907 million) for NEE and $672 million (with an estimated fair value of $672 million) for FPL, without detailed categorization by valuation levels. By 2024, the equity securities in the Special Use Funds had grown significantly, with NEE holding $2,614 million in Level 1 equity securities and FPL holding $1,028 million in Level 1 equity securities, alongside more granular disclosures that included Level 2 and Level 3 valuations. This indicates a substantial increase in equity investments and a shift toward more transparent and detailed reporting of asset valuation methodologies.",
      "llm_answer": "\nBetween 2022 and 2024 the equity securities held in NEE’s Special Use Funds were valued at roughly $6.16 bn (2022), $5.29 bn (2023) and $6.16 bn (2024).  The Level 1 share fell from about 42 % of the portfolio in 2022 to 38 % in 2023 before returning to 42 % in 2024, while the Level 2 portion grew from roughly 54 % to 63 % and then back to 54 %, with a small but steady Level 3 component (≈3‑4 %).  This shift toward Level 2 and the persistent Level 3 exposure shows that NEE’s Special Use Funds became increasingly reliant on internally‑valued, commingled‑fund assets, indicating a modest decline in direct market‑price transparency and a move toward more complex, less‑observable equity investments.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and fails to match the ground truth on multiple levels. (1) Quantitative Accuracy: The dollar amounts are completely wrong — the LLM claims total equity securities of ~$6.16B in 2022 and 2024, while the ground truth reports $906M for NEE and $672M for FPL in 2022 (total ~$1.58B), and $2,614M for NEE and $1,028M for FPL in 2024 (total ~$3.64B). The LLM’s figures are over 4x too high. Additionally, the LLM introduces 2023 data not present in the original answer and fabricates percentages (42%, 38%, etc.) with no basis in the ground truth. (2) Completeness: While the question asks about valuation and categorization evolution and implications for transparency, the LLM invents granular level-based portfolio percentages not supported by the 2022 data, which explicitly states no detailed categorization was provided that year. (3) Entity Accuracy: The companies (NEE, FPL) and time frame (2022–2024) are correctly identified, but the financial metrics (Level 1/2/3 breakdowns for those years) are fabricated. (4) Reasoning: The multi-hop synthesis is flawed — the ground truth shows a move toward greater transparency with the introduction of Level 1–3 disclosures in 2024, whereas the LLM incorrectly infers reduced transparency due to increased Level 2/3 holdings, which contradicts the evidence. (5) Semantic Equivalence: The LLM’s conclusion — that transparency declined — is the opposite of the ground truth, which states there was a shift toward more transparent and detailed reporting. Overall, the answer fabricates data, misrepresents trends, and draws an inverted conclusion, warranting a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 454,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the scope and utilization of Accenture's share purchase program evolve from fiscal 2022 to fiscal 2023, particularly in terms of shares acquired under the public program versus those acquired through employee-related transactions?",
      "original_answer": "In fiscal 2022, Accenture purchased 1,964,612 Class A ordinary shares under the publicly announced open-market share purchase program for an aggregate price of $576 million. Additionally, 97,251 shares were acquired through employee-related transactions, such as share withholding for payroll tax obligations, which do not affect the aggregate available authorization. In fiscal 2023, there is no mention of shares purchased under the public program, but the company continued acquiring shares through employee-related transactions under equity share plans. This indicates a shift where the public share purchase program saw reduced or no activity, while employee-related share acquisitions remained consistent.",
      "llm_answer": "\nFrom fiscal 2022 to fiscal 2023 the share‑purchase programme continued to be driven primarily by the Board‑approved open‑market repurchase plan – in 2022 the public programme accounted for 1.96 million of the 2.06 million shares bought (≈95 % of the total), with only about 97 k shares (≈5 %) acquired through employee‑related transactions such as tax‑withholding for equity awards.  The Board subsequently increased the repurchase authority to $6.1 billion, signalling a larger planned use of the public programme in fiscal 2023, while employee‑related purchases remained a minor, separate component of the overall authorisation.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states that 1,964,612 shares (rounded to 1.96 million) were purchased under the public program in fiscal 2022 for $576 million and that 97,251 shares (~97k) were acquired via employee-related transactions, it incorrectly claims the share purchase program continued in fiscal 2023. The ground truth explicitly states there is no mention of public program activity in fiscal 2023, indicating a reduction or pause—contrary to the LLM's assertion that the Board increased repurchase authority to $6.1 billion signaling expanded use. This claim is unsupported and factually wrong. (2) Quantitatively, the fiscal 2022 numbers are accurate (1.96 million ≈ 1,964,612; 97k ≈ 97,251), and the 95%/5% split is approximately correct. However, the $6.1 billion figure is fabricated and not present in the original answer or implied by the data. No calculation errors are made within the numbers provided, but the introduction of false data undermines quantitative accuracy. (3) The multi-hop reasoning is flawed: the model fails to recognize the absence of public program activity in fiscal 2023 as a key shift. Instead, it infers increased intent based on a non-existent authorization increase, demonstrating incorrect synthesis. The conclusion that the public program remained active or was expanded is the opposite of the truth. (4) Contextual relevance is moderate—the response addresses the right topic (share purchase evolution, public vs employee-related transactions) and correctly characterizes employee-related purchases as minor and separate. However, the core conclusion about program evolution is inverted, making the overall answer misleading despite some correct inputs. Hence, correctness is low due to major factual and inferential errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 497,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did Chevron's financial reporting relationship with Chevron Phillips Chemical Company LLC evolve between 2022 and 2023, particularly in terms of its consolidation status and investment accounting approach?",
      "original_answer": "In 2022, Chevron Phillips Chemical Company LLC was consolidated into Chevron’s financial statements, as indicated by the inclusion of 'Note 8: Summarized Financial Data - Chevron Phillips Chemical Company LLC' among other consolidated subsidiaries. However, in 2023, Chevron explicitly stated that its investment in Chevron Phillips Chemical Company LLC was accounted for using the equity method, and it was no longer consolidated under Chevron U.S.A. Inc.'s financial data. This reflects a significant structural change where Chevron transitioned from consolidating the entity to reporting its investment under the equity method, altering how its financial performance is reflected in Chevron’s consolidated results.",
      "llm_answer": "\nChevron continued to account for its 50 % interest in Chevron Phillips Chemical Company LLC as an equity‑method investment and did not consolidate CPChem in either 2022 or 2023. The 2023 filing (Note 8 and the table on page 76) adds a dedicated “Total CPChem net equity” line and expanded fair‑value disclosures—showing the equity‑method investment’s carrying amount rise to $14.7 bn—whereas the 2022 filing presented only summarized CPChem results without that separate balance‑sheet caption, but the underlying consolidation status and equity‑method accounting remained unchanged.",
      "correctness_score": 2,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 2,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core claim about Chevron's accounting treatment of Chevron Phillips Chemical Company LLC (CPChem). According to the ground truth, CPChem was consolidated in 2022 but transitioned to equity-method accounting in 2023. However, the LLM asserts that Chevron used the equity method in both years and did not consolidate CPChem in either year, which directly contradicts the original answer. This misrepresents a key multi-hop insight: the change in consolidation status over time. While the LLM correctly references Note 8 and mentions a $14.7 billion carrying amount in 2023 (a plausible figure format-wise), this number cannot be verified against the ground truth, which does not include specific dollar amounts. The mention of expanded disclosures in 2023 may reflect accurate observation, but it is used to support an incorrect conclusion. The reasoning fails the multi-hop requirement—instead of identifying a shift from consolidation to equity method, it claims consistency across years. Entity names and years are correctly identified, and the response is contextually relevant to the question, addressing consolidation status and accounting approach. However, the qualitative inaccuracy undermines the entire response. Quantitative accuracy is partially acceptable due to plausible formatting and reference to financial data, but without confirmation of the $14.7B figure and with incorrect interpretation, it cannot score highly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 406,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the role of Hydra-70 rockets in General Dynamics' Combat Systems segment evolved from 2022 to 2023, particularly in terms of contract involvement and production capacity expansion?",
      "original_answer": "In 2022, General Dynamics received a $175 million contract for the production of Hydra-70 rockets as part of its Combat Systems segment. By 2023, the company's role had evolved significantly, with OTS (Orbital Technologies Corporation, part of Combat Systems) maintaining a market-leading position in the supply of Hydra-70 rockets and expanding its production capacity. Specifically, OTS received awards to increase metal parts production capacity for munitions from 18,000 to 86,000 rounds per month by 2025, which includes Hydra-70 rockets as part of its broader munitions portfolio.",
      "llm_answer": "\nFrom 2022 into 2023 the Hydra‑70 rocket moved from a single low‑rate production award (a $175 M contract for initial deliveries) to a core component of the Army’s indirect‑fire modernization effort, with OTS receiving new funding to dramatically scale its manufacture.  The company is expanding metal‑parts capacity from 18 k to 86 k rounds per month by 2025 and propellant capacity from 4 M to 16 M lb per year by 2028, underscoring a deeper contract involvement and a strategic push to boost production capacity for Hydra‑70 rockets.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $175 million contract in 2022 and the expansion of metal parts production capacity from 18,000 to 86,000 rounds per month by 2025, which aligns with the ground truth. However, it introduces additional information not present in the original answer—specifically, the expansion of propellant capacity from 4M to 16M lb per year by 2028—which is factually unsupported by the provided ground truth. This addition affects quantitative accuracy. (2) The numbers related to the contract value and metal parts production increase are accurate and correctly formatted. The timeline for metal parts expansion (by 2025) matches. However, the propellant capacity figures and the 2028 timeline are not mentioned in the original answer and thus represent unverified, extraneous data. (3) The multi-hop reasoning is generally sound: the model correctly infers increased contract involvement and production scaling from 2022 to 2023. It accurately links OTS (Orbital Technologies Corporation) to General Dynamics’ Combat Systems segment and positions Hydra-70 rockets as a growing priority. However, the unsupported propellant expansion claim weakens the reasoning integrity. (4) The answer is highly contextually relevant, addressing both contract evolution and production capacity. The core facts are correct, but the inclusion of unverified details reduces overall correctness. Hence, a score of 7 is justified—key facts are right, but significant embellishment affects precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 419,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has PayPal's treatment of the Global Restricted Stock Unit Award Grant Notice evolved between the 2023 and 2024 filings, particularly in terms of its documentation status and associated agreements?",
      "original_answer": "In the 2023 filing, the Global Restricted Stock Unit Award Grant Notice was listed as Exhibit 10.07+ and was associated with the PayPal Holdings, Inc. 2015 Equity Incentive Award Plan, with its form incorporated by reference from 10-12B/A filed on May 14, 2015. By 2024, the same form of the Global Restricted Stock Unit Award Grant Notice (Exhibit 10.07+) remained in place, still referencing the 2015 plan and incorporated by reference from the same 10-12B/A filing on May 14, 2015. However, in the 2024 filing, there was an updated form of the Global Performance Based Restricted Stock Unit Award Grant Notice (Exhibit 10.08+), which was now filed under the amended and restated plan and was linked to a more recent 10-Q filing on April 30, 2024. This indicates that while the base RSU grant notice remained unchanged, the performance-based variant saw active revision and documentation updates in 2024.",
      "llm_answer": "\nBetween the 2023 and 2024 Form 10‑K filings, PayPal moved the **Global Restricted Stock Unit Award Grant Notice** from an exhibit that was directly attached to the filing (Exhibit 10.07⁺ in the 2023 10‑K) to a document that is now only **incorporated by reference** from the earlier 2015 filing (shown as “Form of Global Restricted Stock Unit Award Grant Notice… under the 2015 Equity Incentive Award Plan” in the 2024 exhibit list).  Consequently, the notice is no longer separately filed in the 2024 filing, and the related award agreements are likewise referenced rather than attached, indicating a shift from explicit inclusion to reliance on prior incorporation.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in its core claim and misrepresents the evolution of the Global Restricted Stock Unit Award Grant Notice between the 2023 and 2024 filings. According to the ground truth, the form of the Global Restricted Stock Unit Award Grant Notice (Exhibit 10.07+) remained unchanged in status between 2023 and 2024: it was incorporated by reference from the May 14, 2015 10-12B/A filing in both years and was not directly filed as a standalone exhibit in either year. The LLM incorrectly asserts that the notice was 'directly attached' in 2023 and moved to 'incorporated by reference' in 2024, which contradicts the ground truth. This is a fundamental factual error in both documentation status and change over time. Additionally, the LLM fails to mention the key development in the 2024 filing: the update to the Global Performance Based Restricted Stock Unit Award Grant Notice (Exhibit 10.08+) under the amended plan and linked to the April 30, 2024 10-Q, which is the actual evolution in documentation. The answer also incorrectly implies that the base RSU notice was more prominently filed in 2023, when in fact it was always incorporated by reference. While the LLM correctly identifies the 2015 plan and the concept of incorporation by reference, its central narrative of a shift in treatment is false. Therefore, despite some correct contextual elements (e.g., reference to the 2015 plan), the answer fails on quantitative accuracy (wrong filing status, incorrect change over time), qualitative accuracy (flawed reasoning and synthesis), and completeness (omits the actual update to the performance-based variant). The contextual relevance is moderate because it discusses the right type of document and plan, but the substance is misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 479,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the role of Opdivo within Bristol-Myers Squibb's portfolio evolved from 2022 to 2024, based on its revenue performance and new regulatory approvals?",
      "original_answer": "In 2022, Opdivo generated $7,523 million in revenue, indicating it was a major contributor to Bristol-Myers Squibb's oncology portfolio. By 2024, Opdivo received a new FDA approval in March 2024 for use in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. This regulatory expansion demonstrates a strategic evolution in Opdivo’s therapeutic application and reinforces its continued importance in the company's oncology pipeline, despite not showing a significant revenue increase from earlier years.",
      "llm_answer": "\nOpdivo has stayed at the core of BMS’s oncology franchise, delivering roughly $7–8 billion in annual sales through 2022‑2024 and expanding its label with several new approvals—including first‑line NSCLC (Oct 2024), EC‑approved Opdivo + Yervoy for colorectal cancer (Dec 2024), and the subcutaneous formulation Opdivo Qvantig (Dec 2024) – while also being used in combination regimens for urothelial carcinoma and other indications (see BMY 10‑K 2024 pp. 44‑45). These regulatory wins broadened the drug’s market reach and reinforced its role as BMS’s primary revenue driver and a key engine of the company’s overall growth from 2022 into 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly regarding dates and approvals. The ground truth states that Opdivo received FDA approval in March 2024 for first-line treatment of unresectable or metastatic urothelial carcinoma in combination with cisplatin and gemcitabine. However, the LLM claims approvals in October 2024 (first-line NSCLC), December 2024 (EC approval with Yervoy for colorectal cancer), and December 2024 (Opdivo Qvantig subcutaneous formulation). These dates are all in the future relative to the 2024 reference point and not supported by the original answer. Additionally, the original answer does not mention NSCLC, colorectal cancer, or the subcutaneous formulation approvals at all. (2) Quantitatively, the LLM correctly estimates Opdivo’s revenue as $7–8 billion annually, which aligns with the $7,523 million reported in 2022. However, it implies sustained revenue without acknowledging the lack of significant growth, which is a key point in the original answer. The LLM also fabricates multiple approvals with specific dates not present in the ground truth. (3) The multi-hop reasoning is partially sound in linking revenue performance and regulatory approvals to assess Opdivo’s evolving role, but it fails in synthesis because the approvals cited are not from the provided truth data. The model invents new information rather than drawing from the given facts, undermining the reasoning chain. (4) Despite the factual errors, the answer is contextually relevant—addressing Opdivo’s role, revenue, and regulatory evolution within BMS’s portfolio. It captures the general idea that Opdivo remains a core asset with label expansions, but the specific support is incorrect. Hence, correctness and quantitative accuracy are low due to fabricated dates and approvals, qualitative accuracy is moderate due to correct framing but flawed details, and contextual relevance is high as the overall theme matches the question's intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 536,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did Chevron's financial involvement and strategic support for Chevron Phillips Chemical Company LLC evolve between 2022 and 2023, particularly in terms of project funding and investment structure?",
      "original_answer": "In 2022, Chevron highlighted its 50% ownership in Chevron Phillips Chemical Company LLC (CPChem), emphasizing ongoing investments in global manufacturing facilities and expansion projects, such as the planned 1-hexene unit in Old Ocean, Texas, and a C3 splitter at Cedar Bayou, with targeted start-ups in 2023. By 2023, Chevron's involvement had evolved to include a direct loan of $387 million to fund a portion of the Golden Triangle Polymers Project in Orange, Texas, in which CPChem owns 51%. This indicates a shift from general equity ownership and project announcements in 2022 to more direct financial support and structured investment in specific projects in 2023.",
      "llm_answer": "\nChevron’s equity investment in Chevron Phillips Chemical Company LLC grew from **$6.8 billion at the end of 2022 to $7.8 billion at the end of 2023** (Note 15, CVX_10K_2023 p. 82), indicating that the partnership moved from planning to capital deployment.  In 2023 the company also **provided a $387 million loan to fund the Golden Triangle Polymers project** and, after a final investment decision, began financing two new petrochemical expansions—a 1‑hexene unit and a C3 splitter at Cedar Bayou—signaling a more project‑specific investment structure that underpins Chevron’s strategic support.  (See CVX_10K_2022 p. 19 for the 2022 project pipeline and CVX_10K_2023 p. 18 for the 2023 FIDs.)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the $387 million loan to fund the Golden Triangle Polymers Project is accurately reported, and the equity investment figures of $6.8 billion in 2022 and $7.8 billion in 2023 are factually correct (per Note 15, CVX_10K_2023 p. 82). The $1 billion increase reflects actual capital deployment, supporting the claim of a shift from planning to execution. (2) The projects mentioned—the 1-hexene unit and C3 splitter at Cedar Bayou—are consistent with the original answer and correctly tied to 2023 final investment decisions (FIDs), with start-ups targeted in 2023 as noted in the 2022 filing. (3) The reasoning is sound: the LLM correctly infers a strategic evolution from general equity ownership and project announcements in 2022 to direct financial support (loan) and project-specific funding in 2023. The mention of the $387M loan and its purpose demonstrates proper multi-hop synthesis between Chevron’s financial statements and CPChem’s project involvement. (4) The only minor shortcoming is that the original answer specifies CPChem owns 51% of the Golden Triangle Polymers Project, a detail omitted in the LLM response. While not critical to the core claim, it adds contextual precision. Otherwise, the LLM captures the evolution in funding and investment structure accurately, with excellent use of source citations and semantic equivalence to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 408,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did PayPal's protection programs evolve between 2023 and 2024 in terms of financial commitments and disclosures regarding transaction loss reserves?",
      "original_answer": "In 2023, PayPal disclosed that it estimated and recorded costs associated with protection programs in transaction and credit losses, but did not specify the exact amounts for the allowance for transaction losses or negative customer balances. In 2024, PayPal provided more detailed disclosures, including specific figures: the allowance for transaction losses increased from $64 million in 2023 to $86 million in 2024, and the allowance for negative customer balances rose from $218 million to $256 million. This indicates a significant increase in PayPal's financial commitments and potential risk exposure under its protection programs in 2024 compared to the prior year.",
      "llm_answer": "\nBetween 2023 and 2024 PayPal markedly expanded the financial commitment of its protection programs – the allowance for transaction‑loss reserves rose from **$64 million (2023) to $86 million (2024)**, and the allowance for negative customer balances increased from **$218 million to $256 million**.  The 2024 Form 10‑K now discloses a full reconciliation of these allowances (beginning balance, provision, realized losses, recoveries, ending balance) and explicitly describes the reserves as “assurance‑type warranties” that are estimated and recorded as part of transaction and credit losses, providing far more detailed transparency about the company’s expected loss exposure.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the allowance for transaction losses increased from $64 million in 2023 to $86 million in 2024, and the allowance for negative customer balances rose from $218 million to $256 million—both figures exactly match the original answer. (2) The answer is complete, addressing both the increase in financial commitments and the enhanced disclosures in 2024, including the new reconciliation and classification of reserves as 'assurance-type warranties,' which reflects deeper transparency not mentioned in 2023. (3) Entity accuracy is perfect: PayPal is correctly identified, the years 2023 and 2024 are properly referenced, and the financial metrics (allowance for transaction losses, negative customer balances) are correctly named and contextualized. (4) The multi-hop reasoning is sound—LLM synthesized changes in both the magnitude of reserves and the qualitative evolution in disclosure practices between two fiscal years, drawing a valid conclusion about increased financial commitment and risk transparency. The semantic meaning and factual content are equivalent to the ground truth, with slightly enhanced detail (e.g., mention of reconciliation and warranty classification) that is consistent with a more detailed 2024 filing. No errors in logic, calculation, or fact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 386,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has McDonald's strategic framing of its relationship with franchisees changed between 2022 and 2024, particularly in terms of franchising as a core business model and the role of franchisee co-investment?",
      "original_answer": "In 2022, McDonald's described its relationship with franchisees in neutral, structural terms, emphasizing the division of responsibilities such as franchised arrangements and license agreements, and presenting franchisees as co-participants in operating restaurants. By 2024, the framing evolved significantly, with franchising being described as 'paramount' to delivering food quality, customer experience, and profitability. The 2024 filing also emphasized the importance of franchisee co-investment, noting that it enables McDonald's to achieve high restaurant performance. This represents a shift from a descriptive to a more strategic and value-laden framing of the franchisee relationship.",
      "llm_answer": "\nBetween 2022 and 2024 McDonald’s continued to present franchising as the cornerstone of its business, but the way it described the franchise‑franchisor relationship shifted from a purely financial model to a strategic partnership.  \n\n- **2022 (Form 10‑K 2022, pp. 42‑44)** – The filing framed franchising as the “heavily franchised business model” that generates stable cash flow, emphasized that franchisees bear most capital costs, and mentioned co‑investment only as a tactical means to fund restaurant upgrades (“the Company may co‑invest… to accelerate implementation of certain initiatives”).  \n- **2024 (Form 10‑K 2024, pp. 4‑5)** – The narrative still calls franchising “paramount” but now presents co‑investment as a collaborative tool that “accelerates implementation of certain initiatives,” modernizes restaurants, caters to consumer preferences, and “increases the value of the McDonald’s brand” while aligning with the company’s broader purpose‑driven goals (e.g., sustainability, community impact).  \n\nThus, by 2024 the company recast franchisee co‑investment from a peripheral financing mechanism into a strategic, value‑creating partnership that supports both financial and purpose‑related objectives.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the shift in McDonald's framing of franchisees from 2022 to 2024: from a structural/financial model to a strategic partnership. The use of 'paramount' in 2024 is accurately cited, and the evolution of co-investment from a tactical to strategic role is well-articulated. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or ground truth, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the answer synthesizes information across two years of 10-K filings, correctly contrasting the language and strategic emphasis. The LLM adds contextual detail (e.g., sustainability, brand value) that is consistent with a deeper strategic framing, which complements the ground truth without contradicting it. (4) The only minor deviation is that the ground truth emphasizes the 2022 framing as 'neutral, structural terms' and 'co-participants,' while the LLM characterizes it as a 'purely financial model'—a slight sharpening of tone, but not factually incorrect. Overall, the answer captures the core evolution in strategic framing with high fidelity, making it semantically equivalent and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1494,
        "completion_tokens": 359,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the FDA's authorization of Marlboro HeatSticks evolved between 2022 and 2023, and what does this indicate about Altria's regulatory progress with heated tobacco products?",
      "original_answer": "In 2022, the FDA had not yet authorized Marlboro HeatSticks and was considering them on a case-by-case basis regarding graphic health warnings. By 2023, the FDA had authorized PMTAs for three new tobacco-flavored varieties of Marlboro HeatSticks in January 2023, marking a significant regulatory milestone. This indicates that Altria made notable progress in securing FDA approval for its heated tobacco product line, which is a key part of its innovation strategy.",
      "llm_answer": "\nBetween March 2022 and January 2023 the FDA moved from granting a Modified‑Risk Tobacco Product (MRTP) designation to the IQOS 3 device (which includes Marlboro HeatSticks) to authorizing three new Marlboro HeatStick flavors through Premarket Tobacco Product Applications (PMTAs) in early 2023. This sequence shows that Altria has secured successive FDA clearances for its heated‑tobacco offerings, but the products remain subject to ongoing post‑market surveillance and potential future rulemaking, indicating that regulatory progress is advancing yet still contingent on continued FDA approval and compliance.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual inaccuracy by claiming that the FDA granted a Modified-Risk Tobacco Product (MRTP) designation to the IQOS 3 device (with Marlboro HeatSticks) in March 2022. The ground truth does not mention any MRTP designation during this period; instead, it states that in 2022 the FDA had not yet authorized Marlboro HeatSticks and was evaluating them case-by-case for graphic health warnings. The only verified regulatory event is the January 2023 PMTA authorization for three new tobacco-flavored HeatStick varieties, which the LLM correctly identifies. (2) The date 'January 2023' is accurate and matches the ground truth. However, the mention of 'March 2022' and the MRTP designation is unsupported and incorrect, undermining quantitative and factual accuracy. There are no numerical values requiring calculation, but the timeline is mischaracterized. (3) The multi-hop reasoning is partially sound—the model attempts to show regulatory progression from 2022 to 2023—but it fabricates a key milestone (MRTP) that was not in the original data, leading to flawed synthesis. The conclusion about Altria making progress is consistent with the ground truth, but the reasoning path is based on incorrect premises. (4) Despite the incorrect MRTP claim, the answer is contextually relevant and captures the broader narrative of regulatory advancement. However, the factual error in a core claim significantly reduces correctness and qualitative accuracy. The contextual relevance remains high because the response addresses both the evolution and its implication for Altria’s strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 446,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did the valuation of mutual fund equity securities held by ACN evolve between 2022 and 2023, and what does this shift indicate about the company's investment positioning in this category?",
      "original_answer": "In 2022, ACN reported $239,293 (in millions) in mutual fund equity securities. By 2023, this figure decreased to $196,226 (in millions), indicating a reduction of $43,067 (in millions). This decline suggests a strategic shift or reallocation away from mutual fund equity securities during the period.",
      "llm_answer": "\nThe fair‑value of ACN’s mutual‑fund equity securities in its defined‑benefit pension plans was $239.3 million as of August 31 2022 (comprised of $4.9 million Level 1 and $234.3 million Level 2). The 2023 filing shows the target equity allocation for non‑U.S. pension assets raised from 21 % to 27 %, and the reported fair‑value of those mutual‑fund equity holdings increased accordingly. This shift signals that ACN is deliberately tilting its pension‑plan portfolio toward equities to pursue higher long‑term returns.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly reports the 2022 value of mutual fund equity securities as approximately $239.3 million (matching the ground truth of $239,293 million), it incorrectly states that the 2023 value increased due to a rise in equity allocation targets. In reality, the 2023 value decreased to $196,226 million, a reduction of $43,067 million. The LLM falsely claims an increase, which contradicts the ground truth. Additionally, the mention of Level 1 and Level 2 valuations, while possibly present in the filing, is irrelevant to the question and distracts from the core trend. (2) The quantitative accuracy is partially correct for 2022 (with acceptable rounding: $239.3M vs $239,293M), but completely wrong for 2023—no support for an increase exists in the ground truth. The calculation of change is therefore incorrect in direction and magnitude. (3) The multi-hop reasoning fails: the model conflates target allocation percentages (which may have increased) with actual reported holdings (which decreased), leading to an erroneous conclusion about investment positioning. It does not synthesize the actual reported values across years correctly. (4) Contextual relevance is moderate because the answer discusses mutual fund equity securities and ACN’s pension plan context, but the conclusion about strategic tilting toward equities is unsupported and opposite to the actual data. The answer misrepresents the trend and thus fails the primary objective of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1216,
        "completion_tokens": 425,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has Chevron's involvement in Angola LNG Limited evolved from 2022 to 2023, particularly in terms of its operational focus and investment emphasis?",
      "original_answer": "In 2022, Chevron operated and held a 36.4% interest in Angola LNG Limited, emphasizing its role in processing and liquefying associated natural gas from multiple fields and operators in Angola. The company was also involved in developing non-associated gas resources to supply the Angola LNG plant. By 2023, Chevron continued to hold the same 36.4% interest, but the disclosure shifted focus to its broader portfolio of equity affiliates and non-equity investments, with Angola LNG Limited being listed alongside other major investments like Tengizchevroil and Chevron Phillips Chemical Company LLC. This indicates a shift in disclosure emphasis from operational development to financial stake and integration within Chevron’s global portfolio.",
      "llm_answer": "\nFrom 2022 to 2023 Chevron trimmed its equity holding in Angola LNG Limited, cutting the book value of the investment from about **$1.96 bn (2022)** to **$1.76 bn (2023)** (see Note 15, page 82).  The company continues to focus on supplying the Angola LNG plant with reliable feedstock—especially through the SLGC gas‑connection project and the development of non‑associated offshore gas—but the modest reduction in its invested balance indicates a strategic pull‑back, with capital being redirected toward other upstream growth areas while still retaining its 36.4 % ownership stake.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states that Chevron retained a 36.4% ownership stake in Angola LNG Limited in both 2022 and 2023 (matching the ground truth), it incorrectly claims that Chevron 'trimmed its equity holding' and 'cut the book value' from $1.96B to $1.76B. The ground truth does not mention any such reduction in book value or a strategic pullback. This financial data appears to be fabricated or misattributed, as no such figures are present in the original answer or supported by the knowledge graph. (2) The quantitative accuracy is low because the dollar amounts ($1.96B, $1.76B) and the claim of a 'modest reduction in invested balance' are not found in the original answer and contradict the stated continuity in Chevron's involvement. There is no mention of Note 15, page 82 in the ground truth, further undermining credibility. (3) The reasoning is partially sound in that it acknowledges the continued 36.4% stake and references ongoing operational efforts like non-associated gas development, which aligns with the original answer. However, the conclusion about a 'strategic pull-back' and capital reallocation is speculative and not supported by the ground truth, which instead notes a shift in disclosure focus—from operational development to financial stake and portfolio integration. The LLM misinterprets a change in reporting emphasis as a change in investment strategy. (4) Contextual relevance is high because the answer addresses the evolution of Chevron's role in Angola LNG Limited over the two years and attempts to discuss both operational focus and investment emphasis as asked. However, the core factual error regarding financial values and strategic intent severely undermines correctness. The answer introduces unsupported specifics that distort the actual situation, leading to a low overall correctness score despite some accurate elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 524,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did MMM's investment in Certificates of Deposit/Time Deposits evolve from 2022 to 2023, and what was the magnitude of this change?",
      "original_answer": "In 2022, MMM held $14 million in Certificates of Deposit/Time Deposits, as disclosed in the fair value measurements. By 2023, this amount increased to $49 million, indicating a significant growth in this category of investment. This represents an increase of $35 million, or approximately 250%, from the prior year.",
      "llm_answer": "\nMMM’s holdings of certificates of deposit/time deposits rose sharply year‑over‑year.  The 2023 10‑K (page 110) shows $49 million of such securities in 2023 versus $21 million in 2022 – an increase of $28 million, or about a 133 % growth from 2022 to 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the direction of change (increase) and the correct year (2023 value of $49 million), which matches the ground truth. However, it reports the 2022 amount as $21 million, which is incorrect—the ground truth states $14 million. This error leads to an incorrect change calculation: the LLM reports a $28 million increase (133%), whereas the correct increase is $35 million (approximately 250%). The quantitative inaccuracies are significant because they involve core financial figures and the derived percentage change, which misrepresents the magnitude of growth. The entity (MMM, Certificates of Deposit/Time Deposits) and time periods (2022 to 2023) are correctly identified, and the answer addresses both parts of the question (evolution and magnitude), so completeness and contextual relevance are strong. The reasoning structure is sound—comparing two years and calculating growth—but based on incorrect input data. While the format of numbers is acceptable ($49 million), the factual inaccuracy in the 2022 figure undermines the overall correctness. Thus, the answer is partially correct but contains major quantitative errors that affect the conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1139,
        "completion_tokens": 334,
        "total_tokens": 1474
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of the percentage of franchised restaurants between 2021 and 2024?",
      "original_answer": "In 2021, 93% of McDonald's restaurants were franchised, while by 2024, this percentage increased to approximately 95%. This indicates a slight but deliberate shift toward further reliance on franchisees to operate McDonald's restaurants, reinforcing the company's strategic emphasis on franchising as a core business model.",
      "llm_answer": "\nBetween 2021 and 2024 the share of McDonald’s restaurants operated by franchisees rose modestly—from about 93 % of the system at the end of 2021 to roughly 95 % by the end of 2024. This incremental increase reflects the company’s ongoing strategy of expanding its heavily franchised model while maintaining a stable, predictable revenue base driven by franchisee sales.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) Quantitative accuracy: The percentages (93% in 2021 and 95% in 2024) are correctly reported, with acceptable rounding ('about' and 'roughly' align with 'approximately' in the original). The years match the question's timeframe. (2) Completeness: The answer addresses the evolution of McDonald's relationship with franchisees through the percentage change in franchised restaurants across the specified period. (3) Entity accuracy: McDonald's is correctly identified, and the metric (percentage of franchised restaurants) and years (2021, 2024) are accurate. (4) Reasoning: The LLM correctly infers a strategic trend toward franchising, consistent with the original answer’s interpretation of a 'deliberate shift' and 'strategic emphasis.' The mention of 'stable, predictable revenue base' adds contextually appropriate insight without contradicting the original. (5) Semantic equivalence: Despite slightly different phrasing, the core information—modest increase from 93% to 95%, strategic focus on franchising—is fully aligned. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1170,
        "completion_tokens": 330,
        "total_tokens": 1500
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did the effective date and structure of the 2015 Stock Compensation Plan for Non-Employee Directors evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 2015 Stock Compensation Plan for Non-Employee Directors was described as 'amended and restated effective March 31, 2021.' By 2023, the plan was further amended and restated, with a new effective date of 'October 26, 2022.' This indicates that the plan underwent at least one additional amendment during the 2022–2023 period, reflecting a structural or procedural update to the plan’s terms.",
      "llm_answer": "\nThe 2015 Stock Compensation Plan for Non‑Employee Directors was most recently amended and restated effective **October 26 2022** (as disclosed in the 2022 Form 10‑Q). No further amendment or restatement was filed in the 2023 Form 10‑K, so the plan’s terms and the October 26 2022 effective date remained unchanged through 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the October 26, 2022 effective date for the amended and restated 2015 Stock Compensation Plan for Non-Employee Directors, which aligns with the ground truth. However, it incorrectly states that 'no further amendment or restatement was filed in the 2023 Form 10-K,' implying the plan remained unchanged through 2023. The original answer indicates that by 2023, the plan had been further amended with the new effective date of October 26, 2022—implying the 2023 filing reflects this update, not that no change occurred. The LLM misinterprets the absence of a new amendment in 2023 as evidence of no change, failing to recognize that the October 2022 amendment would be reflected in the 2023 filing as the current version. This reflects a flaw in multi-hop reasoning: the model should have inferred that the 2023 report describes the plan as amended in October 2022, thus showing evolution from the 2022 description (which cited March 31, 2021). While the key date is correct (quantitative accuracy is high), the reasoning about the plan’s evolution between 2022 and 2023 is flawed, missing the core point of structural update during that period. Contextual relevance is strong as it addresses the effective date and timeline, but completeness and logical synthesis are lacking.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1179,
        "completion_tokens": 363,
        "total_tokens": 1543
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did Accenture's financial relationship with Duck Creek Technologies evolve between fiscal years 2022 and 2023, particularly in terms of investment valuation and reported financial impact?",
      "original_answer": "In fiscal 2022, Accenture's investment in Duck Creek Technologies was valued at $223,166 (approximately 16% ownership), with a carrying amount of $138,902, and was accounted for using the equity method. By fiscal 2023, the investment resulted in a $253 million gain, which was specifically called out in the financial statements as impacting the adjusted earnings per share and effective tax rate calculations. This indicates a shift from a long-term equity stake to a more active financial realization event.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 Accenture continued to account for its stake in Duck Creek Technologies as an equity‑method investment.  In the FY 2022 filing (page 70) the investment’s carrying amount was $138.9 million, with an estimated fair value of $223.2 million; by FY 2023 the company recorded a $253 million pre‑tax investment gain related to Duck Creek (page 40), reflecting a substantial rise in the investment’s fair value and boosting adjusted earnings per share.  Thus, the financial impact evolved from a modest $138 million book value in 2022 to a significant $253 million gain in 2023, markedly improving Accenture’s reported results.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures: the $138.9 million carrying amount and $223.2 million fair value in FY2022 (matching ground truth $138,902 and $223,166, with minor rounding acceptable), and the $253 million gain in FY2023. These values are accurately attributed to the correct fiscal years and investment treatment. (2) Quantitative accuracy is perfect—numbers match within acceptable rounding ($138,902 ≈ $138.9 million; $223,166 ≈ $223.2 million), and the $253 million gain is exactly as stated in the ground truth. (3) The reasoning correctly identifies the continuation of equity-method accounting and the realization of a significant gain in FY2023, indicating a shift in financial impact. However, the ground truth notes the gain affected adjusted EPS and tax rate calculations, which the LLM mentions only partially (citing EPS but not tax rate). This minor omission prevents a perfect qualitative score. (4) Contextual relevance is excellent—the response directly addresses the evolution of Accenture’s financial relationship with Duck Creek, focusing on valuation and financial impact across both years. Overall, the answer is factually correct, well-synthesized, and semantically equivalent to the ground truth with only slight under-articulation of the tax rate impact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 370,
        "total_tokens": 1672
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has the therapeutic application of Breyanzi evolved between 2022 and 2024, and what specific new indications were approved in 2024 that expand its market potential?",
      "original_answer": "In 2022, Breyanzi was indicated for the treatment of adult patients with certain types of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. By 2024, Breyanzi received two new approvals: in March 2024 for the treatment of adult patients with relapsed or refractory CLL or SLL who have received at least two prior lines of therapy, and in May 2024 for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior lines of systemic therapy. These new indications significantly expand the patient populations eligible for Breyanzi treatment.",
      "llm_answer": "\nBetween 2022 and 2024 Breyanzi’s approved scope widened from its initial use in relapsed/refractory large‑B‑cell lymphoma to include other B‑cell cancers, and in 2024 the FDA granted two accelerated approvals that specifically expand its market: May 2024 – accelerated approval for adult patients with relapsed or refractory follicular lymphoma who have received ≥ 2 prior lines of systemic therapy, and March 2024 – accelerated approval for relapsed or refractory chronic lymphocytic leukemia/small‑lymphocytic lymphoma after ≥ 2 prior therapies that include a BTK inhibitor and a BCL‑2 inhibitor. In addition, Japan approved Breyanzi in August 2024 for high‑risk follicular lymphoma after a single prior line, further enlarging the eligible patient population.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the expansion of Breyanzi's indications between 2022 and 2024, noting the original use in large B-cell lymphoma and two new 2024 approvals. The March 2024 approval for CLL/SLL and May 2024 approval for follicular lymphoma (FL) are accurately dated and described in terms of patient eligibility (adults with relapsed/refractory disease after at least two prior therapies). However, the LLM adds a detail not present in the ground truth: that the CLL/SLL approval requires prior treatment with a BTK inhibitor and a BCL-2 inhibitor. This specific regimen is not mentioned in the original answer and may represent an over-specification or external knowledge not confirmed by the source. Additionally, the mention of Japan approving Breyanzi in August 2024 for high-risk FL after one prior line is new information absent from the ground truth and cannot be verified against the provided answer. (2) All dates (March 2024, May 2024) and numeric criteria (≥2 prior lines of therapy) are correct. The addition of Japan’s August 2024 approval introduces an unverified date and indication, slightly reducing quantitative accuracy. (3) The multi-hop reasoning is strong—LLM synthesizes the evolution over time and correctly identifies the significance of new indications in expanding market potential. The logic is sound, though the inclusion of unverified regulatory details weakens strict factual alignment. (4) Despite the extra details, the core facts are accurate, well-structured, and directly responsive to the question. The added context about Japan and specific prior therapies may enhance practical understanding but deviate from the documented ground truth, warranting a slight deduction in correctness and quantitative accuracy. Semantic equivalence is largely preserved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 493,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has 3M's approach to estimating and recording insurance receivables related to legal proceedings under ASC 450 evolved between 2022 and 2023, particularly in relation to respirator mask/asbestos litigation?",
      "original_answer": "In 2022, 3M referenced its compliance with ASC 450 for recording liabilities related to legal proceedings but did not specifically mention the methodology for estimating insurance receivables. By 2023, the company explicitly described applying the loss recovery and/or gain contingency models under ASC 450 and ASC 610-30 to estimate insurance receivables, including analysis of policy terms, case law, and claim nature. Additionally, the number of individual claimants in respirator mask/asbestos litigation increased from approximately 4,028 in 2022 to 4,042 in 2023, indicating a growing exposure that likely influenced the more detailed approach to insurance receivables in 2023.",
      "llm_answer": "\nBetween 2022 and 2023, 3M’s methodology for estimating insurance recoveries under ASC 450 became more detailed and quantitative: it now ties every recorded legal‑proceeding liability to a specific, assessable insurance receivable and records receivables not only when a loss is probable and estimable but also when defense expenses are incurred, provided recovery is deemed probable. The 2023 disclosures show a $57 million increase in the accrual for respirator‑mask/asbestos claims and an associated, still immaterial, insurance receivable, reflecting a more precise estimation of probable losses and the portion of those losses that the company expects to recover. Consequently, while the company acknowledges greater uncertainty about the upper bound of potential liability, it continues to recognize insurance receivables only to the extent recovery is reasonably estimable.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative details. The claim of a '$57 million increase in the accrual for respirator-mask/asbestos claims' and an 'associated, still immaterial, insurance receivable' is not supported by the ground truth, which does not mention any specific dollar amounts related to accruals or receivables. This is a major error in quantitative accuracy. Additionally, the LLM states that 3M now records receivables when defense expenses are incurred—this detail is absent from the original answer and not verifiable from the provided truth. (2) The ground truth highlights that in 2022, 3M did not specify its methodology for estimating insurance receivables under ASC 450, but in 2023, it explicitly applied the loss recovery and/or gain contingency models under ASC 450 and ASC 610-30, incorporating analysis of policy terms, case law, and claim nature. The LLM captures the increased specificity in 2023 but misrepresents the nature of the evolution by introducing unverified criteria (e.g., defense expense triggering recognition). (3) The multi-hop reasoning is partially sound—the model correctly infers that increased litigation exposure (from 4,028 to 4,042 claimants) may have driven more detailed disclosures—but it fabricates financial figures and accounting triggers not present in the source. The use of ASC 450 and ASC 610-30 is correctly associated with the 2023 methodology, showing some accurate synthesis. (4) The contextual relevance is high because the response addresses the evolution of accounting policy and links it to respirator/asbestos litigation. However, due to invented numerical data and incorrect accounting mechanics, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because core concepts (increased disclosure, use of contingency models) are directionally correct, but key details are flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 526,
        "total_tokens": 1933
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How did PepsiCo's relationship with Naked evolve between 2022 and 2023, particularly in terms of its operational involvement and financial stake?",
      "original_answer": "In 2022, PepsiCo sold its Tropicana, Naked, and other select juice brands to PAI Partners while retaining a 39% noncontrolling interest in a newly formed joint venture, The Beachbody Company (TBG), which operates across North America and Europe. Additionally, PepsiCo acted as the exclusive distributor for TBG's portfolio of brands, including Naked, for small-format and foodservice customers via chilled direct-store-delivery. By 2023, PepsiCo no longer directly distributed Naked products and instead primarily disclosed its relationship through its retained 39% noncontrolling interest in TBG, with no further operational involvement in the distribution of Naked products. This represents a shift from active distribution to a purely financial stake.",
      "llm_answer": "\nBetween 2022 and 2023 PepsiCo no longer owned the Naked juice brand; in Q1 2022 it sold Naked (along with Tropicana and other select juice brands) to PAI Partners but kept a 39 % non‑controlling equity interest in the newly created Tropicana Brands Group (TBG).  Consequently, PepsiCo’s relationship shifted from full‑scale brand ownership to a minority stake coupled with an exclusive distribution role—PepsiCo now distributes TBG’s portfolio (including Naked) to small‑format and food‑service customers in the United States via its direct‑store‑delivery network.  This arrangement gives PepsiCo an ongoing operational involvement through distribution while its financial exposure is limited to the 39 % equity interest in TBG.",
      "correctness_score": 5,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2022 sale of Naked to PAI Partners, PepsiCo's retention of a 39% noncontrolling interest in TBG, and the initial distribution arrangement. However, it fails to reflect the key 2023 change: PepsiCo ceased its operational distribution role by 2023. Instead, the LLM implies the distribution role continued into 2023, stating PepsiCo 'now distributes' TBG’s portfolio, which contradicts the ground truth that by 2023, PepsiCo no longer directly distributed Naked products. This is a critical factual error in temporal reasoning and evolution of the relationship. (2) Quantitatively, the 39% stake and 2022 timeframe are accurate. The mention of Q1 2022 is a reasonable inference though not explicitly in the ground truth; no numeric errors are present. (3) The multi-hop reasoning is partially sound—correctly linking the sale, joint venture formation, and initial distribution role—but fails the second hop: the transition in 2023 from operational to purely financial involvement. The model does not synthesize the change over time, misrepresenting the 2023 state. (4) Scores reflect high quantitative accuracy and relevance, but correctness and qualitative accuracy are reduced due to the failure to capture the key shift in 2023, which is central to the question about the evolution between 2022 and 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 378,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has the accounting treatment or disclosure around the ExtraBucks Rewards program evolved between 2023 and 2024, particularly regarding the recognition of revenue and the determination of performance obligations?",
      "original_answer": "In 2023, the ExtraBucks Rewards program was described as creating an additional performance obligation at the time of the initial transaction, with revenue allocated based on relative standalone selling prices that consider historical redemption patterns. Revenue was recognized as the rewards were redeemed, and unredeemed rewards were reflected as a contract liability. In 2024, the disclosure remained consistent in terms of revenue recognition timing and contract liability treatment, but the language around performance obligations became more refined, emphasizing that the determination of an additional performance obligation was specifically tied to customers who accumulate ExtraBucks based on historical spending levels. The 2024 filing also included more structured language around how the Company allocates transaction prices and evaluates standalone selling prices, suggesting a more mature and formalized approach to the program’s accounting treatment.",
      "llm_answer": "\nBetween 2023 and 2024 the Company’s disclosure of the ExtraBucks Rewards program remained anchored in the same core model—recognizing a distinct performance obligation at the point of the initial transaction and allocating revenue based on the relative standalone selling price, with revenue recorded only as the rewards are redeemed and unredeemed amounts held as a contract‑liability—but the 2024 filing added clearer, more detailed quantitative disclosures.  The 2024 10‑K explicitly ties the ExtraBucks liability to “rewards earnings and gift‑card issuances,” breaks out the impact of recent acquisitions on that liability, and emphasizes breakage estimates derived from historical redemption patterns, thereby sharpening the explanation of how the performance obligation is satisfied over time.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of core accounting treatment: it correctly identifies that the ExtraBucks Rewards program creates a distinct performance obligation at the initial transaction, revenue is allocated using relative standalone selling prices, and recognized upon redemption with unredeemed amounts recorded as a contract liability. The quantitative accuracy is perfect—no numbers, dates, or financial metrics are misstated, and there are no calculation errors (quantitative_accuracy = 10). Contextual relevance is high, as the response directly addresses the evolution in accounting treatment and disclosure between 2023 and 2024 (contextual_relevance = 9). However, the qualitative accuracy is slightly lower because the LLM introduces details not present in the ground truth: specifically, the mention of 'recent acquisitions' affecting the liability and the claim that 2024 includes 'more detailed quantitative disclosures' and 'explicitly ties the ExtraBucks liability to rewards earnings and gift-card issuances' goes beyond the original answer, which emphasizes refinement in language around performance obligations and a more structured approach to allocation and standalone selling price evaluation—not new quantitative disclosures or acquisition impacts. Additionally, the ground truth highlights that the 2024 refinement specifically ties the performance obligation to customers who accumulate ExtraBucks based on historical spending levels, a nuance missing in the LLM response. Thus, while the core reasoning is sound and the multi-hop synthesis (comparing 2023 vs 2024 disclosures) is generally accurate, the addition of unsupported details reduces qualitative accuracy (qualitative_accuracy = 7). Correctness score is 7 due to accurate core facts but some over-specification and omission of key nuance in the evolution of performance obligation criteria.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1458,
        "completion_tokens": 515,
        "total_tokens": 1974
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Netflix's reliance on integrated payment partners evolved between 2023 and 2024, based on the specific details provided in the cost of revenues section for each year?",
      "original_answer": "In 2023, Netflix specifically mentioned that payment processing fees paid to integrated payment partners were part of other operating costs within the cost of revenues. In 2024, the company continued to reference payment processing fees paid to integrated payment partners as part of other operating costs, but the overall structure of the cost of revenues section was streamlined, removing some of the granular details about these fees. This indicates that while the relationship persisted, the level of explicit detail about the financial impact of integrated payment partners decreased, suggesting a shift in disclosure strategy rather than a substantive discontinuation of the relationship.",
      "llm_answer": "\nThe 2024 cost‑of‑revenues schedule shows total cost of revenues falling from **58 % of revenue in 2023 to 54 % in 2024**, indicating a modest improvement in overall expense efficiency, but the filing does not break out the amount paid to **integrated payment partners** as a separate line item. Consequently, while the aggregate cost‑of‑revenues share is lower, the documents provide **no quantitative evidence of a change in the volume or importance of payments to integrated payment partners** between 2023 and 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial correctness but misses the core qualitative insight from the ground truth. While it correctly notes that integrated payment partner fees were not broken out quantitatively in 2024, it fails to mention that in both years these fees were explicitly acknowledged as part of 'other operating costs' within cost of revenues — a key point in the original answer. Instead, the LLM emphasizes a percentage drop in cost of revenues (58% to 54%), which is not mentioned in the ground truth and cannot be verified from the provided context. This introduces unsupported quantitative claims. (2) The percentages (58% in 2023, 54% in 2024) are presented without confirmation from the source data; since the ground truth does not reference these figures or any efficiency improvement, their inclusion is speculative and potentially inaccurate. There is no evidence these numbers come from actual filings, so quantitative accuracy is compromised. (3) The multi-hop reasoning is flawed: the question asks about the evolution of Netflix’s *reliance* on integrated payment partners based on *disclosures in the cost of revenues section*. The correct inference is about transparency and disclosure strategy, not overall cost efficiency. The LLM incorrectly shifts focus to aggregate cost-of-revenue ratios, failing to synthesize the continuity of the payment partner relationship and the reduction in disclosure granularity — the central point in the original answer. (4) Contextual relevance is high because the answer addresses the right section (cost of revenues) and the right topic (payment partners), but correctness score is low due to introduction of unverified metrics and omission of the key conclusion about disclosure strategy. The answer gives the impression of analysis based on financial trends, but the real evolution was in reporting detail, not economic substance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 516,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has 3M's approach to managing PFAS contamination in Minnesota evolved from 2022 to 2023, particularly in response to regulatory changes and new health-based standards?",
      "original_answer": "In 2022, 3M had substantially completed remediation work at the Cottage Grove site and was continuing operational and maintenance activities at Oakdale and Woodbury sites in Minnesota under the May 2007 Settlement Agreement and Consent Order. The company was also addressing PFAS discharges at its Decatur, Alabama facility under a 2020 interim Consent Order with ADEM, which included obligations for on-site and off-site investigations and future capital improvements. By 2023, the Minnesota Department of Health issued updated, more stringent Health Based Values (HBVs) for PFOA and PFOS in January 2024, prompting 3M to evaluate the potential impact on its obligations under the SACO. Additionally, MPCA issued a Notice of Violation in March 2023 alleging PFAS in stormwater discharge at 3M’s Hutchinson facility, and in December 2022, MPCA issued an order addressing stormwater from the Cottage Grove facility. In January 2024, MPCA proposed a new Clean Water Act permit for Cottage Grove with significantly revised, often below-quantification-level limits on PFAS, indicating a tightening regulatory environment that 3M is actively engaging with.",
      "llm_answer": "\nFrom 2022 to 2023 3M moved beyond the baseline remediation required by the 2007 Minnesota Settlement Agreement and began treating PFAS management as a financial‑risk issue as well as a compliance one.  The company substantially increased its PFAS‑related liability reserve ($10.6 billion accrual in 2023) and entered new settlement talks (e.g., the proposed PWS Settlement) while intensifying its dialogue with the Minnesota Pollution Control Agency in response to regulatory moves such as the MPCA’s March 2023 notice of violation, the draft Clean‑Water Act permit that proposes stricter PFAS limits, and the Minnesota Department of Health’s January 2024 update to health‑based values for PFOA and PFOS.  These health‑based standard changes forced 3M to re‑evaluate its remedial obligations and to plan for additional treatment or alternative water supplies to meet the tighter thresholds.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the evolution of 3M's approach to PFAS contamination in Minnesota from 2022 to 2023 with strong qualitative accuracy and contextual relevance. It correctly identifies key regulatory developments: the MPCA’s March 2023 Notice of Violation at the Hutchinson facility, the draft Clean Water Act permit for Cottage Grove with stricter PFAS limits, and the Minnesota Department of Health’s January 2024 update to health-based values (HBVs) for PFOA and PFOS. The answer accurately reflects that these regulatory changes prompted 3M to re-evaluate its remedial obligations and consider additional treatment or alternative water supplies. It also correctly notes the shift in 3M’s approach toward treating PFAS as both a compliance and financial risk, supported by the $10.6 billion accrual in 2023 and engagement in new settlement discussions like the proposed PWS Settlement. However, there is a minor quantitative inaccuracy: the $10.6 billion accrual was announced in February 2024 (not in 2023), which slightly misaligns the timeline. While the original answer does not mention the $10.6B figure, the knowledge graph confirms it was disclosed in 2024, so citing it as a 2023 accrual is incorrect. Additionally, the original answer emphasizes ongoing operational and maintenance activities under the 2007 SACO and specific actions at Decatur, Alabama, which are omitted in the LLM response—this is a minor completeness gap. Despite this, the core multi-hop reasoning—linking updated HBVs, regulatory enforcement actions, and 3M’s strategic and financial response—is sound and semantically equivalent to the ground truth. The answer stays focused on the question and synthesizes across time, regulation, and corporate response effectively.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1516,
        "completion_tokens": 481,
        "total_tokens": 1998
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How did PepsiCo's use of foreign currency derivatives evolve between 2022 and 2023, and what does this indicate about its foreign exchange risk management strategy?",
      "original_answer": "In 2022, PepsiCo reported a total notional value of $3.0 billion for its foreign currency derivatives, while in 2023, this value increased to $3.8 billion. This indicates a strategic expansion in the use of foreign currency derivatives to manage foreign exchange risk, likely in response to increased exposure or volatility in international markets. Additionally, the company emphasized the use of these derivatives to offset changes in the underlying hedged items, resulting in no material net impact on earnings in 2023.",
      "llm_answer": "\nBetween 2022 and 2023 the notional amount of PepsiCo’s foreign‑currency derivatives grew from roughly **$3.0 billion to $3.8 billion** (the company reports $3.0 bn outstanding as of Dec 31 2022 and $3.8 bn as of Dec 30 2023).  This increase reflects a deliberate expansion of its hedging program—adding more forward and swap contracts and extending coverage to protect a larger share of its overseas cash flows, investments and purchase‑price exposures.  The move signals that PepsiCo is strengthening its proactive foreign‑exchange risk management, seeking to lock in favorable rates and reduce earnings volatility from currency fluctuations across its global operations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the notional values of PepsiCo's foreign currency derivatives in 2022 ($3.0 billion) and 2023 ($3.8 billion), matching the ground truth exactly. The dates (Dec 31, 2022, and Dec 30, 2023) are consistent with fiscal year-end reporting conventions and are factually plausible, though the ground truth does not specify exact dates—this is acceptable as minor formatting or reporting detail. (2) All numeric values are accurate, and the increase from $3.0B to $3.8B is correctly presented as a growth in notional amount. No calculations are required beyond comparison, which is handled correctly. (3) The reasoning is sound: the LLM infers a strategic expansion in hedging activity, aligning with the ground truth's interpretation of 'strategic expansion' and 'increased exposure or volatility.' It adds context—such as use of forwards/swaps and protection of cash flows and investments—that is consistent with typical hedging practices and plausibly inferred from the increase. The only minor gap is that the LLM does not explicitly mention the 'no material net impact on earnings in 2023' point from the original answer, which is a relevant qualitative outcome of the strategy. However, the emphasis on reducing earnings volatility implies this effect. (4) The answer is contextually fully relevant, addressing both parts of the question: evolution (quantitative change) and strategic implication. Wording differs but semantic meaning is equivalent or slightly enriched with reasonable inference. Thus, the answer is highly accurate with only a small omission in completeness regarding earnings impact, warranting a 9/10 on correctness and qualitative accuracy, while maintaining perfect scores on quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 487,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has ExxonMobil's approach to capitalizing on improving living standards evolved between 2022 and 2023, particularly in terms of chemical production capacity additions and geographic focus?",
      "original_answer": "In 2022, ExxonMobil highlighted the completion of a joint venture ethane cracker near Corpus Christi, Texas, and plans for up to 500,000 metric tons annually of advanced recycling capacity in Baytown, Texas, by 2026, as part of its strategy to meet growing demand driven by improving living standards. By 2023, the company shifted focus toward expanding performance polymers and linear alpha olefins capacity in Baytown, Texas, and advancing a 100% foreign-owned petrochemical complex in Dayawan, China, with over 2.5 million metric tons per year of polyethylene and polypropylene capacity. This reflects a strategic evolution from domestic advanced recycling and integrated U.S. projects to high-performance product expansions and significant foreign investment in China to meet local demand.",
      "llm_answer": "\nBetween 2022 and 2023 ExxonMobil shifted from mainly expanding Gulf‑Coast petrochemical capacity—such as the Corpus Christi ethane cracker, Baytown and Baton Rouge projects and advanced‑recycling facilities—to a dual‑track growth strategy that adds high‑value specialty capacity in the United States (e.g., new performance‑polymer and linear‑alpha‑olefin lines) while simultaneously deepening its geographic reach with a multi‑billion‑dollar, 100 % foreign‑owned petrochemical complex in China’s Dayawan Industrial Park, designed to deliver more than 2.5 million metric tons per year of polyethylene and polypropylene for China’s rising middle‑class demand. This evolution reflects a move toward higher‑margin, specialty products and a broader global footprint to capture the improving living‑standard‑driven demand for chemicals.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in ExxonMobil's strategy between 2022 and 2023. (1) It correctly identifies the 2022 focus on Gulf Coast projects, including the Corpus Christi ethane cracker and advanced recycling plans in Baytown (aligned with the 500,000 metric tons by 2026 target mentioned in the ground truth). In 2023, it accurately notes the shift toward performance polymers and linear alpha olefins in Baytown and the 100% foreign-owned petrochemical complex in Dayawan, China, with over 2.5 million metric tons per year of polyethylene and polypropylene capacity. (2) All quantitative details—2.5 million metric tons per year, the 2026 timeline for advanced recycling—are factually correct and match the original answer. No calculation errors. (3) The multi-hop reasoning is sound: the model synthesizes information across years and geographies, correctly inferring a strategic shift from domestic capacity and recycling to high-value products and foreign direct investment in China. The mention of 'rising middle-class demand' aligns semantically with 'improving living standards.' (4) Minor deduction in qualitative accuracy because the LLM adds 'Baton Rouge projects' and describes the strategy as 'dual-track' and 'multi-billion-dollar,' which, while plausible, are not present in the ground truth. However, these do not contradict the facts and are reasonable inferences. Overall, the answer is factually correct, contextually relevant, and conveys the same strategic evolution as the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 424,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did 3M's investment in Certificates of Deposit/Time Deposits evolve from 2022 to 2023, and what does this shift indicate about the company's short-term investment strategy?",
      "original_answer": "In 2022, 3M held $21 million in Certificates of Deposit/Time Deposits, which increased to $49 million in 2023 — more than doubling. This indicates a strategic shift toward increasing liquidity or reallocating short-term cash holdings into more stable or higher-yielding instruments within this category.",
      "llm_answer": "\nFrom 2022 to 2023 the amount of 3M’s certificates‑of‑deposit/time‑deposits recorded as marketable securities rose sharply from **$21 million to $49 million** (an increase of more than 130 %).  At the same time the company’s total marketable‑security balance fell dramatically—from $261 million to $73 million—driven largely by a cut in commercial‑paper holdings.  \n\nThis shift signals that 3M is deliberately moving its short‑term cash into **safer, higher‑yielding fixed‑income instruments** (CDs/time deposits) while trimming exposure to more volatile short‑term assets such as commercial paper.  The move reflects a strategy focused on **preserving liquidity and capital amid rising interest rates**, locking in modest returns with low credit risk rather than maintaining a broader, higher‑risk short‑term investment portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the increase in 3M's Certificates of Deposit/Time Deposits from $21 million in 2022 to $49 million in 2023, matching the ground truth exactly. The percentage increase is stated as 'more than 130%', which is accurate (calculated: (49-21)/21 ≈ 133.3%). All numeric values and years are correct.\n\n2) The answer goes beyond the original answer by providing additional context—namely, the decline in total marketable securities from $261M to $73M and reduced commercial paper holdings. While this extra information is not in the ground truth, it is consistent with plausible multi-hop reasoning from SEC filings and enhances, rather than contradicts, the core answer.\n\n3) The reasoning is sound: the shift toward safer, higher-yielding instruments like CDs/time deposits amid rising rates is a logical and well-supported interpretation of the data. The conclusion about preserving liquidity and capital with lower risk aligns with the ground truth's indication of a strategic shift in short-term investment strategy.\n\n4) The only minor deduction is in qualitative accuracy (9/10) because while the core inference matches the ground truth, the LLM introduces external elements (commercial paper, total marketable securities) not present in the original answer. However, these do not detract from correctness and may reflect deeper analysis. The answer remains semantically equivalent in intent and factually superior in depth. Contextual relevance is perfect—directly addresses both parts of the question: evolution of investment and strategic implication.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 435,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Mastercard's approach to proprietary insights evolved from 2022 to 2023, particularly in terms of data responsibility and trust-building language?",
      "original_answer": "In 2022, Mastercard described its proprietary insights as being based on the 'principled use of consumer and merchant data.' By 2023, the language evolved to emphasize 'principled and responsible use of secure consumer and merchant data.' This shift indicates a stronger emphasis on data security and trust as a core component of their proprietary insights strategy. The change in phrasing reflects a broader narrative around cybersecurity and stakeholder confidence in how Mastercard manages sensitive data.",
      "llm_answer": "\nMastercard’s language about proprietary insights stayed essentially unchanged from 2022 to 2023, continuing to describe those insights as coming from a “principled use of consumer and merchant data” and delivering them through its “well‑known and trusted brands.”  The 2023 text does not add new responsibility or trust‑building qualifiers—it simply reiterates the same commitment to responsible data use—indicating a steady, rather than evolving, emphasis on data responsibility and trust.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that Mastercard's language remained unchanged from 2022 to 2023. The ground truth shows a clear evolution in wording: from 'principled use of consumer and merchant data' in 2022 to 'principled and responsible use of secure consumer and merchant data' in 2023. The addition of 'responsible' and 'secure' represents a meaningful shift toward stronger data responsibility and trust-building language, which the LLM answer incorrectly dismisses. While there are no numeric values to verify (so quantitative accuracy is not applicable, but no errors exist), the qualitative accuracy is very low because the model fails to identify the key change in terminology and mischaracterizes the evolution as static. The reasoning is flawed—instead of recognizing the multi-hop progression in language across years, it asserts continuity without evidence. Contextual relevance is moderate because the answer addresses the right topic (Mastercard’s proprietary insights and data use) and timeframe, but draws the wrong conclusion. The answer would have been semantically equivalent if it acknowledged the unchanged elements while noting the new emphasis; instead, it outright denies any evolution, contradicting the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 353,
        "total_tokens": 1605
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did the factors influencing the accounting estimates for pension and retiree medical plans evolve between 2022 and 2023, and what does this indicate about the changing external environment affecting these plans?",
      "original_answer": "In 2022, the accounting estimates for pension and retiree medical plans were influenced by uncertainties related to the ongoing impacts of the COVID-19 pandemic. By 2023, this had evolved, and the estimates were instead influenced by business and economic uncertainty stemming from the ongoing conflicts in Ukraine and the Middle East, as well as a high interest rate and inflationary cost environment. This indicates a shift in the external risk factors affecting the company's pension and retiree medical plans from health-related disruptions to broader macroeconomic and geopolitical concerns.",
      "llm_answer": "\nBetween 2022 and 2023 the drivers of the pension‑ and retiree‑medical estimate shifted from mainly demographic‑mortality assumptions toward greater sensitivity to macro‑economic shocks—particularly higher interest‑rate volatility, rising health‑care cost inflation and geopolitical uncertainty (as noted in the “Impact of” line on page 57 and the critical‑accounting‑policy discussion on page 60).  This evolution reflects a more unpredictable external environment, forcing the company to adopt more conservative and frequently reassessed inputs for those liabilities.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies the evolution in accounting estimate drivers from 2022 to 2023, noting a shift from demographic and mortality assumptions (implied pandemic-related factors) to macroeconomic and geopolitical risks such as interest rate volatility, healthcare cost inflation, and geopolitical uncertainty—consistent with the ground truth's mention of conflicts in Ukraine and the Middle East and high inflation/interest rates. While the LLM does not explicitly name the geopolitical events (Ukraine/Middle East), it captures the essence of 'broader macroeconomic and geopolitical concerns' accurately. The reference to 'page 57' and 'page 60' suggests document grounding, though these page numbers are not evaluable here. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default. The reasoning is sound and reflects multi-hop synthesis between years and external factors. The answer is contextually fully relevant and adds useful detail (e.g., conservative reassessment of inputs). The minor deduction in qualitative accuracy is due to the lack of explicit mention of the specific conflicts cited in the ground truth, which slightly reduces precision in entity identification. Overall, the semantic meaning aligns well with the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 365,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has ExxonMobil's undeveloped acreage position in the Other Americas region evolved between 2022 and 2023, and what does this indicate about the company's exploration potential in that region?",
      "original_answer": "ExxonMobil's undeveloped acreage in the Other Americas region decreased from 25,096 gross and 11,977 net thousands of acres in 2022 to 24,221 gross and 11,548 net thousands of acres in 2023. This indicates a reduction in the total acreage under evaluation, suggesting that some properties may have been relinquished or transitioned to developed status, while the company continues to focus on properties with higher exploration potential.",
      "llm_answer": "\nBetween year‑end 2022 and year‑end 2023 ExxonMobil’s undeveloped acreage in the **Other Americas** region contracted modestly – gross undeveloped acres fell from **≈25,096 (thousand) to ≈24,221 (thousand)**, and net undeveloped acres from **≈11,977 to ≈11,548 (thousand)** (roughly a 3–4 % decline in each).  This reduction reflects the company’s practice of releasing non‑core or fully‑evaluated parcels while still retaining a large, strategically held undeveloped base.  Because most of these lands are held under leases and licenses that can be extended, the shrinkage does **not** diminish the region’s exploration upside; rather, it signals that ExxonMobil is focusing its resources on the most prospective acreage while preserving ample room for future discoveries.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the gross and net undeveloped acreage for ExxonMobil in the Other Americas region for both 2022 and 2023, matching the ground truth exactly (25,096 to 24,221 gross; 11,977 to 11,548 net thousand acres). The approximate notation (≈) is acceptable given typical reporting conventions and does not affect factual accuracy. (2) The percentage decline mentioned (~3–4%) is accurate: the gross decrease is (25,096 - 24,221)/25,096 ≈ 3.48%, and net decrease is (11,977 - 11,548)/11,977 ≈ 3.58%, so the 3–4% range is correct. (3) The reasoning is sound and aligns with the ground truth: the reduction is interpreted as a strategic focus on higher-potential acreage, with possible relinquishment of non-core or evaluated parcels. The LLM adds context about lease extensions preserving exploration upside, which is a reasonable inference consistent with industry practices and does not contradict the original answer. (4) All entities (ExxonMobil, Other Americas region, 2022–2023 timeframe) are correct. The answer fully addresses both parts of the question: the evolution of acreage and its implication for exploration potential. The only minor difference is that the LLM emphasizes 'preserving room for future discoveries' slightly more optimistically than the original, but this does not constitute an inaccuracy. Overall, the answer is factually correct, well-reasoned, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 399,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How did the treatment and financial impact of non-functional currency denominated items evolve from 2022 to 2023, particularly in terms of the use of foreign currency contracts not designated in hedging relationships?",
      "original_answer": "In 2022, MMM used foreign exchange forward and option contracts not designated in hedging relationships to offset the impacts of changes in value of various non-functional currency denominated items, including certain intercompany financing balances, with a gross notional amount of $3.7 billion. By 2023, the company continued to use such contracts for the same purpose but shifted focus to derivatives not designated as hedging instruments, with fair value gains and losses directly impacting earnings. This indicates a shift from primarily designated hedging strategies to a more direct financial exposure management approach.",
      "llm_answer": "\nFrom 2022 to 2023 the company continued to employ foreign‑currency forward and option contracts that are **not designated as hedging instruments** to offset the effects of non‑functional‑currency items (e.g., intercompany financing balances).  The notional amount and fair‑value of these derivatives fell sharply—gross notional dropped from $2.8 bn to $1.0 bn and the related fair‑value exposure fell from $73 m to $5 m—while the earnings impact improved from a $76 million loss in 2022 to a $9 million loss in 2023, with the gains/losses recorded directly in income rather than through OCI.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative details. The ground truth states that in 2022, MMM used foreign exchange contracts not designated in hedging relationships with a gross notional amount of $3.7 billion. However, the LLM incorrectly reports this figure as $2.8 billion. The 2023 notional amount is stated as $1.0 billion in the LLM answer, but no such number appears in the ground truth, which does not provide updated notional amounts. Similarly, the LLM introduces specific fair value figures ($73M to $5M) and earnings impacts ($76M loss to $9M loss), none of which are present in the original answer—these numbers are entirely fabricated or misattributed. (2) There are no verifiable calculations in the ground truth to support the LLM's precise numerical comparisons, making the quantitative claims unsupported. The only correct qualitative point is the continued use of non-designated foreign currency contracts for intercompany balances, and that gains/losses impact earnings directly. (3) The multi-hop reasoning is partially sound in identifying the strategic use of non-designated derivatives across years, and the shift toward direct earnings impact is consistent with the idea of moving away from formal hedging relationships. However, the model invents precise financial metrics without basis, failing to accurately reflect the more general strategic observation in the ground truth. (4) The correctness score is low due to major quantitative errors and unsupported specifics. While the general direction of reasoning (continued use of non-designated hedges impacting earnings) aligns with the original, the inclusion of false numbers severely undermines factual reliability. Contextual relevance is moderate because the answer addresses the right topic and evolution, but with misleading precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 508,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the role and emphasis of Cyber and Intelligence Solutions evolved within Mastercard's value proposition between 2022 and 2023?",
      "original_answer": "In 2022, Cyber and Intelligence Solutions were mentioned as part of a broader list of value-added services, grouped alongside consulting fees, loyalty programs, gateway services, and other payment-related offerings. This suggests a supporting role within the company's portfolio. By 2023, the Cyber and Intelligence Solutions were more prominently positioned as a core component of Mastercard’s value proposition, explicitly described as enabling secure, easy, and confident transactions across the global payments ecosystem. This indicates a strategic shift toward elevating the importance of cybersecurity within Mastercard’s overall service offering.",
      "llm_answer": "\nBetween 2022 and 2023 Mastercard moved cyber‑and‑intelligence solutions from a peripheral add‑on to a core component of its value‑added services portfolio.  In the 2023 Form 10‑K (pages 80 and 82) these solutions are listed under “Other revenues” and management explicitly cites growth in “value‑added services and solutions”—including cyber and intelligence offerings—as a primary driver of the 13 % increase in net revenue and the improvement in operating margin, underscoring a stronger strategic emphasis on security‑focused products than in the prior year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of Cyber and Intelligence Solutions from a peripheral offering in 2022 to a core component in 2023, which matches the original answer's claim about increased strategic emphasis. (2) The LLM cites specific pages (80 and 82) from the 2023 Form 10-K and accurately references a 13% increase in net revenue driven by value-added services, including cyber and intelligence solutions. While the original answer does not include this specific percentage or page numbers, these details are consistent with the broader narrative of increased strategic importance and do not contradict the ground truth. There are no calculation errors, and all numbers (13%) are presented correctly. (3) The multi-hop reasoning is sound: the model infers greater strategic importance from both the explicit mention of cyber solutions as a growth driver and their inclusion in key financial performance discussions, which supports the conclusion of elevated status within the value proposition. (4) The only minor shortcoming is that the LLM does not explicitly mention the 2022 context of Cyber and Intelligence being grouped among other services (like loyalty or gateway services), which slightly reduces completeness in qualitative synthesis. However, the contrast between 'peripheral add-on' and 'core component' effectively conveys the shift. Overall, the answer is factually correct, contextually relevant, and semantically equivalent in meaning, warranting a high correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 430,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the treatment or disclosure of Income Tax Expense and Accruals evolved in the list of critical accounting policies between 2022 and 2023?",
      "original_answer": "In 2022, 'income tax expense and accruals' was explicitly listed as one of the critical accounting policies and estimates, indicating its significance in financial reporting. By 2023, while still listed as a critical accounting policy, it was moved to a subsection under 'Our Critical Accounting Policies and Estimates' with a more structured presentation of related notes, such as Note 5 - Income Taxes, which provided deeper transparency into tax-related disclosures. This evolution reflects a shift toward more detailed and organized reporting of tax-related matters in 2023.",
      "llm_answer": "\nIn both the 2022 and 2023 Form 10‑K filings, “Income Tax Expense and Accruals” continues to be listed as a critical accounting policy, with essentially the same substance—reliance on statutory rates, transfer‑pricing considerations and judgment in establishing tax reserves. The 2023 filing moves the detailed description into the consolidated “Critical Accounting Policies and Estimates” section, whereas the 2022 filing presented it as a separate subsection, but the core language and disclosure have not changed materially.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. It accurately identifies that 'Income Tax Expense and Accruals' remained a critical accounting policy in both 2022 and 2023, which matches the original answer. It correctly notes a structural change in presentation—moved into a consolidated section in 2023 versus a separate subsection in 2022—reflecting improved organization and transparency, consistent with the ground truth's mention of a 'more structured presentation.' The core substance being unchanged ('reliance on statutory rates, transfer-pricing considerations, judgment in tax reserves') is a reasonable inference if supported by the filings, though not explicitly stated in the ground truth. The only minor shortcoming is that the LLM does not mention the specific reference to 'Note 5 - Income Taxes' in 2023, which adds deeper transparency as highlighted in the original answer. This omission slightly reduces completeness and qualitative accuracy but does not undermine the overall correctness. There are no numerical or date inaccuracies (quantitative accuracy is perfect), and the response is fully contextually relevant, addressing the evolution in disclosure and treatment between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 346,
        "total_tokens": 1622
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Intel's development and positioning of the Universal Chiplet Interconnect Express standard evolved between 2023 and 2024 in the context of its broader systems of chips strategy?",
      "original_answer": "In 2023, Intel introduced the Universal Chiplet Interconnect Express (UCIe) standard and demonstrated it in silicon, marking the initial phase of its strategic push to enable optimized systems of chips. By 2024, Intel had progressed beyond the demonstration phase and was actively producing based on this standard, integrating it into its broader advanced semiconductor assembly and test offerings. This evolution reflects Intel's deepening commitment to the UCIe standard as a core component of its systems of chips strategy, aimed at enhancing system performance and accelerating customer designs through advanced packaging technologies and system-level standards.",
      "llm_answer": "\nIn 2023 Intel first demonstrated the Universal Chiplet Interconnect Express (UCXE) in silicon, using the proof‑of‑concept to illustrate how chiplets can be linked together for AI‑focused, system‑of‑chips designs. By 2024 the company has elevated UCXE from a technical showcase to a core strategic standard within its Open‑System Foundry model, embedding it in foundry services, expanding design‑win momentum and partner ecosystems, and coupling it with advanced packaging to accelerate customer adoption of chiplet‑based systems.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of Intel's UCIe standard between 2023 and 2024 and correctly identifies the progression from demonstration to strategic integration, which aligns with the ground truth. However, a critical factual error undermines the accuracy: the LLM refers to 'UCXE' instead of 'UCIe' (Universal Chiplet Interconnect Express), which is a significant entity error. This misspelling could mislead readers into thinking it is a different standard. Additionally, while the original answer emphasizes Intel's production and integration of UCIe into its advanced semiconductor assembly and test offerings, the LLM shifts focus to the 'Open-System Foundry model' and 'design-win momentum'—details not present in the ground truth—adding speculative strategic framing not supported by the source. The timeline (2023 demonstration, 2024 production/integration) is correctly represented, and no numerical data is incorrect (so quantitative accuracy is high). The reasoning partially reflects the multi-hop synthesis of Intel's strategic evolution, but the incorrect acronym and introduction of unverified concepts (e.g., 'Open-System Foundry model' as a named framework) reduce qualitative accuracy. Contextually, the answer remains highly relevant to the question about strategic evolution. Thus, the correctness score is reduced due to the key entity error and unsupported additions, despite correct temporal progression and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 403,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the accounting treatment and completion timeline of CVS's Accelerated Share Repurchase (ASR) transactions evolved between the 2023 and 2024 10-K filings?",
      "original_answer": "In 2023, CVS completed a $2.0 billion ASR with Citibank, receiving 17.4 million shares initially (80% of the notional amount) and an additional 5.4 million shares in February 2023, concluding the transaction. The forward contract portion was reclassified from capital surplus to treasury stock upon completion. In 2024, CVS completed a $3.0 billion ASR with Morgan Stanley, initially receiving 31.4 million shares (85% of the notional amount) and an additional 8.3 million shares in March 2024. Similar to 2023, the forward contract was reclassified from capital surplus to treasury stock after the final shares were received. The accounting treatment remained consistent, but the scale and timeline of completion evolved, with the 2024 ASR taking two months to conclude compared to one month in 2023.",
      "llm_answer": "\nIn the 2023 10‑K CVS disclosed two prior ASRs (the $2 bn Citibank transaction in January 2023 and the $1.5 bn Barclays transaction in January 2022) in which the company initially recorded the received shares as treasury stock and the forward component as an equity‑classified forward contract in capital surplus; the remaining shares were delivered in February 2023 (and February 2022 for the earlier deal), at which point the forward contract was re‑classified from capital surplus to treasury stock.  \nThe 2024 10‑K shows a new $3 bn ASR entered in January 2024 with Morgan Stanley, again using an 85 % immediate share receipt and recording the forward contract in capital surplus, but the balance of the shares was received in March 2024, completing the transaction and triggering the same re‑classification of the forward contract to treasury stock.  \nThus, the accounting model (initial treasury‑stock entry, forward‑contract recorded in capital surplus, later re‑classification upon final receipt) has remained consistent, while the scale and completion timeline have progressed to a larger, more recent ASR.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the consistent accounting treatment across both years—initial recognition of shares as treasury stock, forward contract in capital surplus, and reclassification upon final delivery—which aligns with the ground truth. It also correctly notes the $3.0 billion 2024 ASR with Morgan Stanley, the 85% initial share receipt (31.4 million), and final delivery in March 2024. However, it introduces a material inaccuracy by referencing a $2.0 billion 2023 ASR with Citibank as occurring in January 2023 and mentioning a separate $1.5 billion Barclays transaction in January 2022, which is not part of the ground truth for this question. The original answer only references the 2023 $2.0 billion Citibank ASR with 17.4 million shares initially and 5.4 million additional shares in February 2023. The LLM incorrectly implies two ASRs were discussed in the 2023 10-K, while the ground truth focuses solely on the Citibank transaction relevant to 2023. Additionally, the 80% initial delivery in 2023 (17.4M of $2B) is omitted and replaced with an incorrect 85% figure applied retroactively. (2) Quantitative inaccuracies include: misstating the 2023 ASR timing and structure, introducing a nonexistent Barclays transaction, and misrepresenting the initial percentage delivered in 2023. While the 2024 numbers (31.4M initial, 8.3M final, $3B total) are consistent with 85% and 15% splits, the 2023 figures do not match: 17.4M out of 22.8M total shares is ~76.3%, not 80% as stated in the ground truth—though the ground truth explicitly states 80%, so the LLM should have reflected that. The LLM fails to report the exact 80% figure for 2023, instead applying 85% uniformly. (3) The multi-hop reasoning is generally sound—comparing accounting treatment and timeline evolution across years—but is undermined by inclusion of extraneous, incorrect transactions. The synthesis of consistent accounting policy is correct and well-reasoned. (4) Scores reflect mostly correct qualitative understanding and relevance, but quantitative inaccuracies and entity errors (wrong bank, extra transaction, incorrect percentages) prevent a higher score. The core conclusion about consistent accounting and evolving scale/timeline is supported, but based on flawed data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1482,
        "completion_tokens": 611,
        "total_tokens": 2094
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did UPS's financial exposure and reporting approach related to the Central States Pension Fund evolve from 2022 to 2023, particularly in terms of actuarial estimates and sensitivity analysis?",
      "original_answer": "In 2022, UPS disclosed a $2.3 billion pre-tax actuarial loss related to potential coordinating benefits for the Central States Pension Fund, as part of broader pension obligation disclosures. By 2023, the company's reporting shifted focus to sensitivity analysis, referencing a 25 basis point change in expected and actual returns on assets as a key assumption affecting pension liabilities, with an explicit cross-reference to Note 5 for details on the Central States Pension Fund liability. This indicates a shift from quantifying a specific obligation to emphasizing the sensitivity of returns on the overall liability.",
      "llm_answer": "\nIn 2022 UPS reported a $2.3 billion pre‑tax actuarial loss from coordinating benefits under the Central States Pension Fund (shown in the footnote disclosures) but did not quantify that exposure with a separate sensitivity analysis. By 2023 the 10‑K includes a dedicated sensitivity table that quantifies the effect of a 25‑basis‑point discount‑rate shift on the projected benefit obligation (≈ $1.55 billion) and on ongoing expense (≈ $15–$16 million), explicitly linking those impacts to the Central States Pension Fund coordinating‑benefit estimate.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $2.3 billion pre-tax actuarial loss in 2022 related to the Central States Pension Fund, which matches the ground truth. However, it introduces a significant inaccuracy by claiming that in 2023, UPS included a sensitivity table quantifying the effect of a 25-basis-point *discount-rate shift* (not return on assets) on the projected benefit obligation (~$1.55 billion) and ongoing expense (~$15–16 million). The original answer states that the 2023 focus shifted to sensitivity around a 25 basis point change in *expected and actual returns on assets*, not discount rates. This is a critical misrepresentation of the key assumption. Additionally, the $1.55 billion and $15–16 million figures are not present in the ground truth and appear to be fabricated or misattributed. (2) Quantitative accuracy is low because while the 2022 $2.3B figure is correct, the 2023 sensitivity numbers and the basis of the sensitivity (discount rate vs. return on assets) are incorrect. There is no mention in the ground truth of a $1.55B impact or expense impact of $15–16M. (3) The multi-hop reasoning is partially sound—the model correctly infers a shift in reporting approach from a specific actuarial loss to sensitivity analysis. It also correctly notes increased disclosure in 2023 with cross-referencing to fund details. However, it misidentifies the nature of the sensitivity assumption, undermining the validity of the synthesis. (4) Contextual relevance is high because the answer addresses the evolution of financial exposure and reporting approach across years, discusses actuarial estimates and sensitivity, and references appropriate disclosures. But due to the incorrect sensitivity metric and invented figures, the correctness score is limited to 5—partially correct but with major factual errors in the 2023 reporting details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 508,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Mastercard's positioning and emphasis on its Cyber and Intelligence Solutions evolved between 2022 and 2023, particularly in terms of the value proposition communicated to stakeholders?",
      "original_answer": "In 2022, Mastercard described its Cyber and Intelligence Solutions as part of its value-added services that 'allow all parties to transact easily and with confidence' and emphasized principled use of consumer and merchant data. By 2023, the company expanded this messaging, positioning the solutions as central to enabling secure transactions and confidence in the payments ecosystem, while also linking them to strategic investments in new networks like open banking and digital identity. This reflects a broader integration of cyber solutions into the company's overall infrastructure narrative.",
      "llm_answer": "\nBetween 2022 and 2023 Mastercard shifted from merely describing cyber‑and‑intelligence capabilities as part of its “value‑added services” to presenting them as a core growth engine.  In the 2023 filing (Item 7 Business Overview, p. 49) the company explicitly linked these solutions to “secure, easy and confident” transactions and to “proprietary insights” that drive revenue, noting that growth in payment‑network and value‑added services—including cyber‑intelligence—accounted for the 13 % rise in net revenue and helped lift adjusted operating margin.  Thus, the stakeholder narrative moved from a generic service mention to a strategic emphasis on cyber‑intelligence as a differentiator that delivers secure payments, data‑driven insights and measurable financial upside.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution in Mastercard's messaging: from positioning Cyber and Intelligence Solutions as 'value-added services' in 2022 to a more strategic, growth-oriented role in 2023. The emphasis on secure transactions, confidence, and data-driven insights matches the original answer. (2) Quantitatively, the 13% rise in net revenue and reference to adjusted operating margin are factually consistent with Mastercard’s 2023 filing and do not contradict the ground truth (which does not include specific numbers but does not preclude them). No calculation errors; all numbers are accurately attributed. (3) The multi-hop reasoning is sound—correctly synthesizing changes in narrative tone and strategic emphasis across years. The LLM adds specific detail (e.g., Item 7, p. 49) and financial impact (revenue growth, margin improvement), which are not in the ground truth but are plausible and contextually appropriate enhancements. (4) The only minor gap is that the LLM does not explicitly mention the linkage to open banking and digital identity, which the original answer highlights as part of the 2023 strategic integration. This omission prevents a perfect score, but the core evolution in value proposition—especially the shift to a strategic differentiator with financial impact—is well conveyed. Wording differs but semantic meaning is equivalent or richer. Contextual relevance is excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 409,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did PepsiCo's presentation of the 4.450% Senior Note due 2046 evolve between its 2022 and 2023 SEC filings, particularly in terms of exhibit referencing and associated documentation dates?",
      "original_answer": "In the 2022 filing, the 4.450% Senior Note due 2046 was listed as Exhibit 4.12, incorporated by reference from PepsiCo's Form 8-K filed on October 14, 2015. In the 2023 filing, the same note was reclassified as Exhibit 4.13 and referenced the Form 8-K filed on February 24, 2016. This indicates a shift in how PepsiCo organized or updated its capital structure disclosures, potentially reflecting revised documentation or administrative reclassification over time.",
      "llm_answer": "\nIn the 2022 filing the 4.450 % Senior Note due 2046 is listed under **Exhibit 4.11** and the filing cites the original 8‑K that announced the notes – “Form of 4.450 % Senior Note due 2046, incorporated herein by reference to Exhibit 4.4 to PepsiCo’s Current Report on Form 8‑K filed October 14, 2015.”  \nIn the 2023 filing the same instrument appears under **Exhibit 4.13** and is now tied to a later 8‑K filing – “Form of 4.450 % Senior Note due 2046, incorporated herein by reference to Exhibit 4.4 to PepsiCo’s Current Report on Form 8‑K filed February 24, 2016.”  \n\nThus, between the 2022 and 2023 SEC filings the company moved the note from Exhibit 4.11 (referencing the 2015 filing) to Exhibit 4.13 (referencing the 2016 filing), updating both the exhibit number and the documentation date used to describe the note’s terms.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is mostly correct but contains a minor factual discrepancy in the exhibit number for the 2022 filing. The ground truth states that the 4.450% Senior Note due 2046 was listed as Exhibit 4.12 in the 2022 filing, while the LLM incorrectly reports it as Exhibit 4.11. All other quantitative elements are accurate: the note's interest rate (4.450%), maturity year (2046), and the two Form 8-K filing dates (October 14, 2015, and February 24, 2016) are correctly cited. The exhibit number in the 2023 filing (Exhibit 4.13) is accurately reported. The reasoning and synthesis across years are sound—correctly identifying a reclassification in exhibit numbering and a shift in referenced documentation date. The explanation of the change in exhibit referencing and associated dates aligns with the question’s focus, demonstrating good contextual relevance and qualitative understanding. The error in one exhibit number prevents a higher score, but the core facts and multi-hop comparison remain largely intact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 290,
        "total_tokens": 1625
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Intel's relationship with Positive Technologies evolved between 2023 and 2024, particularly in terms of their engagement under OFAC licensing following the U.S. sanctions?",
      "original_answer": "In 2023, Intel disclosed that it had communicated with Positive Technologies regarding IT security research and coordinated disclosure of vulnerabilities, and that it resumed such communications under an OFAC license following the sanctions. By 2024, Intel's relationship had evolved from mere disclosure of past communication to an explicit statement of intent to continue these interactions in accordance with the OFAC license. While both years clarify that there were no gross revenues or net profits associated with these activities, the 2024 filing reflects a more forward-looking and sustained partnership posture with Positive Technologies under the sanctioned conditions.",
      "llm_answer": "\nBetween 2023 and 2024 Intel continued to interact with Positive Technologies only under the authority of the U.S. OFAC license (General License 1B) that permits limited communications for vulnerability‑research and coordinated disclosure.  The 2023 filing notes that, after the 2021 sanctions, Intel resumed those communications on the basis of the OFAC license and “plans to continue these communications in accordance with the terms and conditions of the OFAC license,” and the 2024 filing repeats the same language, confirming that the relationship remained confined to sanctioned‑party activities with no gross revenue or net profit generated.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in terms of dates, entities, and regulatory context (OFAC General License 1B), and correctly states that Intel's interactions with Positive Technologies were limited to vulnerability research and coordinated disclosure under the license, with no revenue or profit generated—matching the ground truth on these points. Quantitative accuracy is perfect: no numerical errors, and the timeline (2023–2024) is correctly referenced. Contextual relevance is strong, as the response directly addresses the evolution of the relationship under U.S. sanctions and OFAC licensing. However, the qualitative accuracy is slightly lower because the LLM fails to capture the nuanced evolution in tone and intent between the 2023 and 2024 filings. The ground truth emphasizes that in 2023, Intel disclosed *past* communication and *plans* to continue, while in 2024, the language shifted to reflect a more sustained and forward-looking partnership posture—indicating a maturation of the relationship beyond repeating the same language. The LLM incorrectly claims the 2024 filing 'repeats the same language,' which undercuts the evolution in Intel’s stated intent. This misrepresents the multi-hop synthesis of how the relationship posture changed, even if the legal boundaries remained the same. Thus, while core facts are correct, the reasoning around the evolution of the relationship is incomplete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 391,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has the balance of CVS's 4.78% Senior Notes due March 2038 evolved between 2023 and 2024, and what does this indicate about the company's long-term debt structure?",
      "original_answer": "The balance of CVS's 4.78% Senior Notes due March 2038 remained stable at $5,000 million in both 2023 and 2024, indicating that the company did not retire or issue additional amounts of this particular debt instrument during the period. This stability contrasts with other senior notes, such as the 2.7% senior notes due August 2040, which decreased from $1,250 million in 2023 to $367 million in 2024, suggesting selective debt management and refinancing activity in other long-term obligations.",
      "llm_answer": "\nThe carrying amount of CVS’s 4.78 % Senior Notes due March 2038 was $5.0 billion in both the 2023 and 2024 filings – it showed no net increase or decrease between the two years.  This stability indicates that, while the company has been actively issuing new senior notes and retiring shorter‑dated debt to reshape its maturity profile, it has kept this large, long‑dated tranche of fixed‑rate debt on the books as a core component of its long‑term capital structure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states that the balance of CVS's 4.78% Senior Notes due March 2038 was $5.0 billion (i.e., $5,000 million) in both 2023 and 2024, matching the ground truth exactly in value and year. The format variation ($5.0 billion vs $5,000 million) is acceptable and semantically equivalent. (2) All numeric values—interest rate (4.78%), maturity date (March 2038), amount ($5.0 billion), and years (2023, 2024)—are accurate. No calculations were required beyond comparison of stability, which is correctly interpreted. (3) The multi-hop reasoning is sound: the LLM infers from the stability of this debt tranche that CVS maintained it as a core part of its long-term capital structure, while implying active management elsewhere (e.g., issuing new notes, retiring short-dated debt). While the LLM does not explicitly mention the contrast with the 2.7% senior notes due August 2040 (which decreased from $1,250M to $367M), this omission is minor given that the primary focus of the question is on the 4.78% notes. The reasoning still captures the broader implication about selective debt management. (4) The answer is contextually fully relevant, directly addressing both parts of the question: the evolution (stable) and what it indicates (core long-term debt component). The qualitative accuracy is slightly reduced due to the lack of explicit contrast with other senior notes, which strengthens the argument in the original answer, but the core logic remains valid and insightful.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 415,
        "total_tokens": 1661
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has the status of the 0.835% Notes due 2032 evolved between the 2022 and 2024 SEC filings for Exxon Mobil Corporation?",
      "original_answer": "In the 2022 filing, the 0.835% Notes due 2032 were listed among other notes with distinct trading symbols, including the 0.142% Notes due 2024 (XOM24B), indicating a broader set of publicly traded debt instruments. By 2024, the 0.835% Notes due 2032 remained listed with the trading symbol XOM32, but the 0.142% Notes due 2024 no longer appeared in the 2024 filing, suggesting that the 2024 notes were either redeemed or no longer publicly traded. Therefore, while the 0.835% Notes due 2032 remained a consistent part of Exxon Mobil's publicly disclosed debt structure, the removal of the 2024 notes indicates a change in the company's short-to-intermediate term debt composition.",
      "llm_answer": "\nThe 0.835 % Notes due 2032 continue to be listed as outstanding registered securities in both the 2022 and the 2024 Form 10‑K filings (they appear in the “Securities Registered” tables with the ticker XOM32 on the NYSE). No redemption, conversion or amendment of the notes is disclosed, so their legal status and terms remain unchanged between the two filings.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in stating that the 0.835% Notes due 2032 remained outstanding and unchanged in both the 2022 and 2024 filings, with the correct trading symbol XOM32. All quantitative elements—interest rate (0.835%), maturity year (2032), ticker (XOM32), and listing on NYSE—are correct, satisfying quantitative accuracy. The answer correctly identifies the entities and time periods. However, it omits a key comparative insight present in the original answer: the disappearance of the 0.142% Notes due 2024 (XOM24B) from the 2024 filing, which provides context for changes in Exxon Mobil's debt composition. While the LLM correctly reports the status of the 2032 notes, it fails to fully address the evolution *between* filings by not acknowledging this broader shift, which weakens the multi-hop synthesis. The reasoning is sound but incomplete. The answer is contextually relevant and directly addresses the question’s focus on the evolution of the 2032 notes, but misses an opportunity to contrast with other notes to illustrate structural changes. Thus, the correctness and qualitative accuracy scores are slightly reduced for incompleteness, not inaccuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 332,
        "total_tokens": 1586
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has American Express's investment strategy toward U.S. Government treasury obligations evolved between 2022 and 2024, particularly in terms of fair value allocation and maturity distribution?",
      "original_answer": "In 2022, American Express held U.S. Government treasury obligations exclusively in short-term instruments with a fair value of $477 million and no long-term exposure. By 2024, the company shifted its strategy to include both short-term ($189 million) and intermediate-term ($98 million) treasury obligations, indicating a more diversified maturity profile. This reflects a transformation in the company's investment approach, expanding beyond less than 12-month instruments to include holdings maturing within 1 to 5 years.",
      "llm_answer": "\nBetween 2022 and the end of 2024 American Express pared back its U.S. Government‑treasury book dramatically – the fair‑value allocation fell from roughly $1.7 billion (cost ≈ $1.68 billion) in 2021 to just $0.29 billion (cost ≈ $0.29 billion) in 2024 – and it reshaped the maturity profile from a sizable long‑dated slice (about $1 billion of securities maturing after 5 years in 2021) to a near‑entirely short‑term ladder of $0.19 billion due within one year and $0.098 billion due in 1‑5 years by 2024.  Consequently, the portfolio moved from a modest unrealized gain of $25 million in 2021 to a small unrealized loss of roughly $2 million in 2024, reflecting both the size reduction and the shift toward shorter‑maturity Treasuries.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, American Express held $477 million in short-term U.S. Treasury obligations with no long-term exposure. However, the LLM incorrectly references 2021 data (not asked in the question) and reports a 2021 fair value of $1.7 billion, which is irrelevant to the 2022–2024 timeframe specified. The LLM also misrepresents the 2024 allocation: it states $0.29 billion total ($190M + $98M), but the ground truth reports $189M short-term and $98M intermediate-term, summing to $287M — while the LLM incorrectly frames this as a 'dramatic pullback' from a prior larger position, which contradicts the ground truth that only 2022 and 2024 are relevant and shows a shift in maturity structure, not necessarily a reduction in total size from $1.7B. (2) The numbers cited for 2024 ($190M short-term, $98M intermediate) are close to the ground truth ($189M and $98M), so there is partial alignment, but the inclusion of incorrect 2021 data and erroneous total portfolio size undermines accuracy. The claim of a shift from long-dated holdings in 2021 is irrelevant since the question focuses on 2022–2024 evolution. (3) The multi-hop reasoning is flawed: the question asks for evolution between 2022 and 2024, but the model incorrectly infers trends from 2021 data not mentioned in the ground truth. It also introduces cost basis and unrealized gains/losses, which are not part of the original answer and distract from the core query about fair value allocation and maturity distribution. (4) The contextual relevance is moderate because the answer discusses maturity distribution and fair value, which are relevant, but the incorrect time frame, numbers, and extraneous details reduce usefulness. The core transformation — from only short-term in 2022 to including intermediate-term in 2024 — is partially captured but buried under inaccuracies. Thus, the correctness score is low due to major factual and temporal errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 542,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did Amazon's introduction and subsequent treatment of the 2.500% Note due 2050 evolve between 2022 and 2024?",
      "original_answer": "In 2022, the 2.500% Note due 2050 was introduced as part of an Officers' Certificate dated June 3, 2020, and was listed alongside other notes in Exhibit 4.5. By 2024, the 2.500% Note due 2050 was reintroduced in Exhibit 4.6, which was an exact replication of Exhibit 4.5 from 2020, indicating that Amazon continued to maintain this long-term debt instrument without modification. The reintroduction in 2024 reaffirmed the note's role in Amazon's capital structure.",
      "llm_answer": "\nAmazon first issued the 2.500 % Note due 2050 in a June 3 2020 officers’ certificate (referenced in the 2020 Form 8‑K and reproduced in the 2022 10‑K as Exhibit 4.6).  The company did not retire, refinance, or amend that tranche in the subsequent 2022 or 2024 filings; it continued to be treated as a long‑term, fixed‑rate debt obligation with the same 2.5 % coupon and 2050 maturity, appearing only in the standard “Description of Securities” and indenture exhibits without any new issuance or modification disclosed through 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth, with only minor differences in emphasis. (1) Quantitative accuracy: All dates (June 3, 2020), percentages (2.500%), and maturities (2050) are correct. The reference to Exhibit 4.6 in the 2022 10-K aligns with the original answer’s mention of Exhibit 4.5 from 2020, noting that the exhibit numbering may vary slightly across filings—this does not constitute an error. (2) Completeness: The answer addresses both the introduction (via the 2020 Officers' Certificate) and the treatment through 2024, confirming no changes were made, which matches the original answer's claim of reintroduction without modification. (3) Entity accuracy: Amazon, the note terms, and exhibit references are correctly identified. (4) Reasoning: The multi-hop synthesis across 2020, 2022, and 2024 filings is sound—correctly inferring continuity based on absence of amendments and consistent exhibit inclusion. (5) Semantic equivalence: Though the LLM cites Exhibit 4.6 (2022) instead of Exhibit 4.5 (2020), it correctly notes the document’s origin and reproduction, and the core conclusion—that the note was maintained unchanged—is fully supported. The original answer notes the 2024 reintroduction in Exhibit 4.6 as a replication, while the LLM emphasizes continuity without highlighting the 2024 exhibit explicitly, but still concludes no changes through 2024. This minor omission in exhibit-level detail does not detract from overall correctness. Thus, the answer earns a 9 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 448,
        "total_tokens": 1689
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did the number of amendments to the Citibank, N.A. Co-Branded Credit Card Agreement evolve between 2022 and 2023?",
      "original_answer": "In 2022, the most recent amendment to the Citibank, N.A. Co-Branded Credit Card Agreement was the Eighth Amendment, filed on March 10, 2022. By 2023, the agreement had undergone further modifications, with the Twelfth Amendment being filed on October 11, 2023, indicating a total of four additional amendments during this period. This demonstrates a continued evolution and refinement of the agreement terms over the 12-month period.",
      "llm_answer": "\nBetween the 2022 and 2023 fiscal years Costco filed five separate amendments to its Citibank, N.A. Co‑Branded Credit Card Agreement: the eighth, ninth and tenth amendments were filed in 2022 (February 13 2022, November 20 2022 and November 20 2022, respectively), and the eleventh and twelfth amendments were filed in 2023 (February 12 2023 and October 11 2023). This progression shows a steady series of updates—three amendments in 2022 followed by two more in 2023—reflecting ongoing revisions to the credit‑card agreement over that period.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that the Eighth Amendment was the most recent in 2022, filed on March 10, 2022. However, the LLM claims three amendments were filed in 2022: eighth (Feb 13), ninth (Nov 20), and tenth (Nov 20), which contradicts the original answer. The original does not mention the ninth or tenth amendments being filed in 2022, nor does it support the claim of three amendments in that year. The LLM correctly identifies the Twelfth Amendment being filed on October 11, 2023, matching the ground truth. However, it incorrectly implies only two amendments in 2023 (eleventh and twelfth), while the ground truth indicates four additional amendments occurred between the Eighth (2022) and Twelfth (2023), meaning the ninth through twelfth — four total — were filed in that period. The LLM’s count of five total amendments (eighth through twelfth) is plausible, but the distribution across years and dates is inconsistent with the ground truth. (2) Date discrepancies: LLM lists Feb 13, Nov 20 (twice) 2022 and Feb 12, Oct 11 2023. Ground truth only confirms March 10, 2022 (Eighth) and October 11, 2023 (Twelfth). The other dates are unverified and likely incorrect. The number of amendments (four additional) is misattributed in the LLM answer — it should be four amendments after the Eighth, but LLM suggests only two in 2023 and two prior in 2022 (ninth and tenth), which doesn’t align. (3) Multi-hop reasoning is partially correct — the model attempts to track amendment progression over time, but fails to correctly infer the sequence and timing based on the ground truth. It introduces Costco as the filer, which is not mentioned in the original answer and may be an incorrect entity assumption. (4) Scores reflect partial correctness: some key facts (Twelfth Amendment date) are accurate, but core quantitative and sequential details are wrong. Contextual relevance is high as the answer addresses the evolution of amendments, but factual accuracy undermines correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 553,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has NVIDIA's approach to CUDA evolved between 2022 and 2024, particularly in terms of its integration with new computing architectures and software ecosystems?",
      "original_answer": "In 2022, NVIDIA emphasized CUDA as a foundational building block across its target markets, including Gaming, Data Center, Professional Visualization, and Automotive, highlighting its role in enabling accelerated computing and deep learning. CUDA was positioned as a core component of the company's unified architecture, supporting a wide range of applications through internal and third-party software stacks. By 2024, NVIDIA had significantly expanded the scope of CUDA's integration, describing it as part of a broader full-stack computing platform that includes the CUDA-X collection of acceleration libraries, APIs, SDKs, and domain-specific application frameworks. Additionally, CUDA was now explicitly tied to NVIDIA's expanded data center platform, which now includes CPUs (introduced in fiscal 2024) alongside GPUs and DPUs, showing a strategic evolution toward deeper integration with heterogeneous computing architectures and enterprise-grade AI ecosystems.",
      "llm_answer": "\nBetween 2022 and 2024 NVIDIA broadened CUDA from a GPU‑only model into a unified, full‑stack programming environment that runs on its new data‑center CPUs (Grace), DPUs, and the Blackwell GPU architecture.  The CUDA‑X library suite and AI‑focused extensions (e.g., NIM, NeMo, AI Blueprints) are now packaged inside the AI Enterprise software stack, allowing the same CUDA code to target GPUs, DPUs and CPUs and to be tightly coupled with networking, storage and cloud services across the company’s accelerated‑computing platforms.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly captures the evolution of CUDA from a GPU-centric model in 2022 to a full-stack, heterogeneous computing platform by 2024. Key points such as the expansion beyond GPUs to include CPUs (specifically named as Grace, which aligns with NVIDIA's fiscal 2024 CPU launch), DPUs, and the Blackwell architecture are factually correct and reflect NVIDIA's strategic direction. The integration of CUDA-X libraries and AI tools (NIM, NeMo, AI Blueprints) into the AI Enterprise software stack is consistent with NVIDIA's 2024 positioning of CUDA as part of a broader enterprise AI ecosystem. While the original answer does not explicitly name 'Grace' or 'Blackwell', these are plausible and accurate details that enhance specificity without contradicting the ground truth. The LLM correctly identifies the shift toward heterogeneous computing (CPUs, GPUs, DPUs) and tighter integration with networking, storage, and cloud services—core elements of the 2024 strategy. There are no numerical values to verify, so quantitative accuracy is scored as 10 by default. The only minor limitation is that the LLM does not explicitly reference the four target markets (Gaming, Data Center, etc.) mentioned in the 2022 context, slightly reducing completeness in multi-hop synthesis, but the overall qualitative and contextual accuracy remains very high. Semantic equivalence is strong, and the answer fully addresses the question about CUDA’s evolving integration with new architectures and software ecosystems.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 429,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did Pfizer's financial relationship with Paxlovid evolve between 2023 and 2024, particularly in terms of revenue recognition and contractual obligations?",
      "original_answer": "In 2023, Paxlovid generated $1.279 billion in revenue, but this figure was significantly impacted by a non-cash revenue reversal of $3.5 billion due to the expected return of 6.5 million treatment courses of EUA-labeled U.S. government inventory. By 2024, this reversal was adjusted favorably by $771 million as only 5.1 million treatment courses were actually returned, and an additional $442 million in revenue was recorded in connection with the creation of the U.S. Strategic National Stockpile (SNS). Furthermore, as of December 31, 2024, Pfizer reported approximately $1 billion in remaining performance obligations related to Paxlovid supply contracts, indicating ongoing but reduced commercial activity compared to the prior year. This evolution reflects a shift from a high-volume, government-driven revenue model in 2023 to a more stable, contracted future delivery model in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 Pfizer moved Paxlovid from a peak‑year government‑contract business to a largely commercial, deferred‑revenue model. In 2023 the company recorded only $1.28 bn of Paxlovid product revenue, but in Q4 2023 it booked a $3.5 bn non‑cash revenue reversal for expected returns of EUA‑labeled courses, and in Q1 2024 it reversed $771 m of that estimate and recognized $442 m from a U.S. SNS supply of 1 m courses. As of 31 Dec 2024 Pfizer had about $1 bn of remaining performance obligations for future Paxlovid deliveries (expected through 2025‑2028), reflecting the shift from large‑scale government purchases to commercial sales and the recognition of revenue only as product is shipped.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth with only minor differences in emphasis. (1) All key facts are correct: 2023 Paxlovid revenue of $1.28 billion (matches $1.279 billion, rounded appropriately), the $3.5 billion non-cash revenue reversal in 2023 due to expected returns of EUA-labeled inventory, the $771 million favorable reversal adjustment in Q1 2024 when only 5.1 million courses were returned (vs. expected 6.5 million), and the $442 million revenue from the U.S. Strategic National Stockpile (SNS) transaction. The remaining performance obligations of $1 billion as of December 31, 2024, are correctly reported. (2) Quantitative accuracy is perfect: all dollar amounts, timeframes (Q4 2023, Q1 2024), and the 1 million SNS courses align with the ground truth. The phrasing 'reversed $771 million of that estimate' correctly reflects the adjustment to the prior reversal. (3) Multi-hop reasoning is sound—LLM correctly synthesizes revenue recognition changes across two years, links contractual obligations to future revenue recognition, and infers the business model shift from government-driven to commercial/contracted. (4) The only minor shortcoming is that the LLM does not explicitly mention the 6.5 million expected vs. 5.1 million actual returned treatment courses, which is a contextual detail supporting the $771 million adjustment. While implied by the reversal explanation, its omission slightly reduces qualitative completeness. However, the core financial evolution is accurately captured, and the answer remains semantically equivalent in substance. Wording differences (e.g., 'deferred-revenue model' vs. 'contracted future delivery model') are acceptable and reflect synonymous interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 479,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has the availability and structure of shares under the 2003 Incentive Program evolved between 2022 and 2024?",
      "original_answer": "In 2022, the 2003 Incentive Program had 65,754,069 shares available for award. By 2024, the total maximum number of shares that could be issued under the program was increased to 220 million, with 47 million remaining available for awards by the end of 2024. This indicates a significant expansion in the program's capacity, although actual usage had grown moderately over time, with restricted stock units granted increasing from 9,392 thousand in 2022 to 10,393 thousand in 2024.",
      "llm_answer": "\nBetween 2022 and 2024 the pool of shares reserved for the 2003 Incentive Program shrank from roughly **66 million shares** that were available for future grants (as disclosed in the 2022 filing) to about **47 million shares** remaining at the end of 2024.  This reduction reflects the issuance of new awards—including the conversion of Pioneer restricted‑stock units—plus vested and forfeited awards, causing the number of outstanding restricted‑stock/RSU awards to rise from **37.8 million at the start of 2024 to 39.6 million by year‑end**.  The program continues to allow grants of options, SARs, restricted stock and RSUs under its 220‑million‑share ceiling, with the same graded‑vesting structure (50 % after three years, the remainder after seven years), while a separate Pioneer LTIP still had about **9.4 million shares** available for future issuance at the end of 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents the evolution of the share availability under the 2003 Incentive Program. (1) Quantitatively, it incorrectly states that the available shares shrank from 66 million in 2022 to 47 million in 2024, implying a reduction in the total pool. However, the ground truth shows that the total maximum number of shares was increased from 65.75 million in 2022 to 220 million in 2024, indicating a substantial expansion, not a shrinkage. The 47 million in 2024 refers to shares *remaining available for awards*, not the total pool. (2) The LLM incorrectly frames the change as a reduction due to issuances and conversions (e.g., Pioneer RSUs), which is not supported by the original answer and introduces entities (Pioneer) and events (conversions) not mentioned in the ground truth. (3) The original answer notes that restricted stock units granted increased from 9,392 thousand (9.392 million) in 2022 to 10,393 thousand (10.393 million) in 2024, but the LLM instead cites outstanding RSUs rising from 37.8M to 39.6M, which contradicts the ground truth and introduces unverified data. (4) The LLM mentions a '220-million-share ceiling' which is correct, but fails to note that this represents an increase from the prior level—this key point of expansion is missed. (5) The mention of a 'separate Pioneer LTIP' and specific vesting structure (50% after three years, etc.) is not present in the original answer and appears fabricated or misattributed. (6) While the LLM attempts to address the question's focus on evolution between 2022 and 2024, it fundamentally mischaracterizes the direction of change (shrinking vs. expanding pool), making the core conclusion incorrect. The contextual relevance is moderate because it discusses share availability and grants, but the reasoning and facts are flawed. Due to major errors in numbers, entities, and synthesis, the correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 524,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has AdSense's role within Google's advertising revenue streams evolved between 2022 and 2024, particularly in relation to the company's broader advertising technology portfolio?",
      "original_answer": "In 2022, AdSense was explicitly cited as a key growth driver within the Google Network, contributing to an $8.6 billion year-over-year revenue increase alongside AdMob and Google Ad Manager. By 2024, while AdSense remained part of the Google Network, it was no longer specifically quantified as a growth lever. Instead, newer AI-powered advertising products like Demand Gen and Performance Max were highlighted as central to advertiser success, suggesting a strategic shift where AdSense became a more foundational, mature offering within Google's broader advertising technology stack.",
      "llm_answer": "\nBetween 2022 and 2024 AdSense remained part of Google’s “Google Network” but its relative importance faded as Google consolidated its advertising technology into a broader, AI‑driven suite.  The 2024 filing emphasizes a unified portfolio of performance‑ and brand‑focused products—such as Performance Max, Demand Gen and Product Studio—that deliver ads across Search, YouTube and partner properties, with AdSense now functioning only as one component of that larger ecosystem rather than a primary growth driver.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that AdSense remained part of the Google Network from 2022 to 2024 and notes its diminished emphasis as a standalone growth driver. The shift toward AI-powered products like Performance Max and Demand Gen is accurately captured, reflecting the strategic evolution in Google's ad tech portfolio. (2) Quantitative accuracy is perfect: while the LLM does not repeat the $8.6 billion year-over-year increase mentioned in the original answer, it does not make any numerical claims, so there is no inaccuracy. The omission of the specific figure slightly reduces completeness but does not affect correctness. (3) The multi-hop reasoning is sound—linking AdSense’s changing role to the rise of newer AI-driven tools across Google’s ecosystem shows proper synthesis across time and product lines. (4) The answer is contextually relevant, directly addressing the evolution of AdSense’s role within Google’s broader advertising technology offerings. The only minor shortcoming is the lack of explicit mention of AdMob and Google Ad Manager as co-drivers in 2022, which slightly weakens completeness but doesn’t detract from the core conclusion. Overall, the semantic meaning matches the original answer closely, with appropriate emphasis on strategic shift and integration into a larger ecosystem.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 383,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did the UPS Retirement Plan's benefit accrual structure evolve between 2022 and 2023, and what specific changes were made to future benefit accruals for non-union participants?",
      "original_answer": "In 2022, the UPS Retirement Plan was described as noncontributory and covering substantially all eligible employees hired before July 1, 2016, who were not part of a collective bargaining unit or certain employees covered by a collective bargaining agreement. The plan provided retirement benefits based on average compensation and was subject to IRS limits. It was also disclosed that the plan would cease accruals of additional benefits for future service and compensation for non-union participants effective January 1, 2023. In 2023, this cessation of accruals was confirmed as effective, and the plan was described with the same eligibility and benefit structure but explicitly stated that no further accruals would occur for non-union participants. This marks a transformational change in the plan's structure, as the accrual freeze was implemented as planned, shifting the plan from an active benefit-accruing structure to a closed one for non-union employees. The change represents a significant strategic shift in UPS's retirement benefit policy.",
      "llm_answer": "\nBetween 2022 and 2023 the UPS Retirement Plan moved from a traditional defined‑benefit accrual that continued to build future benefits for non‑union participants to a “frozen” structure: effective January 1 2023 the plan stopped accruing any additional benefit credits for future service and compensation for those participants. Instead, beginning in 2023 non‑union employees (including those who had been accruing benefits under the UPS Retirement Plan) began receiving a defined‑contribution contribution of 5 %–8 % of eligible pay into the UPS 401(k) Savings Plan, replacing the prior benefit‑accrual mechanism.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies the key change in the UPS Retirement Plan: the cessation of benefit accruals for non-union participants effective January 1, 2023, which aligns with the ground truth. It accurately describes the transition from an active defined-benefit plan to a frozen structure for non-union employees. However, the LLM adds information not present in the original answer — specifically, that non-union employees began receiving 5%–8% defined-contribution contributions into the UPS 401(k) Savings Plan starting in 2023. While this may be true in broader context, it is not included in the provided ground truth and represents an unverified addition. This affects both quantitative and qualitative accuracy, as the percentages (5%–8%) are specific numeric claims not confirmed by the source. The core multi-hop reasoning — linking the 2022 plan structure to the 2023 change in accruals — is sound and correctly synthesized across years and participant groups. The answer is fully relevant and addresses the evolution and specific changes, but the unsupported detail about 401(k) contributions prevents a higher score. Semantic equivalence is mostly preserved, but the added detail introduces factual overreach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 344,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has Amazon's utilization and structure of its short-term credit facilities evolved between 2022 and 2024, particularly in terms of credit capacity, interest rate terms, and outstanding borrowings?",
      "original_answer": "In 2022, Amazon had a $7.0 billion unsecured revolving credit facility with an interest rate of benchmark rate plus 0.50% and a commitment fee of 0.04%, and no borrowings were outstanding under this facility. Additionally, Amazon had $7.2 billion in unused letters of credit as of December 31, 2021. By 2024, Amazon had significantly expanded its credit capacity by entering into a new $15.0 billion unsecured revolving credit facility with a lower interest rate of benchmark rate plus 0.45% and a reduced commitment fee of 0.03%. In addition, Amazon introduced a new $5.0 billion unsecured 364-day revolving credit facility in October 2024, which also carried a rate of SOFR plus 0.45% and a 0.03% commitment fee. Notably, there were still no borrowings outstanding under the main Credit Agreement or the Short-Term Credit Agreement as of December 31, 2024. However, Amazon had $147 million and $151 million in borrowings under other short-term credit facilities as of December 31, 2023 and 2024, respectively, which were included in 'Accrued expenses and other.' The company also increased its unused letters of credit to $8.3 billion by the end of 2024.",
      "llm_answer": "\nBetween 2022 and 2024 Amazon replaced its old $7 bn revolving line (maturing June 2023, LIBOR + 0.50 % with a 0.04 % commitment fee and no drawn balance) with a larger $15 bn unsecured revolving facility (maturing Nov 2028, benchmark + 0.45 % and a 0.03 % fee) and added a $5 bn 364‑day revolving facility (SOFR + 0.45 %, 0.03 % fee, maturing Oct 2025).  The company has kept borrowings under these short‑term facilities essentially zero in 2023‑24, relying instead on modest commercial‑paper draws and the repayment of a $8 bn term loan, indicating a shift toward greater credit capacity, slightly lower‑cost terms and a minimal use of drawn credit.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution of Amazon's credit facilities correctly—expansion from $7.0 billion to $15.0 billion in revolving credit, addition of a $5.0 billion 364-day facility, lower interest rates (from +0.50% to +0.45%), and reduced commitment fees (0.04% to 0.03%). It correctly notes no borrowings under the main credit agreements in 2023–2024. However, it introduces inaccuracies: the original $7.0 billion facility did not mature in June 2023 (the ground truth does not specify maturity date), and the new $15.0 billion facility’s maturity is stated as November 2028, which is not in the ground truth. The LLM also references a 'repayment of an $8 billion term loan' and 'commercial-paper draws,' which are not mentioned in the original answer and are unsupported by the provided data. (2) Quantitative accuracy: The $7.0 billion, $15.0 billion, $5.0 billion, rate reductions, and fee reductions are correct. However, the $8 billion term loan repayment and specific maturity dates (June 2023, Nov 2028, Oct 2025) are not in the ground truth and are therefore incorrect. The original answer mentions $147 million and $151 million in other short-term borrowings (included in 'Accrued expenses and other') for 2023 and 2024, which the LLM omits entirely, instead stating 'essentially zero'—this is a significant omission. (3) Multi-hop reasoning: The LLM correctly synthesizes the expansion and cost reduction in credit facilities over time and infers conservative borrowing behavior. However, it adds unsupported details (term loan repayment, commercial paper) that suggest overinterpretation or hallucination, weakening the reasoning chain. (4) The answer is contextually relevant and well-structured, addressing capacity, rates, and utilization. Despite missing specific figures on other short-term borrowings and adding unverified details, the overall direction and key facts are sound, warranting a 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1465,
        "completion_tokens": 528,
        "total_tokens": 1993
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has Costco's use of variable-priced contracts for energy purchases evolved between 2022 and 2023, and what does this indicate about its commodity price risk management strategy?",
      "original_answer": "In 2022, Costco entered into variable-priced contracts for some purchases of electricity and natural gas, as well as fuel for its gas stations, on an index basis. These contracts met the definition of derivatives but generally qualified for the 'normal purchases and normal sales' exception, requiring no mark-to-market adjustment. By 2023, Costco continued this approach but specifically called out natural gas and fuel for gas stations as key components of its variable-priced contract usage. This indicates a continued reliance on variable-priced contracts as part of its commodity price risk management, with no significant shift away from index-based pricing mechanisms. The strategy remains consistent, showing stability in how Costco manages exposure to energy price fluctuations.",
      "llm_answer": "\nCostco’s filing for both 2022 and 2023 states that it continues to supplement a base of fixed‑price power‑ and gas‑supply contracts with variable‑priced, index‑based agreements for electricity, natural‑gas and fuel, and that these variable contracts are treated as “normal purchases and normal sales” and therefore are not marked‑to‑market.  The wording in the 2023 document mirrors the 2022 description, indicating that the company’s commodity‑price risk management has not changed materially—it still relies on a mixed strategy of fixed‑price contracts for key locations while using variable‑price, index‑based contracts to capture market movements and limit exposure without formal hedging.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All factual elements are correct: Costco used variable-priced, index-based contracts in both 2022 and 2023 for electricity, natural gas, and fuel, and these qualified for the 'normal purchases and normal sales' exception, avoiding mark-to-market accounting. The strategy remained consistent, indicating stable commodity price risk management. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2022 and 2023) are correct. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across two years and infers continuity in strategy, which aligns with the ground truth. (4) The only minor shortcoming is that the LLM slightly generalizes by mentioning 'electricity, natural-gas and fuel' in both years, while the original answer notes that in 2023, Costco specifically highlighted natural gas and fuel for gas stations—slightly more precise focus. However, this does not constitute a factual error, just a small omission of emphasis. Overall, the answer is semantically equivalent, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 351,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has the strategic positioning and commercial role of NVIDIA AI Enterprise evolved within NVIDIA's data center offerings between 2022 and 2024?",
      "original_answer": "In 2022, NVIDIA AI Enterprise was introduced as part of the Compute & Networking segment, indicating its foundational role in NVIDIA's AI and accelerated computing strategy. By 2024, the product had evolved into a more prominent commercial offering, described as a 'comprehensive suite of enterprise-grade AI software' that is actively licensed and integrated into broader data center solutions. This shift reflects NVIDIA's move from positioning it as a strategic initiative to a key monetization vehicle within its full-stack data center platform, alongside offerings like NVIDIA DGX Cloud and the expansion into CPUs and DPUs.",
      "llm_answer": "\nBetween 2022 and 2024, NVIDIA AI Enterprise shifted from a peripheral, license‑only add‑on for enterprise‑grade AI software to a central, revenue‑generating subscription suite that is tightly coupled with the company’s newest data‑center hardware (e.g., the Blackwell GPUs, CPUs and DPUs).  In the 2022 filing (pages 78‑82) AI Enterprise was described only as a paid software layer sold alongside the data‑center platform, but by the 2024 filing (pages 4‑8) it is presented as a strategic, end‑to‑end AI software stack—including NIM, NeMo and AI Blueprints—marketed directly to enterprises and cloud partners as a core component of NVIDIA’s data‑center offering.  This evolution reflects a broader commercial model that emphasizes subscription licensing, deeper integration with the full computing stack, and a dedicated go‑to‑market push to drive data‑center revenue.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution of NVIDIA AI Enterprise from a foundational software layer in 2022 to a central, monetized suite by 2024. The description of it becoming a 'revenue-generating subscription suite' and being tightly integrated with hardware (GPUs, CPUs, DPUs) matches the original answer's emphasis on its role in the full-stack data center platform. (2) There are no numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the LLM draws a clear contrast between the 2022 and 2024 positioning using correct contextual details (e.g., reference to specific product components like NIM, NeMo, AI Blueprints, and integration with DGX Cloud equivalents), demonstrating synthesis across time periods and strategic shifts. (4) Minor deduction in qualitative accuracy due to slightly stronger emphasis on 'subscription' model and 'Blackwell GPUs'—while consistent with NVIDIA's direction, these specifics are not in the ground truth and could be seen as extrapolation. However, they do not contradict known facts and are contextually plausible. Overall, the answer is semantically equivalent, comprehensive, and directly relevant to the question about strategic and commercial evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 384,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did Pfizer's contractual obligations related to Paxlovid evolve between 2023 and 2024, and what does this indicate about the company's future revenue expectations for the product?",
      "original_answer": "In 2023, Pfizer had a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter related to the expected return of an estimated 6.5 million treatment courses of Paxlovid labeled under Emergency Use Authorization (EUA) from the U.S. government. This indicated uncertainty and potential decline in demand for Paxlovid. By 2024, however, remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, signaling a stabilization and expectation of future revenue from existing contracts. This shift from a large revenue reversal to a defined forward-looking contractual obligation suggests improved demand forecasting and a more stable outlook for Paxlovid in 2024 compared to the uncertainty in 2023.",
      "llm_answer": "\nBetween 2023 and 2024 Pfizer’s Paxlovid contracts moved from large‑scale government stock‑piling under EUA‑labelled supply (which generated $5.1 bn of deferred revenue and a $3.5 bn non‑cash reversal in Q4 2023) to commercial‑market agreements; by year‑end 2024 the company had reduced deferred Paxlovid revenue to $2.2 bn, recognized a $771 m favorable adjustment in Q1 2024 and $442 m of revenue from a U.S. SNS shipment in Q3 2024, and disclosed only about $1 bn of remaining contracted revenue to be recognized through 2025‑2028. This shrinkage of deferred obligations and the shift to commercial sales indicate that Pfizer now expects only modest, limited future revenue from Paxlovid rather than the blockbuster sales seen in 2022‑23.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in numbers and misrepresents the nature of the revenue reversal and deferred revenue. The ground truth states a $3.5 billion non-cash revenue reversal in Q4 2023 due to expected returns of 6.5 million treatment courses under EUA, which the LLM correctly identifies. However, the LLM adds details not in the original, such as $5.1 billion of deferred revenue and a reduction to $2.2 billion by year-end 2024, which are not supported by the ground truth. The $771 million favorable adjustment in Q1 2024 and $442 million from a U.S. SNS shipment in Q3 2024 are also not mentioned in the original answer and appear to be fabricated or misattributed. The remaining performance obligations of $1 billion by December 31, 2024, are correctly reported, though the original does not extend the timeline to 2025–2028. (2) The quantitative inaccuracies are significant: while the $3.5 billion reversal and $1 billion remaining obligation are correct, the additional figures ($5.1B deferred, $2.2B remaining, $771M, $442M) lack support and distort the financial narrative. Calculations are not required in this case, but the inclusion of unsupported figures undermines quantitative accuracy. (3) The reasoning partially aligns with the ground truth—recognizing a shift from government EUA-based purchases to commercial agreements and interpreting this as reduced future expectations. However, the original answer interprets the $1 billion obligation as a sign of stabilization and improved forecasting, whereas the LLM interprets it as indicating 'modest, limited future revenue,' which is a more pessimistic and unsupported inference. This misrepresents the implication of the contractual evolution. (4) Contextual relevance is high—the answer addresses the evolution of contractual obligations and attempts to infer revenue expectations. However, due to the inclusion of unverified financial data and a divergent conclusion about future outlook, the correctness score is reduced to 6, reflecting partial accuracy with significant factual deviations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 563,
        "total_tokens": 1946
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "Compare and contrast how Google's exposure to new regulatory costs in international markets evolved between 2022 and 2024, particularly in terms of the scope and nature of regulatory challenges described?",
      "original_answer": "In 2022, Google highlighted that an evolving foreign policy landscape could subject the company to 'new regulatory costs and challenges,' specifically mentioning data transfers between the EU and the UK, as well as new customer requirements. By 2024, the scope of regulatory challenges expanded significantly. The 2024 filing not only reiterated the exposure to 'new regulatory costs and challenges' but also introduced elements like 'uncertainty regarding regulatory outcomes' and the risk of 'other liabilities under local laws that may not offer due process or clear legal precedent.' This indicates a shift from primarily data-related regulatory concerns in 2022 to broader, more unpredictable regulatory risks in 2024, reflecting an increased complexity in Google's international regulatory environment.",
      "llm_answer": "\nBetween 2022 and 2024 the scope of Google’s exposure to international regulatory costs shifted from a focus on structural trade and economic barriers—such as foreign‑ownership limits, currency controls, import‑export tariffs, longer payment cycles, and evolving foreign‑policy‑driven data‑transfer rules—to a broader, geopolitically‑driven set of compliance risks.  In 2024 the filing explicitly cites sanctions, export‑control restrictions, armed conflicts (e.g., Middle East, Ukraine) and new customer‑requirement regulations as sources of additional regulatory costs, expanding the nature of challenges from primarily economic‑trade hurdles to include security‑related and policy‑driven compliance obligations.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is partially correct but diverges significantly from the ground truth in key aspects of entity accuracy and reasoning. (1) What was correct: The answer correctly identifies an evolution in Google's regulatory exposure between 2022 and 2024 and notes an expansion in scope. It accurately references 'evolving foreign-policy-driven data-transfer rules' and 'new customer-requirement regulations,' which aligns with the 2022 original answer. (2) Quantitative accuracy: There are no numeric values in the question or answers, so this dimension is neutral; no errors present. (3) Multi-hop reasoning assessment: The LLM introduces elements not present in the ground truth—specifically 'foreign-ownership limits, currency controls, import-export tariffs, longer payment cycles, sanctions, export-control restrictions, and armed conflicts (e.g., Middle East, Ukraine)'—which are not mentioned in the original 2022 or 2024 filings per the ground truth. The original answer emphasizes a shift from data transfer concerns (EU-UK) in 2022 to broader legal uncertainties and lack of due process in 2024. The LLM instead frames the shift as from economic-trade barriers to geopolitical-security risks, which misrepresents the nature of the regulatory challenges described. (4) Justification for scores: Correctness is scored 5 due to significant factual inaccuracies in the nature and scope of regulatory risks described, despite recognizing a broadening trend. Qualitative accuracy is 5 because the entities (years, company) are correct, but the cited regulatory challenges are not supported by the ground truth. Contextual relevance is 7 because the answer addresses the evolution of regulatory costs, but with incorrect specifics. Quantitative accuracy is 10 by default, as no numbers are involved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 487,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has UPS's approach to funding postretirement medical benefits evolved between 2022 and 2023, particularly in terms of the sources used for expected benefit payments?",
      "original_answer": "In 2022, UPS indicated that expected benefit payments for postretirement medical benefits would be paid from both plan trusts and corporate assets. In 2023, the language remained unchanged, indicating continuity in the funding approach. Therefore, there was no change in the sources used for expected benefit payments for postretirement medical benefits between the two years.",
      "llm_answer": "\nBetween 2022 and 2023 UPS kept the same funding mix for post‑retirement medical benefits—payments are drawn from plan trusts and corporate assets—but the projected cash‑flow amounts were trimmed sharply.  The 2022 filing projected ≈ $1.9 billion of employer contributions for 2022 and $229 million of benefit payments, whereas the 2023 filing shows only $74 million of contributions to the trust (and $92 million to participants) and $216 million of expected benefit payments for 2024.  Thus, while the source of funds remained unchanged, the scale of funding was reduced, reflecting a more conservative approach to covering post‑retirement medical obligations.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies that UPS used both plan trusts and corporate assets as sources for postretirement medical benefits in both years, aligning with the ground truth that there was no change in funding sources. This supports partial credit for qualitative accuracy and contextual relevance. However, the quantitative details are largely incorrect or unsupported by the ground truth. The original answer does not mention specific dollar amounts for projected contributions or benefit payments in either year, nor does it state any reduction in funding scale. The LLM introduces specific figures—$1.9 billion, $229 million, $74 million, $92 million, $216 million—which are not present in the ground truth and cannot be verified from the provided information. These numbers appear fabricated or misattributed, severely undermining quantitative accuracy. Additionally, the LLM references 2024 expected payments in the context of a 2023 filing, which shifts focus away from the 2022–2023 comparison asked in the question. While the core point about unchanged funding sources is correct, the inclusion of unverified financial data and the emphasis on a change in funding scale (which the ground truth does not support) introduce significant factual errors. Thus, despite correct entity identification and some relevant reasoning, the answer fails on key factual and quantitative grounds.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 385,
        "total_tokens": 1650
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has the role and scope of NVIDIA AI Enterprise evolved from its introduction in 2022 to its broader supply and integration in 2024?",
      "original_answer": "In 2022, NVIDIA AI Enterprise was introduced as part of the Compute & Networking segment, described as a software suite aimed at simplifying the deployment of AI applications across data centers and enterprise environments. By 2024, the platform had evolved into a more comprehensive and integrated solution, including components such as NVIDIA NIM, NVIDIA NeMo, and AI Blueprints, with specific performance improvements like a 2.5x increase in token throughput. This reflects a shift from a foundational offering to a full-stack, production-grade generative AI platform with enhanced capabilities and broader deployment options.",
      "llm_answer": "\nFrom its 2022 launch, NVIDIA AI Enterprise was positioned as a paid, enterprise‑grade software suite that bundled tools such as NIM, Nemot and AI Blueprints to streamline the development and deployment of production‑grade generative‑AI workloads on NVIDIA‑accelerated infrastructure. By 2024 the scope had broadened dramatically: the suite was now integrated into the full‑stack data‑center platform (GPUs, DPUs and CPUs), offered through DGX Cloud and sold as a license‑based service, and was being adopted across a wider range of industries and partner ecosystems, with tighter coupling to the Blackwell architecture and expanded capabilities for scaling, security and multi‑cloud deployment.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of NVIDIA AI Enterprise from a software suite to a broader, integrated platform, which aligns with the ground truth. However, there are key factual inaccuracies that reduce correctness. First, the LLM incorrectly states that NIM, NeMo (misspelled as 'Nemot'), and AI Blueprints were part of the 2022 offering; in reality, these components were introduced or emphasized by 2024 as enhancements, not present at launch. This misrepresents the timeline and scope of the product's evolution. Second, while the ground truth specifies a measurable performance improvement (2.5x increase in token throughput), the LLM omits this quantitative detail and instead introduces unverified claims such as 'tighter coupling to the Blackwell architecture' and 'license-based service' without supporting evidence in the original answer. The mention of DGX Cloud and multi-cloud deployment adds contextual detail but goes beyond the provided knowledge. Quantitatively, no incorrect numbers are stated (hence a decent score), but the LLM fails to include the only specific metric in the ground truth (2.5x). The reasoning is partially sound in recognizing a shift toward full-stack integration, but the multi-hop synthesis is flawed due to incorrect attribution of features to the 2022 release. The answer is contextually relevant and addresses the question's scope, but the entity and timeline inaccuracies significantly impact factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 404,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has ExxonMobil's proved reserves through equity companies evolved from 2022 to 2024, and what does this indicate about its strategic positioning in different regions?",
      "original_answer": "In 2022, ExxonMobil's total proved reserves from equity companies amounted to 14 million barrels gross (1 million net) across the United States, Europe, Africa, and Asia. By 2024, these reserves had significantly increased to 467 million barrels of crude oil, 120 million barrels of natural gas liquids, and 5,367 billion cubic feet of natural gas, with the majority of this growth concentrated in Asia. This indicates a major strategic shift toward strengthening its upstream presence in the Asia region through equity companies.",
      "llm_answer": "\nBetween 2022 and 2024 ExxonMobil’s proved reserves that are reported through equity‑company joint ventures grew from roughly **1.2 billion oil‑equivalent barrels to 1.48 billion boe** (an increase of about 23 %).  The bulk of this growth came from **Asia‑Pacific joint ventures and U.S. on‑shore/off‑shore plays**, while reserves in Europe and Africa stayed flat, indicating that the company is deliberately concentrating its equity‑based resource base in higher‑return, growth‑oriented basins (North America and Asia) and scaling back exposure to more mature or politically sensitive regions.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in terms of factual content. The original answer states that in 2022, ExxonMobil's total proved reserves from equity companies were 14 million barrels gross (1 million net), but the LLM claims 1.2 billion boe, which is over 85 times higher. By 2024, the ground truth reports 467 million barrels of crude oil, 120 million barrels of NGLs, and 5,367 Bcf of natural gas—none of which the LLM accurately reflects. Instead, the LLM reports a total of 1.48 billion boe, which does not match any sum derived from the correct figures. (2) Calculations are also flawed: the LLM claims a 23% increase from 1.2 to 1.48 billion boe, but this entire baseline and endpoint are fabricated. The actual data shows a massive increase from a very small base (14 million barrels gross in 2022) to a much larger, diversified reserve base in 2024, dominated by Asia. The LLM’s numbers do not align with this trajectory. (3) The multi-hop reasoning is partially sound in structure—identifying regional shifts and strategic implications—but it is based on false data. While the LLM correctly infers a strategic focus on Asia and North America, the original answer only mentions Asia as the primary growth region, with no indication of U.S. growth through equity companies. The claim that Europe and Africa remained flat is plausible but unsupported by explicit data in the original. (4) Contextual relevance is moderate because the answer addresses the evolution of reserves and strategic positioning as asked, and attempts regional analysis. However, due to severe quantitative inaccuracies and incorrect entity values, the overall correctness score is very low. The answer fabricates magnitudes and metrics not present in the source, undermining trust in its conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 488,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the financial relationship with Google Network Partners evolved between 2022 and 2024, particularly in terms of their role in revenue generation and cost structure?",
      "original_answer": "In 2022, Google Network Partners played a central role in the revenue generation process as Google acted as the principal for ads placed on Google Network properties, reporting advertising revenues on a gross basis, with payments to partners recorded as cost of revenues. By 2024, Google continued to pay Google Network partners, but the focus of the financial reporting shifted to emphasize the net cash flow impact, noting that payments to these partners were a primary use of cash from operating activities. This reflects a more cost-centric framing of the relationship in the later year.",
      "llm_answer": "\nBetween 2022 and 2024, Google Network Partners continued to be a core conduit for Alphabet’s ad‑driven revenue, with “TAC includes amounts paid to Google Network partners primarily for ads displayed on their properties” (p. 53, 56).  The company’s operating‑income commentary notes that the rise in operating income was “partially offset by increases in … TAC,” indicating that payments to these partners grew in absolute dollars as ad revenue expanded (p. 41).  Consequently, while the cost structure shifted slightly toward higher variable outlays for network‑partner payouts, the underlying revenue generated through those partners increased faster, leaving overall profitability still on an upward trajectory.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies that Google Network Partners remained important for revenue generation and that Traffic Acquisition Costs (TAC) paid to them increased, which aligns with the ground truth's emphasis on growing payments. It accurately references disclosures from the 10-K (e.g., p. 53, 56, 41) and correctly characterizes TAC as a growing cost tied to partner payouts. However, it misses a key evolution highlighted in the original answer: the shift in financial reporting treatment and framing—from gross revenue reporting in 2022 (where Google acted as principal and reported revenues gross of partner payments) to a more cost-centric, cash flow–focused narrative in 2024. This change in accounting presentation and emphasis on net cash outflow as a primary use of operating cash is a critical multi-hop insight that the LLM fails to capture. While the LLM notes rising TAC and its impact on operating income, it does not address the structural or reporting evolution in the relationship. Quantitatively, no specific dollar amounts or percentages are cited, so accuracy is based on directional correctness (e.g., 'increases in TAC'), which is acceptable and consistent with the source. The reasoning is sound within the scope of what was discussed but incomplete in synthesizing across years to show a shift in financial framing. Thus, the answer is partially correct with significant gaps in qualitative synthesis and multi-hop reasoning, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 408,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has UPS's foreign currency exchange risk management strategy evolved between 2022 and 2023, particularly in terms of the financial impact of undesignated foreign currency forward contracts on earnings volatility?",
      "original_answer": "In 2022, UPS disclosed that foreign currency exchange forward contracts were used to economically offset foreign currency remeasurement and settlement risk for certain balance sheet assets and liabilities, and that changes in their fair value affected earnings directly. For 2023, UPS expanded the disclosure to emphasize that undesignated derivative settlements are now explicitly linked to earnings volatility, with a specific focus on how these contracts impact income statement recognition. The 2023 filing also introduced a more structured presentation of fair value changes and settlements for these contracts, with amounts for both 2023 and 2022 now reported side-by-side in millions, indicating a more transparent and systematic approach to disclosing the financial effects of these instruments.",
      "llm_answer": "\nBetween 2022 and 2023 the company’s exposure to non‑designated foreign‑currency forwards fell sharply, cutting the earnings hit from these contracts from a $69 million loss in 2022 to only about a $7 million loss in 2023.  The reduction is reflected in the lower notional amounts of outstanding non‑designated currency derivatives (e.g., Hong‑Kong‑dollar exposure dropped from $4.3 bn to $1.8 bn) and a corresponding decline in the amount of gains/(losses) recorded in income under “Investment income and other,” indicating that UPS’s foreign‑exchange risk‑management strategy became less volatile and more reliant on designated or natural hedges.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and introduces specific numerical data not present in the original answer or ground truth. (1) The claim of a $69 million loss in 2022 and $7 million loss in 2023 is unsupported by the original answer, which does not provide any actual financial figures or losses related to undesignated foreign currency forward contracts. Similarly, the notional amounts of $4.3 billion and $1.8 billion for Hong-Kong-dollar exposure are fabricated and not mentioned in the ground truth. (2) There are no calculations or numbers in the original answer to verify against, but the LLM invents precise quantitative changes that do not appear in the source material, failing the quantitative accuracy test completely. (3) The reasoning is flawed: while the original answer notes an evolution in disclosure practices and transparency—particularly a more structured, side-by-side presentation of fair value changes—the LLM incorrectly interprets this as a reduction in exposure and earnings volatility due to decreased notional amounts. The original answer does not state or imply any reduction in the use of undesignated forwards, nor does it compare actual gains/losses between years. (4) The contextual relevance is moderate because the LLM addresses foreign currency risk management and earnings volatility, which are central themes. However, it fails to capture the actual evolution described—enhanced disclosure and structured reporting—and instead fabricates a narrative about reduced exposure and financial impact. The qualitative accuracy is low because the model misidentifies the nature of the change (from behavioral/strategic to presentational/disclosure-focused) and introduces incorrect entities (specific dollar losses, notional amounts, and line items like 'Investment income and other'). Overall, the answer is factually incorrect and misrepresents the evolution of UPS's strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 514,
        "total_tokens": 1894
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the role of the membership format in Costco's profitability strategy evolved between 2022 and 2023, particularly in terms of its impact on member loyalty and fee revenue?",
      "original_answer": "In 2022, the membership format was described as 'an integral part of our business and has a significant effect on our profitability,' with an emphasis on growth in the membership base, increasing Executive member penetration, and sustaining high renewal rates as key drivers of profitability. By 2023, the language evolved to underscore that the membership format 'is an integral part of our business and profitability,' indicating a more consolidated role in the company's financial model. Additionally, in 2023, Costco introduced a new concern about the potential adverse impact of lower renewal rates in newer markets on the worldwide renewal rate, which was not explicitly mentioned in 2022. This suggests that while the membership model remained central to profitability, the company faced emerging challenges in sustaining renewal rates as it expanded into newer markets.",
      "llm_answer": "\nBetween 2022 and 2023 the membership format remained the cornerstone of Costco’s profitability, but the way it generated fee revenue shifted.  In 2022 fee revenue rose 9 % to $4.224 billion, driven by new sign‑ups, Executive‑membership upgrades and an improving renewal rate, while in 2023 the same levers produced a more modest 5 % increase to $4.828 billion, with the company noting that growth in paid memberships may be dampened as more warehouses open in existing markets.  Thus, the strategy moved from aggressive base‑expansion toward extracting higher loyalty‑linked revenue from the existing member base, especially through Executive upgrades and sustained renewal rates.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. It claims that fee revenue increased from $4.224 billion in 2022 to $4.828 billion in 2023 (a 5% increase), but according to the ground truth and actual SEC filings, Costco's membership fee revenue was $4.101 billion in 2022 and $4.523 billion in 2023 — representing approximately a 10.3% increase, not 5%. The LLM's numbers are therefore factually incorrect, undermining the core of its analysis. (2) The calculation of percentage growth is also wrong: a rise from $4.224B to $4.828B would actually be about a 14.3% increase, not 5%, indicating internal inconsistency in the LLM's reasoning. Additionally, the claim that fee revenue rose 9% in 2022 is not supported by the ground truth, which does not provide percentage growth rates but emphasizes qualitative strategic shifts. (3) On qualitative reasoning, the LLM attempts multi-hop synthesis by linking membership growth, Executive upgrades, and renewal rates to profitability — which aligns with the general theme of the original answer. However, it misses the key evolution highlighted in the ground truth: the shift in language from 'significant effect on profitability' in 2022 to 'integral part of our business and profitability' in 2023, which reflects a deeper entrenchment of the membership model. More critically, the LLM fails to mention the new 2023 concern about lower renewal rates in newer markets affecting the worldwide renewal rate — a crucial strategic evolution. Instead, it fabricates a claim about growth being dampened in 'existing markets,' which contradicts the actual concern about 'newer markets.' (4) Despite these errors, the answer is contextually relevant, addressing the role of membership in profitability, fee revenue, loyalty, and strategic evolution. It correctly identifies Executive upgrades and renewals as key drivers. However, due to major quantitative inaccuracies and failure to capture the true strategic nuance from the filings, the correctness score is low. Quantitative accuracy is penalized heavily due to incorrect figures and miscalculations. Qualitative accuracy is moderate because the general direction of reasoning is plausible but not faithful to the source. Contextual relevance is high as the response stays on topic and addresses the core themes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 632,
        "total_tokens": 2029
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has NVIDIA's approach to CUDA evolved between 2022 and 2024, particularly in terms of its integration within the broader data center platform and software ecosystem?",
      "original_answer": "In 2022, CUDA was primarily positioned as a key component of NVIDIA's AI ecosystem, with nearly 3 million developers using CUDA and other software tools to deploy AI and accelerated computing technologies. It was described as central to NVIDIA's partnerships and developer programs, including the Deep Learning Institute and Inception program. By 2024, CUDA had evolved into a more deeply integrated part of a full-stack computing platform, specifically within the data center. It was described as the foundation of the CUDA-X collection of acceleration libraries, APIs, SDKs, and domain-specific frameworks, emphasizing its role in enabling end-to-end optimized computing across GPUs, CPUs, and DPUs. This reflects a strategic shift from promoting CUDA as a developer-focused tool to positioning it as a core infrastructure layer for enterprise-scale computing solutions.",
      "llm_answer": "\nBetween 2022 and 2024 NVIDIA expanded CUDA from a GPU‑only parallel programming model into the heart of a full‑stack data‑center platform, embedding it with new DPUs and CPUs (e.g., Grace), high‑speed networking, and the AI‑Enterprise software suite.  This integration lets CUDA‑accelerated AI workloads be delivered end‑to‑end—through Blackwell‑based appliances, DGX Cloud, and managed services—rather than as isolated GPU compute.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of CUDA between 2022 and 2024 as described in the ground truth. It correctly identifies the shift from a GPU-centric programming model to a full-stack data center platform, emphasizing integration with CPUs (e.g., Grace), DPUs, networking, and enterprise software (AI Enterprise). The mention of end-to-end delivery via Blackwell-based appliances and DGX Cloud aligns with NVIDIA's 2024 platform strategy. While the original answer highlights specific developer programs (Deep Learning Institute, Inception) and the 3 million developer milestone in 2022, the LLM omits these quantitative and programmatic details but still conveys the strategic shift accurately. No numeric inaccuracies are present—the answer avoids stating specific numbers not in the ground truth and does not fabricate statistics. The reasoning is sound, demonstrating correct multi-hop synthesis of CUDA’s evolution from a developer tool to an infrastructure layer. The semantic meaning matches the original answer closely, with only minor omissions of contextual details about developer programs and adoption metrics. Thus, the answer is factually correct, contextually relevant, and well-reasoned, warranting a high score with a small deduction for incompleteness on developer ecosystem specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 370,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has Pfizer's financial commitment and contractual obligations related to Paxlovid evolved from 2023 to 2024, particularly in terms of expected future revenue and product delivery timelines?",
      "original_answer": "In 2023, Pfizer had a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled Paxlovid from U.S. government inventory. By the end of 2024, Pfizer reported remaining performance obligations for Paxlovid at approximately $1 billion, with expected product delivery and revenue realization scheduled from 2025 through 2028, indicating a shift from uncertain returns and revenue reversals to a more defined forward-looking revenue outlook based on firm contracts.",
      "llm_answer": "\nBy the end of 2024 Pfizer had generated about $5.7 billion of Paxlovid revenue—down sharply from the $18.9 billion earned in 2022—and the company now expects only roughly $1 billion of remaining contracted revenue from future Paxlovid sales, to be recognized gradually from 2025 through 2028 under renegotiable long‑term supply agreements. This marks a transition from the large, near‑term government‑procurement (EUA) purchases of 2022‑23 to a commercial‑market model where deliveries are spread over the next few years rather than concentrated in bulk shipments.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $1 billion in remaining contracted revenue for Paxlovid and the 2025–2028 delivery timeline, which aligns with the ground truth. However, it introduces revenue figures ($5.7 billion in 2024 and $18.9 billion in 2022) that are not mentioned or implied in the original answer, making them factually unsupported in this context. The ground truth focuses on a $3.5 billion non-cash revenue reversal in Q4 2023 due to expected returns of 6.5 million treatment courses, which the LLM answer omits entirely. This is a significant factual gap, especially since the reversal explains the shift in financial commitment. (2) The $1 billion remaining performance obligation is accurately reported, as is the 2025–2028 revenue recognition window. However, the inclusion of $5.7B and $18.9B figures—while potentially true in broader context—are not part of the provided ground truth and thus introduce unverified data, reducing quantitative accuracy. There are no calculation errors per se, but the absence of the $3.5B reversal undermines completeness and factual alignment. (3) The reasoning about a transition from government EUA purchases to a commercial model is a reasonable interpretation and reflects sound qualitative synthesis. The model correctly infers a shift in business model and delivery structure, which is consistent with the ground truth’s emphasis on moving from uncertain returns to firm contracts. However, it fails to connect this shift to the specific 2023 non-cash reversal event, missing a key causal element. (4) The answer is contextually relevant and addresses the evolution of financial commitment and delivery timelines, but the omission of the $3.5B reversal and introduction of unsupported revenue totals reduce factual correctness. Scores reflect mostly correct direction and structure but with significant factual omissions and extraneous, unverified numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 522,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2022 and 2024, based on its disclosures around reserves development and advantaged asset reporting?",
      "original_answer": "In 2022, ExxonMobil reported that Guyana was a key contributor to extensions and discoveries, adding approximately 1.3 billion oil-equivalent barrels (GOEB) of proved undeveloped reserves. By 2024, Guyana was explicitly listed as one of the core 'Advantaged Assets' in the company's updated earnings drivers, signaling a strategic shift to highlight Guyana's role in driving earnings through volume growth. This evolution reflects a transition from Guyana being primarily a reserves growth region to being a recognized source of advantaged production and earnings visibility.",
      "llm_answer": "\nBetween 2022 and 2024 ExxonMobil moved Guyana from a peripheral offshore prospect to a core “advantaged asset” in its strategic portfolio.  The 2024 filing explicitly places Guyana in the same “advantaged assets” group as the Permian and LNG projects, and it is cited in the company’s earnings‑driver definitions as a source of future volume growth, indicating that capital and investment focus have been deliberately shifted toward developing its proved reserves and producing the offshore discoveries.  This emphasis is reinforced by ongoing reserve‑development activities that continue to add proved undeveloped barrels and aim to transition them to producing status, underscoring Guyana’s elevated strategic importance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, while the LLM does not repeat the specific 1.3 billion oil-equivalent barrels (GOEB) figure from 2022, it correctly references ongoing reserve development and growth in proved undeveloped reserves, which is consistent with the original answer. The absence of the exact number is a minor omission but does not introduce inaccuracy. (2) The LLM correctly identifies the strategic evolution: Guyana’s elevation to a core 'advantaged asset' by 2024, grouped with Permian and LNG projects, matches the ground truth’s claim about its inclusion in advantaged assets and earnings drivers. (3) The reasoning is sound—LLM synthesizes the shift from reserves growth to earnings-driven strategic emphasis, capturing the multi-hop logic across 2022 and 2024 disclosures. (4) Contextually, the answer is fully relevant, addressing both reserves development and advantaged asset reporting. The only reason for not scoring a 10 is the omission of the precise 1.3 billion BOE reserves addition in 2022, which is a factual detail present in the ground truth and expected for full completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 328,
        "total_tokens": 1658
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did the planned utilization of the ATR 72-600F aircraft evolve from 2022 to 2024, and what does this indicate about its role in the company's fleet strategy?",
      "original_answer": "In 2022, the ATR 72-600F was projected to have a decreasing role in the company's fleet, with planned units dropping from 11 in 2023 to just 1 by 2026. By 2024, however, the company's projections showed a shift, with ATR 72-600F units remaining steady at 7 for 2025 and declining only slightly to 3 by 2026. This indicates that while the aircraft was initially expected to phase out more rapidly, it continued to play a more sustained, albeit reduced, role in the fleet strategy.",
      "llm_answer": "\nFrom the 2022 filing the company had scheduled 6 ATR 72‑600F deliveries for 2024 (with a total of 24 such aircraft committed through 2026), but by the 2024 filing the plan had been trimmed to 3 aircraft for delivery in 2026 (and 7 for 2025), sharply reducing the overall ATR 72‑600F commitment. This pull‑back signals that FedEx is shifting its fleet strategy toward larger, more fuel‑efficient freighters—principally the B767F and B777F—while deprioritizing the smaller ATR 72‑600F for its regional package network.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and timeline. According to the ground truth, in 2022 the plan was for ATR 72-600F units to drop from 11 in 2023 to 1 by 2026. By 2024, this was revised to 7 units in 2025 and 3 in 2026. The LLM incorrectly states that 6 ATRs were scheduled for delivery in 2024 with 24 total committed through 2026 in the 2022 plan—this contradicts the ground truth which shows a reduction from 11 to 1, not a buildup to 24. The 2024 filing update correctly notes a reduction to 7 for 2025 and 3 for 2026, but the LLM misattributes this as a delivery plan of 3 in 2026 and 7 in 2025, reversing the intended meaning (7 units in 2025, not 7 deliveries in 2025 as new units). (2) Quantitative accuracy is low: the numbers 6, 24, and 3 in the LLM answer do not match the ground truth trajectory (11 → 1 originally; revised to 7 → 3). There is no mention of the 11-unit baseline in 2023 or the 1-unit projection by 2026 in the original plan. The claim of 24 committed aircraft through 2026 is entirely unsupported. (3) The reasoning partially captures a strategic shift but misrepresents the evolution. While the conclusion about deprioritizing the ATR 72-600F aligns with the ground truth, the LLM frames it as a shift toward B767F/B777F without grounding in the provided answer, which focuses on the sustained role despite reduction. The multi-hop synthesis fails because it draws on incorrect data points from both years. (4) Contextual relevance is high—the answer addresses fleet strategy evolution and attempts to interpret strategic intent. However, due to major quantitative errors and misrepresentation of the original and revised plans, the correctness score is low. The core message of reduced emphasis is partially valid, but the factual foundation is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 496,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has NVIDIA's approach to offering Omniverse evolved between 2022 and 2024, particularly in terms of its integration with other AI and simulation platforms?",
      "original_answer": "In 2022, NVIDIA Omniverse was primarily described as a virtual world simulation and collaboration platform for 3D workflows, available as a software subscription for enterprise use and free for individual use. It was highlighted as being integrated with VR and AR in enterprise applications such as virtual car showrooms and surgical training. By 2024, NVIDIA's offering of Omniverse had evolved into a more comprehensive development platform and operating system for building and running virtual world simulation applications. It was now emphasized as being used by industrial enterprises to digitalize complex physical assets and processes—such as building digital twins of factories and testing autonomous robots and vehicles—powered by NVIDIA's accelerated computing infrastructure both on-premises and in the cloud. This represents a shift from general 3D collaboration to a more specialized, enterprise-focused simulation and digital twin platform.",
      "llm_answer": "\nBetween 2022 and 2024 NVIDIA broadened Omniverse from a specialized industrial‑digital‑twin/simulation tool into a central hub of its AI‑accelerated platform.  The 2024 releases tied Omniverse directly to the AI Enterprise stack (NIM, NeMo, AI Blueprints) and to the Blackwell GPU architecture, added generative‑AI avatar services (ACE), and opened the environment to both enterprise subscriptions and a free‑tier, enabling synthetic‑data generation, digital‑twin creation and AI‑driven content across automotive, gaming, professional visualization and other domains.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements but misrepresents the evolution of NVIDIA's Omniverse between 2022 and 2024, reversing the direction of change and introducing unsupported details. (1) What was correct: The mention of digital twins, simulation, enterprise use, and integration with AI platforms aligns broadly with the 2024 positioning. The free tier and enterprise subscription model are correctly noted. (2) Quantitative accuracy: There are no numeric values to verify (e.g., dollar amounts, percentages), so this aspect is neutral; no factual errors in dates (2022–2024) are present. (3) Multi-hop reasoning assessment: The reasoning is flawed—the original answer states that in 2022, Omniverse was already available for enterprise and individual use and focused on 3D collaboration, and by 2024 evolved into a more specialized industrial simulation and digital twin platform. The LLM incorrectly claims that in 2022 it was a 'specialized industrial-digital-twin/simulation tool' and then broadened into a 'central hub,' which reverses the actual trajectory. This is a significant factual error in synthesis. Additionally, specific claims like integration with 'Blackwell GPU architecture' and 'NIM, NeMo, AI Blueprints' are not present in the ground truth and cannot be verified from the provided context—these may be plausible but are unsupported. The addition of 'generative-AI avatar services (ACE)' and 'synthetic-data generation' goes beyond the scope of the original answer. (4) Justification for scores: Correctness is scored 6 because core themes (digital twins, enterprise use) are present, but the directional evolution is incorrect and unsupported technical details are added. Quantitative accuracy is 10 because no numbers are misstated. Qualitative accuracy is low (5) due to incorrect reasoning and entity relationships. Contextual relevance is 8 because the answer addresses the right topic and timeframe, even if inaccurately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 526,
        "total_tokens": 1909
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has the role of Google Play in generating non-advertising revenue evolved between 2022 and 2023?",
      "original_answer": "In 2022, Google Play was introduced as part of the company's broader strategy to expand non-advertising revenues, specifically through the sales of apps, in-app purchases, and digital content. By 2023, Google Play had transitioned into a more defined revenue stream under 'platforms,' where it was explicitly tied to revenues from app sales and in-app purchases. This evolution indicates a strategic shift toward solidifying Google Play’s role as a key monetization platform rather than just a component of diversification. The change reflects a more structured categorization and likely a stronger contribution to revenue stability within the ecosystem.",
      "llm_answer": "\nBetween 2022 and 2023 the share of Google Play in Alphabet’s non‑advertising revenue expanded noticeably.  The company’s overall Google Services revenue rose 8 % (an additional $19 billion), and the filing repeatedly notes that “non‑advertising revenues—including sales of apps and in‑app purchases from Google Play—are growing and now represent a larger portion of total revenue.”  While exact dollar figures for Google Play are not disclosed, the upward trend in Google Services and the emphasis on expanding “platforms” such as Google Play show that its contribution to non‑advertising revenue increased materially from 2022 to 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. It claims Google Services revenue rose by $19 billion (8%), but this figure is not supported by the original answer or typical SEC filing data for that period—this specific number cannot be verified and appears fabricated or misattributed. The original answer does not provide any dollar amounts or percentages, so introducing such figures reduces factual accuracy. (2) While the original answer discusses a strategic evolution in how Google Play is categorized and emphasized—from a diversification effort in 2022 to a more defined 'platforms' revenue stream in 2023—the LLM shifts focus to unsupported numerical growth, which distorts the nature of the evolution. (3) The qualitative reasoning is partially sound: the LLM correctly identifies that Google Play contributes to non-advertising revenue via app sales and in-app purchases and notes an increased strategic emphasis. It also correctly infers that Google Play’s role expanded, aligning with the original answer’s theme of growing importance and structural recognition. However, it fails to capture the key nuance of a 'strategic shift toward solidifying Google Play’s role as a key monetization platform' and the change in reporting/categorization, which is central to the original answer. (4) Contextually, the response is relevant and addresses the evolution of Google Play’s role in non-advertising revenue. Despite incorrect numbers, the direction of reasoning—increased importance and contribution—is consistent with the ground truth. The answer would score higher if it avoided unsupported quantification and instead focused on structural and strategic changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 465,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has AIG's use of expected loss ratio methods in workers' compensation reserving evolved between 2022 and 2023, particularly in relation to guaranteed cost and excess of deductible business?",
      "original_answer": "In 2022, AIG generally gave significant weight to expected loss ratio methods for guaranteed cost business only in the most recent accident year, while for excess of deductible business, these methods were given significant weight in the most recent five accident years. The company also noted that changes in claims strategy and loss mitigation efforts were accelerating settlements, increasing paid losses along the latest diagonals. In 2023, the reserving methodology remained broadly consistent, with AIG continuing to use a combination of loss development, frequency/severity, and expected loss ratio methods. However, the 2023 filing emphasized that incurred and paid losses were now presented net of reinsurance and undiscounted, which may reflect a refinement in reporting transparency rather than a change in reserving philosophy. Additionally, the increased proportion of large deductible business continued to slow the reporting pattern of claims in 2023, consistent with the trend noted in 2022.",
      "llm_answer": "\nBetween 2022 and 2023 AIG shifted more of the workers‑compensation reserve weight toward the Expected‑Loss‑Ratio (ELR) technique for the excess‑of‑deductible segment—reflecting the growing share of large‑deductible policies and the slower claim‑development pattern—while still limiting ELR to the most recent accident year for guaranteed‑cost business.  In the 2023 filing the company explicitly noted that ELR inputs for excess‑of‑deductible lines were given “significant weight in the most recent five accident years” and that the selected loss‑ratio estimates were now adjusted for recent inflation, rate changes and market‑condition trends, whereas for guaranteed‑cost business the method remained confined to the latest year but was refined with the same trend‑adjusted inputs.  This evolution reflects a deliberate increase in the weighting and sophistication of ELR estimates for excess‑of‑deductible business, with a consistent but refined approach for guaranteed‑cost business.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general trend in AIG's reserving methodology evolution but introduces inaccuracies and unsupported details not present in the ground truth. (1) Correct elements: The answer correctly identifies that in 2022, expected loss ratio (ELR) methods were given significant weight for guaranteed cost business only in the most recent accident year, and for excess of deductible business in the most recent five accident years. It also correctly notes the continued importance of ELR in 2023 for excess of deductible business and the slower claim development due to large deductible policies. (2) Quantitative accuracy: While no explicit numbers (e.g., percentages, dollar amounts) are incorrect, the answer fabricates specific enhancements—such as ELR inputs being 'adjusted for recent inflation, rate changes and market-condition trends'—which are not mentioned in the original answer. These represent unsupported additions that affect factual reliability. (3) Multi-hop reasoning: The model synthesizes across years and business lines appropriately, but incorrectly implies a 'shift' or 'evolution' toward greater ELR use in 2023, whereas the ground truth states the methodology 'remained broadly consistent.' This misrepresents the core conclusion. (4) The original answer emphasizes reporting changes (net of reinsurance, undiscounted) and transparency, which the LLM omits entirely, instead inventing methodological refinements. Thus, while contextually relevant and partially accurate, the answer overstates changes and introduces speculative details, reducing correctness. Qualitative accuracy is moderate due to correct entity and time period identification but flawed reasoning about change over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1510,
        "completion_tokens": 468,
        "total_tokens": 1978
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has Cisco's product category segmentation evolved between fiscal 2022 and fiscal 2024, particularly in relation to the Collaboration category?",
      "original_answer": "In fiscal 2022, Cisco introduced a product revenue segmentation that included 'Collaboration' as one of six distinct categories, which also included Secure, Agile Networks; Internet for the Future; End-to-End Security; Optimized Application Experiences; and Other Products. By fiscal 2024, Cisco restructured its product categories into four main areas, retaining 'Collaboration' but now grouping it alongside Networking, Security, and a new category called Observability. This indicates a consolidation and realignment of product offerings, with the introduction of Observability as a distinct area and the removal or reclassification of Optimized Application Experiences and Internet for the Future.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Cisco reshaped its product‑category structure: the 2022 reporting used six groups (“Secure Agile Networks,” “Internet for the Future,” “Collaboration,” “End‑to‑End Security,” “Optimized Application Experiences,” and “Other Products”), while beginning in fiscal 2024 it consolidated the portfolio into four broader categories—Networking, Security, Collaboration, and Observability—aligning the taxonomy with its strategic priorities. The Collaboration category remains a distinct segment, but its revenue trajectory shifted: it fell 9 % in fiscal 2023 (driven by weakness in Collaboration Devices and Meetings) before modestly rebounding with a 2 % increase in fiscal 2024, reflecting growth in Calling, Contact‑Center and other Collaboration‑suite offerings despite ongoing softness in Meetings.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the evolution in Cisco's product category segmentation between fiscal 2022 and 2024, noting the shift from six categories to four and the retention of 'Collaboration' as a distinct segment. It accurately names the 2022 categories and correctly reports the 2024 consolidation into Networking, Security, Collaboration, and the newly introduced Observability. This demonstrates sound qualitative understanding and correct multi-hop synthesis of structural changes. However, the answer introduces quantitative claims not present in the original ground truth: specifically, the 9% decline in Collaboration revenue in fiscal 2023 and the 2% increase in fiscal 2024. These figures, while plausible, are not supported by the provided ground truth and represent a significant addition of unverified data. Since the question focuses on structural segmentation changes—not financial performance—these numerical details are extraneous and factually unsupported in this context, undermining quantitative accuracy. The core structural evolution is correctly conveyed (semantic equivalence on the main point), but the inclusion of unsupported financial metrics reduces overall correctness. Contextual relevance is high as the response directly addresses the question’s focus on category evolution, with Collaboration as a key element.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 374,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has Amgen's disclosure regarding the 3.125% 2025 Notes evolved from 2022 to 2023 in terms of financial presentation and associated interest rate framework?",
      "original_answer": "In 2022, Amgen reported a carrying value of $1,000 million for the 3.125% 2025 Notes within its debt table, but no specific interest rate framework was disclosed. By 2023, Amgen included the 3.125% 2025 Notes in a new table that explicitly outlined the interest rate mechanism, identifying it as SOFR + 2.1%. This evolution reflects a shift from a purely quantitative disclosure in 2022 to a more detailed qualitative and quantitative presentation in 2023, including the interest rate benchmark and spread.",
      "llm_answer": "\nFrom 2022 to 2023 Amgen stopped presenting the 3.125% 2025 Notes as a stand‑alone line in the debt‑maturity schedule; the series is now rolled into the aggregate long‑term‑debt balance, with its carrying amount shown only as part of the total $63‑$64 bn debt figure.  At the same time the interest‑rate framework was updated: the 2022 filing disclosed an effective LIBOR + 1.8% rate (after swaps) and a $19 million AOCI reclassification expense, whereas the 2023 filing reports an effective SOFR + 2.1% rate (with a $1 bn notional swap) and a reduced AOCI reclassification expense of $6 million.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents key aspects of Amgen's disclosures. (1) Quantitative Accuracy: The LLM claims the 3.125% 2025 Notes were rolled into an aggregate debt figure of $63–64 billion, which contradicts the ground truth stating a specific carrying value of $1,000 million was reported in 2022. No such aggregate figure or elimination of the line item is supported by the ground truth. The LLM invents a LIBOR + 1.8% rate in 2022, which is not mentioned in the original answer—instead, the ground truth states no interest rate framework was disclosed in 2022. The $19 million and $6 million AOCI reclassification expenses are fabricated and not in the original. The $1 billion notional swap is also unverified. (2) Completeness: While the LLM correctly identifies the 2023 SOFR + 2.1% rate, it incorrectly asserts a change from LIBOR + 1.8%, failing to acknowledge that no rate framework was disclosed in 2022 per the ground truth. (3) Entity Accuracy: The company (Amgen) and the 3.125% 2025 Notes are correctly identified, and the years 2022 and 2023 are accurate. (4) Reasoning: The multi-hop reasoning is flawed—the LLM incorrectly infers a shift from LIBOR to SOFR when the ground truth indicates no rate framework was disclosed in 2022, making the comparison invalid. The conclusion about presentation changes is unsupported. (5) Semantic Equivalence: The overall message is not equivalent—the ground truth describes increased transparency, while the LLM describes consolidation and rate changes not in the original. The only correct element is the 2023 SOFR + 2.1% disclosure, but even this is embedded in an incorrect narrative. Thus, the answer is mostly incorrect with major factual and reasoning errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 477,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2022 to 2024, and what does this indicate about the company's strategic positioning in that geographic area?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure had decreased to 296 billion cubic feet. This indicates a reduction in the company's natural gas holdings in the region over the two-year period, suggesting a potential strategic shift or divestment in that geographic area.",
      "llm_answer": "\nFrom the end of 2022 to the end of 2024 ConocoPhillips’ reported natural‑gas reserves in the Asia Pacific/Middle East fell from **≈326 billion cubic feet (BCF)** to **≈312 BCF** in 2023 and further to **≈296 BCF** in 2024—a decline of roughly **30 BCF (≈9 %)**.  The drop reflects downward price‑related revisions and cost assumptions in that region, even though modest reserve additions came from extensions and discoveries in the Middle East via equity affiliates; the net result is a clear scaling‑back of the company’s focus on the Asia Pacific/Middle East and a re‑allocation of capital toward higher‑return basins such as the Lower 48 and Canada.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2022 (326 BCF) and 2024 (296 BCF) reserve figures from the ground truth, which are accurate. However, it introduces an intermediate 2023 value of 312 BCF that is not present in the original answer or supported by the provided ground truth, making this an unsupported addition. The claimed 30 BCF (≈9%) decline is directionally reasonable (actual drop is 30 BCF, from 326 to 296), so the magnitude of change is correct, but attributing part of the drop to 2023 is speculative without data. (2) The calculation of the total decrease (326 to 296 = 30 BCF) is accurate, but the breakdown across years assumes data not in the ground truth. The percentage decline is approximately correct (30/326 ≈ 9.2%), so minor rounding is acceptable. (3) The reasoning about strategic re-allocation to Lower 48 and Canada, while plausible and consistent with industry trends, goes beyond the original answer’s more cautious 'potential strategic shift or divestment' and adds explanatory detail (e.g., price-related revisions, equity affiliate discoveries) not present in the ground truth. While logically sound, these represent inference beyond the provided facts. (4) Despite the added details, the core multi-hop synthesis — identifying the decline in reserves over time and linking it to strategic positioning — is valid and well-executed. The entities (COP, Asia Pacific/Middle East, natural gas reserves, correct years) are accurate. The answer is highly relevant and addresses both parts of the question. However, the inclusion of unsupported intermediate data (2023 reserves) and over-explained causality reduces quantitative and qualitative accuracy slightly. Correctness score is 7 because key facts and trend are correct, but unverified details reduce precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 491,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did the repurchase activity of Class C Capital Stock by Alphabet change between 2022 and 2023, and what does this indicate about the company's capital allocation strategy?",
      "original_answer": "In 2022, Alphabet repurchased $59.3 billion of Class A and Class C shares, while in 2023, the repurchase amount increased to $62.2 billion. Additionally, in April 2023, the Board authorized an additional $70.0 billion for share repurchases, with $36.3 billion remaining available as of December 31, 2023. This indicates a continued and expanding emphasis on returning capital to shareholders through share repurchases, with a notable increase in the scale of buybacks year-over-year.",
      "llm_answer": "\nBetween 2022 and 2023 Alphabet’s share‑repurchase program expanded: it bought back a total of **$62.2 billion** of Class A and Class C shares in 2023 versus **$59.3 billion** in 2022 – an increase of roughly **$2.9 billion**.  The Class C component rose slightly from about **$52.58 billion** to **$52.87 billion** (shares repurchased fell a bit, but the dollar amount grew), and the company added a fresh $70 billion authorization in April 2023, leaving $36.3 billion of that authority unused at year‑end 2023.  This uptick signals that Alphabet is accelerating its capital‑return strategy, using a larger share of its cash flow to retire stock and support the share price, reflecting confidence in its cash generation and a preference for equity‑based capital allocation over other investments.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the total repurchase amounts for 2022 ($59.3 billion) and 2023 ($62.2 billion), as well as the additional $70.0 billion authorization in April 2023 and the $36.3 billion remaining at year-end 2023 — all of which match the ground truth. However, the LLM introduces a breakdown of Class C repurchases at $52.58 billion in 2022 and $52.87 billion in 2023, which is not present in the original answer and cannot be verified from the provided ground truth. This suggests the model fabricated granular data not supported by the source, undermining quantitative accuracy. (2) The calculation of the year-over-year increase ($2.9 billion) is correct based on $62.2B - $59.3B. But the Class C-specific figures are unsupported and likely incorrect, as the original answer does not separate Class A and Class C repurchases. (3) The multi-hop reasoning is sound in recognizing the trend of increasing buybacks and linking it to capital allocation strategy, including the new authorization and remaining capacity. The conclusion about Alphabet’s confidence and preference for equity-based capital return aligns with the original interpretation. (4) Despite the hallucinated Class C breakdown, the core facts — total repurchase growth, new authorization, remaining availability — are accurate, and the overall strategic interpretation is valid. Hence, correctness is reduced due to unsupported specifics, but not severely because the main narrative holds. Quantitative accuracy is penalized more due to the invented figures, while qualitative reasoning and relevance remain strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 443,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has AIG's use of frequency/severity methods evolved between 2022 and 2023, particularly in terms of the lines of business where they are applied and the reasoning behind their usage?",
      "original_answer": "In 2022, AIG primarily used frequency/severity methods for short-tail classes such as U.S. Property, and explicitly avoided using them for aviation exposures due to the high severity and varying mix of claims year to year. By 2023, AIG expanded the application of frequency/severity methods to include U.S. Workers' Compensation, a long-tail line of business, as part of a combination of methods that also included loss development and expected loss ratio methods. This reflects a strategic shift toward using frequency/severity methods in more complex, long-tail environments, especially where risk-sharing features and large deductible business have increased.",
      "llm_answer": "\nBetween the 2022 and 2023 10‑K filings AIG retained frequency/severity reserving for its short‑tail lines—principally U.S. Property, Special‑Risk and program business—to estimate reserves for low‑frequency, high‑severity losses and to adjust for inflation, rate changes and emerging claim trends. In the 2023 filing the company narrowed the explicit reference to these methods to workers’‑compensation and certain liability subsets, explaining that they are used when loss emergence is slow and that high‑severity lines such as aviation are now handled with expected‑loss‑ratio and development techniques rather than frequency/severity approaches.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains some correct elements but introduces significant inaccuracies in the evolution of AIG's use of frequency/severity methods between 2022 and 2023. While it correctly notes that frequency/severity methods were used in short-tail lines like U.S. Property in 2022, it misrepresents the 2023 developments. The original answer states that AIG *expanded* the use of frequency/severity methods to include U.S. Workers' Compensation—a long-tail line—in 2023. However, the LLM answer incorrectly suggests that in 2023, AIG *narrowed* the use of these methods and applied them only to workers’ compensation and 'certain liability subsets,' which contradicts the direction of change. Furthermore, the LLM claims that high-severity lines like aviation are now handled with expected loss ratio and development techniques—while consistent with 2022 practice—fails to clarify that this was already the case in 2022 and does not reflect a 2023 change. (2) There are no numeric values in the response, so quantitative accuracy is not applicable; however, all mentioned years (2022, 2023) and business lines (U.S. Property, Workers' Compensation, aviation) are factually correct in name and context, hence full score on quantitative accuracy. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the directional shift (expansion vs. narrowing) in method application from 2022 to 2023, which is central to the question. It also omits the key rationale provided in the original answer—increased use in long-tail lines due to risk-sharing features and large deductible business. (4) Correctness is scored at 5 due to partial factual alignment but major errors in the core evolution narrative. Qualitative accuracy is low due to incorrect reasoning and omission of key strategic shift. Contextual relevance is high as the answer addresses the right topic, companies, and general methodology trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 523,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has Amgen's financial relationship with BeiGene evolved from 2022 to 2023, particularly in terms of cost recovery, product sales, and profit and loss sharing?",
      "original_answer": "In 2022, Amgen recovered $199 million in R&D costs from BeiGene, recorded product sales of $64 million, and recognized $53 million in profit and loss sharing expenses. In 2023, these figures changed to $109 million in cost recovery, $125 million in product sales, and $40 million in profit and loss sharing expenses. This indicates a decrease in cost recovery and profit-sharing expenses, but a significant increase in product sales to BeiGene. The shift suggests a maturation of the collaboration, with more product sales occurring in 2023, while the level of R&D cost sharing declined.",
      "llm_answer": "\nFrom 2022 to 2023 Amgen’s collaboration with BeiGene shifted markedly: cost recoveries fell sharply to **$109 million in 2023** (down from **$199 million in 2022**), while product sales to BeiGene rose to **$125 million** (up from **$64 million**).  Accordingly, the profit‑and‑loss‑sharing expense that Amgen records fell to **$40 million** (versus **$53 million** the prior year), and the net amounts receivable from BeiGene for cost recoveries and P&L sharing grew to **$44–$47 million** by year‑end 2023.  This reflects a move from a period of heavy shared costs and modest sales toward higher sales volumes and lower shared expense outlays, with Amgen now paying royalties to BeiGene on Chinese sales once product rights revert.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures from the ground truth: cost recovery decreased from $199 million in 2022 to $109 million in 2023, product sales increased from $64 million to $125 million, and profit and loss sharing expenses decreased from $53 million to $40 million. These numbers are accurately presented with correct years and values, satisfying quantitative accuracy. (2) The only minor discrepancy is the introduction of an additional detail—'net amounts receivable from BeiGene for cost recoveries and P&L sharing grew to $44–$47 million by year-end 2023'—which is not present in the original answer and cannot be verified from the provided ground truth. This does not contradict the data but adds unconfirmed synthesis. Additionally, the mention that 'Amgen now paying royalties to BeiGene on Chinese sales once product rights revert' introduces forward-looking or structural details not supported in the original answer, slightly affecting qualitative accuracy. (3) The multi-hop reasoning is sound: the model correctly identifies the trend across cost recovery, product sales, and P&L sharing, and infers a maturation of the collaboration, which aligns with the original conclusion. The synthesis across years and financial categories is logical and well-structured. (4) Contextual relevance is high—the response directly addresses all components of the question (cost recovery, product sales, profit and loss sharing) and provides a coherent interpretation of the evolution from 2022 to 2023. Overall, the answer is factually correct on all verifiable numbers and delivers a meaningful, well-reasoned summary, meriting a correctness score of 9 due to the minor addition of unverified details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 475,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2022 to 2024, and what specific changes occurred in terms of revisions, production, and purchases during this period?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure decreased slightly to 296 billion cubic feet. During this period, revisions in 2023 added 9 billion cubic feet, but production subtracted 25 billion cubic feet in 2024. Additionally, there were no purchases reported directly affecting this region in 2024, indicating a reduction in active reserve growth strategies compared to earlier years.",
      "llm_answer": "\nFrom the end of 2022 to the end of 2024, proved natural‑gas reserves in the Asia Pacific/Middle East region fell from 326 bcf to 312 bcf to 296 bcf. The decline reflects net downward revisions—particularly a 2 bcf downward revision in consolidated reserves in 2024 and a roughly 26 bcf net downward revision in equity‑affiliate reserves due to lower prices—while production stayed essentially flat at about 25 bcf per year and purchases were essentially nil in this region.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. While the starting (326 bcf in 2022) and ending (296 bcf in 2024) reserve figures match the ground truth, the LLM incorrectly states reserves were 312 bcf in 2023, which is not supported by the original answer—no 2023 total is provided in the ground truth. More critically, the LLM claims a 2 bcf downward revision in 2024 and a 26 bcf net downward revision in equity-affiliate reserves due to lower prices, which directly contradicts the ground truth stating a 9 bcf *addition* from revisions in 2023. The production figure of ~25 bcf/year is directionally close to the 25 bcf subtracted in 2024, but the LLM frames it as flat over the period, which lacks support. Purchases are correctly noted as negligible. (2) Quantitative accuracy is low: the 9 bcf revision (positive) is misrepresented as large downward revisions (totaling ~28 bcf), reversing the direction of change. The 2023 reserve level (312 bcf) is fabricated. (3) Multi-hop reasoning is partially sound—the model attempts to explain changes via revisions, production, and purchases—but the synthesis is flawed due to incorrect data integration, especially around the nature and timing of revisions. (4) Contextual relevance is high as the answer addresses all components of the question (evolution, revisions, production, purchases) and focuses on the correct company (COP), region, and time frame. However, the factual errors severely undermine correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 416,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did FedEx's planned usage of the B767F aircraft evolve from 2022 to 2024, and what does this indicate about its strategic fleet planning?",
      "original_answer": "In 2022, FedEx projected using 14 B767F aircraft in both 2023 and 2024, with a planned reduction to 10 by 2025. By 2024, the projections had changed, showing a decrease to 11 B767F aircraft for 2025 and only 3 by 2026. This indicates a strategic shift toward a more accelerated reduction in the planned use of B767F aircraft, reducing reliance on this model over time.",
      "llm_answer": "\nFrom 2022 to 2024 FedEx’s B767F delivery schedule moved from 14 aircraft slated for 2023, 14 for 2024 and 10 for 2025 (total 38 over 2023‑2025) to a revised plan that calls for only 11 B767Fs in 2025 and 3 in 2026, effectively postponing the remaining 14 aircraft that were previously expected by 2025.  This shift shows that FedEx is using the B767F as a transitional, fuel‑more‑efficient type while it prioritizes newer, higher‑capacity B777F deliveries and delays additional capacity until market demand and cash‑flow considerations justify it, reflecting a more disciplined, long‑term fleet‑modernization strategy rather than rapid expansion.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the shift in FedEx's B767F projections from 14 aircraft planned for 2023–2024 in the 2022 outlook, with a reduction to 10 by 2025, and then the revised 2024 plan showing 11 for 2025 and 3 for 2026. However, the LLM incorrectly states that 14 aircraft were 'slated for 2023' and '14 for 2024' as if those were deliveries in those years, while the original answer frames it as projected usage, not delivery schedule. The total of 38 over 2023–2025 is not supported by the ground truth, which only specifies usage levels per year, not cumulative deliveries. This misrepresents the nature of the data (usage vs. delivery). (2) The numbers themselves (14, 14, 10, 11, 3) are consistent with the ground truth in magnitude and year, but the interpretation as a 'delivery schedule' and the derived total of 38 is an unsupported calculation. The ground truth does not mention deliveries or cumulative totals. (3) The multi-hop reasoning is sound in identifying a strategic shift toward accelerated reduction, and the qualitative interpretation about transitioning to B777Fs and delaying capacity due to demand and cash flow is reasonable and adds insight beyond the ground truth. However, the original answer does not mention B777F prioritization or cash-flow reasoning, so this is an inference not present in the source. While plausible, it goes beyond the provided data. (4) The contextual relevance is high as it directly addresses the evolution and strategic implications. Quantitative accuracy is docked due to the incorrect framing of usage as deliveries and the unsupported sum. Qualitative accuracy is strong but not perfect due to added speculation. Correctness score reflects mostly accurate facts with minor but notable misrepresentations in data type and unsupported calculations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 495,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did AIG's use of Expected Loss Ratio Methods evolve between 2022 and 2023, particularly in terms of the lines of business and the reasoning behind their application?",
      "original_answer": "In 2022, AIG used Expected Loss Ratio Methods primarily for the latest accident year and in combination with other methods like loss development for aviation exposures, due to the high severity nature of claims and varying mix across years. By 2023, AIG applied Expected Loss Ratio Methods more broadly, particularly in U.S. Workers' Compensation, a long-tail line of business, where they used a combination of methods including Expected Loss Ratio, to account for extended loss emergence periods and complex risk-sharing features in policies. This reflects a shift from a focus on short-term forecasting in high-severity contexts to a broader application in long-tail, structurally complex lines.",
      "llm_answer": "\nBetween 2022 and 2023 AIG kept the Expected‑Loss‑Ratio (ELR) approach as its primary tool for the longest‑tail, high‑attachment lines—especially U.S. Excess Casualty, U.S. Workers’ Compensation, U.S. Other Casualty and U.S. Financial Lines—because those businesses show slow, irregular loss development and often lack sufficient historical loss data.  In 2023 the company placed even greater weight on ELR for the most recent accident years, adjusting older loss‑ratio estimates for inflation, rate changes and emerging market conditions, and it increasingly used the ELR‑based Bornhuetter‑Ferguson and Cape‑Cod hybrids to blend premium‑based projections with development‑based factors where data were sparse or reinsurance limited visibility.  This evolution reflects AIG’s need to rely on ELR when loss‑development patterns are inconsistent, when claims emerge very slowly, or when the underlying primary policies are held by other carriers, ensuring a more reliable estimate of ultimate losses for those lines.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually plausible and uses correct terminology, but diverges significantly from the ground truth in key aspects of AIG's use of Expected Loss Ratio (ELR) methods between 2022 and 2023. (1) Correct elements: The answer correctly identifies ELR as a method used in long-tail lines like U.S. Workers' Compensation and mentions appropriate hybrid methods (Bornhuetter-Ferguson, Cape Cod), which aligns with the general actuarial practices. It also correctly notes that ELR is used when loss development is slow or data is sparse. (2) Quantitative accuracy: There are no specific numbers (percentages, dollar amounts) in either the original or LLM answer, so no numeric inaccuracies exist—this aspect is neutral but does not detract. (3) Multi-hop reasoning assessment: The LLM incorrectly states that ELR was already the 'primary tool' in 2022 for long-tail lines like U.S. Workers' Compensation, whereas the ground truth specifies that in 2022, ELR was primarily used for the latest accident year and in aviation (a high-severity context), not broadly in Workers' Comp. The evolution described in the LLM answer—increased reliance in 2023 on ELR for recent accident years with inflation adjustments—while reasonable, is not supported by the ground truth, which emphasizes a shift from short-term, high-severity applications (aviation) to broader use in structurally complex, long-tail lines like Workers' Comp. (4) The LLM introduces U.S. Excess Casualty, U.S. Other Casualty, and U.S. Financial Lines as primary applications without grounding in the original answer, which does not mention these. This overgeneralization and misattribution of the timeline and scope reduce qualitative accuracy. While the reasoning about ELR’s utility in data-sparse or reinsurance-obscured environments is sound, it does not reflect the actual evolution described in the ground truth. Thus, the answer is partially correct but contains significant factual misstatements about the lines of business and the nature of the evolution, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1433,
        "completion_tokens": 554,
        "total_tokens": 1988
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has Cisco's positioning around Enterprise Data Center Transformation evolved between 2022 and 2024, particularly in relation to its strategic alliances and competitive landscape?",
      "original_answer": "In 2022, Cisco highlighted that the enterprise data center was undergoing a fundamental transformation due to the convergence of technologies like computing, networking, storage, and software, with strategic alliance partners sometimes acquiring or aligning with competitors, reducing business with Cisco. By 2024, Cisco continued to emphasize this transformation but expanded its focus on strategic alliances aimed at industry advancement and new market creation, while also updating its competitive landscape to include new entrants like Nvidia Corporation, signaling a shift in market dynamics and alliance strategies.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Cisco moved from describing the enterprise data‑center as a “fundamental transformation” that threatens its traditional hardware business to framing that transformation as an opportunity to co‑develop outcomes with strategic partners.  In 2022 the focus was on the risk that alliance partners could become competitors as the data‑center converged; by 2024 Cisco’s messaging emphasizes joint technology‑exchange, co‑development and expanded alliances (e.g., with cloud, security and observability firms) to deliver end‑to‑end solutions, while competing against hyperscale vendors and niche disruptors on the basis of integrated outcomes, price‑performance and ecosystem breadth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and semantically equivalent to the ground truth. (1) It correctly captures Cisco's evolving positioning from 2022 to 2024: in 2022, the transformation was framed as a risk due to convergence and partner realignments threatening Cisco's hardware business; by 2024, Cisco reframed it as an opportunity through co-development and expanded alliances. This aligns with the original answer’s emphasis on shifting alliance strategies and competitive dynamics. (2) There are no numeric values, dates, or financial figures in dispute—fiscal years 2022 and 2024 are correctly used, and no calculations are required. (3) The multi-hop reasoning is sound: the LLM synthesizes Cisco’s changing narrative around data center transformation, strategic alliances, and competitive threats across time. It correctly infers that partners becoming competitors was a 2022 concern and that by 2024, Cisco emphasized joint development and broader ecosystems. The mention of new competitors like hyperscalers and niche disruptors aligns with the introduction of Nvidia as a new entrant in the competitive landscape. (4) The only minor gap is that the LLM does not explicitly name Nvidia Corporation as a new entrant, which is specified in the original answer. However, referencing 'niche disruptors' and shifting competitive dynamics implies this evolution. Wording differs but meaning is substantively consistent. Thus, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning with near-perfect completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 427,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did the effective interest rate and notional amount associated with the 3.125% 2025 Notes evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 3.125% 2025 Notes were part of a $5.2 billion principal amount on which new interest rate swaps were entered into after the termination of previous swaps, indicating a dynamic hedging strategy due to low interest rates. By 2023, the notional amount of the 3.125% 2025 Notes under interest rate swaps had decreased to $1.0 billion, with an effective interest rate of SOFR + 2.1%. This reflects a reduction in the hedged notional exposure and a shift in the interest rate environment.",
      "llm_answer": "\nBetween 2022 and 2023 the 3.125 % 2025 Notes kept the same outstanding notional amount of **$1 billion** (the $1,000 million figure that appears in the 2022 and 2023 disclosures).  However, the effective interest rate on that tranche was reset: in 2022 the notes were swapped to a **LIBOR + 1.8 %** benchmark, while by the end of 2023 they were swapped to a **SOFR + 2.1 %** benchmark, reflecting the market‑wide transition from LIBOR to SOFR and a modest increase in the spread.  Consequently, the notional stayed constant at $1 bn, but the effective rate rose from roughly LIBOR + 1.8 % to SOFR + 2.1 %.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors in both quantitative and qualitative aspects. (1) QUANTITATIVE INACCURACY: The LLM claims the notional amount was constant at $1 billion in both 2022 and 2023, but the ground truth states that in 2022 the notional was part of a $5.2 billion principal amount, which decreased to $1.0 billion in 2023. This is a major error in financial magnitude and trend. The LLM incorrectly asserts no change in notional, while the core of the evolution is the reduction from $5.2B to $1.0B. (2) INTEREST RATE BENCHMARK ERROR: The LLM states that in 2022 the effective rate was LIBOR + 1.8%, but the original answer does not specify the 2022 effective rate or benchmark—only that new swaps were entered due to low rates. The mention of LIBOR + 1.8% is unsupported by the ground truth and introduces fabricated data. The 2023 rate (SOFR + 2.1%) is correctly reported. (3) REASONING FLAW: The LLM fails to capture the multi-hop evolution—specifically, the reduction in hedged exposure from $5.2B to $1.0B as a strategic shift. Instead, it invents a false narrative of constant notional and a LIBOR-to-SOFR transition with a spread increase, which is not supported. While the SOFR shift context is plausible (market-wide), the specific LIBOR + 1.8% figure and constant notional are incorrect. (4) CONTEXTUAL RELEVANCE: The answer is relevant in structure and attempts to address rate and notional changes, but the factual foundation is flawed. Due to major errors in numbers and unsupported assertions, the correctness score is low despite some surface-level plausibility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 437,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has Cisco's strategic positioning of AppDynamics within its product portfolio evolved from 2022 to 2024, particularly in terms of its emphasis within observability offerings?",
      "original_answer": "In 2022, Cisco explicitly introduced AppDynamics as a key component of its full-stack observability strategy, positioning it alongside Intersight and ThousandEyes to provide application performance monitoring capabilities. However, by 2024, Cisco restructured its product revenue reporting to include a new category called 'Observability,' which subsumed offerings like AppDynamics. This shift indicates a more formalized and integrated strategic emphasis on observability as a standalone pillar within Cisco's broader portfolio.",
      "llm_answer": "\nFrom fiscal 2022 through fiscal 2024 Cisco moved AppDynamics out of a niche APM silo and made it a core pillar of its new **Observability** product category, explicitly grouping it with ThousandEyes and the Splunk‑based Observability Suite.  This re‑positioning was highlighted in the 2024 financial tables (Observability revenue + 27 % YoY) and in the company’s strategic narrative, signaling that AppDynamics now underpins Cisco’s end‑to‑end, full‑stack observability story across networking, security and application performance.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of AppDynamics' strategic positioning from 2022 to 2024: initially as a key component of full-stack observability alongside ThousandEyes and Intersight (2022), and later as part of a formally reported 'Observability' revenue category by 2024. The mention of Splunk-based Observability Suite is contextually accurate given Cisco's acquisition of Splunk in late 2023, which further consolidated its observability offerings—though the original answer does not mention Splunk, this is a reasonable inference for 2024 context. (2) The LLM introduces a specific quantitative claim: 'Observability revenue +27% YoY' in 2024. While this figure is plausible and consistent with Cisco’s reporting trends, it is not present in the original ground truth and cannot be verified from the provided knowledge graph. This introduces a minor overprecision, slightly reducing quantitative accuracy. (3) The multi-hop reasoning is sound—correctly synthesizing changes in product categorization, strategic emphasis, and reporting structure across years. The integration of AppDynamics into a broader observability pillar is accurately conveyed. (4) Semantic equivalence is strong: the core message—that Cisco formalized and elevated AppDynamics within a new Observability category—matches the original. The added detail about Splunk enhances context without contradicting facts. Minor deduction from 10 due to unverified percentage, but overall excellent accuracy and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 428,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did the effective interest rate and notional amount associated with the 4.663% 2051 Notes evolve from 2022 to 2023?",
      "original_answer": "In 2022, the 4.663% 2051 Notes were part of a $5.2 billion principal amount of notes that were hedged using interest rate swaps, with the swaps terminated and replaced at then-current interest rates. In 2023, the notional amount of the 4.663% 2051 Notes was $1.5 billion, and the effective interest rate was SOFR + 4.3%. This indicates a continuation of the hedging strategy but with updated interest rate terms and a more specific disclosure of the notional amount and rate for the 2051 Notes.",
      "llm_answer": "\nThe $1.5 billion notional amount of the 4.663% 2051 Notes was unchanged from 2022 to 2023.  Its effective interest rate moved from a LIBOR‑plus‑4.1% floating structure (which corresponded to an effective rate of roughly 5.6 % in 2022) to a SOFR‑plus‑4.3% floating structure in 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) Quantitative Accuracy: The LLM claims the notional amount was $1.5 billion in both 2022 and 2023, but the original answer states that in 2022, the 4.663% 2051 Notes were part of a $5.2 billion hedged portfolio — not specifically $1.5 billion for the 2051 Notes alone. The $1.5 billion figure is only explicitly disclosed for 2023, with no confirmation it was the same in 2022. Additionally, the LLM introduces specific floating rate structures (LIBOR + 4.1%, SOFR + 4.3%) and an effective rate of ~5.6% in 2022, none of which appear in the ground truth. The original answer does not specify the 2022 effective rate or confirm a LIBOR-based structure; it only states that swaps were terminated and replaced at then-current rates. (2) Completeness: While the question asks about the evolution from 2022 to 2023, the LLM fabricates details for 2022 rather than acknowledging limited disclosure. The ground truth emphasizes a change in hedging strategy with updated terms but does not provide the precise rate or notional for 2022. (3) Entity Accuracy: The use of LIBOR and SOFR is plausible contextually but not supported in the original answer, which only mentions 'then-current interest rates' in 2022 and SOFR + 4.3% in 2023. The notional amount is correctly stated for 2023 but incorrectly assumed for 2022. (4) Reasoning: The multi-hop synthesis fails — the LLM assumes continuity in notional amount and constructs a narrative about rate transition without evidence for 2022. The original answer implies a restructuring or rebalancing (from $5.2B hedged pool to $1.5B specific disclosure), not a stable notional. (5) Semantic Equivalence: The LLM presents a more precise but factually unsupported answer, contradicting the ground truth's emphasis on partial disclosure and strategic update. The fabricated numbers reduce factual correctness despite plausible framing. Thus, the answer is mostly incorrect due to invented quantitative details and flawed reasoning about 2022 conditions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1187,
        "completion_tokens": 557,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has AIG's use of expected loss ratio methods evolved between 2022 and 2023, particularly in terms of the lines of business and segmentation criteria applied?",
      "original_answer": "In 2022, AIG referenced the use of expected loss ratio methods in a general sensitivity analysis related to loss reserve assumptions, without specifying detailed segmentation or particular lines of business. By 2023, AIG explicitly applied expected loss ratio methods to U.S. Workers' Compensation, a long-tail line of business, and introduced more granular segmentation criteria such as risk-sharing features, state and industry subsets, deductible size, and claim handling entities. This indicates a more structured and detailed application of the method in 2023 compared to 2022.",
      "llm_answer": "\nBetween 2022 and 2023 AIG deepened its reliance on the Expected Loss Ratio method for long‑tail lines—especially U.S. Excess Casualty—by giving it significant weight to the five most recent accident years and adjusting the underlying loss‑cost trends for inflation, rate changes and market conditions.  The 2023 reserving methodology also introduced a more granular segmentation, applying the method to sub‑segments defined by underlying primary policies, attachment‑point layers and the “Covered Lines” under its ADC reinsurance program, whereas the 2022 approach used the method more broadly with less explicit layer‑by‑layer segmentation.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements regarding increased granularity and evolution in AIG's use of expected loss ratio methods from 2022 to 2023, but it misidentifies key details. (1) The line of business cited in the LLM answer—U.S. Excess Casualty—is incorrect; the ground truth specifies U.S. Workers' Compensation as the line where expected loss ratio methods were explicitly applied in 2023. This is a significant entity error. (2) The segmentation criteria mentioned in the LLM answer (e.g., attachment-point layers, Covered Lines under ADC reinsurance, primary policies) do not match the ground truth, which identifies risk-sharing features, state and industry subsets, deductible size, and claim handling entities. These are fundamentally different segmentation approaches. (3) The claim about giving 'significant weight to the five most recent accident years' and adjusting for inflation, rate changes, and market conditions is not supported by the original answer and introduces unverified methodological details. (4) While the general direction of more granular segmentation in 2023 vs. broader use in 2022 is consistent with the truth, the specific multi-hop synthesis across years and business lines is flawed due to incorrect entities and criteria. (5) There are no numerical values to verify, so quantitative accuracy is based on absence of incorrect numbers, earning a moderate score. Overall, the answer reflects a plausible but factually inaccurate evolution of AIG's methodology, with core factual errors undermining correctness despite some structurally reasonable reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 437,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did PepsiCo's engagement with the 2.850% Senior Notes due 2026 evolve between 2023 and 2024, particularly in terms of its broader debt issuance strategy as reflected in the additional notes introduced in 2024?",
      "original_answer": "In 2023, PepsiCo referenced the 2.850% Senior Notes due 2026 as part of a broader set of debt instruments, including other senior notes with varying interest rates and maturity dates. By 2024, the company introduced a significantly expanded range of senior notes, including higher-yielding instruments such as the 7.00% Senior Notes due 2029 and the 5.50% Senior Notes due 2035, indicating a more diversified and long-term debt issuance strategy. This evolution suggests that PepsiCo not only maintained its commitment to the 2.850% Senior Notes due 2026 but also broadened its capital structure by incorporating a wider spectrum of debt instruments with different risk-return profiles.",
      "llm_answer": "\nBetween 2023 and 2024 the 2.850 % Senior Notes due 2026 continued to appear in PepsiCo’s Board‑approved term‑sheet resolutions, confirming that the 2026‑maturity tranche remained a core element of its senior‑note ladder. In 2024 the company expanded its issuance program—adding new indentures and issuing additional senior notes such as the 5.125 % due 2026, 4.500 % due 2029 and 5.250 % due 2054 through U.S. and Singapore financing vehicles—demonstrating a broader strategy of diversifying funding sources and extending the maturity profile while keeping the 2.850 % 2026 notes within the mix.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general direction of PepsiCo's debt strategy evolution—maintaining the 2.850% Senior Notes due 2026 as part of its capital structure while expanding its issuance program in 2024—but contains significant factual inaccuracies in the quantitative details. The original answer states that PepsiCo introduced higher-yielding instruments such as the 7.00% Senior Notes due 2029 and the 5.50% Senior Notes due 2035 in 2024. In contrast, the LLM answer incorrectly lists different notes: 5.125% due 2026, 4.500% due 2029, and 5.250% due 2054. These specific interest rates and maturities do not match the ground truth and represent a material deviation. Additionally, the mention of 'U.S. and Singapore financing vehicles' introduces entity-specific details not present or verifiable in the original answer, potentially reflecting hallucination. While the LLM correctly infers that PepsiCo diversified its funding sources and extended maturities, the incorrect specification of the new notes undermines the quantitative accuracy. The reasoning is logically sound in structure—recognizing continuity in the 2026 notes and strategic expansion—but based on incorrect data inputs. The answer is contextually relevant and addresses both parts of the question (evolution of engagement with the 2.850% notes and broader strategy), but the factual mismatch in key financial instruments limits its correctness. Semantic equivalence is partially achieved in intent but not in factual content.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 411,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has Cisco's exposure to channel partner financing guarantees evolved between fiscal years 2022 and 2024, and what does this indicate about the company's financial risk management strategy?",
      "original_answer": "In fiscal year 2022, Cisco disclosed that the volume of channel partner financing was $27.9 billion, with a balance of financing subject to guarantees amounting to $1.4 billion as of July 30, 2022. By fiscal year 2024, while the company continued to provide financing guarantees, the specific volume of channel partner financing and the balance subject to guarantees were no longer explicitly quantified in the disclosures. This shift indicates a potential strategic move toward reducing transparency around these financial commitments, which may reflect a broader risk management approach to limit visibility into contingent liabilities. However, the absence of updated figures prevents definitive conclusions about the actual change in exposure.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 the maximum potential liability Cisco could incur under its channel‑partner financing guarantees rose only modestly – from about **$188 million** (with roughly **$1.4 billion** of guaranteed financing outstanding in 2022) to roughly **$200 million** (with about **$1.5 billion** of guaranteed financing in 2024).  This limited increase occurs despite the company continuing to extend short‑term revolving financing to its channel partners, and it is offset by collateral arrangements and strict credit reviews.  Consequently, Cisco’s risk‑management strategy remains focused on **maintaining a small, well‑collateralized guarantee exposure** rather than broad financial commitments, preserving balance‑sheet strength while still supporting partner liquidity.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in fiscal year 2022, the volume of channel partner financing was $27.9 billion, with $1.4 billion subject to guarantees. The LLM incorrectly states that the 'maximum potential liability' was $188 million in 2022 and $200 million in 2024, which contradicts the disclosed $1.4 billion in guaranteed financing alone as of 2022. Additionally, the LLM claims $1.5 billion of guaranteed financing in 2024, but the original answer states that Cisco no longer disclosed specific figures for 2024, making any quantification speculative. (2) The numbers provided by the LLM ($188M, $200M, $1.5B) are not supported by the ground truth and appear fabricated. The only correct figure mentioned is the $1.4 billion in guaranteed financing as of 2022, though it is misrepresented as 'outstanding' rather than 'subject to guarantees.' (3) The multi-hop reasoning is flawed: the LLM assumes continuity and quantifiability of data into 2024, whereas the ground truth emphasizes the absence of disclosure, indicating a lack of transparency. The conclusion about risk management being focused on 'small, well-collateralized exposure' contradicts the original answer’s caution that reduced disclosure limits the ability to assess actual risk. (4) The contextual relevance is moderate because the answer addresses channel partner financing and risk management, but the incorrect data and overconfident interpretation undermine its validity. The qualitative reasoning fails to reflect the uncertainty introduced by missing disclosures. Correctness is severely compromised by false precision and invented metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 462,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has the status and interest rate structure of the 2.45% 2030 Notes evolved between 2022 and 2023?",
      "original_answer": "In 2022, Amgen disclosed that it had entered into interest rate swap contracts with an aggregate notional amount of $1.0 billion with respect to the 2.45% 2030 Notes, effectively converting the fixed-rate interest to a floating LIBOR-based coupon. By 2023, the 2.45% 2030 Notes remained outstanding with a notional amount of $1.0 billion, but the interest rate structure had transitioned from LIBOR to SOFR, now stated as SOFR + 1.3%. This reflects a continuation of the note's existence but with a modified floating-rate benchmark.",
      "llm_answer": "\nThe 2.45 % 2030 notes remained outstanding with a carrying value of roughly $1.25 bn through 2022 and 2023 – they were not redeemed or refinanced during that period.  However, in 2021 the company entered into interest‑rate swap agreements (≈$1 bn notional) that converted the notes’ fixed 2.45 % coupon into a floating rate tied to SOFR + about 1.3 %, so by 2023 the effective interest‑rate structure of the 2030 notes is no longer the original fixed 2.45 % but a SOFR‑plus‑spread floating rate.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but has key factual inaccuracies. It correctly states that the 2.45% 2030 Notes remained outstanding through 2022 and 2023 with a notional amount of approximately $1.0 billion and that interest rate swaps were used to convert the fixed rate to a floating rate. However, it incorrectly states that the swaps were entered into in 2021 (ground truth: 2022), which is a significant error in timing. Additionally, the LLM claims the floating rate was SOFR + 1.3% from the outset, but the ground truth indicates a transition from LIBOR-based to SOFR-based in 2023, reflecting benchmark reform developments. The LLM skips this evolution and incorrectly implies the rate was tied to SOFR as early as 2021. (2) Quantitative inaccuracies include the $1.25 billion carrying value, which does not appear in the ground truth; the correct notional amount referenced is $1.0 billion. The $1 billion notional for swaps is correct. Percentages (2.45%, SOFR + 1.3%) are accurate. (3) The multi-hop reasoning is partially sound—linking the existence of the notes and the swap activity—but fails to accurately trace the evolution of the interest rate benchmark from fixed to LIBOR (in 2022) and then to SOFR (in 2023). This two-step transition is a critical part of the evolution and is omitted. (4) Despite these errors, the answer is contextually relevant and captures the high-level outcome: the notes are still outstanding and now have a floating rate based on SOFR. The qualitative reasoning is logical but based on incorrect timing and oversimplification of the rate transition. Hence, partial credit is given.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 453,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How has FedEx's relationship with Pass-Through Certificates evolved between 2022 and 2023, particularly regarding its financial guarantees and obligations?",
      "original_answer": "In 2022, FedEx Express had issued $970 million of Pass-Through Certificates, Series 2020-1AA, which were fully and unconditionally guaranteed by FedEx. These certificates were secured by 19 Boeing aircraft with a net book value of $1.8 billion. However, in 2023, FedEx clarified that pass-through certificates associated with leveraged operating leases were not direct obligations of, nor guaranteed by, FedEx or FedEx Express. This indicates a shift from direct financial guarantees in 2022 to a position of no direct financial obligation in 2023.",
      "llm_answer": "\nBetween 2022 and 2023 FedEx’s exposure to pass‑through certificates changed from an off‑balance‑sheet, non‑guaranteed financing arrangement to a fully guaranteed obligation. In the 2022 filing the company stated that the pass‑through certificates “are not direct obligations of, or guaranteed by, FedEx or FedEx Express,” meaning its only financial link was the lease‑payment stream that funded them. By the 2023 filing FedEx reported that the $970 million of Series 2020‑1AA pass‑through certificates are “fully and unconditionally guaranteed by FedEx,” turning the Express unit’s payment obligations into a direct guarantee and adding a contingent liability that could affect the company’s balance‑sheet and cash‑flow commitments.",
      "correctness_score": 1,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core claim about the evolution of FedEx's relationship with Pass-Through Certificates. (1) It states that in 2022, the certificates were 'not direct obligations...guaranteed by FedEx,' but in 2023 they became 'fully and unconditionally guaranteed by FedEx.' This is the exact opposite of the ground truth: in 2022, the $970 million Series 2020-1AA certificates were already fully and unconditionally guaranteed by FedEx, and in 2023, FedEx clarified that such certificates were *not* guaranteed by FedEx or FedEx Express. (2) The quantitative accuracy partially holds: the $970 million amount and Series 2020-1AA are correctly mentioned, and the years 2022 and 2023 are correctly used as reporting periods. However, the LLM misattributes the timing of the guarantee, reversing the actual timeline. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the shift from guaranteed (2022) to non-guaranteed (2023) status, instead asserting the reverse. This indicates a critical misunderstanding of the financial evolution. (4) While the answer discusses relevant concepts (pass-through certificates, guarantees, off-balance-sheet treatment), the reversal of the factual timeline renders the response highly misleading. Contextual relevance is moderate because it addresses the right topic and uses correct terminology, but the conclusion is factually inverted. Thus, the correctness score is very low due to the major factual reversal.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 412,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Mastercard's use of risk mitigation arrangements to manage gross settlement exposure evolve from 2023 to 2024, and what does this indicate about the company's risk management strategy?",
      "original_answer": "In 2023, Mastercard had $75,023 million in gross settlement exposure, with $12,167 million covered by risk mitigation arrangements. By 2024, gross settlement exposure increased to $78,385 million, and the company applied $13,466 million in risk mitigation arrangements, reflecting an increase in both total exposure and the amount mitigated. This indicates that Mastercard's risk management strategy became more robust over time, as it increased its use of mitigation tools in response to growing settlement exposure.",
      "llm_answer": "\nFrom 2023 to 2024 Mastercard’s gross settlement exposure rose ≈ $3.4 billion (from $75.0 bn to $78.4 bn), and the amount of risk‑mitigation collateral applied increased ≈ $1.3 billion (from $12.2 bn to $13.5 bn).  Consequently, net settlement exposure also edged up (from $62.9 bn to $64.9 bn), but the mitigation ratio grew from roughly 16 % to 17 % of gross exposure.  This shows that the company is scaling its collateral and credit‑enhancement programs in step with higher payment volumes, continuously refining its risk‑management methodology and maintaining a proactive, data‑driven approach to keeping settlement risk under control.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually correct in all key aspects. It accurately reports the increase in gross settlement exposure from $75,023 million (rounded to $75.0 billion) in 2023 to $78,385 million (rounded to $78.4 billion) in 2024, and the increase in risk mitigation from $12,167 million ($12.2 billion) to $13,466 million ($13.5 billion). These rounding approximations are acceptable and common in financial reporting. (2) Calculations are sound: the increase in gross exposure (~$3.4 billion) and mitigation (~$1.3 billion) are accurate. The implied net exposure ($75,023M - $12,167M = $62,856M ≈ $62.9B; $78,385M - $13,466M = $64,919M ≈ $64.9B) and mitigation ratios (~16.2% in 2023, ~17.2% in 2024) are correctly estimated and support the conclusion of a rising mitigation ratio. (3) Multi-hop reasoning is strong: the model synthesizes data across two years, computes derived metrics (net exposure, ratios), and correctly infers that Mastercard is proactively scaling risk mitigation in line with growing exposure. (4) The answer goes slightly beyond the original by introducing the mitigation ratio and net exposure trend, but this enhances rather than distorts the conclusion and aligns with the ground truth’s assertion of a more robust risk management strategy. Only minor deduction in quantitative accuracy due to rounding that slightly masks exact figures, but no material error. All entities (Mastercard, years, financial metrics) are correct. Contextual relevance is perfect—directly addresses evolution and strategic implication.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 428,
        "total_tokens": 1729
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Nike's liabilities related to foreign exchange forwards and options designated as hedging instruments change between 2022 and 2024, and what does this indicate about the company's exposure or strategy?",
      "original_answer": "In 2022, Nike reported $37 million in liabilities for foreign exchange forwards and options designated as hedging instruments under accrued liabilities, and $11 million under deferred income taxes and other liabilities, totaling $48 million. By 2024, the liability under accrued liabilities for the same category increased to $110 million, while the amount under deferred income taxes and other liabilities decreased to $5 million, resulting in a total of $115 million. This represents a significant increase in total liabilities for designated hedging instruments related to foreign exchange forwards and options, indicating a potential increase in Nike's foreign exchange risk exposure or a strategic shift in hedging activity.",
      "llm_answer": "\nBetween fiscal 2022 and 2024 the liability for foreign‑exchange forwards and options that Nike has designated as cash‑flow hedges rose sharply—from about **$48 million in 2022** to **$146 million in 2024** (the 2023 figure was $145 million).  This increase shows that Nike is expanding the size of its hedging program, locking in a larger portion of its anticipated foreign‑currency cash flows and thereby reducing exposure to exchange‑rate volatility across its global operations.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, Nike's total liability for foreign exchange forwards and options designated as hedging instruments was $48 million in 2022 (comprising $37M under accrued liabilities and $11M under deferred income taxes and other liabilities) and increased to $115 million in 2024 ($110M under accrued liabilities and $5M under deferred income taxes and other liabilities). However, the LLM claims the 2024 liability was $146 million (with a 2023 figure of $145 million), which is factually incorrect and not supported by the data. The 2022 figure of $48 million is correctly stated, but the 2024 figure is overstated by $31 million. (2) The calculation of change is therefore flawed: the actual increase is $115M - $48M = $67M, not $98M as implied by the LLM. Additionally, the LLM introduces a 2023 figure ($145M) not present in the original answer and inconsistent with the trend (since 2024 is $115M, a drop from $145M would contradict the provided data). (3) The qualitative reasoning about increased hedging activity aligning with greater foreign exchange exposure is plausible and consistent with the direction of change (increase), so the interpretation is partially sound despite incorrect magnitudes. However, the conclusion that Nike is 'locking in a larger portion of its anticipated cash flows' assumes intent not confirmed in the ground truth, which only states the increase 'indicates a potential increase in exposure or strategic shift'—a more cautious interpretation. (4) Contextual relevance is high because the answer addresses both the change in liabilities and its implication for strategy. However, due to major numerical errors and introduction of unsupported data points, the correctness and quantitative accuracy scores are low. The qualitative reasoning is reasonable but based on incorrect inputs, limiting its validity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 518,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did the representation of Bounty within P&G's Baby, Feminine & Family Care segment evolve between the 2022 and 2023 10-K filings, and what does this suggest about its brand visibility?",
      "original_answer": "In the 2022 10-K filing, Bounty was mentioned as part of P&G's Family Care business within the Baby, Feminine & Family Care segment, but it was not explicitly listed among the key brands. In contrast, the 2023 10-K filing explicitly included Bounty among the major brands under the Family Care category. This change suggests an increase in Bounty's brand visibility within P&G's portfolio, though the filings do not provide specific market share or sales figures to quantify this shift. The explicit mention in 2023 indicates a possible strategic move to highlight Bounty's role, though no direct strategic intent is stated in the evidence provided.",
      "llm_answer": "\nIn the 2022 filing (page 19) Bounty is listed among the major brands of the Baby, Feminine & Family Care segment together with Luvs, Pampers, Always, Tampax and Charmin, and the segment accounted for roughly 25 % of net sales and 23 % of net earnings. By the 2023 filing (page 20) the brand roster is streamlined (Always, Tampax Bounty, Charmin, Puffs) and the narrative explicitly highlights Bounty’s North‑American market‑share leadership—“over 40 % for Bounty”—and its central role in the family‑care business, underscoring its continued prominence and heightened brand visibility.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) According to the ground truth, in the 2022 10-K, Bounty was *not* explicitly listed among the key brands in the Baby, Feminine & Family Care segment—this contradicts the LLM's claim that it was listed alongside Luvs, Pampers, Always, Tampax, and Charmin on page 19. The ground truth confirms Bounty was mentioned as part of Family Care but not highlighted as a key brand, making the LLM's assertion false. (2) The LLM incorrectly states that in the 2023 filing, the brand roster was 'streamlined' and includes 'Always, Tampax, Bounty, Charmin, Puffs'—but the ground truth only confirms that Bounty was *explicitly included* among major brands in 2023, without specifying such a list or implying a streamlining. (3) Most critically, the LLM fabricates a quantitative claim: it states Bounty had 'over 40% market share' in North America, which is *not present in the ground truth*—the original answer explicitly says no market share or sales figures are provided in the filings. This is a major hallucination. (4) The LLM also incorrectly attributes segment-level financials (25% of net sales, 23% of net earnings) to the 2022 filing as if they are tied to Bounty’s visibility, but the ground truth does not link these figures to Bounty or suggest they changed. (5) While the LLM correctly infers increased brand visibility in 2023 due to explicit mention, this correct reasoning is based on false premises and fabricated data. The multi-hop synthesis is thus flawed. (6) Contextually, the answer addresses the evolution and visibility question, so relevance is moderate. However, due to severe factual and quantitative errors, the correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 473,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How has Oracle's approach to its hardware business, particularly Oracle Engineered Systems, evolved between fiscal 2022 and fiscal 2023 in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In fiscal 2022, Oracle's hardware business, which includes Oracle Engineered Systems, was described in terms of its contractual activities and revenue recognition, with an emphasis on the timing of revenue recognition for cloud and license contracts. By fiscal 2023, Oracle introduced a more detailed explanation of how hardware and related software are treated as a combined performance obligation, with revenue recognized at the point in time of delivery and ownership transfer. Additionally, in 2023, Oracle emphasized ongoing R&D investments to improve and develop new hardware products and services, which was not explicitly mentioned in 2022. This indicates a shift toward a more strategic focus on innovation and integration of hardware and software components within the hardware business.",
      "llm_answer": "\nOracle’s hardware revenue‑recognition method did not change – product sales are still recognized at the point of delivery and hardware‑support fees are accrued ratably over the support term (as noted in the 2022 10‑K “Hardware” discussion and reiterated in the 2023 10‑K “Hardware Business” section).  However, the strategic emphasis shifted: in FY 2022 hardware contributed roughly 7‑8 % of total revenue and was presented as a separate, lower‑margin infrastructure pillar, whereas by FY 2023 it accounted for only about 6 % of revenue and the company highlighted cloud‑and‑license growth as the primary driver, positioning engineered systems mainly as a complementary, lower‑priority offering within the broader cloud strategy.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partially correct information but diverges significantly from the ground truth in key aspects. While it correctly notes that hardware revenue recognition occurs at delivery and support is recognized ratably, it fails to mention the critical 2023 change in accounting treatment—specifically, the integration of hardware and related software as a combined performance obligation, which is a central point in the original answer. This omission undermines the accuracy of the revenue recognition evolution. The percentages cited (7–8% in FY2022, ~6% in FY2023) are plausible but not present in the ground truth and cannot be verified from the provided knowledge graph; thus, introducing unverified quantitative claims reduces factual reliability. (2) Quantitative accuracy is moderate: the percentages may reflect actual trends but are not supported by the ground truth, which does not provide revenue shares. The absence of incorrect calculations saves it from a lower score, but the introduction of unsupported figures is problematic. (3) Multi-hop reasoning is partially sound—the model infers a strategic downgrading of hardware based on revenue share and emphasis on cloud growth—but misses the core qualitative shift in 2023: increased R&D investment and strategic emphasis on innovation and integration of hardware and software, which contradicts the LLM’s claim that hardware became a 'lower-priority offering.' This is a significant misrepresentation of Oracle’s strategic direction as per the original answer. (4) Contextual relevance is high because the response addresses both revenue recognition and strategic emphasis as asked. However, the qualitative inaccuracy in portraying strategy—downplaying hardware instead of highlighting renewed integration and R&D focus—results in a misleading conclusion despite relevant structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 508,
        "total_tokens": 1901
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did the sales performance of the product ERLEADA evolve between 2022 and 2023, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ERLEADA generated $1,881 million in sales, and by 2023, its sales increased to $2,387 million, representing a 26.9% growth. This indicates a strong upward trajectory for ERLEADA in the market, suggesting increased adoption or improved commercial performance over the period.",
      "llm_answer": "\nERLEADA sales rose sharply from $1.881 billion in 2022 to $2.387 billion in 2023, an increase of ≈ 27 % (operations ≈ 27.5 %). This strong growth signals expanding market acceptance and share gains in metastatic castration‑resistant prostate cancer, pointing to a positive upward trajectory for the product.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reported ERLEADA's sales as $1.881 billion in 2022 and $2.387 billion in 2023, matching the ground truth values exactly (with acceptable format variation: $1,881 million = $1.881 billion). The percentage increase is stated as ≈27% (and notes ≈27.5%), which is a close approximation of the ground truth 26.9%. Given that rounding to 27% is reasonable and commonly accepted, this does not constitute a material error. (2) All numeric values are accurate, and the calculation of growth is approximately correct: (2,387 - 1,881) / 1,881 ≈ 0.269 or 26.9%; the LLM’s ≈27% is semantically equivalent. (3) The multi-hop reasoning is sound—sales figures across two years are correctly compared, and a valid inference about market trajectory is drawn. The addition of context about 'metastatic castration-resistant prostate cancer' and 'share gains' is plausible and enhances the answer without contradicting the ground truth. (4) The answer fully addresses both parts of the question: evolution of sales (quantitative change) and market trajectory (qualitative interpretation). The only minor deviation is the slightly rounded percentage, but this does not affect overall correctness. Thus, the answer is factually accurate, complete, and contextually appropriate, warranting a high score with only a small deduction in qualitative accuracy due to the slight over-rounding of the growth rate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1146,
        "completion_tokens": 393,
        "total_tokens": 1539
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the nature of CMCSA's relationship with local broadcast television stations evolved from 2023 to 2024, particularly in terms of competitive positioning and dependency for content distribution?",
      "original_answer": "In 2023, CMCSA's Media segment directly competed with local broadcast television stations for viewers' attention and advertising revenue. By 2024, the relationship shifted to a more interdependent one, where CMCSA's linear television networks became reliant on local broadcast television stations for retransmission consent, which is necessary for distributing broadcast network programming to video service customers. This marks a shift from competition to dependency, reflecting a strategic and operational evolution in how CMCSA interacts with local broadcast stations.",
      "llm_answer": "\nFrom 2023 to 2024 the relationship shifted from a largely “must‑carry” model—where local stations were carried without compensation—to a greater reliance on negotiated retransmission‑consent fees, driven by industry consolidation and heightened competition that have pushed programming costs higher. This has made CMCSA increasingly dependent on local broadcast stations for audience reach, while also exposing the company to risk if those affiliation agreements cannot be renewed on favorable terms. Consequently, the company’s competitive positioning now hinges more directly on the ability to secure and maintain these carriage deals amid rising costs and market volatility.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies a shift in CMCSA's relationship with local broadcast television stations from 2023 to 2024, emphasizing increased dependency due to retransmission-consent agreements and rising programming costs. It accurately captures the evolving competitive dynamics and operational risks, aligning well with the ground truth’s theme of shifting from competition to dependency. However, it diverges from the original answer by framing the 2023 relationship as a 'must-carry' model without explicit mention of direct competition for viewers and advertising revenue, which is a key element in the ground truth. While 'must-carry' is a legal framework, the original answer emphasizes content and audience competition, not just carriage terms. The LLM also introduces 'industry consolidation' and 'programming costs' as drivers not explicitly present in the ground truth, adding plausible context but not fully matching the documented evolution. There are no numerical values, so quantitative accuracy is scored as 10 by default. The reasoning is logically sound and contextually relevant, but the qualitative accuracy is slightly reduced due to incomplete alignment with the specific nature of the 2023 competitive relationship. Overall, the answer is semantically close and addresses the core of the question, but misses precise nuance in the initial state of the relationship.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 385,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did the value of Held-to-Maturity (HTM) securities held by MA evolve between 2023 and 2024, and what does this shift indicate about the company's investment strategy?",
      "original_answer": "In 2023, MA held $306 million in HTM securities, but by 2024, this amount dropped significantly to $38 million. This indicates a major shift in MA's investment strategy, with a sharp reduction in long-term held securities, likely reflecting a move toward more liquid or short-term investment positions.",
      "llm_answer": "\nThe company’s Held‑to‑Maturity (HTM) portfolio fell sharply from **$306 million at the end of 2023 to only $38 million by the end of 2024** (a decline of roughly 87 %).  This pull‑back from low‑yield, short‑term time‑deposit holdings indicates that Mastercard is reallocating the freed cash toward other uses—such as higher‑return investments, equity stakes, or operational needs—reflecting a strategic shift away from passive, interest‑earning assets toward a more active investment posture.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the HTM values for MA (Mastercard) in 2023 ($306 million) and 2024 ($38 million), matching the ground truth exactly. The calculated decline of roughly 87% is accurate: (306 - 38) / 306 ≈ 0.876, or 87.6%, which rounds to 87%. 2) All numeric values, dates, and calculations are factually correct. Format variations (e.g., $306 million vs $306M) are acceptable and do not affect accuracy. 3) The multi-hop reasoning is sound: the model correctly infers a strategic shift from the significant reduction in HTM securities. While the original answer suggests a move toward more liquid or short-term positions, the LLM interprets this as a shift toward higher-return investments, equity stakes, or operational needs. This is a reasonable and plausible extension of the data, though slightly more speculative than the original. It does not contradict the ground truth but adds interpretive depth. 4) The entities (MA = Mastercard), metric (HTM securities), and years (2023 to 2024) are all correctly identified. The answer fully addresses both parts of the question: the quantitative change and its strategic implication. Semantic equivalence is maintained, with only minor interpretive expansion. The LLM slightly exceeds the original in interpretation but remains factually grounded. Thus, full marks for quantitative accuracy and contextual relevance, near-perfect for qualitative accuracy, and a 9 overall due to the slight interpretive leap in strategy rationale.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1204,
        "completion_tokens": 411,
        "total_tokens": 1616
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the positioning of the Always brand within Procter & Gamble's Baby, Feminine & Family Care segment evolved between 2022 and 2023, particularly in terms of its product categorization and associated sub-categories?",
      "original_answer": "In 2022, Always was categorized under Feminine Care within the Baby, Feminine & Family Care segment, which included sub-categories like Adult Incontinence and Feminine Care. By 2023, the brand remained part of the same reportable segment but was more specifically aligned with 'Menstrual Care' under the updated Feminine Care sub-category, reflecting a more targeted positioning. This evolution indicates a strategic shift in how Always is being categorized to emphasize its core focus area.",
      "llm_answer": "\nBetween 2022 and 2023 the Always brand remained classified under the **Feminine Care** sub‑category of P&G’s **Baby, Feminine & Family Care** segment, but the way that sub‑category was described evolved.  In the 2022 filing it was listed simply as “Feminine Care (Adult Incontinence, Feminine Care),” while the 2023 discussion explicitly calls out Always as a **market‑leading brand in both menstrual‑care and adult‑incontinence** components of that sub‑category, underscoring a strategic shift to position Always as a dual‑focus leader within the broader Feminine Care category.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies that Always remained within the Feminine Care sub-category of the Baby, Feminine & Family Care segment in both 2022 and 2023, and notes a shift in categorization language, which aligns with the ground truth. However, it introduces a significant factual inaccuracy: claiming that Always was positioned as a market-leading brand in both 'menstrual-care and adult-incontinence' components in 2023. The ground truth states that Adult Incontinence was a separate sub-category under the same reportable segment in 2022, but by 2023, Feminine Care was refined to 'Menstrual Care' as a more targeted positioning for Always — not that Always itself leads in adult incontinence. This misrepresents the strategic shift: the evolution was a re-categorization to narrow Always’s focus to Menstrual Care, not an expansion or dual positioning. There are no numerical figures to verify, so quantitative accuracy is high by default. The reasoning is partially sound but fails the multi-hop synthesis by conflating segment structure with brand positioning. Contextually, the response addresses the question’s focus on categorization evolution, but the incorrect linkage of Always to adult incontinence in 2023 undermines the qualitative accuracy. Thus, while the answer captures the surface-level continuity and mentions a strategic shift, it mischaracterizes the nature of the repositioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 388,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has Oracle's positioning and financial contribution of Oracle Engineered Systems evolved between 2022 and 2023, particularly in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In 2022, Oracle Engineered Systems were disclosed as part of hardware revenues, but no specific percentage of total revenue was provided. Revenue recognition for hardware products, including Engineered Systems, was described as occurring at the point in time when the product and related software were delivered. By 2023, Oracle explicitly stated that the hardware business, which includes Engineered Systems, represented 6% of total revenues in both fiscal 2023 and fiscal 2024, indicating a clearer and more consistent measurement of the product line's contribution. Additionally, in 2023, Oracle emphasized ongoing R&D investments to improve hardware offerings and introduced more detailed factors affecting hardware revenue predictability, such as manufacturing partner performance and competitive positioning against cloud infrastructure offerings. This reflects both quantitative and strategic evolution in how Oracle presents and manages the Engineered Systems product line.",
      "llm_answer": "\nBetween fiscal 2022 and 2023 Oracle’s Engineered Systems contributed only about 6 % of total revenue each year, and its revenue was recognized at the point of hardware delivery as a combined performance obligation, with hardware‑support contracts recorded ratably over the support term.  Although the company continues to invest in new engineered‑system products and sells through indirect channels, it treats the hardware business as a low‑margin, relatively stable contributor and is shifting strategic focus toward cloud services—where the share of revenue has been rising—while still emphasizing the importance of choice and flexibility in deployment models.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Oracle Engineered Systems represented 6% of total revenue in fiscal 2023, which aligns with the ground truth. However, it incorrectly claims this 6% figure applied to both 2022 and 2023, whereas the original answer clarifies that no specific percentage was disclosed for 2022—this is a significant factual error. The revenue recognition method (at point of delivery for hardware, ratably for support) is accurately described and consistent with the ground truth. (2) The quantitative inaccuracy lies in asserting the 6% contribution for 2022, which is not supported by the source data. The ground truth explicitly states that while 6% was reported for both 2023 and 2024, no such breakdown was provided for 2022. This misrepresents the evolution over time. (3) The qualitative reasoning partially captures the strategic shift toward cloud services and continued R&D investment, which reflects Oracle’s evolving emphasis. However, it omits key 2023 developments mentioned in the original answer—such as increased transparency in reporting, explicit inclusion of Engineered Systems within the 6% hardware segment, and new risk factors like manufacturing partner performance and competition with cloud infrastructure. These omissions reduce the depth of the multi-hop synthesis. (4) Despite the numerical error and missing details, the answer remains contextually relevant and captures the general trend of declining strategic emphasis on hardware relative to cloud. The core idea of stable but low-margin hardware contribution and shift in focus is semantically aligned, but the incorrect attribution of the 6% figure to 2022 undermines the accuracy of the year-over-year comparison, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 482,
        "total_tokens": 1902
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Comcast's relationship with representation firms evolved in terms of advertising sales strategy between 2023 and 2024?",
      "original_answer": "In 2023, Comcast worked with representation firms as an extension of its sales force to sell a portion of the advertising units allocated to them, recording revenue net of agency commissions. By 2024, Comcast had evolved this relationship into formal representation agreements under which they sell advertising on behalf of third parties, indicating a deeper strategic alignment and expanded role for these firms. This reflects a shift from a co-selling model to a more formalized representation structure.",
      "llm_answer": "\nBetween 2023 and 2024 Comcast moved from a broad reference to “representation agreements” toward a more formal, contract‑driven approach: it now explicitly defines when a contract exists (when the number of advertising units is identified and scheduled) and consistently records the resulting revenue net of agency commissions, treating representation firms as an extension of its own sales force.  The newer disclosures also add details about rating‑guarantee shortfalls and deferred revenue, indicating a tighter control and clearer financial treatment of these third‑party sales channels.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misrepresents the evolution of Comcast's relationship with representation firms between 2023 and 2024. While it correctly notes that Comcast records revenue net of agency commissions and treats representation firms as an extension of its sales force, it inaccurately frames the change as a shift toward more formal contract definitions based on scheduling and identification of advertising units. The ground truth emphasizes a strategic shift from a co-selling model in 2023 (where Comcast sold a portion of ad units through firms) to formal representation agreements in 2024 under which Comcast sells ads on behalf of third parties—indicating a role reversal or expansion where Comcast acts as an agent for others. The LLM instead suggests Comcast merely tightened internal controls and disclosure practices, which is not supported by the original answer. There are no numeric values to verify, so quantitative accuracy is high by default. However, the qualitative reasoning is flawed: the multi-hop synthesis fails because the model misidentifies the direction of the strategic evolution (from selling its own inventory with help to selling third-party inventory via representation). Contextually, the response is relevant and discusses the right topic with appropriate financial treatment details (e.g., net revenue, guarantees), but misses the core strategic pivot. Thus, correctness is reduced due to fundamental mischaracterization of the business model change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 413,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Oracle's approach to its industry-specific hardware offerings evolved between fiscal 2022 and fiscal 2023, particularly in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In fiscal 2022, Oracle described its hardware business as including industry-specific hardware and recognized hardware revenues at the point in time when products and related software were delivered to customers. By fiscal 2023, Oracle introduced a more detailed explanation of revenue recognition for hardware, stating that revenues for combined performance obligations (hardware plus related software) are generally recognized at the point in time of delivery and ownership transfer. Additionally, in 2023, Oracle emphasized ongoing investments in R&D to improve existing hardware offerings and develop new products, signaling a more strategic focus on innovation in this area compared to 2022, where the description was more general and focused on the breadth of offerings.",
      "llm_answer": "\nOracle continues to recognize hardware product revenue at the moment the equipment is delivered and to recognize hardware‑support fees ratably over the contract term in both fiscal 2022 and fiscal 2023; however, the 2023 filing stresses that quarterly hardware sales are highly volatile and that the business now relies on a smaller, lower‑margin contribution that is primarily a support‑driven complement to its cloud and license strategy. Consequently, while the hardware segment still accounts for roughly 6 % of total revenue, Oracle’s strategic emphasis has shifted toward investing in R&D and expanding indirect‑channel sales to sustain its industry‑specific hardware offerings, positioning them as an ancillary, renewal‑focused component of the broader cloud ecosystem.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly notes that Oracle recognizes hardware revenue upon delivery in both years and mentions R&D investments in 2023, aligning with the ground truth. However, it introduces claims not present in the original answer, such as hardware being a 'lower-margin contribution' and 'primarily a support-driven complement,' which are not mentioned in the ground truth. The 6% revenue figure is plausible but not verifiable from the provided ground truth, making it an unsupported addition. (2) The quantitative accuracy is partially correct: the 6% of total revenue is a specific number, but since it does not appear in the ground truth, it cannot be confirmed and may be inaccurate or inferred from external data. No other numbers (e.g., growth rates, dollar amounts) are provided, so there are no calculation errors per se, but the inclusion of unverified metrics reduces accuracy. (3) The multi-hop reasoning is flawed. The ground truth emphasizes a more detailed revenue recognition policy in 2023 and increased strategic emphasis on R&D and innovation. The LLM instead frames the hardware business as declining in strategic importance and margin, which contradicts the ground truth's indication of heightened strategic focus on innovation. This misrepresents the evolution of Oracle's approach. (4) Contextual relevance is high because the answer addresses revenue recognition and strategic emphasis over the two fiscal years, directly responding to the question's focus. However, the qualitative inaccuracy in reasoning and unsupported claims significantly reduce correctness. The answer appears plausible but diverges factually from the ground truth in key aspects of strategic emphasis and business characterization.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 489,
        "total_tokens": 1887
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did the sales performance of IMBRUVICA (ibrutinib) evolve between 2022 and 2023, and what factors contributed to this change?",
      "original_answer": "IMBRUVICA sales decreased from $3.784 billion in 2022 to $3.264 billion in 2023, a decline of 13.7%. In 2022, the growth of IMBRUVICA was already being offset by competitive pressures from novel oral agents and market dynamics related to the pandemic, such as delays in new patient starts. By 2023, this downward trend continued, with the product experiencing a significant drop in sales, reflecting sustained competitive pressures and likely increased market saturation or treatment shifts in the oncology space.",
      "llm_answer": "\nIMBRUVICA (ibrutinib) sales fell sharply – from **$3.78 billion in 2022 to $3.26 billion in 2023**, a **≈13.7 % total decline** (≈13.2 % operational drop).  The downturn was attributed to **greater competitive pressure in the oncology market**, including the entry of rival BTK inhibitors and other generic/next‑generation agents, which eroded market share and pricing power for IMBRUVICA.  This competitive environment, combined with the broader loss of exclusivity pressures on related oncology products, drove the reduction in sales between the two fiscal years.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports the sales figures for IMBRUVICA in 2022 ($3.78 billion) and 2023 ($3.26 billion), which align with the ground truth of $3.784 billion and $3.264 billion—minor rounding is acceptable. The calculated decline of ≈13.7% is accurate (actual: (3.784 - 3.264)/3.784 ≈ 13.74%). The mention of a ≈13.2% operational drop is an additional detail not in the ground truth but does not contradict it and may reflect FX-adjusted performance; it does not reduce accuracy. 2) Quantitatively, all numbers and percentages are correct or appropriately rounded. Calculations are sound. 3) The reasoning correctly identifies competitive pressures as a key factor, specifically naming rival BTK inhibitors and next-generation/generic agents, which aligns with the ground truth's mention of 'competitive pressures from novel oral agents'. The LLM adds 'loss of exclusivity pressures', which is contextually plausible and consistent with market dynamics for a drug facing generics, though not explicitly stated in the original. The core contributing factors—competition and market dynamics—are accurately synthesized. 4) The answer fully addresses both parts of the question: the sales evolution (quantitative change) and the contributing factors (qualitative drivers). The wording differs slightly but maintains semantic equivalence. The only minor gap is the absence of explicit mention of pandemic-related delays in 2022 (noted in ground truth), but this is a secondary contextual point and does not undermine the overall correctness. Thus, the answer is highly accurate, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 442,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Comcast's involvement with Universal Beijing Resort evolved from 2023 to 2024 in terms of debt levels, ownership structure, and financial risk exposure?",
      "original_answer": "In 2023, Universal Beijing Resort had $3.5 billion of debt outstanding, including a $3.1 billion term loan, and was consolidated by Comcast, which owns a 30% interest. By 2024, the debt level slightly decreased to $3.4 billion, with the term loan principal reducing to $3.0 billion. Comcast continues to consolidate Universal Beijing Resort as a VIE, maintaining its 30% ownership stake. The maximum financial risk exposure for Comcast remains limited to its 30% equity interest, indicating a stable risk profile despite the slight reduction in debt. This evolution reflects a minor decrease in leverage but no change in ownership or governance structure.",
      "llm_answer": "\nFrom 2023 to 2024 Comcast’s stake in Universal Beijing Resort remained the same – it continues to hold a 30 % equity interest in the joint‑venture and, because it controls the entity, consolidates the resort in its financial statements.  The resort’s outstanding debt fell modestly, from about **$3.5 billion (including a $3.1 billion term loan) at the end of 2023 to $3.4 billion (with a $3.0 billion term loan) at the end of 2024**, reflecting a small repayment of the construction‑financed loan.  Because the debt is secured only by the resort’s own assets and there are no cross‑guarantees or other financial commitments from Comcast, the company’s exposure to financial risk is limited to its **30 % equity interest**, which is the maximum amount it could lose if the venture’s cash flows proved insufficient.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and fully aligned with the ground truth. (1) All key facts are correct: Comcast maintains a 30% ownership interest and continues to consolidate Universal Beijing Resort as a VIE in both 2023 and 2024. The debt levels are accurately reported: $3.5 billion in 2023 (including a $3.1 billion term loan) and $3.4 billion in 2024 (with a $3.0 billion term loan), reflecting a $100 million reduction in total debt and a $100 million reduction in the term loan. (2) Quantitative accuracy is perfect—numbers match exactly, with acceptable formatting (e.g., 'about $3.5 billion' is consistent with precise reporting). No calculation errors. (3) Multi-hop reasoning is sound: the answer correctly synthesizes information across time (2023 to 2024), entities (Comcast, Universal Beijing Resort), and financial concepts (debt structure, consolidation, risk exposure). It correctly identifies that Comcast’s financial risk remains limited to its 30% equity stake due to non-recourse debt and absence of cross-guarantees. (4) The answer addresses all three dimensions in the question—debt levels, ownership structure, and financial risk exposure—with complete and precise information. Wording differs slightly from the original but maintains full semantic equivalence. No omissions or inaccuracies. All scores are 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 372,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How did the financial commitment related to future lease payments for build-to-suit facilities and equipment evolve from 2022 to 2023, and what does this indicate about FedEx's leasing strategy?",
      "original_answer": "In 2022, FedEx disclosed future undiscounted payments of approximately $3.4 billion for build-to-suit facilities that had not yet commenced, with expected commencement dates from 2023 to 2024. By 2023, the company reported a significant reduction in these future commitments, with undiscounted payments dropping to approximately $0.9 billion for build-to-suit facilities and equipment, with commencement dates expected from 2025 to 2027. This indicates a strategic shift toward fewer long-term build-to-suit lease commitments and a more extended timeline for asset utilization.",
      "llm_answer": "\nIn the 2022 filing (page 96) FedEx noted that it had entered into additional leases—primarily build‑to‑suit facilities and equipment—with undiscounted future payments of roughly **$3.4 billion**, to commence between 2023 and 2024.  By the 2023 filing (page 98‑99, which reflects the May 31 2024 outlook) the company reported only about **$0.9 billion** of undiscounted future payments for similar build‑to‑suit leases, with commencement now expected from 2025 onward.  \n\nThis pull‑back in the scale of future build‑to‑suit commitments indicates that FedEx is scaling down its aggressive, large‑scale build‑to‑suit leasing program and is shifting toward a more conservative leasing strategy that relies more on existing assets and shorter‑term or finance‑type lease arrangements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the key financial figures: $3.4 billion in 2022 and $0.9 billion in 2023 for future undiscounted lease payments related to build-to-suit facilities and equipment. These numbers match the ground truth exactly, and the expected commencement periods (2023–2024 in 2022, shifting to 2025 onward in 2023) are accurately reported. The mention of 'equipment' in the 2023 figure aligns with the original answer, which includes both facilities and equipment. 2) Quantitatively, all numbers and timeframes are correct. The reduction from $3.4B to $0.9B is accurately portrayed, and no calculations are required beyond this comparison. Format variations (e.g., $3.4 billion vs $3.4B) are acceptable and do not affect accuracy. 3) The multi-hop reasoning is sound: the model correctly synthesizes data from two different years (2022 and 2023 filings) and draws a logical conclusion about strategic shift. The interpretation—that FedEx is scaling back its build-to-suit program and adopting a more conservative leasing strategy—is consistent with the ground truth’s conclusion about a strategic shift and extended timeline. The only minor gap is that the LLM answer does not explicitly mention the 'extended timeline for asset utilization' as stated in the original, though it is implied by the shift in commencement dates to 2025 onward. 4) The answer is contextually fully relevant, directly addressing both parts of the question: the evolution of financial commitments and the implication for leasing strategy. Wording differs slightly but maintains semantic equivalence. Overall, this is a highly accurate, well-supported response with only a slight omission in elaborating on the extended timeline, which prevents a perfect 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 476,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Mastercard's relationship with Dynamic Yield LTD evolved between 2023 and 2024, and what does this indicate about the company's strategic focus during this period?",
      "original_answer": "In 2023, Mastercard disclosed that it had acquired Dynamic Yield LTD in April 2022 for $325 million, with $200 million of goodwill attributed to synergies expected after the acquisition. By 2024, the relationship is described as stable, with no new investments or acquisitions involving Dynamic Yield reported during the year. This indicates that the integration of Dynamic Yield was largely completed by 2023, and Mastercard shifted focus to newer acquisitions like Recorded Future in 2024, signaling a strategic pivot toward cybersecurity and threat intelligence.",
      "llm_answer": "\nBetween 2023 and 2024 Mastercard did not acquire or dispose of any additional interest in Dynamic Yield LTD; the company remains part of the portfolio from the 2022 purchase, and the 2024 purchase of Recorded Future was undertaken to extend the analytics‑and‑threat‑intelligence capabilities that Dynamic Yield had introduced.  This continuity shows that Mastercard’s strategic focus in this period has been on deepening its data‑analytics and cybersecurity capabilities—leveraging acquired AI‑driven platforms to grow high‑margin, value‑added services and broaden its global payments ecosystem.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Mastercard did not acquire or dispose of additional interest in Dynamic Yield LTD between 2023 and 2024 and acknowledges the 2022 acquisition, which aligns with the ground truth. However, it incorrectly implies that the 2024 acquisition of Recorded Future was to extend capabilities introduced by Dynamic Yield, which is factually inaccurate—Dynamic Yield focuses on AI-driven personalization and decisioning, not cybersecurity or threat intelligence. The ground truth explicitly states that the acquisition of Recorded Future signals a strategic pivot *away* from Dynamic Yield’s domain and into cybersecurity, indicating a shift rather than continuity or extension. (2) Quantitatively, the LLM answer does not mention the $325 million acquisition price or the $200 million in goodwill attributed to synergies—key financial figures from the original answer. While no incorrect numbers are stated, the omission of these specific figures reduces quantitative completeness. Dates (2022 acquisition, 2023–2024 period) are correctly referenced. (3) The multi-hop reasoning is flawed: the model fails to recognize that the lack of new activity with Dynamic Yield in 2024, combined with the new acquisition of Recorded Future, indicates a strategic shift *from* personalization/AI analytics (Dynamic Yield) *to* cybersecurity (Recorded Future). Instead, it incorrectly frames Recorded Future as a complement to Dynamic Yield, reversing the strategic implication. (4) Contextual relevance is high—the answer addresses the evolution of the relationship and strategic focus. However, due to the misrepresentation of the strategic rationale and missing key financial data, the correctness score is reduced to 6, reflecting partially correct facts but significant errors in interpretation and synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 499,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has the Severance Plan for Senior Officers at Lowe's evolved between 2022 and 2024, particularly in terms of the most recent amendment dates and associated filings?",
      "original_answer": "In 2022, the Severance Plan for Senior Officers was described as 'amended and restated May 29, 2020' and was filed on August 26, 2020 (Exhibit 10.29). By 2024, the plan had been further amended and restated on May 26, 2022, with the updated version filed on November 27, 2024 (Exhibit 10.28). This indicates that Lowe's updated its Severance Plan for Senior Officers at least once between 2022 and 2024, with the most recent amendment occurring in mid-2022 and formally disclosed in late 2024.",
      "llm_answer": "\nThe Severance Plan for Senior Officers was most recently restated — amended and restated effective May 26 2022 — and that revision is identified as Exhibit 10.28 in the company’s Form 10‑Q.  The filing that includes this updated plan was filed on **November 27 , 2024**, which is the latest amendment date reflected in the provided documents; no subsequent amendment is listed for 2024, so the May 2022 restatement remains the most recent version through the 2024 filing.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the most recent amendment date of the Severance Plan for Senior Officers as May 26, 2022, and accurately states that it was filed on November 27, 2024, as Exhibit 10.28 in a Form 10-Q. These details match the ground truth. The 2022 version of the plan referencing the May 29, 2020 amendment and August 26, 2020 filing is not explicitly mentioned in the LLM answer, which constitutes a minor omission. (2) All quantitative elements — dates (May 26, 2022; November 27, 2024) and exhibit number (10.28) — are factually correct and match the ground truth. There are no calculation errors. (3) The reasoning is sound: the LLM correctly infers that the May 2022 restatement is the most recent version as of 2024, even though disclosed later, and synthesizes the timeline accurately. However, it does not fully address the evolution *between* 2022 and 2024 by omitting the prior state of the plan in 2022 (i.e., the 2020 amendment still being current at that time), which is part of the multi-hop requirement. (4) Despite this omission, the answer is highly relevant, factually accurate, and conveys the key update. The absence of the 2020 amendment context slightly reduces completeness but does not undermine the core correctness. Hence, a score of 9 is justified for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 394,
        "total_tokens": 1640
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the fair value of Netflix's 6.375% Senior Notes change between December 31, 2021, and December 31, 2023, and what does this evolution indicate about market perceptions of the company's debt over this period?",
      "original_answer": "The fair value of Netflix's 6.375% Senior Notes increased from $999 million as of December 31, 2021, to $872 million as of December 31, 2023. This indicates a decrease in the fair value of the notes over the two-year period, suggesting a potential decline in market confidence or an increase in required yields for this debt instrument.",
      "llm_answer": "\nThe 6.375 % Senior Notes were valued at **$999 million** on December 31 2021 (fair‑value Level 2 estimate), but by **December 31 2023** that same issue had fallen to **$872 million**, a decline of roughly **$127 million (≈13 %)**.  \n\nThis drop shows that market participants re‑priced the notes downward over the two‑year span—reflecting higher prevailing interest rates, widening credit spreads, or heightened concerns about Netflix’s leverage and cash‑flow outlook—indicating a more cautious or negative perception of the company’s debt during that period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the fair value of Netflix's 6.375% Senior Notes as $999 million on December 31, 2021, and $872 million on December 31, 2023, matching the ground truth exactly. The calculated decline of $127 million and approximate 13% decrease are accurate and correctly derived. (2) All numeric values, dates, and calculations are factually correct. The percentage drop is approximately (127/999) ≈ 12.7%, which rounds to 13%, so the ≈13% figure is appropriately qualified. (3) The multi-hop reasoning is sound: the model correctly identifies the change in fair value over time and synthesizes this into a market interpretation. It correctly infers that a decline in fair value indicates a negative shift in market perception, citing plausible drivers such as higher interest rates, wider credit spreads, and concerns about leverage and cash flow—consistent with the ground truth's implication of declining confidence. (4) The only minor shortcoming is that the original answer explicitly states the decrease 'suggests a potential decline in market confidence or an increase in required yields,' while the LLM adds slightly more specific causal factors (e.g., cash-flow outlook). While these are reasonable, they go slightly beyond the ground truth's more cautious 'potential decline' phrasing. However, the semantic meaning and direction of inference align closely. All entities—Netflix, 6.375% Senior Notes, correct dates, and financial metric—are accurate. The answer fully addresses both parts of the question: the quantitative change and its market implication.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 439,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the sales performance of IMBRUVICA evolve between 2022 and 2023, and what does this indicate about its market position in the oncology segment?",
      "original_answer": "IMBRUVICA's sales decreased from $4,369 million in 2022 to $3,264 million in 2023, representing a decline of 25.2%. This indicates a weakening market position for IMBRUVICA within the oncology segment, especially as other products like DARZALEX and ERLEADA experienced significant growth during the same period.",
      "llm_answer": "\nIMBRUVICA sales fell sharply – from **$3.78 billion in 2022 to $3.26 billion in 2023**, a **13.7 % decline** (see the 2023 sales‑by‑product table).  The drop is attributed to “global competitive pressures” and the loss of exclusivity that is eroding its market share, even though overall oncology sales grew 10.5 % driven by newer agents such as DARZALEX, ERLEADA, CARVYKTI and the launches of TECVAYLI and TALVEY.  Consequently, while IMBRUVICA remains a core oncology product, its growth has stalled and it is being overtaken by newer, higher‑growth oncology therapies.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, IMBRUVICA sales were $4,369 million in 2022, but the LLM incorrectly reports $3.78 billion ($3,780 million), which is off by nearly $600 million. The 2023 sales figure of $3,264 million is correctly stated as $3.26 billion. The calculated decline is therefore wrong: the LLM reports a 13.7% drop based on its incorrect figures, whereas the correct year-over-year decline is (4,369 - 3,264) / 4,369 = 25.2%, a substantial difference. (2) Despite these numerical errors, the qualitative reasoning is partially sound. The LLM correctly identifies competitive pressures and loss of exclusivity as drivers of declining sales and notes that newer oncology products like DARZALEX and ERLEADA are growing, which aligns with the ground truth. It also correctly observes that overall oncology sales are growing, indicating IMBRUVICA is losing relative market position. (3) The multi-hop reasoning is logically structured—linking declining sales to competitive dynamics and portfolio shifts—but is undermined by incorrect base data. The synthesis across factors (sales trend, competitive landscape, portfolio performance) is appropriate and relevant. (4) The contextual relevance is high because the answer addresses both parts of the question: sales evolution and implications for market position. However, the correctness score is low due to major factual and calculation errors in the quantitative foundation, which directly affect the validity of the conclusion. While the direction of change (decline) and the general market trend (being overtaken) are correct, the magnitude and supporting numbers are not, limiting reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 471,
        "total_tokens": 1693
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did LOW's inventory shrink reserve and LCNRV reserve evolve between 2022 and 2024, and what were the implications for net earnings?",
      "original_answer": "Between 2022 and 2024, LOW's inventory shrink reserve increased from $414 million to $427 million, while the LCNRV reserve increased from $168 million to $222 million. In 2024, a 10% change in either the amount of inventory subject to markdown or the weighted average estimated loss rate used in the LCNRV reserve calculation would have affected net earnings by approximately $17 million, and a 10% change in the estimated shrinkage rate would have impacted net earnings by approximately $32 million. These changes indicate a growing need for reserves, particularly for shrinkage, and highlight the increasing sensitivity of net earnings to inventory valuation assumptions.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 the inventory‑shrink reserve edged up from roughly **$425 million to $427 million** (an increase of about $2 million), while the lower‑of‑cost‑or‑net‑realizable‑value (LCNRV) reserve fell from about **$245 million to $222 million** (a decline of roughly $23 million).  The modest rise in the shrink reserve would shave roughly **$6–$7 million off net earnings** (≈ 10 % of the reserve changes equates to a $30‑$35 million earnings impact), whereas the reduction in the LCNRV reserve would add back about **$10–$15 million of earnings**, leaving overall net earnings essentially unchanged but with a slight net drag from the higher shrink reserve.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in key numbers. According to the ground truth, LOW's inventory shrink reserve increased from $414 million to $427 million (a $13M increase), but the LLM incorrectly states it rose from $425M to $427M (only $2M increase). More critically, the LLM claims the LCNRV reserve decreased from $245M to $222M, whereas the truth is it increased from $168M to $222M—an increase of $54M, not a decrease. These are major quantitative inaccuracies that reverse the actual trend. (2) The LLM fabricates earnings impact ranges: it claims a $6–$7M drag from shrink and $10–$15M gain from LCNRV reduction, but the ground truth states that a 10% change in LCNRV assumptions would affect net earnings by ~$17M and a 10% change in shrinkage rate by ~$32M. The LLM confuses actual reserve changes with hypothetical sensitivity impacts and misattributes earnings effects. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the direction and magnitude of reserve changes over time and misinterprets the nature of the sensitivity disclosures (which are hypothetical scenario analyses, not actual P&L impacts of reserve changes). (4) Despite incorrect numbers and reasoning, the answer is contextually relevant—it addresses the right company (LOW), the correct metrics (shrink and LCNRV reserves), and attempts to discuss implications for net earnings. However, due to severe factual and logical errors, the overall correctness score is very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 417,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did Qulipta's status and financial contribution evolve from 2022 to 2023, particularly in terms of its development and commercialization progress?",
      "original_answer": "In 2022, Qulipta was among the products that contributed to the reclassification of $1.0 billion of indefinite-lived research and development intangible assets to developed product rights upon receiving regulatory approvals. By 2023, Qulipta had transitioned from development to commercialization, generating $405 million in revenue in the United States and $3 million internationally, indicating a significant shift from a developmental asset to a revenue-generating product.",
      "llm_answer": "\nFrom 2022 to 2023 Qulipta moved from a near‑zero revenue base to a rapidly growing product: its U.S. net sales rose from $158 million to $405 million and international sales from $158 million to $408 million—a greater‑than‑100 % increase year‑over‑year. This surge was driven by the FDA’s April 2023 approval of Qulipta for the preventive treatment of chronic migraine (followed by EU approval in August 2023 and a January 2024 EU launch), which generated strong market‑share uptake and expanded its commercial footprint, making Qulipta an increasingly meaningful contributor to AbbVie’s net revenues.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 Qulipta did not have $158 million in U.S. or international sales; rather, it was part of a $1.0 billion reclassification of R&D assets upon regulatory approval, indicating it was still in development with no reported revenue. The LLM falsely claims $158 million in both U.S. and international sales in 2022, which is unsupported. Additionally, it states international sales reached $408 million in 2023, whereas the truth is only $3 million internationally—this is a massive overstatement. The 100%+ growth claim is therefore baseless. (2) The only correct number is the 2023 U.S. revenue of $405 million. All other figures—$158M in 2022 sales, $408M international in 2023—are incorrect. The FDA approval date (April 2023) is plausible but not confirmed in the ground truth; EU approval and January 2024 launch are extraneous and unverified. (3) The reasoning fails on multi-hop synthesis: the model incorrectly infers 2022 revenue from the asset reclassification, which was not revenue-generating at that stage. It conflates asset valuation with commercial sales. The transition from development to commercialization is correctly framed, but the financial evolution is misrepresented. (4) Despite correct mention of Qulipta’s growing role and U.S. revenue in 2023, the severe numerical inaccuracies and fabricated data points drastically reduce correctness. Contextual relevance is fair as it addresses development-to-commercialization, but quantitative accuracy is very low due to invented figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 441,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Honeywell's financial dependency on the Resideo subsidiary for environmental liabilities evolved between 2022 and 2023, and what does this indicate about the company's risk exposure?",
      "original_answer": "Honeywell's financial dependency on the Resideo subsidiary for environmental liabilities remained consistent between 2022 and 2023, with Resideo's subsidiary still obligated to pay 90% of Honeywell's annual net spending on environmental matters at specified sites, up to a maximum of $140 million per year. This ongoing arrangement indicates that Honeywell continues to rely on Resideo's payments to offset a significant portion of its environmental costs, suggesting that the risk mitigation strategy through this indemnification agreement has not changed over the two years.",
      "llm_answer": "\nBetween 2022 and 2023 the receivable that Honeywell records for 90 % of its environmental remediation costs rose from **$157 million to $187 million**, and the total outstanding amount due from Resideo (short‑ and long‑term) increased from roughly **$614 million to $661 million**.  This shows that Honeywell’s recovery of environmental spending from the Resideo subsidiary has grown markedly, making the company more dependent on those cash inflows, while the $140 million annual cap and the eventual termination of the obligation leave it exposed to any shortfall or disruption in Resideo’s payments.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that the Resideo subsidiary is obligated to pay 90% of Honeywell's annual net spending on environmental matters, capped at $140 million per year, and that this arrangement remained consistent between 2022 and 2023. However, the LLM claims that the receivable rose from $157 million to $187 million and that the total outstanding amount increased from $614 million to $661 million—figures not present in the ground truth and which contradict the $140 million annual cap. These numbers suggest Honeywell is receiving more than the contractual maximum annually, which is factually incorrect. (2) The quantitative inaccuracies are severe: the $157M to $187M increase implies annual recoveries exceeding the $140M cap, which violates the terms of the agreement. The cumulative receivable increase from $614M to $661M also lacks support in the original answer and introduces data not present in the knowledge base. (3) The multi-hop reasoning is partially sound—the LLM correctly infers that increased reliance on Resideo could heighten risk exposure if payments are disrupted—but this conclusion is based on fabricated data. The original answer emphasizes stability in the arrangement, not growing dependency. (4) While the LLM addresses the question’s intent and discusses risk exposure appropriately, the core financial facts are wrong, leading to an incorrect portrayal of evolving dependency. The contextual relevance is high because it attempts to analyze trends and implications, but correctness is low due to unsupported numbers. Thus, the correctness score is 4 (partially correct with major errors), quantitative accuracy is 3 (major number mismatches), qualitative accuracy is 5 (some logical reasoning but based on false premises), and contextual relevance is 8 (on-topic and analytically framed).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 513,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Target's definition or treatment of 'original maturity' for cash equivalents evolved between 2022 and 2024, and what does this indicate about potential changes in their cash management strategy?",
      "original_answer": "In 2022, Target defined cash equivalents as highly liquid investments with an original maturity of three months or less, with no additional context or clarification. By 2024, the company maintained the same three-month threshold for original maturity but added a broader discussion around fair value measurements for other short-term assets and liabilities, suggesting a more comprehensive approach to short-term financial instruments. This evolution indicates a potential refinement in how Target evaluates and manages its cash and near-cash assets within a broader financial framework.",
      "llm_answer": "\nTarget’s 2022 and 2024 filings both describe cash equivalents as “highly liquid investments with an original maturity of three months or less,” but the 2024 language tightens the phrasing to “original maturity of three months or less from the date of purchase” and explicitly adds that receivables from third‑party credit/debit‑card processors (which settle in five days) are also treated as cash equivalents.  \n\nThis modest evolution shows Target is refining—rather than overhauling—its definition to emphasize ultra‑short‑term, readily convertible assets, especially fast‑settling card‑transaction balances, indicating a strategic focus on tightening working‑capital liquidity and maximizing the speed of cash turnover.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While both the original and LLM answers agree that Target defines cash equivalents as investments with an original maturity of three months or less, the LLM incorrectly claims that in 2024, Target added language specifying 'from the date of purchase' and explicitly included receivables from credit/debit-card processors as cash equivalents. The ground truth does not support these additions—there is no mention of 'date of purchase' refinement or inclusion of card receivables in the definition. These are fabrications or misrepresentations not present in the original data. (2) Quantitatively, there are no numerical values (e.g., dollar amounts, percentages) in either answer, so accuracy hinges on correct characterization of time thresholds (three months), which the LLM gets right. However, the unsupported elaboration on settlement timing (e.g., 'five days') introduces false precision. (3) The multi-hop reasoning is partially sound—the LLM attempts to infer strategic implications about working capital and cash turnover, which aligns with the question’s intent. However, because the underlying factual evolution is incorrect, the reasoning is based on flawed premises. The original answer correctly identifies a shift toward broader fair value discussions without changing the core definition, indicating a more nuanced financial reporting approach, whereas the LLM invents operational changes not present in the filings. (4) Contextual relevance is high because the answer addresses the question’s structure—comparing definitions over time and interpreting strategic implications—but correctness and qualitative accuracy are undermined by unsupported details. The conclusion about refining cash management has some plausibility but is anchored in incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 500,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the valuation and classification of NVDA's 3.50% Notes Due 2040 evolve between 2023 and 2024, and what does this indicate about the company's long-term debt strategy?",
      "original_answer": "In 2023, the 3.50% Notes Due 2040 were listed under liabilities with a carrying value of $851 million as of January 28, 2024, and were categorized as Level 2 in the pricing hierarchy. By 2024, the valuation of the same notes increased to $1,000 million as of January 26, 2025, with a more detailed breakdown including an effective interest rate of 3.54% and a remaining term of 15.2 years. This indicates a strategic emphasis on long-term financing with stable interest rate structures.",
      "llm_answer": "\nBetween the 2023 and 2024 fiscal years the 3.50 % Notes Due 2040 remained classified in the Level 2 tier of NVIDIA’s fair‑value hierarchy (i.e., they are valued using observable market inputs for comparable debt securities rather than quoted prices for identical instruments).  Their reported fair‑value slipped modestly from **$870 million (Jan 29 2023)** to **$851 million (Jan 28 2024)**, while the carrying amount stayed essentially flat at **$1.0 billion** (reflecting amortized cost and the effect of the debt‑discount amortization).  \n\nThis stability in classification and the modest fair‑value decline indicate that NVIDIA continues to treat the 2040 notes as a core component of its long‑term, low‑coupon financing mix—issuing long‑dated senior unsecured debt that is regularly rolled or refinanced as needed, while relying on market‑based (Level 2) valuation rather than mark‑to‑market volatility to support its capital‑structure strategy.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in the quantitative details. According to the ground truth, in 2023 the carrying value of the 3.50% Notes Due 2040 was $851 million as of January 28, 2024 (filing date for FY2023), not $870 million as of January 29, 2023 as claimed. The LLM incorrectly states a 'slip' in fair value from $870M to $851M, but the ground truth does not provide a 2022 or 2023 fair value—only a 2023 carrying value of $851M and a 2024 valuation of $1,000 million. The LLM also misrepresents the 2024 value: the ground truth reports a valuation of $1,000 million as of January 26, 2025 (FY2024), but the LLM fails to mention this increase and instead incorrectly implies the carrying amount remained at $1.0 billion without change. Additionally, the LLM introduces a 'fair-value' decline not supported by the ground truth, which focuses on carrying and updated valuation, not fair-value fluctuations. (2) The effective interest rate of 3.54% and remaining term of 15.2 years in 2024—key details in the original answer—are entirely missing from the LLM response. (3) While the LLM correctly identifies the Level 2 classification in both years, indicating consistent valuation methodology, it misframes the narrative around a 'modest decline' in fair value, which contradicts the ground truth showing an increase in valuation from $851M to $1,000M. This undermines the reasoning about long-term debt strategy: the ground truth interprets the increase as a sign of strategic emphasis on long-term financing, while the LLM incorrectly infers stability due to a supposed decline. (4) Despite these errors, the LLM captures the correct entity (NVDA), correct note (3.50% Due 2040), correct classification (Level 2), and broadly correct strategic interpretation—though based on flawed data. The reasoning is logically structured and contextually relevant, but the quantitative inaccuracies significantly reduce factual correctness. Hence, the correctness score is 5 (partially correct with major errors), quantitative accuracy is 4 (several wrong numbers), qualitative accuracy is 6 (sound reasoning framework but based on incorrect data), and contextual relevance is 8 (on-topic and addresses the right concepts).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 605,
        "total_tokens": 1971
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the financial performance of Venclexta evolve between 2022 and 2023, particularly in terms of total global revenue and the growth rate?",
      "original_answer": "In 2022, Venclexta generated a total global revenue of $2,009 million, with a growth rate of 10.4%. In 2023, the total global revenue from Venclexta increased to $2,288 million, representing a growth rate of 13.9%. This indicates an upward trend in both absolute revenue and growth rate year-over-year.",
      "llm_answer": "\nBetween 2022 and 2023 AbbVie’s Venclexta net revenue rose from **$2,009 million to $2,288 million**—an **≈13.9 % increase at actual currency rates** (about **15 % at constant currency**). The growth was driven by an **8 % rise in U.S. sales** and a **22 % jump in international sales**, translating into an overall **~15 % global revenue expansion** for the product in 2023.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the total global revenue for Venclexta in 2022 ($2,009 million) and 2023 ($2,288 million), matching the ground truth. The year-over-year growth rate from 2022 to 2023 is accurately calculated as approximately 13.9% ((2,288 - 2,009) / 2,009 ≈ 0.1386 or 13.86%, rounded to 13.9%), which aligns with the ground truth. However, the LLM introduces additional figures not present in the original answer—specifically, '15% at constant currency', '8% U.S. sales increase', and '22% international sales'—which, while potentially accurate from another data source, are not part of the verified ground truth and add unverified detail. (2) The core numbers (revenues and growth rate) are quantitatively accurate, but the mention of '15% global revenue expansion' conflicts with the ground truth's stated 13.9% growth rate, creating a discrepancy. This may stem from conflating constant currency with actual growth. (3) The reasoning is mostly sound: the model identifies the correct product (Venclexta), company (AbbVie), and time frame (2022–2023), and performs the correct multi-hop comparison of revenues across years. However, it adds granular regional breakdowns and alternate growth metrics not supported by the provided ground truth, suggesting either overextrapolation or use of external data. (4) The answer is contextually relevant and addresses the evolution of financial performance. The correctness score is 7 due to accurate core data but minor inaccuracies in reported growth rates and inclusion of unsupported details. Quantitative accuracy is 8 because primary numbers are correct but secondary percentages vary. Qualitative accuracy is 7 due to sound reasoning but overextension with unverified metrics. Contextual relevance is 10 as all key aspects of the question are directly addressed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1168,
        "completion_tokens": 498,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How has Netflix's approach to executive severance and retention incentives evolved between the 2022 and 2023 SEC filings, particularly in terms of plan amendments and their effective dates?",
      "original_answer": "In 2022, the filing referenced the 'Amended and Restated Executive Severance and Retention Incentive Plan' with a filing date of September 10, 2021, indicating that the plan had undergone revisions by that date. By 2023, the filing showed further evolution, introducing the 'Executive Severance and Retention Incentive Plan as Amended and Restated effective January 1, 2024,' with a filing date of December 8, 2023. This demonstrates Netflix’s ongoing adjustments to executive compensation frameworks, with a forward-looking amendment effective in 2024.",
      "llm_answer": "\nBetween the 2022 and 2023 filings Netflix updated its executive‑severance framework. The 2022 10‑K disclosed the Amended and Restated Executive Severance and Retention Incentive Plan (originally adopted September 10 2021), while the 2023 10‑K includes a further amendment and restatement of that plan, which the company filed in an 8‑K on December 8 2023 and set to become effective January 1 2024. This restated plan revises the severance and retention terms and marks the most recent evolution of the company’s executive‑incentive approach.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: the 2022 filing references the 'Amended and Restated Executive Severance and Retention Incentive Plan' adopted on September 10, 2021; the 2023 filing discloses a further amendment filed on December 8, 2023, effective January 1, 2024. (2) Quantitative accuracy is perfect: dates (September 10, 2021; December 8, 2023; January 1, 2024) match exactly between the LLM and ground truth. (3) Multi-hop reasoning is sound—LLM correctly synthesizes information across two years of filings, identifies the evolution of the plan, and notes the forward-looking effective date. (4) The answer addresses all parts of the question: plan amendments, effective dates, and the evolution between 2022 and 2023. Wording differs slightly (e.g., reference to 8-K filing), but this adds contextual precision without distorting facts. No omissions or inaccuracies. All scores are maximized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 283,
        "total_tokens": 1567
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did Lowe's documentation and structure of its Benefit Restoration Plan evolve from 2022 to 2024, and what does this indicate about the company's approach to employee retirement benefits?",
      "original_answer": "In 2022, Lowe's maintained the Benefit Restoration Plan as part of its defined contribution retirement offerings, supplementing benefits under the 401(k) Plan for employees affected by IRS limitations. The plan included both employee salary deferrals and employer contributions in the form of a Company Match. By 2024, the company formally introduced an updated and restated version of the Benefit Restoration Plan, effective January 1, 2025, as evidenced by the new exhibit filing (10.3) in the 2024 10-K. This indicates a deliberate effort to formalize and likely enhance the structure of the plan, signaling a more strategic and forward-looking approach to managing executive and high-earner compensation through improved documentation and alignment with long-term benefit policies.",
      "llm_answer": "\nFrom 2022 to 2024 Lowe’s moved the Benefit Restoration Plan from a brief narrative description in the 2022 10‑K (Note 12 – “The Company maintains a Benefit Restoration Plan to supplement benefits provided under the 401(k) Plan…”) to a formally codified, exhibit‑level amendment that is “amended and restated as of January 1 2025” (Exhibit 10.3 in the 2024 filing).  The 2024 filing also bundles the plan with related retirement‑plan documents (the 401(k) Plan, the Cash Deferral Plan, and various amendment notices), indicating a more structured, consolidated approach to retirement‑benefit governance.  This evolution signals that Lowe’s is tightening the documentation and oversight of its supplemental retirement benefits, treating the Restoration Plan as a formal, stand‑alone component of its broader employee‑benefits framework rather than an after‑thought.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 2022 description of the Benefit Restoration Plan as a narrative in Note 12, its purpose to supplement 401(k) benefits due to IRS limits, and the 2024 filing of a formally updated and restated version (Exhibit 10.3) effective January 1, 2025. These details match the original answer exactly. (2) Quantitative elements—dates (January 1, 2025), exhibit number (10.3), and document types (10-K, Note 12)—are all factually correct and consistent with the ground truth. Format and references are precise. (3) The reasoning is sound: the LLM correctly infers that moving from a footnote to a standalone exhibit indicates a more formal, structured approach to retirement benefits, reflecting improved governance. It adds value by noting the bundling of related documents, which strengthens the conclusion about consolidation and strategic oversight. (4) The answer fully addresses both parts of the question: the evolution of documentation/structure and what it indicates about Lowe’s approach. The only minor gap is that the LLM does not explicitly mention employer contributions (Company Match) as part of the plan structure in 2022, which was included in the ground truth. However, this omission does not undermine the core accuracy or interpretation. Overall, the answer demonstrates strong multi-hop synthesis across years and document types, with excellent contextual relevance and factual precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 413,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did NVDA's financial obligations related to the 0.584% Notes Due 2024 evolve between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal year 2023, NVDA reported a liability of $1,185 million for the 0.584% Notes Due 2024. By fiscal year 2024, this obligation was fully repaid, as stated in the 2024 10-K filing. This indicates a complete resolution of this specific debt obligation over the two-year period.",
      "llm_answer": "\nBetween the end of fiscal 2023 and fiscal 2024 the carrying amount of NVIDIA’s 0.584 % Notes Due 2024 grew from about **$1.185 billion** (shown on page 67 for Jan 28 2023) to roughly **$1.250 billion** (shown on page 72 for Jan 28 2024), an increase of roughly **$65 million**.  The notes were then fully retired in fiscal 2025, leaving a zero balance thereafter.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual and reasoning errors. (1) Quantitatively, the LLM incorrectly states that the carrying amount of the 0.584% Notes Due 2024 increased from $1.185 billion in fiscal 2023 to $1.250 billion in fiscal 2024. The ground truth states that the obligation was fully repaid by fiscal year 2024, meaning the liability should have decreased to zero, not increased. The $1.250 billion figure and the $65 million increase are factually incorrect. (2) The LLM claims the notes were 'fully retired in fiscal 2025', but the original answer and 2024 10-K confirm repayment occurred in fiscal 2024, making the timeline wrong. (3) Qualitatively, the reasoning is flawed: instead of recognizing the repayment of debt, the model suggests an increase in liability, which contradicts the actual resolution of the obligation. It fails the multi-hop requirement to compare the liability across two fiscal years and draw the correct conclusion about its retirement. (4) Contextually, the answer addresses the right company (NVDA), debt instrument, and general time frame, so it is relevant, but the core financial evolution is misrepresented. Minor formatting of $1.185 billion vs $1,185 million is acceptable, but the substantive financial narrative is incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1153,
        "completion_tokens": 356,
        "total_tokens": 1509
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did the global revenue performance of Mavyret evolve between 2022 and 2023, and what were the trends in its United States and international markets during this period?",
      "original_answer": "In 2022, Mavyret generated total global revenue of $1,541 million, with $755 million from the United States and $786 million from international markets. By 2023, total revenue from Mavyret decreased to $1,430 million, driven by a decline in both U.S. and international markets. Specifically, U.S. revenue dropped to $659 million, a decrease of 12.7%, while international revenue slightly declined to $771 million, a marginal decrease of 1.9%. This indicates a contraction in Mavyret's market performance across both regions, with a more pronounced decline in the U.S. market.",
      "llm_answer": "\nMavyret’s worldwide net revenue slipped 7 % year‑over‑year, falling from **$1.54 billion in 2022 to $1.43 billion in 2023**. The decline was driven primarily by the U.S. market, where sales dropped **13 %** to **$659 million**, while international sales were almost flat, decreasing only **2 %** to **$771 million**.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key financial figures are correct: $1.54 billion (2022) and $1.43 billion (2023) global revenues match the original $1,541 million and $1,430 million (rounded appropriately). U.S. revenue correctly stated as $659 million in 2023 (down from $755 million), and international revenue as $771 million (down from $786 million). (2) Percentages are accurately approximated: the 12.7% U.S. decline is rounded to 13%, and the 1.9% international decline is rounded to 2% — acceptable under semantic equivalence and common reporting practices. The overall 7% global decline is correctly calculated ((1,541 - 1,430)/1,541 ≈ 7.2%), and the LLM's 7% is a valid rounding. (3) Multi-hop reasoning is sound: the model correctly synthesizes data across U.S. and international markets, identifies the decline in both regions, and attributes the global drop to both, with stronger impact from the U.S. (4) Minor rounding of percentages and revenue (e.g., $1.54B vs $1,541M) does not affect factual correctness. The answer is concise, relevant, and fully addresses the evolution of global revenue and trends in both markets. No entity errors; all metrics and years are correct. Thus, the answer earns a 9 due to slight rounding without explicit acknowledgment, but remains factually and semantically aligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 389,
        "total_tokens": 1618
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Netflix's compliance with covenant limitations related to its Senior Notes evolve between 2022 and 2024, particularly in terms of repayment obligations and the scope of restrictions?",
      "original_answer": "In 2022, Netflix was in compliance with all covenant limitations tied to its Senior Notes, which included restrictions on creating liens, entering into sale and lease-back transactions, incurring additional indebtedness by certain subsidiaries, and merging or transferring substantial assets. These notes included various euro-denominated tranches with principal amounts totaling €5,170 million. By 2024, Netflix remained in compliance with these covenants, but the scope of limitations had slightly evolved—specifically, certain Senior Notes no longer referenced restrictions on sale and lease-back transactions, suggesting a narrowing of covenant scope for some notes. Additionally, in 2024, Netflix repaid $400 million of its 5.750% Senior Notes upon maturity, indicating active debt management and a shift in its debt composition.",
      "llm_answer": "\nBetween 2022 and 2024 Netflix’s senior‑note covenants – which restrict additional indebtedness, mergers, asset sales, liens and other corporate actions – remained materially the same, and the company continued to be in compliance with them (the 2024 filing notes “the Company was in compliance with all related covenants” as of 12/31/24, just as it had been in 2021 and 2020).  However, the **repayment burden grew**: the 5.750 % senior notes maturing in March 2024 were fully repaid ($400 million), and new notes (e.g., the 4.900 % due 2034 and 5.400 % due 2054) were issued, pushing total outstanding senior‑note principal to about $15.6 billion by the end of 2024 (up from roughly $15.4 billion in 2021).  Thus, while the scope of covenantal restrictions did not broaden, the **scale of debt and associated repayment obligations increased**, and Netflix maintained compliance throughout the period.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Netflix's ongoing compliance with covenants in both 2022 and 2024 and notes the repayment of $400 million of 5.750% Senior Notes in March 2024, which aligns with the ground truth. However, it introduces inaccuracies by claiming total senior-note principal increased to $15.6 billion by end-2024 from $15.4 billion in 2021—this misrepresents the time frame (question focuses on 2022–2024) and lacks support in the original answer, which does not provide total dollar principal figures. The issuance of new notes (4.900% due 2034 and 5.400% due 2054) is plausible but not confirmed in the ground truth, making this an unsupported inference. (2) Quantitative accuracy is partially compromised: while the $400 million repayment and 5.750% rate are correct, the $15.6B and $15.4B figures are not present in the original answer, nor is there confirmation of net debt growth. The original answer mentions €5,170 million in euro-denominated tranches in 2022 but does not give total global principal or 2024 totals. (3) The multi-hop reasoning is sound in linking compliance across years and recognizing debt repayment as part of evolving obligations, but it misses a key qualitative shift noted in the ground truth: the narrowing of covenant scope in 2024, specifically the removal of sale and lease-back restrictions in certain notes. This omission weakens the analysis of how the 'scope of restrictions' evolved. Instead, the LLM claims the covenants were 'materially the same,' which contradicts the ground truth. (4) Contextual relevance is high—the response addresses compliance, repayment, and covenant scope as asked. However, due to significant quantitative overreach and failure to capture the narrowing of covenants, the correctness score is limited to 6, reflecting partial accuracy with notable factual and inferential gaps.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1445,
        "completion_tokens": 508,
        "total_tokens": 1953
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Honeywell's approach to the Safety and Retail product line evolve between 2022 and 2023, and what structural change was introduced in 2023 that reflects this evolution?",
      "original_answer": "In 2022, Honeywell reported the Safety and Retail business unit as a standalone component under the Safety and Productivity Solutions segment, generating $2,387 million in revenue. By 2023, the company had realigned its organizational structure, merging the Safety and Retail unit with the Advanced Sensing Technologies unit to form a new business unit called Sensing and Safety Technologies. This structural change, introduced in July 2022 but reported in the 2023 filing, reflects a strategic shift toward integrating sensing capabilities with safety solutions to enhance technological offerings and streamline operations.",
      "llm_answer": "\nBetween 2022 and 2023 Honeywell stopped treating the Safety‑and‑Retail offering as a stand‑alone business unit and instead combined it with its Advanced Sensing Technologies group to create a single “Sensing and Safety Technologies” unit.  In 2023 the company formalized this integration in its segment reporting—re‑classifying the former Safety‑and‑Retail line under the new Sensing and Safety Technologies sub‑segment of the Safety and Productivity Solutions segment—thereby consolidating the safety‑related products and eliminating the separate Retail designation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the essential evolution in Honeywell's approach to the Safety and Retail product line between 2022 and 2023. (1) It correctly states that Safety and Retail was previously a standalone unit and was merged with Advanced Sensing Technologies to form 'Sensing and Safety Technologies'—matching the ground truth. (2) Quantitative accuracy is perfect: while the LLM does not explicitly mention the $2,387 million revenue figure from 2022, this omission does not distort the answer, as the question focuses on structural evolution rather than financial performance. All other dates and entities (e.g., July 2022 realignment reported in 2023 filing) are correctly implied through context. (3) The multi-hop reasoning is sound—LLM synthesizes changes in organizational structure and reporting practices across years, correctly identifying the integration as a formal reclassification in 2023 reporting. (4) The only minor shortcoming is the lack of explicit mention of the $2.387B revenue figure and the precise timing (July 2022) of the structural change, which slightly reduces completeness but does not affect the core correctness. The answer remains semantically equivalent in intent and factual substance, with excellent contextual relevance and clear qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 365,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has the status and role of Class B-2 Common Stock evolved between 2023 and 2024, particularly in terms of its convertibility and impact on corporate governance?",
      "original_answer": "In 2023, Class B-2 Common Stock was described as part of a structure that would become convertible into Class A Common Stock, with potential dilutive effects on voting power and market price. It also played a role in approving significant corporate actions, indicating a governance influence. By 2024, no shares of Class B-2 Common Stock were outstanding prior to the Class B-1 Common Stock exchange offer, suggesting a strategic shift in equity structure. This indicates a transformation in the role of Class B-2 Common Stock, moving from an active governance and conversion position to a non-outstanding status, reducing its influence on corporate decisions.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 the outstanding balance of class B‑2 common stock fell dramatically – the combined B‑1 + B‑2 shares dropped from 245 million to 125 million – reflecting a conversion/retirement of most B‑2 shares as part of the class B‑1 exchange offer.  Class B‑2 remains convertible into class A common stock, with full conversion scheduled under the Europe‑retrospective responsibility plan no later than 2028; any conversion would increase the number of class A shares and dilute the voting power of existing class A shareholders.  Because holders of B‑2 (together with B‑1 and the preferred series) must approve certain mergers, consolidations and other major transactions, their limited but pivotal voting rights give them a gate‑keeping role that can conflict with class A shareholders and thereby shape Visa’s corporate‑governance dynamics.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to correctly represent the evolution of Class B-2 Common Stock between 2023 and 2024. (1) Quantitative Accuracy: The claim that 'combined B-1 + B-2 shares dropped from 245 million to 125 million' is unsupported by the ground truth and introduces specific numbers not present in the original answer. The mention of a 'Europe-retrospective responsibility plan' and a '2028' conversion deadline is entirely fabricated and not in the original data. (2) Completeness: While the question asks about the evolution in convertibility and corporate governance impact, the LLM incorrectly asserts that Class B-2 remains convertible and active in governance, whereas the ground truth states that no shares were outstanding by 2024, indicating it was effectively eliminated. (3) Entity Accuracy: The reference to 'Visa’s corporate-governance dynamics' is incorrect — the original answer does not mention Visa or any specific company, nor does it reference any 'preferred series' or 'exchange offer' details. (4) Reasoning: The multi-hop synthesis is flawed — the LLM infers ongoing governance influence and future conversion plans despite the ground truth stating that Class B-2 was no longer outstanding in 2024, which negates its role. (5) Semantic Equivalence: The core message contradicts the ground truth: instead of a transition from active to non-outstanding status, the LLM portrays Class B-2 as still extant and convertible. The only partially correct aspect is the general idea of conversion potentially causing dilution, but even this is misattributed to a future event rather than a structural feature that became obsolete. Overall, the answer fabricates details, misrepresents the timeline, and fails to capture the key transformation: the elimination of Class B-2 shares.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 495,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has The Home Depot's approach to enhancing the ease of shopping experience evolved between 2023 and 2024, particularly in terms of digital and in-store capabilities?",
      "original_answer": "In 2023, The Home Depot focused on improving the ease of shopping experience by investing in mobile app-enabled store navigation, electronic shelf labels, reconfigured service desks, and enhanced self-checkout options. These efforts were aimed at improving store navigation, convenience, and checkout speed. By 2024, the company expanded its focus to include more personalized digital experiences, such as customer product review summaries and enhanced product content, while continuing to invest in digital platforms to improve navigation and 'shopability.' The 2024 strategy placed greater emphasis on leveraging customer data to meet personalized expectations, indicating a shift toward deeper integration of data-driven insights into the shopping journey.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Home Depot deepened its “interconnected shopping experience” by coupling continued store‑level upgrades—such as refreshed layouts, way‑finding signage, expanded self‑checkout and curbside‑pickup options, electronic shelf‑labeling, and mobile‑app navigation tools—with a suite of digital enhancements that make online research and in‑store fulfillment seamless.  The company also boosted associate productivity and safety through newer handheld “hdPhone” devices, the Sidekick inventory‑guidance app, and Computer‑Vision vision systems, while expanding same‑day/next‑day delivery, omni‑channel fulfillment centers, and a broader network of BOPIS/BOSS pickup points to meet customers’ expectations for speed, convenience, and personalized service across both digital and physical channels.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the original answer in terms of the evolution of The Home Depot's shopping experience from 2023 to 2024. It accurately captures the continuation of in-store improvements such as electronic shelf labels, self-checkout, mobile app navigation, and service desk reconfiguration (referred to as 'refreshed layouts' and 'way-finding signage'), which were emphasized in 2023. The LLM also correctly identifies the expansion into digital and omnichannel capabilities in 2024, including enhanced digital platforms, BOPIS/BOSS, same-day delivery, and omni-channel fulfillment—consistent with the ground truth's focus on improved 'shopability' and seamless online-to-in-store experiences. However, the LLM answer introduces specific tools (e.g., 'hdPhone', 'Sidekick app', 'Computer-Vision systems') and operational details not present in the original answer, which, while plausible, are not verifiable from the ground truth and slightly shift focus toward associate tools rather than customer-facing personalization. The original answer emphasizes 2024's strategic shift toward leveraging customer data for personalized experiences—such as product review summaries and enhanced content—which the LLM answer omits or underemphasizes. There are no numerical values to verify, so quantitative accuracy is 10. Contextual relevance is strong as all content directly addresses the question. The qualitative accuracy is slightly reduced due to the omission of the key 2024 shift to data-driven personalization and the introduction of unverified tools, but the overall reasoning and synthesis across years and channels remain sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 453,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has the structure of the Target Corporation Long-Term Incentive Plan evolved from 2022 to 2024, particularly in terms of the specific forms of equity awards included under the plan?",
      "original_answer": "In 2022, the Long-Term Incentive Plan included forms such as Non-Qualified Stock Options, Restricted Stock Units, Performance-Based Restricted Stock Units, Performance Share Units, Price-Vested Stock Options, Non-Employee Director Non-Qualified Stock Options, and Non-Employee Director Restricted Stock Units. By 2024, the plan introduced new forms of equity awards, including the Cliff-Vested Restricted Stock Unit Agreement and the Performance Award Performance Share Unit Agreement, indicating an expansion in the types of equity compensation vehicles available under the plan.",
      "llm_answer": "\nFrom 2022 through 2024 Target’s Long‑Term Incentive Plan moved from a primarily option‑ and performance‑share‑unit‑focused design (see the 2022 10‑K disclosures of SPP I/II and the 2020 LTIP on pages 65‑69) to a broader suite of restricted‑stock‑unit awards.  The 2024 filing (pages 73‑75) lists explicit award forms—performance‑based RSUs, performance‑share units, cliff‑vested RSUs, non‑employee director RSUs, and a dedicated performance‑award performance‑share‑unit agreement—showing that the plan now incorporates multiple, more granular equity‑award types that replace or supplement the earlier stock‑option and basic performance‑share structures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. It correctly identifies the evolution of Target Corporation's Long-Term Incentive Plan from 2022 to 2024, noting the shift toward a broader range of restricted stock unit (RSU) awards. The specific forms of equity awards mentioned in the 2024 plan—performance-based RSUs, performance-share units, cliff-vested RSUs, non-employee director RSUs, and the Performance Award Performance Share Unit Agreement—are all consistent with the original answer, even if not listed exhaustively. The introduction of 'cliff-vested RSUs' and 'performance-award performance-share-unit agreement' as new forms in 2024 is correctly highlighted, aligning with the ground truth's emphasis on expansion. The reference to 2022 including stock options and performance-based structures is accurate, though the LLM slightly deemphasizes the full list from 2022 (e.g., Non-Qualified Stock Options, Price-Vested Stock Options) without misrepresenting them. There are no numerical inaccuracies—dates (2022, 2024), award types, and structural evolution are all correct. The reasoning is sound, demonstrating multi-hop synthesis across years and plan structures. Minor deduction in qualitative accuracy due to less explicit enumeration of 2022 award types, but overall synthesis and conclusion remain valid. Contextual relevance is perfect—the response directly addresses the evolution in equity award forms over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 404,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Qulipta's commercial performance evolve from its FDA approval in 2021 through 2023, based on AbbVie's financial disclosures?",
      "original_answer": "Qulipta was approved by the FDA in September 2021 for the preventive treatment of episodic migraine in adults, marking its entry into the market. By 2023, Qulipta had generated $405 million in U.S. revenue and $3 million internationally, totaling $408 million. This indicates a significant commercial trajectory following its approval, especially considering it had no revenue in 2021 and only $158 million in U.S. revenue in 2022. The product demonstrated strong growth, suggesting robust market adoption and positioning within AbbVie's portfolio.",
      "llm_answer": "\nAfter its September 2021 FDA approval, Qulipta generated about **$1.71 billion** in net sales in 2021.  The following year sales slipped modestly to **$1.54 billion** (‑9.9% YoY), but in 2023 the product’s revenue **more than doubled**—an increase of **>100%** year‑over‑year (≈ $3.5 billion) driven by continued market‑share gains and the 2023 EU launch—while constant‑currency growth was **5.7%** for the year.  Thus, Qulipta’s commercial trajectory was flat in 2022 and then accelerated sharply in 2023.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains almost entirely incorrect information. According to the ground truth, Qulipta had no revenue in 2021, $158 million in U.S. revenue in 2022, and $408 million total revenue in 2023 ($405M U.S., $3M international). The LLM claims $1.71 billion in 2021, $1.54 billion in 2022, and ~$3.5 billion in 2023—numbers that are 4–8x higher than actual. These figures are not only wrong but suggest a completely different commercial trajectory. (2) All numeric values are incorrect: revenue amounts, year-over-year changes (LLM claims -9.9% then >100% growth; actual growth was from $0 to $158M to $408M, i.e., strong growth in both 2022 and 2023), and the claim of a 2023 EU launch is unsupported in the ground truth (international revenue was only $3M in 2023, suggesting minimal ex-U.S. presence). (3) The multi-hop reasoning is fundamentally flawed: the model fails to correctly synthesize AbbVie’s financial disclosures over time, misrepresents the timeline of revenue generation (implying major sales in 2021), and invents a growth narrative around EU expansion not present in the original data. (4) The contextual relevance is low because the answer discusses EU launches and massive global sales not mentioned in the ground truth, which focuses on U.S. commercial performance and modest international revenue. The only correct detail is the September 2021 FDA approval date. Due to pervasive factual and quantitative errors, the correctness score is near-minimal.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 413,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has Netflix's treatment and disclosure of the 2020 Stock Plan evolved between the 2022 and 2024 SEC filings, particularly in terms of its structural description and associated equity compensation activities?",
      "original_answer": "In 2022, the 2020 Stock Plan was referenced primarily through its inclusion in the exhibit list as a filed document (Def 14A, filed April 22, 2020), with no detailed description of its provisions or activities. In contrast, by 2024, the 2020 Stock Plan was not only explicitly described in detail but also linked to specific equity compensation activities, including the granting of incentive stock options, nonstatutory stock options, and restricted stock units (RSUs) with defined vesting schedules and performance-based criteria. This represents a significant shift from mere documentation to a more comprehensive disclosure of the plan's operational role in equity compensation.",
      "llm_answer": "\nBetween the 2022 and 2024 filings Netflix shifted from a brief, high‑level mention of the 2020 Stock Plan in the 2022 10‑K to a comprehensive, structured disclosure in the 2024 10‑K. The 2024 filing explicitly defines the plan as a stockholder‑approved vehicle that grants incentive and non‑statutory options, RSUs and PSUs, and includes detailed quantitative tables of option grants, exercises, expirations, weighted‑average exercise prices, remaining terms, intrinsic value, as well as RSU/PSU activity, stock‑based compensation expense and unrecognized compensation cost. This evolution reflects a move from a generic reference to a full, transparent presentation of the plan’s structure and the company’s recent equity‑compensation activities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in Netflix's disclosure: from a minimal reference in 2022 to a detailed, structured presentation in 2024. The 2022 filing indeed only listed the 2020 Stock Plan in the exhibit list (Def 14A, filed April 22, 2020) without substantive description, which the LLM captures as a 'brief, high-level mention.' In 2024, the plan is described in detail with specific equity instruments—ISOs, NSOs, RSUs, and PSUs—matching the ground truth's mention of incentive/nonstatutory options and RSUs with vesting and performance criteria. (2) There are no numeric values in the original answer, so quantitative accuracy is not applicable in a traditional sense, but all dates and document references are consistent with the ground truth (e.g., correct plan year 2020, correct filing context). (3) The multi-hop reasoning is sound: the model synthesizes changes in disclosure depth across two time points and correctly infers a shift toward transparency and operational detail. The mention of PSUs (Performance Stock Units) is a slight expansion beyond the ground truth’s 'performance-based criteria' but is semantically reasonable and factually plausible given such criteria typically tie to PSUs. (4) The LLM enhances the original answer with additional specifics like quantitative tables, stock-based compensation expense, and unrecognized cost—details not in the ground truth but consistent with typical 10-K disclosures and do not contradict the known facts. These additions improve completeness without introducing error. Minor deduction in qualitative accuracy due to slight over-enrichment, but overall the answer is factually correct, contextually precise, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 482,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did the company's approach to aluminum purchase agreements evolve between 2022 and 2023, particularly in terms of their classification and strategic use of derivative instruments?",
      "original_answer": "In 2022, the company described its aluminum purchase agreements as derivative instruments entered into for long-term strategic sourcing objectives and non-U.S. business requirements. By 2023, the company continued to use these agreements but provided additional clarity that the quantities of aluminum in these contracts offset each other and are priced at prevailing market prices. This evolution indicates a more refined strategy around market pricing alignment and potentially reduced exposure through offsetting positions.",
      "llm_answer": "\nBetween 2022 and 2023 the company kept its aluminum purchase contracts in the “derivatives not receiving hedge‑accounting treatment” category, so they are carried at fair value with gains and losses recorded in other income rather than in OCI.  The quantitative exposure also contracted sharply—commodity‑derivative not‑hedge contracts fell from roughly $412 million of notional amount in 2022 to about $115 million in 2023—reflecting a more selective, strategic use of these agreements for long‑term sourcing and non‑U.S. business needs rather than broad price‑risk hedging.  (Pages 102 and 104).",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer provides relevant context about the company's use of aluminum purchase agreements as derivatives and their classification in financial statements, which aligns with the question’s focus on classification and strategic use. It correctly identifies that these derivatives were not receiving hedge accounting and were used for strategic sourcing and non-U.S. business needs—consistent with the 2022 description in the ground truth. However, the quantitative details introduced ($412 million in 2022, $115 million in 2023) are not present in the original answer and cannot be verified against the ground truth, which mentions no specific dollar amounts or notional values. This introduces factual inaccuracies that significantly impact correctness. Additionally, while the LLM describes a reduction in notional exposure, the original answer emphasizes a qualitative evolution: clarification that contract quantities offset each other and are priced at prevailing market prices—highlighting improved market alignment and risk management through offsetting positions. This key strategic nuance is missing in the LLM response. The reasoning is partially sound and contextually appropriate, showing awareness of derivative classification and strategic intent, but fails to capture the core multi-hop insight about offsetting positions and pricing mechanisms. Thus, while the answer is relevant and contains plausible financial reporting details, it substitutes unverified quantitative claims for the actual qualitative evolution described in the ground truth, leading to a partially correct but factually divergent response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 443,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has the disclosure or treatment of the Directors' Code of Conduct evolved between 2023 and 2024, particularly in terms of its accessibility and scope?",
      "original_answer": "In 2023, the Directors' Code of Conduct was explicitly referenced and posted on the company's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/inv relations/directors-code-of-conduct.pdf. In 2024, the URL for the Directors' Code of Conduct changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf, indicating a shift in how the document is categorized or accessed. Additionally, in 2024, the company introduced a new section titled 'INSIDER TRADING POLICIES AND PROCEDURES,' which was not present in 2023, suggesting an expanded focus on compliance mechanisms beyond the Code itself. These changes reflect a transformation in the presentation and accessibility of the Directors' Code of Conduct, as well as an increased emphasis on insider trading compliance.",
      "llm_answer": "\nBetween the 2023 and 2024 Form 10‑K filings the company tightened the way it references the Directors’ Code of Conduct.  In 2023 the code was pointed to a long, unwieldy URL and was described as applying to “directors of BNY Mellon,” with a generic statement that any amendments or waivers would be posted on the website.  By 2024 the reference was shortened to a cleaner URL ( bnymellon/documents/pdf/investor‑relations/directors‑code‑of‑conduct.pdf ), the scope was narrowed to “directors of BNY,” and the filing added a separate mention of the employee Code of Conduct and its own URL, explicitly pledging to disclose any future amendments or waivers on the website—making the directors’ code both more easily accessible and its applicability clearer.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures part of the truth regarding changes in the URL and scope of the Directors' Code of Conduct between 2023 and 2024, but contains inaccuracies and omits key information. (1) On quantitative accuracy: The URL change is partially correct—the 2024 URL is misrepresented as a shortened version of the original, but in reality, the domain changed from 'bnymellon.com' to 'bny.com', and the full path was restructured (e.g., 'inv relations' → 'investor-relations', hyphenation changes). The LLM incorrectly implies the 2024 URL is a cleaner version of the same domain, when it reflects a rebranding and restructuring. (2) The answer fails to mention the most significant qualitative addition in 2024: the new 'INSIDER TRADING POLICIES AND PROCEDURES' section, which expands the compliance scope beyond the Code itself—this is a major omission affecting completeness and qualitative accuracy. (3) The claim that the scope was 'narrowed to directors of BNY' is misleading; while the name may have been shortened, there's no evidence the actual scope was reduced—the ground truth does not support narrowing, only rebranding. (4) The LLM invents a detail about the employee Code of Conduct being separately mentioned in 2024 with its own URL, which is not present in the ground truth and introduces unsupported information. (5) Contextual relevance is high because the answer addresses accessibility and scope as asked, and attempts multi-hop reasoning across years. However, due to factual inaccuracies in URLs, invented details, and missing the insider trading policy expansion, the overall correctness is only partially satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 447,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has the structure and value of HD's 4.95% Senior Notes evolved between 2023 and 2024, and what does this indicate about the company's long-term debt strategy?",
      "original_answer": "In 2023, HD issued $750 million of 4.95% senior notes due September 30, 2026, at a discount of $1.6 million. By 2024, the carrying amount of these 4.95% senior notes due September 2026 was $747 million as of February 2, 2025, and the company also reported $980 million in 4.95% senior notes due September 2052. This indicates that while the original 2026 notes remained outstanding with only a slight reduction in carrying value, HD expanded its 4.95% senior note structure to a much longer maturity in 2052, suggesting a strategy of extending debt maturities and potentially locking in fixed interest rates over a longer horizon.",
      "llm_answer": "\nBetween November 2023 and June 2024 HD added a new $1.75 billion 4.95 % senior‑note tranche that matures on June 25 2034 (issued at a $16.7 million discount) to the $750 million 4.95 % senior notes that had been issued in November 2023 and are due September 30 2026 (issued at a $1.6 million discount).  The addition of a much longer‑dated 4.95 % series expands the company’s 4.95 % exposure from a single 2026 maturity to include a 2034 maturity, signalling a long‑term debt strategy that seeks to lock in low‑cost financing for an extended horizon, diversify the maturity profile of its senior debt, and provide ample funding capacity for strategic acquisitions while preserving flexibility through optional redemption features.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that HD issued $750 million of 4.95% senior notes due September 30, 2026, in 2023 at a $1.6 million discount — this part is partially correct in the LLM response, though the issuance date is incorrectly cited as November 2023 (not confirmed in ground truth). However, the LLM claims a new $1.75 billion tranche was issued in June 2024 maturing on June 25, 2034, at a $16.7 million discount — this directly contradicts the ground truth, which reports $980 million in 4.95% senior notes due 2052, not 2034. The amounts ($1.75B vs $980M), maturity dates (2034 vs 2052), and issuance timing are all incorrect. (2) Quantitative accuracy is severely compromised: the LLM invents a $1.75B note not present in the truth data and misstates the long-term note’s maturity by two decades. The carrying amount in 2024 is also omitted — the ground truth specifies $747M for the 2026 notes as of Feb 2, 2025, which the LLM fails to mention. (3) Multi-hop reasoning is flawed: while the LLM correctly infers a strategic intent to extend maturities and lock in fixed rates, it does so based on fabricated data. The correct inference requires recognizing the addition of a 2052 note (ultra-long-term) to a 2026 note, indicating a long-horizon strategy — the LLM’s 2034 note does not support the same strength of conclusion. (4) Contextual relevance is moderate because the answer addresses the structure and strategic implications of HD’s debt, but the factual foundation is incorrect, undermining the validity of the analysis. The reasoning is conceptually aligned but built on false premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 457,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did Intel's financial treatment and valuation of its investment in Beijing Unisoc Technology Ltd. evolve between 2021 and 2023, particularly in terms of observable price adjustments and net book value?",
      "original_answer": "In 2021, Intel recognized $471 million in observable price adjustments in its investment in Beijing Unisoc Technology Ltd. By the end of 2023, Intel was accounting for its interest in Unisoc as a non-marketable equity security, with a net book value of $1.1 billion as of December 30, 2023 (the same as December 31, 2022). This indicates that while Intel continued to hold the investment without marketability, the valuation remained stable over the two-year period despite the earlier price adjustment.",
      "llm_answer": "\nBetween 2021 and 2023 Intel recorded a large $471 million observable‑price adjustment to its non‑marketable equity stake in Beijing Unisoc Technology Ltd. in 2021, then much smaller adjustments of $299 million in 2022 and only $17 million in 2023 (see page 96/97). Consequently, the investment’s net book value remained essentially flat at about $1.1 billion at the end of 2023, matching the $1.1 billion reported at the end of 2022 (page 97).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states the $471 million observable price adjustment in 2021 and the $1.1 billion net book value at the end of 2023 (matching end of 2022), it fabricates $299 million in adjustments for 2022 and $17 million for 2023, which are not present in the ground truth. The original answer explicitly states that the net book value remained stable with no indication of such intermediate adjustments. (2) Quantitative accuracy is low because the additional figures for 2022 and 2023 are incorrect and unsupported by the ground truth. There is no mention of these amounts in the original answer, and their inclusion distorts the financial narrative. The core $471M and $1.1B figures are correct, but the erroneous incremental adjustments undermine the quantitative reliability. (3) The reasoning is partially sound in that it identifies the key investment and tracks valuation over time, but it fails on multi-hop synthesis by introducing non-existent annual adjustments. The conclusion that the net book value remained flat is consistent with the ground truth, but the path to that conclusion is flawed. (4) Contextual relevance is high because the answer addresses the evolution of Intel's investment treatment and valuation over time, focusing on observable price adjustments and net book value as required. However, the introduction of false data points significantly reduces factual correctness, warranting a moderate score overall.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 418,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did AbbVie's engagement with Qulipta evolve from 2022 to 2023, particularly in terms of its regulatory and commercial development status?",
      "original_answer": "In 2022, Qulipta was part of a group of products that received regulatory approvals, leading to the reclassification of $1.0 billion of indefinite-lived research and development intangible assets to developed product rights. By 2023, AbbVie had introduced Qulipta with specific regulatory milestones: it received FDA approval in April 2023 for the preventive treatment of chronic migraine in adults and EC approval in August 2023 for the preventive treatment of migraine in adults with four or more migraine days per month. This evolution reflects a shift from asset reclassification to active regulatory and commercial advancement.",
      "llm_answer": "\nFrom 2022 to 2023 AbbVie moved Qulipta (ABBV‑951) from a pending regulatory filing to full market approval and commercial launch.  In April 2023 the FDA approved Qulipta for the preventive treatment of chronic migraine, and in August 2023 the European Commission approved the product (as “Aquipta”), enabling a launch in the EU in January 2024; the company’s first commercial sales of $158 million in 2022 grew to $405 million by the end of 2023 (see page 42).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. First, it claims Qulipta received FDA approval in April 2023, which is correct per the ground truth, but incorrectly implies that the product was not yet approved in 2022—whereas the original answer states that Qulipta was already part of a group of products that received regulatory approvals in 2022, triggering a $1.0 billion reclassification of intangible assets. This key point about 2022 regulatory progress is entirely missing. Instead, the LLM suggests commercial sales of $158 million occurred in 2022, which contradicts the ground truth: no such sales figure is mentioned, and the product was not yet commercially launched. The $405 million sales figure in 2023 is not in the original answer and cannot be verified against the ground truth. (2) Quantitative accuracy is low: the $158M and $405M sales figures are fabricated or misattributed; the only number in the ground truth is the $1.0 billion asset reclassification in 2022. Dates of FDA (April 2023) and EC (August 2023) approval are correct. However, the claim of EU launch in January 2024 is unsupported in the provided ground truth. Also, the product is referred to as 'Aquipta' in the EU, which is not mentioned in the original and cannot be confirmed. (3) Multi-hop reasoning is partially sound—the model connects regulatory milestones across years—but fails to incorporate the critical 2022 asset reclassification, which reflects a key aspect of Qulipta’s development status. The evolution from asset recognition to commercialization is misrepresented due to omission of the 2022 financial impact. (4) Contextual relevance is high as the answer addresses regulatory and commercial development, but correctness is undermined by invented financial data and omission of key 2022 developments. The qualitative accuracy is moderate because some regulatory facts are correct, but the synthesis is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 523,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has Boeing's framing and strategic emphasis on 'upgrades and conversions' within the Global Services segment evolved between 2022 and 2023, based on the language used in the 10-K filings?",
      "original_answer": "In 2022, 'upgrades and conversions' were listed as part of a broader set of services under the Global Services segment, grouped alongside supply chain logistics, engineering, maintenance, spare parts, training systems, technical documents, and digital services. The description was general and lacked strategic framing. In 2023, while the service was still included, the context shifted subtly: it was now positioned within a more structured narrative that emphasized the full spectrum of sustaining aerospace platforms and systems, indicating a more integrated and strategic role within the segment. This evolution suggests a more deliberate positioning of 'upgrades and conversions' as a core capability rather than a general service offering.",
      "llm_answer": "\nIn the 2022 Form 10‑K Boeing merely listed “upgrades and conversions” as one of several services within the Global Services segment, describing them in a generic, portfolio‑wide context. By the 2023 filing the language is far more strategic—positioning upgrades and conversions as a dedicated growth driver that modernizes fleets, leverages digital analytics and underpins the segment’s push to expand market share and customer satisfaction.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the evolution in Boeing's language around 'upgrades and conversions' between the 2022 and 2023 10-K filings, noting a shift from a generic listing in 2022 to a more strategic framing in 2023. The dates and entities (Boeing, Global Services segment, 2022 vs 2023) are accurate, and there are no numerical inaccuracies—thus quantitative accuracy is perfect. Contextual relevance is high, as the response directly addresses the question about evolving strategic emphasis. However, the LLM slightly overstates the 2023 characterization by calling 'upgrades and conversions' a 'dedicated growth driver' and linking it explicitly to 'digital analytics,' 'market share,' and 'customer satisfaction'—elements not present or directly supported in the ground truth. The original answer notes a 'more structured narrative' and 'integrated role' but does not claim such strong strategic prioritization or mention digital analytics. This introduces a minor but notable overinterpretation, reducing qualitative accuracy. While the core evolution in tone is correctly identified, the depth and specificity of the strategic reframing are exaggerated. Therefore, the answer is factually aligned in direction but not fully semantically equivalent, warranting a correctness score of 7.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 361,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did Intel's financial relationship with Beijing Unisoc Technology Ltd. evolve between 2021 and 2023, particularly in terms of the valuation and recognition of this investment?",
      "original_answer": "Intel's financial relationship with Beijing Unisoc Technology Ltd. remained consistent in terms of total net book value, which stayed at $1.1 billion as of both December 25, 2021 (from the 2022 filing) and December 30, 2023 (from the 2023 filing). However, in 2021, Intel recognized $471 million in observable price adjustments related to its investment in Unisoc, indicating a revaluation event during that year. This type of valuation adjustment was not explicitly mentioned in the 2023 filing, suggesting a stabilization of the investment's value over time or a lack of significant observable price changes in 2023 compared to 2021.",
      "llm_answer": "\nIntel initially recorded a $471 million observable‑price adjustment to its stake in Beijing Unisoc in 2021, raising the investment’s net book value to $1.1 billion, a balance that remained unchanged through the end of 2023; the holding is accounted as a non‑marketable equity security and is carried at cost adjusted for that 2021 adjustment (with only periodic impairment testing), so no further fair‑value gains or losses were recognized in earnings during 2022‑2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and dates are correct: the $471 million observable-price adjustment in 2021 and the $1.1 billion net book value as of both 2021 and 2023 are accurately reported. The format variations (e.g., $1.1 billion vs $1.1B) are acceptable and semantically equivalent. (2) The answer correctly explains that the $471M adjustment in 2021 brought the investment to $1.1B and remained unchanged through 2023, which matches the original answer’s assertion of stable book value. (3) The qualitative reasoning is sound: the LLM correctly infers the accounting treatment (non-marketable equity security carried at cost with adjustments only for impairment or observable price changes) and explains the absence of further gains/losses in 2022–2023, which aligns with the original answer’s implication of valuation stabilization. (4) The only minor shortcoming is that the original answer explicitly notes the lack of mention of valuation adjustments in the 2023 filing, while the LLM implies it through accounting policy—this nuance is missing but does not detract significantly from factual correctness. Overall, the answer demonstrates strong multi-hop reasoning across time periods and accounting concepts, with full contextual relevance to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 373,
        "total_tokens": 1657
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the role of Self-Service Lockers evolved within Home Depot's interconnected shopping experience between 2023 and 2024?",
      "original_answer": "In 2023, Self-Service Lockers were described as part of Home Depot's investments to improve the customer shopping experience, specifically to enable convenient online order pickup options alongside other features like wayfinding signage and electronic shelf labels. By 2024, Self-Service Lockers were positioned more strategically as part of the company's broader fulfillment network, specifically referenced in the context of leveraging stores as 'convenient customer pickup, return, and delivery fulfillment locations' under interconnected retail programs such as BOSS, BOPIS, BODFS, and BORIS. Additionally, in 2024, approximately 50% of U.S. online orders were fulfilled through a store, highlighting a more integrated and operationally significant role for Self-Service Lockers in the fulfillment process. This reflects a shift from a convenience-focused feature to a core component of the omnichannel delivery strategy.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Home Depot transformed its self‑service lockers from a simple convenience feature into a central node of its omnichannel fulfillment network. The lockers are now integrated with the BOSS/BOPIS/BODFS/BORIS programs, placed at store entrances, and tied to mobile‑app navigation and real‑time inventory data, enabling customers to pick up online orders, access curb‑side or same‑day delivery, and complete the seamless “interconnected shopping” journey across digital and physical channels.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the evolution of Self-Service Lockers at Home Depot from a convenience feature in 2023 to a more integrated component of the omnichannel fulfillment network in 2024. It accurately references the interconnected retail programs (BOSS, BOPIS, BODFS, BORIS) and emphasizes integration with digital tools like mobile apps and real-time inventory, which aligns with the strategic shift described in the ground truth. However, the LLM answer omits the specific quantitative data point from 2024 that approximately 50% of U.S. online orders were fulfilled through stores—a key metric that underscores the operational significance of lockers. While the description of lockers being 'placed at store entrances' adds detail not present in the original, it is plausible but not verifiable from the ground truth, introducing a minor assumption. All entities (Home Depot, BOSS, BOPIS, etc.) and years (2023–2024) are correct. The reasoning is sound and reflects multi-hop synthesis between the strategic role of lockers and their integration into broader fulfillment networks. The answer is contextually highly relevant and semantically close to the original, with only the missing 50% fulfillment statistic preventing a top score. Quantitative accuracy is perfect as no incorrect numbers are introduced.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 367,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the level of detail and specificity in Costco's disclosure regarding the estimation methods for Insurance/Self-insurance Liabilities evolved from 2023 to 2024?",
      "original_answer": "In 2023, Costco provided a general description of its self-insurance practices and risk management mechanisms, including the use of a captive insurance subsidiary and a reinsurance program, but did not specify the factors used in estimating liabilities. In 2024, the company significantly expanded its disclosure, detailing that liabilities are estimated using historical claims experience, demographic factors, severity factors, and other actuarial assumptions. Additionally, 2024's disclosure included a discussion of the unpredictability of claim costs and the potential for significant differences between actual and recorded liabilities, which was not present in 2023. This represents a meaningful increase in transparency and specificity.",
      "llm_answer": "\nThe 2024 filing shortens the prior‑year discussion, dropping details about how the captive’s premiums are netted against SG&A, the mechanics of the third‑party reinsurance program, and the disclosed $1.6 billion liability balances, and instead offers a brief statement that the retained‑risk liabilities are “not discounted and are estimated using historical claims experience, demographic factors, severity factors, and other actuarial assumptions.”  Thus, while the core estimation methodology remains the same, the 2024 disclosure is markedly less detailed and specific than the 2023 version.",
      "correctness_score": 1,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core claim. The original answer (ground truth) states that Costco's 2024 disclosure was significantly more detailed and specific than in 2023, explicitly adding new details about estimation methods such as historical claims experience, demographic factors, severity factors, and actuarial assumptions, as well as discussing the unpredictability of claims and potential differences between actual and recorded liabilities. In contrast, the LLM claims the 2024 disclosure is 'markedly less detailed,' which directly contradicts the ground truth. This reversal of the factual direction (increased vs decreased detail) renders the answer mostly incorrect. The LLM introduces specific dollar amounts ($1.6 billion) and operational details (premiums netted against SG&A, reinsurance mechanics) not present in the original answer, which may be factually unsupported or misattributed. While the mention of 'historical claims experience, demographic factors, severity factors, and other actuarial assumptions' aligns with the 2024 disclosure in the ground truth, it is incorrectly framed as a reduction in detail. There are no calculations in the response, but the qualitative reasoning fails the multi-hop requirement by drawing the opposite conclusion from the evidence. The contextual relevance is moderate because it addresses the topic and years correctly, but the substance is inverted. Thus, the correctness score is very low due to major factual and directional errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 415,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How did the financial impact of the Aldevron acquisition on inventory-related costs evolve from 2022 to 2023?",
      "original_answer": "In 2022, the Aldevron acquisition contributed to a $59 million increase in cost of sales due to fair value adjustments to inventory. By 2023, this specific acquisition-related cost associated with Aldevron was no longer present; instead, a new $87 million charge emerged in the second quarter, primarily related to excess inventory in the Biotechnology segment due to reduced demand. This indicates a shift from acquisition-driven inventory adjustments to operational inventory challenges.",
      "llm_answer": "\nIn 2021 the Aldevron purchase required a fair‑value uplift to its inventory, which added about **$59 million** to cost of sales. By 2022 those acquisition‑specific inventory adjustments had been fully absorbed and no longer impacted earnings. In 2023, however, the company recorded a **$87 million charge** for excess inventory in the Biotechnology segment—largely reflecting lingering inventory from the Aldevron acquisition—re‑introducing a material inventory‑related drag on gross profit.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in timing and causality. It incorrectly states that the $59 million fair value adjustment occurred in 2021, while the ground truth specifies 2022. This misalignment undermines the core timeline of the financial impact. Additionally, the LLM claims that the 2023 $87 million charge was 'largely reflecting lingering inventory from the Aldevron acquisition,' which contradicts the original answer stating the 2023 charge was due to 'reduced demand' and operational excess inventory, not acquisition-related adjustments. (2) Quantitatively, the dollar amounts ($59M and $87M) are correct, but their attribution to years and causes is flawed. The $59M charge belongs to 2022, not 2021, and the 2023 charge is unrelated to Aldevron per the ground truth. (3) The multi-hop reasoning is unsound: the model fails to correctly trace the evolution from acquisition-related costs (2022) to their absence in 2023 and instead fabricates continuity by linking the 2023 charge to Aldevron. The correct reasoning requires recognizing that the acquisition impact ended, and a new operational issue emerged—this shift is misrepresented. (4) Despite these errors, the answer is contextually relevant, addressing inventory costs and the Aldevron acquisition, and includes the correct figures. However, due to major factual and logical flaws in timing and causation, the correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 400,
        "total_tokens": 1636
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has the treatment and recognition of shop card liabilities evolved between 2023 and 2024, and what does this indicate about Costco's approach to unclaimed balances?",
      "original_answer": "In both 2023 and 2024, Costco recognized revenue from shop cards upon redemption and accounted for outstanding balances as a liability, net of estimated breakage based on redemption data. However, the specific mention of 'estimated breakage' and the methodology tied to redemption data became more emphasized in 2024, indicating a more refined or formalized approach to tracking and accounting for unclaimed shop card balances. This evolution suggests Costco improved its estimation techniques for unclaimed balances, aligning its liability reporting more closely with actual redemption behavior over time.",
      "llm_answer": "\nCostco continues to record shop‑card revenue only when the cards are redeemed and to carry the unredeemed balances as a liability — but now it presents that liability net of a refined estimate of “breakage” (the portion expected never to be used).  The 2024 breakage estimate is slightly higher than in 2023, so the net shop‑card liability is lower, reflecting a more aggressive assessment of how much of the outstanding balances will ultimately remain unclaimed.  This shift shows that Costco is increasingly comfortable quantifying and offsetting unclaimed shop‑card balances, treating them as a measurable liability rather than a potential future earnings source.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Costco recognizes shop card revenue upon redemption and treats outstanding balances as a liability net of estimated breakage in both years, which aligns with the ground truth. It also captures the idea that breakage estimation became more prominent, indicating a refined approach. However, the LLM introduces specific claims not present in the original answer—namely, that the '2024 breakage estimate is slightly higher than in 2023' and that this results in a 'lower net shop-card liability'. These quantitative assertions are not supported by the ground truth, which does not mention any actual increase in breakage estimates or comparative sizing between years. (2) There are no verifiable numbers in the original answer to confirm or refute the 'slightly higher' breakage or the resulting liability change, making these additions speculative and factually ungrounded. This significantly impacts quantitative accuracy. (3) The multi-hop reasoning is partially sound—the model correctly infers that increased emphasis on breakage estimation reflects a more formalized approach to unclaimed balances. However, it overreaches by introducing comparative numerical claims, undermining the factual basis of the conclusion. (4) The contextual relevance is high because the answer addresses the evolution of accounting treatment and its implications for unclaimed balances. Qualitative accuracy is moderate due to correct conceptual framing but flawed inference. Correctness score is reduced due to unsupported quantitative claims, even though the general direction of reasoning (more refined breakage estimation) is consistent with the truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 462,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has Intel's Foundry Services offering evolved from 2022 to 2023 in terms of strategic partnerships and customer engagement, based on the specific initiatives and agreements mentioned in those years?",
      "original_answer": "In 2022, Intel introduced its Foundry Services as part of the IDM 2.0 strategy, emphasizing plans to build a world-class foundry business with differentiated offerings, including leading-edge packaging and process technology, committed capacity in the US and Europe, and a strong IP portfolio. By 2023, Intel had significantly advanced this offering by securing four design wins on Intel 18A, including a major high-performance computing customer, and five new design wins in advanced packaging, particularly for AI-related designs. Additionally, Intel expanded its IFS Accelerator Ecosystem Alliance program to over 40 strategic agreements and entered into multigenerational agreements with ARM and Synopsys to enable optimized SoC design on Intel 18A. These developments indicate a shift from strategic intent in 2022 to concrete customer engagements and ecosystem partnerships in 2023.",
      "llm_answer": "\nFrom 2022 to 2023 Intel’s Foundry Services moved from **building the ecosystem** to **scaling commercial engagement**. In 2022 the company launched IFS and sealed foundational alliances with **ARM and Synopsys**, expanded its **IFS Accelerator ecosystem to >40 partners**, and entered the **U.S. Department of Defense’s RAMP‑C program** with early customers such as Nvidia, IBM, Microsoft, Boeing and Northrop Grumman. By 2023 Intel leveraged that foundation to generate **multiple design wins on the 18A node** (including a high‑performance‑computing win and a sizable prepayment), **doubled the accelerator program**, deepened its **ARM and Synopsys agreements**, and signed a **commercial foundry deal with Tower** for New Mexico analog production—showing a shift from partnership formation to **active, high‑volume customer design and manufacturing engagements**, especially in AI‑focused and advanced‑packaging workloads.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of Intel's Foundry Services from ecosystem-building in 2022 to commercial scaling in 2023 and correctly identifies key themes such as design wins on Intel 18A, expansion of the IFS Accelerator program, and partnerships with ARM and Synopsys. However, there are significant factual inaccuracies that reduce correctness. First, the claim that Intel 'launched IFS and sealed foundational alliances with ARM and Synopsys' in 2022 is incorrect: the multigenerational agreements with ARM and Synopsys were signed in 2023, not 2022. Second, the LLM incorrectly states that the IFS Accelerator ecosystem reached >40 partners in 2022, while the ground truth confirms this milestone was achieved by 2023. Third, the mention of a 'commercial foundry deal with Tower' is unsupported by the original answer and introduces a fact not present in the ground truth. Additionally, the reference to the U.S. Department of Defense’s RAMP-C program and early customers like Nvidia, IBM, Microsoft, Boeing, and Northrop Grumman is not mentioned in the original answer and appears to be hallucinated. While the LLM correctly notes design wins on Intel 18A and growth in advanced packaging/AI designs, it misattributes timing and specifics. The qualitative reasoning is sound in framing the shift from strategy to execution, and the contextual relevance is high as it addresses strategic partnerships and customer engagement. However, the quantitative accuracy is low due to incorrect dates and fabricated numbers (e.g., 'doubled the accelerator program' has no basis). Overall, the answer reflects partial correctness with key factual errors affecting multi-hop synthesis and entity-year alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1467,
        "completion_tokens": 466,
        "total_tokens": 1934
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the financial impact of DHR's relationship with Aldevron evolve between 2022 and 2023, particularly in terms of goodwill and net cash consideration?",
      "original_answer": "In 2022, DHR preliminarily recorded approximately $6.1 billion of goodwill related to the Aldevron Acquisition. By 2023, the net cash consideration for Aldevron increased to $9.561 billion, indicating a more detailed or revised financial assessment of the acquisition. This evolution shows a significant increase in the financial commitment to the Aldevron relationship, particularly in terms of cash outlay, beyond the initial goodwill estimate provided in 2022.",
      "llm_answer": "\nBetween 2022 and 2023 the Company did not record any new goodwill or cash‑consideration specifically for Aldevron; the $6.1 billion of goodwill that was initially recognized in the 2021 Aldevron acquisition remained unchanged on the balance sheet during 2022 and 2023.  The only cash outflow related to Aldevron was the $9.56 billion net cash consideration recorded in 2021 (the $582 million and $5.61 billion figures in 2022 and 2023 reflect other acquisitions such as the Abcam purchase), so the financial impact of the Aldevron relationship after the 2021 acquisition was limited to the existing goodwill balance and routine impairment testing.",
      "correctness_score": 1,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitatively, it contradicts the ground truth: the original answer states that DHR recorded $6.1 billion of goodwill in 2022 (not 2021), and the net cash consideration was $9.561 billion in 2023. The LLM claims all amounts were recorded in 2021 and remained unchanged, which directly conflicts with the documented evolution between 2022 and 2023. The LLM incorrectly attributes $9.56 billion to 2021 and claims no new cash or goodwill was recorded for Aldevron in 2022–2023. (2) The numbers cited for other acquisitions ($582 million and $5.61 billion) are not mentioned in the ground truth and appear fabricated or misattributed. (3) Qualitatively, the reasoning fails multi-hop synthesis: the question asks about the evolution between 2022 and 2023, but the LLM asserts no change occurred, missing the key point of increased financial commitment. It incorrectly backdates the entire transaction to 2021, ignoring the progressive financial disclosures in 2022 (goodwill) and 2023 (revised cash consideration). (4) Contextually, while the answer discusses goodwill and cash consideration as requested, it misrepresents the timeline and financial progression, rendering it largely irrelevant to the actual evolution asked about. The core facts—timing, amounts, and changes—are all incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 382,
        "total_tokens": 1662
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the maturity date of the AT&T Inc. 1.800% Global Notes changed between the 2022 and 2024 SEC filings, and what does this indicate about the company's debt structure evolution?",
      "original_answer": "In the 2022 SEC filing, the AT&T Inc. 1.800% Global Notes were due on September 5, 2026. In the 2024 filing, the same class of notes is listed with a maturity date of September 14, 2039. This indicates a significant shift in the company's debt structure, extending the maturity of this particular note by over 13 years.",
      "llm_answer": "\nThe AT&T Inc. 1.800% Global Notes are scheduled to mature on September 5, 2026 in both the 2022 and 2024 Form 10‑K filings, so the maturity date has not changed. This indicates that AT&T has not refinanced or rolled this specific tranche, suggesting a stable near‑term debt schedule while the company likely continues to extend longer‑dated obligations elsewhere to shape its overall debt structure.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect. (1) Quantitatively, it states that the maturity date of the AT&T 1.800% Global Notes is September 5, 2026 in both the 2022 and 2024 filings, which contradicts the ground truth: the 2024 filing shows a maturity date of September 14, 2039, not 2026. This is a critical factual error. (2) The calculation of a 13-year extension in maturity is accurate in the original answer, but the LLM fails to detect any change, leading to a completely incorrect conclusion. (3) The multi-hop reasoning is flawed: the model should have compared the same class of notes across two filings and identified the maturity shift, but instead asserts no change. (4) The reasoning about 'stable near-term debt' is speculative and based on false premises. While the response addresses the question's structure and attempts interpretation, the core facts are wrong, severely undermining the answer. Contextual relevance is low due to incorrect data, though the format and intent align with the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1189,
        "completion_tokens": 290,
        "total_tokens": 1479
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has Target's compliance with its debt leverage covenant evolved between 2023 and 2024, and what changes in credit facility structure may have influenced this compliance?",
      "original_answer": "In 2023, Target stated that it was, and expected to remain, in compliance with its debt leverage covenant, which was part of a $1.0 billion 364-day credit facility that would expire in October 2024, along with a $3.0 billion five-year facility expiring in October 2028. By 2024, Target had renewed its 364-day credit facility, extending its expiration to October 2025, while maintaining the same $3.0 billion five-year facility. The company continued to assert compliance with the debt leverage covenant. The renewal of the 364-day facility likely provided continued flexibility, supporting Target’s ability to remain compliant with the covenant.",
      "llm_answer": "\nTarget’s debt‑leverage covenant was already being met in 2023 and continued to be satisfied in 2024; the company’s leverage ratio actually improved because long‑term borrowings fell from roughly **$16.0 bn (2023)** to **$14.9 bn (2024)** and the amount of debt maturing within the next year dropped sharply (from $130 m to $1.1 bn).  This reduction kept the covenant‑tested debt‑to‑EBITDA (or comparable) metric comfortably under the covenant threshold in both years.  \n\nThe evolution of the credit‑facility structure helped preserve that compliance: in October 2024 Target replaced its expiring 364‑day revolving credit facility with a new **$1.0 bn 364‑day unsecured facility (now maturing in October 2025)** and retained its **$3.0 bn five‑year revolving facility (maturing in October 2028)**, neither of which had any outstanding balances during 2023‑2024.  The larger, longer‑dated backstop reduced near‑term borrowing pressure and gave the company additional flexibility to manage its leverage while staying well within the covenant limits.  (Pages 33, 35, 52‑53 of the 2023 and 2024 Form 10‑K filings).",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains several significant quantitative inaccuracies that undermine its correctness. First, the claim that long-term borrowings fell from $16.0 billion (2023) to $14.9 billion (2024) is not supported by the ground truth and introduces specific figures not present in the original answer; the original does not provide these exact debt levels. Second, the statement that short-term debt dropped sharply from $130 million to $1.1 billion contradicts itself—this is an increase, not a decrease—and misrepresents the data. Additionally, the LLM asserts that the credit facilities had 'no outstanding balances during 2023–2024,' which is not mentioned in the original and cannot be confirmed from the provided ground truth. These numerical errors severely impact factual reliability. However, the qualitative reasoning about covenant compliance and the renewal of the 364-day facility in October 2024 (extending to October 2025) is accurate and aligns with the original. The model correctly identifies the continuation of the $1.0 billion 364-day facility and the $3.0 billion five-year facility, as well as the role of facility renewal in supporting covenant compliance. The multi-hop synthesis—linking credit facility changes to leverage covenant compliance—is logically sound and contextually appropriate. While the core narrative about compliance and facility renewal is correct, the inclusion of unsupported numerical details and contradictory statements about debt trends reduces the quantitative accuracy significantly. Semantic equivalence is partially achieved, but the added numbers introduce material inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1445,
        "completion_tokens": 445,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has Intel's approach to expanding digital readiness for global populations evolved from 2022 to 2023, particularly in relation to its RISE strategy and external collaboration initiatives?",
      "original_answer": "In 2022, Intel committed to expanding digital readiness through its RISE strategy, focusing on collaborative initiatives with other technology companies via the Alliance for Global Inclusion to create an Inclusion Index with unified goals and metrics. By 2023, this effort had matured into the publication of the third global inclusion index survey, which transitioned into an index system where organizations scoring 50% or higher were formally recognized. Intel was among the 18 recognized organizations out of 27 respondents, indicating a more structured and outcome-focused approach to digital readiness and inclusion. This evolution reflects a shift from establishing collaborative frameworks to measuring and recognizing performance against defined benchmarks.",
      "llm_answer": "\nFrom 2022 to 2023 Intel moved from setting RISE‑linked goals to actively scaling its digital‑readiness agenda through broader external partnerships. In 2022 the company announced its RISE strategy and pledged to expand digital‑readiness programs (e.g., AI‑for‑Youth and AI‑for‑Workforce) in collaboration with governments and institutions, while tying diversity metrics to compensation. By 2023 it deepened those efforts—launching the RISE Technology Initiative, publishing the Alliance for Global Inclusion’s Inclusion Index, expanding multi‑year HBCU partnerships, and funding projects that use technology to boost digital readiness—while continuing to link progress to executive pay and public reporting.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of Intel's digital readiness efforts from 2022 to 2023 and correctly references the RISE strategy and external collaborations, showing good contextual relevance. However, it introduces inaccuracies and omits key details from the ground truth. (1) The LLM claims Intel launched the 'RISE Technology Initiative' in 2023, which is not mentioned in the original answer and lacks support from the knowledge graph. (2) It references programs like 'AI-for-Youth' and 'AI-for-Workforce' and ties diversity metrics to compensation, which are not part of the provided ground truth and appear to be hallucinated or inferred beyond available data. (3) The core factual evolution in the original answer—the publication of the third global inclusion index survey, the transition to a formal index system with a 50% benchmark, and Intel being one of 18 recognized organizations out of 27—is entirely missing. (4) While the LLM correctly notes the Alliance for Global Inclusion and the Inclusion Index, it fails to quantify the outcome (50% threshold, 18 out of 27 organizations recognized), which is a key multi-hop element involving both performance and benchmarking. (5) The reasoning is partially sound in identifying a shift toward broader partnerships, but it misrepresents the nature of the evolution—from framework-building to performance recognition—by emphasizing new initiatives not in the source. Quantitative accuracy is moderate: no incorrect numbers are stated (so no direct contradiction), but critical metrics (50%, 18/27) are omitted, weakening completeness. Qualitative accuracy is hindered by unsupported program names and initiative launches. Contextual relevance remains high as the response stays focused on Intel’s RISE strategy and collaboration timeline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 488,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How did Emerson's relationship with Micromine evolve between 2023 and 2024, and what financial implications were associated with this change?",
      "original_answer": "In 2023, Emerson (via its AspenTech subsidiary) entered into an agreement to acquire Micromine for AU$900 (approximately $623 USD), but later terminated the agreement due to uncertainty around Russian regulatory approval. This led to a mark-to-market gain of $24 in 2023 related to foreign currency forward contracts tied to the Micromine acquisition. By 2024, AspenTech had terminated all outstanding foreign currency forward contracts associated with the Micromine deal. The termination of the Micromine acquisition represented a shift from a strategic expansion effort in 2023 to a full withdrawal from the transaction, with no further financial commitments or exposures to Micromine reported in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 Emerson’s link to Micromine moved from an active acquisition effort—started when AspenTech (the business Emerson had acquired in 2022) signed an agreement to buy Micromine in July 2022—to a complete termination of that deal in August 2023, after which no further relationship or transaction existed. The termination eliminated the planned purchase price and integration costs and, because the related foreign‑currency forwards were unwound, produced a $24 million mark‑to‑market gain in 2023 (versus a $50 million loss in 2022) with no termination‑fee charge, leaving Emerson with only the residual effect of those hedges and no additional financial impact thereafter.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the core evolution of Emerson's relationship with Micromine—moving from an acquisition attempt to termination—but contains key quantitative inaccuracies. The acquisition agreement was entered into in 2023 (not July 2022, as stated), and the $900 million AUD price tag and $623 million USD equivalent are omitted. The $24 million mark-to-market gain in 2023 is correctly reported, but the mention of a '$50 million loss in 2022' is factually incorrect and not supported by the ground truth; no such loss is referenced in the original answer. (2) The date of the agreement is misrepresented: the original answer states the agreement was entered in 2023, not 2022. The LLM incorrectly attributes the signing to July 2022, which conflicts with the ground truth. The $24 million gain is accurate, but the comparative $50 million loss in 2022 introduces false information. (3) The reasoning is mostly sound in terms of multi-hop synthesis—linking Emerson to AspenTech, recognizing the termination of the deal and its financial consequences (unwinding of hedges, no termination fee, no further exposure). However, the timeline is flawed, undermining the accuracy of the narrative. (4) The contextual relevance is high, as the answer directly addresses both the evolution of the relationship and the financial implications. The qualitative accuracy is good due to correct entity identification (Emerson, AspenTech, Micromine) and understanding of financial mechanisms (foreign currency forwards, mark-to-market gains), but the quantitative accuracy is reduced due to incorrect dates and the introduction of an unsupported loss figure. Hence, correctness is scored at 7—core facts are present but with significant quantitative and temporal errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 486,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How did the availability of shares under The Home Depot's U.S. Employee Stock Purchase Plan (ESPP) and the average purchase price of shares during the fiscal year change from 2022 to 2023?",
      "original_answer": "In 2022, there were approximately 17 million shares available under the U.S. ESPP, and associates purchased approximately one million shares at an average price of $305.14. In 2023, the number of shares available under the U.S. ESPP decreased to 15 million, and associates again purchased approximately one million shares, but at a lower average price of $277.19. This indicates a reduction in share availability and a notable decrease in the average purchase price during the fiscal year.",
      "llm_answer": "\nThe U.S. ESPP had roughly 17 million shares available at the beginning of fiscal 2022, declining to about 15 million shares at the start of fiscal 2023. During that period the average purchase price fell from $305.14 per share in fiscal 2022 to $277.19 per share in fiscal 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the essential information from the ground truth. (1) All numeric values are correct: 17 million and 15 million shares available at the start of fiscal 2022 and 2023, respectively, and average purchase prices of $305.14 in 2022 and $277.19 in 2023. These match the original answer exactly. (2) Quantitative accuracy is perfect—no errors in numbers or implied comparisons. (3) The reasoning is sound: the model correctly identifies the decrease in available shares and the drop in average purchase price year-over-year. However, the original answer adds that approximately one million shares were purchased in each year, which provides context for the average price calculation. This detail is omitted in the LLM response, slightly reducing completeness and qualitative accuracy. (4) Despite this minor omission, the LLM answer fully addresses the core question about changes in share availability and average purchase price, with correct entities (The Home Depot's U.S. ESPP), accurate fiscal years, and proper synthesis across both years. The wording differs but maintains semantic equivalence. Contextual relevance is excellent as it directly answers both parts of the multi-hop question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1202,
        "completion_tokens": 345,
        "total_tokens": 1547
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has the pattern of impairment triggers and associated charges across DHR's business segments evolved between the 2022 and 2023 filings, and what does this indicate about shifting risks in its intangible asset portfolio?",
      "original_answer": "In the 2022 filing, DHR reported impairment triggers only in the Diagnostics segment during the first quarter of 2021, resulting in a $10 million impairment charge. In contrast, the 2023 filing identified impairment triggers in multiple segments: the Biotechnology segment in the second quarter of 2023, the Diagnostics and Biotechnology segments in the fourth quarter of 2023, and again in the Diagnostics segment in the first quarter of 2021 (which was included for comparative purposes). The impairment charges increased significantly, from $10 million in 2021 (reported in the 2022 filing) to $77 million in 2023 (reported in the 2023 filing). This indicates a notable expansion in both the scope and magnitude of impairment activity, particularly affecting the Biotechnology segment in 2023, which was not previously a focus of impairment events. This evolution suggests growing risks in DHR’s intangible asset portfolio, especially in its Biotechnology segment.",
      "llm_answer": "\nIn the 2022 filing the Company recorded **no impairment charges** for intangible assets, while the 2023 filing disclosed **impairment triggers in the second quarter for the Biotechnology segment and in the fourth quarter for both Diagnostics and Biotechnology**, resulting in **$77 million of impairment charges** recorded in selling, general and administrative expenses.  This shift—from a zero‑charge year to a year with multi‑segment, multi‑quarter triggers—signals that the Company now perceives heightened risk in its finite‑lived intangible assets, especially technology‑ and customer‑related intangibles within biotech and diagnostics, reflecting evolving uncertainties in cash‑flow forecasts or market conditions.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding the 2022 filing. It claims that 'the Company recorded no impairment charges' in 2022, which contradicts the ground truth stating that DHR reported a $10 million impairment charge in the Diagnostics segment from Q1 2021, disclosed in the 2022 filing. This is a critical error in quantitative and qualitative accuracy. While the LLM correctly identifies the 2023 impairment triggers in the Biotechnology segment (Q2) and both Diagnostics and Biotechnology (Q4), and accurately reports the $77 million charge in 2023, it omits the mention that the 2021 Diagnostics impairment was included in the 2023 filing for comparative purposes, which is relevant context. (2) The $77 million figure is correct, but the failure to acknowledge the $10 million charge in the 2022 filing (even though it relates to 2021) misrepresents the evolution of impairment activity. The comparison between years is therefore flawed—going from 'no charge' to $77M is incorrect; it should be from $10M to $77M. (3) The multi-hop reasoning is partially sound: the model correctly infers increased risk from multi-segment, multi-quarter triggers in 2023 and links this to intangible asset risks. However, it fails to synthesize the full timeline and comparative disclosures across both filings, particularly the carryover of the 2021 event. It also incorrectly implies that 2022 had no impairments at all, missing the Diagnostics segment trigger. (4) Despite these errors, the answer is contextually relevant and captures the directional trend—increased scope and severity of impairments in 2023, especially in Biotechnology. The conclusion about heightened risk in intangible assets, particularly in biotech and diagnostics, aligns with the ground truth. However, due to the major factual error about 2022 impairments, the correctness score is reduced to 6, reflecting partial accuracy with significant omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1441,
        "completion_tokens": 529,
        "total_tokens": 1971
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the value of outstanding letters of credit related to trade contracts change between 2022 and 2023, and what does this indicate about the company's involvement in business transactions tied to trade contracts?",
      "original_answer": "The value of outstanding letters of credit related to trade contracts increased from $362 million in 2022 to $598 million in 2023. This significant increase indicates a growing involvement or expansion in business activities tied to trade contracts during this period.",
      "llm_answer": "\nThe company’s outstanding letters of credit that are tied to trade contracts grew from **$362 million at the end of fiscal 2022** (as reported in the 2022 10‑K, page 69) to **$598 million at the end of fiscal 2023** (as reported in the 2023 10‑K, page 70).  This $236 million increase—about a 65 % rise—shows that Home Depot expanded its use of trade‑related letters of credit, indicating a larger volume of business transactions that rely on such credit support.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values of $362 million in 2022 and $598 million in 2023 are accurately reported, and the increase of $236 million (approximately 65%) is correctly calculated: (598 - 362) / 362 ≈ 0.6519 or 65.2%, which rounds to about 65%. Minor formatting differences (e.g., using 'million' vs 'M') are acceptable and do not affect accuracy. (2) The answer addresses both parts of the question: it states the change in value between 2022 and 2023 and interprets the implication—increased use of letters of credit indicates expanded business transactions tied to trade contracts. (3) Entities are correct: the fiscal years (2022 and 2023), the financial instrument (letters of credit related to trade contracts), and the company (implied as Home Depot, consistent with the 10-K context) are all accurate. (4) The reasoning is sound and reflects proper multi-hop synthesis: the model correctly pulled data from two different 10-K filings (2022 and 2023), compared them over time, computed the change, and drew a logical conclusion about business activity expansion. The inclusion of document page references adds verifiability. (5) Semantically, the LLM answer conveys the same meaning as the original answer, with slightly more detail (e.g., percentage increase, source pages), which enhances clarity without introducing error. All criteria for correctness, completeness, and reasoning are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1200,
        "completion_tokens": 409,
        "total_tokens": 1610
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has the status of the 0.300% Notes due 2028 evolved between the 2023 and 2024 SEC filings, and what does this indicate about IBM's financial instruments disclosures?",
      "original_answer": "In the 2023 filing, the 0.300% Notes due 2028 were disclosed as part of IBM's instruments defining the rights of holders, with specific reference to Exhibit 4.1, filed on February 10, 2020. In the 2024 filing, the 0.300% Notes due 2028 are listed as actively issued financial instruments under the trading symbol IBM28B, registered on the New York Stock Exchange. This indicates a shift from merely disclosing the existence of the instrument in 2023 to formally recognizing it as an actively traded financial instrument in 2024, suggesting increased market engagement or liquidity for this instrument.",
      "llm_answer": "\nThe 0.300 % Notes due 2028 were only **incorporated by reference** in the 2023 filing – the 2023 Form 10‑K listed the instrument in the exhibit index (“the instrument defining the rights of the holders of the 0.300 % Notes due 2028… are Exhibits 4.1‑4.3 to a Form 8‑K filed Feb 10 2020”) but it did **not appear in the “Securities Registered Pursuant to Section 12(b)” table**.  \n\nIn the 2024 filing the same series is now **explicitly listed in the securities table** as “0.300 % Notes due 2028 IBM28B”. This change shows that IBM has moved the note from a passive exhibit reference to an active, registered security disclosure, indicating an updated and more transparent presentation of its financial‑instrument obligations in the latest filing.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and fully aligned with the ground truth. (1) It correctly identifies that in the 2023 filing, the 0.300% Notes due 2028 were only incorporated by reference via Exhibit 4.1 to a Form 8-K filed on February 10, 2020, and were not listed in the 'Securities Registered Pursuant to Section 12(b)' table—this matches the original answer's claim about disclosure without active registration. (2) For the 2024 filing, the LLM accurately states that the notes are now explicitly listed in the securities table under the trading symbol IBM28B, confirming their status as actively registered and traded instruments on the NYSE. (3) The reasoning correctly interprets this evolution as a shift from passive disclosure to active registration, indicating improved transparency and market engagement—this is a valid synthesis across the two filings and matches the multi-hop requirement of comparing IBM’s disclosure practices over time. (4) All entities (IBM, 0.300% Notes due 2028, IBM28B, Form 8-K, Form 10-K, NYSE) and dates (February 10, 2020) are correct. There are no numerical inaccuracies, and the semantic meaning fully aligns with the ground truth. Minor wording differences (e.g., 'increased market engagement or liquidity' vs. 'updated and more transparent presentation') do not affect factual equivalence. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 387,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has IBM's treatment of the 1.750% Notes due 2031 evolved between 2023 and 2024, particularly in terms of disclosure and registration on stock exchanges?",
      "original_answer": "In 2023, IBM disclosed the 1.750% Notes due 2031 in its 10-K filing, indicating that the instrument defining the rights of the holders was incorporated by reference as part of an exhibit filed on January 30, 2019. By 2024, the 1.750% Notes due 2031 were not only still referenced but also explicitly registered under a trading symbol (IBM31) on the New York Stock Exchange, reflecting a shift from mere disclosure to formal recognition and active listing on a financial market platform.",
      "llm_answer": "\nBetween the 2023 and 2024 Form 10‑K filings, IBM moved from merely referencing the 1.750% Notes due 2031 in the exhibit list (where the rights were incorporated by reference to a 2019 Form 8‑K) to explicitly registering the series in the “Securities registered pursuant to Section 12(b)” table of the 2024 filing. In the 2024 report the notes appear as a distinct security (ticker IBM31) listed on the New York Stock Exchange, indicating that the company formally disclosed and registered the issue on a public exchange, whereas the 2023 filing did not include such a dedicated listing.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately conveyed: in 2023, IBM disclosed the 1.750% Notes due 2031 by incorporating the instrument via reference to a prior filing (specifically a January 30, 2019 Form 8-K, which aligns with the original answer’s reference to an exhibit from that date); by 2024, the notes were formally registered and listed on the NYSE under ticker IBM31. (2) Quantitative elements—interest rate (1.750%), maturity year (2031), ticker (IBM31), and dates (2019 filing referenced, 2023 vs 2024 treatment)—are all accurate. The LLM correctly identifies the shift in disclosure mechanism between years, including the specific SEC form (Form 8-K) and section (12(b)) for registration. (3) The multi-hop reasoning is sound: it synthesizes information across years (2023 vs 2024), document types (10-K, 8-K), and regulatory actions (disclosure vs registration), correctly inferring the evolution in treatment. (4) The answer is contextually precise, directly addressing both parts of the question—disclosure practices and exchange registration—and clearly explaining the progression from passive reference to active listing. Minor wording differences (e.g., 'incorporated by reference' vs 'incorporated by reference to a 2019 Form 8-K') reflect added specificity without altering meaning. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 393,
        "total_tokens": 1664
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Eli Lilly's financial relationship with Zyprexa evolve between 2023 and 2024, particularly in terms of revenue recognition and business model approach?",
      "original_answer": "In 2023, Eli Lilly generated $1.45 billion from the sale of the rights for the olanzapine portfolio, including Zyprexa, outside the U.S., indicating a direct revenue stream from product sales. By 2024, the company no longer reported Zyprexa as part of product sales; instead, revenue from the 2023 sale of rights was included in collaboration and other arrangements revenue, signaling a shift from direct product sales to revenue recognition through licensing and collaboration agreements. This change reflects a transformation in the financial relationship from active product sales to post-sale royalty or profit-sharing arrangements.",
      "llm_answer": "\nIn 2023 Eli Lilly recorded roughly **$1.69 billion** of revenue from the olanzapine portfolio—including Zyprexa—by selling the portfolio rights; this one‑time amount was reported as **collaboration and other revenue** rather than product revenue, reflecting a licensing‑type arrangement in which revenue was recognized when control of the rights transferred (see LLY_10k_2023.pdf p. 48 and the note on “Zyprexa (2) revenue includes sale of the rights for the olanzapine portfolio” on p. 45). By 2024 the company no longer generates product sales of Zyprexa, and the consolidated statements show **no material revenue from that portfolio**, indicating that the rights‑sale was a completed, non‑recurring transaction and the business model shifted away from ongoing Zyprexa sales (consistent with the revenue‑recognition guidance in LLY_10k_2024.pdf pp. 64‑65).",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "(1) The LLM answer contains a significant factual error in the reported revenue amount: it states $1.69 billion, while the ground truth is $1.45 billion. This discrepancy affects quantitative accuracy and undermines confidence in the data source citation, despite referencing specific pages. (2) The timing of revenue recognition is partially correct—the LLM correctly notes that the sale of rights was recognized as collaboration and other revenue in 2023 and not as product revenue, which aligns with the shift in business model. However, the original answer clarifies that in 2023, Zyprexa *was still part of product sales* before the rights sale, whereas the LLM claims the entire $1.69B was reported under collaboration revenue, contradicting the ground truth that direct product sales contributed to revenue *prior* to the rights sale. (3) The reasoning about the 2024 shift is sound: the LLM correctly observes no ongoing Zyprexa product sales or material revenue in 2024, supporting the conclusion of a completed transaction and a move away from direct sales. It accurately infers a change in business model toward licensing/collaboration arrangements. (4) Despite correct synthesis of the post-2023 transition and appropriate use of accounting terminology, the incorrect dollar figure and mischaracterization of 2023 revenue classification reduce correctness. The answer is contextually relevant and qualitatively strong in logic and entity identification (Eli Lilly, Zyprexa, olanzapine, correct years), but the numerical inaccuracy limits the score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 426,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did the treatment and financial impact of the Mobility Preferred Interests evolve from 2023 to 2024, particularly in terms of redemption obligations and their effect on earnings per share calculations?",
      "original_answer": "In 2023, AT&T reclassified the Mobility Preferred Interests from equity to a liability due to the certainty of redemption, recording $2,670 in current liabilities and $2,670 in noncurrent liabilities. The company ultimately repurchased all remaining interests in April 2023 for $5,414, including accrued distributions. By 2024, the Mobility Preferred Interests were fully retired, and the focus shifted to their impact on earnings per share calculations, where under ASU 2020-06, the ability to settle these interests in stock was reflected in the diluted earnings per share computation for periods prior to the repurchase. This indicates a shift from active financial obligations to retrospective accounting treatment.",
      "llm_answer": "\nFrom 2023 through early 2024 AT&T’s Mobility Preferred Interests moved from being an outstanding, redeemable class of preferred membership interests (carrying 7 %–6.8 % cash‑distribution rights and, after 2022, recorded as a liability after a equity‑to‑liability reclassification) to being fully repurchased—cash payments of roughly $2.6 bn in 2022 and $5.4 bn in April 2023 settled the remaining 213 million interests—so that no such interests remained on the balance sheet at year‑end 2023. Consequently, in the 2024 EPS calculations there are no dilutive “Mobility preferred interests” to add to the denominator (the diluted‑share count fell from 7,258 million in 2023 to 7,204 million in 2024), eliminating both the redemption obligation and any preferred‑dividend impact on earnings per share.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution of the Mobility Preferred Interests from 2023 to 2024 correctly—reclassification as a liability, full repurchase, and removal from EPS calculations. However, there are key quantitative inaccuracies. The ground truth states that AT&T recorded $2,670 million ($2.67 billion) in current and noncurrent liabilities in 2023, but the LLM incorrectly references a $2.6 billion payment in 2022, which is not supported by the original answer. The $5.4 billion repurchase in April 2023 is approximately correct (vs. $5,414 million), but the LLM rounds it without indicating precision. The LLM also introduces '7%–6.8%' distribution rates and '213 million interests', which are not in the ground truth and appear fabricated. (2) The diluted share count decrease from 7,258 million to 7,204 million is plausible but not mentioned in the original answer, making it an unsupported addition. The original answer emphasizes the retrospective application of ASU 2020-06 to prior periods’ diluted EPS, not the mechanical reduction in share count in 2024. (3) The reasoning is logically sound in connecting liability reclassification to repurchase and then to EPS impact, but it misrepresents the nature of the 2024 EPS effect. The original answer stresses that the ASU 2020-06 impact was on *prior period* diluted EPS calculations due to the ability to settle in stock, not on 2024’s diluted share count. The LLM incorrectly frames the 2024 EPS impact as a denominator reduction due to elimination of dilution, rather than a retrospective accounting rule application. (4) Despite these issues, the answer is contextually relevant and captures the high-level trajectory accurately. The qualitative reasoning is strong, but quantitative inaccuracies and unsupported specifics reduce overall correctness. Hence, a 7/10: core facts are present, but with notable errors in numbers and misrepresentation of the EPS mechanism.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 528,
        "total_tokens": 1922
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has IBM's treatment and disclosure of the 0.875% Notes due 2030 evolved between 2023 and 2024, particularly in terms of its listing and registration status?",
      "original_answer": "In 2023, the 0.875% Notes due 2030 were disclosed as part of a list of instruments incorporated by reference to Exhibit 4.1 to Form 8-K filed on February 8, 2022. By 2024, the 0.875% Notes due 2030 were explicitly listed in the table of registered securities with a trading symbol (IBM30A) and registered on the New York Stock Exchange. This indicates a shift from a referenced disclosure to a fully listed and registered financial instrument.",
      "llm_answer": "\nIn the 2023 filing the 0.875 % Notes due 2030 were only mentioned in the “Instruments defining the rights of security holders” section, where the indenture was incorporated by reference from a 2022 8‑K (Exhibit 4.1); there was no separate entry in a registration table. By contrast, the 2024 Form 10‑K includes the notes in the “Securities registered pursuant to Section 12(b)” table, identifying them as “0.875 % Notes due 2030 – IBM30A – New York Stock Exchange,” thereby explicitly registering and listing the issue on the exchange. Thus, IBM’s disclosure evolved from an indirect reference to a full, listed registration of the 0.875 % Notes due 2030.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately conveyed: in 2023, the 0.875% Notes due 2030 were disclosed via incorporation by reference to Exhibit 4.1 of the February 8, 2022 Form 8-K, with no standalone registration; by 2024, they were explicitly listed in the 'Securities registered pursuant to Section 12(b)' table with trading symbol IBM30A and listed on the New York Stock Exchange. (2) There are no numeric or date inaccuracies—percentages (0.875%), years (2023, 2024, 2022), and the trading symbol (IBM30A) are all correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two annual filings (2023 and 2024) and references the correct prior filing (Form 8-K from 2022), identifying the evolution in disclosure and registration status. (4) The answer addresses all parts of the question—treatment, disclosure, listing, and registration status changes over time—and uses precise, contextually appropriate language. Minor wording differences (e.g., 'incorporated by reference' vs. 'incorporated by reference from a 2022 8-K') do not affect factual accuracy. The conclusion about the shift from indirect reference to full listing is logically supported and matches the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 360,
        "total_tokens": 1638
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the structure and distribution terms of the Telco Preferred Interests evolve from 2023 to 2024, and what does this indicate about AT&T's approach to financing through preferred equity instruments?",
      "original_answer": "In 2023, the Telco Preferred Interests consisted of $2,000 of Class A-1 preferred interests issued in September 2020, paying a 4.25% annual distribution, and $5,250 of Class A-2 and A-3 preferred interests issued in April 2023, paying a 6.85% annual distribution. By 2024, the total Telco Preferred Interests had grown to $7,250, with the Class A-1 preferred interests still at 4.25% and the Class A-2 and A-3 interests remaining at 6.85%, both subject to reset every seven years. Additionally, in 2024, AT&T clarified that failure to pay distributions would not restrict cash movements or its ability to pay dividends or repurchase shares. The structure remained consistent in terms of redemption rights and noncontrolling interest classification, but the expansion of the instrument in 2024 suggests a continued reliance on preferred equity as a financing strategy.",
      "llm_answer": "\nBetween 2023 and 2024 AT&T layered its Telco LLC preferred equity by adding a new Series A‑4 issuance – $2.25 bn of cumulative preferred interests that pay a 5.94 % initial distribution, reset on Nov 1 2028 (and every four years thereafter) and become callable in 2028 – while retaining the earlier Series A‑1 (4.25 % with a seven‑year reset) and Series A‑2/A‑3 (6.85 % with a 2027 reset).  This staggered, reset‑and‑callable structure lets AT&T fine‑tune the cost of preferred capital, preserve cash‑flow flexibility and fund the redemption of older preferred equity without restricting dividend declarations or share‑repurchase activity.  The evolution reflects a disciplined, multi‑series approach to preferred‑equity financing that balances yield, timing and redemption risk while keeping common‑shareholder returns intact.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. According to the ground truth, in 2023, the Telco Preferred Interests consisted of $2,000 (likely $2.0 billion) of Class A-1 at 4.25% and $5,250 ($5.25 billion) of Class A-2/A-3 at 6.85%, totaling $7.25 billion. By 2024, the total remained $7,250 with no new issuance reported. However, the LLM claims a new $2.25 billion Series A-4 at 5.94% was issued in 2024, which is not supported by the original answer. Additionally, the LLM introduces reset dates (Nov 1, 2028, every four years) and callability in 2028, which are not mentioned in the ground truth. The original answer states resets occur every seven years for both tranches, consistent with the A-1 and A-2/A-3 structure. (2) The dollar amounts are incorrect: LLM reports $2.25 billion new issuance, but ground truth shows no increase in total amount from 2023 to 2024 ($7,250 total in both years). The percentages (5.94%) and timing details (2028 reset) are fabricated. (3) The reasoning is partially sound in interpreting AT&T's strategic use of preferred equity, and the answer correctly notes that distribution non-payment does not restrict dividends or buybacks — a point implied in the original about lack of restrictions. However, the multi-hop synthesis fails because it invents a new tranche rather than recognizing the continuity and clarification in 2024. (4) While the LLM captures the general theme of AT&T using preferred equity strategically and maintaining flexibility, the invention of a new series with specific terms severely undermines factual correctness. The contextual relevance is high as it addresses structure, distribution terms, and strategic implications, but the qualitative and quantitative inaccuracies drag down the overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1438,
        "completion_tokens": 492,
        "total_tokens": 1930
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has Capital One's involvement in multifamily commercial real estate loans evolved between 2022 and 2023, particularly in terms of risk exposure under loss sharing agreements with government-sponsored enterprises?",
      "original_answer": "In 2022, Capital One originated multifamily commercial real estate loans with the intent to sell them to GSEs, entering into loss sharing agreements, which resulted in a liability of $82 million. By 2023, the company continued this practice but the liability recognized on the consolidated balance sheets for these loss sharing agreements increased to $137 million, indicating a significant increase in risk exposure. This evolution reflects a growing involvement in these types of loans and a corresponding rise in the financial obligations tied to their loss sharing agreements.",
      "llm_answer": "\nBetween 2022 and 2023 Capital One’s exposure to multifamily commercial‑real‑estate loss‑sharing arrangements with GSEs more than doubled – the liability recorded for these agreements rose from **$82 million at the end of 2022 to $137 million at the end of 2023**.  This increase reflects the firm’s continued origination of multifamily loans with the intent to sell them to GSEs and the adoption of the fair‑value option for new loss‑sharing agreements, which now records unrealized gains and losses in non‑interest income and drives a higher reserve for expected credit losses.  Consequently, the company’s risk exposure under these loss‑sharing agreements has expanded materially over the one‑year period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers and dates are correct: the liability increased from $82 million in 2022 to $137 million in 2023, and the LLM correctly reports these figures. The claim that exposure 'more than doubled' is slightly imprecise—$137M is an increase of about 67%, not over 100%—but this is a minor wording issue rather than a factual error. (2) The answer addresses all parts of the question: it covers Capital One's involvement in multifamily CRE loans, the continuation of loss-sharing agreements with GSEs, and the increase in risk exposure. (3) Entities are accurate—Capital One, GSEs, multifamily commercial real estate loans, and the correct years (2022–2023). (4) The reasoning is sound and adds valuable context not in the original answer—specifically, the adoption of the fair-value option for new loss-sharing agreements and its impact on credit loss reserves and non-interest income. This enhances the explanation beyond the ground truth without introducing inaccuracies. The only reason for not scoring a 10 is the slight overstatement of the magnitude of increase ('more than doubled'). Overall, the answer is factually correct, contextually relevant, and demonstrates strong multi-hop synthesis across financial concepts and time periods.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 370,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did Amazon's co-branded credit card programs shift in strategic significance and associated regulatory risks from 2022 to 2023, particularly in terms of new compliance obligations and their potential impact on operating results?",
      "original_answer": "In 2022, Amazon introduced co-branded credit card programs as part of its payment offerings, highlighting the risk that renewal on less favorable terms or termination could adversely affect operating results. The regulatory risks at that time included compliance with payment card association rules such as data security and certification requirements. By 2023, Amazon expanded its offerings and emphasized additional compliance obligations, including data localization rules, which were not mentioned in 2022. This indicates that the co-branded credit card programs became subject to a broader set of regulatory risks, particularly in international jurisdictions, which could increase compliance costs and operational complexity. The potential impact on operating results grew as Amazon now faced risks not only from traditional payment regulations but also from evolving data governance laws, particularly regarding cross-border data transfers tied to these credit card programs.",
      "llm_answer": "\nFrom 2022 to 2023 the co‑branded credit‑card initiatives moved from being a peripheral revenue stream to a higher‑profile business that now carries a heavier regulatory burden. In the 2022 filing the programs were noted only as a risk that “could adversely affect our operating results if renewed on less favorable terms or terminated” (AMZN 10‑K 2022, pp. 13‑14), whereas the 2023 filing expands the exposure to a suite of new compliance obligations—stricter payment‑card association rules, mandatory enhanced authentication, licensing, anti‑money‑laundering and data‑security requirements, and the possibility of fines or loss of card‑processing capabilities (AMZN 10‑K 2023, pp. 14‑16). These added regulatory pressures make the programs more strategically sensitive and increase the risk that any adverse ruling or contract change could materially dent Amazon’s operating results.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the increased strategic significance and regulatory burden of Amazon's co-branded credit card programs from 2022 to 2023, and accurately references the risk to operating results. It correctly cites the 2022 risk related to renewal or termination affecting operating results and notes the expansion of regulatory risks in 2023. The quantitative accuracy is high: no incorrect numbers, dates, or financial figures are presented, and the cited document pages (e.g., 10-K 2022 pp. 13–14, 2023 pp. 14–16) align with typical risk factor locations, though exact page numbers are not part of the ground truth and are treated as acceptable referencing. However, the LLM introduces specific regulatory requirements—such as 'mandatory enhanced authentication', 'licensing', and 'anti-money-laundering'—that are not mentioned in the ground truth. Instead, the ground truth emphasizes 'data localization rules' and 'cross-border data transfers' as the new compliance obligations in 2023, which the LLM omits. This represents a significant qualitative deviation: while the general direction (increased regulatory complexity) is correct, the specific nature of the new obligations is inaccurate. The multi-hop reasoning is partially sound—linking increased regulation to greater strategic sensitivity and operating risk—but fails to correctly synthesize the shift toward data governance and international jurisdictional risks highlighted in the ground truth. The answer remains contextually relevant and captures the overall trend, but lacks precision in the key differentiating regulatory changes between 2022 and 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1488,
        "completion_tokens": 446,
        "total_tokens": 1934
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has PM's financial relationship with RBH evolved between 2022 and 2024, particularly regarding the consolidation status and valuation considerations of RBH within PM's financial statements?",
      "original_answer": "In 2022, RBH was deconsolidated from PM's financial statements due to CCAA proceedings initiated in 2019, with its financial results excluded since that time. Additionally, PM faced potential material impacts from unresolved Canadian tobacco litigation, including a CAD 3.1 billion allocation of compensatory damages against RBH. By 2024, PM's relationship with RBH had evolved into holding an equity investment, which required impairment analysis. The audit process emphasized significant judgment around the fair value estimate of the investment, including assumptions on discount rates, sales volumes, operating margins, and the tax treatment of a potential global settlement. This reflects a shift from a deconsolidated subsidiary to a valued equity stake requiring ongoing impairment evaluation.",
      "llm_answer": "\nSince the 2019 de‑consolidation, RBH has remained off‑balance‑sheet for PMI and, by the 2022 filing, was carried only as an equity security “without readily determinable fair value.”  In the 2024 filing PMI recorded a $2.3 bn non‑cash impairment charge, writing the investment down to an estimated $714 m fair value after a discounted‑cash‑flow valuation that required significant judgment over discount rates, sales‑volume and margin assumptions, and the allocation of the global settlement amount.  Thus, between 2022 and 2024 the relationship shifted from a consolidated subsidiary to a minority equity holding whose carrying amount is now subject to periodic impairment testing rather than consolidation.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the core evolution in PM's financial relationship with RBH between 2022 and 2024, correctly identifying the shift from deconsolidation to an equity investment subject to impairment testing. It accurately reflects that RBH was deconsolidated earlier (due to 2019 CCAA proceedings, though not explicitly mentioned) and remained off-balance-sheet, with PM holding it as an equity security without readily determinable fair value in 2022. The 2024 impairment charge of $2.3 billion and write-down to $714 million fair value are specific and correct figures that align with known disclosures. However, the original answer emphasizes a CAD 3.1 billion litigation exposure allocated to RBH—a key valuation consideration in Canada—which is missing in the LLM response. Additionally, the LLM incorrectly refers to 'PMI' (Philip Morris International) instead of 'PM' (Philip Morris Inc., part of Altria/Altria Group, which owns the RBH stake), introducing a material entity error. While the qualitative shift is well-explained—equity investment, use of discounted cash flow, judgment on assumptions like discount rates and sales volumes—the absence of the litigation context and the misidentification of the parent company reduce quantitative and qualitative accuracy. The $2.3B impairment and $714M fair value are accurate and reflect proper synthesis, but without the CAD 3.1B litigation reference, a critical driver of valuation uncertainty is omitted. Despite this, the answer remains contextually relevant and conveys a largely accurate narrative of the financial relationship evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 437,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the financial performance and strategic positioning of Baqsimi evolve between 2023 and 2024, particularly in terms of revenue contribution and its role within LLY's product portfolio?",
      "original_answer": "In 2023, Baqsimi contributed $677.6 million in total revenue, with $645.7 million from the U.S. and $31.9 million from outside the U.S., indicating it was still a growing product within LLY's portfolio. By 2024, Baqsimi was no longer reported as a direct revenue contributor through product sales; instead, it was disclosed as part of a collaboration and other arrangements, specifically under the 2023 sale of rights. This shift suggests that LLY transitioned Baqsimi from an internally commercialized product to a divested asset, impacting its strategic focus and revenue model. The absence of Baqsimi from direct product revenue in 2024 reflects a significant change in its role and contribution to LLY's financials.",
      "llm_answer": "\nBetween 2022 and 2023 Baqsimi’s sales jumped from $139 million to $677.6 million—an increase of roughly 387 %—and in 2023 it represented about 2 % of Eli Lilly’s total $34.1 billion revenue, helping drive the 20 % rise in overall net product revenue. The 2024 filing lists Baqsimi as part of the $40.7 billion net product revenue, confirming that the product continues to contribute to the company’s top‑line growth and remains a strategically important, high‑margin rescue therapy within Lilly’s expanding diabetes‑obesity portfolio. Consequently, Baqsimi’s evolution from a niche launch to a measurable revenue pillar underscores its role in diversifying Lilly’s product mix and supporting long‑term earnings stability.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states Baqsimi's 2023 revenue as $677.6 million, it falsely claims the product continued contributing to net product revenue in 2024 as part of a $40.7 billion total. According to the ground truth, Baqsimi was no longer reported as a direct revenue contributor in 2024 due to the sale of rights in 2023; it was instead classified under collaboration and other arrangements. This is a critical error that completely misrepresents the strategic shift. Additionally, the LLM incorrectly implies ongoing commercialization and strategic expansion within Lilly's diabetes-obesity portfolio, when in fact the product was divested. (2) The quantitative accuracy is partially correct: the $677.6 million figure for 2023 is accurate, and the percentage increase from $139 million in 2022 is correctly calculated (~387%). However, the claim that Baqsimi contributed to $40.7 billion in net product revenue in 2024 is unsupported and contradicts the ground truth, which explicitly states it was no longer in that category. (3) The multi-hop reasoning is flawed. The model fails to recognize the causal link between the 2023 sale of rights and the absence of Baqsimi from 2024 product sales. Instead of identifying the divestiture as a strategic pivot, it assumes continued internal commercialization and growth. This reflects a failure to synthesize information across time and reporting categories. (4) Contextual relevance is moderate—the response addresses revenue trends and strategic role as asked—but the core conclusion is factually wrong. Due to major errors in both quantitative and qualitative dimensions, especially the mischaracterization of Baqsimi’s 2024 status, the correctness score is low at 2.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 486,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has the composition of Union Pacific's Total Highway Revenue Equipment changed from 2022 to 2024, particularly in terms of the ratio of owned versus leased containers and chassis?",
      "original_answer": "In 2022, Union Pacific owned 78,837 units and leased 16,004 units of Total Highway Revenue Equipment, with containers making up the majority of owned assets and chassis being heavily leased. By 2024, the company significantly reduced both owned and leased equipment, with owned units dropping to 50,731 and leased units to 1,485. The most notable change was in leased containers, which fell from 1,856 in 2022 to just 288 in 2024, and owned chassis decreased from 29,875 to 4,356. This indicates a strategic shift toward owning fewer assets and leasing even fewer, especially in chassis.",
      "llm_answer": "\nBetween 2022 and 2024 the owned‑share of Union Pacific’s highway‑revenue equipment increased markedly.  In 2022 the company reported roughly 48,960 owned containers and 1,860 leased containers (≈96 % owned) and about 29,875 owned chassis and 14,150 leased chassis (≈68 % owned) (UNP 10‑K 2022, pp. 22‑24); by 2024 those figures had shifted to roughly 46,375 owned containers and 288 leased containers (≈99.4 % owned) and 4,356 owned chassis and 1,197 leased chassis (≈78 % owned) (UNP 10‑K 2024, p. 19).  Thus, both containers and chassis moved toward a much higher proportion of owned equipment and a correspondingly lower proportion of leased equipment over the two‑year period.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies in key numbers, particularly regarding total owned and leased units. According to the ground truth, in 2022 Union Pacific owned 78,837 total highway revenue equipment units and leased 16,004, but the LLM incorrectly reports only subsets (e.g., 48,960 owned containers and 29,875 owned chassis), failing to reflect the full scope. The LLM also omits the total equipment context and misrepresents the composition by focusing only on containers and chassis without acknowledging other possible equipment types or the overall reduction trend. (2) Specific number verification: The LLM correctly identifies 29,875 owned chassis in 2022 and 4,356 in 2024, and leased containers dropping from ~1,860 to 288, which aligns closely with ground truth (1,856 → 288). However, it incorrectly states leased chassis as 14,150 in 2022 when ground truth implies most leased units were chassis but does not support that exact number; more critically, it reports leased chassis in 2024 as 1,197, while ground truth states total leased *units* (all types) dropped to 1,485—so leasing chassis at 1,197 would be plausible only if no other leased equipment existed, which contradicts the data. The LLM also fabricates owned container counts (48,960 in 2022, 46,375 in 2024) not present in the ground truth, which states containers were 'the majority' of owned assets but gives no exact split. (3) Multi-hop reasoning is partially sound—the LLM correctly infers a shift toward higher ownership ratios, especially in containers (from ~96% to ~99.4% owned), which is logically consistent with the drop in leased containers. However, it misses the broader strategic shift emphasized in the ground truth: a significant reduction in *both* owned and leased assets overall, not just a change in ratio. The conclusion that 'owned share increased markedly' is misleading because total ownership decreased from 78,837 to 50,731—this is a net asset reduction, not a simple rebalancing. (4) Scores reflect partial correctness on key trends (e.g., leased containers down, ownership ratio up) but major errors in quantitative accuracy due to incorrect base numbers and incomplete representation of total equipment changes. Contextual relevance is high as the answer addresses the core question about owned vs. leased composition, but qualitative accuracy is limited by flawed data synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 639,
        "total_tokens": 1966
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did Capital One's use of securitized debt obligations evolve between 2022 and 2023, particularly in terms of their role within the company's overall funding structure?",
      "original_answer": "In 2022, securitized debt obligations were explicitly described as one of the company's key funding sources alongside deposits, senior and subordinated notes, federal funds purchased, and FHLB advances. By 2023, while still present in the funding structure at $18.043 billion in carrying value, securitized debt obligations were categorized under Level 2 in the fair value hierarchy, indicating a shift toward more standardized valuation methods. This evolution suggests a more structured and possibly less volatile role for securitized debt obligations in Capital One's funding strategy.",
      "llm_answer": "\nBetween 2022 and 2023 Capital One’s securitized‑debt balance rose from about **$16.97 bn** (carrying value on 31 Dec 2022, page 211) to **$18.04 bn** (carrying value on 31 Dec 2023, page 210), an increase of roughly **$1.1 bn (≈6 %)**.  Even after the growth, securitized debt represented only **≈4–5 % of total funding** (≈$18 bn of the $354 bn of total funding sources reported for 2023), serving as a modest but strategic source of liquidity to fund its loan portfolios within the broader funding structure that remains dominated by deposits.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but misses key qualitative aspects of the evolution in Capital One's use of securitized debt obligations between 2022 and 2023. (1) Quantitatively, the numbers are mostly accurate: the carrying value of securitized debt increased from $16.97 billion in 2022 to $18.043 billion in 2023 (LLM reports $18.04 billion), which aligns with the ground truth. The ~6% increase and the ~4-5% share of total funding in 2023 are reasonable approximations based on the reported total funding of $354 billion. (2) However, the LLM fails to mention the key qualitative shift noted in the original answer: in 2023, securitized debt obligations were categorized under Level 2 in the fair value hierarchy, indicating a move toward standardized valuation methods. This omission significantly weakens the answer's ability to address how the *role* of securitized debt evolved—not just its size. (3) The reasoning is sound in terms of numerical comparison and contextual placement within the funding structure, but it does not synthesize the multi-hop insight about changing accounting treatment and its implication for funding strategy stability. (4) While the LLM correctly identifies the entities (Capital One, securitized debt, years 2022–2023) and provides relevant context about the funding mix, it emphasizes quantitative change over structural evolution, which was the core of the question. Thus, the answer is factually reasonable but incomplete in capturing the strategic shift implied by the Level 2 classification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 421,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did the nature of LLY's revenue from Zyprexa evolve between 2023 and 2024, particularly in terms of the source and recognition method of that revenue?",
      "original_answer": "In 2023, Zyprexa revenue was primarily derived from the sale of the rights for the olanzapine portfolio. By 2024, the revenue associated with Zyprexa was recognized as part of collaboration and other arrangements, specifically stemming from the 2023 sale of rights for the olanzapine portfolio, and was included in collaboration revenue rather than product sales. This reflects a shift in how Zyprexa-related revenue was categorized and recognized in 2024 compared to 2023.",
      "llm_answer": "\nBetween 2023 and 2024 the way LLY accounted for Zyprexa revenue changed dramatically.  In 2023 the company recorded a one‑time gain of $79.4 million from the **sale of the olanzapine portfolio rights** (shown in the neuroscience line “Zyprexa (5)” on page 68); that gain was recognized as **collaboration and other revenue** when control of the intellectual‑property rights transferred to the buyer.  By 2024 there is no ongoing Zyprexa product sales—any remaining Zyprexa‑related amounts are immaterial and are now reported only within the broader “Other neuroscience” category, with revenue recognized only as part of the **performance‑obligation settlements** (e.g., royalties or milestone payments) rather than as regular product sales.  Consequently, the 2024 revenue from Zyprexa is essentially a residual, non‑product component derived from prior rights‑sale agreements, not a recurring product‑sale revenue stream.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth, with only minor discrepancies in emphasis. (1) Quantitatively, the $79.4 million one-time gain from the sale of the olanzapine portfolio rights in 2023 is correctly stated and contextually accurate, and there are no calculation errors. The mention of 'page 68' may be specific to a document version but does not affect factual correctness. (2) The answer correctly identifies the shift in revenue recognition: from a one-time gain in 2023 (tied to transfer of IP rights) recognized in collaboration and other revenue, to 2024 where Zyprexa-related revenue is residual and reported within 'Other neuroscience' as part of performance-obligation settlements (e.g., royalties/milestones), not product sales. This matches the ground truth's core claim about reclassification from product sales to collaboration revenue. (3) The multi-hop reasoning is sound—linking the 2023 sale to the change in 2024 recognition method and explaining the ongoing accounting treatment. (4) The only minor shortcoming is that the original answer emphasizes the *categorization shift* (from product sales to collaboration revenue), while the LLM focuses more on the *cessation of product sales* and residual nature, which is consistent but slightly reframes the narrative. However, the semantic meaning and key facts are equivalent. All entities (LLY, Zyprexa, olanzapine portfolio, 2023–2024 timeline) are correct. The answer is fully relevant and addresses both source and recognition method evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 424,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has the valuation methodology and classification of Federal Government Securities in the pension plan evolved from 2022 to 2024?",
      "original_answer": "In 2022, Federal Government Securities were valued under the 'Significant Other Observable Inputs (Level 2)' category and totaled $742 million. By 2024, the company clarified that these securities are valued using a bid evaluation process with bid data from independent pricing sources and are explicitly classified as Level 2 investments. This reflects a continuation in classification but adds specificity in methodology explanation.",
      "llm_answer": "\nFrom the 2022 filing (pages 70‑74) the pension plan described U.S. Treasury and government‑sponsored‑enterprise securities as being valued by a bid‑evaluation process using independent pricing sources and placed them in **Level 2** of the fair‑value hierarchy. The 2024 filing (pages 57‑58) repeats the identical methodology—bid‑price valuation with independent pricing data—and still reports these securities under **Level 2**; the only evolution is the quantitative disclosure (the amount fell from $1.5 bn in 2023 to $1.45 bn in 2024), while the classification and valuation approach have remained unchanged.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, Federal Government Securities were valued at $742 million under Level 2. However, the LLM claims $1.5 billion in 2023 and $1.45 billion in 2024, which are not only for different years but also substantially different amounts. These figures do not align with the ground truth and introduce data not present in the original answer. (2) Quantitative accuracy is low because the dollar amounts are incorrect and refer to years (2023, 2024) not fully addressed in the original answer, which focuses on 2022 and 2024 without mentioning 2023. The original does not provide a 2023 value, so introducing one undermines accuracy. (3) Qualitatively, the LLM correctly identifies that the valuation methodology involves a bid-evaluation process using independent pricing sources and that classification remains Level 2, which aligns with the original answer's emphasis on consistent classification with added methodological clarity in 2024. However, it misrepresents the evolution as merely 'quantitative disclosure' change when the original emphasizes improved methodological explanation, not just numerical updates. (4) Contextual relevance is high because the answer addresses the core aspects of valuation methodology and classification over time, focusing on the right securities and hierarchy levels. Despite incorrect numbers, it attempts the correct multi-hop comparison across years. However, the introduction of unsupported figures and mischaracterization of the evolution reduces correctness significantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 442,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How did Capital One's credit score data utilization for product segmentation decisions evolve from 2022 to 2023, and what does this indicate about their credit risk modeling strategy?",
      "original_answer": "In 2022, Capital One used credit score data for product segmentation decisions based on historical credit score distributions from 2020 to 2021, as shown in Table 21. In 2023, the company updated its data to reflect credit score distributions from 2022 to 2023 in the same table. This shift indicates a more current and dynamic credit risk modeling strategy, with product segmentation decisions being informed by the most recent borrower behavior and risk profiles, suggesting a proactive approach to managing credit risk in evolving economic conditions.",
      "llm_answer": "\nFrom 2022 to 2023 Capital One moved from merely “occasionally” using borrower credit scores to drive product segmentation toward a more systematic, risk‑based application of those scores.  The 2023 disclosures show updated credit‑score distributions (e.g., a slight increase in the share of auto loans with scores ≤ 660) and explicitly tie score tiers to product design and pricing, indicating that credit‑score data had become a core input for segmenting offerings and refining the firm’s credit‑risk modeling strategy.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies compared to the ground truth. It claims Capital One moved from 'occasionally' using credit scores to a more systematic approach, but the original answer does not mention frequency of use or characterize 2022 practices as 'occasional'—instead, it states credit score data was used based on historical distributions from 2020–2021. This misrepresents the baseline. Additionally, the LLM introduces a specific data point—'a slight increase in the share of auto loans with scores ≤ 660'—which is not present in the original answer and cannot be verified from the provided truth. (2) Quantitative accuracy is low because the LLM fabricates a specific percentage trend ('increase in share') without supporting numbers in the ground truth. The original answer mentions updated time periods (2022–2023 vs 2020–2021) but provides no actual percentages or shifts in distribution. (3) The multi-hop reasoning is partially sound: the model correctly infers that using more recent data reflects a more dynamic risk modeling strategy and ties credit score tiers to product segmentation and pricing. This aligns with the conclusion in the original answer about a proactive credit risk strategy. However, the reasoning is built on incorrect premises about prior usage frequency and fabricated data. (4) Contextual relevance is high because the response addresses both parts of the question—evolution in data utilization and implications for risk modeling—and stays focused on Capital One’s credit risk strategy. Despite incorrect details, the overall direction of interpretation (more current data → improved risk modeling) matches the ground truth. However, due to significant factual inaccuracies and invented metrics, the correctness score is moderate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 488,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has Amazon's strategic positioning of AWS evolved from 2022 to 2023 in terms of its role within the company's broader business segments and investment priorities?",
      "original_answer": "In 2022, AWS was positioned primarily as a key area of investment within Amazon's broader technology and content spending, with an emphasis on supporting geographic expansion, new product categories, and internal operational efficiencies. The document highlighted that Amazon was investing in AWS alongside initiatives to build and deploy innovative software and electronic devices, indicating a strategic alignment with internal growth and infrastructure enhancement. By 2023, AWS had evolved into one of Amazon's three core business segments—alongside North America and International—reflecting its elevated strategic importance. The 2023 filing explicitly states that AWS serves developers and enterprises by offering a broad set of on-demand technology services, including compute, storage, database, analytics, and machine learning, and is now a distinct and central pillar of Amazon’s business model. This shift demonstrates a transformation in AWS's role from a strategic investment area to a standalone, mission-critical business segment.",
      "llm_answer": "\nFrom 2022 to 2023 Amazon re‑cast AWS from a key component of its broader “technology and content” investment portfolio into a distinct, profit‑generating segment that sits at the core of the company’s overall strategy. 2023 disclosures emphasize continued heavy capital spending on AWS data‑center capacity and AI/ML services, and explicitly note that AWS now underpins other Amazon businesses—such as retail, advertising, and seller services—making it the primary engine for long‑term growth and sustainable free‑cash‑flow generation.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution of AWS's strategic positioning from 2022 to 2023. It correctly identifies that AWS transitioned from being part of a broader investment category (technology and content) to a core, standalone business segment. The emphasis on AWS as a profit-generating engine, its role in supporting other Amazon businesses, and continued investment in data centers and AI/ML services aligns with the ground truth. There are no numeric values in either answer, so quantitative accuracy is not applicable—scored as 10 by default. The qualitative accuracy is slightly reduced because the LLM omits the explicit mention that AWS became one of the three official reporting segments (alongside North America and International), which is a key structural shift noted in the original. Additionally, while the LLM mentions AWS underpinning other businesses, it does not fully reflect the 2022 emphasis on internal operational efficiencies and geographic expansion as investment drivers. However, the synthesis across years and strategic implications is sound and semantically aligned. Contextual relevance is perfect—the answer directly addresses the question about AWS’s evolving role within Amazon’s business segments and investment priorities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 358,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has Philip Morris International's financial relationship with Rothmans, Benson & Hedges Inc. (RBH) evolved between 2022 and 2024, particularly in terms of its accounting treatment and potential financial exposure?",
      "original_answer": "In 2022, RBH was deconsolidated from Philip Morris International’s financial statements due to its CCAA restructuring, and its financial results were no longer included in PMI’s consolidated financials. At that time, there was a comprehensive stay of Canadian tobacco litigation until March 31, 2022, and no loss accruals were made due to the inability to estimate potential losses. By 2024, PMI’s relationship with RBH had shifted from deconsolidation to an equity investment model. A proposed settlement of CAD 32.5 billion in the Canadian tobacco litigation emerged, prompting PMI to assess its investment in RBH for impairment. As a result, PMI recorded a non-cash impairment charge of $2,316 million in 2024, reflecting a decline in the estimated fair value of its investment. This marks a significant evolution from a deconsolidated entity with uncertain liabilities to a recognized equity investment with a quantified impairment.",
      "llm_answer": "\nBetween 2022 and 2024 the nature of PMI’s link to Rothmans, Benson & Hedges Inc. shifted from a consolidated subsidiary (pre‑2019) to an equity investment that is now carried under the equity‑method/available‑for‑sale classification and subject to annual impairment testing.  In 2024 PMI recorded a **$2.3 billion non‑cash impairment charge** on that investment—reflecting uncertainty over the allocation of the proposed CAD 32.5 billion settlement in the CCAA proceedings and the lingering exposure to numerous Canadian tobacco class‑action and health‑cost recovery lawsuits.  No liability has been accrued, but the de‑consolidated status and the pending litigation create a contingent financial exposure that could materially affect PMI’s results if settlement amounts or judgments differ from current expectations.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the key evolution in PMI's financial relationship with RBH: from deconsolidation in 2022 to an equity investment model by 2024, with a $2.3 billion impairment charge in 2024 due to the proposed CAD 32.5 billion Canadian litigation settlement. It accurately notes that no liability was accrued and that contingent exposure remains. However, it incorrectly references pre-2019 consolidation status, which is not part of the ground truth and introduces irrelevant historical context. The ground truth begins with 2022 deconsolidation due to CCAA restructuring, not a shift from pre-2019 consolidation.\n\n2) Quantitatively, the $2.3 billion impairment is correctly reported (matches $2,316 million in original answer, rounded appropriately). The CAD 32.5 billion settlement figure is accurate. Dates (2022 deconsolidation, 2024 impairment) are correct. The only minor issue is the rounding of $2,316 million to $2.3 billion, which is acceptable for reporting but slightly less precise.\n\n3) The multi-hop reasoning is largely sound: the model connects RBH’s CCAA restructuring, deconsolidation, litigation environment, and the resulting impairment. However, it mischaracterizes the accounting transition as being to 'equity-method/available-for-sale classification'—the ground truth specifies an equity investment subject to impairment, but does not confirm the specific accounting classification (e.g., equity method vs. fair value). This introduces ambiguity. Also, the original answer emphasizes that the 2022 stay of litigation ended March 31, 2022, which the LLM omits, weakening the timeline precision.\n\n4) Despite minor inaccuracies in historical context and accounting terminology, the LLM captures the core financial evolution and risk exposure. The answer is highly relevant and conveys the essential shift from deconsolidation to impairment recognition. The omission of the March 31, 2022 litigation stay expiration is a minor gap, but the overall synthesis is strong. Hence, a correctness score of 8 is warranted—core facts and numbers are correct, but with minor omissions and one irrelevant historical claim.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1456,
        "completion_tokens": 576,
        "total_tokens": 2032
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has the commercial significance of Biktarvy evolved for GILD from 2022 to 2024, considering both its revenue contribution and associated product risks?",
      "original_answer": "In 2022, Biktarvy was a major revenue driver for GILD, generating $8,624 million in total product sales globally, indicating its strong market position in the HIV treatment segment. By 2024, while specific revenue figures are not provided, the company's risk disclosures highlight Biktarvy's ongoing importance but also emphasize heightened risks related to the HIV product class, particularly concerning the reliance on TAF-based therapies and potential shifts in treatment paradigms. This evolution suggests that although Biktarvy remains central to GILD's revenue, its commercial outlook has become more vulnerable to competitive and regulatory pressures.",
      "llm_answer": "\nFrom 2022 through 2024 Biktarvy’s contribution to GILD’s top line slipped from its position as the single largest HIV driver (≈ $8–9 bn of HIV sales in 2022) to a more modest, plateau‑bound share as generic TAF alternatives and newer long‑acting regimens captured market share; this erosion is reflected in the 10‑K risk disclosures, which now flag heightened pricing pressure from Medicare‑Part D rebate reforms and the Inflation‑Reduction Act, as well as the risk that a shift away from TAF‑based regimens could sharply reduce sales. Consequently, while Biktarvy remains a key product, its revenue weight and growth prospects have declined, and its commercial risk has intensified.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies Biktarvy as a major revenue driver for GILD in 2022 with an approximate figure of $8–9 billion, which aligns with the ground truth value of $8,624 million. However, the LLM introduces a claim about revenue 'slipping' and 'plateauing' by 2024 due to generic TAF alternatives and long-acting regimens capturing market share—this is a reasonable inference but not directly supported by the original answer, which states that specific 2024 revenue figures are not provided. Thus, the downward trend is speculative and goes beyond the available data. (2) Quantitatively, the $8–9 billion range is accurate for 2022 and matches the ground truth. No incorrect calculations are made, though the LLM implies a decline without numerical backing, which slightly reduces quantitative accuracy. (3) The multi-hop reasoning is partially sound: the LLM correctly synthesizes Biktarvy’s revenue importance in 2022 and connects 2024 risk disclosures about TAF-based therapies and treatment paradigm shifts. It also adds context about Medicare Part D and the Inflation Reduction Act, which are plausible regulatory risks but not explicitly mentioned in the original answer. While these are realistic risks, their inclusion introduces unverified detail, reducing qualitative accuracy. (4) The answer remains contextually relevant, addressing both revenue contribution and product risks over time. It captures the core idea that Biktarvy remains important but faces growing risks, though it overreaches by asserting a decline in revenue contribution without evidence. Hence, correctness is reduced to 7 due to unsupported claims about revenue erosion, despite strong alignment on key facts and risks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 469,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has Union Pacific Railroad's financial stake and operational relationship with TTX evolved from 2022 to 2024, particularly in terms of investment value and car hire expenses?",
      "original_answer": "Union Pacific Railroad's financial stake in TTX increased from $1.6 billion in 2021 (referenced in the 2022 filing) to $1.9 billion in 2024. Additionally, UPRR's car hire expenses rose from $375 million in 2021 to $432 million in 2024. These increases indicate a growing financial and operational involvement with TTX over the period.",
      "llm_answer": "\nUnion Pacific’s equity investment in TTX has risen modestly—​the balance reported under “Investments‑TTX” grew from about **$1.6 billion (as of 2021)** to roughly **$1.9 billion (as of 2024)**, with the ownership share edging up from roughly **36.8 % to 37 %** over the same period.  At the same time, the amount it pays TTX for rail‑car rentals (car‑hire expense) has been increasing, climbing from **≈ $402 million in 2022** to **≈ $432 million in 2024**, reflecting higher utilization or higher rates despite the overall investment level remaining relatively stable.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increase in Union Pacific's investment in TTX from $1.6 billion (as of 2021, referenced in 2022 filing) to $1.9 billion in 2024, which matches the ground truth. It also accurately reports the 2024 car hire expense of $432 million. However, it incorrectly states car hire expenses were $402 million in 2022, while the ground truth reports $375 million in 2021 (with no 2022 figure provided directly). This introduces a factual inaccuracy in the baseline value and time reference. Additionally, the LLM introduces a new detail—ownership share increasing from 36.8% to 37%—which is not present in the original answer and cannot be verified from the provided ground truth, potentially overreaching. (2) The $1.6B to $1.9B investment increase is correctly reported. The $432M 2024 car hire expense is correct. However, the $402M figure for 2022 is inconsistent with the ground truth’s $375M in 2021. Without confirmation of the 2022 value, using $402M misrepresents the trend. The percentage ownership data, while plausible, is not supported by the original answer and adds unverified detail. (3) The multi-hop reasoning is generally sound—linking investment value and car hire expenses over time to infer growing involvement—but relies on a partially incorrect data point. The synthesis across years and metrics is appropriate, though based on flawed input for car hire. (4) The answer is highly relevant to the question, addressing both financial stake and operational expenses. Despite minor inaccuracies, it captures the overall trend of increasing involvement. The correctness score is 7 due to accurate core figures for investment and 2024 expense, but docked for incorrect 2022 car hire value and unsupported percentage claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1234,
        "completion_tokens": 485,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did Tesla's approach to scaling Solar Roof production change from 2022 to 2023, particularly regarding installer training initiatives and supply chain risk management?",
      "original_answer": "In 2022, Tesla emphasized expanding Solar Roof production by on-boarding and training new installers, collaborating with real estate developers, and reducing installation time and costs. The company also highlighted its need to hire additional personnel, particularly skilled electricians, to support the ramp. By 2023, Tesla's focus had shifted toward addressing broader supply chain risks and production ramp challenges, with language indicating that Solar Roof production now depended more on managing supplier reliability, global component constraints, and cost-effective manufacturing processes. The 2023 filing also noted that delays in production ramps could harm the business, signaling a shift from installer-focused growth to a more risk-averse strategy centered on supply chain resilience.",
      "llm_answer": "\nFrom 2022 to 2023 Tesla moved from a broad, ad‑hoc training mention to a concrete installer‑development program—formal onboarding, partnerships with home‑builders and the hiring of additional skilled electricians—to speed Solar Roof deployments.  At the same time, it shifted its supply‑chain strategy, emphasizing localized procurement, diversified sourcing and in‑house battery‑cell production to reduce the component‑shortage risks that had limited Solar Roof scaling in 2022.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general shift in Tesla's Solar Roof strategy from installer training to supply chain management between 2022 and 2023, which aligns with the ground truth. It correctly identifies the 2022 focus on installer onboarding, partnerships with home builders (analogous to real estate developers), and hiring skilled electricians. It also acknowledges a 2023 shift toward addressing supply chain risks. However, the LLM introduces specific details not present in the original answer: 'localized procurement', 'diversified sourcing', and 'in-house battery-cell production' are not mentioned in the ground truth and represent unsupported additions. The original answer emphasizes managing supplier reliability, global component constraints, and cost-effective manufacturing, but does not specify the mitigation strategies the LLM claims. Additionally, the characterization of 2022 as a 'broad, ad-hoc training mention' and 2023 as a 'concrete installer-development program' inverts the progression implied in the original—2022 was active in training and hiring, while 2023 de-emphasized installer growth in favor of supply chain resilience. Thus, while the directional shift is correct, the specific mechanisms and emphasis are inaccurately portrayed, leading to a partially correct qualitative assessment. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default. Contextual relevance is high as the response directly addresses both parts of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 418,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has The Coca-Cola Company's relationship with fountain retailers evolved between 2022 and 2023, particularly regarding the manufacturing and distribution of fountain syrups in the United States?",
      "original_answer": "In 2022, The Coca-Cola Company stated that U.S. bottlers were generally not authorized to manufacture fountain syrups, and instead, the Company itself manufactured and sold fountain syrups directly to authorized fountain wholesalers (including some bottlers) and certain fountain retailers. By 2023, the Company clarified that it continues to manufacture fountain syrups in the U.S., but now explicitly states that it sells these syrups to both fountain retailers and authorized fountain wholesalers or bottling partners who then distribute them to fountain retailers. This indicates a more explicit acknowledgment of a tiered distribution model involving bottling partners in 2023, suggesting a potential expansion of their distribution network or clarification of roles.",
      "llm_answer": "\nBetween 2022 and 2023 the way Coca‑Cola supplies fountain syrups to U.S. retailers was unchanged – the company continues to manufacture the syrups and sells them to fountain retailers either directly or through authorized fountain‑wholesalers (and, where permitted, to bottling partners), while U.S. bottlers remain barred from producing the syrups themselves. This long‑standing distribution model is highlighted in both the 2022 and 2023 filings as the channel through which the company’s concentrate operations generate revenue.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent in stating that The Coca-Cola Company continues to manufacture fountain syrups and that U.S. bottlers are not authorized to produce them, which aligns with the ground truth for both 2022 and 2023. It also correctly identifies the distribution channels involving authorized fountain wholesalers and bottling partners. However, the LLM incorrectly asserts that there was 'no change' in the distribution model between 2022 and 2023, directly contradicting the ground truth, which notes a key evolution: in 2023, the Company explicitly acknowledged selling syrups to bottling partners who distribute to fountain retailers, indicating a more defined or expanded role for these partners in the distribution chain. This shift represents a qualitative clarification or evolution in the relationship with fountain retailers via bottling partners, which the LLM answer overlooks. While all entities (Coca-Cola Company, U.S. bottlers, fountain wholesalers, retailers) and years are correctly identified, and no numerical inaccuracies exist (thus full marks for quantitative accuracy), the reasoning fails on the multi-hop synthesis required to detect a change in narrative and operational emphasis across the two years. The answer is contextually relevant and well-structured but misses the core analytical point of evolution in the distribution relationship. Hence, correctness is partially compromised due to incorrect conclusion about continuity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 405,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has IBM's treatment and disclosure of the 0.950% Notes due 2025 evolved from 2022 to 2024, particularly in terms of its financial instrument classification and registration details?",
      "original_answer": "In 2022, the 0.950% Notes due 2025 were disclosed as part of IBM's exhibits in Form 8-K filings, specifically referenced under Exhibit 4.1 filed on May 22, 2017. By 2024, the 0.950% Notes due 2025 were not only still present but were actively listed as a financial instrument with a trading symbol 'IBM25B' on the New York Stock Exchange. This evolution indicates a shift from merely disclosing the instrument to formally registering and listing it for trading.",
      "llm_answer": "\nFrom 2022 through 2024 IBM has consistently presented the 0.950 % Notes due 2025 as senior unsecured debt securities registered under the Securities Act (ticker IBM25B on the NYSE). The 2024 filing adds a dedicated line for “0.950% Notes due 2025” in the table of registered securities and expands the discussion of these notes in the financing and risk‑factor sections, but the classification and registration details remain unchanged from the 2022 filing.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several inaccuracies that significantly deviate from the ground truth. (1) Quantitatively, while the 0.950% interest rate and 2025 maturity are correctly stated, the claim that the notes were 'registered under the Securities Act' and had ticker 'IBM25B' as early as 2022 is incorrect. The ground truth states that in 2022, the notes were only disclosed as part of an Exhibit 4.1 in a May 22, 2017 Form 8-K filing—there was no indication of active listing or trading symbol at that time. The ticker 'IBM25B' and NYSE listing are only confirmed in 2024, representing an evolution the model fails to capture. (2) The answer incorrectly asserts that classification and registration details 'remain unchanged' from 2022 to 2024, which directly contradicts the ground truth that shows a clear evolution from mere disclosure to formal registration and listing. (3) Qualitatively, the multi-hop reasoning is flawed: the model fails to recognize the progression from passive disclosure (2022) to active listing (2024), which is the core of the question. Instead, it asserts consistency, missing the key shift entirely. (4) Contextually, the answer is relevant and addresses the right instrument and timeframe, and uses appropriate financial terminology, hence the moderate relevance score. However, the central claim about classification and registration being stable over time is factually wrong, leading to a low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 404,
        "total_tokens": 1643
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has GILD's strategic positioning of Biktarvy evolved from 2022 to 2024, particularly in terms of its financial risk exposure and competitive differentiation within the HIV treatment market?",
      "original_answer": "In 2022, Biktarvy was listed among GILD’s key marketed products, indicating its central role in the company's HIV portfolio and suggesting strong commercial positioning. By 2024, the company highlighted increasing financial risk tied to its reliance on nucleoside-based therapies like Biktarvy, particularly due to the potential shift in HIV treatment paradigms away from TAF-based regimens. This evolution reflects a growing concern over Biktarvy’s long-term competitive differentiation and its ability to sustain revenue, especially in the face of rising generic competition and changing therapeutic preferences.",
      "llm_answer": "\nFrom 2022 through 2024 Gilead has moved Biktarvy from a pure “cash‑cow” single‑tablet HIV regimen to a strategic differentiator that it leans on to preserve market share amid generic encroachment and tightening payer‑price controls; the company now markets it as the preferred, once‑daily, high‑barrier‑to‑resistance option with a renal‑friendly TAF backbone, while simultaneously exposing itself to greater financial risk from Medicare‑price‑negotiation and rebate pressures that could compress the pricing premium it has historically enjoyed.  Consequently, Biktarvy’s competitive edge rests on its superior efficacy and safety profile, but its revenue growth is increasingly vulnerable to the same reimbursement and generic‑competition forces that the 2022‑2024 filings flag as material risks.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of GILD's strategic positioning of Biktarvy from 2022 to 2024. It accurately captures the increasing financial risk exposure due to reliance on Biktarvy and highlights competitive differentiation through its safety and efficacy profile, particularly the TAF backbone and high barrier to resistance. The mention of generic competition, payer price controls, and reimbursement pressures reflects accurate synthesis of risk factors noted in the original answer. There are no numeric values in the question or answers, so quantitative accuracy is scored as 10 by default. The qualitative accuracy is slightly reduced because the LLM introduces concepts not explicitly present in the ground truth—such as 'Medicare-price-negotiation' and 'rebate pressures'—which, while plausible, are not mentioned in the original knowledge graph answer. Additionally, the original emphasizes a 'shift in treatment paradigms away from TAF-based regimens' as a core risk, which the LLM reframes more around pricing and access rather than clinical paradigm shifts. Despite this, the LLM correctly identifies the central tension: strong differentiation now versus growing financial and competitive risks. Contextual relevance is high, as all parts of the question—strategic positioning, financial risk, and competitive differentiation—are addressed with appropriate focus and logical flow.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 402,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Lockheed Martin's approach to defined contribution retirement savings plans evolve between 2022 and 2023, particularly in terms of pension obligation transfers and associated financial impacts?",
      "original_answer": "In 2022, Lockheed Martin transferred $4.3 billion of gross defined benefit pension obligations through group annuity contracts, recognizing a noncash pension settlement charge of $1.5 billion. In 2023, instead of another annuity purchase, the company made $414 million in settlement payments to approximately 6,500 former employees who had not yet started receiving benefits. This shift indicates a strategic evolution from transferring large blocks of pension obligations to insurers (as in 2022) to directly settling smaller portions of obligations with individual participants in 2023.",
      "llm_answer": "\nBetween 2022 and 2023 Lockheed Martin did not change the structure of its defined‑contribution (DC) savings plan – the DC plan remained frozen for new salaried hires and was still administered as the enhanced retirement vehicle for employees previously moved out of the qualified defined‑benefit (DB) pension. Instead, the company accelerated its “pension‑obligation‑transfer” strategy: in the second quarter of 2022 it bought group‑annuity contracts that transferred about $4.3 bn of DB liabilities, which required a non‑cash settlement charge of roughly $1.5 bn recorded in 2022, and in the fourth quarter of 2023 it offered a voluntary lump‑sum settlement that eliminated about $0.414 bn of obligations and reduced accumulated other‑comprehensive‑loss, but did not generate a new settlement charge. These transfers lowered the net DB liability and AOCL on the balance sheet while leaving the DC plan’s funding and benefits unchanged.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: $4.3 billion in pension obligations transferred in 2022 with a $1.5 billion noncash settlement charge, and $414 million (or $0.414 billion) in settlement payments in 2023. The years and amounts match exactly, with acceptable format variation (e.g., $0.414 bn = $414 million). (2) The answer correctly identifies the shift in strategy—from using group annuity contracts in 2022 to offering voluntary lump-sum settlements in 2023—though it refers to the 2023 action as a 'voluntary lump-sum settlement' rather than specifying payments to 'approximately 6,500 former employees who had not yet started receiving benefits,' which is a minor omission in detail but does not affect factual correctness. (3) The reasoning is sound: it correctly synthesizes that the defined contribution (DC) plan structure did not change, and the focus was on reducing defined benefit (DB) liabilities through different mechanisms across the two years. It accurately notes the financial impacts—lowering net DB liability and accumulated other comprehensive loss (AOCL) without a new settlement charge in 2023. (4) The only minor shortcoming is that the original answer emphasizes a strategic evolution from large-scale insurer transfers to direct individual settlements, which the LLM captures conceptually but could have articulated more explicitly. However, the core multi-hop synthesis—comparing two different years, two different methods of liability reduction, and their financial impacts—is correct and well-reasoned. Wording differences are acceptable under semantic equivalence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 457,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the composition of IBM's debt instruments maturing in 2025 evolved between 2022 and 2024, particularly regarding the 2.875% Notes due 2025?",
      "original_answer": "In 2022, IBM listed the 2.875% Notes due 2025 (IBM 25A) among other Notes due in 2025, including the 0.950% Notes due 2025 (IBM 25B) and the 0.875% Notes due 2025 (IBM 25C). By 2024, the 2.875% Notes due 2025 (IBM25A) remained, but the 0.875% Notes due 2025 (IBM 25C) were no longer listed, indicating a shift in the debt composition for that year. The 2.875% Notes due 2025 continued to be a key part of IBM's debt structure in 2024, suggesting a strategic decision to maintain this specific financial instrument while retiring or restructuring others.",
      "llm_answer": "\nBetween 2022 and 2024 the only 2025‑maturing debt that IBM continued to list was the **2.875 % Notes due 2025 (IBM 25A)**; it remained on the company’s balance sheet in both filings.  However, the overall 2025 cohort shifted – IBM added newer 2025 issues (e.g., the 0.950 % and 0.875 % Notes due 2025 and a 7 % Debenture due 2025) and retired or rolled‑over some earlier tranches, so the **relative weight of the 2.875 % Notes within the total 2025 maturity bucket declined slightly**, even though the absolute amount of that specific issue was unchanged.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) According to the ground truth, in 2022 IBM had three debt instruments due in 2025: the 2.875% Notes (IBM 25A), the 0.950% Notes (IBM 25B), and the 0.875% Notes (IBM 25C). The LLM incorrectly states that IBM 'added newer 2025 issues' like the 0.950% and 0.875% Notes between 2022 and 2024 — this is false; these were already present in 2022. Furthermore, the LLM claims a '7% Debenture due 2025' was added, which is not mentioned in the original answer and has no support in the ground truth. (2) The ground truth states that by 2024, the 0.875% Notes (IBM 25C) were no longer listed, while the 2.875% Notes (IBM 25A) and possibly the 0.950% Notes (IBM 25B) remained. The LLM incorrectly implies that the 2.875% Notes were the *only* 2025-maturing debt remaining, which contradicts the original answer that confirms the 0.950% Notes were still present. (3) The LLM introduces the concept of the 'relative weight' of the 2.875% Notes declining due to new issuances — a claim unsupported by the original data, which does not mention changes in principal amounts or relative weighting. There is no evidence provided that the absolute amount remained unchanged or that new debt was issued. (4) While the LLM correctly identifies that the 2.875% Notes due 2025 (IBM 25A) remained in both years, this one correct element is outweighed by the incorrect narrative about new issuances, retirements, and shifting composition. The reasoning is flawed because it inverts the actual evolution: the ground truth describes a *simplification* of the 2025 debt bucket (removal of IBM 25C), while the LLM describes an *expansion* with new issues. Thus, despite addressing the question's topic and showing awareness of multi-hop analysis, the answer is factually incorrect on key points, especially regarding which instruments existed when and how the composition changed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 522,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the strategic importance and risk profile of Biktarvy within Gilead's HIV portfolio evolved from 2022 to 2024, particularly in light of competitive pressures and changes in the treatment paradigm?",
      "original_answer": "In 2022, Biktarvy was positioned as a key growth driver for Gilead, with the company noting its 'continued growth in all geographies' and attributing part of the 11% revenue increase to its performance. By 2024, however, the strategic importance of Biktarvy appears more precarious. The 2024 10-K highlights increased risks around Gilead's HIV franchise, noting that 'many of our HIV products contain TAF' and that any shift away from nucleoside-based therapies could materially impact sales. This suggests that while Biktarvy was a growth asset in 2022, by 2024 it was increasingly seen as vulnerable to paradigm shifts in HIV treatment, representing a change in both strategic positioning and risk exposure.",
      "llm_answer": "\nFrom 2022 through 2024 Biktarvy moved from being the chief growth driver of Gilead’s HIV franchise—benefiting from the post‑exclusivity slump of Truvada/Atripla and delivering higher net prices—to a product whose strategic centrality is now being tested by new treatment paradigms (long‑acting injectables and capsid‑inhibitors) and by aggressive price‑containment measures such as the IRA’s Medicare price‑negotiation and rising generic competition. As a result, its risk profile has shifted from modest revenue‑growth risk to heightened exposure to pricing erosion, reimbursement pressure and the possibility of losing market share to newer HIV regimens.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of the evolution of Biktarvy's strategic importance and risk profile from 2022 to 2024, though it introduces some details not present in the original knowledge base. (1) Correctness: The core claim—that Biktarvy transitioned from a key growth driver in 2022 to a more vulnerable asset by 2024 due to shifts in treatment paradigms and increased risks—is fully supported by the original answer. The mention of long-acting injectables and capsid inhibitors aligns with the 'shift away from nucleoside-based therapies' noted in the 2024 10-K. (2) Quantitative Accuracy: There are no specific numbers (e.g., percentages, dollar amounts) in the LLM answer that contradict the original; the 11% revenue increase mentioned in the ground truth is not included in the LLM response, but no incorrect figures are introduced. Thus, quantitative accuracy is high. (3) Reasoning: The LLM correctly performs multi-hop reasoning by inferring increased risk due to new treatment modalities and pricing pressures. However, the reference to the Inflation Reduction Act (IRA) and Medicare price negotiation, while plausible, is not present in the original knowledge base, representing an addition beyond the provided evidence. Similarly, the mention of Truvada/Atripla's post-exclusivity slump adds context not in the source, which may be accurate but is not verifiable from the ground truth. (4) Contextual Relevance: The answer directly addresses the question about strategic importance and risk evolution, competitive pressures, and treatment paradigm changes. It synthesizes across time and risk dimensions effectively. Overall, the answer captures the essential meaning and evolution described in the original, with minor extrapolations, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 494,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did the balance of the U.S. litigation escrow account evolve between the end of fiscal year 2022 and the end of fiscal year 2023, and what were the specific deposit contributions during each period?",
      "original_answer": "The balance of the U.S. litigation escrow account increased significantly from $1,449 million at the end of fiscal year 2022 to $3,089 million at the end of fiscal year 2023. During this time, deposits into the account rose from $1,000 million in fiscal year 2022 to $1,500 million in fiscal year 2023.",
      "llm_answer": "\nThe U.S. litigation escrow account balance rose from **$1.449 billion at the end of fiscal 2022** to **$1.764 billion at the end of fiscal 2023**.  During fiscal 2022 the Company deposited **$850 million** into the escrow, and in fiscal 2023 it added **$1.0 billion** (the $1.0 billion deposit is shown in the “Deposits into the U.S. litigation escrow account” line of the table for the year ended September 30 2023).  These deposits, together with subsequent payments to opt‑out merchants, produced the $0.315 billion net increase in the escrow balance over the two years.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the U.S. litigation escrow account balance increased from $1,449 million ($1.449 billion) at the end of fiscal year 2022 to $3,089 million ($3.089 billion) at the end of fiscal year 2023. However, the LLM incorrectly reports the 2023 balance as $1.764 billion, which is far below the correct value. Additionally, the LLM states that deposits were $850 million in fiscal year 2022 and $1.0 billion in fiscal year 2023, whereas the ground truth specifies $1,000 million ($1 billion) in 2022 and $1,500 million ($1.5 billion) in 2023. These deposit figures are therefore both incorrect. (2) The quantitative inaccuracies are severe: the ending balance is off by over $1.3 billion, and deposit amounts are understated by $150 million and $500 million respectively. The LLM also introduces a 'net increase of $0.315 billion' that does not align with either its own numbers or the ground truth (actual increase is $3,089M - $1,449M = $1,640M). (3) The reasoning is flawed: the model fails to correctly synthesize the multi-hop information across fiscal years and misrepresents the flow of funds. It references a table for September 30, 2023, but draws incorrect conclusions from it. The mention of 'payments to opt-out merchants' is not part of the original question or ground truth and appears to be speculative or misattributed context. (4) Despite addressing the right entities (U.S. litigation escrow account, fiscal years 2022 and 2023), the severe numerical errors and incorrect synthesis drastically reduce correctness. The answer is contextually relevant in structure and intent but fails on core factual accuracy, warranting a low score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 474,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has the role of fountain syrups in Coca-Cola's North America operating segment evolved between 2022 and 2023, particularly regarding the company's manufacturing and distribution responsibilities?",
      "original_answer": "In 2022, Coca-Cola explicitly stated that it manufactured fountain syrups in the United States and sold them directly to fountain retailers or to authorized fountain wholesalers or bottling partners for further distribution. By 2023, the company's description shifted: while it still referenced selling fountain syrups in the North America segment, it also indicated that outside the U.S., bottling partners were authorized to manufacture fountain syrups using company concentrates. This suggests a nuanced evolution where Coca-Cola may be emphasizing a more decentralized, authorization-based model, particularly outside the U.S., while maintaining direct control within the U.S. There is no explicit mention of a change in manufacturing responsibilities within North America itself, indicating operational continuity there.",
      "llm_answer": "\nBetween 2022 and 2023 Coca‑Cola’s handling of fountain syrups in North America did not shift dramatically, but the company’s language clarified the scope of its responsibilities. In both years the company continues to **manufacture fountain syrups in the United States and sell them to fountain retailers (or to authorized fountain wholesalers/bottling partners)**, with those partners then distributing the syrups to the retail outlets that use them. The 2023 disclosures simply reiterated that these syrup sales are reported within the **North America operating segment**, emphasizing that the company’s manufacturing role remains unchanged while the downstream distribution continues to be performed by its bottling partners and wholesalers.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of key facts: Coca-Cola continued to manufacture fountain syrups in the U.S. and sell them directly to retailers or through authorized wholesalers and bottling partners in both 2022 and 2023. It correctly notes that there was no operational change in manufacturing responsibilities within North America, and that distribution remains with partners. The answer accurately reflects that syrup sales are reported in the North America operating segment. However, it omits a key nuance highlighted in the original answer: the 2023 disclosure explicitly expanded the model to note that *outside the U.S.*, bottling partners are authorized to manufacture fountain syrups using company concentrates. This indicates a more decentralized, authorization-based evolution in the company’s global model, even if North America itself was unchanged. The LLM answer does not mention this shift in language or the implication of a broader strategic clarification beyond U.S. borders, which represents a partial gap in completeness and qualitative synthesis. There are no numerical inaccuracies (quantitative accuracy is perfect), and the response is fully contextually relevant. The reasoning is sound but slightly less comprehensive in capturing the full scope of the evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 379,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has the composition of IBM's debt instruments maturing in 2025 evolved between 2022 and 2024, particularly regarding the 0.950% Notes due 2025?",
      "original_answer": "In 2022, IBM had three sets of notes maturing in 2025: the 2.875% Notes due 2025 (IBM 25A), the 0.950% Notes due 2025 (IBM 25B), and the 0.875% Notes due 2025 (IBM 25C). By 2024, the 0.875% Notes due 2025 were no longer listed, leaving only the 2.875% Notes due 2025 (IBM 25A) and the 0.950% Notes due 2025 (IBM 25B). This indicates a reduction in the diversity of interest rate profiles for debt maturing in 2025, with the removal of the 0.875% instrument.",
      "llm_answer": "\nBetween 2022 and 2024 the only debt series that mature in 2025 shown in IBM’s SEC filings are the **2.875 % Notes due 2025 (IBM 25A)** and the **0.950 % Notes due 2025 (IBM 25B)**. The 2024 filing reproduces exactly the same two 2025‑maturing series, indicating that the 0.950 % Notes remained outstanding and unchanged in identity; no new 2025‑maturing issuances were added, so the composition of IBM’s 2025 debt stayed the same, with the 0.950 % tranche coexisting alongside the larger‑coupon 2.875 % tranche.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct in identifying the 2.875% Notes due 2025 (IBM 25A) and the 0.950% Notes due 2025 (IBM 25B) as present in both 2022 and 2024. However, it incorrectly states that these were the only debt instruments maturing in 2025 in 2022. According to the ground truth, in 2022 there were three notes: IBM 25A, IBM 25B, and the 0.875% Notes due 2025 (IBM 25C). The LLM omits IBM 25C entirely, which is a critical factual error. (2) Quantitatively, the percentages (2.875%, 0.950%) and years (2025) are accurate, and no calculations are performed, so there are no numerical errors—just omissions. The claim that the composition 'stayed the same' is factually wrong because the removal of the 0.875% Notes indicates a change. (3) The multi-hop reasoning fails: the question asks how the composition evolved between 2022 and 2024, requiring comparison across years. The LLM incorrectly assumes consistency without acknowledging the disappearance of the 0.875% tranche, thus failing to recognize the evolution in debt structure. (4) While the answer is relevant and uses correct terminology, the core conclusion—that the composition remained unchanged—is incorrect due to missing data. Hence, correctness is significantly penalized despite accurate formatting and partial entity identification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1242,
        "completion_tokens": 370,
        "total_tokens": 1612
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has Disney's strategic approach to cruise ships evolved between 2022 and 2024 based on disclosures in their 10-K filings?",
      "original_answer": "In 2022, Disney mentioned cruise ships as part of its broader travel and resort experiences, indicating that their success depended on consumer demand for out-of-home entertainment and travel. By 2024, Disney had elevated its approach, explicitly stating plans to 'expand investment in our Experiences segment' and 'additional expansion of our fleet of cruise ships.' This evolution reflects a shift from general dependence on consumer demand to an active investment and growth strategy in cruise ship operations. The 2024 filing also notes that new offerings, such as additional cruise ships, come with increased costs and uncertain returns, signaling a more capital-intensive and strategic focus compared to the more passive mention in 2022.",
      "llm_answer": "\nBetween 2022 and 2024 Disney shifted from a single‑destination focus—announcing the 2024 opening of a private Disney Cruise Line port at Lighthouse Point on Eleuthera—to a broader fleet‑expansion strategy.  In its 2024 filing the company disclosed plans to “expand the fleet of cruise ships” and to treat cruise operations as part of its growing Experiences segment, tying the initiative to overall cost‑realignment, DTC‑related investments and a push for higher‑margin, out‑of‑home entertainment experiences.  Thus, the cruise‑ship strategy evolved from a one‑off destination project to an integrated, growth‑oriented expansion of the cruise fleet and related guest‑experience offerings.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains some correct elements but introduces a fact not present in the ground truth — the 2024 opening of a private port at Lighthouse Point. While Disney did develop Lighthouse Point, the original answer does not mention this detail, and the 10-K filings evaluated in the knowledge graph do not highlight it as a strategic shift in cruise ship strategy between 2022 and 2024. The core evolution described in the ground truth is from passive dependence on consumer demand to active fleet expansion and investment, which the LLM partially captures by noting 'expand the fleet of cruise ships' and integration into the Experiences segment. However, it mischaracterizes the 2022 strategy as a 'single-destination focus' when the original answer describes it more broadly as part of travel and resort experiences dependent on consumer demand. (2) Quantitatively, there are no explicit numbers (e.g., dollar amounts, ship counts, dates) in either answer that conflict — the mention of '2024 opening' is plausible but not confirmed in the ground truth, so this is a minor issue. The LLM correctly identifies 2024 as the year of strategic shift, aligning with the original. (3) The multi-hop reasoning is partially sound: the model connects cruise ships to the Experiences segment and notes increased strategic emphasis. However, it fails to accurately contrast the 2022 and 2024 approaches — the original emphasizes a shift from passive reliance on demand to active investment and risk acknowledgment (costs and uncertain returns), which the LLM omits. Instead, it invents a 'one-off destination project' narrative not supported in the ground truth. (4) The contextual relevance is high because the answer addresses Disney’s evolving cruise strategy and ties it to broader business segments and investments. However, due to factual overreach and misrepresentation of the 2022 strategy, the correctness and qualitative accuracy scores are reduced. The answer is plausible-sounding but not fully aligned with the disclosed evolution in the 10-Ks as captured in the knowledge graph.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 564,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How did Lockheed Martin's approach to pension risk transfer transactions evolve from 2022 to 2023, particularly in terms of financial impact and strategic intent?",
      "original_answer": "In 2022, Lockheed Martin detailed a specific pension risk transfer transaction from August 3, 2021, where $4.9 billion of gross defined benefit pension obligations were transferred via group annuity contracts (GACs), resulting in a noncash pension settlement charge of $1.7 billion. The company also noted that since December 2018, it had transferred approximately $11.6 billion in pension obligations, eliminating volatility for around 95,000 retirees. By 2023, the company reiterated its strategic intent to continue evaluating such transactions but shifted focus toward the broader financial and risk implications, including potential future contributions to the pension trust and the possibility of additional noncash settlement charges. The 2023 filing also introduced a nuanced risk: while most GACs relieve Lockheed of pension obligations, some could leave the company liable if the insurer defaults. This reflects a more cautious framing of pension risk transfer, acknowledging residual liability exposure not emphasized in 2022.",
      "llm_answer": "\nBetween 2022 and 2023 Lockheed Martin kept the same core tactic—periodically moving defined‑benefit obligations into group‑annuity contracts—but it shifted from the one‑off $4.9 bn GAC purchase that generated a $1.7 bn non‑cash settlement charge in 2021 to a more cautious stance that emphasizes future risk‑transfer transactions could again produce material non‑cash charges and that the company will make no additional cash contributions to its pension plans, relying instead on CAS pension‑cost recoveries to offset expense.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in Lockheed Martin's pension risk transfer strategy from 2022 to 2023. (1) Quantitatively, it correctly identifies the $4.9 billion pension obligation transfer and the $1.7 billion noncash settlement charge from the August 3, 2021 transaction (disclosed in the 2022 filing), which is accurately attributed as a prior-year event. The dollar amounts and financial impacts are correctly stated, satisfying quantitative accuracy. (2) The answer correctly notes the strategic continuity in using group annuity contracts (GACs) and the shift toward a more cautious outlook in 2023, including the expectation of potential future noncash charges and the decision to make no additional cash contributions, relying instead on CAS cost recoveries. This aligns with the 2023 filing’s emphasis on financial implications and risk management. (3) However, the LLM omits a key qualitative nuance present in the original answer: the 2023 filing introduced the risk of residual liability if insurers default on GACs, which represents a significant shift in risk framing not emphasized in 2022. This omission slightly weakens the completeness of the multi-hop synthesis. (4) Despite this, the answer maintains strong contextual relevance and semantic equivalence on the main points—financial impact, strategic continuity, and increased caution. The reasoning is sound, though not fully comprehensive. Minor deduction from correctness due to missing residual liability risk; otherwise, numbers and logic are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 427,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has Tesla's relationship with its financing partners evolved between 2022 and 2023, particularly in terms of accounts receivable management and leasing program risks?",
      "original_answer": "In 2022, Tesla disclosed that accounts receivable from financing partners could take up to approximately two weeks to settle based on contractual payment terms, directly impacting the company's short-term liquidity and balance sheet fluctuations. By 2023, Tesla highlighted increased complexity and risk in managing its financing programs, noting that its leasing business depends on securing adequate financing or partners, and that residual value risks from leased vehicles could negatively affect profitability. This indicates a shift from a focus on operational cash flow timing in 2022 to a broader concern over credit, compliance, and residual value risks in 2023 as the leasing program scaled.",
      "llm_answer": "\nTesla’s 2022 filing quantified the size of its receivables from financing partners and disclosed allowances for doubtful accounts (e.g., $627 million of long‑term rebates and a $41 million reserve on MyPower notes), whereas the 2023 filing shifts the focus to the risks embedded in those relationships—explicitly warning that partner funding shortfalls or a rise in customer defaults could produce material credit losses and erode the profitability of its direct leasing program. This reflects a move from simply reporting balances to a more proactive, risk‑focused approach to accounts‑receivable management and leasing‑program oversight.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific dollar amounts—$627 million in long-term rebates and a $41 million reserve on MyPower notes—that are not present in the original ground truth answer. These figures are unverified and appear to be fabricated or misattributed, as the ground truth does not mention any specific numerical values related to allowances or receivables. This severely undermines quantitative accuracy. (2) While the original answer notes that receivables took up to two weeks to settle in 2022, the LLM does not mention this timing aspect and instead invents detailed financial disclosures about reserves and allowances that are absent from the source. There is no verification that these numbers appear in Tesla’s 2022 or 2023 filings as described. (3) Qualitatively, the LLM captures a valid shift in tone and focus—from reporting balances in 2022 to emphasizing risk in 2023—which aligns with the ground truth’s description of a transition from liquidity timing concerns to broader credit, compliance, and residual value risks. The reasoning about increased risk focus in leasing and partner dependencies is semantically consistent with the original. (4) Contextually, the response is highly relevant, addressing both accounts receivable management and leasing program risks across 2022 and 2023. However, the inclusion of unsupported quantitative details reduces factual correctness significantly. The core conceptual evolution is correctly interpreted, but the addition of unverified numbers leads to a partial correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 428,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "What changes occurred in Coca-Cola's fountain syrup distribution strategy between 2022 and 2023, and how did the roles of bottlers and fountain wholesalers evolve during this period?",
      "original_answer": "In 2022, Coca-Cola manufactured and sold fountain syrups directly to authorized fountain wholesalers (including certain authorized bottlers), who then sold or delivered the syrups to retailers. Bottlers in the U.S. were generally not authorized to manufacture fountain syrups. By 2023, the strategy evolved such that outside the United States, bottlers were typically authorized to manufacture fountain syrups using Coca-Cola concentrates, which they could sell to fountain retailers or authorized fountain wholesalers. This represents a shift from a more centralized syrup distribution model to a more integrated one, where bottlers play a more active role in the fountain syrup supply chain, particularly in international markets.",
      "llm_answer": "\nBetween 2022 and 2023 Coca‑Cola refined its U.S. fountain‑syrup channel: in 2022 the Company sold syrup to authorized fountain wholesalers (and, where allowed, to bottling partners who then resold to retailers), while bottlers were generally barred from manufacturing the syrup; by 2023 the Company continued to sell directly to those same wholesalers and, where permitted, to fountain retailers, and it further limited bottlers’ involvement to concentrate supply only. Consequently, bottlers’ role in fountain‑syrup distribution receded, and fountain wholesalers assumed the primary responsibility for delivering syrup to restaurants and other end‑users. (See KO_10K‑2022 pp. 6‑7 and KO_10K‑2023 pp. 37‑38.)",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in its core claim about the evolution of Coca-Cola's fountain syrup distribution strategy, directly contradicting the ground truth. (1) What was correct: The answer correctly identifies that in 2022, Coca-Cola sold fountain syrups to authorized fountain wholesalers and that bottlers were generally not authorized to manufacture syrups. It also correctly references the appropriate documents (KO_10K-2022 and KO_10K-2023), and there are no numeric inaccuracies per se, as no specific financial figures are involved—hence a quantitative accuracy score of 8. (2) However, the key error lies in the description of the 2023 strategy: the LLM claims bottlers’ roles were further limited and that their involvement was reduced to concentrate supply only. This is the opposite of the truth. According to the ground truth, by 2023, outside the U.S., bottlers were typically authorized to *manufacture* fountain syrups from Coca-Cola concentrates, indicating an *expansion* of their role internationally, not a reduction. The LLM incorrectly frames the evolution as a contraction of bottler involvement, especially in the U.S., while the actual shift was toward greater integration of bottlers in *international* markets. (3) The multi-hop reasoning is flawed: the model fails to synthesize the geographic distinction (U.S. vs. outside U.S.) and misinterprets the direction of change. Instead of identifying a shift toward a more integrated, bottler-involved model internationally, it asserts a continued centralization with reduced bottler roles. This represents a fundamental misunderstanding of the strategic evolution. (4) Contextual relevance is moderate because the answer discusses the right topic (fountain syrup distribution, bottlers, wholesalers) and cites correct document sources, but the conclusion is factually inverted. Due to the severity of the factual error in the main claim, the correctness score is low at 2, and qualitative accuracy is 2 due to incorrect reasoning and entity-role misattribution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 547,
        "total_tokens": 1916
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2023 and 2024, particularly in terms of receivables and new investment activities?",
      "original_answer": "In 2023, AMD had receivables from the ATMP JV of $9 million, and there was no mention of any direct investment or loan made by AMD to the JV. By 2024, AMD's receivables from the ATMP JV increased to $12 million, and the company entered into a new $100 million one-year term loan agreement with one of the ATMP JVs to support its general corporate purposes. This marks a significant shift from a purely transactional relationship in 2023 to a more financially integrated one in 2024, where AMD is not only a customer but also a creditor and strategic supporter of the JV.",
      "llm_answer": "\nBetween 2023 and 2024 AMD deepened its financial ties with the ATMP joint venture.  It added $17 million of equity capital, pushing the investment’s carrying value up from roughly $99 million (end‑2023) to about $149 million (end‑2024), and it entered a one‑year, $100 million term loan to the JV—recorded as a receivable—while payables to the JV rose to $476 million and receivables increased to $12 million.  These moves reflect a substantially larger equity stake, higher transaction volumes and new lending activity compared with the 2023 relationship.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2023, AMD had $9 million in receivables from the ATMP JV and no direct investment or loan. The LLM incorrectly claims AMD added $17 million of equity capital and increased its carrying value from $99 million to $149 million—this information is entirely absent from the ground truth and contradicts it. Additionally, the LLM mentions payables rising to $476 million, which is not mentioned in the original answer and cannot be verified. While the $100 million one-year term loan and the increase in receivables to $12 million in 2024 are correctly stated, the receivables in 2023 are misrepresented as part of a larger narrative involving equity investment. (2) Quantitative accuracy is low: the $17M equity addition, $99M to $149M carrying value change, and $476M payables are all fabricated or incorrect. Only the $100M loan and $12M receivables in 2024 align with the truth. (3) The multi-hop reasoning is flawed—the model incorrectly infers an equity investment and carrying value change, suggesting a deeper financial integration than supported by the data. It conflates receivables with equity stakes and introduces unrelated payables. (4) Contextual relevance is moderate because the answer addresses the evolution of the financial relationship and mentions the correct JV and time frame, but the core facts are distorted, leading to a misleading conclusion about AMD’s role as an equity investor and strategic stakeholder beyond creditor.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 426,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Lockheed Martin's approach to managing its nonqualified defined benefit pension plans evolve between 2022 and 2023, particularly in terms of pension obligation settlements and associated financial impacts?",
      "original_answer": "In 2022, Lockheed Martin purchased group annuity contracts to transfer $4.3 billion of gross defined benefit pension obligations and recognized a noncash pension settlement charge of $1.5 billion. In 2023, the company continued its strategy of reducing pension liabilities by making voluntary settlement payments of $414 million to approximately 6,500 former employees, significantly smaller in scale compared to the 2022 transaction. This indicates a shift from large-scale pension obligation transfers to a more targeted approach involving smaller settlements with former employees who had not yet started receiving benefits.",
      "llm_answer": "\nBetween 2022 and 2023 Lockheed Martin moved from a single, large‑scale bulk‑transfer of qualified pension liabilities—​the second‑quarter‑2022 purchase of group‑annuity contracts that shifted about $4.3 billion of gross defined‑benefit obligations and generated a one‑time, non‑cash settlement charge of roughly $1.5 billion in 2022​—to a much smaller, targeted voluntary lump‑sum settlement in 2023.  In the fourth quarter of 2023 the company offered a voluntary exit to former employees who had not yet begun receiving benefits, resulting in $414 million of settlement payments that reduced the plan’s benefit obligation and the accumulated‑other‑comprehensive‑loss balance, but because the payment was accounted for as a simple reduction of the liability it did **not** trigger a new settlement charge or earnings impact.  Thus, the evolution reflects a shift from outsourcing a broad swath of qualified pension obligations in 2022 to a more incremental, cash‑based settlement approach in 2023, with the financial effect being a modest reduction in the unfunded status and AOCL rather than a fresh non‑cash expense.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2022, Lockheed Martin purchased group annuity contracts to transfer $4.3 billion of pension obligations and recognized a $1.5 billion noncash settlement charge. In 2023, the company made $414 million in voluntary settlement payments to about 6,500 former employees. These numbers match the original answer exactly, and the shift from large-scale transfer to targeted settlements is correctly characterized. (2) Quantitative accuracy is perfect: all dollar amounts ($4.3 billion, $1.5 billion, $414 million), years (2022, 2023), and timeframes (Q2 2022, Q4 2023) are correct. The answer even adds contextual precision (e.g., 'fourth quarter of 2023') not in the original but consistent with it. (3) The reasoning is sound and reflects multi-hop synthesis: the model correctly infers that the 2023 payments did not trigger a settlement charge because they were accounted for as liability reductions, which is a nuanced but accurate interpretation of pension accounting rules. This insight goes beyond the original answer but is factually correct. (4) The only minor shortcoming is that the original answer explicitly mentions the scale difference and the targeting of former employees not yet receiving benefits, which the LLM covers but slightly overemphasizes the 'qualified' nature of the plans—while the original refers to 'nonqualified defined benefit pension plans' in the question, the LLM refers to 'qualified pension liabilities' in 2022, which may be a mischaracterization. However, the core financial facts and strategic evolution are correctly conveyed. Thus, the answer is semantically equivalent with excellent reasoning and contextual relevance, meriting a 9/10 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1453,
        "completion_tokens": 486,
        "total_tokens": 1940
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did AMD's financial relationship with the ATMP JV evolve between 2023 and 2024, particularly in terms of its investment and equity income?",
      "original_answer": "In 2023, AMD recorded $16 million in equity income from the ATMP JV and had a carrying value of $99 million as of the end of the year. In 2024, AMD contributed an additional $17 million to the JV, increasing its investment's carrying value to $149 million by the end of the year. Equity income also rose to $33 million. This indicates a significant increase in both AMD's investment stake and the returns it received from the ATMP JV.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 AMD’s stake in the ATMP joint venture grew markedly—its equity‑method investment rose from roughly **$99 million (as of Dec 30 2023)** to **about $149 million (as of Dec 28 2024)**, and the related equity‑income recognized on the consolidated statement of operations jumped from **$16 million in 2023 to $33 million in 2024**.  This increase reflects both the higher carrying value of the 15 % interest and the additional earnings generated by the JV (including the $100 million term‑loan AMD extended to the JV in October 2024), underscoring a deepening financial relationship with the ATMP JV over the two years.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures from the ground truth: AMD's 2023 equity income ($16M), 2024 equity income ($33M), 2023 carrying value ($99M), and 2024 carrying value ($149M). The increase in investment from $99M to $149M implies a $50M net increase, which aligns with the $17M additional contribution noted in the original answer when accounting for the $33M equity income earned (which increases carrying value) versus $16M in the prior year. While the LLM does not explicitly state the $17M contribution, it correctly infers the net change in carrying value and attributes it to increased investment and JV earnings. (2) All numbers are quantitatively accurate, with correct dollar amounts and fiscal year-end dates (Dec 30, 2023, and Dec 28, 2024) matching typical AMD fiscal calendar reporting. The mention of a $100M term loan in October 2024 is an additional detail not present in the ground truth; however, it does not contradict it and may reflect supplementary information from the filing. Since the ground truth does not confirm or deny this loan, it is not marked as an error but introduces unverified detail. (3) The multi-hop reasoning is sound: the LLM synthesizes changes in both carrying value and equity income across two years, correctly interpreting the deepening financial relationship. The reference to a 15% interest is not in the ground truth and cannot be verified, so it slightly weakens qualitative accuracy. (4) The answer is contextually relevant, fully addressing the evolution of AMD's financial relationship with ATMP JV in terms of investment and equity income. The minor deduction in qualitative accuracy is due to the unconfirmed percentage interest and the unmentioned explicit $17M contribution, though the net effect is accurately portrayed. Overall, the answer is factually correct, comprehensive, and semantically equivalent to the ground truth with only minor extraneous details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 529,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Johnson & Johnson's financial stake and ownership relationship with Kenvue evolve between 2023 and 2024, particularly in terms of retained equity and associated gains or losses?",
      "original_answer": "In 2023, Johnson & Johnson retained a 9.5% ownership stake in Kenvue valued at $4.3 billion following the exchange offer, which resulted in a non-cash gain of $21.0 billion, including a $2.8 billion gain on the retained shares. By the end of 2024, the company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock, thereby eliminating its ownership stake and incurring a loss of approximately $0.4 billion in the process. This marks a full exit from Kenvue after initially reducing its stake significantly in 2023.",
      "llm_answer": "\nBetween 2023 and 2024 Johnson & Johnson’s ownership in Kenvue fell dramatically: after the May 2023 IPO it held about 89.6 % of Kenvue’s common stock, and after the August 23 2023 exchange it retained roughly 9.5 % (valued at $4.3 bn, later $3.9 bn). By May 17 2024 the company completed a debt‑for‑equity swap that cancelled the remaining 182 million shares, leaving J&J with **no equity stake** in Kenvue. The 2023 transaction generated a **$2.8 bn gain** on the equity it kept (part of a $21 bn total gain), while the 2024 swap produced an **≈ $0.4 bn loss** recorded in other income/expense.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth with only minor discrepancies. (1) Quantitatively: The key numbers are correct — the 9.5% retained stake in 2023 valued at $4.3 billion, the $2.8 billion gain on retained shares (part of a $21 billion total gain), the disposal of 182,329,550 shares (rounded to 182 million, acceptable), and the ~$0.4 billion loss in 2024. The mention of a later revaluation to $3.9 billion is additional context not in the original answer but does not contradict it. (2) The dates are mostly accurate: the August 23, 2023 exchange is correctly cited; the May 17, 2024 completion date for the debt-for-equity swap aligns with known events. (3) Entity and relationship accuracy is strong: Johnson & Johnson, Kenvue, retained equity, gains/losses, and the nature of the transactions (exchange offer, debt-for-equity swap) are correctly identified. (4) Multi-hop reasoning is sound — the answer synthesizes the evolution from partial exit in 2023 to full exit in 2024, including financial impacts. The only minor shortcoming is the lack of explicit mention that the 9.5% stake was post-exchange in 2023 (implied but not clearly framed as a reduction from ~89.6%), and the initial ownership percentage (89.6%) is an addition not in the original, though plausible. Overall, the answer is factually correct, complete, and semantically equivalent to the ground truth with high precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 400,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How did AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. evolve between 2022 and 2023, particularly in terms of its inclusion in guarantee agreements?",
      "original_answer": "AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. remained consistent between 2022 and 2023, with the company continuing to guarantee certain obligations of Southwestern Bell Telephone Co. in both years. In 2022, the guarantee was listed in Exhibit 4-c, which included multiple entities such as Southwestern Bell Telephone Company. In 2023, the guarantee was again referenced in Exhibit 4-c, maintaining the same inclusion of Southwestern Bell Telephone Co. within the list of guaranteed entities. This indicates no change in the nature or scope of the guarantee.",
      "llm_answer": "\nAT&T’s guarantee of Southwestern Bell Telephone Co.’s obligations—first filed as Exhibit 4‑c in the 2011 Form 10‑K—was still being referenced in the company’s 2022 (page 103) and 2023 (exhibit list on page 103) SEC filings. No new or amended guarantee agreement involving Southwestern Bell was disclosed for either year, so the relationship remained unchanged between 2022 and 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct and conveys the same core information as the ground truth: AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. remained unchanged between 2022 and 2023, with the guarantee continuing to be referenced in Exhibit 4-c in both years. The LLM correctly identifies that no new or amended agreement was disclosed, supporting the conclusion of consistency. It adds contextual detail (first filed in 2011, specific page numbers 103 in both years) not in the original answer but consistent with likely filing structures, which does not detract from accuracy. Quantitatively, there are no numerical claims requiring verification, and the dates (2022, 2023) are correct. Entity accuracy is strong: AT&T, Southwestern Bell Telephone Co., and Exhibit 4-c are correctly identified. The reasoning is sound—by noting the absence of amendments and continued reference, the model correctly infers no change. The only minor gap is that the original answer explicitly states Southwestern Bell remained in the list of guaranteed entities in both years, while the LLM implies this through continued reference to the same exhibit. This is a slight omission but does not undermine correctness. Overall, the answer is semantically equivalent and well-supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 360,
        "total_tokens": 1611
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has Lockheed Martin's involvement in hypersonics programs evolved from 2022 to 2023, particularly in terms of strategic positioning and program development responsibilities?",
      "original_answer": "In 2022, Lockheed Martin's involvement in hypersonics programs was described as a growth area that was dependent on U.S. Government authorization and funding, and was listed among other key development areas like classified programs and next-generation franchise programs. By 2023, the company's role had evolved significantly, with hypersonics programs now explicitly listed among major programs under the Space segment, indicating a more concrete and active role in designing, developing, and building hypersonic strike weapons for the U.S. Army and Navy. This reflects a shift from a potential growth area to a clearly defined and active program portfolio.",
      "llm_answer": "\nFrom 2022 to 2023 Lockheed Martin moved hypersonics from a nascent development effort to a strategically prioritized growth pillar.  In 2022 the company was primarily designing and testing several hypersonic strike weapons for the U.S. Army and Navy, but by 2023 it was explicitly highlighting hypersonics among its four near‑term growth areas and noting that multiple programs had completed testing and were entering early‑production phases through 2026—underscoring a deeper, more central role in program development and a broader strategic positioning for the business.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the evolution of Lockheed Martin's involvement in hypersonics from 2022 to 2023, noting a shift toward greater strategic emphasis and program maturation. It accurately reflects increased strategic positioning by stating hypersonics became one of four near-term growth areas in 2023, aligning with the ground truth's indication of a more concrete and active role. The mention of designing and testing weapons for the U.S. Army and Navy in 2022 is consistent with the original answer. However, the LLM introduces specific forward-looking details not present in the ground truth: namely, that multiple programs had completed testing and were entering early-production phases through 2026. This timeline and production status are not supported in the original answer, which does not mention testing completion or production timelines. While the general direction of evolution (from potential growth area to active development) is correctly captured, this addition of unverified specifics constitutes a moderate factual overreach, reducing qualitative accuracy. There are no numerical figures in the question or answers, so quantitative accuracy is scored as 10 by default. Contextual relevance is high, as the response directly addresses strategic positioning and program development responsibilities across both years. The reasoning is mostly sound but includes an unsupported inference about production phases, weakening the multi-hop synthesis accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 408,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How did the balance of the U.S. litigation escrow account evolve from fiscal year 2022 to fiscal year 2023, and what were the respective amounts deposited into the account during those years?",
      "original_answer": "The balance of the U.S. litigation escrow account increased significantly from $1.4 billion as of September 30, 2022, to $3.089 billion as of September 30, 2023. During fiscal year 2022, $850 million was deposited into the account, while in fiscal year 2023, $1.0 billion was deposited.",
      "llm_answer": "\nThe U.S. litigation escrow account balance rose from **$1.4 billion at September 30 2022** to **$1.764 billion at September 30 2023**.  During fiscal 2022 the company deposited **$850 million** into the escrow, and in fiscal 2023 it added **$1.0 billion** (net of payments of $685 million), producing the higher year‑end balance.  (Page 46 of the 2022 filing and the table on page 73 of the 2023 filing.)",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the initial balance of $1.4 billion as of September 30, 2022, and the deposits of $850 million in fiscal 2022 and $1.0 billion in fiscal 2023, which matches the ground truth. However, it incorrectly reports the ending balance for fiscal year 2023 as $1.764 billion instead of the correct $3.089 billion. This is a major quantitative error. (2) The calculation implied by the LLM—adding $1.0 billion deposit and subtracting $685 million in payments from the prior year-end balance—does not align with the ground truth. Starting from $1.4 billion and adding $1.0 billion would yield $2.4 billion before any payments; subtracting $685 million would result in $1.715 billion, close to the $1.764 billion cited, but this contradicts the actual reported balance of $3.089 billion. The ground truth shows a much larger increase, indicating either incorrect source data or flawed reasoning. (3) The multi-hop reasoning is partially sound—linking deposits and balances across two fiscal years—but fails in synthesis because the final balance does not match the documented evolution. The model introduces 'net of payments of $685 million' not mentioned in the original answer, suggesting unsupported inference. (4) Scores reflect that core input figures (deposits) are correct, but the key output (ending balance) is wrong, undermining overall correctness. Contextual relevance is high because the structure and intent align well with the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1184,
        "completion_tokens": 411,
        "total_tokens": 1595
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has the role and positioning of Outdoor Garden within HD's product strategy evolved from 2022 to 2024, based on its classification and performance metrics?",
      "original_answer": "In 2022, Outdoor Garden was disclosed as a distinct product line with $10,317 million in net sales, accounting for 6.8% of total net sales, indicating its importance as a standalone category. By 2024, Outdoor Garden was grouped under the broader 'Hardlines' merchandising department, suggesting a strategic integration into a larger product segment. This shift reflects a change in how HD positions Outdoor Garden within its overall product portfolio, moving from a separate focus area to a component of a consolidated category.",
      "llm_answer": "\nFrom fiscal 2022 through fiscal 2024 Outdoor Garden has stayed within the **Hardlines** product line and has been treated as a core growth category in HD’s merchandising strategy.  Its net sales rose modestly—from **$10.04 B (6.4 % of total sales) in 2022 to $10.28 B (6.7 % in 2023) and $10.31 B (6.5 % in 2024)**—showing a stable contribution to overall revenue despite the 2024 re‑classification of merchandising departments.  Consequently, HD’s positioning of Outdoor Garden has not shifted dramatically; it remains a key, strategically‑prioritized offering within Hardlines, with only incremental growth and a consistently similar share of net sales over the three years.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that in 2022, Outdoor Garden was a distinct product line with $10,317 million ($10.317B) in net sales, accounting for 6.8% of total sales. However, the LLM claims sales were $10.04B (6.4%) in 2022, $10.28B (6.7%) in 2023, and $10.31B (6.5%) in 2024 — none of which match the ground truth for 2022 and introduce fabricated data for 2023 and 2024, which are not present in the original answer. There is no mention of 2023 or 2024 sales figures in the ground truth, so these numbers are hallucinated. (2) The quantitative inaccuracies are severe: the LLM underreports 2022 sales by $277 million and misrepresents the percentage of total sales. It also introduces unsupported year-over-year trends and growth metrics. (3) The qualitative reasoning is flawed: the original answer emphasizes a strategic shift — Outdoor Garden moved from being a standalone category in 2022 to being grouped under 'Hardlines' in 2024, indicating a change in strategic positioning. In contrast, the LLM incorrectly asserts that Outdoor Garden 'has stayed within the Hardlines product line' throughout 2022–2024, directly contradicting the ground truth that it was a distinct line in 2022. This misrepresents the core evolution the question asks about. The LLM concludes there was 'no dramatic shift', which is the opposite of the ground truth. (4) Despite the incorrect facts and reasoning, the answer is contextually relevant — it addresses the right company (HD), product line (Outdoor Garden), and time frame (2022–2024), and attempts to discuss strategic positioning and performance metrics. However, due to major factual and logical errors, especially the denial of a reclassification that actually occurred, the correctness score is low. The answer fails on both quantitative precision and multi-hop synthesis of strategic change over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 519,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has AMD maintained its emphasis on an engaging and open environment as its global workforce expanded from 2023 to 2024, and what does this suggest about its talent retention strategy in a competitive semiconductor industry landscape?",
      "original_answer": "In 2023, AMD reported having approximately 26,000 employees and emphasized being at its best when 'our culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment.' By 2024, AMD’s global workforce grew to approximately 28,000 employees, and the company reiterated the same language, stating it is 'at our best when our culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment.' Despite a 7.7% increase in workforce size, AMD maintained identical messaging around its cultural values. This suggests that AMD is intentionally preserving its inclusive and innovative culture as a strategic element to retain top talent in the highly competitive semiconductor industry, where attracting skilled professionals is critical.",
      "llm_answer": "\nAMD has kept its “engaging and open” culture as it grew from roughly 26,000 employees (2023) to 28,000 (2024) by institutionalising annual workforce surveys, expanding employee‑resource groups, rolling out a company‑wide mentoring and leadership‑development program, and offering flexible, hybrid‑work options together with competitive, equity‑focused rewards.  These practices signal a talent‑retention strategy that leans on strong employee voice, clear career pathways, and inclusive benefits to keep top engineers and managers anchored in a fiercely competitive semiconductor market.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in content despite correct workforce numbers. The ground truth states that AMD maintained the same cultural messaging from 2023 to 2024—specifically repeating the phrase about being 'at our best when our culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment.' However, the LLM answer fabricates specific initiatives such as 'annual workforce surveys,' 'expanding employee-resource groups,' 'company-wide mentoring and leadership-development program,' 'flexible, hybrid-work options,' and 'equity-focused rewards'—none of which are present in the original answer or supported by the knowledge graph. These details are entirely invented and not implied by the source material. (2) Quantitative accuracy is correct: 26,000 employees in 2023 and 28,000 in 2024 are accurate, and the implied ~7.7% growth is also correct (though not explicitly stated in the LLM answer). (3) Multi-hop reasoning is flawed: the original answer draws a conclusion based on consistent messaging despite workforce growth, suggesting cultural continuity as a retention strategy. The LLM instead invents operational programs to explain cultural maintenance, failing to base its reasoning on the actual evidence (repeated public statements). This breaks the chain of valid inference. (4) While the general direction—linking culture to talent retention in a competitive industry—is contextually relevant and aligns with the question’s intent, the lack of fidelity to the source data severely undermines correctness. The answer sounds plausible but is factually unsupported, leading to a low qualitative and overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 476,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did AT&T's relationship with The Ohio Bell Telephone Company evolve between 2022 and 2023, particularly in terms of its guarantee obligations?",
      "original_answer": "In 2022, AT&T had a guarantee obligation covering The Ohio Bell Telephone Company as part of a broader list of subsidiaries under Exhibit 4-c, which was originally filed in 2011. In 2023, although the structure of the guarantee remained similar, the exhibit reference was updated to reflect current documentation practices, indicating a continuation of the guarantee without any explicit discontinuation or expansion. This suggests that the nature of the relationship remained stable, but documentation was maintained in line with current reporting standards.",
      "llm_answer": "\nBetween 2022 and 2023 AT&T did not add any new guarantee commitments to The Ohio Bell Telephone Company. The only reference to a guarantee for Ohio Bell in the filings is the legacy Exhibit 4‑c that was originally filed in the 2011 Form 10‑K and remains listed in the 2022 and 2023 exhibits index—indicating that the prior guarantee is still part of AT&T’s corporate documentation but has not been expanded, amended, or terminated in the intervening years. Consequently, the company’s guarantee obligations toward Ohio Bell stayed unchanged, with no disclosed modifications or new obligations emerging in the 2022‑2023 period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. (1) All key facts are correct: the guarantee obligation stems from the legacy Exhibit 4-c filed in 2011, and it remains referenced in both 2022 and 2023 filings without amendment, termination, or expansion. The dates (2011, 2022, 2023) and exhibit number (4-c) are accurate. (2) Quantitative accuracy is perfect—no numerical errors, and the timeline is correctly represented. (3) The multi-hop reasoning is sound: the model correctly infers that continued inclusion in the exhibits index implies ongoing obligation, and that absence of updates indicates no change in commitment. It synthesizes information across years and filings appropriately. (4) The only minor shortcoming is that the LLM does not explicitly mention the updated exhibit reference in 2023 (e.g., re-embedding under current documentation practices), which the original answer notes. However, stating that the exhibit 'remains listed' implies continuity and administrative maintenance, capturing the essence. Wording differs slightly but meaning is semantically equivalent. No irrelevant or incorrect information is included.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 329,
        "total_tokens": 1626
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did the financial impact of GE's relationship with AerCap evolve between 2023 and 2024, particularly in terms of gains on retained and sold ownership interests?",
      "original_answer": "In 2023, GE reported a $5.7 billion increase in corporate operating profit due to higher gains on retained and sold ownership interests, primarily driven by its AerCap and GE HealthCare investments. However, in 2024, the gains on retained and sold ownership interests decreased by $5.2 billion compared to 2023, again primarily related to AerCap and GE HealthCare. This indicates a significant reduction in the value or realization of these investments year-over-year.",
      "llm_answer": "\nIn 2023 GE recorded a $5.78 billion gain on retained and sold ownership interests—primarily from its AerCap (and GE HealthCare) stakes—fueling a sharp rise in corporate profit (see GE 10‑K 2023, page 13). By 2024 that gain had largely evaporated, falling by roughly $5.2 billion, so the contribution from AerCap‑related sales and retentions was essentially eliminated (GE 10‑K 2024, page 9). This decline reflects the winding‑down of the AerCap relationship and the spin‑offs of GE HealthCare and GE Vernova.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and closely aligns with the ground truth. (1) Quantitatively, the $5.78 billion gain in 2023 is a minor rounding variation from the original $5.7 billion—this is acceptable under format and reporting variations (e.g., more precise internal figures). The $5.2 billion decrease in 2024 matches exactly. (2) The answer correctly identifies that gains were primarily driven by AerCap and GE HealthCare in both years, and that the decline reflects reduced contributions from these investments. (3) Multi-hop reasoning is sound: it synthesizes data from both the 2023 and 2024 10-K filings, compares year-over-year changes, and correctly infers the diminishing financial impact of AerCap. (4) The addition of context about the 'winding-down of the AerCap relationship' and spin-offs of GE HealthCare and GE Vernova goes slightly beyond the original answer but is factually consistent with GE’s strategic moves and adds relevant qualitative insight without introducing error. Only minor deduction is made due to the slight numerical discrepancy in the 2023 gain ($5.78B vs $5.7B), which does not affect overall correctness. All entities, years, and financial metrics are accurate and relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 341,
        "total_tokens": 1590
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has Home Depot's strategic use of HD Supply evolved between 2022 and 2024, particularly in relation to its focus on professional customers and MRO services?",
      "original_answer": "In 2022, Home Depot highlighted the integration risks and challenges associated with its acquisition of HD Supply in 2020, noting that achieving synergies and benefits was subject to significant uncertainty and complexity. By 2024, HD Supply had become a core component of Home Depot’s strategy to serve professional customers, specifically through its MRO offerings to multifamily, hospitality, healthcare, and government housing facilities. The 2024 filing explicitly references HD Supply as a key contributor to Pro-focused growth initiatives, indicating a shift from post-acquisition integration concerns to a more mature and strategic role in supporting Home Depot's professional customer segment.",
      "llm_answer": "\nBetween fiscal 2022 and 2024 Home Depot transformed HD Supply from a stand‑alone MRO distributor into a central pillar of its professional‑customer strategy.  The company deepened integration by expanding HD Supply’s product breadth, adding dedicated sales and credit capabilities (e.g., Pro X Tra loyalty, Pro House Account), and linking its MRO services to the broader interconnected retail and supply‑chain investments—especially after the SRS acquisition—so that MRO now serves as the primary source of value‑added services for professional remodelers, contractors and facility‑management customers.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly captures the evolution of HD Supply's strategic role within Home Depot from 2022 to 2024, particularly its growing importance in serving professional customers through MRO services. It accurately reflects the shift from integration challenges to strategic integration, aligning with the ground truth's core narrative. There are no numeric values in either answer, so quantitative accuracy is not applicable—scored as 10 by default since no numbers are misstated. However, the LLM introduces details not present in the original answer, such as 'Pro X Tra loyalty,' 'Pro House Account,' and the 'SRS acquisition,' which are not mentioned in the ground truth and cannot be verified from the provided context. These additions suggest over-specificity or potential hallucination, reducing qualitative accuracy. While the overall reasoning and direction of the answer are sound—correctly identifying HD Supply’s enhanced role in MRO and professional customer strategy—the unsupported specifics undermine full factual reliability. The answer is contextually relevant and addresses both parts of the question: the timeline (2022–2024) and the strategic focus on professional customers and MRO. Thus, the correctness score is 7: the central claim is accurate, but the inclusion of unverified details prevents a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 371,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has AMD's reliance on cross-licensing agreements evolved between 2023 and 2024, particularly in terms of patent portfolio size and its implications for technology exchange?",
      "original_answer": "In 2023, AMD reported having approximately 18,500 patent matters worldwide, including 12,800 issued patents and 5,600 pending applications. In 2024, this portfolio grew slightly to approximately 18,800 patent matters, with 13,200 issued patents and 5,600 pending applications. This increase in issued patents indicates a strengthening of AMD's intellectual property position, which likely enhances its leverage in cross-licensing agreements. AMD continues to emphasize that these agreements are critical for transferring and receiving technology and intellectual property rights, suggesting that the company's reliance on such agreements remains strong and possibly more strategically advantageous in 2024 due to the expanded patent portfolio.",
      "llm_answer": "\nBetween the 2023 and 2024 filings AMD’s worldwide patent portfolio grew modestly—issued patents rose from about 12,800 to 13,200 while U.S. patents stayed roughly at 7,500 and pending applications remained steady at ≈5,600.  This slight expansion adds more assets that can be offered in cross‑licensing negotiations, reinforcing AMD’s strategy of exchanging patented technology with rivals rather than pursuing costly litigation.  Consequently, the company’s reliance on cross‑licensing and technology‑exchange agreements has remained strong, using the enlarged patent base to broaden the scope of technology sharing while keeping the overall structure of its licensing relationships essentially unchanged.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and closely aligns with the ground truth. (1) Quantitatively, the LLM correctly reports the increase in issued patents from 12,800 in 2023 to 13,200 in 2024 and accurately notes that pending applications remained steady at approximately 5,600. The total portfolio size is implied correctly (12,800 + 5,600 = 18,400 in 2023; 13,200 + 5,600 = 18,800 in 2024), though the LLM does not explicitly state the total patent matters (18,500 in 2023), which is a minor omission. The mention of U.S. patents at ~7,500 is not present in the original answer and may be extraneous or from an unverified source, but it does not contradict the ground truth. (2) The reasoning is sound: the LLM correctly infers that a larger patent portfolio strengthens AMD's position in cross-licensing negotiations and supports continued reliance on such agreements. (3) The multi-hop synthesis—linking patent growth to strategic implications in technology exchange—is logically and accurately presented. (4) The answer addresses all key aspects of the question: evolution over time, patent portfolio size, and implications for technology exchange. The only minor shortcoming is the lack of explicit mention of the 2023 total patent matters (18,500), which slightly affects completeness. Overall, the answer is factually correct, well-reasoned, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 380,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did Johnson & Johnson's financial stake and strategic relationship with Kenvue evolve from 2023 to 2024, particularly regarding the retention and subsequent disposal of Kenvue shares?",
      "original_answer": "In 2023, Johnson & Johnson retained a 9.5% stake in Kenvue valued at $4.3 billion after completing the exchange offer in August. This stake was recorded in other assets and experienced a $0.4 billion expense by year-end due to subsequent changes. By 2024, the company completed a debt-for-equity exchange in May, using its remaining 182,329,550 shares of Kenvue Common Stock to satisfy $3.6 billion of commercial paper. This resulted in a $0.4 billion loss and marked the complete exit from Kenvue, ending any financial stake in the company.",
      "llm_answer": "\nFrom the end of 2023 through May 2024, Johnson & Johnson moved from holding a 9.5 % minority stake in Kenvue (the remainder of the ~89.6 % it owned after the August 2023 exchange) to completely exiting that position.  In May 2024 the company swapped its last 182 million Kenvue shares for $3.6 billion of commercial paper, thereby satisfying and retiring the paper and recording a roughly $0.4 billion loss in other (income) expense—leaving J&J with no Kenvue shares and ending its strategic equity relationship with the consumer‑health spin‑off.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth with only minor imprecisions. (1) Quantitatively: The 9.5% stake, $3.6 billion commercial paper, $0.4 billion loss, and May 2024 timeline are all correct. The share count is approximated as '182 million' versus the exact 182,329,550—this is a reasonable rounding and does not affect factual correctness. The $4.3 billion valuation of the retained stake in 2023 is omitted, which is a minor completeness gap. (2) The expense/loss of $0.4 billion is correctly reported, though the original specifies it was recorded in 'other assets' and 'other (income) expense'—the LLM captures the latter but not the former detail. (3) Multi-hop reasoning is sound: the answer correctly links the 2023 retention of a minority stake post-spin-off to the 2024 debt-for-equity transaction that fully exited the position. It synthesizes the financial and strategic evolution accurately. (4) Entity names (Johnson & Johnson, Kenvue), time periods (2023–2024), and financial instruments (commercial paper, equity stake) are correct. The strategic conclusion—that the swap ended J&J’s financial and equity relationship—is fully supported. The only minor shortcomings are the omission of the $4.3B valuation figure and slight simplification of the share count, which do not undermine the overall correctness. Hence, a score of 9 is appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 389,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has AT&T's relationship with Indiana Bell Telephone Co. Inc. evolved between 2022 and 2023 in terms of its inclusion in guarantee disclosures?",
      "original_answer": "In 2022, Indiana Bell Telephone Co. Inc. was listed among the entities whose obligations were guaranteed by AT&T under Exhibit 4-d. In 2023, the company continued to reference the same guarantee for Indiana Bell Telephone Co. Inc. under Exhibit 4-d, indicating that the guarantee remained in place without any modification or removal. Therefore, there was no change in the nature or status of the guarantee relationship between the two entities from 2022 to 2023.",
      "llm_answer": "\nBetween the 2022 and 2023 filings AT&T stopped listing Indiana Bell Telephone Co. Inc. as a guarantor in its SEC disclosures. The 2022 filing (page 133) still references a 2011 4‑c guaranty that mentions Indiana Bell, but the 2023 filing (pages 101‑105) no longer includes that exhibit, indicating the guarantee relationship was removed. Consequently, Indiana Bell is no longer part of AT&T’s guarantee disclosures in the most recent SEC reports.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both factual content and reasoning. (1) According to the ground truth, Indiana Bell Telephone Co. Inc. remained listed in AT&T's guarantee disclosures in both 2022 and 2023 under Exhibit 4-d, with no changes to the guarantee status. The LLM incorrectly claims that AT&T stopped listing Indiana Bell in 2023 and that the exhibit was removed, which contradicts the original answer. (2) The LLM introduces Exhibit 4-c from 2011, which is not mentioned in the ground truth and appears to be fabricated or misattributed; the correct exhibit is 4-d in both years. (3) The multi-hop reasoning fails: instead of recognizing continuity in the guarantee disclosure, the model erroneously infers removal based on exhibit page differences, which does not reflect actual changes in guarantee status. (4) While the question is about evolution in disclosure and the response attempts to address that, the conclusion is entirely opposite to the truth. The contextual relevance is low due to reliance on incorrect exhibits and false narrative of removal. Minor credit is given for addressing the right entities and time frame, but all substantive claims are false.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 334,
        "total_tokens": 1561
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How did GE's financial relationship with AerCap evolve from 2023 to 2024, particularly in terms of cash involvement and investment gains?",
      "original_answer": "In 2023, GE had a continuing financial involvement with AerCap through a note receivable, product leases, and transition services, which included a net cash payment of $203 million to AerCap. By 2024, GE no longer had continuing operational involvement but instead held an investment stake in AerCap. This shift resulted in a significant financial impact, as GE reported a decrease in gains on retained and sold ownership interests by $5.2 billion, largely attributed to its AerCap and GE HealthCare investments. This indicates a strategic and financial transition from operational collaboration to investment-based returns.",
      "llm_answer": "\nIn 2023 GE finished the divestiture of its last AerCap equity position, recording a $5.2 billion gain on the sale that was part of the overall “gains on retained and sold ownership interests” reported in the 2023 results.  By 2024 the tie‑up had become purely commercial: GE now supplies transition services and holds a note receivable for AerCap and, as disclosed in the 2024 filing, paid a net cash amount of **$203 million** to AerCap—meaning cash now flows out of GE rather than in, and no equity‑related investment gains are recognized.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that reverse the timeline and nature of GE's financial relationship with AerCap, leading to a low correctness score. (1) The key error is the reversal of events: the original answer states that in 2023, GE had operational involvement (note receivable, product leases, transition services) and made a $203M net cash payment to AerCap, while in 2024, GE held an investment stake. The LLM incorrectly claims the equity divestiture and $5.2B gain occurred in 2023, when in fact the $5.2B decrease in gains was reported in 2024 due to the absence of such gains post-divestiture. (2) Quantitatively, the $203 million net cash payment is correctly cited, but it is misattributed in context — it occurred in 2023 per the ground truth, not 2024 as implied by the LLM’s narrative flow. The $5.2 billion figure is mentioned but incorrectly framed as a gain in 2023 rather than a year-over-year decrease in gains in 2024. (3) The multi-hop reasoning is flawed: the LLM fails to correctly synthesize the evolution from operational involvement in 2023 to investment-based position in 2024; instead, it reverses the sequence, suggesting investment activity ended in 2023 and only commercial ties remained in 2024, which contradicts the ground truth. (4) Contextual relevance is moderate — the answer discusses the right entities and financial concepts (note receivable, transition services, gains on ownership), but the incorrect timeline and mischaracterization of cash flows and gains undermine the overall accuracy. Wording flexibility is allowed, but the semantic meaning here is not equivalent due to the reversed causality and chronology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 456,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has The Home Depot's approach to store appearance and its role in competition evolved from 2022 to 2024, particularly in relation to customer experience and digital integration?",
      "original_answer": "In 2022, The Home Depot emphasized store appearance as a competitive factor alongside customer experience, price, and product availability. The company highlighted the importance of store location, appearance, and ease of shopping experience in both brick-and-mortar and online contexts. By 2024, the company expanded its focus, integrating store appearance into a broader 'interconnected shopping experience' that linked physical stores, digital platforms, and on-site services. The 2024 report specifically noted investments in digital platforms to enhance the presentation and ease of navigation for users, reflecting a shift toward digital integration as a core component of store and shopping experience competitiveness. This evolution shows a strategic shift from physical store aesthetics alone to a more holistic, digitally-enhanced customer experience.",
      "llm_answer": "\nFrom 2022 to 2024 Home Depot moved beyond isolated store‑refresh projects (e.g., signage, self‑service lockers, electronic shelf‑labels) to treat store appearance as a platform for a fully digital, omnichannel experience; the 2024 filing shows continued investment in mobile‑app‑enabled navigation, AI‑driven inventory visibility (Computer Vision, hdPhone/Sidekick) and curb‑side/BOPIS fulfillment that tie the physical layout directly to online ordering and real‑time product information.  This evolution positions each store not just as a point of sale but as a seamless extension of the customer’s digital journey, using store design and technology to deliver a more personalized, frictionless experience that differentiates Home Depot in a highly competitive market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly captures the evolution of The Home Depot's approach from 2022 to 2024, emphasizing the shift from physical store appearance to a digitally integrated, omnichannel experience. While the original answer does not mention specific technologies like 'Computer Vision', 'hdPhone/Sidekick', or 'electronic shelf-labels', these are plausible details consistent with Home Depot's known digital investments and do not contradict the ground truth. The LLM correctly identifies the strategic shift toward an interconnected shopping experience linking physical and digital platforms. All dates (2022 to 2024) are accurate, and there are no numerical errors (no specific numbers to verify, but temporal and conceptual references are correct). The reasoning is sound, demonstrating multi-hop synthesis by connecting store appearance, digital integration, customer experience, and competitive positioning across years. The answer is semantically equivalent to the original, with slightly more technical detail but without introducing factual inaccuracies. One point was deducted from qualitative accuracy because the LLM introduces specific tools not explicitly confirmed in the ground truth, though they are reasonable inferences. Overall, the response is complete, relevant, and factually solid.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 378,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2023 and 2024, particularly in terms of resales and new financial arrangements?",
      "original_answer": "In 2023, AMD's resales to the ATMP JV amounted to $14 million, with no mention of direct financial arrangements such as loans. By 2024, AMD's resales to the ATMP JV increased significantly to $121 million. Additionally, in October 2024, AMD entered into a one-year $100 million term loan agreement with one of the ATMP JVs to support the joint venture's general corporate purposes. This indicates a notable deepening of the financial relationship, moving beyond operational services to include direct financial support.",
      "llm_answer": "\nBetween 2023 and 2024 AMD’s purchases from the ATMP joint venture stayed roughly at $1.7 billion, but resales to the JV surged from only $14 million in 2023 to $121 million in 2024, while payables to the JV rose from $363 million to $476 million.  In addition, AMD’s equity stake in the JV grew to about $149 million (up from $99 million) and, in October 2024, it extended a $100 million one‑year term loan to the JV, underscoring a new, larger financial relationship beyond the earlier equity‑method arrangement.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but introduces significant inaccuracies. It correctly states that AMD's resales to the ATMP JV increased from $14 million in 2023 to $121 million in 2024, aligning with the ground truth. It also correctly identifies the October 2024 $100 million one-year term loan to the JV. However, it fabricates or misrepresents other financial figures not present in the original answer, such as AMD’s purchases from the JV being $1.7 billion (not mentioned in ground truth), payables rising from $363M to $476M (absent in source), and equity stake increasing from $99M to $149M (not in original). These numbers, while possibly from actual filings, are not part of the verified knowledge graph answer and introduce unverified multi-hop claims. (2) Quantitative accuracy is compromised because although the resale figures and loan amount/date are correct, the inclusion of unsupported numbers like $1.7B purchases, $363M/$476M payables, and $99M/$149M equity stakes reduces trust in the overall numerical fidelity. The core required numbers (resales, loan) are right, but extraneous incorrect figures lower the score. (3) The reasoning partially captures the deepening financial relationship, correctly inferring that the loan represents a new level of financial involvement. However, the synthesis goes beyond the provided data by implying broader financial trends based on unmentioned metrics, weakening the logical foundation. The model attempts multi-hop reasoning but includes unsupported hops. (4) Contextual relevance is high because the answer addresses the evolution of the financial relationship and highlights the key shift in 2024 with the loan. Despite inaccuracies, it stays focused on AMD-ATMP JV dynamics and the timeline. Final scores reflect partial correctness: core facts about resales and the loan are accurate, but major additions reduce correctness to a 6.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 521,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has Johnson & Johnson's approach to privacy compliance programs evolved between 2023 and 2024, particularly in response to new privacy laws and international data flow regulations?",
      "original_answer": "In 2023, Johnson & Johnson had established privacy compliance programs and controls that its global businesses were required to follow, with an emphasis on addressing new privacy laws expected in 'other territories' and increasing enforcement by governmental authorities, especially concerning data localization and international data flows. By 2024, the company maintained these privacy compliance programs but expanded its focus to include evolving technology and data-driven initiatives across the company, involving multiple vendors and third parties. The 2024 disclosure also specifically notes the expectation of new privacy laws 'globally' (not just in other territories) and highlights legislative actions imposing limitations on the use, sharing, and cross-border flows of personal data. This indicates a broadening of the company's compliance focus and a more anticipatory posture toward global regulatory changes.",
      "llm_answer": "\nJohnson & Johnson has tightened and expanded its privacy‑compliance framework between 2023 and 2024.  In the 2023 filing the Company noted that it “has established privacy compliance programs and controls” [page 23, 2023 10‑K], but in the 2024 filing it adds detailed governance (CISO‑led program, RCSC board oversight) [page 21, 2024 10‑K], mandatory data‑privacy training for all employees, and a structured third‑party risk‑management process that specifically addresses “controls imposed on cross‑border data flows, unauthorized access, and loss of personal data” [page 21, 2024 10‑K].  The 2024 discussion also emphasizes that new global privacy laws—especially data‑localization and international‑data‑transfer requirements—are driving a more proactive, risk‑based approach to protecting personal data across the Company’s worldwide operations.  Thus, the evolution is marked by deeper governance, broader employee training, and explicit focus on emerging cross‑border data‑flow regulations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly identifies the evolution in Johnson & Johnson's privacy compliance programs between 2023 and 2024, emphasizing the expansion of focus from 'other territories' to 'globally' and the increasing regulatory pressure on cross-border data flows and data localization. The LLM adds specific details from the 2024 10-K—such as CISO-led governance, RCSC board oversight, mandatory employee training, and third-party risk management—that are consistent with a more structured and proactive compliance posture, which is a valid inference from the broader trend described in the original answer. While the original answer does not explicitly mention the CISO or RCSC, these details are plausibly part of the 'expanded focus' and 'broader governance' implied in the ground truth, and they do not contradict it. The LLM correctly captures the shift toward anticipating global (not just regional) privacy laws and the emphasis on cross-border data flow controls. There are no numerical inaccuracies (quantitative accuracy is perfect), and all entities (Johnson & Johnson, 2023 vs 2024, privacy laws, international data flows) are correctly identified. The reasoning is sound and reflects proper multi-hop synthesis across years and disclosures. The only reason for not scoring a 10 is that the LLM introduces specific governance structures (CISO, RCSC) not present in the ground truth, which, while likely accurate from the source filing, go beyond the synthesized knowledge provided; this is a minor over-specification, not a factual error. Overall, the answer is factually correct, comprehensive, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1490,
        "completion_tokens": 460,
        "total_tokens": 1950
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has GE's financial exposure to Bank BPH evolved between 2023 and 2024, particularly in terms of estimated borrower litigation losses and related valuation allowances?",
      "original_answer": "In 2023, GE reported $2,669 million in total estimated losses related to borrower litigation for Bank BPH's foreign currency-denominated mortgage portfolio, with $1,712 million in valuation allowances against financing receivables held for sale and $957 million in other liabilities. By 2024, this total estimated loss decreased to $2,461 million, with $1,517 million in valuation allowances and $944 million in other liabilities. Additionally, the valuation allowance fully offset the financing receivables balance by the end of 2024, indicating a strategic shift in how GE managed its exposure to Bank BPH through a settlement program. This represents a reduction in GE's financial exposure to Bank BPH litigation risks over the period.",
      "llm_answer": "\nBetween 2023 and 2024 the estimated borrower‑litigation loss that GE must absorb for its Polish mortgage‑finance unit (Bank BPH) fell sharply – from about **$2.67 billion** in 2023 to **$2.46 billion** in 2024.  Accordingly, the valuation allowance that offsets the financing‑receivable portfolio (the “loss reserve”) was reduced from roughly **$1.71 billion** (2023) to **$1.52 billion** (2024), a decline of roughly **$195 million**.  This reduction is reflected in the discontinued‑operations results, where the pre‑tax loss attributed to Bank BPH dropped from **$1.252 billion** in 2023 to just **$41 million** in 2024, and the net‑of‑tax loss fell from **$1.242 billion** to **$4 million**, indicating that GE’s financial exposure to Bank BPH has been markedly curtailed.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the overall trend of decreasing financial exposure from 2023 to 2024 and reports approximate values for total estimated losses and valuation allowances. However, there are notable quantitative inaccuracies. The original answer states that in 2023, total estimated losses were $2,669 million ($2.669 billion), with $1,712 million in valuation allowances and $957 million in other liabilities. The LLM rounds these to $2.67 billion and $1.71 billion, which is acceptable, but in 2024, the original reports $2,461 million total loss, $1,517 million valuation allowance, and $944 million other liabilities. The LLM reports $2.46 billion (correct) and $1.52 billion (slightly high; should be $1.517 billion). More critically, the LLM introduces figures not present in the original answer: pre-tax loss of $1.252 billion in 2023 and $41 million in 2024, and net-of-tax losses of $1.242 billion and $4 million. These specific line items are not mentioned in the ground truth and represent unverified additions. (2) While the core numbers (total estimated loss and valuation allowance) are approximately correct with minor rounding, the inclusion of unsupported financial figures (pre-tax and net-of-tax losses) undermines quantitative accuracy. The calculation of a $195 million reduction in valuation allowance is close (actual: $1,712M - $1,517M = $195M), so that is accurate. (3) The multi-hop reasoning is sound in interpreting a reduction in exposure and linking it to strategic changes, and the mention of discontinued operations aligns with GE’s reporting structure. However, the answer goes beyond the source by introducing specific P&L impacts not present in the original, which risks misattribution. (4) The contextual relevance is high, as the answer directly addresses the evolution of GE’s exposure to Bank BPH litigation and valuation allowances. The qualitative reasoning is strong, but the correctness score is reduced due to unsupported numerical claims. Overall, the answer captures the main trend and approximate magnitudes but introduces extraneous, unverified data, preventing a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 578,
        "total_tokens": 1963
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has HD's treatment and positioning of the Indoor Garden product line evolved from 2022 to 2024, given its financial performance in 2022 and its merchandising department categorization in 2024?",
      "original_answer": "In 2022, HD's Indoor Garden product line generated $15,546 million in net sales, accounting for 10.3% of total revenue, indicating its significance as a standalone category. By 2024, the Indoor Garden product line was grouped under the 'Hardlines' merchandising department, suggesting a strategic shift to integrate it with related product lines rather than treating it as a distinct category. This reclassification implies a change in how HD is organizing and potentially promoting the product line within its broader offerings.",
      "llm_answer": "\nHD kept the Indoor Garden line in the Hardlines merchandising group both in 2022 and after the 2024 department‑realignment, but its financial footprint expanded modestly—sales rose from about **$10.1 billion (6.4 % of total net sales) in fiscal 2022** to **$10.5 billion (6.6 % of net sales) in fiscal 2024**, underscoring a stable yet slightly growing positioning of the product line within the company’s portfolio.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, HD's Indoor Garden product line generated $15,546 million (i.e., $15.546 billion), not $10.1 billion as stated by the LLM. Additionally, the LLM claims sales rose to $10.5 billion in 2024, but the ground truth does not provide 2024 sales figures—only the reclassification under 'Hardlines'. The percentage of total net sales is also incorrect: 10.3% in 2022 per ground truth vs. 6.4% claimed by LLM. These numerical discrepancies are substantial and materially alter the interpretation. (2) The LLM incorrectly states that the Indoor Garden line was in Hardlines in 2022; the ground truth implies it was a standalone category then and only grouped into Hardlines by 2024. This misrepresents the evolution of the product line’s categorization. (3) The multi-hop reasoning is flawed: the question asks for an analysis based on 2022 financial performance and 2024 merchandising classification. The LLM fabricates 2024 sales data and misstates 2022 data, failing to correctly synthesize the two points. It also misses the strategic implication of reclassification from standalone to integrated category. (4) The contextual relevance is moderate because the answer addresses the right topic (product line positioning over time) and mentions merchandising department and sales trends, but due to severe factual and quantitative errors, the conclusion about 'stable yet growing positioning' contradicts the ground truth narrative of a strategic repositioning following strong standalone performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1249,
        "completion_tokens": 440,
        "total_tokens": 1689
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Colgate-Palmolive's use of sourcing strategies to manage cost volatility evolved from 2022 to 2024, particularly in relation to commodity price fluctuations?",
      "original_answer": "In 2022, Colgate-Palmolive utilized sourcing strategies as part of a broader risk management framework to manage volatility in foreign exchange, interest rates, and commodity prices, specifically mentioning the use of derivative instruments and local currency borrowings. By 2024, the company continued to rely on sourcing strategies but placed greater emphasis on managing raw material cost volatility, including commodities like resins, essential oils, and soybeans, while also incorporating more proactive cost containment and productivity initiatives. The 2024 disclosure highlights increased exposure to geopolitical and climatic disruptions, indicating a shift toward more defensive sourcing and cost management tactics in response to external pressures.",
      "llm_answer": "\nBetween 2022 and 2024 Colgate‑Palmolive kept its core approach of using sourcing‑strategy levers—productivity initiatives, cost‑efficiency programs and only limited commodity‑hedging contracts—to blunt raw‑material price swings. The 2024 filing, however, places greater emphasis on supply‑chain resilience, noting efforts to diversify suppliers, build business‑continuity and contingency plans, and qualify new sources, while still relying on the same limited‑hedging and productivity‑driven cost‑management tactics.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its qualitative assessment of Colgate-Palmolive's evolving sourcing strategies from 2022 to 2024, with accurate contextual framing around supply-chain resilience, supplier diversification, and continued reliance on productivity initiatives. The quantitative accuracy is perfect—no numerical data is misstated, and no incorrect figures are introduced, which aligns with the ground truth that does not include specific numbers. However, the LLM omits key elements from the original answer: it fails to mention the use of derivative instruments and local currency borrowings in 2022, which were part of the broader risk management framework. Additionally, while it references 'limited commodity-hedging contracts,' the original answer does not characterize hedging as 'limited,' potentially misrepresenting the extent of financial instruments used. The 2024 emphasis on raw material cost volatility (e.g., resins, essential oils, soybeans) and increased exposure to geopolitical and climatic disruptions is partially captured through the mention of supply-chain resilience but not explicitly detailed. The multi-hop reasoning is sound in comparing disclosures across years, but the synthesis lacks full fidelity to the original source's specifics. Wording differences are acceptable under semantic equivalence, but the omission of specific commodity examples and financial risk tools reduces completeness. Contextual relevance is high as the response directly addresses the evolution of sourcing strategies in response to cost volatility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 429,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How did the sales performance of TREMFYA evolve between 2023 and 2024, and what factors contributed to this change?",
      "original_answer": "In 2023, TREMFYA (guselkumab) experienced growth driven by market expansion, continued strength in PsO/PsA (Psoriasis and Psoriatic Arthritis), and favorable patient mix. By 2024, TREMFYA achieved sales of $3,670 million, an increase of 16.6% compared to $3,147 million in 2023. The growth in 2024 was attributed to an 18.1% change from operations, despite a negative currency impact of 1.5%. This indicates that TREMFYA not only maintained its market position but also expanded further in its therapeutic areas during this period.",
      "llm_answer": "\nTREMFYA sales rose sharply from about **$3.1 billion in 2023 to $3.7 billion in 2024** (a **≈16 % increase**). The growth was driven by **overall market expansion and gains in market share**, supported by the launch of **sub‑cutaneous formulations and new indications (e.g., ulcerative colitis and Crohn’s disease)**, which boosted physician and patient adoption. Unlike other immunology products that faced biosimilar pressure, TREMFYA’s newer delivery options and expanding therapeutic portfolio helped sustain its upward sales trajectory.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the sales figures for TREMFYA in 2023 and 2024 as approximately $3.1 billion and $3.7 billion, respectively, which aligns with the ground truth values of $3,147 million and $3,670 million. The reported ~16% increase is also accurate (actual: 16.6%), so quantitative accuracy is high. Minor rounding is acceptable. (2) However, the qualitative factors cited for growth differ from the ground truth. The original answer attributes growth to market expansion, strength in PsO/PsA, favorable patient mix, and operational improvements (18.1% from operations offset by -1.5% currency impact). In contrast, the LLM introduces unsupported details such as 'sub-cutaneous formulations,' 'new indications (ulcerative colitis and Crohn’s disease),' and 'gains in market share'—none of which are mentioned in the ground truth. These additions reflect plausible but unverified reasoning and represent a significant deviation in factual causality. (3) The multi-hop reasoning is partially sound—sales trend and growth are correctly synthesized across years—but the contributing factors are incorrectly inferred rather than accurately extracted. The model fails to mention the key point about currency impact and overemphasizes product innovation not cited in the source. (4) Scores reflect strong numerical accuracy and relevance to the question, but reduced qualitative accuracy due to fabricated drivers of growth. Correctness is docked because while the 'what' (sales increase) is right, the 'why' (factors) is not fully aligned with ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 435,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the structural change in Disney's relationship with A&E from 2022 to 2023 affect its reporting of subscriber numbers and financial stake in the partnership?",
      "original_answer": "In 2022, Disney reported A&E as a partner with 69 million domestic subscribers, indicating a collaborative but arms-length relationship. By 2023, Disney's relationship with A&E had evolved into a 50% equity stake, with A+E now classified as a significant equity investment. The 2023 report noted that A+E's channels, including A&E, had 58 million domestic subscribers. This shift from a partnership to a joint ownership model altered how Disney reported both subscriber data and financial performance, moving from simple subscriber counts in 2022 to including A+E’s financial results under 'Equity in the income of investees' in 2023.",
      "llm_answer": "\nThe 2023 filing separates A+E’s audience numbers from the old “equity‑investment” summary and presents them as “domestic subscribers” for each of the three channels (about 58 million each) in the Linear‑Networks table, while still recording Disney’s 50 % stake as “Equity in the income of investees.”  This methodological change—moving from the broader Nielsen estimate that counted both MVPD and OTT subscribers in 2022 to a narrower Nielsen estimate for 2024—lowers the reported subscriber count and makes the partnership’s financial interest explicit as an equity‑method holding rather than an aggregated partnership figure.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains partial factual accuracy but has significant errors in quantitative details and reasoning. (1) QUANTITATIVE INACCURACIES: The LLM claims A+E had 'about 58 million each' subscribers for each of the three channels, which misrepresents the ground truth—58 million is the total domestic subscriber count for A+E channels collectively, not per channel. Additionally, the LLM incorrectly references a 'narrower Nielsen estimate for 2024', which is not mentioned in the original answer or supported by the question timeframe (2022–2023). This introduces a false future date (2024) instead of correctly analyzing 2023 data. (2) COMPLETENESS: The answer captures the shift to a 50% equity stake and the use of 'Equity in the income of investees', which aligns with the original answer. However, it omits the 2022 subscriber number (69 million) and fails to clearly contrast the 2022 partnership model with the 2023 equity model as a structural change. (3) ENTITY & CONTEXTUAL ACCURACY: While A+E, Disney, and the equity method are correctly identified, the misstatement of subscriber numbers and introduction of '2024' undermines entity and temporal accuracy. (4) REASONING: The multi-hop synthesis is partially sound—recognizing the shift from partnership reporting to equity-method accounting—but the flawed data and timeline weaken the logic. The explanation of methodological change is speculative and not fully aligned with the original answer. (5) SEMANTIC EQUIVALENCE: The core idea of structural change affecting reporting is present, but incorrect numbers and timelines prevent full equivalence. Overall, the answer is directionally correct but factually flawed, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 465,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the financial impact of GE's relationship with AerCap evolve between 2023 and 2024, particularly in terms of realized and unrealized gains or losses?",
      "original_answer": "In 2023, GE reported an unrealized gain of $129 million from its investment in and note with AerCap. However, in 2024, the relationship had evolved such that GE recognized a significant decrease in gains on retained and sold ownership interests, which dropped by $5.2 billion compared to 2023, with AerCap being one of the primary contributors to this decline. This indicates a negative shift in the financial performance of the AerCap investment from a gain in 2023 to a loss or significantly reduced gain in 2024.",
      "llm_answer": "\nIn 2023 GE realized a $6.587 billion cash gain by selling its remaining AerCap shares and, separately, recorded a modest $129 million realized/unrealized gain on the AerCap senior note (the only AerCap interest left on its books). By 2024 there were no further disposals, so the AerCap exposure generated only an immaterial, non‑recurring fair‑value adjustment to the senior note that appears in other income (loss); consequently, the relationship no longer produces any material realized or unrealized gains or losses.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) Quantitatively, the claim that GE realized a $6.587 billion cash gain in 2023 from selling AerCap shares is incorrect — the original answer states only an *unrealized* gain of $129 million related to its investment and note with AerCap, with no mention of a $6.587 billion realized gain. This figure appears fabricated or misattributed. (2) The LLM incorrectly asserts that GE sold its remaining AerCap shares in 2023, which is not supported by the original answer; the ground truth does not mention any sale of shares, only an unrealized gain. (3) Regarding 2024, the LLM claims AerCap exposure led to only an immaterial fair-value adjustment, but the original answer states there was a $5.2 billion *decrease in gains* compared to 2023, with AerCap being a primary contributor — indicating a significant negative financial impact, not immaterial activity. This is a major discrepancy in both magnitude and interpretation. (4) The reasoning is flawed: the LLM suggests the reduction in gains is due to lack of disposals, while the original answer implies a deterioration in performance or valuation of retained interests. The multi-hop synthesis fails — the model misrepresents both the nature (realized vs unrealized) and direction (gain vs large drop) of the financial impact. While the $129 million figure is correctly cited (though misclassified as realized/unrealized), this single correct number does not compensate for the broader inaccuracies. The answer is contextually relevant in discussing GE-AerCap financials over 2023–2024 but fundamentally incorrect in its core claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 456,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has Mastercard's multi-layered security approach evolved between 2022 and 2024, particularly in terms of addressing risks associated with third-party service providers, and what does this evolution indicate about the company's strategic response to emerging cybersecurity threats?",
      "original_answer": "In 2022, Mastercard's multi-layered security approach included a robust program to protect its network from cyber and information security threats, with multiple layers of protection and third-party assessments. However, there was no explicit mention of addressing risks related to third-party service providers. By 2024, Mastercard explicitly integrated third-party provider risk management into its security framework, noting that it works with experts across the organization and through public-private partnerships to monitor and respond to threats associated with the use of services provided by third-party providers. This indicates a strategic shift toward strengthening the ecosystem-wide resilience of its security architecture, particularly in response to the growing complexity and interconnectedness of the payments landscape.",
      "llm_answer": "\nBetween 2022 and 2024 Mastercard deepened its multi‑layered security framework by formalizing a dedicated third‑party risk‑management program and by expanding collaboration with external cybersecurity experts, public‑private partnerships and independent assessors to monitor and respond to threats that arise from services supplied by third‑party providers.  At the same time, the company embedded these safeguards into newly launched real‑time, account‑based and disbursement platforms (e.g., Alias‑Based Remittances, VCN and Track BPS), ensuring that the expanded digital‑payment flows are protected by the same layered controls that secure its core network.  This evolution signals a strategic shift toward proactive, ecosystem‑wide cyber resilience, preparing Mastercard for the heightened threat landscape created by broader digital‑payment adoption and increasing reliance on external service partners.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution in Mastercard's security approach between 2022 and 2024: in 2022, the focus was on internal protections and third-party assessments without explicit mention of third-party provider risks, while by 2024, the company explicitly integrated third-party risk management into its framework. The LLM accurately captures this shift and correctly notes the increased collaboration with public-private partnerships and experts. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes the timeline (2022 vs 2024), identifies the change in treatment of third-party providers, and infers the strategic intent behind the evolution. The mention of specific platforms (e.g., Alias-Based Remittances, VCN, Track BPS) adds detail not in the original answer but does not contradict it; these could plausibly be part of the expanded digital-payment flows protected under the enhanced framework. While the original answer does not name these platforms, their inclusion does not reduce accuracy and may reflect additional context from the filings. (4) The conclusion about a strategic shift toward ecosystem-wide resilience is semantically equivalent to the original and well-justified. The only minor gap is that the original emphasizes the absence of explicit third-party provider risk language in 2022, which the LLM implies but does not state outright. Overall, the answer is factually correct, comprehensive, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1471,
        "completion_tokens": 463,
        "total_tokens": 1934
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has Target Corporation's compliance with its debt leverage covenant evolved between 2022 and 2023, particularly in light of changes to its credit facilities?",
      "original_answer": "In 2022, Target Corporation stated that it was in compliance with its debt leverage covenant and expected to remain so, with a $3.0 billion unsecured revolving credit facility set to expire in October 2026. By 2023, Target had obtained a new $1.0 billion 364-day unsecured revolving credit facility (expiring in October 2024) and extended the expiration of its five-year $3.0 billion facility to October 2028. Despite these structural changes to its credit facilities, Target continued to assert compliance with the debt leverage covenant in 2023, indicating consistent adherence to regulatory requirements even as its financing arrangements evolved.",
      "llm_answer": "\nTarget has continued to satisfy the debt‑leverage covenant in both 2022 and 2023, reporting that it is “in compliance with these covenants” in each filing.  The company’s credit‑facility structure was updated in 2023—its prior 364‑day revolving facility was terminated and a new $1 billion 364‑day facility was entered into, while its $3 billion five‑year revolving facility was extended to a 2028 maturity—changes that preserve the same leverage limits but provide longer‑term liquidity.  Consequently, the leverage covenant has remained effectively unchanged, and Target has maintained compliance despite the facility modifications.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Target was in compliance with its debt leverage covenant in both 2022 and 2023; the $3.0 billion five-year facility was extended to October 2028; a new $1.0 billion 364-day facility was established in 2023, expiring in October 2024; and the prior 364-day facility was terminated. These details match the original answer exactly. (2) Quantitative accuracy is perfect: dollar amounts ($1 billion, $3 billion), timeframes (364-day, 2028 maturity), and dates are all correct. Format variations (e.g., $1 billion vs $1.0 billion) are acceptable and semantically equivalent. (3) The multi-hop reasoning is sound—LLM correctly synthesized changes in credit facilities across years and linked them to ongoing covenant compliance. It correctly infers that despite structural changes, the leverage covenant terms were preserved, supporting continued compliance. (4) Minor deduction in qualitative accuracy due to the phrase 'leverage covenant has remained effectively unchanged'—while the spirit is correct, the original answer does not explicitly confirm whether covenant terms (e.g., ratio thresholds) were unchanged, only that compliance was maintained. This is a small inference beyond the provided data. Otherwise, the answer is complete, relevant, and correctly addresses the evolution of compliance and facility changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 392,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has the nature of the risks associated with Salesforce's AI offerings, including generative AI such as Agentforce, evolved from 2023 to 2024?",
      "original_answer": "In 2023, Salesforce's primary risk related to third-party integrations and applications centered on potential claims or liabilities stemming from customer expectations for warranties, despite the company not developing or selling these third-party offerings. By 2024, the risk profile expanded significantly with the increased integration of AI into Salesforce's offerings, particularly generative and agentic AI like Agentforce. The 2024 disclosures highlight new risks such as ethical concerns, regulatory scrutiny, and potential legal liabilities from AI-generated content that may be inaccurate, biased, or infringe on copyright. Additionally, the company now anticipates increased costs related to AI governance, compliance, and testing, which were not specifically tied to AI in 2023.",
      "llm_answer": "\nFrom 2023 to 2024 the AI‑related risk narrative shifted from a broad focus on competition, uncertain monetization and the challenges of integrating generative‑AI features such as Agentforce into existing clouds, to a more concrete set of regulatory, privacy and ethical exposures.  The 2024 filing emphasizes newly‑enacted AI‑specific statutes (e.g., Utah and Colorado AI Acts, the EU AI Act), heightened data‑privacy and cross‑border transfer obligations, and the need for extensive governance around accuracy, bias, copyright and liability of generative‑AI outputs, while also noting pricing volatility from consumption‑based models.  In short, the risks have moved from “will AI sell?” to “how do we comply with emerging AI laws and manage the legal‑ and reputation‑risk of generative‑AI behavior?”.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution of Salesforce's AI-related risks from 2023 to 2024 with strong qualitative and contextual fidelity to the ground truth. It correctly identifies the shift from general integration and monetization concerns in 2023 to specific regulatory, ethical, and legal risks in 2024 tied to generative and agentic AI like Agentforce. The mention of 'newly-enacted AI-specific statutes' (e.g., Utah and Colorado AI Acts, EU AI Act), data privacy obligations, and governance around bias, copyright, and liability aligns well with the expanded risk profile described in the original answer. While the ground truth emphasizes third-party integration liabilities in 2023 (particularly warranty-related expectations), the LLM reframes this as 'competition, uncertain monetization, and integration challenges'—a slightly different emphasis but still within the plausible scope of 2023 risks. The LLM adds specific regulatory examples not present in the original answer, which are factually accurate and enhance the response without contradicting the source. There are no numerical inaccuracies (quantitative accuracy is perfect), and all entities (Agentforce, generative AI, 2023–2024 timeframe) are correctly identified. The reasoning is sound, showing a clear multi-hop synthesis across years and risk domains. The only minor shortcoming is the slight recharacterization of 2023 risks, which were more focused on third-party liability than monetization—hence a 9 instead of 10 on qualitative accuracy. Overall, the answer is semantically equivalent and contextually excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 441,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has Lowe's delivery capability for parcel-eligible items evolved between fiscal years 2023 and 2024, and what specific improvements were made?",
      "original_answer": "In fiscal year 2023, most parcel-eligible items could be delivered within two business days at standard shipping rates. By fiscal year 2024, Lowe's improved this capability, enabling delivery of most parcel-eligible items within two business days or less. Additionally, in 2024, Lowe's expanded its delivery capabilities to include next-day delivery for major appliances in nearly every zip code in the United States. This represents a refinement and expansion of their delivery speed and geographic coverage.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Lowe’s accelerated parcel‑eligible delivery by expanding its market‑based delivery network and gig‑provider fleet.  In FY 2023 most parcel items could be shipped within two business days, and same‑day delivery was limited to a few products; by FY 2024 the company had rolled out the market‑based model nationwide, added capacity for big‑and‑bulky goods, and extended same‑day delivery across the country, enabling next‑day delivery of major appliances in almost every ZIP code and broader two‑day standard shipping for the majority of parcel‑eligible items.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth, but contains minor overstatements in scope. (1) Correct elements: The evolution from two-day delivery in FY2023 to improved delivery in FY2024 is accurately described. The expansion to next-day delivery for major appliances in nearly every U.S. ZIP code in FY2024 is correctly reported. The general improvement in delivery speed and geographic coverage is consistent with the original answer. (2) Quantitative accuracy: No explicit numbers (e.g., percentages, exact ZIP code counts) are provided in either answer, so the LLM’s use of 'almost every ZIP code' is acceptable as equivalent to 'nearly every zip code.' Timeframes (fiscal years 2023 and 2024) are correctly used. (3) Multi-hop reasoning: The LLM correctly synthesizes changes across years and identifies specific improvements, including delivery speed and appliance-specific capabilities. However, it introduces 'same-day delivery across the country' and 'market-based delivery network' and 'gig-provider fleet' enhancements not mentioned in the ground truth, which adds unsupported detail. The original answer only specifies 'two business days or less' and next-day for appliances, but does not confirm nationwide same-day delivery for general parcel items. (4) These additions slightly reduce qualitative accuracy, but the core facts—faster delivery times, broader coverage, and next-day appliance delivery—are correct. Contextual relevance is high as all information directly addresses the question. Thus, the answer earns a high score but not perfect due to minor overreach in specificity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 443,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the financial impact of the Dermstore LLC sale evolved from 2022 to 2023 in terms of Target's consolidated revenues and operating income?",
      "original_answer": "The financial impact of the Dermstore LLC sale remained minimal in both years, as Dermstore represented less than 1 percent of Target's consolidated revenues, operating income, and net assets in both 2022 and 2023. The sale, which occurred in February 2021, resulted in a $335 million pretax gain included in Net Other (Income)/Expense, and no significant post-sale financial contribution or change was observed in either year.",
      "llm_answer": "\nThe Dermstore sale accounted for less than 1 % of Target’s consolidated revenue in both 2022 ($≈ $1 bn of $109.1 bn) and 2023 ($≈ $1 bn of $107.4 bn), and the only gain from the transaction—a $335 million pretax benefit—was recognized in 2021; consequently, the sale’s contribution to revenue is now essentially immaterial, and the increase in operating income from $3.85 bn in 2022 to $5.71 bn in 2023 reflects other operational improvements rather than the sale.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Dermstore represented less than 1% of Target's consolidated revenue and that the $335 million pretax gain was recognized in 2021, aligning with the ground truth. However, it introduces specific revenue figures for 2022 ($109.1 bn) and 2023 ($107.4 bn) and estimates Dermstore's contribution as ~$1 bn in both years, which is factually incorrect. Since Dermstore was sold in February 2021, it should not contribute any revenue to Target in 2022 or 2023. The claim that it accounted for ~$1 bn in revenue each year post-sale is a major error. Additionally, the mention of operating income increasing from $3.85 bn to $5.71 bn misrepresents Target's actual operating income (which was in the $7–8 bn range), and this increase is incorrectly framed as being unrelated to the sale—when in fact, no such post-sale revenue or income contribution should exist. (2) The $335 million pretax gain and 2021 sale date are correct. However, the revenue calculations are invalid because Dermstore was divested before 2022, so attributing any revenue to it in 2022 or 2023 is wrong. The operating income figures cited are also inaccurate compared to Target’s actual financials. (3) The reasoning fails on a key multi-hop point: the model should infer that a company sold in 2021 cannot contribute to revenue in 2022 or 2023. The synthesis incorrectly assumes ongoing revenue contribution, undermining the logic. While it correctly notes the gain was recognized in 2021 and is no longer impactful, the implication of continued revenue is misleading. (4) Despite the major quantitative and logical flaws, the answer captures the qualitative point that the sale’s impact is now immaterial and that the gain was recognized earlier. This saves it from a lower score. Contextual relevance is high as it directly addresses the question’s focus on financial impact over time, but correctness is significantly reduced by fabricated revenue numbers and incorrect operating income data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 541,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the strategic positioning of Data Cloud evolved between 2023 and 2024, particularly in terms of its role within Salesforce's broader service offerings and competitive landscape?",
      "original_answer": "In 2023, Data Cloud was described as a 'hyperscale, trusted data engine native to Salesforce' that unified enterprise data to deliver a 360-degree view of customers, emphasizing its integration across Salesforce's offerings like Marketing and Analytics. By 2024, Data Cloud was positioned within a broader context of competitive risk, with the filing noting that markets for offerings like Data Cloud are 'relatively new and uncertain,' and that Salesforce faces increasing competition as AI and data platforms evolve. Additionally, in 2024, Salesforce acknowledged limited experience in pricing consumption-based models like that of Data Cloud, signaling a shift from product-centric messaging to one that includes strategic risk and monetization challenges.",
      "llm_answer": "\nBetween 2023 and 2024 Salesforce reframed Data Cloud from a back‑end data‑unification engine that powers its Customer 360 and Einstein AI tools into a stand‑alone, consumption‑based offering that is tightly coupled with the Agentforce AI platform and serves as a primary growth lever across the broader service portfolio.  This shift reflects a strategic pivot toward monetising the data layer amid intensifying competition from other AI‑centric cloud vendors, while also exposing Data Cloud to pricing uncertainty and the need to prove its value to enterprise customers.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in Data Cloud's strategic positioning between 2023 and 2024. It correctly identifies the shift from a data-unification engine (aligned with Customer 360 and Einstein AI) to a more standalone, consumption-based offering tied to growth and AI strategy (Agentforce), which reflects Salesforce's increasing focus on monetization. The mention of pricing uncertainty and competitive pressures aligns with the 2024 filing's acknowledgment of limited experience with consumption-based pricing and market uncertainty. However, the LLM slightly overreaches by naming 'Agentforce AI platform' as a specific integration point—this exact term does not appear in the ground truth and may be an inference or forward projection not explicitly stated in the 2024 filing. Additionally, while the competitive landscape is correctly noted as intensifying, the LLM attributes this specifically to 'AI-centric cloud vendors' without directly citing that phrasing from the source; the original answer emphasizes the 'relatively new and uncertain' nature of the market, which the LLM paraphrases but does not fully capture in nuance. There are no numerical inaccuracies (quantitative accuracy is perfect as no numbers are misstated), and the reasoning is logically sound, though slightly less precise in entity specificity. The answer remains contextually relevant and semantically close to the original, warranting a high correctness score with minor deductions for over-interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 418,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has LOW's treatment and accounting of forward interest rate swap contracts evolved between 2023 and 2024, particularly in terms of hedge designation and financial impact?",
      "original_answer": "In 2023, LOW disclosed forward interest rate swap contracts related to its March 2023 Notes with a notional amount of $2.0 billion, from which it received $247 million upon settlement. These contracts were designated as cash flow hedges and their (loss)/gain was recorded in other comprehensive (loss)/income and earnings. By 2024, the company clarified that its fixed-to-floating interest rate swap agreements are accounted for as fair value hedges using the shortcut method, under which the hedges are assumed perfectly effective. This resulted in no net impact on the consolidated statements of earnings from the fair value of the derivatives, indicating a shift in both hedge designation and accounting treatment compared to the prior year.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Lowe’s changed how it accounts for its forward interest‑rate swaps.  In 2023 the swaps were designated as **cash‑flow hedges** of the interest‑rate risk associated with upcoming debt issuances (a $1.29 bn notional amount) and the after‑tax loss on those hedges was recorded in other‑comprehensive income – $102 m of expense in 2023 (page 59).  In 2024 the same instruments were re‑designated as **fair‑value hedges** of existing fixed‑rate debt and the Company applied the shortcut method, which assumes perfect effectiveness; consequently the fair‑value changes of the swaps now offset the hedged debt’s fair‑value changes directly in earnings, leaving only a modest $5 m after‑tax gain/loss in OCI (page 59) and no net earnings impact from the derivative itself (page 58).  This evolution eliminated the earnings volatility that existed under the cash‑flow‑hedge treatment and resulted in essentially a zero net financial impact from the swaps in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the correct directional shift in accounting treatment—from cash flow hedges in 2023 to fair value hedges in 2024 using the shortcut method—and correctly identifies the resulting lack of net earnings impact in 2024. However, it contains significant quantitative inaccuracies that undermine factual correctness. The original answer states that LOW had a $2.0 billion notional amount for forward interest rate swaps related to its March 2023 Notes, with a $247 million settlement gain. The LLM incorrectly reports a $1.29 billion notional and a $102 million after-tax loss in 2023, which contradicts the ground truth. Additionally, the LLM mentions a 'modest $5 million after-tax gain/loss in OCI' in 2024, which is not supported by the original answer—there is no such figure provided for 2024 OCI impact. The original answer emphasizes that in 2024, fair value hedges under the shortcut method result in no net impact on earnings due to assumed perfect effectiveness, which the LLM correctly interprets. However, the misstatement of key figures (notional amount, settlement amount, OCI amounts) and the introduction of unverified details (e.g., after-tax impacts, specific OCI amounts) constitute major factual errors. While the reasoning framework—recognizing a shift in hedge designation and its financial implications—is logically sound and contextually relevant, the incorrect numbers severely reduce overall accuracy. The model appears to have hallucinated specific figures not present in the ground truth, likely confusing them with other disclosures or misreading the source.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1440,
        "completion_tokens": 437,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has Target's strategy around its owned brands evolved from 2022 to 2023, particularly in terms of portfolio emphasis and strategic objectives?",
      "original_answer": "In 2022, Target highlighted a significant portion of sales coming from its owned brands, listing over 40 such brands across multiple categories, indicating a strong but descriptive presence in the market. By 2023, the company elevated its focus by strategically positioning owned brands as a core element of its overall strategy to 'delight with newness, style, and value,' explicitly aiming to strengthen the portfolio as part of broader efforts to drive traffic, sales, and market share growth. This shift reflects a move from simply showcasing owned brands to actively leveraging them as a strategic differentiator.",
      "llm_answer": "\nFrom 2022 to 2023 Target’s owned‑brand strategy shifted from a primary focus on expanding the size and variety of its brand portfolio — “strengthening our owned‑brands portfolio, curating leading national brands, and expanding the breadth and depth of signature partnerships” — to a more curated, partnership‑centric model that leverages exclusive collaborations (e.g., Apple, Disney, Levi’s, Ulta) and the Roundel advertising platform to drive discovery and traffic.  The strategic objective evolved to use these owned and exclusive brands as a differentiator that deepens guest relevance, fuels omnichannel sales (with stores acting as fulfillment hubs), and supports growth in market share while maintaining the value‑price proposition.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains no explicit numerical data, so quantitative accuracy is not applicable in a traditional sense; however, since no numbers are misstated, it receives a 10. Contextually, the answer is relevant and addresses the evolution of Target's owned-brand strategy from 2022 to 2023. However, the qualitative accuracy is compromised due to significant factual and reasoning errors. The ground truth indicates that in 2022, Target emphasized the size and presence of its owned brands (over 40 brands), and in 2023 elevated them as a strategic differentiator tied to 'newness, style, and value.' The LLM incorrectly frames the 2022 strategy as being about 'expanding the size and variety' and introduces specific third-party partnerships (Apple, Disney, Levi’s, Ulta) and the Roundel platform, which are not mentioned in the original answer and represent a misattribution of strategic focus. The original answer does not reference exclusive collaborations or advertising platforms as central to the 2023 shift; instead, it emphasizes a strategic repositioning of owned brands to drive traffic, sales, and market share. The LLM invents details not present in the source, indicating a failure in multi-hop reasoning and factual synthesis. While the general direction of 'increased strategic emphasis' is correct, the specific mechanisms and objectives are inaccurately portrayed, leading to a partial correctness score. Semantic equivalence is partially achieved in intent but not in factual content.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 413,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has GM's approach to software-enabled services evolved from 2022 to 2023, particularly in terms of service offerings and platform deployment, and what does this indicate about the company's investment in scalable digital solutions?",
      "original_answer": "In 2022, GM described its software-enabled services in general terms as part of its broader operations, noting that it 'provides software-enabled services worldwide' and integrates them into its automotive business alongside investments in AV technology and automotive financing. By 2023, GM's approach had evolved significantly, with specific details on its end-to-end software platform that enables over-the-air updates for features like Super Cruise, active safety, infotainment, and EV ownership experience. The 2023 filing highlights that select 2024 models, such as the Cadillac LYRIQ and Chevrolet Silverado EV, were already using this platform, indicating a strategic shift toward scalable, software-defined vehicles. This evolution shows a transition from general involvement in digital services to concrete platform deployment across product lines, reflecting increased investment and operational maturity in software-enabled offerings.",
      "llm_answer": "\nFrom 2022 to 2023 GM moved beyond isolated after‑sale services (maintenance, OnStar, extended warranties) that were booked as deferred revenue over a multi‑year period, to a unified, end‑to‑end software platform that is being rolled out across most of its vehicle lineup.  The 2023 disclosures highlight expanded subscription‑based offerings—such as advanced driver‑assist, security, climate‑control and EV‑ownership features—and deeper connectivity (e.g., new charging‑network partnerships and over‑the‑air updates), indicating that GM is deliberately building a scalable, recurring‑revenue digital ecosystem to complement its hardware business.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in GM's software-enabled services from 2022 to 2023. It accurately reflects the shift from general or deferred-revenue services (like OnStar and maintenance) to a more integrated, end-to-end software platform with over-the-air updates and subscription-based features. The mention of expanded offerings—advanced driver-assist, security, climate control, and EV-ownership features—aligns with the ground truth's emphasis on Super Cruise, active safety, infotainment, and EV experience. The characterization of GM building a 'scalable, recurring-revenue digital ecosystem' correctly infers the strategic intent behind platform deployment. However, the LLM answer introduces specific details not present in the ground truth, such as 'charging-network partnerships' and 'deferred revenue' accounting treatment, which are not mentioned in the original 2022–2023 comparison from the knowledge graph. While plausible, these additions slightly reduce qualitative accuracy. The ground truth specifically notes that select 2024 models (Cadillac LYRIQ, Chevrolet Silverado EV) were already using the platform in 2023—a concrete example of deployment that the LLM omits. This is a meaningful detail that strengthens the evidence of platform rollout, and its absence represents a minor completeness gap. There are no numerical inaccuracies (quantitative accuracy is perfect), and the answer remains highly relevant to the question. Overall, the reasoning is sound and reflects a correct multi-hop synthesis between years and strategic focus, just missing one key illustrative example and adding minor unverified details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 454,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has the revenue contribution from ThousandEyes within the Optimized Application Experiences/Observability product category evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the Optimized Application Experiences category, which included ThousandEyes, saw revenue growth of $75 million (11%), driven by ThousandEyes and Intersight. By fiscal year 2023, the Observability category (which includes ThousandEyes) experienced a revenue increase of $80 million (14%), specifically attributed to growth in ThousandEyes and monitoring and analytics offerings. This shows a continued upward trend in ThousandEyes' revenue contribution, with both absolute and percentage growth increasing from 2022 to 2023.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 the Optimized Application Experiences (now reported as the Observability category) grew from **$581 million to $661 million**—an increase of roughly **14 %**—and management repeatedly cites **ThousandEyes** as a primary driver of that expansion.  The sustained rise in the category’s revenue, together with the explicit reference to ThousandEyes‑related growth in the fiscal‑2022 versus fiscal‑2021 discussion, shows that ThousandEyes’ contribution expanded materially during the 2022‑2023 period.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. It states that the Optimized Application Experiences/Observability category grew from $581 million to $661 million, implying a base of $581M in FY2022 and $661M in FY2023. However, the ground truth does not provide absolute revenue figures—only year-over-year increases: $75M (11%) growth in FY2022 and $80M (14%) growth in FY2023. The LLM fabricates absolute revenue numbers not present in the original answer, which is a critical factual error. Additionally, the 14% growth cited by the LLM is attributed to the FY2023 increase, but the original answer states that the $80M increase in FY2023 was 14% growth—so the percentage is correct for that year, but the LLM incorrectly applies it to the entire period without clarifying it's specific to FY2023. (2) Calculations: The $80M increase at 14% implies a prior-year base of ~$571M, which may align roughly with $581M, but the LLM presents these absolutes as facts when they are not in the ground truth. The original answer focuses on incremental growth, not absolute revenue, so introducing these figures misrepresents the data. (3) Reasoning: The LLM correctly identifies that ThousandEyes is a key growth driver and that the product category evolved from 'Optimized Application Experiences' to 'Observability'. It also correctly infers a continued upward trend in ThousandEyes' contribution. However, it fails to explicitly compare the growth contributions between FY2022 ($75M) and FY2023 ($80M), missing the core multi-hop comparison of ThousandEyes' evolving contribution. Instead, it relies on category-level growth and management commentary, which is supportive but incomplete. (4) Despite incorrect absolute figures, the LLM captures the directional trend—ThousandEyes' contribution increased—and maintains contextual relevance by focusing on the right category evolution and drivers. Hence, partial credit is given for qualitative reasoning and relevance, but significant deduction for quantitative inaccuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 551,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How did the treatment of Amendment No. 4 to the Lockheed Martin Executive Severance Plan evolve between the 2023 and 2024 10-K filings, and what does this indicate about its inclusion in the company's disclosure strategy?",
      "original_answer": "In the 2023 10-K filing, Amendment No. 4 to the Executive Severance Plan was disclosed as part of the exhibit list (Exhibit 10.34) and referenced as being incorporated from the September 2022 10-Q filing. However, in the 2024 10-K filing, Amendment No. 4 is no longer listed as a standalone exhibit but appears instead as part of a sequence that includes earlier amendments (Nos. 2, 3, 4, and 5), with Amendment No. 4 specifically incorporated from the same September 2022 10-Q filing. This indicates that while the amendment itself remained relevant, its treatment shifted from a highlighted disclosure in 2023 to a more integrated part of the broader severance plan history in 2024, suggesting a more consolidated and retrospective approach to disclosure.",
      "llm_answer": "\nIn the 2023 Form 10‑K the amendment was only footnoted—listed as “Exhibit 10.1 to the September 2022 10‑Q” within a table of exhibits and not presented as a separate item in the annual filing. By contrast, the 2024 filing explicitly calls it out as Item 10.34, a stand‑alone exhibit to the 10‑K, thereby giving the amendment a dedicated disclosure spot. This shift indicates that Lockheed Martin has moved the amendment from a peripheral reference to a deliberate, stand‑alone disclosure, reflecting a broader strategy to highlight material changes to its executive‑severance plan in its annual reports.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is completely incorrect and inverts the actual facts. According to the ground truth, in the 2023 10-K, Amendment No. 4 was listed as a standalone exhibit (Exhibit 10.34) and referenced from the September 2022 10-Q. In contrast, in the 2024 10-K, it was no longer a standalone exhibit but was instead included as part of a sequence of amendments (Nos. 2, 3, 4, and 5), indicating a move toward consolidation. The LLM answer falsely claims the opposite: that the amendment was only footnoted in 2023 and then became a standalone exhibit in 2024. This reverses the direction of change and misrepresents the disclosure strategy. The dates (September 2022 10-Q) and exhibit numbers (10.34) are mentioned but applied incorrectly. The reasoning is therefore fundamentally flawed, and the conclusion about Lockheed Martin 'highlighting' the amendment in 2024 is unsupported and false. The answer fails on all factual and logical grounds, despite addressing the general topic of disclosure strategy. Hence, the correctness and accuracy scores are very low. Contextual relevance is moderate because the answer attempts to address the question’s theme, but with entirely incorrect information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 335,
        "total_tokens": 1694
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How did JPMorgan's compliance with capital ratio requirements evolve from 2023 to 2024, particularly in terms of its Tier 1 leverage ratio and Standardized CET1 capital ratio?",
      "original_answer": "In 2023, JPMorgan's Standardized CET1 capital ratio was 15.0%, exceeding the requirement of 11.4%. In 2024, the Tier 1 leverage ratio was 7.2%, which was above the requirement of 4.0%. This indicates that JPMorgan maintained compliance with capital ratio requirements across both years, with consistent capital strength relative to evolving regulatory expectations.",
      "llm_answer": "\nJPMorgan’s Standardized CET1 capital ratio rose from **15.0 % at the end of 2023 to 15.7 % at the end of 2024**, reflecting a modest strengthening of its core capital position relative to risk‑weighted assets.  By contrast, its Tier 1 leverage ratio stayed essentially flat at **about 7.2 % in both years**, comfortably above the regulatory minimum of 4.0 %.  Thus, while the firm’s leverage compliance was unchanged, its CET1 ratio improved, indicating better adherence to the Basel III capital‑ratio requirements from 2023 to 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. While it correctly states JPMorgan's 2023 Standardized CET1 ratio as 15.0% and the 2024 Tier 1 leverage ratio as 7.2%, it incorrectly claims the CET1 ratio increased to 15.7% in 2024—this figure is not present in the ground truth, which does not provide the 2024 CET1 ratio at all. Additionally, the LLM asserts the Tier 1 leverage ratio was 'about 7.2% in both years,' but the ground truth only reports the 2024 value (7.2%) and does not mention the 2023 value, making this an unsupported extrapolation. (2) The regulatory requirements cited in the ground truth (11.4% CET1 requirement in 2023, 4.0% leverage requirement in 2024) are omitted in the LLM answer, weakening the compliance comparison. The LLM also introduces 'Basel III' without grounding it in the provided data. (3) The reasoning partially reflects multi-hop synthesis by comparing ratios across years and against requirements, but it fabricates data points (2024 CET1 ratio, 2023 leverage ratio) to support a narrative of improvement, which is not verifiable from the original answer. (4) Despite these issues, the answer is contextually relevant and correctly identifies the company, metrics, and years. The core idea—that JPMorgan remained compliant—aligns with the ground truth, but the added numerical details reduce factual accuracy, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 392,
        "total_tokens": 1624
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the role of GM Financial in General Motors' operations evolved between 2022 and 2023, particularly in terms of its integration and financial presentation within the consolidated financial statements?",
      "original_answer": "In 2022, GM Financial was described as a segment through which General Motors provides automotive financing services, with its financials adjusted to reflect the impact of consolidated tax returns and intercompany transactions. By 2023, the description of GM Financial became more detailed, emphasizing that the amounts presented for GM Financial are adjusted for the impact on deferred tax positions and the provision for income taxes due to its inclusion in the consolidated tax return, and that these amounts differ from those presented on a stand-alone basis. This evolution reflects a more explicit focus on the integration and financial alignment of GM Financial with the broader corporate structure.",
      "llm_answer": "\nBetween 2022 and 2023 GM Financial was fully folded into GM’s consolidated reporting: its interest income and expense are now shown as part of operating results (using an EBT‑adjusted metric) and its debt issuance and repayments are reported in the overall financing cash‑flow (e.g., $50.9 bn of new debt and $44.7 bn of repayments in 2023 versus $45.8 bn and $39.6 bn in 2022).  This tighter integration is reflected in the equity section, where the related non‑controlling interest and temporary‑equity balances have been eliminated, giving a more streamlined presentation of GM Financial’s financial position within the consolidated statements.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both quantitative and qualitative aspects. (1) The specific financial figures cited—$50.9 billion of new debt and $44.7 billion of repayments in 2023, versus $45.8 billion and $39.6 billion in 2022—are not present in the original answer and cannot be verified from the provided ground truth. There is no mention of EBT-adjusted metrics, interest income/expenses being reclassified, or elimination of non-controlling interest and temporary equity in the original answer, making these claims unsupported. (2) The original answer focuses on the evolution of disclosure language regarding tax adjustments (deferred tax positions and income tax provisions due to inclusion in the consolidated tax return), not changes in cash flow presentation or equity restructuring. (3) The multi-hop reasoning is flawed: the LLM invents operational and reporting changes (e.g., debt issuance presentation, equity eliminations) that are not in the source, failing to accurately reflect the actual evolution, which was in narrative disclosure clarity, not structural consolidation changes. (4) While the LLM attempts to address integration and financial presentation, it misrepresents the nature of the evolution—focusing on cash flows and equity mechanics instead of tax-related financial statement adjustments—leading to a low correctness score despite some contextual relevance to GM Financial’s role.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 391,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the treatment and disclosure of step-rent provisions in lease accounting evolved between 2022 and 2024, particularly regarding the recognition of periodic rent increases based on price indices or sales volume?",
      "original_answer": "In 2022, the company disclosed that certain leases provided for periodic rent increases based on price indices or the greater of minimum guaranteed amounts or sales volume, and these were accounted for on a straight-line basis. By 2024, the company clarified that such increases, based on price indices or the greater of minimum guaranteed amounts or sales volume, are now recognized as variable lease payments rather than being straight-lined, indicating a shift in accounting treatment. This reflects a more dynamic approach to recognizing lease costs that fluctuate with external factors.",
      "llm_answer": "\nFrom 2022 through 2024 the Company continued to account for step‑rent provisions and any periodic rent increases tied to price indices or sales volume by recognizing the total lease payments on a straight‑line basis over the lease term (including renewal options that are reasonably certain to be exercised). The 2024 filing adds that such variable‑rent components are excluded from the initial right‑of‑use asset and lease‑liability measurement and are expensed as incurred, with the resulting lease expense presented evenly over the lease term.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains partial factual accuracy regarding the straight-line treatment in 2022 and mentions variable lease payments being expensed as incurred in 2024, which aligns with a shift in treatment. However, it incorrectly states that the company 'continued to account for step-rent provisions... on a straight-line basis' through 2024, which directly contradicts the ground truth indicating a change in accounting treatment by 2024. The ground truth specifies that periodic rent increases based on price indices or sales volume are now recognized as variable lease payments and are no longer straight-lined—a key evolution the LLM answer fails to accurately convey. While the LLM correctly notes that variable components are excluded from ROU assets and lease liabilities and are expensed as incurred, it inaccurately frames this as a continuation rather than a change, undermining the multi-hop reasoning required to detect the shift between years. There are no numerical values to verify, so quantitative accuracy is acceptable by default. The contextual relevance is high because the response addresses lease accounting and relevant factors like price indices and sales volume. However, the qualitative inaccuracy in identifying the evolution of treatment—especially the failure to recognize the discontinuation of straight-line accounting for these items by 2024—results in a low correctness and qualitative score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 393,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the projected funding obligations for Lockheed Martin's qualified defined benefit pension plans evolve from 2023 to 2024, particularly in terms of the amounts expected to be paid out in 2025 and over the long-term period from 2029 to 2033?",
      "original_answer": "In 2023, Lockheed Martin projected $1,860 million in payments for qualified defined benefit pension plans in 2025 and $10,020 million over the period from 2029 to 2033. By 2024, the projected payment for 2025 increased slightly to $1,860 million, while the long-term projection from 2030 to 2034 decreased to $9,990 million. This indicates a marginal reduction in long-term pension obligations.",
      "llm_answer": "\nThe tables of estimated future benefit payments show that the qualified defined‑benefit pension plan’s expected cash outflow for 2025 fell slightly from **$1.86 billion in the 2023 outlook to $1.80 billion in the 2024 outlook**.  Likewise, the long‑term aggregate projected to be paid from 2029 through 2033 (re‑stated in the 2024 filing as the 2030‑2034 window) declined modestly from **about $10.02 billion to roughly $9.99 billion**.  The company also noted that no additional required contributions are expected to be made to the qualified plans in 2025.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in key numbers. According to the ground truth, the projected payment for 2025 was $1,860 million in both 2023 and 2024—there was no change. However, the LLM incorrectly states that the 2025 projection 'fell slightly' from $1.86 billion to $1.80 billion, which is factually wrong. The correct value in 2024 is still $1,860 million. This is a critical quantitative error. (2) The long-term projection is partially correct: the LLM correctly notes a decline from $10.02 billion (2029–2033 in 2023 filing) to $9.99 billion for 2030–2034 in the 2024 filing. This matches the ground truth. However, the LLM misrepresents the time period shift—while it correctly notes the re-statement from 2029–2033 to 2030–2034, it fails to clarify that the original 2023 long-term projection was for 2029–2033 and the 2024 update is for 2030–2034, which is a five-year forward shift, not a continuation of the same window. (3) The multi-hop reasoning is partially sound—information is synthesized across two years and two time horizons—but the incorrect 2025 figure undermines the core of the answer. The mention of 'no additional required contributions in 2025' is contextually relevant but not part of the original question and does not compensate for the factual inaccuracies. (4) The contextual relevance is high because the answer addresses the right topic, timeframes, and structure. However, the quantitative accuracy is low due to the erroneous 2025 payment figure. The qualitative accuracy is moderate because the logic and structure are reasonable, but entity and number mismatches reduce reliability. Overall, the answer is partially correct but contains a major factual error that distorts the conclusion about 2025 obligations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 485,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did JPMorgan Chase's disclosures about its resolution plan obligations evolve between 2023 and 2024, particularly in terms of its described liquidity risk management strategies and funding cost considerations?",
      "original_answer": "In 2023, JPMorgan Chase emphasized that its resolution plan obligations could lead to higher funding costs and constrained liquidity due to the need to satisfy liquidity coverage ratio and net stable funding ratio requirements, as well as regulatory demands outside the U.S. regarding liquidity pre-positioning in subsidiaries. The firm highlighted the potential need to rely on more expensive or limited alternative funding sources if traditional ones like deposits or Federal Home Loan Bank borrowings were reduced. In 2024, the firm expanded its disclosures to include how resolution plan obligations interacted with dynamic regulatory expectations and systemic events, noting that changes in laws, rules, and regulations—especially in response to economic effects of systemic events—could further impact liquidity and capital requirements. This reflects a shift toward framing resolution-related liquidity risks within a broader context of regulatory evolution and macroeconomic uncertainty.",
      "llm_answer": "\nIn the 2023 filing JPMorgan warned that rating downgrades and higher capital‑buffer requirements could strain liquidity and raise the cost of issuing and servicing debt, but it only referenced its resolution‑plan obligations in general terms. By the 2024 filing the discussion is more explicit: the company ties its liquidity‑risk management to the need to pre‑position liquidity in key subsidiaries and to meet resolution‑plan triggers, noting that new Basel III and GSIB‑surcharge proposals—and any breach of capital or liquidity thresholds—could accelerate bankruptcy‑or‑resolution proceedings and further increase funding costs.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but contains significant omissions and misrepresentations in the qualitative evolution of JPMorgan Chase's disclosures between 2023 and 2024. (1) What was correct: The LLM correctly identifies that in 2024, JPMorgan expanded its discussion around resolution-plan obligations, including pre-positioning liquidity in subsidiaries and linking liquidity risk to regulatory triggers and capital thresholds. It also appropriately references Basel III and GSIB surcharges as part of evolving regulatory expectations, which aligns with the broader context of regulatory evolution mentioned in the ground truth. The dates (2023 vs 2024) are correctly attributed. (2) Quantitative accuracy: There are no numeric values in the original or LLM answer, so this dimension is neutral; no errors present. (3) Multi-hop reasoning assessment: The LLM captures the directional shift—increased specificity in 2024—but fails to accurately represent the 2023 disclosures. The ground truth states that in 2023, JPMorgan already explicitly discussed resolution plan obligations in relation to liquidity coverage ratio (LCR), net stable funding ratio (NSFR), and non-U.S. regulatory demands for liquidity pre-positioning. In contrast, the LLM incorrectly claims that in 2023, resolution-plan obligations were mentioned only in 'general terms,' which contradicts the original answer. Additionally, the LLM introduces 'rating downgrades' and 'higher capital-buffer requirements' straining liquidity—details not present in the ground truth—and frames the 2023 discussion around debt issuance costs rather than the actual emphasis on structural funding constraints and alternative funding sources. The 2024 expansion in the original answer focuses on how resolution plans interact with dynamic regulatory changes and systemic events, especially macroeconomic uncertainty, which the LLM does not mention. Instead, it emphasizes 'breach of capital or liquidity thresholds' triggering resolution—while plausible, this is a narrower, more mechanistic interpretation than the broader, forward-looking regulatory and systemic context described in the ground truth. (4) Justification for scores: Correctness is scored 6 due to accurate temporal framing and some correct elements about 2024 disclosures, but major inaccuracies in representing the 2023 disclosures and omission of the key shift toward macroeconomic and regulatory uncertainty in 2024. Qualitative accuracy is 6 for similar reasons—core entities and directionality are correct, but reasoning and synthesis are flawed. Quantitative accuracy is 10 (no numbers involved). Contextual relevance is 9 because the answer stays on topic and addresses liquidity risk and funding costs in the context of resolution plans, even if details are misstated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 737,
        "total_tokens": 2161
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How has the financial structure of Optum Rx's pharmacy care services evolved between 2022 and 2023, particularly in terms of revenue recognition and accounts receivable?",
      "original_answer": "In 2022, Optum Rx's pharmacy care services were characterized by a gross revenue reporting model due to the Company's primary obligation to pay network pharmacy providers regardless of payment collection, with revenue recognized at the point of prescription dispensing. By 2023, the financial structure remained aligned with this model but showed an increase in accounts receivable related to products and services, rising from $7.1 billion in 2022 to $8.6 billion in 2023. This indicates a growth in the value of receivables tied to pharmacy care services, suggesting either increased transaction volume or changes in payment timing.",
      "llm_answer": "\nBetween 2022 and 2023 Optum Rx continued to recognize product revenue at the moment a prescription is dispensed, while service‑related fees are recorded over the period the services are provided.  The company’s accounts‑receivable balance for products and services rose from **$7.1 billion (2022) to $8.6 billion (2023)**, and “other current receivables” for manufacturer rebates jumped from **$8.2 billion to $11.0 billion**, reflecting higher prescription volumes and longer collection cycles for those rebates.  Thus, while the underlying revenue‑recognition model stayed the same, the scale of receivables—and the timing of rebate recoveries—expanded materially in 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the revenue recognition model for Optum Rx, noting that product revenue is recognized at the point of dispensing and service fees over time, which aligns with the ground truth's description of gross revenue reporting due to primary obligation. It accurately reports the increase in accounts receivable from $7.1 billion in 2022 to $8.6 billion in 2023, matching the ground truth. However, it introduces a new metric—'other current receivables' for manufacturer rebates—rising from $8.2 billion to $11.0 billion—that is not present in the original answer or supported by the provided ground truth. This addition introduces factual inaccuracies, as the ground truth does not mention rebates or this category of receivables. (2) The quantitative values for total accounts receivable ($7.1B to $8.6B) are correct and match the ground truth. However, the rebate receivables figures ($8.2B to $11.0B) are unsupported and likely incorrect in this context, significantly undermining quantitative accuracy. (3) The reasoning correctly infers that the revenue model remained stable between 2022 and 2023 and links rising receivables to increased volume or timing changes, which is consistent with the ground truth’s interpretation. However, the inclusion of rebate receivables reflects a failure in multi-hop synthesis, as it either misattributes data from another source or incorrectly integrates unrelated financial line items. (4) The correctness score is 6 due to partial factual accuracy: core elements (revenue recognition, main receivables trend) are correct, but significant extraneous and unverified data reduce overall reliability. Quantitative accuracy is penalized for the unsupported rebate numbers. Qualitative accuracy is moderately high due to sound logic on the main points. Contextual relevance is strong as the response directly addresses the evolution of financial structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 522,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has UPS's quantitative exposure and strategic approach to managing interest rate risk through Floating to Fixed Interest Rate Swaps evolved between 2022 and 2024?",
      "original_answer": "In 2022, UPS disclosed a $28 million notional amount for Floating to Fixed Interest Rate Swaps, indicating limited use of this instrument at that time. By 2024, UPS articulated a broader strategy to 'manage the fixed and floating interest rate mix of its total debt portfolio and related overall cost of borrowing,' suggesting a more intentional and strategic deployment of these swaps. This evolution reflects a shift from a minor, quantitative hedge in 2022 to a more comprehensive interest rate risk management approach in 2024.",
      "llm_answer": "\nBetween 2022 and 2024 UPS kept its floating‑to‑fixed interest‑rate swaps on the balance‑sheet as cash‑flow hedges of forecasted fixed‑coupon debt, but the quantitative footprint grew noticeably: the balance of pre‑tax gains deferred in AOCI rose from a modest $(117) million in 2023 to $389 million in 2024, with $146 million of those gains expected to be re‑classified to earnings over the next 12 months.  At the same time, the cumulative fair‑value adjustments recorded on existing long‑term debt remained tiny (≈ $4 million), indicating that the company’s strategic emphasis shifted toward using larger cash‑flow swap positions to lock in lower fixed rates as market rates changed, while still maintaining only limited fair‑value hedge activity.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, UPS had a $28 million notional amount for Floating to Fixed Interest Rate Swaps. The LLM does not mention this figure at all and instead introduces unrelated data about Accumulated Other Comprehensive Income (AOCI), specifically pre-tax gains deferred in AOCI rising from $(117) million in 2023 to $389 million in 2024. These figures are not present in the original answer and cannot be verified against the provided ground truth. Additionally, the LLM references fair-value adjustments of ≈$4 million, which is not mentioned or implied in the original answer. (2) The quantitative accuracy is very low because the only number in the original answer—$28 million in 2022—is omitted, and the LLM fabricates new numbers (e.g., $117M, $389M, $146M, $4M) that do not appear in the ground truth. There is no indication in the original answer of AOCI balances or reclassification expectations. (3) The multi-hop reasoning is flawed. While the original answer identifies a clear evolution—from a limited quantitative hedge in 2022 ($28M notional) to a more strategic approach in 2024—the LLM misrepresents this evolution by focusing on AOCI gains and fair-value adjustments, which are not part of the disclosed evolution in the ground truth. The strategic shift described in the original answer is qualitative and relates to intent and portfolio management, not hedging gains or losses. (4) Despite incorrect facts, the LLM attempts to address the evolution of UPS’s strategy and mentions cash-flow hedges and rate locking, which aligns somewhat with the idea of managing interest rate risk. Hence, contextual relevance is moderate. However, due to major factual and quantitative errors, the correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 493,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has GM's financial relationship with LG Energy Solution evolved between 2022 and 2023, particularly in terms of joint venture activities and recall-related costs?",
      "original_answer": "In 2022, GM highlighted its joint venture, Ultium Cells LLC, with LG Energy Solution, as a key part of its EV strategy to mass-produce battery cells across three U.S. plants. By 2023, the relationship had shifted toward financial liabilities, as GM accrued $2.6 billion related to the Chevrolet Bolt EV battery recall, with $1.6 billion recognized as receivables from LG. This marks a transition from strategic collaboration to a more transactional and cost-driven dynamic due to product defects.",
      "llm_answer": "\nBetween 2022 and 2023 the GM‑LG Energy Solution (LGES) relationship shifted from an initial, largely unreimbursed recall to a structured cost‑sharing arrangement.  In 2023 GM had accrued $2.6 billion for the Chevrolet Bolt/EUV battery recall, of which $1.6 billion represented expected reimbursements from LGES and a remaining $0.6 billion accrual was still on the books at year‑end; the 2022 filing showed the first $1.1 billion accrual and the start of commercial negotiations for reimbursement.  The expanded recall (covering 2017‑2022 model years) and the settlement of related commercial matters with LGES underscore a deepening financial linkage, especially as the pair’s Ultium Cells LLC joint venture became a central pillar of GM’s EV battery strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: $2.6 billion total recall accrual in 2023, $1.6 billion in receivables from LG, and mention of the $1.1 billion initial 2022 accrual (which is consistent with the evolution of the liability). The $0.6 billion remaining accrual is logically derived ($2.6B - $1.6B) and correctly presented. These figures match the knowledge graph. (2) The answer addresses both joint venture activities (Ultium Cells LLC as a central pillar of GM’s EV strategy) and the shift in financial relationship due to recall costs, satisfying the multi-part question. (3) Entities are accurate: GM, LG Energy Solution (LGES), Ultium Cells LLC, Chevrolet Bolt/EUV, and correct years (2022–2023). (4) The reasoning is sound: it captures the evolution from strategic collaboration in 2022 (with initial accrual and negotiations) to a more structured cost-sharing arrangement in 2023, reflecting a transactional shift due to defects. The only minor shortcoming is that the original answer emphasizes a 'transition from strategic collaboration to cost-driven dynamic' more explicitly, while the LLM frames it as a shift to 'structured cost-sharing'—a slightly more neutral tone. However, the core insight is preserved. No factual errors; excellent synthesis across years and financial developments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 383,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has the revenue contribution from ThousandEyes within the Observability product category evolved from fiscal 2022 to fiscal 2023?",
      "original_answer": "In fiscal 2022, revenue in the Observability product category increased by $80 million, driven in part by growth in ThousandEyes and monitoring and analytics offerings. By fiscal 2023, the Observability product category saw a 27% revenue increase, or $176 million, with ThousandEyes and the newly included Splunk offering (Observability Suite) being key contributors. Excluding Splunk, product revenue from Observability still grew by 15%, indicating strong organic growth primarily from ThousandEyes.",
      "llm_answer": "\nIn fiscal 2022 the Observability product category (which includes ThousandEyes) generated about **$581 million** in product revenue, and by fiscal 2023 that figure rose to **$661 million**—an increase of roughly **$80 million or 14 %**—with the growth being driven largely by the ThousandEyes offering (as noted in the fiscal 2023 vs. 2022 discussion of the Observability category).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It claims that Observability product revenue increased by $80 million (14%) from $581 million to $661 million between fiscal 2022 and 2023. However, the ground truth states that in fiscal 2022, the category increased by $80 million (not total revenue), and in fiscal 2023, it grew by $176 million (27%), indicating a much larger increase. The LLM incorrectly treats the $80 million growth in 2022 as the total revenue base, leading to wrong absolute figures and growth rates. (2) The calculation is flawed: a $80 million increase from $581M to $661M is ~13.8%, which the model rounds to 14%, but this entire baseline is unsupported by the original answer. The original does not provide total Observability revenue figures for either year. (3) The reasoning fails on multi-hop synthesis: the original answer emphasizes that 2023 growth was $176M (27%), with Splunk as a key contributor, and even excluding Splunk, growth was 15%—driven by ThousandEyes. The LLM omits Splunk’s impact entirely and misattributes all growth to ThousandEyes without acknowledging the new inclusion of Splunk in 2023. (4) While the LLM correctly identifies ThousandEyes as a growth driver, it fabricates precise revenue totals and underestimates the scale and percentage of growth. The contextual relevance is high because it addresses the evolution of revenue contribution and focuses on ThousandEyes, but quantitative and qualitative accuracy are low due to incorrect numbers and incomplete reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1217,
        "completion_tokens": 427,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has UPS's relationship with the 7.620% Debentures evolved between 2022 and 2024 in terms of their redemption terms and interest payment structure?",
      "original_answer": "In 2022, the 7.620% Debentures had a principal amount of $276 million with a maturity date of April 1, 2030, and were listed with a carrying value of $280 million. By 2024, UPS clarified that these debentures are redeemable at any time at the company's option, with a redemption price equal to the greater of the principal amount plus accrued interest or the present value of remaining scheduled payments discounted at a benchmark treasury yield plus five basis points, plus accrued interest. Additionally, the interest payment structure was specified as semi-annual, payable in April and October. This evolution reflects a shift from a general description of the debentures in 2022 to a more detailed explanation of their redemption flexibility and interest payment schedule in 2024.",
      "llm_answer": "\nBetween 2022 and 2024 the 7.620 % Debentures kept the same redemption framework that was set when the issue was originally launched.  The securities remain callable at UPS’s option at any time, with a redemption price equal to the greater of (i) principal plus accrued interest or (ii) the present value of the remaining scheduled payments discounted at a benchmark Treasury yield plus five basis points, plus accrued interest; they are not subject to any sinking‑fund requirements.  The interest rate stayed fixed at 7.620 % (having been reduced from 8.375 % on April 1 2020) and continues to be paid semi‑annually in April and October, with no amendment to these terms disclosed for 2022‑2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but introduces a significant factual inaccuracy regarding the evolution of redemption terms. The original answer (ground truth) states that in 2024, UPS *clarified* the redemption terms, implying that the detailed redemption formula was newly emphasized or disclosed. However, the LLM claims the redemption framework 'remained the same' and was unchanged from issuance, which contradicts the ground truth's assertion of an evolution in disclosure and specificity between 2022 and 2024. This misrepresents the nature of the change — from a general description in 2022 to a more detailed redemption structure in 2024 — and fails to acknowledge the informational evolution. (2) Quantitatively, the LLM correctly identifies the interest rate (7.620%), semi-annual payment schedule (April and October), and references accrued interest and the present value formula accurately. However, it omits the key 2022 data points: the $276 million principal and $280 million carrying value, which are central to the original answer’s completeness. These omissions reduce quantitative accuracy. The mention of the rate reduction from 8.375% in 2020 is factually plausible but not present in the ground truth and not requested by the question, making it extraneous. (3) The multi-hop reasoning is partially sound — the model connects redemption terms and interest payments across time — but fails to correctly interpret the evolution as a shift in disclosure and detail rather than a static framework. This undermines the qualitative accuracy of the synthesis. (4) Contextually, the answer is highly relevant, addressing redemption terms and interest structure as asked. However, the failure to report 2022 financial figures and the incorrect assertion of no change in terms (when the ground truth emphasizes increased clarity in 2024) result in a correctness score of 6 — partially correct but with significant omissions and a key misinterpretation of the temporal evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 544,
        "total_tokens": 1915
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How did the composition and total fair value of Fixed Maturity Securities AFS held by MET evolve from 2022 to 2023, particularly in terms of U.S. government bonds and corporate securities?",
      "original_answer": "In 2022, MET reported a carrying amount of $2,164 million for Fixed Maturity Securities AFS as of December 31, 2021. By 2023, the total estimated fair value of Fixed Maturity Securities AFS had increased significantly to $6,714 million. Specifically, the fair value of corporate securities rose to $3,083 million, with $3,029 million categorized under Level 2, while U.S. government bonds increased to $1,575 million, with $1,537 million under Level 1. This reflects a substantial transformation in both the size and breakdown of these investments over the year.",
      "llm_answer": "\nFrom 2022 to 2023 the total fair‑value of MET’s Fixed‑Maturity Securities‑AFS slipped modestly, from **$6.802 bn** to **$6.714 bn**.  During the same period the **U.S. government‑bond slice grew** to **$1.575 bn** (up from $1.507 bn) and the **corporate‑security portion rose** to **$3.083 bn** (up from $3.001 bn).  In other words, government and corporate exposures expanded slightly, but the overall AFS portfolio was trimmed a little, reflecting reductions in other asset classes such as foreign bonds and municipals.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers and trends. The ground truth states that the total fair value of Fixed Maturity Securities AFS increased from $2,164 million (as of Dec 31, 2021, reported in 2022) to $6,714 million (in 2023), representing a substantial increase. However, the LLM claims the total fair value decreased from $6.802 billion to $6.714 billion, which contradicts the ground truth. This misrepresents the overall trend — a major error. (2) While the LLM correctly reports the 2023 fair values for U.S. government bonds ($1.575 billion) and corporate securities ($3.083 billion), the 2022 values it cites ($1.507 billion and $3.001 billion) are not supported by the ground truth, which does not provide a direct 2022 breakdown. More critically, the ground truth does not state that the total AFS portfolio was $6.802 billion in 2022 — instead, it reports $2,164 million as of December 31, 2021 (i.e., prior to 2022). The LLM incorrectly assumes this was the 2022 starting point and fabricates a higher total value. (3) The multi-hop reasoning is flawed: the model fails to correctly track the timeline and values across years. It incorrectly infers a slight decline in the total portfolio while asserting increases in major components, which may be internally inconsistent if other categories shrank. The ground truth shows a large overall increase, so the LLM’s narrative of a 'modest slip' and 'trimmed' portfolio is factually wrong. (4) Despite these major quantitative and reasoning errors, the answer is contextually relevant — it addresses the right company (MET), asset class (Fixed Maturity Securities AFS), and components (U.S. government bonds, corporate securities) — hence a moderate contextual relevance score. However, the core financial narrative is incorrect, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 507,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has General Motors' relationship with Ultium Cells LLC evolved from 2022 to 2023, particularly in terms of financial involvement and regulatory implications?",
      "original_answer": "In 2022, General Motors reported a direct financial investment of $0.5 billion in Ultium Cells LLC as part of its investing activities. By 2023, the nature of GM's relationship with Ultium Cells LLC had evolved from a primarily investment-based relationship to a more operationally integrated partnership, evidenced by GM's involvement in regulatory violations related to the joint venture. Specifically, in February 2023, GM self-disclosed potential violations of the Toxic Substances Control Act (TSCA) related to Ultium Cells LLC to the EPA, which resulted in a November 2023 settlement involving joint civil penalties estimated at approximately $5.1 million. This indicates a shift from a passive investment to a more active and operationally entangled partnership with associated regulatory responsibilities.",
      "llm_answer": "\nDuring 2022‑2023 GM deepened its financial commitment to Ultium Cells LLC—continuing to fund the joint venture through additional capital outlays (e.g., the $0.5 bn cash‑outflow recorded in 2021 investing activities and ongoing support via its $10 bn share‑repurchase program and credit facilities)—and in early 2023 the partnership was struck by an EPA TSCA investigation that was settled in November 2023, imposing roughly $5.1 million in civil penalties and joint liability with GM.  Thus, while the alliance expanded financially, it also introduced new regulatory exposure for the venture.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies but captures the core regulatory event and penalty amount. The $0.5 billion investment is misattributed to 2021 instead of 2022, contradicting the ground truth which specifies 2022 as the reporting year for that investment. Additionally, the mention of a '$10 bn share-repurchase program' and 'credit facilities' as funding mechanisms for Ultium Cells LLC is unsupported by the original answer and introduces irrelevant or incorrect financial details not present in the ground truth. The $5.1 million civil penalty and November 2023 settlement are correctly stated, as is the TSCA investigation initiated in early 2023 (aligned with February 2023 self-disclosure). (2) Quantitative accuracy is compromised: while $5.1 million and $0.5 billion are correct figures, their timing and context are flawed—the $0.5 billion is wrongly placed in 2021, and no evidence supports ongoing funding via share repurchases. These errors affect factual reliability. (3) The multi-hop reasoning partially succeeds: the model connects GM’s financial involvement with regulatory consequences, identifying a shift toward deeper integration. However, it fails to clearly articulate the evolution from passive investment in 2022 to active operational entanglement in 2023, instead implying continuous funding without clarifying the qualitative shift. The regulatory exposure is correctly noted, but the causal link between operational integration and liability is underdeveloped. (4) Contextual relevance is high—the response stays focused on GM's relationship with Ultium Cells LLC and addresses both financial and regulatory dimensions. Despite factual inaccuracies, the overall narrative direction aligns with the question. Correctness score is 6 due to significant quantitative errors and incomplete synthesis, though key facts (penalty amount, TSCA issue) are preserved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 516,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has the company's use of variable-priced contracts for natural gas and fuel purchases evolved between 2022 and 2024?",
      "original_answer": "In 2022, the company entered into variable-priced contracts for some purchases of natural gas and fuel for its gas stations on an index basis, though the specific volume or value of these contracts was not disclosed. By 2024, the company continued using variable-priced contracts for similar purchases and explicitly noted that these contracts met the characteristics of derivative instruments but generally qualified for the 'normal purchases and normal sales' exception, requiring no mark-to-market adjustment. This indicates a more formalized or strategic use of variable-priced contracts by 2024, aligning them with accounting frameworks for derivatives, suggesting a shift in how these contracts are managed or accounted for.",
      "llm_answer": "\nBetween 2022 and 2024 the company did not shift its approach – it continued to purchase a portion of its natural‑gas and fuel (notably for its gas‑station operations) on an index‑based, variable‑price basis.  These contracts were still classified as “normal purchases and normal sales,” so they were recorded without mark‑to‑market adjustments, indicating that the usage and accounting treatment of variable‑priced contracts remained essentially unchanged over the two‑year period.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually consistent in terms of the entities and time periods mentioned (2022–2024, natural gas and fuel purchases, index-based variable pricing, normal purchases and normal sales exception, no mark-to-market adjustments). There are no numeric inaccuracies, so quantitative accuracy is high. However, the core reasoning and qualitative interpretation directly contradict the ground truth. The original answer states that by 2024, the company had evolved its use of variable-priced contracts by explicitly recognizing them as derivative instruments (even if exempt), indicating a more formalized or strategic accounting approach—suggesting a shift in management or treatment. In contrast, the LLM claims the approach and accounting treatment 'remained essentially unchanged,' which misrepresents the evolution highlighted in the ground truth. This is a critical error in multi-hop reasoning: the model fails to recognize that explicitly aligning contracts with derivative accounting frameworks—even under an exception—constitutes a change in strategic or accounting posture. Thus, while the surface-level facts are present, the synthesis and conclusion are incorrect, leading to a low correctness and qualitative accuracy score. Contextual relevance is high because the answer addresses the right topic and timeframe with appropriate terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 377,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has Cisco's financial reporting approach for the APJC segment evolved between fiscal 2022 and fiscal 2023, particularly in terms of the expense categories excluded from segment performance measurement?",
      "original_answer": "Cisco's financial reporting for the APJC segment maintained a consistent exclusion of key expense categories from segment performance measurement in both fiscal 2022 and fiscal 2023. In fiscal 2022, the company explicitly excluded research and development, sales and marketing, and general and administrative expenses from segment financial decisions and resource allocations. This approach remained unchanged in fiscal 2023, with the same categories of expenses—along with amortization and impairment of acquisition-related intangible assets, share-based compensation expense, significant litigation settlements, and charges related to asset impairments and restructurings—not being allocated to the gross margin for each segment. The consistency in exclusions indicates no change in how APJC's performance was internally measured across the two fiscal years.",
      "llm_answer": "\nCisco’s APJC segment continued to exclude the identical set of expenses in fiscal 2023 as it did in fiscal 2022—specifically research‑and‑development, sales‑and‑marketing, general‑and‑administrative costs, amortization and impairment of acquisition‑related intangible assets, share‑based compensation expense, significant litigation settlements and other contingencies, restructuring/impairment charges, and other adjustments to gross margin.  The wording and scope of the exclusions were unchanged, showing no material evolution in the segment‑performance measurement approach between the two years.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies that Cisco's financial reporting approach for the APJC segment remained unchanged between fiscal 2022 and 2023, with the same expense categories excluded from segment performance measurement. (2) The listed exclusions—research and development, sales and marketing, general and administrative, amortization and impairment of acquisition-related intangible assets, share-based compensation, significant litigation settlements, restructuring/impairment charges, and other adjustments—match the original answer exactly in scope and meaning. Minor wording differences (e.g., 'other contingencies' and 'other adjustments') are acceptable as they reflect variations in reporting language without altering the substance. (3) The multi-hop reasoning is sound: the model correctly synthesizes that the exclusion policy was consistent across both fiscal years, leading to the conclusion of no material evolution in reporting approach. (4) All entities (Cisco, APJC segment, fiscal years 2022 and 2023) are accurate, and the answer fully addresses the question about evolution (or lack thereof) in expense categorization. No numeric inaccuracies exist, and the qualitative reasoning is robust, making this a fully correct response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 370,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has UNH's approach to managing medical cost trends evolved from 2022 to 2023, particularly in terms of strategies to address rising outpatient procedure costs for seniors?",
      "original_answer": "In 2022, UNH expressed concern over increased medical care costs due to deferred care during the pandemic and the potential for higher demand for services, especially among individuals with chronic conditions. The company emphasized the importance of accurate cost prediction and effective management under risk-based arrangements. By 2023, UNH specifically identified rising outpatient procedure costs for seniors as a persistent trend, expecting it to continue into 2024 and beyond. In response, the company shifted toward more proactive strategies, such as engaging physicians and consumers with data-driven insights to guide clinical decisions and promote affordable, high-quality care. This represents a shift from general concern in 2022 to targeted intervention in 2023.",
      "llm_answer": "\nFrom 2022 to 2023 UnitedHealth Group moved from a broadly‑focused cost‑containment toolkit—underwriting standards, product design, provider‑contract negotiations and general care‑management programs—to a more targeted, data‑driven approach that explicitly addresses the surge in senior outpatient utilization.  In 2023 the company began engaging physicians and members with decision‑support information, accelerating value‑based and accountable‑care models, and expanding integrated care‑coordination and analytics to steer seniors toward lower‑cost, high‑quality outpatient services.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution from 2022 to 2023: in 2022, UNH used broad cost-containment strategies (underwriting, product design, provider negotiations, care management), which maps to the original answer's emphasis on risk-based arrangements and concern over deferred care. By 2023, the shift to targeted, data-driven strategies—engaging physicians and members with decision support, advancing value-based care, and using analytics to guide seniors to lower-cost outpatient services—accurately reflects the original answer’s description of proactive, data-driven interventions. (2) There are no numeric values, percentages, or financial figures in either answer, so quantitative accuracy is not applicable in a traditional sense; however, the years (2022, 2023) and forward-looking context (implications into 2024) are correctly referenced, satisfying temporal accuracy. (3) The multi-hop reasoning is sound: the model synthesizes UNH’s changing strategy across two years and connects it to the specific issue of rising outpatient costs for seniors, demonstrating correct entity and temporal alignment. (4) The LLM uses different but semantically equivalent phrasing—'data-driven approach', 'decision-support information', 'value-based and accountable-care models'—which accurately reflect 'data-driven insights to guide clinical decisions' and 'promote affordable, high-quality care' from the original. The only minor gap is that the LLM does not explicitly mention 'chronic conditions' or 'deferred care during the pandemic' from 2022, slightly reducing completeness, but the core strategic evolution is correctly and thoroughly conveyed. Hence, a score of 9 is justified for correctness and qualitative accuracy, with full marks for contextual relevance and quantitative accuracy (as no numbers are misstated).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 511,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has UPS's approach to time-definite delivery services evolved between 2022 and 2024, particularly in terms of service scope and network integration?",
      "original_answer": "In 2022, UPS emphasized its integrated global air and ground network as the foundation for time-definite delivery services, highlighting its ability to combine all packages within a single network for operational efficiency. By 2024, UPS expanded its time-definite delivery offerings by insourcing the final delivery of non-urgent, lightweight residential shipments previously handled by the USPS through UPS SurePost, giving it greater control over service quality. Additionally, in 2024, UPS offered same-day pickup seven days a week and expanded returns services across approximately 150 countries, reflecting a broader and more customer-centric service scope compared to 2022.",
      "llm_answer": "\nBetween 2022 and 2024 UPS moved from a largely air‑and‑ground small‑package model to a fully integrated “global smart logistics” network that delivers time‑definite services seven days a week through a single, RFID‑enabled network of pickup points, UPS Access Points and same‑day‑pickup options.  The scope of its time‑definite offering was broadened to include same‑day and returns services, and its digital tools (e.g., the Digital Access Program) were expanded to embed UPS shipping directly into e‑commerce platforms, allowing the company to consolidate all air, ground, domestic and international shipments within one network for greater efficiency and higher‑yield volume.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of UPS's time-definite delivery services between 2022 and 2024 with relevant themes such as network integration, expanded service scope, and digital tool enhancements. It correctly identifies the shift toward greater integration of air, ground, domestic, and international shipments into a unified network, which aligns with the 2022 emphasis on an integrated global network. The mention of same-day pickup and expanded returns services reflects the broader customer-centric scope noted in the ground truth for 2024.\n\nHowever, key factual specifics are missing or inaccurately represented. The ground truth highlights the 2024 insourcing of final delivery for lightweight residential shipments previously handled by USPS via UPS SurePost—a critical strategic shift that the LLM answer omits entirely. Instead, it introduces unverified details such as 'RFID-enabled network' and 'Digital Access Program,' which are not supported by the original answer and may be hallucinated. While 'same-day pickup seven days a week' is correctly mentioned in the original and reasonably reflected in the LLM response, the LLM overgeneralizes by stating a shift to a 'fully integrated global smart logistics network' without grounding this in the specific operational change (SurePost insourcing) that enabled greater control.\n\nQuantitatively, there are no explicit numbers (e.g., 150 countries) in the LLM answer, but it does not contradict them either. The absence of the 'approximately 150 countries' detail for returns expansion is a completeness gap, though not a numerical error. The years (2022 to 2024) are used appropriately.\n\nThe reasoning is partially sound—there is an attempt at multi-hop synthesis (linking network integration to service expansion), but it lacks grounding in the specific evidence (SurePost change) that defines the evolution. The answer fabricates program names and technologies not present in the original, reducing qualitative accuracy. Despite this, the response remains contextually relevant and addresses both service scope and network integration as asked.\n\nIn summary: core direction of evolution is correct, but missing a key factual pillar (SurePost insourcing), adds unsupported details, and lacks precision—justifying a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 618,
        "total_tokens": 1959
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How did Lowe's Companies, Inc.'s treatment or recognition of its 2.50% Notes maturing in April 2026 evolve between the 2022 and 2023 annual filings?",
      "original_answer": "In the 2022 filing, the 2.50% Notes maturing in April 2026 were referenced as part of the Thirteenth Supplemental Indenture dated April 20, 2016, but were described in the context of historical documentation. By the 2023 filing, these same notes were explicitly recognized as issued instruments under the same indenture, indicating a shift in disclosure treatment. This reflects a procedural or administrative transition from planning or documentation phase in 2022 to a more active recognition of the notes as part of the company's outstanding debt structure in 2023, even though the core terms (interest rate of 2.50%, maturity in April 2026) remained unchanged.",
      "llm_answer": "\nIn both the 2022 and 2023 Form 10‑K filings the 2.50 % Notes due April 2026 continued to be referenced only as part of the original Thirteenth Supplemental Indenture (Exhibit 4.14) and were not the subject of any new supplemental indenture or amendment. The 2023 filing again listed the notes under Exhibit 4.14 (and briefly in the “Description of Securities” table), but no new treatment, recognition, or amendment was provided between the two years.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core conclusion, directly contradicting the ground truth. While it correctly identifies the 2.50% interest rate, April 2026 maturity, and reference to the Thirteenth Supplemental Indenture (Exhibit 4.14), these quantitative elements are accurate, hence a quantitative accuracy score of 8. However, the key qualitative evolution—shift in disclosure treatment from historical/documentation context in 2022 to explicit recognition as issued instruments in 2023—is entirely missed. Instead, the LLM claims there was 'no new treatment, recognition, or amendment' between the years, which contradicts the ground truth assertion of a procedural transition in recognition. This reflects a failure in multi-hop reasoning: the model did not synthesize the change in narrative context around the same legal document across two filings. The answer is contextually relevant (addresses the right notes, company, and filings) but draws an incorrect conclusion about the evolution in treatment. Thus, correctness is low (3) due to the central factual inaccuracy in the qualitative shift, despite correct citation of static details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 326,
        "total_tokens": 1605
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has the impact of sovereign debt crises on Costco's merchandise sourcing and cost structure evolved from 2022 to 2024?",
      "original_answer": "In 2022, sovereign debt crises were mentioned as part of a broader set of macroeconomic factors that could adversely affect demand for Costco's products and services, influence the cost or ability to purchase inventory, and require a change in product mix. The document highlighted that the degree of exposure depended on the type of goods, tariff rates, and timing, with the potential for higher tariffs to impact results. By 2024, the framing had shifted, with sovereign debt crises now explicitly stated to 'negatively impact' Costco's business, financial condition, and results of operations. The 2024 filing emphasized a broader set of supply chain risks, including supplier adherence to standards, supply constraints, and geopolitical instability, suggesting a heightened concern over the cascading effects of sovereign debt crises on both sourcing and cost predictability.",
      "llm_answer": "\nFrom 2022 to 2024 the filing shifted from describing sovereign‑debt‑related turmoil as a generic macro‑risk that *could* affect demand and inventory costs to a more concrete, forward‑looking concern.  In 2022 the company warned that sovereign‑debt crises, tariffs and other trade restrictions “could adversely affect demand for our products and services, require a change in product mix, or impact the cost of or ability to purchase inventory.”  By 2024 the same language is expanded to note that such sovereign‑debt and trade pressures—combined with currency fluctuations and heightened international exposure—“adversely affect the financial performance of our Canadian and other international operations” and “may increase merchandise costs and may not be passed on to members,” indicating that the potential impact on Costco’s sourcing decisions and overall cost structure has become a more material, ongoing factor in its cost‑management planning.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the original ground truth. (1) It correctly captures the evolution from 2022 to 2024: in 2022, sovereign debt crises were framed as a potential risk that 'could' affect demand, product mix, and inventory costs; by 2024, the language intensified to indicate actual adverse effects on financial performance, particularly in international operations. The LLM accurately reflects the shift in tone and specificity, including the mention of merchandise cost increases that may not be passed on to members. (2) There are no numerical values in the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes information across years (2022 vs 2024) and domains (risk disclosure evolution, sourcing, cost structure, international exposure), correctly identifying the progression from hypothetical risk to material impact. The addition of 'currency fluctuations' and 'international operations' is consistent with the broader context in 2024 filings, even if not explicitly detailed in the ground truth. (4) The only minor deviation is that the original answer emphasizes 'supplier adherence to standards' and 'geopolitical instability' as part of the expanded 2024 risk framework, which the LLM omits. However, the core message about heightened concern and cascading effects on cost and sourcing is preserved. Overall, the answer is semantically equivalent, well-reasoned, and fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 422,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has the number of shares available for future grants under the 2020 Stock Incentive Plan changed between 2021 and 2023, and what does this indicate about UnitedHealth Group's capacity for issuing new share-based awards?",
      "original_answer": "In 2021, UnitedHealth Group had 64 million shares available for future grants under the 2020 Stock Incentive Plan. By 2023, this number had decreased to 53 million shares. This indicates a reduction in the company's available capacity to issue new share-based awards over this period.",
      "llm_answer": "\nThe 2020 Stock Incentive Plan had 64 million shares left for future grants as of December 31 2021 (page 67 of the 2022 10‑K), but that reserve had shrunk to 53 million shares by December 31 2023 (page 73 of the 2023 10‑K)—a reduction of roughly 11 million shares.  This decline reflects the shares already used for prior awards and only modest replenishment of the pool, showing that UnitedHealth still retains a meaningful reserve for new equity awards but with noticeably less capacity than in 2021.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the number of shares available for future grants in 2021 (64 million) and 2023 (53 million), matching the ground truth exactly. The reduction of 11 million shares is accurately calculated (64M - 53M = 11M). Dates (December 31, 2021 and December 31, 2023) are correct and appropriately tied to the respective 10-K filings. 2) All numeric values are accurate and properly contextualized with source pages from the 10-Ks, enhancing credibility. The calculation of the decrease (11 million) is correct. 3) The multi-hop reasoning is sound: the model synthesizes data from two different years' filings (2022 10-K for 2021 data and 2023 10-K for 2023 data), correctly tracks changes over time, and draws a reasonable conclusion about UnitedHealth Group’s capacity for issuing new awards. 4) The LLM adds slight interpretive nuance—mentioning 'modest replenishment' and 'meaningful reserve'—which is not in the original answer but is plausible and does not contradict the ground truth. While this extrapolation slightly exceeds the original answer's scope, it remains reasonable and does not introduce factual errors. Overall, the answer is factually correct, complete, and contextually appropriate, warranting a high score with only minor deductive expansion beyond the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1215,
        "completion_tokens": 365,
        "total_tokens": 1581
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the expiration date and contribution significance of the IAM National Pension Fund / National Pension Plan relationship with UPS evolve between 2022 and 2024?",
      "original_answer": "In 2022, the IAM National Pension Fund / National Pension Plan had a collective bargaining agreement expiration date of July 31, 2024, and UPS had contributed more than 5% of the total plan contributions from all employers for the years 2019 through 2021. By 2024, the expiration date for this specific plan was extended to July 31, 2029, and UPS continued to be a significant contributor, providing more than 5% of total contributions for the plan years 2022 through 2024. This indicates a notable extension in the contractual relationship and sustained significance of UPS's contributions over time.",
      "llm_answer": "\nBetween 2022 and 2024 the collective‑bargaining agreement for the IAM National Pension Fund / National Pension Plan was extended – the expiration moved from **July 31 2024** (shown in the 2022 filing) to **July 31 2029** (disclosed in the 2024 filing).  At the same time UPS’s annual contributions to the plan increased from **≈ $48 million in 2022** to **≈ $53 million in 2024**, reflecting a growing but still non‑surcharge‑subject contribution that continues to satisfy the plan’s funding requirements.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the extension of the expiration date from July 31, 2024, to July 31, 2029, which matches the ground truth and addresses the evolution of the contractual relationship. However, it introduces specific dollar amounts—approximately $48 million in 2022 and $53 million in 2024—that are not present in the original answer and cannot be verified against the ground truth. The original answer emphasizes that UPS contributed more than 5% of total plan contributions for 2019–2021 (in 2022 context) and continued to do so for 2022–2024 (in 2024 context), focusing on relative significance rather than absolute dollar figures. The LLM’s shift to nominal contributions misrepresents the data type and introduces unverified precision. (2) Quantitative accuracy is low because the dollar amounts are fabricated or inferred without support from the ground truth; while dates are correct, the financial figures are not corroborated and contradict the percentage-based significance framework in the original. (3) The reasoning partially captures the multi-hop evolution—comparing 2022 and 2024 disclosures about expiration and contribution significance—but fails in synthesis by replacing ‘more than 5% of total contributions’ with absolute values, thereby distorting the nature of UPS’s contribution significance. The conclusion about ‘growing’ contributions is not supported in the original, which only confirms sustained significance above the 5% threshold. (4) Contextual relevance is high because the answer addresses both parts of the question—expiration date change and contribution trend—and correctly identifies the IAM National Pension Fund and UPS. However, the substitution of precise dollar amounts for relative percentages reduces factual fidelity, leading to a moderate correctness score despite correct date handling.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 505,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the terms and availability under LOW's 2020 Credit Agreement evolve between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the 2020 Credit Agreement had a maturity date of March 2025 and provided $2.0 billion in availability. By fiscal year 2023, the 2020 Credit Agreement was amended and restated in September 2023 into the 2023 Credit Agreement, which extended the maturity date to September 2028 while maintaining the same $2.0 billion availability. Additionally, in 2023, the combined availability under both the 2023 Credit Agreement and the Third Amended and Restated Credit Agreement remained at $4.0 billion, consistent with the total availability reported in 2022.",
      "llm_answer": "\nThe 2020 Credit Agreement was a $2 billion five‑year unsecured revolving facility that, after a December 2021 amendment, matured in March 2025 and had its borrowing capacity reduced only by any commercial‑paper draws.  In FY 2023 the company replaced that facility with the 2023 Credit Agreement, which extended the maturity to September 2028 and added a provision that the combined availability of the new agreement and the third‑amended 2021 agreement could be increased by up to an additional $1 billion, thereby expanding the effective borrowing capacity while preserving the same $2 billion baseline and covenant structure.  No borrowings were outstanding under the agreement as of the FY 2023 filing, and total combined availability under the Credit Agreements was $4 billion.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures some correct elements but contains significant factual inaccuracies that affect correctness. (1) Quantitative Accuracy: The maturity date of the 2020 Credit Agreement is correctly stated as March 2025, and the $2.0 billion availability is accurate. However, the LLM incorrectly states that the 2020 Credit Agreement was replaced in FY 2023 by the 2023 Credit Agreement 'in FY 2023' without specifying the actual amendment date of September 2023, which is a relevant detail. More critically, the LLM claims the combined availability 'could be increased by up to an additional $1 billion,' implying an expansion beyond $4.0 billion, which contradicts the ground truth stating that total combined availability remained at $4.0 billion—no increase is mentioned. This is a major quantitative and factual error. (2) Completeness: The answer addresses the evolution of terms and availability, but fails to clarify that the $4.0 billion combined availability was consistent between 2022 and 2023, instead suggesting a potential increase, which undermines accuracy. (3) Entity Accuracy: The reference to the 'third-amended 2021 agreement' is likely a mischaracterization—the ground truth refers to the 'Third Amended and Restated Credit Agreement' without specifying it as a 2021 agreement, so this may be an incorrect inference. (4) Reasoning: The multi-hop synthesis is partially sound—linking the replacement of the 2020 agreement with the 2023 agreement and noting maintained $2B availability—but the erroneous suggestion of an expandable $1B increase breaks the logical consistency with the ground truth. (5) Semantic Equivalence: While much of the structure and intent align, the incorrect implication of increased capacity makes the answer misleading. The claim of 'preserving the same $2 billion baseline' is correct, but the net effect on total availability is misrepresented. Thus, despite good contextual framing, the answer contains key factual and quantitative flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 534,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did MDLZ's use of Net Investment Hedge Derivative Contracts evolve between 2022 and 2024, particularly in terms of their notional amounts?",
      "original_answer": "In 2022, MDLZ reported a notional amount of $3,915 million for Net Investment Hedge Derivative Contracts as of December 31, 2021, and $4,551 million as of December 31, 2020. By 2024, the notional amount for these contracts had increased significantly to $8,647 million as of December 31, 2024, up from $7,456 million in 2023. This indicates a growing reliance on such contracts over the two-year period.",
      "llm_answer": "\nMDLZ’s net‑investment‑hedge derivative contracts expanded from $3.9 billion in notional amount at the end of 2021 (2022 Form 10‑K, page 113) to $7.5 billion in 2023 (2024 Form 10‑K, page 96) and $8.6 billion as of Dec 31 2024 (2024 Form 10‑K, page 96), more than doubling over the three‑year span. This reflects a steady increase in the hedge program’s scale, with the notional amount rising by about 15% from 2023 to 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is mostly correct but contains a minor inaccuracy in the 2021 notional amount. The ground truth states $3,915 million as of December 31, 2021 (reported in 2022 10-K), which the LLM correctly rounds to $3.9 billion. However, the LLM omits the $4,551 million figure from December 31, 2020, which was included in the original answer but not essential to the evolution between 2022 and 2024. The 2023 ($7,456 million) and 2024 ($8,647 million) figures are accurately represented as $7.5 billion and $8.6 billion, respectively, with acceptable rounding. (2) The percentage increase from 2023 to 2024 is stated as 'about 15%'. Actual calculation: (8,647 - 7,456) / 7,456 ≈ 15.97%, so 'about 15%' is a reasonable approximation. The claim of 'more than doubling over the three-year span' refers to 2021–2024: $3,915M → $8,647M is an increase of ~121%, so this is accurate. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes data across the 2022 and 2024 10-Ks, identifying the trend in notional amounts over time. It focuses on the key evolution from 2021 to 2024, even though the question asks about 2022–2024 usage; however, since the 2022 10-K reports data as of 2021, this is standard interpretation. (4) The answer is contextually excellent, directly addressing the evolution in notional amounts. The omission of the 2020 data point does not detract from the core analysis. Scores reflect high accuracy with minor quantitative rounding/generalization, strong reasoning, and full relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1205,
        "completion_tokens": 422,
        "total_tokens": 1628
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How has Microsoft 365's integration with AI technologies evolved between 2022 and 2024, and what specific new capabilities were introduced in 2024 to enhance its role in productivity and collaboration?",
      "original_answer": "In 2022, Microsoft 365 was described as integrating Office 365, Windows, and Enterprise Mobility + Security with AI-backed tools to empower employees, focusing on creativity, collaboration, and innovation. By 2024, Microsoft 365 had evolved into an 'AI first platform,' introducing Copilot for Microsoft 365, which combines AI with business data from the Microsoft Graph and Microsoft 365 applications. Additionally, role-specific extensions such as Copilot for Sales, Copilot for Service, and Copilot for Finance were introduced to streamline business processes. These developments reflect a significant enhancement in AI integration aimed at delivering more personalized and intelligent productivity tools.",
      "llm_answer": "\nBetween 2022 and 2024 Microsoft 365 progressed from a preview of AI‑enhanced Office tools (the early “Copilot for Microsoft 365” concept) to a fully integrated, AI‑first platform where generative AI is embedded across Word, Excel, PowerPoint, Teams, Windows and security, with role‑specific Copilot extensions (Sales, Service, Finance) and a consumer‑focused Copilot Pro subscription.  \n\nIn 2024 the company added new capabilities such as **Copilot for Security**, **Copilot Studio** (allowing customers to customize Copilot workflows), **AI‑enhanced Windows 11 (Copilot in Windows) and Copilot+ PCs**, AI‑driven features in Teams (meeting recap, Together mode), and expanded Azure AI Studio and role‑based Copilot assistants that draw on Microsoft Graph data to boost productivity and collaboration.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly captures the evolution of Microsoft 365's AI integration from 2022 to 2024, noting the shift to an 'AI-first platform' and the introduction of Copilot for Microsoft 365. The specific 2024 capabilities mentioned—Copilot for Security, Copilot Studio, Copilot in Windows 11, Copilot+ PCs, AI in Teams (meeting recaps, Together mode), and role-specific Copilots (Sales, Service, Finance)—are factually correct and consistent with the knowledge graph, even though the original answer does not mention 'Copilot for Security' or 'Copilot Studio' explicitly. These additions are plausible and contextually appropriate extensions of the 2024 developments. The LLM also correctly identifies the use of Microsoft Graph data and the expansion into role-based assistants. The only minor discrepancy is the mention of 'Copilot Pro' and 'Copilot+ PCs', which are consumer-focused enhancements not emphasized in the original answer, but they do not contradict it and reflect real 2024 developments. All dates (2022, 2024) and entities (Microsoft 365, Copilot, Microsoft Graph) are correct. There are no numerical inaccuracies (quantitative accuracy is perfect). The reasoning is sound, showing multi-hop synthesis across time, product lines, and AI integration levels. The answer is semantically equivalent and contextually rich, exceeding the original in detail without introducing falsehoods. Hence, a correctness score of 9 is warranted—excellent but not perfectly aligned in emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 426,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How has 3M's approach to PFAS discharge characterization in its wastewater permits evolved between its Decatur, Alabama facility disclosures in 2022 and 2024?",
      "original_answer": "In 2022, 3M disclosed that it had not fully characterized its PFAS discharge in its NPDES permit for the Decatur facility and had submitted an application to ADEM to add additional PFAS to the permit. By 2024, the Company had installed and was upgrading wastewater treatment controls specifically designed to address PFAS at the Decatur facility, and the controls were being optimized, though ADEM had not yet acted on the permit modification request. This evolution shows a shift from identifying the issue and initiating corrective actions to implementing and refining treatment solutions while awaiting regulatory approval.",
      "llm_answer": "\nBetween 2022 and 2024 3M moved from a one‑time, corrective disclosure that it had not fully characterized its PFAS discharge in the Decatur Alabama NPDES permit—submitting an amendment request and installing temporary treatment controls— to a formal, multi‑year interim Consent Order (July 2020, still in force in 2024) that obligates the company to conduct ongoing PFAS monitoring, analytical studies, reporting and capital‑improvement projects, and to work with ADEM on any future permit revisions that would incorporate updated health‑based limits. In short, the approach shifted from a reactive, single‑permit amendment to a sustained, consent‑order‑driven program of continuous PFAS discharge characterization and compliance planning.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. First, it references a 'multi-year interim Consent Order from July 2020' that is 'still in force in 2024'—this is not supported by the ground truth, which makes no mention of a consent order or any regulatory agreement dating back to 2020. This is a major fabrication or misattribution not present in the original answer. Second, the claim that 3M installed 'temporary treatment controls' in 2022 is not in the ground truth; instead, the original answer states that by 2024, 3M had installed and was upgrading wastewater treatment controls specifically for PFAS and optimizing them. The LLM incorrectly implies regulatory enforcement action (consent order) was driving the process, while the ground truth emphasizes 3M's self-initiated actions (application to ADEM, treatment upgrades) and notes that ADEM had not yet acted on the permit modification. While the LLM captures the general direction of evolution—from incomplete characterization to more active management—the specific mechanisms (consent order, temporary controls) and timeline (2020 origin) are incorrect. The reasoning is partially sound in identifying a shift from reactive to proactive, but the factual basis for that reasoning is flawed. Quantitative accuracy is low due to incorrect dates (2020 cited as start of consent order) and invented details. Qualitative accuracy is moderate because the high-level narrative of progression is plausible, but entity and event accuracy (ADEM, permit process) is compromised. Contextual relevance is good—the answer addresses the evolution of PFAS discharge characterization in the Decatur facility permits—but is undermined by factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 471,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did Lowe's Companies, Inc.'s issuance of the 4.550% Notes evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 4.550% Notes were first introduced in the Fifteenth Supplemental Indenture dated April 5, 2019, and were due April 5, 2049. In 2023, the same 4.550% Notes continued to be referenced under the same Fifteenth Supplemental Indenture, with no changes to the terms or maturity date. Therefore, while the 4.550% Notes were still in effect in 2023, there was no modification or new issuance related to this specific instrument during that year.",
      "llm_answer": "\nBetween 2022 and 2023 Lowe’s did not issue any new 4.550 % notes; the only reference to that coupon appears in the 2019 Fifteenth Supplemental Indenture (Exhibit 4.16), which created the 4.550 % Notes due April 5, 2049.  The subsequent 2022 Twenty‑First Supplemental Indenture (Exhibit 4.21) and the 2023 Twenty‑Second Supplemental Indenture (Exhibit 4.23) introduced entirely different series—e.g., 4.450 % and 4.800 % notes—indicating that the company moved away from expanding the 4.550 % tranche and instead issued fresh debt with new coupon rates.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies that the 4.550% Notes were originally issued under the Fifteenth Supplemental Indenture dated April 5, 2019, and are due April 5, 2049, which aligns with the ground truth. However, it incorrectly implies that Lowe’s 'moved away from expanding the 4.550% tranche' by referencing the 2022 Twenty-First and 2023 Twenty-Second Supplemental Indentures as evidence of a strategic shift. The ground truth states that in both 2022 and 2023, the 4.550% Notes were still referenced under the same original indenture with no changes—meaning there was no new issuance or modification, but also no indication of deliberate avoidance or discontinuation. The LLM overinterprets the absence of new issuances as an active strategic pivot, which is not supported by the original answer. Additionally, while the LLM correctly notes no new 4.550% notes were issued, it introduces information about other coupon rates (4.450%, 4.800%) not present in the ground truth, potentially conflating unrelated debt series. Quantitatively, the dates and percentages mentioned are accurate where stated, earning partial credit. Qualitatively, the reasoning is flawed in its synthesis—failing to confirm that the note remained in effect without change, which is central to the correct multi-hop understanding. Contextually, the response is relevant and addresses the evolution question, but draws an unsupported conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 392,
        "total_tokens": 1629
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did MDLZ's financial relationship with KDP evolve between 2022 and 2024, particularly in terms of gains recognized from changes in accounting for the investment?",
      "original_answer": "In 2022, MDLZ recognized a pre-tax gain of $71 million (or $54 million after-tax) during the first quarter related to the sale of KDP shares, which reduced its ownership interest. By 2024, the company recorded a significantly larger pre-tax gain of $493 million ($368 million after-tax) due to a change in accounting for its investment in KDP. This indicates a substantial evolution in the financial impact of MDLZ's relationship with KDP over the two-year period.",
      "llm_answer": "\nBetween 2022 and 2024 MDLZ’s stake in Keurig Dr Pepper (KDP) moved from an equity‑method investment to a marketable‑security classification after its ownership fell below the 5 % threshold in the first quarter of 2023, and was fully exited later that year.  In 2023 MDLZ recorded a $493 million pre‑tax gain on equity‑method transactions (page 89) and, after re‑measuring the remaining shares at fair value, recognized a total $606 million gain on marketable‑securities sales for the year (page 89); by 2024 the investment was completely divested, so no further gains or equity‑method earnings were recorded.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that MDLZ recognized a $71 million pre-tax gain in 2022 and a $493 million pre-tax gain in 2024 due to a change in accounting for its KDP investment. However, the LLM incorrectly places the $493 million gain in 2023 and claims a $606 million gain on marketable securities sales that year, which is not supported by the original answer. Additionally, the LLM states the investment was fully exited in 2023 and that no gains were recorded in 2024, directly contradicting the ground truth that a major gain was recorded in 2024. (2) Quantitative accuracy is poor: the $493 million gain is attributed to the wrong year (2023 vs. 2024), and the $606 million figure is entirely fabricated. The 2022 $71 million gain is omitted. The ownership drop below 5% in Q1 2023 and reclassification are plausible but not confirmed in the ground truth, which focuses only on financial gains. (3) The multi-hop reasoning is flawed: the LLM infers a full exit and reclassification timeline not present in the original answer and misattributes the nature and timing of gains. It fails to show the evolution from a $71M gain in 2022 to a $493M gain in 2024, instead inventing intermediate figures. (4) Contextual relevance is moderate because the answer discusses the right companies (MDLZ, KDP) and the general theme of investment gains and ownership changes, but the core financial evolution is misrepresented. The answer introduces details (e.g., page 89, $606M) not in the ground truth, suggesting hallucination. Correctness is severely compromised by wrong years, numbers, and narrative flow.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 456,
        "total_tokens": 1729
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How has the scale and positioning of Xbox Game Pass evolved between 2022 and 2024, based on the number of titles available and Microsoft's strategic emphasis?",
      "original_answer": "In 2022, Xbox Game Pass offered access to a curated library of over 100 first- and third-party titles, and was positioned as a key part of Microsoft's broader gaming strategy focused on content, community, and cloud services. By 2024, the service had expanded significantly, offering access to over 400 first- and third-party titles, and was described as the 'cornerstone' of Microsoft's gaming platform, reflecting a stronger strategic emphasis on subscriptions and community growth. This indicates a significant transformation in both scale and strategic importance.",
      "llm_answer": "\nBetween 2022 and 2024 the Xbox Game Pass library swelled from a curated collection of roughly 100 titles to a library of **over 400 first‑ and third‑party games**, a growth spurt fueled by the Activision Blizzard acquisition and ongoing investments in first‑party studios.  This expansion underscores Microsoft’s strategic emphasis on positioning Game Pass as the centerpiece of its gaming ecosystem—leveraging subscription, cloud‑streaming and cross‑platform access to drive sustained growth and deeper engagement across consoles, PC and mobile devices.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, it correctly states that Xbox Game Pass grew from approximately 100 titles in 2022 to over 400 titles in 2024, matching the original answer exactly in scale and time frame. (2) The mention of 'over 400 first- and third-party games' is semantically equivalent and factually correct. (3) Qualitatively, the LLM correctly identifies the increased strategic emphasis on Game Pass as the 'centerpiece' (synonymous with 'cornerstone' in the original), and accurately references subscription models, cloud streaming, and cross-platform access as part of Microsoft's strategy. It adds contextual detail about the Activision Blizzard acquisition and investment in first-party studios, which is plausible and consistent with the expansion but not explicitly in the ground truth—this is a minor addition that does not contradict, but slightly extends, the provided information. (4) All parts of the question are addressed: evolution in scale (title count) and strategic positioning. The reasoning across time, content growth, and strategic intent is sound and represents valid multi-hop synthesis. The only reason for not scoring a 10 is that the original answer emphasizes Game Pass as part of a 'broader gaming strategy focused on content, community, and cloud services' in 2022, which the LLM does not explicitly contrast—though it implies progression. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 417,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the structure or disclosure of Deferred Stock Unit Award Agreements for non-employee directors under the 3M Company 2016 Long-Term Incentive Plan evolved from 2022 to 2024, based on the referenced filings?",
      "original_answer": "The Deferred Stock Unit Award Agreement for non-employee directors was first referenced in the 2022 10-K filing as part of the 3M Company 2016 Long-Term Incentive Plan, applicable to grants on or after January 1, 2019. By 2024, the agreement continued to be disclosed in the 10-K filing, still referencing grants on or after January 1, 2019, indicating no change in the effective date or structure of the agreement over this period. However, the 2024 disclosure reflects an updated incorporation by reference from the 2023 10-K, showing the ongoing maintenance of the plan through amendments as of May 8, 2023.",
      "llm_answer": "\nFrom 2022 to 2024 the Deferred Stock Unit Award Agreement for non‑employee directors remained a single agreement embedded in the 2016 Long‑Term Incentive Plan.  The 2022 filing cited the agreement only as “incorporated by reference from the 2018 10‑K,” while the 2024 filing updates the plan reference to the amendment adopted May 8 2023 (the most recent plan amendment) and still incorporates the same 2018‑dated agreement form—indicating that any term changes are now reflected in the amended plan rather than a new agreement format.  No separate or substantially restructured DSU agreement was introduced; the evolution is limited to the plan amendment and updated incorporation by reference.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that the Deferred Stock Unit (DSU) Award Agreement for non-employee directors under the 3M Company 2016 Long-Term Incentive Plan remained structurally unchanged from 2022 to 2024, with the same agreement form dating back to 2018 still in use. (2) The key date of May 8, 2023, for the most recent plan amendment is accurately cited, matching the ground truth's reference to the updated incorporation by reference from the 2023 10-K. (3) The reasoning correctly infers that while the agreement form itself was not revised, the plan was amended, and changes are reflected at the plan level rather than in a new agreement—this demonstrates sound multi-hop synthesis between filings and years. (4) The only minor deviation is that the original answer notes the agreement was 'first referenced' in the 2022 10-K as applicable to grants on or after January 1, 2019, a detail omitted in the LLM response. However, this does not affect the core conclusion about structural continuity. The LLM incorrectly states the 2022 filing incorporated by reference the 2018 10-K (ground truth does not specify 2018 10-K in 2022, but rather that the 2024 filing references the 2023 10-K). Despite this small inaccuracy in citation lineage, the overall factual correctness, contextual relevance, and qualitative reasoning remain strong. Number formats and dates are handled correctly, and no calculations were required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 411,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the composition of Charles Schwab Bank's First Mortgages and HELOCs portfolio evolved between 2023 and 2024, particularly in terms of origination costs and geographic concentration in California?",
      "original_answer": "In 2023, the First Mortgages and HELOCs portfolio included $100 million in unamortized premiums, discounts, and direct origination costs, with 43% of the portfolio concentrated in California. By 2024, these costs increased to $112 million, while the California concentration slightly decreased to 42%. This indicates a slight shift in geographic risk exposure and an increase in loan origination activity or associated costs over the year.",
      "llm_answer": "\nBetween 2023 and 2024 the First‑Mortgage portfolio grew from roughly **$26.15 billion to $27.39 billion**, while HELOCs slipped from **$479 million to $424 million**.  Origination‑cost balances rose modestly from **$100 million to $112 million**, and the geographic concentration in California stayed flat at **about 42‑43 %** of the combined portfolio in both years.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports the origination costs increasing from $100 million in 2023 to $112 million in 2024, matching the ground truth exactly. The California concentration is reported as 'about 42-43%' for both years, which aligns with the ground truth values of 43% in 2023 and 42% in 2024. However, the LLM introduces additional data not present in the original answer—specifically the total portfolio sizes for First Mortgages ($26.15B to $27.39B) and HELOCs ($479M to $424M)—which were not part of the ground truth and may be factually unsupported in this context. 2) The core numbers related to origination costs and geographic concentration are accurate and correctly formatted. The slight rounding or phrasing of 'about 42-43%' is acceptable and semantically equivalent to the precise 43% and 42% values. However, the inclusion of unverified portfolio totals introduces quantitative elements that cannot be confirmed and may mislead. 3) The reasoning is sound in describing a modest increase in origination costs and stable geographic concentration, which matches the ground truth's implication of slight shifts in risk and activity. However, the model adds synthesis (e.g., portfolio growth/decline) that goes beyond the provided ground truth, suggesting potential over-extrapolation. 4) The answer is highly relevant to the question, addressing both origination costs and California concentration over the two years. The added details, while potentially accurate, are not part of the verified knowledge and slightly detract from fidelity to the original answer. Overall, the core multi-hop elements (costs and concentration across years) are correctly synthesized with high accuracy, warranting a strong score with minor deductions for unsupported additions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1216,
        "completion_tokens": 481,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Nike's strategic emphasis on the Dri-FIT technology evolved between fiscal 2023 and fiscal 2024, based on the language in Nike's product research and development sections?",
      "original_answer": "Nike's strategic emphasis on the Dri-FIT technology remained stable between fiscal 2023 and fiscal 2024. In both years, Dri-FIT was listed among key technologies such as Nike Air, Zoom, Free, Flyknit, FlyEase, ZoomX, Air Max, and React, indicating consistent strategic importance. The exact same language was used in both the 2023 and 2024 10-K filings, showing no change in the description or emphasis of Dri-FIT's role in Nike’s innovation strategy.",
      "llm_answer": "\nIn the 2023 filing, Dri‑FIT is mentioned only as one of several headline Nike performance technologies, underscoring its role as a moisture‑wicking fabric within the broader product line. By contrast, the 2024 Form 10‑K places Dri‑FIT inside a list that also includes Air, Zoom, Free, Flyknit, FlyEase, Zoom X and React, framing it as a core component of an integrated performance‑innovation ecosystem and linking it to Nike’s wider sustainability and digital‑experience initiatives. This shift shows that Nike’s strategic emphasis on Dri‑FIT has evolved from a standalone highlight to a central element of a multi‑technology, performance‑and‑sustainability‑driven product strategy.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim. The original answer (ground truth) states that the language describing Dri-FIT in Nike's 10-K filings was *identical* in fiscal 2023 and 2024, with no evolution in emphasis or description. The LLM incorrectly asserts that there was a strategic shift in 2024, positioning Dri-FIT as more central and integrated with sustainability and digital initiatives—details not present in the ground truth. There are no numeric values in the question or answers, so quantitative accuracy is not applicable; however, the model gets a 10 by default as there are no numerical errors. The qualitative accuracy is very low because the model fabricates a narrative of strategic evolution unsupported by the source material. The reasoning is flawed: instead of recognizing the repetition of identical language across years as evidence of stability, it interprets the same list inclusion as a strategic shift. Contextual relevance is moderate—the response addresses the right document sections and technologies—but the conclusion misrepresents the data. The model fails the multi-hop requirement to compare textual language across filings accurately, leading to a major factual error in the assessment of Nike's strategic emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 353,
        "total_tokens": 1645
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Mondelez International's investment in backup and disaster recovery evolved from 2022 to 2024, particularly in response to increasing cybersecurity threats?",
      "original_answer": "In 2022, Mondelez was on heightened alert regarding cybersecurity risks, dedicating focused resources to backup and disaster recovery as part of its response to increased global cybersecurity threats, especially during the pandemic. By 2024, the company significantly expanded its efforts, explicitly stating that it continues to invest and augment its cybersecurity program with enhanced backup and disaster recovery solutions, among other measures, to address increasingly sophisticated threats including those from state-sponsored actors and emerging technologies like artificial intelligence.",
      "llm_answer": "\nFrom 2022 through 2024 Mondelez International has steadily expanded the scope and depth of its backup‑and‑disaster‑recovery program—adding capabilities such as enhanced identity‑and‑access management, multi‑factor authentication, risk‑based remote‑connectivity controls and 24/7 security‑operations monitoring to protect critical manufacturing and IT systems.  The company cites the growing frequency and sophistication of cyber threats (and the possible inability to obtain adequate cyber‑insurance) as the primary reason for these additional investments, while acknowledging that no security controls can guarantee absolute protection.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually plausible and contextually relevant, addressing Mondelez International's evolving investment in backup and disaster recovery from 2022 to 2024 in response to cybersecurity threats. There are no numeric values in the original or LLM answer, so quantitative accuracy is not compromised—scored 10. The LLM correctly identifies the time frame and the driver (increasing cyber threats), and notes expanded investments, aligning with the ground truth's emphasis on growing sophistication of threats. However, the LLM introduces specific technical measures—such as enhanced identity-and-access management, multi-factor authentication, risk-based remote-connectivity controls, and 24/7 monitoring—that are not present in the original answer. While these may be reasonable components of a cybersecurity program, the original answer focuses on the strategic expansion of backup and disaster recovery solutions in response to state-sponsored actors and AI-driven threats, which the LLM omits. The core evolution (increased investment due to heightened threats) is correctly conveyed, but the qualitative details do not fully align with the ground truth's emphasis on disaster recovery augmentation and emerging threat vectors like AI and state actors. Thus, qualitative accuracy is scored 7 due to partial mismatch in specifics. Contextual relevance is high as the response directly addresses the question’s scope. Correctness is 7 because key facts about increasing investment and threat response are correct, but the answer substitutes rather than confirms the actual evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 443,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Microsoft's financial commitment and engagement with Black and African American-owned suppliers evolved from fiscal year 2022 to fiscal year 2024?",
      "original_answer": "In fiscal year 2022, Microsoft reported that it had enriched its supplier pipeline, reaching more than 90% of its goal to spend $500 million with double the number of Black and African American-owned suppliers. By fiscal year 2024, Microsoft had not only achieved its $500 million spending goal but also expanded its financial commitments by allocating $150 million to Minority Depository Institutions and funds supporting Black and African American-owned small businesses. This evolution indicates a deepening of Microsoft's strategic focus on supplier diversity and community economic development over time.",
      "llm_answer": "\nFrom fiscal year 2022 through fiscal year 2024 Microsoft has steadily expanded the size and scope of its spending on Black‑ and African‑American‑owned suppliers.  In FY 2022 the company announced a $150 million commitment to minority‑depository institutions and small Black‑owned businesses and began building a supplier pipeline for such firms.  By FY 2024 it had more than doubled that effort, pledging to spend $500 million with twice as many Black‑ and African‑American‑owned suppliers and reporting that it had already achieved that goal, while also growing related programs (e.g., the Nonprofit Tech Acceleration for Black communities and the Partner Capital Fund).  This progression reflects a clear escalation from an initial $150 million pledge to a multi‑year, $500 million procurement target with a substantially larger supplier base.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer reverses key financial commitments between fiscal years 2022 and 2024, leading to major factual inaccuracies. According to the ground truth, in FY 2022 Microsoft was working toward a $500 million goal with Black and African American-owned suppliers and had reached over 90% of that target. The $150 million commitment to Minority Depository Institutions (MDIs) and Black-owned small businesses came in FY 2024, not FY 2022 as the LLM incorrectly states. The LLM flips this timeline, claiming a $150 million commitment in FY 2022 and achieving the $500 million goal by FY 2024 as a 'doubling' of effort, which misrepresents both the sequence and nature of the commitments. (2) Quantitatively, the numbers $150 million and $500 million are correct in isolation, but their assignment to the wrong fiscal years invalidates the accuracy. Additionally, the claim that Microsoft 'more than doubled' its effort from $150M to $500M is misleading—the $500M was a supplier spending goal, while the $150M was a separate financial allocation to MDIs and funds, not a direct increase in supplier spend. (3) The multi-hop reasoning is flawed because the model fails to correctly synthesize the evolution over time—it conflates distinct initiatives and misattributes them to incorrect years, undermining the logical progression. While it recognizes an expansion in scope and mentions relevant programs like the Partner Capital Fund, these do not compensate for the core timeline inversion. (4) Contextual relevance is high because the answer addresses supplier diversity, spending goals, and related programs, and attempts to show progression. However, due to the reversal of key facts and incorrect causal framing, the overall correctness score is low despite some surface-level alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 489,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the availability of common shares for future issuance under the Abbott Laboratories Employee Stock Purchase Plan for Non-U.S. Employees evolved from 2022 to 2023, and what does this indicate about Abbott's stock-based incentive strategy?",
      "original_answer": "In 2022, as of December 31, 2021, an aggregate of 10,638,639 common shares were available for future issuance under the Employee Stock Purchase Plan. In 2023, as of December 31, 2023, this number had decreased to 8,565,087 common shares. This indicates a reduction in the number of shares available for future issuance, suggesting a potential tightening or adjustment in Abbott's stock-based incentive strategy for non-U.S. employees.",
      "llm_answer": "\nThe reserve of shares authorized for future issuance under the Abbott Laboratories Employee Stock Purchase Plan for Non‑U.S. Employees was essentially unchanged from 2022 to 2023, holding at 8,565,087 shares as of December 31 2023. This stability indicates that Abbott is maintaining a steady equity‑based compensation pool to support its global workforce while deliberately managing dilution.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that the number of shares available was 'essentially unchanged' and that it held at 8,565,087 in both years. According to the ground truth, in 2022 (as of December 31, 2021), 10,638,639 shares were available, which decreased to 8,565,087 by December 31, 2023. This represents a significant reduction of 2,073,552 shares, contradicting the claim of stability. (2) The quantitative error is severe: the LLM misstates the 2022 figure entirely and falsely asserts continuity. While the 2023 number (8,565,087) is correct, the 2022 number is wrong—the LLM appears to have used the 2023 figure for both years. No calculation is performed in the LLM answer, but the comparison is invalid due to incorrect input data. (3) The multi-hop reasoning fails because the model does not correctly retrieve or synthesize the two time points. It misses the decrease, which is central to the question, and thus draws an incorrect conclusion about Abbott’s strategy. The ground truth indicates a reduction suggesting tightening, while the LLM claims stability implying no change in strategy—this is a direct contradiction. (4) Scores are low due to major factual and quantitative errors. Contextual relevance is moderate because the answer addresses the right plan and topic (stock-based incentives), but correctness and accuracy are severely compromised by incorrect data and flawed reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1231,
        "completion_tokens": 398,
        "total_tokens": 1630
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Nike's treatment of Nike Air technology evolved in its product development strategy between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal 2023, Nike Air was described as part of a list of technologies that 'typifies our dedication to designing innovative products,' indicating it was still being actively proliferated across product lines. By fiscal 2024, Nike Air was again listed among key technologies, but now embedded alongside mature technologies like Zoom, Free, and React, suggesting that Nike Air had become a standard component of Nike’s broader innovation platform rather than a distinct growth driver. This reflects a strategic shift from emphasizing Nike Air as an emerging innovation to treating it as an integrated, foundational offering within Nike’s product development framework.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Nike moved from treating Air mainly as a marketing‑focused cushioning unit to making it a core, vertically‑controlled component of its product‑development pipeline.  In 2024 the company began producing Air‑Sole units through its Air Manufacturing Innovation subsidiary and expanded the Air family (Air Max, Zoom X, etc.) across a broader range of footwear and apparel, reflecting a more systematic R&D and manufacturing emphasis on Air technology than in 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some correct contextual elements but introduces significant factual inaccuracies and misrepresents the strategic evolution of Nike Air technology. (1) Correctly identifies a shift in Nike's treatment of Air technology between fiscal 2023 and 2024, and correctly frames it as becoming more integrated. However, it fabricates key details not present in the original answer or likely in the source filings: the claim that Nike began producing Air-Sole units through an 'Air Manufacturing Innovation subsidiary' in 2024 is unsupported by the ground truth and not mentioned in the original answer. Similarly, the assertion that Nike expanded the Air family to include 'Zoom X' (which is a distinct foam technology, not part of the Air lineage) is factually incorrect. (2) There are no explicit numbers, percentages, or dollar amounts in either answer, so quantitative accuracy is not heavily applicable—minor credit for not inventing false metrics. (3) The multi-hop reasoning is partially sound in that it infers a deeper integration of Air tech, but the LLM overreaches by introducing unverified operational changes (in-house manufacturing) and R&D restructuring. The original answer emphasizes a semantic and strategic repositioning—from innovative differentiator to foundational component—based on textual analysis of the 10-Ks, not new manufacturing initiatives. (4) The LLM answer is contextually relevant and addresses the time frame and topic, but fails on qualitative accuracy due to fabricated entities and processes. The core idea of increased integration aligns with the ground truth, but the explanation is based on incorrect premises, warranting a moderate-low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 464,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Abbott's positioning of Osmolite within its Nutritional Products segment evolved between 2022 and 2023, particularly in terms of its enteral feeding portfolio and associated product line strategy?",
      "original_answer": "In 2022, Osmolite was listed among Abbott's enteral feeding products used in healthcare institutions, alongside Jevity®, Glucerna® 1.2 Cal, Glucerna® 1.5 Cal, Oxepa®, Freego™, Nepro®, and Vital®. By 2023, Osmolite continued to be included in the enteral feeding portfolio, but Abbott's product listing in this category remained largely consistent, indicating a stable strategic positioning of Osmolite within the institutional enteral nutrition segment. There is no indication of Osmolite being newly introduced, discontinued, or significantly repositioned relative to other products in this category during this period.",
      "llm_answer": "\nBetween 2022 and 2023 Abbott kept Osmolite in essentially the same place in its Nutritional Products segment – it remains listed among the core enteral‑feeding products (e.g., Jevity, Glucerna 1.2/1.5 Cal, Oxepa, Freego (Enteral Pump), etc.) that the company markets to health‑care institutions (see the Nutritional Products bullet lists on pages 3‑5 of the 2022 filing and pages 2‑4 of the 2023 filing).  The 2022 narrative emphasized competitive pressures, ingredient innovation and the risk of obsolescence, while the 2023 discussion broadened the focus to include direct‑to‑consumer promotion and the overall product‑line strategy, but there was no substantive shift in how Osmolite itself is positioned within the enteral‑feeding portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. It correctly states that Osmolite remained in Abbott's enteral feeding portfolio in both 2022 and 2023, listed alongside the same core products (Jevity, Glucerna variants, Oxepa, Freego, etc.), and emphasizes no significant repositioning or change in strategic role. The mention of page numbers (pages 3–5 in 2022, pages 2–4 in 2023) adds precision and matches typical 10-K filing structures, though exact page numbers are not part of the ground truth; however, this detail does not affect factual correctness and reflects plausible document referencing. The LLM appropriately infers a stable strategic positioning and adds contextual nuance—such as the shift in narrative tone from competitive pressures and innovation in 2022 to direct-to-consumer promotion in 2023—without overstating changes to Osmolite’s specific role. This additional context is reasonable and enhances the answer without introducing error. There are no incorrect entities, dates, or financial figures. All entities (Osmolite, Jevity, Glucerna, etc.) and timeframes (2022–2023) are accurate. No quantitative errors exist—there are no numbers to compute, but references to years and product lists are correct. The reasoning is sound: the LLM synthesizes information across two years of product listings and interprets consistency in portfolio inclusion as indicative of stable positioning, which is a valid multi-hop inference. The answer fully addresses the question about evolution (or lack thereof) in positioning within the enteral feeding portfolio and product line strategy. The only reason for not scoring a 10 is that the ground truth does not mention narrative shifts (e.g., direct-to-consumer focus), so while plausible, that point slightly extends beyond the confirmed facts. However, it does not contradict them and is likely based on actual filing language, so the qualitative accuracy remains high. Overall, the answer is semantically equivalent to the original, with excellent completeness, contextual relevance, and reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 559,
        "total_tokens": 1915
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has 3M's regulatory engagement and remediation obligations related to PFAS discharge evolved between 2022 and 2024, particularly in Minnesota and Alabama?",
      "original_answer": "In 2022, 3M was actively working under a 2007 Settlement Agreement and Consent Order with the MPCA to address PFAS contamination in Minnesota, with remediation substantially completed at the Cottage Grove site and ongoing operational and maintenance activities at multiple locations. In Alabama, the Company had entered into a July 2020 Interim Consent Order with ADEM, which included obligations for PFAS-related wastewater discharges and air emissions, and had completed installation of a multilayer cap at the Decatur facility. By 2024, regulatory scrutiny had intensified. In Minnesota, MPCA issued a draft Clean Water Act permit for the Cottage Grove facility with significantly revised effluent limits for certain PFAS compounds, some below current quantification levels, and the Company submitted public comments in August 2024. Additionally, in 2024, MPCA published a revised draft permit in December after considering stakeholder input, which could have a significant adverse impact on the Cottage Grove facility's operations. In Alabama, while the 2020 Interim Consent Order remained in effect, the Company's obligations under ongoing investigations and potential future remediation were still expected to involve additional operating costs and capital expenditures over multiple years. The regulatory landscape evolved to include more stringent standards, such as updated HBVs from MDH in January 2024 and proposed HRLs in October 2024, further complicating 3M's compliance path.",
      "llm_answer": "\nBetween 2022 and 2024, 3M’s PFAS regulatory engagement in **Minnesota** moved from the 2022 MPCA order requiring the company to address PFAS‑laden storm‑water at its Cottage Grove plant to a 2024 draft Clean Water Act permit that imposes markedly stricter effluent limits and incorporates the Minnesota Department of Health’s newly updated health‑based values for PFOA and PFOS; the company is now negotiating the final permit while continuing to meet the obligations of the 2007 Settlement Agreement (providing alternative drinking water and remediating soil and groundwater at Oakdale, Woodbury and Cottage Grove).  \n\nIn **Alabama**, the company remains under the 2020 interim Consent Order with ADEM that obligates ongoing PFAS monitoring, off‑site investigations and capital‑improvement work at its Decatur facility, and it faced heightened scrutiny in 2023‑2024 through a grand‑jury subpoena and EPA information requests concerning historic TSCA violations, but no new binding remediation orders were issued—its obligations stayed focused on complying with the existing consent order and responding to EPA inquiries.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of 3M's regulatory engagement and remediation obligations related to PFAS in Minnesota and Alabama between 2022 and 2024. (1) Key facts are correct: In Minnesota, the 2007 Settlement Agreement with MPCA remained in effect, with ongoing remediation at Cottage Grove, Oakdale, and Woodbury; by 2024, a draft Clean Water Act permit with stricter effluent limits was issued, referencing updated health-based values (HBVs) from MDH—consistent with the January 2024 HBV updates and October 2024 proposed HRLs in the ground truth. The LLM correctly notes 3M’s public comment submission (implied in August 2024) and ongoing negotiations. In Alabama, the 2020 Interim Consent Order with ADEM remained in place, with obligations for monitoring, investigations, and capital improvements at Decatur—accurate per ground truth. The LLM adds context about a grand jury subpoena and EPA TSCA inquiries in 2023–2024, which, while not in the original answer, are factually plausible and contextually relevant, reflecting heightened scrutiny without contradicting the source. (2) Quantitative accuracy is perfect: all dates (2007, 2020, 2022, 2024), regulatory bodies (MPCA, ADEM, MDH), and facility locations (Cottage Grove, Decatur) are correct. No numerical errors. (3) Multi-hop reasoning is sound: the LLM synthesizes ongoing obligations under prior agreements with new regulatory developments, correctly distinguishing between binding orders and emerging scrutiny. It accurately conveys that no new binding orders were issued in Alabama, aligning with the original answer’s emphasis on continued obligations under the 2020 order. (4) Minor omission: the LLM does not mention the December 2024 revised draft permit in Minnesota (after stakeholder input), which is a small but notable update in the regulatory timeline. However, this does not undermine the overall correctness. Wording differs but meaning is semantically equivalent. Scores reflect high accuracy with a slight deduction in qualitative accuracy for the omitted December 2024 revision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1656,
        "completion_tokens": 561,
        "total_tokens": 2217
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has The Coca-Cola Company's financial relationship with Coca-Cola HBC AG evolved between 2022 and 2024, particularly in terms of investment classification and stake percentage?",
      "original_answer": "In 2022, Coca-Cola HBC AG was among the listed equity method investees, though the specific ownership percentage was not disclosed in the provided evidence. By 2024, Coca-Cola HBC AG remained an equity method investee, and the company explicitly stated a 22% ownership stake as of December 31, 2024. This indicates a formalization and quantification of the relationship, with Coca-Cola now specifying the exact percentage of ownership, which was absent in the 2022 disclosures.",
      "llm_answer": "\nBetween 2022 and 2024 Coca‑Cola’s ownership in Coca‑Cola HBC AG stayed around 22 % (22 % in 2022, 22 % in 2023 and 22 % in 2024).  The investment was re‑classified from being aggregated in the “Bottling Investments” line to a distinct equity‑method holding, and the 2024 filing reports a 22 % stake, a $1.147 bn carrying value and $1.770 bn of equity income from the venture.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that the ownership percentage was not disclosed in 2022, but the LLM claims it was 22% in 2022 and 2023—this is unsupported by the evidence. Only in 2024 was the 22% stake explicitly stated. The LLM incorrectly asserts that the percentage was known and constant across all years, which contradicts the original answer. Additionally, the LLM introduces specific financial figures—$1.147 billion carrying value and $1.770 billion equity income—that are not present in the ground truth and cannot be verified from the provided information. (2) Quantitative accuracy is low because the percentages for 2022 and 2023 are fabricated, and the dollar amounts appear to be hallucinated. While the 22% figure for 2024 matches the ground truth, the rest of the numbers do not align with the original answer or the available evidence. (3) The reasoning partially captures the idea of increased transparency in disclosure by 2024 but incorrectly frames it as a reclassification from 'Bottling Investments' to a distinct holding, which is not mentioned in the ground truth. The multi-hop synthesis fails because it assumes continuity of stake percentage without evidence and invents financial metrics. (4) Contextual relevance is high because the answer addresses the evolution of the financial relationship, investment classification, and stake percentage as asked. However, the inclusion of unverified numbers and incorrect historical percentages undermines factual reliability. The core idea of formalization in 2024 is correct, but the supporting details are largely inaccurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1221,
        "completion_tokens": 455,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has Oracle's strategic emphasis on hybrid deployments evolved between fiscal 2022 and fiscal 2024, particularly in terms of product development investment and deployment model integration?",
      "original_answer": "In fiscal 2022, Oracle emphasized hybrid deployments as part of its broader deployment model strategy, investing $7.2 billion in research and development to enhance existing offerings and develop new technologies, including hybrid solutions like Oracle Cloud@Customer. By fiscal 2024, Oracle further integrated hybrid deployments into its core offerings, positioning them as a standard deployment choice alongside on-premise and cloud-based models, and reinforcing its commitment to interoperability and customer choice. This reflects a strategic evolution from a development-focused approach to a more mature, integrated deployment model.",
      "llm_answer": "\nOracle has shifted from a license‑centric model toward making hybrid‑cloud (on‑premise + Oracle Cloud/OCI) the centerpiece of its product strategy.  In fiscal 2022 it highlighted hybrid deployments as a key differentiator and began directing a growing share of its R&D spend—$7.2 billion that year—into cloud‑native services, integration tools (e.g., Cloud@Customer, OCI) and the migration pathways that let customers run workloads across both environments.  By fiscal 2024 the company’s financial disclosures stress that hybrid deployment models are now a core growth engine, with cloud services and license‑support revenue representing roughly 71 % of total sales and continued investment aimed at expanding and unifying those hybrid offerings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the $7.2 billion R&D investment in fiscal 2022 matches the original answer. The 71% cloud services and license-support revenue figure is not in the ground truth, but it does not contradict it and is contextually plausible as supporting evidence; since it's not factually incorrect and enhances relevance without distorting facts, it doesn't reduce accuracy. (2) The answer correctly identifies Oracle as the entity and accurately references fiscal 2022 and 2024, satisfying the time frame requirement. (3) Multi-hop reasoning is sound: the LLM synthesizes Oracle’s strategic shift, R&D investment, product development (e.g., Cloud@Customer, OCI), and evolution into a core deployment model by 2024. It captures the evolution from development focus to integrated deployment model, even if it doesn’t explicitly use the phrase 'standard deployment choice.' (4) Semantically, the LLM conveys the same core progression: increased investment in hybrid technologies in 2022 and deeper integration by 2024 as a strategic growth engine. The only minor gap is less explicit emphasis on 'interoperability and customer choice' mentioned in the ground truth, but the focus on migration pathways and unified offerings implies similar intent. Overall, the answer is factually correct, complete, and contextually rich.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 391,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has the filing status of the Mandatory Clawback Policy evolved between the 2023 and 2024 SEC 10-K disclosures for Wells Fargo & Company?",
      "original_answer": "In 2023, the Mandatory Clawback Policy was filed directly as part of the 10-K filing under Exhibit 97. In 2024, instead of being filed directly, it was incorporated by reference to Exhibit 97 from the previous year's 10-K filing. This indicates a procedural change in how the policy is disclosed rather than a substantive change to the policy itself.",
      "llm_answer": "\nThe Mandatory Clawback Policy first appeared in the 2023 Form 10‑K as Exhibit 97, listed only as “Incorporated by reference to Exhibit 97 to the Company’s Annual Report on Form 10‑K for the year ended December 31, 2023.” In the 2024 filing the same policy is again presented as Exhibit 97, but the description now reads “Filed herewith,” indicating that the policy is being filed directly in the 2024 filing rather than merely incorporated by reference. Thus, its status evolved from an incorporated exhibit in 2023 to a directly filed exhibit in 2024.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both direction and fact. According to the ground truth, in 2023 the Mandatory Clawback Policy was filed directly as Exhibit 97 (i.e., 'Filed herewith'), while in 2024 it was incorporated by reference to the 2023 filing. The LLM reverses this: it claims the policy was 'incorporated by reference' in 2023 and 'filed herewith' in 2024, which is the opposite of the truth. This is a critical factual error that completely inverts the evolution of the filing status. There are no correct quantitative elements (dates and exhibit numbers are used but misapplied). The reasoning is flawed as it fails to correctly synthesize the multi-hop information across the two years' filings. While the answer addresses the general topic (evolution of filing status of Exhibit 97), it does so with incorrect substance, making it highly misleading. The contextual relevance is low but not zero since it discusses the right company, policy, and exhibit number over the correct years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1224,
        "completion_tokens": 288,
        "total_tokens": 1512
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How did Thermo Fisher's relationship with CorEvitas, LLC evolve between 2023 and 2024, and what specific financial implications were associated with this change?",
      "original_answer": "In 2023, Thermo Fisher invested $0.91 billion to acquire CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence for medical treatments. By 2024, this relationship had evolved from an investment into a full acquisition, as CorEvitas was integrated into the Laboratory Products and Biopharma Services segment. The acquisition in 2023 was part of a broader strategy that included significant capital expenditures and financing activities, such as issuing $5.94 billion in senior notes and repurchasing $3.00 billion of company stock. In 2024, the company began amortizing the definite-lived intangible assets from CorEvitas over a weighted average period of 18 years, reflecting the long-term strategic value of the acquisition.",
      "llm_answer": "\nThermo Fisher acquired CorEvitas, LLC in early 2023 for a net cash outlay of roughly $910 million (cash paid $730 million plus $184 million of assumed debt, net of $4 million cash acquired), which generated $627 million of goodwill and $351 million of definite‑lived intangible assets that are being amortized over an estimated 17‑year life. By 2024 the business was fully integrated into the Laboratory Products and Biopharma Services segment, and the amortization of those intangibles (and the associated goodwill) is reflected in the company’s non‑GAAP adjustments—most notably the $2.3 billion amortization expense that reduced adjusted operating income and was part of the $0.91 billion cash used for acquisitions reported in investing activities.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the acquisition of CorEvitas, LLC by Thermo Fisher in 2023 and its integration into the Laboratory Products and Biopharma Services segment in 2024, which aligns with the ground truth. However, there are significant discrepancies in the financial figures. The ground truth states a $0.91 billion (i.e., $910 million) investment, which the LLM matches in total amount but breaks down into $730M cash paid, $184M assumed debt, and $4M cash acquired—details not present in the original answer and potentially inferred or misstated. More critically, the LLM claims $351M in definite-lived intangible assets amortized over 17 years, while the ground truth specifies amortization over 18 years. This is a factual error in both amount and duration. Additionally, the LLM introduces a $2.3 billion amortization expense and links it to non-GAAP adjustments and the CorEvitas acquisition, which is not supported by the original answer and appears to be an overextrapolation or confusion with broader company figures (e.g., the $0.91B cash used for acquisitions is correctly cited but misattributed as a single-year figure when it may be part of broader activity). (2) The quantitative accuracy is compromised: while $910M total acquisition cost is correct, the breakdown is unverified and not in the original; the 17-year amortization period conflicts with the stated 18-year period; the $627M goodwill and $351M intangibles are not in the ground truth and thus cannot be confirmed. The $2.3B amortization expense is not mentioned in the original and seems inconsistent. (3) The multi-hop reasoning is partially sound—linking the 2023 acquisition to 2024 integration and amortization is correct, and segment integration is accurately described. However, the LLM overreaches by introducing unverified financial breakdowns and linking specific non-GAAP adjustments to CorEvitas without evidence. (4) Contextual relevance is high—the answer directly addresses the evolution of the relationship and financial implications. Due to correct core facts (acquisition in 2023, integration in 2024, strategic context, and approximate acquisition cost) but significant quantitative inaccuracies and unsupported financial details, the correctness score is 7, with lower quantitative accuracy (6), strong qualitative reasoning (8), and full relevance (10).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 634,
        "total_tokens": 2013
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How did RTX's flight hour payment obligations under its 2012 agreement with Rolls-Royce evolve between 2022 and 2023, particularly in terms of the timing and capitalization treatment of these payments?",
      "original_answer": "In 2022, RTX disclosed that flight hour payments to Rolls-Royce were contingent upon each hour flown through June 2027 by V2500-powered aircraft in service as of the acquisition date, and these payments were considered in 'Other commercial aerospace commitments' and capitalized as collaboration intangible assets as payments were made. In 2023, RTX reiterated the same contingent payment structure tied to flight hours through June 2027 and maintained that these payments would continue to be capitalized as collaboration intangible assets. There was no indication of a change in the magnitude or timing of these obligations between the two years, suggesting a stable commitment structure.",
      "llm_answer": "\nBetween 2022 and 2023 the flight‑hour payments that RTX owes under its 2012 Rolls‑Royce acquisition agreement remained tied to V2500‑powered flight hours through June 2027, but the disclosed schedule shifted forward – the 2022 filing (page 110) listed $1.222 bn due in 2022 and $1.051 bn due in 2023, whereas the 2023 filing (page 101) shows $0.836 bn due in 2024, $0.862 bn in 2025, $0.705 bn in 2026 and $0.687 bn in 2027.  The accounting treatment was unchanged: each payment is recorded as a collaboration intangible asset when made and is subsequently amortized over the underlying economic benefit, rather than being expensed immediately.  Thus, while the timing of when the amounts become payable moved into later years, RTX continued to capitalize the flight‑hour payments as collaboration intangibles as they are incurred.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) The Original Answer (ground truth) states there was no indication of a change in the magnitude or timing of RTX's payment obligations between 2022 and 2023, and that the structure remained stable. However, the LLM claims a 'shift forward' in the payment schedule with specific dollar amounts due in 2024–2027, which is not supported by the ground truth. These figures ($1.222B, $1.051B, $0.836B, etc.) are entirely absent from the Original Answer and represent a fabrication or misattribution not present in the knowledge base. (2) The quantitative accuracy is very low because the dollar amounts and payment schedules cited do not appear in the ground truth and contradict its assertion of no change in timing or magnitude. There is no mention of specific annual payment amounts in either year in the Original Answer. (3) The qualitative reasoning is partially sound—correctly identifying the V2500-powered aircraft, the June 2027 endpoint, and the capitalization treatment as collaboration intangible assets—but fails the multi-hop synthesis by inventing a payment schedule shift that did not occur. The conclusion about unchanged accounting treatment is correct and aligns with the Original Answer. (4) Contextual relevance is moderate because the response addresses the right agreement, companies, and accounting concepts, but introduces false details about payment timing. The core claim of a 'shift forward' in obligations is unsupported, making the overall answer misleading despite some correct elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 437,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has The Coca-Cola Company's financial relationship with fairlife evolved from 2022 to 2024, particularly regarding contingent payments tied to performance milestones?",
      "original_answer": "In 2022, Coca-Cola's acquisition-related disclosures referenced the 2020 acquisition of the remaining ownership interest in fairlife, with no mention of ongoing contingent payments. By 2024, the company disclosed that there was a remaining milestone payment related to the 2020 acquisition of fairlife, contingent on fairlife achieving certain financial targets through 2024, with the payment scheduled for 2025. This indicates that Coca-Cola's relationship with fairlife has evolved from a completed acquisition in 2020 to one where a performance-linked financial obligation remains active through 2024.",
      "llm_answer": "\nFrom 2022 through 2024 Coca‑Cola’s financial tie to fairlife remained a performance‑based milestone payment that is re‑measured each quarter and recorded as a Level‑3 liability; in 2023 the company paid a $275 million milestone after fairlife met a target, reducing the accrued contingent consideration, and the balance that remains is still contingent on achieving further 2024‑2025 financial goals and will be settled in 2025.  The 2024 10‑K (pages 111‑112) shows the liability’s fair‑value hierarchy and notes that any subsequent changes in its fair value are recognized in income, illustrating how the contingent payment evolved from an accrued obligation in 2022 to a partially settled, quarterly‑remeasured liability by 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, there was no mention of ongoing contingent payments, and by 2024, a remaining milestone payment was disclosed—contingent on performance through 2024 and payable in 2025. However, the LLM claims a $275 million payment was made in 2023, which is not supported by the original answer or the knowledge graph. This is a major quantitative error. (2) The numbers are incorrect: the $275 million payment in 2023 is not mentioned in the ground truth, and no specific dollar amount for the remaining liability is provided in the original answer. The LLM fabricates a precise figure and event (payment in 2023) that are not present in the source. (3) The multi-hop reasoning is partially sound in that it tracks the evolution of the contingent payment from 2022 to 2024 and references the 2024 10-K, but it incorrectly introduces quarterly re-measurement and Level-3 liability classification, which are not in the original answer. The core idea—that a contingent payment remains tied to 2024 performance and will be settled in 2025—aligns with the ground truth, showing some correct synthesis. (4) The contextual relevance is high because the answer addresses the evolution of the financial relationship and contingent payments. However, the correctness score is low due to the invention of specific financial data and events not present in the ground truth. The qualitative accuracy is moderate because the structure and intent of the reasoning are reasonable, but the factual foundation is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 438,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has Oracle's strategic positioning of Oracle Cloud Services evolved between 2022 and 2024, particularly in terms of integration with enterprise applications and infrastructure technologies?",
      "original_answer": "In 2022, Oracle emphasized the transformational potential of Oracle Cloud Services, particularly highlighting the Oracle Autonomous Database as a key OCI offering that utilized machine learning to enable leaner business processes and automation. The focus was on flexibility, interoperability, and customer choice across deployment models, including cloud-based, hybrid, and on-premise environments. By 2024, Oracle expanded this positioning by describing Oracle Cloud Services (including SaaS and OCI) as comprehensive and integrated offerings that provide customers with a full suite of applications and infrastructure services. The 2024 filing explicitly frames Oracle Cloud Services as enabling customers to 'choose the best option that meets their specific business needs,' indicating a more mature and customer-centric strategic approach. This evolution reflects a shift from promoting individual innovations (e.g., Autonomous Database) to positioning Oracle Cloud Services as a holistic, integrated platform for enterprise IT transformation.",
      "llm_answer": "\nBetween fiscal 2022 and 2024 Oracle moved Oracle Cloud Services from a supplemental offering to the central pillar of its enterprise stack, tightly coupling SaaS applications (Fusion ERP, HCM, SCM, NetSuite, Advertising, etc.) with Oracle Cloud Infrastructure (OCI).  The company now markets a unified, subscription‑based platform that can be run on‑premise, in Oracle‑hosted OCI, or via Oracle Cloud@Customer, delivering end‑to‑end integration of applications and infrastructure, enabling customers to migrate and modernize core business processes on a single, interoperable cloud foundation.  This shift is reflected in the growing share of cloud‑services and license‑support revenue—rising to roughly 71 % of total sales—and in the expanded, cloud‑native portfolio that emphasizes seamless data flow, consistent upgrades, and AI/ML‑enabled services such as the Autonomous Database.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly captures the evolution of Oracle's strategic positioning from 2022 to 2024, noting the shift from promoting individual innovations like Autonomous Database to a holistic, integrated cloud platform. The mention of tight coupling between SaaS applications (e.g., Fusion ERP, HCM, SCM) and OCI reflects the integration focus in 2024. The LLM correctly identifies deployment flexibility (on-premise, OCI, Cloud@Customer), consistent with the ground truth’s emphasis on customer choice and interoperability. The 71% figure for cloud-services and license-support revenue is factually accurate per Oracle’s 2024 filings and supports the narrative of cloud becoming the central pillar. This number is not in the original answer but is contextually valid and enhances completeness without contradicting the ground truth. The LLM adds value by specifying product names and deployment models not explicitly listed in the original, but these are consistent with known Oracle offerings and filings. The reasoning is sound, demonstrating multi-hop synthesis across years and strategic themes. Minor deduction in quantitative accuracy only because the 71% figure, while accurate, is not referenced in the original answer and could be seen as extrapolation, though it supports the correct conclusion. Overall, the answer is semantically equivalent, factually correct, and contextually rich.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1495,
        "completion_tokens": 401,
        "total_tokens": 1896
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has the treatment or status of the Key/Specified Employee Policy evolved between the 2023 and 2024 SEC filings, particularly in terms of its documentation and incorporation by reference?",
      "original_answer": "In the 2023 filing, the Key/Specified Employee Policy was introduced as part of the company's disclosures, specifically incorporated by reference to Exhibit 10(v) from the Annual Report on Form 10-K for the year ended December 31, 2018. By 2024, the policy was no longer newly introduced but was instead announced as a continuing policy, still relying on the same Exhibit 10(v) from the 2018 filing. This indicates that while the policy remained in place, there were no new amendments or updates to its documentation during this period.",
      "llm_answer": "\nThe Key/Specified Employee Policy is still disclosed as Exhibit 10(r) in both the 2023 and 2024 Form 10‑K filings, and in each filing it is incorporated by reference to the same 2018 filing (Exhibit 10(v) of the 2018 10‑K).  No new exhibit or separate narrative was added in the 2024 filing; the policy continues to be referenced solely through that historical exhibit designation.  Consequently, the documentation and incorporation method for the policy have remained unchanged between the two years.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. First, it incorrectly states that the Key/Specified Employee Policy is disclosed as Exhibit 10(r) in both the 2023 and 2024 filings, while the ground truth specifies Exhibit 10(v) from the 2018 filing as the referenced document. This misidentification of the exhibit number (10(r) vs. 10(v)) is a critical error in entity accuracy. Second, the LLM implies the policy appears as Exhibit 10(r) in the 2023 and 2024 filings themselves, which contradicts the ground truth stating it is incorporated by reference from the 2018 filing, not separately filed in later years. While the LLM correctly notes that the policy continues to rely on the same 2018 exhibit and that no new documentation was added in 2024, this correct reasoning is built upon incorrect foundational facts. The core timeline and incorporation mechanism are partially right—unchanged documentation method and reliance on the 2018 filing—but the erroneous exhibit labels and implied current filing disclosures reduce quantitative and qualitative accuracy. Contextual relevance is high because the answer addresses the evolution, documentation, and incorporation by reference as asked. However, due to the exhibit number error and misrepresentation of where the policy is disclosed, the overall correctness score is significantly reduced.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 383,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the aggregate principal balance of the 6.700% notes due 2028 evolve between 2022 and 2023, and what does this indicate about RTX's debt management strategy?",
      "original_answer": "In 2022, the aggregate principal balance of the 6.700% notes due 2028 was $115 million. By 2023, this amount increased significantly to $285 million. This indicates that RTX increased its outstanding debt related to this particular note, suggesting a strategic decision to retain or expand exposure to this fixed-rate debt instrument.",
      "llm_answer": "\nThe $6.700\\%$ notes maturing in 2028 fell from **$400 million** at the end of 2022 to **$285 million** at the end of 2023—a reduction of roughly **$115 million**.  This decline shows that RTX is deliberately shrinking its legacy debt, using new issuances and cash flows to retire older tranches and thereby streamline its long‑term financing and lower overall leverage.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. According to the ground truth, the aggregate principal balance of the 6.700% notes due 2028 was $115 million in 2022 and increased to $285 million in 2023. The LLM incorrectly states that the balance was $400 million in 2022 and decreased to $285 million, which misrepresents both the starting value and the direction of change. This error fundamentally undermines the answer's correctness. (2) The calculation of a $115 million reduction is based on incorrect inputs ($400M - $285M = $115M), but this number coincidentally matches the correct 2022 balance, leading to a misleading appearance of accuracy. The actual change was an increase of $170 million ($285M - $115M), which the LLM completely misses. (3) The multi-hop reasoning is flawed: instead of recognizing that RTX increased its debt on these notes—suggesting a strategy of expanding fixed-rate debt exposure—the LLM concludes that RTX is reducing legacy debt, which contradicts the evidence. The reasoning is internally logical but based on false premises, failing to correctly synthesize the actual data. (4) Despite addressing both parts of the question (evolution of balance and strategic implication), the answer scores low on correctness (2) due to major factual and directional errors. Quantitative accuracy is very poor (2) because key numbers are wrong. Qualitative accuracy is also low (2) due to incorrect entity values and flawed inference. Contextual relevance is moderate (5) as the structure and intent align with the question, but the substance is inaccurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1180,
        "completion_tokens": 439,
        "total_tokens": 1620
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the carrying value and effective interest rate of TMO's 1.95% 12-Year Senior Notes evolve between 2023 and 2024?",
      "original_answer": "In 2023, the carrying value of the 1.95% 12-Year Senior Notes was $773 million with an effective interest rate of 2.08%. In 2024, the carrying value decreased to $725 million, and the effective interest rate slightly declined to 2.07%. This indicates a reduction in the financial liability associated with these notes and a marginal improvement in the effective borrowing cost.",
      "llm_answer": "\nThe 1.95 % 12‑Year Senior Notes carried a balance of $773 million at year‑end 2023, which declined to $725 million by year‑end 2024.  During this interval the effective interest rate stayed essentially unchanged, holding near 2.08 % (reported as about 2.07 % for 2024).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the carrying value of $773 million in 2023 and $725 million in 2024, matching the ground truth exactly. The effective interest rate is reported as 'about 2.07%' for 2024 and 'holding near 2.08%' for 2023, which aligns with the ground truth values of 2.08% in 2023 and 2.07% in 2024. (2) All numeric values—dollar amounts and percentages—are accurate and correctly attributed to the respective years. There are no calculation errors. Format variations (e.g., 'about', 'near') are acceptable and do not distort the factual meaning. (3) The reasoning is sound: the LLM correctly identifies the trend of declining carrying value and stable-to-slightly-declining effective interest rate. While the original answer includes a brief interpretation ('reduction in financial liability... marginal improvement in borrowing cost'), the LLM omits this qualitative synthesis but still accurately presents the core facts. This minor omission affects completeness but not correctness. (4) The answer is contextually fully relevant, directly addressing the evolution of both carrying value and effective interest rate over the specified period. The slight softening of precision in describing the interest rate (e.g., 'about', 'near') prevents a perfect qualitative score, but the factual core remains intact. Thus, correctness is scored 9 due to missing interpretive context, but quantitative accuracy is perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1155,
        "completion_tokens": 400,
        "total_tokens": 1556
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "What are the corporate governance implications of the change in how BNY Mellon presents its Directors' Code of Conduct between its 2022 and 2024 SEC filings?",
      "original_answer": "In 2022, BNY Mellon explicitly detailed the availability of the Directors' Code of Conduct on its website with a direct URL link, and it was referenced within the broader context of corporate governance disclosures and ethics policies. By 2024, the Code was listed among other governance materials—such as committee charters and by-laws—without a direct link or specific mention of updates or amendments. This shift in presentation may signal a more streamlined or consolidated approach to governance disclosures, potentially reducing the visibility of the Code as a standalone document. While the Code remains accessible, the change could affect transparency and stakeholder engagement with the specific ethical expectations for directors, which may influence perceptions of governance accountability.",
      "llm_answer": "\nThe 2024 filing now lists the Directors’ Code of Conduct as a stand‑alone governance document that is posted on the company’s website alongside the board’s charters and other governance guidelines, whereas the 2022 filing only mentioned it within a broader “Code of Ethics” and pledged to disclose any amendments or waivers on the site. This shift makes the directors’ conduct rules a permanent, easily accessible element of BNY Mellon’s governance framework, signaling greater transparency and formal board oversight.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claims, despite being contextually relevant to corporate governance and using the correct years (2022 and 2024). (1) The original answer states that in 2022, BNY Mellon provided a direct URL to the Directors' Code of Conduct and discussed it within ethics and governance disclosures, while in 2024, it was listed among other governance documents without a direct link or mention of updates. The LLM answer reverses this trajectory: it incorrectly claims that in 2022 the Code was only mentioned within a broader 'Code of Ethics' without a standalone presence, and that in 2024 it became a stand-alone, more visible document. This is the opposite of the truth — the trend was toward reduced visibility, not increased. (2) There are no numeric values or calculations in the question or answers, so quantitative accuracy is not applicable; however, the years (2022 and 2024) are correctly used, hence a score of 10. (3) The multi-hop reasoning is flawed: the LLM fails to correctly synthesize the change in disclosure practice and draws an inverted conclusion about transparency. Instead of identifying a potential reduction in visibility and stakeholder engagement, it asserts greater transparency and formal oversight, which contradicts the ground truth. (4) While the answer addresses corporate governance implications and focuses on the right entity (BNY Mellon) and document (Directors' Code of Conduct), the reversal of factual direction renders the qualitative accuracy very low. The contextual relevance is moderate because the structure and intent of the response align with the question, even if the facts are wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 454,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has Amazon's Short-Term Credit Agreement evolved between 2023 and 2024, particularly in terms of facility size, maturity date, and the timing of its establishment?",
      "original_answer": "In 2023, Amazon entered into a $5.0 billion unsecured 364-day revolving credit facility (Short-Term Credit Agreement) in November, replacing the prior agreement from November 2022, with a maturity date in October 2024. In 2024, Amazon again entered into a new $5.0 billion unsecured 364-day revolving credit facility in October, replacing the 2023 agreement, with a maturity date in October 2025. The facility size remained the same at $5.0 billion, but the establishment date shifted from November to October, and the maturity date moved forward by one year, indicating a procedural renewal rather than a substantive change in the credit structure.",
      "llm_answer": "\nBetween 2023 and 2024 Amazon refreshed its short‑term revolving facility twice. In November 2023 it entered a new $5 billion, 364‑day unsecured revolving credit agreement that replaced the prior $5 billion facility, and in October 2024 it replaced that agreement with another $5 billion, 364‑day facility whose maturity was extended to October 2025 (with a one‑year extension option). Thus, the facility size remained $5 billion, but the maturity date moved from 2024 to 2025, and the agreement was re‑established in late 2023 and again in October 2024. No borrowings were outstanding under the facility as of December 31 2023 or 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $5.0 billion facility size in both 2023 and 2024, the November 2023 establishment date, and the October 2024 renewal with a maturity date in October 2025. These match the ground truth exactly. The only discrepancy is the mention of a 'one-year extension option' in the 2024 facility, which is not present in the original answer and cannot be verified from the provided ground truth—this is a minor addition but does not contradict known facts. (2) All numbers, dates, and dollar amounts are accurate: $5 billion, November 2023, October 2024, maturity in October 2025—all align with the ground truth. No calculation errors. (3) The multi-hop reasoning is sound: the model correctly synthesizes the renewal pattern, recognizes the procedural nature of the change (same size, shifted dates), and tracks the evolution across two years. It correctly infers that the facility was replaced annually. (4) The answer is semantically equivalent to the original, with slightly more detail (e.g., noting no borrowings outstanding), which is acceptable and contextually relevant. The minor over-specification of an 'extension option' prevents a perfect 10, but overall accuracy is very high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 347,
        "total_tokens": 1674
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has AMD's APU strategy evolved from 2022 to 2024 in terms of product integration and target markets, and what implications does this shift have for its revenue potential in the AI PC segment?",
      "original_answer": "In 2022, AMD emphasized external GPU-based solutions for AI and HPC workloads, particularly through the Instinct MI200 series and Radeon PRO V620 GPUs, focusing on data center and cloud applications. By 2024, AMD had shifted toward integrating dedicated AI acceleration directly into client devices, becoming the first company to include a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs. This strategic pivot toward integrated APUs with NPU cores indicates a move to capture revenue growth in the emerging AI PC market, where on-device AI processing is becoming critical. This evolution likely enhances AMD's revenue potential by positioning it as a differentiated player in the AI PC segment, moving beyond traditional CPU-GPU combinations.",
      "llm_answer": "\nFrom 2022 to 2024 AMD shifted its APU roadmap from a pure CPU‑GPU integration aimed at mainstream and commercial PCs toward a **AI‑ready SoC** that adds a dedicated neural‑processing unit and more capable graphics (e.g., Ryzen AI 300 series with an NPU and Ryzen PRO 8000G “integrated AI desktop”).  This tighter hardware‑software integration targets **AI‑centric laptops and desktops for consumers, creators and enterprise users**, expanding the addressable market beyond traditional PC segments.  As a result, AMD can tap a **new, higher‑margin revenue stream in the emerging AI‑PC market**, but the upside will depend on OEM adoption and the growth of on‑device AI software ecosystems.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures AMD's strategic shift from 2022 to 2024: moving from CPU-GPU integration in APUs to incorporating a dedicated NPU in client SoCs (e.g., Ryzen AI 300 series and Ryzen PRO 8000G), which matches the ground truth's emphasis on AMD being the first to integrate an NPU on the same SoC as an x86 CPU. (2) There are no numeric values (e.g., revenue figures, percentages) in either answer, so quantitative accuracy is not compromised—dates (2022 to 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes product evolution (integration of NPU), target market expansion (consumers, creators, enterprise), and implications for revenue (new, higher-margin AI PC segment), which reflects the original answer’s logic about enhanced revenue potential through differentiation in AI PCs. (4) The only minor gap is that the LLM does not explicitly mention AMD’s 2022 focus on external GPUs (Instinct MI200, Radeon PRO V620) for data center/cloud AI, which is a small omission in completeness. However, the contrast between past and present strategy is still clearly implied. Wording differs but semantic meaning is equivalent. Thus, the answer is factually correct, contextually relevant, and well-reasoned, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 396,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has the treatment of Irish income tax liability for U.S. shareholders receiving dividends from Medtronic evolved between 2023 and 2024, particularly in relation to the Irish dividend withholding tax?",
      "original_answer": "In both 2023 and 2024, dividends paid by Medtronic were generally subject to Irish dividend withholding tax at a rate of 25 percent unless an exemption applied. For U.S. residents, exemptions were available based on residency documentation, such as a valid U.S. Certification of Residence (Form 6166) or Irish Non-Resident Form V2. In both years, a U.S. resident who met the exemption criteria and did not hold shares through an Irish branch generally had no Irish income tax liability. Additionally, if a U.S. shareholder was subject to the 25% withholding tax, the payment discharged any Irish income tax liability, provided the shareholder submitted the required statement to the Irish Revenue authorities. There was no change in the tax rate or in the conditions for exemption between the years, indicating a stable regulatory framework.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Medtronic’s disclosures did not introduce any new Irish tax rules – the company continued to state that Irish dividend withholding tax of 25 % applies to dividends on its ordinary shares, but U.S. shareholders can avoid that tax if they provide a valid U.S. certification of residence (Form 6166) or have their broker’s U.S. address on file, and any withheld amount is treated as a full discharge of any Irish income‑tax liability. In short, the treatment of Irish withholding tax for U.S. shareholders remained essentially unchanged, with the 2024 filing merely reaffirming the same exemption conditions and discharge‑of‑liability language.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key facts are correct: the 25% Irish dividend withholding tax rate applied in both 2023 and 2024, U.S. shareholders could avoid it with proper documentation (Form 6166 mentioned, which matches ground truth), and any withheld tax discharged Irish income tax liability. The answer correctly states there was no change between the years. (2) Quantitative accuracy is perfect: the 25% rate is correctly cited, and no incorrect numbers or calculations are present. (3) Reasoning is sound—LLM correctly synthesizes that the treatment remained stable across fiscal years, which is the central point of the question. It slightly omits mention of the Irish Non-Resident Form V2 and the specific requirement to submit a statement to Irish Revenue, but these are minor omissions that do not undermine the overall correctness. (4) The answer is fully relevant, directly addressing the evolution (or lack thereof) in tax treatment. The use of 'broker’s U.S. address on file' as an alternative to Form 6166 is a slight simplification but aligns with practical implementation and does not contradict the ground truth. Overall, the answer is factually correct, well-reasoned, and semantically equivalent to the original, meriting a high score with only minor room for completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 378,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has the risk disclosure around new products and services evolved between 2022 and 2024, particularly regarding the company's platforms operating model initiative?",
      "original_answer": "In 2022, BNY Mellon highlighted that new lines of business, new products and services, or transformational or strategic project initiatives subject the company to new or additional risks. By 2024, this risk disclosure evolved to specifically include the 'transition to a platforms operating model' as a new source of uncertainty. The 2024 filing explicitly states that the company 'may not realize some or all of the expected benefits of our transition to a platforms operating model,' indicating a more focused risk related to this specific strategic initiative. This evolution shows a shift from general strategic risk language to a more concrete acknowledgment of platform-specific implementation risks.",
      "llm_answer": "\nBetween the 2022 and 2024 filings the discussion of risk moved from a generic warning that “new lines of business, new products and services or transformational or strategic project initiatives subject us to new or additional risks” to a dedicated, explicit risk factor that the company “may not realize some or all of the expected benefits of our transition to a platforms operating model.”  The 2024 filing therefore adds a clear, stand‑alone disclosure that the platforms‑operating‑model initiative itself introduces additional operational, technological and regulatory uncertainties, whereas the 2022 filing only referenced such initiatives in the aggregate.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies the evolution of risk disclosure from 2022 to 2024, accurately quoting both the general 2022 language about new products and strategic initiatives and the specific 2024 risk related to the platforms operating model. (2) There are no numerical values requiring calculation, but the years (2022 and 2024) are correct and consistently referenced. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two filings to show a shift from generic to specific risk disclosure, identifying the platforms operating model as a new focal point of risk. (4) The LLM adds slight but appropriate elaboration—mentioning 'operational, technological and regulatory uncertainties'—which is a reasonable interpretation of the implied risks in the 2024 filing and does not introduce inaccuracies. All parts of the question are addressed: the time frame, the evolution in language, and the specific mention of the platforms operating model initiative. Thus, all accuracy and relevance metrics are maximized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 320,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has Amazon's relationship with the 3.600% Note due 2032 evolved between 2023 and 2024, particularly in terms of its debt instrument disclosures?",
      "original_answer": "In 2023, the 3.600% Note due 2032 was disclosed as part of a Supplemental Indenture dated April 13, 2022, among Amazon.com, Inc., Wells Fargo Bank, National Association (as prior trustee), and Computershare Trust Company, National Association (as successor trustee). In 2024, the same note was referenced under the same Supplemental Indenture, but the trustee structure now only referenced Computershare Trust Company, National Association, as successor trustee, indicating a formal transition away from Wells Fargo Bank. This reflects a procedural evolution in the administration of the note, with no changes to the note’s terms or interest rate, but a shift in the trustee relationship.",
      "llm_answer": "\nBetween 2023 and 2024 Amazon did not issue, amend, or retire the 3.600 % Note due 2032; the instrument remained part of the company’s senior unsecured debt under the original April 13 2022 Supplemental Indenture. The note continued to be disclosed in the 10‑K filings, but its reference moved from Exhibit 4.2 in the 2023 filing to the reorganized Exhibit 4.8 (which now bundles the 4.700 % Note due 2032) in the 2024 filing—reflecting only a renumbering of the exhibit list, not a material change in the debt instrument itself.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements but misses the key factual evolution highlighted in the ground truth. (1) Quantitatively, the dates (April 13, 2022 Supplemental Indenture) and note details (3.600% due 2032) are accurate, and the absence of issuance/amendment/retirement is consistent with the original answer—so numeric and date accuracy is acceptable. However, the claim about exhibit renumbering (from Exhibit 4.2 in 2023 to Exhibit 4.8 in 2024) is not corroborated in the ground truth and introduces unverified detail, reducing quantitative reliability. (2) The original answer focuses on a procedural trustee transition—from Wells Fargo Bank (prior trustee) to solely Computershare Trust Company (successor trustee)—which reflects an administrative evolution in the debt instrument's governance. This key point is entirely missing in the LLM response. Instead, the LLM emphasizes exhibit renumbering and bundling with the 4.700% Note, which may be true but is not supported by the ground truth and distracts from the actual trustee change. (3) The reasoning is partially sound in that it correctly identifies no material change to the note’s terms or interest rate, and that it remains under the same Supplemental Indenture. However, it fails the multi-hop synthesis by not connecting the trustee transition across years, which is the core of the 'evolution' asked in the question. (4) While contextually relevant—focusing on debt disclosures and procedural changes—the answer substitutes the actual administrative evolution (trustee update) with an unverified structural filing change (exhibit renumbering), leading to a partially incorrect conclusion. Thus, the correctness score is moderate due to accurate baseline facts but significant omission of the key trustee transition and introduction of unsupported exhibit details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 497,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How did MDLZ's treatment and disclosure of net investment hedge derivative contracts evolve from 2023 to 2024, particularly in terms of their financial impact and presentation within the financial statements?",
      "original_answer": "In 2023, MDLZ disclosed the fair value of derivative assets and liabilities associated with net investment hedge contracts, with $1,347 million and $377 million in other current assets and $250 million and $413 million in other assets as of December 31, 2023 and 2022, respectively. By 2024, the focus shifted to the income statement impact, where the company noted that 'Other income, net' included amounts excluded from the assessment of hedge effectiveness related to these contracts, indicating a change in emphasis from balance sheet valuation to income volatility effects.",
      "llm_answer": "\nIn the 2024 filing MDLZ presents net‑investment‑hedge derivatives as a separate line‑item within “derivatives designated as accounting hedges,” showing a gross asset of $305 million and a liability of $50 million (net $255 million), whereas the 2023 disclosure only showed the contracts as part of the aggregate derivative totals with a net liability of $219 million. This shift moves the hedge from a net liability to a net asset and raises the gains excluded from hedge‑effectiveness to $148 million (2024) from $116 million (2023), reflecting a change in the hedge portfolio’s composition and improved hedge performance.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2023, MDLZ disclosed derivative assets of $1,347 million and $377 million in other current assets, and $250 million and $413 million in other assets for 2023 and 2022 respectively. The LLM answer incorrectly claims a 'net liability of $219 million' in 2023 and introduces a 2024 gross asset of $305 million and liability of $50 million (net $255 million), which are not present in the original answer. Additionally, the LLM claims gains excluded from hedge effectiveness were $148 million in 2024 and $116 million in 2023, but these figures are not supported by the ground truth, which does not provide specific dollar amounts for income statement impacts beyond noting a shift in emphasis. (2) The quantitative inaccuracies are severe: none of the dollar amounts in the LLM answer match the ground truth, and there is no mention in the original answer of a net liability turning into a net asset or specific line-item breakout in 2024. The calculation of changes in excluded amounts ($148M vs $116M) is fabricated. (3) The multi-hop reasoning is flawed. While the original answer notes a shift in disclosure focus from balance sheet valuation (2023) to income statement impact (2024), the LLM invents a detailed evolution in presentation and performance not present in the source, including specific balance sheet line items and performance improvements. It fails to accurately reflect the nature of the evolution, which was in emphasis and disclosure type, not in the reversal of a liability to an asset. (4) The contextual relevance is moderate because the LLM attempts to address the evolution of disclosure and financial impact, but the qualitative and quantitative inaccuracies severely undermine correctness. The answer sounds plausible but is factually incorrect, leading to a low correctness score despite addressing the general topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 526,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the Abrams Main Battle Tank's modernization strategy evolved from 2023 to 2024, particularly in terms of technological development and international demand?",
      "original_answer": "In 2023, General Dynamics was focused on delivering the System Enhancement Package version 3 (SEPv3) for the Abrams tank, which included upgrades in communications, power generation, fuel efficiency, optics, and armor. Additionally, GD announced the development of the M1E3 Abrams, a more significant engineering change aimed at future threats, featuring the latest systems architecture for quicker upgrades and reduced sustainment footprint. By 2024, the company emphasized continued capability enhancement of the Abrams to counter current and potential threats, with increased international demand reflected in a growing installed base across Europe, the Middle East, North Africa, and the Indo-Pacific. While 2023 focused on the technical roadmap (SEPv3 and M1E3), 2024 highlighted the global strategic relevance and procurement momentum of the Abrams platform.",
      "llm_answer": "\nFrom 2023 to 2024 the Abrams modernization moved from incremental enhancements—specifically the delivery of the SEPv3 “system‑enhancement‑package” that adds upgraded communications, power generation, fuel‑efficiency, optics and armor to existing M1A2 tanks and supports upgrades for allied customers—to a more fundamental engineering change: the Army’s announced development of the M1E3 tank, an “engineering‑change” design that adopts a new systems‑architecture standard, promises faster technology refreshes, a smaller sustainment footprint and greater tactical mobility.  Throughout both years NATO and other allies have kept strong demand for Abrams‑type upgrades and new builds, reflected in a growing installed base across Europe, the Middle East, North Africa and the Indo‑Pacific.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key facts are correct: the 2023 focus on SEPv3 upgrades (communications, power, fuel efficiency, optics, armor) and the M1E3 development with new systems architecture, faster tech refreshes, and reduced sustainment footprint are accurately described. The 2024 emphasis on global strategic relevance and growing international demand across Europe, the Middle East, North Africa, and the Indo-Pacific is also correctly reflected. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2023–2024) are correct. (3) Multi-hop reasoning is sound: the answer synthesizes technological development (SEPv3 to M1E3 transition) and shifts in strategic focus (from technical roadmap to global demand), correctly attributing evolving priorities across the two years. (4) Minor deduction in qualitative accuracy due to slightly compressed presentation—while the growing installed base and international demand are mentioned, the original answer more clearly separates 2023’s internal technical focus from 2024’s outward-facing procurement momentum. However, the LLM implies this shift well. Wording differences (e.g., 'tactical mobility' not in original) do not introduce inaccuracy but add minor interpretive content. Overall, the answer is factually correct, contextually complete, and semantically equivalent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 408,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has AMD's role in the development and positioning of APUs evolved between 2022 and 2024, particularly in terms of their market segmentation and strategic emphasis?",
      "original_answer": "In 2022, APUs were discussed as part of AMD's broader Enterprise, Embedded and Semi-Custom product portfolio, which included CPUs, GPUs, and customized SoC products. They were described in general terms without specific market segmentation or strategic emphasis. By 2024, APUs were explicitly included in two of AMD's four reportable segments: the Data Center segment and the Client segment. In the Data Center segment, APUs were listed alongside AI accelerators, CPUs, GPUs, and DPUs, indicating a strategic shift to position APUs as part of data center solutions. In the Client segment, APUs were specifically tied to desktop and notebook CPUs and chipsets, showing a more defined and segmented approach to their market positioning. This evolution reflects a more structured and strategic integration of APUs into AMD's core business segments.",
      "llm_answer": "\nBetween 2022 and 2024 AMD broadened the APU’s footprint — while it remained the core of the **Client segment** (desktop and notebook CPUs/APUs/chipsets), the company began positioning the APU in **new markets** such as **embedded platforms, semi‑custom SoCs for game consoles and handheld devices, and AI‑oriented compute** (e.g., the Silo AI acquisition and Data‑Center AI accelerators that rely on APU‑style heterogeneous processing).  Consequently, the strategic emphasis shifted from a pure “CPU‑plus‑GPU for mainstream PCs” to a **heterogeneous‑computing narrative** that spans client, embedded and semi‑custom segments and underpins AMD’s AI‑accelerator and AI‑software strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general direction of AMD's strategic evolution regarding APUs but introduces speculative and unsupported details not present in the ground truth. (1) Correct elements: The answer correctly identifies that APUs remained central to the Client segment (desktop/notebook) and acknowledges an expanded strategic role beyond traditional PCs. It also correctly notes a shift toward heterogeneous computing, which aligns with the 2024 segmentation. (2) Quantitative accuracy: There are no numeric values to verify, so this score is 10 by default. (3) Multi-hop reasoning: The core reasoning about evolving market segmentation is partially sound, but the LLM overreaches by introducing specific claims not in the original data — such as positioning APUs in 'AI-oriented compute' via the 'Silo AI acquisition' and linking APUs directly to data center AI accelerators. The ground truth states APUs were included in the Data Center segment alongside AI accelerators, but does not state they are part of them or that Silo AI is involved. These are fabrications or unwarranted inferences. (4) The ground truth emphasizes structural reporting changes — APUs being explicitly listed in Data Center and Client segments by 2024 — which the LLM omits in favor of a more narrative-driven, speculative strategy story. While the qualitative shift toward heterogeneous computing is plausible, the LLM fails to accurately reflect the actual documentation-based evolution (from general mention in 2022 to segmented reporting in 2024). Thus, the answer is partially correct but contains significant factual overreach, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 451,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has Medtronic's disclosure regarding the implications of the Financial Transfers Act 1992 on financial transfers between Ireland and third countries evolved from 2023 to 2024?",
      "original_answer": "In 2023, Medtronic disclosed that the Financial Transfers Act 1992 allowed the Irish Minister for Finance to impose restrictions on financial transfers with certain third countries, and that the list of such countries was subject to ongoing change. By 2024, the company continued to disclose the same regulatory framework but no longer emphasized the dynamic nature of the list of restricted countries, suggesting a potential shift in focus or a stabilization in the regulatory environment affecting these transfers.",
      "llm_answer": "\nIn the 2023 filing Medtronic gave only a brief notice that Ireland’s Minister for Finance could restrict financial transfers under the 1992 Act and that “the list is subject to ongoing change,” without specifying which third‑country transfers might be affected. By the 2024 filing the company expanded the disclosure, explicitly stating that the Minister’s restrictions cover all transfers between Ireland and third countries, that the restricted‑country list is regularly updated, and that any transaction involving a sanctioned jurisdiction or party may be blocked—thereby providing a clearer, more detailed picture of how the Act could affect cross‑border cash movements and shareholder‑related financial flows.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in its qualitative claims and contradicts the ground truth. (1) The original answer states that in 2024, Medtronic no longer emphasized the dynamic nature of the restricted country list, suggesting a reduced focus or stabilization. However, the LLM claims the opposite—that the 2024 disclosure was expanded with more detail, including that the list is 'regularly updated' and that transactions may be blocked. This is a direct reversal of the actual evolution. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable—no errors here, hence a score of 10 by default. (3) The multi-hop reasoning is flawed: the question asks for the evolution of disclosure from 2023 to 2024, requiring accurate synthesis of Medtronic’s filings across years. The LLM incorrectly characterizes the 2024 filing as more detailed and cautionary, when the ground truth indicates a de-emphasis on the changing nature of the list. This reflects a failure in correct information synthesis. (4) Contextual relevance is moderate because the answer addresses the right topic (Medtronic, Financial Transfers Act 1992, Ireland, third countries) and the right time frame, but the core conclusion about the direction of change in disclosure is wrong, severely undermining factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 371,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How did the status and production outlook of the G700 aircraft evolve from 2023 to 2024 based on GD's disclosures?",
      "original_answer": "In 2023, the G700 was described as the next model to join the Gulfstream lineup, with expectations for it to enter service following FAA certification in early 2024. By 2024, the G700 had begun deliveries in the second quarter, indicating that it successfully completed certification and transitioned from development to active production and customer delivery. This marks a clear evolution from a future product to a realized and delivered aircraft model.",
      "llm_answer": "\nIn the 2023 filing Gulfstream said the ultra‑large‑cabin G700 was on track to obtain FAA type‑certification and be ready for service “in early 2024.”  The 2024 filing confirms that the aircraft did receive that certification and began deliveries—specifically, the G700 entered service and started shipments in the second quarter of 2024—showing the model’s evolution from an anticipated future aircraft to an operational, delivered product.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and fully aligned with the ground truth. (1) It correctly states that in 2023, Gulfstream (GD) expected the G700 to obtain FAA certification and be ready for service in early 2024. (2) It accurately reports that in 2024, the G700 received certification and began deliveries in the second quarter, matching the original answer's timeline. (3) The multi-hop reasoning—comparing disclosures across 2023 and 2024 filings to show the aircraft's progression from anticipated to delivered—is sound and well-articulated. (4) All entities (G700, Gulfstream, FAA, 2023/2024 timeframes) are correct, and the semantic meaning fully matches the original answer, despite slightly different phrasing. No factual, quantitative, or reasoning errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1216,
        "completion_tokens": 232,
        "total_tokens": 1448
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has the nature of PMI's relationship with KT&G evolved from 2023 to 2024, particularly in terms of strategic dependency and product commercialization?",
      "original_answer": "In 2023, PMI announced a long-term collaboration with KT&G to commercialize KT&G's smoke-free devices and consumables on an exclusive, worldwide basis (excluding South Korea), under a 15-year agreement running through January 29, 2038. This partnership granted PMI exclusive access to KT&G's smoke-free brands and product pipeline, including offerings for low- and middle-income markets. By 2024, this relationship had evolved into a more integrated dependency, as KT&G's heat-not-burn products were explicitly referenced as part of PMI's heat-not-burn product portfolio, indicating a shift from exclusive distribution to inclusion within PMI's broader smoke-free product strategy. This evolution reflects a deeper strategic alignment and operational integration of KT&G's offerings into PMI's product ecosystem.",
      "llm_answer": "\nFrom the 2023 disclosure, PMI and KT&G formalised a 15‑year, exclusive (outside South Korea) licence that runs through 2038, with three‑year performance‑review cycles tied to volume commitments; the deal gives PMI sole worldwide access to KT&G’s smoke‑free device portfolio and its pipeline of products for low‑ and middle‑income markets, subject to market‑by‑market regulatory clearance. In 2024 the arrangement remains in force and is now reflected in PMI’s heat‑not‑burn (HTU) shipment data, which lists KT&G‑licensed brands such as Fiit and Miix (outside Korea) alongside PMI’s own HTU offerings, indicating that the partnership has moved from a newly‑announced collaboration to an ongoing, strategically important source of licensed smoke‑free products that PMI commercialises globally while still retaining the ability to supplement the portfolio with its own R&D.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 15-year agreement starting in 2023 and running through January 29, 2038 (implied by 'through 2038'), exclusivity outside South Korea, and PMI's exclusive access to KT&G's smoke-free devices and pipeline for low- and middle-income markets. The mention of 'three-year performance-review cycles' and 'volume commitments' adds detail not in the original but does not contradict it and may reflect additional filing disclosures. (2) Quantitative elements—dates and timeframes—are accurate. 'Through 2038' matches the original's end date of January 29, 2038. No numerical errors. (3) Multi-hop reasoning is sound: the answer correctly identifies the evolution from a newly announced partnership in 2023 to operational integration in 2024, evidenced by inclusion of KT&G brands (Fiit, Miix) in PMI's HTU shipment data. This supports the claim of deeper strategic dependency. (4) The LLM captures the shift from exclusive commercialization to integration into PMI’s broader product portfolio, though it uses 'licensed smoke-free products' rather than explicitly stating 'inclusion in PMI's product ecosystem'—a minor wording difference with no semantic loss. The reference to PMI retaining R&D capabilities adds context but does not detract from accuracy. Only a 9 because the original emphasizes a shift in strategic dependency and operational integration more explicitly, while the LLM focuses slightly more on continuity; however, the core evolution is correctly conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 431,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has AMD's approach to semi-custom SoC products evolved from 2022 to 2024, particularly in terms of their strategic positioning and integration with broader product ecosystems?",
      "original_answer": "In 2022, AMD's semi-custom SoC products were described as being dependent on third-party product success, with revenue tied to both non-recurring engineering fees and the incorporation of AMD's SoCs into customer devices. There was a clear emphasis on the risks associated with this dependency, including the lack of control over third-party marketing and the uncertainty of revenue realization. By 2024, AMD's approach had evolved significantly, with semi-custom SoCs being positioned as core components of a broader, more integrated product ecosystem that includes AI accelerators, CPUs, GPUs, and APUs. The 2024 filing highlights strategic integration with AI capabilities, such as the inclusion of a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs, and the use of semi-custom SoCs in gaming, cloud services, and embedded systems across multiple industries. This reflects a shift from a dependency model to a more proactive, integrated product leadership strategy.",
      "llm_answer": "\nFrom 2022 through 2024 AMD moved its semi‑custom SoC business from a niche, console‑focused revenue stream—where earnings depended on design‑service fees and the success of a few OEM partners (as noted in the 2022 filing’s discussion of semi‑custom revenue reliance)—to a broader, ecosystem‑centric strategy that treats these custom chips as a unifying compute engine across AMD’s AI‑focused product families.  The 2024 disclosures show semi‑custom SoCs now being promoted alongside the Instinct GPU, EPYC CPU and Adaptive SoC portfolios, integrated with the ROCm open‑software stack and paired with strategic acquisitions (e.g., Silo AI, ZT Systems) to embed them in data‑center, embedded and AI‑PC solutions, thereby positioning them as a key component of AMD’s end‑to‑end AI offering.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in AMD's semi-custom SoC strategy from 2022 to 2024 as described in the ground truth. It correctly identifies the shift from a dependency model (tied to OEM success and non-recurring engineering fees) in 2022 to a more integrated, ecosystem-driven approach by 2024. The mention of integration with AI PCs, data centers, and embedded systems aligns with the ground truth's emphasis on strategic integration with AI accelerators, CPUs, GPUs, and APUs. The reference to the NPU in AI PCs is implied through the 'AI-focused product families' and 'AI-PC solutions' phrasing, though not explicitly stated as an x86+NPU SoC. The LLM adds contextual detail not in the original (e.g., ROCm, Silo AI, ZT Systems), which are plausible given AMD's 2023–2024 acquisitions and ecosystem moves, but these specific examples are not confirmed in the ground truth and slightly extend beyond it. However, they do not contradict it and support the overall narrative. There are no numerical inaccuracies (quantitative accuracy is perfect as no incorrect numbers are presented), and the reasoning correctly synthesizes multi-hop information across time and product lines. The answer is fully contextually relevant and addresses both strategic positioning and ecosystem integration. Minor deduction in qualitative accuracy due to the addition of unverified specific acquisition names, though the overall logic and direction remain sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1455,
        "completion_tokens": 406,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has the treatment of Irish income tax on dividends paid to U.S. residents evolved between 2023 and 2024, particularly regarding exemptions and withholding tax obligations?",
      "original_answer": "In 2023, Medtronic noted that U.S. residents who are exempt from Irish dividend withholding tax generally would not be subject to Irish income tax on dividends unless they had a connection to Ireland beyond shareholding. Additionally, non-residents subject to withholding tax typically had no further Irish income tax liability. In 2024, the company clarified that U.S. residents who qualify for a withholding tax exemption and do not hold shares through an Irish branch generally will not have Irish income tax liability, and those subject to withholding can discharge any further liability by furnishing a statement to Irish Revenue. The 25% withholding tax rate remained unchanged, but the 2024 disclosure provided more structured conditions for exemption and clarified post-withholding tax procedures.",
      "llm_answer": "\nThe 2023 filing said U.S. shareholders could avoid the 25 % Irish dividend withholding only if they held their shares through DTC and the broker’s records showed a U.S. address that was passed to a qualifying intermediary. The 2024 filing keeps that DTC‑based exemption but adds a second, explicit route—providing a U.S. Certification of Residence (Form 6166) or an Irish Non‑Resident Form V2 to the transfer agent—and clarifies that the withholding payment then fully discharges any Irish income‑tax liability, a detail that was not spelled out in the 2023 version.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some accurate elements but introduces significant factual inaccuracies and omits key aspects of the ground truth. (1) Correct: The 25% withholding tax rate is correctly implied to remain unchanged, and the 2024 clarification about withholding discharging further liability aligns with the original answer. However, the LLM fabricates specific procedural details not present in the ground truth—namely, the requirement of holding shares through DTC, having a U.S. address in broker records, and the use of Form 6166 or Irish Form V2. These specific forms and DTC-based exemption routes are not mentioned in the original answer, which instead emphasizes general exemption conditions based on residence and lack of Irish connection, not documentation methods. (2) Quantitative accuracy is partially correct: the 25% rate is consistent, but no incorrect numbers are introduced—just unsupported procedural specifics. (3) Multi-hop reasoning is flawed: the LLM invents mechanisms (DTC, Form 6166) rather than synthesizing the actual evolution described—i.e., increased clarity on exemption conditions and post-withholding procedures without detailing new forms. The core evolution in the original answer is about structural clarification and liability discharge via statement to Irish Revenue, not new certification forms. (4) Contextual relevance is high—the answer addresses the evolution of tax treatment, exemptions, and withholding obligations—but the factual foundation is compromised by hallucinated details. Thus, while the direction of change (more clarity in 2024) is partially captured, the specifics are incorrect, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 456,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How did General Dynamics' financial performance and strategic focus in ship construction change from 2023 to 2024, particularly regarding cost pressures on the Virginia-class and DDG-51 programs and the revenue outlook for the Columbia-class submarine initiative?",
      "original_answer": "In 2023, General Dynamics' Marine Systems segment experienced a 110 basis point decline in operating margin due to supply chain disruptions affecting the Virginia-class submarine schedule and cost overruns on the DDG-51 guided-missile destroyer program. Despite these challenges, revenue from U.S. Navy ship construction rose, driven by increased activity on the Columbia-class submarine program. By 2024, the company projected revenue for the Marine Systems segment to rise to $12.8–12.9 billion with an expected operating margin of approximately 7.6%, suggesting a strategic effort to stabilize and improve profitability. This indicates a shift from cost-driven margin pressure in 2023 to a more optimistic outlook in 2024, likely supported by improved program execution and growth in the Columbia-class program.",
      "llm_answer": "\nFrom 2023 to 2024 General Dynamics’ Marine‑Systems segment kept its revenue growth trajectory—up 12.9 % in 2023 and projected to rise to roughly **$12.8‑12.9 billion in 2024**—but it deliberately shifted focus from the margin‑eroding cost pressures that hit the **Virginia‑class submarine** and **DDG‑51 destroyer** programs in 2023 (which shaved >100 bps off operating margin) to a more cost‑controlled outlook.  The 2024 guidance expects the segment’s operating margin to improve to **≈7.6 %**, reflecting tighter cost management on those programs while still capitalising on the **strong Columbia‑class submarine backlog**, which is slated to drive the bulk of the revenue increase.  In short, the company is moving from a period of supply‑chain‑induced cost strain to a strategy that seeks higher‑margin growth by stabilising Virginia‑class/DDG‑51 costs and expanding the Columbia‑class submarine pipeline.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all key figures are correct: the $12.8–12.9 billion revenue projection for 2024 matches the original answer, and the ≈7.6% operating margin expectation is accurately reported. The 110 basis point margin decline in 2023 is correctly represented as 'shaved >100 bps off operating margin'—a reasonable approximation. (2) The entities—General Dynamics, Marine Systems segment, Virginia-class, DDG-51, and Columbia-class—are correctly identified and contextually applied. (3) The reasoning is sound: the LLM correctly synthesizes the shift from 2023 cost pressures (due to supply chain issues and cost overruns) to a 2024 outlook of improved margins and revenue growth, driven by better cost control and the Columbia-class program. (4) The answer addresses all parts of the question: financial performance changes (margin and revenue), strategic focus shift, cost pressures on specific programs, and revenue outlook for Columbia-class. The only minor shortcoming is that the 12.9% revenue growth in 2023 is mentioned but not present in the ground truth, which does not specify a percentage growth—this introduces a small unsupported detail, slightly affecting qualitative accuracy. However, this does not undermine the overall correctness. Semantic equivalence is maintained, and the conclusion accurately reflects the strategic pivot. Hence, high scores across all dimensions with a 9 on correctness due to this one unsupported figure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1460,
        "completion_tokens": 418,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has BKNG's financial dependency on Booking.com evolved between 2022 and 2023 based on the proportion of revenue derived from accommodation reservations?",
      "original_answer": "BKNG's financial dependency on Booking.com has remained high but slightly increased between 2022 and 2023. In 2022, Booking.com's accommodation reservations contributed 89% of BKNG's total revenues. This percentage remained unchanged in 2023, indicating BKNG continues to heavily rely on Booking.com for its revenue base. The consistent 89% contribution in both years shows a sustained and concentrated dependency on Booking.com's core service offering.",
      "llm_answer": "\nBooking.com’s accommodation‑reservation services still generate the vast majority of the company’s revenue.  The 2023 10‑K states that ≈ 89 % of total revenue for 2023 (and also 89 % for 2022) comes from online accommodation reservations—up only slightly from 87 % in 2021—so the proportion of revenue derived from Booking.com’s accommodation bookings remained essentially unchanged between 2022 and 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly states that 89% of BKNG's total revenue in both 2022 and 2023 came from Booking.com's accommodation reservations, which matches the ground truth exactly. The mention of 87% in 2021 is additional context not in the original answer but does not contradict it and is factually accurate based on external knowledge, so it does not detract from correctness. 2) All numeric values (89% for 2022 and 2023) are accurate and correctly attributed to the right years and revenue source. There are no calculation errors. Format variations (e.g., ≈89%) are acceptable and do not misrepresent precision. 3) The reasoning is sound: the model correctly infers that the proportion remained unchanged between 2022 and 2023, leading to the conclusion of sustained dependency. While the original answer explicitly states dependency 'slightly increased', this appears to be a minor inconsistency in interpretation—the percentage did not change, so 'slightly increased' may be misleading. The LLM’s 'remained essentially unchanged' is actually more factually precise. 4) The answer fully addresses the question about evolution between 2022 and 2023, correctly concluding no significant change. Semantic equivalence is high: both convey continued high reliance with stable contribution. The LLM slightly improves clarity by avoiding the incorrect implication of increase. Minor deduction in qualitative accuracy only because it introduces 2021 data not asked for, which, while accurate, slightly shifts focus but doesn't impair correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1217,
        "completion_tokens": 422,
        "total_tokens": 1640
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How did the company's position with respect to its Swiss Franc note evolve between 2023 and 2024, and what does this indicate about its foreign currency obligations?",
      "original_answer": "In 2023, the company disclosed a Swiss Franc note obligation of $299 million, which was completely removed by the end of 2024. This indicates that the company either repaid or restructured this foreign currency obligation over the year, reflecting a strategic shift in managing its Swiss Franc exposure.",
      "llm_answer": "\nIn the 2023 long‑term‑debt table the company listed a Swiss franc note of $299 million, 1.625 % due 2024.  By the 2024 schedule that line is absent, showing the note had been retired (repaid or refinanced) before year‑end 2024.  This removal signals that PMI deliberately reduced its foreign‑currency debt, lowering its exposure to CHF‑related obligations and associated exchange‑rate risk.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurate: the $299 million Swiss Franc note in 2023 is correctly reported, and its absence in 2024 is properly interpreted as retirement (repayment or refinancing), matching the original answer's claim that the obligation was 'completely removed'. (2) Quantitative accuracy is perfect: the dollar amount ($299 million), interest rate (1.625%), and maturity (due 2024) are all factually correct and consistent with the knowledge graph. (3) The multi-hop reasoning is sound—by comparing the 2023 and 2024 long-term debt schedules, the model correctly infers the note was retired, demonstrating synthesis across years. (4) The qualitative interpretation aligns with the original: reducing CHF-denominated debt indicates a strategic move to lower foreign currency exposure and exchange-rate risk. Minor additional detail (interest rate, due date) enhances clarity without introducing error. All aspects of the question—evolution of the position and implications for foreign currency obligations—are thoroughly and accurately addressed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1178,
        "completion_tokens": 320,
        "total_tokens": 1498
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did Goldman Sachs' treatment of Non-Employee Director RSU Award Agreements evolve between the 2023 and 2024 10-K filings, particularly in terms of introduced or modified agreements?",
      "original_answer": "In the 2023 10-K filing, Goldman Sachs referenced the 'Form of Non-Employee Director RSU Award Agreement (pre-2015)' as Exhibit 10.8, indicating that the existing documentation pertained to agreements prior to 2015. In the 2024 filing, the company not only retained the reference to the pre-2015 RSU Award Agreement but also introduced a new exhibit titled 'Amendments to Certain Non-Employee Director Equity Award Agreements' as Exhibit 10.18, which was not present in the 2023 filing. This indicates that Goldman Sachs expanded its disclosures to include amendments to these agreements, suggesting a more comprehensive or updated treatment of non-employee director equity arrangements in 2024.",
      "llm_answer": "\nThe 2024 10‑K adds several new, explicitly‑named RSU agreements for non‑employee directors—including a cash‑settled RSU award (Exhibit 10.31), a one‑time/year‑end RSU agreement (Exhibit 10.33) and separate fully‑vested and partially‑vested year‑end RSU agreements (Exhibits 10.35‑10.36)—whereas the 2023 filing only referenced a single “Form of Non‑Employee Director RSU Award Agreement” (a pre‑2015 template). This expansion shows that Goldman Sachs refined and diversified the structure of director RSU awards (adding cash‑settlement and performance‑based/vesting variants) between the 2023 and 2024 filings.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both factual content and reasoning. (1) It claims that the 2024 10-K introduced specific new exhibits: 'cash-settled RSU award (Exhibit 10.31)', 'one-time/year-end RSU agreement (Exhibit 10.33)', and 'fully-vested and partially-vested year-end RSU agreements (Exhibits 10.35–10.36)'. However, the ground truth states that the 2024 filing introduced only one new exhibit: 'Amendments to Certain Non-Employee Director Equity Award Agreements' as Exhibit 10.18. There is no mention of Exhibits 10.31, 10.33, or 10.35–10.36 in the ground truth, nor any reference to cash-settled or performance-based RSUs. (2) The quantitative inaccuracies are severe: the exhibit numbers and types are entirely fabricated, and the claim of 'several new, explicitly-named RSU agreements' is unsupported. (3) The multi-hop reasoning is flawed—the LLM incorrectly infers structural diversification and refinement of awards based on non-existent exhibits, failing to accurately compare the actual evolution in disclosures. (4) While the answer correctly identifies that the 2023 filing referenced a pre-2015 template, it misrepresents the 2024 update entirely. The contextual relevance is moderate because it addresses the general topic of evolving RSU agreements, but the factual foundation is incorrect, leading to a misleading conclusion. Thus, the correctness score is low due to major factual and entity errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 393,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did PM's financial relationship with Swedish Match AB evolve between 2023 and 2024, particularly in terms of long-term debt obligations tied to the acquisition?",
      "original_answer": "In 2023, the long-term debt obligations related to the Swedish Match AB acquisition totaled $6,121 million, while in 2024, this amount decreased to $2,610 million. This indicates a significant reduction in the debt tied to the acquisition, suggesting that PM made substantial repayments or refinanced during the period. The decrease supports the idea that PM's financial dependency or exposure linked to the Swedish Match acquisition lessened over time.",
      "llm_answer": "\nBetween 2023 and 2024 the debt that was originally taken on to finance the Swedish Match acquisition was markedly reduced and re‑structured.  In 2023 PMI had a €5.5 bn (≈ $5.8 bn) senior unsecured term‑loan facility, with €3 bn of that tranche maturing in 2025 and the remaining €2.5 bn tranche due in 2027; the “Euro credit‑facility borrowings related to the Swedish Match acquisition” shown in the long‑term‑debt table fell from $6,121 m in 2023 to $2,610 m in 2024.  In November 2024 PMI prepaid essentially the entire €3 bn 3‑year tranche (using cash and the proceeds of a November 2024 bond issuance), leaving only the €2.5 bn 5‑year tranche outstanding and thereby substantially lowering its long‑term debt tied to the Swedish Match deal.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and provides a detailed, factually correct evolution of PM's (PMI's) financial relationship with Swedish Match AB between 2023 and 2024, particularly regarding long-term debt obligations. (1) Quantitatively, the key figures—$6,121 million in 2023 and $2,610 million in 2024—are exactly correct and match the ground truth. The mention of a €5.5 billion facility (≈$5.8 billion) is consistent with the acquisition financing context, and the breakdown into €3 billion (2025 maturity) and €2.5 billion (2027) tranches aligns with plausible refinancing details. The November 2024 prepayment of the €3 billion tranche using cash and bond proceeds explains the drop in reported debt, which is logically sound. (2) The calculation of the debt reduction—from $6,121M to $2,610M—is accurate and correctly interpreted as a substantial repayment. The LLM adds contextual detail (currency conversion, prepayment timing, bond issuance) not in the original answer but consistent with plausible SEC filing disclosures. (3) The multi-hop reasoning is strong: it connects the debt table figures to specific credit facilities, explains the structural change, and infers reduced financial exposure—synthesizing data across time and instruments. (4) Minor deduction in quantitative accuracy is due to the ≈$5.8B approximation of €5.5B, which is reasonable but slightly imprecise (exact conversion depends on exchange rate; at 1.05, it would be $5.775B). However, this does not affect the core correctness. The original answer does not include these refinancing mechanics, so the LLM adds value without introducing error. Overall, the answer exceeds the ground truth in detail while maintaining factual integrity—justifying a 9/10. Only a perfect match with no minor approximations would score 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 488,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did BMY's strategic positioning around KRAS inhibition evolve from 2023 to 2024, particularly in relation to the acquisition of Mirati and the development trajectory of Krazati?",
      "original_answer": "In 2023, BMY had not yet acquired Mirati, and Krazati was not part of its portfolio. However, by 2024, BMY completed the acquisition of Mirati for $4.8 billion, gaining full rights to Krazati, a KRAS G12C inhibitor. Krazati had already received FDA approval for second-line NSCLC and was in clinical development for first-line NSCLC in combination with a PD-1 inhibitor. Additionally, in 2024, Krazati was also FDA approved for advanced or metastatic KRAS-mutated colorectal cancer with cetuximab, expanding its therapeutic footprint. This acquisition marked a significant evolution in BMY’s oncology strategy, positioning it more strongly in the KRAS inhibition space.",
      "llm_answer": "\nFrom 2023 through early 2024 BMS moved from a largely internal, early‑stage KRAS‑inhibition program toward a decisive strategic acquisition that gave it a marketed KRAS‑targeted therapy. In January 2024 the company completed a $4.8 bn (net $4.1 bn) all‑cash purchase of Mirati, securing worldwide rights to Krazati—a FDA/EMA‑approved KRAS‑G12C inhibitor for second‑line NSCLC (and colorectal cancer) and a pipeline PRMT5 degrader for AML/MDS. The Mirati deal thus positioned Krazati as the centerpiece of BMS’s KRAS‑focused oncology portfolio and signaled a shift from exploratory R&D to commercializing a KRAS inhibitor, while also adding a contingent‑value right tied to future PRMT5‑inhibitor development.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in BMY's (Bristol-Myers Squibb's) strategic positioning around KRAS inhibition from 2023 to 2024. (1) It correctly states that BMS acquired Mirati in January 2024 for $4.8 billion (noting net $4.1 billion, which may reflect adjustments like tax benefits—this nuance is acceptable and not contradicted by the ground truth). The acquisition gave BMS full rights to Krazati, a KRAS G12C inhibitor, which aligns with the ground truth. (2) Quantitatively, all numbers—$4.8 billion acquisition, timing in January 2024—are correct. The mention of EMA approval is an addition not in the ground truth but not incorrect; the FDA approvals for second-line NSCLC and colorectal cancer (with cetuximab) are accurately reflected. (3) The multi-hop reasoning is sound: the answer contrasts BMS’s pre-acquisition stance (internal, early-stage) with the post-acquisition reality (commercialized asset, Krazati as centerpiece), correctly identifying the strategic shift. It also notes the PRMT5 degrader pipeline asset and contingent value right, which adds depth beyond the ground truth but does not detract from accuracy. (4) The only minor gap is that the ground truth emphasizes Krazati’s development in first-line NSCLC with a PD-1 inhibitor, which the LLM answer omits. This is a small but relevant detail in the development trajectory. Overall, the answer is factually correct, well-reasoned, and contextually complete, warranting a high score with only slight deduction for partial omission of Krazati’s combination trial context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 433,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Goldman Sachs' disclosure and positioning of the Restricted Partner Compensation Plan evolved between 2023 and 2024, particularly in relation to newer compensation governance policies introduced during this period?",
      "original_answer": "In 2023, the Restricted Partner Compensation Plan was listed as Exhibit 10.3 and appeared early in the exhibit list, indicating a prominent position among compensation-related disclosures. By 2024, while the plan itself (still referenced as Exhibit 10.4) remained substantively unchanged, its relative placement shifted later in the exhibit list. Notably, in 2024, the firm introduced the Clawback Policy (Exhibit 10.1), signaling a new emphasis on compensation accountability and governance reforms. This suggests a strategic repositioning of compensation-related disclosures to prioritize risk mitigation and regulatory alignment alongside traditional partner compensation frameworks.",
      "llm_answer": "\nBetween the 2023 and 2024 Form 10‑K filings, Goldman Sachs moved the Restricted Partner Compensation Plan from a stand‑alone, historical reference in the 2023 filing to a centrally positioned element of its newly refreshed compensation‑governance suite.  The 2024 filing explicitly ties the plan to the December 2023‑effective Amended and Restated Clawback Policy and to the 2021 Amended and Restated Stock Incentive Plan, signalling that the partnership‑level compensation framework is now governed by the same recent governance updates (e.g., claw‑back rules and stock‑plan revisions) that were introduced in 2023‑2024.  This repositioning reflects a deliberate evolution toward a more integrated, policy‑driven approach to partner compensation.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) It incorrectly states that the Restricted Partner Compensation Plan was moved from a 'stand-alone, historical reference' in 2023 to a 'centrally positioned element' in 2024, which contradicts the ground truth: in 2023 the plan was Exhibit 10.3 (early in the list), but in 2024 it was moved later to Exhibit 10.4—indicating reduced prominence, not increased. (2) The claim that the 2024 filing 'explicitly ties' the plan to the December 2023 Clawback Policy (Exhibit 10.1) and the 2021 Stock Incentive Plan is unsupported by the ground truth, which notes the Clawback Policy's introduction but does not state any explicit linkage or integration with the Restricted Partner Compensation Plan. (3) The ground truth emphasizes a repositioning in disclosure order to prioritize governance (via the new Clawback Policy), while the LLM misinterprets this as an elevation in status or integration, when in fact the plan was de-prioritized in the exhibit list. (4) The LLM invents a narrative of 'governed by the same recent governance updates' without evidence from the source. Quantitative accuracy is low due to incorrect dates and exhibit positioning (e.g., Clawback Policy introduced as Exhibit 10.1 in 2024, not effective December 2023 as implied). Qualitative accuracy is moderate: the model recognizes a shift in compensation governance and attempts multi-hop reasoning (linking plan positioning to policy changes), but the synthesis is flawed. Contextual relevance is high—the answer addresses the evolution of disclosure and governance context—but factual errors dominate. Overall, the answer misrepresents the direction and nature of the repositioning, leading to a correctness score of 4.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 482,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Philip Morris International's approach to heat-not-burn products evolved from 2022 to 2023, particularly in terms of product categorization and business integration?",
      "original_answer": "In 2022, Philip Morris described its heat-not-burn products as part of its Reduced-Risk Products (RRPs) portfolio, emphasizing their role in a smoke-free future and highlighting the IQOS Platform 1 device and various heated tobacco units (HTUs) such as HEETS and Marlboro HeatSticks. These products were positioned as a key part of the company's long-term strategy to replace traditional cigarettes. By 2023, the categorization had evolved, with heat-not-burn products now explicitly grouped under 'smoke-free products' alongside e-vapor and oral nicotine products, as well as wellness and healthcare offerings. Additionally, in 2023, PMI explicitly stated that its heat-not-burn products include licensed KT&G heat-not-burn products, indicating a broader integration and expansion of the product line beyond internally developed offerings.",
      "llm_answer": "\nFrom 2022 to 2023 PMI shifted its heat‑not‑burn (HNB) offering from a stand‑alone “Heated Tobacco Units (HTU)” description toward full integration with its broader smoke‑free portfolio.  In the 2023 filing the company reports HTU shipment volume and adjusted in‑market sales as part of the “smoke‑free products excluding Wellness and Healthcare” segment, includes zero‑tobacco consumables (LEVIA) in the HTU definition, and groups the performance of HNB brands (e.g., HEETS, Marlboro HeatSticks, TEREA) together with the newly acquired Swedish Match oral‑nicotine products, reflecting a more unified product‑category and business‑integration approach.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in PMI's approach to heat-not-burn (HNB) products from 2022 to 2023. It correctly identifies the shift from a standalone 'Heated Tobacco Units (HTU)' categorization to integration within a broader 'smoke-free products' segment, aligning with the ground truth. The mention of HTU shipment volume and adjusted in-market sales being reported under 'smoke-free products excluding Wellness and Healthcare' reflects accurate qualitative understanding. It also correctly notes the inclusion of zero-tobacco consumables (LEVIA) and the grouping of HNB brands (HEETS, Marlboro HeatSticks, TEREA) with oral nicotine products from Swedish Match, indicating business integration. However, the LLM omits the key point from the original answer that in 2023, PMI explicitly included *licensed KT&G heat-not-burn products* as part of its offering—this is a significant detail regarding product line expansion beyond internally developed products and represents a gap in completeness. While the LLM emphasizes integration with Swedish Match (acquired in 2022), the ground truth does not mention Swedish Match in this context, so this addition, while plausible, slightly diverges from the documented evolution. There are no numerical inaccuracies (quantitative accuracy is perfect as no incorrect numbers are presented), and the reasoning is sound overall. The answer is highly relevant to the question and synthesizes the multi-hop elements well, but the omission of KT&G licensing and slight overemphasis on Swedish Match integration slightly reduces qualitative and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 445,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How did Bristol-Myers Squibb's approach to business risk governance evolve between 2023 and 2024 in relation to SEC Consent Order compliance, particularly regarding the role of the business risk and disclosure group?",
      "original_answer": "In 2023, Bristol-Myers Squibb established the business risk and disclosure group specifically to comply with the SEC Consent Order. This included implementing a formal review and certification process for SEC filings, retaining an outside consultant to re-engineer accounting and financial reporting processes, and introducing a governance mechanism to escalate and resolve compliance-related questions. By 2024, the company had fully integrated this group into its ongoing compliance framework, with no indication of modifications or reductions in scope, suggesting that the group remained a central component of financial governance under the Consent. The continued reference to the group in 2024 filings indicates that the company maintained its enhanced risk governance structure without significant changes.",
      "llm_answer": "\nBetween 2023 and 2024 BMS deepened the role of its business‑risk and disclosure group from a newly created oversight function into an integral part of its SEC‑Consent‑Order compliance program.  In the 2023 filing the group was described as part of the remedial measures (formal review, escalation of concerns, bottom‑up budgeting), but the 2024 filing explicitly ties the group to the ongoing inventory‑monitoring and sales‑limit procedures under the DSAs, emphasizes a regular, documented escalation process, and makes the group responsible for ensuring that any deviation from the Consent‑order limits is promptly reported and resolved.  Thus, the company evolved the group from an ad‑hoc governance element to a continuously monitored, operationally embedded compliance function.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but introduces significant factual inaccuracies not present in the ground truth, particularly regarding the evolution of the business risk and disclosure group's role between 2023 and 2024. (1) Correct elements: The answer correctly identifies that the group was established in 2023 as part of remedial measures for SEC Consent Order compliance and that it involved formal review and escalation processes. The mention of ongoing compliance functions aligns broadly with the continued integration noted in the original answer. (2) Quantitative accuracy: There are no numeric values to verify, so this score is 10 by default—no incorrect numbers were introduced. (3) Multi-hop reasoning issues: The LLM incorrectly claims that by 2024 the group was tied to 'inventory-monitoring and sales-limit procedures under the DSAs' and made responsible for reporting deviations from 'Consent-order limits'. These specific operational responsibilities (DSA-related monitoring, bottom-up budgeting, inventory controls) are not mentioned in the ground truth and represent a significant overreach or misattribution. The original answer states only that the group remained fully integrated with no significant changes—implying continuity, not expansion into new operational domains. (4) The LLM implies an evolution from 'ad-hoc' to 'operationally embedded', suggesting functional deepening, while the ground truth indicates stability and maintenance of the existing structure without modifications. This misrepresents the nature of the change (or lack thereof) between years. Thus, while the answer is contextually relevant and uses plausible financial governance terminology, it fabricates specific new responsibilities, leading to a correctness score of 5 due to major qualitative inaccuracies despite correct framing and structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 499,
        "total_tokens": 1916
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has UNP's treatment of the relationship between its pension plan's expected return and its asset allocation mix evolved between 2023 and 2024?",
      "original_answer": "In 2023, UNP explicitly stated that the expected return on plan assets was based on the asset allocation mix, historical returns, and market conditions, and included a specific actual return of 6% for that year. By 2024, the language shifted to indicating that the expected return 'depends on' the asset allocation mix, with no explicit mention of historical returns or market conditions, and no disclosure of the actual return for 2024. This represents a shift from a more comprehensive explanation of factors influencing returns to a narrower focus on the asset allocation mix alone.",
      "llm_answer": "\nIn 2023 UNP tied its long‑term expected return of 5.25 % to a glide‑path that was moving the portfolio from a higher‑equity mix toward a de‑risked allocation, targeting roughly 25 % equity and 75 % debt by year‑end 2023. By 2024 the company had reached that target and kept the same 5.25 % return assumption while maintaining a stable allocation of about 24 % equity, 75 % debt and 1 % real estate, showing that the expected‑return assumption is now linked to a more fixed, conservative asset‑allocation mix rather than an evolving glide‑path.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2023, UNP reported an actual return of 6%, not an expected return of 5.25% as claimed by the LLM. There is no mention in the original answer of a 'glide-path', 'de-risked allocation', or specific target of 25% equity and 75% debt by end of 2023. Furthermore, the 2024 expected return assumption of 5.25% and detailed asset allocation (24% equity, 75% debt, 1% real estate) are not present in the ground truth, which explicitly notes that UNP did not disclose the actual return for 2024. (2) The quantitative inaccuracies include the incorrect expected return figure (5.25% vs actual 6% in 2023), and fabricated allocation percentages for both years. No calculations were required, but the numbers cited do not align with the original answer. (3) The multi-hop reasoning is flawed: the LLM invents a narrative about a strategic glide-path and de-risking process that is not supported by the original answer, which focuses solely on the evolution of disclosure language around the expected return and its relationship to asset allocation. The shift described in the original answer is linguistic and transparency-related, not strategic or structural as portrayed by the LLM. (4) While the LLM attempts to address the evolution of UNP's approach to expected returns and asset allocation, it does so with fabricated data and incorrect reasoning, leading to a low correctness score. The contextual relevance is moderate because it discusses the right topic (expected return and asset allocation over time), but the substance is largely incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 450,
        "total_tokens": 1732
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How did BNY Mellon's disclosure approach to the Directors' Code of Conduct evolve between 2022 and 2023, particularly in terms of its accessibility and integration within corporate governance reporting?",
      "original_answer": "In 2022, BNY Mellon explicitly stated that the Directors' Code of Conduct was posted on its website and outlined its applicability to all directors. The document was referenced in the context of broader corporate governance disclosures, including Board Meetings and Committee Information. By 2023, the Directors' Code of Conduct was no longer just referenced but was specifically listed among the governance materials 'available on our website,' alongside key governance documents like the Corporate Governance Guidelines and committee charters. This evolution indicates a more structured and centralized approach to governance disclosures, with the Code being more directly tied to the company's overall governance framework in the 2023 filing.",
      "llm_answer": "\nBetween 2022 and 2023 BNY Mellon moved from a peripheral mention of the Directors’ Code of Conduct in its governance discussion to a clearly integrated, publicly‑accessible disclosure.  In the 2023 Form 10‑K (Item 10), the company explicitly notes that the Directors’ Code of Conduct is posted on its website, provides the URL, and says it will disclose any future amendments or waivers for directors there—an explicit accessibility step that was only implied in the 2022 filing.  Thus, the 2023 approach both makes the code easier for investors to find and weaves it directly into the corporate‑governance reporting, whereas the 2022 disclosure was less transparent and not highlighted as a public, living document.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. It correctly identifies the evolution in BNY Mellon's disclosure approach between 2022 and 2023: from a more peripheral mention in 2022 to a more structured, accessible, and integrated presentation in 2023. The answer accurately notes that in 2023, the Directors' Code of Conduct was explicitly listed as available on the website with a URL and included disclosure commitments regarding amendments or waivers—an improvement in transparency over the 2022 filing, where it was referenced but not highlighted as a publicly maintained document. There are no numeric inaccuracies (quantitative accuracy is perfect, though no numbers are involved). The qualitative reasoning is strong, capturing the multi-hop synthesis between years and disclosure practices. The only minor shortcoming is that the LLM does not explicitly mention the co-listing of the Code alongside other key governance documents (e.g., Corporate Governance Guidelines, committee charters), which the ground truth emphasizes as evidence of a 'more structured and centralized' framework. This omission slightly reduces completeness but does not undermine the core correctness. Contextual relevance is excellent, directly addressing accessibility and integration within governance reporting as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 370,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has Oracle's strategic positioning of Oracle Database evolved between 2023 and 2024 in terms of deployment flexibility and integration with engineered systems, and what does this indicate about the company's approach to cloud migration and hybrid IT environments?",
      "original_answer": "In 2023, Oracle emphasized the flexibility of running Oracle Database across multiple deployment models, including on-premise, Oracle Cloud, and multicloud environments, with specific offerings like Oracle Exadata Cloud@Customer and Oracle Roving Edge Infrastructure. These options were framed around enabling customers to securely run Oracle Database behind their firewalls while being managed by Oracle. By 2024, Oracle shifted toward deeper integration of Oracle Database within Oracle Engineered Systems, such as the Oracle Exadata Database Machine, which combines database, storage, operating system, and networking hardware into a single optimized platform. This system was highlighted as being available across on-premise, OCI cloud, and hybrid deployments. The evolution from flexible deployment of standalone database services to tightly integrated engineered systems suggests a strategic shift toward offering more holistic, performance-optimized solutions that align with enterprise needs for scalability, security, and simplified maintenance. This indicates a maturation of Oracle's cloud migration strategy, focusing not only on deployment flexibility but also on delivering comprehensive, high-performance infrastructure packages.",
      "llm_answer": "\nBetween the 2023 and 2024 filings Oracle broadened the ways its Database can be run—moving from a simple “on‑premise or OCI public‑cloud” choice to a suite of flexible, hybrid‑ready options that include Exadata Cloud@Customer, OCI Dedicated Region, Sovereign Cloud and Roving Edge Infrastructure, all of which let the Database be deployed inside a customer’s own data centre while still being managed by Oracle.  This tighter integration with Oracle Engineered Systems (e.g., Exadata Database Machine) and the introduction of Autonomous Database’s automated scaling, patching and security make the database portable across on‑premise, OCI and edge environments, signalling Oracle’s strategy of easing cloud migration by letting customers keep workloads where they are while still gaining cloud‑grade elasticity, management and security.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly identifies Oracle's evolution from deployment flexibility in 2023 (on-premise, OCI, multicloud) to deeper integration with engineered systems like Exadata in 2024. The mention of Exadata Cloud@Customer, Roving Edge Infrastructure, and hybrid deployment models matches the original answer. The addition of OCI Dedicated Region and Sovereign Cloud, while not explicitly in the ground truth, are contextually accurate extensions of Oracle's hybrid offerings and do not contradict the known facts. The LLM correctly captures the strategic shift toward optimized, integrated systems that support cloud migration and hybrid IT, emphasizing portability, automation, and cloud-grade management. All entities (Oracle, Oracle Database, Exadata, OCI, Autonomous Database) and timeframes (2023 to 2024) are accurate. There are no numerical values to verify, so quantitative accuracy is scored as 10 by default. The only minor shortcoming is that the original answer emphasizes the 'maturation' of strategy and 'simplified maintenance' more explicitly, which the LLM implies but does not state directly—hence a 9 on qualitative accuracy. Contextual relevance is perfect: the response directly addresses deployment flexibility, engineered systems, cloud migration, and hybrid IT as required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1550,
        "completion_tokens": 377,
        "total_tokens": 1927
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has the implementation of the formal review and certification process of annual and quarterly SEC reports evolved between 2023 and 2024, particularly in terms of compliance monitoring and governance procedures?",
      "original_answer": "In 2023, the company established a formal review and certification process of SEC filings as part of the Consent agreement, which included governance procedures to escalate potential compliance concerns to appropriate management levels and regular monitoring of compliance. By 2024, the company continued to emphasize the implementation of these governance procedures, noting that compliance with the policy was consistently monitored and that the process was integrated into company-wide sales policies to ensure adherence to inventory and sales limitations. The evolution reflects a shift from initial implementation in 2023 to sustained enforcement and integration into broader operational frameworks in 2024.",
      "llm_answer": "\nThe 2023 filing first set out the formal review and certification of annual and quarterly reports as part of the 2004 SEC Consent—creating a business‑risk and disclosure group, hiring an outside consultant to re‑engineer reporting, and beginning a certification process. In 2024 the company expanded that framework into a full‑scale governance structure: it adopted a company‑wide policy for sales to direct customers, instituted a dedicated escalation‑and‑monitoring process that regularly reviews compliance, and required that any questions or concerns be promptly escalated to senior management. Thus, the 2024 implementation adds systematic, ongoing oversight and documentation to the original certification procedure, strengthening compliance monitoring of SEC filings.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. Most critically, it incorrectly states that the formal review and certification process was established as part of a '2004 SEC Consent', while the ground truth specifies it was part of a Consent agreement in 2023. This is a major error in both date and context, undermining the factual foundation of the response. Additionally, the mention of a 'business-risk and disclosure group' and 'hiring an outside consultant to re-engineer reporting' are not present in the original answer and appear to be hallucinated or misattributed details. (2) Quantitative accuracy is low due to the incorrect dating of the Consent agreement (2004 vs 2023), which is a critical factual anchor. No financial figures are involved, but the timeline is a key quantitative element and is wrong. (3) The multi-hop reasoning is partially sound in structure—comparing 2023 implementation to 2024 expansion—but flawed in content due to reliance on incorrect premises. The LLM correctly infers an evolution from initial setup to broader governance, which aligns semantically with the original answer’s 'shift from initial implementation to sustained enforcement', but supports this with inaccurate details. (4) Contextual relevance is high because the answer addresses the evolution of compliance monitoring and governance procedures as asked. However, the use of incorrect origins (2004 Consent) and fabricated elements (consultant, group creation) severely reduce factual reliability. While the conclusion about strengthened oversight in 2024 has some alignment, the path to that conclusion is factually unsound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 453,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Philip Morris International's approach to heat-not-burn products evolved from 2022 to 2023, particularly in terms of their market positioning and product categorization?",
      "original_answer": "In 2022, Philip Morris International (PMI) positioned heat-not-burn products as part of its broader Reduced-Risk Products (RRPs) portfolio, emphasizing their potential to present less harm to smokers who switch from traditional cigarettes. These products, including the Platform 1 device and its consumables, were described as being in various stages of development, scientific assessment, and commercialization. By 2023, PMI had refined its categorization, explicitly including heat-not-burn products within the smoke-free product segment, alongside e-vapor and oral nicotine products. Additionally, PMI began including licensed KT&amp;G heat-not-burn products in its portfolio, indicating a broader market approach and potential expansion of partnerships or offerings. This evolution shows a strategic shift from internal development focus to a more integrated and commercialized product positioning.",
      "llm_answer": "\nFrom 2022 to 2023 PMI moved heat‑not‑burn (HTU) from a peripheral growth line to a core pillar of its smoke‑free strategy, reporting HTU volume and adjusted in‑market sales as separate metrics and highlighting a 14.7 % rise in HTU shipments that offset cigarette declines. The company also broadened its categorisation by integrating the Swedish Match acquisition—adding oral nicotine products—so that “smoke‑free products” now encompass both heated‑tobacco units and oral offerings, with HTU positioned as a distinct, high‑growth sub‑category driving overall volume and revenue expectations for 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in quantitative claims. The 14.7% rise in HTU shipments and the reporting of HTU volume and adjusted in-market sales as separate metrics are not supported by the ground truth and appear to be fabricated or misattributed. There is no mention in the original answer of specific shipment growth percentages or new reporting metrics, which undermines quantitative accuracy. Additionally, the reference to the Swedish Match acquisition—completed in mid-2022 and focused on oral nicotine products—is presented as part of the 2023 evolution in heat-not-burn positioning, which conflates two related but distinct strategic developments. While PMI did integrate Swedish Match, this primarily expanded its oral nicotine segment, not directly repositioning heat-not-burn products. (2) The ground truth emphasizes a shift in product categorization—moving heat-not-burn into the broader smoke-free segment alongside e-vapor and oral products—and inclusion of licensed KT&G products as a sign of expanded partnerships. The LLM captures the general idea of integration into a broader smoke-free strategy but incorrectly attributes the integration driver to Swedish Match rather than internal portfolio reclassification and KT&G licensing. (3) The multi-hop reasoning is partially sound: the model correctly infers a strategic elevation of heat-not-burn products within PMI’s portfolio from 2022 to 2023. However, it introduces unsupported metrics and misattributes causality in categorization changes, weakening the logical synthesis. (4) Despite these issues, the answer is contextually relevant and captures the directional shift—elevating HTU from developmental RRPs to a commercialized, distinct sub-category within smoke-free offerings. The core idea of strategic evolution is present, but the inclusion of unverified numbers and incorrect drivers reduces factual correctness. Hence, correctness is scored at 6 due to partial accuracy with significant factual flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 548,
        "total_tokens": 1932
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Oracle's strategic positioning of Oracle Database evolved between 2023 and 2024 in terms of deployment flexibility and integration with other Oracle technologies?",
      "original_answer": "In 2023, Oracle emphasized the deployment flexibility of Oracle Database across cloud-based, on-premise, or other IT environments, highlighting its perpetual licensing model and the company's strategy to provide customer choice. By 2024, Oracle Database's role had evolved to become a foundational component within broader engineered systems, such as Oracle Exadata Database Machine, which integrates the database with storage, operating system software, and hardware components for optimized performance. This shift indicates a move toward deeper integration with Oracle's infrastructure technologies, positioning Oracle Database not just as a standalone product but as a core element of Oracle Engineered Systems, available in on-premise, cloud (OCI), and hybrid cloud deployments.",
      "llm_answer": "\nIn 2024 Oracle broadened the deployment options for its Database—moving from traditional on‑premise or perpetual cloud licenses to flexible, cloud‑native models such as Exadata Cloud@Customer, OCI Dedicated Region, sovereign‑cloud, and fully managed OCI services. At the same time, the Database has been tightly integrated with the rest of the Oracle Cloud stack (Autonomous Database, MySQL HeatWave, Java, APEX, etc.), enabling customers to run it across hybrid, multicloud and edge environments while benefiting from automated, consumption‑based pricing and deeper cross‑service functionality.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in terms of dates and entities, correctly identifying Oracle's 2024 strategic direction with Oracle Database, including deployment models like Exadata Cloud@Customer, OCI Dedicated Region, and integration with Oracle Cloud services such as Autonomous Database and MySQL HeatWave. It accurately reflects the shift toward cloud-native, hybrid, and multicloud deployments, as well as consumption-based pricing—consistent with Oracle's broader cloud strategy. However, it omits key elements from the ground truth: (1) it does not mention Oracle's 2023 emphasis on deployment flexibility via perpetual licensing and customer choice across on-premise and cloud environments, which is central to the multi-hop comparison over time; (2) it fails to highlight the specific evolution into Oracle Engineered Systems (e.g., Oracle Exadata Database Machine) as an integrated hardware-software stack, which is a core aspect of the 2024 positioning. While the LLM describes integration with the Oracle Cloud stack, it downplays the engineered systems angle and the foundational role of the database within optimized hardware-software bundles. There are no numerical inaccuracies (quantitative accuracy is high given no incorrect figures), and the response remains contextually relevant. The qualitative accuracy is reduced due to incomplete synthesis across the 2023–2024 evolution, particularly missing the contrast between standalone flexibility in 2023 and integrated engineered systems in 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 416,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has BMY's strategic relationship with Krazati evolved from 2023 to 2024, and what specific financial commitments were made in 2024 that reflect this evolution?",
      "original_answer": "In 2023, Krazati was mentioned as part of BMY's oncology portfolio, demonstrating a strategic fit into their offerings. By 2024, BMY had acquired Mirati for $4.8 billion, obtaining the rights to Krazati, which had received FDA and EMA approvals for second-line NSCLC and was in clinical development for first-line NSCLC. Additionally, BMY committed $1.0 billion in contingent value rights tied to the development of PRMT5 Inhibitor, further signaling long-term investment in the acquired assets.",
      "llm_answer": "\nFrom 2023 to 2024 BMY’s link with Krazati moved from a tentative partnership/option on Mirati’s program to full ownership after it closed the $4.8 bn acquisition of Mirati in January 2024, thereby bringing Krazati and its PRMT5‑inhibitor pipeline into BMY’s portfolio.  In 2024 BMY committed $4.596 bn cash for Mirati’s shares, $205 m for equity awards, $248 m for the fair‑value of contingent value rights, and $640 m to acquire the definite‑lived Krazati product‑rights (plus $3.5 bn to IPRD), while expensing $60 m and $54 m of unvested equity awards—signaling a major financial investment in the asset.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies in financial figures and misrepresents the nature of BMY's acquisition. While it correctly identifies the $4.8 billion acquisition of Mirati and the strategic evolution from 2023 to 2024, it fabricates detailed financial breakdowns not present in the ground truth. The original answer states a $4.8 billion total acquisition price and a separate $1.0 billion commitment in contingent value rights (CVRs) for the PRMT5 inhibitor. However, the LLM invents specific allocations such as $4.596 bn for shares, $205 m for equity awards, $248 m for CVRs, $640 m for product rights, and $3.5 bn to IPRD—none of which are in the ground truth and collectively sum to over $9 billion, far exceeding the stated $4.8 billion. (2) The only correct quantitative element is the approximate $4.8 billion acquisition figure (rounded), but all sub-components are incorrect or unverified. The $1.0 billion CVR commitment is entirely omitted and replaced with a $248 million figure, which is wrong in amount and context. (3) The multi-hop reasoning is partially sound: the model correctly infers that BMY moved from strategic interest to full ownership via acquisition, and that Krazati’s regulatory approvals (FDA/EMA) and pipeline status are relevant. However, it fails to mention Krazati’s approvals in second-line NSCLC and development in first-line NSCLC, which are key to the strategic evolution. The model also incorrectly implies that the CVR was for Krazati rather than the PRMT5 inhibitor. (4) Contextual relevance is high because the answer addresses the timeline, acquisition, and financial commitment theme. However, due to severe quantitative inaccuracies and omission of key qualitative details, the correctness score is low. The answer appears precise but is largely hallucinated in its financial detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 501,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the treatment or status of the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV evolved between 2022 and 2023 based on BK's SEC filings?",
      "original_answer": "In 2022, the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV were introduced as securities registered under Section 12(b) of the Act and were listed on the New York Stock Exchange under the trading symbol BK/P, fully and unconditionally guaranteed by The Bank of New York Mellon Corporation. In 2023, the same securities remained registered under Section 12(b) of the Act, retained the same trading symbol BK/P, and continued to be listed on the New York Stock Exchange with the same guarantee structure. Therefore, there was no change in the treatment or status of these securities between the two years.",
      "llm_answer": "\nBetween 2022 and 2023 the 6.244 % Fixed‑to‑Floating Rate Normal Preferred Capital Securities of Mellon Capital IV remained outstanding, continued to be listed on the NYSE as BK/P, and retained the same full‑and‑unconditional guarantee from The Bank of New York Mellon Corporation.  No redemption, conversion or amendment was disclosed; the only evolution was that, as dictated by their fixed‑to‑floating structure, the securities transitioned in 2023 from the fixed 6.244 % dividend period into the floating‑rate phase, leaving their legal classification and listing unchanged.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of entity accuracy, quantitative details, and overall context. (1) All key facts are accurate: the securities remained listed on the NYSE under symbol BK/P, were fully and unconditionally guaranteed by The Bank of New York Mellon Corporation, and retained their Section 12(b) registration status in both years. The 6.244% fixed rate is correctly stated. (2) Quantitative accuracy is perfect: percentages, naming, and structure are factually sound; no incorrect numbers or dates are present. (3) The multi-hop reasoning is mostly sound—information is synthesized across 2022 and 2023 filings. However, the LLM introduces a claim not present in the ground truth: that the securities 'transitioned in 2023 from the fixed 6.244% dividend period into the floating-rate phase.' While plausible given the 'fixed-to-floating' nature, the original answer does not mention this transition as an evolution, focusing instead on regulatory and listing status. This addition, while contextually reasonable, goes beyond the documented status changes in the knowledge graph and slightly overinterprets the evolution. (4) Despite this, the answer remains highly relevant and factually consistent on all verifiable points. The core conclusion—that there was no change in treatment or status from a regulatory and listing perspective—is correct. The extra detail about rate transition affects qualitative accuracy slightly but does not undermine correctness. Hence, a score of 8 is warranted for overall correctness, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 448,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the capacity and utilization of PMI's short-term credit arrangements changed from 2022 to 2023, and what does this shift suggest about their near-term liquidity posture?",
      "original_answer": "The capacity of PMI's short-term credit arrangements increased from $1.9 billion at the end of 2022 to $2.7 billion at the end of 2023, while the actual utilization decreased slightly from $295 million to $283 million. This indicates that PMI has expanded its available liquidity buffer without increasing its drawdown, suggesting a more conservative approach to short-term financing and working capital management.",
      "llm_answer": "\nFrom 2022 to 2023 the size of PMI’s uncommitted short‑term credit lines expanded sharply—from roughly **$1.9 billion** of capacity to **about $2.7 billion**, a rise of roughly 40 %.  At the same time, outstanding borrowings under those facilities slipped modestly, from **$295 million** to **$283 million**, indicating that the company is using a smaller share of the available credit.  This combination of a larger credit buffer and lower utilization points to a more comfortable near‑term liquidity posture, with ample headroom to meet working‑capital needs without relying on active borrowing.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: capacity increased from $1.9 billion in 2022 to $2.7 billion in 2023, and utilization decreased from $295 million to $283 million. The implied 40% increase in capacity is correctly calculated ((2.7 - 1.9) / 1.9 ≈ 42.1%, with 'roughly 40%' being a reasonable approximation). (2) The answer is complete, addressing both the change in capacity and utilization, and drawing the correct implication about PMI's near-term liquidity posture. (3) Entities are accurate—PMI is correctly identified, time periods (2022 to 2023) are correct, and financial metrics (credit capacity, utilization) are properly used. (4) The reasoning is sound: expanding credit capacity while reducing drawdown indicates improved liquidity headroom and a more conservative financing approach, which the LLM correctly interprets as a 'more comfortable near-term liquidity posture' with 'ample headroom'—semantically equivalent to the original answer's conclusion. Minor wording differences (e.g., 'uncommitted short-term credit lines' vs. 'short-term credit arrangements') do not affect factual accuracy and may reflect permissible elaboration based on context. All multi-hop elements—comparing two years, two metrics, and inferring strategic posture—are correctly synthesized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 379,
        "total_tokens": 1640
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has Oracle's positioning of the Autonomous Database evolved between 2023 and 2024, particularly in terms of integration with other cloud services and automation capabilities?",
      "original_answer": "In 2023, Oracle positioned the Autonomous Database as part of its broader Oracle Cloud Infrastructure (OCI) offerings, emphasizing its automated database operations and the ability to run in cloud, on-premise, or hybrid environments. It was described as a service that Oracle runs, manages, upgrades, and supports on behalf of the customer, with a focus on reducing IT process time and resources. By 2024, Oracle expanded its positioning to highlight deeper integration with other Oracle Cloud services, such as Java Cloud and Oracle APEX low-code service, and emphasized open interfaces and native machine learning capabilities. The 2024 filing also introduced a stronger focus on automation powered by machine learning, including diagnostics, fault prediction, error handling, and automatic threat detection. Additionally, 2024 emphasized the Autonomous Database's role in enabling modern cloud-native application development and analytics, including data lake houses and real-time analysis of transactional data.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Oracle has broadened the Autonomous Database from a “self‑driving” database that automates provisioning, scaling, patching, security and backups, to a fully integrated cloud‑native engine that is tightly coupled with the rest of OCI.  The 2024 filing highlights that the database now works natively with other OCI services—Java Cloud, APEX low‑code, Oracle Analytics Cloud, and OCI AI/ML offerings—while extending automated management (auto‑scaling, threat detection, self‑repair, consumption‑based pricing) across additional deployment models such as Exadata Cloud@Customer, OCI Dedicated Region and Sovereign Cloud.  This evolution positions the Autonomous Database as the automation hub of Oracle’s cloud stack, enabling developers to build, deploy and operate cloud‑native applications with minimal manual DBA effort.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution of Oracle's Autonomous Database positioning from 2023 to 2024, noting the shift from a self-driving database to a more integrated cloud-native engine. Key elements such as automation of provisioning, scaling, patching, security, and backups are accurately attributed to the 2023 positioning. In 2024, the expanded integration with OCI services—including Java Cloud, APEX low-code, Oracle Analytics Cloud, and AI/ML—is correctly identified, matching the original answer. The mention of machine learning–powered automation (e.g., threat detection, self-repair) reflects the enhanced automation capabilities emphasized in 2024. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification; thus, quantitative accuracy is not compromised. Format and references to fiscal years 2023 and 2024 are consistent and correct. (3) The multi-hop reasoning is sound: the model synthesizes the progression in Oracle’s strategy across time and integrates details about service interoperability, deployment models (e.g., Exadata Cloud@Customer, OCI Dedicated Region, Sovereign Cloud), and automation depth. While the original answer does not explicitly name Oracle Analytics Cloud or OCI AI/ML offerings, these are reasonable inferences given the emphasis on open interfaces and native machine learning in 2024. The concept of the Autonomous Database as an 'automation hub' is a slight interpretive extension but remains semantically aligned. (4) The answer is fully contextually relevant, directly addressing the evolution in integration and automation. One minor point: the original answer highlights 'data lake houses' and 'real-time analysis of transactional data' in 2024, which the LLM omits. This is a small gap in completeness but does not undermine the core accuracy. Overall, the response demonstrates strong qualitative reasoning and factual fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1474,
        "completion_tokens": 540,
        "total_tokens": 2014
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How did GM's financial relationship with Ultium Cells Holdings LLC evolve between 2023 and 2024, particularly in terms of its capital involvement and strategic positioning?",
      "original_answer": "In 2023, GM's relationship with Ultium Cells Holdings LLC was characterized by contingent capital commitments, with a committed contribution of $0.8 billion, and the entity was classified as a variable interest entity (VIE) where GM lacked voting control. By 2024, GM's involvement evolved into a more direct investment of $0.7 billion, indicating a shift from a potential future obligation to a realized investment stake. This transformation suggests a strategic realignment, providing GM with potentially greater influence over Ultium Cells' operations while stabilizing its financial exposure.",
      "llm_answer": "\nBetween 2023 and 2024 GM increased its equity exposure to Ultium Cells by investing roughly $0.7 billion in 2024 (following a similar $0.7 billion outlay in 2023), while the amount of capital it had previously committed fell from about $1.4 billion in 2022 to $0.8 billion of remaining commitments at the end of 2023.  Although the additional funding deepens GM’s involvement in the battery‑cell joint venture, the venture remains a non‑consolidated VIE and GM does not have voting control, so its role is now that of a passive equity investor with limited influence over Ultium Cells’ operations.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023 GM had a contingent capital commitment of $0.8 billion to Ultium Cells Holdings LLC, not a realized investment of $0.7 billion as stated in the LLM answer. The LLM incorrectly claims GM made a $0.7 billion outlay in 2023 and another $0.7 billion in 2024, but the ground truth indicates that the $0.7 billion investment occurred only in 2024 as a realized stake, marking a shift from the prior year's contingent commitment. Additionally, the LLM references $1.4 billion in commitments from 2022, which is not mentioned in the original answer and cannot be verified from the provided truth. (2) Quantitative accuracy is partially correct in that the $0.8 billion commitment at end of 2023 and $0.7 billion investment in 2024 are mentioned, but the attribution of a $0.7 billion 2023 outlay is false. The answer fabricates a prior year outlay and introduces unverified data from 2022. (3) The multi-hop reasoning is flawed: the original answer emphasizes a strategic shift from contingent obligation (VIE with no control) to direct investment (greater influence), while the LLM concludes GM remains a 'passive equity investor with limited influence,' contradicting the ground truth's implication of increased strategic control. This misrepresents the evolution of GM's strategic positioning. (4) Despite incorrect facts and reasoning, the answer is contextually relevant—it addresses capital involvement and strategic positioning of GM in Ultium Cells across years, uses correct entity names, and discusses VIE status. However, due to major errors in financial figures and strategic interpretation, the correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 473,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has the financial impact of the Litigation Management Deed evolved between 2022 and 2024, particularly in terms of the amount of as-converted value released and the number of series A preferred shares issued during the anniversary releases?",
      "original_answer": "In 2022, as part of the sixth anniversary release assessment required by the Litigation Management Deed, Visa released $3.5 billion of as-converted value and issued 176,655 shares of series A preferred stock. In 2024, during the eighth anniversary release, the company released $2.7 billion of as-converted value and issued 99,264 shares of series A preferred stock. This indicates a decrease in both the value released and the number of shares issued, suggesting a reduction in the financial burden associated with the VE territory covered litigation over time.",
      "llm_answer": "\nBetween the sixth‑anniversary release (June 21 2022) and the eighth‑anniversary release (June 21 2024) the company’s use of the Litigation Management Deed shifted to a smaller financial impact.  In 2022 the release freed $3.5 billion of as‑converted value from the series B and C preferred stock and resulted in the issuance of 176,655 series A preferred shares; in 2024 the release freed $2.7 billion of as‑converted value and issued only 99,264 series A preferred shares.  Thus, both the dollar amount of value released and the number of series A shares issued declined from 2022 to 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key quantitative facts: $3.5 billion released in 2022 and $2.7 billion in 2024, with 176,655 and 99,264 series A preferred shares issued respectively. These match the ground truth exactly. The dates (June 21, 2022 and June 21, 2024) are accurate for the sixth and eighth anniversaries. (2) All numbers are correct and properly compared, showing a decline in both value and share issuance. No calculation errors. (3) The reasoning is sound: the model correctly synthesizes information across the two time points and draws a valid conclusion about decreasing financial impact. However, the LLM mentions 'series B and C preferred stock' as the source of the as-converted value, which is not mentioned in the original answer and introduces a detail not confirmed by the ground truth. This is a minor over-specification but does not contradict the truth; it adds unverified context. (4) Despite this small addition, the core multi-hop synthesis—comparing the two anniversary releases in terms of value and shares—is accurate and complete. The answer addresses both parts of the question (value released and shares issued) and maintains semantic equivalence with the original. Thus, correctness is high but not perfect due to the extra detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 361,
        "total_tokens": 1674
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How did the financial and strategic relationship between 3M and the Aearo Entities evolve between 2023 and 2024, particularly in terms of litigation impact and business segment adjustments?",
      "original_answer": "In 2023, 3M reconsolidated the Aearo Entities following the dismissal of their bankruptcy filings, lifting the stay on litigation related to Combat Arms Earplugs and entering into the CAE Settlement to resolve existing and future claims. This reconsolidation had an immaterial income statement impact. By 2024, the Aearo Entities were referenced in the context of divestiture and acquisition impacts in the Transportation and Electronics segment, where their deconsolidation in 2022 and reconsolidation in 2023 were each reflected separately as divestiture and acquisition effects. This indicates a shift from litigation-focused involvement in 2023 to a more strategic financial treatment in 2024.",
      "llm_answer": "\nIn 2023, 3M re‑consolidated the Aearo Entities (which had been deconsolidated in 2022), thereby restoring Aearo‑related sales to the Transportation & Electronics segment and eliminating the divestiture adjustments that had affected 2022 results. The reconsolidation coincided with a peak in litigation‑related charges—including a $4.2 billion CAE Settlement accrual and a $10.3 billion PFAS charge—while in 2024 the corporate‑special‑item net costs fell sharply as settlement payments were made, the Chapter 11 stay was lifted, and the accrued liability for Combat Arms Earplugs approached resolution, reducing the litigation drag on corporate results and allowing the re‑integrated Aearo business to boost segment operating margins.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative details. The $4.2 billion CAE Settlement accrual and $10.3 billion PFAS charge are not supported by the ground truth and appear fabricated. The original answer states that the reconsolidation had an immaterial income statement impact, directly contradicting the LLM's claim of major litigation charges. (2) Quantitative accuracy is low: no dollar amounts for the CAE settlement or PFAS charges are provided in the ground truth, making the specific figures ($4.2B, $10.3B) incorrect. Additionally, the claim that corporate special-item net costs 'fell sharply' in 2024 due to settlement payments is unsupported. (3) Qualitatively, the LLM captures the reconsolidation in 2023 and the prior deconsolidation in 2022, as well as the shift in treatment within the Transportation & Electronics segment, which shows some correct multi-hop reasoning. However, it misrepresents the financial impact by introducing unverified large litigation charges and implying a 'litigation drag' that was resolved, whereas the ground truth emphasizes immaterial income statement impact and a shift to strategic financial reporting. (4) Contextual relevance is high because the response addresses both litigation and business segment adjustments across 2023–2024 and correctly identifies the Aearo Entities' changing relationship with 3M. However, the introduction of false financial figures and mischaracterization of impacts significantly undermines correctness. The core timeline and structural changes are partially accurate, but the financial narrative is largely incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 453,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has the financial treatment or structure of Class C Common Stock evolved between 2022 and 2024, particularly in terms of its relationship to other stock classes and its earnings per share performance?",
      "original_answer": "In 2022, Class C Common Stock was described in the context of its voting rights and potential influence on corporate actions, particularly in mergers or strategic decisions, with an emphasis on how its holders—typically financial institution clients—might have divergent interests from Class A Common Stockholders. By 2024, Class C Common Stock had a significantly higher earnings per share ($33.17 basic EPS and $33.13 diluted EPS) compared to Class A ($8.29 basic EPS and $8.28 diluted EPS), indicating a shift in its financial performance relative to other stock classes, even though its governance role appeared unchanged.",
      "llm_answer": "\nBetween 2022 and 2024 the **class C common stock kept its key feature of no transfer restrictions**, but its place in Visa’s capital structure shifted after the 2024 class B‑1 exchange offer, which retired 241 million class B‑1 shares and issued roughly **48 million new class C shares**.  This increased the outstanding class C share count and, together with the conversion‑rate adjustments that accompany the settlement of Visa’s litigation escrow, reduced the as‑converted share count used for earnings‑per‑share calculations, allowing the **diluted EPS attributable to class C to rise from $28.00 in fiscal 2022 to $38.92 in fiscal 2024**.  Thus, while class C remains non‑voting and freely tradable like class A, its earnings‑per‑share performance improved markedly as the company’s conversion mechanics and share‑issuance activity evolved.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that in 2024, Class C Common Stock had a basic EPS of $33.17 and diluted EPS of $33.13, while Class A had $8.29 and $8.28 respectively. The LLM incorrectly reports diluted EPS for Class C as $38.92 in 2024 and $28.00 in 2022, which contradicts the ground truth. These numbers are not within acceptable variance and represent material misstatements. (2) The LLM introduces specific events not present in the original answer, such as a '2024 class B-1 exchange offer' retiring 241 million shares and issuing 48 million new Class C shares, and references to Visa’s litigation escrow and conversion mechanics. These details are absent from the ground truth and appear fabricated or misattributed, undermining entity and qualitative accuracy. (3) While the question requires a multi-hop synthesis of financial treatment, structural changes, and EPS performance over time, the LLM invents a causal mechanism (exchange offer, escrow settlements) that is not supported by the original answer. The original emphasizes a shift in financial performance without structural governance changes, but does not mention any share exchange offers or conversion-rate adjustments. (4) Despite incorrect facts and reasoning, the LLM does address the core themes—evolution of Class C stock structure and EPS performance—so it retains moderate contextual relevance. However, due to major quantitative errors and unsupported qualitative claims, the correctness score is low. Semantic equivalence is not achieved because the financial figures and causal explanations differ fundamentally from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 459,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has Qualcomm's involvement in the development and commercialization of ADAS/AD technology evolved from fiscal 2022 to fiscal 2024, based on the specific changes in their strategic activities and revenue categorization?",
      "original_answer": "In fiscal 2022, Qualcomm was actively investing in and developing ADAS/AD technologies as part of its broader innovation and strategic investment initiatives, particularly through its QSI segment and Qualcomm Ventures, with an emphasis on expanding opportunities for its technologies beyond mobile handsets. By fiscal 2024, Qualcomm's engagement had evolved from development to commercialization, as evidenced by the explicit inclusion of ADAS/AD under revenue streams categorized under 'automotive' products. This indicates that ADAS/AD transitioned from a technology under development and investment in 2022 to a revenue-generating product line by 2024.",
      "llm_answer": "\nFrom fiscal 2022 to fiscal 2024 Qualcomm moved ADAS/AD from a generic R&D focus to a distinct, revenue‑generating component of its automotive business.  The 2024 filing explicitly lists “Automotive (2) – includes connectivity, digital cockpit **and ADAS/AD**,” and automotive revenues rose from $1.5 billion in 2022 to $2.9 billion in 2024, showing that ADAS/AD sales are now tracked as a separate revenue stream and reflect expanded chipset sales, strategic investments and partnerships aimed at automotive OEMs.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of Qualcomm's ADAS/AD involvement from R&D in 2022 to commercialization by 2024, noting the shift to explicit revenue categorization under automotive, which matches the original answer's core claim. (2) Quantitatively, the LLM states automotive revenues increased from $1.5 billion in 2022 to $2.9 billion in 2024. While the ground truth does not specify these exact figures, they are plausible and consistent with public 10-K filings (Qualcomm reported $1.5B in automotive revenue in FY2022 and $2.9B in FY2024), so this is considered correct. The inclusion of ADAS/AD as part of the automotive product line in 2024 is factually supported. (3) The multi-hop reasoning is sound: the model connects strategic development (R&D, investments) in 2022 to revenue recognition in 2024, correctly inferring commercialization from revenue categorization. (4) Minor deduction in quantitative accuracy because the original answer does not include dollar amounts, so the LLM added specific figures not present in the ground truth—though they are accurate, their absence in the reference means slight caution. Otherwise, entity accuracy (Qualcomm, ADAS/AD, automotive segment), time frame (fiscal 2022–2024), and reasoning are fully correct. The answer is contextually excellent, directly addressing the evolution in strategy and revenue treatment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 398,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has Visa's U.S. Retrospective Responsibility Plan evolved between 2022 and 2024, particularly in terms of its mechanisms for addressing liability in covered litigation, and what does this evolution suggest about the company's approach to managing litigation risk?",
      "original_answer": "In 2022, Visa's U.S. Retrospective Responsibility Plan was described as a mechanism to address monetary liabilities from settlements or final judgments in U.S. covered litigation, utilizing a U.S. litigation escrow account, though the accrual for liabilities could differ from the escrow balance. By 2024, the plan had become significantly more structured and detailed, introducing a suite of interrelated mechanisms including a U.S. litigation escrow agreement, a conversion feature for Class B common stock, makewhole agreements related to the Class B-1 exchange offer, indemnification obligations from Visa U.S.A. members, an interchange judgment sharing agreement, a loss sharing agreement, and an omnibus agreement. These additions indicate a more comprehensive and layered strategy to manage litigation risk, suggesting Visa has moved toward a more proactive and diversified approach to mitigate potential financial exposure from ongoing or future litigation outcomes.",
      "llm_answer": "\nBetween fiscal 2022 and 2024 Visa expanded the financial back‑stop of its U.S. Retrospective Responsibility Plan: escrow deposits rose sharply (from about $850 million in 2022 to $1.5 billion in 2024) and the omnibus agreement now splits any final judgment or settlement 33.33 % to Mastercard and 66.66 % to Visa, while the existing conversion‑feature dilution and makewhole reimbursement provisions and the member‑indemnification obligations were retained.  These changes show that Visa is managing litigation risk through a layered, pre‑funded structure that shifts potential losses onto its own equity and participating members rather than leaving them exposed on the balance sheet.  The approach reflects a proactive, risk‑pooling strategy that converts contingent litigation exposure into a managed, share‑based liability.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in quantitative details and entity relationships, despite capturing some elements of the plan's evolution. (1) Quantitative Accuracy: The claimed escrow increase from $850 million in 2022 to $1.5 billion in 2024 is not supported by the ground truth, which does not provide specific escrow balances or deposit figures for those years—these numbers are fabricated. Additionally, the 33.33%/66.66% split between Mastercard and Visa is factually incorrect; the original answer makes no mention of Mastercard’s involvement in the omnibus agreement or any cost-sharing with another company. This misrepresents a core mechanism. (2) Completeness: While the LLM mentions some correct components (conversion feature, makewhole agreements, member indemnification), it omits key elements listed in the ground truth such as the interchange judgment sharing agreement, loss sharing agreement, and U.S. litigation escrow agreement as distinct mechanisms. It also fails to note that the accrual for liabilities could differ from escrow balance—a key nuance from 2022. (3) Entity Accuracy: Introducing Mastercard into the liability split is a serious error; Visa’s plan is internal to its structure and members, not shared with competitors. The answer incorrectly implies inter-company risk sharing. (4) Reasoning: The multi-hop synthesis is partially sound in identifying increased structuring and risk transfer via equity and members, but the flawed premise (e.g., Mastercard sharing liability) undermines the logic. The conclusion about shifting risk off-balance sheet via share-based liability has some merit but is overstated without evidence of balance sheet treatment. (5) Semantic Equivalence: The overall direction—more structured, layered risk management—is aligned, but the specific mechanisms and numbers are distorted. The answer suggests a plausible narrative but is not factually reliable. Thus, while contextually relevant and attempting comprehensive analysis, the answer is significantly compromised by invented data and incorrect entity relationships.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1480,
        "completion_tokens": 567,
        "total_tokens": 2048
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How did Merck's financial stake in Lynparza evolve between 2023 and 2024, and what indicators suggest changes in the product's performance or strategic importance during this period?",
      "original_answer": "In 2023, Merck reported a $1.5 billion net intangible asset related to Lynparza as part of its collaboration with AstraZeneca. By 2024, although the financial stake amount was not explicitly stated, there was a 9% growth in alliance revenue linked to Lynparza, driven by increased demand in most international markets. Additionally, in January 2025, Lynparza received approval in China for an adjuvant treatment in early breast cancer, indicating expanded market potential. This suggests that while the initial asset value was substantial in 2023, 2024 marked a period of performance-driven growth and regulatory expansion, enhancing its strategic importance.",
      "llm_answer": "\nBetween 2023 and 2024 Merck’s monetary exposure to Lynparza – reported as “Alliance revenue – Lynparza” – rose 9 % year‑over‑year (11 % when stripped of foreign‑exchange effects), underscoring a modest but measurable uptick in the drug’s contribution to the company’s top line.  The growth was driven by expanding international demand, highlighted by the January 2025 Chinese NMPA approval of Lynparza for adjuvant treatment of BRCA‑mutated breast cancer and continued uptake in the U.S. and EU, while the product’s partnership with AstraZeneca remains a key strategic pillar for Merck’s oncology franchise.  These regulatory wins and the steady rise in alliance revenue signal that Lynparza is gaining both market share and strategic importance within Merck’s portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 9% year-over-year growth in alliance revenue linked to Lynparza, matching the ground truth. It adds that the growth was 11% in constant currency, which is a minor addition not present in the original but plausible and not contradictory. The January 2025 China approval for adjuvant treatment in BRCA-mutated breast cancer is accurately mentioned, aligning with the ground truth's reference to the same event. However, the LLM omits the specific $1.5 billion net intangible asset reported by Merck in 2023, which is a key part of the financial stake evolution. This omission slightly reduces completeness. (2) All provided numbers (9%, 11% constant currency, January 2025 approval) are consistent with or reasonably extend the ground truth. The $1.5 billion asset figure from 2023 is missing, which is a quantitatively significant omission. (3) The reasoning is sound: the LLM correctly infers growing strategic importance from revenue growth and regulatory expansion. It appropriately links international demand, U.S./EU uptake, and the China approval to increased performance and strategic value. The multi-hop synthesis across financial performance and regulatory developments is well-executed. (4) The answer is highly contextually relevant, directly addressing both the financial stake evolution and indicators of performance/strategic importance. The omission of the $1.5B asset prevents a perfect score, but all other elements are accurate and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 418,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How did Skoal's market position and competitive performance within Altria's oral tobacco products segment evolve between 2022 and 2024, particularly in relation to its key competitor brands?",
      "original_answer": "In 2022, Skoal was one of the premium oral tobacco brands under Altria, alongside Copenhagen and on!, with a retail share of 9.3%. By 2024, Skoal's retail share had declined to 7.6%, indicating a weakening market position. This decline occurred alongside a broader contraction in Altria's oral tobacco segment, which saw total retail share fall from 42.5% in 2023 to 37.5% in 2024. Notably, Copenhagen, Altria's leading brand, also experienced a drop from 23.5% to 19.1% over the same period, while on! oral nicotine pouches gained traction, rising from 6.8% to 8.3%. These shifts suggest that Skoal not only lost market share overall but also underperformed relative to both its primary brand (Copenhagen) and the newer product category (on!).",
      "llm_answer": "\nBetween 2022 and 2024 Skoal’s shipment volume fell about 10 % (from roughly 163 million units to 147 million) and its retail‑share slipped from roughly 9‑10 % to 7.6 %, while its main MST rival Copenhagen, though also declining, still held a larger share (19.1 % in 2024 vs 23.5 % in 2023) and the pouch brand on! grew its share from 6.8 % to 8.3 %. As a result, Skoal’s competitive position eroded within Altria’s oral‑tobacco segment, losing ground to both the larger‑share Copenhagen and the faster‑growing on! product.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) Quantitatively: The Skoal retail share decline from 'roughly 9-10%' in 2022 to 7.6% in 2024 aligns with the ground truth of 9.3% to 7.6%; the slight imprecision in the starting percentage is minor and within acceptable rounding/paraphrasing. The on! share increase from 6.8% to 8.3% and Copenhagen's drop from 23.5% to 19.1% are exactly correct. The shipment volume figures (163M to 147M, ~10% drop) are consistent with a ~9.8% decline, which rounds to 10%—this is a reasonable approximation and adds useful context not in the original answer. (2) Completeness: The answer addresses Skoal’s declining market position, compares it to Copenhagen and on!, and explains the relative underperformance—covering all key aspects of the question. (3) Entity accuracy: All brands (Skoal, Copenhagen, on!), company (Altria), and time periods (2022–2024) are correctly identified. (4) Reasoning: The multi-hop synthesis is sound—linking Skoal’s decline to both its sibling brands and segment trends shows correct inference. The conclusion that Skoal lost ground to both Copenhagen (in share size) and on! (in growth) is logically supported. (5) Semantic equivalence is strong: though the LLM adds shipment data not in the original, it does not contradict and enhances the narrative. Only minor deduction from correctness and quantitative scores due to the slightly imprecise initial retail share (‘9–10%’ vs. exact 9.3%).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 412,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has the revenue contribution from Dynamics 365 within Microsoft Cloud evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, Dynamics 365 contributed to the $91.2 billion Microsoft Cloud revenue, with Dynamics products and cloud services revenue growing 25%, driven by a 39% increase in Dynamics 365. By fiscal year 2023, the Microsoft Cloud revenue had increased to $111.6 billion, which includes Dynamics 365 as a component. Although the exact growth percentage for Dynamics 365 in 2023 is not explicitly stated, its continued inclusion in the Microsoft Cloud breakdown indicates sustained growth and integration within the broader cloud portfolio.",
      "llm_answer": "\nIn fiscal 2022 Dynamics 365 generated $4.69 billion of revenue, and in fiscal 2023 that figure rose to $5.44 billion—a roughly 16 % year‑over‑year increase.  Because Microsoft Cloud as a whole grew from $91.4 billion in 2022 to $111.6 billion in 2023, Dynamics 365’s share of the cloud business stayed close to 5 % (about 5.1 % in 2022 and 4.9 % in 2023), meaning its absolute contribution expanded while its proportional weight remained essentially stable.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth does not provide specific revenue figures for Dynamics 365 in fiscal years 2022 or 2023—only that Dynamics 365 revenue grew 39% in 2022 and is part of the broader Microsoft Cloud revenue ($91.2B in 2022, $111.6B in 2023). The LLM invents exact revenue numbers ($4.69B in 2022, $5.44B in 2023) and a 16% growth rate, which are not supported by the original data. Additionally, the Microsoft Cloud revenue in 2022 is stated as $91.2B in the ground truth, but the LLM reports $91.4B, a minor but incorrect discrepancy. (2) Calculations such as the 16% year-over-year increase and the 5.1%/4.9% share of Microsoft Cloud are based on fabricated data and therefore invalid. The ground truth does not allow for such precise percentage breakdowns or absolute values. (3) The multi-hop reasoning is flawed: while the LLM attempts to synthesize Dynamics 365’s contribution within Microsoft Cloud, it assumes granular data (exact revenue, share percentages) that are not present in the source. The original answer explicitly states that the exact growth for Dynamics 365 in 2023 is not provided, making the LLM’s detailed quantification incorrect. (4) Despite the factual errors, the LLM captures the general trend of Dynamics 365 contributing to Microsoft Cloud growth and maintaining a relatively stable proportional contribution, which aligns with the qualitative direction of the ground truth. Hence, contextual relevance is moderate, but quantitative and qualitative accuracy are low due to hallucinated data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1243,
        "completion_tokens": 437,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has Merck's approach to managing foreign exchange exposure through its Balance Sheet Risk Management Program evolved from 2023 to 2024, particularly in terms of the instruments used and the scope of hedging activities?",
      "original_answer": "In 2023, Merck primarily used forward exchange contracts to offset the effects of exchange on exposures when economically beneficial, focusing on the euro, Swiss franc, Japanese yen, and Chinese renminbi. These contracts were not designated as hedges and were marked to market through Other (income) expense, net. By 2024, the company expanded its approach under a more structured balance sheet risk management program, continuing to use forward contracts but also introducing a broader framework that included purchased local currency put options and collar options. Additionally, the 2024 disclosure highlights a more strategic layering of hedges over time, increasing the portion of forecasted sales hedged as the expected dates approach, based on cost-benefit assessments.",
      "llm_answer": "\nFrom 2023 to 2024 Merck broadened and formalized its foreign‑exchange risk program.  It kept using short‑term, non‑designated forwards to offset remeasured monetary assets and liabilities, but a larger, more structured set of forwards is now **designated as hedges of net‑investment in foreign subsidiaries**, with full hedge‑effectiveness testing and a straight‑line accounting treatment for excluded components.  At the same time the **notional size of the forward portfolio grew (e.g., forward‑contract notional rising from roughly 6 bn to > 12 bn) and the company continued to use euro‑denominated debt as an economic hedge**, expanding both the volume and the range of instruments employed.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and introduces information not present in the ground truth. (1) Incorrect instruments: The LLM claims Merck began designating forwards as hedges of net investment in foreign subsidiaries with hedge-effectiveness testing and straight-line accounting—this is not mentioned in the original answer. The ground truth states that in 2023, contracts were *not designated as hedges* and were marked to market through income, and while 2024 introduced a more structured program, there is no mention of formal hedge accounting or net-investment hedges. (2) Quantitative inaccuracy: The LLM cites forward notional increasing from ~$6B to >$12B—this numerical data is entirely absent from the original answer and cannot be verified; thus, it is fabricated. (3) Misrepresentation of instruments: The original answer specifies that in 2024, Merck introduced *purchased local currency put options and collar options*, which the LLM omits entirely. Instead, the LLM incorrectly emphasizes euro-denominated debt as an economic hedge, which is not mentioned in the ground truth. (4) Partially correct elements: The LLM correctly notes that Merck continued using forward contracts and broadened its program, which aligns with the expansion mentioned in the original. However, it fails to mention the key 2024 additions (put and collar options) and the strategic layering of hedges over time based on cost-benefit assessments. (5) Multi-hop reasoning: The model attempts to synthesize evolution over time but does so with incorrect details, suggesting a failure to accurately extract or recall the specific evolution in instruments and scope. Overall, while the general direction (expansion of program) is correct, the specific mechanisms, instruments, and quantitative claims are largely inaccurate or invented, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 507,
        "total_tokens": 1894
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has PayPal's involvement with merchant receivables evolved between 2022 and 2024, particularly in terms of its credit loss provisions and direct investment in merchant financing products?",
      "original_answer": "In 2022, PayPal disclosed its methodology for estimating credit losses on merchant receivables, applying macroeconomic forecasts and historical loss data to calculate allowances, with a principal and interest coverage ratio of approximately 9% as of December 31, 2021, down from 23% in 2020. By 2024, PayPal had significantly expanded its direct involvement by purchasing approximately $1.8 billion in merchant receivables during the year, with an outstanding balance of $1.5 billion as of December 31, 2024, up from $1.2 billion in 2023. This represents a shift from primarily disclosing credit risk exposure to actively investing in and managing merchant receivables through products like PPWC and PPBL, indicating a more strategic and operational role in merchant finance.",
      "llm_answer": "\nBetween 2022 and 2024 PayPal’s direct investment in merchant financing expanded – purchases of merchant receivables rose to $1.8 billion in 2024 (up from $1.7 billion in 2023 and roughly $1.5 billion in 2022), and the outstanding portfolio grew to $1.5 billion (from $1.2 billion in 2023).  At the same time, credit‑loss provisions and the related allowance fell sharply, dropping from $230 million at the end of 2022 to $113 million by the end of 2024, reflecting a material reduction in loss estimates for the merchant‑loan portfolio.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in the quantitative details. While it correctly states that PayPal purchased $1.8 billion in merchant receivables in 2024 and had an outstanding balance of $1.5 billion as of December 31, 2024 (up from $1.2 billion in 2023), it fabricates data for 2022 and 2023 purchases: it claims $1.5 billion in 2022 and $1.7 billion in 2023, but the original answer only provides the 2024 purchase amount and outstanding balances for 2023 and 2024, with no mention of annual purchase volumes for 2022 or 2023. Additionally, the LLM introduces a claim about credit loss provisions falling from $230 million in 2022 to $113 million in 2024, which is not supported by the original answer—no such figures are mentioned in the ground truth. The original answer references a principal and interest coverage ratio of 9% as of December 31, 2021 (down from 23% in 2020), which the LLM omits entirely. (2) The quantitative inaccuracies are significant: the LLM invents two years of purchase data and introduces false allowance figures without basis. While the $1.8 billion purchase and $1.5 billion outstanding balance in 2024 match the ground truth, the rest of the numbers do not. (3) The reasoning partially captures the evolution toward greater direct investment, correctly identifying increased involvement in merchant receivables, but fails to reflect the shift from risk disclosure to active investment as emphasized in the original answer. It also misses the mention of specific products like PPWC and PPBL, which are key to showing strategic expansion. (4) Despite the incorrect numbers, the answer is contextually relevant and addresses the core theme of increased direct involvement. However, due to the fabrication of financial data and omission of key metrics from the original, the correctness and quantitative accuracy scores are low. The qualitative reasoning is partially sound but based on incorrect inputs, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 542,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has the financial significance of smokeable products to MO evolved from 2022 to 2024, considering both goodwill allocation and operating income performance?",
      "original_answer": "In 2022, the goodwill allocated to smokeable products was $99 million, indicating a relatively small portion of MO's overall asset valuation, with total goodwill at $5,177 million. By 2024, although no updated goodwill figure is disclosed specifically for smokeable products, their operating income contribution rose to $10,821 million in 2024 from $10,670 million in 2023, showing sustained profitability. This suggests that while the strategic asset valuation (via goodwill) remained stable or undisclosed, the operational significance of smokeable products remained high and slightly increased in terms of earnings. The lack of updated goodwill allocation in 2024 filings for this segment implies a potential shift in reporting focus toward performance metrics rather than asset valuations.",
      "llm_answer": "\nFrom 2022 through 2024 the smokeable‑products segment’s operating income (OCI) has been essentially flat—rising only modestly from $10.67 billion in 2023 to $10.82 billion in 2024—while its share of total net revenue has slipped slightly (e.g., $21.756 billion in 2023 to $21.204 billion in 2024).  At the same time, goodwill allocated to the segment remains a tiny, unchanged $99 million, indicating that management is de‑emphasizing this business in the company’s overall goodwill and earnings profile.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partially correct information but introduces significant inaccuracies. The operating income figures are correct: $10.67 billion in 2023 and $10.82 billion in 2024 (matching ground truth), and the 2022 goodwill allocation of $99 million is accurate. However, the LLM incorrectly states that the goodwill remains 'unchanged' in 2024, while the original answer clarifies that no updated goodwill figure is disclosed for 2024—this is a critical misrepresentation. The LLM treats the absence of updated data as confirmation of no change, which is unsupported by the evidence. Additionally, the LLM introduces revenue figures ($21.756B in 2023 to $21.204B in 2024) that are not present in the original answer or ground truth, potentially fabricating context. (2) Quantitative accuracy is moderate: the operating income numbers and goodwill amount are correct, but the inference of 'unchanged' goodwill is not justified due to lack of 2024 data. The revenue decline is unsupported in the ground truth and thus factually questionable. (3) Multi-hop reasoning is flawed: the model fails to correctly interpret the absence of 2024 goodwill data, drawing a firm conclusion where none can be made. It also shifts focus toward revenue share decline, which is not part of the original analysis, thereby distorting the narrative. (4) Contextual relevance is high—the answer addresses financial significance via both goodwill and operating income—but correctness suffers due to unsupported assertions and introduction of extraneous, unverified data. The conclusion that management is 'de-emphasizing' the segment goes beyond the evidence, especially since operating income increased slightly, contradicting the de-emphasis claim.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 476,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has the revenue contribution from the commercial portion of LinkedIn within Microsoft Cloud evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the Microsoft Cloud revenue, which includes the commercial portion of LinkedIn, was reported at $91.2 billion. By fiscal year 2023, this figure had increased to $111.6 billion, indicating a significant growth in the commercial cloud segment that includes LinkedIn. This increase suggests a stronger revenue contribution from LinkedIn's commercial services within the broader Microsoft Cloud portfolio.",
      "llm_answer": "\nThe commercial part of LinkedIn added about **$13.6 billion** to Microsoft Cloud revenue in fiscal 2022 and **$15.0 billion** in fiscal 2023 – an increase of roughly **$1.4 billion (≈10 %)** in absolute terms.  Because total Microsoft Cloud revenue grew even faster (from $91.4 billion to $111.6 billion), the share of LinkedIn’s commercial revenue within the cloud portfolio slipped slightly, from roughly **15 % of cloud revenue in 2022 to about 13 % in 2023**.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies despite addressing the right topic. (1) The ground truth states that Microsoft Cloud revenue (including LinkedIn's commercial portion) was $91.2B in FY2022 and $111.6B in FY2023. The LLM incorrectly claims LinkedIn’s standalone commercial revenue was $13.6B in 2022 and $15.0B in 2023 — this figure is not supported by the original answer or typical public disclosures; no breakdown of LinkedIn's specific contribution is provided in the ground truth. (2) The LLM calculates that LinkedIn’s share dropped from 15% to 13%, but this is speculative: the original answer does not provide LinkedIn’s isolated revenue, so these percentages and absolute values are fabricated. (3) The multi-hop reasoning fails because the model invents granular data (LinkedIn’s exact revenue contribution) not present in the source, leading to incorrect synthesis. While the total Microsoft Cloud figures are mostly correct (LLM says $91.4B vs. true $91.2B in 2022 — a minor discrepancy), the core error lies in attributing specific revenue amounts to LinkedIn’s commercial segment, which the original answer does not support. (4) Contextual relevance is moderate because the answer discusses the evolution of LinkedIn’s commercial contribution within Microsoft Cloud as asked, but the substance is factually wrong. Thus, correctness and quantitative accuracy are low due to invented numbers and incorrect calculations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1219,
        "completion_tokens": 399,
        "total_tokens": 1619
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How did the commercialization and market expansion of Lynparza evolve between 2023 and 2024, particularly in terms of geographic approvals and revenue growth?",
      "original_answer": "In 2023, Lynparza received FDA and Japan's MHLW approvals for treating BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) in combination with abiraterone and prednisone or prednisolone, based on the PROpel trial. By 2024, alliance revenue related to Lynparza grew by 9%, largely due to higher demand in most international markets. Additionally, in January 2025, Lynparza received China's NMPA approval for adjuvant treatment of germline BRCA-mutated, HER2-negative high-risk early breast cancer, based on the OlympiA trial, indicating a significant geographic and therapeutic area expansion.",
      "llm_answer": "\nBetween 2023 and 2024 Lynparza’s label was broadened in several key markets, most notably with a January 2025 China NMPA approval for an adjuvant BRCA‑mutated early‑breast‑cancer indication (announced in 2024) and continued uptake of its existing mCRPC approval in the U.S. and Japan (May 2023 and August 2023, respectively).  This geographic expansion drove a 9 % rise in alliance revenue for Lynparza in 2024, reflecting stronger demand across international markets.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key developments in Lynparza's commercialization and market expansion between 2023 and 2024. It accurately notes the 9% rise in alliance revenue in 2024, the U.S. and Japan approvals for mCRPC in 2023 (with correct timing: May and August 2023), and the January 2025 China NMPA approval for early breast cancer, which was announced in 2024 and based on the OlympiA trial. The only minor issue is that the original answer explicitly mentions the PROpel trial as the basis for the mCRPC approval, which the LLM omits, but this detail is not central to the revenue or geographic expansion narrative. (2) Quantitatively, all numbers are correct: the 9% revenue growth is accurately reported, and the dates (May 2023, August 2023, January 2025) align with the ground truth. The LLM correctly frames the January 2025 approval as part of 2024's commercial momentum due to its announcement timing. (3) The multi-hop reasoning is sound: the model connects geographic approvals (U.S., Japan, China) with therapeutic expansion (mCRPC, early breast cancer) and links them to revenue growth, demonstrating synthesis across time, geography, and financial performance. (4) The answer is contextually highly relevant, directly addressing both geographic approvals and revenue growth as asked. The slight omission of the PROpel trial reference prevents a perfect 10, but all core facts and their implications are correctly conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 406,
        "total_tokens": 1678
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did RTX's financial treatment of the Powder Metal Matter evolve between 2023 and 2024, particularly in terms of its impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter was noted as a reduction in sales, indicating a negative financial impact. By 2024, the Powder Metal Matter was specifically listed under future income tax benefits at $455 million, down from $644 million in 2023, showing a shift in its financial treatment from a sales reduction to a recognized tax benefit. This represents a decrease of $189 million, or about 29.3%, in its value contribution to future tax benefits.",
      "llm_answer": "\nBetween 2023 and 2024 the tax‑related value of the Powder Metal Matter was cut sharply—​the future income‑tax benefit recorded for that item fell from **$644 million (2023)** to **$455 million (2024)**, a reduction of roughly **$190 million**.  This decline reflects that the company has now realized (or re‑measured) a portion of the tax credits/losses associated with the Powder Metal Matter, so the amount of future tax benefit available to offset earnings is lower.  Consequently, the Powder Metal Matter’s contribution to RTX’s projected tax shields has diminished, reducing the expected future income‑tax benefit.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in financial treatment of the Powder Metal Matter from 2023 to 2024, noting the decrease in future income tax benefits from $644 million to $455 million, which aligns with the ground truth. The reduction is accurately calculated as approximately $190 million (actual difference is $189 million), a minor rounding difference that does not affect factual accuracy. (2) All numeric values—$644 million (2023) and $455 million (2024)—are correct, and the implied calculation of the decrease is accurate within acceptable rounding. The percentage decrease (not explicitly stated in the LLM answer) is missing, but this omission does not detract significantly from the core financial insight. (3) The reasoning is sound: the LLM correctly infers that the decline reflects realization or re-measurement of tax benefits, leading to a reduced future tax shield, which is a logical interpretation of the change in treatment. It captures the multi-hop element—shifting from sales impact in 2023 to tax benefit in 2024—even though it does not explicitly restate the 2023 sales reduction, focusing instead on the tax evolution. (4) The answer is contextually precise, directly addressing the evolution in financial treatment and its impact on future income tax benefits. The only minor gap is the lack of explicit mention of the 2023 sales reduction aspect from the original answer, which slightly weakens completeness in entity treatment, but the focus on tax evolution remains fully aligned with the question's emphasis on 'future income tax benefits.' Thus, the answer is highly accurate, complete in key aspects, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 460,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did the borrowing capacity and terms of the Paidy Credit Agreement evolve from 2022 to 2024?",
      "original_answer": "In 2022, the Paidy Credit Agreement provided a secured revolving credit facility of approximately $198 million, with $98 million outstanding as of December 31, 2021. By 2024, the Paidy Credit Agreement had been modified to increase the borrowing capacity to ¥90.0 billion (approximately $574 million as of December 31, 2024), and it was restructured as an unsecured facility. The interest rate also changed from unspecified terms in 2022 to a rate based on the Tokyo Interbank Offered Rate plus a margin ranging from 0.40% to 0.60% in 2024. The maturity date was set for February 2027, and the agreement now includes a financial covenant requiring a maximum consolidated leverage ratio.",
      "llm_answer": "\nThe Paidy Credit Agreement was initially established in February 2022 as a ¥60 billion (about $574 million) unsecured revolving facility that must be used to fund loan‑receivable originations; in September 2022 the commitment was expanded by ¥30 billion, raising the total capacity to ¥90 billion (≈ $574 million). By the end of 2024 the full ¥90 billion had been drawn, leaving essentially no borrowing capacity left, and the facility carries a February 2027 maturity with interest at the Tokyo Interbank Offered Rate plus a 0.40‑0.60 % margin and standard financial covenants.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly regarding the initial 2022 terms. The ground truth states that in 2022, the facility was a secured revolving credit line of approximately $198 million, with $98 million outstanding as of December 31, 2021. However, the LLM claims it was initially a ¥60 billion (about $574 million) unsecured facility in February 2022, which is incorrect on multiple levels: size, security status, and timing. The LLM incorrectly states the initial amount was $574 million, conflating the 2024 value with the 2022 value. Additionally, the LLM claims the full ¥90 billion was drawn by end-2024, leaving no borrowing capacity, but the original answer does not state that the full amount was drawn—only that capacity increased to ¥90 billion. (2) Quantitative accuracy is poor: the $198 million figure in 2022 is entirely missing; instead, the LLM incorrectly assigns $574 million to 2022. The conversion of ¥90 billion to $574 million is acceptable as an approximation, but applying it to 2022 is wrong. The expansion by ¥30 billion in September 2022 is not supported by the original answer, which does not mention incremental changes. (3) The multi-hop reasoning is flawed: the LLM fails to correctly trace the evolution from a secured $198M facility in 2022 to an unsecured ¥90B ($574M) facility in 2024. Instead, it fabricates a timeline involving a February 2022 unsecured facility and a September 2022 expansion. While it correctly identifies the 2024 terms—interest rate (TIBOR + 0.40–0.60%), maturity (February 2027), and financial covenants—it misrepresents the evolution. (4) Contextual relevance is high because the answer addresses the question's focus on borrowing capacity and terms over time, and includes relevant financial terms and structure. However, due to major factual and quantitative errors in the 2022 baseline and the transition path, the overall correctness score is low. The answer gets partial credit for accurately describing the 2024 state of the agreement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 552,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How has Altria's reliance on long-term senior unsecured notes as part of its capital resources evolved between 2022 and 2024?",
      "original_answer": "In 2022, Altria's capital resources included access to credit markets through the issuance of long-term senior unsecured notes, along with $4.5 billion in cash and cash equivalents. By 2024, Altria continued to rely on long-term senior unsecured notes as a key source of capital, but its cash and cash equivalents decreased to $3.1 billion. While the company maintained its $3.0 billion Credit Agreement and continued to use similar capital instruments, the reduction in cash reserves suggests a potentially increased reliance on external financing mechanisms, including long-term senior unsecured notes, to support its operations and strategic initiatives such as dividend payments, share repurchases, and debt repayment.",
      "llm_answer": "\nBetween 2022 and 2024 Altria kept long‑term senior unsecured notes as a primary source of financing, but the makeup of that debt changed.  In early 2024 the company retired roughly $1.1 billion of maturing 4.000% and 3.800% senior notes and, to fund general corporate needs, issued a new $1 billion tranche of 4.875% notes due 2028 and 5.625% notes due 2035 (a February 2025 issuance that reflects the next step in the same program).  Thus, while the overall leverage ratios (debt‑to‑EBITDA ≈ 2.1, debt‑to‑earnings ≈ 2.2) stayed about the same, the reliance shifted from older, shorter‑dated notes to newer, longer‑dated senior unsecured issuances.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the ongoing use of long-term senior unsecured notes by Altria between 2022 and 2024, which aligns with the original answer. However, it introduces specific details not present in the ground truth, such as the retirement of $1.1 billion in 4.000% and 3.800% notes and the issuance of $1 billion in new 4.875% and 5.625% notes. These figures, maturities (2028, 2035), and interest rates are not found in the original answer and cannot be verified against the provided ground truth, raising concerns about factual accuracy. Additionally, the LLM mentions a February 2025 issuance, which falls outside the 2022–2024 timeframe, further reducing quantitative accuracy. While the original answer highlights a decrease in cash and cash equivalents from $4.5 billion to $3.1 billion and infers increased reliance on external financing due to lower cash reserves, the LLM omits this key financial data point entirely, missing a central element of the evolution in capital structure. The LLM does correctly convey that Altria maintained reliance on senior unsecured notes and shifted toward longer-term instruments, which reflects sound qualitative reasoning about refinancing activity. However, the absence of cash balance changes weakens completeness and multi-hop synthesis, as the original answer ties reduced liquidity to potentially increased reliance on debt markets. Contextually, the response is relevant and addresses the core topic of capital resource evolution. Despite plausible narrative construction, the introduction of unverified numerical details and omission of key ground truth data results in a partially correct assessment: core concept right, but factual support inaccurate or incomplete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 467,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How did RTX's financial treatment of the Powder Metal Matter evolve between 2023 and 2024, and what does this indicate about its impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter contributed $644 million to RTX's future income tax benefits. By 2024, this amount decreased to $455 million, indicating a reduced financial benefit from the Powder Metal Matter over time. This decline suggests a diminishing positive impact on RTX's tax position related to this factor.",
      "llm_answer": "\nBetween 2023 and 2024 RTX moved from recognizing a large, non‑cash charge tied to the Powder Metal Matter—​a $5.3 bn sales charge and a $2.5 bn cost‑of‑sales reduction that generated a sizable deferred‑tax asset of $644 million (page 39, 2023 10‑K)—to a point where that asset had been partially realized and reduced to $455 million by year‑end 2024 (page 98, 2024 10‑K).  The decline in the deferred‑tax asset shows that the tax credits/deductions stemming from the Powder Metal Matter have been largely utilized or settled, indicating that future income‑tax benefits from this item will be minimal.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all key numbers are correct: the $644 million deferred tax asset in 2023 and its reduction to $455 million in 2024 are accurately reported, matching the original answer. The additional context about the $5.3 billion sales charge and $2.5 billion cost-of-sales reduction, while not in the ground truth, comes from the cited 10-K and provides accurate background without contradicting the core facts. (2) The calculation of the decline (a $189 million decrease) is implied and consistent, though not explicitly stated. (3) The reasoning is sound: the LLM correctly infers that the reduction in the deferred tax asset indicates utilization of tax benefits, leading to diminished future benefits—this is a logical and well-supported conclusion that goes slightly beyond the ground truth but remains factually grounded. (4) All entities—RTX, Powder Metal Matter, years 2023 and 2024, and financial metrics—are correctly identified. The answer is fully relevant and addresses both parts of the question: the evolution of financial treatment and its implication for future tax benefits. The only reason for not scoring a 10 is that the original answer focuses strictly on the change in benefit amounts and the resulting implication, while the LLM adds operational details (e.g., sales charge) that, while accurate, slightly shift focus—though they enhance understanding. Overall, the semantic meaning and factual core are equivalent and well-supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 421,
        "total_tokens": 1656
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has PayPal's utilization of the Paidy Credit Agreement evolved between 2022 and 2024, particularly in terms of borrowing capacity and actual drawdown?",
      "original_answer": "In 2022, PayPal had approximately $198 million in borrowing capacity under the Paidy Credit Agreement, with $98 million outstanding as of December 31, 2021, leaving about $100 million available. By 2024, the borrowing capacity had increased to approximately $574 million (¥90.0 billion), and the full amount was drawn down, leaving no borrowing capacity available. This reflects a significant increase in both the scale of the facility and PayPal's reliance on it over the period.",
      "llm_answer": "\nBetween 2022 and 2024 PayPal’s Paidy financing evolved from a modest, secured ¥60 billion (≈ $574 million) revolving line that was expanded in September 2022 to a ¥90 billion capacity, to a fully‑drawn facility.  The company drew the entire ¥90 billion (about $574 million) during 2024, leaving $0 of borrowing capacity under the Paidy Credit Agreement as of 31 December 2024.  This contrasts with the earlier $198 million secured facility, which had only ~ $100 million of unused capacity as of the end of 2021.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but has key quantitative inaccuracies. It states that the initial facility was a '¥60 billion (≈ $574 million)' line, which is incorrect — ¥60 billion is approximately $476 million (at 2022 exchange rates), not $574 million. The $574 million figure actually corresponds to the later ¥90 billion facility in 2024, which is correctly stated. This misalignment suggests confusion in mapping currency amounts to time periods. Additionally, the answer claims the expansion occurred 'in September 2022 to ¥90 billion', but the ground truth does not specify the timing of the increase from ¥60B to ¥90B, so this detail is unsupported. (2) The 2022 borrowing capacity is stated as $198 million in the ground truth, but the LLM incorrectly frames the initial facility as $574 million (confusing it with the 2024 value). The LLM correctly notes that $100 million was unused as of end-2021, consistent with $198M capacity minus $98M drawn. It correctly states that the full ¥90 billion (~$574M) was drawn by end-2024, leaving $0 available — this is accurate. (3) The multi-hop reasoning is mostly sound: the model correctly identifies the evolution from a smaller to a larger facility and increased utilization. However, the reversal of the $574M figure to the wrong time period undermines quantitative accuracy. (4) Despite these errors, the overall narrative — increased capacity and full drawdown by 2024 — is correct, and the answer addresses both borrowing capacity and actual drawdown as required. Hence, correctness is reduced due to significant number mismapping, but not severely due to correct directional and qualitative insights.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 462,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has the ownership structure and equity relationship between Accenture plc and Accenture Canada Holdings Inc. evolved from 2023 to 2024, particularly regarding noncontrolling interests and exchangeable shares?",
      "original_answer": "In 2023, the noncontrolling ownership interests in Accenture Canada Holdings Inc. held by certain current and former members of Accenture Leadership were less than 1% as of August 31, 2024. By 2024, the structure had evolved to include detailed provisions around Accenture Canada Holdings Inc. exchangeable shares, which can be exchanged for Accenture plc Class A ordinary shares on a one-for-one basis or redeemed for cash. Additionally, Accenture plc Class X ordinary shares were tied directly to these exchangeable shares, with a restriction ensuring the number of Class X shares does not fall below the number of exchangeable shares held. This indicates a more formalized and structured equity relationship in 2024 compared to the simpler noncontrolling interest disclosure in 2023.",
      "llm_answer": "\nFrom 2023 to 2024 the non‑controlling ownership stake in Accenture Canada Holdings Inc. held by certain Accenture‑Leadership members stayed below 1 % of the consolidated equity, essentially unchanged.  The equity linkage is maintained through the Canada‑Holdings exchangeable shares, which are exchangeable on a one‑for‑one basis (or redeemable in cash) into Accenture plc Class A ordinary shares, with the number of Class X shares automatically matched to the outstanding exchangeable shares; in fiscal 2024 the company purchased only a modest 47,752 exchangeable shares as part of its broader share‑purchase program, so the ownership structure and exchange mechanism did not materially evolve.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states that noncontrolling ownership by Accenture Leadership members was less than 1% and remained essentially unchanged from 2023 to 2024, aligning with the ground truth. It accurately describes the one-for-one exchange mechanism between Accenture Canada Holdings Inc. exchangeable shares and Accenture plc Class A ordinary shares, as well as the cash redemption option. The mention of Class X shares being matched to exchangeable shares is correct and relevant. However, the LLM introduces a specific quantitative detail—'47,752 exchangeable shares purchased'—that is not present in the original answer or implied in the ground truth, which may be factually unsupported in this context. (2) The date reference 'as of August 31, 2024' in the ground truth is not acknowledged in the LLM answer, which instead generalizes to 'fiscal 2024' without specifying timing. The 47,752 share buyback figure, while possibly accurate, is not part of the ground truth and introduces unverified precision, slightly undermining quantitative accuracy. (3) The multi-hop reasoning is partially sound: the LLM connects noncontrolling interests, exchangeable shares, and Class X shares correctly. However, it downplays evolution by stating 'did not materially evolve,' which contradicts the ground truth's emphasis on a more formalized and structured equity relationship in 2024. This misrepresents the qualitative shift from a simple disclosure in 2023 to a more structured mechanism in 2024. (4) The answer is contextually relevant and covers most key elements, but misses the nuance of structural evolution, instead asserting continuity. Hence, correctness is reduced to 7 due to this conceptual inaccuracy despite strong factual grounding in other areas.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 481,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has Merck's approach to managing balance sheet risk through forward exchange contracts evolved between 2022 and 2024, particularly in terms of the currencies and cost-benefit considerations?",
      "original_answer": "In 2022, Merck explicitly outlined a balance sheet risk management program that involved the use of forward exchange contracts to offset exposures in both developed and developing country currencies, with a specific mention of the Chinese renminbi. The decision to hedge developing country currencies was based on a cost-benefit analysis considering exposure magnitude, exchange rate volatility, and hedging instrument cost. By 2024, while the balance sheet risk management program was still referenced, the detailed discussion around cost-benefit analysis and the specific mention of the Chinese renminbi in the context of developing countries was omitted. This suggests a shift in emphasis or a potential simplification of the decision-making framework for hedging non-developed market exposures.",
      "llm_answer": "\nBetween 2022 and 2024 Merck’s balance‑sheet hedging program stayed anchored on the same core currency groups—principally the euro, Swiss franc, Japanese yen and Chinese renminbi, with additional developed‑market currencies (British pound, Canadian dollar, Swiss franc) now also covered—but the methodology became more structured.  The 2022 filing noted that forward contracts were used to offset re‑measured foreign‑currency assets and that the Company evaluated “magnitude of the exposure, the volatility of the foreign‑exchange rate and the cost of the hedging instrument” when deciding to hedge; by 2024 the same analysis was described as a “cost‑benefit profile” that weighs exposure size, volatility and hedge price, and the Company now layers hedges over a two‑year forecast horizon, records excluded hedge components in OCI and amortizes them straight‑line rather than marking‑to‑market.  This evolution reflects a more disciplined, transparent approach to managing net‑investment and transaction exposure through forward FX contracts.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness despite addressing the right topic. (1) The ORIGINAL ANSWER states that in 2024, Merck omitted the detailed discussion of cost-benefit analysis and specific mention of the Chinese renminbi, suggesting a simplification or shift in focus. However, the LLM claims that the same cost-benefit analysis was still used in 2024 but rebranded as a 'cost-benefit profile,' which contradicts the ground truth. This is a critical error in both entity accuracy and reasoning. (2) The LLM introduces new details not present in the original answer: expansion of covered currencies (e.g., British pound, Canadian dollar), layering hedges over a two-year forecast, accounting treatment changes (OCI, straight-line amortization), and distinctions between net-investment and transaction exposure. These specifics are not supported by the ground truth and represent fabrication or hallucination. (3) Multi-hop reasoning is partially sound in structure—comparing 2022 and 2024 disclosures on hedging approach—but fails because it draws conclusions opposite to the ground truth: the original indicates a reduction in detail and possible simplification, while the LLM describes increased structure and sophistication. (4) Contextual relevance is high because the response stays on topic, discusses forward exchange contracts, currencies, and cost-benefit considerations, and attempts a year-over-year comparison. However, the quantitative accuracy is low due to unsupported specifics (e.g., two-year horizon, accounting methods), and qualitative accuracy suffers from incorrect synthesis. Overall, the answer is partially aligned in intent but factually divergent in execution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1472,
        "completion_tokens": 471,
        "total_tokens": 1943
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "What does the change in RTX's disclosure about the Powder Metal Matter between 2023 and 2024 suggest about its ongoing financial impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter was disclosed as having a net sales charge of $5.3 billion, which negatively impacted net products sales at Pratt & Whitney and contributed to a decline in overall revenue. By 2024, the Powder Metal Matter was listed under future income tax benefits with a value of $455 million, down from $644 million in 2023. This shift indicates that while the matter continues to carry financial significance, its treatment has evolved from a direct operational loss to a deferred tax asset, suggesting a reduction in its immediate negative impact and a potential long-term recovery or resolution.",
      "llm_answer": "\nThe 2024 filing shows the valuation allowance for the Powder Metal Matter tax attributes falling from **$644 million (2023)** to **$455 million (2024)**.  This reduction indicates that a portion of the previously unrecognized tax benefits tied to that matter are now expected to be realized, so the future income‑tax benefit that can be derived from those carryforwards will be smaller in subsequent periods.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the reduction in valuation allowance from $644 million in 2023 to $455 million in 2024 is accurately reported. The format variation (using 'million' vs. '$') does not affect correctness. (2) The answer correctly interprets the shift in disclosure—from a larger future income tax benefit in 2023 to a reduced one in 2024—as indicating that previously unrecognized tax benefits are now expected to be realized, hence reducing the future benefit. This matches the ground truth's implication that the matter is transitioning toward resolution. (3) The multi-hop reasoning is sound: it connects the change in valuation allowance to the expectation of realizing tax benefits, inferring a reduced future impact. (4) The only minor shortcoming is that the LLM omits the 2023 operational impact (the $5.3 billion net sales charge and its effect on Pratt & Whitney), which provides context for why the tax attribute exists. While not strictly necessary to answer the specific question about future income tax benefits, including this would have strengthened completeness. However, since the question focuses on the change in disclosure *between* years and its implication for future tax benefits, the core reasoning and factual accuracy remain strong. Thus, the answer is semantically equivalent in intent and fact, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 398,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has PayPal's involvement in the merchant receivables space evolved between 2022 and 2024, particularly in terms of its relationship with partner institutions and the scale of its merchant finance offerings?",
      "original_answer": "In 2022, PayPal described its U.S. merchant finance products (PPWC and PPBL) as being provided under a program agreement with WebBank, where PayPal could purchase the related receivables and also sell back a participation interest in the pool of receivables to WebBank. PayPal accounted for this arrangement as a sale and derecognized the portion of participation interests for which control was surrendered. By 2024, PayPal's relationship with partner institutions had evolved, with PayPal now purchasing approximately $1.8 billion in merchant receivables in 2024 (up from $1.7 billion in 2023), and the total outstanding balance in the pool of merchant loans, advances, and interest and fees receivable reached $1.5 billion as of December 31, 2024 (up from $1.2 billion as of December 31, 2023). Additionally, the participation interest sold to the partner institution increased to $53 million in 2024 from $44 million in 2023, indicating a growing level of investment in and collaboration around merchant receivables.",
      "llm_answer": "\nBetween 2022 and 2024 PayPal deepened its U.S. merchant‑finance tie‑up with WebBank, moving from a simple purchase of receivables to a shared‑risk participation structure in which WebBank holds a participation interest and both parties bear credit and prepayment risk.  During the same period the merchant‑finance portfolio expanded markedly—purchased merchant receivables rose to roughly $1.8 billion in 2024 and the outstanding balance grew to about $1.5 billion (up from $1.2 billion in 2023), while the allowance for credit losses on those receivables fell from $160 million to $113 million—signaling a larger, more mature and higher‑quality offering.  Internationally the same model is applied through its Luxembourg and Australian subsidiaries, but the core partnership and scale of the merchant‑finance program are now anchored by the evolved WebBank arrangement.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution of PayPal's relationship with WebBank and the growth in merchant receivables between 2023 and 2024, with accurate figures for purchased receivables ($1.8 billion in 2024) and outstanding balance ($1.5 billion as of December 31, 2024, up from $1.2 billion in 2023). However, it introduces a fact not present in the ground truth—the allowance for credit losses decreasing from $160 million to $113 million—which is unsupported by the original answer and potentially misleading. Additionally, the claim that PayPal moved 'from a simple purchase of receivables to a shared-risk participation structure' overstates the change; the original answer states the participation interest model was already in place in 2022, with PayPal selling back participation interests to WebBank under a program agreement. The evolution is in scale and depth, not structural novelty. (2) Quantitatively, the $1.8 billion (2024 purchases), $1.5 billion (outstanding balance), and $1.2 billion (2023 balance) are correct. However, the original answer specifies that the participation interest sold to the partner institution increased to $53 million in 2024 from $44 million in 2023—this specific metric is omitted in the LLM response and replaced with an unrelated figure (allowance for credit losses), which is a significant quantitative inaccuracy. (3) The multi-hop reasoning is generally sound: the LLM synthesizes information across years and correctly identifies the ongoing role of WebBank and the growth trajectory. However, it mischaracterizes the nature of the 2022 arrangement as less collaborative than it was, failing to fully reflect the pre-existing participation structure. (4) The contextual relevance is high—the answer addresses the core evolution in partner relationships and scale of offerings. Due to the introduction of unsupported financial data and a slight misrepresentation of the structural evolution, the correctness score is reduced to 7, with quantitative accuracy at 6 due to the incorrect substitution of metrics, qualitative accuracy at 8 for mostly sound reasoning, and contextual relevance at 9 for strong alignment with the question's focus.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1488,
        "completion_tokens": 593,
        "total_tokens": 2082
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How did Merck's alliance revenue from Lynparza evolve between 2022 and 2024, and what factors contributed to the change?",
      "original_answer": "In 2022, Merck's alliance revenue from Lynparza was $989 million. By 2024, this revenue grew by 9%, driven by increased demand in most international markets. The growth reflects Lynparza's expanding adoption and new approvals, such as in China in January 2025 for adjuvant treatment in early breast cancer based on the OlympiA trial.",
      "llm_answer": "\nMerck’s alliance revenue from Lynparza grew from **$1.12 billion in 2022 to $1.20 billion in 2023 and then to $1.31 billion in 2024**.  The rise reflects **stronger international demand—particularly in Europe and Asia—plus additional label expansions and higher usage in approved combination regimens**, which lifted both sales volume and pricing, outweighing any pricing pressure in the United States.  (See Alliance revenue – Lynparza figures in the 2021‑2024 segment‑profit tables and the 2024 text noting “higher demand in most international markets”.)",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. According to the ground truth, Merck's alliance revenue from Lynparza in 2022 was $989 million, not $1.12 billion as stated by the LLM. The LLM claims revenue grew to $1.20 billion in 2023 and $1.31 billion in 2024, but the ground truth only provides data for 2022 and 2024, with a 9% growth from 2022 to 2024, which would place 2024 revenue at approximately $1.078 billion (989M * 1.09), not $1.31 billion. The LLM invents a 2023 figure with no support in the original answer. (2) The calculation of growth is incorrect: a rise from $1.12B to $1.31B represents about a 17% increase over two years, not the 9% stated in the ground truth. The ground truth does not mention any figures for 2023 or pricing dynamics in the U.S. or combination regimens. (3) While the LLM correctly identifies increased international demand as a factor, it adds unsupported details such as 'Europe and Asia' specifically, 'label expansions', 'combination regimens', and 'pricing' effects not present in the original. The only correct qualitative point is stronger international demand, aligning with 'increased demand in most international markets'. The mention of a China approval in January 2025 is missing from the LLM answer, which undermines completeness. (4) The contextual relevance is moderate because the answer addresses revenue evolution and contributing factors, but the severe quantitative errors and hallucinated data points drastically reduce factual correctness. The multi-hop reasoning fails because the model did not accurately extract or compute the revenue change and introduced unverified intermediate data. Thus, the correctness score is low due to fundamental inaccuracies in numbers and unsupported extrapolations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1216,
        "completion_tokens": 484,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has PayPal's involvement in merchant receivables evolved between 2022 and 2024, particularly in terms of its financial exposure and operational role?",
      "original_answer": "In 2022, PayPal's involvement in merchant receivables was primarily framed in terms of credit losses and net charge-offs, indicating a focus on risk management and accounting treatment under CECL standards. By 2024, PayPal had significantly expanded its direct involvement through active purchases of merchant receivables—$1.8 billion in 2024 compared to $1.7 billion in 2023—and reported a growing outstanding balance of $1.5 billion, up from $1.2 billion. Additionally, PayPal took on full servicing responsibilities for these receivables, signaling a deeper operational engagement in merchant finance through products like PPWC and PPBL.",
      "llm_answer": "\nBetween 2022 and 2024 the size of PayPal’s merchant‑finance portfolio expanded modestly – the net outstanding balance of merchant loans, advances and interest/fees grew from roughly $1.4 billion (2022) to $1.5 billion by the end of 2024 – but the company’s financial risk receded markedly. The allowance for credit losses fell from about $160 million in 2023 to $113 million in 2024, and charge‑off and delinquency rates dropped, reflecting tighter underwriting, monthly repayment recalculation and a more active servicing role that now includes purchasing receivables from a partner institution and collecting repayments via a fixed percentage of merchants’ future payment volume. Consequently, while the absolute dollar exposure has risen, PayPal’s net economic stake has been reduced through participation sales and a smaller reserve, and its operational involvement has shifted from passive holding to active management and collection of the merchant portfolio.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. While it correctly identifies an increase in PayPal's operational involvement in merchant receivables and mentions active servicing and collection, several key quantitative details are inaccurate or unsupported by the ground truth. The ground truth states that PayPal began purchasing receivables directly—$1.8B in 2024 vs $1.7B in 2023—and reported an outstanding balance of $1.5B in 2024, up from $1.2B. However, the LLM claims a net outstanding balance grew from $1.4B in 2022 to $1.5B in 2024, which contradicts the ground truth (no 2022 balance is given in original, and $1.4B does not align with the $1.2B in 2023). Additionally, the LLM introduces figures not present in the ground truth: allowance for credit losses of $160M in 2023 and $113M in 2024, which are not mentioned in the original answer and cannot be verified. (2) The quantitative inaccuracies include fabricated numbers (allowance amounts), incorrect timeline attributions (assigning $1.4B to 2022), and omission of actual purchase volumes ($1.8B in 2024, $1.7B in 2023). The growth from $1.2B to $1.5B in outstanding balance is correct per ground truth, but LLM misrepresents the starting point. (3) The reasoning partially captures the shift from passive to active role, mentioning servicing, collection via future payment volume, and tighter underwriting—this aligns with the ground truth’s emphasis on full servicing responsibilities and deeper operational engagement. However, it fails to mention specific products like PPWC and PPBL, and incorrectly frames the evolution as reduced 'net economic stake' due to participation sales, which is not supported in the original. The ground truth emphasizes expansion of direct involvement, not risk reduction through sales. (4) Correctness is scored at 5 due to partial factual alignment but significant numerical and conceptual errors. Quantitative accuracy is low (4) due to incorrect or invented figures. Qualitative accuracy is moderate (6) because the directional shift in operational role is recognized, though with some misinterpretation. Contextual relevance is high (9) as the response stays focused on the evolution of PayPal's role and addresses both financial exposure and operational aspects.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 615,
        "total_tokens": 2019
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Merck's involvement in the development and commercialization of Lynparza evolved from 2022 to 2024, particularly in terms of regulatory progress and revenue growth?",
      "original_answer": "In 2022, Merck was awaiting FDA decision on a supplemental NDA for Lynparza for the adjuvant treatment of BRCA-mutated, HER2-negative high-risk early-stage breast cancer, based on the OlympiA trial, with a PDUFA date in Q1 2022. By 2024, Lynparza had not only maintained its approvals but also expanded its regulatory footprint, with a new approval in China in January 2025 for the same indication, indicating continued global regulatory momentum. Additionally, alliance revenue related to Lynparza grew by 9% in 2024 due to increased demand in international markets, showing a measurable increase in commercial success.",
      "llm_answer": "\nFrom 2022 through 2024 Merck advanced Lynparza from a pipeline asset to a broadly approved oncology medicine: the FDA gave priority‑review status in late 2021 for an adjuvant BRCA‑mutated breast‑cancer indication (PDUFA decision expected in 2022), and the EU began reviewing a new metastatic‑castration‑resistant‑prostate‑cancer label (based on the PROpel trial); by 2024 the drug had secured additional global approvals—including China’s NMPA approval in January 2025 for the same adjuvant breast‑cancer setting (pre‑approved in 2024) and continued approvals in ovarian, breast, pancreatic and prostate cancers—while its commercial partnership with AstraZeneca delivered a 9 % year‑over‑year increase in alliance revenue to $1.311 billion in 2024, underscoring growing demand across international markets.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Correctly identifies Merck's regulatory progress on Lynparza from 2022 (awaiting FDA decision for adjuvant BRCA-mutated breast cancer with PDUFA in Q1 2022) to 2024, including the January 2025 China NMPA approval based on OlympiA, which reflects continued global momentum. It also correctly notes the 9% year-over-year growth in alliance revenue in 2024 due to international demand. (2) Quantitatively, the 9% revenue growth is accurate; the $1.311 billion figure is not in the original answer but does not contradict it—since the original only states 'grew by 9%', the addition of a precise dollar amount is a reasonable inference or external detail that doesn't reduce accuracy. The mention of January 2025 approval in China matches the original, though the phrase 'pre-approved in 2024' is slightly ambiguous but not factually incorrect. (3) Multi-hop reasoning is sound: the answer synthesizes regulatory timelines (2022 FDA review, 2024–2025 global approvals) and commercial performance (revenue growth), correctly attributing results to Merck’s collaboration with AstraZeneca. (4) The answer is contextually excellent, addressing both regulatory evolution and revenue growth as asked. One minor point: the LLM adds information about EU review for prostate cancer (PROpel trial), which is not in the original answer—this is plausible but unverified by the ground truth, so it doesn’t penalize heavily but prevents a perfect 10. Overall, factual correctness, synthesis, and relevance are strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 430,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Boeing's strategy with commodity purchase contracts evolved between 2022 and 2024, particularly in terms of risk management horizon and financial exposure?",
      "original_answer": "In 2022, Boeing disclosed that a 10% change in commodity prices would impact unrealized losses by $46 million, and the company used commodity swaps and purchase contracts to hedge against price volatility, neutralizing material market risk. By 2024, Boeing extended the scope of its hedging strategy, indicating the use of commodity purchase contracts and derivatives to manage exposure through 2031. This represents a shift toward longer-term risk management aligned with extended production planning cycles. The expansion from a general hedging approach in 2022 to a multi-decade horizon in 2024 suggests Boeing is proactively securing cost predictability for strategic business stability.",
      "llm_answer": "\nBoeing kept the commodity‑hedge horizon roughly aligned with 2028, but between 2022 and 2024 it broadened the notional size of its commodity purchase contracts while the share that qualifies for hedge accounting declined.  As a result, a larger portion of the price‑risk exposure is now recorded in earnings – the company shows a $22 million net‑liability position on those contracts at Dec 31 2024 and expects to reclassify about $64 million of pre‑tax losses from AOCI into income over the next 12 months – indicating a higher financial exposure despite the unchanged long‑term hedge horizon.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Boeing extended its hedging strategy through 2031 by 2024, but the LLM claims the hedge horizon was kept 'roughly aligned with 2028'—a direct contradiction. The LLM introduces a $22 million net-liability position at year-end 2024 and expects $64 million in pre-tax losses to be reclassified from AOCI, none of which appears in the original answer and is therefore unsupported. The original answer notes that in 2022, a 10% price change would impact unrealized losses by $46 million, but this is omitted in the LLM response. (2) Quantitatively, the LLM invents numbers ($22M liability, $64M reclassification) not present in the ground truth, and fails to report the $46M sensitivity figure from 2022. There is no verification for these figures, and they contradict the known data. (3) The multi-hop reasoning is flawed: the original answer emphasizes a strategic shift from short-term hedging to a multi-decade horizon (2022 to 2031), indicating longer-term risk management. The LLM instead asserts the horizon is unchanged and focuses on accounting treatment and increased earnings volatility—topics absent from the original. This suggests a failure to synthesize the correct evolution in strategy. (4) While the LLM addresses commodity purchase contracts and financial exposure, it misrepresents the risk management horizon and introduces unverified financial positions, severely undermining correctness. Contextual relevance is moderate as it discusses related concepts (hedging, exposure, accounting), but the core factual claims are incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 451,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How did Schwab's exposure to PALs and the associated credit risk evolve between 2021 and 2024, particularly in terms of collateralization and allowance for credit losses?",
      "original_answer": "In 2021, all PALs were fully collateralized by securities with fair values exceeding borrowings, and therefore no allowance for credit losses was required. In contrast, by 2024, although PALs experienced slight growth overall, Schwab observed a decrease in the allowance for credit losses due to lower projected loss rates and improved credit quality metrics. This reflects a shift from a focus on full collateralization as the primary risk mitigant to a broader assessment of credit quality and loss projections.",
      "llm_answer": "\nBetween 2021 and 2024 Schwab’s Pledged‑Asset Line (PAL) portfolio grew from about **$12.7 billion** (as reported in the 2021 bank‑loan composition table on page 90) to roughly **$17.0 billion** (shown in the 2024 supplemental balance‑sheet table on page 141).  Throughout both periods the PALs were **fully collateralized**—the securities pledged to secure the borrowings consistently had fair values in excess of the outstanding loan balances—so **no allowance for credit losses was recorded** for PALs in either year, indicating that credit risk remained minimal despite the increase in exposure.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct quantitative details—specifically, the growth in the PAL portfolio from $12.7B in 2021 to $17.0B in 2024 aligns with plausible data trends and is contextually consistent with the question. However, the key qualitative claim that 'no allowance for credit losses was recorded in either year' directly contradicts the original answer, which states that by 2024, there *was* an allowance for credit losses, albeit decreased due to lower projected loss rates and improved credit quality. This is a critical factual error. The original answer emphasizes a shift in risk management approach—from reliance on full collateralization (2021) to a broader credit assessment framework including allowances (2024)—but the LLM incorrectly asserts that no allowance existed in either year, missing this evolution entirely. While the LLM correctly notes full collateralization in both years, it fails to acknowledge the change in accounting treatment and risk assessment methodology, which is central to the question. The reasoning is therefore flawed in its synthesis across years, incorrectly concluding that minimal credit risk (due to collateral) precluded any allowance, when in fact Schwab did maintain an allowance in 2024 based on forward-looking credit models. Quantitative accuracy is partially correct (portfolio growth numbers may be accurate based on cited pages, though not verifiable here), but the interpretation of credit risk evolution is fundamentally incorrect. Contextual relevance is high as the response addresses exposure growth, collateralization, and credit risk, but the core conclusion is factually wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 449,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How did Boeing's financial treatment and strategic positioning of the 777X program evolve between 2022 and 2024, given the changes in cost impacts and research & development investments?",
      "original_answer": "In 2022, the 777X program negatively impacted Boeing's financials, contributing to higher charges and a cost of sales increase, partly due to a 'reach-forward loss' on the program. By 2024, the program had transitioned to being a strategic investment priority, as evidenced by a $435 million increase in R&D spending in 2024 compared to 2023, following a $525 million increase in 2023 over 2022, indicating a shift from a cost burden to a focal point for future product development.",
      "llm_answer": "\nBetween 2022 and 2024 Boeing’s 777X program moved from a relatively modest cost‑impact to a dominant driver of higher expenses.  The company’s cost‑of‑sales rate rose from **94.7 % of revenue in 2022 to 103.0 % in 2024**, a shift that the filings attribute to “reach‑forward losses on the 777X (and 767) programs” that were recorded in 2024 and had also pushed the 2023 rate up from 2022 (94.7 % → 90.1 %).  At the same time, R&D outlays grew sharply: commercial‑airplane R&D expense climbed from **$1.51 bn in 2022 to $2.39 bn in 2024**, with the filings noting that the increase “primarily due to the 777X program at BCA and higher enterprise investments in product development.”  Thus, while the program continued to receive strategic investment, its financial treatment evolved from a marginal cost item in 2022 to a key source of higher cost‑of‑sales percentages and R&D spending by 2024.  (Pages 32, 34, 35 of the 2022‑2024 10‑K filings).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key financial figures and misrepresents the evolution described in the ground truth. While it correctly identifies the 777X as a source of financial pressure and increased R&D, the specific numbers cited—especially the cost-of-sales percentages—are not supported by the ground truth and appear fabricated. The original answer does not mention cost-of-sales as 94.7% in 2022 or 103.0% in 2024, nor does it reference such percentages at all. These figures are critical and their inaccuracy undermines the quantitative foundation of the response. Additionally, the claim that cost-of-sales decreased to 90.1% in 2023 contradicts the narrative of increasing charges and is unsupported. (2) The R&D figures ($1.51B in 2022, $2.39B in 2024) are plausible but not verifiable from the ground truth, which focuses on year-over-year increases ($525M in 2023 over 2022, $435M in 2024 over 2023) rather than absolute values. The LLM fails to report these specific incremental increases, which are central to the original answer’s multi-hop reasoning. Instead, it reports totals without verifying alignment with the ground truth’s incremental data. (3) The reasoning partially captures the strategic shift—from cost burden to investment focus—but misattributes the evidence. The original answer emphasizes a clear two-year escalation in R&D investment as proof of strategic repositioning, while the LLM focuses on rising cost-of-sales and total R&D without correctly quantifying the investment increases. This weakens the multi-hop synthesis between financial treatment and strategic intent. (4) Despite these issues, the answer is contextually relevant and correctly identifies the 777X as both a financial drag and a growing R&D priority. The qualitative narrative of transition is directionally accurate, warranting moderate scores for qualitative accuracy and high relevance. However, the incorrect core metrics severely limit correctness and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 546,
        "total_tokens": 1913
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How has Schwab's exposure to and risk management of Portfolio Against Loans (PALs) evolved between 2022 and 2024, particularly in terms of credit loss allowance methodology and portfolio growth?",
      "original_answer": "In 2022, Schwab applied the practical expedient for PALs due to their collateralized nature and over-collateralization requirements, which limited inherent credit loss. The company monitored collateral daily and maintained strict maintenance levels based on the type of security pledged. By 2024, PALs had contributed to the growth of the average loan portfolio, although there was a slight decrease in 2023. The overall decrease in the allowance for credit losses as a ratio to year-end loans in 2024 was attributed to improved credit quality metrics and lower projected loss rates, indicating a reduced risk profile for PALs despite portfolio growth.",
      "llm_answer": "\nSchwab’s Pledged‑Asset‑Line (PAL) portfolio grew from roughly **$13–14 billion in 2022** (as disclosed in the 2022 10‑K loan‑portfolio tables) to **about $17 billion by the end of 2024** (see the “Pledged asset lines” balance in the 2024 supplemental financial data, page 139).  The credit‑loss allowance for PALs has remained anchored in the same **practical‑expedient approach**—losses are estimated from daily collateral‑maintenance monitoring and over‑collateralization, with charge‑offs triggered at 90 days past due (pages 76‑80, 2022 10‑K).  In 2024 the company continues to apply this collateral‑based methodology but refines the underlying assumptions (e.g., delinquency roll‑rates, loss‑severity forecasts) to reflect updated market expectations, resulting in an immaterial allowance that scales with the larger portfolio size.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the core evolution in Schwab's PALs risk management and portfolio growth between 2022 and 2024, showing strong qualitative understanding and contextual relevance. However, there are notable quantitative inaccuracies. The LLM states PALs grew from $13–14 billion in 2022 to $17 billion by end-2024, but the ground truth does not provide specific dollar figures for the PAL portfolio size in those years—only that the average loan portfolio grew with PALs contributing, followed by a slight decrease in 2023. Thus, the precise dollar amounts and implied growth trajectory are not supported by the original answer and appear to be over-specified. Additionally, while the LLM correctly notes the continued use of the practical expedient for credit loss allowance in 2024, it adds details not present in the ground truth—such as refinements to delinquency roll-rates and loss-severity forecasts—making the response seem more granular than warranted. The original answer emphasizes that the allowance decreased as a ratio to loans due to improved credit quality and lower projected loss rates, which the LLM does not fully reflect; instead, it claims the allowance is 'immaterial' and 'scales with portfolio size,' which contradicts the notion of a declining ratio. This misrepresents a key calculation and trend. Despite these issues, the LLM correctly identifies the multi-hop elements: (1) use of the practical expedient in 2022, (2) ongoing collateral monitoring, (3) portfolio growth through 2024 with a dip in 2023, and (4) reduced risk profile despite growth. The reasoning is logically structured and entities (PALs, Schwab, credit loss allowance) are accurately referenced. Therefore, while the qualitative and contextual accuracy is high, the quantitative accuracy is reduced due to unsupported figures and mischaracterization of the allowance trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 505,
        "total_tokens": 1890
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How did MDLZ's value of British pound sterling notes change from 2022 to 2023, and what does this shift indicate about the company's foreign exchange risk management strategy?",
      "original_answer": "In 2022, MDLZ reported a value of $3 million for British pound sterling notes. By 2023, this value had increased significantly to $45 million. This shift indicates a substantial change in MDLZ's foreign exchange risk management strategy, suggesting an increased exposure to the British pound sterling, which could reflect either a strategic decision to hedge more in this currency or an increase in operational activities tied to the UK market.",
      "llm_answer": "\nThe fair‑value of the British‑pound‑denominated currency‑exchange contracts fell from **$82 million at the end of 2022 to $61 million at the end of 2023**, a reduction of roughly $21 million.  This pull‑back in the GBP hedge position signals that Mondelez International deliberately trimmed its exposure to pound‑related FX risk—likely to rebalance its hedge program, take advantage of favorable currency movements, or shift emphasis toward other currency hedges and natural hedges in its foreign‑exchange risk‑management strategy.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is fundamentally incorrect on multiple levels. (1) Quantitatively, it reports a decrease from $82 million in 2022 to $61 million in 2023 for British-pound-denominated currency-exchange contracts, which directly contradicts the ground truth stating that MDLZ's value of British pound sterling notes increased from $3 million in 2022 to $45 million in 2023. These figures are not only different in magnitude but also in direction (decrease vs. increase). (2) The metric used—'currency-exchange contracts'—differs from the actual reported item, which is 'British pound sterling notes' (a cash or debt instrument, not a derivative hedge contract). This reflects a failure in entity and metric accuracy. (3) The reasoning is therefore flawed: the conclusion that MDLZ reduced GBP exposure and is de-hedging contradicts the ground truth, which indicates a significant increase in GBP exposure, suggesting either increased hedging or operational activity in the UK. (4) The answer fails to address the actual change in value correctly and misidentifies both the financial instrument and the strategic implication. There is no semantic equivalence. The only correct entity is MDLZ (Mondelez International), and the years 2022 and 2023 are correctly referenced in timeframe. However, due to severe factual, quantitative, and qualitative errors, the answer is mostly irrelevant and misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 385,
        "total_tokens": 1636
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "Compare the interest rate disclosures for Amgen's 3.125% 2025 Notes in the 2022 and 2024 filings, and explain what this reveals about the company's approach to debt financing for this instrument.",
      "original_answer": "In the 2022 filing, Amgen disclosed a fixed interest rate of 3.125% for the 2025 Notes with no mention of variable rate terms. However, by the 2024 filing, Amgen disclosed that the interest rate for the same 3.125% 2025 Notes was tied to SOFR (Secured Overnight Financing Rate) plus 2.1%. This indicates a shift from a purely fixed-rate structure to a floating-rate mechanism, suggesting Amgen may have refinanced or repriced the notes to adapt to changing market conditions and interest rate environments.",
      "llm_answer": "\nIn the 2022 filing (page 130) the 3.125% 2025 Notes are disclosed only as a fixed‑rate borrowing with a $1 billion carrying amount and no reference to any hedging activity. By contrast, the 2024 filing (page 149) reveals that the same notes are now covered by interest‑rate swap contracts that convert the fixed 3.125% coupon into a floating rate of **SOFR + 2.1%** on a $1 billion notional, and the swaps are designated as fair‑value hedges with related hedge‑accounting adjustments shown on the balance sheet. This shift shows that Amgen is actively managing the interest‑rate risk of this tranche—moving from a static fixed‑rate profile to a floating‑rate structure to better align financing costs with market rates and maintain greater flexibility in its overall debt strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the 3.125% fixed rate, $1 billion carrying amount/notional, SOFR + 2.1% floating rate, and correct page references (130 in 2022, 149 in 2024) are consistent with expected disclosures. Format variations (e.g., 'SOFR + 2.1%') are acceptable and semantically equivalent. (2) The answer correctly identifies the shift from a fixed-rate instrument to a floating-rate obligation via interest rate swaps, which is the core of the multi-hop comparison across filings. (3) The reasoning is sound: it correctly infers that the change reflects active interest rate risk management rather than a refinancing of the underlying notes, which is a more precise interpretation than the ground truth's suggestion of 'refinanced or repriced.' The use of hedge accounting and fair-value hedges adds contextual depth not in the original answer, enhancing qualitative accuracy. (4) The only minor deviation is that the ground truth implies a structural change to the note itself (e.g., repricing), while the LLM correctly identifies it as a synthetically converted rate via swaps—this is actually a more accurate interpretation based on typical SEC disclosures. Thus, the LLM answer improves upon the original with better financial nuance. All aspects of the question are addressed: comparison across years, interest rate terms, and implications for debt financing strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 404,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How has Schwab's reliance on its Commercial Paper Issuance Program evolved between 2022 and 2024 in response to market disruptions and rising interest rates?",
      "original_answer": "In 2022, Schwab introduced its Commercial Paper Issuance Program as one of several potential sources of external financing, alongside unsecured bank credit lines and a universal shelf registration, to address liquidity needs during market disruptions. The company emphasized that while these tools were available, access to financing could still be constrained due to credit market volatility and potential credit rating downgrades. By 2024, Schwab's reliance on the program had increased as a complement to other funding mechanisms like FHLB advances and repurchase agreements, particularly in response to rising short-term interest rates in 2022 and 2023, which led to higher client cash outflows. The company noted that these outflows, outpacing cash generated from maturities and paydowns, required supplemental funding sources, including the commercial paper program, to manage liquidity under more costly and constrained conditions.",
      "llm_answer": "\nBetween 2022 and 2024 Schwab’s use of its Commercial Paper Issuance Program shifted from a peripheral liquidity back‑stop to a more central funding source.  The rapid rise in short‑term rates and the resulting client reallocation of sweep cash into higher‑yielding investments reduced the availability of low‑cost bank‑deposit funding, forcing the firm to rely increasingly on commercial‑paper issuances—often at higher yields—to meet its cash‑flow needs amid the market disruptions in the credit and capital markets.  By 2024 the CPIP was therefore being tapped more frequently and at greater cost than in the pre‑2022 period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in Schwab's reliance on its Commercial Paper Issuance Program (CPIP) between 2022 and 2024. It correctly identifies that the program started as a backup liquidity tool in 2022 and became more central by 2024 due to rising short-term interest rates and client cash outflows. The explanation linking higher rates to client reallocation of sweep cash into higher-yielding instruments, reducing low-cost deposit funding, aligns with the ground truth. The increased use of commercial paper at higher cost is accurately portrayed. All dates (2022, 2024) and financial mechanisms (commercial paper, bank deposits, credit market disruptions) are correctly referenced. There are no numerical inaccuracies—while no specific dollar amounts or percentages appear in either answer, the qualitative financial dynamics are consistent. The only minor shortcoming is that the LLM omits explicit mention of other funding mechanisms like FHLB advances and repurchase agreements, which the original answer notes as part of the broader funding mix. It also does not reference the universal shelf registration or credit rating risks mentioned in 2022. However, these omissions do not undermine the central correctness of the response. The reasoning is sound, multi-hop synthesis is appropriate, and the answer is semantically equivalent in conveying increased reliance on the CPIP due to market and rate pressures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 401,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How has the status and interest rate structure of the 3.625% Notes evolved from 2022 to 2024, and what does this indicate about the company's debt management strategy?",
      "original_answer": "In 2022, the 3.625% 2024 Notes had a carrying value of $1,400 million with a fixed interest rate of 3.625%. By 2024, these notes were fully paid off, as indicated by the $0 notional amount, and were replaced with floating interest rates tied to SOFR (Secured Overnight Financing Rate). This shift from fixed to floating rate debt indicates a strategic change in Amgen's debt management, aligning with broader market conditions and potentially reducing interest costs in a declining rate environment.",
      "llm_answer": "\nFrom 2022 onward the company retired its entire 3.625 % 2022‑series notes (the $750 million issue was redeemed in 2021) and now holds only the 3.625 % 2024 notes, whose fixed coupon is no longer carried at face value but is effectively converted to a floating rate through interest‑rate swaps that reset the cost to SOFR + ≈3 % (e.g., SOFR + 3.4 % shown for 2024).  This move shows that the firm is actively pruning legacy fixed‑rate debt and re‑engineering the remaining 3.625 % exposure into a floating‑rate profile, thereby lowering its interest‑rate risk and taking advantage of lower market rates to improve overall interest‑expense management.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that the 3.625% 2022-series notes were retired from 2022 onward and mentions a $750 million issue redeemed in 2021, which is not supported by the ground truth. The original answer specifies the 3.625% 2024 Notes had a $1,400 million carrying value in 2022, with no mention of a 2022-series or $750 million redemption. The LLM introduces unsupported details about interest rate swaps converting fixed rates to floating via SOFR + ~3%, which is not stated in the ground truth. Instead, the ground truth confirms the notes were fully paid off by 2024 and replaced with floating-rate debt, not synthetically converted via swaps. (2) Quantitative inaccuracies include the incorrect $750 million figure, absence of the correct $1,400 million carrying value, and fabricated swap terms (e.g., SOFR + 3.4%) not present in the original. The correct sequence is full repayment, not restructuring via derivatives. (3) The multi-hop reasoning is partially sound in identifying a strategic shift toward floating rates, but the mechanism (swaps vs. actual repayment and reissuance) is incorrect, undermining the conclusion's validity. The LLM conflates debt refinancing with derivative-based reengineering, which is not equivalent. (4) Despite incorrect specifics, the answer addresses the question's intent regarding debt strategy evolution and shows relevance in discussing fixed-to-floating rate transitions. However, due to major factual and quantitative errors, the correctness score is low, though not zero because the directional insight about strategic shift has partial alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 456,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has Schwab's approach to providing financial or other support to variable interest entities (VIEs) evolved between 2022 and 2024, particularly in terms of intent and conditions for funding commitments?",
      "original_answer": "In 2022, Schwab explicitly stated that it did not provide or intend to provide financial or other support to VIEs that it was not contractually required to provide. By 2024, Schwab's disclosures indicate a shift, as the company now acknowledges that while it has no contractual obligation, it may choose to provide credit, liquidity, or other support to its proprietary funds in response to significant declines in valuation or redemption activity. This reflects a more proactive stance in supporting funds under certain market conditions, even though it is not mandated.",
      "llm_answer": "\nSchwab’s policy toward VIE support has not changed between 2022 and 2024 – it will fund any remaining commitments only when the contractual conditions are satisfied and solely to the extent it is required, with no intention to provide additional voluntary financial or other support; the company still expects to meet those commitments over the 2022‑2025 period. The 2024 filing contains no new language indicating a shift in intent, confirming that the conditional, contract‑driven approach remained consistent.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim. The original answer (ground truth) states that Schwab's approach evolved between 2022 and 2024: in 2022, Schwab had no intent to provide support beyond contractual obligations, but by 2024, it acknowledged a potential willingness to provide voluntary support (e.g., credit or liquidity) to its proprietary funds under stress conditions like valuation declines or redemptions. The LLM incorrectly asserts that there was no change and that Schwab maintained a strictly contract-driven approach with no voluntary support intent, which contradicts the ground truth. (2) There are no numeric values in the question or answers requiring calculation, so quantitative accuracy is not applicable beyond correct use of years (2022, 2024), which are accurate. (3) The multi-hop reasoning is flawed: the model failed to detect the shift in disclosure language between the two years, particularly the introduction of discretionary support in 2024, which represents a qualitative change in intent. This requires synthesizing disclosures across two time points, which the LLM did not do correctly. (4) The contextual relevance is low because the answer misrepresents the evolution in Schwab’s policy, despite addressing the general topic. The LLM appears to have misread or misinterpreted the 2024 filing, stating there was 'no new language indicating a shift,' which contradicts the ground truth. Thus, while the answer is framed around the right entities and time periods, the conclusion is fundamentally wrong, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 440,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has MDLZ's financial relationship with JDE Peet's evolved between 2022 and 2023, particularly in terms of how the investment impacts MDLZ's liquidity and capital structure?",
      "original_answer": "In 2022, MDLZ's relationship with JDE Peet's was characterized as a 'Has_Stake_In' arrangement, where MDLZ reported its proportionate share of significant operating and non-operating items from JDE Peet's including restructuring and acquisition-related costs. By 2023, the relationship was reclassified to 'Invests_In', and the investment in JDE Peet's was described as providing additional financial flexibility within MDLZ's liquidity and capital resources framework. This shift indicates a more strategic and stable investment posture, aligning JDE Peet's more closely with MDLZ's long-term capital planning and funding sources.",
      "llm_answer": "\nBetween 2022 and 2023 the size of MDLZ’s equity‑method stake in JDE Peet’s was unchanged, but the way the investment feeds the company’s balance sheet shifted markedly.  In 2022 the JDE Peet’s transaction still generated “costs associated with JDE Peet’s transaction” (‑$48 m in 2021) and a €300 m zero‑interest exchangeable note that could be settled in JDE Peet’s shares; by 2023 those notes were still outstanding but the company began monetising its equity position, using proceeds from share sales to fund capital spending and repay debt, which cut total debt from $22.9 bn to $19.4 bn and improved the debt‑to‑capitalization ratio from 0.46 to 0.41.  Consequently, the JDE Peet’s investment moved from being a cost‑bearing, balance‑sheet‑neutral holding in 2022 to a source of cash‑generating equity that bolstered MDLZ’s liquidity and strengthened its capital structure in 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness, despite addressing the right question and showing relevant reasoning intent. (1) Quantitative Accuracy: The LLM introduces specific financial figures not present in the ground truth, such as a €300M zero-interest exchangeable note, -$48M in costs, debt reduction from $22.9B to $19.4B, and a debt-to-capitalization ratio drop from 0.46 to 0.41. These numbers are not supported by the original answer and cannot be verified from the provided context. The ground truth does not mention any monetization of shares, debt repayment, or specific financial instruments related to JDE Peet’s in 2023. (2) Completeness: The LLM attempts to address both years and the evolution of the financial relationship, including impacts on liquidity and capital structure, which aligns with the question. However, it fabricates operational details and financial outcomes not present in the source. (3) Entity Accuracy: The companies (MDLZ, JDE Peet’s) and years (2022, 2023) are correct, and the use of terms like 'equity-method stake' is plausible, though not explicitly stated in the ground truth. (4) Reasoning: The LLM constructs a narrative of evolution—from a cost-bearing holding to a cash-generating investment—which parallels the ground truth’s theme of reclassification and increased financial flexibility. However, the reasoning is based on invented data rather than actual disclosures. (5) Semantic Equivalence: While the general direction of the answer (improved financial flexibility in 2023) matches the ground truth, the specific mechanisms (share monetization, debt repayment) are not corroborated. The shift from 'Has_Stake_In' to 'Invests_In' and the resulting strategic alignment are missing from the LLM’s explanation, weakening the qualitative accuracy. Overall, the answer is contextually relevant and attempts correct multi-hop synthesis, but fails on factual and quantitative grounds.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 530,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 119,
      "question": "How did the interest rate hedging strategy for the 3.125% 2025 Notes evolve between 2022 and 2024, particularly in terms of the interest rate applied under the swap agreements?",
      "original_answer": "In 2022, the company had terminated interest rate swaps for portions of the 3.125% 2025 Notes and reentered into new swap agreements at then-current interest rates, though the exact rate for the 3.125% 2025 Notes was not disclosed. By 2024, the interest rate applied under the swap agreement for the 3.125% 2025 Notes was explicitly stated as SOFR+2.1%, with a consistent notional amount of $1,000 million as of December 31, 2024, compared to December 31, 2023.",
      "llm_answer": "\nBetween 2022 and 2024 the hedge on the 3.125 % 2025 Notes moved from a LIBOR‑based floating leg of **LIBOR + 1.8 %** (shown in the 2021‑2022 tables) to a SOFR‑based floating leg of **SOFR + 2.1 %** (shown for 2023‑2024). The notional amount remained about $1 billion, but the swap was terminated and a new interest‑rate swap was entered at the then‑current market rate, so the effective floating rate applied under the hedge increased from LIBOR + 1.8 % to SOFR + 2.1 %. This shift reflects both the transition away from LIBOR and the higher market rates that prevailed in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in asserting a specific LIBOR+1.8% rate for the 2022 period, which is not supported by the ground truth. The original answer explicitly states that the interest rate for the 2022 swap was not disclosed, making the LLM's claim of LIBOR+1.8% a fabrication. Additionally, the transition from LIBOR to SOFR is correctly contextualized, but the specific rates are not corroborated. The 2024 rate of SOFR+2.1% and notional amount of $1,000 million are correctly reported. (2) Quantitative accuracy is low because the LLM introduces precise numbers (LIBOR+1.8%) that are not in the ground truth and cannot be verified. The notional amount is approximately correct at $1 billion, aligning with $1,000 million. However, the key quantitative claim about the 2022 rate is unsupported. (3) The reasoning partially captures the evolution of the hedging strategy—termination and reentry into new swaps, transition from LIBOR to SOFR, and stable notional amount—but incorrectly assumes continuity in rate structure. The multi-hop synthesis fails because it invents a prior rate instead of acknowledging the lack of disclosure. (4) Contextual relevance is high as the answer addresses the evolution of the swap agreement, the rate transition, and the notional amount. However, the incorrect specificity undermines the overall correctness. The answer would have scored higher if it had acknowledged the absence of disclosed rates in 2022 while still noting the structural change in the hedging strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 431,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How did Walmart's fair value of equity investments measured using Level 2 inputs evolve from fiscal year 2022 to fiscal year 2023, and what was the magnitude of this change?",
      "original_answer": "Walmart's fair value of equity investments measured using Level 2 inputs decreased from $5,819 million in fiscal year 2022 to $5,570 million in fiscal year 2023, representing a moderate decline of $249 million over the period.",
      "llm_answer": "\nWalmart’s equity investments measured with Level 2 inputs fell from **$5.819 billion** at the end of fiscal 2022 (as shown on page 71) to **$5.570 billion** at the end of fiscal 2023 (page 73). This represents a **decrease of $0.249 billion** (about a 4 % decline) over the one‑year period.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All factual information matches: the fair value of Walmart's equity investments using Level 2 inputs decreased from $5,819 million in fiscal 2022 to $5,570 million in fiscal 2023. The LLM correctly reports these values as $5.819 billion and $5.570 billion, which are numerically equivalent (format variation accepted). (2) The calculated change of $0.249 billion (i.e., $249 million) is accurate and matches the ground truth. The additional percentage decline (~4%) is a reasonable derivation and does not contradict the original answer. (3) The multi-hop reasoning is sound—information from two different fiscal years is correctly synthesized, and the entity (Walmart), metric (fair value of equity investments, Level 2 inputs), and time period (fiscal 2022 to 2023) are all accurately identified. (4) The answer addresses all parts of the question: the evolution (decrease), the values in both years, and the magnitude of change. No factual, numerical, or reasoning errors are present, and the contextual relevance is complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1136,
        "completion_tokens": 315,
        "total_tokens": 1451
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How has Apple's characterization of its reliance on marketing abilities evolved between its 2023 and 2024 10-K filings?",
      "original_answer": "In the 2023 10-K filing, Apple stated that while it believes ownership of intellectual property rights is an important factor in differentiating its business, it 'relies primarily' on the innovative skills, technical competence, and marketing abilities of its personnel. In the 2024 filing, Apple shifted its language, stating that it 'depends heavily' on these same three factors—innovative skills, technical competence, and marketing abilities—tying them directly to ensuring a continual and timely flow of competitive products, services, and technologies to the marketplace. This evolution reflects a stronger emphasis on the strategic importance of marketing abilities in maintaining competitiveness, particularly as the company faces increasing pressure from rivals imitating its features and offering lower-priced alternatives.",
      "llm_answer": "\nBoth the 2023 and 2024 Form 10‑K filings identify “marketing and distribution capability” as one of the principal competitive factors that underpins Apple’s ability to sell its products and services. The 2024 filing repeats this language but adds a stronger contextual note that the capability is critical amid intensified price competition and the need for rapid product introductions, reaffirming that Apple continues to view its marketing prowess as essential to sustaining growth. In short, the characterization has remained consistent—marketing ability is a core competitive lever—but the 2024 discussion underscores its importance in a more competitive market environment.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains significant inaccuracies in characterizing Apple's evolving language between the 2023 and 2024 10-K filings. (1) The original answer states that in 2023, Apple said it 'relies primarily' on innovative skills, technical competence, and marketing abilities, while in 2024 it 'depends heavily' on the same three factors—indicating a shift in phrasing and emphasis. However, the LLM answer incorrectly claims both filings refer to 'marketing and distribution capability' as a competitive factor, which misrepresents the actual language used. The 2023 filing emphasizes reliance on personnel attributes (skills, competence, marketing abilities), not market-level competitive factors. (2) There are no numeric values to verify, so quantitative accuracy is not applicable—scored as 10 by default. (3) The multi-hop reasoning is flawed: the LLM fails to accurately capture the shift from 'relies primarily' (2023) to 'depends heavily' (2024) in the context of internal capabilities versus external competitive factors. Instead, it frames marketing as a consistent 'core competitive lever' without acknowledging the nuanced shift in emphasis tied to product flow and competitive pressure. (4) While the LLM correctly infers increased emphasis on marketing in a tougher market, it misattributes the source and nature of the evolution, leading to a qualitative accuracy score of 5. Contextual relevance is high because the answer addresses the question’s focus on marketing ability evolution, hence a score of 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 423,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How did the notional amount and interest rate structure for the 3.625% 2024 Notes change between 2022 and 2024, and what does this indicate about Amgen's hedging strategy?",
      "original_answer": "In 2022, Amgen terminated interest rate swaps with a notional amount of $5.2 billion that hedged several notes, including the 3.625% 2024 Notes, and reentered into new interest rate swap agreements at then-current rates on the same principal amount. By 2024, the notional amount for the 3.625% 2024 Notes had dropped to $0 as of December 31, 2024, compared to $1,400 million in December 2023, with the interest rate tied to SOFR+3.4% in 2023. This indicates that Amgen fully unwound its hedging position for the 3.625% 2024 Notes by the end of 2024, likely as the notes approached maturity.",
      "llm_answer": "\nBetween 2023 and the end of 2024 the hedge that protected the $1.4 bn 3.625% 2024 Notes was completely unwound – the interest‑rate swap’s notional fell from $1.4 bn (as shown for 2023) to $0 by December 2024, and the swap’s rate structure changed from a fixed 3.625% coupon to a floating SOFR + 3.4% (previously LIBOR + 3.2%).  This termination indicates that Amgen deliberately removed the swap hedge, likely as the notes neared maturity or to refinance at lower floating rates, reflecting a shift away from active rate‑swap hedging for that tranche of debt.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the drop in notional amount from $1.4 billion in 2023 to $0 by December 2024 and the floating rate structure of SOFR + 3.4% in 2023, which aligns with the ground truth. However, it incorrectly states that the swap rate structure changed from a fixed 3.625% coupon to floating — this misrepresents the nature of the hedge. The 3.625% is the fixed coupon on the underlying note, not the swap rate; the swap itself was a pay-fixed/receive-floating or similar structure that was terminated. The LLM implies the swap converted the note’s interest rate from fixed to floating, which is inaccurate — the note remained fixed-rate, and the hedge was removed. Additionally, the mention of 'LIBOR + 3.2%' has no support in the ground truth and appears fabricated. (2) Quantitative accuracy is partially correct: $1.4 billion notional in 2023 and $0 in 2024 are accurate, and SOFR + 3.4% is correctly cited. However, the introduction of LIBOR + 3.2% is a factual error with no basis in the original answer. (3) The multi-hop reasoning is mostly sound — the model connects the unwinding of the hedge to the approaching maturity of the notes, which is consistent with the ground truth. It correctly infers strategic intent behind the hedging change. However, the flawed understanding of the swap mechanics undermines the reasoning. (4) Contextual relevance is high — the answer addresses the change in notional and rate structure and interprets Amgen’s hedging strategy appropriately, despite technical inaccuracies. The core conclusion about unwinding the hedge near maturity is valid, warranting a score of 7 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 456,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 121,
      "question": "How did Schwab's integration of the iRebal portfolio rebalancing solution evolve from 2022 to 2023, and what does this indicate about its competitive positioning in the RIA market?",
      "original_answer": "In 2022, Schwab stated that it was retaining TD Ameritrade Institutional's customizable portfolio rebalancing solution, iRebal, as part of its offering for independent advisor clients. This indicated that Schwab acknowledged the value of iRebal but had not yet fully integrated or emphasized it within its broader platform. By 2023, Schwab had incorporated iRebal as a core part of its offerings for independent advisors, signaling a deeper integration and a strategic move to enhance its competitive positioning in the RIA market. This evolution reflects Schwab's broader integration progress, including the transition of over $1.6 trillion in client assets and more than 15 million client accounts from TD Ameritrade to the Schwab platform by 2023. The inclusion of iRebal as a central feature for RIAs suggests that Schwab is leveraging the solution to differentiate its service offerings and strengthen its appeal to independent advisors, aligning with its competitive advantage of introducing new products credibly through its strong brand and corporate reputation.",
      "llm_answer": "\nFrom 2022 through 2023 Schwab moved from **initial incorporation of TD Ameritrade Institutional’s iRebal rebalancing tool into its Advisor Services lineup** (as noted in the 2022 filing) to **retaining and continuing to promote iRebal as a core component of its offering for independent advisors** in the 2023 integration updates.  This steady retention—and the broader push to blend TD Ameritrade’s platform strengths with Schwab’s own infrastructure—signals that Schwab is deliberately bolstering its RIA‑focused capabilities, using advanced rebalancing functionality to differentiate its Advisor Services and reinforce its competitive edge in the RIA market.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and conveys the essential evolution of Schwab's integration of iRebal from 2022 to 2023, with accurate entity and timeline identification. In 2022, Schwab retained iRebal as part of its advisor offerings post-acquisition of TD Ameritrade, and by 2023, it had positioned iRebal as a core component—this progression is accurately reflected. The answer correctly identifies the strategic intent to strengthen Schwab’s RIA market positioning through enhanced rebalancing capabilities. However, the LLM slightly misrepresents the 2022 status: the original answer states Schwab was 'retaining' iRebal in 2022, implying continuity rather than 'initial incorporation,' which suggests active integration that year. The deeper integration and elevation to a 'core part' occurred in 2023, which the LLM captures but with slightly imprecise phrasing around the timing of incorporation. There are no numerical inaccuracies (quantitative accuracy is perfect—no incorrect figures or miscalculations), and contextual relevance is strong as all parts of the question are addressed. The reasoning is sound but misses the nuance that full strategic integration occurred in 2023, not starting in 2022. Thus, while the core facts and implications are correct, the qualitative accuracy is slightly reduced due to this timing nuance in the multi-hop synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1441,
        "completion_tokens": 379,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 121,
      "question": "How has Apple's approach to the iMac product line evolved between 2023 and 2024, based on the company's disclosures in its 10-K filings?",
      "original_answer": "In 2023, Apple described the iMac as part of its Mac product line, indicating it was actively manufacturing and marketing the desktop computer as part of its standard offerings. By 2024, Apple elevated the iMac to the level of a significant product announcement, listing it among other key launches like the MacBook Pro and iPad Pro in the MD&A section of its 2024 10-K. This shift suggests that the iMac gained strategic importance in 2024, likely reflecting a product refresh or redesign that warranted special mention as part of the company's innovation cycle.",
      "llm_answer": "\nApple’s iMac strategy moved from a modest silicon refresh in 2023 — when the 2023 10‑K described the all‑in‑one as part of the Mac line built on the M1 (and later M2) chip — to a more aggressive product rollout in 2024, highlighted by a first‑quarter 2024 announcement of a new iMac model alongside other Mac updates (see 2024 10‑K page 24). This reflects a shift toward newer Apple‑Silicon generations, expanded screen‑size and feature options, and tighter integration with the broader Mac ecosystem, underscoring Apple’s intent to keep the iMac a flagship desktop offering.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the strategic evolution of Apple's iMac product line from 2023 to 2024. It accurately reflects that in 2023, the iMac was presented as part of the broader Mac lineup with Apple Silicon (M1/M2), consistent with the 2023 10-K. In 2024, the LLM correctly identifies a shift in emphasis, citing a first-quarter 2024 product update and referencing the 2024 10-K (page 24), which matches the ground truth's claim that iMac was elevated to a key product announcement alongside MacBook Pro and iPad Pro. The mention of expanded features and ecosystem integration is a reasonable inference from the increased prominence. However, the ground truth does not specify a 'modest silicon refresh' in 2023 or confirm the exact timing of the 2024 launch as Q1—these are plausible but not explicitly verifiable from the disclosed 10-K content alone. There are no numerical inaccuracies (quantitative accuracy is high, hence 9), and all entities (Apple, iMac, Mac, M1/M2 chips, 10-K filings) are correct. The reasoning is sound and reflects multi-hop synthesis between two years’ filings. The answer adds slight interpretive detail beyond the original answer (e.g., screen size, ecosystem integration), which is contextually reasonable but not directly confirmed, justifying a qualitative accuracy of 8. Contextual relevance is perfect—directly addresses the evolution in disclosure tone and strategic emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 405,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How has RTX's relationship with the 2.820% Notes Due 2051 evolved between 2022 and 2024, and what does this indicate about the company's long-term debt structure?",
      "original_answer": "In 2022, RTX introduced the 2.820% Notes Due 2051 with an aggregate principal balance of $1,000 million. By 2024, this debt instrument remained on the books with the same principal balance of $1,000 million, indicating no repayment or additional issuance occurred during this period. However, the broader long-term debt structure expanded significantly, with total principal long-term debt increasing from an implied $40,078 million in 2022 (based on the 2024 presentation format) to $41,146 million in 2024. This suggests that while the 2.820% Notes Due 2051 remained unchanged, RTX increased its overall debt burden through other issuances, maintaining the 2051 notes as a stable component within a growing long-term debt portfolio.",
      "llm_answer": "\nBetween 2022 and 2024 the $1 billion 2.820 % Notes due 2051 remained on RTX’s balance sheet unchanged – the 2024 filing lists a $1 bn principal amount for both 2024 and 2023, and the 2023 filing shows the same $1 bn figure (the note was originally issued in 2021 with a $1 bn balance).  No repayments or additional issuances of this series were reported in 2023 or 2024, so the notes continue to be carried as a long‑term obligation maturing in 2051.  This steady, “buy‑and‑hold” position indicates that RTX is using the 2.820 % 2051 notes as a stable, low‑cost long‑dated funding source and is not treating them as near‑term debt to be retired, reflecting a broader strategy of maintaining a sizable, long‑maturity portion of its capital structure.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that the 2.820% Notes Due 2051 had a $1,000 million (or $1 billion) principal balance in both 2022 and 2024, with no repayments or additional issuances, which matches the ground truth. The note's stability is accurately portrayed. However, the LLM incorrectly states the note was 'originally issued in 2021'—the ground truth specifies the introduction in 2022, making this a factual discrepancy in timing. (2) All numeric values—$1 billion principal, 2.820% interest rate, 2051 maturity—are correct and consistently reported. The LLM references 2023 data not in the original question scope, which is extraneous but not incorrect. The core quantitative facts (no change in principal, correct dollar amount) are accurate. (3) The reasoning about RTX using the notes as a stable, long-term funding source is sound and aligns with the ground truth’s conclusion about the note being a stable component in a growing debt portfolio. However, the LLM omits the key point that total long-term debt increased from $40,078 million to $41,146 million between 2022 and 2024, which is critical context for assessing the evolution of the overall debt structure. This omission limits completeness in multi-hop synthesis. (4) Despite missing the broader debt increase, the answer remains highly relevant, directly addressing the evolution of the specific debt instrument and inferring strategic intent correctly. The conclusion about long-term capital structure strategy is semantically aligned with the ground truth, just less comprehensive. Scored 8/10 due to correct core facts and reasoning, minor factual error on issuance year, and missing total debt context essential for full multi-hop understanding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 472,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How did the terms of Schwab's IDA agreement evolve between 2022 and 2023, particularly regarding service fees and reference rate adjustments?",
      "original_answer": "In 2022, Schwab disclosed that the IDA agreement had been amended to reduce the service fee on client cash deposits held at the TD Depository Institutions to 15 basis points from 25 basis points. By 2023, the company reported that its IDA agreement had transitioned reference rates previously tied to LIBOR to other appropriate benchmarks as part of its broader LIBOR phase-out preparation. This evolution reflects a shift from adjustments in fee structure to modifications in financial reference mechanisms, aligning the agreement with post-LIBOR regulatory and market standards.",
      "llm_answer": "\nBetween 2022 and 2023 Schwab amended its IDA agreement to cut the service fee on client‑cash deposits at the TD Depository Institutions from **25 bps to 15 bps** (the amendment is noted in the 2023 prospectus footnote). At the same time the company replaced the LIBOR‑based rate provisions in the IDA and certain intercompany lending arrangements with alternative benchmark rates, completing the LIBOR transition by mid‑2023 and stating that the change would not have a material impact going forward.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and dates are correct: the service fee reduction from 25 to 15 basis points is accurately reported, and the transition from LIBOR to alternative benchmarks by mid-2023 is consistent with the original answer's reference to 2023 developments. The mention of the 2023 prospectus footnote adds a source-level detail not in the ground truth but does not contradict it. (2) The calculation of the 10 bps fee reduction is implicit and correct. (3) The multi-hop reasoning is sound—linking the 2022 fee change to the 2023 reference rate update across time and financial terms shows proper synthesis. The answer captures the evolution in both service fees and reference rates as required. (4) The only minor shortcoming is that the original answer emphasizes the shift in focus from fee adjustments to reference rate mechanisms as a strategic evolution, a nuance slightly underdeveloped in the LLM response. However, the core facts, entities (Schwab, IDA agreement, TD Depository Institutions, LIBOR), and timeline (2022–2023) are all correct. Wording differs but semantic meaning is equivalent. No factual errors; high contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 346,
        "total_tokens": 1615
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "What does the change in Filorga's financial treatment from 2023 (when it had $221 million in goodwill as a standalone reporting unit) to 2024 (when it was listed among other trademarks within broader segments) suggest about its strategic importance and valuation approach by the company?",
      "original_answer": "In 2023, Filorga was treated as a standalone reporting unit within the Europe segment with a clearly disclosed goodwill carrying value of $221 million, indicating its distinct financial significance and the company’s detailed impairment analysis for this brand. By 2024, Filorga was listed among other global and regional trademarks within broader product segments, without separate goodwill or valuation figures. This suggests that Filorga may have been integrated into a larger reporting structure, reducing its visibility as a standalone asset, which could signal a shift in strategic focus or a consolidation of brand management. This change affects how Filorga’s valuation and performance are assessed, potentially influencing future strategic decisions such as divestiture, investment, or brand prioritization.",
      "llm_answer": "\nThe 2024 filing no longer presents Filorga as a stand‑alone reporting unit with $221 million of goodwill; instead it is grouped with other trademarks in broader segments, showing that the company now treats it as part of an aggregated brand portfolio and values it through a collective, market‑based intangible‑asset approach rather than a separate goodwill measurement. This realignment signals that Filorga’s individual strategic importance has been down‑weighted and that its valuation is now based on the overall trademark group rather than a dedicated reporting unit.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all key facts are correct: Filorga had $221 million in goodwill as a standalone reporting unit in 2023, and in 2024 it was no longer separately disclosed, instead being grouped with other trademarks—this matches the original answer exactly. Number formatting ($221 million) is consistent and accurate. (2) The answer addresses the change in financial treatment and correctly infers that the shift reflects a move from individual to collective valuation of intangibles. (3) The reasoning is sound: integrating Filorga into broader segments suggests reduced standalone strategic emphasis, which the model correctly interprets as a down-weighting of individual strategic importance. The conclusion about valuation shifting to a group-based approach is logically supported by the change in reporting. (4) The only minor limitation is that the LLM does not explicitly mention implications for impairment analysis or future strategic decisions like divestiture or investment, which are present in the original answer and add depth to the strategic interpretation. However, the core insight about strategic down-weighting and valuation change is clearly conveyed. Thus, the answer is factually complete and semantically equivalent on the main points, meriting a high score but not perfect due to slight incompleteness in strategic implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 394,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How does the change in Apple's disclosure about the iPhone 16 Pro between the 2023 and 2024 10-K filings reflect an evolution in its product development and reporting strategy?",
      "original_answer": "In the 2023 10-K filing, Apple announced the iPhone 16 Pro as part of its Fourth Quarter 2024 product lineup, indicating it was still in the planning and launch phase. By contrast, in the 2024 10-K filing, the iPhone 16 Pro is listed among existing product lines like the iPhone 15 and iPhone 14, suggesting it has transitioned into an active and established product within Apple's portfolio. This shift reflects a movement from forward-looking product planning in 2023 to retrospective inclusion in 2024, aligning with the product's lifecycle stage and indicating a more mature reporting posture around the iPhone 16 Pro.",
      "llm_answer": "\nThe 2023 10‑K only aggregates the iPhone line and never names a distinct “iPhone 16 Pro,” whereas the 2024 filing explicitly lists the iPhone 16 Pro (and Pro Max) among the Q4 2024 product roll‑outs, ties the device to the new Apple Intelligence platform, and provides a detailed launch schedule and feature updates. This shift to granular product naming and forward‑looking disclosure shows Apple’s evolution toward highlighting each flagship’s unique technology and market impact, aligning its reporting with a staged, innovation‑driven product development strategy.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth in multiple key aspects. (1) The 2023 10-K did not aggregate the iPhone line without naming the iPhone 16 Pro—according to the ground truth, it explicitly announced the iPhone 16 Pro as part of the Fourth Quarter 2024 product lineup. Conversely, the 2024 10-K does not introduce the iPhone 16 Pro as a new Q4 2024 rollout; rather, it lists it among existing products, indicating it has already launched and is now part of the established product portfolio. The LLM incorrectly reverses the timeline and disclosure direction: it claims the 2024 filing is forward-looking (announcing a future launch), while the ground truth shows it is retrospective (treating the device as already available). (2) There are no numeric values (dates, dollar amounts, percentages) in either answer, so quantitative accuracy hinges on correct interpretation of time periods. However, the LLM misrepresents Q4 2024 as a future launch in the 2024 10-K, when in fact the 2024 filing would cover results up to that period and reflect the product as current, not upcoming. This is a factual error in temporal reasoning. (3) The multi-hop reasoning fails: the core insight in the ground truth is the shift from forward-looking (planning/launch phase in 2023 filing) to backward-looking (established product in 2024 filing). The LLM instead claims Apple evolved from no mention to detailed forward-looking disclosure, which is the opposite of the truth. Additionally, the mention of 'Apple Intelligence platform', 'detailed launch schedule', and 'feature updates' in the 2024 10-K are fabrications not supported by the original answer or implied context. (4) While the question asks about evolution in product development and reporting strategy, the LLM's interpretation—though thematically relevant—is based on incorrect premises, leading to a plausible-sounding but factually wrong conclusion about 'granular product naming' and 'staged innovation-driven strategy'. The contextual relevance is moderate because it addresses the general theme of reporting evolution, but the factual foundation is flawed, severely undermining correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 581,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 123,
      "question": "How has the company's use of Economic Value of Equity (EVE) simulations evolved in assessing interest rate risk, particularly in terms of modeling assumptions and balance sheet dynamics, between 2022 and 2023?",
      "original_answer": "In 2022, the company used EVE simulations to measure long-term interest rate risk, with key assumptions including non-negative investment yields, prepayment speeds of mortgage-related investments, and non-maturity deposit behavior. The EVE analysis was described as highly dependent on asset and liability assumptions based on historical behaviors and expectations of the economic environment. By 2023, the company expanded the role of EVE simulations to specifically capture the impact of client cash allocation changes on the balance sheet, which was not included in the earlier modeling approach. Additionally, in 2023, the company actively updated deposit beta assumptions in a declining interest rate environment for its net interest revenue simulation model, indicating a more dynamic approach to modeling interest rate sensitivity.",
      "llm_answer": "\nBetween 2022 and 2023 Schwab refined its EVE framework by updating key assumptions—especially deposit‑beta behavior, the use of interest‑rate swap derivatives, and more granular prepayment and cash‑flow models—while the 2022 analysis relied on more static historical inputs.  The balance‑sheet profile shifted markedly, with liability duration shortening substantially and a larger allocation to floating‑rate assets, so the 2023 simulations capture a higher EVE sensitivity and a broader set of parallel and non‑parallel rate‑shift scenarios.  Consequently, the 2023 EVE methodology reflects these evolving balance‑sheet dynamics and a more detailed modeling of interest‑rate risk than the prior year.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies and introduces information not present in the ground truth. While it correctly identifies that modeling assumptions evolved between 2022 and 2023, it fabricates specific changes such as 'use of interest-rate swap derivatives', 'shortening liability duration', 'larger allocation to floating-rate assets', and 'higher EVE sensitivity'—none of which are mentioned in the original answer. The ground truth emphasizes the inclusion of client cash allocation changes in 2023 and dynamic deposit beta updates in declining rate environments, neither of which are mentioned in the LLM response. Instead, the LLM incorrectly focuses on deposit beta in general without linking it to declining rate conditions or net interest revenue simulation, as specified in the original. (2) There are no explicit numbers (e.g., percentages, dollar amounts) in either the question or ground truth, so quantitative accuracy is not heavily penalized; however, the LLM invents structural changes (e.g., 'parallel and non-parallel rate-shift scenarios') without factual support, reducing confidence in its numerical reasoning. (3) The multi-hop reasoning is flawed: the LLM fails to correctly synthesize the key evolution—namely, the incorporation of client cash allocation effects in 2023 and updated deposit beta assumptions in a declining rate context. Instead, it extrapolates unrelated balance sheet dynamics and modeling enhancements not supported by the source. (4) Despite these issues, the response is contextually relevant, addressing the general theme of evolving EVE modeling assumptions and balance sheet dynamics. However, due to significant factual inaccuracies and omission of the core developments cited in the ground truth, the correctness and qualitative accuracy scores are low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 496,
        "total_tokens": 1897
      },
      "error": null
    },
    {
      "question_id": 123,
      "question": "How did Qualcomm's strategic shift from enabling wireless access point technologies in 2022 to directly producing them in 2023 affect its competitive positioning and product portfolio breadth in the broader networking market?",
      "original_answer": "In 2022, Qualcomm's involvement with wireless access points was limited to enabling the technology through its foundational wireless innovations and chipset solutions, as noted in its discussion of edge networking growth driven by 5G and Wi-Fi 6 adoption. However, by 2023, Qualcomm had evolved its strategy to directly producing wireless access points as part of its broader networking product suite, which included Wi-Fi chips, routers, and network processors. This shift reflects an expansion of Qualcomm's product portfolio and a more direct role in the networking ecosystem, positioning the company to compete more directly with players like Broadcom and Intel by offering full-system solutions rather than just underlying components.",
      "llm_answer": "\nThe 2023 10‑K shows that Qualcomm’s QCT business now lists “wireless access points and routers” among its core networking products (pages 9‑10), indicating that the company has moved from merely enabling AP technologies through IP and component licensing (as described in the 2022 filing) to designing and selling complete AP hardware itself.  This expansion adds a new hardware tier to Qualcomm’s portfolio, giving it higher‑margin, end‑to‑end networking offerings and allowing it to compete more directly with traditional networking vendors while leveraging its RF, AI and low‑power expertise.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. It correctly identifies the strategic shift from 2022 to 2023: Qualcomm moved from enabling wireless access point technologies via chipsets and IP (as noted in the 2022 10-K) to directly producing complete wireless access point hardware (as stated in the 2023 10-K, pages 9–10). The mention of 'wireless access points and routers' as part of QCT’s product lineup in 2023 is consistent with the expansion of its product portfolio. The reasoning is sound—this shift enables end-to-end solutions, enhances margins, and strengthens competitive positioning against vendors like Broadcom and Intel, though the LLM does not explicitly name those competitors as the original answer does. This omission is minor and does not detract from the core accuracy. All dates (2022, 2023) and business segments (QCT) are correct. There are no numerical inaccuracies (no calculations required), and the semantic meaning fully captures the strategic evolution. The answer is highly relevant, directly addressing both competitive positioning and product breadth. The only reason for not scoring a 10 is the lack of explicit reference to competing with Broadcom and Intel, which slightly reduces completeness in contextual synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 358,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 124,
      "question": "How has the interest-only payment structure of Schwab's HELOC product evolved from 2022 to 2023, based on the percentage of adjustable-rate mortgages with interest-only terms and the portion not scheduled to reset for three or more years?",
      "original_answer": "In 2022, 28% of adjustable-rate mortgages were interest-only loans, with 89% of those not scheduled to reset for three or more years. In 2023, this shifted slightly to 27% of adjustable-rate mortgages being interest-only, with 86% of those not scheduled to reset for three or more years. This reflects a minor decrease in both metrics, suggesting a slight tightening or evolution in the interest-only structure of the HELOC product.",
      "llm_answer": "\nIn 2023, roughly 27 % of Schwab’s adjustable‑rate mortgage portfolio had interest‑only payment terms, down from about 28 % in 2022; similarly, only about 86 % of those interest‑only loans are not scheduled to reset for three or more years, compared with roughly 89 % in 2022.  Consequently, the interest‑only component of the HELOC structure has modestly contracted, with a slightly lower share of loans remaining insulated from near‑term resets.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All numeric values are correct: 28% to 27% for interest-only adjustable-rate mortgages (down 1 percentage point), and 89% to 86% for those not scheduled to reset for three or more years (down 3 percentage points). These match the original answer exactly. (2) The quantitative accuracy is perfect—percentages and years are correctly cited, and no calculation errors are present. (3) The reasoning is sound: the model correctly infers a 'modest contraction' in the interest-only component and notes reduced insulation from near-term resets, which logically follows from the data. This demonstrates proper multi-hop synthesis across years and metrics. (4) The wording differs slightly (e.g., 'roughly', 'about'), but this does not affect factual accuracy and is acceptable under semantic equivalence. The only minor deduction is in qualitative accuracy due to slightly less explicit framing of the evolution as tied directly to the HELOC product structure, though the connection is implied. Overall, the answer is factually complete, contextually relevant, and correctly interprets trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1242,
        "completion_tokens": 327,
        "total_tokens": 1570
      },
      "error": null
    },
    {
      "question_id": 124,
      "question": "How has Qualcomm's involvement in the XR market evolved from 2022 to 2023, based on their strategic investments and product revenue disclosures?",
      "original_answer": "In 2022, Qualcomm's involvement in XR was primarily through strategic investments made via Qualcomm Ventures, targeting early-stage companies in areas including XR to expand opportunities for their technologies. By 2023, this involvement evolved into direct revenue generation, as XR was explicitly listed among the industries and applications for which Qualcomm sold products, indicating a shift from investment to commercialization. This transition reflects a significant change in Qualcomm's engagement with XR, moving from supporting external innovation to deriving tangible revenue from XR-related product sales.",
      "llm_answer": "\nFrom fiscal 2022 to fiscal 2023 Qualcomm kept XR on its strategic‑investment agenda—QSI continued to fund early‑stage XR‑related companies as part of its “IoT (including XR)” focus—but the company’s own revenue data show a clear pull‑back: the IoT segment that encompasses XR devices dropped from **$7.35 billion in 2022** to **$5.94 billion in 2023**, and no new XR‑specific product revenue was disclosed in the 2023 filing.  This decline indicates that Qualcomm’s involvement in the XR market matured and contracted rather than expanded during that period.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual and reasoning errors that contradict the ground truth. (1) Quantitatively, the reported IoT segment revenues of $7.35 billion in 2022 and $5.94 billion in 2023 are not supported by the ground truth data, which does not provide specific revenue figures for XR or IoT segments—only a qualitative shift from investment to revenue generation. The inclusion of precise numbers without grounding misleads the assessment. (2) The claim that Qualcomm's involvement 'contracted' due to a decline in IoT revenue directly contradicts the original answer, which states that XR moved from being a venture investment focus in 2022 to a commercialized product line with explicit revenue generation in 2023—a sign of expansion, not contraction. (3) The LLM incorrectly infers that no new XR-specific revenue was disclosed in 2023, while the ground truth confirms that XR was explicitly listed as an industry for product sales in 2023, indicating direct monetization. (4) The reasoning fails on multi-hop synthesis: it misinterprets continued investment via Qualcomm Ventures as the primary mode of involvement in 2022 and incorrectly assumes that a drop in broader IoT revenue reflects reduced XR engagement, when the ground truth shows an evolution toward commercialization. (5) While the answer addresses strategic investments (correct entity and time frame), it draws the opposite conclusion of the original answer regarding evolution, making it factually incorrect despite some contextual relevance to the topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 422,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the aggregate principal balance of the 3.030% Notes Due 2052 evolved between 2022 and 2024, and what does this indicate about RTX's long-term debt structure?",
      "original_answer": "The aggregate principal balance of the 3.030% Notes Due 2052 remained stable at $1,100 million in both 2022 and 2024. This indicates that RTX has maintained its long-term commitment to this particular debt instrument without any repayments or additional issuances during this period. Despite overall changes in other long-term debt components, the 3.030% Notes Due 2052 remained unchanged, suggesting strategic consistency in managing this portion of its capital structure.",
      "llm_answer": "\nThe $3.030\\%$ Notes due 2052 remained unchanged at **$1.1 billion** from the end of 2022 through the end of 2024—no repayments or new issuances of that tranche were reported in 2023 or 2024. This stability shows that RTX is using a “buy‑and‑hold” approach for its longest‑dated, fixed‑rate debt, relying instead on shorter‑maturity borrowings (e.g., term loans and commercial paper) to manage its liquidity and refinancing needs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly states that the aggregate principal balance of the 3.030% Notes Due 2052 remained unchanged at $1.1 billion (equivalent to $1,100 million) from 2022 to 2024, matching the ground truth in both amount and time frame. The note about no repayments or new issuances aligns with the original answer's implication of stability. 2) Quantitatively, $1.1 billion is equivalent to $1,100 million, and the years 2022 and 2024 are correctly referenced. No calculations were required, but the consistency across years is accurately reported. 3) The multi-hop reasoning is sound: the model correctly infers that the lack of change in this debt tranche indicates a strategic approach to long-term debt, specifically a 'buy-and-hold' strategy for long-dated fixed-rate debt. While the original answer emphasizes 'strategic consistency,' the LLM provides a slightly different but reasonable interpretation by contrasting with shorter-term instruments. 4) The LLM adds contextual insight about RTX relying on shorter-maturity borrowings, which is plausible and relevant but not explicitly stated in the ground truth. This addition does not contradict the original and enhances the explanation, though it slightly extends beyond the provided data. Overall, the answer is factually correct, complete, and contextually appropriate, warranting a high score with only minor divergence in emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 386,
        "total_tokens": 1617
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has AXP's focus on Corporate Card solutions evolved between 2023 and 2024, and what does this shift suggest about its broader commercial payments strategy?",
      "original_answer": "In 2023, AXP emphasized evolving its card value propositions and differentiating its corporate card and accounts payable expense management solutions as part of a broader push to strengthen its position in commercial payments. By 2024, while the focus on commercial payments remained, AXP shifted toward designing 'innovative products and features, including financing, banking and payment solutions for our business customers,' indicating a more integrated and solution-oriented approach. This evolution suggests that AXP is expanding beyond just product differentiation to embedding the Corporate Card into a wider suite of business financial services, aligning it more closely with holistic commercial needs.",
      "llm_answer": "\nBetween 2023 and 2024 AXP’s language shifted from a broad “build on our strong position in commercial payments” to a explicit focus on “evolving our card‑value propositions, further differentiating our corporate‑card and accounts‑payable expense‑management solutions, and designing innovative financing, banking and payment products for business customers.”  This tighter emphasis on corporate‑card offerings signals that the company is deliberately deepening its B2B payments capabilities—leveraging its premium brand and spend‑centric model to capture more corporate spend, expand high‑margin commercial revenue streams, and integrate financial services into the business‑customer value chain.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in AXP's strategy between 2023 and 2024. It accurately reflects the shift from strengthening commercial payments broadly to a more focused emphasis on evolving card value propositions and differentiating corporate card and expense management solutions, then expanding into innovative financing, banking, and payment products. The dates (2023 vs 2024) and entities (AXP, corporate card, commercial payments) are correct. There are no numerical values in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. The qualitative accuracy is high: the LLM correctly synthesizes the strategic shift toward deeper B2B integration and high-margin revenue streams. However, it slightly misrepresents the sequence by combining 2023 and 2024 language without clearly distinguishing the progression—specifically, it does not fully reflect that the 'designing innovative products' language was emphasized in 2024 as a development beyond the 2023 focus. The original answer makes this temporal evolution clearer. Despite this, the LLM infers sound strategic implications (e.g., integration into the business-customer value chain). Contextual relevance is excellent—the response directly addresses both parts of the question: the evolution and what it suggests about broader strategy. Minor deduction in qualitative accuracy due to less precise temporal framing of the strategic shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 404,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the strategic positioning of PCA SKIN within Colgate-Palmolive's Oral, Personal and Home Care segment evolved between 2023 and 2024, particularly in terms of its distribution channels?",
      "original_answer": "In 2023, PCA SKIN was listed among Colgate-Palmolive’s principal global and regional trademarks and was included in the broader category of products sold primarily to traditional and eCommerce retailers, wholesalers, distributors, and dentists. By 2024, PCA SKIN remained a listed principal trademark, but the filing specifically expanded the distribution channels to include sales to skin health professionals in some geographies. This indicates a refinement in positioning PCA SKIN within more specialized skincare distribution channels, though no change in production or brand status is indicated.",
      "llm_answer": "\nIn both the 2023 and 2024 filings PCA SKIN is listed as one of the Company’s principal trademarks within the Oral, Personal and Home Care segment, and the Company continues to describe its sales as being made “primarily to a variety of retailers, wholesalers, distributors, dentists and, in some geographies, skin‑health professionals,” with a modest direct‑to‑consumer component.  The documents do not report any new distribution arrangement or a re‑allocation of PCA SKIN’s channel mix between 2023 and 2024, indicating that its strategic positioning and distribution approach remained essentially unchanged.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually incorrect in its core conclusion about the evolution of PCA SKIN's distribution channels between 2023 and 2024, despite using plausible language and correctly identifying PCA SKIN as a principal trademark in both years. According to the ground truth, in 2023, PCA SKIN was distributed to traditional and eCommerce retailers, wholesalers, distributors, and dentists. By 2024, the distribution channels were explicitly expanded to include 'skin health professionals in some geographies,' indicating a strategic refinement toward specialized skincare channels. However, the LLM claims there was 'no new distribution arrangement' and that the positioning 'remained essentially unchanged,' which directly contradicts the ground truth. There are no numerical figures in this question, so quantitative accuracy is not applicable—however, the model correctly references the relevant segment and trademark status, earning full marks for quantitative accuracy by default. The qualitative accuracy is low because the model failed to detect and report the key multi-hop change in distribution strategy. Contextual relevance is high, as the response stays on topic and references the correct segment, brand, and general distribution framework. The error lies in reasoning and synthesis: the model overlooked the significance of the addition of 'skin-health professionals' in the 2024 filing, which represents a meaningful evolution in strategic positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 404,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the strategic focus and commercial positioning of Opdivo evolved between 2022 and 2023, particularly in terms of new tumor indications and combination therapies, and what implications does this have for its revenue growth trajectory?",
      "original_answer": "In 2022, Opdivo was approved for several anti-cancer indications including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, and stomach cancers, with the Opdivo + Yervoy regimen approved in multiple markets for NSCLC, melanoma, MPM, RCC, CRC, and gastric/esophageal cancers. It reported U.S. revenue growth driven by combinations in NSCLC, kidney cancer, and gastric/esophageal cancers. By 2023, Opdivo's strategic focus expanded into new tumor types and earlier lines of therapy, with an emphasis on broadening its use both as a monotherapy and in combination with Yervoy and other agents. The company also highlighted the potential of a subcutaneous formulation to enhance patient benefits and drive long-term adoption. This evolution indicates a strategic push to sustain revenue growth by diversifying indications and optimizing delivery mechanisms, despite increasing market competition.",
      "llm_answer": "\nBetween 2022 and 2023 the company broadened Opdivo’s commercial footprint – adding new tumor indications such as adjuvant melanoma (U.S. and EU), neoadjuvant NSCLC in combination with platinum‑based chemotherapy (EU and Japan), and expanded use in melanoma and other cancers – and pushed earlier‑line, combination‑therapy regimens (e.g., Opdivo + Yervoy, Opdivo + platinum chemo, and the upcoming subcutaneous formulation).  These moves reposition Opdivo from a mature immunotherapy to a growth‑driving “new‑product” pillar, allowing it to offset the decline of legacy agents like Revlimid and Eliquis and to deliver double‑digit revenue growth that underpins the company’s overall revenue trajectory despite modest total‑company sales pressure.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of strategic evolution of Opdivo between 2022 and 2023. It accurately captures the expansion into new tumor indications (e.g., adjuvant melanoma, neoadjuvant NSCLC) and earlier lines of therapy, as well as the emphasis on combination regimens like Opdivo + Yervoy and Opdivo + chemotherapy. The mention of the subcutaneous formulation as a driver for long-term adoption matches the original answer. The implications for revenue growth are correctly framed, particularly the role of Opdivo in offsetting declines in legacy products and contributing to double-digit growth despite broader company sales pressure. However, the LLM answer introduces specific details not present in the ground truth, such as approvals in 'EU and Japan' for neoadjuvant NSCLC and 'adjuvant melanoma in U.S. and EU'—while plausible, these geographic specifics and the term 'double-digit revenue growth' are not confirmed in the original answer, which only notes U.S. revenue growth in 2022 and a general strategic push for sustained growth. These additions slightly exceed the evidence in the ground truth, affecting qualitative accuracy. There are no numerical inaccuracies (quantitative accuracy is perfect), and the answer is highly relevant to the question. Semantic equivalence is strong, though minor over-specification prevents a top score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 387,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How did American Express's investment in foreign government bonds and obligations evolve between 2023 and 2024 in terms of fair value and maturity distribution?",
      "original_answer": "In 2023, American Express held $549 million in foreign government bonds and obligations with all of it maturing in 12 months or more and a gross unrealized loss of $1 million. By 2024, the fair value of these investments increased significantly to $765 million, with $764 million maturing within one year and only $1 million maturing after one year but within five years. This indicates a substantial increase in exposure to foreign government bonds, primarily in short-term maturities.",
      "llm_answer": "\nBetween 2023 and 2024 the fair‑value of American Express’s foreign‑government‑bond holdings grew from about **$549 million** to roughly **$765 million**.  The maturity structure remained overwhelmingly short‑term – approximately **$764 million (≈99.8 %)** were due within one year, with only **$1–2 million** maturing after 1–5 years and essentially none beyond five years.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the key evolution in American Express's investment in foreign government bonds between 2023 and 2024. (1) Quantitatively, the fair value increase from $549 million in 2023 to $765 million in 2024 is correctly reported. The 2024 maturity distribution is accurately reflected with $764 million maturing within one year and $1 million after one year but within five years. The LLM approximates the latter as '$1–2 million', which is a minor imprecision but does not materially misrepresent the data. (2) The original answer notes a gross unrealized loss of $1 million in 2023, which the LLM omits; this is a small but relevant detail related to fair value accounting, slightly reducing completeness. (3) The reasoning is sound: the model correctly identifies the significant increase in exposure and the shift toward short-term maturities, demonstrating proper multi-hop synthesis across years and maturity buckets. (4) All entities (American Express, foreign government bonds, fair value, maturity distribution) and years (2023, 2024) are correct. Wording differs but semantic meaning aligns closely with the ground truth. The answer is fully contextually relevant, directly addressing both fair value and maturity distribution changes. The minor omission of the unrealized loss and slight rounding in the long-term maturity amount prevent a perfect score, but overall correctness is very high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1218,
        "completion_tokens": 396,
        "total_tokens": 1614
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How has Walmart's use of intercompany financing arrangements evolved between 2022 and 2024, particularly regarding the amount of cash not freely transferable to the U.S. and the conditions under which such transfers occur?",
      "original_answer": "In 2022, Walmart reported $4.3 billion in cash and cash equivalents that may not be freely transferable to the U.S., with $2.2 billion of that amount subject to approval by Flipkart minority shareholders. By 2024, the amount of cash not freely transferable decreased slightly to $3.3 billion, and the language indicates that these transfers are now generally subject to approval from noncontrolling interest shareholders, rather than specifically tied to Flipkart. This reflects a slight reduction in the magnitude of restricted cash and a broader framing of the conditions under which such transfers occur, suggesting a shift in the structure or focus of intercompany financing arrangements.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 the amount of cash that cannot be moved freely into the United States stayed sizeable but modestly declined—about $4.3 billion (of which roughly $2.2 billion could only be accessed through dividends or intercompany financing that required approval of Flipkart’s minority shareholders) in 2022, versus roughly $3.3–$3.5 billion in 2024 that remains subject to local‑law restrictions or the consent of non‑controlling‑interest holders. Walmart continues to use intercompany financing to make cash available in the countries where it is needed, but such transfers are only permitted when local regulations or shareholder approvals (e.g., Flipkart) are satisfied, and the company does not expect these constraints to materially affect its overall liquidity.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and closely aligns with the ground truth. (1) Quantitatively, it correctly reports $4.3 billion in 2022 and $3.3 billion in 2024 (the LLM says $3.3–$3.5 billion, a minor rounding or reporting variation that does not materially affect accuracy). The $2.2 billion tied to Flipkart minority shareholders in 2022 is correctly stated. (2) The answer addresses all parts of the question: the evolution of intercompany financing arrangements, the amount of cash not freely transferable, and the conditions on transfers. (3) Entity accuracy is strong: Walmart, Flipkart, noncontrolling interest shareholders, and fiscal years 2022 and 2024 are correctly identified. (4) The reasoning is sound: it captures the shift from Flipkart-specific approval to a broader condition involving non-controlling interest holders and local regulations, reflecting the structural evolution in financing arrangements. The slight overestimation in the 2024 amount (up to $3.5B vs. $3.3B) prevents a perfect score, but this is within reasonable reporting variance. Overall, the answer demonstrates correct multi-hop synthesis and conveys the same semantic meaning as the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 332,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How did the composition of Texas Instruments' U.S. Retiree Health Care Plan assets evolve between the 2023 and 2024 filings, particularly in terms of fixed income securities and equity securities allocation?",
      "original_answer": "The composition of Texas Instruments' U.S. Retiree Health Care Plan assets remained completely unchanged between the 2023 and 2024 filings. In both years, the plan held $210 million in fixed income securities and cash equivalents, and $54 million in equity securities, resulting in a total of $264 million in plan assets. The fixed income allocation represented approximately 79.5% of the total plan assets, while equity securities represented approximately 20.5% in both years. The identical figures across both filings indicate no evolution in the asset allocation strategy for this plan during the reported period.",
      "llm_answer": "\nBetween the 2023 and 2024 filings the U.S. Retiree Health‑Care plan’s asset base fell modestly (‑$16 million, from $264 million to $248 million).  Fixed‑income securities and cash equivalents dropped from $210 million to $198 million, while equity holdings slipped from $54 million to $50 million.  As a result, the plan remained roughly 80 % fixed‑income and 20 % equity, with the fixed‑income share edging up slightly (≈79.5 % → ≈80 %) and the equity share edging down (≈20.5 % → ≈20 %).",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in all key numerical claims. According to the ground truth, the asset composition remained unchanged between 2023 and 2024: fixed income securities and cash equivalents were $210 million in both years, equity securities were $54 million in both years, and total assets were $264 million in both years. The LLM incorrectly states that total assets decreased from $264M to $248M, fixed income dropped to $198M, and equity slipped to $50M — all of which are false. (2) The calculations in the LLM answer (e.g., $210M → $198M, $54M → $50M, total $264M → $248M) are entirely fabricated and do not match the ground truth. Percentages are also miscalculated based on incorrect totals; while the LLM reports a slight shift to 80%/20%, the actual allocation was exactly 79.5%/20.5% in both years due to no change. (3) The multi-hop reasoning failed completely — the model should have identified that the same values were reported in both filings, indicating no evolution, but instead invented changes. (4) The contextual relevance is low but not zero because the answer addresses the right plan and asset classes, albeit with incorrect data. Due to complete factual inaccuracy in numbers, calculations, and conclusion, the correctness score is 1.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 361,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 127,
      "question": "How did Honeywell's 2006 Stock Plan for Non-Employee Directors evolve between 2022 and 2024 in terms of the specific forms of award agreements offered, and what might this suggest about changes in the company's non-employee director compensation structure?",
      "original_answer": "In 2022, Honeywell's 10-K filing listed both the 'Form of Option Agreement' (Exhibit 10.30) and the 'Form of Restricted Unit Agreement' (Exhibit 10.32) as part of the 2006 Stock Plan for Non-Employee Directors. By 2024, while the 'Form of Option Agreement' was still referenced (Exhibit 10.29), the 'Form of Restricted Unit Agreement' was no longer explicitly mentioned in the exhibit list. This suggests a shift in the types of equity awards offered to non-employee directors, potentially signaling a strategic move toward emphasizing stock options over restricted units in director compensation.",
      "llm_answer": "\nBetween 2022 and 2024 Honeywell replaced the old stock‑option‑only grants under its 2006 Non‑Employee Director Plan with the revised equity forms in the 2016 plan—specifically the “Form of Stock Option Agreement” and a newly adopted “Form of Restricted‑Stock‑Unit Agreement” that include performance‑based vesting and longer holding requirements (as reflected in the 2023 amendment, Exhibit 10.54* to the 2023 Form 10‑K).  This shift indicates that the company is moving from a purely option‑based compensation model to a more balanced mix of equity awards that tie director pay to long‑term shareholder performance.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contains significant factual and reasoning errors. (1) It incorrectly claims that Honeywell replaced awards under the 2006 plan with forms from the 2016 plan, including a 'Form of Restricted-Stock-Unit Agreement' with performance-based vesting and longer holding requirements as of a 2023 amendment (Exhibit 10.54*). However, the ground truth states that in 2022, the 2006 plan still included both the 'Form of Option Agreement' (Exhibit 10.30) and the 'Form of Restricted Unit Agreement' (Exhibit 10.32), and by 2024, only the option agreement remained (Exhibit 10.29), with no mention of the restricted unit form. There is no evidence in the ground truth that the 2016 plan or a 2023 amendment (Exhibit 10.54*) replaced or modified the 2006 plan’s director awards. (2) The dates and exhibit numbers cited in the LLM answer (e.g., 2023 amendment, Exhibit 10.54*) do not align with the ground truth, which tracks exhibits 10.30, 10.32, and 10.29 across 2022 and 2024 filings. (3) The multi-hop reasoning is flawed: instead of observing the removal of restricted unit agreements from the 2006 plan between 2022 and 2024, the LLM fabricates a shift to a new plan with performance-based awards. (4) The conclusion—that Honeywell is moving toward a more balanced mix of equity awards tied to performance—contradicts the ground truth, which suggests a move *away* from restricted units, possibly toward greater reliance on options. While the answer addresses director compensation evolution and is thematically relevant, the factual inaccuracies and incorrect synthesis severely undermine its validity. Minor credit is given for addressing the general topic of award form changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 464,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 127,
      "question": "How did Walmart's strategic position regarding its ownership stake in Flipkart evolve between 2022 and 2024, particularly in terms of financial implications and potential exposure to regulatory risks?",
      "original_answer": "In 2022, Walmart received $3.2 billion in equity funding related to Flipkart, which reduced its ownership stake from 83% to 75%. This signaled a partial financial exit while maintaining majority control. By 2024, however, Walmart disclosed ongoing regulatory scrutiny in India, including a show cause notice issued in July 2021 and subsequent information requests related to alleged violations of India's Foreign Direct Investment rules during the period 2009–2015—prior to Walmart's acquisition of Flipkart in 2018. Despite the reduced ownership stake, Walmart remained exposed to potential regulatory consequences, including share ownership restrictions, and noted its inability to reasonably estimate potential losses or indemnification proceeds from prior shareholders. The evolution reflects a shift from active financial participation to managing legacy risks tied to Flipkart's pre-acquisition history.",
      "llm_answer": "\nBetween fiscal 2022 and 2024 Walmart’s share of Flipkart dropped from roughly 83 % to about 75 % after the subsidiary raised a $3.2 billion equity round, which cut the portion of Flipkart’s earnings that Walmart consolidates and lessened its direct control.  At the same time, Flipkart is facing intensified Indian regulatory pressure—including a Competition Commission of India antitrust probe and a foreign‑direct‑investment show‑cause notice that could impose monetary penalties or ownership‑restriction remedies—creating additional financial and legal exposure for Walmart’s remaining stake.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the reduction in Walmart's ownership stake in Flipkart from 83% to 75% and the $3.2 billion equity funding event, which aligns with the ground truth. These key quantitative facts are accurate. However, the LLM incorrectly implies that the regulatory scrutiny began or intensified between 2022 and 2024, while the original answer clarifies that the show cause notice was issued in July 2021—before the 2022–2024 window—and relates to conduct from 2009–2015, prior to Walmart’s acquisition. This misrepresents the timeline of regulatory risk emergence. (2) All numbers—$3.2 billion, 83%, 75%—are correct and match the ground truth. The fiscal year framing (‘fiscal 2022’) is acceptable as contextually close, though the original does not specify fiscal vs calendar year. No calculation errors. (3) The multi-hop reasoning is mostly sound: the model connects Walmart’s partial exit (via dilution) to reduced financial consolidation and ongoing regulatory exposure. However, it fails to clarify that the regulatory issues predate Walmart’s ownership, which is a key nuance in assessing Walmart’s liability. The LLM mentions a ‘foreign-direct-investment show-cause notice’ correctly but omits that Walmart cannot estimate potential losses or indemnification, weakening completeness. (4) Despite the timeline misrepresentation, the answer captures the core evolution: financial deconsolidation alongside persistent regulatory risk. Wording is semantically close and relevant. Scores reflect high accuracy with minor but notable gaps in temporal precision and completeness of risk disclosure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 448,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How did the composition and strategic emphasis of HON's U.S. cash balances evolve between 2022 and 2024, particularly in terms of total cash holdings and geographic distribution of funds?",
      "original_answer": "In 2022, HON reported holding $11.5 billion of cash and cash equivalents as of December 31, 2021, with an emphasis on safety of principal and diversification among counterparties. By 2024, the company held $11.0 billion in total cash and equivalents as of December 31, 2024, but specifically noted that $8.0 billion of that amount was held in non-U.S. subsidiaries. This represents a shift in geographic distribution, with a larger portion of liquidity positioned outside the U.S., while maintaining the same strategic emphasis on safety and diversification.",
      "llm_answer": "\nBetween 2022 and the end of 2024 Honeywell’s consolidated cash and cash equivalents remained roughly steady at about $11 billion (down slightly from $11.5 billion at the end of 2021 to $11.0 billion in 2024).  The composition changed markedly: roughly $8 billion—about 73 % of the 2024 balance—was held in non‑U.S. subsidiaries, leaving only ~ $3 billion of cash that was effectively U.S.-based, a smaller share than in earlier years.  Consequently, the company’s strategic focus moved toward deploying the abundant offshore cash for acquisitions, share‑repurchase programs, capital expenditures and other investments, while U.S. cash was reserved for domestic liquidity needs and debt repayment, with the remainder of funding sourced from credit facilities and capital‑market issuances.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: $11.5 billion as of end-2021 (reported in 2022), $11.0 billion as of end-2024, and $8.0 billion held in non-U.S. subsidiaries (73% of $11.0 billion is ~$8.0 billion) — calculations and percentages are accurate. (2) The answer correctly identifies the shift in geographic distribution of cash, noting a larger offshore portion, which matches the ground truth. (3) The qualitative reasoning is sound: it correctly infers the strategic emphasis on using offshore cash for acquisitions, buybacks, and investments, while reserving U.S. cash for domestic needs and debt — this is a reasonable interpretation consistent with the stated strategic continuity on safety and diversification, though the original answer does not explicitly mention deployment strategies. This addition is contextually appropriate and commonly implied in such disclosures, so it does not constitute an error. (4) The only minor deviation is that the original answer emphasizes the continued focus on safety and diversification, which the LLM omits, instead elaborating slightly more on deployment strategy. However, the core facts, multi-hop synthesis (across years and geographies), and conclusions are correct. Thus, the answer is factually complete and semantically equivalent with slight expansion, warranting a 9/10 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 399,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How did the financial treatment and liability estimation methodology for the Membership Rewards program evolve from 2023 to 2024, particularly in terms of deferred fees and liability modeling assumptions?",
      "original_answer": "In 2023, the company recognized deferred fees related to Membership Rewards program participants, indicating a focus on the deferral aspect of fee revenue associated with the program. By 2024, the disclosures provided a much more detailed explanation of the liability estimation methodology, including the use of the Ultimate Redemption Rate (URR) and the weighted average cost (WAC) per point. The 2024 filing also quantified the sensitivity of the liability to changes in assumptions, noting that a 25 basis point increase in URR would raise the liability by $197 million, and a 1 basis point increase in WAC per point would increase it by $220 million. This reflects a shift from a simpler mention of deferred fees to a comprehensive, model-driven approach to estimating future redemption liabilities.",
      "llm_answer": "\nIn 2023 the Company recorded a $13.7 bn Membership Rewards liability and $3.44 bn of net deferred card‑and‑other fees, estimating the liability with a weighted‑average cost‑per‑point (WAC) and an ultimate redemption‑rate (URR) derived from 12‑month redemption trends and adjusted for cost changes; in 2024 the same estimation framework is retained but the disclosure adds explicit sensitivity metrics—showing that a 25‑basis‑point increase in URR would raise the liability (and corresponding expense) by roughly $197 m and a 1‑basis‑point increase in WAC would raise it by about $220 m—indicating a more quantified, transparent modeling approach while the deferred‑fee balance remains essentially unchanged.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution in disclosure transparency from 2023 to 2024, noting the introduction of sensitivity metrics for URR and WAC in 2024, which aligns with the ground truth. However, it introduces specific quantitative figures not present in the original answer: the $13.7 billion liability and $3.44 billion net deferred fees in 2023, along with claims about the use of WAC and URR in that year. The ground truth does not state that these modeling assumptions (URR and WAC) were used in 2023—only that deferred fees were recognized, implying a simpler approach. Thus, the LLM retroactively attributes a more sophisticated model to 2023 that the original answer does not support. (2) The sensitivity numbers—$197 million for a 25 bps increase in URR and $220 million for a 1 bps increase in WAC—are accurately reported and match the ground truth. However, the LLM adds precise deferred fee and liability balances that are not in the original answer, making them unverifiable and factually unsupported in this context. (3) The multi-hop reasoning is partially sound: the LLM correctly infers increased transparency and quantification in 2024, and the synthesis of sensitivity analysis as a sign of more advanced modeling is valid. But it incorrectly assumes continuity of the URR/WAC framework into 2023, contradicting the ground truth’s implication of a methodological shift rather than a disclosure enhancement. (4) The contextual relevance is perfect—it directly addresses the evolution in financial treatment and liability modeling. Qualitative accuracy is high due to correct interpretation of the 2024 disclosures and the significance of sensitivity analysis. Quantitative accuracy is reduced because of the inclusion of unsupported dollar figures and the misattribution of modeling techniques to 2023. Correctness score is 7 because the core narrative of increased transparency is correct, but key factual details are inaccurately added or inferred.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 539,
        "total_tokens": 1931
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How has Adobe's strategic positioning and integration of Frame.io evolved between 2022 and 2024, particularly in terms of its alignment with Adobe's broader product ecosystem?",
      "original_answer": "In 2022, Adobe described the integration of Frame.io as part of its Digital Media reportable segment, emphasizing its role as a cloud-based video collaboration platform acquired for $1.18 billion, with integration efforts just beginning. By 2024, Frame.io had transitioned from being a newly acquired integration to being positioned as a core component of Adobe's creative collaboration suite, directly integrated with key applications such as Adobe Premiere Pro, After Effects, Photoshop, and Workfront. Additionally, in 2024, Frame.io was included as part of Adobe GenStudio, indicating a deeper strategic alignment with Adobe's broader content production and collaboration ecosystem. This evolution reflects a shift from initial integration to full ecosystem incorporation.",
      "llm_answer": "\nSince Adobe acquired Frame.io in 2021, the platform has moved from a stand‑alone collaboration service to a core connective layer of the Creative Cloud and Digital Experience suites. By 2022‑2024 it is tightly embedded in the workflows of Premiere Pro, After Effects, Photoshop, Illustrator, Adobe Express and Firefly, feeding content‑creation and review cycles into Document Cloud and the broader Experience Cloud ecosystem, and is positioned as the collaboration engine for Adobe GenStudio to drive recurring ARR growth across Adobe’s creative‑media portfolio.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of Frame.io's integration into Adobe's ecosystem between 2022 and 2024, noting its transition from a standalone platform to a core component of Creative Cloud and alignment with Adobe GenStudio. It accurately reflects strategic positioning improvements and deeper workflow integrations. However, it incorrectly states the acquisition year as 2021, while the ground truth (and public record) confirms the acquisition closed in December 2022. This is a factual error affecting quantitative accuracy. (2) No specific financial figures (e.g., $1.18 billion) are mentioned in the LLM answer, which omits a key detail from the original answer. While not a calculation error, the absence of the acquisition cost reduces completeness and quantitative precision. Dates 2022–2024 are used appropriately as a range, consistent with the question’s scope. (3) The multi-hop reasoning is strong: the model synthesizes Frame.io’s integration across multiple Adobe products (Premiere Pro, After Effects, Photoshop, etc.), links it to broader suites (Digital Experience, Document Cloud, Experience Cloud), and correctly identifies its role in Adobe GenStudio and ARR growth. This reflects sound understanding of ecosystem alignment. (4) Despite the incorrect acquisition year and missing dollar amount, the core qualitative evolution and strategic trajectory are accurately conveyed. The answer is contextually excellent, directly addressing the question’s focus on strategic positioning and ecosystem integration. Minor factual omissions and one date error prevent a top score, but overall reasoning and relevance are strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 457,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 129,
      "question": "How did the composition of private alternative investments, specifically equity-like funds, evolve between 2022 and 2023 in terms of fair value measurements using significant unobservable inputs (Level 3)?",
      "original_answer": "In 2022, equity-like funds under private alternative investments had a fair value of $5.5 million measured using significant unobservable inputs (Level 3). In 2023, this value increased significantly to $25.4 million. This indicates a fivefold increase in the portion of equity-like funds valued using Level 3 inputs, suggesting a shift toward more opaque or complex valuation methodologies for these investments.",
      "llm_answer": "\nBetween 2022 and 2023 the amount of private‑equity‑like funds that is classified as Level 3 (i.e., measured using significant unobservable inputs) fell only modestly—from **$25.4 million** in the 2022 fair‑value table to **$25.1 million** in the 2023 table.  While the overall equity‑like fund allocation stayed roughly stable (about $4.0 billion in 2022 versus $4.09 billion in 2023), the Level 3 component represents an even smaller share of that allocation, declining slightly in absolute terms.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth. (1) Quantitatively, it states that Level 3 equity-like funds decreased from $25.4 million in 2022 to $25.1 million in 2023, while the original answer shows an increase from $5.5 million in 2022 to $25.4 million in 2023. This reverses both the direction and magnitude of change. The LLM also introduces figures not in the ground truth, such as a total equity-like fund allocation of ~$4 billion, which undermines factual accuracy. (2) The calculation of a 'modest fall' is incorrect because the actual trend is a fivefold increase. The LLM misattributes the $25.4 million figure to 2022 when it belongs to 2023. (3) Qualitatively, the reasoning fails on multiple levels: it does not recognize the significant increase in Level 3 valuation, misidentifies the time series, and draws an erroneous conclusion about a 'decline' in Level 3 share. The multi-hop synthesis is flawed—instead of identifying growth in opaque valuations, it suggests stability or reduction. (4) Contextually, while the answer addresses fair value measurements and Level 3 inputs, its core facts are inverted, making it highly misleading. The mention of overall fund allocation adds context not requested and distracts from the specific focus on Level 3 equity-like funds. Overall, the answer fails on correctness due to fundamental factual and directional errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1242,
        "completion_tokens": 389,
        "total_tokens": 1631
      },
      "error": null
    },
    {
      "question_id": 130,
      "question": "How has Adobe's integration and positioning of Frame.io within its Digital Media offerings evolved between 2022 and 2024?",
      "original_answer": "In 2022, Adobe had just acquired Frame.io in October 2021 and was beginning to integrate it into the Digital Media segment as a cloud-based video collaboration platform. By 2024, Frame.io had become a core part of Adobe’s creative collaboration tools, being directly integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront, and was also included in Adobe GenStudio for scalable content production. This reflects a strategic evolution from initial integration to deeper ecosystem embedding.",
      "llm_answer": "\nBetween 2022 and 2024 Adobe shifted Frame.io from a freshly‑acquired video‑review platform into a central pillar of its Digital Media suite.  The 2022 10‑K noted the acquisition and the start of integration with Premiere Pro, After Effects, Photoshop and Lightroom, while the 2024 10‑K shows Frame.io now embedded in the end‑to‑end workflow of Creative Cloud and Adobe Express, offered through Adobe GenStudio and powered by Firefly AI for large‑scale content creation and real‑time collaboration.  This evolution positions Frame.io not just as a collaboration add‑on but as a core, AI‑enhanced collaboration hub that ties together video, design and generative‑AI assets across Adobe’s Digital Media offerings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: Frame.io was acquired in October 2021, integration began in 2022 with core Creative Cloud apps (Premiere Pro, After Effects, Photoshop, Lightroom), and by 2024 it was deeply embedded in Adobe's Digital Media ecosystem. The mention of Adobe GenStudio and AI-powered collaboration via Firefly (implied by 'powered by Firefly AI') reflects the strategic evolution. (2) There are no numeric values to verify, but dates and timelines are accurate—acquisition in 2021, integration phase in 2022, mature integration by 2024. (3) Multi-hop reasoning is sound: the model correctly synthesizes Frame.io’s progression from a standalone video review tool to a central collaboration hub across Creative Cloud, Adobe Express, and AI-driven workflows. (4) The only minor deviation from the original answer is the mention of 'Firefly AI' and 'Adobe Express' integration, which are plausible enhancements by 2024 but not explicitly confirmed in the ground truth. However, since Adobe GenStudio and AI scaling are mentioned in the original, and Firefly is Adobe’s known generative AI engine, this is a reasonable inference. The core evolution—strategic deepening of integration into Adobe’s ecosystem—is accurately conveyed. Wording differs but semantic meaning matches. No factual errors, minor extrapolation does not undermine correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 393,
        "total_tokens": 1694
      },
      "error": null
    },
    {
      "question_id": 130,
      "question": "How has CVS's approach to Medication Management evolved between 2022 and 2024, particularly in terms of clinical programs and digital tools aimed at improving medication adherence and cost efficiency?",
      "original_answer": "In 2022, CVS emphasized formulary management through its National Pharmacy and Therapeutics Committee, promoting the use of generic drugs and offering real-time benefit information to guide members toward lower-cost alternatives. The company also operated mail order and specialty pharmacies, and provided clinical programs focused on medication adherence and utilization management, including an industry-leading approach to limit opioid prescriptions to seven-day supplies for acute cases. By 2024, CVS had expanded its Medication Management offerings with the introduction of digital tools like the NovoLogix preauthorization platform and enhanced analytics for identifying lower-cost drug alternatives. The company also launched the CVS Weight Management program, integrating GLP-1 medication optimization with lifestyle coaching, and expanded its value-based care initiatives through Oak Street Health, operating 239 primary care centers across 27 states to better manage chronic conditions and medication use. These developments reflect a shift from primarily cost-containment strategies to a more integrated, digitally enabled, and clinically proactive model of medication support.",
      "llm_answer": "\nBetween 2022 and 2024 CVS moved from a set of stand‑alone medication‑therapy and utilization‑management programs to a fully integrated, data‑driven medication‑management ecosystem.  The company added digital‑first tools such as the Health Engagement Engine/Canopy AI platform, real‑time formulary and cost‑saving analytics (Pharmacy Advisor, Drug Savings Review, NovoLogix pre‑authorization), and expanded in‑home health‑evaluation and virtual MinuteClinic services that deliver medication reviews and adherence outreach at scale.  These clinical‑digital extensions—bolstered by the Signify Health acquisition, Oak Street Health value‑based clinics, and the Cordavis biosimilar initiative—have broadened adherence support while driving greater cost efficiency across its PBM and health‑services operations.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of CVS's medication management strategy from cost-containment to a more integrated, digital, and clinically proactive model, which aligns with the ground truth. It correctly identifies key 2024 developments such as the NovoLogix pre-authorization platform, value-based care via Oak Street Health, and digital tools enhancing cost efficiency and adherence. However, several elements in the LLM response are either inaccurate or not supported by the original answer: (1) The 'Health Engagement Engine/Canopy AI platform' and 'Pharmacy Advisor, Drug Savings Review' are not mentioned in the ground truth and appear to be fabricated or misattributed. (2) The 'Signify Health acquisition' and 'Cordavis biosimilar initiative' are not referenced in the original answer and thus introduce unsupported details. (3) While the original answer notes Oak Street Health operating 239 centers in 27 states by 2024, the LLM omits this specific, verifiable data point, reducing completeness. (4) The original highlights specific 2022 programs like the seven-day opioid supply limit and real-time benefit tools, which the LLM generalizes without precise mention. (5) The LLM implies a full integration by 2024 ('fully integrated ecosystem') that goes beyond the original's more measured description of expansion and enhancement. Quantitatively, no explicit numbers are misstated (e.g., no incorrect figures), so quantitative accuracy is high. Contextually, the answer is highly relevant and addresses the core theme of digital and clinical evolution. However, qualitative accuracy is reduced due to introduction of unverified programs and lack of precise grounding in the source facts, undermining multi-hop reasoning fidelity. Overall, the answer is directionally correct but contains significant hallucinated details, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1512,
        "completion_tokens": 508,
        "total_tokens": 2020
      },
      "error": null
    },
    {
      "question_id": 131,
      "question": "How has Adobe's integration and positioning of Frame.io within its Creative Cloud ecosystem evolved from 2022 to 2024, and what specific enhancements were made to its collaboration features during this period?",
      "original_answer": "In 2022, Adobe acquired Frame.io and began integrating its cloud-based video collaboration platform into Adobe Creative Cloud, with initial enhancements focused on deeper integration into Premiere Pro and After Effects to deliver native collaborative workflows for video editing. By 2024, Frame.io had evolved into a more comprehensive cloud-native creative collaboration platform, offering real-time upload, review, and approval features not only for video but also for still images, design files, and PDFs. It expanded its integration across Adobe Photoshop, Lightroom, and Workfront, and introduced Camera to Cloud functionality, enabling automatic upload of footage directly into Frame.io from cameras on set. These enhancements reflect a strategic shift from a video-specific collaboration tool to a broader creative asset production and review platform within Adobe’s ecosystem.",
      "llm_answer": "\nFrom 2022 to 2024 Adobe moved Frame.io from a stand‑alone review platform into the core of Creative Cloud, embedding its real‑time upload, frame‑accurate commenting and approval workflows directly inside Premiere Pro, After Effects, Photoshop and Lightroom and linking them to Creative Cloud Libraries and Adobe Express.  The 2024 enhancements added native Camera‑to‑Cloud ingestion, AI‑driven generative review tools via Firefly, tighter integration with Adobe GenStudio for enterprise‑scale content production, and made the service available across the entire Creative Cloud suite as a unified, AI‑augmented collaboration hub.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly captures the timeline (2022–2024) and the core evolution of Frame.io from a standalone platform into Creative Cloud, with accurate emphasis on real-time collaboration, integration into Premiere Pro, After Effects, Photoshop, and Lightroom, and the introduction of Camera-to-Cloud functionality—key points aligned with the ground truth. The mention of expanded Creative Cloud Libraries and Adobe Express integration adds relevant context. However, the LLM introduces elements not present in the ground truth: (1) AI-driven generative review tools via Firefly and integration with Adobe GenStudio are not mentioned in the original answer and lack support from the provided knowledge; (2) describing Frame.io as available 'across the entire Creative Cloud suite as a unified, AI-augmented collaboration hub' overreaches the documented scope, which emphasizes expansion to Photoshop, Lightroom, and Workfront but does not claim full suite-wide integration or AI augmentation. These additions introduce speculative or unverified enhancements, affecting qualitative accuracy. Quantitatively, there are no numerical claims to verify, so accuracy is 10. Contextually, the answer is highly relevant and addresses both parts of the question—evolution and feature enhancements—with strong synthesis. The reasoning is mostly sound but slightly compromised by unsupported AI feature claims. Thus, the answer is factually strong on core integration points but partially incorrect on advanced features, warranting a 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 422,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 132,
      "question": "How has the use of recently executed transactions in the valuation of loans and other assets evolved from 2023 to 2024, particularly in terms of their role in fair value determination?",
      "original_answer": "In 2023, recently executed transactions were a key input for determining the fair value of corporate loans and contingent lending commitments, often used alongside market price quotations, implied yields, and proprietary valuation models. By 2024, the role of recently executed transactions remained significant but was more specifically tied to the held-for-sale category of loans and lending commitments, and also extended to the valuation of other assets such as other investments, where they were used in conjunction with discounted cash flow models and comparable company multiples. This reflects a more targeted application of transaction data in valuation practices.",
      "llm_answer": "\nFrom 2023 to 2024 the Firm kept using recently‑executed transactions as a core input for fair‑value measurement of loans and other assets, but the 2024 disclosures show a more explicit linkage of those transaction prices to the final valuation – especially for corporate loans, mortgage‑ and asset‑backed securities and other debt – with clearer adjustments for funding spread, credit spread, loss‑given‑default and correlation.  In 2023 the reliance was mainly on observable market data (Level 2) and benchmarking to comparable trades; by 2024 the same transactions are treated as the primary reference point, moving them to Level 2 when market liquidity supports them and to Level 3 only when the inputs are unobservable, while the underlying methodology and hierarchy remain unchanged.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains significant deviations from the ground truth in terms of qualitative accuracy and reasoning. (1) Correct elements: The answer correctly identifies that recently executed transactions remained important in both 2023 and 2024 for fair value determination, and notes an evolution in their application, which aligns with the original answer. It also correctly frames the use of transaction data alongside other market inputs. (2) Quantitative accuracy: There are no specific numbers, percentages, or dollar amounts in either the ground truth or the LLM answer, so no numerical inaccuracies exist—this aspect is neutral and does not detract from the score. (3) Multi-hop reasoning assessment: The LLM introduces concepts not present in the ground truth, such as movement between Level 2 and Level 3 of the fair value hierarchy and specific adjustments (funding spread, credit spread, LGD, correlation), which are not mentioned in the original answer. While plausible in a financial context, these details are unsupported by the ground truth and represent an overextension of the provided information. Additionally, the LLM broadens the scope to mortgage- and asset-backed securities and other debt, which are not referenced in the original answer. Conversely, it fails to mention the key point from the ground truth that in 2024, the use of transaction data became more specifically tied to held-for-sale loans and lending commitments and was extended to 'other investments'—a critical evolution that the LLM omits. (4) Justification for scores: The correctness score is 5 due to partial factual alignment but significant omissions and additions that distort the actual evolution described. Quantitative accuracy is 10 because no incorrect numbers are present. Qualitative accuracy is 5 due to incorrect entity linkages and unsupported methodological claims. Contextual relevance is 8 because the answer stays on topic and addresses the general trend in transaction use, even if specifics are flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 547,
        "total_tokens": 1922
      },
      "error": null
    },
    {
      "question_id": 132,
      "question": "How has Adobe's approach to the Substance 3D Stager product evolved between 2022 and 2024, particularly in terms of its positioning within the broader Substance 3D ecosystem?",
      "original_answer": "In 2022, Substance 3D Stager was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio but without detailed information about its functionality or strategic positioning. By 2024, Adobe introduced a more comprehensive view of Substance 3D as an ecosystem, where Stager is specifically described as a tool for building and assembling 3D scenes. This evolution reflects a strategic shift from simply offering the product to integrating it into a broader suite of 3D tools, including Painter, Sampler, Designer, and Modeler, emphasizing its role in enabling end-to-end 3D content creation workflows.",
      "llm_answer": "\nBetween 2022 and 2024 Adobe moved Substance 3D Stager from being described simply as one of several desktop tools in the “Substance 3D Collection” toward a strategy that treats Stager as the central, cloud‑connected hub for building and publishing 3D scenes.  The 2022 filing (page 11) lists Stager alongside Painter, Sampler, Designer and Modeler as standalone desktop apps, while the 2024 filing (page 12) emphasizes that Stager is now tightly integrated with Adobe’s generative‑AI (Firefly) services, offered within Creative Cloud subscriptions, and positioned to feed 3D assets into the broader Substance 3D ecosystem and Adobe’s Experience Cloud.  This evolution reflects a shift from a fragmented desktop suite to a unified, cloud‑enabled platform that sits at the heart of Adobe’s end‑to‑end 3D content workflow.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Adobe's positioning of Substance 3D Stager between 2022 and 2024. It accurately identifies that in 2022, Stager was listed among other desktop tools (referencing the trademark filing on page 11), and by 2024, it was more strategically positioned within a broader ecosystem. The mention of integration with Firefly AI, Creative Cloud, and Experience Cloud adds relevant context that reflects Adobe’s expanded vision, which is consistent with the direction in the original answer. However, the LLM overstates the case by describing Stager as the 'central, cloud-connected hub' and 'at the heart' of Adobe’s 3D workflow — language that goes beyond the original answer’s more measured claim that Stager is 'a tool for building and assembling 3D scenes' within an integrated suite. The ground truth does not support the hierarchical centrality or cloud-first framing emphasized in the LLM response. There are no numerical inaccuracies (quantitative accuracy is perfect, scoring 10), and all entities (Substance 3D tools, years, Adobe ecosystem components) are correctly identified. The reasoning is sound and multi-hop synthesis across years and documents is appropriate, though slightly over-interpreted. Contextual relevance is excellent, directly addressing the question’s focus on strategic evolution and ecosystem integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 393,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How did GE's strategic positioning regarding grid-scale batteries evolve from 2022 to 2023, particularly in terms of their role in the company's energy transition strategy and level of strategic reliance?",
      "original_answer": "In 2022, GE mentioned grid-scale batteries as part of a broader set of emerging technologies that 'may become more important over time' in achieving deep decarbonization goals, indicating GE was considering them as a potential future investment. By 2023, GE explicitly listed grid-scale batteries as one of the key technologies 'that may become more important over time' and integrated them into the company’s strategic narrative as a dependency, noting that achieving decarbonization goals would 'depend in part' on such technologies. This reflects a shift from viewing grid-scale batteries as a speculative investment to a more central component of GE's energy transition strategy.",
      "llm_answer": "\nFrom 2022 to 2023 GE shifted its view of grid‑scale batteries from a peripheral, “emerging‑technology” footnote in its energy‑transition narrative to a core strategic pillar. In the 2022 filing the company merely noted that grid‑scale batteries (and other storage) might become important for deep decarbonization, but in the 2023 filing it explicitly states that achieving deep‑decarbonization goals for power will depend on grid‑scale storage, signals continued investment and resource allocation to develop and commercialize these solutions, and integrates them into its Power and Renewable‑Energy growth strategy. This evolution reflects a higher level of strategic reliance on grid‑scale batteries as a key enabler of GE’s energy‑transition objectives.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in GE's strategic positioning on grid-scale batteries from 2022 to 2023. (1) All factual elements are correct: in 2022, GE viewed grid-scale batteries as an emerging technology that 'may become more important over time,' and by 2023, they were framed as a dependency for decarbonization, with the language shifting to 'depend in part' on such technologies. The LLM correctly identifies this shift from peripheral consideration to strategic reliance. (2) There are no numeric values, dates, or financial figures in the original or LLM answer beyond the years 2022 and 2023, which are correctly used. (3) The multi-hop reasoning—comparing GE’s disclosures across two years and inferring increased strategic reliance—is sound and well-synthesized. The LLM accurately infers the deeper integration into GE’s Power and Renewable-Energy strategy, which aligns with the ground truth’s emphasis on integration into the strategic narrative. (4) The only minor gap is that the LLM mentions 'signals continued investment and resource allocation,' which is a slight interpretive extension not explicitly stated in the original answer, though it is a reasonable inference. This prevents a perfect 10 but does not undermine correctness. Overall, the answer is semantically equivalent, contextually precise, and factually robust.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 381,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How has CVS's disclosure regarding the use of broker quoted debt securities in its fair value measurements evolved between 2022 and 2024, particularly in terms of its presence or impact on financial reporting?",
      "original_answer": "In 2022, CVS explicitly stated that it did not have any broker quoted debt securities for the years ended December 31, 2021, and 2020, and that it only used internal pricing for certain private placements. By 2024, the company continued to disclose that it had no broker quoted debt securities for the years ended December 31, 2024 and 2023, indicating a consistent absence of such securities in its portfolio. However, the 2024 disclosure no longer mentions any negative impact or specific review process related to broker quoted debt securities, suggesting a reduced emphasis or relevance of this topic in the company's fair value measurement disclosures over time.",
      "llm_answer": "\nBetween the 2022 and 2024 filings CVS consistently reports that it holds **no broker‑quoted debt securities** in its fair‑value hierarchy—​the 2022 Form 10‑K (page 146) notes “the Company did not have any broker‑quoted debt securities for the years ended December 31, 2021 and 2020,” and the 2024 Form 10‑K (page 146) repeats the same statement for 2024 and 2023. Because such securities are absent, they do not enter the Level 3 valuation inputs and therefore have **no material impact on CVS’s financial‑statement fair‑value measurements or related disclosures** over this period.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies the key fact from both the 2022 and 2024 filings: CVS consistently disclosed having no broker-quoted debt securities for the relevant years (2020/2021 in 2022 filing; 2023/2024 in 2024 filing), which aligns with the ground truth. The quantitative accuracy is perfect—dates, years, and the absence of securities are correctly reported, and the reference to no material impact due to absence is logically sound. However, the LLM omits a key qualitative nuance present in the original answer: the 2024 disclosure no longer mentions any negative impact or specific review process related to broker quoted debt securities, indicating a reduced emphasis over time. This evolution in disclosure tone and content—beyond mere repetition of absence—is a critical part of the question about how the disclosure 'evolved.' While the LLM captures the continuity in factual absence, it fails to note the change in disclosure detail or emphasis, which is central to the multi-hop reasoning required. Thus, while factually accurate and contextually relevant, the answer lacks completeness in capturing the qualitative shift in reporting, warranting a slight deduction in qualitative accuracy and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 345,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 134,
      "question": "How did the composition of BlackRock's Equity Securities at FVTNI change between 2023 and 2024, particularly in terms of equity securities/mutual funds and equity method investments?",
      "original_answer": "In 2023, BlackRock reported $1,211 million in equity securities/mutual funds under Equity Securities at FVTNI, while equity method investments totaled $1,895 million. By 2024, the value of equity securities/mutual funds increased to $1,950 million, and equity method investments rose to $2,783 million. This reflects a significant increase in both categories, indicating a strategic expansion in these investment areas.",
      "llm_answer": "\nBetween 2023 and 2024 the Equity Securities at FVTNI that are classified as mutual‑fund/equity securities rose in fair‑value from **$1.585 bn to $1.950 bn** (an increase of roughly **$0.365 bn**, or about **23 %**).  At the same time the equity‑method investment portfolio measured using NAV grew from **$2.51 bn (2023) to $2.58 bn (2024)**, a modest rise of **≈$0.07 bn (≈2.8 %)**.  Thus the composition shifted toward a larger share of liquid mutual‑fund exposure, while the private‑equity/real‑asset exposure captured through equity‑method investments expanded only slightly.  (See BLK_10k_2023.pdf pp. 90, 92; BLK_10k_2024.pdf pp. 96, 92.)",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. According to the ground truth, in 2023, equity securities/mutual funds were $1,211 million, but the LLM reports $1.585 billion ($1,585 million), which is incorrect. The 2024 value of $1,950 million is correct. For equity method investments, the ground truth reports $1,895 million in 2023 and $2,783 million in 2024, but the LLM incorrectly states $2.51 billion ($2,510 million) in 2023 and $2.58 billion ($2,580 million) in 2024. These errors affect both absolute values and calculated changes. (2) Calculations are based on wrong inputs: the LLM reports a $0.365 billion increase in mutual funds, but the actual increase is $1,950M - $1,211M = $739 million, not $365 million. The percentage increase is therefore closer to 61%, not 23%. Similarly, the equity method increase is reported as $70 million (~2.8%), but the actual increase is $2,783M - $1,895M = $888 million (~47%), making the LLM's figure vastly understated. (3) While the LLM attempts multi-hop reasoning by comparing two years and two investment categories across filings, it fails in accurate synthesis due to reliance on incorrect source data. The qualitative observation about a shift toward mutual funds has some basis in the correct 2024 mutual fund figure, but the conclusion is undermined by incorrect 2023 baselines. (4) Contextual relevance is high as the structure and intent align with the question, discussing both categories and changes over time. However, quantitative accuracy is very low due to major discrepancies in reported figures. Qualitative accuracy is partially preserved due to correct identification of categories and direction of change, but reasoning is flawed. Correctness score is low because financial accuracy is critical in SEC-based analysis and core numbers are wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 503,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 134,
      "question": "How did UnitedHealth Group's evaluation and treatment of credit-related impairments for available-for-sale debt securities evolve from 2022 to 2024, particularly in terms of unrealized losses and the allowance for credit losses?",
      "original_answer": "In 2022, UnitedHealth Group reported that unrealized losses in its available-for-sale debt securities were primarily driven by interest rate increases and not credit deterioration, with no significant credit deterioration observed since purchase. The allowance for credit losses was noted to be not material as of December 31, 2021. By 2024, the company's evaluation methodology remained consistent in terms of assessing present value of expected cash flows, issuer credit condition, and fair value relative to amortized cost. However, the allowance for credit losses is now explicitly described as being recorded as a separate component through an allowance account, with credit-related impairments impacting investment and other income, indicating a more structured recognition of credit risk. This evolution shows a shift from a qualitative, low-risk assessment to a more formalized impairment accounting framework.",
      "llm_answer": "\nUnitedHealth Group’s assessment of credit‑related impairment for available‑for‑sale debt securities—comparing the present value of expected cash flows to amortized cost and examining issuer credit quality—has remained essentially the same from 2022 through 2024.  It records any credit‑related shortfall as an allowance against the security (charged to investment and other income) while non‑credit impairments are routed through other comprehensive income, and the company has continued to view the majority of unrealized losses as interest‑rate‑driven rather than credit‑driven, keeping the allowance for credit losses immaterial.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of key facts and reasoning. (1) It accurately states that UnitedHealth Group's methodology for evaluating credit-related impairments—assessing present value of expected cash flows, issuer credit quality, and amortized cost—remained consistent from 2022 to 2024. It correctly notes that unrealized losses were primarily due to interest rate changes, not credit deterioration, and that the allowance for credit losses remained immaterial. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised; dates (2022–2024) are correctly referenced. (3) The multi-hop reasoning is sound: the model synthesizes information across time periods and accounting treatments, correctly identifying the continuity in methodology and the nature of unrealized losses. However, the LLM answer omits a key evolution highlighted in the ground truth: the explicit shift toward a more structured impairment framework in 2024, where the allowance is now recorded through a separate allowance account, indicating formalization in accounting practice. This nuance—moving from a qualitative low-risk assessment to a more formalized system—is missing, which slightly weakens the qualitative accuracy. (4) Despite this omission, the answer remains contextually relevant and factually accurate on core elements, warranting a high score but not perfect, as the evolution aspect of the question is underdeveloped.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 424,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 135,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2022 and 2023, particularly in terms of investment value and equity income?",
      "original_answer": "In 2022, AMD's carrying value of its investment in the ATMP JV was $83 million, and it recorded $14 million in equity income from the JV. By 2023, the carrying value increased to $99 million, and equity income rose to $16 million. This indicates a growing financial stake and increased profitability from the joint venture over the two-year period.",
      "llm_answer": "\nBetween 2022 and 2023 AMD’s stake in the ATMP joint venture grew markedly – the carrying value of its equity investment rose from roughly **$63‑69 million** (as of the end of 2020‑21) to **about $99 million** by the end of 2023, and the equity‑method income it records jumped from **$5‑6 million** per year to **$14‑16 million** in 2022‑23.  This expansion reflects a sharp increase in the volume of business with the JV (purchases of **$1.7 billion** in 2023 versus **$831 million** in 2020) and larger receivable/payable balances, underscoring a deepening financial relationship that now generates substantially more earnings for AMD.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. According to the ground truth, in 2022, AMD's carrying value was $83 million and equity income was $14 million; in 2023, these were $99 million and $16 million respectively. However, the LLM incorrectly states that the 2022 carrying value was 'roughly $63–69 million' and equity income was '$5–6 million per year' during 2020–21, conflating years and misrepresenting the baseline. It only correctly reports the 2023 carrying value ($99 million) and approximates the 2022–2023 equity income range ($14–16 million), but misattributes timing. (2) The cited purchase volumes ($1.7 billion in 2023 vs $831 million in 2020) and receivables are not part of the original question or ground truth and introduce unsupported details, potentially confusing the evaluation. These figures, while possibly factual from another context, are irrelevant to the specific query about investment value and equity income. (3) The multi-hop reasoning is partially sound in identifying a trend of growth in AMD's financial relationship with ATMP JV, but fails in precise cross-year comparison due to incorrect data referencing. The conclusion about a deepening relationship aligns with the ground truth, but the reasoning is undermined by inaccurate inputs. (4) The contextual relevance is high because the answer addresses the evolution of the financial relationship and attempts to explain the trend. However, the quantitative accuracy is low due to incorrect figures for 2022, and completeness is compromised because it does not clearly and correctly report the two specific data points for the two years as required. The qualitative accuracy is moderate due to correct use of financial terms and logical interpretation, despite flawed data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 490,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 135,
      "question": "How has UnitedHealth Group's exposure to tort claims evolved between 2022 and 2024, particularly in terms of the nature of the claims and the potential financial impact?",
      "original_answer": "In 2022, UnitedHealth Group specifically highlighted self-insured liabilities related to medical malpractice claims against affiliated physicians and the potential for actual losses to significantly exceed recorded liabilities. The document emphasized increasing legal actions alleging medical malpractice and general professional liabilities, with litigants seeking recoveries under new theories of liability that might not be subject to damage caps. By 2024, while tort claims remained a concern, the focus shifted slightly to broader legal risks tied to the delivery of health care services, including claims related to clinical quality and patient safety standards. The 2024 filing also emphasized the potential for reputational harm and adverse effects on business relationships, indicating a broader and more systemic risk profile compared to the more narrowly defined exposure in 2022.",
      "llm_answer": "\nBetween 2022 and 2024 UnitedHealth’s tort exposure remained focused on medical‑malpractice and other provider‑related liability claims (e.g., lawsuits against affiliated physicians, hospitals and health‑care professionals that fail to meet clinical or safety standards).  The 2024 filing notes that the volume of such claims has risen and that, because the company is largely self‑insured, actual losses can exceed the amounts it has reserved—meaning the potential financial impact is now characterized as “significantly greater” and could produce material monetary damages, higher defense costs and reputational harm.  Thus, while the nature of the claims (medical‑malpractice and provider liability) has not changed, the 2024 disclosures signal an increased likelihood of larger financial exposure.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of key facts, entities, and timeline. (1) It correctly identifies that UnitedHealth Group faces tort claims primarily related to medical malpractice and provider liability, with self-insurance increasing financial exposure—consistent across both 2022 and 2024. The nature of the claims (against affiliated physicians and healthcare providers) is accurately described. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised; the score reflects full alignment on available data. (3) The multi-hop reasoning is mostly sound: the LLM correctly infers continuity in claim types from 2022 to 2024 and notes increased financial risk due to rising claim volume and self-insurance. However, it misses a key qualitative shift noted in the original answer: in 2024, the focus expanded beyond malpractice to broader systemic risks including clinical quality, patient safety standards, and reputational harm affecting business relationships. While the LLM mentions reputational harm, it frames it as a consequence of the same types of claims rather than a shift in the nature of exposure. (4) The answer is highly contextually relevant, directly addressing the evolution of tort claims and financial impact. The minor omission of the broadening risk profile in 2024 prevents a top score, but core facts and implications are accurately conveyed, warranting a high correctness score of 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 423,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How has the structure and capacity of Boeing's three-year revolving credit agreement evolved between 2023 and 2024, and what does this indicate about the company's liquidity strategy?",
      "original_answer": "In 2023, Boeing had a legacy three-year revolving credit agreement expiring in August 2025 with $3.0 billion of total commitments. In 2024, this agreement remained in effect, but Boeing also entered into a new $4.0 billion five-year revolving credit agreement expiring in May 2029 while terminating two other credit facilities. This evolution indicates a strategic shift to enhance liquidity capacity and extend maturity timelines, reinforcing Boeing's financial flexibility and commitment to managing corporate borrowing needs.",
      "llm_answer": "\nBetween 2023 and 2024 Boeing kept its **$3.0 bn three‑year revolving credit facility (maturing August 2025)** unchanged in size and maturity, but it bolstered the overall credit package by **adding a new $4.0 bn five‑year revolving line (maturing May 2029)** and retiring the older **$0.8 bn 364‑day facility and the $3.2 bn five‑year facility** that had been in place.  This extension of maturities and increase in total available credit shows that Boeing is **maintaining a strong, flexible liquidity buffer and extending its debt‑maturity profile** to support cash‑flow needs while keeping borrowing costs under control.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $3.0 billion three-year revolving credit agreement from 2023 maturing in August 2025, and the new $4.0 billion five-year facility expiring in May 2029 added in 2024. It accurately notes that the original facility remained in effect while two others were terminated. The dollar amounts ($3.0B, $4.0B), maturities (August 2025, May 2029), and the nature of the facilities (revolving credit) are all factually correct. (2) Quantitative accuracy is perfect: all numbers match the ground truth, including the $3.0B legacy facility and the $4.0B new facility. The mention of retiring a $0.8B 364-day facility and a $3.2B five-year facility is consistent with the termination of two prior facilities, though the original answer does not specify their sizes. This additional detail may come from deeper filing data and does not contradict the ground truth; it enhances completeness without introducing error. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes across years and facilities, recognizing that Boeing maintained its existing agreement while adding a larger, longer-dated facility and retiring older ones. The conclusion about extending maturities and enhancing liquidity aligns with the ground truth’s interpretation of strengthened financial flexibility. (4) The only reason for not scoring a 10 is minor: the original answer emphasizes the strategic shift in liquidity strategy more explicitly, while the LLM focuses on cost control, which is plausible but not directly stated in the ground truth. However, the core facts, synthesis, and implications are substantially aligned. Thus, the answer is highly accurate, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 474,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How did the financial impact of the 2017 Performance-based Options evolve between 2023 and 2024, particularly in terms of the fair value of options vested and the intrinsic value of options exercised?",
      "original_answer": "In 2023, the fair value of the 2017 Performance-based Options that vested was $56 million, and the intrinsic value of options exercised was $44 million. By 2024, the fair value of the options vested decreased slightly to $52 million, but the intrinsic value of options exercised saw a significant increase to $373 million. This indicates that while the value of options vesting declined slightly in 2024, the actual financial benefit realized from exercised options increased substantially compared to the prior year.",
      "llm_answer": "\nIn 2023 the 2017 performance‑based options generated $56 million of stock‑based compensation expense from vested portions, whereas in 2024 that expense fell to $52 million.  By contrast, the cash intrinsic value realized from exercising those options jumped from $44 million in 2023 to $373 million in 2024.  (Pages 100 & 107)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures: $56 million fair value (vested) in 2023, $52 million in 2024, and intrinsic value of $44 million in 2023 rising to $373 million in 2024. These match the ground truth exactly. (2) Quantitative accuracy is perfect—no calculation errors, and the numbers align precisely with the original answer. Format variations (e.g., $56 million vs $56 million) are acceptable and do not affect meaning. (3) The reasoning is sound: the model correctly contrasts the slight decline in vesting-related value with the sharp rise in intrinsic value from exercised options. While the LLM uses the term 'stock-based compensation expense' instead of 'fair value of options vested,' this is a reasonable proxy in context and reflects proper multi-hop synthesis from financial statements. The slight terminology shift does not distort the meaning but may slightly reduce precision in financial semantics. (4) The answer is fully relevant, directly addressing both parts of the question—evolution of fair value and intrinsic value across 2023 and 2024. The citation of pages adds contextual support. The only minor deduction is for terminology nuance, not factual error, justifying a 9/10 on correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1224,
        "completion_tokens": 358,
        "total_tokens": 1583
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How did AMD's approach to estimating adjustments for product return rights evolve between 2022 and 2023, and what specific changes were made in the methodology used for these estimates?",
      "original_answer": "In 2022, AMD estimated adjustments for product return rights using trended actual historical product return rate information, adjusted for known information or events. By 2023, AMD maintained the use of historical data but placed additional emphasis on 'rights of return and rebates' as part of variable consideration under ASC 606-10-32-8 through 14, explicitly stating that these estimates were based on the 'most likely amount' of consideration expected after adjustments for returns, rebates, and price protection. This reflects a more structured and codified approach to estimating returns, aligning more closely with specific accounting standards.",
      "llm_answer": "\nBetween 2022 and 2023 AMD moved from a broad, historical‑experience‑based estimate of return‑related adjustments to a more granular, data‑driven approach.  In the 2023 filing the company explicitly cites “trended actual historical product‑return rate information” that is “adjusted for actual known information or events” and ties those adjustments to internal and external market data, whereas the 2022 discussion only referenced “actual historical activity and experience” and generic “known events or current economic conditions.”  This refinement adds a clearer, trend‑based methodology for quantifying the variable consideration tied to product‑return rights, distributor price‑incentives and OEM rebates.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the evolution in AMD's methodology between 2022 and 2023 with accurate entity and year references. It correctly notes that in 2022, AMD used historical experience and known events, and in 2023, refined this approach with more specific reference to trended data and adjustments based on known information. The answer also appropriately highlights the inclusion of distributor incentives and OEM rebates, which aligns with the ground truth's mention of rebates and price protection. However, the LLM answer misses the key technical accounting shift emphasized in the original answer: the explicit alignment with ASC 606-10-32-8 through 14 and the use of the 'most likely amount' method for variable consideration. This is a significant qualitative omission, as the question specifically asks about changes in methodology, and the codified accounting standard reference is central to the 2023 change. While the LLM describes a 'more granular, data-driven approach,' it does not accurately characterize the shift as a more structured application of ASC 606 guidance, which is the core of the actual change. There are no numerical inaccuracies (hence perfect quantitative score), and the contextual relevance is high since the response stays focused on the question. The reasoning is partially sound but lacks the precise multi-hop synthesis of accounting standards and policy changes that the ground truth captures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 398,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 137,
      "question": "How did the number of shares under option for the 2017 Performance-based Options evolve from 2023 to 2024, and what does this indicate about the exercise and forfeiture trends of these options?",
      "original_answer": "The number of shares under option for the 2017 Performance-based Options decreased significantly from 1,549,080 shares at the end of 2023 to 625,825 shares at the end of 2024. This indicates that a large portion of these options were exercised (905,219 shares) and some were forfeited (18,036 shares) during 2024, showing a trend of completion in the lifecycle of these options as they approached their final vesting date.",
      "llm_answer": "\nFrom 2023 to 2024 the outstanding shares underlying the 2017 performance‑based options fell sharply, from **1,549,080** at Dec 31 2023 to **625,825** at Dec 31 2024.  The reduction of roughly **923,000 shares** is almost entirely attributable to the **exercise of about 905,000 options** (with only ~18,000 shares forfeited), indicating that the majority of the vested 2017 options were converted into common stock rather than being left to expire or cancelled.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the key numbers: 1,549,080 shares at the end of 2023 and 625,825 at the end of 2024, matching the ground truth. It accurately states that approximately 905,000 shares were exercised and about 18,000 were forfeited, which aligns with the ground truth values of 905,219 exercised and 18,036 forfeited. The minor discrepancy is in the total reduction calculation: the actual decrease is 1,549,080 - 625,825 = 923,255 shares, which the model rounds to 'roughly 923,000'—this is acceptable rounding. However, it says 'reduction of roughly 923,000 shares' is 'almost entirely attributable' to exercise of 905,000 and forfeiture of 18,000, which sum to 923,000—this is numerically consistent and reasonable given rounding. (2) All calculations are approximately correct with acceptable rounding; no factual errors in numbers or dates. (3) The multi-hop reasoning is sound: the model correctly infers from the drop in outstanding shares that most were exercised rather than forfeited, and links this to the lifecycle completion of the 2017 options, which matches the ground truth interpretation. (4) The answer is contextually fully relevant, addressing both the quantitative evolution and the implied trend in exercise and forfeiture. The only reason for not scoring a 10 is the slight imprecision in presenting the reduction (923,000 vs exact 923,255), though this does not affect the overall correctness. Thus, the answer is factually accurate, well-reasoned, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 425,
        "total_tokens": 1658
      },
      "error": null
    },
    {
      "question_id": 137,
      "question": "How has the role and scope of Optum Rx's Pharmacy Care Services evolved between 2022 and 2024, particularly in terms of its service offerings and strategic positioning within UnitedHealth Group's broader health care ecosystem?",
      "original_answer": "In 2022, Optum Rx was described as managing $112 billion in pharmaceutical spending, including $45 billion in specialty pharmaceutical spending, and was positioned as a provider of pharmacy care services through a network of over 67,000 retail pharmacies, home delivery, specialty pharmacies, and infusion services. It emphasized clinical programs, digital tools, and medication management to help clients reduce costs and improve health outcomes. By 2024, Optum Rx was more strategically integrated into Optum’s broader vision of creating a 'value-oriented and more connected approach to health care,' with an emphasis on leveraging 'data and analytics, pharmacy care services, health care operations, population health and health financial services' to improve the overall health system performance. While specific spending figures were not provided in 2024, the service was elevated as a core component of Optum’s mission to enhance affordability, quality, and patient experience across the health care continuum.",
      "llm_answer": "\nBetween 2022 and 2024 Optum Rx grew from a pharmacy‑care business that managed roughly **$112 billion** of drug spend (including **$45 billion** in specialty medications) and operated mainly through a network of >67,000 retail pharmacies, home‑delivery and specialty sites, to a far broader, integrated platform that now oversees **$178 billion** of pharmaceutical spending (including **$74 billion** in specialty) and adds services such as infusion therapy, rare‑disease/gene‑therapy support, direct‑to‑consumer channels, and pharmacist‑led multidisciplinary care teams.  This expansion reflects a strategic repositioning of Optum Rx as a data‑driven, end‑to‑end pharmacy hub that links medical, behavioral and financial outcomes across UnitedHealth Group’s Optum and UnitedHealthcare ecosystems, reinforcing the company’s push toward value‑based, whole‑person care and cost containment.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies, particularly in quantitative claims. According to the ground truth, in 2022 Optum Rx managed $112 billion in pharmaceutical spending, including $45 billion in specialty pharmaceuticals. However, the LLM falsely claims that by 2024, Optum Rx managed $178 billion in spending (including $74 billion in specialty), which is not supported by the original answer—no spending figures were provided for 2024. These invented numbers severely undermine factual correctness. (2) The quantitative accuracy is very low because the LLM fabricates precise figures for 2024 that do not appear in the source. There is no indication in the ground truth that spending increased to $178B or that specialty spending rose to $74B; thus, these values are incorrect. (3) Qualitatively, the LLM captures some correct directional trends: Optum Rx is increasingly integrated into a broader, data-driven, value-based care model within UnitedHealth Group, with emphasis on analytics, cost containment, and whole-person care. Mentions of infusion therapy, specialty services, and multidisciplinary teams align broadly with the 2022 description, though the 2024 evolution is overstated. The reasoning implies a level of growth and service expansion not confirmed in the ground truth. (4) Contextually, the answer is relevant and addresses the evolution of Optum Rx’s role and strategic positioning. It correctly identifies integration with UnitedHealthcare and Optum ecosystems and emphasizes data, affordability, and care coordination—consistent with the 2024 strategic vision. However, the inclusion of fabricated metrics undermines overall correctness. While the narrative flow and structure are strong, the invention of specific financial figures results in a low correctness score despite some accurate qualitative insights.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1496,
        "completion_tokens": 501,
        "total_tokens": 1997
      },
      "error": null
    },
    {
      "question_id": 138,
      "question": "How did the composition and valuation of BlackRock's Equity Securities at FVTNI change between 2023 and 2024, particularly in terms of investments held for deferred cash compensation plans?",
      "original_answer": "In 2023, BlackRock reported $9 million invested in Equity Securities at FVTNI as part of the investments held to economically hedge deferred cash compensation plans. By 2024, this specific category was no longer listed under Equity Securities at FVTNI but instead appeared under 'Investments related to deferred cash compensation plans' within the Equity Method section with a value of $173 million. This indicates a reclassification or realignment of how these investments were categorized and reported in the financial statements, reflecting a significant change in the composition of Equity Securities at FVTNI.",
      "llm_answer": "\nBetween 2023 and 2024 the fair‑value of BlackRock’s Equity Securities at FVTNI climbed from **$1.585 bn to $1.950 bn**, an increase of roughly **$365 m**, largely reflecting higher market values of its mutual‑fund holdings.  At the same time, the portion of the portfolio used to economically hedge deferred‑cash‑compensation liabilities shrank from **$241 m (2023) to $173 m (2024)**, indicating a reduced exposure to those compensation‑related investments while the overall equity‑security portfolio expanded.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023, BlackRock reported only $9 million (not $241 million) in Equity Securities at FVTNI related to deferred cash compensation plans. The LLM incorrectly states that the compensation-related portion decreased from $241 million to $173 million, which contradicts the original answer. Additionally, the LLM introduces aggregate figures for total Equity Securities at FVTNI ($1.585 bn in 2023 and $1.950 bn in 2024) that are not present in the ground truth and are therefore unsupported. (2) The quantitative values are largely incorrect: the key number for 2023 compensation-related investments is off by over 2,500% ($9M vs $241M). The $173 million figure for 2024 is correct but misinterpreted, as it is no longer classified under FVTNI but under Equity Method investments. The LLM fails to note the reclassification, instead implying a simple reduction in exposure within the same category. (3) The multi-hop reasoning is flawed. The original answer highlights a reclassification in reporting—moving from FVTNI to Equity Method—which indicates a change in accounting treatment or presentation. The LLM misses this entirely and instead frames the change as a mere reduction in investment size within the same category, which misrepresents the nature of the change. (4) While the LLM attempts to address the question’s focus on changes in composition and valuation, it does so with incorrect data and reasoning. The contextual relevance is moderate because it discusses the right topic (deferred compensation investments and FVTNI), but the factual and conceptual errors severely undermine accuracy. Correctness score is low due to major factual and interpretive errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 483,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 138,
      "question": "How has the aggregate available authorization for Accenture's open-market share purchase program changed between 2022 and 2024, and what does this indicate about the company's capital allocation strategy?",
      "original_answer": "The aggregate available authorization for Accenture's open-market share purchase program decreased from $3,129,296 in 2022 to $2,694,281 in 2024. This indicates a reduction in the company's capital allocated for share repurchases over this period, suggesting a more conservative approach to capital deployment or a strategic shift in how the company is managing its equity structure.",
      "llm_answer": "\nThe open‑market share‑purchase authorization fell from **$3.13 billion as of August 31 2022** to **$2.69 billion as of August 31 2024**, a reduction of roughly **$0.44 billion (≈14 %)**.  This pull‑back in the authorized repurchase amount indicates that Accenture is scaling back its discretionary share‑buying program and is likely reallocating cash toward other priorities—such as dividend increases, strategic investments, or maintaining greater liquidity—reflecting a more conservative capital‑allocation stance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the decrease in aggregate available authorization from $3.13 billion in 2022 to $2.69 billion in 2024, which aligns with the ground truth values of $3,129,296 and $2,694,281 (rounded appropriately to billions). The calculated reduction of $0.44 billion (~14%) is accurate: $3.129B - $2.694B = $0.435B, which rounds to $0.44B, and (0.435 / 3.129) ≈ 13.9%, correctly stated as ~14%. (2) All numeric values, dates (August 31, 2022 and August 31, 2024), and calculations are factually correct and match the ground truth within acceptable rounding. Format variations ($3.13 billion vs $3,129,296) are acceptable and common in financial reporting. (3) The multi-hop reasoning is sound: the model correctly infers that a reduction in share repurchase authorization indicates a strategic shift in capital allocation, such as prioritizing dividends, investments, or liquidity, which is consistent with the ground truth interpretation of a more conservative capital-deployment approach. (4) The answer is semantically equivalent to the original, with slightly more detailed interpretation (e.g., suggesting possible reallocation targets), but does not introduce inaccuracies. The only minor point preventing a perfect 10 is that the ground truth emphasizes 'reduction in capital allocated for share repurchases,' while the LLM focuses on 'scaling back discretionary buying,' which is slightly interpretive but still reasonable. Thus, all scores are high, with correctness at 9 due to slight interpretive expansion without overreach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 431,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How has the treatment and disclosure around Accenture Canada Holdings Inc. Exchangeable Shares evolved between 2022 and 2024, particularly in terms of share repurchase activity and shareholder rights?",
      "original_answer": "In 2022, Accenture disclosed its intention to use a significant portion of cash generated from operations for share repurchases during fiscal 2023, including purchases and redemptions of Accenture Canada Holdings Inc. exchangeable shares. The company noted that the number of shares repurchased would depend on various factors such as share price and market conditions. By 2024, the disclosures had evolved to include more detailed descriptions of the rights associated with Accenture Canada Holdings Inc. exchangeable shares, particularly their exchangeability on a one-for-one basis for Accenture plc Class A ordinary shares, and the company's commitment to align the number of Class X ordinary shares with outstanding exchangeable shares. Additionally, as of August 31, 2024, the company had a specific remaining authorization of $2,694,281 for share repurchase programs, indicating a more structured and quantified approach compared to the more general intentions expressed in 2022.",
      "llm_answer": "\nThe 2022 filing only disclosed that Accenture Canada Holdings Inc. exchangeable shares were redeemable at par, carried no dividend rights, and could be exchanged one‑for‑one for Class A ordinary shares, with a redemption restriction that would not reduce a holder’s exchangeable‑share balance. In the 2024 filing the company quantifies this activity—47,752 exchangeable shares were repurchased for $15,254 in fiscal 2024—and adds a $4 billion increase to its share‑repurchase authority (raising total authority to $6.694 billion), explicitly stating that exchangeable shares are eligible for the open‑market purchase program and may be exchanged at market price, thereby clarifying that holders receive the same distribution and redemption rights as Class A shareholders.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several significant factual inaccuracies that undermine its correctness. (1) Quantitative Accuracy: The claim that '47,752 exchangeable shares were repurchased for $15,254 in fiscal 2024' is not supported by the ground truth, which does not provide specific repurchase volumes or dollar amounts for exchangeable shares in 2024—only a remaining authorization of $2,694,281 for the overall share repurchase program as of August 31, 2024. The LLM incorrectly presents specific transaction data absent from the original answer. Additionally, the statement about a '$4 billion increase' raising 'total authority to $6.694 billion' is unsupported; the ground truth only mentions a remaining authorization of $2.694 billion, not a total of $6.694 billion. These numerical claims are fabricated or misstated. (2) Completeness: While the answer touches on shareholder rights (e.g., one-for-one exchangeability), it omits the evolution from general intent in 2022 to structured, quantified disclosure in 2024—the core of the original answer. It also fails to mention that in 2022, Accenture disclosed intentions for repurchases in fiscal 2023, which is a key part of the timeline. (3) Entity Accuracy: The company name and share types (exchangeable shares, Class A ordinary shares) are correctly identified. However, the fiscal year reference to '2024' in the context of repurchase activity is ambiguous and potentially misleading, as the ground truth refers to disclosures as of August 31, 2024, not fiscal 2024 activity. (4) Reasoning: The multi-hop synthesis is partially sound—comparing 2022 and 2024 disclosures on rights and repurchase programs—but the reasoning is undermined by invented numbers. The conclusion about equal rights is plausible but not explicitly confirmed in the ground truth. (5) Semantic Equivalence: The overall thrust of increased disclosure clarity in 2024 is present, but the inclusion of false quantitative details severely compromises factual equivalence. The answer appears more specific but is less accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1453,
        "completion_tokens": 550,
        "total_tokens": 2003
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How did the global revenue from Electrophysiology Devices evolve between 2023 and 2024, and what was the percentage change in this revenue, excluding the impact of foreign exchange fluctuations?",
      "original_answer": "In 2023, the global revenue from Electrophysiology Devices was $2,195 million, which increased to $2,467 million in 2024. This represents a total change of 12.3%, with the change excluding the impact of foreign exchange fluctuations being 14.4%.",
      "llm_answer": "\nThe Electrophysiology segment’s sales rose from **$2,195 million in 2023 to $2,467 million in 2024**.  This corresponds to a **12.3 % increase** in total change, and a **14.4 % increase** when the effect of foreign‑exchange fluctuations is excluded.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: 2023 revenue is correctly stated as $2,195 million, 2024 revenue as $2,467 million, total percentage change as 12.3%, and the foreign exchange-excluded change as 14.4%. The calculations are correct: (2,467 - 2,195) / 2,195 ≈ 12.3%, and the organic growth of 14.4% is properly reported. (2) The answer is complete, addressing both parts of the question: the revenue evolution between 2023 and 2024 and the percentage change excluding foreign exchange impact. (3) Entity accuracy is perfect: the segment 'Electrophysiology Devices' is correctly identified, and the years 2023 and 2024 are accurately referenced. (4) The reasoning is sound and reflects proper multi-hop synthesis—revenue figures from two years are compared, and both reported and organic growth rates are correctly attributed. (5) The semantic meaning is equivalent to the original answer, with clear, concise restatement using bold formatting for emphasis but without altering factual content. All evaluation criteria are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1135,
        "completion_tokens": 318,
        "total_tokens": 1454
      },
      "error": null
    },
    {
      "question_id": 140,
      "question": "How has Accenture's financial relationship with Duck Creek Technologies evolved between fiscal 2022 and fiscal 2024, particularly in terms of investment valuation and its impact on financial performance?",
      "original_answer": "In fiscal 2022, Accenture's investment in Duck Creek Technologies was valued at $223,166 (approximately 16% ownership), with the investment accounted for under the equity method. By fiscal 2024, this investment resulted in a $253 million gain, indicating a significant increase in value and a shift in how the investment contributed to Accenture's financial performance. This demonstrates both a quantitative increase in the investment's value and a qualitative change in its impact on Accenture's earnings.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Accenture’s stake in Duck Creek Technologies remained an equity‑method investment, but its valuation rose sharply.  In the 2022 10‑K the investment was carried at **$138.9 million** with an estimated fair value of **$223.2 million**; by fiscal 2023 the company recorded a **$253 million gain** from that investment, reflecting a substantial increase in fair value that was included in adjusted earnings per share and lifted reported earnings, though it did not affect operating margin or core consulting performance.  Thus, the investment’s appreciation provided a one‑time boost to reported earnings and EPS in fiscal 2023, but its impact on Accenture’s ongoing financial results was limited to that non‑operating gain.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in the quantitative details. The original answer states that Accenture's investment in Duck Creek Technologies was valued at $223,166 in fiscal 2022 (approximately 16% ownership), accounted for under the equity method. However, the LLM claims the investment was carried at $138.9 million with a fair value of $223.2 million in 2022, which contradicts the ground truth. The $223.2 million figure appears to be a misinterpretation—possibly confusing carrying value with fair value or misreading the unit (thousands vs. dollars). The $253 million gain is correctly cited but attributed to fiscal 2023 in the LLM answer, while the original answer specifies fiscal 2024. This one-year discrepancy in timing is significant for financial accuracy. (2) Calculations: While the $253 million gain is correctly mentioned, the LLM implies it occurred in fiscal 2023, which misaligns with the ground truth (fiscal 2024). Additionally, the breakdown of carrying vs. fair value is not present in the original answer and appears to be fabricated or misattributed. (3) Multi-hop reasoning: The LLM correctly identifies the investment as equity-method and recognizes that the gain impacted earnings, showing understanding of accounting treatment and financial statement impact. It also correctly notes that the gain was non-operating and did not affect operating margin—adding contextual insight beyond the original answer. However, it fails to mention the 16% ownership stake, a key detail in the original. (4) Despite these errors, the LLM captures the core narrative of a significant valuation increase and its positive impact on financial performance, particularly in reported earnings and EPS. The reasoning about limited ongoing impact is reasonable and contextually sound. Thus, while the qualitative and contextual understanding is strong, the quantitative inaccuracies—especially the incorrect valuation figures and misdated gain—reduce overall correctness. The answer is partially correct but contains significant factual flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 564,
        "total_tokens": 1894
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has the composition and scale of Union Pacific's retention share and unit awards changed between 2022 and 2023, and what does this indicate about the company's executive compensation strategy?",
      "original_answer": "In 2022, Union Pacific disclosed that 389,207 retention shares were outstanding under the 2021 Stock Incentive Plan as of December 31, 2021. By 2023, the company disclosed that 954,405 retention shares had been issued and were outstanding, along with 366,046 retention units that do not have an exercise price. This represents a significant increase in the number of outstanding retention instruments, indicating a shift toward greater use of retention-based compensation. The introduction of retention units in 2023 suggests a possible expansion or refinement of the company's long-term incentive strategy for executives.",
      "llm_answer": "\nBetween 2022 and 2023 the composition of Union Pacific’s executive equity awards moved away from a large pool of traditional, time‑vesting retention shares toward a smaller, performance‑focused set of retention units and already‑issued shares.  The 2022 filing showed roughly 1.3 million unvested retention shares (with $87 million of unrecognized compensation to be recognized over ~1.4 years), whereas the 2023 proxy lists only about 366,000 unvested retention units (no exercise price) and 954,000 retention shares that have already been issued, with a much larger remaining pool of ≈ 32 million shares available for future grants.  This shift indicates that the company is tightening its executive compensation program by emphasizing performance‑linked equity awards and reducing the amount of future dilution‑ary equity that can be granted.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that 389,207 retention shares were outstanding as of December 31, 2021 (reported in the 2022 filing), not 1.3 million unvested shares in 2022. The 2023 data correctly notes 954,405 retention shares and 366,046 retention units, which the LLM approximates as 954,000 and 366,000—this part is acceptably close. However, the LLM incorrectly claims that the 2022 filing showed 1.3 million unvested retention shares and $87 million in unrecognized compensation over 1.4 years—this data is not in the ground truth and appears fabricated or misattributed. (2) The calculation and comparison of numbers are flawed: there is no support for a reduction in retention instruments; in fact, the ground truth shows a significant increase from ~389k to over 954k shares, contradicting the LLM’s claim of a move to a 'smaller' set. The mention of a 'remaining pool of ≈32 million shares' is not addressed in the ground truth and introduces unsupported context. (3) The multi-hop reasoning is partially sound in that the LLM attempts to compare 2022 and 2023 disclosures and infer strategic intent, but the conclusion—that the company is reducing future dilution and tightening compensation—is contradicted by the actual increase in retention instruments. The introduction of retention units in 2023 is correctly interpreted as a strategic refinement, but the overall direction of change is misrepresented. (4) The contextual relevance is high because the answer addresses composition, scale, and strategic implications, but the correctness score is low due to major quantitative errors and a misleading interpretation stemming from incorrect data. The qualitative accuracy is moderate because the framework of analysis is reasonable, but the entities and numbers are often wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 514,
        "total_tokens": 1893
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has MetLife's application of GAAP guidance for adjusted earnings evolved between 2023 and 2024, particularly in terms of the exclusions related to market volatility and asymmetrical accounting adjustments?",
      "original_answer": "In 2023, MetLife updated its calculation of adjusted earnings due to the adoption of LDTI, which led to the exclusion of certain adjustments related to the amortization of DAC, VOBA, and related intangibles, as well as changes in measurement of certain guarantees. Adjusted earnings excluded changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance. By 2024, MetLife continued to refine these exclusions, particularly expanding the scope of policyholder liability remeasurement gains (losses) to exclude asymmetrical accounting associated with in-force reinsurance. Additionally, in 2024, net investment income exclusions were expanded to include adjustments relating to joint ventures under the equity method, which was not explicitly mentioned in 2023. This reflects a more detailed and structured application of GAAP guidance over time.",
      "llm_answer": "\nBetween 2023 and 2024 MetLife kept the same overall principle—adjusted earnings is GAAP‑defined earnings that excludes market‑volatility items and asymmetrical/non‑economic accounting—but the 2024 guidance sharpened those carve‑outs.  The 2024 filing adds explicit exclusions for the amortization of basis adjustments on de‑designated fair‑value hedges and for inflation‑indexed benefit adjustments, and it clarifies that asymmetrical accounting related to in‑force reinsurance is removed from both other revenues and policyholder benefits, whereas the 2023 description only mentioned “asymmetrical accounting” in the aggregate.  Consequently, the market‑volatility exclusions (net investment gains/losses, derivative gains/losses, MRB remeasurements, goodwill impairments, discount‑rate changes on annuitization guarantees, etc.) remain, but they are now tied to the specific line‑items where those adjustments arise.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general direction of MetLife's evolution in adjusted earnings exclusions between 2023 and 2024, particularly around asymmetrical accounting and market volatility, which aligns with the question's focus. However, there are significant factual discrepancies in the details. The ground truth states that in 2023, MetLife updated its adjusted earnings due to LDTI adoption, excluding DAC/VOBA amortization and certain guarantee measurements, and specifically excluding MRB fair value changes, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance. By 2024, exclusions were expanded to include policyholder liability remeasurement gains/losses related to in-force reinsurance and equity method adjustments in joint ventures. The LLM answer incorrectly introduces exclusions not mentioned in the ground truth—specifically 'amortization of basis adjustments on de-designated fair-value hedges' and 'inflation-indexed benefit adjustments'—which are not part of the documented evolution. Additionally, while the LLM correctly notes a refinement in how asymmetrical accounting is applied across line items in 2024, it fails to mention the key 2024 expansion to joint ventures under the equity method, a critical new exclusion. The dates (2023 vs 2024) and entities (MetLife, GAAP, adjusted earnings) are correct, and the overall theme of increasing specificity in exclusions is reasonably conveyed. Quantitative accuracy is high because there are no numerical errors per se (the answer avoids specific numbers), but the qualitative accuracy suffers due to incorrect exclusions and missing key ones. Contextual relevance is strong as the response stays on topic and addresses the evolution of GAAP guidance application. However, the incorrect additions and omissions prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1478,
        "completion_tokens": 500,
        "total_tokens": 1978
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has Accenture's approach to achieving compressed transformations evolved from 2022 to 2024, particularly in terms of the technologies leveraged and the scope of transformation services offered?",
      "original_answer": "In 2022, Accenture focused on using technologies like digital twins, AI, IoT, cloud/Edge, 5G, advanced robotics, and metaverse to help clients achieve compressed transformations by redefining product design, engineering, sourcing, manufacturing, and servicing. By 2024, the company expanded its technological toolkit to include generative AI, artificial reality / virtual reality, and advanced robotics, while also enhancing its own development of automation equipment and commercial hardware to support client operations. Additionally, the scope of transformation broadened to include digitally transforming capital projects such as plant and asset construction, public infrastructure, power grids, and data centers. This reflects a more integrated and advanced technological approach to compressed transformations over the two-year period.",
      "llm_answer": "\nFrom 2022 to 2024 Accenture shifted from a general push to build digital cores, automate processes and apply AI across the enterprise toward a more industry‑specific model that embeds AI, generative AI, digital‑twin, edge/5G and advanced‑robotics technologies directly into product design, engineering and manufacturing.  This evolution adds an explicit “compressed transformation” offering—combining strategy, technology and operations—to re‑engineer how products are created and delivered, while expanding the technology stack to include quantum, space and metaverse capabilities and deepening ecosystem partnerships.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of Accenture's approach to compressed transformations and correctly identifies several key technologies used in both years, such as AI, generative AI, digital twins, 5G/edge, and advanced robotics. It also correctly notes a shift toward deeper integration of technology into product design and manufacturing, which aligns with the ground truth. However, there are significant factual discrepancies: (1) The claim that Accenture added 'quantum, space and metaverse capabilities' by 2024 is not supported by the original answer—while metaverse was mentioned in 2022, there is no mention of quantum or space technologies in the ground truth. (2) The original answer specifies that Accenture expanded into transforming capital projects (e.g., plant construction, power grids, data centers), which the LLM answer omits entirely. (3) The LLM incorrectly frames the 2022 strategy as a 'general push to build digital cores' and 'apply AI across the enterprise,' which mischaracterizes the original focus on redefining product lifecycle functions using specific technologies. (4) The LLM mentions 'deepening ecosystem partnerships,' which is not present in the ground truth. While the answer gets the direction of evolution correct (more integrated, advanced tech), it introduces unsupported technologies and misses key expansions in service scope. Quantitative accuracy receives full marks because there are no numerical claims to evaluate. Contextual relevance is high as the response stays on topic and attempts multi-hop synthesis. Qualitative accuracy is reduced due to incorrect entity inclusion and omission of critical scope expansion details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 458,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How did Abbott's use of interest rate hedge contracts evolve between 2023 and 2024 in managing exposure to changes in the fair value of fixed-rate debt?",
      "original_answer": "In 2023, Abbott had interest rate hedge contracts totaling approximately $2.2 billion at December 31, 2023, to manage exposure to changes in the fair value of fixed-rate debt due to long-term benchmark interest rate fluctuations. These contracts were designated as fair value hedges, effectively converting fixed-rate debt to variable-rate debt. In 2024, Abbott continued to maintain interest rate hedge contracts with notional values totaling $2.2 billion, indicating a consistent strategy in hedging interest rate risk. However, the average interest rate on long-term debt increased from 3.6% in 2023 to 3.8% in 2024, suggesting a shift in the underlying debt structure or market interest rate conditions despite the stable hedge notional amount.",
      "llm_answer": "\nBetween 2023 and 2024 the size of Abbott’s fair‑value interest‑rate hedge program fell modestly – the notional amount of outstanding swaps dropped from roughly **$2.9 billion in 2022 to about $2.2 billion in 2023** and stayed essentially at that level in 2024 after the $700 million of contracts that matured in 2023 were not fully replaced.  The company continues to designate these swaps as fair‑value hedges of fixed‑rate debt, marks them to market each period, and offsets the resulting gains or losses by adjusting the carrying amount of the hedged debt, thereby managing its exposure to movements in long‑term benchmark interest rates.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. While it correctly states that Abbott maintained $2.2 billion in interest rate hedge contracts in 2023 and 2024, it incorrectly introduces a $2.9 billion figure for 2022, which is not mentioned in the original answer and is irrelevant to the question about 2023–2024 evolution. This misrepresents the trend by implying a decline from $2.9B to $2.2B, when the ground truth indicates stability at $2.2B between 2023 and 2024. Additionally, the claim that $700 million of contracts matured in 2023 and were not fully replaced is unsupported by the original answer and introduces speculative reasoning. (2) The only correct quantitative elements are the $2.2 billion notional amount in 2023 and 2024. However, the LLM fails to mention the key fact from the original answer that the average interest rate on long-term debt increased from 3.6% in 2023 to 3.8% in 2024—a critical data point showing a shift in debt or market conditions despite stable hedges. This omission undermines the completeness and accuracy of the response. (3) The qualitative reasoning is partially sound: the LLM correctly identifies that Abbott uses fair value hedges to convert fixed-rate debt to variable-rate debt and that gains/losses are offset by adjusting the carrying amount of debt. However, it fails to synthesize the key insight from the original answer—that the stable hedge notional amount combined with rising average interest rates suggests a change in underlying debt structure or market conditions. This multi-hop inference is missing. (4) The answer is contextually relevant, addressing Abbott’s use of interest rate hedges and their role in managing fair value exposure. But due to major quantitative errors and missing key comparative data (the interest rate increase), the overall correctness score is low. Minor wording differences would be acceptable, but fabricated numbers and omitted core facts reduce accuracy significantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 542,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 142,
      "question": "How has MetLife's treatment and definition of Adjusted Earnings evolved between 2023 and 2024, particularly in relation to GAAP guidance and segment performance measurement?",
      "original_answer": "In 2023, MetLife updated its calculation of Adjusted Earnings due to the adoption of LDTI, removing certain adjustments related to the amortization of DAC, VOBA, and related intangibles, and instead adjusted for changes in measurement of certain guarantees. Adjusted Earnings in 2023 excluded changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance. By 2024, Adjusted Earnings remained the GAAP measure of segment performance, but the exclusions were more clearly delineated to include market volatility impacts, asymmetrical and non-economic accounting adjustments, revenues and costs from divested businesses, and results from discontinued operations. Specifically, 2024 Adjusted Earnings excluded net investment gains/losses, derivative gains/losses, MRB remeasurement gains/losses, and goodwill impairments, with more structured exclusions such as inflation-indexed benefit adjustments and non-economic losses from single premium annuity contracts. This represents a refinement and expansion of the exclusions introduced in 2023.",
      "llm_answer": "\nBetween 2023 and 2024 MetLife refined its Adjusted‑Earnings definition to make it the **GAAP‑compliant measure of segment performance** that the CODM uses to evaluate results and to set compensation.  The 2023 description focused on “adjusted revenues less adjusted expenses (net of tax)” and removed LDTI‑related amortization of DAC/VOBA, but the 2024 filing expands the exclusions to **market‑volatility items, asymmetrical/non‑economic accounting, divested or discontinued‑operation results, and related GAAP adjustments**, while still excluding preferred‑stock dividends and certain contingent‑liability impacts.  In short, the metric’s purpose and exclusions were broadened and formalized to align with GAAP segment‑reporting guidance.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in MetLife's Adjusted Earnings definition between 2023 and 2024. It correctly identifies the 2023 change due to LDTI adoption, specifically the removal of DAC/VOBA amortization adjustments, which aligns with the ground truth. It also accurately notes that in 2024, Adjusted Earnings remained the GAAP measure for segment performance and that exclusions were broadened to include market volatility, asymmetrical/non-economic accounting, and results from divested or discontinued operations. The mention of continued exclusion of preferred stock dividends and contingent liabilities is consistent with the direction of the original answer, though these specific items are not emphasized in the ground truth. The LLM correctly conveys that the 2024 definition represents a refinement and formalization of the 2023 changes. However, it omits specific 2024 exclusions mentioned in the ground truth such as net investment gains/losses, derivative gains/losses, MRB remeasurement, goodwill impairments, inflation-indexed benefit adjustments, and non-economic losses from single premium annuity contracts. While it generalizes these under 'market-volatility items' and 'GAAP adjustments', the lack of specificity on key excluded items reduces completeness. There are no numerical inaccuracies (quantitative accuracy is perfect as no incorrect numbers are presented), and the reasoning is sound in capturing the multi-hop progression from LDTI impact in 2023 to structured exclusions in 2024. The answer is highly relevant to the question and synthesizes the evolution well, just missing some granular detail from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1473,
        "completion_tokens": 458,
        "total_tokens": 1932
      },
      "error": null
    },
    {
      "question_id": 142,
      "question": "How has the funding and utilization of Accenture's share purchase program evolved from 2022 to 2024, particularly in terms of available authorization and share acquisition methods?",
      "original_answer": "In 2022, Accenture reported an aggregate available authorization of $3,129,296 for its publicly announced open-market share purchase program and other related share purchase programs. This included acquisitions of Accenture plc Class A ordinary shares and Accenture Canada Holdings Inc. exchangeable shares held by current and former members of Accenture Leadership. By 2024, the company clarified that its open-market share purchase program applied specifically to Accenture plc Class A ordinary shares, which were held as treasury shares for employee benefits, such as equity awards. Additionally, in fiscal 2024, Accenture acquired Class A ordinary shares primarily through share withholding for payroll tax obligations tied to employee equity plans. These purchases did not impact the aggregate available authorization for the public share purchase programs, indicating a shift in acquisition methods while maintaining a focus on funding levels.",
      "llm_answer": "\nFrom fiscal 2022 to fiscal 2024 Accenture’s board cut the total authorization for its share‑purchase programs from **$3.13 billion (as of 31 Aug 2022)** to **$2.69 billion (as of 31 Aug 2024)**.  However, the company actually spent more on repurchases—**$4.11 billion in FY 2022 versus $4.51 billion in FY 2024**—driven primarily by larger open‑market purchases (≈11.8 M shares in FY 2024 vs. 9.6 M shares in FY 2022) and modest activity in the other approved programs (e.g., redemptions of Class A and exchangeable shares held by leadership).  The additional shares acquired in FY 2024 also included purchases under employee‑share‑withholding plans, which do not draw on the publicly announced authorization.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) QUANTITATIVE INACCURACY: The ground truth states that in 2022, the aggregate available authorization was $3,129,296 (~$3.13 million, not billion), but the LLM incorrectly reports it as $3.13 billion—off by a factor of 1,000. Similarly, the LLM claims a reduction to $2.69 billion in 2024, which is not supported by the original answer; the ground truth does not specify a new authorization amount for 2024, only that the program continued with a clarified focus. The LLM also fabricates spending figures: $4.11B in FY2022 and $4.51B in FY2024 are orders of magnitude higher than any figure implied in the original answer and are entirely unsupported. Share purchase volumes (9.6M and 11.8M shares) are also invented. (2) COMPLETENESS: While the LLM correctly identifies share withholding for payroll taxes as a method not impacting public authorization, it misrepresents the evolution of funding and overemphasizes open-market purchases, which contradicts the ground truth indicating a shift *away* from public programs toward employee-related withholding. (3) ENTITY & REASONING: The core reasoning is flawed—instead of showing a shift in acquisition methods with stable funding levels, the LLM suggests increased spending and reduced authorization, which misrepresents the trend. It fails to mention that in 2024, the program was specifically clarified to apply only to Accenture plc Class A shares held as treasury for employee benefits, a key qualitative shift. (4) SEMANTIC EQUIVALENCE: Despite mentioning correct concepts (e.g., share withholding not affecting authorization), the overwhelming numerical errors and incorrect narrative about spending and authorization changes make the answer misleading. Minor contextual elements are relevant, but factual foundation is unsound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 505,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 143,
      "question": "How did MetLife's treatment and valuation methodology for Unit-linked Securities evolve from 2023 to 2024, particularly in terms of cost basis and fair value sensitivity?",
      "original_answer": "In 2023, MetLife described the cost basis for Unit-linked and FVO securities as primarily equity and fixed maturity securities, with cost representing original cost for equities and amortized cost for fixed maturities. By 2024, Unit-linked securities were included in Level 3 fair value measurements and subjected to valuation techniques involving significant unobservable inputs such as mortality rates, lapse rates, and equity volatility. Additionally, the 2024 disclosures emphasized sensitivity of fair value to changes in these inputs, indicating a more dynamic and assumption-driven valuation approach compared to the more static cost-based method described in 2023.",
      "llm_answer": "\nFrom 2023 to 2024 MetLife continued to carry Unit‑linked and FVO securities at estimated fair value rather than amortized cost, but the way it reports the drivers of that fair value changed.  The 2024 roll‑forward (page 252) separates the impact of each Level‑3 input—mortality, lapse, utilization, withdrawal, equity‑volatility and non‑performance risk—into explicit “increase in estimated fair value” figures, whereas the 2023 tables (page 321) only disclosed total gains/(losses) in net income and AOCI without a granular sensitivity matrix.  Consequently, while the cost‑basis definition (original cost reduced by premium/discount amortization) remained the same, the 2024 disclosure adds a more detailed quantitative sensitivity analysis that shows how each unobservable input moves the fair‑value balance (e.g., a $1 million rise in equity volatility adds roughly $13 million to net‑income‑related gains).",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the evolution in MetLife's valuation methodology for Unit-linked Securities from 2023 to 2024, emphasizing the shift toward more granular, assumption-driven fair value disclosures involving Level 3 inputs. It accurately identifies that fair value treatment continued, but the 2024 disclosures introduced a more detailed sensitivity analysis of unobservable inputs (e.g., mortality, lapse, equity volatility), which aligns with the ground truth. The qualitative reasoning is strong: it correctly notes the move from aggregated gains/losses in 2023 to a breakdown by input in 2024, reflecting improved transparency and a more dynamic valuation approach. However, there are minor quantitative inaccuracies. The LLM claims 'a $1 million rise in equity volatility adds roughly $13 million to net-income-related gains,' which is not present in the original answer and lacks corroboration from the ground truth—this specific numerical example appears to be fabricated or misattributed. Additionally, while the original answer does not specify page numbers or exact dollar impacts, the LLM introduces precise page references (p. 252, p. 321) and a quantitative sensitivity figure not found in the ground truth, which risks overprecision. These additions, while plausible, introduce unverified details that affect quantitative accuracy. The core entities (MetLife, Unit-linked Securities, 2023–2024 timeframe, Level 3 inputs) and multi-hop synthesis (comparing disclosure depth across years) are correct. The answer is highly relevant and conveys the essential evolution in methodology, meriting a high correctness score with a deduction for unsupported numerical claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 460,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 143,
      "question": "How has the structure and vesting timeline of market-based RSUs evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, market-based RSUs generally vested over four years and grantees could receive between 0% and 300% of the original grant based on total stockholder return (TSR) relative to an index group. By fiscal year 2023, while four-year vesting remained common, the company also introduced market-based RSUs that vested over five years, with vesting contingent on achieving stock price performance milestones. This indicates an expansion in the types of market-based RSUs offered, adding a new vesting structure based on specific stock price targets.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 the company broadened its market‑based RSU program.  In 2022 the awards were generally four‑year grants that vested only when the relative total‑stockholder‑return (TSR) condition was satisfied, with an expected term of about 3.4 years.  In 2023 the program added a new tranche of market‑based RSUs that are scheduled to vest over **five years** and are tied to specific stock‑price performance milestones, and the weighted‑average expected term rose to **4.8 years** (page 85).  This shift—larger grant volumes, a longer service‑plus‑performance horizon, and the inclusion of five‑year performance milestones—represents the evolution of the RSU structure and vesting timeline from FY 2022 to FY 2023 (pages 85‑86).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in FY 2022, market-based RSUs generally had a four-year vesting period tied to relative total stockholder return (TSR), with payout ranging from 0% to 300%—though the LLM does not explicitly mention the 0%-300% range, it correctly notes vesting was contingent on TSR conditions. (2) For FY 2023, the LLM accurately states the introduction of five-year market-based RSUs tied to stock price performance milestones, which matches the ground truth. It adds specific quantitative details—expected term rising to 4.8 years from 3.4 years—citing page 85, which are not in the original answer but are plausibly derived and do not contradict it. These numbers suggest deeper document insight and enhance precision. (3) The reasoning is sound: the LLM correctly synthesizes the evolution as an expansion in structure, noting longer timelines and new performance conditions. (4) Minor deduction in quantitative accuracy because the 0%-300% payout range is omitted, which is a key feature of the FY 2022 plan. However, the core structural evolution—four-year to five-year vesting and shift toward stock price milestones—is correctly identified and well-supported. The added detail about weighted-average expected term improves completeness but slightly exceeds the original scope without misrepresenting facts. Overall, the answer is factually correct, contextually relevant, and demonstrates strong multi-hop reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 415,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 145,
      "question": "How did the phase-in treatment of the CECL standard's ongoing impact on regulatory capital evolve between 2023 and 2024, and what specific regulatory capital treatment applied during the phase-in period?",
      "original_answer": "In 2023, the CECL Transition Election allowed for the cumulative 'day 2' ongoing impact to be phased into regulatory capital at 25% per year from January 1, 2022, through December 31, 2024. By 2024, this phase-in treatment remained consistent, with the ongoing impact continuing to be phased in at 25% annually, indicating that the regulatory capital treatment under the CECL Transition Rule was applied uniformly across both years as part of the multi-year transition framework.",
      "llm_answer": "\nBetween 2023 and 2024 the company progressed from having phased in 50 % of the $2.4 billion CECL‑transition add‑back (recorded as of 31 Dec 2023) to adding the next 25 % installment in 2024, so that ≈ 75 % of the total amount was now reflected in regulatory capital (the remaining 25 % will be phased in in 2025).  During this phase‑in period the firm was allowed to add back the “day‑1” CECL impact and the 25 %‑per‑year portion of the ongoing “day‑2” impact to its CET1, Tier 1 and total capital, which lifted its CET1 ratio to 13.5 % (13.3 % on a fully‑phased‑in basis) while still satisfying the minimum capital‑conservation buffer requirements.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and introduces unverified specifics not present in the ground truth. (1) Quantitative inaccuracy: The ground truth states the phase-in period was from January 1, 2022, through December 31, 2024, at 25% per year, meaning 100% completion by end of 2024. The LLM incorrectly claims that 75% was phased in by 2024 and 25% would be phased in in 2025, which contradicts the 2024 end date. It also introduces a specific dollar amount ($2.4 billion) and a CET1 ratio (13.5%) not mentioned or supported by the original answer. (2) Completeness: While the question asks about the evolution between 2023 and 2024 and the regulatory treatment, the LLM adds extraneous, unverified financial figures and misrepresents the timeline. (3) Entity accuracy: The answer refers to 'the company' and specific capital ratios without identifying any firm, suggesting a hallucinated context. The original answer is general and regulatory-focused, not firm-specific. (4) Reasoning: The multi-hop synthesis fails because the LLM assumes a post-2024 phase-in despite the rule ending in 2024, and conflates 'day-1' and 'day-2' impacts incorrectly—only the ongoing 'day-2' impact is phased in at 25% annually per the CECL Transition Election. The original specifies only the 'day-2' ongoing impact is phased in, not 'day-1'. (5) Semantic equivalence: The core regulatory framework (25% annual phase-in) is partially correct, but the incorrect extension to 2025 and fabricated metrics severely undermine factual alignment. The contextual relevance is moderate because it addresses phase-in treatment but drifts into unsupported specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 452,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 146,
      "question": "How has Broadcom's relationship with Wilmington Trust, National Association evolved between 2022 and 2023 in terms of the types and terms of senior notes issued under their indentures?",
      "original_answer": "In 2022, Broadcom had an ongoing relationship with Wilmington Trust, National Association as trustee under indentures governing senior notes issued in January 2021, which included notes with interest rates as low as 1.950% (due 2028) and as high as 3.750% (due 2051). By 2023, the relationship had evolved to include new indentures dated April 18, 2022, and July 12, 2024, under which Broadcom issued higher-yielding senior notes, including a 4.926% note due 2037 and later, in October 2024, notes ranging from 4.150% (due 2028) to 4.800% (due 2034). This reflects a shift toward issuing longer-term debt with higher interest rates over time.",
      "llm_answer": "\nBetween 2022 and 2023 Broadcom moved from a single 2022 indenture (dated April 18 2022) that governed the issuance of a 4.926 % senior note due 2037 and a 4.15 % senior note due 2032, to a supplemental indenture (dated July 12 2024 but reflecting 2023 issuances) that added multiple new tranches—5.05 % to 5.15 % coupons with maturities spanning 2027 through 2034—still under Wilmington Trust, National Association as trustee. This expansion introduced higher‑coupon, longer‑dated senior notes while retaining the same trustee relationship.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that the April 18, 2022 indenture was a '2022 indenture' governing notes issued in 2022, but the original answer clarifies that the relationship in 2022 was based on senior notes issued in January 2021, not 2022. The LLM also misrepresents the 2023 evolution by citing a July 12, 2024 supplemental indenture as reflecting 2023 issuances, which contradicts the timeline—July 12, 2024 is a future date relative to 2023 and cannot reflect 2023 activity. (2) Quantitative inaccuracies include: claiming a 4.15% note due 2032 (ground truth states 4.150% due 2028), inventing coupons of 5.05% to 5.15% not present in the original, and misstating maturities (2027–2034 range not supported). The original mentions a 4.800% note due 2034, but not in a 5.05–5.15% range. (3) Multi-hop reasoning is flawed: the LLM fails to correctly trace the evolution from pre-existing 2021 notes (carried into 2022) to new 2022/2024 indentures with higher yields. It incorrectly frames the April 18, 2022 indenture as the starting point in 2022, omitting the January 2021 notes that were still active. It also fabricates a 'supplemental indenture' in 2024 as part of 2023 developments, which distorts the chronological and contractual evolution. (4) While the general theme of issuing higher-yielding, longer-term debt under the same trustee is partially aligned, the specific facts, dates, rates, and reasoning are largely incorrect, leading to a low correctness score. Contextual relevance is moderate because the answer addresses the right entities (Broadcom, Wilmington Trust, senior notes, indentures) and attempts to describe an evolution in terms, but the factual foundation is unsound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 479,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How did Capital One's regulatory capital add-back under the CECL Transition Rule evolve from 2023 to 2024, and what was the specific phase-in progression during this period?",
      "original_answer": "In 2023, Capital One had already added back $2.4 billion to its regulatory capital under the CECL Transition Rule, with a phase-in of 50% as of January 1, 2023. By January 1, 2024, the phase-in had progressed to 75%, indicating a 25 percentage point increase over the year. This reflects the structured five-year phase-in process under the CECL Transition Rule, where 25% of the cumulative impact was phased in annually after 2021.",
      "llm_answer": "\nFrom 2023 to 2024 the Company’s CECL‑Transition add‑back grew as the five‑year phase‑in moved forward: in 2023 it was adding back ≈ 50 % of the cumulative “day‑2” CECL impact (the 25 %‑per‑year increment that began in 2022), and by the end of 2024 that share had risen to ≈ 75 % of the cumulative day‑2 impact, bringing the total regulatory‑capital add‑back closer to its full, “fully‑phased‑in” level expected in 2025.  This incremental increase is reflected in the 2024 CET1 ratio of 13.5 % (including the partial CECL add‑back) versus 13.3 % on a fully‑phased‑in basis.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the correct evolution of Capital One's regulatory capital add-back under the CECL Transition Rule from 2023 to 2024. It correctly identifies that the phase-in increased from approximately 50% at the beginning of 2023 to 75% by the end of 2024, aligning with the ground truth's specification of a 25 percentage point increase over the year (from 50% to 75%) under the five-year phase-in schedule. The dollar amount of $2.4 billion mentioned in the ground truth is not explicitly stated in the LLM answer, which is a minor omission affecting completeness but not overall correctness, as the percentage-based progression is accurately described. The reference to the CET1 ratios (13.5% vs 13.3%) adds contextual detail consistent with regulatory reporting practices and supports the explanation of partial versus full phase-in, though these specific ratios are not part of the original question or ground truth and do not detract from accuracy. The reasoning correctly reflects the annual 25% incremental phase-in starting in 2022, culminating in full phase-in by 2025. All entities (CECL Transition Rule, phase-in progression, time periods) are correctly identified and synthesized. Minor use of approximations (≈50%, ≈75%) is acceptable given typical reporting conventions. The answer fully addresses the two-part question on evolution and phase-in progression. Thus, the response is factually sound, well-reasoned, and contextually appropriate, warranting a high score with only a slight deduction for missing the explicit $2.4 billion figure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 433,
        "total_tokens": 1691
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How did the treatment of VMware stock options for non-employee directors evolve between 2022 and 2023 following the Broadcom acquisition?",
      "original_answer": "In 2022, the 10-K filing stated that all outstanding in-the-money VMware stock options and RSU awards held by non-employee directors would be accelerated and converted into the right to receive cash and shares of Broadcom common stock, in equal parts, upon the completion of the acquisition. By 2023, this provision had been realized, with the statement confirming that these awards were indeed accelerated and converted into the right to receive cash and Broadcom shares. This reflects a transition from a planned conversion to an actualized event following the completion of the acquisition.",
      "llm_answer": "\nThe merger agreement (first disclosed in the 2022 VMware‑merger filing) required that all in‑the‑money VMware stock options held by non‑employee directors be **accelerated and settled in a combination of cash and Broadcom shares on an equal basis**. When the transaction closed on Nov 22 2023, that provision was executed—those options were therefore **converted into cash and Broadcom stock**, ending their life as VMware equity awards.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and conveys the essential information from the ground truth. (1) It correctly states that in-the-money VMware stock options for non-employee directors were accelerated and settled in equal parts cash and Broadcom shares upon acquisition, which aligns with the 2022 plan and its 2023 realization. (2) The date of transaction close—November 22, 2023—is accurate and matches the timeline in the knowledge graph, enhancing quantitative precision. (3) The reasoning correctly synthesizes the evolution: from a planned treatment in 2022 (disclosed in the merger filing) to actual execution in 2023 post-closing, demonstrating sound multi-hop logic across time and filings. (4) The only minor shortcoming is that the LLM omits explicit mention of RSUs (restricted stock units), which were also part of the original provision alongside stock options. While the focus on stock options is justified, full completeness would include both award types. However, this omission does not undermine the core correctness. Wording differs but maintains semantic equivalence. All entities (VMware, Broadcom, non-employee directors, stock options) are correctly identified. The answer is highly relevant and accurately reflects the transition from plan to execution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 357,
        "total_tokens": 1612
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How has the therapeutic positioning of Vraylar evolved from 2022 to 2024 based on AbbVie's disclosures?",
      "original_answer": "In 2022, Vraylar was described as being evaluated in Phase 3 clinical trials as an adjunctive treatment for major depressive disorder (MDD), with one trial meeting its primary endpoint and the other showing numerical but not statistically significant improvement. By 2024, Vraylar was disclosed as being indicated for a broader range of psychiatric conditions, including acute and maintenance treatment of schizophrenia, acute treatment of manic or mixed episodes associated with bipolar disorder, acute treatment of depressive episodes associated with bipolar I disorder, and as an adjunctive treatment in major depressive disorder. This reflects a clear expansion and solidification of its therapeutic positioning over time.",
      "llm_answer": "\nFrom the 2022 filing (page 6) Vraylar was marketed only for schizophrenia, bipolar mania/mixed episodes and bipolar‑depression, with an “adjunctive treatment of major depressive disorder” listed as a secondary indication.  The 2024 disclosure (pages 7‑8) highlights the results of two Phase 3 trials and the subsequent FDA approval of Vraylar as an adjunctive therapy for major depressive disorder, positioning the drug to target depression in addition to its established antipsychotic and bipolar indications.  Thus, between 2022 and 2024 AbbVie expanded Vraylar’s therapeutic focus from primarily psychotic and bipolar uses to a broader role that includes adjunctive treatment of major depressive episodes.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, Vraylar was indicated for schizophrenia, bipolar mania/mixed episodes, and bipolar depression, with adjunctive treatment of MDD as a secondary or developmental indication. By 2024, it notes the FDA approval for adjunctive MDD treatment based on Phase 3 trial results—consistent with the expansion described in the original answer. (2) There are no numeric values requiring verification (e.g., percentages, dollar amounts), but the years (2022, 2024) and trial phases (Phase 3) are correctly cited. (3) The multi-hop reasoning is sound: the model synthesizes information across two time points (2022 vs 2024 disclosures), correctly infers the evolution in therapeutic positioning, and links clinical trial outcomes to regulatory approval and expanded labeling. (4) The only minor shortcoming is that the 2022 status slightly misrepresents the adjunctive MDD indication—as per ground truth, it was still under evaluation in Phase 3 trials and not yet marketed, whereas the LLM says it was 'listed as a secondary indication,' which may imply approval. However, the overall trajectory and conclusion about broadening therapeutic use are correct. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 385,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has GE's accounting policy for long-term services agreements evolved from 2022 to 2024, particularly in terms of revenue recognition method and contract billing estimates?",
      "original_answer": "In 2022, GE recognized revenue for long-term services agreements on a straight-line basis, primarily in the Healthcare and Renewable Energy segments, with periodic invoicing as services were provided. By 2024, GE shifted to using the percentage of completion method for revenue recognition, predominantly within the CES segment, based on costs incurred relative to total expected costs. Additionally, in 2024, GE reported a long-term services agreements net liability balance of $6.6 billion, representing approximately 4.1% of total estimated life of contract billings of $162 billion, indicating a more detailed and forward-looking estimation process involving asset utilization and cost improvements, which was not explicitly mentioned in 2022.",
      "llm_answer": "\nGE continues to recognize revenue on its long‑term services contracts using the percentage‑of‑completion method—revenue is recorded based on costs incurred to date relative to the total estimated cost of the agreement. From 2022 to 2024 the company sharpened this approach by incorporating more detailed, forward‑looking utilization forecasts, applying stricter validation to any anticipated cost‑improvements, and explicitly evaluating contract modifications, price‑concession impacts, and credit‑risk adjustments; the 2024 disclosures also added quantitative metrics (e.g., a $6.6 bn net liability representing 4.1 % of $162 bn of total estimated contract billings, with a $0.4 bn effect for each percentage‑point change in estimated profitability).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution in GE's accounting policy from 2022 to 2024. While the original answer notes that in 2022 GE used the straight-line method, the LLM answer states that GE 'continues to recognize revenue... using the percentage-of-completion method,' which slightly misrepresents the change — it implies continuity rather than a shift from straight-line to percentage-of-completion. However, the rest of the answer accurately captures the enhanced methodology in 2024, including forward-looking utilization forecasts, cost-improvement validation, and evaluation of contract modifications and credit risk. (2) All quantitative values are correct and match the ground truth: $6.6 billion net liability, 4.1% of $162 billion in total estimated billings, and the $0.4 billion sensitivity per percentage point (implied in the original via the ratio: $6.6B / 4.1% ≈ $161B, and $0.4B ≈ 1% of $6.6B × sensitivity). These are accurately reported with proper context. (3) The multi-hop reasoning is strong: the model synthesizes changes in revenue recognition method, evolution in estimation practices, and integration of new disclosure metrics across years and segments (implied CES focus). The only gap is the lack of explicit mention of the 2022 straight-line method, which weakens the contrast. (4) Despite this minor omission, the answer conveys the core evolution in policy and enhanced estimation rigor, with full numerical accuracy and high relevance. The qualitative accuracy is slightly reduced due to the mischaracterization of method continuity, but overall the response is factually rich and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 455,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has IBM's disclosure of the 1.250% Notes due 2027 evolved between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, IBM disclosed the 1.250% Notes due 2027 as part of a list of instruments defining the rights of holders, with Exhibit 4.3 to Form 8-K filed on January 30, 2019, referenced for the notes. In the 2023 10-K filing, the 1.250% Notes due 2027 are listed under registered securities with the trading symbol IBM 27B on the New York Stock Exchange. This evolution reflects a shift from referencing the instrument defining the rights to identifying the notes as a registered class of securities.",
      "llm_answer": "\nIn the 2022 Form 10‑K the 1.250% Notes due 2027 were shown only as a generic “Notes due 2027” item in the table of registered securities, without any series identifier. The 2023 Form 10‑K lists the same securities as “1.250% Notes due 2027 (IBM 27B)” and places them alongside the other 2027 debentures, adding a specific series ticker and grouping them with the other 2027 notes. This change makes the debt issuance more precisely identified and integrated into IBM’s broader 2027 financing disclosures.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements but significantly misrepresents the nature of the disclosure evolution between the 2022 and 2023 10-K filings. (1) Quantitatively, the percentage (1.250%), year (2027), and ticker (IBM 27B) are correctly identified, which supports a moderate quantitative accuracy score. However, the claim that in the 2022 10-K the notes were listed as a 'generic Notes due 2027' without a series identifier is incorrect. According to the ground truth, in the 2022 10-K, the notes were not merely listed generically in the registered securities table, but were instead disclosed as part of the instruments defining the rights of holders, with Exhibit 4.3 to the Form 8-K from January 30, 2019, referenced. This is a critical factual error. (2) The 2023 10-K correctly lists the notes with the trading symbol IBM 27B on the NYSE, which the LLM correctly notes, though it adds the unsupported detail about 'grouping with other 2027 debentures' not present in the ground truth. (3) The multi-hop reasoning is flawed because the LLM fails to capture the shift in disclosure type—from a reference to a governing instrument in 2022 to a formal registered securities listing in 2023. Instead, it frames the change as a mere addition of detail within the same context (registered securities table), which mischaracterizes the evolution. (4) While the LLM answer is relevant to the question and attempts to describe a progression in disclosure, it misses the core factual distinction in how and where the notes were disclosed across years, leading to a low qualitative and overall correctness score despite some accurate surface details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1242,
        "completion_tokens": 450,
        "total_tokens": 1693
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has the structure and performance criteria of AbbVie's performance-vested RSUs evolved between 2022 and 2024, particularly in terms of vesting increments and performance metrics?",
      "original_answer": "In 2022, performance-vested RSUs had the potential to vest in one-third increments over a three-year performance period, with performance measured based on AbbVie's return on invested capital (ROIC) relative to a defined peer group of pharmaceutical, biotech, and life science companies for awards granted in 2021 and 2020. By 2024, the vesting structure remained similar—allowing for one-third increments over a three-year period—but the description of performance metrics was streamlined, focusing primarily on ROIC performance against the same peer group, without mention of specific years tied to tranches as seen in 2022. This indicates a simplification or standardization of the performance criteria over time.",
      "llm_answer": "\nBetween 2022 and 2024 the performance‑vested RSUs still operate under a three‑year performance period and vest in three equal (one‑third) increments, but the criterion for earning those increments was changed.  In 2022 the awards were tied to EPS and total‑stock‑holder‑return targets, whereas by the 2023‑2024 plan they are earned only when AbbVie achieves a specified return‑on‑invested‑capital (ROIC) relative to a defined peer group, with the one‑third tranche structure remaining the same.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies despite capturing some structural elements correctly. (1) It incorrectly states that in 2022, performance-vested RSUs were tied to EPS and total stockholder return targets—this contradicts the ground truth, which specifies that performance was based on ROIC relative to a peer group for awards granted in 2021 and 2020, with no mention of EPS or TSR. (2) The claim that the criteria changed by a '2023–2024 plan' is unsupported; the original answer notes a streamlining of language by 2024 but does not indicate a change in metrics from EPS/TSR to ROIC—ROIC was already the metric in use. (3) The vesting structure (one-third increments over three years) is correctly identified in both answers, satisfying quantitative and structural accuracy. (4) However, the multi-hop reasoning fails because the model misidentifies the earlier performance metric, leading to an incorrect evolution narrative. While the answer is relevant and addresses the question's intent, the core factual error regarding performance metrics severely undermines correctness. Minor flexibility is allowed in phrasing, but misrepresenting the key performance criteria as EPS and TSR instead of ROIC constitutes a major factual deviation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 352,
        "total_tokens": 1664
      },
      "error": null
    },
    {
      "question_id": 149,
      "question": "How did GE's financial relationship with AerCap evolve from 2022 to 2024, based on the realized and unrealized gains or losses associated with its investment?",
      "original_answer": "In 2022, GE reported an unrealized loss of $865 million related to its investment in and note with AerCap, indicating a negative valuation impact during that year. By 2024, this position had shifted to a realized and unrealized gain of $38 million, suggesting that GE had either exited part of its position or the value of the remaining investment had improved. This represents a significant turnaround in the financial performance of the AerCap investment over the two-year period.",
      "llm_answer": "\nFrom 2022 through 2024 the “Investment in and note with AerCap” line in Note 19 swung from an **$865 million unrealized loss in 2022** to an **unrealized gain of $129 million in 2023** and a **much smaller gain of $38 million in 2024** [GE 10‑K 2022 p. 68; GE 10‑K 2024 p. 68].  At the same time the fair‑value of the AerCap note on the balance sheet rose modestly from **$944 million (2023)** to **$982 million (2024)** [GE 10‑K 2024 p. 70], showing a gradual improvement in the investment’s valuation, though the gains were modest compared with the earlier loss.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth, but contains a minor discrepancy in quantitative accuracy. (1) Correct elements: The $865 million unrealized loss in 2022 is accurately reported. The $38 million gain in 2024 matches the ground truth, which describes it as a combined realized and unrealized gain. The mention of fair value increasing from $944M to $982M adds relevant context. (2) Quantitative issue: The LLM introduces a figure not present in the original answer — a $129 million unrealized gain in 2023 — which, while possibly accurate based on filings, is not part of the ground truth and introduces information beyond what was provided. The original answer skips 2023 and focuses on the 2022-to-2024 shift, so including 2023 data changes the narrative slightly by adding an intermediate step not confirmed in the reference. (3) Reasoning and synthesis: The LLM correctly interprets the trend of improvement in GE's financial relationship with AerCap and supports it with balance sheet valuation trends. However, the original answer emphasizes a turnaround from loss to net gain without detailing annual fluctuations, so the added 2023 figure, while potentially valid, introduces a level of granularity not confirmed in the ground truth and slightly deviates from the intended multi-hop comparison between 2022 and 2024 only. (4) Despite this, the core facts are correct, the direction of change is accurately described, and the conclusion about improved valuation is supported. The answer remains contextually relevant and semantically close to the original, warranting a high score but not perfect due to the unverified inclusion of the 2023 gain figure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 461,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 149,
      "question": "How has IBM's treatment of the 0.300% Notes due 2026 evolved between the 2022 and 2023 SEC filings, particularly in terms of its disclosure status and visibility in financial instruments?",
      "original_answer": "In 2022, the 0.300% Notes due 2026 were disclosed as part of IBM's exhibits under Exhibit 4 to Form 8-K filed November 1, 2016, indicating it was referenced in the context of legal instruments defining holder rights. By 2023, the 0.300% Notes due 2026 were no longer just referenced in exhibits but were explicitly listed as a titled class of notes registered on the New York Stock Exchange under the trading symbol IBM 26B, showing increased visibility and formal recognition in the company's capital structure.",
      "llm_answer": "\nIn the 2022 Form 10‑K the 0.300 % Notes due 2026 were not entered in the “Securities registered pursuant to Section 12(b)” table; they appeared only in the narrative sections and were therefore only implicitly disclosed. By contrast, the 2023 filing places the 0.300 % Notes due 2026 in the explicit securities table (listed as IBM 26B on the NYSE), giving the instrument a clear, front‑page disclosure and ticker identifier that makes it far more visible to investors.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. (1) All key facts are correct: the 0.300% Notes due 2026 were not listed in the 'Securities registered pursuant to Section 12(b)' table in 2022 but were included in narrative/exhibit disclosures (specifically Exhibit 4 to Form 8-K filed November 1, 2016, as per ground truth), and in 2023 they were explicitly listed in the securities table with the NYSE ticker IBM 26B. (2) Quantitative elements—interest rate (0.300%), maturity year (2026), ticker symbol (IBM 26B)—are all accurate. No calculations required. (3) The multi-hop reasoning is sound: the model correctly infers increased visibility and formal recognition by comparing disclosure formats across years, synthesizing information about exhibit references versus formal registration. (4) The only minor shortcoming is that the LLM does not explicitly mention the Exhibit 4 to Form 8-K reference from 2016, which is part of the original answer’s basis for 2022 disclosure status. However, stating the note was 'only implicitly disclosed' in narrative sections is semantically consistent. Wording differs slightly but meaning matches. Thus, high scores across all dimensions with a small deduction in qualitative accuracy for partial omission of sourcing detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 361,
        "total_tokens": 1617
      },
      "error": null
    },
    {
      "question_id": 150,
      "question": "How has GE's approach to the RISE Program evolved between 2022 and 2024, particularly in terms of its strategic emphasis and investment focus?",
      "original_answer": "In 2022, GE announced the RISE Program as a collaborative technology development initiative with Safran, targeting a reduction of more than 20% in fuel consumption and CO2 emissions compared to current engines. This marked the initial phase of the program as a forward-looking announcement aimed at shaping the future of sustainable aviation. By 2024, GE's engagement with the RISE Program had evolved into a more concrete investment strategy, with the company making 'significant investments' in the RISE program suite of technologies. This shift indicates a transition from conceptual development to active, funded R&D aimed at enabling a sustainable future of flight. The change reflects a deepening strategic commitment to sustainability and technological leadership in aviation.",
      "llm_answer": "\nBetween 2022 and 2024 GE moved the RISE program from an early‑stage, partnership‑driven R&D effort to a core strategic priority that now receives dedicated, scaled‑up investment.  In the 2022 filing (R&D = $2.1 bn, customer‑funded RISE work) the company was just beginning to test Open‑Fan and hybrid‑electric concepts, but by 2024 it had logged >250 Open‑Fan tests, deepened collaborations with Safran and the U.S. Army, and earmarked a larger share of its $2.7 bn 2024 R&D budget for RISE‑related technologies to mature them for commercial production and to achieve its ≈20 % fuel‑burn reduction goal.  This shift reflects a stronger emphasis on turning RISE innovations into market‑ready products and integrating them into GE Aerospace’s long‑term growth plan.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the core evolution of GE's RISE Program from a collaborative R&D initiative in 2022 to a strategically prioritized, heavily invested program by 2024, which aligns well with the ground truth. The qualitative shift—from conceptual development to active, funded R&D with a focus on commercialization—is accurately conveyed, and key partners (Safran, U.S. Army) and technologies (Open-Fan, hybrid-electric) are correctly identified, demonstrating sound multi-hop reasoning and entity accuracy. However, there are notable quantitative inaccuracies: the original answer does not mention specific R&D budget figures ($2.1B in 2022 or $2.7B in 2024), customer-funded work, >250 Open-Fan tests, or exact budget allocations. These numbers, while plausible, are not supported by the ground truth and introduce unsupported specifics. The 20% fuel-burn reduction goal is consistent with the 'more than 20%' target in the original, so that is acceptable. The answer is highly relevant and synthesizes the strategic emphasis and investment focus as asked, but the inclusion of unverified financial and testing metrics reduces quantitative accuracy. Thus, while the reasoning and direction are correct, the unsupported numbers prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 350,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 150,
      "question": "How has the role and emphasis on asset securitizations within American Express's funding strategy evolved from 2022 to 2023, based on the specific disclosures in the respective 10-K filings?",
      "original_answer": "In 2022, American Express defined asset securitizations in a glossary entry, describing the mechanics of transferring loans to trusts that issue asset-backed securities, and noted that securitized loans and receivables were reported as assets while the securities were reported as liabilities. This definition was part of a broader explanation of financial terminology rather than a strategic focus. By 2023, asset securitizations were explicitly positioned as a core component of the company's funding strategy, listed alongside deposits and unsecured debt as key funding sources. The 2023 filing emphasized the importance of diversity in funding sources, with securitizations playing a role in mitigating disruptions in any single funding channel. This represents a shift from a definitional disclosure in 2022 to a strategic emphasis in 2023.",
      "llm_answer": "\nFrom 2022 to 2023 American Express shifted asset‑securitizations from a peripheral source of liquidity to a strategically‑managed funding pillar: the 2023 filing explicitly integrates securitizations into its funding policy, highlights that they are “rated separately,” and provides concrete issuance figures (e.g., $3.5 bn of Fixed‑Rate Class A certificates) that are tied to the company’s overall debt‑maturity and liquidity objectives. In contrast, the 2022 10‑K mentions securitizations only as an occasional financing tool without the same level of strategic emphasis or detailed quantitative disclosure.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies a strategic shift in the role of asset securitizations from 2022 to 2023, aligning with the ground truth's core claim of increased emphasis. It accurately notes that securitizations were mentioned more peripherally in 2022 and became more strategically integrated in 2023. However, it introduces specific quantitative details not present in the original answer or implied by the ground truth, such as '$3.5 bn of Fixed-Rate Class A certificates' and the claim that securitizations are 'rated separately.' These details are not found in the provided ground truth and cannot be verified from the knowledge graph output, making them potentially hallucinated. (2) The quantitative accuracy is low because the dollar amount ($3.5 billion) and security class details are not supported by the original answer, which contains no such figures. There is no mention of ratings or specific tranches in the ground truth, so these additions undermine factual reliability. (3) The multi-hop reasoning is partially sound: the model correctly infers a shift from definitional disclosure to strategic emphasis. However, it overreaches by introducing unverified specifics, suggesting access to granular filing details not reflected in the ground truth. The synthesis captures the directional change but adds unsupported detail. (4) Despite the hallucinated numbers, the overall qualitative assessment is moderate because the central theme—increased strategic importance—is correct. Contextual relevance is high as the response directly addresses the evolution in funding strategy. The correctness score is reduced due to the inclusion of unverified quantitative claims, which violate the principle of factual fidelity even if the general trend is accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 485,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 151,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve from 2022 to 2023, particularly in terms of investment returns and operational integration?",
      "original_answer": "In 2022, Emerson's relationship with AspenTech was characterized by a minority investment, with AspenTech contributing $656 in sales and a $12 earnings gain, while holding total assets of $14,484. By 2023, Emerson significantly deepened its involvement by acquiring Heritage AspenTech, gaining a 55% ownership stake in the newly formed AspenTech. This acquisition positively impacted gross margins by 0.6 percentage points in 2023 and marked a strategic shift from a passive investment to an active controlling interest, indicating a transformation in the nature of the relationship.",
      "llm_answer": "\nFrom fiscal 2022 to 2023 Emerson’s stake in AspenTech moved from a 57 % minority interest (acquired in May 2022) to a fully integrated software segment, with AspenTech’s sales rising from $319 million to $656 million and its earnings shifting from a small loss to $12 million—contributing positively to Emerson’s pretax earnings and generating $1.274 billion of intangible amortization in 2024 that reflects growing synergies.  At the same time, Emerson launched a cash proposal in late 2023 to buy the remaining shares, signaling a strategic intent to eliminate the minority interest and capture the full financial upside of the combined automation‑software platform.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. It incorrectly states that Emerson had a 57% minority interest in AspenTech in May 2022, while the ground truth indicates a minority investment without specifying ownership percentage, and certainly not 57%. The claim of 'fully integrated software segment' and 'fully integrated' by 2023 is misleading—Emerson acquired a 55% stake in the newly formed AspenTech in 2023, not full ownership. The sales figure of $319 million in 2022 is fabricated; the ground truth reports $656 million in sales in 2022 (not 2023 as implied by the comparison), so the LLM reverses the timeline and invents a prior lower number. The earnings shift 'from a small loss' is unsupported; the ground truth states a $12 million earnings gain in 2022, not a loss. The $1.274 billion intangible amortization in 2024 is entirely extraneous and not mentioned in the original answer or context, and it introduces a future year (2024) not part of the question. (2) Quantitative accuracy is severely compromised: all key numbers (319M, 656M as 2023, 57%, 1.274B) are either reversed, invented, or misattributed. The only correct number is $12 million in earnings, but it is misrepresented as a turnaround from a loss when the truth states it was a gain in 2022. (3) Multi-hop reasoning fails: the LLM misrepresents the evolution from minority stake to control—Emerson did not have 57% in 2022, nor did it achieve full integration by 2023. The strategic shift is partially captured (increased control), but the acquisition of 'Heritage AspenTech' and 55% stake forming a new entity is omitted. The mention of a 'cash proposal in late 2023' to buy remaining shares is speculative and not in the ground truth. (4) Contextual relevance is moderate—the answer addresses investment returns and operational integration themes, but with incorrect data and timeline. Due to major factual and numerical errors, especially in financial figures and ownership percentages, the correctness score is low at 3. Quantitative accuracy is 2 due to widespread number errors. Qualitative accuracy is 3 for partial grasp of strategic shift but flawed reasoning. Contextual relevance is 6 as the topic alignment exists but content is unreliable.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 603,
        "total_tokens": 1922
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How did Emerson's financial relationship with AspenTech evolve between 2022 and 2023, particularly in terms of noncontrolling interest accounting and acquisition-related impacts on equity and expenses?",
      "original_answer": "In 2022, Emerson completed the creation of New AspenTech by contributing its industrial software business and $6.0 billion in cash, resulting in a 55% ownership stake. A noncontrolling interest of $5.9 billion was recorded, with a decrease to additional paid-in capital of $550 million. By 2023, the AspenTech acquisition positively impacted gross margins by 0.6 percentage points and contributed to increased SG&A expenses, which rose by $572 million compared to 2022, partly due to the AspenTech transaction and higher stock compensation expenses. This shows that while the initial accounting impact was significant in 2022, by 2023, the focus had shifted to operational integration and financial performance effects.",
      "llm_answer": "\nBetween 2022 and 2023 Emerson’s stake in AspenTech was unchanged – it owned 55 % of the company and continued to carry a $5.9 billion non‑controlling interest for the 45 % held by former Heritage AspenTech shareholders, a balance that had been recorded at fair value and had reduced additional‑paid‑in‑capital by roughly $550 million in the 2022 acquisition accounting (Notes 4‑5, page 56).  In 2023 no new equity was issued or retired, so the non‑controlling interest remained on the balance sheet, but the acquisition continued to affect earnings through higher amortization of acquired intangibles (amortization expense rose from $430 million in 2022 to $678 million in 2023) and the $84 million of acquisition‑related costs reported in 2023 (page 25), while the inventory step‑up from the purchase began to be amortized into cost of sales, pressuring margins.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in key financial figures and impacts. While it correctly identifies Emerson's 55% ownership and the $5.9 billion noncontrolling interest from 2022, it introduces new details not in the ground truth: specifically, the increase in amortization expense from $430M to $678M and $84M in acquisition-related costs in 2023. These numbers are not mentioned in the original answer and contradict the focus on SG&A and gross margin impacts. The ground truth states that SG&A increased by $572M and gross margins improved by 0.6 percentage points, which the LLM answer omits entirely. Instead, it claims inventory step-up amortization pressured margins—directly contradicting the original answer’s statement of positive margin impact. (2) The quantitative accuracy is low because the LLM invents specific figures (amortization: $430M → $678M, $84M acquisition costs) that are not in the ground truth and misrepresents the margin impact. While the $5.9B noncontrolling interest and $550M reduction in additional paid-in capital are correct, the rest of the financial data is either incorrect or unsupported. (3) The reasoning is partially sound in tracking the continuity of noncontrolling interest accounting from 2022 to 2023 and recognizing ongoing acquisition impacts. However, it fails to correctly synthesize the operational impacts—specifically missing the SG&A increase and the positive gross margin effect, instead asserting margin pressure. This indicates a failure in multi-hop reasoning to connect acquisition accounting with actual P&L outcomes as reported. (4) Contextual relevance is high because the answer addresses noncontrolling interest, acquisition accounting, and ongoing financial impacts. However, due to significant factual errors and omission of key ground truth data, the correctness score is moderate—partially correct but with major flaws in financial accuracy and direction of impact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 534,
        "total_tokens": 1944
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How has IBM's treatment and disclosure of the 6.22% Debentures due 2027 evolved between the 2022 and 2023 SEC filings?",
      "original_answer": "In 2022, IBM disclosed the 6.22% Debentures due 2027 by referencing the instrument defining the rights of its holders, which was filed as Exhibit 3 to Form 8-K on August 1, 1997. In contrast, the 2023 filing introduces a more structured and visible disclosure by listing the 6.22% Debentures due 2027 with its respective trading symbol (IBM 27) and explicitly identifying it among other registered securities on the New York Stock Exchange. This evolution reflects a shift from a purely historical reference to a more transparent and current market-oriented presentation.",
      "llm_answer": "\nIn the 2022 Form 10‑K the 6.22% Debentures due 2027 appeared only in the generic exhibit list (e.g., “Exhibit 3 to the 1997 Form 8‑K”), without a separate line in the cover‑page securities table. The 2023 filing adds a dedicated entry for the issue in the “Securities Registered Pursuant to Section 12(b)” table—listed as “6.22% Debentures due 2027 – IBM 27”—and repeats the same exhibit reference, giving the debenture a distinct ticker and more explicit disclosure.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: the 2022 filing referenced the 6.22% Debentures due 2027 via Exhibit 3 to the 1997 Form 8-K without a dedicated entry, while the 2023 filing includes a distinct listing in the 'Securities Registered Pursuant to Section 12(b)' table with the trading symbol 'IBM 27'. (2) Quantitative elements—interest rate (6.22%), maturity year (2027), exhibit reference (Exhibit 3, Form 8-K, August 1, 1997)—are all accurate, with no calculation errors. (3) The multi-hop reasoning is sound: the model correctly contrasts disclosure practices across two years, synthesizing information about presentation format, visibility, and market-oriented updates. (4) The answer fully addresses the evolution in treatment and disclosure, capturing the shift from a passive, historical reference to an active, transparent, and market-integrated format. Wording differs slightly but conveys identical meaning. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 302,
        "total_tokens": 1555
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How has UnitedHealth Group's exposure to financial risk through risk-based arrangements with healthcare providers evolved from 2023 to 2024, and what implications does this have on its cost estimation and service delivery responsibilities?",
      "original_answer": "In 2023, UnitedHealth Group assumed economic risk under risk-based arrangements where it was responsible for funding healthcare costs, and it recognized premium revenues based on estimated premiums earned, net of projected rebates. The company also highlighted its involvement in value-based arrangements where it received per-patient-per-month premiums and recognized revenue as services were made available. By 2024, the company's exposure expanded as it noted increased responsibility for unpaid healthcare claims if risk-based providers faced financial difficulties or failed to meet their obligations. Additionally, the 2024 disclosures emphasized greater operational risk tied to providers' ability to manage costs, maintain solvency, and provide necessary data for cost estimation, indicating a broader and more complex financial exposure compared to 2023.",
      "llm_answer": "\nFrom 2023 to 2024 UnitedHealth’s risk‑based contracts with physicians, hospitals and other providers expanded sharply—accounting for nearly 80 % of consolidated revenue—and moved toward fully‑accountable, value‑based arrangements that shift both medical and administrative cost risk to the Company.  This deeper exposure forces the firm to rely on more sophisticated actuarial estimates and tighter cost‑management, while also expanding its service‑delivery duties (e.g., care coordination, data‑driven pricing and compliance with CMS risk‑adjustment and AI/ML regulations) and heightening the financial‑risk implications of provider solvency and claim‑cost accuracy.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces a specific quantitative claim—'nearly 80% of consolidated revenue'—that is not present in the original answer (ground truth) and cannot be verified from the provided context. This is a significant factual overreach, as no percentage or numerical metric regarding the scale of risk-based arrangements was mentioned in the ground truth for either 2023 or 2024. This unsupported figure undermines quantitative accuracy. (2) While the original answer confirms UnitedHealth’s increasing exposure to financial risk in 2024, particularly around provider solvency and cost estimation, it does not quantify the extent of risk-based arrangements or state they account for 80% of revenue. Thus, the quantitative inaccuracy is material. (3) Qualitatively, the LLM captures the correct direction of evolution—increased financial and operational risk, greater responsibility in cost estimation, and expanded service delivery duties such as care coordination and data use. It correctly identifies the shift toward value-based arrangements and heightened reliance on actuarial estimates, which aligns with the ground truth’s emphasis on expanded responsibilities in 2024. The mention of CMS risk-adjustment and AI/ML regulations adds plausible context but is not present in the original and may be speculative. (4) Contextual relevance is high, as the answer addresses both parts of the question: evolution of financial risk exposure and implications for cost estimation and service delivery. The reasoning reflects a sound multi-hop synthesis of how deeper risk-based involvement increases UnitedHealth’s operational and financial responsibilities. However, the inclusion of an unverified statistic reduces overall correctness. The answer is semantically aligned in direction and theme but fails on strict factual precision due to the unsupported percentage.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 509,
        "total_tokens": 1915
      },
      "error": null
    },
    {
      "question_id": 153,
      "question": "How did Emerson's financial relationship with AspenTech evolve between 2022 and 2023, particularly in terms of investment magnitude and strategic involvement?",
      "original_answer": "In 2022, Emerson's relationship with AspenTech was primarily financial, as shown by its investment reflected in the Automation Solutions segment, where Emerson reported $362 million invested in AspenTech in 2022. By 2023, the relationship evolved into a strategic partnership following the introduction of a major transaction where Emerson contributed its Industrial Software Business along with approximately $6.0 billion in cash to Heritage AspenTech stockholders, creating 'New AspenTech.' Emerson gained 55% ownership of AspenTech's outstanding shares, marking a significant shift from a minority investment to a controlling stake.",
      "llm_answer": "\nBetween fiscal 2022 and 2023 Emerson’s exposure to AspenTech grew both in dollar magnitude and strategic importance.  In 2022 the company contributed two of its own industrial‑software businesses and paid cash to acquire a 55 % equity stake in AspenTech, recording $148 million of intangible‑asset amortization and generating $656 million of AspenTech sales (page 77) with a modest pretax earnings of $12 million (page 77).  By 2023 that same 55 % stake remained, but the financial footprint expanded—Amortization of AspenTech intangibles rose to $242 million (page 79), and the segment’s sales and earnings stayed at $656 million and $12 million respectively, reflecting a larger investment and deeper integration that set the stage for the 2024 proposal to acquire the remaining shares (pages 24‑27).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 Emerson had a minority financial investment of $362 million in AspenTech. However, the LLM incorrectly states that in 2022 Emerson already acquired a 55% equity stake by contributing businesses and paying cash, which actually occurred in 2023. This misrepresents the timeline and nature of the relationship evolution. (2) Quantitative inaccuracies include: claiming $148 million in intangible amortization and $656 million in sales in 2022 — these figures are not supported by the ground truth and contradict the actual $362 million investment reported for 2022; similarly, the $242 million amortization in 2023 is not mentioned in the original answer. The ground truth emphasizes a $6.0 billion cash contribution in 2023, which is entirely missing from the LLM response. (3) The multi-hop reasoning is flawed: the LLM fails to correctly sequence the evolution from financial investment (2022) to strategic control (2023), instead asserting the strategic move happened in 2022. It also introduces a '2024 proposal to acquire remaining shares' not present in the original answer, adding unsupported forward-looking information. (4) Despite incorrect facts and timeline, the answer is contextually relevant in that it attempts to describe a growing financial and strategic relationship between Emerson and AspenTech, and references integration and increasing footprint. However, due to major errors in entities, timing, and financial figures, the overall correctness is very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 436,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 153,
      "question": "How has Adobe Target's role within Adobe's customer journey solutions evolved from fiscal 2022 to fiscal 2023, and what does this evolution indicate about Adobe's strategic direction in AI-driven personalization?",
      "original_answer": "In fiscal 2022, Adobe Target was described as part of a broader set of customer journey solutions, specifically noted alongside Marketo Engage, Adobe Campaign, and Journey Optimizer. It was characterized as a tool for testing, targeting, and personalizing content across channels. By fiscal 2023, Adobe Target was elevated in prominence and described specifically as an 'AI- and machine learning-driven personalization engine' with capabilities for omnichannel personalization and large-scale A/B and multivariate testing through AI-powered automation. This evolution indicates Adobe is placing greater strategic emphasis on AI-driven personalization as a core capability within its customer journey offerings, aligning with its broader push toward AI-powered solutions.",
      "llm_answer": "\nIn fiscal 2022 Adobe Target was described primarily as an AI‑ and machine‑learning‑driven engine for testing and optimizing content across channels, but it was positioned as a standalone personalization tool within the broader Adobe Experience Cloud. By fiscal 2023 the language had shifted: Target is now presented as a core, real‑time personalization component of the Adobe Experience Platform that works natively with Journey Optimizer and the Real‑Time Customer Data Platform to deliver AI‑powered, one‑to‑one experiences at scale. This evolution reflects Adobe’s strategic push to embed AI‑driven personalization throughout the entire customer‑journey workflow, using automation and generative‑AI capabilities to create hyper‑personalized, omnichannel experiences.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution of Adobe Target from fiscal 2022 to 2023 and Adobe's strategic direction toward AI-driven personalization. However, there is a factual inaccuracy in the characterization of Adobe Target in fiscal 2022: the original answer states it was described as part of a broader set of customer journey solutions alongside Marketo Engage, Adobe Campaign, and Journey Optimizer, and as a tool for testing, targeting, and personalizing content—without explicitly calling it 'AI- and machine-learning-driven' in that year. The LLM incorrectly attributes the AI-focused language to 2022, whereas the ground truth shows this shift occurred in 2023. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. (3) The multi-hop reasoning is generally sound: the model correctly synthesizes information across years and infers strategic direction. However, the misattribution of AI language to 2022 weakens the qualitative accuracy, as it misrepresents the timeline of Adobe's messaging evolution. (4) Contextual relevance is high—the answer directly addresses both parts of the question and remains focused on Adobe Target’s role and strategic implications. The core facts about 2023 positioning and strategic direction are correct, warranting a correctness score of 7 for minor but notable factual inaccuracy in the 2022 description.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 407,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How did Emerson's relationship with AspenTech evolve from 2022 to 2023, particularly in terms of its financial stake and post-acquisition integration activities?",
      "original_answer": "In 2022, Emerson reported a balance of $8,326 million related to AspenTech as part of its acquisitions, indicating a significant financial stake following the acquisition of Heritage AspenTech. By 2023, the relationship had evolved into a more integrated structure, with AspenTech operating as a separate publicly traded company under Emerson's acquisition framework. This included the continuation of AspenTech's stock-based compensation plans, such as stock options and restricted stock units, which were now aligned with AspenTech's own equity structure. Additionally, Emerson was actively managing performance stock units tied to predefined goals like annual contract value and free cash flows, showing a shift from a purely financial stake to a more operationally integrated and incentive-driven relationship.",
      "llm_answer": "\nFrom fiscal 2022 to 2023 Emerson moved from a minority equity interest in AspenTech to full consolidation after its third‑quarter 2022 acquisition; this is evident in the jump in goodwill for the AspenTech segment from about $1.0 bn (2021) to $8.3 bn (2022) and in intangible assets rising from roughly $4.1 bn to $10.1 bn.  As part of the integration Emerson assumed and converted AspenTech’s stock‑based compensation awards, recognized an additional ≈ $50 m of stock‑compensation expense in 2023 (including about $43 m of integration‑related costs), and began reporting the combined results within its seven‑segment structure.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution of Emerson's relationship with AspenTech from 2022 to 2023, correctly identifying the shift from acquisition to integration and operational alignment. However, there are key quantitative inaccuracies. The original answer states Emerson reported an $8,326 million balance related to AspenTech in 2022 as part of its acquisitions, which the LLM rephrases as goodwill increasing to $8.3 billion. While this appears to reference the same event, the original does not specify that the $8,326M was goodwill—this is an assumption by the LLM. In fact, the $8,326M likely includes both goodwill and intangibles. The LLM incorrectly splits this into $8.3B goodwill and $10.1B intangible assets, which are not supported by the original answer. Additionally, the $50M stock-compensation expense and $43M integration-related costs are not mentioned in the ground truth, making them fabricated details. (2) The original answer does not provide 2021 goodwill or pre-acquisition intangible asset figures, so the LLM’s comparison of intangibles rising from $4.1B to $10.1B lacks grounding. These numbers may come from external data but are not in the provided truth, reducing quantitative accuracy. (3) The multi-hop reasoning is sound in structure—LLM infers integration from compensation plan alignment and financial consolidation—but it introduces unsupported specifics. The original emphasizes AspenTech operating as a separate publicly traded company under Emerson’s acquisition framework, which the LLM omits, instead implying full consolidation. This misrepresents the structural relationship. (4) Despite these issues, the LLM correctly identifies the shift from financial stake to operational integration and mentions stock-based compensation alignment, which is semantically consistent. Contextual relevance is high as all content addresses the question directly. Due to significant but not fundamental quantitative errors and a minor misrepresentation of corporate structure, the correctness score is 7.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 552,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How has Adobe Experience Platform's role within Adobe's customer journey solutions evolved from 2022 to 2023, particularly in terms of its integration with AI-powered tools and cross-channel campaign orchestration?",
      "original_answer": "In 2022, Adobe Experience Platform was described as the foundational infrastructure for Adobe Experience Cloud, enabling data standardization and integration with Adobe Sensei to provide AI-powered services such as automated insights, sentiment analysis, and enhanced anomaly detection. It was central to Adobe's differentiation, supporting applications like Adobe Analytics and Adobe Audience Manager. By 2023, Adobe Experience Platform's role had evolved to become the underlying engine for cross-channel campaign orchestration, particularly through its integration with Adobe Journey Optimizer. This app allowed brands to deliver personalized, connected customer journeys across any channel, using real-time data profiles and cloud-native scalability. Additionally, Adobe Mix Modeler, introduced in 2023 and powered by Adobe Sensei, leveraged cross-channel datasets in Adobe Experience Platform to provide machine learning-driven insights for optimizing marketing investments. This indicates a shift from a general AI-enhanced infrastructure role to a more specialized and actionable function in campaign planning and customer journey orchestration.",
      "llm_answer": "\nFrom 2022 to 2023 Adobe Experience Platform shifted from being a primarily data‑and‑audience foundation that fed Adobe Analytics, Product Analytics and the broader Experience Cloud suite into the core engine that **natively orchestrates cross‑channel campaigns**.  In the 2023 filing the platform is highlighted as the “scalable app” (Journey Optimizer) that **combines real‑time profile activation, AI‑driven insights (Sensei and GenAI) and automated personalization** to plan, execute and measure end‑to‑end journeys across email, mobile, web and offline channels—all within a single, open architecture.  This evolution means AEP now **drives AI‑powered decision‑making and campaign orchestration directly**, rather than just supplying data for separate Adobe tools.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of Adobe Experience Platform (AEP) from 2022 to 2023 as described in the ground truth. It correctly identifies the shift from AEP being a data foundation and enabler of AI-powered insights (via Adobe Sensei) in 2022 to becoming the core engine for cross-channel campaign orchestration in 2023, particularly through Adobe Journey Optimizer. The mention of real-time profile activation, AI-driven insights, and automated personalization aligns with the ground truth's emphasis on real-time data profiles and cloud-native scalability. The LLM also correctly highlights integration with Adobe Sensei and introduces GenAI, which is a reasonable extension given Adobe's AI focus in 2023, though the original answer does not explicitly mention GenAI—this is a minor addition but not factually incorrect. The LLM accurately reflects the platform’s role in enabling end-to-end journey orchestration across channels, matching the ground truth’s emphasis on personalization and connected experiences. It also correctly implies a shift from supporting tools to driving orchestration directly. The only minor gap is the omission of Adobe Mix Modeler, a specific 2023 addition powered by Sensei that leveraged AEP for marketing investment optimization. While the LLM broadly covers AI-driven insights, it misses this concrete example, which slightly reduces completeness. However, the core multi-hop reasoning—synthesizing AEP’s evolving role across time, AI integration, and campaign orchestration—is sound and factually aligned. All entities (Adobe Experience Platform, Adobe Sensei, Journey Optimizer, Experience Cloud) and years (2022 to 2023) are correct. No numerical or date inaccuracies are present, hence perfect quantitative accuracy. The answer is contextually highly relevant and semantically equivalent to the original in intent and substance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1497,
        "completion_tokens": 513,
        "total_tokens": 2010
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How did UnitedHealth Group's approach to care delivery models evolve from 2023 to 2024 in response to Medicare Advantage funding pressures?",
      "original_answer": "In 2023, UnitedHealth Group emphasized accelerating the transition to value-based care delivery models, investing in clinical engagement, integrated care coordination technology, and new delivery channels like in-home and virtual care. The company viewed these innovations as key to future growth despite initial costs. However, by 2024, the company faced significant funding pressures in the Medicare Advantage program, including reduced benchmarks and risk adjustment changes, which led to operational adjustments. These included selective changes to provider networks, benefit structures, and county-level decisions about plan offerings, indicating a shift from expansion-focused investment to cost containment and strategic retrenchment in response to external financial constraints.",
      "llm_answer": "\nFrom 2023 to 2024 UnitedHealth Group accelerated its move toward fully‑accountable, value‑based care—expanding integrated in‑clinic, in‑home, behavioral and virtual services and using data‑analytics to coordinate senior outpatient care.  In response to ongoing Medicare Advantage funding pressure, including lower benchmark rates and revised risk‑adjustment models, the company intensified medical‑cost and operating‑cost management, refined benefit designs and premiums, and began making county‑by‑county enrollment decisions to offset reduced capitation while continuing its transition away from fee‑for‑service delivery.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in UnitedHealth Group's care delivery model from 2023 to 2024 in response to Medicare Advantage funding pressures. (1) It correctly identifies the 2023 focus on value-based care expansion, including in-home, virtual, behavioral, and integrated care models, along with data analytics for care coordination—aligning with the ground truth's emphasis on clinical engagement, technology, and new delivery channels. (2) For 2024, it accurately reflects the shift due to funding pressures—citing lower benchmark rates and risk adjustment changes—as leading to cost management, benefit design refinements, and localized (county-by-county) enrollment decisions. This matches the ground truth's description of strategic retrenchment, provider network adjustments, and plan offering decisions. (3) While the LLM uses slightly different phrasing (e.g., 'intensified medical-cost and operating-cost management' vs. 'selective changes to provider networks'), the semantic meaning and factual content are equivalent. The multi-hop reasoning—linking external MA funding changes to internal strategic shifts—is sound and well-synthesized. (4) No numeric inaccuracies are present; the answer avoids unsupported figures and correctly references qualitative financial pressures. The only minor shortcoming is a slightly less explicit mention of 'capitation reduction' as a driver for retrenchment, but 'reduced capitation' is mentioned, which preserves factual integrity. Overall, the answer is factually correct, contextually precise, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 443,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 157,
      "question": "How has the composition of TMO's debt instruments evolved between 2022 and 2023, particularly regarding the 1.950% Notes due 2029?",
      "original_answer": "In 2022, the 1.950% Notes due 2029 were listed among TMO's outstanding debt instruments with the trading symbol TMO 29. In 2023, the 1.950% Notes due 2029 remained present with the same trading symbol TMO 29, indicating continuity in this debt instrument. However, TMO introduced new debt instruments in 2023, such as the 3.200% Notes due 2026 and the 3.650% Notes due 2034, suggesting a broader shift in financing strategy. The continued presence of the 1.950% Notes due 2029 indicates no change in this specific liability, even as TMO expanded its debt portfolio.",
      "llm_answer": "\nBetween the 2022 and 2023 Form 10‑K filings the roster of registered notes was largely unchanged – the 1.950 % Notes due 2029 (series TMO 29) appears in both tables with the same coupon and maturity, indicating that this tranche was neither retired nor repriced during that period.  What did shift was the addition of newer debt series (e.g., 3.200 % Notes due 2026 and 3.650 % Notes due 2034) and a modest reshuffling of maturities, but the composition of the 1.950 % 2029 notes remained the same, staying on the balance sheet as a stable, long‑dated borrowing.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and closely aligns with the ground truth. (1) All key information is correct: the 1.950% Notes due 2029 (TMO 29) are correctly identified as present in both 2022 and 2023, with no changes to this instrument. The introduction of new debt instruments—the 3.200% Notes due 2026 and 3.650% Notes due 2034—is accurately noted. (2) Quantitative accuracy is perfect: percentages (1.950%, 3.200%, 3.650%), maturities (2026, 2029, 2034), and the trading symbol TMO 29 match the original answer exactly. No calculations were required, but all numeric references are correct. (3) The multi-hop reasoning is sound—comparing TMO’s debt instruments across two years and identifying continuity in one instrument while noting expansion in the overall portfolio. The LLM correctly infers that the unchanged status of the 1.950% Notes indicates stability, even as new debt is added. (4) The only minor shortcoming is slightly less explicit emphasis on the 'broader shift in financing strategy' mentioned in the original, though the addition of new notes implies this. Wording differs slightly (e.g., 'roster of registered notes', 'modest reshuffling of maturities'), but semantic meaning is equivalent. No factual errors or omissions affect the core correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 356,
        "total_tokens": 1634
      },
      "error": null
    },
    {
      "question_id": 159,
      "question": "How has the composition of TMO's debt instruments evolved between 2022 and 2023, particularly regarding the 0.500% Notes due 2028 and the introduction of new note categories?",
      "original_answer": "In 2022, TMO listed the 0.500% Notes due 2028 alongside other debt instruments, including the 1.375% Notes due 2028. By 2023, TMO continued to list the 0.500% Notes due 2028, but introduced new debt categories such as the 3.200% Notes due 2026 and the 3.650% Notes due 2034, while maintaining similar categories like the 1.375% Notes due 2028. This indicates a strategic shift toward diversifying TMO's debt portfolio with new interest rate structures and maturity timelines.",
      "llm_answer": "\nBetween 2022 and 2023 the company kept its 0.500 % Notes due 2028 (listed as TMO 28A) but expanded the overall debt mix with several new note issuances.  The 2023 filing introduced higher‑coupon tranches such as the 3.200 % Notes due 2026 (TMO 26B) and the 3.650 % Notes due 2034 (TMO 34), adding longer‑dated, higher‑yielding instruments to the portfolio while the existing 0.500 % 2028 notes remained in place.  This reflects a shift toward a broader range of maturities and coupon rates in TMO’s debt composition.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: the 0.500% Notes due 2028 were retained from 2022 to 2023, and new notes introduced in 2023 include the 3.200% Notes due 2026 and the 3.650% Notes due 2034. The mention of 'TMO 28A', 'TMO 26B', and 'TMO 34' as identifiers, while not present in the original answer, do not contradict it and may reflect internal labeling in filings; they are not factually inaccurate. (2) Quantitative accuracy is perfect: all percentages (0.500%, 3.200%, 3.650%) and maturity years (2026, 2028, 2034) match the ground truth exactly. (3) The multi-hop reasoning is sound—LLM correctly infers a strategic shift in debt composition by comparing instruments across years, noting the addition of higher-coupon, longer-dated notes while retaining existing ones. (4) The only minor shortcoming is that the original answer also notes the continued presence of the 1.375% Notes due 2028, which the LLM omits. This is a small but relevant detail for completeness, especially since it was explicitly mentioned in both years. However, the core of the question—evolution regarding the 0.500% Notes due 2028 and introduction of new categories—is fully addressed. The LLM captures the strategic diversification message effectively. Hence, a score of 9 is warranted for correctness, with full marks in quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 391,
        "total_tokens": 1646
      },
      "error": null
    },
    {
      "question_id": 160,
      "question": "How has the range of excess fair value over carrying value for DHR's reporting units changed between the 2023 and 2024 annual goodwill impairment analyses?",
      "original_answer": "In 2023, the excess of the estimated fair value over carrying value for DHR's reporting units ranged from approximately 140% to 495%. In 2024, this range decreased to between approximately 70% and 450%. This indicates a reduction in the lowest excess fair value percentage, suggesting a decline in the overall cushion before potential impairment.",
      "llm_answer": "\nIn the 2023 goodwill‑impairment testing the excess of estimated fair value over carrying value for DHR’s reporting units was roughly **140 % to 495 %** of carrying value. For the 2024 analysis that cushion shrank to about **70 % to 450 %**, showing a noticeable reduction in the excess fair‑value margin across all units.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the percentages for both years are accurate: 140% to 495% in 2023 and 70% to 450% in 2024, with correct formatting and semantic equivalence (e.g., 'roughly', 'about' are acceptable approximations). (2) The answer addresses all parts of the question by clearly comparing the range of excess fair value over carrying value between 2023 and 2024. (3) Entities are correct—DHR is accurately referenced, and the years 2023 and 2024 are properly associated with their respective goodwill impairment analyses. (4) The reasoning is sound: the LLM correctly interprets the narrowing of the range as a 'shrink' or reduction in the margin, which aligns with the ground truth's observation about a decline in the cushion before potential impairment. No calculation errors or factual inaccuracies are present. The answer is contextually relevant, concise, and conveys the same informational content as the original answer with equivalent precision and clarity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1169,
        "completion_tokens": 298,
        "total_tokens": 1467
      },
      "error": null
    },
    {
      "question_id": 161,
      "question": "How did the treatment of canceled RSUs and tax-withheld shares under the 2022 Employee Stock Plan evolve from 2022 to 2023 in terms of their impact on the available share pool?",
      "original_answer": "In 2022, the 2022 Employee Stock Plan specified that canceled RSUs and shares withheld to satisfy tax withholding obligations would increase the number of shares available for grant under the plan by a factor of two times the number of RSUs canceled or shares withheld. However, in 2023, this specific language regarding the factor of two times for RSUs canceled or shares withheld was omitted, indicating a change in how these events were accounted for in the share pool calculation.",
      "llm_answer": "\nFrom 2022 to 2023 the company cancelled fewer RSUs (about 8.1 million vs 9.7 million) and withheld fewer shares for tax obligations (≈ 37 million vs ≈ 41 million). Because the 2022 Employee Stock Plan adds twice the number of canceled RSUs or tax‑withheld shares to the share reserve, the smaller cancellation and withholding figures meant a reduced increase in the pool of shares available for future grants in 2023 compared with 2022.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim. The original answer states that the treatment of canceled RSUs and tax-withheld shares changed from 2022 to 2023 because the 'two times' provision was removed in 2023. However, the LLM incorrectly assumes the two-times rule still applied in 2023 and bases its reasoning on quantitative differences in the number of RSUs canceled and shares withheld. This misrepresents the actual policy evolution. (2) The numeric values (8.1M vs 9.7M RSUs, 37M vs 41M tax-withheld shares) are not present in the original answer and appear to be fabricated or sourced from elsewhere; there is no mention of specific quantities in the ground truth. Therefore, the quantitative claims cannot be verified and are likely inaccurate in context. (3) The multi-hop reasoning is flawed: instead of analyzing the change in plan language (which is the key point), the model focuses on volume differences and their impact under a rule it assumes persisted, when in fact the rule itself was removed. This reflects a failure to correctly synthesize the policy change across years. (4) While the answer is relevant to the topic of share pool impact, it misses the fundamental qualitative shift in plan mechanics, leading to a low correctness score despite some plausible-sounding details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 371,
        "total_tokens": 1608
      },
      "error": null
    },
    {
      "question_id": 162,
      "question": "How has Danaher's strategic relationship with Aldevron evolved between 2023 and 2024, particularly in terms of its financial stake and integration into Danaher's business segments?",
      "original_answer": "In 2023, Danaher had a significant financial stake in Aldevron, as evidenced by the $9,561 million in net cash consideration allocated to Aldevron in the acquisition table, indicating a direct ownership interest. By 2024, Aldevron was no longer listed as a separately accounted stake but had been integrated into the Life Sciences segment as part of Danaher's broader portfolio of acquisitions, including Beckman Coulter, Pall, and IDT. This reflects a strategic shift from holding a standalone stake to full operational integration, aligning Aldevron's capabilities in biopharma research and manufacturing with Danaher’s broader life sciences offerings.",
      "llm_answer": "\nBetween 2023 and 2024 Danaher did **not** change its ownership stake in Aldevron – the company remains a wholly‑owned subsidiary that is fully consolidated into Danaher’s **Life Sciences** segment.  Aldevron’s operations (including its plasmid‑DNA, mRNA and protein‑consumable portfolio, branded under names such as **ALDEVRON**) now contribute to the segment’s recurring revenue and are reflected only in the segment‑wide sales, goodwill and intangible‑asset balances; there is no separate financial line item for Aldevron.  The strategic relationship has simply deepened through continued integration of Aldevron’s product lines into Danaher’s broader Life Sciences offering, but the financial impact is captured as part of the Life Sciences segment’s overall performance.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Aldevron is fully integrated into Danaher's Life Sciences segment by 2024 and no longer reported as a separate financial stake, which aligns with the ground truth. However, it contradicts the original answer by stating Danaher did *not* change its ownership stake between 2023 and 2024, whereas the ground truth indicates a shift from a separately accounted stake (with $9,561 million in net cash consideration explicitly allocated) in 2023 to full integration in 2024—implying a change in financial reporting and strategic treatment. This omission or misrepresentation of the change in stake status is a significant factual inaccuracy. (2) The $9,561 million figure is missing from the LLM answer, which fails to acknowledge the specific financial allocation in 2023 that demonstrates a distinct accounting treatment. While the LLM does not provide incorrect numbers, it omits a key quantitative datum essential to the multi-hop comparison. (3) The reasoning about integration into the Life Sciences segment and the absence of a separate line item is sound and reflects correct synthesis across years and segments. However, the conclusion that the ownership stake 'did not change' contradicts the evolution implied by the shift from standalone allocation to full absorption, indicating a flaw in interpreting the financial implications of the integration. (4) Despite missing the key financial figure and mischaracterizing the continuity of the stake, the LLM captures the post-integration state accurately and maintains contextual relevance. Hence, correctness is reduced due to the critical omission and misstatement about the evolution of the financial stake, but not fully penalized as the integration aspect is well-handled.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 485,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 163,
      "question": "How has Microsoft's strategic positioning of Microsoft 365 evolved between 2023 and 2024, particularly in terms of its integration with AI technologies and its role in the company's commercial business metrics?",
      "original_answer": "In 2023, Microsoft 365 was described as an 'AI first' platform integrating Office, Windows, Copilot, and Enterprise Mobility + Security, with Copilot for Microsoft 365 combining AI with business data to enhance productivity. By 2024, Microsoft had expanded the Microsoft 365 Consumer subscribers metric to include Microsoft 365 Basic subscribers, aligning with internal business management practices and signaling a broader consumer focus. This evolution reflects a strategic shift toward enhancing AI integration and expanding the product's market reach, particularly within the commercial segment.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Microsoft reframed Microsoft 365 as the central AI‑first engine of its commercial business, embedding Copilot (and role‑specific Copilot for Sales, Service and Finance) across Office, Teams, Viva and Windows and launching the consumer‑focused Copilot Pro subscription.  This AI layer is now captured in the “Microsoft Cloud” revenue metric and in the expanded Microsoft 365 subscriber count (which now includes Basic users), helping drive double‑digit growth in Office 365 Commercial seats and contributing to the 23 % rise in Microsoft Cloud revenue and the modest improvement in its cloud‑gross‑margin percentage.  Consequently, Microsoft 365’s AI integration has become a primary growth driver that is explicitly reflected in the company’s commercial‑business performance metrics.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core strategic evolution of Microsoft 365 between 2023 and 2024 with strong qualitative accuracy, correctly identifying the 'AI-first' positioning, integration of Copilot across Office, Teams, Windows, and the expansion into role-specific AI features. It appropriately notes the inclusion of Microsoft 365 Basic subscribers in the metric, aligning with the ground truth's point about broader consumer focus. However, the quantitative accuracy is compromised by introducing unsupported figures: the '23% rise in Microsoft Cloud revenue' and 'double-digit growth in Office 365 Commercial seats' are not present in the original answer and cannot be verified from the provided ground truth. Similarly, the mention of 'cloud-gross-margin percentage' improvement is extraneous and not supported. While the LLM correctly links AI integration to commercial metrics, these specific numbers represent overreach or hallucination. The reasoning is logically sound and synthesizes multi-hop concepts (AI integration → product evolution → impact on business metrics), but the inclusion of unverified percentages reduces factual reliability. The answer remains contextually relevant and semantically aligned in direction, though not in precise quantitative claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 355,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 164,
      "question": "How has Microsoft's positioning and emphasis on Copilot Pro evolved between 2023 and 2024, particularly in terms of its role within Microsoft 365 apps and web-based AI assistance?",
      "original_answer": "In 2023, Copilot Pro was introduced as a consumer subscription service that offered 'faster and more powerful AI assistance in Microsoft 365 apps and on the web.' By 2024, while the core definition remained consistent, the emphasis on Copilot Pro's differentiation and innovation appeared more pronounced, with language such as 'faster and more powerful AI assistance' retained but now embedded within a broader narrative of AI-driven transformation across Microsoft's ecosystem. This suggests a strategic evolution where Copilot Pro is not only a standalone offering but increasingly integrated into the broader AI-first positioning of Microsoft's productivity suite.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Microsoft moved Copilot Pro from a newly‑launched consumer subscription to a core element of its AI‑first Microsoft 365 strategy.  In 2023 the filing introduced Copilot Pro as a service that “offers faster and more powerful AI assistance in Microsoft 365 apps and on the web,” positioning it as an optional add‑on to the broader Copilot stack.  By 2024 the emphasis shifted to embedding that capability directly into the Microsoft 365 suite—highlighting its role in delivering AI‑enhanced productivity within Office, Teams, Windows and the web—so that Copilot Pro is now presented as a key driver of the AI‑first experience across the company’s productivity platform.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Copilot Pro was introduced in 2023 as a consumer subscription offering 'faster and more powerful AI assistance in Microsoft 365 apps and on the web,' and by 2024, its positioning evolved to be more central within Microsoft's AI-first strategy. The LLM correctly captures the shift from an optional add-on to a core component of Microsoft 365's AI-driven experience. (2) There are no numeric values, dates, or financial figures in the question or answer that require verification—only fiscal years (2023 and 2024), which are correctly used. (3) The multi-hop reasoning is sound: the model synthesizes the evolution of Copilot Pro’s strategic role across two time points and connects it to broader ecosystem integration (Office, Teams, Windows), which reflects the intended inference from the original answer. (4) Semantic equivalence is strong—while the LLM adds slight elaboration (e.g., naming specific apps), it does not introduce inaccuracies and enhances clarity without deviating from the source meaning. The only reason for not scoring a 10 is minor: the original emphasizes 'broader narrative of AI-driven transformation,' a slightly more strategic framing than 'core element of its AI-first strategy,' but the difference is one of nuance, not factual inaccuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 382,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 164,
      "question": "How has the structure and availability of the 2007 Omnibus Incentive Plan evolved between 2023 and 2024, particularly in terms of remaining shares available for issuance?",
      "original_answer": "In 2023, the 2007 Omnibus Incentive Plan was described in the context of PSU and RSU awards, vesting conditions, and valuation methods, but no specific figure was provided regarding the remaining shares available for issuance. In contrast, by 2024, the plan explicitly stated that approximately 47 million shares of Danaher common stock remained available for issuance under the plan as of December 31, 2024 (excluding shares underlying outstanding awards). This indicates a more transparent disclosure and potential depletion or tracking of the share pool since the plan's inception, showing a shift in how the company communicates the availability of shares under the plan.",
      "llm_answer": "\nThe 2007 Omnibus Incentive Plan still authorizes up to ≈ 135 million shares, but the pool of unissued shares that can be used for new grants slipped from about 50 million at the end of 2023 to roughly 47 million by the end of 2024.  The decline reflects the shares that were consumed by vested RSUs/PSUs, option exercises and related tax‑withholding, as well as the modest reduction tied to the company’s 2024 share‑repurchase activity, while the plan’s governing terms and award types (options, RSUs, PSUs, etc.) remained unchanged.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that no specific figure was provided for remaining shares available in 2023, but the LLM claims approximately 50 million shares were available at the end of 2023, which is not supported by the original data. Additionally, the LLM asserts the plan authorizes up to ~135 million shares, which is not mentioned or verifiable from the ground truth. While the 47 million shares remaining as of December 31, 2024, is correct and aligns with the original answer, the comparison to 2023 is fabricated. (2) Quantitative accuracy is low because the 50 million figure for 2023 is incorrect or at least unsupported, and the 135 million authorized shares figure is unverified. The 47 million number is accurate, but the implied calculation (50M → 47M) is invalid due to lack of 2023 data. (3) The reasoning is partially sound in that it identifies the types of awards (RSUs, PSUs, options) and factors affecting share depletion (vesting, exercises, tax withholding), but it incorrectly assumes continuity and transparency in disclosure that the ground truth does not confirm for 2023. The mention of share repurchases affecting the pool is speculative and not in the original. (4) Contextual relevance is high because the answer addresses the evolution of share availability and plan structure, but the inclusion of unsupported numbers undermines correctness. The core improvement in disclosure transparency noted in the ground truth is missed, replaced with a false quantitative narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 432,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 165,
      "question": "How did Microsoft's accounting policy regarding the estimated useful lives of server and network equipment evolve between fiscal years 2023 and 2024, and what factors influenced this change?",
      "original_answer": "In fiscal year 2023, Microsoft increased the estimated useful lives of server and network equipment from four years to six years, effective beginning fiscal year 2023. This change was driven by investments in software that improved operational efficiencies and advances in technology. In fiscal year 2024, the policy remained consistent with the updated six-year estimate, indicating that the initial change was sustained and likely integrated into ongoing asset management practices. The continued focus on cloud and AI infrastructure investments further supported the rationale behind extending the useful lives of these assets.",
      "llm_answer": "\nMicrosoft extended the estimated useful life of its server and network equipment from **four years to six years**, and this six‑year estimate was applied beginning in fiscal 2023 and continued unchanged through fiscal 2024. The change was driven by **greater software‑enabled efficiencies in operating those assets and advances in technology** that made longer lifespans realistic. No further adjustment was reported for FY 2024; the policy remains the six‑year useful‑life estimate.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) Quantitatively, all key facts are accurate: the change from four to six years occurred beginning in fiscal year 2023, and the policy remained unchanged in fiscal year 2024. These numbers and timeframes match the original answer exactly. (2) The driving factors—software-enabled efficiencies and technological advances—are correctly identified and align with the stated rationale in the ground truth. (3) The multi-hop reasoning is sound: the model correctly synthesizes that the policy change was implemented in FY2023 and sustained in FY2024, indicating continuity. (4) The answer addresses both parts of the question: the evolution (change and continuation) and the influencing factors. No factual errors, omissions, or misstatements are present. Wording differs slightly but conveys identical meaning. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 274,
        "total_tokens": 1564
      },
      "error": null
    },
    {
      "question_id": 165,
      "question": "How did MDT's exposure to auction rate securities evolve from 2022 to 2023 in terms of fair value and classification within the balance sheet?",
      "original_answer": "In 2022, MDT reported auction rate securities with a fair value of $33 million and classified them under 'Total' in the investment portfolio without specifying a separate balance sheet classification. By 2023, the fair value of auction rate securities remained at $33 million, but they were explicitly classified under 'Other Assets' instead of being included in the broader investment category. This indicates a shift in how MDT categorized these securities on its balance sheet, moving from a general investment classification to a more distinct reporting under other assets.",
      "llm_answer": "\nBetween fiscal 2022 (April 29, 2022) and fiscal 2023 (April 28, 2023) Medtronic’s auction‑rate‑security exposure was essentially unchanged – the securities carried a cost of $36 million, an unrealized loss of $3 million and a fair‑value of $33 million, and they remained classified in the “Other Assets” line of the consolidated balance sheet (Level 3).",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains partially correct quantitative information but fails on key qualitative and reasoning aspects. (1) Quantitatively, the fair value of $33 million is correct for both years, and the cost/unrealized loss details ($36M cost, $3M loss) are plausible but not present in the original answer, so their accuracy cannot be verified against ground truth. The fiscal dates (April 29, 2022, and April 28, 2023) are specific but not contradicted by the original. (2) However, the critical error is in classification: the LLM claims auction rate securities were classified under 'Other Assets' in both years, while the ground truth states they were classified under 'Total' in the investment portfolio in 2022 and only moved to 'Other Assets' in 2023. This misrepresents a key evolution in balance sheet classification. (3) The multi-hop reasoning is flawed because the model fails to recognize the change in classification over time — a central part of the question. Instead, it asserts no change in classification, contradicting the original answer. (4) Contextually, the response is relevant and addresses exposure in terms of fair value and classification, but the incorrect portrayal of the classification timeline significantly undermines factual correctness. Thus, while numbers are mostly aligned, the reasoning and entity classification accuracy are deficient, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1231,
        "completion_tokens": 389,
        "total_tokens": 1621
      },
      "error": null
    },
    {
      "question_id": 167,
      "question": "How did the net gains or losses from Cisco's available-for-sale debt investments change between fiscal years 2023 and 2024, and what does this indicate about the company's investment performance in this category?",
      "original_answer": "In fiscal year 2023, Cisco reported a net loss of $21 million from its available-for-sale debt investments, while in fiscal year 2024, this loss increased to $67 million. This indicates a significant worsening in investment performance related to this category year-over-year.",
      "llm_answer": "\nThe company’s available‑for‑sale debt portfolio generated an unrealized loss of **$67 million in fiscal 2024**, compared with a **$21 million loss in fiscal 2023** – an increase of roughly **$46 million**. This widening loss, disclosed in the “Other Income (Loss), Net” table (page 55 of the 2024 filing) and reflected in the fair‑value declines shown for the debt securities, indicates that the portfolio’s performance deteriorated over the year, likely due to falling bond prices amid rising interest rates.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the net losses for both fiscal years: $21 million in 2023 and $67 million in 2024, matching the ground truth exactly. The calculated increase in loss of $46 million ($67M - $21M) is accurate. (2) All numeric values are correct and properly formatted; the calculation of the difference between the two years is precise. (3) The reasoning is sound: the answer correctly synthesizes that the increase in net loss indicates deteriorating investment performance, and it appropriately infers a plausible cause (falling bond prices due to rising interest rates), which aligns with typical market dynamics for available-for-sale debt securities. While the ground truth does not include the interest rate explanation, the LLM's addition is reasonable and contextually supported, not speculative. (4) The answer fully addresses both parts of the question: the change in net gains/losses and what it indicates about performance. The only minor point preventing a perfect 10 is that the LLM attributes the data to a specific page (page 55) and table, which, while potentially accurate, goes slightly beyond the scope of the ground truth verification and introduces a detail not confirmed in the reference. However, this does not affect factual correctness. Overall, the answer is factually accurate, complete, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1213,
        "completion_tokens": 381,
        "total_tokens": 1594
      },
      "error": null
    },
    {
      "question_id": 170,
      "question": "How did Cisco's approach to the APJC region evolve between 2023 and 2024 in terms of operational structure versus financial investment, and what implications does this have for its revenue model in that region?",
      "original_answer": "In 2023, Cisco directly operated in the APJC region as one of its three geographic segments, indicating a strong operational presence focused on delivering products and services. By 2024, Cisco's relationship with APJC evolved to include financial investments, specifically through equity instruments categorized as marketable equity securities, non-marketable equity securities, and equity method investments. While the 2023 filing emphasized operational delivery and customer engagement in APJC, the 2024 financial statements suggest a parallel strategy of capital participation, potentially signaling a shift toward leveraging local market growth through investment rather than solely through direct sales. This dual approach could indicate a broader revenue model incorporating both operational income and investment returns, though the filings do not quantify the specific financial impact of these investments on Cisco's APJC revenue.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Cisco moved away from the capital‑intensive, inventory‑heavy structure it used in APJC—evidenced by the 2023 10‑K’s inventory write‑downs and purchase‑commitment liabilities (page 66 (e))—and toward a leaner, service‑oriented model in which third‑party financing is used more selectively and revenue is recognized over time (pages 66 (g)‑(h) and the 2024 Notes on leases and deferred revenue).  As a result, the APJC revenue mix has shifted from large, one‑off hardware sales to a higher proportion of recurring software‑and‑services (subscription) income, making the region’s cash flow more predictable but also more dependent on continued adoption of those recurring offerings.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and does not align with the ground truth. (1) It introduces claims not present in the original answer, such as Cisco moving away from a 'capital-intensive, inventory-heavy structure' in APJC, citing inventory write-downs and purchase-commitment liabilities from page 66(e) of the 10-K. However, the ground truth makes no mention of such operational shifts or specific financial disclosures related to inventory or capital structure. Instead, the original answer focuses on a shift from direct operational presence to including financial investments (marketable and non-marketable equity securities, equity method investments) in 2024. The LLM completely misses this key point. (2) There are no verifiable numbers in the LLM response (e.g., no dollar amounts, percentages, or specific financial figures), and it references document pages (e.g., page 66) and sections (leases, deferred revenue) not corroborated by the ground truth, undermining quantitative accuracy. (3) The multi-hop reasoning is flawed: the question asks about evolution in operational structure versus financial investment, but the LLM conflates this with a shift from hardware to software/services revenue and third-party financing, which is not supported by the original answer. The ground truth emphasizes a dual strategy of operational delivery plus new financial investments, not a replacement of hardware sales with subscriptions. (4) While the LLM attempts to address Cisco's evolving model in APJC, it fabricates the nature of that evolution, making the response factually inaccurate despite being contextually in the right domain. The mention of recurring revenue and service orientation may be plausible for Cisco generally but is not what the ground truth identifies as the key change between 2023 and 2024 in APJC. Thus, the answer fails on correctness and qualitative reasoning, though it is somewhat relevant to the region and timeframe.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 525,
        "total_tokens": 1953
      },
      "error": null
    },
    {
      "question_id": 172,
      "question": "How has Apple's approach to App Store commissions and regulatory compliance evolved between 2022 and 2024, particularly in response to legal and market pressures?",
      "original_answer": "In 2022, Apple acknowledged that changes to the App Store, including those in response to legal and market conditions, could reduce the volume of sales and the commission it earns on those sales, potentially affecting its financial condition. By 2024, Apple had implemented specific changes, particularly in the U.S. and the European Union, to address legal pressures such as the Digital Markets Act (DMA). These changes included new business terms, alternative fee structures, alternative app distribution methods, and additional developer tools and APIs. These adjustments reflect a shift from a more general acknowledgment of potential changes to concrete actions taken in response to regulatory demands, which could significantly affect App Store revenue and commission structures.",
      "llm_answer": "\nBetween 2022 and 2024 Apple shifted from a largely static 30 percent commission model to a more tiered structure that includes a 15 percent rate for small‑business developers and new “alternative‑payment” and “alternative‑distribution” options required by the EU Digital Markets Act.  The changes were driven by antitrust litigation (e.g., the Epic case), U.S. and EU regulatory pressure, and market demands, leading Apple to revise how it communicates in‑app purchasing, to offer lower‑fee pathways for certain categories, and to adjust its App Store fee schedule—while still retaining the standard 30 percent fee for the majority of apps.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Apple's shift from a static 30% commission model to a more flexible structure, including the 15% rate for small developers, which matches known App Store Small Business Program terms. While the original answer does not specify the 15% rate, this detail is factually correct and adds precision. (2) The mention of alternative-payment and alternative-distribution options in response to the EU's Digital Markets Act (DMA) is accurate and reflects concrete 2024 changes. The LLM correctly ties these to regulatory pressures like the Epic litigation and broader antitrust scrutiny. (3) The reasoning is sound: it synthesizes Apple’s evolving stance from general risk acknowledgment (2022) to specific structural changes (2024), demonstrating multi-hop understanding across time, regulation, and business model shifts. (4) The answer is contextually excellent—directly addressing how legal and market pressures shaped commission and compliance evolution. The only minor limitation is that it doesn’t explicitly reference Apple’s 2022 risk disclosure about potential revenue impact, though the implication is present. Overall, the answer is factually rich, semantically equivalent, and slightly exceeds the original in specificity without introducing errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 374,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 175,
      "question": "How did the allocation strategy for Texas Instruments' U.S. Retiree Health Care Plan evolve between fixed income securities and equity securities from 2022 to 2024?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan had a diversified mix of fixed income securities and equity securities, with fixed income and cash equivalents totaling $248 million and equity securities at $137 million. By 2024, the allocation strategy showed a significant shift toward a more conservative posture, with fixed income securities and cash equivalents comprising 80% of the portfolio, while equity securities made up only 20%. This reflects a notable increase in emphasis on fixed income securities compared to equities, even though the relative proportions remained the same between 2023 and 2024, suggesting a strategic decision to prioritize capital preservation.",
      "llm_answer": "\nBetween 2022 and 2024 the U.S. Retiree Health Care Plan kept a heavy fixed‑income tilt, with the proportion of plan assets in fixed‑income securities edging up from roughly 78 % in 2022 to about 80 % in 2024, while equity holdings remained steady at roughly 20 % (staying within the 15‑25 % target range). This modest shift reflects the plan’s strategy of maintaining a dominant fixed‑income base while holding a relatively constant, low‑to‑mid‑teens equity exposure.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the overall trend of increasing fixed income allocation from 2022 to 2024 and stable equity exposure, aligning with the ground truth's emphasis on a more conservative posture. However, there is a discrepancy in the 2022 fixed income and equity percentages. The ground truth reports $248 million in fixed income and cash equivalents and $137 million in equities in 2022, which totals $385 million. This implies fixed income was approximately 64.4% ($248M / $385M) and equities 35.6% in 2022, not the 78% and 20% cited by the LLM. The LLM’s claim of a 'modest shift' from 78% to 80% fixed income is therefore factually incorrect. Additionally, the ground truth does not mention a '15–25% target range' for equities or characterize the 20% as 'low-to-mid-teens,' which introduces unsupported detail. (2) The dollar amounts from 2022 are missing in the LLM answer, and the percentages are miscalculated or misreported. While the 2024 allocation (80% fixed income, 20% equities) matches the ground truth, the 2022 figures do not. (3) The reasoning about a strategic shift toward conservatism is sound and reflects correct multi-hop synthesis between years, but the justification based on incorrect 2022 percentages weakens the quantitative foundation. The LLM correctly infers stability between 2023 and 2024, consistent with the ground truth. (4) The contextual relevance is high as the answer directly addresses the evolution of allocation strategy. Qualitative accuracy is good due to correct directional interpretation, but quantitative accuracy is reduced due to incorrect percentages and unsupported target ranges. Correctness score is 7 because core facts about the 2024 allocation and strategic conservatism are right, but key 2022 data is wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 489,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 177,
      "question": "How has Texas Instruments' strategic emphasis on Embedded Processing Products evolved from 2022 to 2024, particularly in terms of its contribution to the company's competitive advantages and segment reporting structure?",
      "original_answer": "In 2022, Texas Instruments described Embedded Processing as one of its core product lines within a broader business model that emphasized four competitive advantages: manufacturing and technology strength, a broad product portfolio, strong market channels, and product diversity and longevity. Embedded Processing was positioned as part of this integrated strategy but was not highlighted as a standalone reportable segment. By 2024, Embedded Processing was elevated to a reportable segment alongside Analog, indicating a strategic shift where the company explicitly called out Embedded Processing as a key driver of value. This change suggests that Embedded Processing has become more central to TI's competitive positioning, particularly in terms of enabling optimized performance, power, and cost across a range of customer applications. The elevation to a reportable segment also implies greater operational and financial focus, aligning with the company’s long-term objective of strengthening its competitive advantages and driving free cash flow growth.",
      "llm_answer": "\nFrom 2022 through 2024 Texas Instruments kept Embedded Processing as a distinct reportable segment, but the segment’s revenue fell from **$3.26 billion (2022)** to **$2.53 billion (2024)** and its operating profit dropped from **$1.25 billion (2022)** to **$0.35 billion (2024)** (see TXN_10k_2022 pp. 20‑21 and TXN_10k_2024 pp. 30‑31).  The company continues to treat Embedded Processing as one of the four sustainable competitive advantages—providing “digital brains” that complement its analog signal‑conditioning portfolio and driving growth in industrial and automotive end‑markets—but the strategic emphasis has shifted toward leveraging Analog’s higher‑margin cash generation, making Embedded Processing a smaller, yet still strategic, contributor to overall segment revenue and profit.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth in both factual content and reasoning. (1) QUANTITATIVE ACCURACY: The provided financial figures ($3.26B revenue in 2022, $2.53B in 2024, and operating profit dropping from $1.25B to $0.35B) are not supported by the ground truth, which does not include any specific financials for Embedded Processing in those years. More critically, the claim that Embedded Processing was a 'reportable segment' in 2022 is false according to the original answer, which states it was *not* a standalone reportable segment until 2024. (2) COMPLETENESS: The answer fails to correctly describe the evolution of the segment reporting structure—asserting it was always reportable when in fact the key strategic shift was its *elevation* to reportable status in 2024. This misrepresents the core of the question. (3) ENTITY & REASONING: The LLM incorrectly identifies the timeline of segment classification, undermining the multi-hop reasoning. The strategic emphasis is misrepresented: rather than being 'smaller' due to declining profits, the ground truth indicates Embedded Processing became *more* strategically central by being elevated to a reportable segment. (4) SEMANTIC EQUIVALENCE: The LLM conveys the opposite of the correct narrative—downplaying Embedded Processing’s role due to alleged financial decline, while the truth is that TI increased its strategic focus and structural importance. The mention of competitive advantages (e.g., complementing analog portfolio) is partially aligned but used to support an incorrect conclusion. Overall, the answer contains fabricated numbers and a flawed premise, warranting a low correctness score despite addressing the general topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1481,
        "completion_tokens": 469,
        "total_tokens": 1951
      },
      "error": null
    },
    {
      "question_id": 177,
      "question": "How did TMO's issuance and valuation of its 2.00% 10-Year Senior Notes evolve between 2022 and 2024?",
      "original_answer": "In 2022, TMO reported $1,200 million in 2.00% 10-Year Senior Notes due on October 15, 2031, with an effective interest rate of 2.23%. By 2024, the same category of 2.00% 10-Year Senior Notes showed no change in the principal amount at $1,200 million, and the effective interest rate remained at 2.23%. This indicates that TMO maintained a consistent position on this specific debt instrument over the two-year period, with no new issuances or repayments affecting this line item.",
      "llm_answer": "\nThe $2.00 % 10‑Year Senior Notes (due 10/15/2031) were originally issued in 2021 and continued to be outstanding through 2024.  Both the 2022 10‑K (page 87) and the 2024 10‑K (page 47) show the notes carried at a $1.20 billion carrying amount with an effective interest rate of 2.23 %—the same figure in each year, indicating only routine amortization of the original discount and issuance costs and no new issuance or redemption between 2022 and 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the principal amount ($1.20 billion = $1,200 million), effective interest rate (2.23%), and maturity date (October 15, 2031) as stated in the ground truth. It accurately notes no change between 2022 and 2024 in the carrying amount or interest rate, aligning with the original answer's conclusion of a consistent debt position. The only minor discrepancy is the mention of issuance in 2021, which is factually likely correct but not part of the original answer's scope (which focused on 2022–2024 evolution); this does not detract from correctness. (2) All numeric values—$1.20 billion (equivalent to $1,200 million), 2.23% effective rate, 2.00% coupon rate, and 2031 maturity—are quantitatively accurate. Format variation ($1.20 billion vs $1,200 million) is acceptable and semantically equivalent. (3) The multi-hop reasoning is sound: the model correctly synthesizes data from both the 2022 and 2024 10-K filings, compares the carrying amount and interest rate over time, and infers no new issuance or repayment occurred. It supports this with specific document references (page numbers), demonstrating strong evidence-based reasoning. (4) The answer is fully contextually relevant, directly addressing how the issuance and valuation evolved (or did not evolve) over the specified period. The conclusion about routine amortization is a reasonable qualitative inference from unchanged carrying value and effective rate. Overall, the answer matches the ground truth in substance and adds minor contextual detail (2021 issuance) without introducing error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1221,
        "completion_tokens": 439,
        "total_tokens": 1661
      },
      "error": null
    },
    {
      "question_id": 178,
      "question": "How has the financial performance of REMICADE evolved between 2022 and 2024, and what does this indicate about its role in Johnson & Johnson's Pharmaceutical segment?",
      "original_answer": "In 2022, REMICADE was listed as a key product in Johnson & Johnson's Pharmaceutical segment, specifically within the Immunology therapeutic area, indicating its importance in treating immune-mediated inflammatory diseases. By 2024, REMICADE's sales had declined significantly, from $1,839 million in 2023 to $1,605 million in 2024, representing a 12.8% decrease. This decline suggests a diminishing contribution of REMICADE to the company's Immunology revenue, potentially due to market saturation, increased competition, or the emergence of newer biologics within the segment.",
      "llm_answer": "\nREMICADE’s revenue has been on a steep downward trajectory: $1.84 billion in 2023 (‑12.8 % YoY) and $1.60 billion in 2024 (‑12.8 % YoY), following an even larger decline from roughly $2.0 billion in 2022.  The drop reflects persistent biosimilar competition and share loss—especially in Europe and the United States—so that the drug now contributes only a modest, legacy‑type cash flow to the Pharmaceutical segment, while growth in the segment is increasingly driven by newer immunology and specialty products such as TREMFYA, STELARA and the oncology pipeline.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the declining trend in REMICADE's financial performance and attributes it to biosimilar competition, which aligns with the ground truth. It also correctly notes the drug's reduced role in Johnson & Johnson's Pharmaceutical segment, emphasizing legacy cash flow and shift toward newer products like TREMFYA and STELARA—this matches the original answer’s implication about diminishing contribution due to competition and newer biologics. (2) Quantitatively, the LLM states $1.84 billion in 2023 and $1.60 billion in 2024, which are acceptable rounding approximations of the true values ($1,839 million and $1,605 million). However, it incorrectly claims a -12.8% YoY decline in both 2023 and 2024. The 12.8% drop refers only to the 2023-to-2024 decline (from $1,839M to $1,605M), not the prior year. Additionally, the claim of ~$2.0 billion in 2022 is unsupported by the original data—no 2022 sales figure was provided in the ground truth, so this extrapolation introduces inaccuracy. (3) The multi-hop reasoning is strong: the model connects REMICADE’s declining sales to its strategic role within J&J’s Immunology portfolio and correctly contrasts it with newer growth drivers. This demonstrates sound synthesis across time and product lines. (4) Despite minor numerical overreach and one unsupported inference (2022 sales), the answer captures the core trend and strategic implication accurately. Hence, correctness is high but not perfect due to the quantitative inaccuracies and unverified 2022 figure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 426,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 179,
      "question": "How did the sales performance of REMICADE evolve from 2022 to 2024, and what does this indicate about its market position within JNJ's Immunology portfolio?",
      "original_answer": "In 2022, REMICADE had sales of $3,190 million, showing a decline of 14.9% compared to 2020. By 2024, its sales had further decreased to $1,605 million, representing a 12.8% drop from 2023. This consistent decline indicates a weakening market position of REMICADE within JNJ's Immunology portfolio over time.",
      "llm_answer": "\nREMICADE’s sales have continued to slide – $1.84 billion in fiscal 2023, down from roughly $1.9 billion in fiscal 2022, and falling further to $1.61 billion in fiscal 2024 (a 12.8 % drop from 2023).  This sustained decline, driven by biosimilar competition and share loss, has reduced REMICADE’s contribution to J&J’s Immunology portfolio, leaving newer Immunology assets such as STELARA and TREMFYA to shoulder the bulk of growth.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the declining trend in REMICADE sales from 2022 to 2024 and attributes it to biosimilar competition and loss of market share, which aligns with the ground truth's implication of a weakening market position. It also correctly notes the 12.8% drop from 2023 to 2024. However, the sales figures for 2022 and 2023 are inaccurate. The ground truth states 2022 sales were $3,190 million, but the LLM reports 'roughly $1.9 billion', which is off by over $1.2 billion. The LLM’s 2024 figure ($1.61 billion) is close to the ground truth ($1,605 million), but the 2023 figure ($1.84 billion) is not supported by the ground truth, which does not provide 2023 data directly but implies a value based on a 12.8% drop from 2024. (2) The 12.8% decline from 2023 to 2024 is correctly cited, but the earlier comparison to 2022 is flawed—ground truth uses 2020 as a reference point (14.9% decline from 2020 to 2022), which the LLM omits entirely. The LLM incorrectly frames the decline as ongoing from 2022 to 2023 to 2024 with incorrect magnitudes. (3) The multi-hop reasoning is partially sound: the model infers declining market position within JNJ’s Immunology portfolio and correctly contrasts REMICADE with newer assets like STELARA and TREMFYA, which is contextually valid and adds useful qualitative insight not in the ground truth but logically consistent. (4) The correctness score is 7 because core facts (downward trend, 12.8% recent drop, weakening position) are accurate, but early sales numbers are significantly wrong. Quantitative accuracy is 6 due to major discrepancies in 2022 sales. Qualitative accuracy is 8 due to sound reasoning and correct interpretation of market dynamics. Contextual relevance is 10—answer fully addresses the question’s scope and adds relevant context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1187,
        "completion_tokens": 496,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 180,
      "question": "How has the sales performance of REMICADE evolved between 2021 and 2024, and what factors contributed to this change?",
      "original_answer": "REMICADE's sales declined significantly from $16.8 billion in 2021 (as part of total Immunology sales) to $1,605 million in 2024, reflecting a 12.8% decrease from 2023 to 2024 alone. This decline was primarily driven by biosimilar competition in the U.S. and other global markets, which intensified over time and led to a continued reduction in REMICADE sales.",
      "llm_answer": "\nBetween 2021 and 2024 REMICADE’s sales fell sharply—from roughly **$3.2 billion in 2021 to $1.84 billion in 2023 and $1.61 billion in 2024**, a cumulative decline of about **50 %** over the period. The drop is attributed primarily to **intensifying biosimilar competition** (including European biosimilar entrants and U.S. launches), **loss of patent‑derived market exclusivity**, and **share erosion in the immunology portfolio**, which together outweighed any modest growth from the broader immunology franchise.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key financial figures. The ground truth states REMICADE's sales were part of a $16.8 billion Immunology category in 2021, but the LLM incorrectly reports REMICADE-specific sales as $3.2 billion in 2021, which is not supported by the original data. The 2024 figure of $1.61 billion in the LLM answer is close to the ground truth of $1,605 million (i.e., $1.605 billion), so this number is acceptable with rounding. However, the 2023 figure of $1.84 billion in the LLM answer does not align with the ground truth implication of a 12.8% drop to $1,605 million in 2024 — working backward, this would place 2023 sales at approximately $1,842 million, so $1.84 billion is numerically consistent for 2023. Still, the starting point in 2021 is fundamentally wrong. (2) Calculations: The LLM claims a 50% cumulative decline, but using its own numbers ($3.2B to $1.61B) this is roughly 49.7%, so calculation is accurate — but based on incorrect inputs. The ground truth implies a much steeper decline from a higher base, which the LLM fails to capture. (3) Multi-hop reasoning: The LLM correctly identifies biosimilar competition, loss of patent exclusivity, and market share erosion as drivers, which aligns with the ground truth’s emphasis on biosimilar competition in the U.S. and global markets. This qualitative reasoning is sound and reflects proper synthesis of contributing factors. (4) Contextual relevance is high — the answer addresses both parts of the question (sales evolution and contributing factors) and stays focused on REMICADE’s performance. However, the severe error in the 2021 sales figure undermines overall correctness, as it misrepresents the scale and trajectory of the decline. The model appears to have confused REMICADE’s standalone sales with a subset or misattributed segment data. Final scores reflect partial credit for correct directional trend, accurate 2023–2024 numbers, and valid causal factors, but heavy penalty on quantitative accuracy due to incorrect baseline sales in 2021.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1211,
        "completion_tokens": 559,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 181,
      "question": "How did the status and commercial performance of STELARA (ustekinumab) evolve between 2022 and 2024?",
      "original_answer": "In 2022, STELARA was in the filing stage for the treatment of pediatric patients with juvenile psoriatic arthritis in the U.S., indicating it was under regulatory review but not yet approved. By 2024, STELARA had achieved significant commercial success, generating $10,361 million in sales, a decrease from $10,858 million in 2023, representing a 4.6% decline in total sales. This reflects that STELARA had transitioned from a product in active regulatory development to a mature, high-revenue-generating drug facing slight sales decline, suggesting market saturation or increased competition.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 STELARA’s sales peaked and then began to fall – worldwide sales dropped 4.6 % in 2024 to $10.36 bn (down from $10.86 bn in 2023), with the decline driven by share loss in Europe as biosimilar entrants entered the market and by ongoing biosimilar competition in the U.S. U.S. sales of STELARA were about $6.7 bn in 2024, and the company expects biosimilar launches in both Europe and the United States in 2025 to further pressure its commercial performance.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and addresses the evolution of STELARA's status and commercial performance between 2022 and 2024. (1) Quantitatively, the LLM reports a 4.6% decline in 2024 with sales of $10.36 billion, down from $10.86 billion in 2023. The ground truth specifies $10,361 million (i.e., $10.361 billion) and $10,858 million ($10.858 billion), so the LLM's rounding to $10.36B and $10.86B is acceptable, though $10.86B slightly overstates the 2023 figure by $2 million. The percentage decline is correctly calculated as ~4.6%. (2) The LLM adds contextual detail not in the original answer—such as U.S. sales (~$6.7B in 2024), biosimilar competition in Europe and the U.S., and expected 2025 biosimilar launches—which is factually plausible and enhances relevance, though not present in the ground truth. (3) Regarding multi-hop reasoning: the LLM correctly infers declining sales trend and contributing factors, but does not mention the 2022 regulatory status (filing for pediatric use in the U.S.), which is a key part of the original answer and reflects product lifecycle progression. This omission reduces completeness. (4) Entity accuracy is strong: STELARA, correct years (2022–2024), and financial metrics are properly used. The answer is semantically aligned with the ground truth in commercial performance, but misses the regulatory development aspect in 2022. Thus, while the commercial trajectory is accurately conveyed, the full evolution of 'status' (regulatory + commercial) is not fully captured, justifying a score of 8 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 428,
        "total_tokens": 1688
      },
      "error": null
    },
    {
      "question_id": 182,
      "question": "How did the total net revenue from Restasis in the United States change between 2023 and 2024, and what was the percentage decrease in each year?",
      "original_answer": "In 2023, the United States net revenue from Restasis was $382 million, which decreased to $172 million in 2024. This represents a 38.5% decrease in 2023 compared to 2022, and a further 55.2% decrease in 2024 compared to 2023.",
      "llm_answer": "\nThe United States Restasis net revenue fell 38.5 % in 2023, dropping from $621 million in 2022 to $382 million in 2023, and then slipped another 55.2 % in 2024 to $172 million (down from $382 million in 2023).",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: $621 million in 2022 (implied from context), $382 million in 2023, and $172 million in 2024. The percentage decreases of 38.5% from 2022 to 2023 and 55.2% from 2023 to 2024 are correctly stated and align with the original answer. (2) The calculations are sound: a 38.5% decrease from $621M to $382M and a 55.2% decrease from $382M to $172M are mathematically accurate. (3) The multi-hop reasoning is correct—the model synthesizes data across three years (2022, 2023, 2024), correctly identifying the year-over-year changes even though the question only explicitly asked about 2023 and 2024. (4) The answer is semantically equivalent to the original, providing the same core information with slightly more context (including 2022 revenue), which enhances clarity without introducing error. All entities (Restasis, United States net revenue, correct years) are accurately referenced. The response fully addresses both parts of the question: the change in total net revenue between 2023 and 2024, and the percentage decrease in each year (interpreted as year-over-year change for 2023 and 2024). No factual, numerical, or reasoning errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1108,
        "completion_tokens": 354,
        "total_tokens": 1463
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has the role and strategic importance of Master Lease Agreements evolved between 2022 and 2023 in supporting AMT's international growth and tenant relationships?",
      "original_answer": "In 2022, AMT emphasized that master lease agreements were comprehensive in nature and instrumental in building strong strategic partnerships with tenants, significantly reducing colocation cycle times and enabling rapid deployment of equipment across its international portfolio of approximately 177,000 communications sites. By 2023, AMT reiterated the importance of these agreements in providing consistent, long-term revenue and reducing non-contractual churn, while operating an expanded international portfolio of approximately 182,000 communications sites. The evolution reflects a continued strategic focus on leveraging master lease agreements to support international growth and tenant retention, with an emphasis on mitigating risks such as customer consolidation and regulatory changes.",
      "llm_answer": "\nBetween 2022 and 2023 the Master Lease Agreements shifted from being merely a source of recurring rent to a strategic‑partnership tool that underpins AMT’s international expansion.  By locking in multi‑year, escalation‑linked terms across its overseas sites, the MLAs reduce churn, accelerate colocation cycles and give tenants the ability to deploy equipment quickly—enabling AMT to grow its portfolio in emerging markets (Asia‑Pacific, Africa, Europe and Latin America) while preserving predictable, long‑term cash flow amid heightened churn in the U.S. and India.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core strategic evolution of Master Lease Agreements (MLAs) from 2022 to 2023 in supporting AMT's international growth and tenant relationships, aligning well with the ground truth in intent and context. It correctly identifies MLAs as strategic tools that reduce churn, accelerate colocation, and enable rapid deployment—supporting international expansion. However, it omits specific quantitative details present in the original answer: the exact size of AMT’s international portfolio (177,000 sites in 2022 and 182,000 in 2023). While the LLM mentions expansion in regions like Asia-Pacific, Africa, Europe, and Latin America, the ground truth does not specify these regions, making that addition speculative. The answer correctly emphasizes long-term revenue, reduced churn, and cash flow predictability, especially amid U.S. and Indian market challenges, which is consistent with the 2023 focus on mitigating customer consolidation and regulatory risks. The reasoning is logically sound and synthesizes the strategic shift across years, but lacks explicit mention of 'non-contractual churn' and 'regulatory changes' as risk factors. Quantitative accuracy is high in terms of conceptual alignment (e.g., portfolio growth implied), but the absence of exact site numbers reduces precision. Overall, the answer is contextually relevant and semantically close, with minor omissions affecting completeness rather than correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 399,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has the role of Google Marketing Platform in the company's advertising revenue generation evolved between 2023 and 2024, particularly in relation to how advertising revenues are recognized and managed across Google Network properties?",
      "original_answer": "In 2023, Google Marketing Platform was directly involved in the recognition of advertising revenues on a gross basis for Google Network properties, meaning the full amount billed to customers was recorded as revenue. By 2024, the platform's role evolved to include a more nuanced evaluation of its principal versus agent status, with an emphasis on its control over advertising inventory before transfer to customers, further supporting the gross revenue reporting. Additionally, 2024 introduced a more detailed explanation of the platform's role in managing advertising across Google Network properties, highlighting its central function in both performance and brand advertising delivery.",
      "llm_answer": "\nBetween 2023 and 2024 the filing shows that Google Marketing Platform continues to serve as a primary channel for advertisers to purchase inventory on Google’s Network properties, but the way that advertising revenue is recognized and managed has not changed materially.  In both years the company evaluates whether it is the principal (gross basis) or agent (net basis) for ads placed on the Network; it generally reports those revenues on a **gross basis**—recording the full amount billed to the customer as revenue and the corresponding payments to Network partners as cost of revenues—​and this treatment is explicitly described for Google Marketing Platform in the 2023 and 2024 notes on advertising‑revenue recognition (pages 56‑59 of the 2023 10‑K and pages 58‑59 of the 2024 10‑K).  Consequently, the Platform’s contribution to advertising revenue remains governed by the same gross‑basis recognition and the same principal‑vs‑agent assessment across Google Network properties in both fiscal years.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually accurate in stating that Google Marketing Platform reports advertising revenue on a gross basis in both 2023 and 2024 and correctly references the principal-versus-agent evaluation. It also accurately cites the relevant pages in the 10-K filings, which supports contextual relevance. However, the core of the question asks about the *evolution* of the platform’s role between 2023 and 2024, and the LLM incorrectly concludes that there was 'no material change,' which directly contradicts the ground truth. According to the original answer, the platform's role *did* evolve in 2024 with a more nuanced assessment of principal vs. agent status and an enhanced explanation of its central function in managing both performance and brand advertising. This evolution is a key multi-hop insight that the LLM failed to capture, resulting in a significant qualitative inaccuracy. While all entities (Google Marketing Platform, Google Network properties, gross revenue recognition) and years are correctly identified, and no numerical inaccuracies exist (hence high quantitative accuracy), the failure to identify and articulate the change over time undermines the correctness of the response. The answer is relevant and well-structured but misses the central analytical point of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1447,
        "completion_tokens": 364,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did the volume and fair value of Federal Funds Purchased & Sec Loaned change between 2023 and 2024, and what does this indicate about BAC's short-term funding strategies?",
      "original_answer": "In 2023, the volume of Federal Funds Purchased & Sec Loaned showed a net change of $16,466 million, indicating a significant increase in short-term funding liabilities. By 2024, the fair value of this category was reported at $192,859 million, a substantial increase from the prior year. This suggests that BAC significantly expanded its reliance on short-term secured funding mechanisms in 2024, likely to support its trading and liquidity management activities.",
      "llm_answer": "\nThe 2023 10‑K reports an average balance of Federal‑funds purchased / securities loaned of **≈ $301 bn**, whereas the 2024 filing shows the fair‑value of that liability at **≈ $482 bn** (a roughly 60 % increase).  This jump in both the amount borrowed and its fair‑value signals that Bank of America deliberately expanded its short‑term wholesale funding in 2024—using more federal‑funds and securities‑loan arrangements to finance loan growth and manage liquidity amid higher interest‑rate volatility.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies in numbers and metrics. The ground truth states that in 2023, the net change in volume was $16,466 million (not an average balance of $301 billion), and in 2024, the fair value was $192,859 million (not $482 billion). The LLM's figures are more than double the correct values, making them severely incorrect. Additionally, the LLM incorrectly reports the 2023 figure as an 'average balance' and the 2024 figure as 'fair value', failing to align with the ground truth's description of a net volume change in 2023 and fair value in 2024. The claimed ~60% increase is unsupported due to incorrect base numbers. (2) Calculations are invalid: using $301B and $482B implies a ~60% increase, but the actual increase from the ground truth data (from a net $16.5B increase in 2023 to a total fair value of $192.9B in 2024) cannot support that percentage without knowing the 2023 base level. The LLM misrepresents the nature of the data (net change vs. total balance). (3) Multi-hop reasoning is flawed: the model fails to correctly interpret the type of data (net volume change vs. average balance vs. fair value), leading to incorrect synthesis. It also attributes the increase to 'loan growth' and 'interest-rate volatility', which are not mentioned or implied in the original answer. (4) Despite incorrect numbers and reasoning, the LLM captures the general direction (increase in short-term funding) and the relevance to BAC's short-term funding strategy, which supports a moderate contextual relevance score. However, the severe quantitative errors dominate the evaluation, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 456,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has PepsiCo's disclosure regarding the sensitivity of pension and retiree medical plan liabilities to market fluctuations evolved between 2022 and 2024?",
      "original_answer": "In 2022, PepsiCo mentioned that the exposure of pension and retiree medical plan assets and liabilities to risks related to market fluctuations was discussed in 'Our Critical Accounting Policies and Estimates.' By 2024, the company expanded this disclosure, explicitly linking the sensitivity of these liabilities not only to market fluctuations but also to inflationary, deflationary, and recessionary conditions. This broader context indicates a more detailed characterization of the macroeconomic risks affecting these obligations, beyond just market volatility.",
      "llm_answer": "\nBetween 2022 and 2024 the discussion moved from a generic statement that pension and retiree‑medical plan assets and liabilities are exposed to market‑driven factors such as interest‑rate and inflation changes (2022 “Critical Accounting Policies and Estimates”) to a concrete, quantitative disclosure in the 2024 Form 10‑K.  The 2024 filing reports a $272 million increase in other pension and retiree‑medical benefits expense, attributing it to lump‑sum settlement payments and a group‑annuity purchase, and explicitly explains how these market‑related actions affect the liability’s valuation.  Thus, the company’s disclosure evolved from a high‑level risk note to a detailed, financially‑quantified explanation of the sensitivity of its pension and retiree‑medical obligations to market fluctuations.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) The claim that PepsiCo provided a 'concrete, quantitative disclosure' in 2024 of a '$272 million increase in other pension and retiree-medical benefits expense' due to lump-sum settlements and group-annuity purchases is not supported by the ground truth. The original answer makes no mention of this specific dollar amount or event, nor does it reference any quantitative financial impact. This figure appears to be fabricated or misattributed. (2) The ground truth states that the evolution in disclosure was a broadening of risk factors from market fluctuations (2022) to include inflationary, deflationary, and recessionary conditions (2024). The LLM incorrectly frames the change as a shift from 'generic statement' to 'quantitative disclosure,' which misrepresents the nature of the evolution. (3) While both answers agree that the 2022 disclosure referenced 'Critical Accounting Policies and Estimates,' the LLM adds unsupported detail by claiming the 2022 discussion included 'interest-rate and inflation changes'—the ground truth only confirms market fluctuations were noted, without specifying those drivers. (4) The multi-hop reasoning is partially sound in that it attempts to compare disclosures across years, but it fails to accurately represent the content of either year’s filing, especially 2024. The emphasis on quantification and specific transactions (annuity purchases) introduces details absent from the ground truth, leading to a materially incorrect conclusion. (5) Despite these issues, the answer is contextually relevant—it addresses the evolution of risk disclosures around pension and retiree medical liabilities and correctly identifies the general direction of increased detail. However, the lack of quantitative accuracy and mischaracterization of the disclosures result in a low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 518,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Adobe's approach to Adobe Scan evolved between 2023 and 2024, particularly in terms of its positioning within Adobe's broader document management ecosystem?",
      "original_answer": "In 2023, Adobe Scan was positioned as a free mobile scanning tool that converts paper documents into editable, searchable PDFs via Adobe Document Cloud services, emphasizing its utility for individual users. By 2024, Adobe Scan remained part of Adobe Document Cloud, but the broader ecosystem placed increased emphasis on integration with cloud-based productivity tools and AI-driven features like Content Credentials and Firefly-powered generative AI workflows, indicating a shift toward deeper integration within enterprise document workflows and enhanced digital trust mechanisms.",
      "llm_answer": "\nBetween 2023 and 2024 Adobe reframed Adobe Scan from a standalone mobile scanner that simply creates searchable PDFs and syncs to Document Cloud into the front‑end capture layer of the unified Adobe Document Cloud ecosystem.  The 2024 positioning emphasizes tight integration with Acrobat’s AI Assistant, automated workflows, e‑signature and form‑filling capabilities, making Scan a pivotal entry point for end‑to‑end document management and personalized experience workflows across Adobe’s broader cloud platform.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of Adobe Scan from a standalone mobile scanning tool in 2023 to a more integrated component of the Adobe Document Cloud ecosystem in 2024. The core facts—positioning shift, integration with cloud workflows, and role as an entry point for document management—are correct. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification; all temporal references (2023, 2024) are accurate. (3) The multi-hop reasoning is sound: the LLM synthesizes information about product positioning across two years and connects Adobe Scan to broader ecosystem capabilities like AI Assistant, e-signature, and automated workflows. While the original answer emphasizes 'Content Credentials' and 'Firefly-powered generative AI' as specific AI features, the LLM answer generalizes this as 'Acrobat’s AI Assistant' and 'automated workflows', which captures the essence but omits those precise feature names. This is a minor omission, not an error. (4) The answer is contextually excellent—directly addressing how Adobe Scan's role evolved within Adobe’s document management strategy. The slight lack of specificity around Firefly and Content Credentials prevents a perfect 10, but the overall qualitative and factual accuracy is very high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 382,
        "total_tokens": 1661
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Gemini's role and integration across Google's products evolved from its initial launch in 2023 to 2024, and what specific advancements were made in its multimodal capabilities?",
      "original_answer": "In 2023, Gemini was introduced as a multimodal AI model capable of understanding and operating across different types of information, including text, code, audio, images, and video. It was intended to be leveraged across Alphabet to enhance product experiences. By 2024, Gemini had evolved significantly, with the launch of Gemini 2.0, which became the most capable model yet. It was integrated into all seven of Google's two billion-user products—Android, Chrome, Gmail, Maps, Play Store, Search, and YouTube—powering AI features across these platforms. Additionally, in 2024, Gemini was used in experimental research prototypes such as Project Astra and Project Mariner, showcasing broader and more advanced applications than in 2023.",
      "llm_answer": "\nSince its debut in 2023, Gemini has moved from a newly‑introduced native multimodal model to Gemini 2.0—Google’s most capable version—by 2024.  The 2024 release expands Gemini’s multimodal reach to all seven of Google’s two‑billion‑user products (Android, Chrome, Gmail, Maps, Play Store, Search and YouTube) and embeds it deeper in the Google Cloud stack (Vertex AI, Cloud Workspace, Cloud cybersecurity, etc.), while adding new capabilities such as real‑time video understanding (Project Astra), on‑device coding and image‑generation (Gemini app), and tighter integration with Search (AI Overviews) and Workspace (Duet AI).  These advances give Gemini the ability to seamlessly understand and combine text, code, audio, images and video, delivering more natural, faster and more personalized AI experiences across Google’s ecosystem.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Gemini launched in 2023 as a multimodal model and evolved into Gemini 2.0 by 2024, becoming Google's most capable model. It was integrated into all seven of Google's two-billion-user products—Android, Chrome, Gmail, Maps, Play Store, Search, and YouTube—matching the original answer. The mention of Project Astra (real-time video understanding) aligns with the experimental prototypes noted in 2024. (2) Quantitative accuracy is perfect: no incorrect numbers, dates, or misstatements of scale (e.g., 'two-billion-user products' is correctly interpreted). (3) Multi-hop reasoning is sound: the answer synthesizes evolution over time, product integration, and capability advancements across multiple platforms. (4) Minor deduction in qualitative accuracy due to the addition of some details not in the ground truth—such as 'on-device coding and image-generation (Gemini app)', 'Duet AI', and 'Cloud cybersecurity'—which, while plausible, are not confirmed in the provided truth. However, these do not contradict the truth and are contextually reasonable. Overall, the answer is semantically equivalent, comprehensive, and highly relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 347,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Linde's relationship with helium evolved between 2022 and 2024, particularly in terms of its impact on sales and operating profit?",
      "original_answer": "In 2022, helium was listed as a supply for Linde, indicating a positive or neutral relationship. However, by 2024, the relationship had evolved, and helium was reported to negatively impact the company. Specifically, in 2024, lower volumes in global helium contributed to a 2% decrease in sales for the 'Other' segment, which includes global helium wholesale. Additionally, higher costs due to helium partially offset an insurance recovery for Linde Advanced Materials Technology (LAMT), limiting the operating profit growth in that segment despite a 44% overall increase in operating profit for 'Other'.",
      "llm_answer": "\nBetween 2022 and 2024 the helium‑related business in Linde’s “Other” segment moved from modest growth to a slight contraction—2024 sales fell about 2 % (≈ $32 million) due to lower volumes—while the segment’s operating profit rose sharply, increasing roughly 44 % as insurance recoveries and cost reductions more than offset the sales dip.  Thus helium now contributes a smaller, more volatile share of revenue, but its net effect on profitability is neutral to slightly positive because the profit gains from insurance and cost management outweigh the modest sales decline.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies compared to the ground truth. While it correctly identifies the 2% sales decrease in the 'Other' segment due to lower helium volumes, it incorrectly attributes a 44% increase in operating profit to the segment as a whole and claims that insurance recoveries and cost reductions led to strong profit growth. However, the ground truth states that higher helium costs *partially offset* an insurance recovery in Linde Advanced Materials Technology (LAMT), thereby *limiting* operating profit growth—contradicting the LLM's claim of strong net profit gains. The LLM incorrectly concludes that helium’s net effect on profitability is 'neutral to slightly positive,' when the original answer clearly states helium had a *negative impact* in 2024. (2) The 2% sales decline is correctly cited, and the ≈$32 million estimate could be a reasonable approximation depending on total segment revenue (though not verifiable from the ground truth, which doesn’t provide dollar amounts), so quantitative accuracy is partially acceptable. However, the 44% operating profit increase is misleading—it refers to the 'Other' segment overall, not specifically helium, and the LLM fails to clarify that helium’s impact was detrimental within that context. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the negative evolution of Linde’s relationship with helium. It misses the key shift from neutral/positive in 2022 to negative in 2024 due to volume declines and cost pressures. It also conflates segment-level profit growth with helium’s contribution, when the truth is that helium *dragged down* profitability despite other positive factors. (4) Contextual relevance is high—the answer addresses the timeframe, the 'Other' segment, and the impact on sales and profit. However, due to major errors in qualitative reasoning and factual representation of helium’s impact, the correctness score is low. The answer gets some numbers right but misrepresents the core conclusion about helium’s role.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 557,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did the net value of acquired franchise rights evolve from 2022 to 2024, and what was the magnitude of this change?",
      "original_answer": "In 2022, the net value of acquired franchise rights was $789 million, while in 2024 it decreased to $598 million. This represents a significant decline in value over the two-year period.",
      "llm_answer": "\nThe carrying amount of acquired franchise rights fell from **$1.891 billion at the end of 2023 to $1.858 billion at the end of 2024**, a decline of **$33 million (about 1.7 %)**. The provided excerpts do not include a 2022 balance for acquired franchise rights, so the exact change from 2022 to 2024 cannot be calculated from the information given.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both numbers and reasoning. (1) Quantitative Accuracy: The ground truth states the net value was $789 million in 2022 and $598 million in 2024, showing a decrease of $191 million. The LLM instead reports values of $1.891 billion (2023) and $1.858 billion (2024), which are not only from incorrect years but also over twice as large as the correct figures. These numbers do not match the ground truth in magnitude or time frame. (2) Completeness: The question asks for the evolution from 2022 to 2024; the LLM claims no 2022 data is available, which contradicts the original answer that explicitly provides the 2022 value. Thus, the LLM fails to address the core request. (3) Entity Accuracy: The LLM references 2023 and 2024 values for 'carrying amount' rather than the 'net value' in 2022 and 2024 as required. The metric and years are misaligned. (4) Reasoning: The multi-hop synthesis is flawed—the LLM appears to pull data from unrelated documents or misreads the time periods, and incorrectly concludes that 2022 data is missing. (5) Semantic Equivalence: The direction (decline) is consistent, but the values, years, and magnitude are all wrong, so the core information does not align. The answer fails on factual correctness despite minor relevance in discussing franchise rights depreciation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1127,
        "completion_tokens": 372,
        "total_tokens": 1499
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did Chevron's natural gas delivery commitments and production volumes related to Tengizchevroil evolve from 2023 to 2024?",
      "original_answer": "In 2023, Chevron reported that its natural gas volumes included 596 million cubic feet per day consumed in operations and 7,148 million cubic feet per day as sold, which included its share from Tengizchevroil in Kazakhstan. By 2024, these figures increased to 609 million cubic feet per day consumed and 7,569 million cubic feet per day as sold, indicating a growth in both operational consumption and market delivery. This reflects an increase in Chevron’s involvement and dependency on Tengizchevroil for natural gas production and delivery commitments.",
      "llm_answer": "\nFrom 2023 to 2024 Chevron’s contractual natural‑gas delivery obligations that involve its Kazakh affiliate Tengizchevroil did not change – the company continued to meet the same delivery arrangements that were already in place, with no new volume commitments disclosed in the filings.  During the same period the net natural‑gas output from Tengizchevroil was essentially flat, slipping only slightly from about **114 billion cubic feet per day in 2023 to 113 billion cubic feet per day in 2024**, while its oil‑equivalent production held steady at roughly **26  thousand barrels per day**.  (See page 9 production tables and page 10 delivery‑commitments discussion.)",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth in multiple critical ways. (1) Quantitative Accuracy: The LLM reports natural gas production from Tengizchevroil as '114 billion cubic feet per day' in 2023 and '113 billion cubic feet per day' in 2024 — this is off by a factor of over 100,000 (the correct unit is million cubic feet per day, not billion). The actual figures from the ground truth are 7,148 million cubic feet per day sold in 2023 and 7,569 million in 2024 — a significant increase, not a flat trend. The LLM also fabricates oil-equivalent production at '26 thousand barrels per day', which is orders of magnitude too low for a major project like Tengizchevroil. (2) Completeness: The question asks about both delivery commitments and production volumes; the LLM incorrectly claims delivery obligations 'did not change' and that volumes were flat, directly contradicting the documented increase in sold volumes. (3) Entity Accuracy: While Chevron and Tengizchevroil are correctly identified, the data attributed to them is entirely wrong. (4) Reasoning: The multi-hop synthesis fails — the LLM does not correctly interpret or report the evolution of gas volumes from 2023 to 2024. Instead, it asserts no change, missing the growth trend entirely. (5) Semantic Equivalence: The answer conveys the opposite meaning of the ground truth — claiming stability when there was growth — and uses implausible numbers, indicating a fundamental error in data retrieval or interpretation. The contextual relevance is low, but the answer at least addresses Chevron and Tengizchevroil in the correct time frame.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 446,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the role of Google Network partners in Google's advertising revenue model evolved between 2023 and 2024, based on changes in the way payments to these partners are described?",
      "original_answer": "In 2023, Google Network partners were described as part of the primary uses of cash from operating activities, specifically noting payments made to these partners as a standard operating expense. By 2024, the description evolved to categorize payments to Google Network partners under Traffic Acquisition Costs (TAC), explicitly linking them to ads displayed on partner properties and tying them directly to revenue generation. This shift indicates a more strategic and performance-based dependency on these partners within the advertising ecosystem.",
      "llm_answer": "\nBetween 2023 and 2024 the accounting language shifted from a generic “cost of revenues” entry to a distinct, named component—“traffic‑acquisition costs (TAC)”—that explicitly identifies the amounts paid to Google Network partners as payments for ads displayed on their properties. In the 2023 filing (page 40) the partners were merely noted as a cost‑of‑revenues item, whereas the 2024 filing (page 60) isolates those payments within TAC and describes them as a separate, material cost, highlighting a more central and formally tracked role for Network partners in Google’s advertising‑revenue model.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the shift in accounting language from 2023 to 2024: in 2023, payments to Google Network partners were included under 'cost of revenues' as a general operating expense (referencing page 40), and in 2024, they were explicitly categorized under 'Traffic Acquisition Costs (TAC)' (referencing page 60), which ties them directly to ad revenue generation. (2) There are no numeric values or calculations in the question or answer, so quantitative accuracy is not applicable in terms of numbers, but the years (2023, 2024) and page numbers (40, 60) are correctly cited and consistent with the expected level of detail. (3) The multi-hop reasoning is sound: the model synthesizes changes in disclosure language across two years and interprets the implications for Google's advertising model—showing evolution from a generic cost to a strategic, performance-linked expense. (4) The LLM answer conveys the same core insight as the original answer: that the reclassification reflects a more central and formally tracked role for Network partners. The only minor shortcoming is that it does not explicitly use the phrase 'primary uses of cash from operating activities' as in the ground truth, but it accurately captures the substance by identifying the cost's placement in financial statements. Wording differences are acceptable under semantic equivalence. Overall, the answer is factually correct, complete, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 418,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the impact of public policies on Bank of America's climate-related regulatory requirements evolved from 2023 to 2024, particularly in terms of jurisdictional divergence and compliance risks?",
      "original_answer": "In 2023, Bank of America highlighted increasing global regulatory focus on climate change, noting that new or heightened regulatory requirements across state, federal, and non-U.S. jurisdictions were expected to increase legal, compliance, and public disclosure risks and costs. The company specifically mentioned jurisdictional divergence as a challenge. By 2024, this concern intensified, with the company noting that existing and pending disclosure requirements in various jurisdictions, along with jurisdictional divergence, were now actively impacting legal, compliance, and public disclosure risks and costs. This indicates a shift from anticipation of increased risk to experiencing tangible impacts due to evolving public policies.",
      "llm_answer": "\nBetween 2023 and 2024 the regulatory climate for Bank of America moved from a broadly emerging set of expectations to a markedly fragmented, jurisdiction‑specific regime—U.S. states, the EU, the United Kingdom and other jurisdictions are each adopting distinct emissions‑reduction, disclosure and reporting rules.  This growing jurisdictional divergence heightens compliance risk, forcing the bank to monitor and adapt to multiple, sometimes conflicting, policy requirements and increasing the likelihood that any perceived shortfall in its climate‑related goals or disclosures could trigger legal, regulatory or reputational penalties.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the evolution of public policy impact on Bank of America's climate-related regulatory requirements from 2023 to 2024, with high factual accuracy. (1) There are no numeric values (e.g., dollar amounts, percentages) in either the ground truth or LLM response, so quantitative accuracy is not applicable—scored as 10 by default. (2) The LLM accurately identifies the key concept of increasing jurisdictional divergence across U.S. states, the EU, the UK, and other regions, aligning with the original answer’s emphasis on state, federal, and non-U.S. regulatory fragmentation. (3) The reasoning is sound: it correctly synthesizes the shift from anticipated regulatory pressure in 2023 to active compliance challenges in 2024, reflecting the multi-hop requirement of tracking change over time. The LLM conveys that this divergence increases legal, compliance, and reputational risks—consistent with the ground truth’s mention of heightened legal, compliance, and disclosure costs. (4) The only minor shortcoming is that the LLM does not explicitly state the shift from 'anticipation' in 2023 to 'tangible impacts' in 2024 using those precise terms, though the meaning is semantically equivalent. Wording differs slightly but the core factual progression is preserved. Overall, the answer is contextually rich, factually correct, and fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 385,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has General Motors' strategic emphasis on full-size pickup trucks evolved from 2022 to 2024, and what quantitative indicators in 2024 suggest a shift toward stronger performance and market positioning for this product line?",
      "original_answer": "In 2022, General Motors identified the success of its full-size SUVs and full-size pickup trucks as a key risk factor, indicating that their performance was critical to the company's competitive position and financial health. By 2024, this strategic emphasis had evolved into a demonstrated strength, as evidenced by a significant increase in net wholesale volumes driven by higher sales of full-size pickup trucks. Additionally, the 2024 report highlights that full-size pickup trucks contributed favorably to the company's EBIT-adjusted results, with a variable profit of approximately 160% for trucks on a weighted-average basis, reflecting improved profitability and market demand for this product line.",
      "llm_answer": "\nBetween 2022 and 2024 GM moved full‑size pickups from a supporting model to the core of its North‑American growth strategy. In 2024, wholesale shipments of full‑size pickups rose 10 % to 3,464 units, driving a $12.8 B increase in GMNA net sales and contributing to an 18 % jump in GMNA EBIT‑adjusted to $14.5 B; truck residual values climbed to $7,458 and trucks now deliver roughly 160 % of the portfolio’s variable profit, signaling a clear shift toward stronger performance and market positioning.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in the quantitative details. While it correctly identifies the strategic shift and the 160% variable profit contribution for full-size trucks in 2024—aligning with the ground truth—other key numbers are incorrect or implausible. For example, claiming 'wholesale shipments of full-size pickups rose 10% to 3,464 units' is factually wrong; General Motors sells hundreds of thousands of full-size pickups annually, not 3,464 total units. This number is off by orders of magnitude and severely undermines quantitative accuracy. The $12.8B increase in GMNA net sales and $14.5B EBIT-adjusted figure, while directionally plausible, are not supported by the ground truth, which mentions favorable EBIT contributions and higher volumes but does not specify dollar increases or overall EBIT figures. Similarly, 'truck residual values climbed to $7,458' is not mentioned in the original answer and appears fabricated. (2) The only correct quantitative element is the '160% of the portfolio’s variable profit,' which matches the ground truth's 'variable profit of approximately 160% for trucks on a weighted-average basis.' However, the phrasing '160% of the portfolio’s variable profit' is misleading—it should reflect that trucks generated 160% variable profit margin, not that they contributed 160% of total profit. (3) The reasoning partially captures the multi-hop evolution: from risk in 2022 to strength in 2024. It correctly infers a strategic pivot and links volume growth to profitability. However, it fails to mention that in 2022, GM identified truck performance as a key risk, which is a critical part of the evolution. Instead, it vaguely references a shift 'to the core of its North-American growth strategy' without grounding it in risk context. (4) Despite strong contextual relevance—addressing both strategic evolution and performance indicators—the answer's severe quantitative inaccuracies and missing foundational context (2022 risk factor) limit correctness. The qualitative reasoning is partially sound but lacks fidelity to source data. Thus, correctness is scored low due to critical number errors, even though the 160% metric and directional narrative are partially aligned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 606,
        "total_tokens": 1929
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did the allocation to U.S. Treasury and government agency securities within the nuclear decommissioning trusts evolve from 2022 to 2024, and what does this shift indicate about the company's investment strategy?",
      "original_answer": "In 2022, the allocation to U.S. Treasury and government agency securities was $21 million for Alabama Power and $293 million for Georgia Power. By 2024, this allocation decreased slightly to $20 million for Alabama Power but increased significantly to $349 million for Georgia Power. The overall trend shows a shift in focus toward Georgia Power’s portfolio, indicating a possible reallocation of safer, fixed-income assets to that subsidiary.",
      "llm_answer": "\nThe exposure to U.S. Treasury and government‑agency securities in the nuclear decommissioning trusts fell dramatically, from roughly $369 million at the end of 2022 to only about $9 million by the end of 2024. This sharp reduction shows that Southern Company is intentionally trimming its low‑yielding sovereign‑debt position in the trusts, reallocating toward higher‑return or more diversified assets to better match the long‑term funding and risk‑management goals of the decommissioning portfolio.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both quantitative and qualitative aspects. According to the ground truth, Alabama Power had $21M in 2022 and $20M in 2024, while Georgia Power had $293M in 2022 and $349M in 2024. The total allocation increased from $314M ($21M + $293M) in 2022 to $369M ($20M + $349M) in 2024, not decreased as claimed. The LLM incorrectly states a drop from $369M to $9M, which is factually wrong and misrepresents the trend. (2) The calculation of totals is incorrect: the LLM uses $369M as the 2022 total (which is actually close to the correct 2024 total) and invents a $9M figure for 2024 with no basis in the ground truth. No such data point exists. (3) The multi-hop reasoning fails: the model does not recognize that the data is split across two subsidiaries (Alabama and Georgia Power) and instead fabricates a consolidated trend in the opposite direction. It also misses the key insight about a strategic shift toward Georgia Power’s portfolio. (4) The contextual relevance is moderate because the answer discusses investment strategy in the context of nuclear decommissioning trusts and asset allocation, but the factual foundation is so flawed that the conclusion about shifting to higher-return assets is unsupported. The reasoning is plausible but based on false data, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 377,
        "total_tokens": 1630
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has PepsiCo's relationship with independent bottlers evolved from 2022 to 2024 in terms of financial incentives and strategic dependency?",
      "original_answer": "In 2022, PepsiCo provided sales incentives and discounts to independent bottlers primarily through funding of advertising and other marketing activities, with accruals based on annual targets and historical experience. By 2024, the company's relationship had evolved into a more structured dependency, with bottler funding negotiated annually and specifically allocated across trade and consumer programs such as advertising support, new product launches, and vending equipment placement. Additionally, in 2024, sales through independent bottlers contributed to a significant portion of revenue, with Walmart alone accounting for approximately 14% of consolidated net revenue, highlighting increased strategic dependency on these bottlers.",
      "llm_answer": "\nBetween 2022 and 2024 PepsiCo kept its core financial incentive for independent bottlers—annual “bottler funding” that reimburses advertising, consumer‑promotion, new‑product support and vending/cooler‑equipment placement and is recorded as a reduction of revenue with accruals tied to performance targets.  At the same time, the company’s strategic dependence on bottlers deepened, because they hold exclusive territorial rights and supply the concentrate used in finished‑goods sold to major customers (e.g., Walmart), making the bottler network an increasingly critical component of PepsiCo’s go‑to‑market and revenue strategy.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the continuity of PepsiCo's financial incentives from 2022 to 2024, noting that bottler funding covers advertising, consumer promotions, new product support, and vending equipment placement, with accruals tied to performance targets. This aligns with the ground truth description of incentives based on annual targets and historical experience. However, the LLM omits the specific evolution mentioned in the original answer—namely that by 2024, funding was more explicitly negotiated annually and allocated across specific trade and consumer programs. While the core mechanism is accurately described, the nuance of increased structuring and specificity in 2024 is missing. Additionally, the LLM fails to include the key quantitative fact that Walmart accounted for approximately 14% of consolidated net revenue in 2024, which is a critical piece of evidence for the increased strategic dependency. (2) Quantitatively, the LLM does not introduce any incorrect numbers, but it omits the 14% figure related to Walmart’s contribution, which is central to the original answer’s argument about strategic dependency. No incorrect calculations are made, but the absence of this percentage reduces quantitative completeness. (3) The reasoning is sound in recognizing that bottlers hold exclusive territorial rights and distribute concentrate to major customers like Walmart, supporting the claim of growing strategic dependency. This reflects correct multi-hop synthesis between bottler operations, distribution control, and revenue reliance. However, the failure to incorporate the 14% revenue dependency weakens the evidentiary support for the conclusion. (4) The answer remains contextually relevant and well-structured, addressing both financial incentives and strategic dependency as asked. Despite missing a key quantitative data point and some evolution details, the overall qualitative assessment remains strong due to accurate terminology, correct entity identification (PepsiCo, independent bottlers, Walmart), and logical flow. Hence, correctness is rated 7 for missing key details, quantitative accuracy 8 for no errors but incomplete data, qualitative accuracy 8 for solid reasoning, and contextual relevance 10 for fully on-topic response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 613,
        "total_tokens": 1954
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has Adobe Firefly's role within Adobe's product innovation strategy evolved from 2023 to 2024, based on its positioning in the company's trademark listings and risk disclosures?",
      "original_answer": "In 2023, Adobe Firefly was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio. By 2024, Adobe Firefly was specifically highlighted in the risk factors section as a newly released generative AI product, reflecting its strategic importance in Adobe's innovation efforts. This evolution shows a shift from being a registered brand to becoming a central part of Adobe's forward-looking product development and AI strategy, with explicit mention of its role in addressing market demands for generative AI capabilities.",
      "llm_answer": "\nAdobe Firefly shifted from a newly‑launched generative‑AI brand in 2023—listed in the 2023 10‑K trademark schedule as a distinct AI‑driven offering—to a core, company‑wide innovation pillar by 2024, where it is repeatedly referenced in both the trademark filings and the AI‑focused risk disclosures that warn of intensified competition, regulatory scrutiny and reputational exposure tied to its AI products. This evolution shows Firefly moving from a experimental feature to a strategically central, and therefore higher‑risk, component of Adobe’s product roadmap.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of factual content and reasoning. (1) It accurately identifies Adobe Firefly's presence in trademark listings in 2023 and its elevated strategic role by 2024, particularly through inclusion in risk disclosures. The characterization of Firefly evolving from a distinct AI offering to a central innovation pillar matches the original answer’s theme of increased strategic importance. (2) There are no numeric values, dates, or financial figures in the question or answers that are incorrect—dates (2023, 2024) are accurate and consistently used. (3) The multi-hop reasoning—linking trademark listings in 2023 to risk disclosures in 2024 as evidence of strategic evolution—is sound and correctly synthesizes information across time and document sections. However, the LLM slightly overreaches by describing Firefly in 2023 as 'newly-launched' and 'experimental,' which is not supported in the original answer; the ground truth only states it was listed among trademarks, not that it was new or experimental. Similarly, the emphasis on 'repeatedly referenced' in 2024 goes beyond the original answer’s 'specifically highlighted in the risk factors section.' These are minor interpretive additions but do not invalidate the core correctness. (4) Despite slight embellishments, the answer captures the essential evolution and strategic shift accurately, making it contextually relevant and qualitatively strong. The correctness score is 8 due to these minor overstatements, but quantitative accuracy is perfect, and reasoning remains logically sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 442,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the role of contractual rent escalations in driving tenant billing growth changed between 2022 and 2023, particularly in light of the increased churn and lease cancellations in 2023?",
      "original_answer": "In 2022, contractual rent escalations were highlighted as a key factor contributing to tenant billing growth, listed alongside new colocation activity and lease amendments. By 2023, while contractual rent escalations remained a stated driver of growth, the context shifted due to an elevated churn rate of approximately 3%, primarily in the U.S. & Canada segment. This churn, expected to remain elevated through 2025 due to T-Mobile's lease cancellations, introduced a countervailing force against the positive impact of rent escalations, suggesting a more challenging environment for maintaining organic revenue growth solely through escalations.",
      "llm_answer": "\nContractual rent escalations—generally a fixed ~3 % annual increase in the United States (or inflation‑linked abroad)—have long been a primary lever for boosting tenant billings.  In 2022 the escalations continued to drive growth because churn remained modest (≈4 % of billings in 2021 and not materially higher in 2022), so the higher rents translated almost directly into higher revenue.  By 2023, however, churn rose to about 3 % of tenant billings, driven largely by lease cancellations in the U.S. & Canada (e.g., T‑Mobile and legacy Sprint leases), which offset much of the upside from the scheduled escalations; thus, the same escalation rates contributed a smaller net increase to billing growth because a larger share of revenue was being lost through cancellations.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that contractual rent escalations were a key driver of tenant billing growth in 2022 and remained a factor in 2023, despite increased churn. The mention of T-Mobile and legacy Sprint lease cancellations in the U.S. & Canada is consistent with the original answer. (2) Quantitatively, the LLM states churn rose to about 3% in 2023, which matches the ground truth's 'elevated churn rate of approximately 3%'. However, the LLM incorrectly references 2021 churn (≈4% of billings) not mentioned in the original answer and implies 2022 churn was not materially higher—this is a minor extrapolation not supported in the ground truth, though not directly contradictory. The ~3% annual escalation rate is plausible but not explicitly confirmed in the original answer, so it's a reasonable assumption but not verifiable from the ground truth. (3) The multi-hop reasoning is sound: the model correctly synthesizes the tension between rent escalations (a growth driver) and increased churn (a headwind), concluding that escalations contributed less net growth in 2023 due to cancellations—this reflects the core insight of the original answer. (4) The answer is contextually excellent, directly addressing how the role of escalations changed due to churn and lease cancellations. The only deductions are for the unverified 2021 churn figure and the assumed escalation rate, which, while plausible, are not in the ground truth. Overall, the semantic meaning and analytical depth match the original very closely.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 436,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Chevron's (CVX) relationship with Tengizchevroil evolved between 2023 and 2024 in terms of capital expenditure commitments and production involvement?",
      "original_answer": "In 2023, Chevron indicated that nearly half of its Affiliate Capex, which was expected to be $3 billion in 2024, was allocated to Tengizchevroil's FGP/WPMP Project in Kazakhstan. By 2024, Chevron continued to highlight its production involvement with Tengizchevroil, noting that production volumes included Chevron's share from affiliates such as Tengizchevroil in Kazakhstan. While 2023 focused on capital commitments for project development, 2024 emphasized ongoing production contributions from the same entity, indicating a shift from investment to operational phase.",
      "llm_answer": "\nBetween 2023 and 2024 Chevron kept the Tengizchevroil partnership a priority of its affiliate‑capital program—annual affiliate capex stayed near $3 billion, with roughly ½ still earmarked for the FGP/WPMP expansion in Kazakhstan (down slightly from $3.5 billion in 2023).  At the same time, production attributable to the joint venture edged up from about 406 k bbl/d of oil‑equivalent in 2023 to roughly 413 k bbl/d in 2024, reflecting a modest increase in output from the same project.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. The ground truth states that Chevron expected $3 billion in Affiliate Capex in 2024, with nearly half allocated to Tengizchevroil's FGP/WPMP project. The LLM incorrectly claims that affiliate capex was $3.5 billion in 2023, which is not mentioned in the original answer and cannot be verified from the provided context. There is no mention of actual production volumes (e.g., 406k or 413k bbl/d) in the original answer, making these figures fabricated. (2) The quantitative inaccuracies are significant: the $3.5 billion 2023 capex figure is unsupported; the production volumes (406k and 413k bbl/d) are specific but absent from the ground truth. The original answer does not provide any production volume numbers or trends, only stating that Chevron included its affiliate production share in reporting. (3) The reasoning partially captures the shift from capital investment (2023 focus) to production involvement (2024 focus), which aligns with the multi-hop synthesis of evolving relationship phases. However, the addition of precise production numbers and incorrect capex figures undermines the validity of the reasoning. (4) The contextual relevance is high because the answer addresses both capital expenditure and production involvement across the two years and correctly identifies Tengizchevroil and the FGP/WPMP project. However, the quantitative inaccuracies severely reduce correctness and qualitative accuracy, resulting in a partial but misleading answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 423,
        "total_tokens": 1691
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the specificity of UPS's bond matching approach evolved in determining the discount rate for U.S. pension and postretirement benefit plans between 2023 and 2024?",
      "original_answer": "In 2023, UPS described using a bond matching approach to select specific bonds that would satisfy projected benefit payments, emphasizing its belief that this method reflects the process they would employ to settle pension and postretirement obligations. By 2024, the language evolved to place stronger emphasis on the bond matching approach as a guide for selecting bonds that align with projected benefit cash flows, without any material change in the mechanics of the method. However, the 2024 disclosure included a more precise statement indicating that the approach 'guides' the selection process, suggesting a subtle shift in how the policy is framed operationally, even though the underlying practice remained consistent.",
      "llm_answer": "\nBetween 2023 and 2024 the company kept the same bond‑matching concept but made the wording more precise: in the 2024 filing it explicitly says the discount rate is set by selecting particular high‑quality bonds whose cash‑flow timing and amounts match the projected U.S. pension and post‑retirement benefit payments—reflecting the exact settlement process—and that this selection is applied to both pension and post‑retirement medical plans and updated each measurement date. The 2023 description was more generic, merely noting a “bond‑matching approach” without detailing the bond‑selection criteria or the annual refresh of the assumptions.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of UPS's bond matching approach between 2023 and 2024. It correctly identifies that the core methodology remained unchanged but the 2024 disclosure provided more precise language around bond selection. The answer accurately notes that in 2024, UPS emphasized selecting specific high-quality bonds matching the timing and amount of projected benefit payments, reflecting the settlement process—this is consistent with the ground truth's statement about the approach 'guiding' selection. It also correctly contrasts the 2023 description as more generic. However, the LLM adds details not present in the original answer, such as stating the approach is 'updated each measurement date' and explicitly applied to both pension and post-retirement medical plans. While plausible, these specifics are not mentioned in the ground truth and represent an over-assertion. The ground truth emphasizes a subtle shift in framing (from describing the method to saying it 'guides' selection), which the LLM captures in spirit but reframes with added operational detail. There are no numerical inaccuracies (quantitative accuracy is perfect), and the entities (UPS, U.S. pension and postretirement plans, 2023–2024 timeframe) are correct. The reasoning is sound and contextually relevant, but the slight addition of unverified procedural details prevents a top score in qualitative accuracy and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 410,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Linde's relationship with helium evolved from 2022 to 2024, and what financial impact did this change have on the company's sales and operating profit during this period?",
      "original_answer": "In 2022, helium was a supply input for Linde, indicating a supportive role in operations. By 2024, helium had a negative impact on operations, with a $32 million, or 2%, decrease in sales for the Other segment primarily due to lower volumes in global helium and LAMT. Additionally, helium-related costs contributed to downward pressure on operating profit, partially offset by an insurance recovery for LAMT. This reflects a shift from a neutral or positive relationship to one that posed operational challenges.",
      "llm_answer": "\nLinde’s helium wholesale shifted from a modest, growing contributor in 2022 to a contracting, cost‑intensive line by 2024 – volumes fell enough that “Other” segment sales dropped about 2 % (≈ $32 million) in 2024, while operating profit in that segment rose 44 % (≈ $19 million) as insurance recoveries and productivity gains more than offset the higher helium‑related costs.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in Linde's relationship with helium from 2022 to 2024 and notes the $32 million (2%) decrease in sales for the Other segment due to lower helium volumes, which aligns with the ground truth. However, it incorrectly states that operating profit in the segment rose 44% (≈$19 million), which contradicts the original answer indicating downward pressure on operating profit due to helium-related costs. While the original mentions an insurance recovery partially offsetting the costs, it does not state that profit increased—let alone by 44%. This is a major factual error. (2) The $32 million and 2% sales decline are accurately reported, with acceptable formatting. However, the 44% operating profit increase and $19 million figure are unsupported by the ground truth and appear to be fabricated or misinterpreted. No such positive impact on operating profit is stated; instead, the truth emphasizes negative impacts partially mitigated by recovery. (3) The multi-hop reasoning is partially sound—linking helium volume declines to sales impact is correct. But the synthesis breaks down when assessing operating profit: the model incorrectly infers a strong profit gain rather than recognizing the net negative effect with partial offset. This undermines the core financial impact analysis. (4) Scores reflect partial correctness: quantitative accuracy docked for incorrect profit figures; qualitative accuracy penalized for flawed reasoning about profitability; contextual relevance remains high as the answer addresses the right entities, time frame, and general trend, despite factual inaccuracies in key metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 457,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How did Bank of America's unfunded capital contributions for renewable energy investments evolve between 2023 and 2024, and what was the corresponding change in recognized tax credits related to these investments?",
      "original_answer": "In 2023, Bank of America had unfunded capital contributions for renewable energy investments of $6.2 billion, and it recognized tax credits and other tax benefits of $4.0 billion. By 2024, the unfunded capital contributions decreased to $4.6 billion, and the recognized tax credits slightly declined to $3.9 billion. This indicates a reduction in the Corporation's near-term funding commitments to renewable energy projects, even as the tax benefits remained relatively stable.",
      "llm_answer": "\nBank of America’s unfunded capital commitments for renewable‑energy projects fell sharply, dropping from **$6.2 billion at the end of 2023 to $4.6 billion at the end of 2024** (a reduction of roughly **$1.6 billion**).  At the same time, the tax credits the company recognized from those renewable‑energy equity investments slipped slightly, from **$4.0 billion in 2023 to $3.9 billion in 2024** (a decline of about **$0.1 billion**).",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: unfunded capital contributions decreased from $6.2 billion in 2023 to $4.6 billion in 2024, and recognized tax credits declined from $4.0 billion to $3.9 billion. The calculated differences ($1.6 billion and $0.1 billion) are correct. (2) The answer is complete, addressing both parts of the question: the evolution of unfunded capital contributions and the corresponding change in tax credits. (3) Entities are correctly identified—Bank of America, the correct years (2023 and 2024), and the correct financial metrics (unfunded capital contributions and recognized tax credits). (4) The reasoning is sound: the LLM correctly infers a sharp drop in commitments and a slight decline in tax benefits, which aligns with the ground truth's interpretation of reduced near-term funding with stable tax benefits. (5) Semantic equivalence is maintained—though the LLM uses more concise phrasing and includes calculated differences not explicitly stated in the original, this enhances clarity without distorting meaning. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 334,
        "total_tokens": 1578
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has General Motors' approach to fleet sales involving commercial fleet customers evolved from 2022 to 2024, particularly in terms of sales channels and profitability considerations?",
      "original_answer": "In 2022, General Motors highlighted that fleet transactions, especially sales to daily rental car companies, were generally less profitable compared to retail sales, and these vehicles were sold either directly or through the dealer network. By 2024, the company emphasized that fleet sales, including those to commercial fleet customers, were completed through the dealer network and in some cases directly with fleet customers, suggesting a more structured and possibly optimized approach to fleet sales. This evolution indicates a strategic shift toward balancing fleet sales with profitability by leveraging both direct and dealer-based channels.",
      "llm_answer": "\nFrom 2022 through 2024 GM trimmed the share of low‑margin fleet transactions—particularly sales to daily‑rental and other “fleet‑only” customers—from about 12 % of total vehicle sales to under 10 %, and it now routes most commercial‑fleet business through its dealer network or dedicated EV‑focused programs (e.g., BrightDrop EV600/EV410) rather than direct bulk contracts.  At the same time, the company has become more selective, using fleet sales only for higher‑margin commercial‑vehicle opportunities (especially electric commercial models) and pulling back from unprofitable rental‑fleet deals, reflecting a clear shift toward profitability‑driven channel strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general strategic shift in GM's fleet sales approach from 2022 to 2024, emphasizing increased selectivity, profitability focus, and use of dealer networks and EV programs like BrightDrop. However, it introduces specific quantitative claims not present in the original answer: stating that fleet sales dropped from 'about 12%' to 'under 10%' of total vehicle sales. This data is absent from the ground truth and cannot be verified from the provided information, making it a significant factual overreach. Additionally, the mention of 'BrightDrop EV600/EV410' and 'dedicated EV-focused programs' adds detail not supported in the original answer, which does not reference specific models or programs. While the original confirms a shift toward more structured sales through dealers and direct channels, the LLM over-specifies the mechanism and adds unsupported metrics. The qualitative reasoning about profitability and channel strategy aligns well with the original, showing sound multi-hop understanding of GM's evolving strategy. The answer is contextually relevant and addresses both sales channels and profitability considerations. However, the inclusion of unverified percentages and specific product lines reduces quantitative accuracy significantly, even though the directional trend (reducing low-margin fleet sales) is consistent with the original's implication. Thus, while the core idea is plausible and logically inferred, the addition of unsupported specifics lowers overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 417,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How did PepsiCo's relationship with Sabra evolve between 2022 and 2024, and what financial implications were associated with this change?",
      "original_answer": "In 2022, PepsiCo owned the Sabra brand as part of its joint venture portfolio. However, by 2024, PepsiCo no longer had full ownership but instead held a 50% equity stake, which was remeasured at fair value, resulting in a pre-tax gain of $122 million. This indicates that PepsiCo divested a portion of its ownership in Sabra during the intervening period, marking a strategic shift in its relationship with the brand.",
      "llm_answer": "\nBetween 2022 and 2024 PepsiCo pared back its ownership in Sabra—from a 50 % equity stake that it re‑measured at fair value (producing a $122 million pre‑tax gain, $92 million after‑tax, in 2022) to a 39 % non‑controlling interest that remained after the 2022 sale of Tropicana, Naked and other juice brands.  The carry‑over equity then generated further accounting adjustments—including impairment and credit‑loss provisions that reduced earnings by roughly $0.42 per share after‑tax in 2024—so the change in the Sabra relationship translated into a one‑time gain in 2022 followed by smaller, negative earnings impacts in the subsequent years.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) According to the ground truth, PepsiCo owned Sabra fully in 2022 as part of a joint venture and then retained a 50% equity stake by 2024 after a divestment, with a $122 million pre-tax gain from remeasuring the remaining stake. In contrast, the LLM claims PepsiCo had only a 50% stake in 2022 and reduced it to 39% by 2024, which contradicts the original answer. (2) The LLM incorrectly states the $122 million gain occurred in 2022 as a result of the remeasurement, but the original answer does not specify the year of the gain—only that the change occurred between 2022 and 2024. Worse, the LLM fabricates a 39% non-controlling interest and links it to the sale of Tropicana and Naked brands, which is not mentioned in the ground truth and represents a conflation of unrelated events. (3) The mention of impairment and credit-loss provisions reducing earnings by $0.42 per share in 2024 is unsupported by the original answer and introduces new, unverified financial impacts. (4) The multi-hop reasoning is flawed: instead of correctly identifying a shift from full ownership to 50% ownership with a resulting gain, the model misrepresents the ownership trajectory and injects extraneous details. While the $122 million pre-tax gain is correctly mentioned, its context and timing are misrepresented. The answer is partially relevant to the question about Sabra’s relationship and financial implications, hence a moderate contextual relevance score, but the core facts—ownership percentages, timeline, and associated financials—are incorrect or invented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 447,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Adobe's treatment of Adobe Scan evolved between 2023 and 2024, particularly in terms of its positioning within Adobe's product ecosystem?",
      "original_answer": "In 2023, Adobe Scan was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio. By 2024, Adobe Scan was explicitly positioned as part of Adobe Document Cloud, which includes Acrobat, Acrobat Sign, and other apps and API services that support digital document and signature workflows. This evolution shows a shift from mere trademark recognition to a more integrated and strategically emphasized role within Adobe’s broader document management and productivity offerings.",
      "llm_answer": "\nBetween 2023 and 2024 Adobe moved Adobe Scan from a peripheral, stand‑alone mobile scanner to a core, tightly‑integrated component of its Document Cloud ecosystem.  In the 2024 filing the company explicitly lists Scan alongside Acrobat Reader as a free download that “captures paper documents as images and transforms them into full‑featured PDFs via Adobe Document Cloud services,” and it is positioned together with Acrobat Sign, Acrobat AI Assistant and other Document Cloud APIs—highlighting Scan’s role in the end‑to‑end PDF creation, sharing and e‑signature workflow rather than as a isolated tool.  This reframing places Scan squarely within Adobe’s broader productivity and cloud‑based document suite, emphasizing its free, mobile‑first accessibility while tying its output to the same cloud services that power Acrobat, Sign and AI‑enhanced document interactions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: Adobe Scan evolved from a standalone product in 2023 (recognized via trademark) to an integrated component of Adobe Document Cloud in 2024. The LLM correctly identifies its positioning alongside Acrobat, Acrobat Sign, and other Document Cloud services. (2) There are no numeric values, dates, or calculations in the question or answer that require verification—dates (2023, 2024) are used appropriately and consistently with the original answer. (3) The multi-hop reasoning is sound: the model synthesizes information about Adobe Scan’s status in two different years and infers a strategic shift in positioning based on integration into Document Cloud and alignment with PDF workflows and cloud services. (4) The LLM adds contextual detail not in the original (e.g., 'transforms images into full-featured PDFs', 'mobile-first accessibility', 'AI-enhanced document interactions') that are plausible and consistent with Adobe’s ecosystem but slightly extend beyond the ground truth. These enhancements do not introduce inaccuracies but represent reasonable elaboration. The only reason for not scoring a 10 is that the original answer emphasizes the shift from 'trademark recognition' to strategic integration, a nuance slightly underemphasized in the LLM response. Overall, the answer is factually correct, comprehensive, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 401,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has General Motors' financial exposure and nature of obligations to Stellantis evolved from 2022 to 2024, particularly regarding indemnifications and historical liabilities?",
      "original_answer": "In 2022, General Motors continued to have supply-related transactions with Stellantis following the sale of the Opel/Vauxhall business, indicating an ongoing operational relationship. By 2024, the nature of GM's exposure to Stellantis had shifted from operational supplies to financial guarantees and indemnifications tied to legacy liabilities. Specifically, GM had agreed to indemnify Stellantis for certain emissions-related lawsuits, Takata-related recalls, and potential penalties from European regulatory investigations into end-of-life vehicle practices. Additionally, as of December 31, 2024, GM had accrued an immaterial amount related to these matters, showing a continued but reduced financial exposure compared to earlier liabilities. This reflects a transformation from active supply chain involvement to a more passive, indemnification-based financial relationship.",
      "llm_answer": "\nFrom 2022 through 2024 GM’s indemnification obligations to Stellantis under the 2017 Master Agreement remained essentially the same – the Seller (GM) continues to indemnify Stellantis for inaccuracies in representations and warranties, certain emissions‑related claims, product‑liability matters and some recall costs, with those obligations lasting until 2025‑2029 or until specific events occur and being subject to caps, thresholds and a corporate guarantee (see GM 10‑K 2022 pp. 89‑93; GM 10‑K 2024 p. 91).  However, GM has repeatedly stated that it cannot estimate any reasonably possible loss from these indemnifications, has recorded only immaterial accruals, and believes the potential exposure is remote, so the financial risk has not materially increased despite the ongoing historical liabilities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that GM's obligations to Stellantis stem from the 2017 Master Agreement and persist through 2025–2029, which matches the multi-year indemnification framework in the original answer. The statement that GM has accrued only an immaterial amount as of 2024 is consistent with the ground truth’s mention of 'immaterial amount' accrued by December 31, 2024. (2) There are no numeric inaccuracies—dates (2022–2024), timeframes (obligations lasting until 2025–2029), and financial terms (immaterial accruals, inability to estimate losses) are all factually correct and supported by cited 10-K pages. Format and references are appropriately used. (3) The reasoning is sound: the LLM synthesizes information across years and correctly characterizes the nature of obligations (emissions-related claims, product liability, recall costs) as ongoing but with remote financial exposure. It captures the shift from operational to indemnification-based exposure implied in the original answer, though it does not explicitly mention the 2022 supply-related transactions. This omission slightly weakens completeness but does not distort the overall evolution. (4) The answer is contextually fully relevant, directly addressing the evolution of financial exposure and indemnifications. The only minor gap is the lack of explicit reference to Takata recalls and end-of-life vehicle investigations—though 'recall costs' and 'product-liability matters' likely encompass these. Overall, the answer demonstrates strong multi-hop reasoning and semantic equivalence with the ground truth, warranting a high correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 462,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has PepsiCo's relationship with co-packers evolved between 2022 and 2024, particularly in terms of operational dependency and strategic involvement?",
      "original_answer": "In 2022, PepsiCo described its relationship with co-packers as part of a 'highly distributed network of plants, warehouses and distribution centers' that are owned or leased by these third parties, indicating an operational dependency. By 2024, the company's language shifted to emphasize co-packers as part of 'strategic alliances or joint ventures in which we have an equity interest,' suggesting a more active and ownership-based strategic involvement. This evolution reflects a shift from a primarily operational partnership to a more integrated and strategic stake in co-packers.",
      "llm_answer": "\nBetween 2022 and 2024 PepsiCo moved from a largely outsourced model toward a more integrated partnership with its co‑packers.  The 2024 10‑K explicitly notes that the company now relies on a “highly distributed network of plants, warehouses and distribution centers that are owned or leased by our contract manufacturers, co‑packers, strategic alliances or joint ventures in which we have an equity interest,” indicating both greater operational dependence on these facilities and a deeper strategic role—through equity stakes and shared‑service arrangements— in their governance and planning.  This evolution reflects a shift from simple contract manufacturing to collaborative, equity‑backed relationships that shape PepsiCo’s supply‑chain strategy.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the evolution in PepsiCo's relationship with co-packers from 2022 to 2024, noting a shift from operational dependency to more strategic, equity-backed involvement. It accurately reflects the 2024 language about 'strategic alliances or joint ventures in which we have an equity interest,' aligning with the ground truth. However, it misattributes the combined 2024 description to a single quote that merges language from both years. Specifically, the LLM implies that the phrase 'highly distributed network of plants, warehouses and distribution centers that are owned or leased by our contract manufacturers, co-packers...' is new to 2024, when in fact this language was present in 2022 to describe third-party arrangements. The 2024 update adds the equity interest component but does not replace the earlier description. This conflation slightly distorts the evolution, making it seem like the operational model changed when it was the strategic layer that was added. There are no numerical inaccuracies (quantitative accuracy is perfect as no numbers are involved), and the reasoning is mostly sound with strong contextual relevance. The answer addresses both operational dependency and strategic involvement as required. The qualitative accuracy is slightly reduced due to the misrepresentation of how the language evolved across years, though the overall conclusion about increased strategic involvement is valid.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 399,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did SPG's financial relationship with ABG evolve between 2023 and 2024, particularly in terms of gains recognized and strategic investments?",
      "original_answer": "In 2023, SPG recognized multiple non-cash pre-tax gains related to its relationship with ABG, including $59.1 million from deemed disposals due to ABG's capital transactions and $157.1 million from the sale of a portion of its ABG interests. Additionally, SPG recorded a $145.8 million gain from the dilution of its ownership in SPARC Group. In 2024, SPG disclosed a pre-tax gain of $18.8 million from the sale of a portion of its ABG interest in December 2021, along with a strategic partnership with ABG to become the core licensee and operating partner for Reebok in the U.S., indicating a shift toward deeper operational collaboration rather than just financial transactions.",
      "llm_answer": "\nBetween 2023 and 2024 SPG systematically unwound its stake in ABG, first selling a partial interest in Q4 2023 (recognizing a $157.1 million pre‑tax gain, a $10.3 million non‑cash gain from the resulting deemed disposal, and $39.3 million of tax expense) and then disposing of the remaining ownership in Q1 2024 (generating a $414.8 million pre‑tax gain and $103.7 million of tax expense).  These sales—recorded in “gain due to disposal, exchange, or revaluation of equity interests, net”—marked the culmination of a strategic shift that had begun with earlier acquisitions of ABG equity and licensing‑venture interests, allowing SPG to monetize its ABG investment and re‑deploy the proceeds toward other growth initiatives.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to correctly represent the financial relationship between SPG and ABG in 2023 and 2024. (1) Quantitative Accuracy: The LLM claims SPG recognized a $157.1 million gain in Q4 2023 from selling a portion of its ABG interest — this aligns partially with the ground truth (correct amount but missing context of other gains). However, it incorrectly states a $414.8 million pre-tax gain in Q1 2024 from disposing of remaining ownership, which is not supported by the original answer; the 2024 gain mentioned in the ground truth is only $18.8 million (from a December 2021 sale). The $10.3 million non-cash gain and tax expenses are not in the original answer and appear fabricated. (2) Completeness: The LLM omits key 2023 gains: $59.1 million from deemed disposals due to ABG’s capital transactions and $145.8 million from dilution in SPARC Group. It also completely misses the strategic shift in 2024 toward operational collaboration (Reebok partnership), instead portraying 2024 as a continuation of stake monetization, which contradicts the ground truth. (3) Entity Accuracy: While SPG and ABG are correctly identified, the timeline is wrong — the 2024 disclosure refers to a gain from a 2021 transaction, not a 2024 disposal. The LLM incorrectly implies active divestments in both 2023 and 2024. (4) Reasoning: The multi-hop synthesis is flawed. The model infers a narrative of systematic unwinding and full exit, but the ground truth shows SPG still engaged with ABG in 2024 via a strategic partnership, indicating ongoing collaboration, not just divestment. (5) Semantic Equivalence: The overall message is misleading — the original emphasizes a shift from financial gains to strategic collaboration, while the LLM portrays a straightforward exit. Due to major errors in numbers, timing, and strategic interpretation, the correctness score is low despite some correct figures appearing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 524,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has Lockheed Martin's involvement in Sikorsky helicopter programs evolved from 2022 to 2024, particularly in terms of production volume and program scope?",
      "original_answer": "In 2022, Lockheed Martin's RMS segment experienced a $560 million increase in product costs, partly due to higher production volume on various Sikorsky helicopter programs. By 2024, RMS explicitly listed Sikorsky helicopter programs—such as those related to the Black Hawk, Seahawk, and CH-53K King Stallion—as key components of its portfolio, indicating a continued and potentially expanded focus. This evolution reflects a shift from being a cost driver to being a clearly defined strategic product line within the RMS segment.",
      "llm_answer": "\nFrom 2022 through 2024 Lockheed Martin’s Sikorsky portfolio moved from steady production of legacy Black Hawk and Seahawk models toward a higher‑volume ramp‑up of the next‑generation CH‑53K heavy‑lift helicopter and the completion of the VH‑92A Presidential‑helicopter program in 2024.  The company’s 10‑K filings note that “higher production volume on various Sikorsky helicopter programs” added roughly $560 million to product costs in 2021 and continued to drive sales growth in 2022‑2024, reflecting an expanded scope that now includes new lift‑capability variants and broader sustainment and training services for U.S. and foreign customers.  (Pages 44 & 43 of the 2022 10‑K; pages 4‑5 of the 2024 10‑K).",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increased production volume and strategic importance of Sikorsky helicopter programs from 2022 to 2024, aligning with the ground truth's emphasis on evolving scope and continued focus. It accurately references the $560 million increase in product costs linked to higher production volume. However, it incorrectly states this cost increase occurred in 2021, while the original answer and 2022 10-K clearly attribute it to 2022. This misattribution affects quantitative accuracy. (2) The dollar amount ($560 million) is correct, but the year is off by one—this is a significant error in temporal precision, especially for financial reporting contexts. Other numbers (e.g., program timelines) are generally consistent, with the VH-92A completion in 2024 plausible but not explicitly confirmed in the ground truth. (3) The reasoning is sound in synthesizing production trends and program scope expansion across years, correctly identifying CH-53K, Black Hawk, and Seahawk as key programs. The mention of expanded sustainment and training services adds context not in the ground truth but is plausible and relevant. However, the shift from 'cost driver' to 'strategic product line'—a key nuance in the original answer—is not fully captured. (4) Despite the year error, the answer remains contextually rich and relevant, addressing both production volume and program scope evolution. The core facts are mostly correct, but the incorrect year for the $560M cost impact prevents a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 424,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did Walmart's ownership stake and financial investment in Alert Innovation evolve between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, increasing its ownership to approximately 100%. By fiscal 2024, there was no mention of Walmart retaining ownership of Alert Innovation, indicating that the company had fully exited its stake, likely through a sale or divestiture.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Walmart’s interest in Alert Innovation did not change – the company had acquired 100 % of Alert Innovation in fiscal 2023 (a $0.4 billion purchase that gave it full ownership), and no additional capital outlay or new equity stake in Alert Innovation is reported for fiscal 2024; the stake remained at 100 % until the business was later sold and de‑consolidated in fiscal 2025.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "(1) The LLM answer is factually incorrect in its core conclusion: it claims Walmart retained 100% ownership through fiscal 2024 and only exited in fiscal 2025, while the ground truth states there was no mention of ownership in fiscal 2024, indicating a full exit by then. This contradicts the original answer and misrepresents the timeline. (2) Quantitatively, the $0.4 billion acquisition amount and 100% ownership in fiscal 2023 are correctly stated, so numeric accuracy for those elements is preserved. However, the introduction of 'fiscal 2025' as the divestiture year is unsupported by the provided information and introduces a fabricated data point. (3) The reasoning is flawed: the LLM assumes continuity of ownership into fiscal 2024 and invents a future deconsolidation in 2025, failing to recognize that the absence of mention in fiscal 2024 filings indicates an already-completed exit. This breaks the multi-hop logic required to infer ownership changes based on disclosure patterns. (4) While the answer addresses the question's structure and uses correct entities (Walmart, Alert Innovation, correct fiscal years), the central claim is incorrect, warranting a low correctness and qualitative accuracy score. Contextual relevance is moderate because it discusses the right companies and investment, but with incorrect conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1175,
        "completion_tokens": 371,
        "total_tokens": 1546
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did SPG's utilization and management of the Supplemental Facility evolve between 2023 and 2024, particularly in terms of borrowing activity and repayment strategy?",
      "original_answer": "In 2023, SPG utilized the Supplemental Facility as part of its broader capital strategy, borrowing €750.0 million under this facility, which was later repaid on November 17, 2023, following the issuance of senior unsecured bonds. By 2024, there was no outstanding balance under the Supplemental Facility, indicating a full repayment and a shift away from its use. This evolution shows a strategic reduction in reliance on the Supplemental Facility, with SPG opting instead to refinance through long-term unsecured notes, such as the $1.0 billion issuance in September 2024.",
      "llm_answer": "\nBetween 2023 and 2024 SPG’s use of the Supplemental Facility shifted from active borrowing and rapid repayment to a standby‑capacity role.  In 2023 the Operating Partnership drew €750 million (≈$815 million) under the Supplemental Facility and then retired that debt within weeks using proceeds from a €750 million Euro‑bond issuance (page 61), leaving essentially no outstanding balance at year‑end 2023.  By 2024 the facility remained available with an extended maturity to January 2029 (and a one‑year extension to 2030) and a $3.5‑$4.5 billion borrowing capacity (page 68), but the company reported no new draws; instead it relied on the broader Credit Facility and commercial‑paper market for liquidity, using the Supplemental Facility only as a contingent source of funding.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in SPG's use of the Supplemental Facility between 2023 and 2024. It accurately reports the €750 million draw in 2023 and its repayment using proceeds from a bond issuance, aligning with the ground truth. The statement that there was no outstanding balance at year-end 2023 and no new draws in 2024 correctly reflects the reduced reliance on the facility. However, the LLM introduces a detail not present in the original answer — the extension of the facility’s maturity to January 2029 with a one-year extension to 2030 and the $3.5–$4.5 billion capacity — which, while potentially true, is not part of the ground truth and adds unverified context. Additionally, the LLM mentions repayment occurred 'within weeks' and references a '€750 million Euro-bond issuance', whereas the ground truth specifies the repayment date (November 17, 2023) and notes the issuance of senior unsecured bonds without specifying currency or exact size. The ground truth also includes a key forward-looking data point — the $1.0 billion bond issuance in September 2024 — which the LLM omits, missing a critical element of SPG’s refinancing strategy that explains the continued non-use of the Supplemental Facility in 2024. This omission slightly weakens completeness. Quantitative accuracy is high: €750 million is correct, and the approximate conversion to $815 million is reasonable. Dates are not contradicted, though specificity is reduced. The reasoning is sound and synthesizes the shift in financing strategy, correctly identifying the Supplemental Facility’s transition to a contingent role. The answer remains contextually relevant and well-structured. The score is reduced from 9 to 8 due to the omission of the 2024 $1.0 billion bond issuance and the introduction of unverified details about facility capacity and maturity extension.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 508,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How has Linde's treatment of helium in its industrial gases business evolved between 2023 and 2024, particularly in terms of its positioning as a primary product and associated supply strategies?",
      "original_answer": "In 2023, helium was explicitly listed as one of Linde's primary products within its industrial gases business, specifically called out alongside gases like oxygen, nitrogen, and hydrogen. The 2023 filing also described helium's distribution through merchant delivery, with contracts typically lasting three to seven years and without minimum purchase requirements. By 2024, helium was no longer specifically named as a distinct product in the industrial gases segment. Instead, it was subsumed under more general descriptions of gas supply methods and contracts, suggesting a reduced emphasis on helium as a standalone offering. This shift indicates a strategic repositioning of helium within Linde's broader gas portfolio, aligning it more closely with other merchant gases rather than maintaining its prior distinct status.",
      "llm_answer": "\nLinde still treats helium as one of its core process gases—listed alongside hydrogen, oxygen, nitrogen, etc.—and continues to market it as a primary product within the industrial‑gases business.  The company supplies helium mainly through its merchant and on‑site distribution models, using long‑term contracts that often contain minimum‑purchase requirements and price‑escalation provisions, a strategy that has remained unchanged between the 2023 and 2024 filings.  No material shift in positioning or supply‑chain approach for helium is disclosed in the provided 2023‑2024 SEC excerpts.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claims, directly contradicting the ground truth. (1) It states that helium was still listed as a core product alongside hydrogen, oxygen, and nitrogen in both 2023 and 2024, but the original answer confirms that while helium was explicitly named in 2023, it was no longer specifically mentioned as a distinct product in 2024, indicating a strategic de-emphasis. (2) The LLM claims that long-term contracts 'often contain minimum-purchase requirements,' but the ground truth states that 2023 contracts had 'no minimum purchase requirements,' and there is no mention of a change in 2024—thus the LLM introduces an incorrect detail. (3) The LLM concludes there was 'no material shift' in positioning or supply strategy, while the original answer identifies a clear shift in how helium is positioned—specifically, its removal as a named primary product, signaling a repositioning within the portfolio. (4) There are no numerical values in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default due to absence of numeric errors. (5) The reasoning is flawed: the LLM fails the multi-hop requirement to compare the two years' disclosures and infer strategic change from omission and reclassification. Instead, it asserts continuity without evidence. (6) Contextual relevance is moderate—the response addresses the topic of helium in Linde’s business and supply strategies—but it misrepresents the evolution, making it misleading despite topical alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 420,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the allocation of assets in the U.S. Retiree Health Care Plan evolve between 2022 and 2023, particularly in terms of fixed income securities and equity securities?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan had $248 in fixed income securities and cash equivalents and $137 in equity securities, totaling $385. In 2023, the plan's allocation changed to $210 in fixed income securities and cash equivalents and $54 in equity securities, totaling $264. This indicates a decrease in both categories, with a more significant reduction in equity securities.",
      "llm_answer": "\nBetween 2022 and 2023 the U.S. Retiree Health‑Care plan moved substantially toward fixed‑income holdings and away from equities.  In 2022 the plan’s assets were roughly $182 million in fixed‑income and cash‑equivalents and $98 million in equity (total ≈ $280 million); by 2023 those figures had risen to about $210 million in fixed‑income (an increase of ~15 %) and fallen to only $54 million in equity (a drop of ~45 %), shifting the mix from roughly one‑third fixed‑income/ two‑thirds equity to about four‑fifths fixed‑income/ one‑fifth equity.  This reallocation reflects a deliberate tilt toward more stable, interest‑rate‑sensitive assets in the plan’s portfolio.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 the U.S. Retiree Health Care Plan had $248 in fixed income and cash equivalents and $137 in equity securities (total $385), not $182 and $98 million as stated by the LLM. In 2023, the correct values are $210 in fixed income and $54 in equity (total $264), which the LLM partially gets right for equity but incorrectly states fixed income as increasing from $182M to $210M when it actually decreased from $248 to $210. The LLM incorrectly claims a shift toward fixed income, while both categories actually decreased, with a more pronounced drop in equities. (2) The LLM's calculations are based on wrong base numbers: it reports a 15% increase in fixed income, but this is false because $210 is less than $248 (a ~15% decrease, not increase). The 45% drop in equities is approximately correct ($137 to $54 is a ~60% drop, so even this is understated). The total plan assets are misrepresented in both years. (3) The multi-hop reasoning is flawed: the LLM misidentifies the direction of change in fixed income allocation, incorrectly asserting a strategic shift toward fixed income when both asset classes declined. It fails to note the overall reduction in plan size and mischaracterizes the 2022 allocation mix. (4) The contextual relevance is moderate because the answer addresses asset allocation changes in the correct plan and years, and discusses fixed income and equities as requested, but the core quantitative and directional claims are incorrect, severely undermining factual correctness. Thus, the correctness score is low due to major factual and numerical errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 460,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the financial performance and strategic positioning of Trodelvy evolve between 2022 and 2023, particularly in terms of revenue generation and regulatory milestones?",
      "original_answer": "In 2022, Trodelvy generated $380 million in total product sales, primarily in the U.S., indicating its early commercial presence. By 2023, there was a strategic shift in Trodelvy's positioning as it received significant regulatory approvals: FDA approval for treating HR+/HER2- metastatic breast cancer and EC approval for a similar indication. These developments suggest a strong enhancement in its market potential and therapeutic footprint, although specific revenue figures for 2023 are not provided.",
      "llm_answer": "\nBetween 2022 and 2023, Trodelvy’s product sales jumped 56 % to roughly **$1.1 billion**, fueled by stronger demand across both new and existing geographies (see page 40/70).  In parallel, the company achieved two key regulatory milestones—**European Commission approval** and **U.S. FDA approval** of Trodelvy as a monotherapy for HR⁺/HER2‑negative metastatic breast cancer (after prior endocrine therapy and ≥2 systemic treatments) (see page 39).  These approvals cemented Trodelvy’s strategic positioning as a growing oncology asset and expanded its commercial footprint.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies in financial figures. The ground truth states that Trodelvy generated $380 million in 2022, but the LLM claims a 56% increase to $1.1 billion in 2023—this implies a 2022 base of approximately $705 million, which contradicts the $380 million figure. The $1.1 billion revenue and 56% growth are entirely unsupported by the original answer, which explicitly states that 'specific revenue figures for 2023 are not provided.' (2) Quantitative accuracy is severely compromised: the dollar amounts and percentage growth are fabricated or misattributed, failing basic calculation checks. Even allowing for format variation, $380 million vs $1.1 billion is a more than 2x discrepancy. (3) Qualitatively, the LLM correctly identifies the two key regulatory milestones—FDA and European Commission approval for HR+/HER2- metastatic breast cancer—which aligns with the original answer and shows correct multi-hop reasoning in linking regulatory events to strategic positioning. However, it overreaches by asserting commercial growth 'across new and existing geographies' without evidence. (4) Contextual relevance is high because the response addresses both revenue and regulatory aspects of the question and focuses on the correct drug and time frame. Despite correct entity identification (Trodelvy, FDA, EC, indication), the severe numerical inaccuracies undermine the core of the financial performance claim, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 414,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did Chevron's downstream-related earnings and investment relationship with GS Caltex evolve from 2022 to 2024, and what does this indicate about the strategic importance of the joint venture?",
      "original_answer": "In 2022, Chevron reported higher downstream-related earnings from GS Caltex in Korea, contributing to improved income from equity affiliates. By 2024, Chevron maintained a 50% ownership stake in GS Caltex Corporation, which operates as a joint venture with GS Energy, importing, producing, and marketing petroleum products, petrochemicals, and lubricants. Additionally, in 2024, Chevron reported $13,850 million in sales and other operating revenues with affiliated companies, including GS Caltex, compared to $16,286 million in 2022. This indicates that while the joint venture remained strategically important, the level of downstream-related revenue with affiliated companies slightly decreased over the period.",
      "llm_answer": "\nChevron’s 50% stake in GS Caltex stayed around $4.3 bn through 2022‑23 but slipped to $4.14 bn by 2024, while earnings from the joint venture fell sharply from about $874 m in 2023 to $437 m in 2024, cutting the contribution in half. This decline reflects weaker downstream margins in Korea and shows that, although the JV remains a strategic gateway to the South Korean market, its contribution to Chevron’s overall downstream profitability is diminishing. Consequently, the partnership’s strategic importance appears to be shifting from a profit driver to a market‑access asset.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Chevron maintained a 50% ownership stake in GS Caltex and reports downstream-related earnings and revenues from affiliated companies, but does not provide specific earnings figures for GS Caltex alone or Chevron’s equity investment value in the joint venture. The LLM invents precise numbers—$4.3B stake in 2022–23 dropping to $4.14B in 2024, and GS Caltex earnings falling from $874M in 2023 to $437M in 2024—which are not present in the original answer and cannot be verified from the provided truth. These fabricated figures severely undermine quantitative accuracy. (2) The original answer cites Chevron’s total sales and other operating revenues with affiliated companies (including GS Caltex) as $16,286 million in 2022 and $13,850 million in 2024—a decrease, but not broken down by year or by JV. The LLM incorrectly attributes this decline to GS Caltex specifically and introduces unsupported year-to-year earnings drops. There is no mention in the ground truth of a sharp earnings halving or stake value decline. (3) The multi-hop reasoning is flawed: while the LLM attempts to infer strategic implications (shifting from profit driver to market-access asset), this conclusion is based on incorrect data. The original answer suggests the JV remains strategically important despite a slight revenue decrease, whereas the LLM overstates the decline and draws a stronger, unsupported conclusion about diminishing strategic role. (4) Contextually, the LLM addresses the evolution of the relationship and strategic importance, which aligns with the question, earning moderate relevance. However, due to major quantitative errors and incorrect entity-specific financials, the correctness score is low. The qualitative reasoning would be stronger if based on accurate data, but as it stands, the answer misrepresents the financial reality of the joint venture.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 529,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did the financial performance and production status of the CH-53K program evolve from 2022 to 2024, particularly in terms of risk retirements and production volume?",
      "original_answer": "In 2022, the CH-53K program contributed to higher operating profit for Sikorsky helicopter programs, with approximately $140 million in increased profit driven by higher risk retirements and production volume. By 2024, while the CH-53K remained a key product within RMS, the overall operating profit for RMS declined significantly—by 73%—partially due to lower profit booking rate adjustments across the portfolio. Although specific profit figures for CH-53K were not disclosed in 2024, the broader profit decline suggests that the gains from risk retirements observed in 2022 may have diminished as the program matured and entered higher-volume production.",
      "llm_answer": "\nFrom 2022 to 2024 the CH‑53K heavy‑lift helicopter—part of Lockheed Martin’s Rotary and Mission Systems (RMS) segment—helped drive a rise in segment net sales from **$16.1 B to $17.3 B**, with about **$140 million of the 2024 increase** directly attributed to higher production volume on the CH‑53K program.  Operating profit for the segment edged up from **$1.91 B (2022) to $1.92 B (2024)**, but the **favorable profit‑booking (risk‑retirement) adjustments linked to the CH‑53K fell by roughly $155 million in 2024** compared with the prior year, offsetting much of the volume‑driven gain.  Thus, while production on the CH‑53K accelerated, the program’s earnings impact was muted by a reduction in risk‑retirement benefits in 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) QUANTITATIVE INACCURACY: The LLM claims net sales rose from $16.1B (2022) to $17.3B (2024) and attributes $140M of the 2024 increase to CH-53K, but the original answer does not mention segment net sales or such a revenue increase. More critically, it states that risk-retirement adjustments fell by $155M in 2024—this figure is fabricated and contradicts the ground truth, which states that specific CH-53K profit figures were not disclosed in 2024. The LLM also falsely claims operating profit increased slightly from $1.91B to $1.92B, while the ground truth reports a 73% decline in RMS operating profit by 2024. These numbers are entirely inconsistent with the source. (2) COMPLETENESS: While the LLM attempts to address production volume and risk retirements, it misrepresents the trend—ground truth indicates that the 2022 profit boost was due to risk retirements and volume, but by 2024, overall RMS profits collapsed despite continued production, suggesting diminishing returns. The LLM incorrectly frames this as a modest shift rather than a major decline. (3) ENTITY & CONTEXTUAL ACCURACY: The CH-53K is correctly placed within RMS, and the focus on risk retirements and production volume is relevant. However, the use of precise financial figures not present in the original (e.g., $1.91B, $1.92B, $155M decline) introduces false precision. (4) REASONING: The LLM performs a multi-hop synthesis but bases it on incorrect data, leading to flawed conclusions. It incorrectly implies that volume gains were offset by reduced risk retirements, whereas the ground truth suggests broader portfolio issues and lack of disclosed program-level profitability in 2024. Overall, while the general direction (maturity reducing risk retirement benefits) is plausible, the answer fabricates key data and misrepresents financial performance, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 527,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has PayPal's approach to seller protection programs evolved between 2022 and 2023, particularly in terms of risk exposure and strategic emphasis?",
      "original_answer": "In 2022, PayPal highlighted that its seller protection programs carried risk exposure tied to regional variations and regulatory changes, with historical transaction loss rates ranging between 0.09% and 0.15% of TPV. By 2023, the company placed a stronger strategic emphasis on these programs as a competitive differentiator, explicitly linking them to merchant trust and platform growth. While 2022 focused on risk management and potential loss implications, 2023 framed seller protection as part of a broader value proposition to attract and retain merchants, integrating it with analytics, risk management, and other merchant services.",
      "llm_answer": "\nBetween 2022 and 2023 PayPal shifted its seller‑protection narrative from a pure loss‑provision view—where transaction‑and‑credit losses were disclosed mainly as a financial‑risk metric tied to macro‑economic factors and allowance estimates—to a strategic emphasis that treats robust protection as a growth driver for merchants.  The 2023 filing highlights expanded investment in buyer‑ and seller‑protection programs, risk‑management systems, and data‑driven safeguards, positioning these protections as core to deepening merchant engagement and differentiating the PayPal/Venmo ecosystem, while still quantifying exposure through allowances for transaction losses.  In short, the company moved from “managing credit‑loss risk” to “leveraging seller‑protection as a strategic advantage.”",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution in PayPal's approach: from a risk-focused perspective in 2022 to a strategic, growth-oriented emphasis in 2023. The core ideas—shift from risk management to competitive differentiation, integration with merchant trust and platform growth, and linkage to broader ecosystem value—are all present and correctly represented. (2) Quantitatively, while the LLM does not repeat the specific 0.09%–0.15% loss rate range or explicitly mention TPV, it does reference 'allowances for transaction losses' and 'transaction-and-credit losses' as financial risk metrics, which is consistent with the original. The absence of the exact percentage range is a minor omission but not a factual error—no incorrect numbers are presented. (3) The multi-hop reasoning is sound: the model synthesizes changes in tone, strategic framing, and business rationale across years, correctly identifying the shift in emphasis. It also appropriately links seller protection to merchant engagement and ecosystem differentiation, reflecting cross-year and cross-functional synthesis. (4) The answer is contextually excellent—directly addressing both risk exposure and strategic emphasis as asked. The phrasing 'leveraging seller-protection as a strategic advantage' effectively summarizes the 2023 shift. The only reason for not scoring a 10 is the omission of the specific historical loss rate range (0.09%–0.15%), which was part of the original answer’s quantitative grounding. However, since the LLM does not make up numbers and still conveys the risk exposure concept accurately, this is a minor gap. Overall, the answer is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 476,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Starbucks' approach to its ready-to-drink beverages evolved between 2023 and 2024, particularly in terms of revenue recognition and supplier dependency?",
      "original_answer": "In 2023, Starbucks recognized revenue from ready-to-drink beverages under the 'Other Revenues' category, where sales were generally recognized upon shipment to customers depending on contract terms. By 2024, the company's focus shifted to supplier dependency and supply chain resilience, emphasizing that ready-to-drink beverages are sourced from specialty suppliers under long-term contracts, indicating a strategic move toward securing stable supply rather than just reporting revenue. While 2023 included ready-to-drink beverages in broader revenue disclosures without specific figures, 2024 highlighted the importance of supplier relationships to mitigate delivery risks, signaling a shift from revenue-centric reporting to a supply-chain risk management focus.",
      "llm_answer": "\nBetween the 2023 and 2024 10‑K filings Starbucks has kept the same core revenue‑recognition rule for its ready‑to‑drink (RTD) products—revenue is recognized when control of the product passes to the external customer, which the company generally treats as shipment (or when control is transferred under the delivery‑platform model).  What has changed is the supply‑chain structure: whereas earlier the company handled most RTD production and distribution internally, by 2024 the RTD line is largely packaged and distributed through Nestlé under the Global Coffee Alliance, making Nestlé the primary third‑party supplier for those beverages and shifting much of the supply‑risk and logistics dependence to that partner.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains significant factual inaccuracies in entity identification and reasoning, despite accurate revenue recognition timing. (1) Correct elements: The revenue recognition principle—upon shipment or transfer of control—is consistent with the ground truth and correctly noted as unchanged between 2023 and 2024. (2) Quantitative accuracy: There are no explicit numbers (e.g., dollar amounts, percentages) in either the original or LLM answer, so no numeric errors exist; thus, quantitative accuracy is high. (3) Multi-hop reasoning and entity accuracy issues: The LLM incorrectly claims that by 2024, Starbucks' ready-to-drink (RTD) beverages are 'largely packaged and distributed through Nestlé under the Global Coffee Alliance.' This is factually incorrect—Starbucks' RTD products in North America are primarily produced and distributed in partnership with PepsiCo (under the North American Coffee Partnership), not Nestlé. The Global Coffee Alliance with Nestlé pertains to retail coffee products outside North America, not core RTD beverage distribution. Additionally, the original answer emphasizes a shift in disclosure focus—from revenue recognition in 2023 to supplier dependency and supply chain resilience in 2024—but does not state that internal production was replaced by external suppliers like Nestlé. The LLM invents a structural change not present in the ground truth. (4) The answer is contextually relevant and addresses both revenue recognition and supplier dependency, but the core claim about Nestlé undermines the qualitative accuracy. While the direction of increased supplier reliance is aligned with the original, the specific entity and extent of dependency are incorrect, leading to a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 481,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did the geographic reach and regulatory approvals of Trodelvy evolve between 2022 and 2023?",
      "original_answer": "In 2022, Trodelvy generated $370 million in U.S. sales and $10 million in Europe, with no sales reported in other international markets, indicating limited geographic reach. By 2023, Trodelvy received significant regulatory approvals: it was approved by the FDA for treating adult patients with HR+/HER2- metastatic breast cancer, and it obtained EC approval for monotherapy treatment of unresectable or metastatic HR+/HER2- breast cancer. These approvals suggest an expansion of Trodelvy's market access and therapeutic application, likely contributing to broader geographic distribution beyond what was reported in 2022.",
      "llm_answer": "\nBetween 2022 and 2023 Trodelvy’s regulatory footprint moved from its initial approvals in the United States (accelerated approval for metastatic urothelial cancer and full approval for metastatic triple‑negative breast cancer) and the European Union (EU marketing authorization for the same TNBC indication in November 2021) to new approvals in both the United States and the European Commission for a distinct indication—unresectable or metastatic HR⁺/HER2‑negative breast cancer.  These 2023 approvals expanded the drug’s geographic reach to additional EU markets and reinforced its presence in North America, extending its use beyond TNBC to a broader breast‑cancer population.  (See GILD_10k_2023 pages 38‑39 for the EU and FDA approvals of the HR⁺/HER2‑negative breast‑cancer indication.)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, no specific sales figures for 2022 are mentioned in the LLM answer ($370M US, $10M Europe), which is a minor omission, but the focus is on regulatory evolution rather than sales data, so this does not undermine correctness. All dates and approvals are correctly cited: 2023 FDA and EC approvals for HR+/HER2- metastatic breast cancer are accurately reported, consistent with the original answer. (2) The LLM correctly identifies the expansion of regulatory approvals from prior indications (TNBC and urothelial cancer) to the new HR+/HER2- indication in both the U.S. and EU, demonstrating sound multi-hop reasoning across time and geography. (3) Entity accuracy is strong: Gilead (GILD), Trodelvy, FDA, EC, and correct disease indications (HR+/HER2-, TNBC) are all properly referenced. The mention of GILD_10k_2023 pages 38–39 adds verifiable sourcing. (4) While the original answer includes 2022 sales data to illustrate limited geographic reach, the LLM infers geographic expansion from regulatory approvals—still a valid and logical interpretation, especially given the emphasis on regulatory evolution. The core conclusion—that Trodelvy’s reach expanded in 2023 due to new approvals—is fully supported and semantically equivalent. Only a perfect score is withheld due to the omission of the specific 2022 sales figures that ground the initial geographic limitation, which slightly reduces completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 411,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Simon Property Group's ownership stake and financial gains from transactions involving ABG evolve between 2023 and 2024?",
      "original_answer": "In 2023, Simon Property Group (SPG) experienced multiple dilutions of its ownership stake in ABG through capital transactions, including a reduction from approximately 12.3% to 11.8%, then to 11.7%, and finally to approximately 9.6%. These transactions resulted in non-cash pre-tax gains of $36.4 million, $12.4 million, and $10.3 million, respectively. By contrast, in 2024, SPG no longer disclosed active changes in its ownership stake in ABG. Instead, it referenced a prior transaction from December 20, 2021, where it sold a portion of its interest in ABG for a pre-tax gain of $18.8 million and later acquired additional interests for $100.0 million. This indicates a shift from active stake reduction and financial recognition in 2023 to a more passive disclosure stance in 2024, with no new transactions reported.",
      "llm_answer": "\nSimon’s ABG stake fell from roughly 12 % at the beginning of 2023 to about 9.6 % after a Q4‑2023 capital transaction and to 0 % after it sold the remaining interest in Q1‑2024.  The 2023 dilutive transactions generated non‑cash pretax gains of $36.4 million (Q2), $12.4 million (Q3) and $157.1 million from the sale of a portion in Q4, plus a $10.3 million gain on the related deemed disposal (pages 73‑74).  In Q1‑2024 the complete sale of the rest of the stake produced a $414.8 million pretax gain (page 73).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Simon Property Group's (SPG) ownership stake in ABG decreased from approximately 12.3% to 9.6% through multiple dilutions in 2023, but it did not drop to 0% in Q1-2024. The claim that SPG sold its remaining interest and reached 0% ownership in Q1-2024 is incorrect. Additionally, the financial gains reported are largely wrong: the LLM states a $157.1 million gain in Q4-2023 and a $414.8 million gain in Q1-2024, which contradicts the ground truth that reports only three non-cash pre-tax gains in 2023 of $36.4M, $12.4M, and $10.3M respectively, with no new gains reported in 2024. (2) Quantitative accuracy is severely compromised: the dollar amounts and percentages are incorrect. The ground truth does not mention any $157.1M or $414.8M gains, nor does it state a complete sale in 2024. The stake reduction ends at 9.6%, not 0%. The only correct numbers are the $36.4M and $12.4M gains, though the $10.3M gain is misattributed as part of a 'deemed disposal' linked to a larger transaction, which is unsupported. (3) The multi-hop reasoning is flawed: the model incorrectly infers a full exit from ABG in 2024, whereas the ground truth indicates SPG stopped disclosing active changes and instead referenced a prior 2021 transaction. The shift from active stake reduction in 2023 to passive disclosure in 2024 is completely missed. (4) Contextual relevance is moderate because the answer addresses ownership changes and financial gains, but the core facts are wrong, leading to a misleading narrative. The answer fabricates transactions and gains not present in the original data, undermining correctness and qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 473,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has the 2012 Equity Incentive Plan evolved between the 2023 and 2024 filings, particularly in terms of amendments and forms of award agreements disclosed?",
      "original_answer": "In 2023, the 2012 Equity Incentive Plan was disclosed as amended, including the Third Amendment to the plan, and referenced forms of award agreements from 2012 and 2017. In 2024, the filing included a Fourth Amendment dated August 1, 2024, and introduced additional forms of award agreements from April 2024, showing continued evolution and expansion of the plan over time.",
      "llm_answer": "\nBetween the 2023 and 2024 filings the 2012 Equity Incentive Plan was updated with an additional amendment— the **Fourth Amendment**—which was disclosed in the 2024 Form 10‑K (Exhibit 10.2(C)+).  Along with that amendment, the company continued to file newer “forms of award agreements” (e.g., the 2023 10.2(J)+ and 2024 10.2(K)+ exhibits) that reflect revised vesting, performance‑metric and settlement terms, showing a progressive evolution of the plan’s documentation and conditions.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is mostly correct and captures the core evolution of the 2012 Equity Incentive Plan between the 2023 and 2024 filings. It correctly identifies the Fourth Amendment disclosed in 2024 and references updated forms of award agreements, aligning with the ground truth. However, there are minor discrepancies: the ground truth specifies that the 2023 filing included the Third Amendment and referenced 2012 and 2017 award agreement forms, while the LLM answer does not mention the 2012 and 2017 forms and instead references 2023 (10.2(J)+) and 2024 (10.2(K)+) exhibits, which are not in the original answer. While it's plausible these are the April 2024 forms mentioned in the ground truth, the absence of explicit mention of the earlier forms (2012, 2017) and the potential misattribution of exhibit dates reduces completeness and precision. The date of the Fourth Amendment (August 1, 2024) is not mentioned, which is a factual omission. The reasoning is sound in identifying progression and evolution, and the answer is contextually relevant, addressing both amendments and award agreement updates. Wording differences are acceptable under semantic equivalence, but missing key details from the 2023 disclosure lowers the score slightly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1217,
        "completion_tokens": 348,
        "total_tokens": 1566
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the treatment and valuation of capitalized software licenses evolve between 2022 and 2023, and what does this indicate about the company's investment in software licensing?",
      "original_answer": "In 2022, capitalized software licenses were described as being generally amortized on a straight-line basis over the term of the license, indicating a clear policy for their depreciation over time. By 2023, the company disclosed the actual carrying value of these licenses on the balance sheet at $223 million, up from $152 million in 2022. This increase suggests a growing investment in software licensing, despite the unchanged amortization policy. The evolution from a disclosed accounting method in 2022 to a quantified asset in 2023 reflects a more tangible and increasing role of capitalized software licenses in the company's asset structure.",
      "llm_answer": "\nBetween 2022 and 2023 the balance‑sheet amount of capitalized software licenses rose sharply—from **$152 million to $223 million**—and the related amortization expense increased from **$54 million to $63 million**.  The company continues to amortize these licenses on a straight‑line basis over their contractual terms, writing off fully amortized assets against accumulated amortization.  This growth shows that Texas Instruments is investing more heavily in purchased software licenses (e.g., design‑tool and IP licenses), underscoring a strategic focus on expanding its software‑enabled semiconductor development and support capabilities.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the increase in capitalized software licenses from $152 million in 2022 to $223 million in 2023, matching the ground truth. It also accurately notes the unchanged straight-line amortization policy. However, the LLM introduces an additional detail not present in the original answer: amortization expense increased from $54 million to $63 million. This data point is not mentioned in the ground truth and cannot be verified from the provided information, making it an unsupported addition. 2) The quantitative values for the carrying amounts ($152M and $223M) are correct and properly formatted. The implied increase of $71M is accurate. However, the amortization expenses ($54M and $63M) are extraneous and not corroborated by the original answer, which only discusses carrying value and amortization method. 3) The reasoning is largely sound: the LLM correctly infers growing investment in software licensing based on the increase in capitalized value and ties it to strategic development in software-enabled semiconductor capabilities. The synthesis across years is valid, though the conclusion is slightly overextended due to the inclusion of unverified amortization expense data. 4) The answer is highly relevant to the question, addressing both the evolution in treatment/valuation and the implication for investment. The core facts are correct, but the addition of unconfirmed expense figures prevents a top score. The mention of 'Texas Instruments' is not in the original answer and assumes a company not explicitly named in the question or ground truth, which may be incorrect. This affects entity accuracy. Despite this, the overall interpretation aligns well with the ground truth's intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 471,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did PayPal's utilization of European customer balances for credit activities evolve between 2022 and 2023, and what does this indicate about its strategic approach to funding credit products?",
      "original_answer": "In 2022, PayPal had approved $3.8 billion of European customer balances for credit activities, representing approximately 37% of European customer balances available for corporate use. In 2023, this approved amount decreased to $3.0 billion, representing 39% of European customer balances. This indicates a slight reduction in the total approved funding base but a higher percentage utilization of available balances, suggesting a more efficient use of existing customer balances for credit activities. Additionally, PayPal entered into a new €40 billion agreement in 2023 to sell consumer installment receivables, with $5.5 billion sold during the year, signaling a strategic shift toward external funding mechanisms to support credit product expansion.",
      "llm_answer": "\nBetween 2022 and 2023 the amount of European customer balances that PayPal could earmark for funding its credit products fell modestly—from **$3.8 billion (≈37 % of European balances) in 2022 to $3.0 billion (≈39 % of European balances) in 2023** [PYPL_10k_2022.pdf p.49; PYPL_10k_2023.pdf p.49].  At the same time the company disclosed a **June 2023 multi‑year agreement to sell up to €40 billion of eligible consumer installment receivables** and reported $5.5 billion of loan and interest sales under that program during 2023 [PYPL_10k_2023.pdf p.49].  This indicates that PayPal is **shifting its funding mix toward external sources—particularly securitization and partnership‑based financing—while still using a stable share of customer deposits as a supplemental, regulated source of credit‑product capital**.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer is factually correct in all quantitative aspects: the $3.8 billion in 2022 (37%), $3.0 billion in 2023 (39%), and the $5.5 billion in receivables sold under the €40 billion agreement are all accurately reported. The years and sources (2022 and 2023 10-Ks, page 49) are correctly cited. 2) Quantitative accuracy is perfect—numbers, percentages, and timeframes match the ground truth exactly. Format variations (e.g., $3.8 billion vs $3.8B) are acceptable and do not affect meaning. 3) The reasoning is sound: the LLM correctly infers a strategic shift toward external funding (via the securitization agreement) while maintaining a stable reliance on customer balances. It accurately notes the slight reduction in absolute approved balances but higher percentage utilization, indicating efficiency. The term 'supplemental, regulated source' aligns with the original answer's implication of continued but optimized use. 4) The answer fully addresses both parts of the question—evolution of balance utilization and strategic implications—and synthesizes information across two years and two mechanisms (internal balances and external receivables sales). The only minor shortcoming is a slightly less explicit mention of 'more efficient use' compared to the original, but the concept is implied through the percentage increase. Thus, qualitative accuracy is high but not perfect. Contextual relevance is excellent as all information directly addresses the query.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 405,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Starbucks' investment relationship with Valor Siren Ventures I L.P. evolved between fiscal years 2023 and 2024, particularly in terms of the carrying value of the investment and its financial impact on Starbucks' consolidated statements?",
      "original_answer": "In fiscal 2023, Starbucks held a limited partnership interest in Valor Siren Ventures I L.P., with the total carrying value of such investments not specifically disclosed for that year. The financial impact of these investments, including Valor Siren Ventures I L.P., was included in 'interest income and other, net' and was not considered material. By fiscal 2024, the total carrying value of Starbucks' investments in Valor Siren Ventures I L.P. and II L.P. combined was $211.9 million as of September 29, 2024. The investment relationship evolved from a general equity stake to a more defined and quantified investment with ongoing monitoring, though the financial impact remained non-material and continued to be reported in 'interest income and other, net.'",
      "llm_answer": "\nStarbucks’ limited‑partner interest in Valor Siren Ventures I L.P. (and the related Valor Siren Ventures II L.P.) grew from $24.2 million at the end of fiscal 2023 to $211.9 million at the end of fiscal 2024 – an increase of roughly $188 million that is reflected on the balance sheet under “Other investments.”  The company’s share of any income or loss from these private‑equity funds is recorded in “interest income and other, net” on the consolidated statement of earnings, but the amounts are considered immaterial to the overall consolidated financial results.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative claim that the carrying value was $24.2 million at the end of fiscal 2023. The original answer (ground truth) explicitly states that the carrying value for Valor Siren Ventures I L.P. was not specifically disclosed in fiscal 2023, making the $24.2 million figure incorrect and unsupported. The $211.9 million figure for fiscal 2024 is correct and matches the ground truth, which correctly refers to the combined carrying value of both Valor Siren Ventures I and II L.P. (2) The calculation of a $188 million increase is based on the false premise of a $24.2 million starting value, rendering the entire quantitative comparison invalid. There is no evidence in the ground truth that Starbucks disclosed a specific amount for 2023, so the LLM invented a number. (3) Qualitatively, the LLM correctly identifies the nature of the investment (limited partnership), the reporting line 'interest income and other, net', and the non-material financial impact—these aspects reflect accurate synthesis. It also correctly notes the evolution toward a more defined investment structure, though it overstates the specificity for 2023. (4) Contextually, the answer is well-structured and addresses the core question about evolution, carrying value, and financial impact. However, the major error in fabricating a disclosed carrying value for 2023 undermines the correctness score. While the direction of growth and reporting treatment are plausible, the lack of disclosed 2023 value makes the central comparison false. Thus, despite good contextual framing and partial qualitative accuracy, the quantitative inaccuracy severely limits overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 475,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has the strategic positioning of Analog Products evolved between 2022 and 2023 in terms of TI's competitive advantages and financial contribution?",
      "original_answer": "In 2022, Analog Products were central to TI's strategic focus, contributing to a gross margin of 67.5% driven by the efficiency of their manufacturing strategy, including 300-millimeter production. By 2023, Analog Products remained a core pillar but were framed more explicitly within the context of TI's four sustainable competitive advantages, particularly emphasizing lower costs and greater control of the supply chain. Additionally, the 2023 report reinforced the role of Analog Products in enabling TI to generate and return significant cash, with a renewed emphasis on long-term free cash flow per share growth as the ultimate performance metric.",
      "llm_answer": "\nBetween 2022 and 2023 Analog’s financial contribution slipped: revenue fell 15 % to $13.0 bn and operating profit dropped 30 % to $5.8 bn, pulling its profit margin down from 54.4 % to 44.6 % and reducing its share of TI’s overall cash‑flow generation. Nevertheless, TI still treats Analog as one of its four core sustainable competitive advantages—built on a strong manufacturing foundation, a broad portfolio, extensive market reach and long‑life product diversity—while continuing to invest to counter the margin pressure from lower factory loadings and higher production costs.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Analog Products contributed to a gross margin of 67.5% in 2022 and remained a core strategic pillar in 2023 with emphasis on TI's sustainable competitive advantages and cash flow generation. However, the LLM claims that Analog's operating profit dropped 30% to $5.8B and revenue fell 15% to $13.0B, with profit margins declining from 54.4% to 44.6%. These figures are not supported by the original answer and contradict the positive strategic framing in the ground truth. There is no mention of revenue or profit declines in the original; instead, the focus is on sustained strategic importance and gross margin strength. (2) Quantitative accuracy is severely lacking: the original answer only provides a 67.5% gross margin for 2022 and implies continued strength in 2023, while the LLM fabricates detailed revenue, operating profit, and margin figures that do not appear in the ground truth. The claimed 15% revenue drop and 30% profit drop are entirely incorrect. Additionally, the original mentions gross margin (67.5%), not operating margin (54.4%), making the LLM's metric substitution misleading. (3) The multi-hop reasoning is flawed. The original answer synthesizes information about strategic positioning across two years, linking Analog Products to TI’s four sustainable competitive advantages (especially cost and supply chain control) and long-term free cash flow per share. The LLM incorrectly frames the evolution as a decline in financial performance while still being a competitive advantage, which misrepresents the narrative. It does correctly identify that Analog remains one of the core advantages and references manufacturing and portfolio breadth, but this is overshadowed by false financial data. (4) Contextual relevance is moderate—the answer addresses the strategic role of Analog and TI’s competitive advantages, so it stays on topic. However, due to the fabricated financials and incorrect characterization of performance trends, the overall correctness score is very low. The qualitative accuracy is slightly higher because some conceptual elements (manufacturing foundation, competitive advantages) are mentioned, but reasoning is undermined by false data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 610,
        "total_tokens": 1920
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Chevron's capital allocation strategy in the Lower 48 region evolved from 2022 to 2023, based on the changes in depreciation, depletion, amortization, and impairments?",
      "original_answer": "Chevron's capital allocation in the Lower 48 region increased significantly from 2022 to 2023, as evidenced by the rise in depreciation, depletion, amortization, and impairments from $4,854 million in 2022 to $5,729 million in 2023. This indicates a growing focus on asset development and operational expansion in the Lower 48, contrasting with relatively stable or declining figures in other geographic segments like Europe, Middle East and North Africa.",
      "llm_answer": "\nFrom 2022 to 2023 the Lower 48 segment’s depreciation, depletion and amortization climbed to **$5.73 bn** (up from **$4.85 bn** in 2022), a roughly **18 % increase**, while the overall impairment charge for the segment slipped modestly (total impairments fell from $813 m to $674 m).  This rise in D&A mirrors the jump in capital expenditures for the region—**$6.49 bn in 2023 versus $5.63 bn in 2022**—showing that ConocoPhillips is allocating more capital to develop and sustain Lower 48 assets, with a slight improvement in impairment trends.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. While the D&A figures are approximately correct ($4.85 billion in 2022 and $5.73 billion in 2023, aligning with the ground truth of $4,854 million and $5,729 million), the answer incorrectly attributes the data to ConocoPhillips instead of Chevron. This is a critical entity error that invalidates the entire response. (2) The quantitative values for D&A are close (rounding $4,854M to $4.85B and $5,729M to $5.73B is acceptable), but the inclusion of specific impairment figures ($813M to $674M) and capital expenditures ($5.63B to $6.49B) is unsupported by the ground truth, which does not mention these numbers or trends. These appear to be fabricated or misattributed from another source. (3) The multi-hop reasoning is flawed: the answer attempts to link D&A increases to capital expenditures and impairments, but the original question and ground truth only support an inference based on D&A and impairments as a proxy for capital allocation. More critically, the reasoning is applied to the wrong company. (4) The contextual relevance is partially correct in that it discusses D&A trends in the Lower 48 region and interprets them as a sign of increased capital allocation, which matches the ground truth’s logic. However, due to the wrong company and unsupported data points, the answer is largely incorrect. The correctness score is low due to the fundamental error of misidentifying the company, which undermines all other elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 415,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Verizon's approach to FWA Broadband evolved between 2023 and 2024, particularly in terms of its positioning within the company's product portfolio and its target customer segments?",
      "original_answer": "In 2023, Verizon provided FWA broadband through both 5G and LTE networks, targeting both Consumer and Business customers, and reported 3.1 million FWA broadband connections. By 2024, the company continued to offer FWA broadband primarily under the Verizon Consumer and Business Group segments, but with a more integrated positioning as an alternative to traditional landline internet access and as part of a broader portfolio that includes IoT and advanced communication services. The shift from 'provides' in 2023 to 'produces' in 2024 indicates a more strategic and product-centric approach to FWA broadband.",
      "llm_answer": "\nBetween 2023 and 2024 Verizon moved FWA broadband from a peripheral add‑on to a strategic pillar of its 5G‑driven product suite, explicitly integrating it into both the Consumer and Business segments.  The company is leveraging its expanding C‑Band spectrum and the Intelligent Edge Network to broaden coverage and is targeting underserved residential households as well as small‑to‑medium and enterprise customers, positioning FWA as a complementary alternative to fiber and a gateway to edge‑centric services.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Verizon's continued focus on FWA broadband for both Consumer and Business segments, aligning with the ground truth. However, it introduces details not present in the original answer, such as 'C-Band spectrum' and 'Intelligent Edge Network', which were not mentioned in the ground truth and cannot be verified from the provided data. The claim that FWA moved from a 'peripheral add-on to a strategic pillar' is a reasonable interpretation but goes beyond the ground truth's more measured observation about a shift in language from 'provides' to 'produces'. The target customer segments (residential, SME, enterprise) are consistent with the original answer's mention of Consumer and Business customers. (2) There are no numeric values in the LLM answer, so no quantitative inaccuracies exist; thus, quantitative accuracy is full. (3) The multi-hop reasoning is partially sound — it correctly synthesizes FWA’s role across segments and its strategic positioning — but overreaches by adding unverified technological drivers and strategic framing not present in the source. (4) The answer is contextually relevant and captures the core evolution in positioning, but lacks explicit mention of the 3.1 million connections in 2023 and the subtle linguistic shift ('provides' to 'produces') that was a key indicator in the ground truth. These omissions reduce qualitative accuracy despite strong overall alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 403,
        "total_tokens": 1694
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Emerson's relationship with AspenTech evolved from 2022 to 2024, and what financial impact did this evolution have on Emerson's gross margin and equity structure?",
      "original_answer": "In 2022, Emerson partnered with AspenTech, leveraging its asset optimization software to enhance industrial operational efficiency. By 2024, Emerson had significantly deepened this relationship by acquiring a 55% ownership stake in AspenTech as part of a strategic transaction that created 'New AspenTech.' This acquisition contributed positively to Emerson’s gross margin, benefiting it by 0.6 percentage points in 2023 and further influencing financial structure in 2024 with increased SG&A expenses tied to the integration. Additionally, the equity structure was impacted through the recognition of gains and losses associated with the AspenTech stock plans and the broader restructuring of industrial software assets.",
      "llm_answer": "\nFrom 2022 through 2024 Emerson’s stake in AspenTech grew from the 55 % ownership it obtained after combining its industrial‑software businesses with AspenTech (creating “New AspenTech”) to roughly 57 % of the publicly‑traded company, and in late‑2024 Emerson announced a cash proposal to acquire the remaining shares and take AspenTech fully private.  This progression lifted Emerson’s consolidated gross margin – the 2024 gross margin rose 1.8 percentage points to 50.8 % and the Adjusted EBITA‑as‑%‑of‑sales increased to 24.7 % – because the Test‑and‑Measurement acquisition (which includes AspenTech’s software assets) added higher‑margin revenue, although acquisition‑related inventory step‑up amortization of $231 shaved about 1.3 pts off the margin.  At the same time, Emerson’s equity structure changed: its investment in AspenTech moved from an equity‑method minority interest to a majority holding that will be fully consolidated once the cash acquisition closes, adding goodwill and intangible‑asset balances and requiring financing that will be reflected in the company’s consolidated balance sheet and debt‑to‑equity ratios.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness, despite addressing the right question and attempting multi-hop synthesis. (1) The timeline is incorrect: the original answer states Emerson acquired a 55% stake in AspenTech by 2024 as part of forming 'New AspenTech', implying the 55% ownership was established in 2024, not in 2022 as the LLM claims. The LLM incorrectly asserts Emerson already had 55% in 2022 and grew it to 57% by 2024, which contradicts the ground truth. (2) The financial figures are fabricated: the LLM cites a 1.8 percentage point increase in gross margin to 50.8% and Adjusted EBITA margin of 24.7%, none of which appear in the original answer. The original only states the acquisition contributed 0.6 percentage points to gross margin in 2023. The $231 million inventory step-up amortization and its 1.3-point margin impact are also not in the ground truth. (3) The late-2024 cash proposal to take AspenTech private is not mentioned in the original answer, making it an unsupported addition. (4) While the LLM correctly identifies the shift from minority equity-method investment to majority control and consolidation impact, this qualitative reasoning is built on incorrect premises. (5) The mention of 'Test-and-Measurement acquisition' is not in the original and appears to conflate unrelated transactions. Overall, the answer misrepresents key facts, timelines, and financial impacts, though it correctly frames the strategic evolution and general financial implications like consolidation and equity structure changes. Hence, the correctness score is low due to major quantitative and factual errors, despite relevant context and some correct conceptual reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1470,
        "completion_tokens": 469,
        "total_tokens": 1939
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did the financial relationship between NEE and FPL Group Capital Inc evolve from 2022 to 2023, particularly in terms of the nature of their obligations and capital structure involvement?",
      "original_answer": "In 2022, the relationship was characterized by a guarantee agreement between FPL Group, Inc. and FPL Group Capital Inc. dated October 14, 1998, indicating a direct obligation from FPL Group, Inc. to FPL Group Capital Inc. By 2023, this relationship had evolved into a more complex capital structure involvement, with NEE issuing multiple series of junior subordinated debentures to FPL Group Capital Inc., including Series B, C, L, M, N, O, and P, with maturity dates ranging from 2057 to 2082. This transition reflects a strategic shift from a simple guarantee to a long-term capital financing arrangement.",
      "llm_answer": "\nBetween 2022 and 2023 the link between NEE and FPL Group Capital Inc stayed anchored by the 1998 guarantee and the series of pledge agreements that secure NEE’s obligations (see the guarantee and pledge exhibits on page 122 and the related indenture exhibits on pages 116‑117).  However, the capital‑structure role of FPL Group Capital expanded: NEE issued additional floating‑rate notes and new Series J, K and L junior‑subordinated debentures through FPL Group Capital, extending maturities to 2025‑2073 and adding collateral‑backed floating‑rate securities, while the original guarantee/pledge framework remained in place.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains a mix of correct and incorrect information, with significant factual discrepancies in the financial instruments and dates, undermining overall correctness. (1) On quantitative accuracy: The LLM claims NEE issued Series J, K, and L debentures with maturities from 2025–2073, but the ground truth states Series B, C, L, M, N, O, and P were issued with maturities from 2057 to 2082. The 2025 maturity is factually inconsistent with the long-term nature (2057–2082) described in the original answer. Additionally, the LLM introduces 'floating-rate notes' and 'collateral-backed floating-rate securities' not mentioned in the ground truth, which specifies junior subordinated debentures without reference to floating rates or collateral backing. (2) Completeness: The answer addresses the evolution from guarantee to capital structure involvement, satisfying the multi-part nature of the question. However, it misrepresents the specific instruments and omits key series (B, C, M, N, O, P), while adding non-existent ones (J, K). (3) Entity accuracy: The entities (NEE, FPL Group Capital Inc.) and the 1998 guarantee are correctly identified, but the financial instruments and their attributes are inaccurate. (4) Reasoning: The model correctly infers a continuation of the 1998 guarantee framework and an expansion of capital structure involvement, which aligns with the ground truth’s narrative of strategic shift. However, the synthesis is flawed due to incorrect instrument details, suggesting potential confusion between different filings or time periods. (5) Semantic equivalence: While the general direction of evolution (from guarantee to deeper capital involvement) is preserved, the specific financial mechanisms are misrepresented, reducing factual fidelity. The contextual relevance is high as the response stays focused on the relationship evolution, but the quantitative and qualitative inaccuracies limit its reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 524,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has the positioning and market acceptance of InterStim II evolved between 2022 and 2024, particularly in relation to other InterStim neurostimulators and broader Pelvic Health therapies?",
      "original_answer": "In 2022, InterStim II was described as part of a suite of InterStim neurostimulators including InterStim Micro and InterStim X, with an emphasis on continued acceptance and growth in treating overactive bladder, urinary retention, and bowel incontinence. By 2024, InterStim II was specifically highlighted as a recharge-free neurostimulator, grouped alongside InterStim X and InterStim Micro (now differentiated by recharge status), and positioned within a broader context of continued acceptance and growth of Pelvic Health therapies. This evolution indicates a shift toward emphasizing device-specific attributes (e.g., recharge-free) and integration into a more mature and diversified product portfolio.",
      "llm_answer": "\nBetween 2022 and 2024 Medtronic’s InterStim II moved from a niche adjunct to a core pillar of its Pelvic‑Health portfolio, with its acceptance expanding in parallel with the newer InterStim Micro and InterStim X platforms.  The company highlighted “continued acceptance and growth of our Pelvic Health therapies, including our InterStim therapy with InterStim II and InterStim Micro” (MDT 2024 10‑K, pp. 39‑41), and Pelvic‑Health sales grew double‑digit in 2022 and remained on an upward trend through 2024, driven by the launch of InterStim II’s smaller, recharge‑free form factor and broader clinical adoption for overactive bladder and fecal incontinence.  Consequently, InterStim II now competes more directly with other sacral‑neuromodulation devices and with conventional pharmacologic/surgical Pelvic‑Health treatments, capturing a larger share of the market as clinicians increasingly choose it as the preferred neuromodulation option.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures some correct elements about the market positioning and growth of InterStim II between 2022 and 2024, particularly its role within Medtronic’s Pelvic Health portfolio and its clinical applications (e.g., overactive bladder, fecal incontinence). However, there are significant inaccuracies and unsupported claims that reduce factual correctness. (1) The claim that InterStim II moved from a 'niche adjunct to a core pillar' is not supported in the ground truth, which emphasizes continuity in 'continued acceptance and growth' rather than a strategic repositioning. (2) The LLM introduces a specific citation (MDT 2024 10-K, pp. 39–41) and asserts double-digit sales growth in 2022 and upward trends through 2024—this quantitative data is absent from the ground truth and cannot be verified, making it a hallucination. (3) The statement that InterStim II has a 'smaller, recharge-free form factor' compared to other models introduces a comparative detail not present in the original; while the ground truth does confirm by 2024 that InterStim II is described as recharge-free, it does not state this was a new feature introduced during this period or that it was smaller than predecessors. (4) The claim that it now 'competes more directly' and is the 'preferred neuromodulation option' reflects an overstatement of market dynamics not present in the original answer, which focuses on product differentiation by recharge status and portfolio diversification. (5) The ground truth emphasizes a shift in *positioning language* (toward device-specific attributes like recharge-free), while the LLM overinterprets this as a broader market shift with competitive and clinical preference implications. Thus, while the answer is contextually relevant and contains plausible qualitative themes, it introduces unsupported quantitative and strategic claims, leading to a partial correctness score. Multi-hop reasoning is attempted but flawed due to reliance on inferred rather than stated facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 537,
        "total_tokens": 1961
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Simon Property Group's utilization and management of the Supplemental Facility evolved between 2022 and 2024, particularly in terms of borrowing capacity, interest rate strategies, and repayment actions?",
      "original_answer": "In 2022, the Supplemental Facility had an initial borrowing capacity of $3.5 billion, which could be increased to $4.5 billion, with a maturity date of January 31, 2026. Borrowings under the facility bore interest based on SOFR or similar rates, with a margin determined by the company's credit rating. By 2024, SPG had borrowed €750.0 million under the Supplemental Facility, which was repaid on November 17, 2023, following the issuance of exchangeable bonds. Additionally, interest rate swaps were used in 2023 to fix the rate on these borrowings at 3.81%. This indicates a shift from passive availability in 2022 to active utilization and strategic interest rate management in 2024.",
      "llm_answer": "\nBetween 2022 and 2024 Simon Property Group moved the Supplemental Facility from a dormant back‑stop line to an active financing tool, expanding its maximum commitment to $4.5 billion and extending its maturity to January 2029 (with a one‑year extension to January 2030).  It now borrows at SOFR + ≈ 72.5 bps (plus a credit‑rating‑linked spread) and frequently hedges that exposure with interest‑rate swaps to lock in near‑term fixed rates, while repaying draws through bond issuances, note redemptions and cash‑flow from operations—evidenced by the $815 million of facility borrowings repaid in late 2023 with proceeds from €750 million bond issuance and the $1.9 billion of net debt repayments recorded for 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. The maturity date of the Supplemental Facility is incorrectly stated as January 2029 (with extension to 2030), while the ground truth specifies January 31, 2026 (no mention of extension). The amount borrowed and repaid is stated as $815 million in the LLM answer, but the original answer specifies €750.0 million (repaid November 17, 2023), which does not equate to $815 million without a specified exchange rate and timing. The interest rate margin is cited as 'SOFR + ≈72.5 bps plus credit-linked spread', but the ground truth does not specify this exact margin—only that the rate is based on SOFR with a margin tied to credit rating. The $1.9 billion net debt repayments in 2024 are not mentioned in the original answer and appear fabricated. (2) The only correct quantitative element is the €750 million bond issuance, which aligns with the original answer, though the repayment amount and timing are misrepresented. The interest rate swap fixing at 3.81% in 2023 is omitted entirely in the LLM answer, a key detail in the ground truth. (3) The multi-hop reasoning is partially sound in that the model attempts to show evolution from passive to active use and links borrowing to bond issuance and repayment, but it fails to accurately synthesize the actual timeline and financial instruments. The strategic use of swaps is acknowledged in concept but not with the correct rate or timing. (4) The contextual relevance is fair because the answer addresses borrowing capacity, interest rate strategy, and repayment actions as asked, but the factual foundation is flawed. Due to major quantitative errors and incorrect dates, the correctness score is low despite some structural alignment with the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 483,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Verizon's approach to device payment plans evolved from 2023 to 2024, particularly in terms of customer financing structure and promotional incentives?",
      "original_answer": "In 2023, Verizon permitted customers to acquire equipment using device payment plans that allowed installment payments over time, with no mention of structured promotional incentives or trade-in rights. By 2024, Verizon formalized the device payment plan structure, describing it as a non-interest-bearing installment note typically repaid over a 36-month term, and introduced a defined promotional feature that allows customers to upgrade to a new device after paying a specified portion of their plan and trading in their current device in good working order. This represents a shift from a general financing mechanism to a more structured and incentive-driven model.",
      "llm_answer": "\nFrom 2023 to 2024 Verizon kept the core of its device‑payment offering—a 36‑month, non‑interest‑bearing installment note paired with a month‑to‑month service contract—but it tightened the way it accounts for the financing element and the associated promotions.  The 2024 filing explicitly states that the financing component is evaluated at the contract level and, based on current facts, is considered non‑significant for direct‑channel plans (so no separate interest income is recognized), while still requiring a periodic assessment for indirect‑channel receivables.  At the same time, promotional billing‑credits are now treated as variable consideration that is allocated to the performance obligations based on their relative selling price and recognized when earned, and any trade‑in upgrade guarantees are recorded as a distinct guarantee liability, giving a clearer picture of how incentives affect revenue.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some accurate elements but diverges significantly from the ground truth in key aspects of Verizon's evolution in device payment plans from 2023 to 2024. (1) Correctly identifies the 36-month, non-interest-bearing installment note structure in 2024, which aligns with the original answer. However, it incorrectly implies this structure was already in place in 2023, whereas the ground truth states that in 2023 there was no formalized structure or mention of promotional incentives—this represents a factual inaccuracy in temporal evolution. (2) The LLM introduces detailed accounting treatments (e.g., 'financing component evaluated at contract level', 'variable consideration', 'guarantee liability') that are not present in the original answer and appear to reflect internal revenue recognition policies rather than customer-facing changes in financing structure or promotional incentives. These details, while possibly accurate from an accounting perspective, misalign with the question’s focus on customer-facing features. (3) The original answer highlights a key customer-facing evolution: the introduction of a structured upgrade program tied to trade-ins after paying a portion of the plan. The LLM mentions 'trade-in upgrade guarantees' but frames them as accounting liabilities rather than promotional incentives available to customers, thus missing the core shift described in the ground truth. (4) The LLM fails to contrast the absence of promotional incentives in 2023 with their formalization in 2024, which is central to the multi-hop reasoning required. Instead, it assumes continuity in plan structure and focuses on backend accounting changes, which were not asked for. While the answer is relevant and uses correct terminology, it substitutes customer-facing evolution with financial reporting details, leading to a partially correct but misleading response. Quantitative accuracy is moderate—no incorrect numbers are stated, but the timeline (2023 vs 2024) is misrepresented. Qualitative accuracy suffers due to incorrect synthesis and emphasis on irrelevant (though possibly true) accounting nuances. Contextual relevance is high as it addresses device payment plans and promotions, but not the actual evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 607,
        "total_tokens": 2007
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has The Coca-Cola Company's legal relationship with Aqua-Chem evolved between 2023 and 2024, particularly in terms of its stance on liability for Aqua-Chem's asbestos-related claims?",
      "original_answer": "In 2023, Coca-Cola maintained that it had no obligation to Aqua-Chem for any liabilities or expenses related to claims or lawsuits against Aqua-Chem, as outlined in the Georgia Case. By 2024, while the litigation status remained largely unchanged, Coca-Cola's disclosure now includes a more detailed description of the insurance policies issued during its ownership of Aqua-Chem, particularly highlighting the involvement of multiple insurers and the ongoing coverage litigation. This indicates a shift in emphasis from outright denial of liability to a more nuanced stance centered on insurance coverage and shared responsibility among insurers.",
      "llm_answer": "\nIn the 2023 – 2024 filings the Company reiterates that the Wisconsin insurance‑coverage litigation that once tied it to Aqua‑Chem’s asbestos claims was fully settled and affirmed on appeal, confirming that the insurers—not the Company—are responsible for those liabilities; consequently, the Company continues to take the position that it has **no legal liability** for Aqua‑Chem’s asbestos‑related claims. The only remaining procedural matter is the 2004 stay of the original Georgia case, which remains in effect, and no new liability or settlement has been introduced in the 2023‑2024 disclosures.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) It incorrectly states that the Wisconsin insurance-coverage litigation was 'fully settled and affirmed on appeal,' which is not supported by the original answer; the ground truth indicates that coverage litigation is still ongoing and no such final settlement has occurred. (2) It asserts that Coca-Cola continues to take the position of 'no legal liability,' which misrepresents the evolution described in the original answer: in 2024, Coca-Cola shifted toward a more nuanced stance focused on insurance coverage and shared insurer responsibility, rather than outright denial. (3) The mention of a '2004 stay of the original Georgia case' is factually inconsistent—the original answer does not specify the year of the stay, so asserting 2004 introduces unverified detail. (4) The LLM fails to capture the key multi-hop insight: the evolution from denial of obligation (2023) to a more detailed discussion of insurance policies and shared insurer roles (2024), which represents a strategic shift in disclosure emphasis. While the answer correctly identifies the Georgia case and the general context of asbestos claims, it fundamentally misrepresents the status of litigation and Coca-Cola's evolving position. Quantitative accuracy is partially acceptable due to correct reference to 2023–2024 timeframe, but invented details like the 2004 stay reduce precision. Qualitative accuracy is low due to flawed reasoning and incorrect synthesis across years. Contextual relevance is moderate as it addresses the right companies and topic, but with incorrect conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 450,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did Intel's utilization of non-US tax credits impact its long-term income tax liabilities in 2024 compared to 2022, and what does this indicate about the company's international tax strategy?",
      "original_answer": "In 2022, Intel reported long-term income taxes payable of $4.3 billion, which included the transition tax from Tax Reform and uncertain tax positions, reduced by non-US tax credits. By 2024, this figure had decreased to $1.6 billion, indicating that the company's utilization of non-US tax credits had a stronger offsetting effect over time. This suggests a strategic shift or increased effectiveness in leveraging international tax credits to reduce overall tax liabilities.",
      "llm_answer": "\nIn 2024 Intel’s non‑U.S. tax credits—chiefly the R&D credit and the benefit from income taxed at lower foreign rates—produced only about **$5.6 million** of tax benefit, down sharply from **$11.4 million** in 2022 (and far below the $99 million benefit seen in 2023).  Because these credits were much smaller, the company’s effective tax rate jumped to **71.6 %** in 2024 (versus a near‑zero rate in 2022), driving up its long‑term income‑tax liability even though long‑term tax payable fell to $1.6 billion.  The decline in credit utilization signals that Intel is **relying less on foreign tax incentives and is shifting its international tax strategy away from the aggressive use of non‑U.S. tax holidays and credits**.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. According to the ground truth, Intel's long-term income taxes payable decreased from $4.3 billion in 2022 to $1.6 billion in 2024, indicating that non-US tax credits had a stronger offsetting effect over time. However, the LLM claims that non-U.S. tax credits produced only $5.6 million in benefit in 2024 (down from $11.4 million in 2022), which contradicts the ground truth implication that these credits were increasingly effective. The LLM also states the effective tax rate jumped to 71.6% in 2024 versus near-zero in 2022, but this is unsupported by the original answer and misrepresents the trend. (2) The numeric values for tax credits ($5.6M, $11.4M, $99M) and effective tax rates (71.6%, near-zero) are entirely absent from the ground truth and appear fabricated. The only correct number is the $1.6 billion long-term tax payable in 2024; the 2022 figure of $4.3 billion is omitted. (3) The multi-hop reasoning is flawed: instead of concluding that increased use of non-US tax credits reduced liabilities over time (as per the original answer), the LLM incorrectly infers a reduction in credit utilization and a strategic pullback from international tax planning—exactly the opposite of what the ground truth suggests. (4) The contextual relevance is moderate because the answer addresses tax credits and international strategy, but the conclusions are factually inverted. Due to severe quantitative and qualitative errors, the correctness score is low at 2.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 422,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has the treatment and risk exposure of pension risk transfers evolved between 2022 and 2024, particularly in terms of interest rate sensitivity and regulatory influence?",
      "original_answer": "In 2022, pension risk transfers were part of the Retirement and Income Solutions business, which was described as containing both short- and long-duration products, and was subject to interest rate scenarios that could impact asset-liability management (ALM) strategies. By 2024, regulatory changes, particularly around defined benefit pension plan funding, were found to potentially reduce the likelihood or delay corporate plan sponsors from terminating their plans or transferring pension obligations. This regulatory evolution increased the potential for a shift in the mix of pension risk transfers toward non-guaranteed funding products, indicating a strategic and regulatory-driven change in exposure.",
      "llm_answer": "\nBetween 2022 and 2024 the company’s pension‑risk‑transfer activities shifted from a largely defensive, margin‑compression focus—using interest‑rate derivatives and ALM to offset the effects of a low‑rate environment, with regulatory caps on crediting‑rate changes—to a model that explicitly ties the transfers’ earnings to interest‑rate movements, reflecting both the upside of higher‑yield reinvestment and the downside of rising crediting rates.  At the same time, newer solvency and pension‑funding regulations have increased oversight of how these transfers are capitalized and disclosed, shaping the mix and risk profile of the exposures.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains significant deviations from the ground truth in terms of reasoning and factual synthesis. (1) There are no explicit numbers, percentages, or dollar amounts in either the original or LLM answer, so quantitative accuracy is not compromised—scored 10. (2) The LLM introduces concepts not present in the ground truth, such as 'margin-compression focus', 'regulatory caps on crediting-rate changes', and 'earnings tied to interest-rate movements reflecting upside of higher-yield reinvestment', which are not supported by the original answer. These suggest a more dynamic and strategic shift in earnings model that isn't mentioned in the ground truth. (3) The multi-hop reasoning is flawed: while both answers note a shift in pension risk transfer exposure and mention interest rate sensitivity and regulatory influence, the original answer emphasizes regulatory changes (specifically around defined benefit pension plan funding) reducing the likelihood or delaying plan terminations, leading to a shift toward non-guaranteed funding products. The LLM instead frames the evolution around internal capital management, solvency regulations, and earnings sensitivity without clearly identifying the causal link between regulatory changes and corporate behavior (i.e., delayed plan terminations). (4) Contextually, the answer is relevant and addresses interest rate sensitivity and regulatory influence, but misrepresents the nature and direction of the strategic shift. Thus, while some elements like ALM and regulatory impact are correctly identified, the core causal mechanism and strategic outcome differ, warranting a correctness score of 5 for partial accuracy with significant omissions and misattributions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 474,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Medtronic's positioning and product strategy around the InterStim Micro neurostimulator evolved between 2022 and 2024?",
      "original_answer": "In 2022, Medtronic positioned the InterStim Micro as part of its broader InterStim therapy offering for treating overactive bladder, urinary retention, and bowel incontinence, alongside InterStim II and InterStim X neurostimulators. It was described as part of a growing and accepted product line within the Pelvic Health therapies under the Specialty Therapies division. By 2024, Medtronic specifically highlighted the InterStim Micro as a 'rechargeable neurostimulator' while emphasizing the continued acceptance and growth of InterStim therapy, particularly in the U.S., and distinguishing it from the recharge-free InterStim X and InterStim II models. This indicates a more targeted marketing and differentiation strategy for the InterStim Micro within the evolving Pelvic Health product portfolio.",
      "llm_answer": "\nFrom 2022 to 2024 Medtronic moved the InterStim Micro from a newly launched, rechargeable micro‑neurostimulator for overactive‑bladder and urinary‑retention therapy (highlighted in the 2022 Neuroscience net‑sales discussion) to a broadly adopted core of its Pelvic‑Health portfolio, gaining additional indications (including fecal incontinence) and deeper integration into the AiBLE spinal‑technology and robotic‑assisted surgery platforms, positioning it as a key growth driver within the Neuromodulation segment.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies compared to the ground truth. While it correctly identifies that InterStim Micro is a rechargeable neurostimulator used for overactive bladder and urinary retention (consistent with 2022 positioning), it falsely claims that by 2024 it gained additional indications including fecal incontinence, which is not supported by the original answer—InterStim therapy as a platform treats bowel incontinence, but no new indication for InterStim Micro specifically is mentioned. More critically, the LLM introduces unsupported technological integrations with 'AiBLE spinal-technology and robotic-assisted surgery platforms,' which are not referenced in the ground truth and represent a major fabrication. It also misrepresents the evolution by calling InterStim Micro a 'newly launched' product in 2022, whereas the original answer describes it as part of an already growing and accepted product line, not a new launch. (2) There are no numeric values, percentages, or financial figures in either the question or answers, so quantitative accuracy is not applicable—no errors in this domain, hence a score of 10 by default. (3) The multi-hop reasoning is flawed: the model fails to accurately synthesize the evolution of product positioning from general inclusion in the portfolio (2022) to targeted differentiation as a rechargeable option (2024). Instead, it invents a narrative of technological integration and expanded indications without evidence. The original answer emphasizes marketing differentiation, not clinical or platform integration. (4) Contextual relevance is moderate—the response addresses Medtronic and the InterStim Micro’s role in pelvic health, so it stays on topic, but introduces irrelevant and incorrect details that undermine accuracy. Correctness and qualitative accuracy are low due to hallucinated information and misrepresentation of strategic evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 525,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Simon Property Group's use of the Supplemental Facility evolved between 2022 and 2024, particularly in terms of outstanding borrowings and repayment actions?",
      "original_answer": "In 2022, Simon Property Group had a weighted average outstanding balance under the Credit Facilities (including the Supplemental Facility) of $519.9 million, with a maximum aggregate outstanding balance of $2.1 billion during the year. By 2024, the weighted average outstanding balance under the Facilities had decreased to $311.1 million, and the company had repaid a significant portion of its borrowings, including €750.0 million ($815.4 million U.S. dollar equivalent) under the Supplemental Facility on November 17, 2023. This indicates a strategic reduction and refinancing of debt drawn from the Supplemental Facility over the two-year period.",
      "llm_answer": "\nBetween the end of 2021 and 2022 Simon Property Group carried a $1.05 billion draw on its Supplemental Facility, but it repaid that amount in full in January 2022 using proceeds from newly issued unsecured notes.  By 2024 the facility’s maturity had been extended to January 2026 (with a one‑year extension option) and its capacity raised to $4.5 billion, yet outstanding borrowings were modest—averaging about $310 million and never exceeding $325 million during the year—reflecting a shift from large‑scale debt‑refinancing to a flexible liquidity source for acquisitions and working‑capital needs.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. It claims Simon Property Group had a $1.05 billion draw on the Supplemental Facility between 2021 and 2022, which was repaid in January 2022 using proceeds from unsecured notes. However, the ground truth states that the weighted average outstanding balance under the Credit Facilities (including the Supplemental Facility) was $519.9 million in 2022, with a maximum of $2.1 billion during the year—not $1.05 billion specifically on the Supplemental Facility, nor a repayment in January 2022. There is no mention in the ground truth of a $1.05 billion draw or its repayment in January 2022, nor of unsecured notes being used for that purpose. (2) The 2024 figures are partially correct: the LLM reports an average of about $310 million, which aligns closely with the ground truth's $311.1 million weighted average. However, it omits the key repayment event of €750.0 million ($815.4 million) under the Supplemental Facility on November 17, 2023, which is central to the evolution of borrowing. Instead, it focuses on facility capacity and maturity extension, which, while potentially true, are not mentioned in the ground truth and distract from the core trend of repayment. (3) The multi-hop reasoning is flawed: the model fails to connect the 2022 and 2024 data through the actual repayment event in late 2023, instead constructing a narrative around a repayment that occurred in early 2022 and a structural change in the facility. This misrepresents the timeline and strategic shift. (4) Despite incorrect numbers and missing key events, the answer is contextually relevant, addressing the evolution of the Supplemental Facility use and correctly identifying a reduction in borrowings by 2024. The qualitative reasoning about a shift toward flexible liquidity use is plausible but not directly supported by the ground truth, which emphasizes debt reduction and refinancing. Thus, while the direction of change is correctly inferred, the factual basis is unsound, leading to a low correctness and quantitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 574,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did COP's investment activity in the Lower 48 region evolve from 2022 to 2023, based on the changes in depreciation, depletion, amortization, and impairments expenses?",
      "original_answer": "In 2022, COP reported $4,854 million in depreciation, depletion, amortization, and impairments expenses for the Lower 48 region, which increased to $5,729 million in 2023. This indicates a significant increase in investment activity or asset utilization in the Lower 48 region over that period.",
      "llm_answer": "\nDepreciation, depletion, amortization and impairment (DDA) expenses for the Lower 48 segment climbed from **$4,854 million in 2022 to $5,729 million in 2023**, an increase of **$875 million (≈18 %)**.  This rise reflects a higher level of capital deployment—more development wells, lease‑hold acquisitions and a larger depletion base—indicating that ConocoPhillips stepped up its investment activity in the Lower 48 region during 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values for DDA expenses in 2022 ($4,854 million) and 2023 ($5,729 million) are accurate, and the calculated increase of $875 million is correct (5,729 - 4,854 = 875). The percentage increase is accurately approximated as 18% (875 / 4,854 ≈ 0.1803 or 18.03%). (2) The answer is complete, addressing the evolution of investment activity based on changes in DDA expenses across the two years. (3) Entities are correct: COP refers to ConocoPhillips, the Lower 48 region is properly identified, and the financial metric (DDA) is accurately used. (4) The reasoning is sound: the increase in DDA expenses is correctly interpreted as indicative of higher capital deployment and increased investment activity, which aligns with the logic in the original answer. The LLM adds context (e.g., development wells, leasehold acquisitions) that is reasonable and consistent with industry understanding, without introducing inaccuracies. Overall, the answer demonstrates accurate multi-hop synthesis of financial data and correct qualitative interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1188,
        "completion_tokens": 322,
        "total_tokens": 1511
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Verizon's approach to corporate networking solutions evolved from 2023 to 2024, particularly in terms of service description and business segment emphasis?",
      "original_answer": "In 2023, Verizon's Business segment explicitly described offering a broad portfolio of network connectivity products, including private networking services, private cloud connectivity services, and software-defined networking services, with Enterprise and Public Sector revenues reaching $15.1 billion, or approximately 50% of Business's total revenues. By 2024, the Business segment's description became more streamlined, focusing on wireless and wireline communications services and products, including corporate networking solutions, without specifying the same level of detail in offerings or segment revenue. This indicates a shift toward a more generalized presentation of services, potentially signaling a strategic consolidation or simplification of messaging around corporate networking solutions.",
      "llm_answer": "\nIn the 2024 filing Verizon’s Business segment description was sharpened to list “private‑networking services, private‑cloud connectivity, virtual and software‑defined networking and managed network services” as the core corporate‑networking offerings—language that was only implied in the 2023 filing, which referred more generally to “corporate networking solutions, security and managed network services.”  At the same time the revenue mix shifted: the Enterprise & Public Sector line slipped from roughly $15.1 bn (2023) to $14.2 bn (2024), while Business Markets & Other rose from about $12.7 bn to $13.1 bn, indicating a strategic pivot from a heavy focus on large‑enterprise/government contracts toward a broader mid‑market and wholesale‑oriented corporate‑networking emphasis.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and introduces unsupported data. (1) Quantitative Accuracy: The ground truth states that in 2023, Enterprise and Public Sector revenues were $15.1 billion, accounting for about 50% of Business segment revenues, but does not provide 2024 revenue figures or mention a decline to $14.2 billion. Similarly, there is no mention in the original answer of 'Business Markets & Other' rising from $12.7B to $13.1B. These numbers are fabricated or misattributed, failing the quantitative accuracy test. (2) Completeness: While the question asks about evolution in service description and business segment emphasis, the LLM incorrectly claims more detailed service listings in 2024, whereas the ground truth indicates a *streamlining* and *reduction* in descriptive detail. This reverses the actual trend. (3) Entity Accuracy: The companies (Verizon), segments (Business, Enterprise & Public Sector), and years (2023–2024) are correctly identified. (4) Reasoning: The multi-hop synthesis is flawed—instead of recognizing a move toward generalized messaging, the LLM asserts increased specificity in 2024, which contradicts the source. The supposed revenue shift and strategic pivot toward mid-market and wholesale are not supported by the original answer. (5) Semantic Equivalence: The overall meaning diverges significantly—the original describes a simplification of messaging; the LLM describes a sharpening and strategic reorientation with false financial backing. Thus, despite addressing the general topic, the answer is factually incorrect on key points, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 446,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did MetLife's valuation approach and sensitivity to fair value changes for FVO securities evolve from 2022 to 2024, particularly in terms of the impact of U.S. dollar appreciation?",
      "original_answer": "In 2022, MetLife reported that FVO securities had an estimated fair value of $1.6 billion and were sensitive to changes in the U.S. dollar, with a 10% appreciation leading to a $54 million decrease in value. By 2024, while no direct fair value figure for FVO securities is provided, the company emphasized a broader sensitivity framework where nonperformance risk spreads and unobservable inputs varied by duration and currency, indicating a more nuanced and dynamic valuation methodology. This evolution shows a shift from a static sensitivity model to a more complex, duration- and currency-dependent approach.",
      "llm_answer": "\nMetLife continued to classify its Fair‑Value‑Option securities as Level 3 and to value them with market‑based pricing and consensus quotes, so the underlying valuation methodology did not change between 2022 and 2024.  In the 2022 sensitivity analysis a 10 % U.S.‑dollar appreciation would have lowered the estimated fair value of FVO securities by roughly $54 million (page 150), whereas the 2024 roll‑forward shows only a modest $13 million net increase in unrealized gains for those securities and no AOCI impact, indicating that the fair‑value sensitivity to dollar strength has largely disappeared.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains partial factual accuracy but exhibits significant errors in both quantitative and qualitative aspects. (1) Quantitatively, the $54 million decrease from a 10% U.S. dollar appreciation in 2022 is correctly reported, aligning with the ground truth. However, the claim of a 'modest $13 million net increase in unrealized gains' in 2024 is not supported by the original answer, which does not provide any fair value figure for FVO securities in 2024—this number appears to be misinterpreted or incorrectly inferred. (2) The original answer states that no direct fair value for FVO securities is provided in 2024, but the LLM asserts a specific gain amount, introducing a false data point. (3) Qualitatively, the LLM incorrectly concludes that sensitivity to U.S. dollar appreciation 'has largely disappeared,' which contradicts the ground truth indicating a shift to a more nuanced, dynamic valuation framework incorporating duration and currency effects. Instead of disappearing, the sensitivity evolved. The LLM fails to recognize this evolution and instead interprets the absence of a reported sensitivity as reduced impact, showing flawed multi-hop reasoning. (4) The original answer emphasizes a methodological shift toward a more complex, currency- and duration-dependent model, but the LLM claims the 'valuation methodology did not change,' directly contradicting the ground truth. This fundamental misrepresentation undermines the core of the question about evolution in approach. (5) Contextually, the answer addresses the right topic and time frame, and references appropriate concepts like Level 3 classification and sensitivity, so it remains relevant, but the incorrect synthesis and fabricated figures severely limit accuracy. Overall, major factual and reasoning errors result in a low correctness score despite some correct elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 503,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has NextEra Energy's engagement in power marketing activities evolved between 2022 and 2023, particularly in terms of its energy trading services and associated financial performance?",
      "original_answer": "In 2022, NextEra Energy (NEE) was actively engaged in power and fuel marketing and trading activities, primarily providing full energy and capacity requirements services to distribution utilities, including load-following and ancillary services, while also optimizing the value of electricity and fuel contracts and generation assets. By 2023, NEE's subsidiary NEER had expanded its role in power marketing and trading, contributing to a significant increase in net income, which rose from $285 million in 2022 to $3,558 million in 2023. This indicates a substantial evolution and growth in the scale or profitability of NEE’s power marketing and trading activities over the period.",
      "llm_answer": "\nBetween 2022 and 2023 NextEra’s power‑marketing and trading operations flipped from a **$2.67 bn loss on non‑qualifying commodity hedges in 2022 to a $2.53 bn gain in 2023** (see NEE 2023 10‑K p. 40).  This swing helped lift total operating revenue by **$5.95 bn** and accounted for a **$3.27 bn increase in net income** (from $285 m to $3.56 bn) (p. 40).  The company continued to expand its full‑energy and capacity‑requirements marketing and trading services—leveraging fair‑value accounting for trading contracts to capture favorable commodity‑price movements—so that energy‑trading activities now contribute a material, positive financial result to NextEra’s results.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the key figures are correct: the net income increase from $285 million in 2022 to $3.56 billion in 2023 (ground truth: $3,558 million, which rounds to $3.56 billion) is accurate. The $3.27 billion increase in net income is correctly calculated ($3,558M - $285M = $3,273M). The $5.95 billion increase in operating revenue and the swing from a $2.67 billion loss to a $2.53 billion gain in commodity hedges are consistent with the 2023 10-K (p.40) and represent precise multi-hop synthesis. Minor rounding differences (e.g., $3.56B vs $3,558M) are acceptable. (2) Completeness: The answer addresses both the evolution of power marketing activities and the associated financial performance, including expansion of services and the financial impact. It adds valuable detail (e.g., fair-value accounting, commodity hedges) not in the original but factually grounded. (3) Entity accuracy: NextEra Energy (NEE), NEER (implied via context), correct years (2022–2023), and financial metrics (net income, operating revenue, hedge gains/losses) are all correctly identified. (4) Reasoning: The logic is sound—linking the reversal in hedge performance to revenue and net income changes demonstrates strong multi-hop reasoning. The conclusion that trading now contributes materially and positively is well-supported. The only reason for not scoring 10 is that the original answer emphasizes NEER’s expanded role, while the LLM focuses more on financial swings; however, the LLM’s added context enhances rather than distorts. Overall, the answer is factually correct, well-reasoned, and contextually complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 459,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has The Coca-Cola Company's financial relationship with Coca-Cola FEMSA evolved between 2023 and 2024, particularly in terms of its stake ownership and implications for equity income?",
      "original_answer": "In 2023, Coca-Cola FEMSA was referenced as one of the key bottlers whose financial performance could influence The Coca-Cola Company's credit ratings, indicating an indirect financial dependency. By 2024, The Coca-Cola Company held a 28% ownership stake in Coca-Cola FEMSA, which was accounted for under the equity method. This shift from a dependency-based relationship to a direct ownership stake suggests a strategic evolution, where Coca-Cola now has a more direct financial interest in FEMSA's performance, which will directly impact its equity income (loss) - net line item.",
      "llm_answer": "\nBetween the end of 2023 and the end of 2024 Coca‑Cola’s equity‑method ownership in Coca‑Cola FEMSA stayed constant at **28 % of the bottler’s outstanding shares** (see the 2023 filing’s note on equity‑method investments and the 2024 table that lists the same 28 % stake).  Because the stake was unchanged, the **equity‑income‑net generated by FEMSA rose modestly**—from **$1.69 billion in 2023 to $1.77 billion in 2024** (2024 Note 6 and 2023 Note 6), reflecting higher earnings of FEMSA and the continued contribution of that 28 % interest to Coca‑Cola’s consolidated results.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains significant quantitative inaccuracies that undermine its correctness. While it correctly states the 28% ownership stake in Coca-Cola FEMSA for both 2023 and 2024 (consistent with the equity method), it fabricates specific equity income figures—$1.69 billion in 2023 and $1.77 billion in 2024—that are not present in the original answer or implied by the ground truth. The original answer makes no mention of specific dollar amounts or year-over-year changes in equity income; instead, it emphasizes a strategic shift from indirect financial dependency to direct ownership with implications for equity income. Thus, the inclusion of precise but unverified financial figures constitutes a serious factual error. However, the qualitative reasoning is sound: the LLM correctly identifies the continuity of the 28% stake and the accounting under the equity method, and it logically infers that FEMSA’s performance impacts Coca-Cola’s equity income. It also correctly frames the relationship in terms of consolidated financial results. The answer is contextually relevant and addresses the evolution of the financial relationship, but the invented numbers severely reduce overall correctness. Multi-hop synthesis is partially accurate—tying ownership to income impact—but the lack of source support for the figures breaks factual fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 375,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has the financial investment and operational focus on the Lower 48 region evolved between 2022 and 2023 based on production volumes and depreciation expenses?",
      "original_answer": "In 2022, the Lower 48 region showed strong production volumes, particularly in crude oil (447 thousand barrels daily) and natural gas (1,340 million cubic feet daily), indicating a significant operational focus. In 2023, the financial emphasis on the Lower 48 increased further, as evidenced by a rise in depreciation, depletion, amortization, and impairments expenses from $4,854 million in 2022 to $5,729 million in 2023. This reflects a growing financial investment in the region despite stable or moderate production levels in the prior year.",
      "llm_answer": "\nBetween 2022 and 2023 the company poured more money into the Lower 48 – capital spending rose from roughly $5.6 billion to $6.5 billion and depreciation expense for the play climbed from about $4.9 billion to $5.7 billion, signalling a larger, longer‑lived asset base.  At the same time, production in the core Delaware‑Basin portion of the Lower 48 stayed strong (the Delaware Basin area grew to 162 million barrels‑equivalent and natural‑gas output remained robust), underscoring a strategic shift toward concentrating operational resources and growth in the Lower 48 region.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increase in depreciation expense from $4.9 billion in 2022 to $5.7 billion in 2023, which aligns with the ground truth values of $4,854 million and $5,729 million (rounded appropriately). However, the LLM introduces capital spending figures ($5.6B to $6.5B) that are not present in the original answer or implied by the provided ground truth, making this an unsupported addition. Additionally, the mention of 'Delaware Basin area grew to 162 million barrels-equivalent' and specific focus on the Delaware Basin is not in the original answer and lacks grounding in the provided truth. (2) The depreciation numbers are quantitatively accurate when rounded ($4.9B ≈ $4,854M; $5.7B ≈ $5,729M), but the capital expenditures and production volume figures (e.g., 162 million barrels-equivalent) are not verifiable from the ground truth and appear fabricated or misattributed. The original answer discusses daily production volumes (447K bbl/d crude oil, 1.34B cf/d gas) but the LLM does not reference these correctly. (3) The reasoning is partially sound: the link between rising DD&A expenses and increased financial investment is correctly inferred and aligns with the original conclusion. The synthesis of increasing financial commitment despite stable production is conceptually consistent, though the LLM substitutes unverified production data. (4) The correctness score is 7 because the core financial trend (rising depreciation indicating increased investment) is accurately captured, but the answer adds unverified quantitative details and narrows the focus to the Delaware Basin without basis. Quantitative accuracy is penalized due to unsupported numbers. Qualitative and contextual scores are higher because the logical flow and relevance to the question’s theme—evolving financial and operational focus—are well maintained.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 509,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Verizon's strategic relationship with its 4G LTE network evolved between 2023 and 2024 in terms of its role within the company's network infrastructure and growth initiatives?",
      "original_answer": "In 2023, Verizon's 4G LTE network was positioned primarily as a foundational component of its wireless services, specifically highlighted as a means to provide FWA broadband as an alternative to traditional landline internet access. By 2024, the strategic role of the 4G LTE network had evolved into being part of a broader integrated network vision that includes C-Band spectrum, millimeter wave spectrum, and fiber infrastructure, aimed at driving innovative products and services and fueling growth. This shift indicates a move from viewing 4G LTE in a service delivery context to a more strategic asset within a multi-technology ecosystem.",
      "llm_answer": "\nVerizon continued to treat its 4G LTE network as the foundational platform for its fixed‑wireless access (FWA) broadband service, using spectrum holdings and densification to add capacity and support a growing FWA customer base (see 2023 10‑K pages 95‑99, which describe FWA delivered over 5G or 4G LTE, and 2024 10‑K pages 21‑25, which note that “wireless mobility investments provide the foundation for our growing FWA broadband business”).  At the same time, the company is shifting strategic emphasis toward 5G and fiber‑based expansion, leveraging 4G LTE mainly to boost network capacity and to underpin the rollout of 5G services, thereby positioning the legacy LTE infrastructure as a complementary layer that enables, rather than drives, its primary growth initiatives.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Verizon's 4G LTE network strategy between 2023 and 2024. It accurately identifies that in 2023, 4G LTE served as a foundational platform for Fixed Wireless Access (FWA) broadband, citing relevant sections from the 2023 and 2024 10-K filings. The answer correctly notes that 4G LTE continues to support FWA and network capacity, which is consistent with the original answer’s description of its foundational role. The shift in strategic emphasis toward 5G, C-Band, millimeter wave, and fiber in 2024 is also acknowledged, though the LLM frames it more as a 'shift toward 5G and fiber-based expansion' rather than explicitly describing 4G LTE as now being part of an integrated multi-technology ecosystem. While the core idea of integration is implied through phrases like 'complementary layer that enables... 5G services,' the LLM does not fully capture the strategic repositioning of 4G LTE as a component of a broader innovative ecosystem aimed at driving growth through combined technologies. This is a minor omission in nuance but affects completeness in conveying the full strategic evolution. There are no numerical inaccuracies (quantitative accuracy is perfect, score 10), and all entities (Verizon, 4G LTE, FWA, 5G, fiber) and years (2023, 2024) are correctly identified. The reasoning is sound and based on proper synthesis across the two years’ filings, though slightly less precise in articulating the positive strategic elevation of 4G LTE (from service delivery to integrated asset) and more focused on its diminishing primary role. Contextual relevance is excellent—the response directly addresses the question and uses appropriate evidence. Thus, correctness is high but not perfect due to incomplete articulation of the strategic upgrade in 4G LTE’s role.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 504,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve from 2022 to 2024, particularly in terms of stake value, ownership structure, and the impact on financial metrics such as backlog and gross margin?",
      "original_answer": "In 2022, Emerson held a stake in AspenTech with a backlog value of $1,042 million, indicating a strategic business relationship. By 2024, this relationship evolved significantly as Emerson completed a transaction that resulted in the creation of 'New AspenTech,' where Emerson owned 55% of the outstanding shares. This acquisition had a measurable impact on financial metrics: gross margin in 2023 increased by 3.3 percentage points, partly due to the AspenTech acquisition, and backlog in 2024 reached $8,053 million, up from $6,533 million in 2021, showing the influence of the AspenTech integration.",
      "llm_answer": "\nFrom 2022 to 2024 Emerson’s stake in AspenTech grew from the ~55 % it held after the 2022 Heritage‑AspenTech transaction to roughly 57 % by the November 2024 proposal to acquire the remaining shares, with the stake valued at about $8–9 billion on the implied $15.3 billion fully‑diluted market cap.  The deepening ownership added high‑margin software assets that helped lift consolidated gross margin to 50.8 % in 2024 (up 1.8 pts), although this gain was partially offset by acquisition‑related inventory step‑up amortization, while AspenTech’s backlog expanded from $328 million in 2021 to $1.0 billion in 2022 and continued to grow, supporting overall order growth.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. According to the ground truth, Emerson did not hold a 55% stake in AspenTech in 2022; rather, the 55% ownership refers to its stake in 'New AspenTech' after a transaction completed by 2024. The LLM incorrectly states Emerson already had ~55% in 2022, which contradicts the timeline. The $8–9 billion valuation and $15.3 billion fully diluted market cap are not mentioned in the original answer and lack support. The gross margin increase is cited as 1.8 percentage points in 2024 in the LLM answer, but the ground truth reports a 3.3 percentage point increase in 2023 due to the acquisition—this misaligns both the magnitude and the year. Backlog figures are significantly off: the LLM claims AspenTech’s backlog was $328 million in 2021 and $1.0 billion in 2022, while the original answer states a backlog value of $1,042 million in 2022 and $8,053 million in 2024 (up from $6,533 million in 2021), indicating the LLM underreports backlog by billions. (2) Calculations and comparisons are flawed: the LLM’s stated backlog growth from $328M to $1.0B does not match the ground truth’s $6.5B to $8.0B trajectory. The gross margin improvement is both numerically and temporally incorrect. (3) Multi-hop reasoning is partially sound—the LLM recognizes the strategic deepening of ownership and links it to margin and backlog impacts—but fails to correctly synthesize the timeline, ownership evolution, and financial impacts across years. It conflates pre- and post-acquisition metrics and invents unsupported valuations. (4) Scores reflect major quantitative errors (3/10), partial qualitative accuracy in identifying strategic trends but with incorrect entities and timing (5/10), and decent contextual relevance as it addresses stake value, ownership, and financial metrics (7/10). Correctness is low (4/10) due to core factual and numerical mismatches.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 518,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has NEE's financial commitment to the Mountain Valley Pipeline evolved between 2022 and 2023, and what does this indicate about its investment strategy?",
      "original_answer": "In 2022, NEE's involvement in the Mountain Valley Pipeline was described as part of its equity method investments, with an ownership stake ranging between 32% and 55%. By 2023, NEE, through its subsidiary NEER, had a more defined 32.8% equity investment in the Mountain Valley Pipeline, which was accompanied by a 20-year natural gas transportation agreement valued at approximately $70 million per year. This indicates a strategic deepening of NEE's commitment to the pipeline, moving from a general equity investment toward a more structured, long-term contractual relationship tied to infrastructure development.",
      "llm_answer": "\nBetween 2022 and 2023 NEE went from holding an equity stake in the Mountain Valley Pipeline to completely writing‑off that investment after a $1.5 billion impairment charge in 2020 and an additional full write‑off in early 2022 (Note 8, page 96).  In the 2023 disclosures the only reference to the project is a modest “equity contribution in 2024” listed under other capital‑expenditure items (Commitments table, page 109), with no material carrying amount or earnings impact reported.  This shift shows that NEE has largely disengaged from the pipeline venture and is now directing its capital toward regulated utility and renewable‑generation projects that offer more predictable, rate‑base returns.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth. (1) It claims NEE wrote off its investment in the Mountain Valley Pipeline with a $1.5 billion impairment in 2020 and a full write-off in early 2022, but the ground truth states NEE maintained an equity stake (32%-55%) in 2022 and increased its commitment in 2023 to a defined 32.8% stake with a $70 million/year, 20-year transportation agreement. There is no mention of write-offs or impairments in the original answer. (2) The quantitative inaccuracies are severe: the $1.5 billion impairment charge and full 2022 write-off are factually wrong; the 'equity contribution in 2024' cited from a commitments table does not negate the ongoing 2023 investment and misrepresents future intent as minimal. The correct figures—32.8% ownership and $70M/year contract—are entirely absent. (3) The reasoning is flawed: instead of showing deepening strategic commitment as per the ground truth, the LLM concludes disengagement, which is the opposite conclusion. This fails the multi-hop synthesis by misrepresenting the direction of NEE's investment strategy. (4) Contextual relevance is low because the answer discusses disengagement and write-offs not present in the source, while omitting the key evolution—increased contractual and equity commitment. The only minor relevant element is mentioning NEE's capital allocation, but it's used to support an incorrect narrative. Overall, the answer is factually and logically inverted from the truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 414,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Coca-Cola's relationship with Costa Limited evolved from 2023 to 2024 in terms of its operational integration and strategic positioning within the Global Ventures segment?",
      "original_answer": "In 2023, Costa Limited was referenced as part of Coca-Cola's direct retail operations, specifically through retail stores operated by Costa, and was included within the Global Ventures operating segment. By 2024, Costa Limited was more strategically embedded within the Global Ventures segment, which now also included the results of innocent and doğadan businesses, as well as fees earned under distribution coordination agreements. This indicates a deeper integration and broader strategic role for Costa within Coca-Cola’s diversified beverage portfolio.",
      "llm_answer": "\nFrom 2023 to 2024 Coca‑Cola kept Costa Limited inside its Global Ventures segment, but the 2024 filing underscores a tighter operational integration by reporting Costa’s results and the fees earned under its distribution‑coordination agreements as a core contributor to the segment’s growth strategy. This shift positions Costa not merely as an ancillary brand but as a strategic pillar within Global Ventures, emphasizing its role in driving expansion and sustainability initiatives for the Company.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that Costa Limited remained within the Global Ventures segment from 2023 to 2024 and notes the deeper integration in 2024, which matches the original answer's claim of 'more strategically embedded.' The mention of 'fees earned under distribution-coordination agreements' is factually correct and reflects a key detail from the 2024 filing. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2023–2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information about operational integration over time and infers strategic elevation based on reporting changes. While the original answer explicitly mentions innocent and doğadan as new additions to Global Ventures, the LLM omits this detail but still captures the broader strategic expansion by emphasizing Costa’s enhanced role. This is a minor omission, not an error. (4) The LLM conveys semantic equivalence by highlighting Costa’s shift from a retail operator to a 'strategic pillar,' which reflects the original answer’s emphasis on deeper integration and broader strategic role. Wording differs but meaning is preserved. Contextual relevance is perfect—directly addresses operational integration and strategic positioning as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 387,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Intel's investment in financial institution instruments evolved between 2022 and 2024, particularly in terms of the fair value of economically hedged marketable debt investments?",
      "original_answer": "In 2022, Intel recorded net losses of $748 million on economically hedged marketable debt investments. By 2024, the fair value of these hedged investments had decreased to $13.5 billion from $17.1 billion in 2023, with Intel recording net losses of $464 million in 2024. This indicates a reduction in both the size of the hedged investment portfolio and the magnitude of losses compared to two years prior.",
      "llm_answer": "\nIntel’s economically‑hedged marketable debt investments declined from **$17.1 billion at the end of 2023** to **$13.5 billion at the end of 2024** (a reduction of roughly $3.6 billion, or about 21%).  Consequently, the hedged portfolio shifted from a **$534 million gain in 2023** to a **$464 million loss in 2024**, after having recorded a **$748 million loss in 2022**.  This shows a clear contraction in both the size and the profitability of the hedged debt‑investment position over the 2022‑2024 period.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the fair value of Intel's economically hedged marketable debt investments at $13.5 billion in 2024 and references the $748 million loss in 2022, which aligns with the ground truth. However, it introduces a $534 million gain in 2023 that is not present in the original answer or implied by the data provided — this is an unsupported addition and factually problematic since the original answer does not mention 2023 performance. Additionally, while the $464 million loss in 2024 is correct, the comparison across years is skewed by the inclusion of this unverified 2023 gain. (2) The quantitative values for 2022 losses ($748M) and 2024 fair value ($13.5B) and losses ($464M) are accurate. The 2023 fair value of $17.1B is correctly cited. However, the claim of a $534M gain in 2023 lacks support in the ground truth, which does not provide any such figure, making this a significant factual overreach. The calculation of the portfolio decline (from $17.1B to $13.5B) is correct (~$3.6B, ~21%), but this comparison is between 2023 and 2024, not 2022 and 2024 as the question implies — the original answer only provides 2023 and 2024 fair values, so the evolution from 2022 must be inferred cautiously. (3) The multi-hop reasoning is partially sound: the model connects fair value changes and financial performance across years, but it fabricates a data point (2023 gain) to create a narrative of shifting from gain to loss, which undermines the reasoning integrity. The original answer emphasizes reduction in portfolio size and narrowing losses from 2022 to 2024, but the LLM distorts this by inserting an intermediate year’s performance not in the source. (4) Despite the fabrication of the 2023 gain, the core facts about 2022 and 2024 are correct, and the direction of change (shrinking portfolio, decreasing losses) is consistent. Hence, a score of 7 is justified — the answer captures key facts but introduces a significant unsupported detail that affects quantitative and qualitative accuracy. Contextual relevance is perfect as it directly addresses the evolution of Intel's investments as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 577,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did AMT's financial focus regarding communications sites evolve from 2023 to 2024, particularly in terms of recurring revenue generation and asset retirement liabilities?",
      "original_answer": "In 2023, AMT emphasized recurring revenue generation from communications sites, noting that 99% of total revenues came from property operations, which included leasing space on communications sites. By 2024, the focus expanded to include significant liabilities tied to these assets, with an estimated $4.5 billion in undiscounted future cash outlay for asset retirement obligations as of December 31, 2024. This reflects a shift from primarily highlighting revenue streams to also addressing the long-term financial responsibilities associated with site decommissioning.",
      "llm_answer": "\nBetween 2023 and 2024 AMT continued to lean on its long‑term, escalating tenant leases—whose revenue it describes as “the vast majority … recurring” and essential for meeting debt covenants and REIT distributions.  In the 2024 filing the company explicitly quantifies its asset‑retirement obligations at roughly **$4.5 billion** of undiscounted future cash outlays, highlighting a heightened focus on the liability side of its communications‑site portfolio and on how those obligations affect its liquidity and cash‑flow planning.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the $4.5 billion figure for undiscounted future cash outlays related to asset retirement obligations as of December 31, 2024, is correctly stated, matching the original answer exactly. The year 2024 is properly referenced for this liability disclosure. (2) The LLM correctly identifies AMT’s continued emphasis on recurring revenue from long-term leases, consistent with the 99% of revenue from property operations noted in 2023. While the exact '99%' figure is not repeated, the phrase 'the vast majority … recurring' effectively captures the same meaning and is semantically equivalent in context. (3) The multi-hop reasoning is sound: the model synthesizes information across years (2023 to 2024), showing evolution from a focus on revenue generation to increased attention on liabilities. It correctly infers that the explicit quantification of $4.5 billion in 2024 represents a heightened focus on financial responsibilities tied to site decommissioning. (4) The answer is contextually relevant and directly addresses both parts of the question: recurring revenue generation and asset retirement liabilities. The only minor shortcoming is the omission of the specific '99%' statistic from 2023, which slightly reduces completeness but does not impair the overall correctness. Hence, a score of 9 is justified for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 415,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has XOM's strategic positioning in Guyana evolved between 2023 and 2024, particularly in terms of its legal operating framework and business growth emphasis?",
      "original_answer": "In 2023, XOM's operations in Guyana were governed by the Petroleum Activities Act 2023, which allowed for an exploration period typically up to 10 years and a production period of 20 years for oil fields with a renewal period of up to 10 years. By 2024, Guyana was specifically highlighted as one of XOM's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, indicating a strategic shift to emphasize Guyana as a key contributor to earnings through volume growth and integration. This evolution shows that Guyana transitioned from being a jurisdiction with defined exploration and production terms to being a core growth asset within XOM's portfolio.",
      "llm_answer": "\nBetween 2023 and 2024 ExxonMobil moved from establishing the legal basis for its Guyana operations—grounded in the Guyana Petroleum Activities Act 2023, which provides up to a 10‑year exploration term and a 20‑year production term (renewable for another decade)—to positioning Guyana as a core “advantaged asset” in its growth strategy.  In the 2024 filing the company explicitly lists Guyana among its advantaged growth projects and ties it to the “Advantaged Volume Growth” earnings driver, emphasizing commercial development, scale‑up of offshore production and integration with LNG and high‑value product initiatives.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the original answer. (1) All key facts are correct: the Petroleum Activities Act 2023 is accurately described with a 10-year exploration term and 20-year production term renewable for up to 10 years. (2) The strategic evolution in 2024 is correctly captured—Guyana is identified as an 'advantaged asset' under the 'Advantaged Volume Growth' earnings driver, aligning with the ground truth. (3) Multi-hop reasoning is sound: the answer synthesizes legal framework information from 2023 and strategic business emphasis from 2024, correctly inferring a shift from regulatory establishment to core growth positioning. (4) The LLM adds slight elaboration (e.g., 'integration with LNG and high-value product initiatives') that is consistent with XOM's strategy and does not contradict the ground truth. All entities (XOM, Guyana, 2023/2024, Advantaged Volume Growth) are correctly identified. No numerical or qualitative inaccuracies present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 288,
        "total_tokens": 1615
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Caterpillar's involvement in the diesel-electric locomotives business evolved between 2023 and 2024, particularly in terms of its strategic positioning and operational responsibilities?",
      "original_answer": "In 2023, Caterpillar's involvement in diesel-electric locomotives was described as part of its broader Machinery, Energy & Transportation (ME&T) segment, which included responsibilities such as remanufacturing Caterpillar reciprocating engines and components, as well as product support for on-highway vocational trucks in North America. By 2024, Caterpillar's positioning had evolved, with diesel-electric locomotives and related components being explicitly tied to integrated systems and solutions for industries like electric power generation, marine, oil and gas, and industrial sectors. Additionally, 2024 emphasized the development of electrified powertrains and zero-emission power sources, signaling a strategic shift toward more advanced and environmentally focused technologies in the locomotive space.",
      "llm_answer": "\nCaterpillar continues to house diesel‑electric locomotives and their components within the Energy & Transportation segment, retaining responsibility for remanufacturing, leasing and after‑market support for rail products (see page 116 and page 39).  Between 2023 and 2024 the segment’s external sales rose 3 % and its operating profit jumped 16 %, driven largely by favorable price realization, indicating that the company is deliberately strengthening the strategic positioning of its diesel‑electric locomotive business and treating it as a higher‑margin core offering (see page 40).  Operationally, the responsibilities for remanufacturing and leasing remain the same, but the improved financial performance reflects a more focused, profit‑oriented approach to this line of business.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some correct elements but diverges significantly from the ground truth in key aspects. (1) Quantitatively, the 3% increase in external sales and 16% rise in operating profit are not present in the original answer and cannot be verified against the provided ground truth, which contains no financial figures. These numbers may be factually accurate in context but are not supported by the original answer, making their inclusion misleading. (2) The LLM claims operational responsibilities 'remain the same', which contradicts the original answer's emphasis on a strategic evolution toward electrified powertrains and zero-emission technologies in 2024. This represents a major omission and mischaracterization of Caterpillar's strategic shift. (3) The original answer highlights a multi-hop synthesis: from a general ME&T segment inclusion in 2023 to a 2024 focus on integrated systems and environmental innovation in locomotive technology. The LLM fails to capture this evolution, instead emphasizing financial performance and continuity, which are not mentioned in the ground truth. (4) While the LLM correctly identifies Caterpillar's involvement in remanufacturing and after-market support, it misrepresents the nature of the strategic evolution by focusing on profitability rather than technological and environmental advancement. The segment name 'Energy & Transportation' is consistent with the original's 'Machinery, Energy & Transportation', so entity accuracy is acceptable. However, the reasoning is flawed due to unsupported financial claims and failure to recognize the core strategic pivot. Thus, the answer is partially correct in context but factually misaligned with the ground truth on critical qualitative points.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 474,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has the company's reliance on securitized debt obligations as a funding source evolved from 2022 to 2024, and what does this indicate about its funding strategy?",
      "original_answer": "In 2022, the company disclosed that it raised funding through the issuance of securitized debt obligations, among other instruments, though the exact amount was not provided. By 2024, the company reported a carrying value of $14,264 million for securitized debt obligations, indicating a concrete quantification of this funding source. This evolution suggests a more defined and potentially increased reliance on securitized debt obligations, aligning with a broader strategic emphasis on structured financing.",
      "llm_answer": "\nFrom the 2022 filing the company reported securitized‑debt obligations of about **$15 billion** (≈ 4 % of total funding), a level that had risen modestly from the prior year due to net issuances in its securitization programs.  The 2024 filing shows the carrying amount of those obligations fallen to **$14.26 billion**, while total funding remained near $354 billion, indicating a slight pull‑back from securitization.  This reduction points to a funding strategy that is shifting back toward **deposit‑based sources and other debt markets** rather than relying on securitized debt.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, the company did not disclose an exact amount for securitized debt obligations, but the LLM claims a specific figure of $15 billion (≈4% of total funding), which is unsupported. The 2024 value of $14.264 billion is correctly reported in the LLM answer (rounded to $14.26 billion), but the context is misrepresented. (2) The calculation of 4% of total funding and the claim of total funding being $354 billion are not present in the original answer and appear to be fabricated. There is no mention of deposits or other debt markets in the ground truth, so the conclusion about a strategic shift is unfounded. (3) The multi-hop reasoning is flawed: instead of recognizing that the 2024 disclosure represents a new quantification of a previously acknowledged but unspecified funding source, the model incorrectly infers a reduction in reliance and a strategic pullback. The original answer suggests increased clarity and potentially greater reliance on securitized debt, while the LLM concludes the opposite. (4) The contextual relevance is moderate because the answer addresses the general topic of securitized debt evolution and funding strategy, but the incorrect data and reversed conclusion severely undermine accuracy. Quantitative accuracy is very low due to invented numbers; qualitative accuracy is low due to faulty logic and unsupported synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 405,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has McDonald's treatment of developmental licensees evolved between 2023 and 2024, particularly in terms of financial reporting and relationship management?",
      "original_answer": "In 2023, McDonald's disclosed that developmental licensees paid royalties based on a percentage of sales and generally paid initial fees, and the company allocated consideration among lease and non-lease components using historical methods. By 2024, the company emphasized its ongoing evaluation of business relationships, including those with developmental licensees, to identify potential variable interest entities, although it concluded that consolidation of such entities was not appropriate. Additionally, in 2024, McDonald's updated its rounding presentation to the nearest whole number for reported amounts, which affected how financial figures were presented, though the company clarified that these changes were not significant.",
      "llm_answer": "\nBetween 2023 and 2024 McDonald’s refined the way it reports and manages its developmental‑licensee relationships.  The company continued to recognize royalties and initial fees from these licensees as non‑lease revenue and, pursuant to the new FASB ASU 2023‑07 on segment reporting, began disclosing a more detailed breakdown of that income within the “International Developmental Licensed Markets & Corporate” segment, highlighting the growth in licensed‑restaurant count (from 8,684 to 9,247) and the corresponding rise in royalty receipts.  Operationally, the firm maintains its historic allocation of lease versus non‑lease components, but the enhanced disclosures and the upcoming ASU 2024‑03 (expense disaggregation) signal a tighter, more transparent financial linkage between McDonald’s and its developmental partners.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and introduces information not present in the ground truth. (1) Quantitatively, the LLM claims developmental licensee restaurant counts increased from 8,684 to 9,247 between 2023 and 2024 and that royalty receipts rose accordingly, but this data is not in the original answer and cannot be verified from the provided truth. There are no such figures in the ground truth. (2) The LLM references FASB ASU 2023-07 and ASU 2024-03, suggesting new disclosure requirements drove changes in reporting, but the original answer makes no mention of these accounting standards—instead citing a change in rounding to the nearest whole number. These specific ASUs are fabrications or misattributions not supported by the source. (3) Qualitatively, the LLM incorrectly implies enhanced segment-level disclosures were implemented due to new standards, while the ground truth states McDonald’s evaluated variable interest entities and concluded consolidation was unnecessary. The core evolution in treatment—regarding VIE assessment and rounding changes—is entirely missed. (4) Contextually, the answer stays on topic regarding financial reporting and relationship management, but the reasoning is flawed and based on non-existent multi-hop connections (e.g., linking ASUs to reporting changes). The actual multi-hop synthesis required—comparing 2023 vs 2024 disclosures on royalty allocation, VIE evaluation, and presentation changes—is absent. The answer invents a narrative rather than reporting the documented evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 427,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Southern Company's approach to its Equity and Incentive Compensation Plan evolved between 2023 and 2024, particularly in terms of share availability and executive award disclosures?",
      "original_answer": "In 2023, Southern Company had 26.9 million shares available for awards under the Equity and Incentive Compensation Plan, indicating a reserve for future compensation initiatives. By 2024, the company increased transparency around executive compensation by disclosing specific terms for Named Executive Officer equity awards granted under the 2021 Equity and Incentive Compensation Plan, which was effective May 26, 2021. This evolution shows a shift from internal planning and reserve allocation in 2023 to more detailed public disclosure of executive-level compensation mechanisms in 2024, suggesting a more formalized and transparent governance approach for top-level incentives.",
      "llm_answer": "\nIn the 2023 filing Southern Company disclosed that 26.9 million shares were available for future grants under its Equity and Incentive Compensation Plan (the plan, adopted May 26 2021, had 131 million shares reserved in total). The 2024 filing still references that same plan but does not give a new share‑availability figure; instead it expands executive‑award disclosures by adding amended change‑in‑control severance and deferred‑compensation agreements while continuing to describe the plan’s award forms (stock options, performance share units) and the EPS‑dilution methodology.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that in 2023, 26.9 million shares were available under the Equity and Incentive Compensation Plan, matching the ground truth. It also accurately notes the plan was adopted on May 26, 2021, aligning with the original answer. However, the ground truth emphasizes a shift in 2024 toward greater transparency in executive award disclosures, specifically Named Executive Officer (NEO) equity award terms. The LLM answer captures this general trend but adds details not in the original—such as 'amended change-in-control severance and deferred-compensation agreements'—which, while plausible, are not mentioned in the ground truth. This introduces minor over-specificity without confirmation. (2) Quantitatively, all numbers (26.9 million shares, May 26, 2021 adoption date) are correct. The LLM correctly notes the absence of a new share availability figure in 2024, which is consistent with the original answer’s implication that the focus shifted from availability to disclosure. (3) The multi-hop reasoning is sound: the model connects 2023 share availability with 2024 disclosure practices under the same plan, correctly inferring an evolution in transparency. However, it slightly overreaches by citing specific agreement types not referenced in the ground truth, reducing qualitative precision. (4) Despite minor additions, the core evolution—from reserve reporting in 2023 to enhanced executive disclosure in 2024—is accurately conveyed, making the answer contextually relevant and largely factually correct. The answer is slightly more detailed than the original but remains within semantic equivalence on key points.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 455,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did the revenue performance of Inlyta evolve between 2022 and 2023, and what factors contributed to the change in its growth trajectory?",
      "original_answer": "In 2022, Inlyta contributed to Pfizer's operational growth, specifically mentioned among products like Comirnaty, Eliquis, and Vyndaqel that drove growth in the U.S. and international markets. By 2023, Inlyta's global revenue reached $1,036 million, reflecting a 3% total increase and a 5% operational growth. The growth was primarily attributed to the adoption of immune checkpoint inhibitor combinations with Inlyta for first-line treatment of advanced RCC in the U.S., despite lower volumes and net price in certain European markets. This indicates a continuation of growth, albeit at a more moderate pace compared to the broader portfolio dynamics in 2022.",
      "llm_answer": "\nInlyta’s worldwide sales rose only modestly—from about **$1.00 billion in 2022 to $1.04 billion in 2023** (≈ 3 % growth), with U.S. revenue up roughly 5 % (from $618 M to $642 M) and international sales up about 3 % (from $385 M to $394 M).  The slight uptick was driven primarily by **greater clinical adoption of Inlyta in combination with immune‑checkpoint inhibitors for first‑line treatment of advanced renal‑cell carcinoma and continued expansion in emerging markets**, while growth was tempered by **price reductions in several international markets and ongoing competitive pressures**.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually correct and aligns closely with the ground truth. It accurately reports Inlyta's 2023 global revenue as $1.04 billion (matching the $1,036 million in the original answer, rounded appropriately) and correctly identifies a ≈3% total growth and 5% operational growth. The U.S. and international revenue figures ($642M and $394M in 2023) sum to $1,036M, confirming internal consistency. The 2022 baseline of $1.00 billion is a reasonable approximation of $1,006 million (implied by 2023 $1,036M and 3% growth). (2) Quantitative accuracy is high: the 3% total growth and 5% U.S. growth align with the original answer’s emphasis on operational growth and market dynamics. The breakdown into U.S. and international components, while not explicitly in the ground truth, is plausible and consistent with the mention of U.S. adoption and European pricing pressures. (3) Multi-hop reasoning is sound: the LLM correctly synthesizes that growth was driven by U.S. adoption of Inlyta in combination with immune checkpoint inhibitors for advanced RCC, while being tempered by price reductions in international markets—directly reflecting the causal factors in the original answer. (4) The answer is contextually complete, addressing both the revenue evolution and contributing factors. The only minor limitation is that it introduces granular regional revenue splits not present in the source, but these are reasonable inferences and do not contradict the ground truth. Overall, the answer is semantically equivalent, factually accurate, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 435,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has McDonald's relationship with its franchisees evolved from 2023 to 2024 in terms of financial structure and dependency, particularly regarding revenue recognition and cost-sharing for technology platforms?",
      "original_answer": "In 2023, McDonald's described its relationship with franchisees as a collaborative partnership focused on consistency, quality, and revenue generation through rent, royalties based on a percent of sales, and initial fees. The business model was designed to generate stable and predictable revenue largely tied to franchisee sales. By 2024, the relationship evolved to reflect a stronger dependency on franchisees, particularly in the context of technology platforms. McDonald's began recognizing revenue from franchisees for technology services on a gross basis, with related expenses recorded in 'Other restaurant expenses,' indicating a more integrated and cost-sharing approach. This shift reflects a transformation in the nature of the relationship, with franchisees becoming more operationally interdependent with the company through shared technology infrastructure.",
      "llm_answer": "\nBetween 2023 and 2024 McDonald’s continued to depend on its heavily franchised model—about 95 % of restaurants were franchised and conventional franchisees paid rent, royalties and initial fees (pages 44 & 45).  In 2024 the Company began recording “technology‑platform” fees paid by franchisees on a **gross** basis and matched those receipts against the related expenses incurred, noting that such fees are not intended to generate margin but to recover costs (page 46).  Consequently, the financial structure of the franchise relationship stayed stable in terms of franchisee count, but the share of revenue derived from cost‑sharing for digital platforms increased, reinforcing a tighter, expense‑recovery partnership with franchisees.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the 95% franchised model, revenue streams (rent, royalties, initial fees), and the 2024 change in revenue recognition for technology platform fees are accurately described. The shift to gross revenue recognition and cost recovery (not for profit) is correctly noted, with proper linkage to 'Other restaurant expenses' implied via context. (2) Quantitative accuracy is perfect: no incorrect numbers, percentages, or misstatements of financial terms. The reference to pages 44, 45, and 46 suggests document fidelity, though page numbers are not part of the ground truth evaluation. (3) Multi-hop reasoning is sound: the model synthesizes information across years (2023 vs 2024), entities (McDonald’s and franchisees), and financial concepts (revenue recognition, cost-sharing). It correctly infers that the gross basis accounting reflects a deeper operational interdependence, even if the term 'dependency' is framed as 'tighter partnership.' (4) Semantic equivalence is strong—while the original answer emphasizes 'evolved relationship' and 'operational interdependence,' the LLM captures this through 'tighter, expense-recovery partnership.' One minor point preventing a 10 is that the LLM does not explicitly state that this change indicates a more integrated financial structure with franchisees bearing shared costs via gross reporting; this is implied but not directly articulated. Overall, the answer is factually complete, contextually relevant, and logically sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 433,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the fair value of energy-related derivatives held by Southern Company's subsidiaries evolve from 2022 to 2023, and what does this indicate about the company's exposure to energy market fluctuations?",
      "original_answer": "In 2022, Southern Company's subsidiaries reported a net fair value of $101 million for energy-related derivatives (Mississippi Power: $59 assets, $32 liabilities; Southern Power: $8 assets, $12 liabilities; Southern Company Gas: $28 assets, $65 liabilities). In 2023, the subsidiaries showed a shift with Alabama Power reporting $15 in assets and $110 in liabilities, and Georgia Power reporting $13 in assets and $124 in liabilities for energy-related derivatives. This indicates a significant increase in net liability exposure, rising from a net liability of $54 million in 2022 to a net liability of $219 million in 2023, suggesting a greater exposure to energy market fluctuations.",
      "llm_answer": "\nThe subsidiaries’ recorded fair‑value of energy‑related derivatives fell from **$199 million (assets) and $210 million (liabilities) in 2022** to **$55 million (assets) and $358 million (liabilities) in 2023**.  This shift reduced the net positive position to a sizable net liability, indicating that the company’s hedging portfolio moved from a modest net asset to a net liability, thereby increasing its vulnerability to adverse movements in energy prices.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative details. According to the ground truth, in 2022, the total assets from energy-related derivatives were $59M (Mississippi Power) + $8M (Southern Power) + $28M (Southern Company Gas) = $95M, and total liabilities were $32M + $12M + $65M = $109M, resulting in a net liability of $14M, not the $199M assets and $210M liabilities claimed by the LLM. The LLM overstates both assets and liabilities in 2022. In 2023, the LLM reports $55M in assets and $358M in liabilities. However, the ground truth only provides data for Alabama Power ($15M assets, $110M liabilities) and Georgia Power ($13M assets, $124M liabilities), totaling $28M in assets and $234M in liabilities. The LLM invents or aggregates unreported data for Southern Power and Southern Company Gas, adding $27M in unaccounted assets and $124M in unaccounted liabilities. (2) Calculations are incorrect: the 2022 net liability was $14M (not $11M net liability as implied by $199M vs $210M), and in 2023 it should be $206M net liability based on reported entities, not $303M as implied. The ground truth states a net liability increase from $54M to $219M — this $54M figure may include additional adjustments or subsidiaries not itemized, but the LLM’s numbers still deviate substantially. (3) Multi-hop reasoning is partially sound — the LLM correctly infers that a shift from net asset to net liability indicates increased exposure to energy market fluctuations. However, it misrepresents the starting point: the company was already in a net liability position in 2022 per ground truth ($54M), contrary to the LLM’s claim of a 'net positive position.' Thus, the reasoning is based on flawed premises. (4) Despite incorrect numbers, the LLM captures the directional trend (increasing net liability) and draws a relevant qualitative conclusion about increased vulnerability, which maintains contextual relevance. However, due to major quantitative errors and incomplete/misattributed entity data, the correctness and quantitative accuracy scores are low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 564,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has the treatment and significance of the Procter & Gamble 2019 Stock and Incentive Compensation Plan evolved from 2022 to 2024, based on its disclosure context in the 10-K filings?",
      "original_answer": "In 2022, the 2019 Stock and Incentive Compensation Plan was introduced with detailed references to its adoption by shareholders on October 8, 2019, and its additional terms and conditions, indicating its formal establishment and integration into the company's compensation framework. By 2024, the plan was listed among other equity compensation plans as part of the company's broader disclosure on stock ownership and equity compensation, showing that it had become a standard and active component of the company's long-term incentive structure. This evolution reflects the plan's transition from a newly introduced policy to an established part of PG's equity compensation offerings.",
      "llm_answer": "\nThe 2019 Stock and Incentive Compensation Plan, adopted in October 2019, has become Procter & Gamble’s primary equity‑incentive vehicle, superseding the earlier 2009 and 2014 plans. In the 2022 and 2024 10‑K filings the plan is repeatedly cited in the Compensation and Leadership Development Committee regulations and in updated “additional terms and conditions” disclosures, confirming that its 187 million‑share reserve (with roughly 119 million shares still available) and its award‑counting rules (full‑value awards counted as five shares) remain central to executive compensation, with only minor wording refinements between 2022 and 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific quantitative details not present in the original answer, such as the 187 million-share reserve, 119 million shares available, and the five-share counting rule for full-value awards. These figures are not mentioned in the ground truth and cannot be verified from the provided context, making them potentially inaccurate or hallucinated. The adoption date (October 2019) is correct and aligns with the original answer. However, the claim that the 2019 plan superseded the 2009 and 2014 plans is not confirmed in the ground truth, which only states the plan's introduction and later integration into broader disclosures. (2) There are no calculations in the answer, but the inclusion of unverified numbers (e.g., share reserves, availability) significantly undermines quantitative accuracy. The original answer contains no such figures, so their presence in the LLM response suggests fabrication or overreach beyond the source material. (3) The reasoning correctly identifies the plan’s continued relevance in 2022 and 2024 filings and notes its presence in committee disclosures and updated terms, which aligns with the evolution described in the ground truth—from newly introduced to established. However, the LLM adds unsupported specifics about award-counting rules and share reserves, indicating flawed multi-hop synthesis where precise data was assumed rather than inferred. (4) Contextually, the answer addresses the evolution of the plan’s disclosure and significance over time, which is relevant and well-framed. While the core qualitative trajectory (from new to standard) matches the original, the addition of unverified quantitative details reduces factual correctness. Thus, the correctness score is moderate due to plausible reasoning but significant quantitative inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 498,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has Southern Company's approach to managing the risk of large losses in its pension plan assets evolved from 2023 to 2024, and what specific changes in risk management emphasis can be observed?",
      "original_answer": "In 2023, Southern Company emphasized a formal rebalancing program and external investment manager oversight as key components of managing the risk of large losses, with a strong focus on long-term investment expectations for return and risk. In 2024, while maintaining a diversified asset strategy and rebalancing program, the emphasis on external manager oversight was reduced, and the risk of large losses was more directly linked to the broader market volatility and interest rate fluctuations. This indicates a subtle shift in risk management emphasis from active oversight to market-driven risk exposure.",
      "llm_answer": "\nSouthern Company’s risk‑management framework for its pension‑plan assets kept its core focus on broad diversification, but in 2024 the company placed added emphasis on formal, rules‑based rebalancing and tighter governance.  The 2024 discussion explicitly notes a “formal rebalancing program” and that external managers are bound by written guidelines, indicating a more structured approach to keeping actual allocations aligned with the 41 % equity / 30 % fixed‑income / 12 % real‑estate target mix.  This added procedural rigor—combined with continued use of derivatives for hedging and close monitoring of asset‑class deviations—represents the key evolution in how the company now manages the risk of large losses.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in describing Southern Company's risk management evolution. While it correctly notes the continued use of a formal rebalancing program and diversified asset strategy, it incorrectly states that in 2024 there was an 'added emphasis' on formal rebalancing and tighter governance. The ground truth indicates that the emphasis on external manager oversight was reduced in 2024, with risk now more directly linked to market volatility and interest rates—reflecting a shift toward market-driven risk exposure rather than increased procedural rigor. The LLM instead implies a strengthening of internal controls and oversight, which contradicts the documented shift away from active external manager oversight. (2) The quantitative elements—such as the 41% equity, 30% fixed-income, and 12% real estate allocation—are not present in the original answer and appear to be fabricated or misattributed. The ground truth does not specify exact target allocations, so these numbers are unsupported and reduce quantitative accuracy. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the shift in emphasis from active oversight (2023) to market-driven risk exposure (2024). Instead, it constructs a narrative of increasing procedural control, which is the opposite of the actual trend. This represents a failure in qualitative reasoning and cross-year comparison. (4) Despite these issues, the answer remains contextually relevant—it addresses pension risk management, rebalancing, and external managers—and retains some correct elements like the mention of a formal rebalancing program and diversification. However, the core evolution is misrepresented, warranting a low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 485,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has NVIDIA's role in the development and supply of the CUDA platform evolved between 2022 and 2023, and what does this shift indicate about the company's strategic focus?",
      "original_answer": "In 2022, NVIDIA's relationship with the CUDA platform was primarily as a supplier, providing the platform as part of its accelerated computing offerings. By 2023, NVIDIA's role had evolved into that of a developer, emphasizing a more active and strategic engagement in the platform's expansion and integration within its broader software ecosystem, including CUDA-X libraries, APIs, and domain-specific frameworks. This shift indicates a strategic move toward strengthening its full-stack computing platform to deliver more comprehensive data center-scale solutions.",
      "llm_answer": "\nBetween 2022 and 2023 NVIDIA’s description of CUDA shifted from a GPU‑centric parallel‑programming layer that underpins its graphics and AI accelerators to the foundational software stack of a **full‑stack accelerated‑computing platform** that now spans GPUs, CPUs (Grace), DPUs (Mellanox), networking, and cloud services such as DGX Cloud and AI Enterprise.  This evolution signals a strategic pivot toward offering **end‑to‑end AI and data‑center solutions**—monetizing software, services and ecosystem growth rather than focusing solely on hardware sales.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of NVIDIA's role with CUDA from a supplier in 2022 to a developer in 2023, emphasizing deeper software integration and ecosystem expansion. While the original answer uses 'supplier' and 'developer' explicitly, the LLM conveys the same shift by describing CUDA’s transformation into a 'full-stack accelerated-computing platform' and highlighting NVIDIA's broader strategic focus. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification—both reference 2022 and 2023 correctly. (3) The multi-hop reasoning is sound: the LLM synthesizes the platform evolution (from GPU-centric to full-stack) and infers the strategic implication (shift toward end-to-end solutions and software monetization), which matches the original answer’s conclusion about a strategic move toward comprehensive data center-scale solutions. (4) The LLM adds contextual details not in the original—such as Grace CPUs, Mellanox DPUs, DGX Cloud, and AI Enterprise—which are factually consistent with NVIDIA’s 2023 strategy and enhance the explanation without introducing inaccuracies. The only minor gap is that the LLM does not explicitly mention 'CUDA-X libraries, APIs, and domain-specific frameworks' from the original, but it broadly covers this under 'full-stack' and 'ecosystem growth.' Overall, the answer is semantically equivalent, highly relevant, and factually correct, warranting a 9 for correctness and qualitative accuracy due to slight differences in emphasis but no material errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 445,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How did Pfizer's financial relationship with Viatris evolve between 2022 and 2023, particularly in terms of supply agreements and outstanding balances?",
      "original_answer": "In 2022, Pfizer reported $780 million in revenue growth from PC1, primarily reflecting manufacturing of legacy Upjohn products for Viatris under supply agreements. By 2023, the financial relationship had evolved, as indicated by the net amounts due to Viatris under various agreements, which decreased from $94 million as of December 31, 2022, to $33 million as of December 31, 2023. Additionally, most transitional services under the TSAs were completed by the end of 2023, signaling a reduction in operational interdependence.",
      "llm_answer": "\nBetween 2022 and 2023 the financial ties that Pfizer had with Viatris – which stemmed from the Upjohn‑Mylan separation and the related interim manufacturing, rebate‑billing and MSA agreements – were largely wound down.  At the end of 2022 Pfizer still had about **$94 million** of amounts due under those agreements (and a $277 million pre‑separation dividend had been paid in 2021), but by **December 31 2023** the outstanding balance had fallen to **≈ $33 million** as the transitional services and manufacturing arrangements were completed, marking the near‑termination of Pfizer’s supply‑related financial relationship with Viatris.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all key figures are correct: the $94 million balance due to Viatris as of December 31, 2022, and the reduction to $33 million by December 31, 2023, are accurately reported. The mention of the $277 million pre-separation dividend in 2021, while not part of the original answer, is factually consistent with external knowledge and does not contradict the ground truth; it adds context without introducing error. (2) The core financial evolution—winding down of supply agreements and reduction in outstanding balances—is correctly captured. (3) The reasoning is sound: the LLM correctly infers that the decline in receivables and completion of transitional services (implied by the drop in balance) signals a reduction in interdependence, which matches the multi-hop synthesis required. (4) The only minor shortcoming is the omission of the specific $780 million revenue growth from PC1 in 2022 related to manufacturing legacy Upjohn products, which was a key component of the original answer and directly addressed the supply agreement revenue aspect. While the LLM describes the winding down of agreements, it does not explicitly mention this significant 2022 revenue figure, resulting in a slight completeness gap. However, the overall semantic meaning and trajectory of the financial relationship are accurately conveyed. Wording differences are acceptable and do not affect factual integrity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 409,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has the treatment and disclosure of communications sites in relation to debt obligations evolved between 2023 and 2024?",
      "original_answer": "In 2023, communications sites were explicitly referenced as collateral securing debt obligations, such as the 3,343 communications sites securing the Series 2015-2 Notes and the repayment of $1.3 billion in Series 2013-2A Notes funded by the 2023 Securitization. In 2024, while there was no explicit mention of specific communications sites securing debt, the company disclosed broader financial commitments, such as $4.5 billion in estimated undiscounted future cash outlay for asset retirement obligations as of December 31, 2024. This shift indicates a move from site-specific debt disclosures to more general obligations, suggesting a change in how communications sites are framed in relation to financial liabilities.",
      "llm_answer": "\nBetween 2023 and 2024 the Company’s disclosure shifted from a broad statement that the cash‑flows generated by its communications sites are “only available for payment of the securitized debt” to a detailed, quantitative framework that ties those cash‑flows to specific debt‑service‑coverage‑ratio (DSCR) tests, cash‑trap and amortization triggers, and explicit conditions limiting any excess‑cash distributions. In the 2024 filing the Company spells out the 1.30× Cash‑Trap DSCR, the 1.15× Minimum DSCR, the resulting reserve‑account requirements, and the impact on its ability to fund capital expenditures and REIT distributions—showing a more precise treatment of the sites as collateral and of the cash‑flow restrictions tied to its debt obligations.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and misrepresents the evolution of disclosures between 2023 and 2024. (1) It claims that in 2024 the company adopted a more detailed, quantitative framework linking cash flows from communications sites to specific DSCR tests (1.30× Cash-Trap DSCR, 1.15× Minimum DSCR), reserve accounts, and distribution limits. However, the ground truth states that in 2024 there was *no explicit mention* of specific communications sites securing debt, and instead the company reported broader obligations like a $4.5 billion asset retirement liability. This is the opposite of increased specificity. (2) The original answer notes a shift *away* from site-specific disclosures in 2024, while the LLM claims a shift *toward* more granular cash flow restrictions and collateral treatment—this contradicts the ground truth. (3) No numbers in the LLM response (e.g., 1.30×, 1.15×) appear in the original answer, and there is no mention of DSCR tests or cash-trap mechanisms in the ground truth. The only correct numeric reference in the LLM answer—$1.3 billion—was tied to the 2023 repayment of Series 2013-2A Notes via securitization, but the LLM incorrectly associates it with 2024 disclosures and DSCR mechanics. (4) The multi-hop reasoning fails: the LLM invents a narrative of increasing disclosure specificity, while the actual trend was a move toward general financial obligations and reduced site-level detail. The contextual relevance is moderate because the answer addresses debt and communications sites, but the factual and directional claims are incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 432,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Comcast's approach to retransmission consent agreements evolved between 2022 and 2023, particularly in terms of revenue recognition and distribution models?",
      "original_answer": "In 2022, Comcast recognized revenue from retransmission consent agreements on a monthly basis as programming was provided, with fees tied to the number of subscribers and generally collected within 60 days. By 2023, the company's Media segment emphasized a combined linear and streaming distribution model, with retransmission fees now explicitly including both traditional and virtual multichannel video providers. The 2023 filing also highlighted a broader integration of Peacock into the distribution ecosystem, suggesting a strategic shift toward hybrid distribution models that blend traditional and streaming services.",
      "llm_answer": "\nBetween 2022 and 2023 Comcast moved from treating retransmission‑consent fees as part of an aggregated “programming and content‑licensing” line item (as seen in the 2022 10‑K, pages 92‑96, where they were included in overall programming revenue without separate disclosure) to explicitly identifying those fees as “fees received from multichannel video providers under NBC and Telemundo retransmission‑consent agreements” in the 2023 10‑K (pages 9‑10).  The 2023 filing also clarifies that the fees are earned under multiyear, subscriber‑based distribution agreements and that revenue is recognized on a monthly basis as the programming is provided, reflecting a shift to a more granular, subscription‑oriented recognition and distribution model.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its description of Comcast's evolving revenue recognition and disclosure practices for retransmission consent agreements between 2022 and 2023. It correctly identifies that in 2022, retransmission fees were embedded within broader programming revenue without separate disclosure (per 2022 10-K), and that by 2023, Comcast began explicitly identifying these fees in its 10-K (pages 9–10), marking a shift toward more transparent, granular reporting. The answer accurately states that revenue is recognized monthly as programming is provided and that fees are tied to subscriber-based distribution agreements—consistent with the ground truth.\n\nHowever, the LLM answer omits a key element from the original answer: the strategic expansion of distribution models to include both traditional and virtual multichannel video providers, as well as the integration of Peacock into the distribution ecosystem. This reflects a significant qualitative shift toward hybrid (linear + streaming) models, which the LLM does not mention. While the LLM captures the accounting and disclosure evolution accurately (strong quantitative and partial qualitative accuracy), it fails to synthesize the broader strategic context emphasized in the ground truth, particularly the role of Peacock and the combined distribution model. This missing multi-hop insight reduces the completeness and qualitative accuracy of the response. The contextual relevance remains high because the answer directly addresses revenue recognition and distribution models, albeit incompletely. No numerical inaccuracies are present, and all cited document references align with the reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 457,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Caterpillar's involvement in the production and strategic positioning of diesel-electric locomotives evolved from 2023 to 2024?",
      "original_answer": "In 2023, Caterpillar's involvement in diesel-electric locomotives was described as part of its broader ME&T segment, which included responsibilities such as remanufacturing Caterpillar reciprocating engines and components, as well as providing product support for on-highway vocational trucks in North America. By 2024, Caterpillar's engagement had evolved into a more defined production role under the Energy & Transportation segment, which explicitly stated that Caterpillar 'produces' diesel-electric locomotives and components, signaling a more direct and strategic emphasis on this product line. Additionally, in 2024, Caterpillar highlighted competitive pressures in rail-related businesses, naming companies like Wabtec Corp and Siemens Mobility A/S, which was not present in 2023. This indicates a shift from a general operational inclusion to a more prominent and competitive product focus.",
      "llm_answer": "\nFrom 2023 to 2024 Caterpillar continued to produce and support diesel‑electric locomotives as part of its Energy & Transportation segment, but the 2024 filing broadens that segment to include electrified powertrains and zero‑emission power solutions, signaling a strategic shift toward more sustainable rail offerings.  The 2024 document also emphasizes new financing and match‑funding initiatives and heightened competition with other rail‑equipment manufacturers, reflecting a more digitally integrated and sustainability‑focused positioning of Caterpillar’s locomotive business.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements but diverges significantly from the ground truth in key aspects of Caterpillar's strategic evolution regarding diesel-electric locomotives from 2023 to 2024. (1) Correctly identifies that Caterpillar is involved in diesel-electric locomotives and that the Energy & Transportation segment is relevant in 2024, and notes increased competitive context and strategic shifts. However, it incorrectly states that Caterpillar 'continued to produce' these locomotives in both years, whereas the original answer clarifies that in 2023, the company’s role was more general—part of ME&T with remanufacturing and support responsibilities—without explicit mention of 'producing' locomotives. The shift to 'produces' in 2024 is a critical factual distinction that the LLM answer overlooks. (2) There are no numeric values to verify, so quantitative accuracy is not compromised. (3) The multi-hop reasoning is partially sound—linking segment evolution and competitive landscape—but introduces unverified elements such as 'electrified powertrains', 'zero-emission power solutions', and 'financing and match-funding initiatives' that are not present in the original answer and thus represent unsupported additions. (4) While the answer is contextually relevant and reflects a plausible strategic direction, it fails to accurately represent the nature of the evolution: from indirect operational inclusion to direct production emphasis. The mention of sustainability and digital integration appears speculative and is not supported by the ground truth. Thus, while the answer is well-structured and relevant, it lacks fidelity to the actual documented changes, resulting in a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 469,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of revenue recognition and cost-sharing arrangements between 2023 and 2024?",
      "original_answer": "In 2023, McDonald's revenue from franchisees primarily included rent and royalties based on a percentage of sales with minimum rent payments, and initial fees. The company also mentioned that all restaurants were either operated by McDonald's or by franchisees under franchised arrangements. By 2024, the revenue recognition model remained consistent, but the company provided more detailed disclosures on how it recognizes revenue from franchisees, including the treatment of technology platform fees, which are now presented on a gross basis on the Consolidated Statement of Income. Additionally, in 2024, McDonald's clarified its cost-sharing arrangements for restaurant improvements, where it may fund certain projects and allocate costs between Property and Equipment and Accounts Receivable during the project, finalizing the allocation upon completion. This level of detail on cost-sharing was not present in the 2023 filing, indicating a more nuanced and transparent approach to franchisee financial interactions in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 McDonald’s did not alter the core way it recognizes revenue from its franchisees—royalties and rent are still recorded when the underlying sales occur, initial franchise fees are amortized over the typical 20‑year term, and technology‑platform fees are now reported gross because the Company acts as the principal, with related expenses charged to “Other restaurant expenses.”  At the same time, cost‑sharing arrangements remain anchored in percent‑of‑sales contributions to advertising cooperatives and shared improvement‑cost allocations (with the Company allocating those costs between property‑and‑equipment and receivables and adjusting depreciation accordingly), but the 2024 filings place greater emphasis on disclosed details of these arrangements (e.g., expanded segment‑expense disclosures required by ASU 2023‑07 and the upcoming ASU 2024‑03).  In short, the economic substance of the franchisee‑Company relationship is unchanged, though reporting has become more transparent.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly states that McDonald's core revenue recognition model from franchisees did not change between 2023 and 2024—retaining rent, royalties based on sales percentage, and amortization of initial fees over a 20-year term. This matches the original answer’s description of consistent revenue recognition. (2) The LLM accurately notes the key 2024 update: technology platform fees are now presented on a gross basis in the income statement because McDonald’s acts as the principal, which is a factual detail confirmed in the ground truth. (3) Regarding cost-sharing, the LLM correctly identifies that McDonald’s funds certain restaurant improvement projects and allocates costs between Property and Equipment and Accounts Receivable during and after project completion, with adjustments to depreciation—this synthesis of cost allocation and accounting treatment is consistent with the original answer. (4) The LLM adds contextual precision by referencing ASU 2023-07 and upcoming ASU 2024-03 as drivers for enhanced segment-expense disclosures, which explains the increased transparency in 2024 filings. While this specific regulatory context is not in the ground truth, it does not contradict it and plausibly supports the observed increase in disclosure detail. The only minor gap is that the original answer emphasizes the *absence* of such cost-sharing detail in 2023, which the LLM implies but does not explicitly contrast. However, the core facts, multi-hop synthesis across years, entity accuracy (McDonald’s, franchisees, financial arrangements), and reasoning are sound. All financial concepts and timelines are correct, and semantic equivalence is maintained with slightly more technical elaboration. No numeric inaccuracies exist—dates, percentages, and accounting treatments are correctly represented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1509,
        "completion_tokens": 510,
        "total_tokens": 2020
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Southern Company's approach to executive equity compensation evolved between 2023 and 2024, particularly regarding plan documentation and award terms?",
      "original_answer": "In 2023, Southern Company disclosed that stock-based compensation, primarily in the form of performance share units (PSUs) and restricted stock units (RSUs), was granted under the Equity and Incentive Compensation Plan to employees ranging from line management to executives. By 2024, the company formalized the terms for Named Executive Officer equity awards under the same plan, indicating a more structured approach to executive compensation. Additionally, the 2024 filing included detailed documentation practices, such as the designation of specific exhibits for equity award terms, which was not present in the 2023 filing. This reflects a shift toward greater specificity and transparency in executive equity compensation documentation.",
      "llm_answer": "\nSouthern Company’s equity‑compensation framework remained anchored in the 2021 Equity and Incentive Compensation Plan, but the 2024 filings show a deliberate shift toward consolidating and modernising the underlying documentation.  The company restated the Deferred Compensation Plan (effective Jan 1 2025) and re‑issued the Executive Change‑in‑Control Severance Plan (re‑stated Aug 15 2022), adding explicit language that unvested PSUs and RSUs automatically vest upon a change‑in‑control where Southern is not the surviving entity and that awards vest immediately for retirement‑eligible employees.  These updates reflect a more streamlined, future‑dated plan documentation and clearer award‑term provisions (especially around vesting triggers) compared with the 2023 disclosures.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some accurate elements but diverges significantly from the ground truth in key areas. (1) Correct aspects: Southern Company does use the Equity and Incentive Compensation Plan (though the LLM specifies '2021', which is not in the original answer and unverified), and PSUs/RSUs are part of executive compensation. The mention of vesting triggers like change-in-control and retirement eligibility reflects plausible award terms. (2) Quantitative accuracy: The date 'Jan 1 2025' for the Deferred Compensation Plan restatement and 'Aug 15 2022' for the Executive Change-in-Control Severance Plan restatement are specific but not present or verifiable in the original answer, which focuses on 2023–2024 evolution. These dates introduce unconfirmed details, reducing factual reliability. (3) Multi-hop reasoning: The LLM fails to correctly synthesize the core evolution described in the original answer—i.e., the shift toward formalized documentation and exhibit-level transparency in 2024. Instead, it emphasizes plan restatements and vesting rules not mentioned in the ground truth, suggesting a misalignment in reasoning. (4) The original answer highlights increased specificity and structured documentation in 2024 (e.g., designated exhibits), which the LLM omits entirely. Conversely, the LLM introduces new plans and vesting mechanics absent from the original, indicating factual overreach. While the general direction—more structured terms—aligns thematically, the lack of support from the ground truth and introduction of unverified details result in a partially correct but misleading response. Hence, correctness is scored low despite some plausible context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 457,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Procter & Gamble's strategic reliance on membership club stores evolved from 2022 to 2024, and what does this shift indicate about the company's broader retail channel strategy?",
      "original_answer": "In 2022, Procter & Gamble identified membership club stores as one of its key retail channels, listing them among a broad set of distribution partners such as mass merchandisers, grocery stores, and e-commerce platforms. However, by 2024, the company's language shifted to emphasize dependency on these membership club stores, indicating a deeper strategic alignment or increased reliance on this channel. This evolution suggests that membership club stores have become more central to P&G's distribution and retail execution strategy, likely reflecting growth in this channel's importance to consumer purchasing behavior and overall market dynamics.",
      "llm_answer": "\nFrom 2022 to 2024 the 10‑K filings show that membership‑club stores remain listed as a “key customer” channel, but the 2024 filing (pages 7‑8) places far more emphasis on e‑commerce, social‑commerce and direct‑to‑consumer relationships and warns that “continued concentration among our retail customers could create significant cost and margin pressure.”  This shift signals that P&G is deliberately reducing its strategic dependence on wholesale‑club formats and is instead diversifying into higher‑growth, higher‑margin digital and specialty retail channels as part of a broader omni‑channel retail strategy.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its interpretation of Procter & Gamble's strategic shift. The original answer (ground truth) states that P&G's reliance on membership club stores increased from 2022 to 2024, with language in the filings evolving from identifying them as a 'key retail channel' to indicating 'dependency'—suggesting deeper strategic alignment. In contrast, the LLM claims P&G is reducing dependence on wholesale-club formats and shifting toward e-commerce and direct-to-consumer channels, which contradicts the ground truth. There are no numeric values in the question or answers requiring quantitative verification, so quantitative accuracy is scored as 10 by default (no errors in numbers). However, the qualitative accuracy is very low because the model misidentifies the direction of the strategic shift and incorrectly infers a reduction in reliance on club stores. The reasoning is flawed: it fails the multi-hop synthesis by drawing an opposite conclusion from the evidence it cites (e.g., mentioning 'continued concentration among retail customers' as a risk does not imply reduced reliance on club stores). Contextual relevance is low because the answer focuses on a diversification narrative into digital channels not supported by the ground truth, thereby missing the core point about increasing centrality of membership club stores. The answer may reflect plausible industry trends but does not align with the specific evidence in the knowledge graph.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 409,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did AMT's involvement with Nigeria Letters of Credit evolve between 2023 and 2024, and what does this indicate about its financial obligations related to this instrument?",
      "original_answer": "In 2023, AMT had a $3.4 million obligation under the Nigeria Letters of Credit as part of its variable rate debt portfolio. However, by 2024, this obligation was no longer present, as indicated by the $0 carrying value in both denominated currency and USD. This indicates that AMT fully settled or otherwise exited its financial obligations tied to Nigeria Letters of Credit within this period.",
      "llm_answer": "\nBetween the 2023 and 2024 filings, AMT’s exposure to the Nigeria Letters of Credit dropped from a $3.4 million carrying amount at the end of 2023 to $0 million by the end of 2024, indicating that the drawn letters of credit were either matured, repaid, or otherwise settled during the year. Consequently, the company no longer holds a financial obligation for this instrument, reflecting that any prior commitments under the Nigerian letters of credit have been resolved.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers and dates are correct: the $3.4 million obligation in 2023 and $0 in 2024 are accurately reported, with acceptable formatting ($3.4 million vs $3.4 million). (2) The answer correctly identifies the change in AMT's financial obligation over the two years and concludes that the obligation was settled, which matches the ground truth. (3) The reasoning is sound—by noting the drop to $0 and interpreting it as maturity, repayment, or settlement, the LLM correctly synthesizes the implication of the carrying value change. The only minor shortcoming is that it does not explicitly mention that the $0 value was reported in both denominated currency and USD, a small detail from the original answer that adds precision but does not alter the conclusion. (4) All entities—AMT, Nigeria Letters of Credit, 2023, 2024—are correctly identified, and the response fully addresses both parts of the question: the evolution of involvement and the implication for financial obligations. The answer is semantically equivalent to the ground truth with slightly different phrasing. Thus, the correctness score is 9 due to this minor omission, but all other dimensions are strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1223,
        "completion_tokens": 353,
        "total_tokens": 1576
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the valuation methodology and composition of GD's Retirement Annuity Contracts change between 2022 and 2024, and what does this indicate about the company's approach to reporting these assets?",
      "original_answer": "In 2022, GD reported Retirement Annuity Contracts as part of Level 3 assets with a fair value of $35 million as of December 31, 2021, and this value remained relatively stable through December 31, 2020 at $38 million. The contracts were disclosed within a detailed table showing actual returns, unrealized gains and losses, and net purchases or sales. By 2024, Retirement Annuity Contracts were still categorized under Level 3 assets but were now described as being valued using NAV (net asset value) as a practical expedient, excluded from the formal fair value hierarchy. This indicates a shift in GD's reporting methodology from detailed fair value disclosures to a more simplified NAV-based approach, aligning with broader changes in how these contracts are categorized and disclosed.",
      "llm_answer": "\nIn the 2022 filing (GD 10‑K 2022, page 94) the retirement‑annuity contracts were reported at a fair value of **$38 million** and disclosed as **Level 3** assets—i.e., valued using significant unobservable inputs (discounted‑cash‑flow assumptions). By the 2024 filing (GD 10‑K 2024, page 94) the same line item had fallen to **$22 million**, still classified as Level 3 but representing a smaller share of total Level 3 assets, reflecting lower present‑value estimates (driven by higher discount rates and contract payouts). This shift shows that General Dynamics continues to treat these contracts as highly estimated, relying on internal assumptions rather than observable market prices, and adjusts the reported balance as the underlying contracts mature and market conditions change.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the fair value was $35 million as of December 31, 2021 (reported in 2022 filing), and $38 million as of December 31, 2020 — not $38 million in 2022 as stated. The LLM incorrectly reports a decline to $22 million by 2024, which is not supported by the original answer; no such figure appears in the ground truth. These numerical errors severely undermine the answer’s validity. (2) The quantitative inaccuracies are critical: the values, trends, and timeframes are all misaligned. The original answer indicates stability between 2020 and 2021, with no data provided for 2023 or 2024 beyond methodology changes. The LLM fabricates a drop to $22 million and attributes it to higher discount rates and payouts — details absent from the ground truth. (3) The reasoning is partially sound in that it recognizes Level 3 classification in both years, but it completely misses the key methodological shift: in 2024, GD began using NAV as a practical expedient and excluded these contracts from the formal fair value hierarchy. This is the central change in reporting approach, yet the LLM fails to mention it, instead asserting continued use of unobservable inputs without noting the NAV transition. (4) Contextual relevance is moderate — the answer addresses valuation methodology and changes over time, but due to incorrect numbers and omission of the core disclosure change (NAV as practical expedient), the conclusion about GD’s reporting approach is misleading. The original answer emphasizes a move toward simplified reporting; the LLM implies only a recalibration of assumptions within the same framework, which is incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 470,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has the composition and value of restricted cash for securitization investors changed between 2022 and 2024, particularly in terms of its fair value hierarchy classification?",
      "original_answer": "In 2022, the company reported restricted cash for securitization investors as part of consolidated VIEs, with the assets and liabilities presented on the consolidated balance sheets. By 2024, the restricted cash for securitization investors was valued at $441 million, with the entire amount classified under Level 1 of the estimated fair value hierarchy, indicating a shift toward more transparent or market-based valuation methods. This reflects a more defined and standardized valuation approach in 2024 compared to 2022, where the fair value hierarchy was not explicitly detailed for this category.",
      "llm_answer": "\nBetween 2022 and 2024 the restricted cash held for securitization investors was essentially unchanged at $441 million, and in both years it is classified as Level 1 in the fair‑value hierarchy—meaning it is valued using quoted prices in an active market with no reliance on unobservable inputs.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer correctly identifies the $441 million value in 2024 and the Level 1 classification, which aligns with the ground truth. However, it incorrectly states that the amount and classification were the same in 2022, directly contradicting the original answer, which specifies that in 2022 the fair value hierarchy was not explicitly detailed and no Level 1 classification was reported. (2) Quantitatively, the $441 million figure is accurate for 2024, but the claim that it was 'essentially unchanged' implies continuity in both value and classification, which is unsupported for 2022. There is no evidence in the ground truth that the 2022 amount was $441 million or classified as Level 1. (3) The multi-hop reasoning fails because the model assumes consistency between years without evidence, and it overlooks the key change emphasized in the original answer: the shift toward transparency and standardized valuation in 2024 due to explicit Level 1 classification, which was absent in 2022. (4) While the answer is contextually relevant and includes correct terminology, the factual inaccuracy regarding 2022 significantly undermines correctness and qualitative reasoning, warranting a moderate score only for partial numerical accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 348,
        "total_tokens": 1581
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of financial recognition and asset management between 2023 and 2024?",
      "original_answer": "In 2023, McDonald's relationship with franchisees was primarily characterized by the acquisition of restaurants from franchisees, resulting in goodwill that was either fully or partially written off depending on the time of sale relative to acquisition. The Company used a discounted cash flow methodology to determine the fair value of acquired restaurants. By 2024, the relationship had transformed into a more dependency-based model, particularly in the area of technology platform services. McDonald's now provides distinct technology-related goods and services to franchisees, recognizing revenue on a gross basis and corresponding expenses within 'Other restaurant expenses.' This marks a shift from asset acquisition and goodwill management toward ongoing service-based financial interactions with franchisees.",
      "llm_answer": "\nBetween 2023 and 2024 McDonald’s kept the core of its franchise‑fee accounting unchanged—royalties and minimum rent are recognized as underlying sales occur and initial fees are amortized over the typical 20‑year franchise term.  However, the company markedly deepened its direct involvement with franchisees by acquiring 228 restaurant locations in 2024, recording roughly $240 million of goodwill and $270 million of identifiable intangibles, and tightening the allocation of shared improvement costs (shifting them between property‑and‑equipment and accounts‑receivable) while performing more frequent impairment testing of goodwill and long‑lived assets.  This reflects a strategic evolution toward greater on‑balance‑sheet ownership and more rigorous financial‑recognition of its franchise‑related assets.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents the evolution of McDonald's relationship with franchisees between 2023 and 2024. (1) Quantitative inaccuracies: The claim that McDonald's acquired 228 restaurant locations in 2024 and recorded $240 million of goodwill and $270 million of identifiable intangibles is not supported by the ground truth, which does not mention specific numbers of restaurants acquired or dollar amounts for goodwill in 2024. The original answer notes that in 2023, goodwill was written off depending on timing, but provides no such figures. These numbers appear fabricated. (2) The qualitative shift described in the LLM answer—toward greater on-balance-sheet ownership and asset acquisition—is partially aligned with 2023 dynamics but incorrectly projects it into 2024 as the primary evolution. In contrast, the ground truth states that by 2024, the relationship shifted to a dependency-based model centered on technology platform services, with revenue recognized on a gross basis and expenses in 'Other restaurant expenses.' This key strategic pivot to service-based financial interactions is entirely missing from the LLM response. (3) Multi-hop reasoning failure: The question requires synthesizing changes across two years and two financial models (asset acquisition vs. service provision). The LLM fails this synthesis, instead doubling down on asset acquisition in 2024, which contradicts the ground truth. (4) Contextual relevance is moderate because the answer discusses franchisee financial relationships and asset management, but it misses the core 2024 transformation, rendering it substantially incorrect. Minor correct elements include the mention of goodwill and impairment testing, which aligns loosely with 2023 practices. However, the overall direction and conclusion of the answer are factually wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 505,
        "total_tokens": 1910
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has the treatment of the 2019 Stock and Incentive Compensation Plan evolved between 2022 and 2024 in Procter & Gamble's disclosures, particularly regarding its relationship with other compensation plans and its role in equity compensation?",
      "original_answer": "In 2022, the 2019 Stock and Incentive Compensation Plan was disclosed as part of a broader set of compensation plans, with specific reference to its adoption by shareholders in 2019 and its regulation in conjunction with other plans like the 2014 Stock and Incentive Compensation Plan. By 2024, the 2019 Plan was still included in the list of active equity compensation plans, but it was now referenced in the context of security ownership and the total shares available for issuance, indicating a shift from adoption and governance details to its role in the company's overall equity compensation structure. This reflects a transformation in how the plan is positioned within the company's disclosures, moving from procedural governance to a more strategic ownership framework.",
      "llm_answer": "\nBetween 2022 and 2024 P&G’s filings shifted from simply listing the 2019 Stock and Incentive Compensation Plan among several active plans and noting its “additional terms and conditions,” to explicitly stating that the 2019 Plan is the only plan that still authorizes future equity grants, describing how its awards are counted (full‑value awards such as RSUs/PSUs are treated as five shares) and revealing that roughly 77 million shares remain available for issuance. The 2024 disclosure also ties the 2019 Plan to the 2014 Plan in the Compensation and Leadership Development Committee’s regulations, showing that the newer plan now serves as the primary vehicle for equity compensation while older plans are referenced only for historical and regulatory context.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. It correctly identifies the evolution in Procter & Gamble's disclosure of the 2019 Stock and Incentive Compensation Plan from 2022 to 2024. While the original answer emphasizes a shift from procedural governance to a strategic ownership framework, the LLM provides more granular detail: it notes that by 2024, the 2019 Plan became the sole source for future equity grants, includes the share counting ratio (full-value awards counted as five shares), and specifies ~77 million shares remaining—details not in the ground truth but consistent with plausible, deeper disclosure. These additions do not contradict the original answer but enrich it. The mention of the 2014 Plan being referenced under the Committee’s regulations aligns with the original’s point about ongoing relationship with prior plans. All entities (2019 Plan, 2014 Plan, P&G, equity compensation) and years (2022, 2024) are correct. The quantitative figure of 'roughly 77 million shares' is plausible and format-appropriate; no calculation errors. The reasoning is sound multi-hop synthesis across time and plans. The only reason for not scoring a 10 is that the LLM introduces specifics (e.g., 5x share counting, 77M shares) not verifiable from the provided ground truth, which takes a higher-level view—so slight overprecision without confirmation. Still, the core evolution in disclosure treatment is accurately captured with strong qualitative and contextual fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 415,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Salvatore Ferragamo's presence in Simon Property Group's international outlet locations evolved between 2022 and 2023?",
      "original_answer": "In 2022, Salvatore Ferragamo was listed as a tenant in three of Simon Property Group's international outlet locations in Japan: Gotemba Premium Outlets, Kobe-Sanda Premium Outlets, and Sano Premium Outlets. By 2023, Salvatore Ferragamo appeared in only one of SPG's outlet locations, specifically Las Vegas Outlets North in Nevada, USA. This indicates a significant reduction in Salvatore Ferragamo's presence across SPG's outlet portfolio, shifting from multiple locations in Japan to a single location in the U.S.",
      "llm_answer": "\nSalvatore Ferragamo continued to be listed as a tenant in the same eight international premium‑outlet properties in both 2022 and 2023—specifically the four Japanese outlets (Gotemba, Kobe‑Sanda, Rinku and Sano), plus Punta Norte in Mexico, Yeoju in South Korea, Johor in Malaysia and Montreal in Canada.  This indicates that the brand’s presence in SPG’s international outlet portfolio remained stable, with no net additions or removals between the two years.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect. (1) Quantitatively, it claims Salvatore Ferragamo was present in eight international outlets in both 2022 and 2023, while the ground truth states it was in three locations in Japan in 2022 and only one (Las Vegas Outlets North, USA) in 2023. The number of locations (8 vs. actual 3 then 1), geographic distribution, and direction of change are all wrong. (2) The listed outlets—Rinku, Punta Norte, Yeoju, Johor, Montreal—are not supported by the ground truth and appear fabricated. The inclusion of non-Japanese and non-U.S. locations contradicts the original data. (3) The reasoning is flawed: the conclusion of 'stable presence' directly contradicts the ground truth, which shows a significant reduction and geographic shift from Japan to the U.S. (4) The answer fails on multi-hop synthesis: it should have compared tenant lists across years and geographies but instead invents consistent presence across eight locations. Only minimal contextual relevance is retained as it addresses tenant presence in SPG outlets over time, but all factual content is incorrect. Thus, the correctness, quantitative, and qualitative accuracy scores are very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 334,
        "total_tokens": 1573
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has COP's natural gas position in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about its operational focus in the region?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas in the Asia Pacific/Middle East region, while in 2024, this figure slightly decreased to 296 billion cubic feet. This indicates a minor reduction in natural gas reserves in the region, suggesting a potential shift or stabilization in operational focus rather than aggressive growth.",
      "llm_answer": "\nBetween the end of 2023 and the end of 2024 ConocoPhillips’ reported natural‑gas reserves in the Asia‑Pacific/Middle‑East region slipped only slightly—from about **312 billion cubic feet to 296 billion cubic feet**—but the undeveloped portion grew and the company added reserves through extensions and discoveries, especially in the Middle East via its equity affiliates.  These trends show that, despite flat total reserves, ConocoPhillips is keeping its operational focus on developing existing gas assets and pursuing new discoveries in the region rather than seeking large‑scale reserve growth.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the natural gas reserves for COP in the Asia Pacific/Middle East region as 312 billion cubic feet in 2023 and 296 billion cubic feet in 2024, matching the ground truth exactly. These numbers are accurate and properly formatted. (2) The quantitative accuracy is perfect—both values are correct, and the slight decrease (16 billion cubic feet) is implied. (3) The multi-hop reasoning is mostly sound: the answer correctly identifies the minor reduction in total reserves and adds context about undeveloped reserves growing and new discoveries via equity affiliates, which is consistent with operational focus. However, this additional detail about 'extensions and discoveries' and 'equity affiliates' is not present in the ground truth and may introduce unsupported inference. While plausible, it goes beyond the provided data, slightly weakening the qualitative accuracy. (4) The answer addresses both parts of the question—evolution of gas position and implications for operational focus—and correctly infers stabilization rather than aggressive growth, aligning semantically with the ground truth. The slight deduction in qualitative accuracy reflects the introduction of unverified details not in the source. Overall, the answer is factually correct on core metrics and relevant implications, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 383,
        "total_tokens": 1624
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Comcast's approach to wireless gateways evolved from 2022 to 2024, particularly in terms of strategic emphasis and investment?",
      "original_answer": "In 2022, Comcast offered wireless gateways as part of its broadband services, combining modem and Wi-Fi router capabilities to enhance in-and-out-of-home coverage. The focus was on customer-facing features like the xFi whole-home application and advanced security. By 2024, the company elevated its strategic emphasis by shifting from merely offering wireless gateways to actively investing in their deployment as part of its broader network infrastructure upgrades. This included plans to increase capacity and deliver multigigabit symmetrical speeds, signaling a deeper integration of wireless gateways into its long-term network strategy.",
      "llm_answer": "\nFrom 2022 through 2024 Comcast’s capital program shifted from a broad‑based emphasis on scalable infrastructure, line‑extensions and general customer‑premise‑equipment spend toward a more focused investment in the **Connectivity & Platforms** segment, where the **deployment of wireless gateways** is now highlighted as a strategic pillar for delivering multigigabit symmetrical speeds, expanding capacity and supporting bundled services (e.g., X1/Flex, xFi Pods, bundled wireless).  In the 2022 filing (pages 5‑9) wireless gateways were described as part of the “customer premise equipment” category, while the 2024 filing (pages 51, 53 and the capital‑expenditure discussion) explicitly calls out “continued deployment of wireless gateways” as a key component of its network‑upgrade capex, even as overall capex on customer‑premise equipment fell slightly (from $2.23 bn in 2023 to $2.01 bn in 2024).  Thus, the evolution is marked by a strategic refocus on wireless gateways as an enabler of next‑generation broadband platforms rather than a standalone line‑item, with investment aligned to broader platform and theme‑park initiatives.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly captures the evolution in Comcast's approach from 2022 to 2024: in 2022, wireless gateways were part of customer premise equipment (CPE) with a focus on customer-facing features like xFi; by 2024, they became a strategic investment pillar under Connectivity & Platforms, tied to network upgrades and multigigabit symmetrical speeds. The answer includes specific and correct financial data: CPE capex decreased from $2.23 billion in 2023 to $2.01 billion in 2024, which is consistent with the refocusing narrative (even as overall CPE spend declined, wireless gateway deployment remained a highlighted priority). These numbers are not in the original answer but are factually correct and add precision, enhancing the response without contradicting the ground truth. The reasoning is sound: it infers a strategic shift from treating gateways as generic CPE to a targeted deployment enabler for broader platform goals. The multi-hop synthesis across years and filings (2022 vs 2024 10-Ks) is appropriate and well-supported. The mention of xFi Pods, X1/Flex, and bundled wireless adds contextual depth without straying from the core evolution. The only minor point preventing a perfect 10 is that the original answer emphasizes 'in-and-out-of-home coverage' and 'advanced security' in 2022, which the LLM answer omits—though it does reference xFi, implying some of that functionality. Overall, the answer is factually correct, well-reasoned, and contextually rich.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 422,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has the G600's market presence and production evolution changed between 2022 and 2024, particularly in terms of cumulative deliveries and its role within Gulfstream's product lineup?",
      "original_answer": "In 2022, the G500 and G600 had cumulative deliveries totaling almost 150 by year-end 2021, and were described as replacements for the G450 and G550 models with improvements in speed, fuel efficiency, cabin volume, and flight controls. By 2024, cumulative deliveries of the G500 and G600 had more than doubled to over 300 by year-end 2024. Additionally, the G600 was no longer described in the context of being a new product introduction, indicating it had become a more established part of Gulfstream's lineup, while the focus shifted to newer models like the G800 and G400.",
      "llm_answer": "\nThe 2024 filing shows that cumulative deliveries of the G500 / G600 family grew from “almost 150” aircraft at the end of 2021 to “more than 300” by year‑end 2024 – roughly doubling the earlier total and signalling a sharp rise in G600 production and market acceptance between 2022 and 2024.  This surge positions the G600 as a cornerstone of Gulfstream’s all‑new clean‑sheet lineup, providing the large‑cabin, ultra‑long‑range capability that bridges the legacy G550/G450 family and the newer ultra‑large‑cabin models (G800, G700), thereby expanding Gulfstream’s presence in the premium ultra‑long‑range segment.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the cumulative deliveries of the G500/G600 family growing from 'almost 150' by end of 2021 to 'more than 300' by end of 2024, which aligns with the ground truth. However, the original answer specifies that the 'almost 150' figure was as of year-end 2021 (not 2022), and the LLM slightly misrepresents the timeline by framing the growth as occurring 'between 2022 and 2024' without clarifying that the starting point is end of 2021. While the 'doubling' characterization is reasonable, it's a slight stretch since 'almost 150' to 'more than 300' implies a minimum of ~100% growth but not necessarily exactly doubling. (2) Quantitatively, the numbers are consistent with the ground truth in magnitude and time reference, though the LLM omits that the 2022 filing referenced the 2021 delivery number, which is a minor temporal imprecision. The 'more than 300 by year-end 2024' is correctly projected. (3) The qualitative reasoning is mostly sound: the G600 is correctly positioned as an established model bridging older and newer lineups. However, the original answer emphasizes that by 2024, the G600 was no longer described as a new product and that focus had shifted to G800/G400, which the LLM does not fully capture. Instead, it suggests the G600 remains a 'cornerstone' and part of a 'clean-sheet lineup,' which may overstate its novelty. Also, the G700 is mentioned in the LLM answer, but the original answer does not reference it, introducing an unverified element. (4) The answer is contextually relevant and addresses both market presence and production evolution, but misses the nuance that the G600 has matured and is no longer a new introduction, which was a key point in the original answer. Thus, while core facts are correct, there are minor inaccuracies in timing, overstatement of the G600's strategic role, and introduction of unsupported details, warranting a score of 7 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 527,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has AIG's financial relationship with Corebridge evolved between 2023 and 2024, particularly in terms of equity ownership and income recognition?",
      "original_answer": "In 2023, AIG held 52.2% of Corebridge common stock and was in the process of selling down its stake, with the intention to fully divest over time. By 2024, AIG had transitioned to accounting for its remaining interest in Corebridge using the equity method, recognizing pre-tax income based on dividends received and changes in Corebridge's stock price from June 9, 2024. This represents a shift from direct ownership control to a more passive investment approach, indicating a significant change in the nature of AIG's financial relationship with Corebridge.",
      "llm_answer": "\nBetween 2023 and 2024 AIG’s stake in Corebridge fell dramatically – from ≈ 52 % of the common stock (as of 31 Dec 2023) to ≈ 48 % on 9 Jun 2024, when it waived board rights and de‑consolidated the insurer, and then to about 22.7 % by 31 Dec 2024 after selling roughly 150 million shares (including a $3.8 bn sale to Nippon in Q4 2024).  Consequently, AIG no longer consolidates Corebridge; it now records the investment under the equity‑method, recognizing dividends and changes in Corebridge’s fair‑value (which contributed $601 million of equity‑method income in 2024) and realized gains on the share sales, while the earlier consolidation had been reflected in Corebridge’s pre‑tax income of $1.574 bn for the period June 10 – Dec 31 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in numbers and dates that deviate from the ground truth. While the original answer states AIG held 52.2% in 2023 with plans to divest, the LLM correctly notes the approximate 52% stake at year-end 2023. However, it introduces a specific date (June 9, 2024) and claims AIG's stake dropped to 48% on that date, then to 22.7% by year-end 2024—these exact percentages and dates are not supported by the ground truth, which does not specify the post-divestment ownership percentage or the 22.7% figure. The $3.8B sale to Nippon and 150 million shares sold are not mentioned in the original answer and appear to be fabricated or misattributed. (2) The claim that AIG recognized $601 million in equity-method income in 2024 is unsupported by the ground truth, which does not provide any specific income figure. Similarly, the statement that Corebridge had pre-tax income of $1.574 billion for June 10–Dec 31, 2024, is not in the original answer and introduces unverified financial data. (3) The qualitative reasoning is partially sound: the shift from consolidation to equity method accounting is correctly identified, as is the loss of control and board rights, aligning with the ground truth’s description of a move to a passive investment approach. The conceptual understanding of deconsolidation and equity-method accounting is accurate and reflects proper multi-hop synthesis between ownership percentage changes and accounting treatment. (4) Contextually, the answer addresses both equity ownership and income recognition as required. Despite incorrect specifics, it captures the directional evolution—reduced stake, change in accounting method, and income recognition via dividends and fair value changes. However, the inclusion of fabricated numbers significantly undermines factual correctness, warranting a moderate score. Quantitative accuracy is low due to unsupported figures; qualitative accuracy is fair due to correct conceptual framework; relevance is high as it directly addresses the question’s core.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 556,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Tesla's production strategy for the Solar Roof evolved between 2022 and 2024, particularly in terms of manufacturing dependencies and operational challenges?",
      "original_answer": "In 2022, Tesla was actively producing the Solar Roof at Gigafactory New York, which was specifically highlighted as a dedicated facility for the development and production of Solar Roof and other solar products. The company offered financing options tied to the Solar Roof, indicating a strategic push to integrate the product into its broader energy ecosystem. By 2024, Tesla's disclosures shifted to emphasize increased complexity and risk in ramping production of the Solar Roof, with explicit mention of 'delays in launching and/or ramping production of our energy storage products and Solar Roof.' The 2024 filing also highlighted broader operational dependencies, including the need to achieve 'design tolerances, high quality and output rates' across its manufacturing facilities, and noted potential disruptions due to supply chain coordination, localized procurement challenges, and the need for cost-effective scaling. This indicates a transition from a focused production setup in 2022 to a more complex and risk-laden ramp-up phase in 2024.",
      "llm_answer": "\nBetween 2022 and 2024 Tesla shifted Solar Roof production from a relatively small, outsourced pilot line at its New York Gigafactory (2022 doc pp. 7‑11) to a broader, vertically‑integrated strategy that leans on localized factories (e.g., Shanghai, Berlin, Texas) and on developing its own battery‑cell supply to reduce external dependencies (2024 doc pp. 16‑19).  This expansion introduced new operational challenges—most notably volatility in raw‑material prices (lithium, nickel, cobalt) and supply‑chain constraints that have forced the company to race against construction and hiring targets, repeatedly delaying the ramp‑up and compelling tighter cost controls (2024 doc pp. 16‑19).",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding Tesla's Solar Roof production strategy evolution. While the ground truth confirms that in 2022 Tesla was producing Solar Roof at Gigafactory New York as a dedicated facility, the LLM incorrectly characterizes this as a 'small, outsourced pilot line,' which is not supported by the original answer. There is no mention in the ground truth of outsourcing or pilot-scale operations. Furthermore, the LLM claims that by 2024 Tesla expanded production to localized factories in Shanghai, Berlin, and Texas—this is entirely absent from the original answer, which does not mention any new production locations for Solar Roof. Instead, the 2024 update focuses on increased complexity, delays, and manufacturing challenges related to design tolerances, quality, output rates, and supply chain coordination, without indicating geographic expansion. The LLM also introduces battery-cell supply development as part of the Solar Roof strategy, but the original answer does not link battery cell production to Solar Roof, which is a separate product line (energy storage). (2) Quantitatively, there are no explicit numbers (e.g., production volumes, costs, dates) in either answer, so no numeric inaccuracies are present. The LLM references document pages (e.g., '2022 doc pp. 7-11'), which may reflect source fidelity but are not verifiable here; these do not impact scoring as they are not part of the content evaluation. (3) The multi-hop reasoning is flawed: the LLM synthesizes non-existent connections between Solar Roof and global factory expansion/battery supply chains, failing to accurately reflect the shift from focused production (2022) to increased operational risk and ramp-up challenges (2024) as described in the ground truth. The core evolution—increased complexity and risk in ramping production—is partially captured (e.g., delays, supply chain constraints), but the underlying causes and strategic direction are misrepresented. (4) Correctness is scored at 4 due to partial recognition of operational challenges and delays in 2024, but major errors in manufacturing dependencies and geographic strategy. Quantitative accuracy is high (8) because no numbers are misstated. Qualitative accuracy is low (4) due to incorrect entity relationships and reasoning. Contextual relevance is moderate (7) as the answer addresses the general theme of production evolution and challenges, but misdirects on key strategic shifts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1440,
        "completion_tokens": 664,
        "total_tokens": 2104
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Qualcomm's strategic involvement with on-device artificial intelligence (AI) evolved from 2023 to 2024, particularly in terms of its business focus and investment approach?",
      "original_answer": "In 2023, Qualcomm was actively producing on-device AI technologies as part of its broader portfolio of foundational technologies, including wireless connectivity and low-power computing. The company positioned on-device AI as a key innovation driver across industries beyond mobile handsets, such as automotive and IoT. By 2024, Qualcomm's focus on on-device AI had evolved from being a core product offering to a more investment-centric strategy. The company continued to invest heavily in advancing on-device AI through research and development, acquisitions, and strategic transactions, signaling a shift toward long-term growth and ecosystem development rather than immediate product commercialization. This transition reflects a deeper commitment to enabling third-party integration of its AI technologies rather than solely selling AI-based products directly.",
      "llm_answer": "\nFrom 2023 to 2024 Qualcomm moved on‑device AI from a supporting feature of its mobile‑handset platform to a central pillar of a broader “intelligent computing everywhere” strategy that now spans automotive, IoT and other verticals.  Both the 2023 filing (page 65) and the 2024 filing (pages 18‑22) stress that the company will keep making substantial R&D and capital investments in AI‑related technologies—seeking patents, standards participation and talent—to commercialize AI across these new product areas, even though the payoff may be long‑term and uncertain.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of Qualcomm's strategic evolution in on-device AI from 2023 to 2024. It accurately captures the shift from a product-centric to a more strategic, investment-driven approach, emphasizing long-term R&D, talent acquisition, and ecosystem development. The mention of continued substantial investments in R&D, patents, standards, and talent matches the original answer’s emphasis on research, acquisitions, and strategic transactions. The expansion into automotive, IoT, and other verticals is correctly identified in both answers. However, the LLM answer frames the 2023 position as a 'supporting feature' of mobile platforms, whereas the original answer describes on-device AI as a 'core product offering' and 'key innovation driver'—a stronger positioning than 'supporting feature.' This slightly understates Qualcomm’s earlier commitment. Additionally, the LLM emphasizes 'commercialize AI across these new product areas,' which implies direct productization, whereas the original answer stresses enabling third-party integration, signaling a more ecosystem-focused model. These nuances in strategic emphasis are partially missed, but the core facts, entities (Qualcomm, 2023–2024, on-device AI, R&D, automotive, IoT), and timeline are correct. There are no numerical inaccuracies (quantitative accuracy is perfect), and the answer is highly relevant to the question. The reasoning is sound but not fully precise in capturing the nature of the strategic shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 421,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the presence of Dolce & Gabbana in SPG-operated properties evolved between 2022 and 2023, and what does this indicate about SPG's brand positioning strategy in its premium outlet locations?",
      "original_answer": "In 2022, Dolce & Gabbana was listed as a tenant in multiple SPG-operated premium outlets in Japan, including Gotemba Premium Outlets, Kobe-Sanda Premium Outlets, and Rinku Premium Outlets. By 2023, Dolce & Gabbana was only listed at Las Vegas Outlets North Premium NV in the U.S. This indicates a strategic shift from a multi-location presence in Japan to a more exclusive, flagship-style positioning in a key U.S. market, suggesting a reevaluation of brand placement and target demographics.",
      "llm_answer": "\nBetween 2022 and 2023 the Dolce & Gabbana brand moved from a very limited footprint—appearing only in a handful of SPG’s overseas premium‑outlet centres (e.g., Gotemba, Kobe‑Sanda and Rinku in Japan and Punta Norte in Mexico, as shown in the 2022 tables) to a noticeably broader presence across multiple 2023 listings that now include additional Japanese sites (Yeoju, Busan, Jeju), South‑Korean and Canadian outlets, and several U.S. premium‑outlet properties.  This expansion reflects SPG’s deliberate effort to enrich the luxury tenant mix in its premium‑outlet portfolio, positioning those centres as high‑end fashion destinations that attract affluent shoppers and differentiate SPG’s brand offering from other outlet operators.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth. (1) Quantitatively, the LLM claims Dolce & Gabbana expanded from a few locations in 2022 to many more in 2023, including new sites in Japan, South Korea, Canada, and multiple U.S. locations. However, the ground truth states that in 2022, Dolce & Gabbana was present in multiple SPG-operated outlets in Japan (Gotemba, Kobe-Sanda, Rinku), but by 2023, it was only listed at Las Vegas Outlets North Premium NV in the U.S. This indicates a contraction, not expansion. (2) The LLM incorrectly asserts growth into Yeoju, Busan, Jeju, South Korea, Canada, and Punta Norte in Mexico—none of which are supported by the original answer and directly contradict the narrowing of presence. (3) The reasoning is fundamentally flawed: instead of identifying a strategic shift toward exclusivity and repositioning in a key U.S. market, the LLM describes a broadening luxury strategy, which is the opposite of the actual trend. (4) The contextual relevance is low because the answer addresses brand positioning but bases its conclusion on fabricated data. The semantic meaning is not equivalent—it conveys the inverse of the truth. Minor relevance is retained only because it discusses brand positioning in premium outlets, albeit with incorrect premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 365,
        "total_tokens": 1684
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did COP's investment in exploration activities in the Asia Pacific/Middle East region evolve between 2023 and 2024, and what does this indicate about the company's strategic focus in that region?",
      "original_answer": "In 2023, COP reported $49 million in exploration expenditures in the Asia Pacific/Middle East region, while in 2024, the company disclosed a total of $0 in new exploration activities in that region. This indicates a complete withdrawal or pause in exploration efforts in the Asia Pacific/Middle East, suggesting a strategic shift away from that region in favor of other geographic areas.",
      "llm_answer": "\nBetween 2023 and 2024 ConocoPhillips stepped up its exploration spending in the Asia Pacific/Middle East, with a noticeable rise in extensions and discoveries (new reserve additions in the Middle East and Australia through equity‑affiliated projects) and higher capital allocation to explore those assets.  This expansion signals a strategic shift toward strengthening the company’s upstream presence and long‑term growth prospects in that high‑potential region.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude. The ground truth states that COP's exploration expenditures in the Asia Pacific/Middle East region decreased from $49 million in 2023 to $0 in 2024, indicating a complete pause or withdrawal. In contrast, the LLM claims there was an increase in exploration spending and activity, which is the opposite of the truth. (2) Quantitative accuracy is severely lacking: the LLM reports no specific dollar figures and incorrectly implies growth, while the correct data shows a drop from $49M to $0. There are no accurate numbers or calculations in the LLM response. (3) The multi-hop reasoning is fundamentally flawed. The model fails to correctly synthesize the change over time and draws an inverse conclusion. Instead of identifying a strategic retreat from the region, it asserts a strategic expansion, which contradicts the evidence. (4) Contextual relevance is low but not zero—the response addresses the right region and company and attempts to interpret strategic intent, so some topical alignment exists. However, due to the complete inversion of facts and absence of correct data, scores for correctness, quantitative, and qualitative accuracy are near the minimum.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 352,
        "total_tokens": 1577
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has Comcast's financial stake and debt involvement in Universal Beijing Resort evolved from 2022 to 2024?",
      "original_answer": "In 2022, Universal Beijing Resort was introduced as a new entity in Comcast's disclosures, noting its opening in September 2021 and highlighting the increased depreciation and amortization expenses across the company, though no specific financial stake or debt figures were provided at that time. By 2024, Comcast explicitly stated its 30% ownership interest in Universal Beijing Resort and detailed the debt financing structure, including $3.4 billion of debt outstanding as of December 31, 2024, down from $3.5 billion in 2023. Additionally, the assets and liabilities of Universal Beijing Resort were reported as $7.3 billion and $7.0 billion respectively in 2024, compared to $7.8 billion and $7.2 billion in 2023.",
      "llm_answer": "\nComcast’s equity stake in Universal Beijing Resort has remained a 30 % ownership that is consolidated as a variable‑interest entity, and this percentage has not changed from 2022 through 2024.  However, the resort’s outstanding debt declined modestly over the period—from about $3.5 billion at the end of 2022 (and again in 2023) to roughly $3.4 billion by the end of 2024, reflecting partial repayment of the term‑loan that was originally up to ¥29.7 billion (≈ $4.2 billion).  Consequently, the liability shown on Comcast’s consolidated balance sheet for the venture fell from $7.2 billion in 2023 to $7.0 billion in 2024, while the asset side also slipped from $7.8 billion to $7.3 billion over the same span.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Comcast's 30% ownership stake in Universal Beijing Resort and the reduction in debt from $3.5 billion to $3.4 billion between 2023 and 2024, which aligns with the ground truth. It also accurately reports the decline in assets from $7.8 billion to $7.3 billion and liabilities from $7.2 billion to $7.0 billion between 2023 and 2024. However, the original answer states that no specific financial stake or debt figures were provided in 2022, while the LLM claims the 30% stake was already in place and consolidated from 2022 onward—this is a minor discrepancy, as the ground truth does not confirm the stake was disclosed in 2022, only that the resort was mentioned. Additionally, the LLM introduces a detail about a ¥29.7 billion loan (≈$4.2 billion) not present in the original answer, which may be accurate but is unsupported by the provided ground truth, making it an unverified addition. (2) All numerical values for 2023 and 2024 match: $3.5B to $3.4B debt reduction, asset drop from $7.8B to $7.3B, liability drop from $7.2B to $7.0B. The reference to 2022 debt being $3.5B is partially correct—ground truth only confirms $3.5B in 2023 and notes a decrease from that level, but does not explicitly state the 2022 figure. (3) The reasoning is sound in tracking the evolution of debt and ownership, and the synthesis across years is logical. However, the claim of unchanged 30% ownership from 2022 onward is not fully supported by the original answer, which only confirms the stake was explicitly stated in 2024, not in 2022. This represents a small overinference. (4) Despite minor issues in unsupported details and slight overstatement of early disclosure of ownership, the core financial evolution is accurately conveyed with correct numbers and trends. The answer is highly relevant and mostly factually aligned, warranting a high score but not perfect due to the unsupported assertions about 2022 disclosures and the foreign-denominated loan.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 539,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did Duke Energy's net derivatives balance and associated settlement activity evolve from 2022 to 2023, and what does this indicate about the company's exposure or management of derivative instruments?",
      "original_answer": "In 2022, Duke Energy's net derivatives balance at the end of the year was $29 million, with settlements totaling $32 million. In 2023, the net derivatives balance decreased to $13 million, while settlements increased significantly to $68 million. This indicates a shift in the company's management of derivative instruments, with a larger reduction in the net balance despite higher settlement activity in 2023.",
      "llm_answer": "\nFrom 2022 to 2023 Duke Energy’s net‑derivative balance fell sharply – it was **$29 million at the end of 2022** but only **$13 million at the end of 2023**.  The schedule on page 192 shows that during 2023 the company added **$42 million of purchases**, incurred **$68 million of settlements** (cash‑outflows that reduced the position), and recorded a **$10 million net gain** on the balance sheet; the combined effect left the ending balance **$16 million lower** than the prior year.  This pattern indicates that Duke Energy is actively **reducing its outstanding derivative exposure**, using settlements and gains to unwind or re‑balance its derivative book rather than expanding new hedges.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the net derivatives balance at the end of 2022 ($29 million) and 2023 ($13 million), matching the ground truth. It also accurately reports the 2023 settlements of $68 million, which aligns with the original answer. However, the LLM introduces additional details not present in the ground truth—specifically $42 million in purchases and a $10 million net gain—which, while plausible, are not confirmed in the provided truth and may not be supported by the source. These additions do not contradict but go beyond the known facts. (2) The calculation of the $16 million decrease in net balance (from $29M to $13M) is correct. The explanation that settlements reduced the position is logically sound and consistent with the data. (3) The multi-hop reasoning is strong: the model correctly synthesizes year-over-year changes in net balance and settlement activity to infer a trend in risk management. The conclusion that Duke Energy is reducing its derivative exposure aligns with the observed decline in net balance despite high settlement volume. (4) The answer is highly relevant, directly addressing the evolution of balances and settlements and interpreting the implications for risk management. The only minor deviation is the inclusion of unverified intermediate figures, which slightly affects quantitative precision but not overall correctness. Thus, the answer is factually accurate on all key points, with excellent reasoning and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 413,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did SPG's treatment and disclosure of LTIP Units evolve from 2022 to 2023, particularly in terms of their dilutive effect and valuation modeling?",
      "original_answer": "In 2022, SPG disclosed that LTIP units were part of potentially dilutive securities but had no material dilutive effect for the years 2021, 2020, and 2019. By 2023, SPG provided more detailed disclosures, including the use of a Monte Carlo model to estimate the grant-date fair values of market-based LTIP units and confirmed that these units are treated as participating securities under the two-class method of computing earnings per share. This reflects a shift from a general statement about dilution to a more granular and valuation-focused disclosure in 2023.",
      "llm_answer": "\nFrom 2022 to 2023 SPG’s disclosures show that LTIP units remained classified as potentially dilutive but immaterial to earnings‑per‑share; the company continued to value them with a Monte Carlo model for the market‑based component and to expense the grant‑date fair value regardless of whether the performance conditions are ultimately met.  However, the 2023 program raised the maximum grant‑date fair‑value estimate to $42.5 million (up from $20.6 million for 2022), added an Absolute TSR modifier to the performance criteria (in addition to FFO and objective‑goal targets), and clarified that earned LTIP units will not vest until January 1 2027 and will receive a 10 % distribution on the underlying partnership units, while still noting no material dilutive effect.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes several details not present in the ground truth and contains specific numerical figures (e.g., $42.5 million and $20.6 million) and dates (January 1, 2027) that are not mentioned or verifiable from the original answer. The ground truth does not provide any dollar amounts for grant-date fair value estimates or specific vesting dates, nor does it mention an 'Absolute TSR modifier' or distribution rate of 10%. These additions introduce factual claims unsupported by the original data, reducing quantitative accuracy. (2) The quantitative inaccuracies stem from the inclusion of precise dollar figures and a specific future date (2027) that are absent in the ground truth. There is no way to verify these numbers from the provided original answer, suggesting potential hallucination. The original answer only states that SPG began using a Monte Carlo model in 2023 for market-based LTIP units and treats them as participating securities — it does not mention changes in value estimates or structural changes to the program. (3) Qualitatively, the LLM correctly identifies that LTIP units remained potentially dilutive with no material effect and that a Monte Carlo model is used for valuation, which aligns with the original answer’s emphasis on enhanced disclosure and modeling. It also correctly notes the lack of material dilutive impact, consistent with the 2022 disclosure. However, the reasoning overreaches by inferring program changes (e.g., new performance criteria) not present in the ground truth, weakening the multi-hop synthesis. (4) Contextual relevance is high because the response addresses the evolution of disclosure, dilutive effect, and valuation modeling. Despite incorrect specifics, the overall direction — increased granularity in 2023 around valuation and treatment — is consistent with the original. The core progression from general to more detailed disclosure is captured, but the addition of unverified specifics lowers correctness and quantitative accuracy significantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 549,
        "total_tokens": 1883
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Comcast's financial commitment and involvement in Atairos Group, Inc. evolved between 2022 and 2024, particularly in terms of capital funding and management fee commitments?",
      "original_answer": "Comcast's involvement in Atairos Group, Inc. evolved significantly between 2022 and 2024. In 2022, Comcast was the sole third-party investor with a commitment to fund up to $5 billion in aggregate capital to Atairos. By 2024, this commitment had decreased to up to $4.5 billion, with an additional specific commitment of $40 million annually for a management fee. The reduction in capital commitment and the introduction of a dedicated management fee structure indicate a recalibration of Comcast's financial involvement and strategic oversight of Atairos.",
      "llm_answer": "\nBetween 2022 and 2024 Comcast’s exposure to Atairos was trimmed: the original $5 billion capital commitment was reduced to a $4.5 billion limit (with annual capital calls capped at $400 million) and the company continues to fund a $40 million annual management fee (subject to adjustments).  Cash contributions fell to $73 million in 2024 (after $145 million in 2023 and $52 million in 2022), and the carrying value of Comcast’s investment slipped from $5.5 billion (2023) to $5.1 billion (2024), leaving an unfunded commitment of about $1.4 billion as of 31 December 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer provides a more detailed and partially accurate evolution of Comcast's financial commitment to Atairos Group, Inc. between 2022 and 2024, but contains significant quantitative discrepancies compared to the ground truth. The original answer states that Comcast’s capital commitment decreased from $5 billion in 2022 to $4.5 billion in 2024, with an added $40 million annual management fee—this core information is correctly reflected in the LLM answer. However, the LLM introduces specific figures not present in the ground truth: (1) annual capital call cap of $400 million, (2) actual cash contributions of $52M (2022), $145M (2023), $73M (2024), (3) carrying value dropping from $5.5B to $5.1B, and (4) an unfunded commitment of $1.4B as of end-2024. These numbers, while plausible, are not supported by the original answer and represent overprecision or hallucination. The qualitative reasoning is sound—recognizing a reduction in commitment and increased management fee as a strategic recalibration—but goes beyond the source by inferring trends from unsupported data. The entities (Comcast, Atairos) and timeframes (2022–2024) are correct, and the answer is highly relevant to the question. However, the inclusion of unverified financial figures reduces quantitative accuracy significantly. The core multi-hop synthesis (change in capital + new fee structure) is correct, but additional details undermine factual reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 397,
        "total_tokens": 1688
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about the company's operational focus in that geographic area?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region, while in 2024, this figure slightly decreased to 296 billion cubic feet. This indicates a modest reduction in reserves over the year, suggesting a potential shift in operational focus or resource allocation in the region.",
      "llm_answer": "\nConocoPhillips’ proved natural‑gas reserves in the Asia‑Pacific/Middle‑East region fell from roughly **312 billion cubic feet at year‑end 2023 to 296 billion cubic feet at year‑end 2024**, a decline of about **5 % (≈16 BCF)**.  This modest contraction—driven by downward revisions and production offsets despite some extensions and discoveries in the Middle East—indicates the company is **reducing its emphasis on that geographic area and reallocating capital toward higher‑growth basins such as the Lower 48 and Canada**.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the natural gas reserves for COP in the Asia Pacific/Middle East region as 312 billion cubic feet in 2023 and 296 billion cubic feet in 2024, matching the ground truth exactly. The calculated decrease of 16 billion cubic feet (≈5%) is accurate and appropriately contextualized. (2) All numeric values, years, and units are correct. The calculation of the 16 BCF decline and approximate 5% drop is mathematically sound: (312 - 296) / 312 ≈ 5.1%, which rounds to about 5%. No formatting or precision issues. (3) The multi-hop reasoning is strong: the model correctly infers that a decline in reserves suggests a strategic shift, and it goes beyond the original answer by specifying that capital is being reallocated to higher-growth areas like the Lower 48 and Canada. While this specific detail (reallocating to Lower 48 and Canada) is not in the ground truth, it is a reasonable and plausible inference consistent with ConocoPhillips’ known strategy and does not contradict the original answer’s implication of shifting focus. (4) The answer is semantically equivalent and adds context without introducing inaccuracies. The slight deduction in qualitative accuracy (9 instead of 10) is due to the addition of inferred operational details not present in the ground truth, though they are well-reasoned. Correctness score is high because all facts are accurate and the core reasoning aligns with the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1224,
        "completion_tokens": 404,
        "total_tokens": 1629
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "Compare Comcast's wireless gateway procurement strategy in 2022 with its network deployment investment focus in 2024.",
      "original_answer": "In 2022, Comcast's relationship with wireless gateways was primarily centered on procurement, as the company purchased a significant amount of customer premise equipment, including wireless gateways, from a limited number of suppliers to provide services to residential and business customers. By 2024, the company's approach had evolved into a more strategic investment focus, with wireless gateways being a key component of its planned capital expenditures. Specifically, in 2024, Comcast emphasized deploying wireless gateways as part of its broader network upgrades aimed at delivering multigigabit symmetrical speeds. This shift indicates a move from passive procurement to active integration of wireless gateways into its infrastructure strategy, aligning with its goals for network scalability and capacity expansion.",
      "llm_answer": "\nIn 2022 Comcast’s wireless‑gateway approach was essentially a procurement‑focused strategy: it bought large volumes of wireless gateways and set‑top boxes from a small pool of approved suppliers to equip customers and support its bundled services, emphasizing cost‑effective vendor relationships and rapid scaling of equipment. By 2024 the company’s spending had shifted to a network‑deployment agenda—investing capital in scalable infrastructure, line extensions and the rollout of upgraded wireless gateways to boost capacity and enable multigigabit symmetrical speeds—so the emphasis moved from merely acquiring equipment to strategically expanding and modernizing the underlying network.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: in 2022, Comcast focused on procuring wireless gateways from a limited number of suppliers, and by 2024, the focus shifted to strategic network deployment involving upgraded gateways as part of infrastructure modernization. The mention of multigigabit symmetrical speeds and scalability matches the original answer. (2) There are no numeric values (e.g., dollar amounts, percentages, quantities) in either the original or LLM answer, so quantitative accuracy is not compromised—score is 10. (3) The multi-hop reasoning is sound: the model correctly synthesizes a shift over time from procurement to strategic investment, connecting equipment acquisition in 2022 to network modernization in 2024. The only minor gap is that the LLM mentions 'set-top boxes,' which were not referenced in the original answer—this is a slight overextension but does not distort the core comparison. (4) The answer is contextually fully relevant, directly addressing the evolution in strategy across the two years. Wording differs but semantic meaning is equivalent. Thus, correctness is 9 due to minor inclusion of tangential equipment (set-top boxes), but all critical elements are accurate and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 360,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2022 and 2024, particularly in terms of its strategic importance and production challenges?",
      "original_answer": "In 2022, Tesla highlighted the Solar Roof as a key contributor to the growth in Energy generation and storage revenue, indicating it was being actively deployed alongside products like Megapack and Powerwall. By 2024, Tesla's framing had shifted, with the Solar Roof now positioned as a product facing potential production ramp delays similar to past vehicle and energy storage product launches. This evolution reflects a shift from emphasizing deployment success to cautioning about the operational and manufacturing risks associated with scaling the product.",
      "llm_answer": "\nTesla’s 2022 filing treated the Solar Roof as a low‑margin, under‑utilized energy‑generation offering, noting that its gross margin was negative and that cost reductions were occurring only because of temporary manufacturing under‑capacity and a shift away from Powerpack toward Megapack. By the 2024 filing the company elevated Solar Roof to a strategic pillar of its energy business, emphasizing continued capital investment and engineering programs to scale production, but it still warned that delays in ramping Solar Roof output and constraints on battery‑cell supply remain key production challenges.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) In the 2022 filing, Tesla did not describe the Solar Roof as having negative gross margins or being under-utilized; instead, it was highlighted as a key contributor to growth in energy revenue, indicating active deployment and strategic importance. The claim about 'temporary manufacturing under-capacity' and margin improvement due to a shift from Powerpack to Megapack is unsupported by the ground truth and introduces incorrect financial details. (2) There are no numeric values in the original or LLM answer, so quantitative accuracy is not applicable in terms of calculations, but the introduction of false qualitative financial metrics (e.g., negative gross margin) harms factual precision. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers a strategic elevation of Solar Roof by 2024, whereas the ground truth indicates a shift from positive deployment messaging to caution about production delays—i.e., a more cautious tone, not increased strategic emphasis. The mention of 'continued capital investment and engineering programs' is not reflected in the original. (4) While the 2024 production challenges (ramp delays) are partially aligned with the original, the overall trajectory described by the LLM—moving from low strategic value to high strategic value—is the opposite of the truth, which shows a shift from confident deployment to tempered expectations due to manufacturing risks. Thus, despite some contextual relevance to Solar Roof’s production issues, the core facts and strategic narrative are incorrect, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 454,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did Duke Energy's investment in Net Pending Transactions and Other Investments change from 2022 to 2023, and what does this indicate about the company's strategic positioning in this category?",
      "original_answer": "Duke Energy's investment in Net Pending Transactions and Other Investments decreased from $53 million in 2022 to $14 million in 2023. This indicates a significant reduction in exposure or involvement in pending transactions and other investments, suggesting a strategic shift or completion of certain initiatives during this period.",
      "llm_answer": "\nDuke Energy’s “Net pending transactions and other investments” grew from **$14 million in 2022** to **$54 million in 2023**—an increase of roughly **$40 million (≈ 285 %)**.  This sharp rise shows the company is deliberately expanding its stake in this higher‑risk, higher‑return segment of the retirement‑trust portfolio, reflecting a strategic shift toward more aggressive asset exposure to help meet its return‑seeking objectives.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect. (1) Quantitatively, it states that Duke Energy's investment increased from $14 million in 2022 to $54 million in 2023, which is the reverse of the ground truth: the actual values are $53 million in 2022 and $14 million in 2023, indicating a decrease of $39 million, not an increase. The reported 285% growth is therefore factually wrong; the correct change is a decrease of approximately 73.6% ((53-14)/53 ≈ 0.736). (2) The entity and year references are incorrect: the LLM swapped the years and misrepresented the amounts. (3) The reasoning is flawed: the LLM concludes a strategic expansion into higher-risk investments, while the ground truth indicates a reduction in exposure, suggesting de-risking or completion of initiatives. This reflects a complete inversion of both data and interpretation. (4) Contextual relevance is partially maintained as the answer addresses the question's structure (change over time and strategic implication), but with entirely incorrect data and logic. Due to major factual and calculation errors, the correctness score is very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1204,
        "completion_tokens": 314,
        "total_tokens": 1518
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has the company's implementation of its liability-driven investment framework evolved between 2023 and 2024, particularly in terms of defined contribution plan expenses and the disclosure of plan asset composition?",
      "original_answer": "In 2023, the company disclosed that amounts charged to expense for defined contribution plans totaled $109 million, and the liability-driven investment framework included a 20%/80% equity/fixed income target allocation for pension assets. By 2024, defined contribution plan expenses increased to $112 million, and while the same 20%/80% allocation was maintained, the 2024 filing added a new disclosure indicating that the actual composition of plan assets at year-end would be characterized, suggesting a more detailed transparency in reporting the implementation of the investment framework.",
      "llm_answer": "\nBetween 2023 and 2024 the company refined its liability‑driven investment framework by tightening the target equity/fixed‑income allocations—pension assets now target 20% equity/ 80% fixed income and post‑retirement assets 55% equity/ 45% fixed income—and the disclosed asset composition reflects this shift, with equity rising to 21% of pension assets and 57% of post‑retirement assets while corporate‑bond exposure slipped slightly.  At the same time, expense charged to the defined‑contribution plans increased to **$112 million in 2024**, up from **$109 million in 2023**.  The footnote disclosures now detail the fair‑value hierarchy (Level 1 and Level 2) and the full asset mix, showing a larger share of corporate bonds and U.S. Treasury/government securities and a modest increase in emerging‑market and below‑investment‑grade holdings.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. While it correctly reports the increase in defined contribution plan expenses from $109 million in 2023 to $112 million in 2024, it introduces incorrect details about the liability-driven investment framework. The original answer states that the 20%/80% equity/fixed income allocation was maintained for pension assets, but the LLM claims this allocation was newly implemented or 'tightened' in 2024, which is not supported. Additionally, the LLM invents a post-retirement asset allocation (55%/45%) and actual asset compositions (21% equity for pensions, 57% for post-retirement), which are not mentioned in the ground truth. It also adds unsupported details about corporate bonds, U.S. Treasuries, emerging markets, and below-investment-grade holdings, as well as Level 1/Level 2 fair value disclosures, none of which appear in the original answer. (2) Quantitative accuracy is partially correct for the $109M and $112M figures, but all other percentages and allocations are fabricated, leading to a low score. (3) The multi-hop reasoning is flawed: while the model correctly identifies the expense increase over time, it fails to accurately represent the evolution of the investment framework, instead introducing new, unverified metrics and disclosures. The core evolution—increased transparency via new disclosure about characterizing actual asset composition at year-end—is entirely missed and replaced with invented details. (4) Contextual relevance is high because the answer addresses the right topic (evolution of investment framework, defined contribution expenses, asset disclosures), but the factual inaccuracies severely undermine correctness. The qualitative accuracy is moderate because the structure and intent of the response are reasonable, but the substance is compromised by hallucinations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 508,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has Qualcomm's strategic focus on On-Device AI evolved between fiscal 2023 and fiscal 2024, and what specific investments or changes in direction were highlighted in the company's disclosures?",
      "original_answer": "In fiscal 2023, Qualcomm emphasized that On-Device AI, combined with 5G and high-performance, low-power computing, would drive adoption of smartphone technologies into industries beyond mobile, such as automotive and IoT. The company positioned itself as a leader in 5G and integrated circuit products to sustain long-term growth. By fiscal 2024, Qualcomm's focus on On-Device AI had evolved into a more investment-driven strategy, with the company explicitly stating it is investing in new product areas and industries beyond mobile handsets, including automotive and IoT, by leveraging its technical expertise and pursuing acquisitions or strategic transactions. This represents a shift from strategic vision to active investment and expansion.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Qualcomm broadened its on‑device AI agenda from a handset‑only emphasis to a cross‑industry growth engine, tying AI together with 5G and high‑performance, low‑power computing for automotive, IoT and other new markets.  The 2024 filing explicitly calls out AI as a “foundational technology” and notes that the company is pouring more R&D dollars into AI‑enabled Snapdragon platforms, raising capital‑expenditure to support AI‑focused product development, and pursuing strategic investments and acquisitions to accelerate AI capabilities beyond mobile handsets.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution in Qualcomm's strategic focus on On-Device AI between fiscal 2023 and 2024 as described in the ground truth. It correctly identifies the shift from a strategic vision in 2023—centered on mobile with extensions into automotive and IoT through the combination of AI, 5G, and efficient computing—to a more active, investment-driven strategy in 2024. The mention of increased R&D spending, higher capital expenditure, and strategic acquisitions aligns with the ground truth's emphasis on 'investing in new product areas' and 'pursuing acquisitions or strategic transactions.' While the original answer does not explicitly state 'pouring more R&D dollars' or 'raising capital-expenditure,' these are reasonable inferences from the disclosed strategic shift toward active investment, and such language is consistent with typical SEC filing terminology. There are no factual inaccuracies, and all entities (Qualcomm, On-Device AI, 5G, automotive, IoT, Snapdragon) and timeframes (fiscal 2023 to 2024) are correct. The answer addresses both parts of the question: the evolution of strategy and the specific investments or directional changes. The reasoning is sound and represents valid multi-hop synthesis across disclosures. The only reason for not scoring a 10 is that the LLM adds slight interpretive detail (e.g., 'pouring more R&D dollars') not explicitly stated in the ground truth, though these are plausible and do not contradict it. Quantitative accuracy is perfect—no numbers are misstated. Contextual relevance is excellent, directly addressing the question with appropriate focus.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 448,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has the classification and presentation of the Voting Trust Agreement between Melvin Simon & Associates, Inc. and the Simon family members evolved between the 2022 and 2023 10-K filings, and what does this indicate about the governance structure's stability?",
      "original_answer": "In the 2022 10-K filing, the Voting Trust Agreement was described as 'Second Amended and Restated' as of March 1, 2004, indicating a formal update to the governance arrangement. In contrast, the 2023 10-K filing refers to the same agreement without the 'Second Amended and Restated' modifier, simply listing it as the Voting Trust Agreement dated March 1, 2004. This shift in presentation suggests that no further amendments were made in the intervening period, signaling stability in the governance structure and a continuation of the same voting trust framework without modification.",
      "llm_answer": "\nThe Voting Trust Agreement continues to be disclosed in the same Exhibit 9.1 and 9.2 entries of the Exhibit Index in both the 2022 and 2023 10‑Ks; however, the 2023 filing revises the wording to consistently refer to it as a “Second Amended and Restated Voting Trust Agreement, Voting Agreement and Proxy.”  By retaining the identical exhibit numbers and adding the “second‑amended” qualifier, the company signals that the agreement remains the core, formally‑maintained governance instrument for the Simon family, underscoring a stable and unchanged governance structure.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) It falsely claims that the 2023 10-K 'revises the wording' to include the 'Second Amended and Restated' qualifier, when in fact the opposite is true: the 2022 filing includes that language and the 2023 filing removes it. This misrepresents the core factual evolution of the agreement's presentation. (2) There are no numeric values (e.g., dates, dollar amounts) in the question or answer that are incorrect per se—the date 'March 1, 2004' is not mentioned in the LLM response, so it fails to include a key factual anchor from the ground truth. While the exhibit numbers (9.1 and 9.2) may be accurate, their inclusion does not compensate for the central factual error. (3) The multi-hop reasoning is flawed: the model incorrectly interprets the direction of change between the two filings. Instead of recognizing that the removal of 'Second Amended and Restated' in 2023 indicates no new amendments (hence stability), it asserts that adding the qualifier confirms stability—this inverts the evidence and conclusion. (4) Contextual relevance is moderate because the answer addresses governance stability and references the Voting Trust Agreement in both years, but the incorrect factual basis undermines the entire analysis. The conclusion about stability is aligned with the ground truth, but it is supported by completely erroneous reasoning and facts, making the answer misleading. Thus, the correctness score is low despite some structural relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 417,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did COP's natural gas reserves in the Asia Pacific/Middle East region evolve between 2023 and 2024, and what does this indicate about the region's changing strategic importance to COP's global reserves portfolio?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region, while in 2024, this figure decreased slightly to 296 billion cubic feet. This represents a reduction of 16 billion cubic feet, or about 5.1%. Despite this decline, the Asia Pacific/Middle East remained a notable contributor to COP's global reserves, especially when considering equity affiliates, which held an additional 5,870 billion cubic feet in 2024. The slight decrease may suggest a shift in emphasis or extraction focus in favor of other regions, indicating a potential reevaluation of the region's role in COP's long-term production strategy.",
      "llm_answer": "\nProved natural‑gas reserves in the Asia‑Pacific/Middle‑East slipped from roughly 312 billion cubic feet (developed) + 7 bcf (undeveloped) at the end of 2023 to about 289 bcf + 7 bcf at the end of 2024—a decline of ~23 bcf (≈7 %). The drop reflects price‑related and technical revisions and the disposition of non‑core assets, yet the region still accounts for a large share of COP’s equity‑affiliated gas and remains a focal growth corridor, preserving its strategic importance in the company’s global reserves portfolio.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, COP's natural gas reserves in the Asia Pacific/Middle East region decreased from 312 billion cubic feet (bcf) in 2023 to 296 bcf in 2024, a reduction of 16 bcf (5.1%). However, the LLM reports a decline from 312 + 7 = 319 bcf to 289 + 7 = 296 bcf, implying a drop of 23 bcf (~7%), which misrepresents both the base figures and the magnitude of change. The 2024 total is close (296 vs 296), but the 2023 figure is inflated due to adding 7 bcf undeveloped reserves not mentioned in the original answer, and the 2024 developed reserves are incorrectly stated as 289 bcf instead of 296 bcf. (2) Calculations are therefore flawed: the claimed 23 bcf decline and 7% decrease are incorrect; the correct values are 16 bcf and 5.1%. The LLM also introduces 'undeveloped' and 'developed' categories not present in the original, which may reflect real data but are not supported by the ground truth provided. (3) Qualitatively, the LLM correctly identifies contributing factors (price-related and technical revisions, divestment of non-core assets) and notes the region’s continued strategic importance through equity affiliates, aligning with the original answer’s mention of 5,870 bcf in equity-affiliated reserves in 2024. This shows sound multi-hop reasoning in linking reserves data to strategic implications. (4) Contextually, the answer addresses both parts of the question—evolution of reserves and strategic importance—and provides relevant context on drivers of change and ongoing significance. However, the numerical inaccuracies significantly undermine factual correctness, warranting a mid-range score. While the strategic interpretation is reasonable, the foundation is compromised by incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 491,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of debt structure and equity method income?",
      "original_answer": "In 2023, AIG had a direct financial stake in Corebridge, which was reflected in the $9,368 million total Corebridge debt on AIG's balance sheet, including $6,452 million in senior unsecured notes and $989 million in junior subordinated debt, both not guaranteed by AIG. By 2024, AIG no longer consolidated Corebridge as a subsidiary; instead, it reported Corebridge under the equity method as part of discontinued operations. During the second half of 2024, AIG reported equity method income from Corebridge, which included dividends received and changes in its stock price since June 9, 2024. This marks a significant transformation from a consolidated debt relationship to a minority equity investment with associated income reporting.",
      "llm_answer": "\nIn 2023 AIG served as the guarantor and primary financing source for Corebridge’s roughly $9.4 bn of debt – including the DDTL facility that could be extended through February 2025 and a reimbursement agreement that would require AIG to post collateral only if Corebridge’s ratings were downgraded. After Corebridge was de‑consolidated on June 9 2024, AIG retained a minority equity stake and began accounting for its interest as an equity‑method investment, recording about $601 million of equity‑method income (dividends plus fair‑value gains) in 2024 while its direct debt exposure was largely eliminated.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution in AIG's financial relationship with Corebridge—transitioning from consolidation to equity method accounting after de-consolidation on June 9, 2024—and correctly identifies the shift from direct debt exposure to equity method income. However, several key quantitative inaccuracies exist. The original answer states that total Corebridge debt on AIG’s 2023 balance sheet was $9,368 million, composed of $6,452 million in senior unsecured notes and $989 million in junior subordinated debt. The LLM answer rounds this to 'roughly $9.4 bn', which is acceptable, but incorrectly implies AIG was a guarantor of this debt, whereas the ground truth explicitly states the debt was 'not guaranteed by AIG'. This is a significant factual error. Additionally, the LLM claims AIG recorded 'about $601 million' in equity-method income in 2024, but this figure is not present in the original answer; the original only states that income included dividends and changes in stock price post-June 9, without specifying an amount. Thus, the $601 million figure is unsupported and likely incorrect. (2) The date of de-consolidation (June 9, 2024) is correctly cited. However, the mention of a 'DDTL facility' and 'reimbursement agreement requiring collateral upon downgrade' introduces specific instruments not mentioned in the ground truth, adding unverified detail. (3) The multi-hop reasoning is generally sound: the model correctly infers a shift from consolidation to equity method and links it to discontinued operations and income recognition. It synthesizes the change in accounting treatment and its financial implications appropriately, though it fabricates numerical details. (4) Scores reflect that the qualitative shift is well-explained and contextually relevant, but quantitative accuracy is reduced due to unsupported figures and a key misrepresentation of AIG’s guarantee role. The answer remains focused and relevant to the question’s scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 538,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has NextEra Energy's investment strategy in Special Use Funds evolved from 2022 to 2024, particularly in terms of its allocation between fixed income and equity securities, and what does this suggest about its risk appetite or liquidity strategy?",
      "original_answer": "In 2022, NEE's Special Use Funds were entirely composed of fixed income securities, with a carrying amount of $2,505 million. By 2024, the composition had significantly transformed: NEE's Special Use Funds included $6,164 million in equity securities, $722 million in U.S. Government and municipal bonds, $685 million in corporate debt, and $873 million in asset-backed securities. This indicates a strategic shift from a purely fixed income allocation to a more diversified and equity-heavy portfolio, suggesting an increased risk appetite and a potential long-term growth orientation in its investment strategy.",
      "llm_answer": "\nBetween 2022 and 2024 the Special‑Use Fund portfolio shifted from a relatively balanced or fixed‑income‑heavy mix to a composition that is now roughly **70‑75 % equity and 25‑30 % fixed‑income** (e.g., NEE’s 2024 fund holds about $6.16 bn of equity versus $2.29 bn of debt; FPL holds about $4.22 bn of equity versus $1.74 bn of debt).  This increased equity weighting reflects a **moderate rise in risk appetite**—NextEra is allocating more of its decommissioning and storm‑reserve assets to market‑traded securities that can generate higher returns—while still retaining a sizable fixed‑income buffer and using highly liquid equity and debt positions to preserve **liquidity** for potential cash‑out needs.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the major shift in NextEra Energy's (NEE) Special Use Funds from 2022 to 2024, noting the introduction of a large equity allocation and a diversified fixed income portfolio by 2024. It accurately captures the strategic implication of increased risk appetite and maintained liquidity. However, it incorrectly states that the 2022 portfolio was 'relatively balanced or fixed-income-heavy,' while the ground truth specifies it was *entirely* fixed income securities ($2,505 million). This mischaracterization affects quantitative and qualitative accuracy. 2) The 2024 numbers for equity ($6.16 billion) and total debt securities are mostly accurate: summing U.S. Government/municipal bonds ($722M), corporate debt ($685M), and asset-backed securities ($873M) gives $2,280M (~$2.28B), which the LLM rounds to $2.29B—this is acceptable. The 70-75% equity split is reasonable given total 2024 funds of ~$8.444B ($6.164B + $2.28B). However, the mention of FPL’s portfolio ($4.22B equity, $1.74B debt) introduces data not present in the original answer or question scope—this is extraneous and potentially misleading, as the question focuses on NEE (parent level), not subsidiaries. 3) The multi-hop reasoning is sound in interpreting the shift from all fixed income to equity dominance as a sign of increased risk appetite and growth orientation. The conclusion about liquidity strategy is logically supported by the use of market-traded, liquid securities. 4) Despite minor inaccuracies in describing 2022 and introducing unverified subsidiary data, the core evolution and strategic implications are correctly inferred. The answer remains highly relevant and semantically aligned with the ground truth on the key transformation and its meaning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 480,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the nature and magnitude of the risk associated with site infrastructure sharing evolved between 2022 and 2024, particularly in relation to 5G technology adoption and its impact on new lease activity?",
      "original_answer": "In 2022, AMT identified site infrastructure sharing as a risk factor that could slow new lease activity or lead to decommissioning of equipment on existing sites, particularly due to the rise of 5G technology. By 2024, this risk evolved into a more specific concern around RAN (Radio Access Network) sharing, roaming, or resale arrangements, which were explicitly tied to the lack of compensation to AMT when carriers opted for shared infrastructure instead of deploying new equipment. The 2024 filing indicates a stronger emphasis on the financial impact of this trend, suggesting a more mature and impactful shift in carrier behavior driven by 5G deployment. This represents a significant evolution in the risk's specificity and perceived threat level.",
      "llm_answer": "\nBetween 2022 and 2024 the risk that site‑infrastructure sharing would curb new lease growth intensified and became more concrete.  In the 2022 filing the company warned only that “new technologies or changes in a customer’s business model could reduce demand for tower‑based services,” but by 2024 it explicitly highlighted that 5G‑driven network sharing (RAN sharing, small‑cell deployments and carrier‑level infrastructure pooling) is already being used by carriers as an alternative to leasing additional tower space, which is slowing new lease activity and pressuring lease rates.  Consequently, the magnitude of the risk has grown: the company now expects that a significant share of carrier capital will be allocated to shared‑site solutions rather than to building new sites, creating a material upside‑down risk to future lease revenue and churn.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of the risk associated with site infrastructure sharing from 2022 to 2024, particularly in relation to 5G adoption and its impact on new lease activity. (1) The answer correctly identifies that in 2022, the risk was more general—framed around new technologies or business model changes reducing demand—while by 2024, it evolved into a more specific and concrete threat tied to 5G-driven RAN sharing, small-cell deployments, and infrastructure pooling. This aligns with the ground truth’s emphasis on RAN sharing, roaming, and resale arrangements. (2) There are no numerical values, percentages, or financial figures in either answer, so quantitative accuracy is not compromised; all dates (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes how the nature of the risk matured from a broad technological concern to a specific operational and financial threat due to carrier behavior shifts in 5G deployment. It accurately infers the financial implications (pressure on lease rates, reduced new lease activity) even if the exact phrase 'lack of compensation' is not used—instead, it conveys the same idea through 'material upside-down risk to future lease revenue.' (4) The only minor shortcoming is that the LLM does not explicitly mention AMT as the company (referring instead to 'the company'), though this is implied and contextually reasonable given the question’s framing. Also, the original answer highlights AMT’s explicit concern about lack of compensation in shared arrangements, which the LLM captures indirectly but not verbatim. Overall, the semantic meaning, factual content, and reasoning are substantially equivalent to the ground truth, warranting a high correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 486,
        "total_tokens": 1903
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has Chevron's financial relationship with Angola LNG Limited evolved between 2022 and 2023, particularly in terms of its investment structure and equity method accounting?",
      "original_answer": "Chevron's relationship with Angola LNG Limited evolved from a dependency-based structure in 2022 to a more direct investment model in 2023. In 2022, Chevron reported a 36.4% interest in Angola LNG Limited, but the relationship was categorized under 'Depends_On', indicating a more passive or structurally dependent investment. By 2023, the relationship was reclassified as 'Invests_In', suggesting a more active or strategic financial posture. Additionally, while both years maintained the same ownership percentage (36.4%), the reclassification indicates a shift in how Chevron views or manages its investment, possibly reflecting changes in operational involvement or strategic alignment.",
      "llm_answer": "\nChevron’s 36.4 % equity interest in Angola LNG Limited was unchanged between 2022 and 2023, but the investment’s carrying amount fell from about **$1.96 billion** at year‑end 2022 to **$1.76 billion** at year‑end 2023, reflecting the normal equity‑method adjustments (share of earnings/losses and dividends). Consequently, Chevron continued to record its share of Angola LNG’s results as a loss in the consolidated income statement, with the 2023 loss reducing the investment balance.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains partially correct quantitative information but fails to address the core qualitative evolution described in the ground truth. (1) Correct elements: The 36.4% ownership percentage is accurate and consistent with the original answer. The mention of equity method accounting and adjustments (earnings/losses, dividends) is contextually appropriate. However, the specific dollar amounts ($1.96B and $1.76B) are not present in the ground truth and cannot be verified; they represent a level of financial detail absent from the original knowledge base, making their accuracy uncertain. (2) Quantitative accuracy is scored moderately because while percentages match, the large dollar figures are unverified and potentially fabricated, as the ground truth does not include carrying amounts or losses. (3) Qualitative inaccuracy: The LLM completely misses the key point about the relationship reclassification from 'Depends_On' to 'Invests_In'—a central aspect of the structural evolution. Instead, it focuses on investment carrying value changes and losses, which are not mentioned in the ground truth. This reflects a failure in multi-hop reasoning: the model conflates equity method mechanics with structural investment changes, misrepresenting the nature of the evolution. (4) Contextual relevance is moderate because the answer discusses Chevron's equity interest and accounting treatment, which are relevant topics, but it fails to capture the actual shift in investment structure that the question emphasizes. Overall, the answer substitutes plausible financial details for the actual structural classification change, resulting in a partially correct but fundamentally misaligned response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 464,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the G600 aircraft's role in Gulfstream's product lineup evolved from 2022 to 2023, particularly in terms of its performance metrics and production status?",
      "original_answer": "In 2022, the G600 was described as a recent addition to the Gulfstream fleet, having entered service in 2019, and was positioned as a clean-sheet aircraft replacing the G550. By 2023, the G600 was no longer characterized as 'new' but rather as a mature product within the lineup, with over 250 cumulative deliveries by year-end 2023. Additionally, in 2023, the G600's advanced technologies, such as the Symmetry Flight Deck, were highlighted as foundational features being extended to newer models like the G700, G800, and G400. This indicates a shift from product introduction to integration within the broader Gulfstream platform.",
      "llm_answer": "\nFrom 2022 into 2023 the G600 moved from a brand‑new clean‑sheet design to a mature, high‑volume production model—cumulative deliveries had risen to **over 250 aircraft** by the end of 2023 and the Savannah line kept building them.  Its performance figures that Gulfstream continues to highlight—**Mach 0.85 cruise, a range of roughly 6,000 nautical miles, a cabin that is larger and more ergonomically designed, and about 40 % lower fuel burn/emissions versus the legacy models it replaced**—remained the benchmark that positions the G600 as the current long‑range, large‑cabin flagship while the upcoming G700 prepares for service.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes some correct elements but introduces significant inaccuracies. The claim of 'over 250 cumulative deliveries by end of 2023' aligns with the original answer and is factually consistent. However, the LLM adds specific performance metrics—Mach 0.85 cruise, 6,000 nautical mile range, 40% lower fuel burn/emissions—that are not present in the ground truth and cannot be verified from the provided knowledge graph. These numbers may be plausible but are not supported by the source, making them potentially misleading. (2) Quantitative accuracy is compromised because while the delivery number is correct, the other numerical claims (range, speed, fuel burn) are unverified and not mentioned in the original answer. There is no indication in the ground truth that these specific metrics were highlighted in 2022–2023 as key differentiators. (3) The reasoning partially captures the evolution from 'new' to 'mature' product, which is accurate and reflects multi-hop understanding of the G600’s lifecycle. However, it misses the key point that the G600’s technologies (like the Symmetry Flight Deck) became foundational for newer models (G700, G800, G400), which is a critical aspect of its evolving role. Instead, it incorrectly positions the G600 as the 'current long-range flagship' while the G700 is 'upcoming,' which contradicts Gulfstream's actual product trajectory where the G700 supersedes the G600. (4) Contextual relevance is high because the answer addresses the timeframe, production status, and performance evolution. However, correctness score is reduced due to unsupported quantitative claims and failure to capture the technological spillover that defines the G600’s strategic role shift. The answer fabricates performance benchmarks not in the original data, which undermines factual reliability despite a structurally reasonable narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 511,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of financial involvement and strategic collaboration between 2022 and 2024?",
      "original_answer": "In 2022, McDonald's relationship with franchisees was primarily framed around franchised arrangements and license agreements, with franchisees contributing revenue through rent, royalties, and initial fees, while the company did not typically invest in restaurant capital under developmental licenses. By 2024, the company had introduced a more active investment role, co-investing with franchisees to fund restaurant improvements and operating system upgrades. These co-investments were aimed at catering to consumer preferences, improving local performance, and enhancing the brand through modernization. This marks a strategic shift from a largely passive franchising model to a more collaborative and financially engaged partnership.",
      "llm_answer": "\nBetween 2022 and 2024 McDonald’s shifted from a purely royalty‑and‑rent franchise model to a more collaborative, co‑investment framework.  The company now routinely partners with franchisees to fund restaurant upgrades, technology platforms and supply‑chain improvements—often matching their capital outlays—while tightening operational standards and tying revenue to joint performance goals.  This deeper financial involvement is framed as a strategic alliance that seeks to modernize stores, accelerate innovation and strengthen the brand, even as the core franchising revenue (rent, royalties and initial fees) remains the backbone of the system.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution from a traditional franchising model in 2022—based on rent, royalties, and fees—to a more collaborative, co-investment approach by 2024. The core financial and strategic shift is accurately represented: McDonald's moved from not typically investing in capital to actively co-investing with franchisees in restaurant improvements and operational upgrades. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised; dates (2022 and 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes changes over time in financial involvement and strategic collaboration, correctly identifying the shift from passive revenue extraction to active partnership. The mention of co-funding technology, supply chain, and store modernization aligns with the original's focus on modernization and consumer preferences. (4) Minor deduction in qualitative accuracy due to slight overstatement: the original specifies co-investment began by 2024 but does not say McDonald's 'routinely' partners or 'matches' outlays—these imply a broader or more formalized program than explicitly stated. However, the overall semantic meaning and strategic insight remain correct. Contextual relevance is perfect—the answer directly addresses financial involvement and strategic collaboration across the specified time frame.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 414,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did the financial performance of smokeable products evolve from 2022 to 2023, particularly in terms of net revenues and operating income?",
      "original_answer": "In 2022, smokeable products generated $22,476 million in net revenues and contributed $10,688 million to operating income. In 2023, net revenues from smokeable products decreased slightly to $21,756 million, and operating income from this segment also declined marginally to $10,670 million. This reflects a small decrease in both revenue and profitability year-over-year.",
      "llm_answer": "\nFrom 2022 to 2023 the smokeable‑products segment saw a modest pull‑back in sales: net revenues fell from **$22,476 million in 2022 to $21,756 million in 2023**, a decline of roughly **$720 million (about 3 %)**.  Operating income also slipped only slightly, moving from **$10,688 million in 2022 to $10,670 million in 2023**, a reduction of about **$18 million (≈0.2 %)**.  Thus, while revenue contracted modestly, profitability remained essentially flat year‑over‑year.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) All numeric values are accurate: net revenues of $22,476 million in 2022 and $21,756 million in 2023, and operating income of $10,688 million in 2022 and $10,670 million in 2023. (2) Calculations are precise: the revenue decrease is correctly calculated as $720 million (22,476 - 21,756), which is approximately 3% (720 / 22,476 ≈ 3.2%), and the operating income decrease is $18 million (10,688 - 10,670), or about 0.17%, rounded appropriately to ≈0.2%. (3) The multi-hop reasoning is sound—information from two years and two financial metrics is correctly synthesized to describe the year-over-year trend. (4) The answer addresses both parts of the question (net revenues and operating income) and conveys the same conclusion as the original: a slight decline in both revenue and profitability. Wording differs slightly but maintains semantic equivalence. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1209,
        "completion_tokens": 284,
        "total_tokens": 1494
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the role of Opdivo within BMY's product development and commercialization strategy evolved from 2022 to 2024, particularly in terms of its collaborative framework and new therapeutic approvals?",
      "original_answer": "In 2022, Opdivo was primarily positioned within a joint development and commercialization framework with Ono, where profits, losses, and development costs were shared—either equally for combination therapies or under an 80-20 split for single-party compounds. Additionally, Opdivo was part of a broader alliance that included other products like Yervoy and Orencia, with structured co-promotion and supply responsibilities. By 2024, Opdivo's role had evolved significantly, marked by a new FDA approval in March 2024 for use in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma. This reflects a shift from a co-development focus to a more independent product introduction strategy, with BMY taking the lead in expanding Opdivo’s therapeutic applications in key oncology markets.",
      "llm_answer": "\nFrom 2022 through 2024 Opdivo moved from a primarily regional, co‑promoted immuno‑oncology asset with Ono (Japan, South Korea and Taiwan) toward a globally integrated franchise.  New collaborative updates—such as the 2020 amendment with Nektar that shares development costs and profits for the Opdivo + NKTR‑214 combination and revised profit‑share terms with Ono—combined with a series of regulatory wins (FDA approval of Opdivo Qvantig subcutaneous, EC approval of Opdivo + Yervoy for MSI‑high colorectal cancer, and first‑line approvals in urothelial carcinoma and NSCLC) have expanded Opdivo’s therapeutic scope and positioned it as a central pillar of BMS’s oncology strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of Opdivo within BMY's (Bristol Myers Squibb's) strategy from a co-promoted asset to a central oncology franchise, which aligns with the ground truth. However, there are significant factual inaccuracies that reduce correctness. First, the mention of a collaboration with Nektar (NKTR-214) is not supported in the original answer and appears to be extraneous or outdated information; the ground truth emphasizes the Ono partnership, not Nektar. Second, the LLM cites a 2020 amendment, which falls outside the 2022–2024 timeframe specified in the question and is not mentioned in the ground truth. Third, while the LLM correctly notes new approvals, it misrepresents the key 2024 FDA approval: the ground truth specifies Opdivo in combination with cisplatin and gemcitabine for urothelial carcinoma in March 2024, whereas the LLM vaguely references 'first-line approvals in urothelial carcinoma and NSCLC' without specifying the exact regimen or date. Additionally, the LLM mentions EC approval for MSI-high colorectal cancer and Opdivo Qvantig subcutaneous approval, which are not in the original answer and cannot be verified against the ground truth. While the shift toward a more independent, globally integrated strategy is thematically consistent, the specific collaborative framework evolution (e.g., 80-20 vs. 50-50 cost/profit splits with Ono) is omitted. The answer also fails to mention the broader alliance including Yervoy and Orencia with co-promotion and supply roles, reducing completeness. Quantitative accuracy is moderate: no explicit numbers are wrong, but key dates (2020) and unverified approvals introduce inaccuracies. Reasoning is partially sound but includes unsupported collaborations and approvals. Contextual relevance is high as the answer addresses strategic evolution and approvals. Overall, the answer reflects a plausible narrative but introduces unverified details and omits key factual elements from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 535,
        "total_tokens": 1932
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has AMT's disclosure regarding interest rate benchmarks for debt instruments evolved between 2022 and 2024, particularly in terms of referenced rates and associated covenants?",
      "original_answer": "In 2022, AMT's debt instruments referenced LIBOR, EURIBOR, and a defined base rate for USD and EUR denominated borrowings, with the 2021 credit facilities tied to debt ratings and commitment fees ranging from 0.080% to 0.300%. By 2024, AMT disclosed that new drawings under letters of credit in Nigeria bore interest at SOFR (Secured Overnight Financing Rate) plus a spread, indicating a shift away from LIBOR-based instruments. Additionally, while 2022 disclosures detailed specific covenants and optional renewal periods for various credit facilities, the 2024 disclosure focused on the consequences of covenant non-compliance without specifying interest rate structures or renewal terms, suggesting a simplification or evolution in the presentation of covenant-related disclosures.",
      "llm_answer": "\nBetween 2022 and 2024 AMT moved from describing its borrowing costs as variable rates tied to LIBOR or EURIBOR (with margin adjustments and covenants that referenced those benchmarks) to disclosing fixed‑rate securitization notes (e.g., 5.490 % for the 2023‑Series A securities and 5.735 % for the 2023‑Series R securities) that no longer cite LIBOR/EURIBOR.  The newer disclosures replace the old benchmark‑based interest‑rate language with explicit contractual rates and shift the related covenants from LIBOR‑linked financial tests to DSCR‑based cash‑flow and cash‑trap restrictions that govern excess‑cash‑flow distribution.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents AMT's disclosure evolution. (1) Quantitatively, the LLM introduces specific fixed-rate securitization notes (5.490% for 2023-Series A and 5.735% for 2023-Series R) that are not mentioned in the ground truth and cannot be verified from the provided information. These figures appear fabricated or misattributed. (2) The claim that AMT shifted to 'fixed-rate securitization notes' is incorrect per the original answer, which states that new drawings in Nigeria bore interest at SOFR plus a spread—indicating a floating rate, not fixed. This mischaracterizes the nature of the debt instruments. (3) The original answer notes a transition from LIBOR/EURIBOR to SOFR as the reference rate, but the LLM incorrectly frames the shift as moving from LIBOR-based variable rates to fixed-rate instruments, missing the SOFR transition entirely. (4) Regarding covenants, the LLM claims a shift to DSCR-based cash-flow and cash-trap restrictions, which is not supported in the ground truth; while the original answer notes that 2024 disclosures focused more on consequences of non-compliance rather than detailing terms, it does not mention DSCR or cash-trap mechanisms. (5) The multi-hop reasoning is flawed: the LLM fails to correctly synthesize the actual evolution—LIBOR/EURIBOR to SOFR—and instead invents a narrative around fixed-rate notes and new covenant structures not present in the source. (6) Contextually, the answer addresses the general theme of benchmark evolution and covenant changes, so it remains relevant in topic, but the specifics are largely incorrect. Overall, the answer diverges substantially from the ground truth in both factual content and reasoning, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 480,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has McDonald's relationship with franchisees evolved in terms of real estate ownership and co-investment strategy between 2022 and 2024?",
      "original_answer": "In 2022, McDonald's emphasized Systemwide coordination and alignment to manage ESG initiatives, including environmental sustainability and responsible sourcing, which required franchisee cooperation. However, the specific role of franchisees in real estate ownership was not detailed. By 2024, the company explicitly outlined its conventional franchise model, where it typically owns or secures long-term leases on land and buildings, while franchisees invest in equipment, signs, seating, and décor. This co-investment model was described as enabling McDonald's to achieve high restaurant performance levels. The shift from a general emphasis on franchisee collaboration in 2022 to a clearly defined real estate and co-investment strategy in 2024 reflects a more structured and strategic approach to franchise relationships.",
      "llm_answer": "\nBetween 2022 and 2024 McDonald’s kept its core model of owning or securing long‑term leases on the land and building for most conventional franchised restaurants, with franchisees supplying the equipment, signage and interior fit‑out.  In recent years the company has deepened its co‑investment approach—partnering with franchisees to fund restaurant renovations, technology upgrades and other improvements that modernize stores, boost sales and increase brand value, and in developmental‑license markets the franchisee now typically owns the real‑estate and bears the capital investment.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies McDonald's core real estate model—owning or securing long-term leases on land and buildings while franchisees invest in equipment, signage, and interior fit-out—which aligns with the 2024 ground truth. It also accurately notes the co-investment strategy involving renovations and technology upgrades, reflecting the evolving relationship. However, the answer introduces information not present in the ground truth: specifically, the claim that in developmental-license markets the franchisee 'now typically owns the real estate and bears the capital investment' is not mentioned or supported in the original answer, which focuses only on the conventional franchise model. This addition, while potentially true, is not part of the documented evolution between 2022 and 2024 in the provided knowledge graph. Additionally, the LLM does not clearly contrast the 2022 emphasis on ESG coordination (without real estate specifics) with the 2024 clarification of the co-investment model, missing a key element of the evolution. There are no numerical inaccuracies (quantitative accuracy is high), and the response is contextually relevant. The reasoning is partially sound but lacks the multi-hop synthesis of contrasting the two years' strategic focus. Thus, the answer is factually plausible and captures the general direction of evolution but omits the specific shift in disclosure clarity and adds unverified details about developmental-license markets.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 407,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the status and documentation of the 2015 Stock Compensation Plan for Non-Employee Directors change between 2022 and 2023, and what does this evolution indicate about Altria's governance approach to director compensation?",
      "original_answer": "In 2022, the 2015 Stock Compensation Plan for Non-Employee Directors was disclosed with 703,256 shares available for issuance under the plan. By 2023, the plan was formally amended and restated effective October 26, 2022, and was incorporated by reference from Altria's September 30, 2022, Form 10-Q filing. This indicates a formal update to the plan’s structure and governance, suggesting Altria refined its director compensation framework mid-cycle, potentially to align with evolving governance standards or internal compensation strategies.",
      "llm_answer": "\nBetween 2022 and 2023 the 2015 Stock Compensation Plan for Non‑Employee Directors remained the same amended‑and‑restated plan that was approved on October 26 2022 (first disclosed in the 2022 Form 10‑Q) and was still cited in the 2023 filing with no additional amendment or replacement noted.  This continuity reflects Altria’s governance approach of making infrequent, shareholder‑approved updates to director compensation rather than routine or ad‑hoc changes, signaling a stable, transparent, and board‑focused compensation framework.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the key date of October 26, 2022, for the amendment and restatement of the 2015 Stock Compensation Plan for Non-Employee Directors, and correctly notes that the plan was first disclosed in the 2022 Form 10-Q and carried into the 2023 filing. However, it omits the specific quantitative detail from the ground truth — that 703,256 shares were available for issuance in 2022 — which is a material piece of information directly stated in the original answer. This omission reduces completeness and factual richness. (2) The date (October 26, 2022) is accurate and correctly attributed. No calculations are required, but the failure to include the share availability number — a key metric in assessing the plan’s status — is a significant gap in quantitative reporting. (3) The reasoning about governance is plausible and contextually sound: the LLM infers stability and transparency from the lack of further changes in 2023. However, the original answer interprets the mid-cycle amendment as evidence of active refinement, while the LLM interprets continuity as evidence of infrequent updates. These are differing inferences — the ground truth suggests proactive governance evolution, whereas the LLM suggests conservative stability. This represents a divergence in qualitative interpretation, though not a complete misreading. (4) The answer is contextually relevant and well-structured, addressing both the status change and governance implication. However, the absence of the share number and the divergent interpretive conclusion prevent a higher score. The model synthesizes information across years correctly but misses a key data point and offers an interpretation that, while reasonable, contrasts with the ground truth’s implication of mid-cycle refinement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 490,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the impact of roaming and resale arrangements among wireless service providers on AMT's leasing activity evolved from 2022 to 2024, and what does this indicate about the competitive pressures affecting new lease growth?",
      "original_answer": "In 2022, AMT noted that roaming or resale arrangements among wireless service providers, particularly with the rise of 5G technology, could slow new lease activity if carriers opted to share infrastructure rather than deploy new equipment. By 2024, this concern evolved into a broader risk involving RAN sharing and resale arrangements, which not only threatened new lease activity but also led to potential decommissioning of existing equipment due to redundancy. This indicates a growing competitive pressure where infrastructure sharing is becoming a more viable and widespread alternative to leasing, directly impacting AMT’s revenue growth prospects.",
      "llm_answer": "\nFrom 2022 through 2024 the company repeatedly warned that expanding roaming, RAN‑sharing and resale arrangements—driven by 5G and other advanced network technologies—are being used by carriers as an alternative to leasing additional tower space.  In the 2022 filing the risk was described as a possible slowdown in new lease activity; by 2024 the language is stronger, noting that such sharing “may cause new lease activity to slow … or result in the decommissioning of equipment on existing sites,” indicating that the competitive pressure has deepened and is now a more pronounced constraint on AMT’s lease‑growth prospects.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate, complete, and semantically equivalent to the ground truth. (1) It correctly identifies the evolution from 2022 to 2024: in 2022, roaming and resale arrangements were seen as a potential slowdown to new lease activity; by 2024, the risk expanded to include decommissioning of existing equipment due to RAN sharing and resale. All key facts—5G as a driver, carriers using infrastructure sharing as an alternative to leasing, and the impact on AMT’s lease growth—are present and correctly represented. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), but the years (2022, 2024) are accurate and correctly attributed to the progression of risk language in filings. (3) The multi-hop reasoning is sound: the model synthesizes information across time (2022 vs 2024), identifies the shift in risk scope (from new leases to decommissioning), and correctly infers that this reflects increasing competitive pressure from infrastructure sharing. (4) The answer uses slightly different phrasing (e.g., 'language is stronger', 'more pronounced constraint') but conveys the same meaning as the original. No omissions or inaccuracies; all entities (AMT, wireless carriers, 5G, RAN sharing, resale arrangements) are correctly identified and contextualized. Scores are maximized across all dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 378,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has McDonald's relationship with its franchisees evolved between 2022 and 2024, particularly in terms of strategic investment and operational expectations?",
      "original_answer": "In 2022, McDonald's highlighted the impact of the COVID-19 pandemic on franchise operations, emphasizing risks related to labor availability, supply chain disruptions, and the importance of executing its 'Accelerating the Arches' strategy to maintain growth. The focus was on franchisees' ability to adapt to changing consumer behavior and operational restrictions. By 2024, McDonald's had shifted toward a more active investment role, co-investing with franchisees to modernize restaurants and improve local performance. The company emphasized franchisee reinvestment in their businesses and introduced structured co-investment initiatives designed to increase the value of the McDonald's brand through restaurant modernization and enhanced consumer appeal. This marks a shift from pandemic-driven operational challenges to a more strategic, investment-backed growth approach.",
      "llm_answer": "\nBetween 2022 and 2024 McDonald’s shifted from a largely “franchisee‑only” capital model to a more collaborative one in which the corporation increasingly **co‑invests with franchisees** to fund restaurant remodels, technology upgrades and other strategic initiatives (e.g., the “Accelerating the Arches” agenda).  At the same time, **operational expectations have been tightened** – the company now requires franchisees to be active, non‑passive partners who meet rigorous brand, digital‑adoption and ESG standards and who can finance and implement the initiatives that drive system‑wide sales and profitability.  (Pages 26‑30 of the 2022 10‑K describe the traditional franchise structure and risk of franchisee investment; pages 2‑6 of the 2024 10‑K detail the newer co‑investment approach and the heightened performance expectations placed on franchisees.)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution in McDonald's relationship with franchisees from 2022 to 2024: shifting from a franchisee-led investment model during the pandemic to a co-investment strategy focused on modernization and performance. Key elements such as the 'Accelerating the Arches' strategy, operational expectations around digital adoption and ESG, and the emphasis on franchisee reinvestment are all present and factually consistent. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised—no errors in dates or financial figures. (3) The multi-hop reasoning is sound: the LLM synthesizes information across the 2022 and 2024 10-K filings, correctly inferring a strategic shift based on changes in language and emphasis over time. It references specific page ranges (2022: pp. 26–30; 2024: pp. 2–6), which supports traceability and reflects proper cross-document analysis. (4) The only minor shortcoming is that the original answer emphasizes the pandemic’s impact (labor, supply chain) more explicitly as a 2022 backdrop, which the LLM mentions implicitly but could have highlighted more directly. However, the core transformation—from reactive operational management to proactive, co-invested growth—is clearly and correctly conveyed. Wording differs slightly but maintains semantic equivalence. Thus, the answer is factually correct, comprehensive, and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 433,
        "total_tokens": 1870
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did NextEra Energy's investment strategy in equity securities within its Special Use Funds evolve from 2022 to 2024?",
      "original_answer": "In 2022, NextEra Energy held $8,922 million in Special Use Funds, with no explicit breakdown of equity securities provided in the filing. By 2024, the company disclosed a more detailed composition, with $6,164 million specifically allocated to equity securities under Special Use Funds. This evolution suggests a strategic shift toward transparency and a potentially greater emphasis on equity investments within these funds. While the total amount in Special Use Funds decreased, the explicit allocation to equities in 2024 indicates a more defined and possibly more aggressive investment posture compared to 2022.",
      "llm_answer": "\nBetween 2022 and 2024 the equity portion of NextEra’s Special Use Funds grew from roughly $5.3 bn to $6.2 bn.  The fund’s Level 2 holdings – which consist of commingled funds whose underlying securities are marked‑to‑market using observable prices – rose from about $2.7 bn (2022) to $3.3 bn (2024), while the Level 3 direct‑equity slice increased only modestly from $199 m to $229 m.  This shift shows a strategic move toward larger, more liquid, market‑observable equity exposures (Level 2) with a relatively stable, small allocation to less‑liquid, Level 3 assets.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, NextEra Energy held $8,922 million in Special Use Funds with no explicit breakdown of equity securities. However, the LLM claims that the equity portion was $5.3 billion in 2022, which is not supported by the original data. Similarly, the LLM reports $6.2 billion in equities in 2024, which aligns approximately with the ground truth's $6,164 million in equity securities in 2024 (acceptable rounding), but incorrectly implies a growth trend from a precisely broken-out $5.3B in 2022, which was not disclosed. The LLM introduces Level 2 and Level 3 classifications and specific values ($2.7B, $3.3B, $199M, $229M) that are not present in the original answer and cannot be verified from the provided ground truth. (2) Quantitative accuracy is low: the 2022 equity value is fabricated; no breakdown existed in the filing. The only number that is approximately correct is the 2024 equity allocation (~$6.2B vs $6.164B). The rest of the figures (Level 2, Level 3) are unsupported. (3) The reasoning is internally logical—showing a shift toward more liquid equity exposures—but this synthesis is based on non-existent or hallucinated data. The multi-hop reasoning fails because it invents granular disclosures (by level and category) that were not part of the source material. (4) Contextual relevance is moderate because the answer addresses investment strategy evolution in Special Use Funds and attempts to characterize a strategic shift, but it does so using incorrect and fabricated data. The conclusion about increased focus on equities has some alignment, but the path to it is factually unsound. Overall, the answer misrepresents the available information and introduces false precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 489,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did the financial performance of smokeable products evolve from 2022 to 2023, particularly in terms of net revenues and operating income?",
      "original_answer": "In 2022, smokeable products generated $22,476 million in net revenues and contributed $10,688 million to operating income. In 2023, net revenues from smokeable products decreased slightly to $21,756 million, and operating income from this segment also declined to $10,670 million. This indicates a marginal decrease in both revenue and profitability year-over-year.",
      "llm_answer": "\nFrom 2022 to 2023 the smokeable‑products segment’s net revenues fell from **$22,476 million to $21,756 million** – a decline of roughly **$720 million (about 3 %)**.  Its operating income also slipped only slightly, moving from **$10,688 million in 2022 to $10,670 million in 2023**, a decrease of about **$18 million (≈0.2 %)**.  Thus, revenue contracted modestly while profitability remained essentially flat.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) All numeric values are accurate: net revenues of $22,476 million in 2022 and $21,756 million in 2023, and operating income of $10,688 million in 2022 and $10,670 million in 2023. (2) Calculations are correct: the revenue decrease is $720 million, which is approximately 3% (720 / 22,476 ≈ 3.2%), and the operating income decrease is $18 million, or about 0.17%, rounded to 0.2%—both acceptable. (3) The reasoning is sound and synthesizes the correct financial metrics across two years for the smokeable products segment, demonstrating proper multi-hop understanding. (4) The answer addresses both parts of the question—net revenues and operating income—and conveys the same conclusion as the original: a marginal decline in both metrics. Wording differs slightly but maintains semantic equivalence. No factual, quantitative, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1193,
        "completion_tokens": 271,
        "total_tokens": 1464
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the utilization of Accenture plc Class A Ordinary Shares evolved between 2022 and 2023, particularly in terms of share purchase programs and their intended usage?",
      "original_answer": "In 2022, Accenture disclosed an aggregate available authorization of $3,129,296 for publicly announced open-market share purchase programs and other share purchase programs involving Accenture plc Class A Ordinary Shares and Accenture Canada Holdings Inc. exchangeable shares. By 2023, the company clarified that Class A Ordinary Shares acquired through these programs were being held as treasury shares and intended for employee benefits, such as equity awards. Additionally, in fiscal 2024, shares were acquired via share withholding for payroll tax obligations under employee equity share plans, which were separate from the publicly announced share purchase authorization. This indicates a shift in focus toward internal employee compensation mechanisms while maintaining a formal buyback program.",
      "llm_answer": "\nBetween fiscal 2022 and 2023 Accenture’s Class A share purchases remained focused on acquiring treasury shares for employee‑benefit and equity‑award programs.  In 2022 it bought about 12.2 million shares for roughly $4.1 bn under its open‑market and other purchase programs, and in September 2022 the Board added $3 bn of repurchase authority—raising the total authorization to $6.13 bn—so that the same pool of treasury shares could be used for future open‑market purchases and redemptions of Class A (and exchangeable) shares to fund employee benefits and equity awards.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, Accenture had an aggregate available authorization of $3,129,296 (approximately $3.13 million), not $6.13 billion as claimed by the LLM. The LLM incorrectly states that the Board added $3 billion in repurchase authority in September 2022, raising total authorization to $6.13 billion—this figure is off by three orders of magnitude and is not supported by the original answer. Additionally, the LLM introduces specific figures like '12.2 million shares' and 'roughly $4.1 bn' in purchases, which are not present in the ground truth and appear fabricated. (2) The quantitative inaccuracies are severe: the actual authorization was ~$3.13 million, not billions, and no share volume or dollar amount of actual purchases was provided in the original answer, making the LLM's numbers unsupported. There is no mention in the ground truth of a $3 billion addition or total $6.13 billion authorization. (3) The qualitative reasoning partially captures the intended usage of shares—namely, for employee benefits and equity awards—and correctly identifies that shares were held as treasury shares, which aligns with the 2023 update. However, it fails to mention the key 2023 clarification about treasury share usage and omits the 2024 detail about share withholding for payroll taxes, which is relevant context. The model invents a detailed financial narrative not present in the source. (4) Due to major numerical errors and hallucinated data, the correctness score is low at 3. Quantitative accuracy is 2 due to completely incorrect dollar amounts. Qualitative accuracy is 4 because the general direction (use for employee benefits) is correct, but reasoning is flawed. Contextual relevance is 6 because the topic and intent are aligned with the question, even if facts are wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 509,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the nature and structure of AMT's operating covenants evolved between 2022 and 2024, particularly in terms of the types of debt instruments involved and associated interest rate benchmarks?",
      "original_answer": "In 2022, AMT's operating covenants were tied to a variety of credit facilities and loans that referenced LIBOR and EURIBOR as the interest rate benchmarks. These included the 2021 Multicurrency Credit Facility, the 2021 Credit Facility, and several term loans. By 2024, AMT's disclosures indicate a shift in the interest rate benchmark to SOFR, specifically for letters of credit drawn in Nigeria, which were subject to a rate equal to SOFR at the time of drawing plus a spread. This reflects a transition away from LIBOR-based covenants toward SOFR-based structures, signaling a strategic and regulatory evolution in how AMT manages its debt obligations and associated covenants.",
      "llm_answer": "\nBetween 2022 and 2024 the core financial‑covenant structure (e.g., DSCR‑based cash‑trap and minimum‑DSCR tests, limits on additional indebtedness, and mandatory reporting) has remained, but the covenants now apply to a broader set of debt instruments—including the low‑coupon 0.400 % and 0.950 % senior notes, the 2023 securitization tranches, and the euro‑denominated delayed‑draw term loans—while the interest‑rate benchmarks have stayed tied to LIBOR for USD borrowings and EURIBOR for EUR borrowings, each with a 1.125 % spread, and are explicitly linked to the anticipated repayment dates of the securitized components.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to correctly represent the evolution of AMT's operating covenants between 2022 and 2024. (1) The key claim that interest rate benchmarks remained tied to LIBOR and EURIBOR with a 1.125% spread is directly contradicted by the ground truth, which states that by 2024, AMT shifted to SOFR for Nigerian letters of credit, reflecting a transition away from LIBOR. This misrepresents a core regulatory and structural shift. (2) The LLM introduces specific debt instruments such as '0.400% and 0.950% senior notes', '2023 securitization tranches', and 'euro-denominated delayed-draw term loans' that are not mentioned in the original answer and lack corroboration in the ground truth. These appear to be fabricated or hallucinated details. (3) The assertion that benchmarks are 'explicitly linked to the anticipated repayment dates of the securitized components' is unsupported and not present in the original. (4) Quantitatively, the percentages (0.400%, 0.950%, 1.125%) and references to specific years (2023) are not validated by the ground truth, which does not mention coupon rates or securitization tranches. (5) The multi-hop reasoning is flawed: while the question asks about evolution in covenants and benchmarks, the LLM incorrectly concludes continuity in LIBOR/EURIBOR usage instead of identifying the shift to SOFR. It also fails to mention the Nigeria-specific SOFR transition, a key detail. (6) Contextually, the answer addresses covenant structure and debt instruments, so it remains relevant in topic, but the substance is largely incorrect. The only partial accuracy is the mention of continued covenant frameworks, but even this is overshadowed by incorrect financial details. Overall, the answer reflects a fundamental misunderstanding of the transition from LIBOR to SOFR, a critical point in the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 509,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did Disney+ Hotstar's subscriber base evolve between the 2023 and 2024 SEC filings, and what impact did the consolidation of Star+ into Disney+ in Latin America have on Disney's international streaming strategy?",
      "original_answer": "In the 2023 SEC filing, Disney+ Hotstar reported approximately 36 million paid subscribers as of September 28, 2024. The 2024 filing noted that in certain Latin American countries prior to July 2024, Disney offered both Disney+ and Star+ as separate services, but these were merged into a single Disney+ product offering by the end of June 2024. This consolidation suggests a strategic shift toward streamlining international service offerings, potentially aligning with the model used for Disney+ Hotstar by integrating diverse content into a unified brand to enhance user experience and operational efficiency.",
      "llm_answer": "\nDisney+ Hotstar’s paid subscriber base grew from roughly **30 million** at the end of fiscal 2023 (as disclosed in the 2023 filing, page 7) to **≈36 million** by September 2024 (2024 filing, page 7), an increase of about **6 million** (≈20 %).  At the same time, the company combined the standalone **Star+** service into the **Disney+** platform in Latin America (noted on page 58 of the 2024 filing), eliminating the separate Star+ tier and moving those users onto Disney+.  This consolidation creates a single, more scalable streaming offering in the region, bolstering Disney’s international subscriber count and simplifying its go‑to‑market strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error in the starting subscriber count for Disney+ Hotstar. The original answer (ground truth) states that Disney+ Hotstar had approximately 36 million paid subscribers as of September 28, 2023 (in the 2023 filing), not 30 million. The LLM incorrectly claims growth from 30 million to 36 million, implying an increase, while the ground truth does not provide a prior-year number for direct comparison and only confirms 36 million in both filings. Thus, the 6 million increase and 20% growth are unsupported and incorrect. (2) The date reference is also problematic: the 2023 SEC filing would report data as of September 2023 (fiscal year end), not 'September 2024' as stated in the LLM answer. The 2024 filing reports data as of September 28, 2024 — this is correctly cited, but the misattribution of the 30 million figure to the 2023 filing is wrong. (3) On qualitative accuracy, the LLM correctly identifies the consolidation of Star+ into Disney+ in Latin America by June 2024, as reported in the 2024 filing, and interprets this as a strategic move to streamline offerings, which aligns with the ground truth’s interpretation about operational efficiency and unified branding. This shows sound multi-hop reasoning across services and regions. (4) Contextual relevance is high — the answer addresses both parts of the question: subscriber evolution and strategic impact — even though the numerical foundation is flawed. The synthesis between subscriber data and strategic consolidation is appropriate and adds value. Overall, the answer is partially correct with major quantitative inaccuracies but reasonable qualitative interpretation and good contextual alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 471,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the number of employees covered under collective labor agreements changed from 2022 to 2023, and what does this indicate about the company's labor agreement strategy?",
      "original_answer": "In 2022, the company expected to negotiate agreements covering approximately 3,000 employees in the following year. In 2023, the company projected negotiations covering 2,100 employees for the upcoming year. This indicates a reduction in the number of employees involved in labor renegotiations, suggesting a shift in the company's labor agreement strategy, possibly due to fewer expiring agreements or proactive resolution of collective bargaining terms.",
      "llm_answer": "\nFrom the 2022 disclosures the company expected to renegotiate 21 collective‑agreement contracts that would cover roughly 3,000 employees, whereas the 2023 outlook projects renegotiating 20 agreements that will cover about 2,100 employees. This reduction in both the number of agreements and the employee headcount shows that GD is scaling back the scope of its labor‑agreement negotiations, adopting a more focused, streamlined approach rather than expanding collective‑bargaining coverage.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the numbers are correct: 3,000 employees in 2022 and 2,100 in 2023 are accurately reported. The mention of 21 vs. 20 agreements adds detail not in the original answer but does not contradict it and may reflect additional context from the filing. (2) The calculation of a reduction in both agreements and employee count is sound and supports the conclusion. (3) The reasoning is logical and consistent with the original: the reduction indicates a shift in labor strategy, interpreted here as a 'more focused, streamlined approach'—a reasonable inference from the data. The original suggests 'fewer expiring agreements or proactive resolution,' while the LLM infers strategic scaling back; this is a slightly stronger interpretation but still within plausible bounds. (4) All entities (years, employee counts, collective agreements) are correctly identified and synthesized across years. The only minor gap is that the LLM attributes the change more definitively to strategy ('scaling back') without acknowledging possible external factors like fewer expirations, but this does not invalidate the conclusion. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1243,
        "completion_tokens": 356,
        "total_tokens": 1600
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did NextEra Energy's investment in U.S. Government and municipal bonds evolve from 2022 to 2024, and what was the change in total value across these years?",
      "original_answer": "In 2022, NextEra Energy's investment in U.S. Government and municipal bonds totaled $137 million. By 2024, this investment had increased significantly to $161 million under 'Other investments' for NEE. This represents a growth of $24 million, or approximately 17.5%, indicating a strategic increase in this asset class over the two-year period.",
      "llm_answer": "\nBetween 2022 and 2024 the amount of NextEra Energy’s holdings in U.S. Government and municipal bonds fell from about **$777 million** (2022) to **$757 million** (2023) and then to **$722 million** (2024).  This reflects a **$20 million decline from 2022 to 2023** and a **further $35 million drop from 2023 to 2024**, for a total reduction of roughly **$55 million** over the two‑year period.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect in both direction and magnitude. (1) Quantitatively, the LLM reports a decrease from $777M (2022) to $722M (2024), whereas the ground truth states an increase from $137M (2022) to $161M (2024). These values are not only vastly different in amount but also contradict the actual trend—growth vs. decline. The LLM’s calculated drop of $55M is completely inaccurate; the correct change is a $24M increase. (2) Calculations are internally consistent within the LLM’s false numbers (e.g., $777M → $757M → $722M does reflect $20M and $35M drops), but they are based on fabricated data. (3) Qualitatively, the reasoning fails multi-hop synthesis: it misidentifies the investment category and company, possibly confusing NextEra Energy (NEE) with another entity or misreading 'Other investments' as total bond holdings. The answer also introduces a 2023 figure not requested, without correctly anchoring it to the actual trend. (4) Contextually, while the answer addresses the time frame and asset class, the severe factual errors render it misleading. The core facts—starting value, ending value, direction of change—are all wrong, warranting a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1187,
        "completion_tokens": 338,
        "total_tokens": 1525
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the role of Opdivo in Bristol-Myers Squibb's product portfolio evolved between 2022 and 2024, particularly in terms of its manufacturing strategy and therapeutic approvals?",
      "original_answer": "In 2022, Opdivo was referenced as a product with both internal manufacturing capability and reliance on third-party manufacturers to meet demand, highlighting its strategic importance in BMY's supply chain. By 2024, Opdivo received a new FDA approval in March for combination therapy with cisplatin and gemcitabine for first-line treatment of unresectable or metastatic urothelial carcinoma, indicating an expansion of its therapeutic applications. This evolution reflects both continued manufacturing investment and increased clinical positioning of Opdivo within BMY's oncology portfolio.",
      "llm_answer": "\nBetween 2022 and 2024 Opdivo moved from being solely an intravenous anti‑PD‑1 therapy to a broader, multi‑modal product: the FDA approved the subcutaneous formulation **Opdivo Qvantig** (Dec 2024) and the company obtained new regulatory nods for Opdivo + Yervoy in colorectal cancer, neoadjuvant NSCLC, and urothelial carcinoma (2024), cementing its leadership in immunotherapy across several tumor types.  To support this expansion, BMS leveraged its **flexible manufacturing network**—using both its own biologics‑focused facilities and third‑party contract manufacturers—and invested in new co‑formulation capabilities (nivolumab + hyaluronidase) for the Qvantig product, allowing faster scale‑up and supply resilience while maintaining the same high‑quality cGMP standards.  Thus, Opdivo’s role deepened both therapeutically and in its production strategy, positioning it as a cornerstone of BMS’s IO portfolio with a diversified, globally‑scaled manufacturing footprint.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. Most critically, the FDA approval of Opdivo Qvantig (subcutaneous nivolumab + hyaluronidase) was in December 2024, which is outside the 2022–2024 evaluation window (assuming cutoff before end of 2024), and this approval is not reflected in the ground truth. Additionally, the ground truth specifies a March 2024 FDA approval for Opdivo in combination with cisplatin and gemcitabine for urothelial carcinoma, but the LLM incorrectly attributes the 2024 urothelial approval to Opdivo + Yervoy rather than the correct chemo-combination. The LLM also introduces approvals in colorectal cancer and neoadjuvant NSCLC not mentioned in the ground truth, which lacks evidence in the provided context. (2) Quantitative accuracy is low: the December 2024 approval date falls outside the scope (2022–2024), and the specific regimen (chemotherapy combo) and timing (March 2024) are incorrect. The manufacturing details about co-formulation capabilities for Qvantig are plausible but not supported in the ground truth, which only notes continued use of internal and third-party manufacturing without mentioning new formulation investments. (3) The reasoning shows multi-hop synthesis—linking manufacturing strategy with therapeutic expansion—but is based on incorrect or unsupported approvals and timelines. The core idea of expanding therapeutic use and flexible manufacturing aligns with the ground truth, but the specific evidence used is inaccurate. (4) Contextual relevance is high because the answer addresses both manufacturing strategy and therapeutic approvals as asked, and frames Opdivo’s evolving role appropriately, even if the facts are flawed. Overall, partial credit is given for correct direction and structure, but significant factual and quantitative errors reduce correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 501,
        "total_tokens": 1901
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has Disney's relationship with National Geographic magazine evolved between 2023 and 2024 in terms of its business structure and strategic positioning within the company's portfolio?",
      "original_answer": "In 2023, National Geographic magazine was explicitly described as part of the Entertainment segment under Content Sales/Licensing, and was noted as being 73% owned by Disney. By 2024, the magazine was still reported under Content Sales/Licensing, but the emphasis on its ownership percentage was removed, and it was described more as a publication 'published' by the company rather than a business in which Disney has a direct equity stake. This shift indicates a more operational rather than ownership-focused relationship in 2024 compared to 2023.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Disney kept National Geographic magazine inside the Entertainment segment’s Content‑Sales/Licensing unit (reported alongside the National Geographic television channels) and maintained an essentially unchanged ownership stake (≈73 % Disney, 27 % National Geographic Society).  The magazine’s audience remained steady—internal management reports listed roughly 66 million unique subscribers in September 2024, essentially the same level as the prior year—while the company continued to leverage the title as a strategic pillar for its linear‑network and international‑distribution businesses, using it to drive advertising and licensing revenue across Disney’s broader portfolio.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding Disney's evolving relationship with National Geographic magazine. While it correctly states that the magazine remained under the Entertainment segment’s Content Sales/Licensing unit in both years, it incorrectly asserts that Disney maintained a '≈73%' ownership stake in 2024. The ground truth explicitly notes that in 2024, Disney removed emphasis on the 73% ownership and instead described the relationship more operationally, as 'published by' the company, signaling a shift away from highlighting equity ownership. This key qualitative change in strategic positioning is entirely missed by the LLM, which instead assumes continuity in ownership structure. Additionally, the LLM introduces a figure of '66 million unique subscribers' in September 2024, which is not present in the original answer and cannot be verified against the ground truth—this number is likely fabricated or misattributed. (2) Quantitative accuracy is partially correct: the 73% ownership figure is accurate for 2023, but its extension to 2024 is unsupported. The '66 million unique subscribers' figure has no basis in the provided ground truth and represents a clear factual error. (3) Multi-hop reasoning is flawed: the question asks about evolution in business structure and strategic positioning, requiring synthesis of changes in reporting, ownership language, and corporate framing between 2023 and 2024. The LLM fails this synthesis, instead asserting continuity where the ground truth indicates a meaningful shift in how Disney characterizes its relationship—from ownership-based to operational. (4) Contextual relevance is high, as the response addresses the correct segment, time frame, and general strategic role of National Geographic. However, the failure to capture the core structural and linguistic shift in Disney’s reporting significantly undermines factual correctness, warranting a low correctness score despite relevant framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 540,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has PayPal's description of its transaction management databases' capabilities evolved between 2023 and 2024, particularly in relation to global payment processing in different currencies?",
      "original_answer": "In 2023, PayPal described its transaction management databases as part of a platform that allowed consumers to withdraw funds in 56 currencies. By 2024, the company updated this figure to 57 currencies, indicating a slight expansion in the global reach of its transaction processing capabilities. Additionally, while both years emphasize the role of these databases in enabling customers to utilize PayPal's suite of products, the 2024 filing introduced a more consumer-centric framing, placing 'consumers' ahead of 'merchants' in describing the ecosystem served by the platform. These changes suggest a refinement in how PayPal positions its transaction management systems within its broader global payments infrastructure.",
      "llm_answer": "\nIn the 2023 10‑K (pages 8‑12) PayPal described its transaction‑management databases as part of an end‑to‑end platform that can route payments in ≈ 200 markets and in ≈ 140 currencies, with funds withdrawable in ≈ 57 currencies and balances held in ≈ 24 currencies. The 2024 filing (pages 7‑11) retains the same wording but updates the figures to “approximately 150 currencies” for payments and “56 currencies” for withdrawals, reflecting a modest expansion of global currency coverage while still emphasizing the same proprietary, two‑sided transaction‑management infrastructure.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023 PayPal stated withdrawal capabilities in 56 currencies, increasing to 57 in 2024. The LLM incorrectly claims that in 2023, withdrawals were possible in 'approximately 57 currencies' and then reverses the trend by stating 56 currencies in 2024, which contradicts the ground truth. Additionally, the LLM introduces figures not present in the original answer, such as 'approximately 140 currencies' for payments in 2023 and '150 currencies' in 2024, which are not mentioned in the ground truth and appear to be fabricated or misattributed. (2) The quantitative inaccuracies are severe: the direction of change (56 → 57) is reversed, and unsupported numbers (e.g., 140, 150 currencies) are introduced without basis in the provided truth. The claim about balances held in 24 currencies and routing in 200 markets is not part of the original answer and lacks verification. (3) The multi-hop reasoning is flawed. While the LLM attempts to compare two years' descriptions, it fails to correctly identify the evolution: the ground truth emphasizes a one-currency increase and a shift in language (merchants → consumers), but the LLM misses the consumer-centric framing change entirely and instead invents changes in payment currency coverage. (4) Contextual relevance is moderate because the answer addresses PayPal's transaction management databases and global currency processing, but the incorrect data and missing qualitative shift reduce its accuracy. The answer appears detailed but is largely factually incorrect, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 453,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did the interest rate terms associated with the Series K Debentures evolve between 2023 and 2024, and what does this indicate about NEE's financing strategy?",
      "original_answer": "In 2023, the Series K Debentures had their interest rate reset to 6.051% per year as part of a remarketing completed in March 2023. By 2024, the terms of the Series K Debentures were further updated through a letter dated March 1, 2023, which set forth certain terms effective March 1, 2023, indicating a continuation of the updated rate and terms from the 2023 remarketing. This suggests that NEE adjusted its financing strategy in response to market conditions, locking in a higher interest rate to secure funding.",
      "llm_answer": "\nBetween 2023 and 2024 the Series K Debentures (due March 1, 2025) kept the interest‑rate reset that was executed in March 2023 – the debentures were repriced to a fixed 6.051 % annual rate and have remained at that level through 2024, with no subsequent reset or amendment reported. This shows that NEE is deliberately using equity‑linked, long‑dated debentures to lock in medium‑term fixed financing costs and extend its maturity profile, while taking advantage of market‑driven resets to manage interest‑rate exposure and preserve liquidity.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the key fact that the Series K Debentures were reset to 6.051% in March 2023 and remained at that rate through 2024, which matches the ground truth. The date of the remarketing (March 2023) and the interest rate (6.051%) are accurate. The LLM correctly notes no further reset occurred in 2024, consistent with the original answer’s implication that the terms set in March 2023 remained effective. (2) Quantitative accuracy is perfect: the percentage (6.051%), the year of reset (2023), and the absence of a new rate in 2024 are all correct. The maturity date (March 1, 2025) is an additional detail not in the ground truth but is factually consistent and adds context without error. (3) The multi-hop reasoning is sound: the LLM infers from the stable rate that NEE is using long-dated, equity-linked debentures to lock in fixed financing, which aligns with the ground truth’s conclusion about adjusting financing strategy in response to market conditions. The LLM extends this to discuss maturity extension and liquidity preservation—reasonable inferences that are contextually appropriate and enhance the analysis without contradicting the ground truth. (4) The only minor gap is that the LLM does not explicitly mention the March 1, 2023 letter that formalized the terms, which is referenced in the original answer. However, this omission does not affect the core factual or strategic conclusions. Overall, the answer is semantically equivalent, highly accurate, and contextually rich, warranting a high score with only a slight deduction for missing one procedural detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 444,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has ExxonMobil's application of the Unit-of-Production Depreciation method evolved between 2022 and 2023, particularly in response to changes in proved reserves and asset life assumptions?",
      "original_answer": "In 2022, ExxonMobil applied the Unit-of-Production Depreciation method based on proved reserves or proved developed reserves, switching to straight-line depreciation when asset life did not correlate with reserves, and using SEC price-based reserves only when proved reserves were substantially de-booked. By 2023, the company maintained the same core methodology but placed greater emphasis on using the most recent SEC price to determine reserves for depreciation in cases where reserves had been significantly reduced, ensuring a more meaningful allocation of asset costs over the expected life of the asset. This reflects a refinement in the company's approach to align depreciation with updated economic conditions and production realities.",
      "llm_answer": "\nBetween 2022 and 2023 ExxonMobil shifted the basis of its unit‑of‑production depreciation from reserve estimates calculated with the prior‑year average SEC prices to using the most recent SEC‑price‑derived proved‑reserve figures, adjusting those reserves for actual production and technical changes.  The 2023 filing also adds a safeguard: when proved reserves are substantially de‑booked, the asset is switched to straight‑line depreciation to ensure the cost is fully recovered over the asset’s remaining useful life, reflecting a more responsive approach to revised reserve volumes and longer‑term asset‑life assumptions.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general direction of ExxonMobil's methodological refinement in 2023 regarding the use of the most recent SEC prices for proved reserves in unit-of-production depreciation, which aligns with the ground truth. It correctly identifies the increased emphasis on current SEC pricing and links it to depreciation calculations. However, there is a significant factual inaccuracy in the claim that a 'safeguard' was introduced in 2023 switching to straight-line depreciation when reserves are substantially de-booked. The original answer states that straight-line depreciation was already used in 2022 when asset life did not correlate with reserves, and specifically when reserves were substantially de-booked—this was not a new development in 2023. The LLM incorrectly frames this as a 2023 change, misrepresenting the evolution. Additionally, the LLM implies a full 'shift' in basis from prior-year to current-year SEC prices, while the ground truth indicates the 2023 approach was a refinement—greater emphasis in specific cases—not a wholesale change. This mischaracterization affects the qualitative accuracy and correctness. Quantitatively, no specific numbers are involved, so accuracy is high by default. Contextually, the response is relevant and addresses the core question about methodological evolution. The multi-hop reasoning is partially sound but flawed in synthesizing the timeline and nature of changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 396,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Netflix's strategic emphasis on original programming evolved between 2023 and 2024, particularly in terms of its reliance on third-party production partners versus internal studio scaling?",
      "original_answer": "In 2023, Netflix emphasized its investments in original programming and highlighted the risks associated with third-party production partners, including potential liability and loss due to legal violations, insolvency, or fraud. It also noted its acquisitions like Scanline and Animal Logic as part of scaling internal studio operations. By 2024, the company shifted its language to focus on the growing complexity of managing original content production and placed greater emphasis on the need to improve internal systems, corporate culture, and operational practices related to content creation. The explicit mention of third-party risks present in 2023 was omitted in 2024, suggesting a reduced dependency on external partners and a stronger strategic move toward internal control and scaling.",
      "llm_answer": "\nBetween the 2023 and 2024 filings Netflix moved from a model that leaned heavily on external production partners toward a strategy that emphasizes building its own studio capacity.  The 2023 filing notes that the company “contracts with third parties related to the development, production, marketing and distribution of our original programming,” while the 2024 filing explicitly states that it is “scaling our own studio operations to produce original content, including through acquisitions such as Scanline and Animal Logic,” signaling a deliberate shift to internal production and reduced dependence on outside producers.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct and aligns closely with the ground truth. It accurately captures the strategic shift between 2023 and 2024: in 2023, Netflix relied on third-party partners and acknowledged associated risks (though the LLM does not explicitly mention risks like legal violations or insolvency, which were in the original answer), and by 2024, the company emphasized scaling internal studio operations through acquisitions like Scanline and Animal Logic. The LLM correctly identifies the change in language and strategic emphasis toward internal production. All entities (Netflix, Scanline, Animal Logic, 2023, 2024) and years are accurate. There are no numerical figures requiring calculation, so quantitative accuracy is 10. The only minor shortcoming is the omission of the specific risks related to third-party partners (e.g., fraud, insolvency) that were highlighted in 2023 and the absence of the 2024 emphasis on internal systems and corporate culture improvements. However, the core reasoning and multi-hop synthesis—comparing strategic language across two years to infer reduced reliance on external partners and increased internal scaling—are sound and semantically equivalent. Thus, the answer is highly accurate with only minor contextual omissions, warranting a 9/10 on correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 371,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has the strategic positioning of Mastercard's Cyber and Intelligence Solutions evolved between 2022 and 2023?",
      "original_answer": "In 2022, Cyber and Intelligence Solutions were positioned as part of 'Other revenues' and primarily described as products and services offered to prevent, detect, and respond to fraud, ensuring the safety of transactions made on Mastercard products. By 2023, the Cyber and Intelligence Solutions were elevated in strategic importance, being explicitly described as a value-added service that enables secure, easy, and confident transactions across the entire payments ecosystem, indicating a broader role in supporting Mastercard’s core operations and new network investments.",
      "llm_answer": "\nBetween 2022 and 2023 Mastercard moved Cyber and Intelligence Solutions from a peripheral “value‑added” offering to a core strategic growth pillar.  In 2022 the solutions were described simply as fraud‑prevention and security services within other revenues, but by 2023 the company was explicitly tying them to its broader digital‑identity and open‑banking agenda—highlighting investments such as the Ekata acquisition and the pending Dynamic Yield purchase—and reporting that these solutions contributed to the strong rise in adjusted net revenue and overall value‑added sales.  This shift reflects a more central positioning of cyber‑and‑intelligence capabilities as a driver of revenue and differentiation across Mastercard’s payments network.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the strategic evolution of Mastercard's Cyber and Intelligence Solutions from 2022 to 2023, aligning with the ground truth in key aspects: in 2022, the solutions were part of 'Other revenues' and focused on fraud prevention; by 2023, they gained strategic prominence as a value-added service supporting broader ecosystem goals. The answer accurately reflects the elevated role and integration with Mastercard’s core operations. However, the LLM introduces specific details not present in the original answer—such as the Ekata acquisition, the pending Dynamic Yield purchase, and direct attribution to adjusted net revenue growth—which, while potentially true, are not part of the provided ground truth and represent over-enrichment. These additions do not contradict the original but go beyond the documented knowledge graph, slightly reducing qualitative accuracy. There are no numerical figures in the question or answers, so quantitative accuracy is scored as 10 by default. The reasoning is sound and multi-hop synthesis is appropriate, showing a clear understanding of strategic positioning shifts. The answer is fully contextually relevant and addresses the evolution in strategic positioning as requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 348,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Tesla's approach to energy storage products evolved from 2023 to 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2023, Tesla emphasized its modular design and in-house expertise in power electronics and software to optimize the manufacturing and performance of its energy storage products like Megapack. By 2024, Tesla's focus shifted to addressing production ramps and supply chain dependencies, citing potential bottlenecks and the need for efficient, cost-effective manufacturing capabilities. The company also highlighted risks related to supplier reliability and the challenges of scaling production to meet planned output rates and quality standards for energy storage products.",
      "llm_answer": "\nFrom 2023 to 2024 Tesla shifted from relying almost entirely on outside suppliers such as Panasonic and CATL for battery cells toward accelerating its own cell‑development and manufacturing program, investing heavily in new gigafactories (e.g., Texas, Germany and the planned Mexico site) to produce proprietary cells at scale.  This transition introduced new production hurdles—including bottlenecks in cell ramp‑up, steep capital outlays, and heightened exposure to fluctuations in lithium, nickel, cobalt and other raw‑material prices—making the company’s energy‑storage growth increasingly dependent on both the successful scaling of in‑house cell production and secure, long‑term raw‑material supply contracts.",
      "correctness_score": 3,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and introduces unsupported claims not present in the ground truth. (1) The claim that Tesla 'relied almost entirely on outside suppliers such as Panasonic and CATL for battery cells' in 2023 is not supported by the original answer, which emphasizes Tesla's in-house expertise in power electronics and software, not supplier dependency for cells. The shift to in-house cell production is not mentioned in the ground truth as a 2023–2024 evolution. (2) There are no numeric values (dates, dollar amounts, percentages) in either answer, so quantitative accuracy is neutral—no errors but no verifiable numbers to assess. (3) The multi-hop reasoning is flawed: the LLM fabricates a narrative about gigafactories in Texas, Germany, and Mexico scaling proprietary cell production, which is not reflected in the original answer. The original focuses on modular design, production ramps, supply chain dependencies, and supplier reliability—not cell manufacturing strategy. (4) While the LLM touches on production challenges and supply chain risks (aligning somewhat with the 2024 focus), it misattributes the source of those challenges (in-house cell scaling vs. general manufacturing scalability and supplier reliability). The contextual relevance is moderate because it discusses production hurdles and dependencies, but the core evolution described is factually incorrect. Thus, the correctness score is low due to major factual deviations despite some thematic overlap.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 416,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How did NextEra Energy Capital Holdings' issuance strategy for floating rate debentures evolve from 2023 to 2024, particularly in terms of the principal amount and maturity structure?",
      "original_answer": "In 2023, NextEra Energy Capital Holdings disclosed the sale of $600 million in floating rate debentures due in 2026. By 2024, the company formalized this issuance through an Officer's Certificate dated January 31, 2024, specifying the Floating Rate Debentures, Series due January 29, 2026. While the principal amount was not explicitly updated in 2024, the maturity structure remained consistent with the 2026 horizon, indicating a focused strategy on short-to-medium-term floating rate debt. This reflects a continuation of the prior year's approach without significant expansion or restructuring of the floating rate debenture program.",
      "llm_answer": "\nFrom 2023 to 2024 NEE Capital shifted its floating‑rate program from a single, relatively small tranche—about $400 million of variable‑rate debentures that were set to mature in 2024 (shown in the 2023 debt table on page 103)—to a series of larger, longer‑dated floating‑rate issuances.  In 2024 the company issued new floating‑rate debentures such as the $400 million floating‑rate debentures due February 4 2028 (Exhibit 4(xx) on page 122) and the $400 million‑plus Series R junior subordinated debentures due June 15 2054 (Exhibit 4(rr) on page 123), expanding the absolute floating‑rate principal by several hundred million dollars and extending the weighted‑average maturity out to the mid‑2050s.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth in multiple critical aspects. (1) Quantitative Accuracy: The LLM claims a $400 million issuance in 2023 maturing in 2024, but the ground truth states a $600 million issuance due in 2026. The LLM then claims two new issuances in 2024: $400 million due 2028 and $400 million-plus due 2054. However, the ground truth confirms no new principal amount was disclosed in 2024, and the only referenced maturity is 2026. These numbers, dates, and instruments (e.g., Series R junior subordinated debentures) are not supported by the original answer. (2) Completeness: While the question asks about evolution in principal amount and maturity structure, the LLM invents data rather than reporting the continuity emphasized in the ground truth. It fails to note that the 2024 Officer's Certificate formalized the same 2026 series without updating the principal. (3) Entity Accuracy: The LLM misidentifies the company's actions, referencing exhibits and debt series (e.g., Exhibit 4(xx), 4(rr), Series R) not mentioned or implied in the ground truth. It also confuses debenture types (e.g., junior subordinated vs. general floating rate debentures). (4) Reasoning: The multi-hop synthesis is flawed. Instead of recognizing that 2024 involved formalization of an existing plan, the LLM fabricates an expansion strategy with longer maturities and higher principal, drawing erroneous conclusions about shifting strategy and extending weighted-average maturity to the 2050s—completely unsupported. (5) Semantic Equivalence: The LLM suggests a strategic shift toward larger, longer-dated debt; the ground truth indicates continuity and consistency. These are diametrically opposed. The only partial relevance is that both discuss floating rate debentures and issuance activity across 2023–2024, but all specific claims diverge factually. Hence, the correctness score is 1 due to complete factual inaccuracy despite addressing the general topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 536,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Intel's approach to industry initiatives related to supply chain responsibility evolved from 2023 to 2024, particularly in terms of collaboration focus and supplier engagement scope?",
      "original_answer": "In 2023, Intel announced a significant expansion of its supplier engagement activities under its RISE strategy, aiming to increase the number of suppliers covered in sustainability and compliance programs, and set a goal to achieve net-zero upstream Scope 3 greenhouse gas emissions by 2050. By 2024, Intel's approach evolved to emphasize broader collaboration on responsible minerals sourcing and transparency around climate and water impacts, with a continued focus on capability-building programs for suppliers but without explicit mention of expanding the number of suppliers engaged. The shift indicates a move from announcing strategic expansions to reinforcing and deepening existing industry partnerships.",
      "llm_answer": "\nFrom 2023 to 2024 Intel moved beyond its internal audit‑and‑engagement model for direct suppliers and modest diversity‑spending goals, toward a far more collaborative, ecosystem‑wide approach.  The 2024 disclosures show expanded industry partnerships (e.g., the SCIP agreement with Apollo, CHIPS‑Act government incentives, and the Alliance for Global Inclusion’s global inclusion index) and a broader scope of supplier engagement that now includes upstream Scope‑3 emissions, water stewardship, circular‑economy targets, and formal performance‑linked incentives for both Intel and its suppliers.  This evolution reflects a shift from isolated compliance programs to integrated, multi‑stakeholder initiatives that tie supplier sustainability and diversity outcomes to corporate incentives and industry standards.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2023, Intel expanded supplier engagement under its RISE strategy with a goal of net-zero upstream Scope 3 emissions by 2050, and in 2024 shifted focus to responsible minerals sourcing, transparency on climate and water, and deepening existing partnerships. The LLM incorrectly claims that in 2024 Intel introduced 'formal performance-linked incentives', 'circular-economy targets', and 'expanded industry partnerships' such as a 'SCIP agreement with Apollo' and 'Alliance for Global Inclusion’s global inclusion index'—none of which are mentioned or supported in the original answer. These specific programs and collaborations are fabricated or misattributed. (2) There are no numeric values in the original answer, so quantitative accuracy is not applicable beyond correct use of years (2023, 2024), which the LLM gets correct. However, it invents program names and initiatives without basis, failing on factual precision. (3) The multi-hop reasoning is flawed: the original answer emphasizes a shift from announcing expansions (2023) to reinforcing existing collaborations (2024), whereas the LLM portrays an expansion into new, specific programs that aren't in the source. This misrepresents the evolution. (4) While the LLM attempts to address collaboration focus and supplier engagement scope, it does so with hallucinated details, reducing correctness. Contextual relevance is moderate because it discusses supplier engagement and collaboration themes, but the specifics are inaccurate, leading to a low overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 446,
        "total_tokens": 1838
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has the characterization of the assumptions underlying the standardized measure of discounted future cash flows evolved between XOM's 2022 and 2023 disclosures, particularly regarding the company's framing of its dependency on first-day-of-the-month average prices?",
      "original_answer": "In XOM's 2022 filing, the standardized measure of discounted future cash flows was described as being 'prepared on the basis of certain prescribed assumptions,' which included first-day-of-the-month average prices. This framing emphasized that the assumptions were foundational to the calculation but did not explicitly highlight the degree of dependency on them. In contrast, the 2023 filing reflects a shift in tone by emphasizing that the standardized measure 'depends on' these prescribed assumptions, particularly first-day-of-the-month average prices, which are described as discrete points in time that 'may cause significant variability in cash flows from year to year as prices change.' This indicates a more explicit acknowledgment of the sensitivity and dependency of the measure on these assumptions, even though the actual calculation methodology remained unchanged, using the same 10 percent discount factor, year-end costs, and legislated tax rates.",
      "llm_answer": "\nIn the 2022 filing the standardized‑measure note merely stated that the calculation “applies first‑day‑of‑the‑month average prices” as a prescribed accounting assumption, without drawing attention to the price‑sensitivity of the result. By the 2023 filing the same description was expanded to emphasize that the measure is “highly sensitive to first‑day‑of‑the‑month average prices, which represent discrete points in time and therefore may cause significant variability in cash flows from year to year,” and that the metric “does not provide a reliable estimate of the Corporation’s expected future cash flows.” Thus, the 2023 disclosure explicitly frames the company’s results as dependent on, and vulnerable to, fluctuations in those first‑day‑of‑the‑month average prices.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in XOM's disclosure between 2022 and 2023. It correctly identifies that in 2022, the use of first-day-of-the-month average prices was presented as a prescribed assumption without emphasis on sensitivity, while in 2023, the framing shifted to highlight dependency and variability due to these discrete pricing points. The LLM accurately reflects that the calculation methodology (e.g., 10% discount rate, year-end costs, tax rates) remained unchanged, though this detail is implied rather than explicitly stated. The addition that the 2023 measure 'does not provide a reliable estimate of the Corporation’s expected future cash flows' is consistent with the more cautious framing in the updated disclosure and aligns with the ground truth's emphasis on increased acknowledgment of sensitivity. All entities (XOM, standardized measure, first-day-of-the-month prices), years (2022 vs 2023), and concepts (prescribed assumptions, variability, dependency) are correctly identified and synthesized. There are no numerical inaccuracies—no specific numbers are misstated, and the qualitative reasoning is sound. The only minor shortcoming is that the LLM slightly expands on the original answer by including a direct quote about reliability not explicitly present in the ground truth, though this is a reasonable inference from the emphasized variability. This does not constitute a factual error but represents a small deviation in wording emphasis. Overall, the answer is factually correct, contextually relevant, and demonstrates strong multi-hop reasoning across years and disclosures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1465,
        "completion_tokens": 448,
        "total_tokens": 1914
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has MA's digital identity solutions evolved between 2022 and 2023, particularly in terms of their integration with open banking capabilities and reach across financial institutions?",
      "original_answer": "In 2022, MA introduced its digital identity solutions as part of an open banking platform that enabled data providers and third parties to access consumer data on a permissioned basis, aiming to improve customer experience and financial inclusion. The platform leveraged data principles such as consumer protection and consent management, and it focused on identity verification across people, devices, and transactions. In 2023, MA expanded its open banking capabilities, achieving connectivity to over 95% of deposit accounts in the U.S. and approximately 3,000 banks across Europe, which significantly enhanced the reach and application of its digital identity solutions. Additionally, in 2023, MA partnered with leading financial institutions to launch an ACH payment solution using its open banking infrastructure, indicating a deeper integration of digital identity within broader financial services.",
      "llm_answer": "\nBetween 2022 and 2023 Mastercard broadened the reach of its digital‑identity platform by embedding it in its open‑banking API network, which in 2023 connected to more than 95 % of U.S. deposit accounts and to roughly 3,000 banks across Europe (directly and via partners).  This expansion enabled the company to launch a 2023 ACH bill‑payment solution that uses the same consent‑centric, device‑intelligence and biometric identity capabilities to provide seamless, secure payments across those financial institutions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of MA's digital identity solutions between 2022 and 2023. (1) Quantitatively, all numbers are correct: 'over 95% of U.S. deposit accounts' and 'approximately 3,000 banks across Europe' match the ground truth exactly, with acceptable phrasing variations ('more than 95%' = 'over 95%'). (2) The answer correctly identifies the expansion of open banking connectivity in 2023 and the launch of an ACH payment solution using digital identity capabilities, which aligns with the ground truth. (3) The multi-hop reasoning is sound—linking digital identity to open banking infrastructure, then showing enhanced reach and application via integration with financial institutions. (4) Minor omission: the 2022 context about consumer protection, consent management, and identity verification across people, devices, and transactions is not explicitly mentioned, though 'consent-centric, device-intelligence and biometric identity capabilities' implicitly covers it. The answer focuses more on 2023 developments but still conveys the evolution. No factual errors—only slight reduction in completeness regarding 2022 details. Hence, a high score of 9 is justified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 340,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2023 and 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2023, Tesla emphasized the engineering and design maturity of the Solar Roof, highlighting its aesthetic appeal, durability, and integration with Powerwall. The company positioned Solar Roof as a customized solution within its broader energy product suite. However, by 2024, Tesla acknowledged that the production ramp of Solar Roof faced delays similar to those experienced with other products. The 2024 filing also noted that the company's future success 'depends in large part' on scaling mass-market vehicle production, which indirectly signals a potential strategic prioritization shift that could affect Solar Roof's development and deployment timelines.",
      "llm_answer": "\nBetween 2023 and 2024 Tesla moved Solar Roof from a pilot‑scale offering toward a broader rollout, but the product still depends on a tightly controlled supply of its proprietary solar‑tile modules and integrated battery‑cell components.  To meet growing demand the company is expanding production at new sites such as Texas (and the planned Mexico Gigafactory) and is investing in in‑house battery‑cell manufacturing, yet it continues to confront bottlenecks in tile fabrication, raw‑material price volatility and the need to synchronize Solar Roof output with its overall energy‑storage and battery‑cell ramp‑up.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains no specific numeric values, dates, or calculations that contradict the ground truth, so quantitative accuracy is acceptable by default (score 10). However, the content diverges significantly from the original answer in key qualitative aspects. The ground truth states that in 2023, Tesla emphasized the design maturity and integration of Solar Roof with Powerwall, positioning it as a customized solution, while in 2024, Tesla acknowledged production ramp delays and signaled strategic prioritization of mass-market vehicle production as a dependency for future success. The LLM answer incorrectly frames the 2023–2024 evolution as a move from 'pilot-scale' to 'broader rollout'—a claim not supported in the original. It introduces unverified details such as expansion at Texas and Mexico Gigafactories and in-house battery-cell manufacturing investments specifically for Solar Roof, which are not mentioned in the ground truth. While it correctly identifies ongoing production bottlenecks, it misattributes dependencies to battery-cell and tile supply rather than correctly reflecting Tesla’s stated strategic dependency on mass-market vehicle scaling. The reasoning is partially sound in recognizing production challenges, but fails the multi-hop synthesis by not connecting the 2024 strategic dependency to potential impacts on Solar Roof timelines. Thus, while contextually relevant and discussing related themes, the answer fabricates operational details and misses the core strategic shift highlighted in the original, warranting a partial correctness score of 5.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 434,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has NextEra Energy, Inc.'s use of Pledge Agreements evolved between 2023 and 2024, particularly in terms of the dates and counterparties involved?",
      "original_answer": "In 2023, NextEra Energy, Inc. disclosed a Pledge Agreement dated September 1, 2022, involving Deutsche Bank Trust Company Americas and The Bank of New York Mellon. By 2024, the company introduced two new Pledge Agreements dated June 1, 2024, and October 1, 2024, with the same counterparties. This indicates an evolution in the structure and timing of these agreements, expanding their use over time.",
      "llm_answer": "\nBetween 2023 and 2024 NextEra Energy added two new pledge‑agreement filings—one executed on **June 1 2024** and another on **October 1 2024**—that replace the earlier 2022 pledge (dated September 1 2022). In each 2024 agreement **NextEra Energy, Inc.** is the pledgor, **Deutsche Bank Trust Company Americas** serves as collateral agent, custodial agent and securities intermediary, and **The Bank of New York Mellon** acts as the purchase‑contract agent; the June 2024 pledge backs the Series N junior subordinated debentures, while the October 2024 pledge secures the Series O debentures. Thus, the company’s use of pledge agreements has evolved from a single 2022 structure to multiple, contemporaneous pledges in 2024 with the same counterparties but tied to newer series of debt.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth, but contains a minor inaccuracy in characterizing the 2024 agreements as 'replacing' the 2022 agreement, which is not supported by the original answer. The original states that NextEra 'introduced two new Pledge Agreements' in 2024, indicating an expansion rather than a replacement. All dates (September 1, 2022; June 1, 2024; October 1, 2024) and counterparties (Deutsche Bank Trust Company Americas and The Bank of New York Mellon) are accurately reported. The LLM adds specific detail about the roles of the counterparties and the debt series (N and O) secured by the pledges, which is consistent with plausible 10-K disclosures and enhances completeness without contradicting the ground truth. The evolution from a single prior agreement to multiple 2024 agreements with the same counterparties is correctly interpreted. Quantitative accuracy is high—dates match exactly and are correctly attributed. The qualitative reasoning is sound in identifying a structural evolution in the use of pledge agreements, though the 'replacement' framing introduces a slight logical error in the relationship between the agreements. Contextual relevance is excellent, directly addressing the question’s focus on evolution, dates, and counterparties. Minor deduction from correctness and qualitative scores due to the unsupported replacement claim, but core facts and multi-hop synthesis (across years and agreements) are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 409,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Intel's strategic positioning in Edge AI evolved from 2023 to 2024, particularly in terms of its software platform offerings and ecosystem partnerships?",
      "original_answer": "In 2023, Intel emphasized its edge-native software platform with modular building blocks, premium services, and support offerings, aiming to enable developers to build, deploy, run, manage, connect, and secure distributed edge infrastructure and Edge AI across multiple verticals. The platform was described as a horizontal approach to scaling infrastructure for intelligent edge and hybrid AI, supporting diverse architectures and avoiding vendor lock-in. By 2024, Intel's strategy had evolved under its NEX initiative, which aimed to transform networks and edge compute systems from fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud-native software on programmable hardware. Intel highlighted broader ecosystem partnerships and a focus on rapid digital transformation from cloud to edge, leveraging core strengths in compute, connectivity, software, and large-scale manufacturing. This shift indicates a more integrated and scalable approach to Edge AI, with a stronger emphasis on cloud-native programmability and collaboration with partners to drive automation and secure data integrity at the edge.",
      "llm_answer": "\nIn 2024 Intel shifted from a hardware‑only AI‑accelerator focus in 2023 to a full‑stack edge‑AI strategy, launching the Gaudi 3 AI accelerator, the programmable Jaguar Shores GPU and the 4th‑Gen Xeon D processors while expanding its OpenVINO‑based, edge‑native software platform with modular building blocks for AI workloads.  At the same time it broadened its ecosystem, collaborating with more than 500 network builders and key partners such as Ericsson, Nokia, Cisco, Dell, HPE, Lenovo, Amazon, Google and Microsoft to deliver end‑to‑end AI‑enabled compute and connectivity solutions for the intelligent edge.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes some correct elements but introduces significant inaccuracies. It correctly identifies Intel's shift toward a more comprehensive edge-AI strategy and mentions ecosystem partnerships, aligning with the ground truth's emphasis on broader collaboration. However, it incorrectly claims that in 2023 Intel had a 'hardware-only AI-accelerator focus,' which contradicts the original answer stating that in 2023 Intel already had a modular, software-centric edge-native platform. This mischaracterization undermines the evolution narrative. Additionally, the LLM introduces specific products—Gaudi 3, Jaguar Shores GPU, 4th-Gen Xeon D—as if they were central to the 2024 strategic shift, but these are not mentioned in the ground truth and may be factually out of scope or incorrectly timed. (2) Quantitatively, the claim of 'more than 500 network builders' lacks corroboration in the original answer, which does not provide a number for partners—this is an unsupported addition. All other numbers (none explicit beyond the 500) are consistent by absence. (3) The multi-hop reasoning is partially sound: the model attempts to contrast 2023 and 2024 strategies and integrates software and partnerships. However, it fails to capture the core conceptual shift from a horizontal edge platform to the NEX initiative focused on cloud-native, general-purpose compute on programmable hardware. Instead, it emphasizes new hardware launches not in the ground truth, indicating flawed synthesis. (4) Correctness is scored 6 due to partial factual alignment but major strategic misrepresentation. Quantitative accuracy is 8 because only one unverified number (500) is added. Qualitative accuracy is 5 due to incorrect framing of Intel’s 2023 position and unsupported product-centric evolution. Contextual relevance is 9 as the response stays on-topic and addresses software, ecosystem, and evolution across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1445,
        "completion_tokens": 521,
        "total_tokens": 1967
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How did the composition and value of CVS's long-term debt related to senior notes due in 2030 evolve between 2023 and 2024, particularly regarding the 1.75% senior notes due August 2030?",
      "original_answer": "In 2023, the 1.75% senior notes due August 2030 had a value of $1,250 million. In 2024, this value remained unchanged at $1,250 million. However, other senior notes due in 2030, such as the 3.75% senior notes due April 2030, decreased from $1,500 million in 2023 to $1,500 million in 2024, indicating stability in some areas of long-term debt but no change in the 1.75% notes specifically.",
      "llm_answer": "\nBetween 31 December 2023 and 31 December 2024 the $1.25 billion aggregate principal of CVS’s 1.75 % senior notes maturing in August 2030 was unchanged, but its share of the company’s long‑term debt fell as total long‑term borrowings rose from about $58.6 billion (net of discounts) to roughly $60.5 billion.  Consequently, while the note’s face value and its net carrying amount after discounts remained essentially $1.25 billion, the 2030 series became a smaller component of the overall senior‑note portfolio, which was reshaped by the 2024 issuances of new 5.4 %–6.05 % senior notes and the repurchase/early redemption of earlier convertible and other notes.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the $1.25 billion value of the 1.75% senior notes due August 2030 as unchanged between 2023 and 2024, which aligns with the ground truth. However, the ground truth states that other 2030 notes (3.75% due April 2030) remained stable at $1,500 million, while the LLM does not mention this and instead introduces new information about 2024 issuances of 5.4%-6.05% notes and repurchases, which is not in the original answer and cannot be verified from the provided truth. (2) The quantitative values for the 1.75% notes ($1.25 billion) are accurate and correctly formatted. However, the LLM introduces total long-term debt figures of $58.6 billion (2023) and $60.5 billion (2024), which are not present in the ground truth and cannot be confirmed; these numbers may be factually correct but represent unverified extrapolation. The claim about the note's 'share falling' due to rising total debt is speculative and not supported in the original answer. (3) The multi-hop reasoning is partially sound: the model correctly tracks the specific 1.75% notes over time. However, it adds synthesis about portfolio composition changes not present in the ground truth, going beyond the data provided. The original answer emphasizes stability across 2030-dated notes, while the LLM implies a shift in composition that isn't corroborated. (4) The correctness score is 6 due to accurate core facts about the 1.75% notes but significant unverified additions. Quantitative accuracy is 6 because while the key number is correct, unsupported totals reduce precision. Qualitative accuracy is 7 due to sound reasoning on the specific note but overreach in portfolio interpretation. Contextual relevance is 9 as the response directly addresses the question's focus on evolution of debt composition and value.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 495,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did Netflix's ad-supported subscription plan evolve between 2023 and 2024 in terms of its role within the company's pricing strategy and membership growth objectives?",
      "original_answer": "In 2023, Netflix introduced the ad-supported subscription plan as a new, lower-priced option aimed at expanding its membership base and addressing competitive pressures by offering a more accessible entry point. This was part of broader efforts to adjust pricing models and membership plans to improve value perception. By 2024, the ad-supported plan had become a core component of Netflix's pricing strategy, explicitly included in a range of plans designed to meet varied consumer needs, indicating its integration into the company's long-term growth framework. This evolution reflects a shift from experimental pricing to a strategic offering intended to support sustained membership growth across different market segments.",
      "llm_answer": "\nBetween 2023 and 2024 Netflix moved the ad‑supported tier from a pilot offering to a core element of its pricing mix, explicitly positioning a new, lower‑priced ad‑supported subscription plan as a way to attract price‑sensitive households and broaden overall membership growth.  In its 2024 filing the company repeatedly cites the ad‑supported plan as a key lever for driving subscriber additions and meeting its operating‑margin target, underscoring its strategic role in the firm’s pricing strategy and membership‑growth objectives.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that Netflix introduced the ad-supported plan in 2023 as a lower-priced option to attract price-sensitive users and expand membership, and that by 2024 it had become a core part of the pricing strategy—matching the original answer's claim about its evolution from an experimental to a strategic offering. (2) There are no numeric values (e.g., dollar amounts, percentages, subscriber counts) in either the question or the answers, so quantitative accuracy is not compromised; dates (2023 and 2024) are correct and consistently used. (3) The multi-hop reasoning is sound: the LLM synthesizes the plan’s introduction, its strategic intent (growth, pricing segmentation), and its elevated role in 2024 based on Netflix’s own framing in filings. It correctly infers strategic integration from repeated emphasis in the 2024 filing. (4) The only minor shortcoming is that the LLM answer does not explicitly mention the 'value perception' or 'competitive pressures' context from 2023, nor does it frame the 2024 role as part of a 'range of plans' for varied consumer needs—slight omissions in completeness, but the core strategic evolution is accurately conveyed. Overall, the answer is semantically equivalent and contextually precise, warranting a high correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 379,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Tesla's approach to the Tesla Semi evolved between 2023 and 2024, based on its production status and strategic positioning?",
      "original_answer": "In 2023, Tesla stated that it had begun early production and deliveries of the Tesla Semi, indicating initial market introduction and limited availability. By 2024, Tesla's production status for the Tesla Semi had advanced to 'pilot production' at its Nevada facility, suggesting a more structured and expanded phase of manufacturing, though not yet full-scale commercial production. This evolution reflects Tesla's strategic progression from initial rollout to a more mature testing and scaling phase for the commercial electric vehicle.",
      "llm_answer": "\nBetween 2023 and 2024 Tesla moved the Semi from an early‑stage, limited‑run commercial truck to a formally pilot‑production model (now being assembled at the Nevada Gigafactory) and tied its future scaling to the company’s broader product‑and‑manufacturing roadmap.  The 2024 filing emphasizes that the Semi’s growth will depend on ramping Gigafactory capacity, in‑house battery‑cell production, cost‑reduction initiatives and integration with Tesla’s autonomous‑driving/FSD platform—positioning the truck as a cornerstone of the company’s commercial‑EV strategy rather than a niche side project.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution in Tesla's approach: from early production/deliveries in 2023 to pilot production in Nevada in 2024, which matches the original answer. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is unaffected and remains perfect. (3) The multi-hop reasoning is sound—synthesizing production status changes and strategic positioning across years. The LLM adds contextual depth (e.g., linking Semi’s scaling to Gigafactory capacity, battery-cell production, cost reduction, and FSD integration) that is consistent with a strategic shift toward treating the Semi as a core part of Tesla’s commercial EV strategy, which is implied in the original answer’s 'cornerstone' framing. (4) Minor deduction in qualitative accuracy because the original answer does not explicitly mention FSD/autonomous integration or cost-reduction initiatives—these are plausible inferences but not confirmed in the ground truth. However, they do not contradict it and enhance strategic context without introducing errors. Overall, the answer is factually correct, complete, and relevant, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 351,
        "total_tokens": 1631
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "What does the expansion of NextEra Energy's Executive Retention Employment Agreements from 2023 to 2024 suggest about the company's approach to leadership continuity and its strategic emphasis on executive talent retention?",
      "original_answer": "In 2023, NextEra Energy had active Executive Retention Employment Agreements with executives including Mark Lemasney (signed January 1, 2023) and Armando Pimentel, Jr. (signed February 15, 2023), indicating a focus on retaining key leadership at that time. By 2024, the company not only maintained those agreements but also introduced a new agreement with Brian Bolster, dated May 6, 2024, showing an expansion in the number of covered executives. This evolution suggests that NextEra Energy has placed increasing strategic importance on securing leadership continuity and minimizing executive turnover risk, particularly during periods of potential transition or uncertainty. The addition of new executives under retention agreements implies a proactive approach to talent management, which could signal confidence in leadership or a response to external pressures affecting executive mobility.",
      "llm_answer": "\nThe 2024 SEC filings add new Executive Retention Employment Agreements—most notably for Nicole J. Daggs (effective Jan 1 2024) and Brian Bolster (effective May 6 2024), extending a pattern that began with 2023 contracts for Mark Lemasney and Armando Pimentel. This expansion signals NextEra’s deliberate effort to lock in senior leadership as it scales, underscoring a strategic focus on continuity and the retention of top‑tier executive talent to drive its long‑term growth agenda.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the continuation of Executive Retention Employment Agreements from 2023 (Mark Lemasney and Armando Pimentel) and the addition of new agreements in 2024. However, it incorrectly names Nicole J. Daggs as a new 2024 executive with an agreement effective January 1, 2024, which is not present in the ground truth. The only new 2024 executive confirmed in the original answer is Brian Bolster (effective May 6, 2024), whose date is accurately reported. The inclusion of Daggs introduces an entity error, though the core expansion narrative remains valid. (2) Dates for Brian Bolster (May 6, 2024) and the 2023 executives are correct. The January 1, 2023, date for Lemasney and February 15, 2023, for Pimentel are not contradicted, though not fully specified in the LLM answer—minor omission, not error. The incorrect addition of Daggs with a specific effective date reduces quantitative accuracy. (3) The multi-hop reasoning is sound: the model correctly infers that expanding the number of executives under retention agreements suggests a strategic emphasis on leadership continuity and talent retention. The conclusion aligns with the original answer’s interpretation, showing proper synthesis across years and executives. (4) Despite the erroneous inclusion of Daggs, the LLM captures the key trend and strategic implication accurately. The core facts about expansion and intent are correct, warranting a high score, but the incorrect entity prevents a 9–10. Contextual relevance is perfect—the answer directly addresses leadership continuity and talent retention as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 444,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Intel's approach to xPU products evolved from 2023 to 2024, particularly in terms of strategic focus and product development priorities?",
      "original_answer": "In 2023, Intel's focus on xPU products was part of a broader R&D strategy that included process and packaging technology, AI, and software, with $16.0 billion spent on R&D. The company faced challenges in timely product development and manufacturing process introductions, which had previously caused delays and cost overruns. By 2024, Intel had evolved its approach by embedding xPU products more deeply into its strategic priorities, specifically under the theme of 'product competitiveness.' The company announced the creation of an advisory group to expand the x86 ecosystem and emphasized the xPU family of products—including client and data center GPUs, IPUs, FPGAs, and other accelerators—as a way to meet diverse computing needs. This represents a shift from a general R&D focus to a more structured and strategic product development initiative.",
      "llm_answer": "\nFrom 2023 to 2024 Intel moved from simply building and stabilizing its xPU portfolio (client‑ and data‑center GPUs, IPUs, FPGAs, etc.) and coping with process‑technology delays, to a deliberate, ecosystem‑focused strategy.  In 2024 the company created an advisory group to broaden the x86 ecosystem, emphasized open‑platform standards, and positioned its xPU family as the core of an AI‑centric “compute‑everywhere” roadmap, while using external foundry capacity and Smart‑Capital financing to accelerate product rollout and scale manufacturing.  This reflects a shift from defensive product development to an aggressive, open‑ecosystem push to democratize compute and capture growth in AI, edge and networking.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in Intel's xPU strategy from 2023 to 2024 as described in the ground truth. (1) It correctly identifies the shift from a broad R&D and stabilization focus in 2023—mentioning process-technology delays—to a more strategic, ecosystem-driven approach in 2024. The creation of an advisory group to expand the x86 ecosystem is accurately reflected. (2) There are no numeric inaccuracies; the LLM does not introduce any incorrect figures and avoids making claims about R&D spending ($16.0 billion in 2023) that it cannot fully contextualize, which is acceptable given the focus on strategic evolution rather than financials. (3) The multi-hop reasoning is sound: it synthesizes the shift in strategic focus, product development priorities, and ecosystem expansion. The mention of external foundry use and Smart Capital aligns with Intel’s broader 2024 strategy, even if not in the original answer—this is a reasonable inference and does not contradict the ground truth. (4) The LLM enhances the original answer with terms like 'AI-centric compute-everywhere roadmap' and 'democratize compute,' which are semantically consistent with positioning xPUs to meet diverse computing needs. The only minor gap is that the original emphasizes 'product competitiveness' as the strategic theme, which the LLM does not explicitly name, but the concept is implicitly covered. Overall, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 419,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Netflix's approach to advertising technology evolved between 2023 and 2024, particularly in terms of organizational development and infrastructure investment?",
      "original_answer": "In 2023, Netflix emphasized its limited experience with advertising and outlined several dependencies, particularly on third-party service providers for ad management and the need to attract and retain advertisers. The company also highlighted risks related to developing the necessary advertising technology infrastructure. By 2024, Netflix shifted toward a more proactive stance, emphasizing its ability to 'develop and expand an advertising sales and advertising technology organization team' and 'develop the technology and related infrastructure to support advertising and drive value to advertisers.' This indicates a strategic evolution from reliance on external providers to internal development and investment in ad tech capabilities.",
      "llm_answer": "\nBetween 2023 and 2024 Netflix shifted from merely acknowledging that its advertising business was “new” and “subject to numerous risks” — highlighting the lack of operating history and the need to attract advertisers — to explicitly stating that it is building a dedicated advertising‑sales and ad‑technology organization and investing in the underlying ad‑serving, measurement and analytics infrastructure needed to support that effort. The 2024 filing emphasizes expanding the ad‑sales team, developing proprietary ad‑technology and partner ecosystems, and creating scalable infrastructure to drive advertiser value and sustain growth in the ad‑supported subscription tier.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution in Netflix's approach from 2023 to 2024: in 2023, Netflix acknowledged its limited experience, risks, and reliance on external partners; by 2024, it emphasized internal development of advertising sales teams and technology infrastructure. All key factual elements—lack of operating history, need to attract advertisers, shift toward building internal ad tech and sales teams, investment in ad-serving, measurement, analytics, and scalable infrastructure—are present and correctly represented. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or the original answer, so quantitative accuracy is not applicable beyond correct use of years (2023 and 2024), which are accurate. (3) The multi-hop reasoning is sound: the model synthesizes Netflix’s changing stance across two years, contrasting risk-aware caution in 2023 with proactive organizational and infrastructural development in 2024. The mention of 'proprietary ad-technology' and 'partner ecosystems' adds slight elaboration beyond the original but remains consistent with the source. (4) The only reason for not scoring a perfect 10 is minor semantic expansion (e.g., 'partner ecosystems' is implied but not explicitly stated in the ground truth), but this does not detract from factual correctness. Overall, the answer is contextually precise, factually correct, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 416,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Tesla's approach to free Supercharging programs evolved between 2023 and 2024, particularly in terms of revenue recognition and program structure?",
      "original_answer": "In 2023, Tesla's free Supercharging programs were included under Automotive Sales Revenue as part of the revenue associated with new vehicle deliveries, indicating they were bundled with vehicle sales and recognized over time. By 2024, Tesla began deferring revenue related to features such as FSD (Supervised), internet connectivity, and free Supercharging, recognizing these as liabilities to be amortized over time rather than immediately upon vehicle delivery. This structural shift reflects a more formalized and segmented approach to monetizing these features, including free Supercharging, which allows Tesla to better align revenue recognition with service delivery.",
      "llm_answer": "\nTesla continues to treat free Supercharging as a separate performance obligation and to recognize the related revenue on a straight‑line basis over the vehicle’s expected ownership period (i.e., not when the charge is used).  The deferred‑revenue balance for these services grew from $3.536 billion at the end of 2023 to $3.599 billion at the end of 2024, and revenue recognized from the balance increased to $1.188 billion in 2024 versus $595 million in 2023—showing a modest expansion of the program but no change in the underlying recognition method.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies in both quantitative and qualitative aspects, despite addressing the right topic. (1) Quantitatively, the LLM provides specific figures—$3.536 billion deferred revenue at end of 2023, $3.599 billion at end of 2024, and revenue recognized of $1.188 billion in 2024 vs $595 million in 2023—that are not present in the original answer and cannot be verified from the provided ground truth. These numbers appear fabricated or misattributed, as the original answer does not include any dollar amounts related to deferred revenue balances or recognized revenue. (2) Qualitatively, the LLM claims Tesla 'continues to treat free Supercharging as a separate performance obligation' with no change in method, which directly contradicts the original answer stating a structural shift occurred in 2024: Tesla began deferring revenue for features like free Supercharging rather than including them in Automotive Sales Revenue at delivery. This represents a key change in revenue recognition policy, but the LLM incorrectly asserts the method remained unchanged. (3) The multi-hop reasoning is flawed because the LLM fails to recognize the evolution between 2023 and 2024—specifically, the move from bundling free Supercharging revenue into vehicle sales to deferring it as a liability. Instead, it assumes consistency, undermining the core of the question. (4) Contextually, the answer is relevant and uses appropriate financial terminology (e.g., performance obligation, straight-line basis, deferred revenue), but the incorrect assertion of a static policy and inclusion of unsupported numerical data severely reduce factual accuracy. While the general idea of deferral over time aligns with the 2024 practice, the denial of a change in approach makes the conclusion invalid.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 491,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has NextEra Energy's approach to issuing Series O Junior Subordinated Debentures evolved between 2023 and 2024, particularly in terms of coupon structure and maturity dates, and what might this shift indicate about their financing strategy?",
      "original_answer": "In 2023, NextEra Energy issued the Series O Junior Subordinated Debentures due on May 1, 2079, with no explicit coupon rate disclosed in the filing. This indicates a potentially fixed or deferred interest structure typical for long-dated junior subordinated instruments. By 2024, the Series O Debentures were issued with a defined coupon rate of 5.55% and a significantly shorter maturity date of November 1, 2029. This represents a strategic shift toward issuing more conventional debt instruments with shorter durations and clearly defined interest costs. This evolution suggests a possible recalibration of NextEra’s capital structure strategy, favoring shorter-term, more predictable financing over long-dated, potentially lower-yielding instruments.",
      "llm_answer": "\nBetween 2023 and 2024 NextEra Energy moved away from relying on the long‑dated, fixed‑rate Series O junior subordinated debentures (originally issued in 2019 with a May 1 2079 maturity) and began supplementing the capital stack with newer junior‑debt tranches that have shorter maturities and varied coupons.  In the 2024 filings the company issued Series S and Series T junior subordinated debentures at 5.90 % due August 15 2055, as well as a floating‑rate junior debenture due February 4 2028, while the original Series O remains outstanding but is no longer the vehicle for fresh issuance.  This shift signals a more flexible financing strategy that emphasizes staggered, shorter‑term maturities and higher‑coupon or floating‑rate features to better match cash‑flow needs and take advantage of evolving market conditions.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to correctly represent the evolution of NextEra Energy's Series O Junior Subordinated Debentures between 2023 and 2024. (1) QUANTITATIVE INACCURACY: The ground truth states that in 2023, the Series O debentures were issued with a maturity of May 1, 2079, and no explicit coupon; in 2024, the same Series O was reissued with a 5.55% coupon and a maturity of November 1, 2029. The LLM instead claims that in 2024, NextEra issued Series S and Series T debentures (not Series O), with maturities in 2055 and 2028 and a coupon of 5.90%, which are entirely different securities not mentioned in the ground truth. These numbers, series names, and dates are incorrect. (2) COMPLETENESS: The question specifically asks about the evolution of the Series O debentures, but the LLM shifts focus to Series S and T, failing to mention the 5.55% coupon or the 2029 maturity for Series O in 2024. It also incorrectly states that the Series O is no longer used for fresh issuance, contradicting the ground truth which implies a restructuring of Series O itself. (3) ENTITY ACCURACY: The LLM misidentifies the financial instruments involved—Series O is central to the question, but the answer discusses unrelated series (S and T), indicating a failure in entity recognition. (4) REASONING: The multi-hop reasoning is flawed because it draws conclusions about financing strategy based on incorrect instruments. While the general idea of shifting to shorter maturities and defined coupons aligns with the ground truth, it is applied to the wrong securities, undermining the logic. (5) SEMANTIC EQUIVALENCE: The overall message about strategic shift has partial alignment, but due to incorrect entities and numbers, the answer does not convey the same information. The conclusion about flexible financing is plausible but unsupported by accurate data. Thus, the correctness score is low due to major factual and quantitative errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 530,
        "total_tokens": 1950
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has ExxonMobil's consideration of OPEC investment activities evolved in its impairment assessment framework from 2022 to 2023, particularly in relation to long-term oil supply dynamics?",
      "original_answer": "In 2022, ExxonMobil explicitly stated that OPEC investment activities and production policies had an impact on world oil supplies and were considered in the context of impairment assessments. By 2023, while the company still acknowledged OPEC's influence on global oil supply, the discussion of OPEC was embedded more broadly within a comprehensive cash flow assessment framework that included forward-looking variables such as greenhouse gas emission costs and net-zero targets. This indicates a shift from a direct focus on OPEC's role to a more integrated view of macroeconomic and environmental factors affecting long-term asset valuation.",
      "llm_answer": "\nFrom 2022 to 2023 ExxonMobil moved from a generic acknowledgement that OPEC investment and production policies affect world oil supplies to explicitly embedding those policies in the long‑term price and cash‑flow assumptions used in its impairment testing.  The 2023 disclosures stress that OPEC’s supply decisions are a core driver of the Corporation’s outlook for future oil volumes, margins and commodity prices, and therefore a critical input when evaluating whether the carrying value of upstream assets is recoverable.  Consequently, the impairment framework now treats OPEC‑related supply dynamics as a fundamental, long‑term factor—not a temporary market blip—when judging asset recoverability.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim about ExxonMobil's evolution from 2022 to 2023. According to the ground truth, ExxonMobil shifted *away* from a direct focus on OPEC in 2023, instead embedding OPEC-related considerations within a broader framework that includes environmental and macroeconomic factors like greenhouse gas costs and net-zero targets. However, the LLM claims the opposite — that ExxonMobil moved *toward* more explicit integration of OPEC policies into long-term assumptions, treating them as a 'core driver' and 'fundamental factor' in 2023. This misrepresents the direction of change. There are no numerical values in the question or answers, so quantitative accuracy is not applicable in a traditional sense, but the temporal facts (2022 vs 2023) and qualitative descriptions of disclosure content are incorrect. The reasoning is internally logical but based on a reversed premise, failing the multi-hop synthesis requirement by drawing the opposite conclusion from the evidence. While the answer is relevant to the topic and discusses impairment, OPEC, and long-term dynamics, it fails on factual correctness of the evolution. Thus, the correctness and qualitative accuracy scores are low, while contextual relevance and technical precision (where applicable) are acceptable.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 365,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Netflix's approach to its ad-supported subscription plan evolved from 2023 to 2024, based on the level of detail and strategic emphasis provided in the filings?",
      "original_answer": "In 2023, Netflix's ad-supported subscription plan was mentioned in the context of uncertainty and risk, particularly around consumer adoption and the lack of operating history with such offerings, which could lead to discrepancies between forecasts and actual results. By 2024, the ad-supported plan was presented as part of the company's broader pricing strategy, explicitly included in the description of plans offered to meet a variety of consumer needs. This shift indicates a move from a risk-focused perspective to a more confident, strategic positioning of the ad-supported plan as a core part of Netflix's business model.",
      "llm_answer": "\nIn the 2023 filing the ad‑supported subscription tier is mentioned only in passing—as “a range of pricing plans, including our ad‑supported subscription plan”—without any dedicated strategic discussion. By the 2024 filing the plan is framed as a core element of Netflix’s growth and margin strategy, explicitly highlighted as a key lever for diversifying pricing, attracting price‑sensitive members and driving operating‑margin targets, and is referenced more prominently in the company’s strategic narrative.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth in terms of the evolution of Netflix's ad-supported subscription plan from 2023 to 2024. It correctly identifies that in 2023, the plan was mentioned only briefly and without strategic emphasis, which matches the original answer's characterization of it being discussed in the context of uncertainty and risk. In 2024, the LLM correctly notes a shift toward strategic prominence, describing the plan as a 'core element' of growth and margin strategy, used to diversify pricing and attract price-sensitive users—this reflects the original answer’s point about integration into broader pricing strategy and consumer needs. There are no numeric values to verify, so quantitative accuracy is 10. The qualitative accuracy is slightly reduced (9 instead of 10) because the LLM does not explicitly mention the 'risk' framing in 2023 (e.g., lack of operating history, forecast uncertainty), which is a key nuance in the ground truth. However, the implication of minimal strategic discussion covers part of this. The reasoning is sound, showing a clear multi-hop synthesis across years and strategic narratives. Contextual relevance is perfect—the response directly addresses the evolution in level of detail and strategic emphasis. Minor omission of risk language prevents a full 10 on correctness, but overall the answer is semantically equivalent and highly accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 396,
        "total_tokens": 1686
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Amazon's approach to shipping offers evolved between 2022 and 2024, particularly in terms of cost drivers and strategic focus on fulfillment efficiency?",
      "original_answer": "In 2022, Amazon highlighted that shipping costs were expected to increase as customers increasingly adopted its shipping offers, used faster delivery methods, and as the company expanded its fulfillment network. Shipping costs in 2021 were $76.7 billion, and the company anticipated continued growth in these costs. The strategic emphasis was on mitigating these increases through higher sales volumes, network optimization, supplier negotiations, and operational efficiencies. By 2024, the focus had shifted: while the company still invested in expanding its fulfillment network, it emphasized fulfillment network efficiencies as a key cost offset. The 2024 report notes that increased sales and network investments drove up fulfillment costs, but these were partially offset by efficiency gains. This marks a strategic evolution from a customer-driven cost increase in 2022 to a more operations-centric efficiency focus by 2024.",
      "llm_answer": "\nBetween 2022 and 2024 Amazon continued to treat fast, low‑cost shipping (including Prime‑eligible offers) as a strategic marketing tool, but the economics of those offers shifted from pure network expansion and labor‑driven cost spikes to a greater emphasis on scale‑driven efficiency.  In the earlier period, fulfillment costs were driven mainly by higher volumes, rising wages, constrained labor markets and the need to add new fulfillment sites; by 2024 the company reported that the same cost pressures persisted, yet it was offsetting them with “fulfillment network efficiencies,” higher sales volumes, better supplier terms and reduced per‑unit shipping expenses, even as it kept expanding its warehouse footprint to meet growing shipment demand.  Consequently, the cost‑driver mix moved from “investment‑heavy” to “efficiency‑focused” while still using shipping offers to boost sales and customer loyalty.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: the shift from cost increases due to network expansion and customer adoption in 2022 to a focus on fulfillment efficiency by 2024 is accurately captured. While the LLM does not explicitly cite the $76.7 billion shipping cost from 2021 mentioned in the original answer, it correctly references rising fulfillment costs driven by volume, labor, and network expansion without introducing any incorrect figures—thus not violating quantitative accuracy. (2) No incorrect numbers, dates, or calculations are present; the absence of the $76.7B figure is a minor omission but not an error, as the LLM focuses on the trend rather than specific dollar amounts. (3) The multi-hop reasoning is sound: the model correctly synthesizes Amazon’s evolving strategy across 2022 and 2024, identifying the shift from investment-heavy growth to efficiency-driven cost management. It accurately links increased sales, supplier negotiations, and network efficiencies as offsetting factors. (4) The semantic meaning matches the original answer—phrasing like 'efficiency-focused' and 'offsetting cost pressures with fulfillment network efficiencies' reflects the strategic evolution described in the ground truth. The answer is fully contextually relevant, addressing both cost drivers and strategic focus on fulfillment efficiency. One point is deducted from qualitative accuracy for not referencing the 2021 cost baseline, which provides important context for the 2022 outlook, though the overall reasoning remains robust.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1464,
        "completion_tokens": 437,
        "total_tokens": 1901
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did Duke Energy's utilization and reporting of the Master Retirement Trust evolve between 2023 and 2024, particularly in terms of asset allocation and disclosure practices?",
      "original_answer": "In 2023, Duke Energy's Master Retirement Trust was described in terms of its investment objective, focusing on achieving sufficient returns for plan benefits, with specific mention of VEBA trusts and their target and actual asset allocations. By 2024, the reporting evolved to include a more detailed breakdown of how different subsidiaries were allocated portions of the trust, such as Duke Energy Progress at 15% and Duke Energy Florida at 18%. Additionally, 2024 introduced a reconciliation of beginning and ending balances for pension and post-retirement assets, including Level 3 fair value disclosures, which was not present in 2023. This reflects a shift toward more granular and transparent reporting on trust assets and their valuation methodologies.",
      "llm_answer": "\nBetween 2023 and 2024 Duke Energy updated the Master Retirement Trust’s asset‑allocation targets and disclosed a more detailed fair‑value hierarchy: the 2024 tables show a modest rise in equity securities ( $2.46 bn vs $2.22 bn ) and cash ( $15 m vs $7 m ), a slight reduction in “not‑categorized” assets, and a lower Level‑3 balance ( $68 m vs $76 m ), while the subsidiary‑allocation percentages (≈27‑33 % each) remained unchanged.  The 2024 disclosures also introduce new target mixes—e.g., the RCBP portfolio is now 35 % liability‑hedging/65 % return‑seeking and the DELPP portfolio 80 % liability‑hedging/20 % return‑seeking—and provide a reconciliation of beginning‑to‑ending Level‑3 balances, reflecting a more granular reporting of asset‑class allocations and valuation levels.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant quantitative inaccuracies and introduces specific numerical data not present in the ground truth. The ground truth does not provide dollar amounts such as $2.46 billion or $2.22 billion for equity securities, $15 million vs $7 million for cash, or Level 3 balances of $68 million vs $76 million—these figures are fabricated or hallucinated. Additionally, the claim that subsidiary allocations were '≈27-33% each' contradicts the ground truth, which states Duke Energy Progress was allocated 15% and Duke Energy Florida 18% in 2024; no 2023 subsidiary percentages are given, so asserting they 'remained unchanged' is unsupported. The mention of specific portfolio targets (e.g., RCBP 35%/65%, DELPP 80%/20%) also does not appear in the original answer and lacks verification. However, the LLM correctly identifies a key qualitative evolution: the introduction of a reconciliation of beginning and ending Level 3 balances in 2024, reflecting more granular reporting on valuation methodologies. It also correctly notes increased disclosure around asset allocation and fair value hierarchy, aligning with the ground truth’s emphasis on enhanced transparency. While the direction of change (more detailed, granular reporting) is accurately captured, the use of precise but incorrect numbers undermines factual reliability. The reasoning partially reflects multi-hop synthesis—comparing disclosure depth across years—but is weakened by invented metrics. Contextually, the response stays focused on asset allocation and disclosure practices, satisfying relevance despite factual flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 439,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has Google's financial relationship with Google Network Partners evolved between 2022 and 2024, particularly in terms of the cost structure and payment obligations?",
      "original_answer": "In 2022, Google's cost of revenues included significant Traffic Acquisition Costs (TAC) paid to Google Network partners, primarily for ads displayed on their properties, with a noted higher cost percentage compared to Google Search properties due to the substantial share of advertiser revenues paid out as TAC. By 2024, Google Network partners were referenced in the context of operating cash outflows, indicating that payments to these partners had become a primary use of operating cash. This shift suggests a transformation in the nature of the financial relationship, from a cost-of-revenue model to a more direct operational cash flow obligation, reflecting a potential increase in the scale or structure of Google's dependency on these partners.",
      "llm_answer": "\nGoogle’s payments to Network Partners continue to flow through the traffic‑acquisition‑cost (TAC) framework that the 2022 filing describes as the primary cost component for ads placed on Google Network properties and notes that these costs represent a larger share of revenue for Network placements than for Search ads. The 2024 financials (pages 40‑44) show Google Services operating income rising to $121 billion, but the segment profitability table still lists TAC within cost of revenues, confirming that the obligation to remit a substantial portion of Network ad revenue to its partners persisted and grew in absolute amount alongside the expansion of Network revenues, while the underlying cost‑structure remained unchanged.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies that Traffic Acquisition Costs (TAC) remain the mechanism for payments to Google Network Partners in both 2022 and 2024, and accurately notes that TAC is a larger share of revenue for Network placements than for Search ads—this aligns with the original answer's point about higher cost percentages. It also correctly states that TAC is still included in cost of revenues in 2024, citing segment profitability tables and operating income figures ($121B), which are plausible and contextually appropriate (quantitative accuracy is high, hence score of 8). However, the LLM misses a key evolution highlighted in the ground truth: the shift from viewing these payments merely as a cost-of-revenue item to recognizing them as a major operating cash outflow in 2024, indicating a structural change in financial obligation. Instead, the LLM concludes the 'cost structure remained unchanged,' which contradicts the original answer’s assertion of a transformation in the nature of the relationship. This reflects a failure in multi-hop reasoning—synthesizing the shift in financial classification and implication over time—leading to a lower qualitative accuracy score. While the entities (Google, Network Partners, TAC) and years (2022, 2024) are correct and the response is highly relevant to the question, the incorrect interpretation of the evolution in cost structure significantly undermines the correctness of the conclusion, warranting a 6 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 410,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did the treatment and financial impact of offsetting swap positions evolve between 2022 and 2023, particularly in terms of fair value changes and settlements reported in the consolidated income?",
      "original_answer": "In 2022, UPS reported fair value changes and settlements of interest rate swaps, foreign currency exchange forwards, and investment market price forward contracts not designated as hedges, with specific figures for 2021 and 2020 provided (e.g., $163M net gain in 2021 and $124M net gain in 2020). In 2023, the company continued to report these derivatives at fair value with unrealized gains and losses in earnings, but the disclosure now included data for 2023 and 2022, showing a shift in focus to more recent periods. The explicit mention of terminating contracts or entering into offsetting swap positions remained consistent, but the financial impact in 2023 was not quantified in the excerpt, indicating a change in transparency around current-year derivative impacts.",
      "llm_answer": "\nBetween 2022 and 2023 the company kept offsetting swap positions on its balance sheet but did not elect to present them net; gross asset‑derivative fair value fell from $425 million to $158 million and gross liability‑derivative fair value rose from $32 million to $92 million, so the “net‑if‑offset” amounts dropped from $398 million to $92 million (assets) and from $5 million to $26 million (liabilities). As a result, the income‑statement impact of the related unrealized gains and losses shrank dramatically—from a $69 million loss in 2022 to a $7 million loss in 2023—reflecting both smaller fair‑value adjustments and settlements of the offsetting swaps.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in terms of quantitative accuracy and fails to align with the ground truth. (1) The numbers provided—such as gross asset-derivative fair value dropping from $425M to $158M, liability rising from $32M to $92M, and income statement impacts of $69M loss in 2022 and $7M loss in 2023—are not present in the original answer and contradict the ground truth, which does not quantify the 2023 financial impact at all. The original explicitly states that 'the financial impact in 2023 was not quantified in the excerpt,' making the LLM's precise figures factually wrong. (2) There are no calculations in the ground truth to verify; the LLM fabricates a detailed quantitative narrative unsupported by the source. (3) The qualitative reasoning is partially sound in that it recognizes the ongoing use of offsetting swaps and fair value reporting, and mentions lack of net presentation, which could be consistent with accounting standards. However, it incorrectly implies that detailed 2023 settlement and fair value change data were available and showed a reduction in losses, whereas the ground truth emphasizes a *lack* of current-year transparency. (4) Contextually, the answer addresses the evolution of derivative treatment and income statement impact, so it stays on topic, but the invented specifics severely undermine correctness. The core failure is multi-hop synthesis: instead of noting the shift in disclosure focus and reduced transparency, the model invents a false quantitative trend, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 426,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "What does the increased prominence of the Directors' Savings Plan in Duke Energy's 2024 disclosures indicate about the company's director compensation strategy compared to 2023?",
      "original_answer": "In 2023, the Directors' Savings Plan was referenced primarily through historical amendments listed in exhibit references (e.g., Exhibit 10.12), with no detailed description of its structure or strategic role in compensation. In contrast, the 2024 filing provides a substantive description of the plan, explaining how outside directors may defer annual compensation, the phantom investment options available, and how balances are adjusted accordingly. This increased prominence indicates a shift toward emphasizing the plan as a core component of director compensation and deferral flexibility, suggesting a more strategic and transparent approach to director-level financial incentives in 2024.",
      "llm_answer": "\nThe 2024 filing gives the Directors’ Savings Plan a dedicated slot in the equity‑compensation table and explains its deferred‑compensation mechanics in detail—something that was only a brief footnote in the 2023 filing.  This heightened visibility shows that Duke Energy is deliberately using the plan as a core element of its director‑pay strategy, emphasizing deferred, performance‑linked benefits and greater flexibility for retaining outside directors, whereas in 2023 the plan was mentioned only in passing.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core shift in Duke Energy's director compensation strategy between 2023 and 2024. It correctly identifies that the Directors' Savings Plan was only briefly mentioned in 2023 (as a footnote or passing reference) versus receiving a dedicated, detailed explanation in 2024, including deferred-compensation mechanics. This aligns with the ground truth, which notes the 2023 mention was limited to exhibit references (e.g., Exhibit 10.12) without substantive description, while 2024 includes a full explanation of deferral options and phantom investments. The LLM accurately infers that this reflects a strategic shift toward using the plan as a core component for director pay, emphasizing flexibility and retention—consistent with the ground truth’s conclusion about increased strategic and transparent use. The only minor shortcoming is that the LLM mentions 'performance-linked benefits,' which is not explicitly supported in the original answer (the ground truth emphasizes deferral and phantom investment adjustments, not performance linkage). This introduces a slight overinterpretation, preventing a perfect 10. All entities (Duke Energy, Directors' Savings Plan, 2023 vs 2024), years, and reasoning are correct. No numerical inaccuracies—both qualitative and quantitative elements are sound, with strong multi-hop synthesis between years and disclosure depth. The answer is fully contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 400,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has American Express's approach to developing value propositions evolved between 2022 and 2024, particularly in response to competitive pressures and changing customer behaviors?",
      "original_answer": "In 2022, American Express highlighted the challenge of developing compelling value propositions in the face of growing competition, particularly from alternative payment providers and digital wallets, which threatened to fragment customer spending and reduce the competitiveness of its offerings. The company emphasized the need to evolve its value propositions to retain relevance and attract customers amid rising Card Member rewards costs and shifting consumer preferences, especially in mobile and online payments. By 2024, the company's strategy had evolved to focus on expanding leadership in premium consumer and commercial payments, particularly targeting Millennial and Gen-Z consumers, and enhancing digital capabilities through investments in AI, automation, and the Amex app. It also emphasized the importance of strategic partnerships, dining platform expansion (including Tock and Rooam), and global merchant coverage growth as key enablers of its value proposition strategy. This represents a shift from a reactive stance on competition to a more proactive, innovation-driven approach.",
      "llm_answer": "\nBetween 2022 and 2024 American Express moved from a primarily “product‑refresh and cobrand‑protection” focus to a broader, experience‑driven value‑proposition strategy.  In the 2022 filing the company highlighted the need to refresh cards, protect and renegotiate premium partner relationships, and invest in technology and marketing to meet shifting consumer expectations, while warning that intense competition for merchants, surcharge‑driven pricing pressure and the rise of alternative payment mechanisms could erode discount rates.  By the 2024 filing the narrative emphasizes expanding leadership in the premium consumer space—especially with Millennial and Gen‑Z shoppers—by delivering personalized, digitally‑enabled rewards, travel‑and‑dining platforms, and AI‑enhanced services, all aimed at differentiating the brand amid growing competitive pressure on pricing, merchant acceptance and non‑traditional payment rivals.  Thus, the approach evolved from safeguarding existing partnerships to proactively shaping a differentiated, technology‑forward value proposition that aligns with changing customer behaviors.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the shift from a reactive to proactive strategy, focus on premium consumer and commercial payments, targeting Millennials and Gen-Z, investment in digital capabilities (AI, app), and strategic partnerships in dining (Tock, Rooam) and global merchant coverage. While the LLM does not explicitly name Tock and Rooam, it accurately captures the broader dining platform expansion theme. (2) There are no numeric values, percentages, or dollar amounts in either the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes information across 2022 and 2024 filings, identifying the evolution in strategy in response to competitive pressures (alternative payments, surcharge models) and changing customer behaviors (digital, mobile, experience-driven expectations). (4) The LLM uses different but semantically equivalent phrasing—e.g., 'product-refresh and cobrand-protection' vs. 'reactive stance', 'experience-driven value-proposition' vs. 'innovation-driven approach'—but conveys the same core evolution. The only minor omission is the lack of specific mention of 'commercial payments' and the exact names of dining platforms (Tock, Rooam), which slightly affects completeness but not overall correctness. Hence, a 9 is justified for qualitative accuracy and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1564,
        "completion_tokens": 408,
        "total_tokens": 1973
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has Exxon Mobil's approach to long-term debt financing evolved between 2022 and 2024, particularly regarding the composition of its long-term notes?",
      "original_answer": "In 2022, Exxon Mobil disclosed a broader range of debt instruments, including the 0.142% Notes due 2024, 0.524% Notes due 2028, 0.835% Notes due 2032, and the 1.408% Notes due 2039. By 2024, the company no longer listed the 0.142% Notes due 2024, indicating that those obligations had matured or been repaid. However, the 1.408% Notes due 2039 remained in the disclosure, suggesting a continued emphasis on long-term financing instruments with distant maturity dates. This shift reflects a strategic evolution in the company's capital structure, focusing more heavily on extended-term debt while retiring shorter-duration obligations.",
      "llm_answer": "\nBetween 2022 and 2024 Exxon Mobil moved its long‑term debt profile toward a larger share of low‑coupon, longer‑dated notes.  In 2022 the company’s long‑term notes were dominated by a handful of medium‑term series (e.g., 0.142 % due 2024 and higher‑coupon issues maturing in the mid‑2030s), but by the 2024 filing the outstanding long‑term notes had been reshaped around three new fixed‑rate series – 0.524 % due 2028, 0.835 % due 2032 and 1.408 % due 2039 – which together now constitute the bulk of its long‑term debt and reflect a lower weighted‑average interest cost and a strategic extension of the maturity horizon.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth, but contains a minor inaccuracy in framing. (1) Quantitatively, all cited notes—0.142% due 2024, 0.524% due 2028, 0.835% due 2032, and 1.408% due 2039—are accurately reported with correct interest rates and maturity years, matching the original answer. The absence of the 2024 note in 2024 is correctly implied as matured/repaid. (2) However, the LLM incorrectly states that the 2024 filing shows the long-term debt 'reshaped around three new fixed-rate series', implying these were newly issued between 2022 and 2024. The ground truth does not confirm they are new; it only confirms their continued presence. The 0.524%, 0.835%, and 1.408% notes may have been issued earlier and simply still outstanding. This misrepresents the evolution as more active restructuring than supported by the data. (3) The reasoning correctly infers a strategic extension of maturities and lower interest costs, which is consistent with retiring short-term debt (2024 note) and retaining longer-dated instruments. The synthesis across years is sound, though the conclusion about 'new' series introduces a speculative element. (4) Despite this, the core message—ExxonMobil extended its debt maturity profile and focused on longer-term, lower-coupon debt—is factually supported. The answer is highly relevant and captures the strategic shift. Minor deduction for implying issuance of new notes without evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 402,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has American Express's approach to corporate card solutions evolved between 2022 and 2024, particularly in terms of strategic emphasis and product differentiation?",
      "original_answer": "In 2022, American Express emphasized evolving card value propositions and differentiating corporate card and accounts payable expense management solutions as part of its broader commercial payments strategy. By 2024, the company continued to focus on commercial payments but introduced a more integrated global network approach, aiming to increase merchant acceptance and provide enhanced fraud protection and marketing insights. This shift indicates a move from internal product development focus in 2022 to a more externally integrated ecosystem strategy by 2024.",
      "llm_answer": "\nBetween 2022 and 2024 American Express moved from a broad‑based push to expand premium consumer membership toward a sharper focus on commercial‑payment growth, positioning corporate‑card and expense‑management offerings as a distinct profit centre.  The company began differentiating these solutions with added financing, banking‑type features and B2B payment capabilities (e.g., OptBlue, debit‑card expansions and data‑analytics tools), while also deepening merchant‑engagement programs and leveraging new leadership to accelerate product innovation and partnership‑driven value for business customers.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies American Express's strategic shift toward commercial payments between 2022 and 2024 and notes product differentiation in corporate card solutions, which aligns with the ground truth. However, it introduces elements not present in the original answer, such as a 'broad-based push to expand premium consumer membership' in 2022, which is not mentioned in the ground truth and may misrepresent the strategic context. The mention of specific products like OptBlue, debit-card expansions, and 'banking-type features' adds detail not supported by the original answer, which focuses on integrated global networks, fraud protection, and marketing insights. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not applicable—scored as 10 by default since no numbers are incorrect. (3) The multi-hop reasoning is partially sound: the model correctly infers a strategic evolution from internal product development to broader commercial emphasis, but it overreaches by introducing unverified product specifics and a consumer-focused prior strategy not in the source. The core evolution from product differentiation to a more integrated ecosystem is implied but not fully captured with accuracy. (4) The contextual relevance is high because the answer addresses the evolution in strategic emphasis and product differentiation as asked. However, the qualitative accuracy is reduced due to unsupported additions. The correctness score is 7 because the central idea of a shift toward commercial payments and enhanced offerings is correct, but the specifics diverge from the documented evolution in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 464,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has Amazon's financial relationship with AWS Services evolved between 2022 and 2024, particularly in terms of cash flow generation and strategic emphasis?",
      "original_answer": "In 2022, AWS Services were primarily discussed in the context of competitive pressures and risks, with an emphasis on the challenges of operating in a rapidly evolving and intensely competitive market. By 2024, AWS had transitioned into a key financial contributor, with Amazon reporting $115.9 billion in operating cash flow for that year, up from $84.9 billion in 2023, driven in part by AWS and other enterprise services. This reflects a shift from viewing AWS as a risk-laden venture to a core revenue generator funding broader corporate initiatives.",
      "llm_answer": "\nBetween 2022 and 2024 AWS moved from a major profit contributor to the dominant cash‑generating engine of Amazon: its net sales rose sharply—from roughly $90 billion in 2023 to $107.6 billion in 2024 (19 % YoY growth), expanding its share of total sales to 17 %—and that profitability helped lift operating cash flow from $84.9 billion to $115.9 billion.  To sustain this growth, Amazon dramatically increased capital spending on AWS‑focused technology infrastructure, raising cash capital expenditures from $48.1 billion in 2023 to $77.7 billion in 2024, underscoring a strategic shift to make the cloud platform the primary driver of cash flow and future innovation.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in AWS's role from a profit contributor to a dominant cash-generating engine, aligning with the ground truth's narrative of strategic evolution. It accurately reports the $84.9 billion and $115.9 billion operating cash flow figures for 2023 and 2024, respectively, which supports the core claim of increasing cash flow generation. However, the LLM introduces a net sales figure of $90 billion in 2023 and $107.6 billion in 2024, which are not present in the original answer and cannot be verified from the provided ground truth. These numbers may be factually correct but are not supported by the knowledge graph answer, making their inclusion a deviation. Additionally, the 19% YoY growth and 17% sales share are unsupported additions. The capital expenditure figures ($48.1B to $77.7B) are also not mentioned in the original answer, representing an overreach in detail not grounded in the provided truth. (2) While the operating cash flow numbers are correct and match the ground truth, the net sales and capex figures lack corroboration and introduce potential inaccuracies. The calculation of 19% growth from $90B to $107.6B is mathematically accurate, but the source of these numbers is unclear. (3) The multi-hop reasoning is strong: the model infers a strategic shift based on financial trends and correctly links increased investment to AWS's growing importance. It synthesizes the idea that AWS evolved from a competitive risk to a core financial driver, which is consistent with the original answer’s theme. (4) The correctness score is 8 because the central financial facts (cash flow figures) and strategic narrative are accurate and well-supported, but the addition of unverified sales and capex data reduces quantitative accuracy. Qualitative accuracy remains high due to sound reasoning and correct interpretation of strategic emphasis. Contextual relevance is perfect—the answer directly addresses cash flow and strategic evolution as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 543,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How did the scope or focus of trend analyses used in evaluating the historical consistency of regulatory asset balances evolve between 2023 and 2024?",
      "original_answer": "In 2023, trend analyses were used to evaluate the historical consistency of regulatory asset balances in general, without specific reference to asset retirement obligations. By 2024, the scope of the trend analyses remained focused on regulatory asset balances, but the audit procedures expanded to include a specific evaluation of the ongoing regulatory recoverability of asset retirement obligations related to coal ash, indicating a shift in focus toward more specialized regulatory compliance areas.",
      "llm_answer": "\nBetween 2023 and 2024 the trend‑analysis procedures grew from a general check of historical balance‑of‑regulatory‑asset consistency—comparing recorded balances to an independently derived expectation and testing deferred fuel and storm‑cost recoverability—to a more targeted review that also examined management’s forward‑looking estimate of storm‑cost recoveries not yet addressed in a commission order and incorporated representation from management that those costs are probable of recovery. In 2024 the firm added procedures to evaluate external regulatory filings and to test the completeness of the recorded balances, broadening the focus of the trend analysis toward the likelihood of future recovery of newly identified storm and fuel cost items.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in terms of the actual evolution of trend analyses for regulatory asset balances between 2023 and 2024, as described in the ground truth. While it correctly references trend analyses in the context of regulatory asset balances and mentions recoverability testing (e.g., deferred fuel and storm costs), it fabricates key details not present in the original answer. Specifically: (1) The original answer highlights a shift in 2024 toward evaluating the regulatory recoverability of asset retirement obligations related to coal ash—a critical and specific focus area—but the LLM answer omits this entirely and instead invents procedures around 'forward-looking estimate of storm-cost recoveries', 'external regulatory filings', and 'completeness testing' that are not supported by the ground truth. (2) The LLM introduces new elements such as 'independently derived expectation' and 'management representation on probable recovery' that do not appear in the original and misrepresent the nature of the audit procedure changes. (3) The core evolution in focus—from general consistency in 2023 to coal ash-related asset retirement obligations in 2024—is completely missed, indicating a failure in multi-hop reasoning or data synthesis. (4) Quantitatively, there are no explicit numbers (e.g., dollar amounts, percentages, dates beyond years) in either answer, so the LLM does not introduce numerical inaccuracies—hence a moderate score on quantitative accuracy. (5) Contextually, the answer stays within the domain of regulatory asset audits and trend analysis, so it is relevant, but it addresses a different aspect of regulatory recoverability (storm and fuel costs) than what was specified (coal ash AROs), leading to significant factual divergence. Overall, the answer fails to capture the correct scope change and introduces unsupported details, warranting a low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 521,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How did Costco's strategy regarding the penetration of private-label items evolve between 2022 and 2023 in response to cost and pricing pressures?",
      "original_answer": "In 2022, Costco responded to higher-than-recent inflation in merchandise costs by employing several strategies, including absorbing some cost increases internally, purchasing earlier and in larger volumes, and selectively passing on cost increases to members, all of which were aimed at maintaining pricing authority while managing gross margin pressures. In 2023, Costco continued to emphasize increasing the penetration of its private-label items as part of its broader merchandising and pricing strategy to adapt to ongoing cost increases and competitive pressures. This indicates a shift from a more reactive approach in 2022 to a more strategic and sustained emphasis on private-label offerings in 2023 to maintain competitive pricing and member value.",
      "llm_answer": "\nBetween fiscal 2022 and 2023 Costco moved from a general wording that it was “increasing the penetration of our private‑label items” to a more explicit, cost‑driven focus on private‑label growth as a way to absorb rising merchandise costs and limit price increases.  In 2022 the comment appeared as one of several pricing levers; by 2023 the same language was repeated in the context of “responding to cost and pricing pressures,” signalling that expanding private‑label share had become a central tactic for sustaining low‑price perception amid inflation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. It correctly identifies the evolution in Costco's strategy between 2022 and 2023 regarding private-label penetration in response to cost and pricing pressures. Quantitatively, no specific numbers (e.g., percentages, dollar amounts) are mentioned in either the original or LLM answer, so accuracy is not compromised—this is consistent with the source. The LLM correctly notes that in 2022, private-label growth was mentioned among other pricing levers, while in 2023 it became more central and explicitly tied to managing cost pressures, reflecting a strategic shift. This captures the multi-hop reasoning required: synthesizing changes in tone, context, and strategic emphasis across two fiscal years. The only minor shortcoming is that the LLM does not explicitly mention Costco's tactics in 2022 such as absorbing costs, buying in bulk, or selective price pass-throughs, which were part of the original answer and provide important context for the reactive vs. strategic shift. However, the core insight—that private-label expansion evolved into a central tactic by 2023—is clearly and correctly conveyed. Wording differs but semantic meaning and analytical depth are equivalent. All entities (Costco, private-label items, 2022–2023 timeframe, cost and pricing pressures) are accurate and correctly contextualized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 384,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has the financial outlook for Paxlovid evolved between 2023 and 2024 based on Pfizer's remaining performance obligations?",
      "original_answer": "In 2023, Pfizer did not disclose specific remaining performance obligations for Paxlovid. However, by the end of 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, indicating a clear financial commitment from customers for future delivery of the product. This evolution suggests increased contractual certainty and forward-looking revenue expectations for Paxlovid between the two years.",
      "llm_answer": "\nBased on the 10‑K disclosures, Pfizer’s remaining performance obligations for Paxlovid fell dramatically from roughly $5 billion of deferred revenue at the end of 2023 to only about $1 billion of contracted revenue expected to be recognized through 2025‑2028 as of December 31 2024.  This decline reflects the shift from large government stock‑purchase contracts to commercial‑market sales, with future revenue now tied to the limited set of long‑term delivery obligations that will be recognized as courses are shipped rather than from advance payments.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Pfizer did not disclose specific remaining performance obligations (RPOs) for Paxlovid in 2023, but the LLM claims there was $5 billion in deferred revenue at the end of 2023, which is not supported by the original answer and contradicts it. The only accurate number is the $1 billion in RPOs as of December 31, 2024, which matches the ground truth. However, the claim of a 'decline' from $5B to $1B is incorrect because no such $5B figure was disclosed in 2023. (2) The quantitative inaccuracies are severe: the $5 billion figure is entirely fabricated in this context, and the timeline of revenue recognition (2025–2028) is not mentioned in the ground truth, introducing unsupported details. (3) The reasoning is flawed—while the shift from government to commercial sales may be contextually plausible, the LLM builds this narrative on false financial data. The multi-hop synthesis fails because it invents a prior obligation that was not disclosed, undermining the comparison between 2023 and 2024. (4) Despite incorrect facts, the answer is contextually relevant—it addresses the evolution of financial outlook and attempts to interpret RPOs correctly. However, the core quantitative error (inventing a $5B figure) severely undermines correctness, warranting a low score of 3. Quantitative accuracy is scored 2 due to one correct number but one major false figure. Qualitative accuracy is 3 due to correct terminology and some logical interpretation, but based on false premises. Contextual relevance is 6 because the structure and intent align with the question, even if facts are wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 462,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has American Express's use and assumptions around the Reasonable and Supportable (R&S) Period evolved between 2022 and 2024 in estimating credit loss reserves, and what does this indicate about the company's approach to financial risk management?",
      "original_answer": "In 2022, American Express explicitly described its use of the R&S Period as a key component in estimating reserves for credit losses on Card Member loans, incorporating historical loss experience and current/future economic conditions over that period. The reserves stood at $3.3 billion as of December 31, 2021, and the R&S Period was a central assumption in modeling expected credit losses. By 2024, while the R&S Period was still referenced, it was no longer introduced as a newly explained concept and instead appeared embedded within a more mature and established process, indicating it had become a standard part of the company's financial risk modeling framework. This evolution suggests a shift from introducing the methodology (2022) to relying on it as a foundational element in credit loss estimation (2024).",
      "llm_answer": "\nBetween 2022 and 2024 American Express lengthened and refined the “reasonable and supportable” (R&S) horizon it uses to estimate credit‑loss reserves—moving from a largely historical, short‑term loss‑rate approach in 2022 to a forward‑looking framework that explicitly incorporates current and projected economic conditions, probability‑of‑default and exposure‑at‑default modeling, and qualitative adjustments for emerging portfolio trends.  This shift shows that the company is adopting a more data‑driven, forward‑looking risk‑management stance, placing greater emphasis on forward‑looking economic assumptions and broader risk considerations when quantifying expected credit losses.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that American Express used the R&S Period in 2022 as a key component in credit loss estimation and by 2024 it had become embedded in a mature process. However, the LLM incorrectly claims that the company 'lengthened and refined' the R&S horizon and shifted from a 'short-term loss-rate approach' to a forward-looking framework, which is not supported by the original answer. There is no mention in the ground truth of a methodological shift or refinement in the R&S Period itself between 2022 and 2024—only that its presentation evolved from being newly explained to being a standard part of the framework. (2) Quantitative accuracy is low because the LLM introduces concepts like 'probability-of-default and exposure-at-default modeling' and 'qualitative adjustments for emerging portfolio trends' that are not present in the original answer. The only numeric data in the ground truth is the $3.3 billion reserve as of December 31, 2021, which the LLM omits entirely. (3) The multi-hop reasoning is flawed: while the question requires synthesis of how R&S assumptions evolved in presentation and use, the LLM fabricates a narrative of methodological advancement rather than correctly identifying the shift in disclosure maturity. The original answer emphasizes consistency in use but evolution in how it's discussed, not in technical implementation. (4) Contextual relevance is moderate because the LLM addresses the general topic of R&S Period evolution and risk management approach, but the specific claims about lengthening the horizon and adopting new models are unsupported. The conclusion about a 'more data-driven, forward-looking stance' overreaches the evidence provided in the ground truth, which only indicates institutionalization of the existing methodology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 506,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has Amazon's approach to debt financing evolved between 2022 and 2024, particularly with respect to the 0.800% Note due 2025?",
      "original_answer": "In 2022, Amazon's filings referenced the 0.800% Note due 2025 as part of its broader debt structure, originally introduced in the Officers' Certificate dated June 3, 2020. By 2024, Amazon not only continued to reference the 0.800% Note due 2025 in its filings but also introduced new debt instruments with different interest rates and maturity dates, such as the 4.600% Note due 2025. This indicates a shift in Amazon's debt financing strategy, incorporating a wider range of interest rates and maturities to potentially manage cash flow and interest rate risk more effectively.",
      "llm_answer": "\nBetween 2022 and 2024 Amazon moved away from its original 0.800 % senior unsecured note that matures in 2025 (first issued in 2020) toward higher‑priced debt.  In the 2022 filing the company added a new 4.600 % note due 2025 (Exhibit 4.8), and by the 2024 filing the only reference to the 0.800 % 2025 note remains the legacy 2020 issuance, while the firm emphasized newer term notes and larger revolving‑credit facilities (Exhibits 10.8 and 10.9).  This shift reflects a strategy of refinancing the cheap, long‑dated 0.800 % debt with higher‑coupon bonds and credit lines to take advantage of evolving market conditions and reduce reliance on the low‑rate instrument.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies that significantly affect correctness. (1) It incorrectly states that Amazon 'moved away' from the 0.800% Note due 2025 and that by 2024 the only reference is the 'legacy 2020 issuance', implying it is no longer active. However, the ground truth indicates Amazon continued to reference the 0.800% Note in 2024 filings as part of its debt structure, not as a deprecated instrument. (2) The claim that the 4.600% Note due 2025 was added in the 2022 filing is incorrect: the original answer does not specify when this note was introduced, only that it existed by 2024. (3) The LLM introduces specific exhibit numbers (Exhibit 4.8, 10.8, 10.9) and claims about refinancing and strategic emphasis not present in the ground truth, adding unsupported detail. (4) The characterization of Amazon 'refinancing' the 0.800% note with higher-coupon debt is speculative and not supported by the original answer, which only notes the coexistence of multiple notes as part of a broader diversification strategy. Quantitatively, the percentages (0.800%, 4.600%) and maturity year (2025) are correct, earning partial credit. Qualitatively, the reasoning is flawed due to incorrect inference of a phase-out and refinancing narrative. Contextually, the answer addresses the evolution of debt strategy and mentions relevant instruments, so relevance is high. Overall, the answer captures the general trend of diversification but misrepresents the status of the 0.800% note and adds unsupported specifics, warranting a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 427,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the treatment or disclosure of the Twenty-third Supplemental Indenture evolved between the 2022 and 2024 SEC filings, and what does this indicate about its ongoing relevance or status?",
      "original_answer": "In the 2022 filing (DUK_10k_2022.pdf), the Twenty-third Supplemental Indenture was explicitly listed and dated June 1, 1978, incorporated by reference to Exhibit 2(c), File No. 2-61611. However, in the 2024 filing (DUK_10k_2024.pdf), there is no direct mention or continued reference to the Twenty-third Supplemental Indenture. Instead, the focus shifts to more recent supplemental indentures, such as the Forty-ninth Supplemental Indenture dated March 14, 2024. This indicates that the Twenty-third Supplemental Indenture was not reaffirmed or highlighted in the most recent disclosure, suggesting it may have diminished in operational or reporting significance over time.",
      "llm_answer": "\nIn the 2022 filing the Twenty‑third Supplemental Indenture is explicitly listed in the exhibit index (e.g., “Twenty‑third Supplemental Indenture, dated June 1 1978 … incorporated by reference”), showing that it was still being disclosed as an active component of Duke Energy’s indenture schedule. By the 2024 filing that specific indenture no longer appears as a current exhibit; it is only mentioned in a historical list of older indentures, indicating that the 23rd supplemental indenture has been retired and is no longer a material or ongoing disclosure item.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. It correctly identifies that the Twenty-third Supplemental Indenture was explicitly listed in the 2022 filing with the correct date (June 1, 1978), and notes its absence as a current exhibit in the 2024 filing. The conclusion that it is now only mentioned in a historical context and likely retired matches the ground truth's implication of diminished relevance. The only minor difference is that the ground truth specifically references Exhibit 2(c) and File No. 2-61611, and mentions the Forty-ninth Supplemental Indenture as the current focus—details not included in the LLM answer. However, these omissions do not affect the core factual accuracy or reasoning. All entities (Duke Energy, indenture number, years 2022 and 2024) are correct. The reasoning is sound: the disappearance from current exhibits and shift to historical listing supports the conclusion of reduced operational significance. Quantitative elements (dates, numbering of indentures) are accurate. The answer is semantically equivalent and contextually appropriate, addressing both the evolution in disclosure and the implication for ongoing relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 337,
        "total_tokens": 1658
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did the repurchase activity for Class C Capital Stock evolve from 2022 to 2024, and what was the total value of shares repurchased in each year?",
      "original_answer": "In 2022, Alphabet repurchased $59.3 billion of Class A and Class C shares, while in 2023 the amount increased to $62.2 billion, and in 2024 it remained high at $62.0 billion. This demonstrates a consistent and significant level of share repurchase activity over the three-year period, with a slight peak in 2023 followed by a minor decline in 2024.",
      "llm_answer": "\nFrom 2022 through 2024 the Class C repurchase program expanded sharply in 2023 and then eased slightly in 2024 – the company bought back roughly **$52.9 billion of Class C shares in 2023**, the peak annual amount, and **about $50.2 billion in 2024**.  Overall, the repurchase program spent **$59.3 billion of Class A and C shares in 2022**, **$62.2 billion in 2023**, and **$62.0 billion in 2024**, with Class C comprising the bulk of those totals (≈$53 billion in 2023 and ≈$50 billion in 2024).",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the total repurchase amounts for each year ($59.3B in 2022, $62.2B in 2023, $62.0B in 2024), which matches the ground truth. However, it introduces specific figures for Class C shares—$52.9B in 2023 and $50.2B in 2024—that are not present in the original answer and cannot be verified from the provided ground truth. The original answer does not break down the totals by share class, only stating that repurchases included both Class A and Class C shares. Thus, these Class C-specific numbers are unsupported and likely incorrect or speculative. (2) The total repurchase values per year are accurate and correctly formatted. But the breakdown by Class C is an over-interpretation and introduces quantitative inaccuracies. The claim that Class C 'comprised the bulk' is plausible but not confirmed in the ground truth, making the inference risky. (3) The reasoning correctly tracks the trend—slight increase from 2022 to 2023, then a minor decline in 2024—and correctly synthesizes the total repurchase activity over the three years. However, the model fails to acknowledge that the original data combines Class A and C repurchases, and instead attempts a granular breakdown not supported by the source. This undermines the multi-hop synthesis. (4) The contextual relevance is high, as the answer addresses the evolution of repurchase activity and annual totals. The qualitative reasoning is sound except for the unsupported disaggregation. Correctness score is 7 due to accurate totals but significant over-attribution to Class C; quantitative accuracy is penalized more heavily (6) due to the introduction of unverified figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1211,
        "completion_tokens": 459,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "What changes occurred in the treatment and documentation of the American Express Company Salary/Bonus Deferral Plan between the 2022 and 2024 SEC filings?",
      "original_answer": "In the 2022 filing, the Salary/Bonus Deferral Plan was referenced through historical amendments, including Exhibit 10.16 (1988 plan) and Exhibit 10.17 (1994 amendment). The 2024 filing reintroduces the plan through Exhibit 10.13, referencing the same 1988 plan, and also includes Exhibit 10.14, which references the 1994 amendment. Notably, the 2024 filing adds Exhibit 10.16, which incorporates the 1997 amendments to the plan. This indicates that while the foundational documentation remained consistent, the 2024 filing expanded the disclosure to include a broader historical record of amendments, providing more context on the plan's evolution.",
      "llm_answer": "\nIn the 2022 filing the Salary/Bonus Deferral Plan appears as a stand‑alone exhibit (Exhibit 10.1) and is accompanied by a separate amendment reference (Exhibit 10.17), with the plan described as a distinct “Salary/Bonus Deferral Plan” dating back to 1988. In the 2024 filing the same plan is no longer listed as a primary exhibit; it is relegated to a later exhibit number (Exhibit 10.13) and is only incorporated by reference to the original 1988 filing, with no new amendment or restatement disclosed. This shift reflects a move from explicit, separate disclosure of the plan to a more implicit incorporation within the broader set of exhibits.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents the treatment of the American Express Company Salary/Bonus Deferral Plan in both the 2022 and 2024 filings. (1) In the 2022 filing, the plan was not listed as Exhibit 10.1; according to the ground truth, it was referenced through Exhibit 10.16 (1988 plan) and Exhibit 10.17 (1994 amendment). The claim that it was a 'stand-alone exhibit (Exhibit 10.1)' is incorrect. (2) In the 2024 filing, the LLM incorrectly states that the plan is 'no longer listed as a primary exhibit' and that 'no new amendment or restatement' was disclosed. In fact, the 2024 filing reintroduces the plan via Exhibit 10.13 (1988 plan), Exhibit 10.14 (1994 amendment), and notably adds Exhibit 10.16 for the 1997 amendments—indicating expanded, not reduced, disclosure. The LLM's assertion that the plan was 'relegated' and 'incorporated by reference' with no new amendments directly contradicts the ground truth that new historical amendments were explicitly added. (3) The multi-hop reasoning is flawed: the model fails to recognize that the 2024 filing broadened the historical record, which is the central point of the original answer. Instead, it infers a reduction in transparency, which is unsupported. (4) While the question is addressed in topic (treatment and documentation changes), the answer is factually inverted and lacks key details, resulting in low correctness and qualitative accuracy. Contextual relevance is moderate because it discusses exhibit numbering and disclosure trends, but the substance is incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 431,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has Starbucks' exposure to interest rate swaps evolved between 2022 and 2024, particularly in terms of their balance sheet classification and magnitude of liability?",
      "original_answer": "In 2022, Starbucks reported an interest rate swap liability of $34.0 million under 'Other long-term liabilities'. By 2024, the company's interest rate swap position had shifted significantly, with a liability of $19.2 million under 'Other long-term liabilities' and an additional $41.4 million liability from interest rate swaps reported for the prior year (2023), indicating a decrease in liability from the previous year but a continued significant exposure. This reflects a transformation in the company's interest rate swap position, with a shift in balance sheet classification and a notable reduction in total swap liability.",
      "llm_answer": "\nBetween fiscal 2022 and 2024 Starbucks’ interest‑rate‑swap liability dropped sharply – it was about **$46 million in 2022** (roughly $12 million recorded in accrued liabilities and $34 million in other long‑term liabilities) and fell to **≈ $20 million by September 2024** (about $0.3 million in accrued liabilities and $19 million in other long‑term liabilities).  The classification remained the same (designated swaps in “other long‑term liabilities” and the non‑designated portion in “accrued liabilities”), but the magnitude of the liability was cut by more than half, a change also reflected in the reduced fair‑value‑hedging adjustment on the hedged long‑term debt (from a $40 million negative adjustment in 2021 to $17.8 million negative by the end of 2024).",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. The ground truth states that Starbucks had a $34.0 million interest rate swap liability in 2022 under 'Other long-term liabilities', but the LLM claims a total liability of $46 million in 2022, with $34 million in long-term liabilities and $12 million in accrued liabilities — the latter figures are not supported by the original answer and introduce non-existent short-term classifications. In 2024, the ground truth reports a $19.2 million liability in 'Other long-term liabilities', which the LLM approximates as $19 million — this is acceptable. However, the LLM fails to mention the additional $41.4 million liability from 2023 swaps that was still reported in 2024, a key point in the original answer indicating prior-year exposure. Instead, the LLM incorrectly implies a total liability of ~$20 million in 2024 without acknowledging the multi-year reporting aspect. (2) Calculations: The LLM claims a drop from $46M to $20M (over 50% reduction), but since the original data starts at $34M and ends at $19.2M (with context on $41.4M prior-year), the baseline is wrong, making the comparison invalid. The mention of fair value hedging adjustments ($40M in 2021 to $17.8M in 2024) introduces data not present in the original answer, making it extraneous and unsupported in context. (3) Multi-hop reasoning: The LLM correctly identifies a reduction in liability and consistent classification in long-term liabilities, but misrepresents the balance sheet classification by introducing 'accrued liabilities' as a category for non-designated swaps, which is not mentioned in the ground truth. It also fails to capture the core evolution described in the original — the shift involving a prior-year $41.4M liability in 2023 that remains relevant in 2024 — indicating incomplete synthesis across years. (4) Despite incorrect numbers and missing key details, the LLM captures the general trend of decreasing liability and consistent classification, earning partial credit. Contextual relevance is high as it addresses the question's focus on evolution, classification, and magnitude. However, factual correctness is undermined by invented figures and omissions of critical multi-hop details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 605,
        "total_tokens": 1960
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has the treatment of the Directors' Savings Plan evolved between 2022 and 2024, and what does this suggest about Duke Energy's approach to director compensation governance and deferral mechanisms?",
      "original_answer": "In 2022, the Directors' Savings Plan was formally introduced in the 10-K filing with a specific amendment dated December 16, 2021, indicating active documentation and policy updates around director deferrals. By 2024, the plan is referenced in the context of phantom investment options and deferred compensation mechanics, with an emphasis on unfunded accounts tied to the Duke Energy Common Stock Fund. This evolution suggests a shift from policy establishment to operational transparency, highlighting how deferrals are structured and invested, which may reflect a broader governance strategy to align director compensation with long-term shareholder interests and company stock performance.",
      "llm_answer": "\nBetween 2022 and 2024 Duke Energy’s disclosures show that the **Directors’ Savings Plan remained in force**, but the company refined how it describes the arrangement. The 2022 filing (Amendment effective Dec 16 2021) set out that outside directors could defer all or part of their retainers into an unfunded account that earns phantom‑stock credits and is only paid out when a director leaves the board. In the 2024 filing the plan is referenced again in the equity‑compensation table footnotes, explicitly linking deferred amounts to potential share issuances and labeling it a “non‑qualified deferred compensation plan,” thereby emphasizing that director pay is **deferred, performance‑linked, and settled only upon termination of service**. This evolution signals that Duke Energy uses the Directors’ Savings Plan as a governance tool to align director interests with shareholders while retaining tight control over the timing and form of director compensation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the December 16, 2021 amendment date is accurately cited, the unfunded nature of the account, phantom stock credits tied to Duke Energy Common Stock, deferral of retainers, and payout upon board departure are all consistent with the original answer. (2) Quantitative accuracy is perfect: no numerical errors, and the dates (Dec 16, 2021 amendment reflected in 2022 filing) are correctly interpreted. (3) Multi-hop reasoning is sound—LLM synthesizes information across 2022 and 2024 filings to show evolution from plan documentation to more detailed disclosure of mechanics and classification as a non-qualified deferred compensation plan. It correctly infers the governance intent: aligning director and shareholder interests through deferral and stock linkage. (4) The only minor gap is that the LLM does not explicitly mention 'phantom investment options' or 'operational transparency' as in the original, but it effectively conveys the same concept by describing phantom-stock credits and increased disclosure in footnotes. Wording differs slightly but semantic meaning and intent are preserved. The conclusion about governance strategy is logically supported and equivalent in substance. Thus, the answer earns a 9 for correctness due to slight omission of phrasing around 'operational transparency,' but all key facts, dates, and reasoning are accurate and complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 407,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has the positioning and associated risk profile of Costco's Kirkland Signature brand evolved between 2022 and 2023?",
      "original_answer": "In 2022, Costco emphasized the Kirkland Signature brand as a strategic asset, highlighting its high quality, competitive pricing, and contribution to higher margins. The company planned to continue increasing the sales penetration of these private-label items. However, by 2023, the risk disclosures included broader mentions of how supply chain disruptions, foreign exchange fluctuations, and catastrophic events could negatively impact the business—including private-label brands like Kirkland Signature. While the 2022 filing focused on growth and brand strength, the 2023 filing introduced a more risk-focused lens, indicating that the brand's expansion and reliance could expose Costco to greater operational and financial volatility.",
      "llm_answer": "\nBetween 2022 and 2023 Costco deepened Kirkland Signature’s strategic role—moving from a high‑quality, low‑price private‑label that simply boosted margins and sales penetration (2022 10‑K, p. 6) to a brand that is now explicitly tied to the company’s ESG targets and sustainability commitments (2023 10‑K, pp. 15‑18).  This shift expands the risk profile of the brand: alongside the traditional supply‑chain and quality‑control exposures, Costco now faces heightened regulatory, compliance and reputational risks if it fails to meet the ESG expectations and disclosures that govern its private‑label products.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is partially correct in recognizing a shift in the risk and strategic positioning of Kirkland Signature between 2022 and 2023, but introduces significant factual inaccuracies not supported by the ground truth. (1) The claim that Kirkland Signature was tied to ESG targets and sustainability commitments in the 2023 10-K (with specific page references) is not present in the original answer or supported by the provided ground truth. The ground truth states that the 2023 risk profile expanded to include supply chain disruptions, foreign exchange fluctuations, and catastrophic events—general operational and financial risks—not ESG-related regulatory or reputational risks. (2) There are no numbers, dates, or financial figures in the response, so quantitative accuracy is not applicable; however, the absence of incorrect numbers allows a score of 10 by default. (3) The multi-hop reasoning is flawed: while the model correctly identifies a strategic evolution, it fabricates a new dimension (ESG linkage) not present in the source material, indicating a failure in accurate synthesis across filings. (4) Contextually, the answer addresses the evolution of risk and positioning, which is relevant, but the introduction of unsupported ESG claims undermines factual correctness. The core accurate point—that the brand's growing strategic role increases exposure to broader risks—is aligned with the ground truth, but the reasoning and factual basis are significantly distorted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 409,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How did COP's natural gas reserves in the Asia Pacific/Middle East region evolve from 2022 to 2024, and what were the key changes in terms of volume and sources of additions?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure decreased slightly to 296 billion cubic feet. Over this period, the company experienced revisions and production activities that impacted reserves, with minimal extensions and discoveries contributing to the region. In 2024, there were no sales or significant reserve additions in this region, indicating a reduction in focus or activity compared to earlier years.",
      "llm_answer": "\nBetween the end of 2022 and the end of 2024 ConocoPhillips’ proved natural‑gas reserves in the Asia‑Pacific/Middle‑East region fell from about 326 billion cubic feet (BCF) to roughly 296 BCF – a decline of roughly 30 BCF.  The only notable positive additions came from extensions and discoveries in equity‑affiliated assets (≈ 17–20 BCF per year), while downward revisions (price‑ and cost‑related) and production consumption of ~ 25 BCF annually more than offset those gains, and no material purchases were made in the region.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the starting and ending reserve volumes (326 BCF in 2022 and 296 BCF in 2024), which matches the ground truth. The calculated decline of ~30 BCF is accurate. However, the LLM introduces specific figures not present in the original answer—such as extensions and discoveries contributing ≈17–20 BCF per year and annual production of ~25 BCF—which are not supported by the ground truth. The original answer states only that there were 'minimal extensions and discoveries' and does not quantify annual production or revisions. (2) While the core numbers (326 and 296 BCF) are correct and the difference is accurately computed, the additional quantifications (e.g., 17–20 BCF/year, 25 BCF/year) are speculative and not in the source, reducing quantitative accuracy. (3) The reasoning partially aligns with the original: the LLM correctly infers that downward revisions and production led to a net decline, but it over-specifies the sources of additions with unsupported precision. The original emphasizes 'no sales or significant reserve additions in 2024' and a reduction in activity, which the LLM does not explicitly mention, missing a key qualitative point about reduced focus. (4) Despite the over-quantification, the LLM captures the overall trend and direction of change correctly and addresses both volume change and sources of additions, albeit with added detail not in the original. Contextual relevance is high as it directly answers the question’s scope. The correctness score is 7 due to accurate core data but unsupported specifics in the explanation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 440,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has FedEx's strategic relationship with the Boeing 767F evolved between 2022 and 2024, particularly in terms of fleet ownership and modernization focus?",
      "original_answer": "In 2022, FedEx directly owned 114 Boeing 767F aircraft, indicating a significant owned asset position in its fleet strategy. By 2024, while no updated ownership figures were disclosed, FedEx emphasized the Boeing 767-300 Freighter (B767F) as a key component of its aircraft modernization programs. The company described these aircraft as significantly more fuel-efficient per unit than older models and noted that expenditures for these aircraft are necessary for long-term operating savings and fleet replacement, with limited flexibility to delay purchases without incurring significant costs.",
      "llm_answer": "\nBetween 2022 and 2024 FedEx moved from a fleet that **owned 114 Boeing 767‑300 Freighters (B767F)** – as shown in the 2022 10‑K fleet table (page 41) – to a much tighter acquisition pipeline in which only **14 B767Fs remain on order for delivery in 2025‑2026** (11 in 2025 and 3 in 2026) as listed in the 2024 10‑K purchase‑commitment schedule (page 117).  This reflects a strategic shift toward modernizing the express fleet: the airline is using the remaining 767F orders, together with a larger commitment to the newer Boeing 777F, to replace older, less‑fuel‑efficient aircraft while limiting further 767F purchases.  The change underscores a focus on fuel‑efficiency and long‑term operating‑cost savings rather than expanding the 767F fleet.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains a mix of correct and incorrect information, with significant issues in quantitative accuracy but reasonable qualitative reasoning. (1) QUANTITATIVE INACCURACY: The LLM claims FedEx owned 114 Boeing 767-300 Freighters in 2022, which aligns with the ground truth. However, it incorrectly states that only 14 B767Fs remain on order for delivery in 2025–2026 based on the 2024 10-K. The original answer does not mention any specific number of outstanding orders or delivery schedules, and no such data is confirmed in the ground truth. This introduces unsupported specifics not present in the source. (2) COMPLETENESS: The question asks about evolution in fleet ownership and modernization focus. The LLM correctly identifies modernization and fuel efficiency as strategic drivers, which matches the ground truth. However, it fabricates delivery timelines and order numbers (14 aircraft, 11 in 2025, 3 in 2026), which are not in the original answer and cannot be verified from the provided truth. (3) ENTITY ACCURACY: All entities (FedEx, Boeing 767F, 777F, 2022–2024 timeframe) are correctly identified. (4) REASONING: The multi-hop logic is partially sound—linking fleet modernization to fuel efficiency and cost savings is supported—but the conclusion about a 'strategic shift' away from 767F expansion is inferred beyond the evidence. The ground truth states the 767F remains a key modernization component, with necessary expenditures due to limited flexibility, suggesting continued reliance, not a drawdown. The LLM overinterprets a reduction in orders as a strategic pivot, which isn't explicitly supported. (5) SEMANTIC EQUIVALENCE: The overall thrust—modernization, efficiency, continued use of 767F—is directionally correct, but the inclusion of unverified order details reduces factual fidelity. The answer adds granularity not present in the truth, leading to a partially incorrect portrayal. Thus, while contextually relevant and reasonably reasoned, the answer is undermined by unsupported numbers, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 554,
        "total_tokens": 1892
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How did Starbucks' involvement with roasted coffee evolve from 2022 to 2024 in terms of inventory value and production infrastructure?",
      "original_answer": "In 2022, Starbucks reported an inventory value of roasted coffee at $310.3 million, reflecting its role in holding roasted coffee as part of its merchandise. By 2024, the company had expanded its infrastructure dedicated to roasting, with facilities in York, PA; Minden, NV (Carson Valley); Kunshan, China; and Kent, WA, indicating a significant increase in its direct involvement in the roasting process. This represents a shift from primarily holding roasted coffee inventory to actively producing and distributing it at scale.",
      "llm_answer": "\nFrom fiscal 2022 to 2024 the recorded value of roasted‑coffee inventory grew modestly—rising from $310.3 million (as of Oct 2 2022) to a higher level reflected in the 2024 disclosures, driven by larger green‑coffee purchase commitments and a bigger overall inventory balance.  At the same time Starbucks expanded its production footprint, adding new roasting sites (e.g., a 630,000‑sq‑ft plant in Kunshan, China and upgrades to its York, PA facility) and increasing its leased warehousing and distribution capacity to support a global network of roughly 21,000 company‑operated stores.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 2022 roasted coffee inventory value as $310.3 million, matching the ground truth. However, it does not specify the exact inventory value for 2024, instead vaguely stating it rose to a 'higher level,' which omits a key data point expected in a complete answer. The ground truth does not provide a 2024 inventory number either, but emphasizes infrastructure expansion as evidence of increased involvement—this shift in focus is reasonable. (2) The mention of a 630,000-sq-ft plant in Kunshan and upgrades in York, PA aligns with known expansions, though the exact square footage is not in the ground truth and may be extraneous but not incorrect. The use of 'Oct 2, 2022' as the fiscal year-end is accurate for Starbucks’ 2022 reporting. (3) The multi-hop reasoning is partially sound: the LLM connects inventory trends with infrastructure growth, correctly inferring increased roasting involvement. However, it fails to explicitly name all roasting facilities listed in the ground truth (Minden, NV; Kent, WA; Kunshan, China; York, PA), omitting Minden and Kent, which weakens completeness. (4) The answer is contextually relevant and captures the evolution in infrastructure and inventory strategy. While the qualitative shift from holding inventory to active production is implied, it is not stated as clearly as in the original. The score reflects accurate core facts with minor omissions in entity completeness and lack of specific 2024 inventory value.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 414,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has PepsiCo's utilization of the 2.750% Senior Notes due 2025 evolved between 2023 and 2024, based on the specific debt instruments referenced in the filings?",
      "original_answer": "In 2023, the 2.750% Senior Notes due 2025 were listed among other notes in a Board of Directors Resolutions document that authorized officers to establish terms for several senior notes, including the 2.750% Senior Notes due 2025. By 2024, PepsiCo not only retained the 2.750% Senior Notes due 2025 in its list of authorized instruments but also introduced a new 2.750% Senior Notes due 2030. This indicates that PepsiCo extended its debt strategy involving this interest rate to a longer-term horizon, signaling a strategic evolution in its financing approach.",
      "llm_answer": "\nIn the 2023 filing the 2.750 % Senior Notes due 2025 are listed in the exhibit of senior‑note forms (Item 4.34) and are included among the series of notes the Board authorized in the 2023 indenture documentation. The 2024 filing repeats the same 2.750 % Senior Notes due 2025 in the Board‑resolution section, showing that the instrument remains authorized and outstanding but has not been newly issued, retired, or otherwise modified between 2023 and 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually accurate in terms of quantitative details: the 2.750% Senior Notes due 2025 are correctly referenced with the right interest rate, maturity year, and filing years (2023 and 2024), and no incorrect numbers or dates are presented. Thus, quantitative accuracy is perfect. However, the qualitative accuracy and overall correctness are limited because the LLM fails to capture the key evolution highlighted in the ground truth: the strategic extension of the 2.750% interest rate to a new long-term instrument, the 2.750% Senior Notes due 2030, introduced in 2024. The LLM correctly notes that the 2025 notes remain authorized and unchanged, but it omits the critical multi-hop insight that PepsiCo expanded its use of this rate to a new 2030 note, indicating a strategic shift in debt structuring. This omission significantly weakens the reasoning and completeness of the response. While the answer is relevant and factually sound regarding the 2025 notes' status, it does not fully address the evolution in utilization between 2023 and 2024 as required by the question. Therefore, the correctness and qualitative accuracy scores are moderate, reflecting partial but incomplete synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 339,
        "total_tokens": 1597
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did FedEx's planned utilization of the B777F aircraft change from 2022 to 2024, and what does this indicate about its strategic role in the fleet?",
      "original_answer": "In 2022, FedEx planned to operate 4 B777F aircraft in 2024 and 2 in 2025. By 2024, the updated plan showed 2 B777F aircraft operating in 2025, with no further plans beyond that year. This indicates a reduction in the strategic emphasis on the B777F fleet, moving from a gradually decreasing role to a complete phase-out, suggesting a shift in aircraft preference or operational strategy.",
      "llm_answer": "\nFrom the 2022 filing FedEx had scheduled **eight** B777F deliveries (2 in 2023, 4 in 2024 and 2 in 2025), but by the 2024 filing the commitment had shrunk to **only two** B777Fs—both slated for delivery in 2025 and none beyond 2026.  This pull‑back signals that the B777F is being de‑emphasized in FedEx’s fleet strategy, serving only a limited, specialized long‑haul cargo role while the company shifts its modernization and fuel‑efficiency efforts toward the newer, more economical B767F and other aircraft types.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and timing. According to the ground truth, in 2022, FedEx planned to operate 4 B777F aircraft in 2024 and 2 in 2025 — not eight total deliveries as stated. The LLM incorrectly claims eight B777F deliveries were scheduled (2 in 2023, 4 in 2024, 2 in 2025), which contradicts the original answer. The 2024 update correctly notes only 2 B777Fs operating in 2025 with no plans beyond, but the baseline from 2022 is misrepresented. (2) Quantitative accuracy is low: the original answer specifies 4 aircraft planned for 2024 operations (not deliveries in 2024), whereas the LLM treats them as deliveries and inflates the total. There is no mention in the ground truth of 2023 deliveries or a total of eight aircraft; these are fabrications or misinterpretations. (3) The reasoning partially captures the strategic de-emphasis and phase-out trend, which aligns with the conclusion in the original answer about reduced strategic role. However, the multi-hop synthesis is flawed because it misrepresents the initial plan, undermining the validity of the comparison. (4) Despite incorrect numbers, the LLM identifies the correct direction of change (reduction) and infers a plausible strategic shift toward more fuel-efficient aircraft like the B767F, which adds contextual relevance. However, the core factual errors in quantities and timing severely limit correctness. Semantic equivalence fails on key metrics, though the general trend interpretation is reasonable.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 424,
        "total_tokens": 1650
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did Starbucks' foreign currency - other derivative liabilities and their impact on net gains/(losses) included in AOCI evolve from 2022 to 2024, and what does this indicate about the company's exposure to foreign currency fluctuations?",
      "original_answer": "In 2022, Starbucks reported foreign currency - other derivative liabilities of $0.3 million under accrued liabilities, while in 2024, the net gains included in AOCI related to foreign currency - other were $11.5 million. This indicates a significant shift from a minimal liability position in 2022 to a more substantial unrealized gain in 2024, suggesting increased exposure to or hedging of foreign currency fluctuations.",
      "llm_answer": "\nBetween fiscal 2022 and 2024 the net gains on foreign‑currency‑other derivatives that remain in AOCI fell sharply—from $55.3 million in 2022 to $39.6 million in 2023 and $11.5 million in 2024—while the related derivative liabilities grew from $0.3 million to roughly $9 million. This decline shows that Starbucks is generating fewer unrealized hedge gains, reflecting reduced foreign‑currency exposure (e.g., a stronger U.S. dollar), and that the remaining hedge gains are being increasingly re‑classified into earnings rather than staying in OCI.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, Starbucks had foreign currency - other derivative liabilities of $0.3 million, and in 2024, the net gains in AOCI were $11.5 million. However, the LLM claims that net gains in AOCI were $55.3 million in 2022 and $39.6 million in 2023—values not supported by the ground truth—and that liabilities grew to $9 million, which is also not mentioned in the original answer. These numbers are entirely fabricated or misattributed. (2) The only correct quantitative figure is the $11.5 million net gains in AOCI for 2024 and the $0.3 million liability in 2022. All other numbers (e.g., $55.3M, $39.6M, ~$9M) are incorrect and unsupported. There is no verification of intermediate years (2023) in the ground truth, so introducing them undermines accuracy. (3) The multi-hop reasoning is flawed: the original answer indicates a shift from minimal liability to a gain in AOCI, suggesting increased exposure or hedging activity. The LLM incorrectly infers reduced exposure due to declining gains, which contradicts the ground truth implication of growing unrealized gains and thus potentially increasing exposure or hedging. The reasoning is based on false data and leads to an opposite conclusion. (4) While the LLM attempts to address the evolution over time and interpret foreign currency exposure, the severe quantitative errors and resulting incorrect interpretation drastically reduce correctness. Contextual relevance is moderate because the structure and intent align with the question, but factual foundation is weak.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 445,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has PepsiCo's engagement with the 2.625% Senior Notes due 2026 evolved between 2023 and 2024, particularly in terms of its broader debt instrument disclosures?",
      "original_answer": "In 2023, the 2.625% Senior Notes due 2026 were listed among other notes in a section that included Board of Directors Resolutions authorizing officers to establish terms for various senior notes. By 2024, PepsiCo not only retained the 2.625% Senior Notes due 2026 in its disclosures but also introduced a significantly expanded list of senior notes, including newer maturities such as the 3.000% Senior Notes due 2027 and the 2.625% Senior Notes due 2029. This indicates a broader and more diversified set of debt instruments, suggesting an active capital markets strategy involving the issuance of notes with different maturities and rates.",
      "llm_answer": "\nBetween 2023 and 2024 the 2.625 % Senior Notes due 2026 shifted from a peripheral mention among a generic list of senior‑note forms in the 2023 filing to a more prominent, explicitly‑cited item within the Board‑Director resolutions and accompanying indenture language.  In the 2024 Form 10‑K the notes are again referenced in those resolutions, but they are now presented alongside a broader set of authorizations and are accompanied by updated Global‑Note and related‑entity disclosures, indicating a more integrated and expanded disclosure of PepsiCo’s debt instruments.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually accurate in terms of the specific note (2.625% Senior Notes due 2026) and the years referenced (2023 and 2024), satisfying quantitative accuracy. The percentages and maturity date are correct, and no numerical calculations are required. However, the qualitative analysis diverges from the ground truth: the original answer emphasizes PepsiCo's broader debt strategy through the addition of new notes (e.g., 3.000% due 2027, 2.625% due 2029), indicating diversification. The LLM answer instead focuses on a shift in disclosure prominence and 'updated Global-Note and related-entity disclosures,' which are not mentioned in the ground truth. It mischaracterizes the evolution as a change in disclosure formatting or integration rather than an expansion in the number and variety of debt instruments. This reflects a failure in multi-hop reasoning—while the LLM correctly identifies the continued presence of the 2026 notes, it does not synthesize the key point about new maturities and a more diversified debt portfolio. The answer is contextually relevant and addresses the question’s focus on evolution in engagement and disclosure, but the reasoning and conclusion are partially misaligned with the evidence. Thus, correctness is reduced due to incorrect qualitative interpretation despite accurate entities and dates.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 373,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has Cisco's exposure to and reliance on overcoming technical hurdles evolved from 2022 to 2024, particularly in relation to its strategic investments and product development timelines?",
      "original_answer": "In 2022, Cisco acknowledged facing technical hurdles that could delay successful execution of its vision, especially in areas like product planning, timing, and resource allocation, which could lead to loss of market share and earnings. By 2024, the company's exposure to technical hurdles had transformed into a more specific dependency on overcoming these challenges in a timely manner to maintain competitive advantage, particularly in delivering complex software subscription offerings and introducing new technologies such as those related to artificial intelligence, security, observability, and cloud. The 2024 disclosures emphasize that failure to overcome these hurdles could not only result in loss of market share but also reputational damage, legal liability, and reduced customer retention. This represents a shift from internal execution risk to a broader operational and strategic dependency.",
      "llm_answer": "\nFrom 2022 to 2024 Cisco’s reliance on overcoming technical hurdles moved from a primary focus on perfecting complex hardware‑software products and launching new programmable‑networking, AI‑security and cloud technologies—efforts that required large, uncertain R&D investments—to a strategy that couples those advances with a shift toward software‑subscription and cloud‑based services, especially after acquisitions such as Splunk.  The company now ties its product‑development timelines to the ability to scale subscription platforms, integrate acquired technologies, and deliver AI‑driven security and “End‑to‑End Security” solutions, meaning that success depends not only on solving technical challenges but also on meeting subscription‑adoption and service‑delivery milestones, which can delay or dilute the expected benefits of its strategic investments.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the original answer in terms of the evolution of Cisco's exposure to technical hurdles from 2022 to 2024. It accurately captures the shift from internal execution risks (product planning, timing, resource allocation) in 2022 to a more strategic and operationally critical dependency on overcoming technical challenges by 2024, particularly in delivering software subscriptions and integrating new technologies like AI, security, and cloud. The mention of Splunk as an acquisition that influenced Cisco’s shift toward software-subscription and cloud-based services is contextually accurate and adds relevant detail not explicitly in the ground truth, but consistent with Cisco’s actual strategy. However, the original answer emphasizes a broader risk expansion in 2024 to include reputational damage, legal liability, and reduced customer retention upon failure—risks not mentioned in the LLM response, representing a minor omission. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default. The reasoning is sound and reflects multi-hop synthesis across years and strategic themes. Wording differs but semantic meaning is substantially equivalent. Thus, the answer is highly accurate with only a slight gap in completeness regarding the full scope of 2024 risks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1452,
        "completion_tokens": 379,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did the role of Google Ad Manager in driving Google Network revenues change between 2022 and 2023, based on the specific mentions of its performance and positioning across those years?",
      "original_answer": "In 2022, Google Ad Manager was explicitly cited as one of the key drivers behind the $8.6 billion year-over-year increase in Google Network revenues, alongside AdMob and AdSense. By 2023, while Google Ad Manager remained a core advertising platform used by customers, it was listed among several platforms (including Google Ads, Display & Video 360, and the Marketing Platform) without specific attribution to revenue growth. This indicates a shift from being a standout growth contributor in 2022 to being part of a broader suite of advertising tools in 2023, suggesting a more integrated but less singularly emphasized role.",
      "llm_answer": "\nIn 2022 the filing highlighted Google Ad Manager as the key platform that enabled Alphabet to “monetize the advertising inventory” on Google Network properties on a gross‑basis, emphasizing that this control “is further supported by us being primarily responsible to our customers and having a level of discretion in establishing pricing,” which the company said was driving growth in Network revenues. In 2023 the narrative reinforced that same positioning, noting that Ad Manager continued to be the primary engine for delivering ads on Network properties and that its strong performance and pricing discretion remained a central driver of the Network’s revenue expansion.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) It falsely claims that in 2023, Google Ad Manager was still described as a 'central driver' of revenue growth and the 'primary engine' for ad delivery, while the original answer states that in 2023, it was no longer specifically attributed to revenue growth and was instead listed among several platforms without standout emphasis. This misrepresents the key shift identified in the ground truth: from being a named growth driver in 2022 to a de-emphasized, integrated platform in 2023. (2) There are no correct quantitative elements; the $8.6 billion year-over-year increase in Google Network revenues in 2022 — a critical data point in the original answer — is entirely omitted. The LLM introduces unverified qualitative descriptions (e.g., 'monetize on a gross-basis', 'pricing discretion') not present in the ground truth and not supported by the evaluation context. (3) The multi-hop reasoning fails: the model does not correctly synthesize the change in narrative tone and positioning between years. Instead of identifying a downgraded role in 2023, it asserts continuity and sustained emphasis, which is factually wrong. (4) Contextual relevance is moderate because the answer discusses Google Ad Manager and Google Network revenues across the correct years, but the substance misaligns with the actual filings' messaging. Due to major factual and interpretive errors, the correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 405,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did Starbucks' derivative liabilities related to foreign currency - other evolve from 2022 to 2024, and what was the magnitude of change?",
      "original_answer": "In 2022, Starbucks reported derivative liabilities related to foreign currency - other at $0.3 million under accrued liabilities. By 2024, this amount had increased to $4.7 million under the same category. This indicates a significant increase in the company's liabilities tied to foreign currency derivatives over the two-year period.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 the total derivative liability for foreign‑currency‑other contracts grew from $0.3 million (reported on page 68 for Oct 2 2022) to $8.8 million (reported on page 72 for Sep 29 2024), an increase of roughly $8.5 million (a $1.7 million rise from 2022→2023 and a further $6.8 million jump to 2024).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Starbucks' derivative liabilities related to foreign currency - other increased from $0.3 million in 2022 to $4.7 million in 2024. However, the LLM claims the 2024 amount is $8.8 million, which is incorrect. The calculated increase of $8.5 million is therefore also wrong; the correct increase is $4.4 million. Additionally, the LLM introduces a $1.7 million rise from 2022 to 2023 and a $6.8 million jump to 2024, which are not supported by the ground truth and introduce false intermediate data. (2) The fiscal years and reporting dates (Oct 2, 2022, and Sep 29, 2024) may align with Starbucks' reporting calendar, but the dollar amounts are not accurate. The $0.3 million figure for 2022 matches the ground truth, but the $8.8 million for 2024 does not—correct value is $4.7 million. Calculations based on incorrect inputs are invalid. (3) The reasoning structure is sound in that the model attempts to trace the evolution over time and compute changes, but it fails on multi-hop synthesis because it uses an incorrect 2024 value, undermining the entire analysis. There is no indication in the ground truth of intermediate 2023 values or stepwise increases. (4) Contextual relevance is high—the answer addresses the right metric, company, and time frame, and attempts a detailed evolution analysis. However, due to major quantitative errors, the correctness and qualitative accuracy scores are low. Minor formatting differences like 'million' vs 'M' are acceptable, but magnitude errors of $4.1 million are not.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1165,
        "completion_tokens": 443,
        "total_tokens": 1609
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has PepsiCo's issuance of the 4.600% Senior Notes due 2045 evolved between 2023 and 2024, and what does this indicate about the company's debt structure strategy?",
      "original_answer": "In 2023, the 4.600% Senior Notes due 2045 were listed among other senior notes in the Board of Directors Resolutions that authorized PepsiCo's officers to establish terms for various notes, including the 4.600% Senior Notes due 2045. By 2024, the 4.600% Senior Notes due 2045 remained part of the company's debt structure, but were now referenced alongside a broader range of newly introduced senior notes, such as the 4.000% Senior Notes due 2047 and Floating Rate Notes due 2026. This indicates that while the 4.600% Senior Notes due 2045 remained a part of PepsiCo's long-term debt strategy, the company expanded its debt portfolio with additional instruments, suggesting a more diversified approach to long-term financing in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 PepsiCo added the 4.600 % Senior Notes due 2045 to its long‑dated debt stack – the notes were first referenced in a 2023 8‑K filing and then re‑approved in a February 2024 board resolution (page 130) that listed the 4.600 % 2045 notes among a suite of newly authorized senior unsecured issues.  This incremental, re‑opening of a 30‑year fixed‑rate tranche shows the company’s strategy of extending the maturity of its balance‑sheet debt, locking in relatively low coupons in a higher‑rate environment, and diversifying its funding base (including offshore vehicles) to manage the debt‑maturity wall and preserve financial flexibility.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies the 4.600% Senior Notes due 2045 as part of PepsiCo's debt structure and references their authorization in 2023 and 2024, aligning with the ground truth. However, it inaccurately states that the notes were 'added' or 'first referenced' in a 2023 8-K filing and then 're-approved' in a February 2024 board resolution, implying issuance occurred or was re-authorized in 2024. The ground truth indicates that the 2024 document only reaffirmed the notes as part of a broader portfolio that now included new instruments like the 4.000% Senior Notes due 2047, not that the 2045 notes were re-authorized or newly issued. (2) Quantitatively, the percentage (4.600%), maturity year (2045), and mention of other notes (e.g., 4.000% due 2047) are correct. However, the claim about a 'February 2024 board resolution (page 130)' introducing or re-authorizing the 2045 notes is not supported by the ground truth, which only states the notes remained part of the structure. The reference to a specific page and filing type (8-K) introduces unverified details. (3) The multi-hop reasoning is partially sound—linking 2023 and 2024 documents to assess evolution—but misinterprets the nature of the 2024 update. The conclusion about extending maturities and locking in rates is plausible but not directly supported by the provided ground truth, which emphasizes diversification through new instruments rather than re-opening tranches. (4) The contextual relevance is high as the answer addresses the evolution and strategic implications, but the qualitative accuracy is reduced due to incorrect characterization of the issuance timeline and authorization process. The core fact that the 4.600% notes remained in the portfolio is correct, but the narrative around their 'addition' and 're-approval' misrepresents the evolution, leading to a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 527,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has COP's natural gas position in the Asia Pacific/Middle East region evolved between 2022 and 2024, and what does this indicate about its strategic focus in the region?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas in the Asia Pacific/Middle East region. By 2024, this figure had decreased slightly to 296 billion cubic feet. This indicates a minor reduction in natural gas reserves in the region over the two-year period. The decline, although modest, suggests a potential shift in strategic focus, possibly due to market dynamics or operational adjustments in the region.",
      "llm_answer": "\nBetween the end of 2022 and the end of 2024 ConocoPhillips’ reported natural‑gas reserves in the Asia‑Pacific/Middle East fell modestly—from roughly **326 billion cubic feet** to **296 billion cubic feet**—while production in the region stayed flat at about **25–50 billion cubic feet per year**.  At the same time, the share of those reserves held through **equity‑affiliate partners grew** (from 5,753 million boe to 5,870 million boe), indicating that COP is shifting from direct, large‑scale development to a **strategy that leans on joint‑venture and partnership arrangements** to maintain a stable, low‑growth presence in the region.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the natural gas reserves for COP in the Asia Pacific/Middle East region in 2022 (326 billion cubic feet) and 2024 (296 billion cubic feet), matching the ground truth. However, it introduces additional data not present in the original answer—specifically, production levels (25–50 billion cubic feet per year) and equity-affiliate reserves in million boe (barrels of oil equivalent)—which are not mentioned or verifiable from the ground truth. These additions, while potentially plausible, are unsupported by the provided knowledge graph and represent factual overreach. (2) The core numbers for reserves are accurate and correctly formatted, but the inclusion of unverified production figures and affiliate reserve data (5,753 to 5,870 million boe) undermines quantitative accuracy. There is no indication in the ground truth that these metrics were reported or relevant. (3) The reasoning leap to a strategic shift toward joint ventures based on equity-affiliate data is not supported by the original answer, which only suggests a potential strategic shift due to market dynamics or operational adjustments—without citing specific partnership trends. This represents a failure in multi-hop reasoning, as the model infers a causal relationship from data not present in the ground truth. (4) While the LLM addresses the evolution of COP's natural gas position and attempts to interpret strategic focus, it adds speculative data and reasoning, reducing factual correctness. The contextual relevance is high because it directly addresses the question’s intent, but the qualitative and quantitative inaccuracies prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 456,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has Google Play's role in Google's non-advertising revenue strategy evolved from 2022 to 2023, based on the specific revenue sources mentioned in the filings?",
      "original_answer": "In 2022, Google Play was specifically mentioned as generating revenues from 'sales of apps and in-app purchases and digital content sold in the Google Play store.' By 2023, Google Play's revenue focus had evolved to be more narrowly described as primarily coming from 'apps and in-app purchases,' and it was grouped under the broader category of 'platforms' within non-advertising revenue sources. This indicates a shift in emphasis toward core app-based monetization within Google's strategic narrative around Play.",
      "llm_answer": "\nFrom 2022 to 2023 the filings treat Google Play the same way — as a source of revenue from app and in‑app purchases and digital content sold through the store — but the context shifts. In the 2022 filing Google Play is listed simply under “Google Services” as one of the non‑advertising revenue streams, while the 2023 filing places it alongside other non‑advertising sources such as hardware sales (Fitbit, Pixel devices) and consumer subscriptions (YouTube Premium/TV, NFL Sunday Ticket). This reflects a strategic evolution: Google Play is no longer highlighted as an isolated revenue line but as a component of a broader, diversified non‑advertising portfolio that the company is expanding through hardware and subscription services.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a key factual inaccuracy in its characterization of Google Play's revenue description evolution. The ground truth states that in 2023, Google Play's revenue sources were described more narrowly as 'apps and in-app purchases' and were grouped under the broader category of 'platforms' within non-advertising revenue. However, the LLM claims that in 2023, Google Play was grouped with hardware sales and consumer subscriptions under a diversified non-advertising portfolio, which is not supported by the original answer. The original does not mention 'hardware' or 'subscriptions' in relation to Google Play’s categorization in 2023, nor does it state that Play was grouped with those specific categories. Instead, the shift was toward framing Play as part of 'platforms' with a narrowed revenue focus. The LLM correctly identifies that Play was under 'Google Services' in 2022 and that its contextual presentation changed in 2023, showing some accurate synthesis. There are no numerical inaccuracies (quantitative accuracy is high), and the response is contextually relevant, addressing the evolution question. However, the incorrect entity grouping and misrepresentation of the 2023 categorization undermine the qualitative accuracy and overall correctness, resulting in a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 370,
        "total_tokens": 1688
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has the projected utilization of the Cessna SkyCourier 408 evolved from 2022 to 2024, and what does this indicate about FedEx's strategic reliance on this aircraft model?",
      "original_answer": "In 2022, FedEx projected the Cessna SkyCourier 408 to have a total of 49 aircraft in operation across the years 2023 to thereafter. By 2024, this projection was reduced to a total of 31 aircraft for the years 2025 through 2029. However, in the 2024 report, the relationship to the Cessna SkyCourier 408 shifted from 'Increases' to 'Depends_On', indicating a change in strategic importance. This suggests a moderated but still significant reliance on the aircraft model over time.",
      "llm_answer": "\nFrom the 2022 filing FedEx expected to receive 11 SkyCourier 408s in 2023, 12 in 2024 and 12 in 2025 (rising to 14 by 2026).  In the 2024 filing the 2025 commitment had already been lifted to 17 aircraft (with 14 still planned for 2026), showing a clear upward revision of the delivery schedule.  This increase demonstrates that FedEx is placing growing strategic emphasis on the Cessna SkyCourier 408 as a key, fuel‑efficient asset for expanding its regional/middle‑mile package network and replacing older turboprops.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude. The ground truth states that FedEx reduced its projected utilization of the Cessna SkyCourier 408 from 49 aircraft (2023 onward) in the 2022 report to 31 aircraft (2025–2029) in the 2024 report, indicating a downward revision. However, the LLM claims an 'upward revision' with increasing deliveries (11 in 2023, 12 in 2024, etc.), which contradicts the ground truth. (2) The numbers provided in the LLM answer (e.g., 11, 12, 14, 17 aircraft) are not supported by the original answer and appear fabricated. There is no mention of annual delivery breakdowns in the ground truth—only total projected aircraft over time. The calculation of increasing deliveries and upward trend is therefore invalid. (3) The multi-hop reasoning is flawed: instead of recognizing the reduction in total projected aircraft and the shift in strategic relationship from 'Increases' to 'Depends_On', the LLM incorrectly infers growing strategic emphasis. This misrepresents the core conclusion. (4) While the LLM attempts to address the strategic reliance question, it does so based on false quantitative premises, leading to an incorrect qualitative assessment. The contextual relevance is moderate because it discusses the right topic (strategic use of SkyCourier) but with entirely inaccurate data and direction of change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 385,
        "total_tokens": 1642
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has AIG's use of expected loss ratio methods evolved between 2022 and 2023, particularly in terms of segmentation and the types of casualty lines analyzed?",
      "original_answer": "In 2022, AIG used expected loss ratio methods primarily for the three latest accident years in the U.S. Excess Casualty line, segmenting analysis by attachment point and further differentiating between automobile and non-automobile claims, including special treatment for latent exposures like construction defects and mass torts. In 2023, AIG continued to apply expected loss ratio methods but shifted focus to U.S. Workers' Compensation, where the company grouped business by risk-sharing features such as high deductibles and retrospective rating, and analyzed separately by state, industry, and claim handling entity. The increase in large deductible business also affected the reporting pattern of claims, indicating a broader application context for the method. This reflects a strategic evolution in where and how expected loss ratio methods are applied across different casualty lines.",
      "llm_answer": "\nBetween the 2022 and 2023 filings AIG moved from a relatively coarse, aggregate application of expected‑loss‑ratio estimates for its excess‑casualty book to a more granular segmentation. In 2023 the company explicitly splits the book into automobile‑related and non‑automobile lines, further subdivides the non‑automobile segment into latent exposures such as construction‑defect and mass‑tort claims, and analyzes standard claims by attachment‑point bands—allowing the expected‑loss‑ratio method to be applied separately to each segment and to the three most recent accident years with adjustments for rate, inflation and market changes. This added segmentation was not present in the 2022 disclosures, which treated excess‑casualty losses more holistically.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies regarding the evolution of AIG's use of expected loss ratio methods between 2022 and 2023. It incorrectly states that in 2023, AIG applied more granular segmentation (by automobile vs. non-automobile, latent exposures, attachment point) to the U.S. Excess Casualty line, implying an increase in segmentation over 2022. However, the ground truth indicates that this segmentation was already in place in 2022 for U.S. Excess Casualty. More critically, the LLM fails to identify the key evolution: a shift in focus from U.S. Excess Casualty in 2022 to U.S. Workers' Compensation in 2023. The 2023 application involved grouping by risk-sharing features (e.g., high deductibles, retrospective rating), and analysis by state, industry, and claim handling entity—details entirely missing from the LLM response. Instead, the LLM incorrectly suggests that the segmentation evolved within the same line (Excess Casualty), when in fact the method was applied to a different casualty line. While the LLM correctly mentions segmentation by automobile/non-automobile and latent exposures, it misattributes the year and context. Quantitative accuracy is moderate: no explicit numbers are wrong because none are cited, but the temporal and contextual framing of methodological changes is incorrect. The reasoning is flawed due to incorrect multi-hop synthesis—failing to recognize the shift in casualty lines analyzed. Contextual relevance is fair as the answer discusses segmentation and expected loss ratio methods, but misses the core strategic shift. Thus, the answer is partially correct on components but fundamentally wrong on the overall evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 460,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did the classification and reporting of unallocated products evolve between fiscal years 2022 and 2024, particularly in terms of how they are categorized within Nike's consumer construct?",
      "original_answer": "In fiscal year 2022, unisex products were classified within Men's, and certain products not allocated to Men's, Women's, NIKE Kids', and Jordan Brand were included in 'Others' with adjustments not allocated by consumer. By fiscal year 2024, 'Others' continued to include products not allocated to Men's, Women's, Kids', and Jordan Brand, but there was no specific mention of unisex product classification within Men's, suggesting a potential shift or integration of unisex products within broader categories.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Nike’s consumer‑segmentation was formalized around Men’s, Women’s, Kids’ and Jordan Brand, and any products that do not fit those groups (e.g., certain licensing lines, niche offerings and internal adjustments) are now isolated in an “Others” line item. In the 2022 filing (page 35) the “Others (4)” caption was defined as “products not allocated to Men’s, Women’s, Kids’ and Jordan Brand, as well as certain adjustments that are not allocated to products designated by consumer,” and the 2024 filing (page 38) retains the same caption but explicitly ties it to “products not allocated to Men’s, Women’s, Kids’ and Jordan Brand” and notes that they are presented separately to isolate revenue outside the core consumer construct. Thus, while the label “Others” remains unchanged, its definition and placement have been clarified to reflect the refined consumer‑construct reporting.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the consistent use of the 'Others' category in both fiscal years 2022 and 2024 for products not allocated to Men's, Women's, Kids', and Jordan Brand, and notes the clarification in reporting language—this aligns with the ground truth. It accurately references the filings (page 35 for 2022, page 38 for 2024) and correctly describes the definition of 'Others' in both years, supporting quantitative and contextual accuracy. However, the LLM omits a key point from the original answer: in fiscal year 2022, unisex products were explicitly classified within Men's, and by 2024, there was no mention of that classification, suggesting a shift. This absence of discussion on unisex product treatment weakens the qualitative accuracy, as it fails to fully address the evolution in classification of unallocated products—particularly unisex items—within the consumer construct. While the 'Others' category is well-explained, the core of the question focuses on how unallocated (especially unisex) products evolved, which is underdeveloped. Thus, despite strong contextual framing and correct entity/date usage, the answer misses a critical comparative insight, warranting a score of 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 344,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did PepsiCo's engagement with the 3.500% Senior Notes due 2025 evolve between 2023 and 2024, and what does this indicate about the company's debt management strategy?",
      "original_answer": "In 2023, PepsiCo's 3.500% Senior Notes due 2025 were listed among other notes, indicating they were part of the company's existing debt structure. By 2024, the 3.500% Senior Notes due 2025 were still present, but they were now accompanied by a broader range of new notes, including longer-term instruments such as the 3.500% Senior Notes due 2040 and the 3.550% Senior Notes due 2034. This suggests that PepsiCo expanded its debt portfolio in 2024, introducing more long-term financing options while maintaining its commitment to the 3.500% Senior Notes due 2025. The addition of new notes indicates a strategic shift toward diversifying its debt maturity structure.",
      "llm_answer": "\nBetween 2023 and 2024 PepsiCo moved from simply carrying the 3.500 % Senior Notes due 2025 as part of its legacy long‑term debt (as shown in the 2023 filing where the note is only listed among prior issuances) to formally setting its terms through a Board‑approved resolution in the 2024 filing (page 130, “Board of Directors Resolutions Authorizing … the 3.500 % Senior Notes due 2025”).  This explicit authorization in the 2024 10‑K signals that the company is proactively managing the upcoming 2025 maturity—likely preparing to refinance or extend the obligation—reflecting a debt‑management strategy that emphasizes deliberate structuring of maturities and the use of formal governance steps to lock in financing conditions.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some correct elements but diverges significantly from the ground truth in key aspects of reasoning and factual synthesis. (1) Quantitatively, the 3.500% Senior Notes due 2025 are correctly identified with the right interest rate and maturity year, and the years 2023 and 2024 are properly referenced—this supports a quantitative accuracy score of 8. There are no numerical calculations, so accuracy hinges on correct identification of financial instruments and dates, which is mostly accurate. (2) However, the LLM introduces a claim not present in the original answer: that in 2024, the 3.500% Senior Notes due 2025 were 'formally set' via a Board resolution, implying a re-authorization or restructuring. The ground truth does not mention any such governance action or procedural change; instead, it emphasizes the *coexistence* of the 2025 notes with *newly issued longer-term notes* (e.g., due 2034, 2040) as evidence of maturity diversification. This is a critical factual discrepancy. (3) The multi-hop reasoning is flawed: the LLM interprets increased documentation detail (a Board resolution mention) as strategic refinance preparation, while the ground truth infers strategy from the *addition of new long-term debt instruments*. The LLM fails to mention the new notes (2034, 2040), which are central to the original answer’s conclusion about debt diversification. Thus, the qualitative accuracy is reduced to 5—some correct entities and logical flow, but missing core evidence and introducing unsupported claims. (4) Contextual relevance is moderate: the answer addresses PepsiCo's debt management and the 2025 notes’ evolution, but misattributes the strategic signal. It focuses on procedural formalization rather than portfolio diversification, misaligning with the ground truth’s emphasis. Overall, the answer is partially correct but contains significant factual and inferential errors, warranting a correctness score of 4.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 526,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did COP's financial disclosures regarding the Lower 48 region evolve between 2022 and 2024, particularly in terms of capital expenditures and future cash inflow revisions?",
      "original_answer": "In 2022, COP reported capital expenditures for the Lower 48 region at $3,129 million, indicating significant active investment in the area. By 2024, the company disclosed that certain amounts in the Lower 48 had been revised to reflect additional future cash inflows and future production costs, although no new capital expenditure figure was provided. This shift suggests a transition from active investment to a focus on revising financial projections based on updated expectations for production and cost dynamics in the region.",
      "llm_answer": "\nFrom 2022 to 2024 ConocoPhillips markedly expanded its Lower 48 capital program—development outlays rose from roughly $4.6 bn to about $6.3 bn and proved‑property acquisitions jumped from $0.25 bn to $12.1 bn—while the SEC‑mandated discounted future net‑cash‑flow metric slipped from $55.9 bn in 2022 to $33.3 bn in 2023 before recovering modestly to $38.7 bn in 2024, a shift driven by lower commodity prices and reserve‑quantity revisions that offset the higher spending.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and fails to align with the ground truth on multiple levels. (1) Quantitatively, the capital expenditures cited are wrong: the ground truth states $3,129 million (approx. $3.13 billion) for 2022, but the LLM claims $4.6 billion in 2022 and $6.3 billion in 2024—neither of which matches. Additionally, the LLM introduces a $12.1 billion proved-property acquisition in 2024, which is not mentioned or implied in the original answer. The future cash flow figures ($55.9B, $33.3B, $38.7B) are entirely fabricated and not supported by the ground truth, which states that no new capital expenditure figure was provided for 2024 and only mentions revisions to future cash inflows and production costs without specific numbers. (2) The original answer does not mention any SEC-mandated discounted future net cash flow metric or commodity price impacts, so these are extraneous and incorrect additions. (3) Qualitatively, the reasoning is flawed: the LLM suggests increasing investment and ties cash flow changes to commodity prices and reserve revisions, while the ground truth indicates a shift from active investment to revising financial projections—no such trend in spending is supported. The multi-hop synthesis fails because the LLM invents data rather than correctly interpreting the evolution from reported capex in 2022 to revised future inflows in 2024. (4) Contextually, the answer appears relevant on the surface (discussing capex and cash flows in the Lower 48), but the substance is factually misaligned, making it misleading. The core claim of increased spending contradicts the ground truth’s implication of reduced active investment. Overall, the answer fabricates numbers, misrepresents trends, and introduces unsupported metrics, warranting a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 492,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did Comcast's financial commitments and governance arrangements with Atairos Group evolve between 2023 and 2024, particularly regarding capital obligations and control structures?",
      "original_answer": "In 2023, Comcast had a Fourth Amended and Restated Shareholders Agreement with Atairos Group, Inc., which was further amended in June 2023. This agreement outlined Comcast's role as the sole third-party investor and included governance terms among Atairos-related entities. By 2024, the relationship evolved into a more formalized investment framework under the equity method accounting. In this framework, Comcast reduced its capital commitment from up to $5 billion to $4.5 billion, limited annual capital calls to $400 million, and agreed to separately fund $40 million annually for management fees. Additionally, the 2024 filing clarified that Comcast absorbs approximately 99% of Atairos’ losses and receives approximately 86% of residual returns, while Atairos’ management companies (led by Comcast’s former CFO) retained all voting rights. These changes reflect a recalibration of financial exposure and a clearer delineation of control.",
      "llm_answer": "\nBetween 2023 and 2024 Comcast’s financial exposure to Atairos contracted: the company recorded only $73 million of cash capital contributions in 2024 versus $145 million in 2023, and the remaining unfunded commitment stood at $1.4 billion as of 31 December 2024.  Governance did not change materially – Atairos remains a VIE that Comcast does not consolidate because it holds no voting rights or control, only limited consent rights and a passive equity‑method interest, with the management companies (led by the former CFO) retaining all voting power and Comcast absorbing ~99 % of losses and ~86 % of residual gains.  Consequently, Comcast’s maximum risk is now limited to the $1.4 billion unfunded capital commitment and its existing investment balance, with no new liquidity guarantees or related‑party financial commitments introduced in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies that Comcast absorbs ~99% of losses and ~86% of residual returns, and that Atairos’ management companies (led by the former CFO) retain voting rights—this aligns with the ground truth. However, it fails to mention the key structural change in 2024: the reduction of Comcast’s total capital commitment from $5 billion to $4.5 billion and the cap on annual capital calls at $400 million, which are central to the evolution of financial commitments. Instead, the LLM cites actual cash contributions ($73M in 2024 vs $145M in 2023) and a remaining unfunded commitment of $1.4 billion as of end-2024—details not present in the ground truth and potentially misleading, as the original answer does not provide actual contribution figures or remaining balances. (2) Quantitative accuracy is compromised: while percentages (~99%, ~86%) are correct, the $1.4 billion unfunded commitment and the year-over-year contribution figures are not supported by the original answer and may be fabricated or misattributed. The original answer specifies a $4.5 billion total commitment but does not state how much has been drawn down, so the $1.4 billion figure cannot be verified and appears inconsistent with a $5B → $4.5B reduction. (3) The reasoning partially captures the governance continuity—correctly noting lack of voting rights and control, VIE status, and equity-method accounting—but misses the nuance that the 2024 framework formalized a new investment structure with defined limits, which represents a meaningful evolution, not just a static risk profile. The conclusion that governance 'did not change materially' contradicts the ground truth’s assertion of a 'clearer delineation of control' and recalibration. (4) Contextual relevance is high—the answer addresses both financial commitments and governance, uses appropriate financial terminology, and focuses on the right entities and time frame. However, the failure to report the key commitment reduction and misrepresentation of actual contributions undermines factual correctness. The answer synthesizes some multi-hop elements (e.g., linking economic exposure to lack of control) but omits the core contractual evolution. Thus, while semantically plausible and contextually focused, it lacks key facts and introduces unsupported numbers, warranting a partial correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1457,
        "completion_tokens": 647,
        "total_tokens": 2104
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did FedEx's projected utilization of the Cessna SkyCourier 408 change between 2022 and 2023 filings, and what does this indicate about its strategic role in the fleet compared to other aircraft?",
      "original_answer": "In the 2022 filing, FedEx projected a total of 49 Cessna SkyCourier 408 aircraft to be in service through 2027. By the 2023 filing, this projection dropped significantly to only 31 Cessna SkyCourier 408 aircraft through 2029. This indicates a strategic reduction in the planned reliance on the Cessna SkyCourier 408, especially when compared to other aircraft types like the B767F and B777F, which saw more stable or less reduced projections. This shift suggests FedEx may have reassessed the aircraft's role in its long-term fleet strategy.",
      "llm_answer": "\nThe 2022 filing projected 49 Cessna SkyCourier 408 deliveries through 2026 (e.g., 11 in 2023, 12 in 2024, 12 in 2025, 14 in 2026), while the 2023 filing reduces that outlook to only 31 aircraft— 17 slated for 2025 and 14 for 2026—and eliminates any 2023‑2024 deliveries. Thus the projected utilization falls by about 18 units (≈ 37 %), indicating that FedEx is scaling back the SkyCourier’s role and treating it as a supplemental, niche asset rather than a core fleet‑expansion aircraft, with greater emphasis now placed on other types such as the ATR 72‑600F, B767F and B777F.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the reduction in projected Cessna SkyCourier 408 aircraft from 49 in the 2022 filing to 31 in the 2023 filing, which matches the ground truth. However, there are discrepancies in the delivery timeline: the 2022 filing projects deliveries through 2027, not 2026 as stated by the LLM, and the 2023 filing extends to 2029, not just 2026. Additionally, the LLM incorrectly specifies delivery breakdowns (e.g., 11 in 2023, 12 in 2024, etc.) and claims deliveries were eliminated for 2023–2024, which is not supported by the ground truth—no such annual breakdown or cancellation details are present in the original answer. The ≈37% reduction calculation is approximately correct (18/49 ≈ 36.7%), though the '18 units' difference is slightly off (49–31=18, which is accurate), but the characterization of delivery years undermines precision. (2) The core numbers (49 and 31) are correct, but the added granular delivery schedule is fabricated or misattributed, reducing quantitative accuracy. (3) The reasoning is strong: the LLM correctly infers a strategic downgrading of the SkyCourier’s role and appropriately contrasts it with other aircraft like the B767F and B777F. Mention of the ATR 72-600F is an addition not in the original, but does not contradict the overall strategic interpretation. The conclusion that the aircraft is now seen as a 'supplemental, niche asset' aligns with and even enriches the ground truth’s assertion of reduced strategic importance. (4) The answer fully addresses both parts of the question—change in projection and strategic implication—and remains highly relevant. Despite minor factual inaccuracies in timing details, the core multi-hop synthesis (comparing two filings, identifying trend, inferring strategic shift) is sound. Scored 8 due to correct key numbers and valid strategic interpretation, but docked for unsupported delivery-year specifics and slight misrepresentation of timeframes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 531,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has Nike's approach to the Air Max product line evolved from 2022 to 2024, particularly in terms of revenue transparency and technological innovation emphasis?",
      "original_answer": "In 2022, Nike included Air Max in a general list of technologies within the revenue disaggregation table, indicating its presence in the product portfolio but without specific revenue figures. By 2024, while no direct revenue numbers were disclosed, Nike emphasized Air Max as a central example of its innovation strategy, highlighting its integration into broader product categories and consumer applications. This shift reflects a strategic move from passive acknowledgment to positioning Air Max as a key innovation driver, despite the continued lack of standalone financial metrics for the product line.",
      "llm_answer": "\nBetween fiscal 2022 and 2024 Nike shifted from reporting only total footwear revenue to a fully disaggregated schedule that separates footwear, apparel and equipment and breaks sales down by geography and channel—making the Air Max line (reported only under “Footwear”) traceable within the $29.1 billion 2022 footwear total and the $35.6 billion 2022 overall revenue.  At the same time, the 2024 filing explicitly lists “Air Max” among the key cushioning technologies (e.g., Nike Air, Zoom, Free, React) in its R&D narrative, highlighting a sustained focus on technological innovation for that product line.  Thus, Nike’s approach has evolved to be both more transparent about Air Max’s revenue contribution and more vocal about the innovation behind it.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly claims that Nike's 2022 reporting allowed the Air Max line to be 'traceable' within the $29.1 billion footwear revenue, which contradicts the ground truth stating that Air Max was only included in a general list of technologies without specific revenue figures. The $29.1 billion footwear and $35.6 billion total revenue figures for 2022 are not confirmed in the ground truth and appear fabricated. (2) The quantitative inaccuracies are severe: the LLM invents precise revenue numbers not present in the original answer, and falsely implies disaggregation enabled tracking of Air Max revenue, which the ground truth explicitly denies. (3) The reasoning is flawed—while the LLM correctly notes increased emphasis on innovation in 2024, it incorrectly infers improved revenue transparency, when the ground truth states there was 'continued lack of standalone financial metrics.' The multi-hop synthesis fails because it misinterprets the nature of Nike's reporting changes. (4) Despite misrepresenting financial transparency, the LLM correctly identifies Nike's growing narrative emphasis on Air Max as an innovation driver in 2024, which aligns with the ground truth. This partial alignment with the innovation aspect prevents a score of 0, but the core claim about revenue transparency is false, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 393,
        "total_tokens": 1738
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Comcast's capital expenditure strategy regarding Epic Universe evolve from 2023 to 2024, particularly in terms of specific investment amounts and thematic park development priorities?",
      "original_answer": "In 2023, Comcast specifically noted an increase in capital expenditures directly related to the development of Epic Universe in Orlando, with a total of $8.2 billion allocated to Connectivity & Platforms, which included investments in scalable infrastructure and line extensions. By 2024, the company continued to emphasize investment in existing and new attractions at Universal theme parks, including Epic Universe, as part of its broader capital expenditure plan for 2025. While specific figures for Epic Universe alone were not disclosed in 2024, the company indicated an ongoing commitment to theme park development, particularly in expanding attractions and enhancing capacity. The evolution shows a shift from initial infrastructure and development focus in 2023 to a more sustained investment strategy in 2024 that includes both infrastructure and guest experience enhancements.",
      "llm_answer": "\nFrom 2023 to 2024 Comcast shifted Epic Universe spending from early‑stage, land‑acquisition costs (which were part of the $8.2 billion total capital‑expenditure base in 2023) to a focus on active construction.  The 2024 filing notes that total capital expenditures were essentially flat at **$8.286 billion** (versus $8.241 billion in 2023) but that “spending on theme‑park attractions increased in 2024, and included costs associated with the construction of Epic Universe,” indicating that a larger share of the capex budget was now devoted to completing the Universal theme‑park project.  While the filing does not break out a separate dollar amount for Epic Universe, the increase in theme‑park capex and the explicit reference to Epic Universe as a priority show the evolution of the strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in quantitative details. The ground truth states that $8.2 billion was allocated to Connectivity & Platforms in 2023, which included Epic Universe investments, but the LLM incorrectly presents the total capex as $8.241 billion in 2023 and $8.286 billion in 2024—specific figures not found in the original answer and not supported by the provided ground truth. These precise numbers suggest a level of disclosure that does not align with the source, which did not provide total capex figures for 2023 or 2024 at that granularity. Additionally, the LLM introduces 'land-acquisition costs' and 'early-stage' spending in 2023, which are not mentioned in the original answer—misrepresenting the nature of 2023 investments. (2) The original answer emphasizes that no specific dollar amount for Epic Universe was disclosed in 2024, which the LLM correctly acknowledges. However, the LLM's claim of flat total capex with exact figures undermines this by implying more detailed reporting than actually occurred. (3) Qualitatively, the reasoning is partially sound: the shift from infrastructure focus in 2023 to active construction and guest experience in 2024 is consistent with the evolution described in the ground truth. The LLM correctly infers that a larger share of capex was directed toward Epic Universe in 2024 based on thematic park spending increases, demonstrating reasonable multi-hop synthesis. (4) Contextual relevance is high—the answer directly addresses the evolution of capital expenditure strategy, investment amounts, and development priorities. Despite incorrect specific numbers, it captures the directional shift and ongoing commitment. However, the fabrication of exact capex totals significantly reduces quantitative accuracy, warranting a moderate overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1432,
        "completion_tokens": 502,
        "total_tokens": 1934
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did FedEx's utilization of the ATR 72-600F aircraft evolve between 2022 and 2023 as reflected in their fleet projections for the same planning periods?",
      "original_answer": "In 2022, FedEx projected operating 11 ATR 72-600F aircraft in 2023, 6 in 2024, 6 in 2025, and only 1 in 2026. By 2023, the projections for the same time periods changed significantly, with 7 ATR 72-600F aircraft planned for 2025 and only 3 for 2026. This indicates a notable reduction in planned usage of the ATR 72-600F by FedEx over time.",
      "llm_answer": "\nBased on the 2022 10‑K (pages 38‑42) FedEx had scheduled **11 ATR 72‑600F deliveries in 2023** and a total of **24 ATR 72‑600F** through 2026 (11 in 2023, 6 in 2024, 6 in 2025, 1 in 2026). The 2023 10‑K (pages 115‑119) shows only **7 ATR 72‑600F for delivery in 2025 and 3 in 2026**, cutting the earlier schedule and effectively phasing the type out of its near‑term fleet plans. Thus, between 2022 and 2023 the company reduced its ATR 72‑600F commitments and shifted focus to other freighter models (e.g., 767F/777F) in its projected fleet.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the 2022 projection included 11 ATR 72-600F aircraft for 2023, 6 for 2024, 6 for 2025, and 1 for 2026—totaling 24, as correctly stated. The 2023 update shows 7 for 2025 and 3 for 2026, which matches the ground truth. (2) The answer correctly identifies the shift in fleet planning between the two reporting years, noting the reduction in projected utilization, which reflects the core of the multi-hop comparison across 2022 and 2023 filings. (3) The reasoning is sound: it synthesizes data from two different 10-Ks (2022 and 2023), compares projections for overlapping years, and draws the correct conclusion about reduced commitment. (4) The only minor shortcoming is that the LLM mentions 'deliveries' rather than 'operating' or 'projected utilization,' which slightly mischaracterizes the nature of the data (fleet usage vs. delivery timing), but the overall interpretation of reduced planned usage is correct. The mention of shifting focus to 767F/777F adds context not in the ground truth but is plausible and does not detract from accuracy. All key facts are present, correctly interpreted, and semantically equivalent to the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 353,
        "total_tokens": 1576
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did Nike's approach to estimating product return reserves evolve between fiscal 2022 and fiscal 2024, and what does this indicate about changes in their revenue recognition methodology?",
      "original_answer": "In fiscal 2022, Nike disclosed that the estimated cost of inventory for expected product returns was $269 million, and these reserves were recorded in Prepaid expenses and other current assets. By fiscal 2024, while the specific dollar amount of the product return reserve was not disclosed, Nike described a more formalized estimation process, stating that it calculates anticipated reductions in revenue—such as sales returns—by determining the 'most likely amount' it will be entitled to receive. This indicates a shift toward a more probabilistic and forward-looking revenue estimation methodology, aligning with the broader revenue recognition framework where variable consideration is estimated at the time revenues are recognized.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Nike continued to estimate product‑return reserves using the same three‑point approach—historical return rates, specific identification of outstanding returns, and forward‑looking forecasts—but the 2024 disclosures show a reduced reserve balance ($1.015 bn vs. $1.077 bn in 2022) and a lower estimated cost of inventory for expected returns ($194 m vs. $269 m in 2021).  This downward adjustment reflects a more refined estimation of future returns and indicates that Nike is now recognizing revenue net of a smaller, more precisely quantified return reserve, aligning its revenue‑recognition practice with ASC 606’s variable‑consideration guidance.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. The ground truth states that in fiscal 2022, the estimated cost of inventory for expected product returns was $269 million, but the LLM incorrectly claims $194 million in 2024 and references $269 million in 2021 (not asked and not in the original answer). The LLM also fabricates reserve balances of $1.015 billion in 2024 and $1.077 billion in 2022, which are not mentioned in the original answer. These numbers are entirely unsupported and significantly distort the facts. (2) The quantitative inaccuracies are severe: no dollar amounts for 2024 are provided in the ground truth, yet the LLM invents precise figures. The comparison between years is therefore invalid. Additionally, the reference to '2021' is a clear error, as the question and original answer focus on 2022 and 2024. (3) The reasoning is flawed. The original answer describes a qualitative shift in methodology—toward a 'most likely amount' approach under ASC 606—but does not mention a 'three-point approach' or continuity in method. The LLM incorrectly asserts that the same method was used throughout, contradicting the original's emphasis on increased formalization and a more probabilistic framework. The conclusion about alignment with ASC 606 is directionally correct but based on false premises. (4) While the LLM attempts to address revenue recognition changes, it fails on correctness due to fabricated data and misrepresentation of methodology evolution. The contextual relevance is moderate because it discusses the right topic (return reserves and revenue recognition), but the qualitative and quantitative inaccuracies severely undermine the response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 464,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did the planned fleet composition of the Cessna SkyCourier 408 change between 2022 and 2023 for the years 2025 and beyond, and what does this indicate about the company's strategic reliance on this aircraft model?",
      "original_answer": "In 2022, FDX projected a total of 12 Cessna SkyCourier 408 aircraft to be in operation by 2025 and planned to maintain that number through 2026. By 2023, the company increased its planned fleet count for 2025 to 17 but reduced it to 14 for 2026. This indicates a short-term increase in strategic reliance on the Cessna SkyCourier 408, followed by a moderate decline in planned usage by 2026, suggesting a recalibration of fleet strategy.",
      "llm_answer": "\nThe 2022 filing projected 12 Cessna SkyCourier 408 deliveries for 2025, while the 2023 filing (updated in the 2024 10‑K) raises that to 17 aircraft for 2025 and adds 14 more for 2026 (pages 114 and 118). This upward revision shows FedEx is expanding its commitment to the SkyCourier 408, signaling a strategic shift toward greater reliance on this model to grow its regional package network beyond 2025.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the increase from 12 to 17 Cessna SkyCourier 408 aircraft planned for 2025 between the 2022 and 2023 filings, which matches the ground truth. However, it incorrectly states that 14 more aircraft are planned for 2026, implying an addition to the 17, when in fact the 2023 plan reduced the 2026 fleet count to 14 from the previously maintained 12. The ground truth specifies that the 2022 plan was to maintain 12 through 2026, while the 2023 update increased 2025 to 17 but reduced 2026 to 14—this nuance is misrepresented. (2) The numbers for 2025 (12 and 17) are accurate, but the interpretation of the 2026 figure is wrong: '14 more for 2026' incorrectly suggests cumulative growth rather than a planned decrease from 17 to 14. This is a critical quantitative and interpretive error. (3) The multi-hop reasoning is partially sound—information is synthesized across two years of filings—but the conclusion misrepresents the strategic trajectory. The LLM concludes an ongoing expansion 'beyond 2025', while the ground truth indicates a short-term increase followed by a moderate decline, suggesting strategic recalibration, not continued growth. (4) Scores reflect partial correctness: numbers for 2025 are right, but 2026 is misinterpreted; reasoning is flawed in synthesis; relevance is high as the model addresses the core question with correct context and citations, but draws an incorrect strategic implication due to factual inaccuracy in fleet count trajectory.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1228,
        "completion_tokens": 416,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Mastercard's real-time account-based payments infrastructure evolved from 2023 to 2024, particularly in terms of operational scale and integrated security capabilities?",
      "original_answer": "In 2023, Mastercard operated or was implementing real-time payments infrastructure in 13 markets globally, offering instant payments with enhanced data and messaging capabilities. The company emphasized a distributed network architecture that enabled intelligent routing and applied value-added services like fraud scoring and tokenization in real time. By 2024, Mastercard expanded its capabilities by enhancing its ACH and real-time account-based payment systems to provide more secure, simple, and smart payment solutions across its global network. The company also reinforced its multi-layered security approach, integrating additional protections and partnerships to safeguard the payments ecosystem. These developments indicate a strategic shift toward strengthening both the scale and security of its real-time payments infrastructure.",
      "llm_answer": "\nFrom 2023 to 2024 Mastercard expanded its real‑time account‑based payments platform beyond the 13 markets where it was operating in 2023, scaling the clearing‑and‑settlement infrastructure to support a far larger global footprint and higher transaction volumes.  At the same time, the company reinforced the solution with a multi‑layered security architecture that adds real‑time fraud scoring, tokenization, 24‑hour availability and third‑party assessments, delivering end‑to‑end protection across the entire payment flow.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the mention of 13 markets in 2023 matches the original answer exactly, and no incorrect numbers or dates are introduced. The expansion beyond 13 markets in 2024 is consistent with the stated global scale-up. (2) The LLM correctly identifies key security capabilities: real-time fraud scoring and tokenization are explicitly mentioned in both answers. The addition of '24-hour availability' and 'third-party assessments' is not contradicted by the original and can be interpreted as reasonable elaborations of the 'multi-layered security approach' and 'partnerships' referenced in the ground truth. (3) The reasoning is sound: the LLM synthesizes information about operational scale (expansion from 13 markets) and security enhancements (multi-layered architecture), correctly framing the evolution from 2023 to 2024. (4) The answer is contextually relevant, directly addressing both operational scale and security capabilities as required. The only minor gap is that the original emphasizes 'enhanced data and messaging capabilities' and 'intelligent routing' in 2023, which the LLM omits, but these are secondary to the core focus on scale and security. Overall, the answer captures the essential facts, correct numbers, and logical progression, warranting a high score with only slight deduction for minor completeness gaps.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 391,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did Nike's use of foreign exchange forwards and options evolve between 2022 and 2024, particularly in terms of their impact on financial liabilities and hedging strategy?",
      "original_answer": "In 2022, foreign exchange forwards and options had a net gain of $8 million after tax, impacting various income categories such as revenues, cost of sales, and other (income) expense, net. By 2024, the liabilities associated with these instruments increased to $110 million under accrued liabilities and $5 million under deferred income taxes and other liabilities, indicating a shift in how these derivatives were managed or reported. This reflects a strategic evolution in Nike's hedging activities and financial exposure management.",
      "llm_answer": "\nBetween fiscal 2022 and 2024 Nike scaled back its foreign‑exchange forward and option program – the notional amount of designated cash‑flow hedges fell from roughly $18.5 bn to about $16 bn, and total derivative assets dropped from $557 m to $343 m while derivative liabilities slipped only slightly from $180 m to $151 m. This reduction lowered the company’s derivative‑related liabilities on the balance sheet and cut the amount of deferred gains/losses being re‑classified from accumulated other comprehensive income into earnings, although the firm still uses forwards and options to hedge product‑cost, revenue and intercompany foreign‑currency exposures. The strategy remains one of hedging up to 100 % of identified exposures, but with a more limited set of contracts than in 2022.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to align with the ground truth. (1) Quantitative Accuracy: The numbers provided in the LLM answer (e.g., notional hedges dropping from $18.5B to $16B, derivative assets from $557M to $343M, liabilities from $180M to $151M) are not present in the original answer and contradict the ground truth, which reports only liabilities related to foreign exchange forwards and options increasing to $110M under accrued liabilities and $5M under deferred income taxes in 2024. There is no mention of asset reductions or notional amounts in the ground truth. (2) Completeness: The LLM introduces new metrics (notional amounts, derivative assets, reclassifications from AOCI) not referenced in the original, while failing to mention the key point about the net gain of $8M after tax in 2022 and the shift in liability classification that indicates strategic evolution. (3) Entity Accuracy: While Nike and the instruments (forwards and options) are correctly identified, the years (2022–2024) are used appropriately but associated data is fabricated. (4) Reasoning: The LLM concludes a 'scaling back' of the program, which contradicts the ground truth indicating an increase in liabilities, suggesting potentially expanded or more heavily utilized hedging instruments. The reasoning is therefore flawed and based on unsupported data. (5) Semantic Equivalence: The overall message diverges significantly—the ground truth suggests increased liability reporting and strategic shift, while the LLM claims a reduction in hedging activity. Despite addressing the general topic of hedging strategy evolution, the answer is factually incorrect on key points, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 470,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has the product category classification of Puffs within the Baby, Feminine & Family Care segment evolved between 2022 and 2023?",
      "original_answer": "In 2022, Puffs was categorized under the Family Care sub-category, which included Paper Towels, Tissues, and Toilet Paper. By 2023, Puffs remained in the Family Care category, but the specific mention of 'Tissues' replaced 'Tissues' with a more general listing without sub-category breakdowns, indicating a simplification or consolidation of how the segment details were reported.",
      "llm_answer": "\nBetween fiscal 2022 and 2023 the classification of Puffs within the Baby, Feminine & Family Care segment was refined but did not move to a different segment. In the 2022 filing (PG 10‑K 2022, page 19) Puffs appears in the “Major Brands” list for the segment alongside baby‑care and feminine‑care brands, without a specific sub‑category label. In the 2023 filing (PG 10‑K 2023, page 19) the same brand list is retained, but Puffs is now explicitly grouped with the segment’s “Family Care” sub‑category (tissues) together with Charmin, indicating a shift from a mixed‑category mention to a clear placement in the tissue/family‑care line‑up. Thus, Puffs remained in the Baby, Feminine & Family Care segment, but its categorization became more precisely defined as a tissue‑brand within the Family Care sub‑category.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains accurate dates (2022 and 2023), correct company (Procter & Gamble, implied via PG 10-K), and correct segment (Baby, Feminine & Family Care), satisfying quantitative and entity accuracy. However, the core factual claim about Puffs' categorization evolution contradicts the ground truth. The original answer states that in 2022, Puffs was explicitly under Family Care (with Tissues listed), and in 2023, the reporting became *less* detailed—'Tissues' was replaced with a more general listing, indicating simplification. In contrast, the LLM claims Puffs went from *no specific sub-category* in 2022 to being *more precisely defined* under Family Care (tissues) in 2023—this is the inverse of the truth. This major reversal in the direction of change (increased specificity vs. decreased) undermines the reasoning and factual correctness. While the answer correctly identifies Puffs as remaining in the same segment and references the right filings, the multi-hop synthesis is flawed: it misinterprets the nature of the reporting change. The LLM likely confused the presence of a brand in a list with increasing specificity, when the ground truth indicates a move toward consolidation and less granular disclosure. Thus, despite correct entities and dates, the qualitative inaccuracy in the evolution narrative significantly reduces correctness. Semantic equivalence is not achieved due to this key contradiction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 394,
        "total_tokens": 1689
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has the positioning of Tampax within P&G's product portfolio evolved between 2022 and 2023, particularly in terms of its categorization and associated product lines?",
      "original_answer": "In 2022, Tampax was categorized under 'Feminine Care' within the 'Baby, Feminine & Family Care' segment, which also included 'Baby Care' and 'Family Care' sub-categories. By 2023, the product category was refined, and Tampax was associated solely with 'Menstrual Care' under the same broader segment. This reflects a more focused positioning of Tampax, separating it from general 'Family Care' items and aligning it more specifically with menstrual health needs.",
      "llm_answer": "\nBetween fiscal 2022 and 2023 Tampax continued to be reported under the **Baby, Feminine & Family Care** reportable segment, specifically within the **Feminine Care** sub‑category alongside the Always and Always Discreet brands.  The company’s disclosures show no change in its categorisation – it remains a core brand of the Feminine Care portfolio and is still grouped with other feminine‑care products (e.g., Tampax Bounty) in P&G’s segment‑level sales and earnings tables for both years.  Consequently, its positioning relative to other product lines stayed stable, continuing to drive share growth within the feminine‑care category under the broader Baby, Feminine & Family Care umbrella.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim about Tampax's categorization remaining unchanged between 2022 and 2023, directly contradicting the ground truth. According to the original answer, there was a meaningful repositioning: in 2022, Tampax was under 'Feminine Care' within the 'Baby, Feminine & Family Care' segment, but by 2023 it was specifically associated with 'Menstrual Care', reflecting a more focused positioning separate from general 'Family Care'. The LLM incorrectly states there was no change in categorization and that Tampax remained in the 'Feminine Care' sub-category alongside Always and Always Discreet, with no mention of the shift to 'Menstrual Care'. It also erroneously references 'Tampax Bounty', which is not a real product (Bounty is a P&G brand in paper towels, unrelated to Tampax), indicating a hallucination. While the broader segment ('Baby, Feminine & Family Care') is correctly identified and dates are accurate, the failure to report the key reclassification undermines the answer’s correctness. The reasoning is flawed due to missing the multi-hop insight that P&G refined its category structure to better align Tampax with menstrual health, which is central to the question. Thus, despite correct dates and segment names, the answer misses the evolution in positioning, resulting in low qualitative and overall correctness scores.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 382,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Oracle's strategy and positioning of Oracle Engineered Systems evolved between fiscal 2022 and fiscal 2023, particularly in terms of revenue contribution and research investment expectations?",
      "original_answer": "In fiscal 2022, Oracle highlighted that its hardware business, which includes Oracle Engineered Systems, involved point-of-sale revenue recognition for hardware and related software, with the majority of products sold through indirect channels. By fiscal 2023, Oracle introduced a more forward-looking strategy, explicitly stating plans to continue investing in research and development to improve existing hardware products and develop new offerings. Additionally, in fiscal 2023, Oracle noted that hardware represented 6% of total revenues, a figure not specified in 2022, indicating a clearer emphasis on the segment's strategic positioning.",
      "llm_answer": "\nOracle still generates only about 6 percent of its total revenue from Engineered Systems, but between fiscal 2022 and fiscal 2023 the company refocused the business from a stand‑alone hardware line toward a cloud‑integrated offering—emphasizing programs that let customers migrate their Oracle licenses to the Oracle Cloud and expanding the cloud‑services footprint of those systems.  Because the hardware segment now carries lower margins, Oracle says it will continue to allocate substantial R&D resources to modernize and broaden its engineered‑system portfolio, improve existing products, and build the capacity and geographic reach needed to support its cloud‑centric growth.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that hardware (including Engineered Systems) contributed 6% of total revenue in fiscal 2023, which matches the ground truth. However, the ground truth does not state this percentage for fiscal 2022, nor does it mention a shift from 'stand-alone hardware' to 'cloud-integrated offering' or specific migration programs—these are plausible inferences but not explicitly supported in the provided truth. The claim about 'lower margins' in the hardware segment is not present in the original answer and represents an unsupported addition. (2) Quantitatively, the 6% revenue figure is accurate and correctly attributed to fiscal 2023. No calculations are required, and there are no numeric errors. (3) The multi-hop reasoning is partially sound: the model connects fiscal 2022 and 2023 strategies and notes increased R&D investment, aligning with the truth. However, it introduces strategic shifts (cloud integration, license migration) not mentioned in the ground truth, which only states Oracle emphasized continued R&D investment and clarified the 6% revenue contribution. The original does not mention cloud-centric growth or geographic expansion. (4) The answer is contextually relevant and addresses revenue contribution and R&D expectations, but adds unverified strategic details, reducing factual accuracy. While the core facts about revenue share and R&D are correct, the expanded narrative goes beyond the evidence, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 414,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did Honeywell's investment in private funds for its Non-U.S. pension plans evolve between 2022 and 2023, particularly in terms of allocation and classification across fair value hierarchy levels?",
      "original_answer": "In 2022, Honeywell reported $1,105 million invested in private funds for its U.S. pension plans, with the amount classified under Level 3 of the fair value hierarchy. By 2023, the company reported $115 million in private fund investments for its Non-U.S. pension plans, with $41 million classified under Level 2 and $74 million under Level 3 of the fair value hierarchy. This represents a significant decrease in overall private fund allocation, particularly in U.S. plans, and a shift in classification for the remaining private fund investments under the Non-U.S. plans.",
      "llm_answer": "\nBetween 2022 and 2023 Honeywell’s non‑U.S. pension‑plan investment in private funds grew from **$90 million to $115 million**.  The composition changed markedly: Level 2 holdings fell from **$54 million to $41 million**, while Level 3 holdings rose from **$36 million to $74 million**, shifting a larger share of the private‑fund portfolio into the lowest tier of the fair‑value hierarchy.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. The original answer states that in 2022, Honeywell reported $1,105 million in private fund investments for its *U.S.* pension plans (not Non-U.S.), all classified under Level 3. However, the LLM incorrectly claims $90 million in Non-U.S. investments in 2022, which is not supported by the ground truth. The 2023 data is partially correct: $115 million in Non-U.S. private fund investments with $41 million in Level 2 and $74 million in Level 3 matches the original answer. But the LLM fabricates 2022 Non-U.S. figures ($54M Level 2, $36M Level 3) that are not present in the ground truth. (2) Quantitative accuracy is low: the LLM invents numbers for 2022 Non-U.S. allocations that do not exist in the original answer. The only correct numbers are the 2023 Non-U.S. totals. The claim of growth from $90M to $115M is false because the original answer does not report $90M in 2022 Non-U.S. investments. (3) Multi-hop reasoning is flawed: the LLM fails to correctly distinguish between U.S. and Non-U.S. pension plans in 2022. It incorrectly assumes a breakdown of Level 2 and Level 3 for Non-U.S. plans in 2022, which the original answer does not provide. The original answer emphasizes a shift from U.S. to Non-U.S. plans and a significant decrease in overall allocation, which the LLM misrepresents as growth. (4) Contextual relevance is moderate because the answer discusses the right topic (private fund allocation in Non-U.S. pension plans across fair value levels) and correctly reports 2023 data, but the incorrect baseline (2022) and fabricated comparisons undermine the validity. The conclusion about shifting to Level 3 is partially aligned but based on false premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 474,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the status and management of the 2014 USD Notes evolve between 2023 and 2024, and what specific actions were taken regarding this debt in 2024?",
      "original_answer": "In 2023, the 2014 USD Notes were classified as short-term debt, net of unamortized discount and debt issuance costs, with a maturity date of April 2024. By 2024, the company reported that in April 2024, $1 billion of principal related to the 2014 USD Notes matured and was paid in full. This indicates that the company transitioned the obligation from a near-term liability in 2023 to a fully settled debt instrument in 2024.",
      "llm_answer": "\nBy the end of 2023 the 2014 USD Notes—$1 billion of 3.375 % senior unsecured notes that were scheduled to mature in April 2024—were listed as short‑term debt (page 96).  In April 2024 the company allowed the notes to mature and paid the full $1 billion principal, removing the issue from the balance sheet (page 60).  The repayment was financed in part by the $4 billion of new 2024 USD Notes that Mastercard issued later in the year (pages 56‑57).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: the 2014 USD Notes were $1 billion, classified as short-term debt in 2023 with a maturity in April 2024, and were paid in full in April 2024. The inclusion of the 3.375% interest rate and the reference to specific pages (e.g., page 96, 60, 56–57) adds detail not in the original answer but does not contradict it. (2) Quantitative accuracy is perfect: $1 billion principal, April 2024 maturity and repayment, and the issuance of $4 billion in new 2024 USD Notes are all factually correct and consistent with the knowledge graph. (3) The multi-hop reasoning is sound—linking the repayment of the 2014 notes to the issuance of new debt in 2024 shows synthesis across time and instruments. The only minor gap is that the original answer does not mention the financing source ($4B 2024 notes), so while this addition is plausible and contextually relevant, it slightly extends beyond the provided ground truth. However, since it doesn’t conflict and likely reflects accurate document knowledge, it doesn’t reduce correctness. (4) The answer fully addresses both parts of the question: the 2023 status (short-term debt, maturity upcoming) and 2024 actions (matured and paid in full), with enhanced context on funding. Thus, the answer is semantically equivalent and slightly more detailed. Scores reflect near-perfect performance with only a slight deduction in qualitative accuracy due to the added detail not confirmed in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1219,
        "completion_tokens": 421,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How has the treatment and documentation of Lowe's Officer Indemnification Agreements evolved between 2022 and 2024, and what does this indicate about the company's executive risk management and governance continuity?",
      "original_answer": "Between 2022 and 2024, Lowe's maintained the same form of Officer Indemnification Agreement, first filed as Exhibit 10.43 on April 2, 2019, and refiled without amendment in both the 2022 and 2024 10-K filings. This indicates that the company did not modify the terms or structure of these agreements over this period, suggesting consistent governance practices and a stable approach to executive risk management and retention. Investors can interpret this continuity as a sign of predictable leadership protections and aligned corporate governance priorities.",
      "llm_answer": "\nBetween 2022 and 2024 Lowe’s continued to file the same “Form of Lowe’s Companies, Inc. Officer Indemnification Agreement” as Exhibit 10.23 in its annual and quarterly reports (first listed in the 2019 10‑K and still referenced unchanged in the 2022 10‑K and the 2024 10‑K).  The agreement’s consistent numbering, description and incorporation‑by‑reference treatment across filings show that the company has not revised or replaced the indemnification language, underscoring a stable executive‑risk‑management framework and a governance approach that maintains continuity in protecting senior officers against personal liability.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct in all key aspects: it accurately states that Lowe's used the same form of Officer Indemnification Agreement between 2022 and 2024, originally filed in 2019 and unchanged in subsequent years. The description of consistent filing, lack of amendments, and implications for executive risk management and governance continuity aligns with the ground truth. The only minor discrepancy is the exhibit number: the LLM cites 'Exhibit 10.23', while the ground truth specifies 'Exhibit 10.43'. This is a factual error in exhibit labeling, though it does not affect the core conclusion about continuity and lack of amendments. All dates (2019, 2022, 2024) and the reasoning about governance stability are correct. The answer correctly synthesizes information across multiple filings (multi-hop reasoning) and draws a logically sound inference about governance practices. Wording differs slightly but maintains semantic equivalence. Quantitative accuracy is perfect—no numerical or date errors beyond the exhibit number. Contextual relevance is excellent, fully addressing both the evolution (or lack thereof) and its implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 325,
        "total_tokens": 1640
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the market share and category positioning of Always Discreet in the adult incontinence market change between the 2022 and 2023 Procter & Gamble 10-K filings?",
      "original_answer": "In the 2022 filing, Always Discreet was explicitly stated to have over 10% market share in the key adult incontinence markets where Procter & Gamble competes. However, in the 2023 filing, while Always Discreet is still listed as a major brand in the Feminine Care category under the Baby, Feminine & Family Care segment, no specific market share figure is provided for the brand. This suggests a shift in how the brand's performance is communicated, moving away from a quantified market share disclosure to a more general category association.",
      "llm_answer": "\nIn the 2022 filing (page 19 of PG_10k_2022.pdf) P&G notes that Always Discreet holds “over 10 %” of the adult‑incontinence market in the key markets where it competes. The 2023 filing (page 19 of PG_10k_2023.pdf) updates that figure to “about 15 %” share, indicating that Always Discreet’s market share in the adult‑incontinence sub‑category has risen noticeably and its positioning within the Baby, Feminine & Family Care segment has been strengthened.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in a critical way. (1) According to the ground truth, the 2022 filing states that Always Discreet had 'over 10%' market share, which the LLM correctly identifies. However, the 2023 filing does NOT report a market share of 'about 15%'—in fact, it provides no specific market share figure at all. The LLM falsely claims an increase to 15%, which is not supported by the source. This is a major quantitative inaccuracy. (2) The calculation or comparison of market share growth from 10% to 15% is entirely fabricated, making the quantitative accuracy score very low. (3) The reasoning is flawed: instead of recognizing the absence of a disclosed figure in 2023 and interpreting the shift in disclosure strategy, the model invents data, failing the multi-hop synthesis. It incorrectly infers improved positioning based on non-existent data. (4) While the answer addresses the right entities (Always Discreet, adult incontinence market, P&G, correct segment), and attempts to compare two years’ filings, the core factual claim is false. The contextual relevance is moderate because it addresses the right topic and structure, but the conclusion is unsupported. Thus, the overall correctness score is 1 due to the severe factual error in market share numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 358,
        "total_tokens": 1612
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How has Oracle's strategic positioning of Engineered Systems evolved between 2022 and 2023, particularly in terms of their role within the hardware business and implications for Oracle's cloud transformation narrative?",
      "original_answer": "In 2022, Oracle Engineered Systems were described as pre-integrated products central to both cloud and on-premise data center infrastructure, emphasizing their technical advantages such as improved performance, scalability, and simplified maintenance. However, by 2023, Oracle elevated the strategic importance of Engineered Systems by positioning them as part of a broader hardware business that now includes servers, storage, and operating systems, all tightly integrated and accounted for as combined performance obligations. The 2023 filing also highlighted that hardware revenues, including Engineered Systems, represented 6% of total revenues in both fiscal 2023 and 2024, and underscored ongoing R&D investments to enhance these offerings. This evolution suggests that Oracle is leveraging Engineered Systems not just as technical solutions but as foundational components in its hybrid cloud and on-premise strategies, aligning them more closely with its cloud transformation narrative while acknowledging the lower-margin nature of the hardware business.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 Oracle reframed Engineered Systems from a standalone, on‑premise hardware line into a strategic conduit for its cloud agenda.  The company began marketing these systems—Exadata, servers, storage, and industry‑specific offerings—as integral parts of Oracle Cloud Infrastructure, Cloud@Customer and Dedicated Region, emphasizing migration, hybrid‑cloud deployment and the ability to run workloads across on‑premise, OCI and other clouds.  Consequently, Engineered Systems now serve less as a pure hardware profit center and more as a growth engine that validates and accelerates Oracle’s cloud‑transformation narrative, even though their revenue share (≈ 6 % of total) and margins remain modest.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the 6% revenue share is correctly reported (≈6% in LLM vs 6% in original), and fiscal years 2022–2023 are properly referenced. No calculation errors. (2) The LLM correctly identifies the strategic shift: Engineered Systems evolved from standalone hardware to integrated components of Oracle Cloud Infrastructure (OCI), Cloud@Customer, and Dedicated Region—consistent with the original answer’s emphasis on hybrid cloud and tighter integration. (3) The qualitative reasoning is sound: the LLM captures the multi-hop synthesis that Engineered Systems now serve as enablers of Oracle’s cloud transformation narrative, despite modest margins and revenue contribution. It correctly infers the strategic pivot from on-premise focus to cloud-aligned hybrid solutions. (4) Minor omission: the LLM does not explicitly mention the inclusion of operating systems or the term 'combined performance obligations' from the 2023 filing, nor does it reference R&D investments, which are part of the original answer. However, these are secondary details. The core evolution in strategic positioning, role in hardware business, and implications for cloud transformation are accurately and succinctly conveyed. Wording differs but semantic equivalence is strong. No factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1466,
        "completion_tokens": 375,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the disclosure regarding the 2020 Stock Plan's relationship with the 2011 Stock Plan evolve between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, the 2020 Stock Plan disclosure included the detail that 5,530,106 shares previously available under the 2011 Stock Plan were carried forward and made available for award grants under the 2020 Stock Plan. However, in the 2023 10-K filing, this specific reference to the 2011 Stock Plan and the carry-forward of shares was omitted. This indicates a shift in how the company chose to present the lineage and transition between the two stock plans, focusing only on the 2020 Stock Plan without linking it to its predecessor in the disclosed text.",
      "llm_answer": "\nIn the 2022 10‑K the company explicitly said that the 2020 Stock Plan succeeded the 2011 Stock Plan and that the shares still reserved under the 2011 Plan were being made available for grant under the 2020 Plan. By the 2023 10‑K that explicit reference to the 2011 Plan is gone—the filing simply describes the 2020 Plan’s share reserve and features without any mention of the earlier plan, indicating that the relationship is now implied rather than expressly disclosed.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct and aligns well with the ground truth. It accurately captures the key difference between the 2022 and 2023 10-K filings: in 2022, the company explicitly disclosed that shares previously available under the 2011 Stock Plan were carried forward into the 2020 Stock Plan, while in 2023, this linkage was omitted. The LLM correctly notes the absence of the explicit reference to the 2011 Plan in the 2023 filing and interprets it as a shift toward implied rather than express disclosure. While the ground truth specifies the exact number of shares carried forward (5,530,106), the LLM answer omits this figure. This is a minor omission but does not undermine the core accuracy of the response, as the focus of the question is on the evolution of disclosure language rather than the precise number. All entities (2020 Stock Plan, 2011 Stock Plan, 2022 and 2023 10-Ks) are correctly identified, and the reasoning across filings is sound. The answer is semantically equivalent to the original, with only slight compression of detail. Quantitative accuracy is perfect where numbers are mentioned (none incorrectly stated), and contextual relevance is strong as it directly addresses the evolution in disclosure practice.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 348,
        "total_tokens": 1606
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How has Honeywell's allocation strategy toward private funds evolved between 2022 and 2023, and what might this indicate about the company's capital deployment priorities?",
      "original_answer": "In 2022, Honeywell reported $1,244 million invested in private funds, as disclosed in the 2022 10-K filing. By 2023, this amount increased slightly to $1,265 million, as noted in the 2023 10-K filing. This represents a modest increase of approximately 1.7%, suggesting that Honeywell maintained a relatively stable allocation strategy toward private funds despite broader reductions in total assets under the U.S. plans. This slight upward trend may indicate a strategic decision to preserve or slightly expand exposure to alternative investments, potentially to capitalize on expected higher returns or diversification benefits from private fund investments.",
      "llm_answer": "\nBetween 2022 and 2023 the fair‑value of Honeywell’s private‑fund holdings in its non‑U.S. pension plans more than doubled—from $36 million to $74 million—while the U.S. “direct private‑investments” balance stayed essentially flat around $1.28 billion.  At the same time the company trimmed its real‑estate‑fund exposure and let insurance‑buy‑in contracts grow, indicating a purposeful shift toward allocating a larger share of plan assets to private‑fund investments.  This move reflects a capital‑deployment priority of seeking higher‑return, longer‑duration private‑equity/debt assets to enhance portfolio returns and meet long‑term funding objectives without requiring additional cash contributions.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It claims that Honeywell's private-fund holdings in non-U.S. pension plans more than doubled from $36 million to $74 million, and that U.S. direct private investments were around $1.28 billion—none of which aligns with the ground truth. The original answer states that Honeywell reported $1,244 million in private funds in 2022 and $1,265 million in 2023, with no breakdown between U.S. and non-U.S. plans provided in the context. The LLM introduces a U.S./non-U.S. distinction and specific figures for those categories that are not supported by the ground truth. Additionally, the LLM mentions real estate fund reductions and insurance buy-in growth, which are not referenced in the original answer. (2) Quantitatively, the numbers are incorrect: $1,244M and $1,265M are the correct totals; the LLM reports $1.28B (close but not exact) for U.S. only and introduces unrelated $36M and $74M figures. The claimed 'more than doubled' and implied allocation shift are unsupported. The 1.7% increase in the original is modest, not a 'more than doubling'. (3) The multi-hop reasoning is flawed—the LLM incorrectly segments the data by geography and asset class, inventing a strategic shift not present in the ground truth. It fails to correctly synthesize the actual evolution: a slight increase in total private fund allocation. (4) While the general theme of 'continued or slightly increased focus on private funds' is directionally plausible, the specific evidence and reasoning are factually wrong. The answer is contextually relevant in topic but fails on correctness due to fabricated data and misattribution of figures. Hence, low scores on correctness and quantitative accuracy; moderate on contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 485,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the status and disclosure of Class B-2 Common Stock evolve between 2023 and 2024, particularly regarding its outstanding status and relationship to other stock classes?",
      "original_answer": "In 2023, Class B-2 Common Stock was subject to conversion rate adjustments tied to the U.S. litigation escrow account under the U.S. retrospective responsibility plan, which caused dilution in as-converted shares. Additionally, it was noted that no shares of Class B-2 were outstanding prior to the Class B-1 exchange offer. By 2024, the 10-K filing only referenced Class B-2 Common Stock in relation to its lack of outstanding shares prior to the Class B-1 exchange offer, with no further updates or disclosures regarding its conversion mechanics or dilution impacts, suggesting a reduced emphasis or potential discontinuation of its active role in the capital structure.",
      "llm_answer": "\nClass B‑2 common stock had no outstanding shares at the end of fiscal 2023; it was created in early 2024 when Visa’s exchange offer converted 241 million class B‑1 shares into roughly 120 million class B‑2 shares, which are now reported as 120 million shares issued and outstanding. These newly issued B‑2 shares have the same conversion‑to‑class A rights as other class B series but their conversion‑rate adjustments have double the impact, and like other class B shares they remain restricted from transfer or conversion until the U.S. litigation escrow is fully resolved.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. According to the ground truth, no Class B-2 shares were outstanding prior to the Class B-1 exchange offer, and in 2023, Class B-2 was subject to conversion rate adjustments causing dilution in as-converted shares. However, the LLM incorrectly states that Class B-2 had no outstanding shares at the end of fiscal 2023 and was 'created in early 2024'—this contradicts the original answer, which implies Class B-2 existed in 2023 but with no outstanding shares before the exchange. The LLM also fabricates a specific exchange of 241 million Class B-1 shares into 120 million Class B-2 shares, which is not present in the ground truth. (2) Quantitative accuracy is poor: the numbers (241 million, 120 million) are entirely made up, and there is no mention in the original answer of shares being 'issued and outstanding' in 2024—on the contrary, the 2024 filing only referenced the lack of outstanding shares prior to the exchange. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers creation and issuance of Class B-2 in 2024, whereas the original answer emphasizes a reduction in disclosure and lack of updates in 2024, suggesting diminished relevance, not activation. The LLM also introduces Visa as the company, which is not mentioned in the original answer or question context, indicating a potential entity hallucination. (4) Contextual relevance is moderate because the answer discusses stock classes and conversion mechanics, but the core facts—timing, existence, disclosure trends—are incorrect. The ground truth focuses on evolving disclosure and reduced emphasis, while the LLM invents a detailed but false narrative of issuance and conversion. Thus, the correctness score is low due to major factual and reasoning errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 491,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the financial obligations related to the Target Circle program change between 2022 and 2024, and what does this indicate about the program's evolution?",
      "original_answer": "In 2022, the deferred revenue related to the Target Circle program was $89 million as of January 29, 2022, while in 2024, the deferred revenue related to the program was $117 million as of February 3, 2024. This indicates a significant increase in the company's liability tied to unredeemed rewards, suggesting growth in program participation or changes in redemption patterns. However, by February 1, 2025, the deferred revenue had dropped to $19 million, signaling a sharp decline, which may reflect either a surge in reward redemptions or a strategic change in how the program's liabilities are recognized or managed.",
      "llm_answer": "\nBetween fiscal 2023 (ended Feb 3 2024) and fiscal 2024 (ended Feb 1 2025) the liability for Target Circle rewards—recorded as deferred revenue in accrued and other current liabilities—fell dramatically from **$117 million** to **$19 million** (see 2024 10‑K p. 49 and the same table in the 2022 10‑K p. 45).  This sharp decline indicates that the company has largely redeemed or recognized the accrued rewards and is scaling back the standalone Target Circle program’s financial obligations, reflecting a shift toward integrating those rewards into broader loyalty and marketing initiatives.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the $117 million deferred revenue as of February 3, 2024, and the drop to $19 million by February 1, 2025, which aligns with the ground truth. However, the original answer also includes the 2022 figure of $89 million as of January 29, 2022, which the LLM omits entirely. This missing data point is critical because the question asks about changes between 2022 and 2024, not just 2024 to 2025. The LLM incorrectly frames the comparison as between fiscal 2023 and fiscal 2024, when the question specifically asks about 2022 to 2024. (2) The numbers cited ($117M and $19M) are accurate and correctly attributed to the right fiscal year-ends and 10-K pages. However, the absence of the $89M figure from 2022 undermines quantitative completeness. The calculation of the change is implied but not fully supported across the required time frame. (3) The reasoning about the decline indicating redemption or strategic shift is plausible and consistent with the ground truth’s interpretation. However, the LLM fails to note the *increase* from $89M to $117M between 2022 and 2024, which is a key part of the program’s evolution—first growing, then sharply declining. This missing step in the multi-hop reasoning weakens the overall analysis. (4) Despite the omission, the answer remains contextually relevant, accurately interpreting the significance of the drop in liabilities. The conclusion about integration into broader initiatives is a reasonable inference, though not explicitly stated in the ground truth. The answer would have scored higher if it had included the full trajectory: growth in obligations through 2024, followed by a sharp decline by 2025.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 463,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the fair value of Netflix's 4.375% Senior Notes change between December 31, 2022, and December 31, 2023, and what does this indicate about investor perception or market conditions?",
      "original_answer": "The fair value of Netflix's 4.375% Senior Notes decreased from $980 million on December 31, 2022, to $996 million on December 31, 2023. This indicates a shift in investor perception or market conditions, as the fair value moved closer to the principal amount at par, suggesting a stabilization or improved outlook for the company's debt.",
      "llm_answer": "\nThe fair‑value of Netflix’s 4.375% Senior Notes rose modestly from **$980 million on December 31 2022 to $996 million on December 31 2023** (an increase of roughly $16 million, or about 1.6%).  This slight uptick—reflecting higher market‑quoted prices for the notes in the Level‑2 valuation hierarchy—suggests that investors continued to view the debt as relatively stable and perhaps slightly more attractive, likely supported by Netflix’s strong cash‑flow profile and the favorable interest‑rate environment that made its senior unsecured issuance still competitive.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that the fair value of Netflix's 4.375% Senior Notes *increased* from $980 million to $996 million, implying a rise in value. However, the ground truth states that the fair value *decreased* from $980 million to $996 million, which is a contradiction in direction. This is a critical factual error. (2) The numbers themselves ($980 million and $996 million) are correctly cited, and the time periods (December 31, 2022, and December 31, 2023) are accurate. However, the calculation of a $16 million *increase* is factually wrong because the ground truth describes a *decrease* in fair value — this suggests a fundamental misinterpretation of the data. The percentage change (1.6%) may be arithmetically correct for an increase, but it misrepresents the actual trend. (3) The multi-hop reasoning fails because the LLM draws an incorrect conclusion about investor perception: it claims the rise in fair value indicates improved attractiveness due to cash flow and interest rate environment, while the ground truth indicates the *decrease* in fair value brought it closer to par, suggesting stabilization. The LLM’s reasoning is internally consistent but based on a false premise. (4) The contextual relevance is moderate because the answer addresses the right metric, company, and time frame, and attempts to interpret market implications, but the core factual error in the direction of change severely undermines correctness. Thus, the correctness score is low due to a major quantitative and qualitative error despite correct entity and date identification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 440,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the equity structure related to Class C Common Stock evolve between 2023 and 2024, particularly in terms of share issuance and equity classification?",
      "original_answer": "In 2023, Visa conducted an exchange offer where 241 million shares of Class B-1 common stock were tendered, and in exchange, approximately 48 million shares of Class C common stock were issued. This indicates active restructuring of stock classes tied to the Visa Europe retrospective responsibility plans. By 2024, the balance of Class C common stock remained at 10 shares issued and outstanding, as stated in the equity section of the balance sheet. This suggests that while there was active movement and restructuring involving Class C shares in 2023, the 2024 disclosures indicate a stabilization or conclusion of that phase of equity restructuring.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Visa issued roughly 48 million new Class C shares as part of its May 2024 class B‑1 exchange offer, increasing the outstanding Class C share balance from about 10 million shares at the end of 2023 to a higher level (the filing lists 10 million shares for both years, reflecting the post‑issuance total).  These securities remain classified as Class C common stock with a $0.0001 par value—a distinct, non‑traded class used for the exchange and conversion rights—and their equity classification was unchanged during the period.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It claims that Visa issued 48 million new Class C shares in a May 2024 exchange offer, which contradicts the ground truth stating the exchange occurred in 2023. The LLM incorrectly states that the Class C share balance increased from about 10 million to a higher level, but the ground truth clarifies that only 10 shares were outstanding in 2024, not millions. This is a major quantitative and temporal error. (2) The numbers are largely incorrect: the 48 million shares were issued in 2023, not 2024; the outstanding shares in 2024 were 10 (ten), not 10 million. The LLM misrepresents both the timing and scale of the share issuance. (3) The reasoning is flawed in terms of multi-hop synthesis: the model fails to correctly link the 2023 exchange event with the 2024 stabilization of Class C shares. It incorrectly infers ongoing activity in 2024 when the ground truth indicates stabilization. (4) While the LLM correctly identifies the par value and non-traded nature of Class C stock, and the context of exchange rights, the core facts about timing, share counts, and evolution are wrong, leading to a low correctness score. Contextual relevance is moderate because the answer addresses the right topic and classification, but with incorrect details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 370,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Lowe's engagement with Rough Plumbing evolved from 2022 to 2024, particularly in terms of its business classification and service offerings?",
      "original_answer": "In 2022, Rough Plumbing was classified under the 'Building Products' category, indicating it was primarily offered as a product within Lowe's merchandise divisions. By 2024, Lowe's had expanded its engagement with Rough Plumbing by integrating it into both installation services and protection plans, signaling a shift from a pure product offering to a more service-oriented approach. This evolution reflects a strategic move to bundle Rough Plumbing with labor and extended protection, contributing to the approximately 5% of total sales attributed to installed sales in 2024.",
      "llm_answer": "\nFrom 2022 through 2024 Lowe’s continued to place Rough Plumbing in the **Building Products** group (2022 Note 3 shows it under “Building Products” and the 2024 product‑category list repeats this classification), but the way it engages the business has broadened.  In the 2024 filing the company reports that Rough Plumbing is a key driver of **installed sales** (≈ 5 % of total sales) and is supported by remote quoting, a central selling team, on‑site specialists and protection‑plan/repair services, moving the offering from a pure product line to an integrated sales‑and‑installation service across its omnichannel channels.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Rough Plumbing remained in the 'Building Products' category in both 2022 and 2024, and by 2024 it was integrated into installed sales, contributing approximately 5% of total sales. The mention of protection plans, remote quoting, on-site specialists, and omnichannel service expansion reflects the service-oriented evolution. (2) Quantitatively, the ≈5% of total sales is correctly reported, matching the original answer. No calculation errors. (3) The multi-hop reasoning is sound—LLM correctly synthesized information across years and filings to show continuity in classification but evolution in engagement. It identifies the shift from product-only to service-integrated offering, though it could have more explicitly stated the 'strategic move' framing from the original. (4) Wording differs slightly but maintains semantic equivalence. The only minor omission is not explicitly stating that the 2022 classification indicated a 'pure product offering,' which would have strengthened the contrast. Otherwise, all entities (Lowe's, Rough Plumbing, years, metrics) are accurate and relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 336,
        "total_tokens": 1638
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did the introduction and subsequent status of Class B-2 common stock evolve between 2023 and 2024, and what does this indicate about its role in the company's capital structure?",
      "original_answer": "In 2023, Class B-2 common stock was newly introduced with 77 million shares outstanding, indicating its initial incorporation into the company's equity structure. By 2024, the company disclosed that no shares of Class B-2 common stock were outstanding prior to the Class B-1 common stock exchange offer, suggesting a strategic shift where Class B-2 shares may have been replaced or restructured as part of a broader capital realignment. This indicates a transformation in the role of Class B-2 common stock within the company’s capital structure.",
      "llm_answer": "\nClass B‑2 common stock was created in May 2024 when Visa amended its charter and ran an exchange offer that retired 241 million Class B‑1 shares and issued roughly 120 million new Class B‑2 shares (along with 48 million Class C shares); there were no B‑2 shares outstanding before this transaction. The newly issued B‑2 shares now appear in the 2024 EPS and balance‑sheet tables, and because their conversion‑rate adjustments are double those of Class B‑1, they are being used to retire restricted B‑1 stock and to fine‑tune litigation‑related conversion rates, indicating that B‑2 plays a strategic role in reshaping Visa’s capital structure.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) The introduction date of Class B-2 common stock is incorrect: the ground truth states it was introduced in 2023 with 77 million shares outstanding, but the LLM claims it was created in May 2024 with roughly 120 million shares issued—this contradicts the original answer on both timing and quantity. (2) The LLM incorrectly asserts that 241 million Class B-1 shares were retired and that Class B-2 shares were issued as part of an exchange offer, which is not supported by the ground truth; instead, the original answer notes that no Class B-2 shares were outstanding prior to the Class B-1 exchange offer in 2024, implying a potential replacement or restructuring, but does not specify the mechanics described by the LLM. (3) The mention of Class C shares and conversion-rate adjustments being 'double those of Class B-1' introduces details absent from the ground truth and not inferable from it, suggesting fabrication or hallucination. (4) While the LLM correctly infers a strategic role in capital structure evolution, this reasoning is based on incorrect premises. The multi-hop synthesis fails because it misrepresents the timeline and numerical facts. Although the answer addresses the question's intent regarding the role of Class B-2 stock, the core facts—when it was introduced, how many shares, and what happened between 2023 and 2024—are factually wrong. Quantitative accuracy is very low due to incorrect dates and share counts. Qualitative accuracy suffers from flawed reasoning based on non-existent data. Contextual relevance is moderate because the response attempts to explain the stock’s role, but the foundation is incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 470,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How has the financial liability associated with the Target Circle program changed between 2022 and 2024, and what does this indicate about the program's growth or evolution?",
      "original_answer": "In 2022, the Target Circle program was described primarily in terms of its benefits to customers, such as earning 1% rewards on non-RedCard purchases, but no specific liability figure was disclosed. By 2024, the deferred revenue related to the Target Circle program had grown to $117 million as of February 3, 2024, indicating a significant increase in the program's financial liability and suggesting substantial growth or expansion of the program. This increase reflects a greater number of participants or increased transactional activity within the program.",
      "llm_answer": "\nThe Target Circle program’s deferred‑revenue liability fell dramatically — from **$117 million as of February 3 2024** (the 2023 fiscal year) to **$19 million as of February 1 2025** (the 2024 fiscal year), a decline of roughly **$98 million** (about an 84 % reduction).  This sharp drop shows that the program’s accrued, unearned revenue has been largely recognized as members redeem rewards, indicating that Target Circle has matured and is generating more immediate revenue rather than accumulating deferred liabilities.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both direction and magnitude. (1) The original answer states that no liability was disclosed in 2022, and by 2024 (as of February 3, 2024), the deferred revenue for Target Circle was $117 million. The LLM incorrectly claims that the liability was $117 million in 2024 and then dropped to $19 million in 2025, which is not supported by the ground truth and reverses the trend. (2) The quantitative inaccuracies are severe: the LLM fabricates a $19 million figure for 2025 and calculates an 84% reduction, none of which appears in the original data. There is no mention of a decline or any 2025 data in the ground truth. (3) The reasoning is flawed: the LLM concludes the program has matured and is recognizing more revenue due to a liability drop, but the original answer indicates growth due to an increase in liability. This is a complete inversion of the correct multi-hop inference. (4) Contextual relevance is low because the answer discusses a decline not present in the data, though it does address the Target Circle program and deferred revenue conceptually. The core facts, trend, and implications are all incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 328,
        "total_tokens": 1606
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has NVDA's exposure to and concern about pollution limits evolved between 2023 and 2024, particularly in terms of regulatory impact on operations and customer data center expansion?",
      "original_answer": "In 2023, NVDA highlighted that pollution limits and related climate regulations could increase direct and indirect costs, including compliance, energy, and capital expenditures, and could require changes to manufacturing processes and supply chain operations. By 2024, the company expanded its concern to include not only cost increases but also the potential for land and permitting constraints tied to pollution limits, which could impair customers' ability to expand data center capacity—an essential market for NVDA's products. This indicates a growing concern that regulatory tightening around pollution could directly affect demand for NVDA's offerings.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 NVIDIA moved from a generic reference to “climate‑change‑related laws and pollution limits” toward a concrete warning that **new carbon‑tax, emissions‑limit and water‑availability regulations can directly constrain the ability of its customers to expand data‑center capacity**, which in turn limits demand for its GPUs and related services.  The 2024 filing explicitly ties these regulatory pressures to **higher compliance costs, potential restrictions on energy or water use, and the risk of delayed or cancelled data‑center expansions**, indicating that NVIDIA’s exposure to and concern about pollution‑related rules has deepened markedly.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution in NVDA's concern about pollution limits between 2023 and 2024. It correctly identifies that in 2023, NVDA referenced climate regulations and pollution limits in general terms, noting potential cost increases and operational changes. By 2024, the company expanded its risk disclosure to include direct constraints on customer data center expansion due to emissions, water use, and permitting issues—linking regulatory pressures to potential demand reduction for its GPUs. This aligns with the ground truth, which emphasizes the shift from internal cost impacts (2023) to external demand-side risks via customer expansion limitations (2024). All entities (NVDA, fiscal years 2023 and 2024, data center expansion, pollution regulations) are correct. There are no numerical figures in the original or LLM answer, so quantitative accuracy is not applicable but assumed perfect. The reasoning is sound and reflects proper multi-hop synthesis: connecting regulatory trends to customer behavior and then to NVDA’s market demand. The only minor shortcoming is that the LLM slightly overemphasizes 'water-availability' regulations, which while plausible and contextually relevant, is not explicitly highlighted in the ground truth—land and permitting constraints are the primary new concern. However, this does not materially distort the overall message. Semantic equivalence is strong, and the answer is fully contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 407,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did the composition and valuation of the company's Guaranteed Senior Notes evolve between 2023 and 2024, particularly in terms of issuance, repayment, and fair value inputs?",
      "original_answer": "In 2023, the company's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%. These notes were valued using Level 3 inputs. In 2024, the Japanese subsidiary repaid $77 of these Guaranteed Senior Notes. The fair value of long-term debt, including Guaranteed Senior Notes, was approximately $5,412 at the end of 2024, compared to $5,738 at the end of 2023. This indicates a reduction in the overall fair value of long-term debt, partially driven by repayments on the Guaranteed Senior Notes.",
      "llm_answer": "\nBetween 2023 and 2024 the company’s Guaranteed Senior Notes grew from $0.5 billion (issued in Nov 2023) to about $0.92 billion on the balance sheet, reflecting a net addition of roughly $0.44 billion after the July 2024 repayment of $77 million of those notes.  The notes continue to be valued using Level 3 inputs (unobservable assumptions about future cash‑flows and discount rates), and no material fair‑value adjustments were recorded during the period.  Consequently, the carrying amount of other long‑term debt rose from $484 million in 2023 to $919 million in 2024, while the fair‑value hierarchy input level remained Level 3.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. According to the ground truth, the Japanese subsidiary issued approximately $500 million in Guaranteed Senior Notes in 2023 (not $0.5 billion net of repayments as implied), and repaid $77 million in 2024. However, the LLM incorrectly states that the notes 'grew' to $0.92 billion after a $77 million repayment, which contradicts the truth — there was no new issuance in 2024, and the overall long-term debt fair value actually decreased from $5,738 million to $5,412 million. The LLM’s claim of a net addition of $0.44 billion is entirely unsupported and incorrect. (2) The quantitative errors are severe: the LLM fabricates a balance sheet increase to $0.92 billion and invents a carrying amount rise in other long-term debt from $484M to $919M, which are not in the original answer and contradict the stated total fair value of long-term debt (which includes these notes) declining from $5,738M to $5,412M. The $77 million repayment is correctly mentioned, but misused in context. (3) The multi-hop reasoning fails: the model incorrectly infers growth in the Guaranteed Senior Notes despite repayments and no new issuances in 2024. It also confuses carrying amount with fair value and introduces unrelated figures (e.g., 'other long-term debt') not mentioned in the ground truth. While it correctly identifies Level 3 inputs for valuation, it adds unsupported claims about 'no material fair-value adjustments,' which is not in the original. (4) The contextual relevance is moderate because it addresses issuance, repayment, and fair value inputs, but the qualitative and quantitative inaccuracies severely undermine correctness. The reasoning is flawed, and the numbers are largely fabricated or misinterpreted, warranting a low correctness score of 2.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 494,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did Netflix's investment in streaming service improvements and associated risk exposure evolve from 2022 to 2024, based on the specific personnel and cybersecurity-related changes disclosed in those years?",
      "original_answer": "In 2022, Netflix disclosed a $384 million increase in personnel-related costs driven by headcount growth to support production activity and improve the streaming service. By 2024, the focus had evolved to include significant emphasis on cybersecurity, with detailed descriptions of enterprise-wide security programs, third-party risk management, and the potential financial impact of cyber incidents. The company highlighted the risk of unauthorized data releases and digital content theft, noting that such events could adversely affect business operations and financial results. This represents a shift from purely growth-oriented investment in streaming to a more risk-aware posture as the service matured.",
      "llm_answer": "\nBetween 2022 and 2024 Netflix continued to pour resources into streaming‑service upgrades—technology‑and‑development headcount and spending rose sharply, and the company formalized a dedicated security leadership role (the Vice President of Security and Privacy Engineering) who reports regularly to senior management and the Audit Committee.  At the same time, the cybersecurity risk profile intensified: the 2022 filing highlighted the VP’s oversight and board‑level risk reporting, while the 2024 filing disclosed a higher frequency of content‑leak and third‑party‑vulnerability incidents and warned that any major service disruption or data breach could materially harm the business, underscoring growing exposure despite the ongoing investment in streaming improvements.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the evolution of Netflix's investment and risk exposure from 2022 to 2024 but omits the key quantitative figure from the ground truth—Netflix's $384 million increase in personnel-related costs in 2022. This is a significant omission as the question specifically asks about investment levels and the original answer includes a precise dollar amount. The LLM mentions 'spending rose sharply' but provides no numeric value, which reduces quantitative accuracy. (2) No other numbers are present in either answer, so there are no calculation errors per se, but the absence of the $384M figure—explicitly stated in the ground truth—means the LLM fails on a core factual element. (3) The qualitative reasoning is strong: the LLM correctly identifies a shift in focus from streaming investment to cybersecurity risk, notes the creation of a dedicated security leadership role (VP of Security and Privacy Engineering), and traces increased disclosure around cyber incidents, third-party risks, and board-level reporting. It synthesizes multi-hop information by connecting personnel growth (implied investment) with evolving risk disclosures across years. (4) Contextually, the answer is highly relevant, directly addressing how investment and risk exposure evolved. While it does not mention 'digital content theft' explicitly, it refers to 'content-leak incidents,' which is semantically equivalent. The main shortcoming is the lack of the specific financial figure, which is critical for full factual accuracy. Thus, correctness is reduced to 7 due to this omission, though reasoning and relevance remain strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 449,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did The Bank of New York Mellon Corporation's approach to restricted stock unit agreements evolve between the 2023 and 2024 filings, particularly in terms of the lifecycle management of these equity instruments and their implications for executive compensation strategy?",
      "original_answer": "In the 2023 filing, the '2024 Form of Restricted Stock Unit Agreement' was newly introduced and explicitly stated as 'Filed herewith,' indicating it was a current and newly adopted form for that year. This suggests the company was actively updating its equity compensation framework to align with strategic goals for executive retention and incentives. By the 2024 filing, this '2024 Form' was no longer newly filed but instead was referenced as 'Previously filed,' signaling it had become an established part of the company's compensation structure. Additionally, in 2024, the company introduced the '2025 Form of Restricted Stock Unit Agreement,' which was marked as 'Filed herewith,' showing a forward-looking update to the equity compensation strategy. This evolution indicates a consistent, proactive approach to managing executive compensation frameworks, with new forms being introduced annually and the prior year’s forms transitioning into reference documents. This reflects a mature, iterative process in shaping executive incentives and aligning them with long-term corporate objectives.",
      "llm_answer": "\nThe 2023 filing disclosed the then‑current 2023 Restricted Stock Unit (RSU) and Performance Share Unit (PSU) agreements (Exhibits 10.26 – 10.27) as previously filed in quarterly reports, whereas the 2024 filing introduces a newly designated 2024 RSU agreement (Exhibit 10.29) and amends the Executive Severance Plan (Exhibit 10.30), demonstrating that the company systematically refreshes these equity‑award documents each year to adjust performance criteria, vesting triggers and severance linkages—an explicit lifecycle‑management approach that tightens the tie between RSU/PSU payouts and long‑term executive compensation strategy.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general idea of annual updates to restricted stock unit (RSU) agreements and links them to executive compensation strategy, which aligns with the question's intent. However, it contains significant factual inaccuracies that reduce its correctness. First, the LLM incorrectly states that the 2023 filing disclosed the '2023 RSU agreement' as 'previously filed'—but the ground truth indicates that the '2024 Form of RSU Agreement' was introduced in the 2023 filing and marked as 'Filed herewith,' not prior-year agreements. This misrepresents the timeline and document status. Second, the LLM references Exhibits 10.26–10.27 for 2023 and Exhibit 10.29 for 2024, but the ground truth does not confirm these exhibit numbers or the inclusion of Performance Share Units (PSUs) or Executive Severance Plan amendments, making these details unverifiable and potentially incorrect. While the model correctly infers a pattern of annual refreshment in equity documents, it fails to accurately describe the specific evolution: the transition of the 2024 Form from 'Filed herewith' in 2023 to 'Previously filed' in 2024, and the introduction of the '2025 Form' in 2024 as 'Filed herewith.' These are key multi-hop details that the LLM omits or distorts. The reasoning is partially sound in identifying lifecycle management, but the factual foundation is flawed. Quantitative accuracy is moderate—dates (2023, 2024) are correct, but document statuses and exhibit details are not. Qualitative accuracy suffers due to incorrect entity-document mappings. Contextual relevance is high, as the answer addresses lifecycle management and compensation strategy appropriately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1465,
        "completion_tokens": 456,
        "total_tokens": 1921
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has the status and structure of the 4.90% Senior Notes evolved from 2023 to 2024, particularly in terms of their carrying amount and maturity timeline?",
      "original_answer": "In 2023, the 4.90% Senior Notes were newly issued in November 2023, with a principal amount of $750 million, a discount of $3.4 million, and a maturity date of April 15, 2029. Interest payments were scheduled semi-annually starting April 15, 2024. By 2024, these notes remained outstanding, with a carrying amount of $743 million as of January 28, 2024. The maturity date remained unchanged at April 2029, and the notes continued to be listed among the company’s long-term debt obligations. The carrying amount slightly decreased, reflecting the initial discount and amortization progress over the year.",
      "llm_answer": "\nThe $750 million, 4.90 % senior notes that were issued in November 2023 (maturing on April 15, 2029) were recorded at a carrying amount of $746.6 million after a $3.4 million discount (see HD 10‑K 2023 page 60). By the end of fiscal 2024 the notes were still outstanding, with a reported carrying amount of roughly $744–$746 million on the February 2 2025 balance sheet (see HD 10‑K 2024 page 62), and they retain the same April 15, 2029 maturity date. The notes continue to accrue interest semi‑annually and remain callable under the indenture, but no redemption or refinancing has occurred to date.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the issuance of the 4.90% Senior Notes in November 2023 with a $750 million principal and $3.4 million discount, and correctly states the maturity date as April 15, 2029. It also correctly notes that the notes remained outstanding in 2024 and that interest is paid semi-annually. However, there is a discrepancy in the carrying amount. The ground truth states the carrying amount was $743 million as of January 28, 2024, while the LLM reports $744–$746 million as of February 2, 2025 (fiscal 2024 end), which is inconsistent with the ground truth timeline and amount. The initial carrying amount should be $750M - $3.4M = $746.6M in 2023 (correctly stated), but by early 2024 (Jan 28), it should have amortized slightly to $743M, not remain around $744–$746M a full year later. This suggests an error in amortization progression. (2) Quantitative accuracy is reduced due to this carrying amount inconsistency—while $746.6M in 2023 is correct, the 2024 figure does not align with the expected amortization. The range $744–$746M is too high given the ground truth $743M as of Jan 2024. (3) Qualitatively, the reasoning is sound: the model recognizes the notes are outstanding, unchanged in maturity, and part of long-term debt. It correctly references semi-annual interest and callability, showing good synthesis. (4) Contextual relevance is perfect—the answer directly addresses the evolution of the notes’ status and structure across 2023–2024, including carrying amount and maturity. The core facts are mostly correct, but the quantitative misalignment in the 2024 carrying amount prevents a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 453,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did the issuance and repayment of Guaranteed Senior Notes by Costco's Japanese subsidiary evolve between 2023 and 2024?",
      "original_answer": "In 2023, Costco's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%. In 2024, the subsidiary repaid $77 of these Guaranteed Senior Notes. Additionally, the proceeds from the issuance of these notes were referenced in the 2024 filing as a source of financing activity, indicating continued financial engagement with this instrument.",
      "llm_answer": "\nBetween November 2023 and July 2024, Costco’s Japanese subsidiary issued a $500 million series of Guaranteed Senior Notes (four separate tranches with fixed rates of 1.400%–2.120% and maturities from 2033 to 2043). In July 2024 the subsidiary repaid $77 million of those notes, reducing the outstanding balance but leaving the remainder of the $500 million issuance still outstanding. No additional issuances or further repayments of the Guaranteed Senior Notes were disclosed for the remainder of 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: $500 million issuance (matching the ~$500 in the original), interest rates (1.400%–2.120%), and $77 million repayment in 2024 are accurately reported. The time frame (November 2023 to July 2024) adds precision not contradicted by the original. (2) The answer correctly identifies the entity (Costco’s Japanese subsidiary) and financial instrument (Guaranteed Senior Notes), and notes the continued outstanding balance—consistent with the original’s implication of ongoing financial engagement. (3) Multi-hop reasoning is sound: it synthesizes issuance in 2023 and repayment in 2024, correctly framing the evolution of the debt instrument. (4) The only minor limitation is that the original does not specify the maturities (2033–2043) or that the $77M repayment occurred in July 2024—details not present in the ground truth—so while plausible, they slightly exceed the provided information. However, this does not introduce inaccuracy but adds reasonable detail. Overall, the answer is factually correct, complete, and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 333,
        "total_tokens": 1558
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has the risk associated with competitors developing after-market parts for DHR's products evolved from 2022 to 2023, particularly in terms of its impact on the company's business and financial statements?",
      "original_answer": "In 2022, the risk of competitors developing after-market parts was described as a direct threat that could 'detract from our sales,' with an emphasis on how commoditization and private-label offerings could reduce market prices and erode DHR's competitive position. By 2023, the framing of this risk shifted to being 'Impacted By' such competition, with a broader contextualization within cost containment trends in the healthcare industry and pricing pressures from managed care and government reimbursement policies. While the core risk remained, it was presented as one of several external pressures rather than a primary threat, suggesting a relative de-emphasis in severity or a strategic recalibration in how the company perceives this risk.",
      "llm_answer": "\nThe 2022 and 2023 Form 10‑K filings both list the same explicit risk language—“competitors may also develop after‑market services and parts for our products which may detract from our sales”—and place it within the “Business and Strategic Risks” section.  This wording shows that the threat has not diminished; rather, it remains a material concern that could erode demand, increase pricing pressure and adversely affect Danaher’s revenue and profitability.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses a key qualitative shift identified in the ground truth. (1) The LLM correctly identifies that the same risk language appears in both the 2022 and 2023 10-K filings and that the risk relates to competitors developing after-market parts that could detract from sales, impact pricing, and affect revenue and profitability—this aligns with the original answer’s description of the ongoing risk. However, it fails to capture the evolution in how the risk is framed: in 2023, the risk was repositioned as being 'Impacted By' broader industry trends (e.g., cost containment, managed care pricing pressures), indicating a relative de-emphasis or contextualization within a larger set of external pressures. This shift in tone and strategic framing is central to the question about how the risk 'evolved' and its changing impact on business and financial statements. (2) There are no numerical values in this question, so quantitative accuracy is not applicable—scored as 10 by default. (3) The multi-hop reasoning is incomplete: while the model correctly retrieves the consistent risk disclosure, it does not synthesize the change in categorization or contextual framing between years, which is required for full accuracy. (4) Contextual relevance is high because the answer addresses the core risk and its financial implications, but the lack of analysis on the evolution of the risk’s presentation reduces qualitative accuracy and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 409,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has Netflix's approach to membership plans evolved from 2022 to 2024, particularly in terms of pricing strategy and service features, and what business challenges were these changes intended to address?",
      "original_answer": "In 2022, Netflix experienced a 19% revenue increase driven by an 11% growth in average paying memberships and a 7% rise in average monthly revenue per membership, partly due to price increases and favorable foreign exchange rates. However, paid net membership additions dropped by 50% compared to the prior year, signaling early signs of member acquisition challenges. By 2024, Netflix responded by introducing a lower-priced ad-supported subscription plan and enforcing terms of use to limit multi-household usage. These changes were aimed at addressing fluctuating member acquisition, retention pressures, and increasing competition in the streaming and broader entertainment market. The company acknowledged that macroeconomic conditions, content competition, and consumer sensitivity to pricing adjustments could negatively impact membership growth and profitability.",
      "llm_answer": "\nFrom 2022 through 2024 Netflix moved away from a static three‑tier subscription model toward a more flexible pricing architecture that added a low‑cost, ad‑supported plan and began modestly raising prices on its standard and premium tiers, while also tightening rules that limit sharing across households. These changes were designed to counter slowing membership growth, boost average revenue per user, and diversify income streams in the face of intensifying competition and rising content‑cost pressures—issues highlighted in the 2022 filing’s discussion of pricing tests and in the 2024 filing’s emphasis on expanding the ad‑supported offering and enforcing household‑sharing restrictions.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of Netflix's membership plans from 2022 to 2024, noting the introduction of an ad-supported tier, price increases on existing tiers, and enforcement of household-sharing restrictions. It accurately identifies the business challenges—slowing membership growth, competition, content costs, and the need to boost revenue per user—as intended by the changes. While the original answer includes specific quantitative data (19% revenue increase, 11% membership growth, 7% rise in ARPU, 50% drop in net additions), the LLM answer does not reproduce these exact figures but conveys their implications (e.g., 'slowing membership growth' aligns with the 50% drop). (2) Quantitative accuracy is slightly reduced because the LLM omits the precise percentages from 2022 (e.g., 19% revenue growth, 11% membership increase), though it correctly references pricing tests and strategic shifts tied to those years. No incorrect numbers are stated, and no erroneous calculations are made—just a lack of explicit stats. (3) The multi-hop reasoning is sound: the model synthesizes information across 2022 and 2024 filings, linking pricing strategy changes to business challenges like competition and content costs. It correctly infers that ad-tier expansion and sharing enforcement were responses to earlier growth slowdowns. (4) The answer is semantically equivalent in intent and meaning, with only minor omissions of specific metrics. Wording differs but core facts and logic match the ground truth. Contextual relevance is perfect—it directly addresses all parts of the question: pricing strategy, service features, timeline, and business rationale.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 462,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has Boeing's approach to in-orbit incentive payments evolved between 2022 and 2023, particularly in terms of risk exposure and financial recognition?",
      "original_answer": "In 2022, Boeing highlighted the financial risks associated with in-orbit incentive payments, particularly in the context of potential program cancellations or failure to meet performance criteria, which could trigger termination provisions or loss of payments. The company noted that these risks were part of ongoing fixed-price development programs like Commercial Crew, KC-46A Tanker, and VC-25B. By 2023, Boeing had recorded $1,585 million in additional losses on its five most significant fixed-price development programs, which included those mentioned in 2022, and explicitly stated that in-orbit incentive payments were at risk if satellites failed to meet performance criteria over up to 15 years post-acceptance. The company also emphasized that the net present value of these fees was recognized as revenue during the construction period, increasing financial exposure if performance issues arose. This represents a shift from general risk acknowledgment in 2022 to a more specific quantification of losses and a detailed explanation of revenue recognition practices tied to in-orbit performance in 2023.",
      "llm_answer": "\nBoeing still records the net‑present‑value of expected in‑orbit incentive fees as revenue during the satellite‑construction phase, but the fees are contingent on the spacecraft meeting performance specifications for up to 15 years after launch. In 2022 the risk was disclosed simply as a possible loss of future payments and the need for refunds if the satellite under‑performs; by 2023 the language stresses that these incentives are now embedded in increasingly fixed‑price development contracts and can trigger material reach‑forward losses or earnings charges if performance criteria are not met, reflecting a higher‑visibility risk exposure.",
      "correctness_score": 8,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the evolution in Boeing's approach to in-orbit incentive payments from 2022 to 2023, emphasizing increased risk exposure and financial recognition practices. It accurately describes the contingent nature of payments based on performance over up to 15 years and the recognition of net present value during construction, aligning with the ground truth. The qualitative reasoning is strong: it identifies the shift from general risk disclosure in 2022 to a more explicit linkage with fixed-price contracts and material financial impacts in 2023. However, the LLM omits the key quantitative detail from the original answer—Boeing recorded $1,585 million in additional losses on its five major fixed-price development programs in 2023. This is a significant omission because the question specifically asks about financial recognition, and the dollar amount is central to the 'quantification of losses' mentioned in the ground truth. While the LLM mentions 'material reach-forward losses,' it fails to provide the actual figure, reducing quantitative accuracy. All entities (Boeing, in-orbit incentive payments, fixed-price development programs) and years (2022, 2023) are correct, and the multi-hop synthesis between risk disclosure and financial reporting practices is sound. The answer is contextually relevant and semantically close to the original, but the missing $1,585 million figure prevents a higher correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 400,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the disclosure and accessibility of the Directors' Code of Conduct evolved between 2023 and 2024?",
      "original_answer": "In 2023, the Directors' Code of Conduct was explicitly described as being posted on the company's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/invrelations/directors-code-of-conduct.pdf, and the company stated its intention to disclose amendments or waivers on the website. In 2024, while the Code remained accessible, it was referenced more generally as part of a broader list of governance materials available on the company’s website, including committee charters and governance guidelines, without repeating the direct URL. The change indicates a shift from detailed disclosure of access to a more consolidated and implicit reference, suggesting a streamlined but less direct approach to public access in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 the company moved from a brief mention of the Directors’ Code of Conduct in the ethics section with a PDF link (2023 Form 10‑K, pp. 11‑13) to an explicit listing of the code among the corporate‑governance materials that are posted on its website and referenced in the “Available Information” section (2024 Form 10‑K, pp. 2‑3).  The 2024 filing also states that any amendments or waivers of the Directors’ Code will be disclosed on the website, making the code more transparent and easier for investors to locate and review.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in describing the evolution of disclosure. According to the ground truth, in 2023 the Directors' Code of Conduct was explicitly posted with a direct URL and the company committed to disclose amendments or waivers on the website. In 2024, the reference became more general, embedded within a broader list of governance materials without repeating the URL—indicating a less detailed, more consolidated approach. However, the LLM incorrectly claims that the 2023 filing only had a 'brief mention' and that the 2024 filing improved transparency by explicitly listing the code and reiterating amendment disclosures. This is the opposite of the truth: 2023 had more explicit disclosure (with URL), while 2024 was more implicit. (2) Quantitatively, the LLM correctly references years (2023, 2024) and sections (Form 10-K pages), though specific page numbers (pp. 11–13, pp. 2–3) cannot be verified from the ground truth provided. No financial figures or calculations are involved, so numerical accuracy is not applicable beyond dates and locations, which are plausibly presented. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the direction of change—ground truth shows a move toward less direct disclosure in 2024, but the LLM asserts increased transparency. This misrepresents the core trend. (4) Contextual relevance is moderate: the answer addresses the right topic (disclosure of the Directors' Code of Conduct across years) and uses appropriate context (Form 10-K, website posting, amendment disclosure), but draws an incorrect conclusion about the nature of the evolution. Thus, while the structure and intent are relevant, the factual and qualitative inaccuracies severely undermine correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 488,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the role and deployment strategy of Mobileye Drive™ evolved between 2022 and 2023?",
      "original_answer": "In 2022, Mobileye launched the SAE L4 Self-Driving System (SDS), Mobileye Drive™, and secured multiple collaborations for commercial use, including with Udelv for autonomous cargo delivery and with Transdev for self-driving mobility services. Additionally, Mobileye achieved its first consumer L4 design win with Geely. By 2023, Mobileye’s strategy had evolved to focus on supplying the Mobileye Drive™ self-driving system to transportation network companies, public transit operators, and suppliers of AV-ready vehicle platforms, with plans to bundle it with Moovit’s urban mobility and transit intelligence application. This shift indicates a more defined go-to-market strategy targeting fleet deployment and mobility-as-a-Service (MaaS) ecosystems.",
      "llm_answer": "\nBetween 2022 and 2023 Mobileye Drive™ moved from a research‑grade, end‑to‑end L4 platform used in limited pilot programs to a commercial, licensable self‑driving stack that powers revenue‑generating Robotaxi services (e.g., SIXT in Germany and other MaaS partners) and is being offered to fleet operators and public‑transport providers.  The deployment strategy shifted toward licensing the Drive system to mobility‑service companies and bundling it with Moovit’s mobility‑intelligence platform, while the hardware roadmap (EyeQ 6L/H and the upcoming EyeQ Ultra) was introduced to scale performance and support higher‑level autonomy.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Mobileye Drive™’s role and deployment strategy between 2022 and 2023. (1) It accurately captures the shift from initial commercial pilots in 2022 to a more defined go-to-market strategy in 2023 focused on licensing to mobility-as-a-service (MaaS) providers, fleet operators, and public transit. The mention of bundling with Moovit’s platform is correct and reflects the strategic integration highlighted in the original answer. (2) There are no numeric values, dates, or financial figures in either answer, so quantitative accuracy is not compromised—score is 10. (3) The LLM adds specific examples not in the original answer (e.g., SIXT in Germany), which are plausible but not verifiable from the ground truth; this introduces a minor overreach, though it doesn’t contradict known facts. It also references the EyeQ 6L/H and EyeQ Ultra chips, which are contextually relevant to Mobileye’s autonomy roadmap but not part of the original answer’s scope on Mobileye Drive™’s deployment strategy. While technically accurate, this adds peripheral detail not required by the question. (4) The core multi-hop reasoning—synthesizing 2022 launch and partnerships with 2023 strategic pivot toward MaaS and bundling—is sound and semantically equivalent to the original. The answer is highly contextually relevant. Minor deductions in correctness and qualitative accuracy are due to the introduction of unverified specifics (SIXT) and hardware details beyond the scope of the original answer’s focus on deployment strategy evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 457,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has the structure and distribution rate of the Tower Preferred Interests evolved from 2022 to 2024?",
      "original_answer": "In 2022, the Tower Preferred Interests were divided into two series: the September series (Class A-1) totaling $1,500 with a 5.0% initial preferred distribution, and the December series (Class A-2) totaling $4,500 with a 4.75% initial preferred distribution. These distributions reset every five years. By 2024, the structure was amended in August 2024 to reclassify all 2019 Tower preferred interests into Fixed Rate Class A Limited Membership Interests (Tower Fixed Rate Interests) paying a 5.90% preferred distribution. Additionally, a portion of these fixed-rate interests will transition annually into Floating Rate Class A Limited Membership Interests (Tower Floating Rate Interests), which will pay a distribution equal to SOFR plus 250 basis points. This represents both a structural and rate evolution in the Tower Preferred Interests.",
      "llm_answer": "\nFrom 2022 through 2024 the Tower Preferred Interests kept the same two series—a $1.5 bn Class A‑1 tranche that paid a 5.0 % quarterly distribution and a $4.5 bn Class A‑2 tranche that paid 4.75 %—but in August 2024 the company amended the 2019 Tower preferred interests. The amendment reset the rates and restructured the securities: all of the interests are now designated Fixed‑Rate Class A Limited Interests that pay a higher 5.90 % quarterly distribution, while a portion will transition to Floating‑Rate Class A Limited Interests that pay SOFR + 250 bps (capped at $525 million by 2028). The reset schedule remains every five years, and the redemption and liquidation rights are unchanged.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2022 structure with two series—Class A-1 and Class A-2—and their respective distribution rates of 5.0% and 4.75%. It also correctly notes the August 2024 amendment that restructured the Tower preferred interests into Fixed-Rate and Floating-Rate Class A Limited Interests, with the 5.90% fixed rate and SOFR + 250 bps floating rate. However, there are significant quantitative inaccuracies: the original answer states the 2022 amounts as $1,500 and $4,500, which likely refer to $1.5 billion and $4.5 billion (a reasonable interpretation), but the LLM explicitly writes '$1.5 bn' and '$4.5 bn', which is not directly supported in the ground truth and introduces a potential magnitude error (unless '000s are implied). More critically, the LLM introduces a detail not present in the original answer: a cap of $525 million by 2028 on the floating-rate transition. This cap is not mentioned in the ground truth and represents a factual addition. (2) The reset schedule being every five years is correctly preserved, and the August 2024 timing is accurate. However, the original specifies that the 2019 Tower preferred interests were reclassified, while the LLM generalizes to 'the company amended the 2019 Tower preferred interests'—this is plausible but slightly less precise. (3) The multi-hop reasoning is sound: the model connects the 2022 structure to the 2024 amendment, synthesizing structural and rate changes over time. It correctly identifies the evolution from fixed series to a hybrid fixed/floating structure. (4) The contextual relevance is perfect—the answer directly addresses the evolution in structure and distribution rate. Due to the unverified $525 million cap and the unsupported 'bn' scaling (despite likely intent), the quantitative accuracy is reduced. The core facts and direction of change are correct, warranting a 7 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 519,
        "total_tokens": 1893
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the investment approach and unrealized gains/(losses) for Level 3 assets related to the Balanced Index Fund evolve from 2022 to 2023?",
      "original_answer": "In 2022, the company disclosed unrealized losses for Level 3 assets still held at year-end, including ($16) million for corporate fixed income securities and ($11) million for mortgage-backed and asset-backed fixed income securities. By 2023, these values shifted to unrealized gains of $2 million for corporate fixed income securities and $6 million for mortgage-backed and asset-backed fixed income securities. This indicates a significant turnaround in the performance of these assets. Additionally, while the Balanced Index Fund's composition remained at approximately 60% equities and 40% debt securities in both years, the valuation methodology in 2023 explicitly referenced a market approach based on quoted market prices (Level 1), suggesting a more transparent and standardized valuation process.",
      "llm_answer": "\nFrom 2022 to 2023 the Balanced Index Fund continued to be valued by a **market‑approach (Level 1) using quoted prices of identical instruments**, so the valuation methodology did not change.  However, the **unrealized gains on the Fund’s Level 3‑classified holdings swung from a $90 unrealized loss in 2022 to a $14 unrealized gain in 2023**, driven by positive net gains of $5 in corporate fixed‑income, $7 in mortgage‑backed securities and $3 in other fixed‑income that offset prior losses.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that in 2022, Level 3 assets had unrealized losses of ($16) million for corporate fixed income and ($11) million for mortgage-backed and asset-backed securities, totaling $27 million in losses. In 2023, these turned into gains of $2 million and $6 million respectively, totaling $8 million in gains. The LLM incorrectly reports a $90 million unrealized loss in 2022 and a $14 million gain in 2023, which are entirely wrong both in magnitude and direction (the actual 2022 loss was $27M, not $90M). Additionally, the LLM attributes $5M, $7M, and $3M gains to specific categories, which do not match the ground truth. (2) The valuation methodology claim is incorrect: the original answer states that in 2023 the methodology 'explicitly referenced a market approach based on quoted market prices (Level 1)', implying a shift toward more Level 1 usage or transparency, but the LLM claims the Fund was 'continued to be valued by a market-approach (Level 1)' in both years, which contradicts the original statement that Level 3 assets were involved and that the methodology evolved. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the change in unrealized gains/losses across years and misrepresents the valuation approach evolution. It invents a $90M loss and $14M gain not present in the data. (4) Despite these issues, the answer is contextually relevant—it addresses the Balanced Index Fund, Level 3 assets, unrealized gains/losses, and attempts to compare 2022 to 2023—hence a moderate relevance score. However, due to severe quantitative and qualitative errors, the correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 469,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has BNY Mellon's emphasis on accounting developments in its forward-looking statements evolved between 2023 and 2024, and what does this reveal about the changing influence of accounting standards on its strategic priorities?",
      "original_answer": "In 2023, BNY Mellon included accounting developments among a broader list of potential influences on forward-looking statements, noting they 'may impact our businesses' without specific elaboration. By 2024, the company expanded this language, explicitly stating that accounting developments 'may impact our businesses, regulatory, technology, market, economic or accounting developments and the impacts of such developments on our businesses.' This shift indicates a more integrated view of accounting changes as part of strategic risk and planning considerations. The inclusion of terms like 'capital plans including dividends and repurchases' and 'efficiency savings' in 2024 further suggests that accounting developments are increasingly tied to concrete business decisions and performance metrics.",
      "llm_answer": "\nIn the 2023 filing, references to accounting developments appear only as part of the generic forward‑looking “expectations” language, but the 2024 Form 10‑K elevates them to a stand‑alone risk factor that explicitly warns that “changes in accounting standards governing the preparation of our financial statements … could have a material impact on our reported financial condition, results of operations, cash flows and other financial data.” This shift indicates that BNY Mellon now regards accounting‑standard updates as a central strategic driver—shaping its reporting framework, capital‑planning and risk‑management priorities rather than treating them as a peripheral concern.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its characterization of the increased emphasis on accounting developments in BNY Mellon's 2024 filing compared to 2023, and correctly identifies a shift in tone and strategic importance. It accurately reflects that accounting developments were more prominently featured in 2024, with stronger language about material impacts on financial reporting. However, there is a discrepancy in the nature of the change: the original answer states that accounting developments remained part of a broader list in forward-looking statements but were elaborated upon, while the LLM claims they became a 'stand-alone risk factor'—a structural claim not supported by the ground truth. This overstates the change in presentation. Additionally, the LLM introduces the phrase 'changes in accounting standards governing the preparation of our financial statements' as a direct quote, which is not present in the original answer and cannot be verified here. While the overall direction of reasoning is sound—accounting developments gaining strategic importance—the specific evidence cited is partially inaccurate or exaggerated. There are no numerical errors (quantitative accuracy is perfect), and the answer remains contextually relevant and well-reasoned at a high level, but the qualitative accuracy is reduced due to incorrect sourcing of the change (e.g., 'stand-alone risk factor') and unsupported quoting. The core insight about growing strategic significance aligns with the ground truth, warranting a solid but not top score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 424,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the evolution of risks related to store safety and cybersecurity in 2023 potentially impact the associate experience, as compared to the engagement-focused initiatives highlighted in 2022?",
      "original_answer": "In 2022, HD emphasized internal initiatives to improve the associate experience through engagement surveys, a digital engagement platform, and recognition programs, which historically showed that four out of five associates were emotionally committed. However, in 2023, the company highlighted external risks such as increased store shrink, particularly from organized retail crime, and cybersecurity threats that could compromise associate data and store safety. These risks were noted to potentially erode trust, impact associate morale and retention, and damage the company's reputation. This shift indicates that while HD was actively fostering associate engagement in 2022, the emergence or escalation of external risks in 2023 introduced new challenges that could undermine those earlier gains in associate experience.",
      "llm_answer": "\nIn 2023 the company’s risk profile shifted from the 2022 focus on engagement‑driven programs (surveys, DEI, recognition, culture‑building) to new safety and cyber‑threats that could directly affect how associates work.  The 2022 ESG materials highlighted store‑safety measures and data‑privacy safeguards, but the 2023 risk disclosures stress that “failure to maintain a safe and secure store environment” and “data‑governance failures…could adversely affect our reputation and business” – meaning higher shrink, organized‑retail crime, ransomware and system‑downtime that add compliance burdens, limit scheduling flexibility and increase daily stress for associates.  Consequently, while 2022’s initiatives were designed to boost emotional commitment, the evolving 2023 risks introduced operational pressures that could dampen that engagement if not fully mitigated.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the shift from 2022 engagement-focused initiatives (surveys, recognition, culture) to 2023 safety and cybersecurity risks. Key elements like organized retail crime, store shrink, ransomware, system downtime, and impacts on associate stress and morale are accurately reflected. (2) There are no numeric values in the question or ground truth, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across years (2022 vs 2023), contrasting proactive engagement efforts with emerging external risks that could undermine associate experience. It references 'emotional commitment' (implied from the ground truth's 'four out of five associates emotionally committed') and links operational pressures to potential erosion of engagement. (4) The only minor shortcoming is that the LLM slightly overstates the presence of store safety and data privacy in 2022 ESG materials as 'highlights', whereas the ground truth positions 2022 as primarily engagement-focused, with safety and cyber risks becoming prominent in 2023. This nuance is mostly preserved, but the emphasis could be clearer. Overall, the answer is factually correct, contextually relevant, and semantically equivalent to the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 382,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the role of the 'learning curve' in influencing cost and production estimates evolved between 2022 and 2023, particularly in relation to program profitability and risk management?",
      "original_answer": "In 2022, the 'learning curve' was identified as a risk factor that could negatively impact program profitability due to production complexities, rework, and delays—especially in programs like the 787—potentially leading to additional losses and abnormal production costs. By 2023, the 'learning curve' was no longer framed solely as a risk but was integrated into the company's cost estimation process, factored into production rate assumptions, supplier performance trends, and internal labor efficiency projections. This shift indicates that Boeing began treating the learning curve as a predictable and manageable component of production planning rather than an unpredictable risk.",
      "llm_answer": "\nBetween 2022 and 2023 the learning‑curve shifted from a peripheral variable in program‑accounting estimates to a central driver of cost and production assumptions.  The 2023 disclosures explicitly link learning‑curve performance to abnormal production costs, reach‑forward losses and a $1.4 billion increase in valuation allowances, showing that inaccurate learning‑curve forecasts now directly erode program profitability and force more conservative margin forecasts and heightened risk provisions.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general evolution of the learning curve's role from 2022 to 2023 in Boeing's cost and production planning, which aligns with the question's focus on profitability and risk management, giving it contextual relevance. However, it introduces a specific dollar amount—'$1.4 billion increase in valuation allowances'—that is not present in the original answer or supported by the provided ground truth. This figure cannot be verified and appears to be hallucinated or derived from external data, severely undermining quantitative accuracy. Additionally, while the original answer emphasizes a structural shift in how the learning curve was integrated into cost estimation (e.g., supplier performance, labor efficiency), the LLM focuses on financial consequences (abnormal costs, reach-forward losses) without clearly conveying the proactive, predictive use of the learning curve in planning. The reasoning is partially sound in linking learning curve inaccuracies to profitability impacts, but it misrepresents the nature of the evolution: the original highlights a move from 'risk' to 'predictable component,' whereas the LLM frames it as increased financial penalties. This mischaracterization affects qualitative accuracy. No other entities (e.g., 787 program) or years are incorrect, but the unsupported numeric claim significantly reduces overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 382,
        "total_tokens": 1689
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the treatment or disclosure of the Dividend Reinvestment Plan evolved between the 2023 and 2024 SEC filings, particularly in relation to officer or director participation and associated trading arrangements?",
      "original_answer": "In the 2023 filing, the Dividend Reinvestment Plan was mentioned in the context of officer or director participation alongside the employee stock purchase plan and 401(k) plan, with specific reference to elections to have shares withheld for tax purposes or to pay the exercise price of stock awards. The disclosure also included a detailed description of how these elections may be structured under Rule 10b5-1 or non-Rule 10b5-1 trading arrangements as defined in Item 408(c) of Regulation S-K. In the 2024 filing, the Dividend Reinvestment Plan was again referenced in the context of officer or director participation, but the detailed explanation of Rule 10b5-1 and non-Rule 10b5-1 trading arrangements was omitted, indicating a simplification or standardization of the disclosure without the earlier level of specificity regarding trading frameworks.",
      "llm_answer": "\nBoth the 2023 and 2024 Form 10‑K filings disclose that officers and directors may elect to participate in the company’s dividend‑reinvestment (and employee‑stock‑purchase) plan, and that any such participation can involve withholding shares to cover withholding taxes or to pay the exercise price of stock awards. The language in the 2024 filing is essentially unchanged from the 2023 filing—it still notes that these elections may be made “to satisfy the affirmative‑defense conditions of Rule 10b5‑1 … or may constitute non‑Rule 10b5‑1 trading arrangements,” indicating that the treatment and disclosure of the DRIP with respect to insider participation has remained consistent across the two filings.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim about the consistency of disclosure between the 2023 and 2024 filings. According to the ground truth, the 2023 filing included a detailed description of how officer or director participation in the Dividend Reinvestment Plan (DRIP) could be structured under Rule 10b5-1 or non-Rule 10b5-1 trading arrangements as defined in Item 408(c) of Regulation S-K, while the 2024 filing omitted this detailed explanation. However, the LLM asserts that 'the language in the 2024 filing is essentially unchanged' and that the disclosure about Rule 10b5-1 and non-Rule 10b5-1 arrangements 'is still' present—this directly contradicts the ground truth, which states the detailed trading arrangement language was omitted in 2024. There are no numerical values in the question or answer, so quantitative accuracy is scored as 10 by default. The qualitative accuracy is low because the model fails to identify a key change in disclosure and incorrectly asserts consistency. Contextual relevance is moderate because the answer addresses the right topic (officer/director participation in DRIP and trading arrangements) and the general context of tax withholding and stock awards, but draws the wrong conclusion about disclosure evolution. The multi-hop reasoning fails: the model should have compared the presence vs. absence of Rule 10b5-1 details across years but instead assumed continuity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 394,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has The Home Depot's investment in creating an interconnected shopping experience evolved from fiscal 2021 to fiscal 2023, and what specific changes were made in the way this experience is tailored to customers?",
      "original_answer": "In fiscal 2021, The Home Depot invested $2.6 billion in capital expenditures focused on supporting an interconnected customer experience. By fiscal 2023, the company had advanced this strategy by leveraging enhanced merchandising information technology tools to build an interconnected shopping experience tailored to customers' shopping intent and location. This represents a shift from general investment in interconnectedness to a more refined, data-driven personalization strategy.",
      "llm_answer": "\nFrom fiscal 2021 through fiscal 2023 the company moved from a broad‑based build‑out of digital and BOPIS capabilities toward a fully integrated, “interconnected” experience that is now customized to each shopper’s intent and location.  In 2023 the retailer added personalized, location‑aware marketing messages, richer product‑page data, same‑day/next‑day omni‑channel delivery (including market‑delivery hubs for appliances), electronic‑shelf‑labels, curb‑side lockers, self‑checkout and computer‑vision inventory tools, and expanded Pro‑focused online portals, credit and loyalty programs—all of which tailor the shopping journey across stores, online and on‑the‑job sites.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly captures the evolution of The Home Depot's strategy from a broad investment in digital infrastructure in fiscal 2021 to a more personalized, interconnected experience by fiscal 2023. It accurately reflects the shift toward tailoring the experience based on customer intent and location, which aligns with the ground truth. However, it omits the specific $2.6 billion capital expenditure figure from fiscal 2021, which is a key quantitative detail in the original answer. While it adds many specific enhancements (e.g., electronic shelf labels, curb-side lockers, computer vision tools), these are not present in the ground truth and may be plausible but unverified extrapolations or confabulations.\n\n2) Quantitative accuracy is compromised because the $2.6 billion investment in fiscal 2021 is missing. No incorrect numbers are stated, but the absence of this key figure—central to the original answer—reduces precision. The LLM does not introduce false numerical claims, but fails to include the only explicit number provided in the ground truth, which is a significant omission for a multi-hop financial question.\n\n3) The reasoning is logically sound: the LLM infers a progression from general digital investment to personalized, data-driven experiences. It correctly identifies the core theme of tailoring by shopping intent and location. However, the added specifics (e.g., market-delivery hubs, self-checkout, Pro portals) go beyond the information in the ground truth and are not supported by the provided data, suggesting potential over-generation or use of external knowledge. This affects qualitative accuracy despite strong thematic alignment.\n\n4) Contextual relevance is excellent—the response directly addresses both parts of the question: the evolution over time and the specific changes in personalization. The language is focused, relevant, and structured to match the query. Despite unsupported details, the overall direction and synthesis are appropriate. The score of 7 reflects correct core reasoning and relevance, but deductions for missing key data and introducing unverified specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 571,
        "total_tokens": 1879
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the financial relationship between DHR and Aldevron evolved between 2022 and 2023, particularly in terms of capital investment and acquisition-related expenditures?",
      "original_answer": "In 2022, DHR anticipated capital expenditures of approximately $1.5 billion, with a portion of this spending attributed to increased manufacturing capacity for products related to the Aldevron Acquisition, among others. This reflects a growing capital commitment tied to Aldevron. By 2023, the financial relationship had evolved significantly, as evidenced by the net cash consideration paid to Aldevron amounting to $9,561 million, indicating that Aldevron had transitioned from being primarily a capital investment target to a core component of DHR's consolidated assets. This represents a substantial shift in the nature of their relationship from a dependency to a stakeholding and integration model.",
      "llm_answer": "\nBetween 2022 and 2023 Danaher’s exposure to Aldevron stayed at the level established by the 2021 $9.6 bn acquisition – the goodwill from that deal (≈ $6.1 bn) remained on the balance sheet and was only subject to the usual annual impairment review, with no new purchase‑price allocation or material transaction‑cost charges recorded in 2023.  Capital investment did increase, however, as the company continued to fund capacity‑expansion projects for Aldevron (capital expenditures rose to roughly $1.5 bn in 2022 and were expected to stay elevated in 2023), while acquisition‑related outlays were essentially settled, with only minor post‑closing adjustments (e.g., the $28 m of integration costs recorded in 2021) and no further major acquisition spending.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) Quantitatively, it incorrectly states that the Aldevron acquisition occurred in 2021 for $9.6 billion, while the ground truth indicates that the net cash consideration of $9,561 million was paid in 2023—this is a critical error in both timing and context. The $9.6 billion figure may be an approximation of $9,561 million, but attributing it to 2021 misrepresents the timeline. Additionally, the LLM claims goodwill of approximately $6.1 billion and references $28 million in integration costs from 2021, which are not mentioned or verifiable in the ground truth. (2) The answer incorrectly asserts that 'acquisition-related outlays were essentially settled' and that 'no further major acquisition spending' occurred in 2023, directly contradicting the ground truth that DHR paid $9,561 million in net cash consideration in 2023—this is the central financial event of the period. (3) Qualitatively, the reasoning fails on multi-hop synthesis: instead of recognizing the evolution from capital investment (2022) to full acquisition integration (2023), the model assumes the acquisition was completed earlier, fundamentally mischaracterizing the nature and timing of the financial relationship. (4) Contextually, the answer addresses capital expenditures correctly (~$1.5 billion in 2022), which aligns with the ground truth, and notes continued elevated spending, which is relevant. However, the core transformation—the 2023 acquisition payment—is entirely misrepresented. Thus, while some contextual elements are present, the key financial evolution is inaccurately portrayed, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 462,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has the structure and total value of Telco LLC's preferred interests evolved from 2022 to 2024, and what changes were made to the distribution rates and reset schedules during this period?",
      "original_answer": "In 2022, Telco LLC had $2,000 in nonconvertible cumulative preferred interests (Telco Class A-1) with an initial preferred distribution rate of 4.25% annually, subject to reset every seven years. By 2024, Telco LLC expanded its preferred interests with the issuance of an additional $5,250 in preferred interests (Telco Class A-2 and A-3) in April 2023, bringing the total cumulative preferred interests to $7,250. The new preferred interests (Class A-2 and A-3) carried a significantly higher initial preferred distribution rate of 6.85% annually, with the first reset scheduled for November 1, 2027, and every seven years thereafter. This represents both a structural expansion in the capital stack and a strategic shift toward higher-yielding preferred instruments.",
      "llm_answer": "\nBetween 2022 and the end of 2024 the Telco LLC preferred equity grew from a single $2 bn Class A‑1 series (4.25 % annual distribution, reset on the original seven‑year schedule) to a multi‑series structure that, as of 31 Dec 2024, consists of $2 bn of Class A‑1, $2.5 bn of Class A‑2 and $2.75 bn of Class A‑3 (total $7.25 bn). The original Class A‑1 continues to pay a 4.25 % distribution and resets every seven years, while the 2023‑issued Classes A‑2 and A‑3 pay a higher 6.85 % distribution and are scheduled to reset on 1 Nov 2027 (and thereafter on each seven‑year anniversary). A new Class A‑4 series with a 5.94 % distribution is slated for issuance in Q1 2025 and will reset on 1 Nov 2028 (and every four years thereafter).",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the total value of preferred interests in 2024 as $7.25 billion and accurately reports the initial $2 billion Class A-1 with a 4.25% distribution rate and seven-year reset. It also correctly states that the new classes (A-2 and A-3) issued in 2023 carry a 6.85% rate and reset on November 1, 2027, and every seven years thereafter. However, the LLM introduces a Class A-4 series with a 5.94% rate scheduled for Q1 2025, which is not mentioned in the original answer and is therefore factually unsupported. Additionally, the breakdown of $2.5 billion A-2 and $2.75 billion A-3 (summing to $5.25 billion) is consistent with the total increase, but the original answer does not specify this split, making the precision of these sub-amounts potentially speculative. (2) The total amount ($7.25 billion) is correct, and the $2 billion + $5.25 billion math checks out. However, the inclusion of future Class A-4 issuance (Q1 2025) introduces data beyond the 2022–2024 scope, violating the time frame of the question. Also, the original answer does not mention a four-year reset cycle—preferred resets are every seven years, so stating 'every four years thereafter' for A-4 is incorrect and inconsistent. (3) The multi-hop reasoning is mostly sound: the model correctly synthesizes the expansion in structure and higher distribution rates. However, it extrapolates beyond the provided data by introducing a new class and reset schedule not in the ground truth, indicating a failure in strict factual adherence. (4) The answer is contextually relevant and captures the core evolution: structural expansion and higher yields. Due to the introduction of unsupported future instruments and incorrect reset frequency, quantitative accuracy is reduced, but overall qualitative reasoning and relevance remain strong. Hence, correctness is partially compromised but the main facts are intact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 520,
        "total_tokens": 1907
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has AIG's use of Expected Loss Ratio Methods evolved between 2022 and 2024, particularly in terms of the types of insurance lines and the rationale for their application?",
      "original_answer": "In 2022, AIG used Expected Loss Ratio Methods primarily for the latest accident year and in combination with other methods like loss development for aviation exposures, due to their high-severity nature. By 2024, AIG expanded the use of Expected Loss Ratio Methods to include U.S. Workers' Compensation, a long-tail line of business, where it was used in combination with loss development and frequency/severity methods. This reflects a broader application of the method across different insurance lines with varying claim characteristics.",
      "llm_answer": "\nBetween 2022 and 2024 AIG expanded the Expected‑Loss‑Ratio (ELR) approach beyond excess‑of‑deductible and long‑tail lines to more data‑sparse classes such as U.S. Property, Specialty, Aviation and program business.  The rationale shifted to using ELR for the most recent accident years when development patterns are inconsistent, applying refined rate‑change, inflation and market‑trend adjustments and supplementing the method with ground‑up claim projections to produce more reliable, up‑to‑date reserve estimates.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures the general trend of AIG expanding its use of the Expected Loss Ratio (ELR) method between 2022 and 2024, which aligns with the ground truth. However, there are significant discrepancies in the specifics. The original answer states that in 2022, ELR was used primarily for the latest accident year and in aviation, combined with other methods due to high severity. In 2024, it was expanded to U.S. Workers' Compensation—a long-tail line—used alongside loss development and frequency/severity methods. The LLM answer incorrectly claims expansion 'beyond excess-of-deductible and long-tail lines' to include U.S. Property, Specialty, Aviation, and program business, which contradicts the ground truth that highlights U.S. Workers' Compensation as the key expansion. Aviation was already in use in 2022, so including it as a 2024 expansion is inaccurate. The rationale about inconsistent development patterns, rate change, inflation, and ground-up projections is plausible but not mentioned in the original answer, introducing unverified details. While the direction of evolution (broader use over time) is correct, the specific lines of business and reasoning differ, leading to partial correctness. Quantitative accuracy is high because there are no explicit numbers, percentages, or dates to verify—only years (2022, 2024), which are correct. Qualitative accuracy is moderate due to correct temporal framing but incorrect entity mapping and synthesis. Contextual relevance is good as the response stays on topic and addresses the evolution of ELR use, though with incorrect examples.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 437,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has Target's approach to its owned brands evolved from 2023 to 2024, particularly in terms of strategic emphasis and product portfolio development?",
      "original_answer": "In 2023, Target emphasized expanding its owned brands portfolio as a core strategic element to drive relevancy and market share growth. By 2024, the company shifted focus to producing a broad range of owned and exclusive brands, listing over 40 distinct brands across various categories, indicating a more concrete execution phase of brand development and diversification.",
      "llm_answer": "\nTarget’s owned‑brand strategy shifted from a primary focus on “strengthening our owned‑brands portfolio” (2023) to a more curated, partnership‑driven expansion in 2024.  The 2024 filing highlights a vastly broader roster of exclusive labels—over 150 distinct brands—and emphasizes new design collaborations (e.g., Apple, Disney, Levi’s, Ulta Beauty) and shop‑in‑shop concepts, positioning owned brands as a growth engine that now accounts for roughly one‑third of merchandise sales.  This evolution reflects a strategic emphasis on deeper category coverage, higher‑margin exclusive products, and leveraging data‑driven marketing (Roundel, Target Circle) to differentiate the portfolio and drive traffic through stores and digital channels.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Target had 'over 40 distinct brands' in 2024, but the LLM claims 'over 150 distinct brands,' a major overstatement. Additionally, the LLM introduces specific partnership examples (Apple, Disney, Levi’s, Ulta Beauty) and shop-in-shop concepts not mentioned in the original answer or supported by the knowledge graph. It also claims owned brands account for 'roughly one-third of merchandise sales,' a specific metric absent from the ground truth. (2) Quantitative accuracy is poor: 'over 150' vs. 'over 40' brands is a substantial error. The 'one-third of merchandise sales' figure is unsupported. No calculations are required in the question, but the introduction of false metrics undermines numerical reliability. (3) While the LLM correctly identifies a strategic evolution from portfolio strengthening (2023) to broader brand development (2024), it fabricates details about execution (design collaborations, Roundel, Target Circle) that go beyond the provided information, failing the multi-hop synthesis test by inventing data. (4) Contextual relevance is moderate—the response addresses strategic emphasis and product portfolio development as asked—but the high level of hallucinated detail reduces its accuracy. Correctness score is low due to core factual errors in numbers and unsupported claims about partnerships and performance metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 401,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "What does IBM's continued listing of the 0.875% Notes due 2030 in 2024 alongside the new 2.900% Notes due 2030 suggest about its debt financing strategy and the market conditions for long-term borrowing?",
      "original_answer": "In 2023, IBM listed the 0.875% Notes due 2030 (trading symbol IBM30A) among its registered securities, indicating its initial issuance of this long-term debt instrument. By 2024, IBM not only maintained the 0.875% Notes due 2030 in its capital structure but also introduced a new 2.900% Notes due 2030 (trading symbol IBM30C). The significant increase in the interest rate—from 0.875% to 2.900%—for the same maturity year suggests that IBM may have pursued additional financing in 2024 under less favorable interest rate conditions, or it may be targeting different investor segments with varied risk-return profiles. This dual listing could also indicate a strategic effort to diversify its debt portfolio and manage refinancing risks by having multiple instruments maturing in the same year but with different coupon rates.",
      "llm_answer": "\nIBM kept its existing 0.875 % Notes due 2030 on the 2024 filing while simultaneously adding a brand‑new 2.900 % Notes due 2030, indicating that it is maintaining a staggered maturity ladder and using the newer, higher‑coupon issue to supplement its long‑term funding mix. This move signals that IBM still sees attractive market conditions for issuing long‑dated debt—it can refinance or expand its capital base at reasonable rates and retain flexibility—while also preserving the lower‑cost legacy notes for future cash‑flow management.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the key facts: IBM maintained the 0.875% Notes due 2030 and issued a new 2.900% Notes due 2030 in 2024. All numeric values—interest rates (0.875% and 2.900%), maturity year (2030), and timing (2024 filing)—are accurate and match the ground truth. There are no calculation errors, and the quantitative accuracy is perfect. (2) However, the LLM's reasoning diverges from the ground truth in interpretation. While the original answer emphasizes that the rate increase suggests less favorable borrowing conditions or targeting different investor segments, the LLM claims IBM issued the new debt because it 'still sees attractive market conditions' and 'reasonable rates'—which contradicts the implication of higher borrowing costs. This misrepresents the market conditions aspect. (3) The multi-hop reasoning is partially sound: the model connects the continued listing with the new issuance and infers a strategic debt management approach. But it fails to acknowledge the significance of the sharply higher coupon rate as an indicator of deteriorated financing conditions, instead framing it positively without evidence. (4) The answer is contextually relevant and well-structured, addressing both debt instruments and IBM’s financing strategy. Due to correct numbers and entities but flawed qualitative interpretation of market conditions and strategy, the correctness score is 7—core facts are right, but key inference is misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 408,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the composition of AT&T's long-term debt instruments evolve between 2022 and 2024, particularly regarding the 4.000% Global Notes due June 1, 2049 and the addition of new long-term notes?",
      "original_answer": "In 2022, AT&T listed the 4.000% Global Notes due June 1, 2049 (T 49A) among other long-term debt instruments, but did not include the 4.300% Global Notes due November 18, 2034. By 2024, the 4.000% Global Notes due 2049 remained registered under the same symbol (T 49A), and the company added the 4.300% Global Notes due 2034 (T 34C). This indicates that AT&T expanded its long-term debt portfolio by introducing new maturities while maintaining existing long-dated obligations like the 2049 notes.",
      "llm_answer": "\nBetween 2022 and 2024 AT&T retained its 4.000 % Global Notes maturing June 1, 2049 — which appears in the registration tables of both the 2022 and 2024 Form 10‑K filings — but it broadened its long‑term debt mix by issuing several new global notes.  The 2024 filing adds higher‑coupon, longer‑dated series such as 4.375 % notes due 2029, 4.250 % notes due 2043, 4.875 % notes due 2044 and a 7.000 % note due 2040, as well as later‑maturity issues (e.g., 5.350 % due 2066, 5.625 % due 2067), diversifying the maturity profile and expanding the overall amount of outstanding long‑term debt.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that AT&T added the 4.300% Global Notes due November 18, 2034 (T 34C) by 2024, while retaining the 4.000% Global Notes due June 1, 2049 (T 49A). However, the LLM incorrectly lists multiple new notes (e.g., 4.375% due 2029, 4.250% due 2043, 4.875% due 2044, 7.000% due 2040, 5.350% due 2066, 5.625% due 2067) that are not mentioned in the ground truth. These specific coupon rates and maturities are fabricated or misattributed, failing the quantitative accuracy test. The only correct element is the retention of the 4.000% Global Notes due 2049, which aligns with the original answer. The reasoning about broadening the debt mix has some qualitative merit, but the failure to identify the correct new instrument (4.300% due 2034) and the invention of others breaks the multi-hop synthesis requirement. The context of evolving debt composition is addressed, hence moderate relevance, but the answer is largely incorrect in specifics. Thus, the correctness score is low due to major factual and numerical errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 319,
        "total_tokens": 1603
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the financial impact of the Heritage AspenTech acquisition evolve between 2023 and 2024, particularly in terms of intangibles amortization and restructuring costs?",
      "original_answer": "In 2023, the intangibles amortization related to the Heritage AspenTech acquisition was $258, while in 2024, this figure decreased to $97. Additionally, restructuring costs were $72 in 2023 and increased to $228 in 2024. This indicates a reduction in the amortization burden but a significant rise in restructuring expenses over the two years.",
      "llm_answer": "\nIn 2023 the Heritage AspenTech acquisition contributed roughly **$258 million** of intangible‑asset amortization, forming part of the **$482 million** total amortization recorded that year; by 2024 total intangibles amortization jumped to **$1.08 billion**, driven largely by **$560 million** of new amortization from the NI purchase, so the Heritage AspenTech amortization remained in the mix but its relative weight declined.  At the same time, restructuring expenses rose sharply from **$72 million in 2023 to $228 million in 2024**, reflecting additional integration‑related cost cuts—especially **$97 million in Software & Control and $78 million in Test & Measurement**—much of which stemmed from the ongoing assimilation of the Heritage AspenTech business.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. According to the ground truth, intangibles amortization for the Heritage AspenTech acquisition decreased from $258 million in 2023 to $97 million in 2024. However, the LLM claims that Heritage AspenTech amortization was $258 million in 2023 (correct) but incorrectly states it remained part of a much larger total amortization driven by a new NI purchase, implying the Heritage AspenTech amortization did not decrease — instead, it falsely suggests the figure was still substantial and merely overshadowed. Most critically, the LLM states that 'Heritage AspenTech amortization remained in the mix' but provides no updated value for 2024, and instead introduces a fabricated $560 million from an unrelated 'NI purchase', which is not mentioned in the ground truth. This distorts the core financial evolution. Additionally, the LLM invents a total amortization of $482 million in 2023 and $1.08 billion in 2024, which are unsupported by the original answer. While the restructuring cost numbers ($72M in 2023, $228M in 2024) are correctly reported, the LLM adds granular breakdowns ($97M in Software & Control, $78M in Test & Measurement) that are not in the ground truth, introducing unverified detail. (2) Quantitative accuracy fails on the amortization trend: the correct answer shows a decline from $258M to $97M, but the LLM implies continuity or stable contribution, contradicting the stated decrease. The introduction of unrelated acquisitions (NI) and fabricated totals severely undermines numerical correctness. (3) The multi-hop reasoning is flawed: instead of cleanly synthesizing the two-year evolution of two specific cost items (amortization and restructuring) for the Heritage AspenTech acquisition, the LLM conflates it with other acquisitions and misattributes cost drivers. It fails to clearly state the reduction in amortization, which is a key point in the original answer. (4) Despite these issues, the answer is contextually relevant — it addresses the right acquisition, correct years, and correct cost categories, and correctly identifies rising restructuring costs. The qualitative reasoning is partially sound but undermined by hallucinated data. Thus, the correctness score is low due to major quantitative errors, though not zero because some core facts (2023 amortization, restructuring costs) are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 644,
        "total_tokens": 1927
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has AIG's use of expected loss ratio methods for workers' compensation evolved between 2022 and 2024, particularly in relation to the segmentation of business types and the impact of large deductible accounts?",
      "original_answer": "In 2022, AIG applied expected loss ratio methods primarily to guaranteed cost business in the most recent accident year, while for excess of deductible business, these methods were given significant weight in the most recent five accident years. The company also noted that the proportion of large deductible business had increased, slowing the reporting pattern of claims. By 2024, AIG continued to use expected loss ratio methods but placed greater emphasis on segmentation by deductible size and claim handling (AIG vs. third-party administrators), and explicitly highlighted the increasing influence of large deductible accounts on slowing claim emergence. Additionally, 2024 disclosures emphasized limitations in claim count data due to aggregation and reinsurance exclusions, which were not as prominently noted in 2022.",
      "llm_answer": "\nBetween 2022 and 2024 AIG deepened its reliance on expected‑loss‑ratio models for workers‑compensation reserves, giving them greater weight in the most recent accident‑year calculations.  It also refined the segmentation of the book—splitting guaranteed‑cost and excess‑of‑deductible layers and then further dividing those by state, industry and, importantly, by deductible size and claim‑handling arrangement (AIG‑administered versus third‑party).  Because the share of large‑deductible business has risen and causes slower claim emergence, AIG adjusted its tail‑factor assumptions and placed more emphasis on the expected‑loss‑ratio method for those segmented groups.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in AIG's use of expected loss ratio methods between 2022 and 2024. (1) It correctly identifies the increased reliance on expected loss ratio methods and the segmentation by deductible size and claim handling (AIG vs. third-party administrators), which aligns with the 2024 developments. It also accurately notes the rising proportion of large deductible business and its impact on slower claim emergence, a key point in both years. (2) There are no specific numbers, percentages, or dates in the original or LLM answer beyond '2022' and '2024', so quantitative accuracy is fully preserved. (3) The multi-hop reasoning is sound: the model synthesizes changes over time, connects business segmentation to methodological emphasis, and links large deductible accounts to actuarial assumptions (e.g., tail factors). However, the LLM omits a specific detail from the ground truth: the 2024 emphasis on limitations in claim count data due to aggregation and reinsurance exclusions, which were not highlighted in 2022. This is a minor but notable omission affecting completeness. (4) Despite this omission, the answer remains contextually relevant and semantically close to the original, with accurate entity identification (AIG, workers' compensation, guaranteed cost, excess of deductible, large deductible accounts) and correct temporal framing. The explanation of slowed claim emergence and segmentation refinements matches the ground truth. The score is reduced slightly for missing the data limitation disclosure in 2024, but no factual errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 441,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has Target's approach to cybersecurity threat investigation and response evolved from 2023 to 2024, particularly in terms of its Cyber Fusion Center operations and collaboration with external organizations?",
      "original_answer": "In 2023, Target operated its Cyber Fusion Center as part of its threat investigation and response capabilities, and emphasized collaboration with organizations across industries to share threat intelligence and best practices. By 2024, Target not only maintained its Cyber Fusion Center but also introduced a more structured incident response program with a coordinated escalation model to inform management and the Board of Directors during security incidents. Additionally, in 2024, Target expanded its external engagement by incorporating regular training and compliance activities for team members, and by leveraging third-party vendors to assess and test its cybersecurity program. This represents a more comprehensive and mature approach to cybersecurity threat response and collaboration.",
      "llm_answer": "\nTarget’s cyber‑fusion‑center operations were expanded and formalized between the 2023 and 2024 filings.  In the 2024 Form 10‑K the company describes a more structured incident‑response workflow that includes a coordinated escalation model to senior management and the Board, regular penetration‑testing, vulnerability‑scanning and attack‑simulation of its controls, and validation of its security framework through both internal and independent assessments.  At the same time, Target notes an increased level of external collaboration—continually sharing threat‑intelligence and best‑practice insights with other industry groups to strengthen its threat‑investigation and response capabilities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in Target's cybersecurity approach from 2023 to 2024. It correctly identifies the continued operation of the Cyber Fusion Center and the formalization of a more structured incident response program in 2024, including a coordinated escalation model to senior management and the Board—matching the ground truth. The mention of regular penetration testing, vulnerability scanning, and attack simulations aligns with the 2024 expansion of third-party assessments and testing. The LLM also correctly notes ongoing external collaboration with industry groups for threat intelligence sharing. One minor omission is that the original answer specifies the inclusion of 'regular training and compliance activities for team members' as part of 2024 enhancements, which the LLM does not mention. However, this does not undermine the overall correctness, as the key multi-hop elements—evolution of internal operations (Cyber Fusion Center to structured response) and enhanced external collaboration (third-party testing, industry sharing)—are accurately synthesized. No numerical inaccuracies are present; all dates and descriptions are factually consistent. The reasoning is sound, and the answer is fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 357,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did Eli Lilly's financial relationship with Baqsimi evolve between 2023 and 2024, particularly in terms of revenue recognition and contractual arrangements?",
      "original_answer": "In 2023, Eli Lilly reported $579.0 million in revenue specifically attributed to the sale of the rights for Baqsimi. By 2024, Baqsimi was included within broader collaboration and other revenue disclosures, reflecting its integration into revenue from collaborations and other arrangements, which included the 2023 sales of rights for both the olanzapine portfolio and Baqsimi. This shift indicates a move from direct product revenue to a more complex revenue recognition model under collaborative arrangements, suggesting a strategic evolution in how the company accounts for and manages its financial relationship with Baqsimi.",
      "llm_answer": "\nBetween 2023 and 2024 the Baqsimi relationship moved from a one‑time licensing transaction to ordinary product sales. In 2023 the sale of Baqsimi rights generated a $677.6 million revenue line (including $139 million in 2022) that was recorded as collaboration and other revenue, with any upfront payment recognized when the rights were transferred. By 2024 the rights sale is complete and Baqsimi sales are reported solely as net product revenue, recognized at shipment and subject to the same returns‑reserve and rebate accounting used for all other products.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The reported 2023 revenue from Baqsimi rights is stated as $677.6 million, which contradicts the ground truth of $579.0 million. Additionally, the mention of $139 million in 2022 is not supported by the original answer and introduces unverified data. (2) The quantitative inaccuracies are critical: the dollar amounts are incorrect, and there is no mention of the correct $579.0 million figure. The LLM also fabricates a timeline involving 2022, which was not part of the question or ground truth. (3) The reasoning is fundamentally flawed. The LLM claims that in 2024, Baqsimi sales shifted to net product revenue, whereas the ground truth states the opposite: Baqsimi moved *into* collaboration and other revenue disclosures in 2024, not out of them. This reverses the actual evolution of revenue recognition. The model incorrectly frames the shift as moving from licensing to product sales, when the truth indicates integration into broader collaborative revenue arrangements, reflecting a more complex accounting model. (4) Contextual relevance is moderate because the answer addresses revenue recognition and contractual changes over time, but the incorrect direction of the shift and fabricated numbers severely undermine accuracy. The qualitative reasoning fails on multi-hop synthesis, misrepresenting the nature of the financial relationship evolution. As a result, the correctness score is low due to major factual and directional errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 419,
        "total_tokens": 1720
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did AT&T's approach to managing its capital structure through preferred interests evolve from 2023 to 2024, particularly regarding the repurchase of Mobility Preferred Interests and the expansion of Tower Holdings and Telco LLC preferred interests?",
      "original_answer": "In 2023, AT&T repurchased the remaining 213 million Mobility Preferred Interests for $5,414, removing $2,650 from 'Accounts payable and accrued liabilities' and $2,670 from 'Other noncurrent liabilities.' This repurchase was primarily funded by the issuance of $5,250 in new Telco LLC preferred interests, which carried a 6.85% annual distribution rate. By 2024, AT&T had shifted focus toward expanding its Tower Holdings preferred interests, where $6,000 in 2019 Tower preferred interests were restructured into fixed and floating rate classes with a 5.90% base rate and SOFR + 250 bps, respectively. Additionally, the total Telco LLC preferred interests increased to $7,250, including the original $2,000 (Telco Class A-1) and the 2023 additions. This reflects a strategic pivot from repurchasing legacy preferred interests to leveraging new preferred structures with more flexible redemption and distribution terms to manage capital and liquidity.",
      "llm_answer": "\nFrom 2023 through 2024 AT&T completed the full repurchase of the original Mobility II cumulative perpetual preferred interests (all were retired in April 2023), eliminating that legacy series.  In 2024 the company shifted to expanding and restructuring preferred‑equity in its tower and Telco subsidiaries—amending the 2019 Tower preferred interests with new fixed‑rate (5.90 %) and floating‑rate tranches, issuing an additional $2.25 bn of Telco LLC preferred interests (including a new Class A‑4 series slated for 2025), and maintaining the newly created Series B non‑controlling preferred interests in Mobility II—thereby moving capital‑structure management from retiring legacy preferreds to issuing and resetting layered preferred stakes that can be called and have refreshed distribution terms.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the core strategic evolution in AT&T's capital structure management from 2023 to 2024 accurately and provides a coherent narrative of shifting from repurchasing legacy preferred interests to expanding and restructuring new preferred equity tranches. However, there are minor quantitative inaccuracies that affect precision. The original answer states that AT&T repurchased 213 million Mobility Preferred Interests for $5,414 million (i.e., $5.414 billion), funded primarily by issuing $5,250 million ($5.25 billion) in new Telco LLC preferred interests. The LLM answer omits these exact figures and instead states that an 'additional $2.25 bn' of Telco LLC preferred interests were issued, which does not align with the $5.25 billion issuance in 2023. While it correctly notes the total Telco LLC preferred interests reached $7.25 billion (implying $5.25B added to the original $2B), this total is not explicitly broken down in the LLM response, and the $2.25B figure appears incorrect or poorly specified. The LLM correctly identifies the 2024 restructuring of the 2019 Tower preferred interests into fixed-rate (5.90%) and floating-rate (SOFR + 250 bps) tranches, though it refers to SOFR without specifying the spread, slightly reducing precision. It also correctly identifies the strategic pivot in capital structure management—retiring legacy Mobility II preferreds and introducing layered, callable preferred stakes with updated terms. The mention of a 'new Class A-4 series slated for 2025' introduces a detail not present in the ground truth, which may be speculative or extraneous. Despite these issues, the qualitative reasoning and multi-hop synthesis—linking 2023 repurchases to 2024 expansions across subsidiaries—are sound and contextually relevant. The answer fully addresses the question's components: repurchase of Mobility interests, expansion of Tower Holdings, and growth in Telco LLC interests. Therefore, while factually strong and well-reasoned, the numerical discrepancies prevent a top score on quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1464,
        "completion_tokens": 552,
        "total_tokens": 2017
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Emerson's relationship with AspenTech evolve from 2023 to 2024, and what financial impacts did this transformation have on Emerson's gross margin and ownership structure?",
      "original_answer": "In 2023, Emerson had a business relationship with AspenTech as part of its Software and Control offerings. By 2024, this relationship transformed into a more significant strategic position, as Emerson acquired a 55% ownership stake in 'New AspenTech' (formerly Heritage AspenTech) following a transaction that included approximately $6.0 billion in cash. This change in relationship had a measurable financial impact: the AspenTech acquisition contributed to a 3.3 percentage point increase in gross margin in 2023 and was part of broader changes that led to a 1.8 percentage point increase in gross margin in 2024. Additionally, the ownership stake marked a structural shift in Emerson’s involvement with AspenTech, moving from a partner to a majority shareholder.",
      "llm_answer": "\nFrom 2023 to 2024 Emerson’s stake in AspenTech shifted from a 57 % minority holding—where AspenTech contributed only modest earnings ($12 million profit in 2023 and a small loss in 2024)—to a announced cash‑and‑stock offer to acquire the remaining ~43 % of the company at $240 per share, which would give Emerson 100 % ownership.  The integration of AspenTech’s software portfolio helped lift Emerson’s overall net sales and contributed to a 1.8‑percentage‑point rise in gross margin to 50.8 % in 2024, although acquisition‑related inventory step‑up amortization of $231 shaved roughly 1.3 percentage points off that margin.  Consequently, the transformation changed Emerson’s ownership structure from a partial equity interest to full consolidation of AspenTech, eliminating the minority stake and re‑classifying its results as wholly owned.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. According to the ground truth, Emerson acquired a 55% ownership stake in 'New AspenTech' in 2024 via a $6.0 billion cash transaction, not a cash-and-stock offer for 100% ownership. The LLM incorrectly states Emerson had a 57% minority stake in 2023, whereas the original answer indicates only a business relationship (not ownership) in 2023. The claim that AspenTech had a $12 million profit in 2023 and a small loss in 2024 is unsupported by the ground truth and contradicts the reported positive margin contributions. The LLM also misattributes the 1.8 percentage point gross margin increase in 2024 solely to AspenTech integration, while the ground truth states AspenTech contributed 3.3 points in 2023 and was part of broader changes leading to a 1.8-point increase in 2024. The $231 million inventory step-up amortization and its 1.3 percentage point margin impact are not mentioned in the original and appear fabricated. (2) Key numbers are incorrect: ownership stake in 2023 (57% vs. no ownership), 2024 ownership (100% vs. 55%), transaction value ($6.0B cash vs. unspecified total value of cash-and-stock offer), margin contributions (misattributed timing and magnitude), and unsupported financials like $12M profit. (3) The multi-hop reasoning is flawed: the model fails to correctly trace the evolution from non-owner to 55% owner and incorrectly infers a full acquisition. It also misaligns financial impacts across years and invents granular data not present in the source. (4) Scores reflect major factual and quantitative errors, despite addressing the general theme of ownership evolution and margin impact. The answer is contextually relevant but deeply inaccurate in specifics, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 488,
        "total_tokens": 1898
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has AIG's Japan pension plans' contribution to non-U.S. pension obligations evolved between 2022 and 2024, and what change occurred in the weighted average discount rate applied to these plans during this period?",
      "original_answer": "In 2022, AIG's Japan pension plans accounted for 61% of total non-U.S. pension assets, with an expected long-term rate of return of 1.85%. By 2024, the Japan pension plans' share of non-U.S. projected benefit obligations decreased to 50% as of December 31, 2024, from 54% in 2023, and the weighted average discount rate increased to 1.81% in 2024 from 1.48% in 2023. This indicates a relative decline in the size of the Japan pension plans within AIG's non-U.S. pension structure, accompanied by a notable increase in the discount rate applied, likely reflecting changes in market conditions or investment strategy.",
      "llm_answer": "\nJapan’s defined‑benefit plans accounted for roughly half of the non‑U.S. pension obligations—about 51 % in 2022 and essentially unchanged at around 50 % in 2024—so their contribution remained stable. Over the same period the weighted‑average discount rate applied to these plans rose from approximately 1.48 % to 1.81 %, an increase of roughly 0.33 percentage points.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in key quantitative details. According to the ground truth, Japan's share of non-U.S. pension *obligations* was 54% in 2023 and decreased to 50% in 2024, not 51% in 2022 and 'unchanged' at 50% in 2024. The original answer does not state Japan's obligation percentage for 2022 directly—only that it accounted for 61% of non-U.S. *pension assets* in 2022, which is a different metric (assets vs. obligations). The LLM incorrectly conflates assets with obligations and misrepresents the 2022 figure. Additionally, the LLM claims the share was 'essentially unchanged,' but the ground truth shows a decline from 54% to 50% between 2023 and 2024, indicating a meaningful drop, not stability. (2) The discount rate values are correct: 1.48% in 2023 and 1.81% in 2024, with an increase of 0.33 percentage points—this calculation is accurate. However, the LLM omits the 2022 discount rate, which was not provided in the ground truth, so this omission is acceptable. (3) The multi-hop reasoning is partially sound: the model correctly identifies the trend in discount rates and attempts to assess the relative size of Japan's plans, but it fails to accurately track the evolution from 2022 to 2024 due to incorrect initial data. It also misses the nuance that the 61% figure in 2022 refers to *assets*, not *obligations*, leading to a flawed synthesis. (4) Despite these errors, the answer is contextually relevant and captures the directional trend in discount rates correctly. The conclusion about stability in Japan's contribution is incorrect based on the decline from 54% to 50%, but the rate increase is properly noted. Hence, partial credit is given for correct rate data and general structure, but significant deductions apply for factual inaccuracies in percentages and mischaracterization of trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 503,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Amazon's disclosure about the impact of competitive stores on its business evolve between the 2022 and 2023 10-K filings, particularly in terms of the framing of external market conditions?",
      "original_answer": "In the 2022 10-K filing, Amazon described competitive stores as a general factor among many that could impact sales and operating results, listing them alongside internal capabilities such as inventory management and customer satisfaction. The 2022 filing included the phrase: 'the introduction of competitive stores, websites, products, services, price decreases, or improvements' as a potential cause of sales fluctuations. In contrast, the 2023 filing retained the same core language but embedded it within a broader context that emphasized external economic and geopolitical conditions, stating that revenue and operating profit growth 'depends on the continued growth of demand for the products and services offered by us or our sellers, and our business is affected by, among other things, general economic, business, and geopolitical conditions worldwide.' This indicates a shift toward framing competitive pressures as part of a larger set of external risks rather than a standalone concern.",
      "llm_answer": "\nIn the 2022 10‑K the reference to “the introduction of competitive stores, websites, products, services, price decreases, or improvements” appears only as one item in a long list of risk‑drivers, without a separate discussion of the external market forces that generate that competition. By contrast, the 2023 filing embeds the same language inside a broader statement that “as international physical, e‑commerce and omnichannel retail … grow, competition will intensify, including through adoption of evolving business models,” explicitly framing competitive store launches as part of an external, market‑driven intensification of rivalry and noting the inherent advantage of local players. This shift reflects a move from a generic risk bullet to a more explicit framing of competitive‑store impacts as shaped by external market conditions.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct in its assessment of the evolution between Amazon's 2022 and 2023 10-K filings regarding competitive stores and external market conditions. It accurately identifies that in 2022, 'competitive stores' were listed as one item among many in a general risk factor without deeper contextual framing. The 2023 filing is correctly described as embedding similar language within a broader discussion of external market forces, including intensifying competition due to market growth and the rise of local players. The core factual claim—that Amazon shifted from treating competitive stores as a generic risk to framing it within broader external market dynamics—is supported by the ground truth and correctly interpreted by the LLM. However, there is a minor discrepancy: the LLM attributes to the 2023 filing a quote about 'international physical, e-commerce and omnichannel retail ... grow, competition will intensify' that does not appear verbatim in the provided ground truth. While the sentiment aligns (broader external framing), the specific phrasing and attribution of 'inherent advantage of local players' go beyond the original answer and may reflect inference or external knowledge. This introduces a small factual overreach, though not a major error. All entities (Amazon, 2022 vs 2023 10-Ks), years, and qualitative reasoning are accurate. There are no numerical inaccuracies (quantitative accuracy is 10). The answer fully addresses the question about framing evolution and maintains high contextual relevance. The reasoning is sound but slightly overreaches in quoting unverified text, warranting a qualitative accuracy of 8 and overall correctness of 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1473,
        "completion_tokens": 460,
        "total_tokens": 1933
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has Target's exposure to port security risks evolved between 2023 and 2024, particularly in terms of geographic focus and operational impact?",
      "original_answer": "In 2023, Target specifically highlighted California ports as a key area affected by port security issues, mentioning that these ports were where the company received a significant portion of its imported merchandise. By 2024, Target broadened its focus, referring to 'major U.S. ports' without specifically naming California, indicating a more generalized concern across multiple locations. Additionally, in 2023, the company noted it had made alternative arrangements due to past disruptions, while in 2024, the emphasis shifted to potential future impacts, including increased costs and inventory supply issues, due to ongoing global conflicts and labor disputes.",
      "llm_answer": "\nTarget’s 2023 filing framed port‑security risk chiefly around occasional closures and congestion at U.S. West Coast ports—especially California—where disruptions could cause stock‑outs and force alternative shipping routes. The 2024 filing broadens that risk to a wider set of global ports, tying them to political‑economic instability, trade‑policy shifts and rising transport‑cost inflation, and stresses that any such port disruption would raise inventory costs and compel the company to seek alternate sources, thereby heightening the operational impact on margins and supply‑chain resilience.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Target's port security risk exposure between 2023 and 2024. It correctly identifies the 2023 focus on U.S. West Coast ports, particularly California, and the operational impact of disruptions such as stock-outs and alternative routing. It also accurately captures the 2024 shift to a broader concern encompassing 'major U.S. ports' and global ports, linking them to geopolitical instability, trade policy, and cost pressures. The emphasis on increased inventory costs and supply-chain resilience in 2024 matches the original answer's point about potential future impacts on costs and supply. However, the LLM slightly overreaches by stating the 2024 filing refers to 'global ports'—the original answer specifies a shift to 'major U.S. ports' without naming California, not an expansion to global ports outside the U.S. This is a minor but notable overgeneralization. Additionally, while the original answer notes Target had already made alternative arrangements in 2023 due to past disruptions, the LLM does not explicitly mention this backward-looking action, instead focusing on forward-looking responses. There are no numerical inaccuracies (quantitative accuracy is perfect as no incorrect numbers are cited), and the reasoning is sound overall, with strong synthesis across years and risk dimensions. The answer is highly relevant to the question. Thus, the correctness score is 8 due to minor factual overstatement and omission of a specific detail about past actions, but core facts and evolution are accurately conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 443,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did Emerson's financial relationship with Heritage AspenTech evolve between 2023 and 2024, particularly in terms of acquisition-related amortization and restructuring costs?",
      "original_answer": "In 2023, Emerson reported $258 million in intangibles amortization related to the Heritage AspenTech acquisition. By 2024, this specific amortization was no longer reported, indicating that the focus had shifted away from AspenTech as a newly acquired entity. Additionally, restructuring costs increased significantly from $72 million in 2023 to $228 million in 2024, suggesting that Emerson undertook more extensive restructuring activities in 2024, potentially reflecting integration efforts or strategic realignments following the AspenTech acquisition.",
      "llm_answer": "\nBetween 2023 and 2024 the amortization of the intangibles acquired in the Heritage AspenTech deal grew from $258 million in 2023 (shown as the “Heritage AspenTech acquisition” line in the 2023 amortization table on page 55) to a much larger share of the $1.077 billion total intangible amortization in 2024—most of the increase being driven by the $560 million of new amortization from the NI acquisition, with the remainder continuing to write‑off the Heritage AspenTech customer and IP intangibles.  At the same time, restructuring costs linked to the integration of Heritage AspenTech rose sharply from $10 million in 2023 to $97 million in 2024 (part of the overall $228 million of restructuring expense reported on page 56), reflecting higher integration‑related expenses as Emerson continued to realign the combined business.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Emerson reported $258 million in intangibles amortization related to the Heritage AspenTech acquisition in 2023, and this specific amortization was no longer reported in 2024. However, the LLM claims that the AspenTech-related amortization grew and continued into 2024 as part of the $1.077 billion total, which contradicts the ground truth. Additionally, the LLM states that restructuring costs linked to AspenTech rose from $10 million in 2023 to $97 million in 2024, but the ground truth reports total restructuring costs (not specifically tied to AspenTech) increased from $72 million in 2023 to $228 million in 2024. The LLM invents a $10 million figure for 2023 and assigns $97 million of the 2024 total to AspenTech integration without evidence. (2) Quantitative errors include: incorrect 2023 restructuring cost ($10M vs. $72M), incorrect attribution of $97M of 2024 restructuring to AspenTech without source, and misrepresentation of AspenTech amortization continuing into 2024 when it was explicitly no longer reported. The mention of a 'NI acquisition' introducing $560 million in amortization is not in the ground truth and introduces an unverified external event. (3) The multi-hop reasoning is flawed: the model incorrectly infers ongoing AspenTech amortization and ties specific portions of restructuring costs to AspenTech without support. It fails to recognize that the cessation of AspenTech-specific amortization in 2024 is a key signal of transition from new acquisition status. (4) Despite these issues, the answer is contextually relevant—it addresses the right companies, time frame, and types of costs (amortization and restructuring)—but the core financial facts and synthesis are incorrect, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 502,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has AIG's use of Expected Loss Ratio methods evolved between 2022 and 2024, particularly in terms of the weight given to this method across different lines of business and accident years?",
      "original_answer": "In 2022, AIG applied Expected Loss Ratio methods primarily for more recent accident years in lines such as D&O, E&O, EPLI, and professional liability, where losses are low frequency and high severity. The method was also used in conjunction with IBNR factor methods for low frequency/high severity losses, with factors continually reevaluated based on emerging claim experience and market factors. By 2024, AIG continued to use Expected Loss Ratio methods but expanded their application to include U.S. Workers' Compensation, a long-tail line of business, where they were used in combination with loss development and frequency/severity methods. This reflects a broader application of the method across different risk profiles and a more integrated approach to reserving in complex portfolios.",
      "llm_answer": "\nBetween 2022 and 2024 AIG kept the Expected‑Loss‑Ratio (ELR) approach in its reserve toolkit but refined how it is weighted.  The 2022 filing (pages 268‑272) said the ELR method “may be given significant weight in the most recent five accident years,” while the 2024 filing (pages 149‑153) explicitly states that ELR is “given weight for the more recent accident years” and singles out excess‑of‑deductible, U.S. Financial Lines, cyber/M&A and other low‑frequency/high‑severity coverages as the lines where the method receives the strongest emphasis because development patterns are less reliable.  Consequently, AIG has shifted from a broad “weight the ELR in the last five years” rule to a more targeted practice that places greater reliance on ELR for recent years and for those lines where loss‑development data are sparse or volatile.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct and captures key aspects of AIG's evolving use of the Expected Loss Ratio (ELR) method between 2022 and 2024, but misses a critical factual development noted in the ground truth: the expansion of ELR to U.S. Workers' Compensation, a long-tail line, by 2024. The LLM correctly identifies that ELR was used in 2022 for recent accident years and in low-frequency/high-severity lines like D&O, E&O, and professional liability, and notes the shift toward more targeted use in recent years and volatile lines. It also accurately reflects the change in language from 'most recent five accident years' in 2022 to a more nuanced weighting in 2024. However, it fails to mention the significant expansion into U.S. Workers' Compensation, which is a core part of the evolution described in the original answer. This omission limits completeness and affects qualitative accuracy. The LLM introduces new lines (cyber/M&A, excess-of-deductible) not mentioned in the ground truth, which may be contextually plausible but are not supported by the provided truth. Quantitative accuracy is high—no numerical errors, and the references to filing pages and timeframes are consistent. Contextual relevance is strong, as the response directly addresses the evolution of weighting and application across lines and years. The reasoning is logical but incomplete due to the missing Workers' Compensation detail, weakening the multi-hop synthesis. Overall, the answer conveys a plausible narrative but lacks a key factual pivot in AIG’s methodology expansion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 428,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has the monetization strategy for Amazon's film groups evolved between 2022 and 2023, based on changes in capitalized video and music content costs and associated expenses?",
      "original_answer": "Amazon's monetization strategy for film groups evolved between 2022 and 2023, as evidenced by an increase in both the capitalized video and music content costs and the associated expenses. In 2022, the capitalized costs were $16.7 billion with total video and music expenses of $16.6 billion, while in 2023, these figures increased to $17.4 billion and $18.9 billion, respectively. This indicates a more aggressive investment in content and a corresponding rise in monetization efforts.",
      "llm_answer": "\nBetween 2022 and 2023 Amazon’s capitalized outlay for video and music content grew modestly—from **$16.7 billion to $17.4 billion**—while the amount of expense recognized from that content jumped more sharply, from **$16.6 billion to $18.9 billion**.  This rise in both capitalized costs and expense reflects a heavier investment in acquiring and producing original titles and larger licensing spend, even as the film‑group model (monetized primarily through Prime memberships across major geographies) remains unchanged, with impairment testing still applied to each film‑group’s carrying value.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports all key numerical values: capitalized video and music content costs increased from $16.7 billion in 2022 to $17.4 billion in 2023, and associated expenses rose from $16.6 billion to $18.9 billion. These figures match the ground truth exactly, with acceptable formatting (e.g., $16.7 billion vs $16.7B). 2) Quantitative accuracy is perfect—no calculation errors, and the comparisons (modest increase in capitalized costs, sharper rise in expenses) are mathematically sound. The difference in expense growth ($2.3 billion) versus capitalized cost growth ($0.7 billion) is correctly implied. 3) The reasoning is strong: the LLM correctly infers heavier investment in original content and licensing, aligning with the ground truth's 'more aggressive investment' interpretation. It adds context not in the original—monetization via Prime memberships and impairment testing—without contradicting the core conclusion. This extra detail is accurate and enhances the answer, though not strictly required. 4) The answer fully addresses the question about evolution in monetization strategy based on cost and expense trends. While the ground truth emphasizes increased monetization efforts, the LLM focuses on investment intensity but correctly implies strategic continuity (unchanged monetization model). This is a minor difference in emphasis, not in substance. Overall, the answer is factually correct, well-reasoned, and contextually appropriate—just shy of perfect due to slightly different framing of the strategic implication, but not inaccurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 431,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has Philip Morris International's financial relationship with RBH evolved between 2022 and 2024, particularly in terms of its stake and associated impairment?",
      "original_answer": "In 2022, Philip Morris maintained a trademark relationship with RBH, continuing to report volume of brands sold by RBH such as HEETS and other heated tobacco units. By 2024, PMI held an equity investment in RBH, which became subject to a significant impairment charge of $2,316 million due to unresolved allocation of a $32.5 billion Canadian tobacco litigation settlement among RBH, ITL, and JTIM. This reflects a shift from a trademark and brand licensing relationship to a more direct equity investment facing financial impairment.",
      "llm_answer": "\nBetween 2022 and 2024 Philip Morris International did not acquire or divest any additional shares in Rothmans, Benson & Hedges – it continued to hold the same equity stake that had been left on its books after the 2019 de‑consolidation.  However, the proposed CAD 32.5 bn settlement of Canadian tobacco litigation (which remained unresolved in 2024) created significant uncertainty about the allocation of the liability among RBH, Imperial Tobacco Canada and JTI, prompting PMI to test the investment for impairment.  As a result, PMI recorded a $2.3 bn non‑cash impairment charge in 2024, writing down the carrying value of its RBH equity investment to below its fair value.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth, but has minor discrepancies in completeness and precision. (1) Quantitatively, the $2.3 billion impairment charge is correctly reported (matches $2,316 million in original answer, acceptable rounding). The CAD 32.5 billion litigation settlement amount is accurate. The 2024 timing of the impairment is correct. (2) The answer correctly identifies that PMI did not change its equity stake post-2019 deconsolidation, which adds context not in the original answer but is factually accurate and improves completeness. (3) However, the original answer notes a shift from a trademark/brand licensing relationship in 2022 to an equity investment subject to impairment in 2024, emphasizing an evolution in the financial relationship. The LLM answer downplays this evolution by focusing only on the unchanged equity stake, missing the qualitative shift in reporting and relationship emphasis (e.g., volume reporting of HEETS in 2022). (4) The reasoning is sound: it correctly links the unresolved litigation allocation among RBH, Imperial Tobacco Canada (ITL), and JTI to the impairment test and resulting charge. (5) Entities and years are accurate. (6) Semantic equivalence is mostly preserved, but the LLM omits the 2022 brand volume reporting aspect, which is a key part of the 'evolution' asked in the question. This partial omission reduces completeness on the multi-hop aspect of relationship evolution. Hence, high scores for quantitative accuracy and contextual relevance, slightly lower for qualitative and overall correctness due to incomplete synthesis of the relationship shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 450,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did the sensitivity of LLY's net product revenue to changes in sales return, rebate, and discount liabilities evolve between 2023 and 2024, based on the disclosures in the respective 10-K filings?",
      "original_answer": "In 2023, LLY disclosed that a 5% change in its consolidated sales return, rebate, and discount liability would result in a $615 million change in revenue. In 2024, while the company continued to describe the accounting policy for revenue recognition and accruals for rebates and discounts, it did not provide an updated sensitivity figure. This omission suggests that the company did not disclose a revised estimate for the impact of liability changes on revenue in 2024, indicating a lack of updated quantitative disclosure compared to 2023.",
      "llm_answer": "\nThe disclosures show that the estimated revenue impact of a 5 % change in the combined sales‑return, rebate and discount liabilities fell slightly from about **$615 million in 2023** to **$600 million in 2024**.  This modest decline indicates that the sensitivity of LLY’s net product revenue to those accrual balances weakened a bit between the two years.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that the sensitivity decreased from $615 million in 2023 to $600 million in 2024. The ground truth explicitly states that LLY did not provide an updated sensitivity figure in 2024, meaning no such $600 million number was disclosed. This is a major factual error. (2) Quantitative accuracy is very low because the $600 million figure is fabricated; there is no support for this number in the 2024 filing according to the ground truth. The 2023 figure ($615 million) is correctly cited, but the 2024 figure is not. (3) The multi-hop reasoning is flawed: instead of recognizing the absence of 2024 quantitative disclosure as a key point, the model incorrectly assumes and reports a specific number, leading to a false conclusion about declining sensitivity. The correct qualitative interpretation should focus on the lack of updated disclosure, not a numerical change. (4) Contextual relevance is moderate because the answer addresses the right topic (sensitivity of revenue to liabilities) and the correct company (LLY) and time frame (2023–2024), but it fails on correctness due to the invented data point. The conclusion about 'weakened' sensitivity is unsupported and misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 349,
        "total_tokens": 1588
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has the role and revenue contribution of Bulk shipments evolved from 2022 to 2024, based on Union Pacific's disclosures?",
      "original_answer": "In 2022, Bulk shipments had an average revenue per car of $3,305 in 2021 (referenced in the 2022 filing), showing a 6% increase from 2020. By 2024, Bulk shipments had grown in strategic importance, contributing 32% of total freight revenues, with detailed operations covering grain, fertilizer, and coal markets, including international connections to Mexico and access to Canadian interline routes. This indicates a transformation in the Bulk segment's role from a revenue-per-unit perspective to a more strategically embedded and revenue-significant component of Union Pacific's operations.",
      "llm_answer": "\nUnion Pacific’s 2024 filing (page 6) reports that Bulk shipments generated **32 % of total freight revenue**, essentially the same share the company earned in 2022 (roughly 30 % of freight revenue, as reflected in the 2022 outlook and the 2021 historical tables on pages 33‑35).  Thus, Bulk’s contribution has remained stable—hovering around one‑third of freight revenue—with only a modest increase to 32 % by 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 32% contribution of Bulk shipments to total freight revenue in 2024, which matches the ground truth. However, it inaccurately states that Bulk contributed roughly 30% in 2022, citing the 2022 filing's reference to 2021 data, but the ground truth does not provide a 2022 percentage—only a 2021 average revenue per car and its 6% increase from 2020. The LLM incorrectly infers stability in revenue share, while the ground truth emphasizes a strategic evolution and increased significance, not just stable percentages. (2) The quantitative accuracy is partially correct: the 32% figure for 2024 is accurate, but the 30% figure for 2022 is not directly supported in the ground truth, which does not state the 2022 revenue share. The average revenue per car of $3,305 in 2021 is omitted entirely, and no mention is made of the 6% increase from 2020, missing key quantitative context. (3) The multi-hop reasoning is flawed: the LLM fails to synthesize the evolution from revenue-per-unit metrics in earlier years to strategic integration by 2024. Instead, it concludes stability, contradicting the ground truth’s emphasis on transformation and growing strategic importance. The answer downplays the evolution by focusing only on revenue share stability, missing the broader operational expansion into grain, fertilizer, coal, and international connections. (4) Contextual relevance is high—the answer addresses the question about revenue contribution and time frame—but the qualitative interpretation is misleading. While the 32% figure is correct, the conclusion of 'stable' contribution contradicts the ground truth’s narrative of growing strategic role. Thus, the correctness score is moderate due to partial factual accuracy but significant omission and misinterpretation of the evolution in role.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 501,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the interest rate of IBM's Notes due 2028 evolve between 2023 and 2024, and what does this indicate about IBM's debt strategy?",
      "original_answer": "In 2023, IBM had 1.750% Notes due 2028 (IBM 28A) listed, and in 2024, the same 1.750% Notes due 2028 (IBM 28A) were still present in the disclosures. This indicates that the interest rate for this specific issuance remained unchanged over the two years. However, IBM introduced new notes with different interest rates in 2024, such as the 2.900% Notes due 2030 and the 3.150% Notes due 2033, suggesting a broader strategy to issue debt at higher rates for longer maturities.",
      "llm_answer": "\nThe coupon on IBM’s 2028 notes was 0.300 % in both the 2023 and 2024 Form 10‑K filings (the parallel 1.750 % series was likewise unchanged). Because the rate did not shift, IBM is deliberately locking in low‑cost, long‑dated financing and extending the maturity of its debt, reflecting a strategy of maintaining a conservative, low‑interest debt profile and preserving financial flexibility.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that the coupon rate on IBM's 2028 notes was 0.300% in both 2023 and 2024. The ground truth clearly states that the interest rate was 1.750% for the Notes due 2028 (IBM 28A) in both years. The mention of a '0.300%' rate is entirely inaccurate and unsupported by the original answer. Additionally, the reference to a 'parallel 1.750% series' is misleading and not mentioned in the ground truth — there is only one series referenced: the 1.750% Notes due 2028. (2) Quantitative accuracy is severely compromised: the correct rate is 1.750%, not 0.300%, and no such lower rate is indicated in the original data. The answer fabricates a key financial figure. (3) The reasoning is partially sound in interpreting a stable rate as indicative of a strategy to lock in low-cost financing, which aligns with the general logic in the original answer. However, the LLM fails to mention IBM’s introduction of new higher-rate, longer-term debt (e.g., 2.900% Notes due 2030 and 3.150% due 2033), which is a critical part of the multi-hop reasoning and strategic analysis in the ground truth. Thus, the synthesis is incomplete and based on incorrect data. (4) While the answer attempts to address both parts of the question (rate evolution and strategy), it does so with incorrect core data, leading to a low correctness score. Contextual relevance is moderate because the structure and intent align with the question, but factual accuracy is critically flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1213,
        "completion_tokens": 416,
        "total_tokens": 1629
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did AT&T's capital structure strategy regarding preferred interests evolve from 2023 to 2024, particularly in relation to the Mobility Preferred Interests and the introduction of new preferred instruments?",
      "original_answer": "In 2023, AT&T repurchased all of its Mobility Preferred Interests, which had a redemption value of approximately $5,340 million and paid annual cash distributions of $373 million. This marked a significant shift in strategy, as the company eliminated this class of preferred interests. In 2024, AT&T introduced structural modifications to other preferred instruments, including the restructuring of its Tower Holdings preferred interests to include both fixed and floating rate components, and the expansion of Telco LLC preferred interests to a total of $7,250 million. This evolution indicates a strategic pivot from Mobility-based preferred capital to more diversified and strategically tailored preferred instruments tied to infrastructure and telecommunications assets.",
      "llm_answer": "\nBy the end of 2023 AT&T had fully retired the original Mobility II cumulative perpetual preferred interests—completing their repurchase in April 2023 so that no Mobility preferred equity remained on the balance sheet. In 2024 the company replaced that legacy class with a new suite of preferred instruments: a $2 bn‑plus redeemable non‑controlling interest in Mobility II (Series B) that pays a 6.8 % distribution, a restructuring of the Tower‑Holdings preferred equity into fixed‑rate and floating‑rate tranches with reset schedules, and a planned $2.25 bn Class A‑4 preferred issuance in Telco LLC to fund future redemptions—thereby shifting from winding‑down the old Mobility preferred equity to deploying more flexible, reset‑able preferred structures while still preserving dividend and share‑repurchase flexibility.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer captures the core evolution in AT&T's capital structure strategy: retiring the Mobility Preferred Interests in 2023 and introducing new preferred instruments in 2024. However, there are key quantitative inaccuracies. The original answer states the redemption value of the Mobility Preferred Interests was approximately $5,340 million and annual distributions were $373 million. The LLM answer omits these specific figures and instead introduces a new $2 billion-plus Series B instrument in Mobility II (6.8% distribution), which is not mentioned in the ground truth. Additionally, the LLM claims a 'planned $2.25 billion Class A-4 preferred issuance in Telco LLC,' but the ground truth states the total expansion of Telco LLC preferred interests reached $7,250 million—suggesting the $2.25B figure may be a subset or misstatement. 2) The date of repurchase (April 2023) is a plausible detail not contradicted by the original, but the original does not specify the month. The 6.8% distribution rate and $2B+ figure for Series B are unsupported by the ground truth, which does not mention any new Mobility-related preferred issuance. The restructuring of Tower Holdings into fixed/floating rate tranches aligns with the original. 3) The reasoning is logically sound: the model correctly infers a strategic pivot from Mobility-based to infrastructure/telecom-focused preferred instruments. It synthesizes the repurchase and new issuances into a coherent narrative of strategic evolution. 4) Despite incorrect or unverified numbers, the answer is contextually relevant and addresses all parts of the question—2023 retirement, 2024 new instruments, and strategic shift. The qualitative understanding is strong, but quantitative inaccuracies reduce overall correctness. Minor formatting variations are acceptable, but introducing unsupported figures (e.g., $2B+, 6.8%, $2.25B) constitutes factual deviation. Hence, correctness is reduced to 7 due to partial factual inaccuracy in numbers, though the strategic direction is correctly interpreted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 550,
        "total_tokens": 1965
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has Amazon's characterization of the competitive threat from websites evolved between 2022 and 2023, and what specific changes in language indicate a shift in the nature of this competition?",
      "original_answer": "In 2022, Amazon described competitive websites as part of a broader list of fluctuating business factors, indicating a general awareness of competitive pressures. By 2023, Amazon's language evolved to reflect a more direct and strategic competitive stance, specifically highlighting the introduction of 'competitive stores, websites, products, services, price decreases, or improvements' as a central concern. This shift indicates a more focused and intensified competitive threat from digital platforms, suggesting an evolution from a general operational risk to a more strategic and dynamic competitive challenge.",
      "llm_answer": "\nIn the 2022 10‑K Amazon warned that “as international physical, e‑commerce and cloud services grow, competition will intensify” and highlighted the advantage of local players, but it did not single out rival online stores. In the 2023 10‑K the wording shifts to explicitly mention “the introduction of **competitive stores, websites, products, services, price decreases, or improvements**,” directly acknowledging that rival e‑commerce sites and price‑driven offerings are a concrete competitive threat, signalling a move from a broad growth‑related risk to a focused recognition of competitive pressure from other websites.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the shift in Amazon's language between 2022 and 2023: in 2022, competition is framed as a general risk tied to market growth, without specific mention of rival websites; in 2023, Amazon explicitly references 'competitive stores, websites, products, services, price decreases, or improvements,' which the LLM accurately quotes and interprets. (2) There are no numerical values to verify, so quantitative accuracy is not applicable—scored as 10 by default since no numbers are misstated. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of 10-K filings and correctly infers a strategic shift in how Amazon characterizes competition, moving from a broad, growth-related risk to a focused threat from digital competitors. (4) The LLM captures the core semantic meaning of the original answer, including the intensification and concretization of competitive threats. The only minor shortcoming is that it does not explicitly state that the 2022 characterization placed websites among 'fluctuating business factors,' which slightly reduces qualitative completeness, but the overall reasoning and conclusion remain robust. Contextual relevance is perfect—the response directly addresses both parts of the question: the evolution in characterization and the specific language indicating the shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 394,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has PM's relationship with KT&G evolved from 2022 to 2024, particularly in terms of its strategic reliance on KT&G's heat-not-burn products within PMI's smoke-free product portfolio?",
      "original_answer": "In 2022, PM had a global collaboration agreement with KT&G that allowed PMI to exclusively distribute KT&G's smoke-free products, including heat-not-burn products like LIL Mini and LIL Plus, outside of South Korea. This agreement was initially for three years, indicating a strategic partnership aimed at expanding KT&G's products globally. By 2024, this relationship had evolved such that KT&G's heat-not-burn products were no longer just distributed by PMI but were integrated into PMI's broader smoke-free product portfolio, specifically being listed among PMI's own heat-not-burn offerings. This indicates a deeper strategic reliance on KT&G's product line within PMI's own commercialization efforts, suggesting a shift from a distribution partnership to a more embedded supplier or technology partner role for KT&G.",
      "llm_answer": "\nFrom 2022 through 2024 PMI moved the 2020 three‑year “global collaboration” with KT&G into a fully‑scale, exclusive distribution model that now covers multiple regions outside South Korea, embedding KT&G’s licensed heated‑tobacco brands (e.g., Fiit, Miix, LIL products) as core components of PMI’s smoke‑free portfolio.  This partnership has become a primary growth engine for PMI’s heated‑tobacco unit shipments—double‑digit volume gains year‑over‑year—and underpins PMI’s strategic reliance on KT&G’s heat‑not‑burn products to replace cigarettes.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies. First, it incorrectly states the collaboration began in 2020, while the ground truth specifies a three-year agreement starting in 2022. This is a critical factual error affecting timeline accuracy. Second, the LLM claims 'double-digit volume gains year-over-year' as a result of the partnership, but no such quantitative performance metric appears in the original answer, making this an unsupported addition. Third, the LLM lists product names like 'Fiit' and 'Miix', which are not mentioned in the ground truth (which specifies LIL Mini and LIL Plus), raising entity accuracy concerns. (2) Quantitative accuracy is compromised due to the incorrect start date (2020 vs 2022) and the introduction of unverified growth metrics (double-digit gains) not present in the original. No actual numbers (e.g., shipment volumes, financials) were in the ground truth, so the LLM's inclusion of performance figures appears speculative. (3) The multi-hop reasoning is partially sound: the LLM correctly infers increased strategic reliance and broader integration of KT&G’s products into PMI’s portfolio. It captures the evolution from distribution to deeper integration, aligning with the shift toward viewing KT&G as a core supplier. However, it overreaches by framing the partnership as a 'primary growth engine' with quantified impact not supported by the source. (4) Despite these issues, the answer remains contextually relevant and captures the qualitative trajectory of the relationship—increased reliance and portfolio integration. The core idea of strategic deepening is correct, but factual precision on dates, products, and performance metrics reduces overall correctness. Hence, a score of 6 reflects partial accuracy with significant factual flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 490,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did IBM's use of the PWCC Plan for funding employee awards evolve between 2022 and 2024, particularly in terms of its administration and scope?",
      "original_answer": "In 2022, the PWCC Plan was described as being used solely to fund awards for employees of PwCC who joined IBM after the acquisition, and it was stated that the plan would continue to be used for this purpose. By 2024, while the plan's administration and terms remained substantively identical to the 2001 Plan, IBM emphasized that the PWCC Plan 'has been and will continue to be used solely' for funding awards for former PwCC employees, indicating a reaffirmation rather than a change in scope. However, the shift in language from 'has been and will continue to be' in 2022 to a more definitive tone in 2024 suggests a stronger commitment to maintaining the plan’s current usage without expansion.",
      "llm_answer": "\nIBM kept the PWCC Plan administered by the Executive Compensation and Management Resources Committee and, in both the 2022 and 2024 filings, continued to use it solely to fund awards for employees who joined IBM after the 2002 PwCC acquisition—senior executives are expressly excluded. The 2024 filing restates the plan’s original terms without any expansion or administrative change, indicating that its scope and governance remained unchanged between 2022 and 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of key facts: the PWCC Plan continued to be used solely for funding awards for former PwCC employees post-acquisition, its administration remained unchanged, and there was no expansion in scope between 2022 and 2024. The date of the PwCC acquisition is correctly cited as 2002 (consistent with historical facts), though this detail was not explicitly in the original answer; however, it does not contradict it. The exclusion of senior executives is mentioned in the LLM answer but not in the original—this is a minor addition but not inaccurate. The core evolution—or lack thereof—is accurately conveyed: no administrative or scope changes occurred. However, the LLM answer omits the nuanced shift in language from 2022 to 2024 ('has been and will continue to be' to a more definitive tone), which the original answer highlights as indicating a stronger commitment. This subtlety in rhetorical emphasis, while not altering the factual state, is part of the evolution in how IBM presented the plan’s usage and was thus a missed qualitative point. Quantitatively, all dates and references are accurate. Contextually, the response is fully relevant and addresses the question’s focus on administration and scope. The reasoning is sound, though the multi-hop synthesis slightly underrepresents the linguistic evolution noted in the original, which reflects IBM's deepening commitment. Hence, high scores across the board but not perfect due to the missing nuance in tone interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 427,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How did AT&T's financial obligations and strategic approach to Mobility Preferred Interests evolve between 2023 and 2024, and what does this shift indicate about its broader capital structure management?",
      "original_answer": "In 2023, AT&T repurchased all remaining Mobility Preferred Interests for a total of $5,414 million, which included accrued and unpaid distributions, effectively eliminating this financial obligation. By 2024, there was no mention of Mobility Preferred Interests in the disclosures, indicating a complete exit from this instrument. This contrasts with AT&T's treatment of other preferred interests, such as the Tower Holdings and Telco LLC preferred interests, which remained outstanding and were even expanded or restructured in 2024. This shift indicates a strategic move to reduce certain long-term liabilities while maintaining or adjusting other capital instruments for flexibility, suggesting a selective approach to managing its capital structure.",
      "llm_answer": "\nBetween 2023 and 2024 AT&T eliminated the original Mobility II Series A cumulative perpetual preferred interests—fully repurchased in April 2023—so that no equity‑like “Mobility Preferred” obligation remained on its balance sheet.  In 2024 the company introduced new redeemable preferred structures (the Mobility II Series B non‑controlling interests and the reset Tower Fixed‑Rate and Floating‑Rate Interests, plus the upcoming Telco LLC Class A‑4 preferred issuance) that carry higher, reset distribution rates, call features and explicit redemption triggers, effectively moving the obligation from long‑dated equity to a liability‑like instrument with greater flexibility.  This shift signals AT&T’s intent to tighten its capital structure, use preferred equity with redemption and rate‑reset mechanics to manage cash‑flow and leverage, and adapt to a higher‑interest‑rate environment while preserving financial flexibility for dividends and share repurchases.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that AT&T repurchased all remaining Mobility Preferred Interests in 2023 for $5,414 million and completely exited the instrument, with no mention in 2024. However, the LLM claims that in 2024, AT&T introduced new redeemable preferred structures like 'Mobility II Series B' and 'upcoming Telco LLC Class A-4 preferred issuance', which contradicts the original answer stating that Mobility Preferred Interests were fully eliminated and not replaced. There is no evidence in the ground truth of new Mobility-related preferred interests being introduced in 2024. (2) Quantitative accuracy is low: while the LLM does not provide specific dollar amounts or dates beyond 'April 2023' (which may align generally), it fabricates financial instruments and restructuring events not present in the ground truth, leading to incorrect implications about capital structure evolution. The $5,414 million repurchase figure is omitted entirely. (3) Multi-hop reasoning is flawed—the LLM incorrectly infers a strategic shift toward new liability-like instruments in 2024, whereas the ground truth emphasizes a selective reduction of Mobility obligations while maintaining others (Tower Holdings, Telco LLC), not expanding them. The conclusion about 'reset distribution rates' and 'explicit redemption triggers' is unsupported by the provided truth. (4) Despite these errors, the answer is contextually relevant, addressing capital structure management and attempting to interpret strategic intent. However, the qualitative accuracy suffers due to incorrect entity identification (new Series B, Class A-4) and misrepresentation of AT&T’s actions. The core claim—that AT&T moved away from Mobility Preferred Interests—is partially correct, but the portrayal of 2024 developments is factually wrong, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1443,
        "completion_tokens": 516,
        "total_tokens": 1959
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has IBM's relationship with stock exchange regulations evolved in terms of regulatory exposure for its debt securities between 2022 and 2024?",
      "original_answer": "In 2022, IBM described stock exchange regulations as one of several factors influencing the value of its debt securities, placing it among other external variables beyond the company's control. By 2024, IBM's language shifted to indicate a more direct regulatory exposure, stating it is 'subject to' stock exchange regulations, which implies a heightened recognition of their binding impact on the company's financing activities. This evolution reflects a stronger acknowledgment of regulatory influence in 2024 compared to the more general mention in 2022.",
      "llm_answer": "\nIBM’s debt‑security exposure is governed by the same baseline regulatory framework in both filings: the 2022 10‑K (pp. 20‑24) and the 2024 10‑K (pp. 9‑13) each note that the company’s publicly‑issued bonds are subject to SEC reporting, NYSE listing requirements and can be affected by rating‑agency actions, market‑liquidity conditions, and foreign‑exchange or interest‑rate changes. The evolution between 2022 and 2024 is modest—while the 2024 filing adds more detail on how emerging cybersecurity, AI and ESG‑related regulations could indirectly influence the company’s reputation and thus the market perception of its debt, the core regulatory exposure remains anchored to the unchanged SEC and exchange‑listing rules that have always applied.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but diverges significantly from the ground truth in terms of the core evolution described. (1) Correct elements: The answer accurately notes that IBM's debt securities are subject to SEC reporting and NYSE listing requirements in both years, which aligns with general regulatory context. It also correctly identifies that external factors like market conditions and rating agencies affect debt value. (2) Quantitative accuracy is high: no specific numbers are cited in either answer, so no discrepancies exist in dollar amounts, dates, or percentages. (3) Multi-hop reasoning is flawed: the ground truth emphasizes a qualitative shift in language—from describing stock exchange regulations as an influencing factor (2022) to stating IBM is 'subject to' them (2024), indicating a stronger recognition of direct regulatory exposure. The LLM answer downplays this shift as 'modest' and instead introduces new elements (cybersecurity, AI, ESG regulations) not mentioned in the original answer, which misrepresents the nature of the evolution. (4) While contextually relevant and well-structured, the LLM fails to capture the key semantic shift emphasized in the ground truth—increased acknowledgment of binding regulatory impact—thus missing the central point of the evolution. This results in a moderate correctness score due to factual plausibility but significant deviation in qualitative interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 396,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did Disney's financial relationship with A&E evolve from 2022 to 2024, particularly in terms of equity income contribution?",
      "original_answer": "In 2022, Disney's equity investment in A&E was a significant component of its equity income, with A&E being one of the most notable equity method investees alongside CTV Specialty Television. By 2024, Disney's equity in the income of investees had decreased by $207 million, specifically due to lower income generated from A+E. This indicates a material decline in the financial contribution from A&E to Disney over the two-year period.",
      "llm_answer": "\nFrom fiscal 2022 through fiscal 2024 Disney’s equity stake in A+E (held 50 % by Disney and 50 % by Hearst) shifted from a relatively strong contributor to a diminishing source of earnings.  The “Equity in the income of investees, net” line fell from $782 million in 2023 to $575 million in 2024—a $207 million drop that Disney explicitly attributed to “lower income from A+E” (page 35).  This decline reflects the impact of impairments, strategic cut‑backs in A+E’s linear‑channel portfolio and the broader move toward direct‑to‑consumer distribution, causing A+E’s equity‑income contribution to shrink markedly over the 2022‑2024 period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the $207 million decrease in equity income from 2023 ($782M) to 2024 ($575M) matches the stated drop, and this is explicitly attributed to lower income from A+E, consistent with the original answer. Although the original answer references 2022 as the starting point, the LLM correctly identifies the trend over 2022–2024 and uses the most specific data available (2023 and 2024 figures), which supports the conclusion of a decline. (2) The entity names are accurate—A+E (correctly noting Disney’s 50% stake with Hearst)—and the financial metric 'Equity in the income of investees, net' is properly used. (3) The reasoning is sound: the LLM correctly synthesizes the financial trend and provides plausible qualitative context (impairments, linear channel cutbacks, shift to DTC) that explains the decline, even if those details are not in the ground truth—this adds value without contradicting facts. (4) The original answer does not mention 2023 data, but the LLM uses it appropriately to illustrate the trend between 2022 and 2024, enhancing clarity. The only minor gap is that the original emphasizes A&E's significance in 2022 as a top investee (alongside CTV Specialty Television), which the LLM does not explicitly mention, slightly reducing completeness. However, the core multi-hop synthesis—linking Disney’s declining equity income to A+E’s performance across years—is correctly executed. Thus, the answer is factually robust, contextually relevant, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 442,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did the carrying value of securitized debt obligations change from 2022 to 2023, and what does this indicate about the company's long-term funding strategy?",
      "original_answer": "In 2022, the long-term funding, which primarily consists of securitized debt obligations and senior and subordinated notes, stood at $42.3 billion as of December 31, 2021, with a significant portion driven by securitized debt obligations. By December 31, 2023, the carrying value of securitized debt obligations alone decreased to $18.043 billion. This indicates a strategic shift or reduction in reliance on securitized debt obligations as part of the company's long-term funding structure over this period.",
      "llm_answer": "\nThe carrying value of the company’s securitized debt obligations rose from **$16.97 billion at the end of 2022** (see COF_10K_2022.pdf, page 211) to **$18.04 billion at the end of 2023** (see COF_10K_2023.pdf, page 212), an increase of roughly **$1.07 billion (≈6 %)**.  \n\nThis growth shows that Capital One is deliberately expanding its asset‑backed securitization program, using securitized debt as a key source of long‑term funding to support loan‑portfolio growth and diversify its financing base. The higher reliance on securitizations indicates a strategic focus on stable, low‑cost, long‑term capital markets to fund its lending activities.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is fundamentally incorrect in direction and magnitude. The ground truth states that the carrying value of securitized debt obligations decreased to $18.043 billion by December 31, 2023, from a prior level that was part of a total long-term funding of $42.3 billion as of December 31, 2021. The LLM incorrectly claims the value increased from $16.97 billion in 2022 to $18.04 billion in 2023, which contradicts the downward trend indicated in the original answer. The cited numbers ($16.97B in 2022, $18.04B in 2023) are not supported by the ground truth, which does not provide a 2022 standalone figure but implies a decline from a much higher prior level. (2) The calculation of a $1.07 billion (6%) increase is therefore based on false inputs and is incorrect. The ground truth indicates a significant reduction in securitized debt, not an increase. (3) The multi-hop reasoning fails: the LLM misidentifies the trend and draws an opposite conclusion about the company's strategy. Instead of recognizing a strategic reduction in reliance on securitized debt, it claims expansion, which is inconsistent with the evidence. (4) While the LLM attempts to address both parts of the question (change in value and strategic implication), its factual errors severely undermine completeness and reasoning. The contextual relevance is moderate because it discusses the right topic and metric, but the conclusions are inverted due to incorrect data. Minor formatting like $18.04B vs $18.043B is acceptable, but directional and magnitude errors are critical.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 433,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has Disney's approach to scripted programming evolved between 2022 and 2024, particularly in terms of its international general entertainment channels and its strategic shift toward DTC platforms?",
      "original_answer": "In 2022, Disney operated approximately 220 General Entertainment channels outside the U.S., primarily under the Fox, National Geographic, and Star brands, featuring a mix of scripted, reality, and documentary programming across multiple languages and regions. By 2024, there was a notable strategic shift, with increased emphasis on DTC platforms and less focus on traditional linear channels. The 2024 report highlights that Disney, along with Fox Corporation and Warner Bros. Discovery, planned a joint venture (Venu Sports) to distribute sports content via a DTC platform, signaling a broader move toward streaming. Additionally, Disney announced plans to launch a new DTC offering in early fall 2025 that would include live linear streams of ESPN channels and ESPN+. This reflects a strategic pivot from scripted linear content toward live and sports-driven DTC offerings, indicating a transformation in Disney’s programming and distribution priorities.",
      "llm_answer": "\nBetween fiscal 2022 and 2024 Disney moved away from relying on traditional linear general‑entertainment channels overseas and began concentrating its scripted and general‑entertainment content on direct‑to‑consumer services.  The company merged its Latin‑American streaming offerings (e.g., Disney+ + Star+), added ESPN‑branded tiles to Disney+ abroad, and announced plans for a new DTC platform that will carry live ESPN channels, signaling a strategic shift from licensing linear channels to monetising programming primarily through subscription and advertising revenue on its DTC platforms.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core strategic shift in Disney's approach from linear international general entertainment channels to DTC platforms between 2022 and 2024. It correctly identifies the move away from traditional linear channels and the focus on DTC monetization through subscription and advertising. The mention of merging Latin American streaming offerings (Disney+ and Star+) and adding ESPN-branded content internationally aligns with Disney's regional DTC integration strategy. The announcement of a new DTC platform carrying live ESPN channels is also accurate and contextually relevant.\n\nQuantitatively, there are no specific numbers (e.g., 220 channels) mentioned in the LLM answer, but it does not misstate any figures, so quantitative accuracy is not penalized. The original answer includes the detail of ~220 international general entertainment channels in 2022, which the LLM omits, representing a minor completeness gap.\n\nQualitatively, the LLM misses the multi-hop detail about the Venu Sports joint venture with Fox Corporation and Warner Bros. Discovery, which is a key indicator of the broader strategic pivot toward sports-driven DTC offerings. This omission reduces completeness and weakens the full synthesis of Disney’s evolving strategy, particularly around live sports content.\n\nThe reasoning is sound and the answer is semantically aligned with the ground truth, though slightly less detailed. The contextual relevance is high, as all points directly address the evolution in programming and distribution strategy. The answer would score higher if it included the Venu Sports joint venture and the specific brand names (Fox, Star, National Geographic) of the international channels being phased out or repurposed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 480,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Tesla's financial and operational challenges related to energy storage products evolve from 2022 to 2023, particularly in terms of accounts receivable and production scaling dependencies?",
      "original_answer": "In 2022, Tesla disclosed significant long-term government rebates receivable related to its energy storage products, with a balance of $627 million as of December 31, 2021, indicating extended collection periods of up to a year or more. By 2023, the focus shifted from financial implications of receivables to operational dependencies, as Tesla highlighted production scaling risks for energy storage products, including bottlenecks, supplier constraints, and facility ramp delays at factories in Nevada, Texas, and other locations. These changes reflect a shift from financial exposure tied to receivables to broader production and supply chain dependencies affecting the company's ability to meet cost and profitability targets.",
      "llm_answer": "\nFrom 2022 into 2023 Tesla’s energy‑storage receivables grew substantially—larger balances of government‑rebate and financing‑partner amounts lengthened collection cycles and forced the company to increase its allowance for doubtful accounts.  At the same time, scaling storage‑product volume deepened reliance on a limited set of battery‑cell suppliers and amplified exposure to raw‑material price volatility and component‑shortage risks, making production ramps more precarious than in the prior year.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies and omissions compared to the ground truth. While it correctly identifies a shift in Tesla's challenges from financial to operational aspects, it fabricates or misrepresents key quantitative details. The original answer states that Tesla had $627 million in long-term government rebates receivable as of December 31, 2021 (disclosed in 2022), but the LLM claims receivables 'grew substantially' in 2022–2023 without providing any correct figures or citing the $627M balance. There is no mention of the actual $627 million figure or the correct timing (balance as of end-2021, disclosed in 2022), leading to major quantitative inaccuracy. (2) The LLM introduces unsupported claims such as 'increase its allowance for doubtful accounts' and 'financing-partner amounts'—neither of which appear in the original answer and lack grounding in the provided truth. These are speculative additions not present in the knowledge graph. (3) On qualitative reasoning, the LLM correctly identifies a shift from financial (receivables) to operational (supply chain, supplier constraints) challenges, aligning with the multi-hop evolution from 2022 to 2023. It appropriately links scaling energy storage production to supplier and material risks, echoing the original's emphasis on bottlenecks and facility ramp delays. However, it omits specific locations mentioned (Nevada, Texas) and fails to reference the shift from 'extended collection periods' to 'production scaling risks' as a transition in focus. (4) Contextually, the answer is relevant and addresses both parts of the question—evolution of financial and operational challenges—but sacrifices factual precision for plausible-sounding elaboration. The core idea of increasing dependency on suppliers and production risks in 2023 is consistent, but the lack of accurate numbers and inclusion of unverified details (e.g., allowance for doubtful accounts) significantly reduce correctness. Thus, while the direction of reasoning is partially sound, factual fidelity is compromised.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 559,
        "total_tokens": 1879
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the role of syrups in Coca-Cola's business model evolved between 2022 and 2023, particularly in relation to its bottling partners and fountain retailers?",
      "original_answer": "In 2022, Coca-Cola's relationship with syrups was primarily defined by its sales to both consolidated and unconsolidated bottling partners, with revenue and volume recognition dependent on the ownership structure of those partners. Specifically, concentrate and syrup sales were not recognized until finished products were sold to third parties in the case of consolidated bottlers, while recognition occurred immediately for unconsolidated bottlers. By 2023, the company's description of syrups shifted to emphasize their role as a dependency within a broader operational framework, particularly in relation to fountain retailers. In 2023, the company clarified that it manufactures fountain syrups and sells them directly to fountain retailers or authorized wholesalers and bottlers, highlighting a more integrated and strategic role for syrups in its finished beverage delivery system. This represents a shift from a primarily volume-driven metric to a more operationally embedded component of the business model.",
      "llm_answer": "\nBetween 2022 and 2023 the share of revenue derived from concentrate (syrup) operations grew modestly—from 56 % to 58 % of total net operating revenue (and from 82 % to 83 % of the segment mix)—showing that syrups have become a slightly larger driver of the Company’s top line.  At the same time, the MD&A notes that the Company now applies an incidence‑based, variable‑pricing model and recognizes concentrate revenue when control passes to bottling partners, with volume‑based incentives and channel‑mix considerations (especially for fountain‑retail sales) shaping the relationship with both consolidated and unconsolidated bottlers.  This evolution reflects a tighter integration of syrup sales with the Company’s bottling partners and fountain retailers as a key growth channel.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative claims. The ground truth does not mention any revenue share percentages (56% to 58%, 82% to 83%) for syrup/concentrate operations—these figures are entirely absent from the original answer and cannot be verified. There is no support in the original text for any numerical change in revenue share, making these numbers fabricated or hallucinated. (2) The quantitative accuracy is very low because the core numbers presented (percentages of revenue and segment mix) are not present in the ground truth and contradict the qualitative nature of the original response, which focuses on operational and recognition policy changes rather than financial proportions. (3) Qualitatively, the LLM captures a partial shift toward tighter integration with bottling partners and fountain retailers, and correctly references variable pricing and control-based revenue recognition, which aligns with the 2023 emphasis on operational integration. However, it misrepresents the nature of the evolution: the original answer emphasizes a shift in *accounting recognition logic* and *strategic framing* of syrups (from volume-driven to operationally embedded), not revenue growth or pricing models. The multi-hop reasoning is partially sound but misdirected—while it attempts to synthesize operational and financial trends, it invents metrics to support a narrative not present in the source. (4) Contextual relevance is high because the answer addresses the core entities (syrups, bottling partners, fountain retailers) and attempts to describe a strategic evolution between 2022 and 2023. However, the introduction of unsupported percentages severely undermines factual correctness, warranting a low overall score despite relevant framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1453,
        "completion_tokens": 489,
        "total_tokens": 1943
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did Disney's investment in Other Mortgage- and Asset-Backed Securities (MBS & ABS) evolve from fiscal year 2022 to fiscal year 2024, and what was the trend in its proportion relative to the overall fair value hierarchy?",
      "original_answer": "In fiscal year 2022, Disney's investment in Other MBS & ABS was valued at $96 million, representing 1% of the total plan asset mix. By fiscal year 2024, this investment increased to $120 million, maintaining a 1% share of the total plan asset mix. While the absolute value of the investment grew moderately, its proportional representation within the portfolio remained stable.",
      "llm_answer": "\nDisney’s Other‑mortgage‑ and asset‑backed securities (MBS/ABS) rose from **$84 million** in the 2022 fair‑value hierarchy (Level 2, ≈ 1 % of the total hierarchy) to **$166 million** in the 2024 hierarchy (Level 2, ≈ 1.5 % of the total hierarchy).  The absolute amount more than doubled, and its share of the overall fair‑value hierarchy increased modestly from about 1 % to 1.5 % over the same period.  (Pages 104 & 107 of the 2022 and 2024 10‑K filings.)",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Disney's investment in Other MBS & ABS was $96 million in fiscal year 2022 and $120 million in fiscal year 2024, both representing 1% of the total plan asset mix. However, the LLM reports $84 million in 2022 and $166 million in 2024, which are incorrect. Additionally, the LLM claims the proportion increased from ~1% to 1.5%, while the ground truth states it remained stable at 1%. These errors affect both absolute values and relative proportions. (2) The quantitative inaccuracies are substantial: the 2022 value is off by $12 million (84 vs 96), the 2024 value by $46 million (166 vs 120), and the percentage share is incorrectly reported as increasing when it did not. The claim that the investment 'more than doubled' is false—it grew from $96M to $120M, a 25% increase. (3) While the LLM attempts multi-hop reasoning by comparing two fiscal years and analyzing both absolute and relative changes, the synthesis is based on incorrect data, undermining the logic. The reference to 'Level 2' and specific page numbers may reflect real filing locations, but this does not compensate for factual errors. (4) Scores are low on correctness and quantitative accuracy due to major factual and numerical discrepancies. Qualitative accuracy is slightly higher because the structure of the response and intent to compare trends is appropriate. Contextual relevance is high as the answer addresses the right topic, time frame, and type of investment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 425,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did the focus areas of Skunk Works' advanced development programs evolve between 2022 and 2023 in relation to next-generation military aircraft capabilities?",
      "original_answer": "In 2022, Skunk Works' Advanced Development Programs focused on future systems including unmanned and manned aerial systems and next-generation capabilities for hypersonics, intelligence, surveillance, reconnaissance, situational awareness, and air mobility. By 2023, the focus had evolved to emphasize air dominance, hypersonics, intelligence, surveillance, reconnaissance, situational awareness, and air mobility. The shift highlights an increased emphasis on air dominance as a core next-generation capability while maintaining focus on hypersonics and ISR. This represents a refinement of priorities rather than a complete overhaul of focus areas.",
      "llm_answer": "\nBetween 2022 and 2023 the Skunk Works Advanced Development Programs broadened and sharpened its focus. In 2022 the ADP was described as pursuing “future systems, including unmanned and manned aerial systems and next‑generation capabilities for hypersonics, intelligence‑surveillance‑reconnaissance, situational‑awareness and air‑mobility.” By 2023 the language was updated to emphasize “next‑generation capabilities for **air dominance**, hypersonics, intelligence‑surveillance‑reconnaissance, situational‑awareness and air‑mobility,” explicitly adding air‑dominance as a core thrust while retaining the earlier domains. Thus, the evolution reflects a deliberate shift toward prioritizing air‑dominance and advanced hypersonic strike systems as key enablers of next‑generation military aircraft capability.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual information is correct: the 2022 focus areas (unmanned and manned aerial systems, hypersonics, ISR, situational awareness, air mobility) and the 2023 shift to include air dominance as a highlighted priority are accurately represented. The LLM correctly identifies that prior domains were retained while air dominance was explicitly added. (2) There are no numeric values requiring verification (e.g., dates are correct—2022 to 2023), so quantitative accuracy is perfect. (3) The multi-hop reasoning is sound: the model synthesizes the evolution between two time points and correctly infers a strategic refinement rather than a complete change, emphasizing air dominance as a growing priority. (4) The only minor shortcoming is that the LLM describes the evolution as 'broadened and sharpened,' which slightly overstates broadening—since air dominance may have been implicit in earlier efforts—whereas the original answer frames it as a 'refinement' and 'increased emphasis.' This nuance is minor and does not undermine the core accuracy. Overall, the answer is semantically equivalent, contextually precise, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 341,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has Tesla's approach to the Powerwall product evolved from 2022 to 2023, particularly in terms of integration strategy and production emphasis?",
      "original_answer": "In 2022, Tesla emphasized cross-selling Powerwall with residential solar energy products due to better availability and growing grid stability concerns. The company was also focused on improving installation capabilities and price efficiencies for Solar Roof, which is closely related to Powerwall integration. By 2023, Tesla had advanced its integration strategy by designing both Solar Roof and solar energy systems to specifically integrate with Powerwall, indicating a more deliberate and engineered approach to product synergy. This evolution reflects a shift from a sales and availability focus to a deeper technical and strategic integration within Tesla's energy ecosystem.",
      "llm_answer": "\nFrom 2022 to 2023 Tesla moved the Powerwall from a primarily “stand‑alone” home‑battery sold through direct installers toward a tightly integrated component of its broader energy‑generation portfolio.  The 2023 disclosures highlight that Powerwall is now designed to work seamlessly with Solar Roof, Megapack and the company’s new software‑controlled dispatch platform, and Tesla is scaling dedicated production capacity (e.g., the Lathrop Megafactory and in‑house cell manufacturing) to meet rising demand and support both residential and utility‑scale deployments.  Consequently, the emphasis shifted from modest, vehicle‑derived battery output to a purpose‑built, high‑volume manufacturing strategy that underpins the company’s integrated energy‑storage offering.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution in Tesla's Powerwall strategy from 2022 to 2023 with generally accurate qualitative direction, but introduces details not present in the ground truth, affecting precision. (1) Correct elements: the shift from standalone to integrated product, emphasis on integration with Solar Roof, and increased production focus are consistent with the original answer. The mention of deeper integration with Tesla’s energy ecosystem aligns semantically with 'designed to work seamlessly' in 2023. (2) Quantitative accuracy: no specific numbers (e.g., dollar amounts, percentages, production volumes) are mentioned in either answer, so no factual discrepancies exist—this earns full marks. (3) Multi-hop reasoning: the model correctly infers a strategic shift over time based on integration and production changes, but overreaches by referencing 'Megapack', 'software-controlled dispatch platform', 'Lathrop Megafactory', and 'in-house cell manufacturing', which are not mentioned in the ground truth and go beyond the provided context. These additions, while plausible, introduce unsupported specifics. (4) The original answer emphasizes a shift from cross-selling and availability (2022) to engineered integration with Solar Roof and solar systems (2023), without mentioning utility-scale deployments or vehicle-derived batteries. The LLM answer reframes the narrative around manufacturing scale and broader system integration not fully substantiated by the ground truth. Thus, while the central idea of deeper integration is correct, the elaboration contains speculative details, warranting a 7 for correctness and qualitative accuracy. Contextual relevance remains high as the response directly addresses the question’s focus on integration and production emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 485,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has Gilead's strategic positioning around Biktarvy evolved between 2022 and 2024, particularly in terms of its role within the company's HIV portfolio and associated commercial risks?",
      "original_answer": "In 2022, Biktarvy was prominently positioned as a key revenue-generating product within Gilead’s HIV portfolio, highlighted as a single-tablet regimen combining bictegravir, emtricitabine, and tenofovir alafenamide (TAF), emphasizing its convenience and efficacy. By 2024, while Biktarvy remained a core product, the company faced heightened commercial risk as it became more dependent on HIV products containing TAF. A shift in treatment paradigms or reduced preference for nucleoside-based therapies could significantly impact Biktarvy’s sales and, by extension, Gilead’s financial stability. This reflects a transition from a focus on product innovation to increased vulnerability due to overreliance on a narrow therapeutic class.",
      "llm_answer": "\nBetween 2022 and 2024 Gilead shifted Biktarvy from a stand‑alone growth driver to a central pillar of its HIV franchise that is now deliberately protected against rising commercial pressures.  In 2022 the drug was highlighted as a flagship product whose sales underpinned overall HIV revenue, but by 2024 the company’s disclosures emphasized that Biktarvy’s profitability is increasingly exposed to IRA‑driven rebate obligations, payer‑price negotiations and generic competition, prompting Gilead to reinforce its pricing and market‑access strategies and to diversify its HIV pipeline to offset those risks.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but diverges significantly from the ground truth in key qualitative aspects. (1) Correct elements: The answer correctly identifies Biktarvy as a central product in Gilead’s HIV portfolio in both 2022 and 2024 and acknowledges increasing commercial risks. It appropriately frames the evolution as a shift from growth driver to a product under pressure. (2) Quantitative accuracy: There are no numeric values in either the ground truth or LLM answer, so this dimension is neutral; no errors present. (3) Multi-hop reasoning assessment: The LLM introduces specific risk factors—IRA-driven rebate obligations, payer-price negotiations, and generic competition—that are not mentioned in the ground truth. While these may be plausible external risks, the ground truth emphasizes a different core risk: Gilead’s increasing dependence on TAF-based therapies and vulnerability to shifts in treatment paradigms away from nucleoside-based regimens. This represents a significant deviation in the central argument. The LLM focuses on pricing and access risks, while the ground truth highlights therapeutic class overreliance and scientific/clinical vulnerability. (4) The answer is contextually relevant and well-structured, but misses the key strategic insight about TAF dependency and the shift from innovation emphasis to portfolio fragility. Thus, while the direction of reasoning is sound, the core factual basis of the risk evolution is misaligned, leading to a correctness score of 6—partially correct with significant omissions and a shift in emphasis away from the documented strategic concern.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 443,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How did the composition of the U.S. Retrospective Responsibility Plan change between 2022 and 2023, particularly regarding the mechanisms referenced in relation to the U.S. Litigation Escrow Agreement?",
      "original_answer": "In 2022, the U.S. Retrospective Responsibility Plan included mechanisms such as the U.S. Litigation Escrow Agreement, the conversion feature of Class B common stock, indemnification obligations of Visa U.S.A. members, an interchange judgment sharing agreement, a loss sharing agreement, and an omnibus agreement. By 2023, the composition evolved to include a new element — 'makewhole agreements relating to the Class B-1 common stock exchange offer' — while retaining the U.S. Litigation Escrow Agreement and other previously listed mechanisms. This indicates an expansion of the plan to incorporate additional financial safeguards or compensatory measures.",
      "llm_answer": "\nBetween fiscal 2022 and 2023 the set of mechanisms that make up Visa’s U.S. Retrospective Responsibility Plan – the U.S. litigation‑escrow agreement, the class B‑stock conversion feature, the makewhole agreements, the indemnification obligations of Visa U.S.A. members, the interchange‑judgment‑sharing agreement, the loss‑sharing agreement and the omnibus agreement – remained the same; no new mechanisms were introduced.  What did change was the **composition of the escrow‑funding side** of the plan: the 2023 disclosures show a substantially larger escrow balance ($3.089 bn at 30 Sept 2023 vs $1.764 bn a year earlier) with **higher deposits** into the escrow account ($1.5 bn in 2023 versus $1.0 bn in 2022) and **much lower net payments** to opt‑out merchants ($0.175 bn vs $0.685 bn).  This shift reflects a greater reliance on the escrow account (and its dilutive impact on class B‑stock conversion) to fund potential litigation liabilities, while the underlying list of mechanisms stayed unchanged.  (Pages 72‑73 of the 2023 10‑K and the comparable tables in the 2022 10‑K).",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains accurate quantitative data regarding the escrow account balances and deposits (e.g., $3.089 billion vs $1.764 billion, $1.5 billion vs $1.0 billion, and net payments of $0.175 billion vs $0.685 billion), which aligns with typical disclosures in Visa's 10-K filings, so quantitative accuracy is high. However, the core qualitative claim — that no new mechanisms were introduced — directly contradicts the ground truth. The Original Answer correctly states that in 2023, a new element was added: 'makewhole agreements relating to the Class B-1 common stock exchange offer.' The LLM incorrectly asserts that the list of mechanisms remained unchanged, thereby missing a key multi-hop insight: the addition of a new mechanism represents a compositional change in the plan’s structure, not just a change in funding levels. This is a critical factual error. The LLM also mischaracterizes the role of 'makewhole agreements' as pre-existing in 2022, when according to the ground truth, they were introduced in 2023 as part of the evolution of the plan. Thus, while the answer is relevant and contains accurate numbers, it fails on the primary factual point of whether the composition changed. The reasoning is flawed because it interprets 'composition' narrowly as funding levels rather than the set of legal/financial mechanisms, which is the focus of the question. Therefore, despite strong number reporting, the answer is substantially incorrect in substance, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1449,
        "completion_tokens": 414,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has the strategic importance of Biktarvy evolved for GILD from 2022 to 2024, based on its patent protection timeline and the company's risk disclosures around HIV product dependency?",
      "original_answer": "In 2022, Biktarvy was listed with a U.S. patent expiration in 2033 and no expiration listed in the E.U., indicating strong long-term protection and likely a key revenue driver. By 2024, although patent details were not explicitly mentioned, the company highlighted heightened risk around its HIV products, including Biktarvy, due to market competition and potential shifts in treatment paradigms. This suggests that despite long-term patent protection, Biktarvy's strategic position has become more vulnerable due to external market and regulatory pressures.",
      "llm_answer": "\nBetween 2022 and 2024, Biktarvy remained GILD’s flagship HIV asset, protected by composition‑of‑matter and process patents (including pediatric exclusivity) that extend U.S. and EU exclusivity to 2033 — a timeline highlighted in the 2022‑2024 10‑K patent tables (p. 13) and reinforced by the 2022 filing that received a new low‑dose pediatric label (p. 10).  However, the company’s 2024 risk disclosures (p. 18) increasingly flagged concentration risk: any shift away from nucleoside‑based HIV regimens or pricing pressures from Medicare‑Part D reforms could erode Biktarvy’s sales, prompting GILD to diversify into oncology and cell‑therapy to lessen its reliance on this HIV product.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all key facts are correct: Biktarvy's patent protection extends to 2033 in both the U.S. and EU, consistent with the 2022 disclosure in the original answer (which noted 2033 U.S. expiration and no E.U. expiration listed—implying long-term protection). The LLM adds specificity by referencing composition-of-matter and process patents and pediatric exclusivity, which are plausible extensions but not contradicted by the ground truth. (2) The timeline (2022–2024) is correctly handled, and the evolution in risk disclosures is accurately captured: the 2024 filing highlights increased concentration risk around HIV products, including Biktarvy, due to treatment paradigm shifts and pricing pressures (e.g., Medicare Part D reforms), matching the original answer’s emphasis on growing vulnerability despite strong IP. (3) Multi-hop reasoning is sound—LLM synthesizes patent data (from 2022–2024 10-Ks) with evolving risk factor language in 2024, correctly inferring strategic vulnerability despite long IP life. (4) The LLM adds contextual detail (e.g., diversification into oncology and cell therapy) not in the original answer but logically consistent with GILD’s strategic response, enhancing completeness without introducing error. One minor point: the original answer notes that 2024 patent details were 'not explicitly mentioned,' whereas the LLM implies continuity of 2033 protection into 2024 without noting the absence of explicit confirmation—this is a slight overconfidence in data availability but does not invalidate the conclusion. Overall, the answer is factually correct, well-reasoned, and contextually rich.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 465,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "Have there been any modifications to the financial guarantees provided by AT&T for Illinois Bell Telephone Company between 2022 and 2023, particularly in terms of guarantee structure or referenced documentation?",
      "original_answer": "The financial guarantee relationship between AT&T and Illinois Bell Telephone Company remained structurally unchanged between 2022 and 2023. In 2022, AT&T's guarantee for Illinois Bell Telephone Company was referenced under Exhibit 4-d to Form 10-K for the period ending December 31, 2011. In 2023, the same guarantee was still in place and referenced under the identical exhibit number (Exhibit 4-d) and filing history (Form 10-K for the period ending December 31, 2011). There is no indication of modifications to the guarantee structure, terms, or documentation between the two years.",
      "llm_answer": "\nNo. The filings for 2022 and 2023 do not disclose any amendment, restatement, or new guarantee replacing the existing “Guaranty of certain obligations of Illinois Bell Telephone Company, Inc.” that is cited as Exhibit 4‑c (originally filed in the 2011 Form 10‑K). The only reference in the provided pages is the unchanged 2011 exhibit, and there is no indication of a revised guarantee structure or new documentation for the 2022‑2023 period.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly conveys that there were no modifications to the financial guarantee provided by AT&T for Illinois Bell Telephone Company between 2022 and 2023, which aligns with the ground truth. The key factual elements—unchanged structure, continued reliance on the same historical exhibit, and absence of new or amended documentation—are accurately represented. However, there is a minor discrepancy in the exhibit number: the original answer states Exhibit 4-d, while the LLM answer refers to Exhibit 4-c. This inconsistency affects entity accuracy but does not alter the overall conclusion about the lack of changes. The dates (2011 Form 10-K) and years under review (2022–2023) are correct. The reasoning is sound—no new filings imply no structural changes—and the answer addresses both parts of the question (guarantee structure and documentation). Despite the exhibit number mismatch, the core message of no modifications is supported by both answers, warranting a high correctness score with a slight deduction for the exhibit reference error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 301,
        "total_tokens": 1575
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "What does the consistent Class C to Class A common stock conversion rate between 2022 and 2023 suggest about the potential impact on Class A common stockholders' voting power in significant corporate transactions?",
      "original_answer": "In 2022, the Class C common stock had a conversion rate of 4.0000 into Class A common stock, and this rate remained unchanged in 2023. Despite the as-converted Class A common stock value increasing slightly from 38 million in 2022 to 39 million in 2023, the unchanged conversion rate suggests that the relative voting power dilution for Class A common stockholders remained stable. This stability implies that there was no structural change in how Class C stockholders could influence significant corporate decisions through their voting rights tied to Class A equivalents.",
      "llm_answer": "\nThe fact that the Class C‑to‑Class A conversion rate was left unchanged from 2022 to 2023 indicates that the number of Class A shares that Class C holders would receive upon conversion is the same each year. As a result, there is no additional dilution of Class A voting power arising from that conversion, so any significant corporate transaction that requires shareholder approval will affect Class A holders’ voting influence in the same way as it did previously.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct and aligns well with the ground truth. (1) It correctly identifies that the Class C to Class A conversion rate remained unchanged between 2022 and 2023, which is accurate per the original answer (4.0000 in both years). While the LLM does not explicitly state the numerical rate or the as-converted Class A stock values (38M in 2022, 39M in 2023), it correctly infers the implication of the stable conversion rate. (2) The quantitative accuracy is high—no incorrect numbers are presented, and the absence of specific figures does not detract from correctness since the question asks about the implication of consistency, not the values themselves. (3) The reasoning is sound: the LLM correctly connects the unchanged conversion rate to stable voting power dilution for Class A stockholders, accurately concluding that their voting influence in significant corporate transactions remains structurally unaffected. This reflects proper multi-hop synthesis—linking conversion mechanics to voting power impact. (4) The answer is contextually relevant and fully addresses the question’s focus on voting power implications. The only minor shortcoming is the omission of the slight increase in as-converted Class A value (38M to 39M), which the original answer uses to reinforce that despite value growth, the dilution effect remained stable due to the fixed rate. This nuance is missing but does not invalidate the core conclusion. Hence, a score of 9 is appropriate—excellent accuracy with a small completeness gap.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 422,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Tesla's relationship with the Solar Roof evolve from 2022 to 2023 in terms of production focus and strategic dependencies?",
      "original_answer": "In 2022, Tesla directly produced the Solar Roof at Gigafactory New York, indicating active involvement in its manufacturing. However, by 2023, Tesla's disclosures shifted to emphasizing dependencies and risks associated with scaling production, including potential delays, supply chain constraints, and challenges in launching and ramping products like the Solar Roof. This reflects a transition from a production-centric view to a more cautionary outlook on strategic execution risks.",
      "llm_answer": "\nFrom 2022 to 2023 Tesla moved Solar Roof from an aggressive scaling effort at its Buffalo Gigafactory—where production was buoyed by the 26 % federal solar‑tax credit and by external suppliers for glass and solar cells—into a more restrained posture that recognized the credit’s impending phase‑out and the need to tie the roof’s output to its own battery‑cell manufacturing. Consequently, the company’s strategic dependence shifted from external solar‑module and incentive reliance toward internal battery‑cell supply and cost‑control, and it now warns that any slowdown in Solar Roof ramp‑up could force curtailment of both vehicle and energy‑storage production.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific details not present in the ground truth, such as the 26% federal solar-tax credit, external suppliers for glass and solar cells, and the claim that a Solar Roof slowdown could force curtailment of vehicle and energy-storage production. These are not supported by the original answer and appear to be speculative or derived from external knowledge. The ground truth does not mention tax credits, specific suppliers, or cascading production impacts on vehicles and storage. (2) The quantitative claim of a '26%' tax credit is factually plausible (referring to the federal Investment Tax Credit), but it is not mentioned in the original answer and thus cannot be verified from the provided knowledge graph. No other numbers (dates, dollar amounts) are present, so the only numeric value introduced—26%—is extraneous. (3) The multi-hop reasoning is partially sound: the model infers a strategic shift from production focus to risk awareness, which aligns with the ground truth. However, it overextends by attributing the shift to specific dependencies (battery-cell manufacturing, tax credit phase-out) that are not in the original data. The synthesis goes beyond the provided evidence, introducing causal links not present in the ground truth. (4) The contextual relevance is high because the answer addresses the evolution of Tesla's Solar Roof strategy across 2022–2023 and discusses production focus and dependencies. However, correctness is reduced due to unsupported specifics and overinterpretation. While the directional shift (from active production to caution) is consistent, the added details lower factual accuracy. Hence, a mid-range score of 5 is justified for correctness, with higher marks for reasoning and relevance but low quantitative accuracy due to unsupported numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 498,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How has the role of syrups in Coca-Cola's business model evolved between 2022 and 2023, particularly in terms of their relationship to finished beverage production and distribution channels?",
      "original_answer": "In 2022, Coca-Cola described syrups as intermediate products used primarily in fountain beverage production, where bottling partners or fountain retailers mix them with water and sweeteners to create finished beverages for immediate consumption. The company emphasized that syrups were a key part of the concentrate operations, which generally yield lower net operating revenues but higher gross profit margins compared to finished product operations. By 2023, the company expanded its description to emphasize that fountain syrup sales in the U.S. were directly managed by Coca-Cola and sold to both fountain retailers and authorized wholesalers or bottling partners. Additionally, the 2023 filing highlighted that fountain syrup operations were specifically included in the North America operating segment, indicating a more structured and regionally focused approach to syrup distribution. This evolution reflects a strategic shift toward tighter control and segmentation of syrup-related revenue streams within the broader beverage production ecosystem.",
      "llm_answer": "\nBetween 2022 and 2023 the company continued to sell syrups to its bottling partners, who use the syrups (together with water and sweeteners) to produce finished beverages that are distributed through the same bottling and distribution network.  The 2023 Form 10‑K shows that revenue from concentrate operations—including syrups—rose to **58 %** of total net operating revenue in 2023 versus **56 %** in 2022, while finished‑product revenue fell to **42 %** from **44 %**.  This modest shift indicates that the syrup‑to‑bottler model remained central to Coca‑Cola’s production and distribution, but the company’s revenue mix is tilting slightly more toward concentrate/syrup sales.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in the quantitative claims. It states that revenue from concentrate operations (including syrups) rose to 58% of total net operating revenue in 2023 from 56% in 2022. However, the ground truth does not provide any such percentage breakdown of revenue by concentrate vs. finished products, nor is this data present in Coca-Cola's publicly filed 10-Ks for 2022 or 2023. This 56% → 58% shift is fabricated or misattributed, making the core quantitative claim incorrect. Additionally, the LLM frames syrup use exclusively in relation to bottling partners producing finished beverages, which conflates bottle/can production with fountain syrup usage. The ground truth clarifies that syrups are primarily used in *fountain* beverage production, not standard bottling, and that by 2023, Coca-Cola directly managed fountain syrup sales in the U.S., selling to both retailers and wholesalers—a key strategic evolution that the LLM omits entirely. The answer also fails to mention the reclassification of fountain syrup operations under the North America operating segment in 2023, a critical organizational shift indicating tighter control and segmentation. While the LLM correctly identifies that syrups are intermediate products used with water and sweeteners to make finished beverages, and that concentrate operations are part of the business model, it misses the multi-hop nuance of how the *role* and *distribution model* of syrups evolved—especially the shift toward direct management and regional operational integration. Thus, while contextually relevant and partially accurate in general business logic, the answer is factually flawed in key quantitative and qualitative aspects, undermining its correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1445,
        "completion_tokens": 481,
        "total_tokens": 1926
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has the company's operational focus on Africa/Eurasia evolved between 2022 and 2024, particularly in terms of its geographic reporting structure and financial contribution?",
      "original_answer": "In 2022, Africa/Eurasia was reported as part of the Oral, Personal and Home Care segment with an operating profit of $203 million, indicating a relatively minor financial contribution compared to other regions. By 2024, the company maintained Africa/Eurasia as a distinct reportable operating segment within the Oral, Personal and Home Care geographic structure. Additionally, in 2024, the company realigned its skin health business, shifting it from Europe to North America, signaling a strategic refinement in geographic reporting. This change suggests a more nuanced operational focus in how the company organizes and evaluates its regional performance, including in Africa/Eurasia.",
      "llm_answer": "\nBetween 2022 and 2024 the company kept Africa/Eurasia as one of the five distinct geographic reportable operating segments within its Oral, Personal & Home‑Care business; the only structural change was the July 2024 realignment that moved the skin‑health business out of Europe into North America, which left the Africa/Eurasia segment unchanged.  Financially, Africa/Eurasia’s net sales rose modestly from roughly $1.08 billion in 2023 to $1.10 billion in 2024, and its operating profit increased from about $228 million to $253 million, keeping the segment’s contribution at roughly 5 % of total Oral, Personal & Home‑Care sales while showing a slight upward trend in both revenue and profitability.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that in 2022, Africa/Eurasia was not a distinct reportable segment but was part of the broader Oral, Personal and Home Care segment with an operating profit of $203 million. However, the LLM claims it was already a distinct geographic segment in 2022, which contradicts the ground truth. Additionally, the LLM introduces financial figures for 2023 and 2024 (net sales of $1.08B and $1.10B, operating profit rising from $228M to $253M) that are not present in the original answer and are factually unsupported by the provided ground truth. The original answer only provides 2022 operating profit ($203M) and does not mention 2023 or 2024 financials. (2) The quantitative inaccuracies are severe: the LLM fabricates two years of financial data (2023 and 2024) with precise numbers that do not appear in the ground truth. There is no mention of net sales in the original answer, nor any percentage contribution (e.g., '5% of total sales'), making those additions speculative and incorrect. The operating profit in 2022 is stated as $203M in the truth, but the LLM reports $228M for 2023, implying growth not verified in the source. (3) The multi-hop reasoning is flawed. While the LLM correctly identifies the July 2024 realignment of the skin-health business from Europe to North America, it incorrectly assumes this left Africa/Eurasia unchanged, whereas the original answer frames this as part of a broader strategic refinement in geographic reporting that includes Africa/Eurasia. The LLM fails to capture the evolution from being a non-distinct part of a segment in 2022 to a distinct reportable segment in 2024. (4) The contextual relevance is moderate because the answer addresses geographic structure and financial contribution, but the factual foundation is incorrect. Due to major quantitative and qualitative errors, especially the fabrication of financial data and misrepresentation of segment status, the correctness score is low at 3, with similarly low quantitative accuracy. The qualitative reasoning is partially sound but based on false premises, and the answer remains relevant in topic despite inaccuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 594,
        "total_tokens": 1948
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has Johnson & Johnson's strategic presentation of its Orthopaedics business evolved between 2023 and 2024, particularly in terms of global sales performance and emphasis on enabling technologies?",
      "original_answer": "In 2023, JNJ's Orthopaedics segment was presented primarily through quantifiable sales figures, with global revenue reaching $8,942 million, showing a 4.1% increase from the prior year. The 2023 data emphasized steady growth, particularly in the U.S. ($5,525 million, up 3.8%) and modest international growth ($3,417 million, up 4.6%). By 2024, the strategic framing of Orthopaedics shifted from financial metrics to a qualitative emphasis on innovation and enabling technologies. The 2024 filing described Orthopaedics as a portfolio 'supported by products and enabling technologies' across hips, knees, trauma, spine, and sports medicine, without revisiting specific revenue figures. This reflects a strategic pivot from highlighting quantitative performance to underscoring technological leadership and product diversification within the segment.",
      "llm_answer": "\nBetween 2023 and 2024 the Orthopaedics business showed only modest top‑line growth—global sales of roughly $8.9 billion in 2023 (U.S. $5.5 B, International $3.4 B), up about 3.8 % from 2022—and was previously framed as a stable, mature MedTech pillar.  The 2024 filing, however, reframes the segment as a strategic growth engine, placing strong emphasis on “enabling technologies” such as robotic‑assisted and navigation tools that support hips, knees, trauma and spine procedures, signaling a shift from incremental volume gains to an innovation‑driven expansion strategy.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the core evolution in Johnson & Johnson's strategic presentation of its Orthopaedics business from 2023 to 2024, noting the shift from financial metrics to innovation and enabling technologies. The 2023 global sales figure is accurately reported as approximately $8.9 billion, with U.S. and international figures close to the ground truth ($5.5B and $3.4B vs. actual $5,525M and $3,417M). However, the percentage growth cited (3.8% from 2022) is slightly off—ground truth states overall growth of 4.1%, with U.S. up 3.8% and international up 4.6%. The LLM incorrectly generalizes the U.S. growth rate to the total. Additionally, the LLM implies a direct year-over-year comparison from 2022 to 2023, but does not specify that the 3.8% refers only to U.S. growth, leading to a minor misrepresentation. (2) The numbers are directionally accurate and rounded appropriately, but the conflation of U.S. growth with total growth is a quantitative inaccuracy. The absence of exact 2024 revenue figures is correct per the ground truth, as 2024 reporting shifted focus. (3) The multi-hop reasoning is strong: the model correctly infers a strategic pivot based on the absence of revenue data in 2024 and the increased emphasis on 'enabling technologies' like robotics and navigation tools across key product areas. It synthesizes the change in narrative tone between years effectively. (4) The answer is contextually excellent, directly addressing both parts of the question—sales performance and emphasis on enabling technologies—and correctly identifying the strategic reframing. The minor quantitative error prevents a 9–10 in correctness, but qualitative and contextual accuracy remain high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 472,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has Visa's approach to managing litigation liabilities through loss sharing agreements evolved between 2022 and 2023, particularly in terms of the scope of U.S. covered litigation and liability allocation?",
      "original_answer": "In 2022, Visa detailed specific amendments to its loss sharing agreement, including the October 2015 amendment that expanded the scope of U.S. covered litigation to include opt-out actions from the Rule 23(b)(3) Settlement Class in MDL 1720 that arose out of similar facts or circumstances. This amendment was part of a broader framework involving the omnibus agreement, under which Visa assumed 66.6667% of any monetary liability in covered settlements or judgments, with Mastercard assuming 33.3333%. In 2023, Visa consolidated its approach under the U.S. Retrospective Responsibility Plan, which now encompasses the loss sharing agreement as part of a broader set of mechanisms designed to address potential liabilities from U.S. covered litigation. Notably, the 2023 filing emphasizes that U.S. covered litigation now includes matters that have been 'settled or otherwise fully or substantially resolved,' indicating a shift toward resolution and consolidation of past liabilities. The evolution from a focus on specific amendments and liability sharing with Mastercard in 2022 to a more comprehensive and retrospective liability framework in 2023 suggests a strategic pivot toward finalizing and managing legacy litigation exposure.",
      "llm_answer": "\nBetween 2022 and 2023 Visa kept the same loss‑sharing framework but clarified and slightly broadened the scope of “U.S. covered litigation.”  The 2022 filing (Notes 5‑U.S. and Europe Retrospective Responsibility Plans) defined the covered matters as the Interchange MDL 1720 and any pre‑IPO claims, and it added any opt‑out actions filed after Oct 22 2015 that are substantially similar to those claims.  The 2023 filing (pages 70‑72) retained that definition but emphasized the 2015 amendment that brought those opt‑out actions within the loss‑sharing umbrella and reaffirmed that, under the omnibus agreement, liability for any settlement or judgment is split 66.6667 % to Visa (calculated by each member’s membership proportion and subject to indemnification by Visa U.S.A. members) and 33.3333 % to Mastercard.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in terms of quantitative details and core facts but misses a key qualitative evolution described in the original answer. (1) Quantitatively, all numbers and dates are accurate: the 66.6667%/33.3333% liability split between Visa and Mastercard, the October 2015 amendment (correctly referenced as Oct 22, 2015 in LLM answer), and the inclusion of opt-out actions from MDL 1720 are all correctly reported. The LLM accurately cites the omnibus agreement and the scope of U.S. covered litigation as including Interchange MDL 1720, pre-IPO claims, and post-Oct 2015 opt-outs with similar facts. (2) However, the LLM fails to capture a critical shift in 2023: the integration of the loss sharing agreement into the broader U.S. Retrospective Responsibility Plan and the explicit inclusion of 'settled or otherwise fully or substantially resolved' matters. This reflects a strategic pivot toward resolving legacy liabilities, which is a central point in the original answer. The LLM implies continuity ('kept the same framework') but does not acknowledge the consolidation and retrospective focus emphasized in 2023. (3) The multi-hop reasoning is partially sound—information across 2022 and 2023 filings is synthesized correctly regarding scope and liability split—but the deeper strategic evolution in Visa’s approach is underdeveloped. (4) Therefore, while factually accurate on key metrics and definitions, the LLM answer lacks completeness in conveying the conceptual shift from amendment-based adjustments to a comprehensive resolution framework, warranting a 7 for correctness and qualitative accuracy. Contextual relevance remains high as the response directly addresses the question’s focus on scope and liability allocation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1528,
        "completion_tokens": 476,
        "total_tokens": 2005
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did CL's investment in Guaranteed Investment Contracts evolve between 2022 and 2024, and what does this shift indicate about the company's pension plan asset strategy?",
      "original_answer": "In 2022, CL held $1 million in Guaranteed Investment Contracts under its United States Pension Plans and $55 million under its International Pension Plans. By 2024, the company had completely phased out Guaranteed Investment Contracts from its United States Pension Plans, reducing the International allocation to $34 million. This represents a significant shift away from Guaranteed Investment Contracts in the U.S. and a moderate decrease internationally, indicating a strategic reallocation of pension plan assets.",
      "llm_answer": "\nBetween 2022 and 2024 the company’s holdings of Guaranteed Investment Contracts (GICs) fell sharply – from roughly **$55‑$56 million** (about $1 million in the U.S. and $55 million internationally in the 2021/2022 filings) to **$34 million in 2023** and **$30 million in 2024**, with the U.S. GIC position eliminated entirely.  \n\nThis pull‑back signals a deliberate reallocation of plan assets away from the low‑yield, contract‑based GIC exposure toward a higher‑weighting of fixed‑income securities, pooled funds and other investments that better match the plans’ liability‑matching and return objectives, reflecting a shift toward a more diversified and potentially higher‑return asset strategy.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer captures the overall trend correctly: a significant reduction in Guaranteed Investment Contracts (GICs) from 2022 to 2024, with complete elimination in the U.S. and a decline internationally. However, there are key quantitative inaccuracies. According to the ground truth, in 2022, CL held $1M (U.S.) and $55M (International), totaling $56M. The LLM correctly identifies these figures but references '2021/2022 filings', which introduces ambiguity about the exact year. More critically, the LLM states that GICs were $34M in 2023 and $30M in 2024 internationally, but the ground truth specifies $34M in 2024 (with no mention of 2023 or $30M). Thus, the $30M figure for 2024 is incorrect, and the $34M is misattributed to 2023. 2) Calculations: The total drop is misrepresented—ground truth shows a drop to $34M in 2024 (not $30M), so the final number is wrong. The U.S. elimination is correctly noted. 3) Multi-hop reasoning is sound: the model correctly synthesizes U.S. and international data across years and infers a strategic shift in asset allocation. The interpretation—that this reflects a move toward diversified, higher-return assets like fixed income and pooled funds—is reasonable and aligns with the ground truth’s implication of strategic reallocation. 4) Despite incorrect 2024 figures and a minor temporal misstatement, the core conclusion about strategic reallocation is valid and relevant. The answer is semantically close but penalized for factual inaccuracy in the final numbers and lack of clarity on reporting years. Hence, correctness is reduced to 7 due to significant quantitative errors, though qualitative and contextual aspects remain strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 458,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has the strategic positioning and functionality of the Mastercard Developer Platform evolved between 2022 and 2024, particularly in terms of its role in enabling integration of digital assets and new technologies?",
      "original_answer": "In 2022, the Mastercard Developer Platform was described as a single access point that enables customers and partners to leverage Mastercard's digital assets and services, with an emphasis on ease of integration into new and existing solutions. By 2024, the platform continued to serve this role but expanded its strategic positioning by explicitly aligning with emerging technologies such as blockchain and digital currencies. In 2024, the platform was referenced in the context of enabling integration with the Mastercard Multi-Token Network™, which supports programmable payments and facilitates secure, scalable, and interoperable blockchain-based transactions. This evolution shows a shift from a general digital integration platform to one that specifically supports next-generation financial technologies and programmable commerce solutions.",
      "llm_answer": "\nBetween 2022 and 2024 Mastercard reframed its Developer Platform from a generic API‑access point into a strategic gateway for digital‑asset integration.  The 2024 disclosures highlight that the platform now provides a single, secure interface for connecting to Mastercard’s multi‑token network, AI‑driven fraud and decision tools, and blockchain‑focused services—enabling partners to embed programmable payments, crypto‑purchase and spend capabilities, and other emerging payment flows directly into their solutions.  This evolution positions the platform as the primary conduit for developers to leverage Mastercard’s expanding suite of digital‑asset and next‑generation technologies.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of the Mastercard Developer Platform from 2022 to 2024, noting its shift from a general API access point to a strategic gateway for digital assets and emerging technologies. The core factual elements—such as the platform’s role in enabling integration with blockchain, digital currencies, and the Mastercard Multi-Token Network™—are accurately reflected. (2) There are no numeric values, dates, or financial figures in dispute; all time references (2022, 2024) are correct and consistent with the original answer. (3) The multi-hop reasoning is sound: the model synthesizes information across years and technological developments, correctly inferring the platform’s expanded strategic positioning. The mention of the 'multi-token network' and 'programmable payments' matches the original answer’s emphasis. (4) The only minor deviation is the inclusion of 'AI-driven fraud and decision tools' and 'crypto-purchase and spend capabilities,' which are plausible extensions of Mastercard’s ecosystem but not explicitly mentioned in the ground truth. While these may be contextually accurate, they slightly extend beyond the provided evidence, preventing a perfect 10. However, the overall semantic meaning, completeness, and factual correctness remain very high. The answer is fully relevant to the question and captures the platform’s evolving functionality and strategic positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 410,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has the company's investment in U.S. common stocks within its pension plans evolved between 2022 and 2024, and what does this indicate about its strategic asset allocation?",
      "original_answer": "In 2022, the company reported no investments in U.S. common stocks within its pension plans, while by 2024, there was still no allocation to U.S. common stocks in the U.S. pension plan. However, the international pension plan maintained a $2 million investment in U.S. common stocks in both years. This indicates a continued strategic decision to avoid direct exposure to U.S. common stocks in the domestic pension portfolio while maintaining a minimal presence in the international portfolio.",
      "llm_answer": "\nBetween 2022 and 2024 the U.S. defined‑benefit pension plans held **zero shares of Colgate‑Palmolive common stock**—the company did not purchase any of its own shares in 2023 or 2024, and it had already sold its entire holdings in 2020. As a result, the plan’s allocation to the company’s own equity remained at **0 %**, reflecting a deliberate strategic shift to eliminate self‑stock exposure and rely on a broader, diversified mix of external assets.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to align with the ground truth on multiple levels. (1) The original answer states that there was no investment in U.S. common stocks in the U.S. pension plan in both 2022 and 2024, but the international pension plan held a $2 million investment in U.S. common stocks in both years. The LLM answer incorrectly shifts focus to 'Colgate-Palmolive common stock' and claims the company held zero shares of its own stock, which is a completely different metric and not equivalent to 'U.S. common stocks' as a broad asset class. (2) Quantitatively, the LLM introduces a fact about selling holdings in 2020 and not purchasing any in 2023 or 2024, which is not present in the ground truth and irrelevant to the question about U.S. common stock allocations in pension plans. The $2 million investment in the international plan is entirely omitted. (3) The reasoning is flawed: the LLM draws a conclusion about eliminating 'self-stock exposure', but the question and ground truth are about strategic allocation to U.S. common stocks broadly, not company-specific stock. This represents a failure in multi-hop reasoning and entity disambiguation. (4) While the answer is relevant to pension plan investments and asset allocation strategy, it addresses a different aspect (own-company stock vs. general U.S. equities), making it contextually related but factually and semantically divergent. The core facts, numbers, and synthesis are incorrect, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 414,
        "total_tokens": 1658
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How did Disney's strategic focus on cruise ships evolve between 2022 and 2023, particularly in terms of capital investment plans and operational risk considerations?",
      "original_answer": "In 2022, Disney highlighted cruise ships as a key part of its capital investment strategy within the Parks & Experiences segment, noting that a majority of its capital spending was directed toward theme parks, resorts, and cruise ships. This indicated a growth-oriented approach focused on expanding physical assets. By 2023, the emphasis had shifted toward operational risks associated with cruise ships, particularly in the context of external disruptions like hurricanes and global events (e.g., the impact of Hurricane Milton on Walt Disney World operations). The 2023 filing framed cruise ships more as an operational exposure rather than a growth engine, signaling a shift from investment to risk mitigation. This evolution reflects a recalibration of strategic focus from asset expansion to managing volatility and external threats.",
      "llm_answer": "\nBetween fiscal 2022 and 2023 Disney moved from treating cruise‑ship spending as part of a broad parks‑and‑experiences capital program to making explicit fleet‑expansion a strategic priority, announcing plans to add new ships and increase investment in the Experiences segment.  The 2023 10‑K notes that while these investments are intended to grow the cruise‑line business, they also raise execution and forecasting risks, potential write‑downs and exposure to economic, competitive and regulatory pressures that could affect profitability.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim about Disney's strategic evolution. The ground truth states that Disney shifted from a growth-oriented investment focus in 2022 to emphasizing operational risks in 2023, particularly due to external disruptions like hurricanes. In contrast, the LLM claims that Disney elevated cruise expansion to a 'strategic priority' in 2023 and increased investment focus, which contradicts the documented shift toward risk mitigation. This fundamental misrepresentation of the strategic direction severely undermines the answer's correctness. (2) There are no specific numeric values (e.g., dollar amounts, percentages, ship counts) in either the original or LLM answer, so quantitative accuracy is not heavily applicable; however, the LLM does not fabricate numbers, so no quantitative errors are present—hence a score of 8. (3) The multi-hop reasoning is flawed: the LLM fails to correctly synthesize the shift from capital investment emphasis (2022) to operational risk exposure (2023). Instead, it incorrectly asserts continued or heightened investment focus in 2023, missing the pivot entirely. The mention of 'execution and forecasting risks' is partially aligned with the original answer’s mention of risks, but it is framed as a side effect of growth rather than a central strategic concern, distorting the overall narrative. (4) Contextual relevance is moderate—the answer discusses cruise ships, capital investment, and risks in the relevant timeframe, so it stays on topic. However, due to the incorrect characterization of strategic focus, the qualitative accuracy is low. The answer conveys the opposite trend of what the ground truth describes, warranting a correctness score of 3—mostly incorrect with some relevant elements but major factual errors in synthesis and interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 502,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Mastercard's use of short duration foreign exchange derivative contracts evolved between 2022 and 2024, particularly in terms of their role in managing foreign exchange risk during daily settlement activities?",
      "original_answer": "In 2022, Mastercard used short duration foreign exchange derivative contracts to manage foreign exchange risk associated with daily settlement activities, aiming to reduce exposure to volatility from currency fluctuations on anticipated receipts and disbursements. By 2024, the company continued this practice, maintaining the same stated objective of minimizing volatility in gains and losses due to foreign exchange fluctuations. However, the context changed as the company actively adjusted its hedging strategies involving euro-denominated debt, de-designating and re-designating portions of it in 2023 and 2024, which indicates a more dynamic approach to managing foreign exchange exposure across the period. The continuity in the use of short duration contracts contrasts with the evolving structure of the company’s broader foreign exchange risk management strategy.",
      "llm_answer": "\nBetween 2022 and 2024 Mastercard moved from an informal, low‑volume use of short‑duration FX forwards to a more structured hedging program that still targets the few‑day foreign‑exchange exposure inherent in daily settlement but now covers far larger notional amounts (e.g., $3.9 bn of cash‑flow hedges and $2.7 bn of non‑designated contracts in 2024).  The contracts are still recorded in general‑and‑administrative expense, but the expanded book—encompassing cash‑flow, net‑investment and non‑designated derivatives—reflects a deliberate scaling of short‑term FX derivatives to manage settlement‑related currency volatility.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The claim that Mastercard moved from 'informal, low-volume use' in 2022 to a 'structured hedging program' in 2024 is not supported by the ground truth, which states that the company maintained the same objective and use of short-duration contracts throughout the period. The ground truth emphasizes continuity in the use of these contracts, not a shift in structure or scale. (2) The quantitative figures cited—$3.9 billion of cash-flow hedges and $2.7 billion of non-designated contracts in 2024—are not present in the original answer and cannot be verified against the provided ground truth. There are no dollar amounts or notional values mentioned in the original answer, so these numbers are fabrications or hallucinations. This severely undermines quantitative accuracy. (3) The multi-hop reasoning is flawed. While the LLM correctly identifies that short-duration FX derivatives are used for managing daily settlement risk, it incorrectly infers an evolution in strategy based on scaling and formalization. The actual evolution noted in the ground truth is not in the short-duration contracts themselves, but in the broader foreign exchange risk management strategy involving euro-denominated debt de-designation and re-designation in 2023 and 2024—information entirely missing from the LLM response. (4) Contextual relevance is moderate because the answer addresses the role of short-duration FX contracts in settlement risk, but it misrepresents the nature of change over time. The qualitative accuracy is low because the reasoning misattributes strategic evolution to the wrong instruments. The correctness score is low due to major factual and quantitative errors, despite some correct context about the purpose of the derivatives.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 492,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Salesforce's strategic relationship with enterprise cloud companies evolved from 2023 to 2024, particularly in terms of investment focus and ecosystem integration?",
      "original_answer": "In 2023, Salesforce maintained a portfolio of strategic investments in enterprise cloud companies, technology startups, and system integrators, with a focus on digitally transforming industries and expanding its solution ecosystem. These investments were described as ranging from early to late-stage companies, including those concurrent with initial public offerings. By 2024, Salesforce's relationship with enterprise cloud companies shifted from primarily investing to a broader strategic dependency, leveraging these partners as part of its ecosystem to accelerate reach into new markets and industries. The 2024 filing emphasized the Salesforce Platform's role in enabling third-party developers and ISVs to create and deliver cloud-based applications through the AppExchange, indicating a deepened integration and dependency on enterprise cloud partners beyond mere financial investment.",
      "llm_answer": "\nFrom fiscal 2023 through fiscal 2024 Salesforce’s strategic relationship with enterprise‑cloud partners shifted from a broad portfolio of investments in external cloud vendors toward a focused, AI‑centric platform strategy.  In 2024 the company emphasized native AI capabilities—Agentforce, Data Cloud and Industries AI—tightly integrating them with its core CRM, Slack and MuleSoft ecosystem, and leveraged a expanded partner and developer network (AppExchange, system‑integrators, ISVs) to deliver industry‑specific, autonomous agents and end‑to‑end connected experiences.  Consequently, investment priorities moved from acquiring and funding outside cloud businesses to building and scaling AI‑driven, industry‑focused services that deepen ecosystem integration and drive cross‑selling within the Salesforce platform.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Salesforce's strategic relationships from 2023 to 2024. It accurately captures the shift from a focus on financial investments in enterprise cloud companies and startups to a broader ecosystem integration strategy centered on platform enablement and partner collaboration. The mention of AppExchange, ISVs, and system integrators matches the original answer's emphasis on third-party developers and ecosystem leverage. The LLM adds specific AI-centric capabilities (Agentforce, Data Cloud, Industries AI) and integration with Slack and MuleSoft, which are contextually plausible extensions of Salesforce’s 2024 strategy but not explicitly mentioned in the ground truth. While these details may reflect real developments, they go beyond the provided knowledge graph, introducing elements not confirmed in the original answer. However, they do not contradict it and support the overall narrative of deeper ecosystem integration. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default. The reasoning is sound and reflects multi-hop synthesis—comparing strategic focus across years and inferring a shift from investment to integration. The answer is highly relevant and addresses both investment focus and ecosystem integration as required. The slight deduction in qualitative accuracy and overall correctness is due to the introduction of unverified AI-specific product details not present in the ground truth, though the core evolution in strategy is correctly interpreted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 443,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the company's approach to accrual rates for vendor funding programs evolve between fiscal 2023 and fiscal 2024, particularly in terms of sensitivity to projected purchase volumes?",
      "original_answer": "The company's approach to accrual rates for vendor funding programs remained methodologically consistent between fiscal 2023 and fiscal 2024, with no material changes in the recognition methodology over the past three fiscal years. However, in fiscal 2023, the company specifically highlighted sensitivity to 'graduated purchase volumes' that could impact accrued amounts, emphasizing the importance of projected volumes in determining accrual rates. In fiscal 2024, this explicit reference to 'graduated purchase volumes' was omitted, suggesting a potential simplification or stabilization in how accrual rates were adjusted throughout the year, despite continued monitoring of historical purchase trends and vendor confirmations.",
      "llm_answer": "\nThe company’s vendor‑funding accruals continue to be derived from the individual vendor agreement terms, with periodic review of historical purchase trends and volumes throughout the year.  In the fiscal 2024 discussion the firm stresses that actual purchase volumes are compared to projections and that accrual rates are adjusted when those volumes differ—especially for programs that increase funding at graduated volume thresholds—making the 2024 approach more explicitly sensitive to volume variance than in fiscal 2023.  Thus, while the underlying methodology remained the same, the 2024 reporting places greater emphasis on the impact of projected purchase volumes on the accrued funding amount.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains a fundamental misrepresentation of the evolution between fiscal 2023 and 2024, reversing the direction of emphasis on purchase volumes. According to the ground truth, in fiscal 2023 the company explicitly highlighted sensitivity to 'graduated purchase volumes,' but this language was omitted in fiscal 2024, suggesting reduced emphasis or stabilization. However, the LLM claims that the 2024 approach is 'more explicitly sensitive' and places 'greater emphasis' on volume variance—this is directly contradicted by the original answer, which indicates a de-emphasis in 2024. While the LLM correctly notes that the underlying methodology remained consistent and that historical trends and vendor confirmations are monitored (contextually relevant), it inverts the key qualitative change. There are no numerical figures to verify, so quantitative accuracy is high by default (no incorrect numbers, only misstated trends). The reasoning is internally logical but based on incorrect synthesis—this is a critical multi-hop failure where the model misinterprets the comparative disclosure across years. As such, the correctness and qualitative accuracy scores are low despite some accurate contextual elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 342,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has the strategic relationship between LLY and Boehringer Ingelheim evolved from 2022 to 2024, particularly in terms of legal involvement and collaborative dependency on the Jardiance product?",
      "original_answer": "In 2022, LLY was not a direct party to the Jardiance patent litigation initiated by Boehringer Ingelheim (BI) against generic drug manufacturers under the Hatch-Waxman Act, indicating a more arms-length relationship in legal matters. By 2024, LLY's business became significantly dependent on the Jardiance collaboration, as the product was selected under the Inflation Reduction Act (IRA) for government-set pricing with a 66% discount compared to the 2023 list price, directly impacting LLY's revenue projections and business strategy. This shift reflects a deeper strategic entanglement and dependency on BI's partnership for navigating regulatory and pricing pressures.",
      "llm_answer": "\nFrom 2022 through 2024 the Lilly‑Boehringer Ingelheim partnership has moved beyond simple co‑marketing of Jardiance to a tighter legal and financial interdependence.  Boehringer Ingelheim now defends and indemnifies Lilly in the growing product‑liability suits involving Jardiance (page 102) and the two firms jointly confront patent‑infringement disputes that have been stayed (page 102), while the IRA’s selection of Jardiance for government‑set pricing—identified as part of the Lilly‑BI collaboration (page 45)—has increased Lilly’s reliance on BI’s market‑access expertise and shared revenue to mitigate the resulting revenue‑erosion risk.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of the LLY-Boehringer Ingelheim relationship toward greater interdependence, particularly around Jardiance and the IRA pricing impact, which aligns with the ground truth. However, there are significant factual discrepancies that reduce correctness. First, the ORIGINAL ANSWER states that in 2022, LLY was *not* a direct party to the Hatch-Waxman litigation initiated by BI—indicating legal separation—whereas the LLM claims by 2024 that BI now defends and indemnifies LLY in 'growing product-liability suits' and that they 'jointly confront patent-infringement disputes.' This contradicts the ground truth: the original answer implies a shift from legal distance to dependency, but does not state or imply that BI indemnifies LLY or that they are jointly litigating. These specific legal arrangements (indemnification, joint defense) are not supported by the ground truth and appear to be fabricated or misattributed. Second, while the IRA’s 66% discount and selection of Jardiance for government pricing is correctly identified as a key driver of LLY’s increased dependency, the LLM does not mention the 66% figure—a quantitatively important detail—reducing quantitative accuracy. The reference to 'page 102' and 'page 45' suggests document citations, but without verification, these cannot be assessed; however, their inclusion does not compensate for factual misrepresentation. The reasoning is partially sound in connecting IRA pricing to increased collaboration dependency, but the legal evolution is inaccurately portrayed, undermining the multi-hop synthesis. Thus, while the strategic direction (increased dependency) is correct, the specific legal mechanisms and omission of key numbers reduce correctness. Contextual relevance is high as the answer addresses both legal and collaborative dimensions over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 502,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How did Disney's capital investment strategy toward cruise ships evolve from 2022 to 2023, particularly in relation to its broader Parks & Experiences business?",
      "original_answer": "In 2022, Disney's 10-K filing highlighted cruise ships as part of its broader Experiences segment but did not specifically emphasize capital investment in them, instead noting general risks from macroeconomic conditions such as inflation, supply chain delays, and currency fluctuations that could impact the implementation of business plans, including those for parks and resorts. By 2023, Disney explicitly listed cruise ships as part of its significant capital investments, indicating a strategic elevation in focus. The 2023 filing stated that the majority of the company’s capital spend was directed toward parks and experiences, including 'new attractions, cruise ships, capital improvements and systems infrastructure.' This shift demonstrates a clear prioritization of cruise ships as a key growth area within the broader Experiences segment.",
      "llm_answer": "\nFrom fiscal 2022 through fiscal 2023 Disney moved from a single‑project focus on a new private cruise‑line destination (the 550‑acre Lighthouse Point development slated for a 2024 opening) to a broader, multi‑year capital‑investment program that treats cruise‑ship construction and fleet expansion as a core pillar of its Parks & Experiences growth strategy.  The 2023 filing explicitly lists “new attractions, cruise ships, capital improvements and systems infrastructure” alongside theme‑park expansions, showing that Disney’s capital strategy evolved to allocate sustained funding to the Disney Cruise Line as an integral component of its overall Experiences portfolio.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the strategic shift in Disney's capital investment from 2022 to 2023, noting that cruise ships became a more explicit and sustained focus in 2023. It accurately reflects the broader Parks & Experiences context and cites the key phrase from the 2023 filing—'new attractions, cruise ships, capital improvements and systems infrastructure'—which aligns with the ground truth. However, the LLM introduces specific details not present in the original answer or implied by the question: namely, the '550-acre Lighthouse Point development' and its '2024 opening.' These details are factually questionable in this context—the original answer does not mention Lighthouse Point or any specific cruise-related project, nor does it provide acreage or opening dates. This constitutes a significant addition not supported by the ground truth. (2) Quantitative accuracy is partially compromised due to the inclusion of unverified specifics: '550-acre' and '2024 opening' are precise numbers not found in the original answer and cannot be confirmed from the provided knowledge graph. The original answer makes no mention of a private destination or timeline, so these figures are extraneous and potentially misleading. (3) The multi-hop reasoning is generally sound—the model correctly infers a strategic evolution from implicit to explicit capital allocation toward cruise ships and ties it to the broader Experiences segment. However, the reasoning is weakened by fabricating a prior state (single-project focus) that isn't substantiated in the ground truth. The original answer states that cruise ships were part of the segment in 2022 but not emphasized in capital investment, not that the focus was solely on Lighthouse Point. (4) Despite the overreach in specifics, the core conclusion—that Disney elevated cruise ships in its capital strategy by 2023—is correct and well-supported. The answer remains contextually relevant and captures the essence of the strategic shift, warranting a score of 7 for correctness. Quantitative accuracy is lower due to unsupported numbers, while qualitative and contextual scores remain high due to strong reasoning and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 589,
        "total_tokens": 1973
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has Mastercard Foundry's role in fostering innovation evolved between 2022 and 2024, particularly in relation to its engagement with emerging technologies and fintech partnerships?",
      "original_answer": "In 2022, Mastercard Foundry (formerly known as Mastercard Labs) was primarily described as a vehicle for bringing customers and partners access to thought leadership, innovation methodologies, new technologies, and early-stage fintech players. By 2024, its role had evolved into a more active innovation engine, with continued emphasis on identifying and experimenting with future technologies, start-ups, and trends. Specifically, in 2024, Foundry was positioned as a key enabler of blockchain-based business models and programmable payments through the Mastercard Multi-Token Network™, indicating a strategic shift toward deeper integration with next-generation financial technologies.",
      "llm_answer": "\nBetween 2022 and 2024 Mastercard Foundry moved from a primarily exploratory “lab” function to a more formalized innovation platform that actively co‑creates with fintech partners and integrates emerging technologies.  In 2022 it was described as a source of thought‑leadership and early‑stage fintech exposure, but by 2024 the Foundry was delivering concrete programs such as Launchpad prototyping workshops, AI‑driven fraud tools (Decision Intelligence Pro), blockchain‑enabled programmable payments via the Mul‑Token Network, and expanded open‑banking APIs—all of which reflect deeper, structured collaborations with fintechs and a focus on AI, tokenization, crypto‑services and real‑time payment flows.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly captures the evolution of Mastercard Foundry from a thought-leadership and early-stage innovation lab in 2022 to a more active, structured innovation engine by 2024. The key developments—engagement with blockchain via the Multi-Token Network, programmable payments, AI-driven tools (Decision Intelligence Pro), and fintech collaboration through programs like Launchpad—are consistent with the strategic shift described in the original answer. The mention of 'Mul-Token Network' appears to be a typographical error for 'Multi-Token Network,' but this does not significantly detract from factual accuracy. The LLM adds specific program names (e.g., Launchpad, Decision Intelligence Pro, open-banking APIs) not explicitly listed in the ground truth, but these are plausible extensions of Foundry’s 2024 activities and do not contradict the source. There are no numerical values to verify, so quantitative accuracy is scored as 10. The reasoning is sound, demonstrating correct multi-hop synthesis across time periods and strategic focus areas. The answer fully addresses the question’s focus on emerging technologies and fintech partnerships. Semantic equivalence is strong, with only minor wording differences and one minor error in product name spelling.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 371,
        "total_tokens": 1729
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the financial and strategic nature of the collaboration with Boehringer Ingelheim evolved between 2022 and 2024, particularly in terms of regulatory designations and pricing pressures?",
      "original_answer": "In 2022, the collaboration with Boehringer Ingelheim included the development of a therapy that had received Breakthrough Therapy and Fast Track designations from the FDA, indicating early-stage regulatory support and potential expedited development. By 2024, the collaboration faced significant pricing pressures under the Inflation Reduction Act, with Jardiance—part of the LLY-Boehringer Ingelheim partnership—selected for government-set pricing effective in 2026, subject to a 66% discount compared to the 2023 U.S. list price. This marks a shift from regulatory facilitation to regulatory-driven financial constraints.",
      "llm_answer": "\nBetween 2022 and 2024 the Lilly‑Boehringer Ingelheim partnership moved from a phase of accelerated regulatory approvals—empagliflozin (Jardiance) received Fast‑Track and Breakthrough‑Therapy designations and was submitted for, and later obtained, FDA approval for heart‑failure with preserved ejection fraction and chronic‑kidney‑disease indications (2022)—to a stage in which the product is now subject to the United States’ new price‑setting regime.  Under the Inflation‑Reduction Act, the Medicare program will impose a ~66 % discount on Jardiance in 2026 and similar rebate obligations, creating direct pricing pressure on the co‑developed therapy and forcing both companies to adjust their reimbursement and access strategies (e.g., 340B litigation, payer negotiations).  Thus, the collaboration’s financial and strategic focus shifted from securing regulatory speed‑ups to managing steep, government‑mandated price reductions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all key figures are correct: the ~66% discount on Jardiance under the Inflation Reduction Act and the 2026 effective date match the original answer. The mention of 2022 regulatory designations (Fast Track and Breakthrough Therapy) is consistent. (2) The LLM correctly identifies the shift from regulatory facilitation (in 2022) to pricing pressures (by 2024), capturing the core evolution in the collaboration's financial and strategic nature. (3) The reasoning is sound and multi-hop: it connects the early-stage regulatory support (FDA designations and approvals for specific indications) with later-stage government price-setting under the IRA, demonstrating synthesis across time and policy domains. (4) Minor deduction in qualitative accuracy because the LLM implies Jardiance received Breakthrough Therapy and Fast Track designations in 2022 for heart failure and CKD indications—while the original answer states the therapy (not necessarily Jardiance for those indications) had those designations, without specifying approval timing. However, this is a nuanced distinction and does not materially misrepresent the strategic shift. The addition of strategic responses (e.g., 340B litigation, payer negotiations) provides useful context beyond the ground truth and enhances relevance without introducing error. Overall, the answer is factually correct, comprehensive, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 411,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has the strategic positioning of the CH-53K King Stallion heavy lift helicopter evolved within Lockheed Martin's Rotary and Mission Systems segment from 2023 to 2024?",
      "original_answer": "In 2023, the CH-53K King Stallion heavy lift helicopter was described as part of Lockheed Martin's near-to-mid-term growth elements, specifically under the Rotary and Mission Systems (RMS) segment, alongside radar surveillance systems. By 2024, the CH-53K remained a highlighted program within RMS, but the emphasis shifted to framing it within a broader context of advancing all-domain mission solutions and digital technologies such as AI/ML and autonomy. While no specific revenue figures are provided, the helicopter's positioning evolved from being a growth driver among several others to being part of a more integrated, technologically advanced portfolio aimed at improving interoperability and supporting multi-domain solutions.",
      "llm_answer": "\nFrom 2023 to 2024 Lockheed Martin moved the CH‑53K King Stallion from a niche heavy‑lift asset—highlighted only by the 2023 Israel order—to a core growth pillar of its Rotary and Mission Systems segment. The 2024 filing explicitly places the CH‑53K in the company’s 21st Century Security strategy, underscoring expanded production for the U.S. Marine Corps, continued foreign‑military‑sales momentum, and deeper integration into joint all‑domain mission solutions.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains no explicit numerical data, so quantitative accuracy is not applicable—scored as 10 by default since no numbers were misstated. However, the qualitative accuracy is lower due to significant factual and reasoning discrepancies. The original answer states that in 2023, the CH-53K was part of near-to-mid-term growth elements within RMS alongside radar systems, with no mention of a 2023 Israel order—this detail is factually incorrect and unsupported by the ground truth. There is also no evidence in the original answer that the CH-53K was previously a 'niche heavy-lift asset' or that its positioning shifted from niche to 'core growth pillar'; rather, it remained a highlighted program with an evolved framing toward digital technologies and all-domain solutions. The LLM incorrectly infers a strategic elevation in status (from niche to core) not present in the source, and introduces specific claims (e.g., 'expanded production', 'foreign military sales momentum', '21st Century Security strategy') that are either unsupported or go beyond the original information. While the mention of 'joint all-domain mission solutions' aligns semantically with the 2024 emphasis on multi-domain interoperability, this is only partially accurate without the broader context of AI/ML and autonomy integration. The answer is contextually relevant and addresses the evolution question, but with overreach in specificity and unsupported claims, leading to a partial correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 410,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "What does the change in LLY's diabetes product portfolio co-commercialized with Boehringer Ingelheim between 2022 and 2024 indicate about the companies' shifting strategic priorities or market focus?",
      "original_answer": "In 2022, LLY and Boehringer Ingelheim were jointly developing and commercializing a broader portfolio of diabetes products, including Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR, and Basaglar. By 2024, the portfolio had narrowed to include only Jardiance, Glyxambi, Synjardy, and Trijardy XR. This indicates a strategic refocusing, potentially driven by lifecycle management, shifting market demand, or prioritization of products with stronger commercial performance or longer patent protection. The removal of Trajenta, Jentadueto, and Basaglar may reflect declining market relevance, generic competition, or a strategic decision to streamline the collaboration around products with greater growth potential or therapeutic differentiation.",
      "llm_answer": "\nThe 2022‑2024 filings show that Lilly and Boehringer Ingelheim have trimmed and refocused their co‑commercialized diabetes lineup around a smaller set of higher‑value, cardiometabolic products (e.g., Jardiance, Basaglar, Trulicity) and are now leveraging the partnership to push new access‑focused initiatives such as LillyDirect for obesity and diabetes.  This consolidation signals a strategic shift from a broad, diversified therapeutic portfolio toward a payer‑driven emphasis on obesity‑diabetes‑cardiovascular indications—areas where the companies can secure formulary placement and long‑term revenue growth.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies that significantly undermine its correctness. First, it incorrectly states that Basaglar and Trulicity are part of the co-commercialization portfolio with Boehringer Ingelheim in 2024. According to the ground truth, Basaglar was removed from the portfolio by 2024, and Trulicity is not mentioned as part of the co-commercialized products at all—Trulicity is a Lilly product but not co-commercialized with Boehringer Ingelheim. This misrepresentation of key entities (products) leads to an incorrect characterization of the strategic shift. Additionally, the LLM introduces 'LillyDirect for obesity and diabetes' and claims the partnership is pushing 'access-focused initiatives'—information not present in the original answer or supported by the knowledge graph, making it speculative. While the general idea of portfolio narrowing and strategic refocusing is correctly identified (hence partial credit), the specific products cited and the reasoning around obesity-cardiovascular focus are not aligned with the ground truth. The timeline (2022–2024) is correctly referenced, and the notion of consolidation is directionally accurate, but the core factual errors in product lineup and introduced concepts reduce the correctness. Quantitative accuracy is moderate because there are no explicit numbers, but the years are correct. Qualitative accuracy suffers due to incorrect entity mapping and unsupported strategic inferences. Contextual relevance is fair as the answer addresses the question's intent but with flawed content.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 431,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did the financial performance and strategic importance of the JASSM program evolve between 2023 and 2024, particularly in terms of production activity and its contribution to backlog?",
      "original_answer": "In 2023, JASSM was a product under the Missiles and Fire Control (MFC) segment, contributing to the company's portfolio of tactical missiles, but there was no specific mention of significant changes in its production volume or backlog contribution. By 2024, JASSM experienced a production ramp-up, contributing to a $1.2 billion increase in tactical and strike missile programs within MFC. Additionally, JASSM was specifically cited as a key contributor to the increase in backlog alongside PAC-3 and GMLRS. This indicates a notable rise in both production activity and strategic importance for JASSM in 2024.",
      "llm_answer": "\nIn 2024 the Missiles and Fire Control segment posted a 13 % rise in net sales to $12.68 bn, with JASSM accounting for roughly $1.2 bn of that growth as production ramped up; backlog climbed to $38.8 bn, driven by higher orders on JASSM (alongside PAC‑3 and GMLRS).  At the same time, operating profit fell 73 % YoY, because profit‑booking rate adjustments turned negative and a $1.4 bn loss on a classified program offset the volume gains, highlighting JASSM’s strategic importance for order growth even as it pressures near‑term margins.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the production ramp-up of JASSM in 2024 and its contribution to a $1.2 billion increase in tactical and strike missile programs, aligning with the ground truth. It also correctly notes JASSM's role in driving backlog growth alongside PAC-3 and GMLRS. However, the LLM introduces specific figures not present in the original answer, such as a 13% rise in net sales to $12.68 billion and a backlog of $38.8 billion, which are not mentioned in the ground truth and cannot be verified from it. Additionally, the claim about a 73% YoY drop in operating profit and a $1.4 billion loss on a classified program is absent from the original answer and represents extraneous, unverified information. (2) While the $1.2 billion contribution from JASSM is consistent with the ground truth, other numbers (e.g., $12.68B sales, $38.8B backlog, 13%, 73%, $1.4B loss) lack support in the original answer and may be factually incorrect in this context. The model appears to conflate or supplement with data outside the provided knowledge graph. (3) The multi-hop reasoning is partially sound: the model correctly infers increased strategic importance from production ramp-up and backlog contribution. However, introducing unmentioned financial impacts (profit decline due to classified program) reflects a reasoning overreach not supported by the source. (4) The correctness score is 7 because the core facts about JASSM’s increased production and backlog role are accurate and well-synthesized, but the addition of unsupported quantitative details reduces factual reliability. Quantitative accuracy is 6 due to several unverified numbers. Qualitative accuracy is 8 because the reasoning structure and entity identification (JASSM, MFC, PAC-3, GMLRS) are correct. Contextual relevance is 10 as the answer directly addresses the evolution of JASSM’s performance and strategic role.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 517,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has JPM's focus in evaluating credit risk for Business Banking Loans evolved between 2023 and 2024, and what implications does this shift have for identifying early signs of borrower distress?",
      "original_answer": "In 2023, JPM focused on Business Banking Loans as part of its broader prime consumer credit strategy, emphasizing loan performance and scoring models within the 'Consumer, excluding credit card loan portfolio' segment. By 2024, the focus shifted toward delinquency rates as the primary credit quality indicator, particularly noting that loans more than 30 days past due serve as early warnings of financial difficulty. This evolution suggests a more proactive stance in identifying early signs of borrower distress, aligning Business Banking Loans with broader consumer loan risk frameworks where early delinquency tracking enhances risk mitigation. The shift indicates a strategic move toward earlier intervention and more granular performance monitoring.",
      "llm_answer": "\nBetween 2023 and 2024 JPM shifted its Business‑Banking loan risk review from a largely delinquency‑focused approach to a multi‑factor, leading‑indicator model.  The 2023 disclosures relied mainly on payment‑status metrics (30‑149 days past due, 150+ days past due and gross charge‑offs), whereas the 2024 discussion adds detailed credit‑quality levers such as current LTV ratios, refreshed FICO scores, geographic concentration and Chapter 7 bankruptcy status as key signals of stress.  Consequently, early signs of borrower distress now include deteriorating credit scores, high‑LTV positions and emerging regional economic weakness—factors that can flag at‑risk borrowers before they reach formal delinquency.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both direction and content compared to the ground truth. (1) The original answer states that in 2023, JPM focused on loan performance and scoring models within the consumer segment, and in 2024 shifted to using delinquency rates (specifically >30 days past due) as the primary indicator—indicating a move toward earlier detection via delinquency tracking. In contrast, the LLM claims the opposite: that JPM moved *away* from delinquency-focused metrics in 2023 to a multi-factor model in 2024, which contradicts the ground truth. (2) Quantitatively, the LLM introduces specific metrics like '30-149 days past due', '150+ days past due', 'LTV ratios', 'refreshed FICO scores', 'geographic concentration', and 'Chapter 7 bankruptcy'—none of which appear in the original answer. There are no numerical values in the original to verify, but the LLM fabricates detailed metrics and categorizations not supported by the source. (3) The multi-hop reasoning is flawed: the original describes a convergence of Business Banking Loans with broader consumer risk frameworks via early delinquency tracking, while the LLM invents a sophisticated leading-indicator model absent from the source. This reflects a failure to correctly synthesize or retrieve the actual evolution. (4) While the LLM attempts to address the question’s structure—discussing a shift and implications—the substance is factually inverted and embellished. The contextual relevance is moderate because it discusses credit risk evolution in a plausible framework, but the factual inaccuracies severely undermine correctness. Thus, the correctness score is low at 3 due to major factual and directional errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 462,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did Target Corporation's SPP II plan terms evolve between the 2022 and 2023 filings, and what does this suggest about the company's executive compensation framework?",
      "original_answer": "In the 2022 filing, the SPP II plan was described under the 2016 Plan Statement, as amended and restated effective April 3, 2016. However, in the 2023 filing, the SPP II plan was updated to the 2022 Plan Statement, as amended and restated effective May 1, 2022. This indicates that Target Corporation revised the SPP II plan within this timeframe, reflecting a shift in the structure or terms of the plan. Such changes could signal adjustments in the company's executive compensation strategy, potentially aligning incentives more closely with updated business objectives or governance standards.",
      "llm_answer": "\nThe 2022 and 2023 Form 10‑K filings both list Target’s “Target Corporation SPP II (2016 Plan Statement) (as amended and restated effective April 3, 2016) (11)” without any noted amendment or new version between the two years. Thus, the substantive terms of SPP II—its performance‑metric triggers, award types (e.g., performance‑share units, restricted‑stock units, cash retention awards) and overall structure—have remained unchanged from the 2022 filing to the 2023 filing. This continuity signals that Target’s executive‑compensation framework is deliberately stable, relying on a long‑standing, performance‑driven incentive plan that has not been revised or expanded in the most recent reporting period.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core claim that the SPP II plan remained unchanged between the 2022 and 2023 filings. According to the ground truth, the plan evolved from the '2016 Plan Statement, as amended and restated effective April 3, 2016' in the 2022 filing to the '2022 Plan Statement, as amended and restated effective May 1, 2022' in the 2023 filing. This key factual detail — the update in the plan statement and effective date — is entirely missed by the LLM, which incorrectly asserts no change occurred. The LLM's claim of 'no noted amendment' contradicts the ground truth and suggests a failure in information retrieval or synthesis. As a result, the reasoning and conclusion about 'deliberate stability' in executive compensation are based on false premises and are therefore invalid. While the general description of award types (e.g., performance-share units) may be contextually plausible, they do not compensate for the central factual error. The answer fails the multi-hop requirement to compare plan terms across years and misidentifies the entity state (plan version) for 2023. Quantitative accuracy is low due to incorrect dates (April 3, 2016 cited as latest version when May 1, 2022 is correct). Contextual relevance is moderate because the answer addresses the right topic (SPP II, executive compensation) but draws incorrect inferences from inaccurate data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 386,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did the financial obligations related to Incyte under the Olumiant collaboration evolve from 2022 to 2024, particularly regarding potential future milestone payments?",
      "original_answer": "In 2022, Incyte was eligible to receive up to $100.0 million in additional development-related regulatory milestones and another $100.0 million in sales-based milestones under the Olumiant agreement. By 2024, there is no mention of remaining regulatory milestones, suggesting they were either paid out or no longer applicable, and only ongoing royalty payments based on sales tiers (up to 20%) and a low teens royalty for sales exceeding a threshold in the context of COVID-19 treatment are explicitly referenced. This indicates a shift from a structure with both regulatory and sales milestones to one focused primarily on sales-based compensation.",
      "llm_answer": "\nFrom 2022 through 2024 the Olumiant partnership with Incyte moved from a standing‑by schedule of up to **$100 million of regulatory‑milestone payments and $100 million of sales‑milestone payments** (as disclosed in the 2022 filing, Note 4/Note 5) toward near‑term realization of those targets.  By the 2024 filing the company reports that the $260 million and $210 million milestones that were capitalized in 2020‑2021 have been amortized, and the only remaining contingent amounts are modest additional regulatory milestones for new indications—none of which are material to cash flow.  Consequently, the company’s future financial obligation to Incyte under the Olumiant collaboration is now limited to the standard tiered royalty (up to 20 % on net sales) and the low‑teens royalty on COVID‑19 sales, with essentially **no material additional milestone payments expected** beyond what has already been recorded.  (LLY_10k_2022.pdf pp. 71‑73; LLY_10k_2024.pdf pp. 73‑74).",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of financial obligations from milestone-based to royalty-focused, correctly identifying the shift to tiered royalties (up to 20%) and low-teens royalty for COVID-19 sales, which aligns with the ground truth. However, there are significant quantitative inaccuracies: the LLM claims that '$260 million and $210 million milestones that were capitalized in 2020-2021 have been amortized,' which is not supported by the original answer or consistent with the $100M regulatory and $100M sales milestones mentioned in 2022. These figures ($260M, $210M) do not appear in the ground truth and represent a major factual error. Additionally, the original answer does not mention amortization of past milestones, nor does it confirm whether the $100M regulatory milestones were paid—only that they are no longer mentioned in 2024. The LLM overreaches by asserting 'no material additional milestone payments expected' based on amortization details absent from the source. While the qualitative shift is correctly interpreted (from dual milestones to sales-based royalties), the reasoning is flawed due to fabricated numerical details. The context and structure of the response are highly relevant, and the entity (Incyte, Olumiant) and timeline (2022 to 2024) are accurate. Thus, while the direction of change is right, the use of incorrect dollar amounts and unsupported calculations severely undermines factual correctness, warranting a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 407,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has Cisco's financial exposure in the APJC region evolved between fiscal 2022 and fiscal 2023, based on its segment reporting and asset balances?",
      "original_answer": "In fiscal 2022, Cisco reported its business performance across geographic segments including APJC, though specific financial figures for APJC were not disclosed in the provided data. By fiscal 2023, Cisco's balance sheet showed that its assets in the APJC region stood at $5,382 million as of July 29, 2023, following additions from acquisitions and foreign currency translation adjustments. This indicates a more detailed financial disclosure regarding APJC in 2023 compared to 2022, where segment-level asset values were not explicitly itemized.",
      "llm_answer": "\nCisco’s APJC revenue slipped modestly from $8.03 billion in fiscal 2022 to roughly $7.7 billion in fiscal 2023, and the company’s long‑lived assets in the region fell from $997 million (end‑FY22) to about $900 million (end‑FY23), indicating a slight reduction in tangible exposure.  At the same time, goodwill allocated to APJC was essentially unchanged – rising only $22 million to $5.38 billion at the close of FY 2023 – so the region’s financial exposure shifted marginally toward acquired intangibles rather than a major change in overall asset balances.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Cisco did not disclose specific financial figures for the APJC region in fiscal 2022, but the LLM claims precise revenue and asset numbers for both years (e.g., $8.03 billion revenue in FY22, $7.7 billion in FY23, long-lived assets of $997 million and $900 million), which are not supported by the provided data. The only confirmed figure in the ground truth is APJC assets of $5,382 million as of July 29, 2023, which the LLM mischaracterizes as 'goodwill' rather than total assets. While the LLM correctly notes a shift in disclosure practices, it fabricates comparative financials for 2022 that were not available. (2) Quantitative accuracy is very low: revenue figures are entirely absent from the ground truth, and the $997M to $900M decline in long-lived assets is unsupported. The $5.38 billion figure is misrepresented as goodwill when it refers to total APJC assets. No calculations are required in the original, but the use of false inputs invalidates any derived conclusions. (3) The multi-hop reasoning is flawed because the model assumes segment-level revenue and asset disclosures were made in 2022 when they were not. It incorrectly synthesizes non-existent 2022 data with 2023 asset balances, leading to a false narrative of declining exposure. The observation about increased disclosure detail in 2023 is partially aligned with the ground truth, but this is overshadowed by fabrication. (4) Scores are low due to major factual errors, especially in quantitative claims and entity misidentification (total assets vs. goodwill). Contextual relevance is moderate because the answer addresses the right region and time frame and attempts to discuss financial exposure trends, albeit incorrectly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 491,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the strategic collaboration between LLY and Boehringer Ingelheim, specifically regarding Jardiance, evolved from 2022 to 2024 in response to regulatory changes?",
      "original_answer": "In 2022, Jardiance revenue was growing significantly, with a 30% increase in the U.S. and 28% outside the U.S., driven by increased demand and volume respectively. By 2024, the collaboration was significantly impacted by the Inflation Reduction Act (IRA), which introduced government-set pricing for certain drugs, including Jardiance. In August 2023, Jardiance was selected as one of the first ten medicines subject to government-set prices, and in August 2024, a 66% discount was applied compared to the 2023 U.S. list price, significantly affecting revenue projections and business strategy.",
      "llm_answer": "\nFrom 2022 through 2024 the Lilly‑Boehringer Ingelheim partnership on Jardiance shifted from a pure growth‑driven launch to a strategy that must now accommodate U.S. price‑control rules.  While revenue had been expanding (e.g., a 30 % U.S. increase in 2021 and continued double‑digit gains in 2022), the Inflation‑Reduction Act forced HHS in August 2023 to name Jardiance among the first ten drugs subject to government‑set pricing, and in August 2024 a 66 % discount relative to the 2023 list price was announced.  In response, Lilly and Boehringer have begun renegotiating commercial terms, tightening cost‑control and emphasizing non‑U.S. markets and new cardiovascular indications to offset the anticipated revenue erosion from the mandated price cuts.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth with only a minor discrepancy in quantitative detail. (1) Correctly identifies the strategic shift due to the Inflation Reduction Act (IRA), the August 2023 selection of Jardiance for government pricing, and the 66% discount implemented in August 2024. It accurately reflects the impact on the LLY-Boehringer Ingelheim collaboration, including strategic responses like renegotiating terms, cost control, and focus on non-U.S. markets and new indications. (2) Quantitative accuracy: The LLM states a 30% U.S. increase in 2021, but the ground truth specifies this growth occurred in 2022. This is a factual error in year attribution, though the percentage (30%) and context (U.S. growth) are correct. All other numbers—28% ex-U.S. growth (implied in context), 66% discount in August 2024—are consistent with the truth. (3) Multi-hop reasoning is sound: the model correctly links regulatory change (IRA) → HHS action (August 2023 selection) → price cut (August 2024) → strategic response by both companies. It synthesizes cause-effect across time and entities. (4) Semantic equivalence is strong; wording differs but meaning matches. The added detail about renegotiation and cost control is reasonable inference and enhances completeness without introducing error. The single misattribution of the 30% growth to 2021 instead of 2022 prevents a perfect 10, but overall correctness remains very high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 408,
        "total_tokens": 1751
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did GM's emphasis on the financial and reputational risks of product safety recalls evolve between 2022 and 2023, particularly concerning global platforms like the Chevrolet Bolt EV and the company's positioning in EV/AV technologies?",
      "original_answer": "In 2022, GM specifically highlighted the Chevrolet Bolt EV recall as an example of how global platform-related recalls could significantly increase costs due to their scale. The focus was on the financial burden and logistical complexity tied to such large-scale campaigns. By 2023, while the concern around global platforms remained, GM expanded its risk disclosure to emphasize the reputational damage to brand image and equity, particularly in relation to its leadership aspirations in EV and AV technologies. This evolution suggests a shift from a primarily cost-centric concern to a broader strategic risk tied to innovation and market positioning.",
      "llm_answer": "\nBetween 2022 and 2023 GM’s disclosures shifted from a general warning that a recall on a global platform—exemplified by the Chevrolet Bolt EV—could “exacerbate” recall costs and damage reputation, to a more pronounced emphasis that safety‑related recalls and perceived defects in its EV and AV technologies could trigger product delays, lost sales, regulatory action and substantial brand‑damage.  The 2023 filing expands the narrative to stress that concerns about the safety of its advanced‑technology vehicles, whether raised by regulators, consumers or internally, could materially harm GM’s reputation, erode consumer trust and jeopardize its positioning in the EV/AV market, underscoring a heightened focus on both the financial and reputational risks of product‑safety recalls as the company pushes deeper into electric and autonomous mobility.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution in GM's risk disclosures between 2022 and 2023 with strong semantic equivalence to the ground truth. (1) It correctly identifies the Chevrolet Bolt EV as the key example in 2022 and notes the focus on increased costs and logistical challenges due to the global platform scale. In 2023, it accurately reflects the expanded emphasis on reputational damage, consumer trust, brand equity, and implications for GM’s leadership in EV/AV technologies. (2) There are no numeric values in the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes information across years and themes (financial → reputational risk), connects the Bolt EV recall to broader platform risks, and links safety concerns to strategic positioning in emerging technologies. The only minor shortcoming is that the LLM slightly overstates the 2022 stance by saying it included 'damage reputation'—the original indicates 2022 focused primarily on financial burden, while reputational concerns became prominent in 2023. This nuance is mostly preserved, but not perfectly, justifying a 9 instead of 10 on qualitative accuracy. (4) The response is fully contextually relevant, directly addressing the evolution in GM's emphasis concerning global platforms, EV/AV positioning, and product safety recalls.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 390,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the Guaranteed Senior Notes issued by Costco's Japanese subsidiary evolve between 2022 and 2024, and what does this indicate about the company's long-term financing strategy?",
      "original_answer": "In 2022, the Guaranteed Senior Notes issued by Costco's Japanese subsidiary were described in general terms, indicating only their existence and that they were valued using Level 3 inputs. By 2024, the company provided significantly more detailed information, disclosing that in November 2023, the subsidiary issued four new Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%, with maturities extending from 2033 to 2043. Additionally, in July 2024, the subsidiary repaid $77 of these notes. This evolution indicates a more transparent and strategic approach to long-term financing, with a focus on fixed-rate debt and extended maturities to manage future liquidity needs.",
      "llm_answer": "\nBetween 2022 and 2024 the balance of the Japanese subsidiary’s Guaranteed Senior Notes rose from roughly **$590 million (2022)** to **$484 million (2023)** and then to **$919 million (2024)**—driven by a **~$500 million issuance in November 2023** and a **partial $77 million repayment in July 2024**, leaving a net increase.  This pattern shows that Costco is intentionally expanding long‑term, low‑cost foreign‑currency financing through its Japan unit to fund overseas operations and diversify its overall capital structure.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. According to the ground truth, in 2022, no specific balance was disclosed for the Guaranteed Senior Notes—only that they existed and were valued using Level 3 inputs. The LLM incorrectly states the balance was $590 million in 2022, $484 million in 2023, and $919 million in 2024. These figures are not supported by the original answer and contradict the disclosed net issuance and repayment. The $500 million issuance in November 2023 is correctly identified in magnitude but mischaracterized as increasing the balance to $919 million, which is inconsistent with the repayment of $77 million. The original answer states that approximately $500 was issued and $77 was repaid, but does not provide a cumulative balance, let alone the specific figures cited by the LLM. (2) The dates are partially correct—the November 2023 issuance and July 2024 repayment are accurately placed—but the LLM fabricates balances for years not disclosed in the ground truth. The interest rates (1.400% to 2.120%) and maturities (2033–2043) are omitted entirely, which are key qualitative details. (3) The reasoning is flawed: the LLM infers a rising balance trend that is not substantiated and attributes it to a net increase, but the original answer does not provide enough data to support such a trajectory. The conclusion about expanding foreign-currency financing is plausible but not directly supported by the disclosed information, which emphasizes transparency and fixed-rate, long-term debt rather than capital structure diversification. (4) The contextual relevance is moderate—the answer addresses the evolution and strategy—but the severe quantitative errors and missing key disclosures (interest rates, maturities, lack of 2022 balance) undermine correctness. The qualitative reasoning is partially sound but built on false numerical premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 513,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the value of Cisco's available-for-sale debt investments change between 2022 and 2023, and what does this indicate about the company's investment strategy?",
      "original_answer": "In 2022, Cisco reported gains from available-for-sale debt investments at $9 million, indicating a relatively minor role in their investment portfolio. By 2023, the total value of these investments dropped significantly from $15,592 million to $9,865 million, a decrease of $5,727 million. This indicates a strategic reduction in the company's holdings of available-for-sale debt instruments, suggesting a shift in investment focus or risk management approach.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 Cisco’s available‑for‑sale debt investments grew from **$11.9 billion** (as of July 30 2022) to **$15.6 billion** (as of July 29 2023), an increase of roughly **$3.6 billion (≈30 %)**.  This rise indicates that Cisco is deploying excess cash into high‑quality, investment‑grade debt securities—enhancing portfolio yield while preserving liquidity for strategic uses such as future acquisitions, stock repurchases and dividend payments.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both direction and magnitude of change in Cisco's available-for-sale debt investments between 2022 and 2023. According to the ground truth, the value of these investments decreased from $15,592 million to $9,865 million—a drop of $5,727 million—indicating a strategic reduction. However, the LLM claims an increase from $11.9 billion to $15.6 billion, which is factually wrong. The cited values do not match the ground truth: the starting value in 2022 is misstated ($11.9B vs actual $15,592M), and the ending value, while close to the 2022 figure in the truth, is misrepresented as a 2023 increase. The calculation of a $3.6 billion increase is therefore erroneous. Furthermore, the conclusion that Cisco is expanding its investment in debt securities contradicts the actual trend of divestment. The reasoning and synthesis are unsound, failing to reflect the correct multi-hop facts across years and misrepresenting the strategic implication. While the answer addresses the question's structure (change in value and interpretation), its factual foundation is entirely flawed, leading to a very low correctness score. Contextual relevance is moderate because it attempts to interpret investment strategy, but the interpretation is based on false data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 360,
        "total_tokens": 1597
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has JPMorgan Chase's exposure to system damage risks evolved from 2023 to 2024, particularly in relation to third-party vendor attacks and data recovery challenges?",
      "original_answer": "In 2023, JPMorgan Chase highlighted risks related to system damage primarily through unauthorized access, zero-day vulnerabilities, and disruptions from distributed denial-of-service attacks. The company emphasized the risk of undetected vulnerabilities due to incomplete system enhancements and the potential for data loss or manipulation. By 2024, the exposure evolved to include more specific emphasis on ransomware attacks targeting third-party vendors and the risk of losses exceeding cyber insurance coverage. Additionally, JPMorgan Chase noted increased complexity in recovering from data theft or destruction, with a new concern around the inability to prevent systems from processing fraudulent transactions. These changes indicate a growing awareness of external cyber threats and their financial implications.",
      "llm_answer": "\nFrom 2023 to 2024 the firm’s warning moved from a generic caution about reliance on third‑party providers and the possibility of operational breakdowns to a more pointed focus on ever‑more sophisticated cyber threats—such as AI‑driven fraud, quantum‑computing vulnerabilities and ransomware—that can compromise data integrity and extend the time needed to restore it. The 2024 filing also stresses that after a breach the ability to fully recover stolen or manipulated information may be delayed, increasing the risk of prolonged downtime, higher remediation costs and greater regulatory or litigation exposure.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general trend of increasing cyber risk concerns from 2023 to 2024 and correctly identifies heightened focus on third-party risks and data recovery challenges, which aligns with the question's intent. However, it introduces speculative and unsupported elements not present in the ground truth, such as 'AI-driven fraud' and 'quantum-computing vulnerabilities,' which are not mentioned in the original 2023 or 2024 disclosures. The original answer specifies that in 2023, JPMorgan highlighted risks from unauthorized access, zero-day vulnerabilities, and DDoS attacks, with concerns about undetected vulnerabilities and data manipulation. In 2024, the evolution included a more specific focus on ransomware attacks targeting third-party vendors and the risk of losses exceeding cyber insurance coverage, as well as an emerging concern about inability to prevent fraudulent transaction processing post-breach. The LLM answer correctly notes increased complexity in data recovery and prolonged downtime, which is semantically close to the original's 'inability to fully recover stolen or manipulated information.' However, it fails to mention key factual developments like insurance coverage limits and fraudulent transaction processing, while adding unverified technological threats. There are no numerical values to assess, so quantitative accuracy is scored as 10 by default. The reasoning is partially sound but includes incorrect attribution of new risks not documented in the source, reducing qualitative accuracy. Contextually, the response remains relevant to the topic of evolving cyber risks and third-party exposure, hence a higher relevance score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 457,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "What operational investments has Costco made by 2024 to support the private-label growth strategy mentioned in its 2022 filing?",
      "original_answer": "In 2022, Costco emphasized increasing the penetration of its private-label items as a merchandising strategy to manage inflationary pressures and maintain competitive pricing. By 2024, Costco had made tangible operational investments to support this strategy, including the operation of various processing, packaging, and manufacturing facilities dedicated to the production of private-label items. These facilities, referenced in the 2024 filing, represent a significant evolution from the earlier strategic focus, demonstrating a shift from sourcing private-label products externally to building internal production capabilities to scale the initiative.",
      "llm_answer": "\nBy the end of 2024 Costco had deployed capital to enlarge its private‑label production base – building and upgrading processing and packaging facilities that actually manufacture private‑label items – and had simultaneously expanded its warehouse footprint (e.g., opening dozens of new stores and adding over 130 million sq ft of floor space) to give the broader private‑label assortment the shelf‑space and distribution capacity it needs. These investments also strengthened the supply‑chain and logistics network that moves the newly produced private‑label goods from the facilities to the expanded store base.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core qualitative idea that Costco made operational investments in processing, packaging, and manufacturing facilities to support private-label growth, which aligns with the ground truth. It correctly identifies the strategic intent and mentions supply chain and distribution enhancements. However, it introduces specific quantitative claims not present in the original answer or supported by the provided context: (1) 'over 130 million sq ft of floor space' and (2) 'dozens of new stores' are unsupported by the ground truth, which does not include any numerical data about store openings or square footage. These fabricated figures significantly reduce quantitative accuracy. Additionally, while the ground truth emphasizes a shift from external sourcing to internal production capabilities as a key evolution, the LLM answer does not clearly convey this strategic transformation. The reasoning is partially sound—linking production facilities to distribution and shelf space is logical—but fails to emphasize the strategic shift from sourcing to in-house production that is central to the original answer. The entities (Costco, private-label, 2024 investments) and timeframes are accurate, and the answer remains contextually relevant to the question. Semantic equivalence is partially achieved, but the inclusion of unverified quantitative details undermines factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 388,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How did UnitedHealth Group's approach to Medicaid managed care contract bidding evolve between 2022 and 2023, particularly in terms of assumptions and risks associated with bid accuracy?",
      "original_answer": "In 2022, UnitedHealth Group emphasized the risk of losing Medicaid members if it failed to renew state Medicaid managed care contracts, highlighting the importance of contract renewals to retain enrolled members. By 2023, the company placed greater emphasis on the assumptions behind its bids, noting that if these assumptions—such as enrollment, utilization, and medical costs—were materially incorrect due to unforeseen program changes or competitor pricing, it could materially affect results of operations and cash flows. This reflects an evolution from a focus on contract renewal risk to a more detailed discussion of the assumptions and competitive dynamics involved in the bidding process itself.",
      "llm_answer": "\nBetween 2022 and 2023 UnitedHealth sharpened its Medicaid‑managed‑care bidding approach by tying each bid more directly to CMS‑calculated benchmarks—particularly the enrollee‑premium threshold required for automatic low‑income enrollment under Medicare Part D—and by subjecting those bids to heightened risk‑adjustment data‑validation audits.  The company still based its bids on assumptions about enrollment, utilization and medical‑cost trends, but it now emphasizes that any material miss‑specification—whether from unexpected policy changes, competitor under‑bidding, or audit‑driven recoupments or fines—could result in loss of contracts, premium adjustments or other financial penalties, making the accuracy of those assumptions a more central risk.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some correct elements but introduces significant inaccuracies and misrepresents the evolution described in the ground truth. (1) Correct aspects: The emphasis on assumptions like enrollment, utilization, and medical costs in 2023 aligns with the original answer, as does the idea that incorrect assumptions could materially affect operations. The general shift toward greater scrutiny of bid accuracy is contextually relevant. (2) Quantitative accuracy is acceptable because no specific numbers (e.g., dollar amounts, percentages) are provided or misstated—dates (2022–2023) are correct. (3) However, the qualitative accuracy is low because the LLM fabricates key details not present in the original: references to 'CMS-calculated benchmarks', 'Medicare Part D', 'automatic low-income enrollment', and 'risk-adjustment data-validation audits' are entirely absent from the ground truth and mischaracterize Medicaid managed care bidding. These are Medicare-related mechanisms and do not align with the actual focus on state-level Medicaid contract renewals and bid assumptions. Additionally, the original answer highlights a shift from *contract renewal risk* (2022) to *bid assumption risk* (2023), which the LLM does not clearly capture. Instead, it invents a more technical and regulatory-heavy evolution that is unsupported by the source. (4) Contextual relevance is moderate because the answer stays within the domain of Medicaid bidding risks but drifts into incorrect regulatory frameworks. The core multi-hop reasoning—comparing UnitedHealth’s changing risk disclosures across years—is partially sound but based on fabricated content rather than accurate synthesis. Thus, while the direction of change (increased focus on bid accuracy) is roughly correct, the specifics are factually wrong, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 500,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How did MET's investment in Municipals evolve from 2022 to 2023, particularly in terms of its valuation hierarchy classification?",
      "original_answer": "In 2022, MET's investment in Municipals was valued at $14,212 million and primarily categorized under 'Estimated Fair Value' without a detailed breakdown of valuation hierarchy levels. By 2023, the investment in Municipals decreased to $159 million and was explicitly classified under 'Level 2' of the fair value hierarchy. This indicates a significant reduction in the size of the Municipals investment and a more transparent categorization within the fair value hierarchy in 2023.",
      "llm_answer": "\nFrom 2022 to 2023 MetLife’s municipal‑bond holdings stayed in the Level 2 tier of the fair‑value hierarchy, but their reported fair value slipped modestly from **$159 million (2022)** to **$147 million (2023)**. This decline reflects a slight reduction in the municipal portfolio’s size, while the classification remained Level 2 (i.e., valuations based on independent pricing sources or other observable inputs rather than quoted prices in an active market). No Level 3 classification was reported for municipals in either year.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual errors in both direction and magnitude of the investment change. According to the ground truth, MET's investment in Municipals was $14,212 million in 2022 and dropped to $159 million in 2023—a massive reduction. However, the LLM incorrectly states that the value decreased from $159 million (2022) to $147 million (2023), reversing the trend and misrepresenting the scale of the change by over 98%. This is a critical quantitative error. (2) The valuation hierarchy classification is partially correct: the LLM correctly notes that in 2023 the investment was classified as Level 2. However, it incorrectly claims that it was already Level 2 in 2022, whereas the original answer states that in 2022 the investment was categorized under 'Estimated Fair Value' without a detailed breakdown of hierarchy levels. Thus, the LLM fabricates a Level 2 classification for 2022 that is not supported by the ground truth. (3) The multi-hop reasoning is flawed: the question asks about evolution in both valuation amount and hierarchy classification across two years. The LLM fails to capture the dramatic decrease in investment size and misrepresents the transparency improvement in hierarchy disclosure. It also misses the key point that 2023 introduced explicit Level 2 classification where 2022 lacked such granularity. (4) Despite these serious errors, the answer is contextually relevant—it addresses the right company (MET/MetLife), the right asset class (Municipals), and the right concept (fair value hierarchy). The explanation of Level 2 is accurate in general terms. However, due to severe inaccuracies in numbers and misrepresentation of historical classification, the overall correctness score is very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 478,
        "total_tokens": 1727
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has Microsoft's approach to Office 365 subscriptions evolved in terms of licensing flexibility and customer agreement models from fiscal year 2022 to 2024?",
      "original_answer": "In fiscal year 2022, Office 365 subscriptions were primarily managed under volume licensing programs and were recognized as part of unearned revenue, invoiced annually at the beginning of each contract period and recognized ratably over the coverage period. By fiscal year 2024, Microsoft introduced more structured and flexible customer agreement models, including the Microsoft Customer Agreement, Microsoft Online Subscription Agreement, and Microsoft Products and Services Agreement, which allowed customers to subscribe to cloud services seamlessly and directly, with options for monthly or annual subscriptions and no organization-wide commitment. This represents a shift toward enhanced customer-centric licensing flexibility.",
      "llm_answer": "\nBetween fiscal 2022 and 2024 Microsoft broadened how customers can obtain Office 365/Microsoft 365, moving from a mainly volume‑licensing/Software Assurance model to a suite of simplified, non‑expiring subscription agreements—Enterprise Agreements, Microsoft Customer Agreements, Microsoft Online Subscription Agreements, and Microsoft Products & Services Agreements—that can be used for perpetual licenses with optional SA or pure subscription terms. This greater flexibility lets organizations of all sizes choose perpetual, subscription‑only, or consumption‑based options, and the company now recognizes Office 365 revenue ratably over the subscription period as a single performance obligation.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its overall narrative and correctly identifies the shift in Microsoft's licensing and agreement models from fiscal 2022 to 2024. It accurately names key agreements introduced by 2024: Microsoft Customer Agreement, Microsoft Online Subscription Agreement, and Microsoft Products & Services Agreement, aligning with the ground truth. The recognition of revenue ratably over the subscription period is also factually correct and consistent with the original answer.\n\nHowever, there are some qualitative inaccuracies in reasoning and entity representation. The LLM incorrectly suggests that perpetual licenses and Software Assurance (SA) are part of the new flexible subscription models (e.g., 'perpetual licenses with optional SA'), which contradicts the ground truth emphasis on cloud-based, no-commitment, direct subscriptions. The original answer highlights a move *away* from traditional volume licensing toward customer-centric, flexible cloud subscriptions—particularly for organizations wanting to avoid long-term or organization-wide commitments. The mention of 'Enterprise Agreements' as part of the new flexible model is misleading; these were legacy volume licensing vehicles, not part of the newer flexible agreements.\n\nAdditionally, the LLM implies that consumption-based options are explicitly part of the 2024 model, which is not mentioned in the ground truth and represents an unsupported extension.\n\nQuantitatively, there are no numbers, dates, or financial figures in the question or answer, so quantitative accuracy is not applicable—scored as 10 by default. Contextual relevance is high, as the answer directly addresses the evolution in licensing and agreement models. The core facts about increased flexibility and new agreement types are correct, but the reasoning contains some mischaracterizations of the nature of the shift, particularly around perpetual licensing, which reduces the qualitative and overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 534,
        "total_tokens": 1895
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the composition of MET's Level 3 Fixed Maturity Securities AFS change between 2022 and 2023, and what does this indicate about the company's investment strategy?",
      "original_answer": "In 2022, MET's Level 3 Fixed Maturity Securities AFS included $1 million in Corporate bonds, $1 million in Foreign Bonds, and $11 million in Equity Securities. By 2023, the Level 3 composition shifted significantly, with $54 million in Corporate bonds, $2 million in Foreign Bonds, and $828 million in Other Investments. This indicates a strategic shift toward increasing exposure in Other Investments while maintaining a relatively small position in Level 3 fixed maturity securities overall. The significant increase in Other Investments within Level 3 suggests a more aggressive approach to portfolio diversification or risk management.",
      "llm_answer": "\nBetween 2022 and 2023 the Level 3 Fixed‑Maturity‑Securities‑AFS portfolio edged up from **$58 million to $64 million**.  The corporate component stayed essentially unchanged (~$55 M), while the “other” Level 3 slice grew from $3 M to $8 M and a new $2 M foreign‑bond position appeared, so the 2023 mix includes a small but noticeable increase in foreign sovereign and other less‑observable assets.  \n\nThis modest shift indicates that MetLife is **gently diversifying its Level 3 holdings—adding foreign‑bond and alternative‑type exposures—while still keeping Level 3 assets a tiny fraction of the overall fixed‑maturity book**, reflecting a cautious, yield‑enhancing investment strategy that avoids large‑scale commitments to illiquid, complex securities.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, MET's Level 3 Fixed Maturity Securities AFS consisted of $1M in Corporate bonds, $1M in Foreign Bonds, and $11M in Equity Securities (totaling $13M, not $58M). In 2023, it was $54M in Corporate bonds, $2M in Foreign Bonds, and $828M in Other Investments (totaling $884M, not $64M). The LLM incorrectly reports total portfolio sizes, misidentifies $55M as the corporate component in 2022 (when it was only $1M), and completely omits the $828M in Other Investments in 2023, instead reporting only $8M. The LLM also incorrectly states that Equity Securities were replaced by 'Other' investments growing from $3M to $8M, which contradicts the ground truth. (2) Calculations are fundamentally wrong: the LLM claims a total increase from $58M to $64M, but the actual total increased from $13M to $884M—a massive shift the LLM fails to capture. The reported $55M corporate bond holding in 2022 is off by a factor of 54x. (3) Multi-hop reasoning is flawed: the LLM fails to recognize the strategic shift toward 'Other Investments' as a dominant new category, instead characterizing the change as 'gentle diversification' with minor additions. This misrepresents the scale and nature of the strategic shift. (4) Contextual relevance is moderate—the answer addresses the question structure (change over time and strategy implication) and mentions diversification, but due to severe factual errors, the conclusion about a 'cautious, yield-enhancing strategy' is incorrect; the ground truth suggests a more aggressive shift into Level 3 'Other Investments,' indicating a significant strategic change, not a cautious one.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 469,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How has Microsoft's strategic positioning of Office 365 evolved between 2022 and 2024, particularly in terms of its role within the broader cloud services portfolio and its response to competitive pressures from AI-driven offerings?",
      "original_answer": "In 2022, Office 365 was explicitly listed as a key component of Microsoft's service and other revenue, positioned alongside Azure, Dynamics 365, and Xbox as a core cloud-based solution. By 2024, Office 365 had evolved into a more integrated part of Microsoft’s broader AI-infused cloud services portfolio, reflecting the company's strategic shift to infuse generative AI capabilities into commercial offerings. The 2024 filing notes that Microsoft is devoting significant resources to develop and deploy AI models, platforms, and infrastructure to meet customer needs, indicating that Office 365 is now part of this AI-enhanced competitive strategy. This shift was driven by increasing competitive pressures from companies entering the AI market and offering alternative models such as free applications funded by advertising or open-source AI models, which Microsoft must counter with enhanced, integrated cloud experiences.",
      "llm_answer": "\nBetween 2022 and 2024 Microsoft deepened Office 365’s integration into its broader cloud portfolio, continuing to treat the service as a single, bundled performance obligation whose revenue is recognized ratably over the subscription term.  At the same time the company has layered generative‑AI capabilities (e.g., Copilot and other AI‑enhanced features) into Office 365 and Azure, positioning the suite as a central, AI‑enabled hub to counter the surge of AI‑driven competition and to sustain its cloud‑services growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of Microsoft's strategic positioning of Office 365 between 2022 and 2024. It correctly identifies the continued treatment of Office 365 as a bundled performance obligation with ratable revenue recognition, which aligns with the financial reporting context implied in the original answer. The key strategic shift—deepening integration into the broader cloud portfolio and the infusion of generative AI (specifically naming Copilot and AI-enhanced features)—is accurately reflected, matching the ground truth's emphasis on AI integration across Office 365 and Azure. The competitive response is also well-articulated, noting the need to counter AI-driven competition and sustain cloud growth. The only minor omission is the lack of explicit mention of competitive pressures from 'free applications funded by advertising or open-source AI models,' which were specified in the original answer as key drivers. However, the general reference to 'AI-driven competition' captures the essence. All entities (Microsoft, Office 365, Azure, Copilot) and timeframes (2022–2024) are correct. No numerical inaccuracies are present—the answer avoids specific figures but correctly references qualitative financial reporting practices. The reasoning is sound, demonstrating multi-hop synthesis between financial reporting, product strategy, and competitive dynamics. The answer is semantically equivalent to the ground truth with only slight compression of competitive context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 418,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did UnitedHealth Group's recognition and handling of credit-related impairments evolve between 2022 and 2023, particularly in terms of their evaluation methodology and financial impact?",
      "original_answer": "In 2022, UnitedHealth Group evaluated available-for-sale debt securities for credit-related impairments by analyzing expected cash flows, underlying credit quality, and credit ratings of issuers, concluding that there was no significant credit deterioration since purchase and that unrealized losses were primarily due to interest rate increases. The allowance for credit losses was not material. By 2023, the company formalized its impairment recognition process by distinguishing between credit-related and non-credit-related impairments, recording credit-related impairments as an allowance against investment income and non-credit-related impairments through other comprehensive income. Additionally, the company emphasized a more structured evaluation framework that includes present value of expected cash flows, the extent of fair value decline relative to amortized cost, and issuer-specific financial conditions. This reflects a more detailed and segmented approach to impairment recognition and financial reporting.",
      "llm_answer": "\nBetween 2022 and 2023 UnitedHealth continued to use the same credit‑impairment framework—evaluating each available‑for‑sale debt security by comparing its present‑value of expected cash flows to amortized cost, examining the extent to which fair value was below cost, and assessing the issuer’s credit quality and near‑term prospects.  The company explicitly separated credit‑related impairments (recorded as an allowance against earnings) from non‑credit impairments (recorded in other comprehensive income), and it emphasized that the 2023 unrealized losses were driven by interest‑rate movements rather than credit deterioration.  Consequently, the allowance for credit losses remained immaterial, resulting in no material credit‑related impairment charge or earnings impact in either year.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of key facts, entities, and financial impact. (1) It accurately identifies that UnitedHealth Group evaluated available-for-sale debt securities using expected cash flows, fair value relative to amortized cost, and issuer credit quality in both years. It correctly states that unrealized losses in 2023 were due to interest rate movements, not credit deterioration, and that the allowance for credit losses remained immaterial—consistent with the original answer. (2) There are no numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not compromised; all references to materiality and financial impact are consistent. (3) The multi-hop reasoning is sound: the model synthesizes information about methodology evolution and financial treatment across years. However, it misses a key qualitative nuance: the original answer emphasizes that 2023 involved a *formalization* and *more structured* framework compared to 2022, suggesting an evolution in methodology, whereas the LLM implies the framework was unchanged ('continued to use the same'). This downplays the methodological advancement noted in the ground truth. (4) Despite this, the answer captures the core distinction between credit and non-credit impairments, their respective accounting treatments, and the lack of material impact—making it contextually relevant and factually strong overall. The minor omission of the 'evolution' aspect prevents a perfect score, but the answer remains substantially accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1465,
        "completion_tokens": 434,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did the allocation and valuation of Fixed Maturity Securities AFS in MET's pension and other postretirement benefit plans evolve from 2022 to 2023?",
      "original_answer": "In 2022, Fixed Maturity Securities AFS accounted for 84% of U.S. Pension Benefits and 95% of U.S. Other Postretirement Benefits. By 2023, the total estimated fair value of Fixed Maturity Securities AFS was $6,714 million for Pension Benefits and $1,274 million for Other Postretirement Benefits. This indicates a shift from a primarily percentage-based allocation in 2022 to a more detailed valuation breakdown in 2023, showing both the scale and composition of MET's holdings.",
      "llm_answer": "\nFrom 2022 to 2023 the estimated fair‑value of Fixed‑Maturity‑Securities AFS in MET’s pension and other post‑retirement benefit plans fell modestly, from **$6.80 bn to $6.71 bn**.  The portfolio’s composition shifted toward higher‑level inputs: Level 2 holdings dropped from $5.09 bn to $4.92 bn, while Level 1 rose from $1.65 bn to $1.73 bn and Level 3 edged up from $58 m to $64 m.  Consequently, corporate bonds and U.S. government securities increased their share of the allocation, whereas short‑term investments and federal‑agency securities were reduced.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, Fixed Maturity Securities AFS were reported as percentages of the portfolio (84% for U.S. Pension Benefits and 95% for Other Postretirement Benefits), not as a total fair value of $6.80 billion. The LLM incorrectly asserts a dollar value for 2022 that is not present in the original answer. While the 2023 fair value for Pension Benefits ($6,714 million ≈ $6.71 bn) is approximately correct, the LLM omits the $1,274 million for Other Postretirement Benefits in 2023, which is a major omission. (2) The LLM introduces detailed Level 1/2/3 valuation data ($5.09 bn, $1.65 bn, etc.) and asset category shifts (corporate bonds, U.S. government securities) that are not present in the original answer and cannot be verified against the ground truth. These numbers appear fabricated or hallucinated. (3) The multi-hop reasoning is flawed: the original answer highlights a shift in reporting format—from percentage allocations in 2022 to absolute valuations in 2023—whereas the LLM assumes comparable dollar amounts across both years and invents a narrative of portfolio rebalancing based on unverified inputs. (4) The contextual relevance is moderate because the LLM addresses the evolution of Fixed Maturity Securities AFS in MET’s plans, but the factual foundation is unsound. Due to major quantitative errors, invented data, and failure to reflect the actual structure of the ground truth (percentage vs. valuation shift), the correctness score is low at 3.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 430,
        "total_tokens": 1691
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did Lowe's strategic positioning of the Kitchens & Bath product category evolve between 2022 and 2023, and what does this suggest about its relative importance in the company's product portfolio?",
      "original_answer": "In 2022, Kitchens & Bath was grouped under the Home Décor division alongside categories like Appliances, Décor, Flooring, and Paint, suggesting a more design-focused positioning. By 2023, Kitchens & Bath was listed among core construction and renovation categories such as Lumber, Building Materials, and Rough Plumbing, indicating a strategic repositioning toward home improvement and remodeling. This shift suggests that Lowe's placed greater strategic emphasis on Kitchens & Bath as a key growth area tied to higher-value home projects, aligning with its broader 'Total Home' strategy.",
      "llm_answer": "\nBetween 2022 and 2023 Lowe’s kept Kitchens & Bath inside the Home Décor segment, which delivered roughly 35 % of total net sales in both years (35.3 % in 2022 vs. 35.2 % in 2021) — so its sales share was stable 【page 55】.  However, the 2023 filing reframes the category as a strategic growth pillar: it is highlighted in the “installed‑sales” model as one of the primary drivers of Pro‑customer revenue and is specifically cited when discussing the expansion of localized assortments, Pro‑penetration initiatives and installation services【pages 6‑7】.  This emphasis shows that, while Kitchens & Bath is only a modest portion of overall sales, Lowe’s is positioning it as a key category for higher‑margin, service‑linked growth within its Total Home strategy.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains both correct and incorrect information. It incorrectly states that Kitchens & Bath remained within the Home Décor segment in 2023, directly contradicting the ground truth, which confirms a repositioning into core construction and renovation categories (e.g., Lumber, Building Materials). This is a major factual error. However, the LLM correctly identifies a strategic emphasis on Kitchens & Bath in 2023 through installed sales, Pro-customer initiatives, and localized assortments, aligning with the 'Total Home' strategy, which supports the ground truth's conclusion about increased strategic importance.\n\n(2) Quantitatively, the LLM cites a 35.3% share of net sales for Home Décor in 2022 and compares it to 35.2% in 2021, claiming stability. However, the ground truth does not provide any sales percentages, and the LLM introduces a metric not present in the original answer. While the numbers may be pulled from a filing, they are not part of the verified ground truth and cannot be confirmed as contextually accurate for assessing Kitchens & Bath specifically. The category-level sales data is not in the original answer, making this a potential hallucination or misattribution. No calculation errors are present, but the use of unsupported quantitative claims reduces reliability.\n\n(3) The multi-hop reasoning is partially sound: the LLM infers strategic importance from mentions in Pro initiatives and installation services. However, it fails the core structural shift — the reclassification of Kitchens & Bath from a design-focused grouping to a construction/remodeling one — which is central to the ground truth’s reasoning. This omission or error breaks the logical synthesis required for full accuracy.\n\n(4) Despite the significant factual error in entity categorization, the LLM captures the qualitative direction of increased strategic emphasis, hence a partial score. Contextual relevance is high because it addresses the evolution and strategic implications, even if based on flawed premises. The answer is well-structured and relevant but built on a key incorrect assumption about organizational grouping.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 575,
        "total_tokens": 1925
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How has Mondelez International's strategic focus on Cheese & Grocery evolved between 2022 and 2024, and what does this suggest about its prioritization of snack categories for long-term growth?",
      "original_answer": "In 2022, Mondelez directly produced Cheese & Grocery products, generating $1,990 million in total net revenues from this category. By 2024, the company no longer reported direct production in this category and instead indicated only a strategic stake in Cheese & Grocery, positioning it as an adjacent category within its broader snacking portfolio. This shift suggests a refocusing on core snack categories like biscuits and chocolate, while maintaining a presence in Cheese & Grocery through a lighter footprint. The change aligns with Mondelez's stated strategy of prioritizing long-term growth in core snacking segments and managing costs amid inflationary pressures.",
      "llm_answer": "\nBetween 2022 and 2024 the company’s references to Cheese & Grocery shifted from a brief mention in the 2022 filing (where it was listed only as an “adjacent, locally relevant” category) to being grouped with other adjacency businesses in the 2024 MD&A (page 34).  However, the 2024 discussion emphasizes core snacking—chocolate, biscuits and snack bars—and outlines strategic priorities such as “accelerating consumer‑centric growth” and “scaling sustainable snacking,” while the Cheese & Grocery segment receives no separate investment or growth‑target commentary.  This signals that Mondelez views Cheese & Grocery as a secondary, market‑specific opportunity rather than a primary long‑term growth pillar, and that its strategic focus remains on the core snack categories that drive margin and revenue growth.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct in describing Mondelez's shifting strategic focus on Cheese & Grocery, noting reduced emphasis by 2024 and prioritization of core snacks like biscuits and chocolate. However, it misses or misrepresents key factual details from the ground truth. Crucially, the LLM claims Cheese & Grocery was only mentioned as an 'adjacent, locally relevant' category in 2022, whereas the ground truth states Mondelez *directly produced* these products and generated $1,990 million in revenue from them that year. This major quantitative and qualitative fact is omitted, undermining the answer’s accuracy. (2) The LLM fails to include any financial figures—specifically the $1,990 million in 2022 revenue—and does not acknowledge the shift from direct production to a strategic stake by 2024. These omissions represent significant quantitative and factual gaps. While no incorrect calculations are made (because none are attempted), the absence of revenue data and production status changes results in a low quantitative accuracy score. (3) The reasoning about strategic prioritization is sound: the LLM correctly infers from the 2024 filing that core snacking categories are the focus and that Cheese & Grocery lacks dedicated investment or growth targets. This reflects valid multi-hop reasoning based on document language. However, because it mischaracterizes the 2022 position (downplaying direct involvement), the synthesis across years is flawed. (4) Contextually, the answer addresses the evolution of strategic focus and draws a reasonable conclusion about long-term prioritization, making it relevant and logically structured. But due to the omission of critical financial and operational facts, the overall correctness is significantly compromised, warranting a mid-low score of 5.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 495,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did Abbott's presentation of its enteral feeding product lineup, specifically the positioning of Jevity relative to Freego™ products, change between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, Jevity was listed first among enteral feeding products, followed by Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite®, Oxepa®, Freego™ (Enteral Pump), and Freego™ sets. In the 2023 filing, Jevity remained listed first, but the Freego™ (Enteral Pump) and Freego™ sets were now mentioned immediately after Jevity, before the Glucerna and Osmolite® product lines. This change in listing order suggests a shift in product emphasis within the enteral feeding category, with Freego™ products receiving more prominent placement alongside Jevity in 2023 compared to 2022.",
      "llm_answer": "\nIn the 2022 filing Jevity appears only as one item in a generic list of enteral‑feeding products under the Nutritional Products segment, with no explicit linkage to the Freego™ line. By contrast, the 2023 filing still lists Jevity alongside Freego™ (Enteral Pump) and Freego™ sets, but the surrounding text frames Jevity as the companion formula that is used with the Freego™ pump system, positioning the two as an integrated enteral‑feeding solution rather than separate, unrelated products.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim about the nature of the change in Abbott's product presentation. The ground truth states that the change between the 2022 and 2023 10-K filings was a reordering of the product list: in 2022, Jevity was listed first, followed by Glucerna and Osmolite lines before Freego™ products; in 2023, Jevity remained first, but Freego™ (Enteral Pump) and Freego™ sets were moved up immediately after Jevity, ahead of Glucerna and Osmolite. This indicates a shift in emphasis through listing order. However, the LLM answer incorrectly asserts that the 2023 filing 'frames Jevity as the companion formula used with the Freego™ pump system' and presents them as an 'integrated solution'—a qualitative interpretation not supported by the ground truth. There is no mention in the original answer of any change in narrative framing or explicit linkage between Jevity and Freego™ beyond their reordered listing sequence. The LLM introduces a new, unsupported claim about product integration and contextual framing that goes beyond the actual data. Quantitatively, there are no numbers or dates in dispute, so quantitative accuracy is high. Contextually, the answer addresses the right documents and products, but the reasoning is flawed—instead of reporting a change in listing order, it fabricates a change in narrative positioning. This represents a significant failure in multi-hop synthesis and factual fidelity, warranting a low correctness score despite correct identification of entities and years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 422,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did MET's investment in municipals evolve from 2022 to 2023 in terms of fair value and classification, and what does this suggest about the company's credit risk management strategy?",
      "original_answer": "In 2022, MET held $14,212 million in municipals, classified under the 'fixed maturity securities AFS' category, with a fair value that included $2,464 million in gross unrealized gains and only $13 million in gross unrealized losses. By 2023, this investment had significantly declined to just $159 million, now categorized under the 'fixed maturity securities AFS' and classified entirely within Level 2 of the fair value hierarchy, indicating a shift in MET's positioning. This dramatic reduction suggests a strategic move to reduce credit exposure to municipals, likely as part of a broader risk management adjustment to limit potential losses in this asset class.",
      "llm_answer": "\nFrom 2022 to 2023 MetLife’s municipal exposure in its available‑for‑sale portfolio slipped from **$159 million to $147 million**, a $12 million reduction, and remained classified as a **Level 2** fair‑value measurement (i.e., it continued to be valued using observable inputs other than quoted prices).  This pull‑back in municipal holdings—while keeping the same classification—reflects a deliberate de‑risking of the portfolio, signaling that the company is trimming lower‑rated or higher‑volatility municipal securities to curb credit‑risk concentrations and to better protect its balance sheet against potential defaults.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. It states that MetLife's municipal investment decreased from $159 million in 2022 to $147 million in 2023, which is the reverse of the truth. According to the ground truth, the investment was $14,212 million in 2022 and dropped to $159 million in 2023—a massive reduction of over 98%, not a minor $12 million decrease. The LLM completely inverts the direction and magnitude of the change. Additionally, the LLM incorrectly claims the investment was $159 million in 2022, when that was actually the 2023 value. (2) The quantitative inaccuracies are severe: the correct values are $14,212 million (2022) and $159 million (2023), not $159M and $147M. The difference is $14,053 million, not $12 million. The LLM also omits key data from the original answer: the $2,464 million in gross unrealized gains and only $13 million in gross unrealized losses in 2022, which are critical for understanding the valuation context. (3) The reasoning is partially sound in interpreting the reduction as a de-risking move, which aligns with the original conclusion about credit risk management. However, because the core data is wrong, the multi-hop synthesis fails—there is no evidence the LLM correctly retrieved or connected the correct data points across years and classifications. The classification detail (Level 2, AFS) is partially correct, but the LLM fails to note that the 2022 data also falls under 'fixed maturity securities AFS', making the continuity of classification less significant than implied. (4) The correctness score is low (2) due to major factual and directional errors in numbers. Quantitative accuracy is 2 because almost all numbers are incorrect. Qualitative accuracy is 3 because while the general strategic interpretation (de-risking) is plausible, it's based on false premises. Contextual relevance is 5 because the answer addresses the right topic (municipals, classification, risk strategy) but with incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 538,
        "total_tokens": 1871
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did Abbott's use of interest rate hedge contracts evolve between 2022 and 2023, particularly in terms of their notional value and the impact on fixed-rate debt management?",
      "original_answer": "In 2022, Abbott had interest rate hedge contracts totaling approximately $2.2 billion, which were used to manage exposure to changes in the fair value of fixed-rate debt by converting fixed-rate obligations into variable-rate obligations. By 2023, Abbott continued to use these contracts for the same purpose, and the notional value remained consistent at approximately $2.2 billion. However, in 2023, the company provided more detailed disclosures about the impact of these contracts on the carrying value of fixed-rate debt, indicating a more refined approach to interest rate risk management.",
      "llm_answer": "\nAbbott’s interest‑rate hedge contracts shrank from roughly $2.9 billion of notional exposure at the end of 2022 to about $2.2 billion at the end of 2023—a decline of roughly $0.7 billion caused by the maturity of $700 million of swaps and the repayment of the matching fixed‑rate notes. Because these swaps are designated as fair‑value hedges that convert a slice of the company’s fixed‑rate debt to a variable rate, the reduced hedge coverage left a smaller portion of the fixed‑rate portfolio offsetting benchmark‑rate movements, thereby increasing Abbott’s interest‑rate risk and limiting the amount of fair‑value adjustments that offset the carrying amount of its fixed‑rate debt.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Abbott's notional value of interest rate hedge contracts remained consistent at approximately $2.2 billion in both 2022 and 2023. However, the LLM claims the notional value decreased from $2.9 billion in 2022 to $2.2 billion in 2023, which is incorrect. This misstatement undermines the entire analysis. (2) The quantitative inaccuracies are critical: the starting notional amount is wrong ($2.9B vs $2.2B), and the claimed $0.7B decline due to maturity of swaps and repayment of debt is unsupported by the ground truth, which states no change in notional value. The calculation of a $700 million reduction is therefore factually incorrect. (3) The reasoning is flawed because it assumes a reduction in hedge coverage and increased interest rate risk, while the original answer indicates continuity in hedging strategy and notional value, with only enhanced disclosure in 2023. The LLM incorrectly infers operational changes from what was merely improved transparency. (4) While the LLM correctly identifies the purpose of fair-value hedges (converting fixed-rate to variable-rate debt), this qualitative understanding does not compensate for the core factual errors. The contextual relevance is moderate because the response addresses the right topic and mechanism of hedging, but the incorrect data and resulting conclusions severely limit its accuracy. Correctness score is low due to major factual and numerical errors contradicting the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 428,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How did 3M's issuance and management of fixed rate registered notes evolve between 2022 and 2024, particularly in terms of repayment activity and interest rate strategies?",
      "original_answer": "In 2022, 3M had a significant amount of fixed rate registered notes, including $600 million of 10-year notes due 2030 with a coupon rate of 3.05%, and $650 million of 30-year notes due 2050 with a coupon rate of 3.70%. The company also issued $3.25 billion in fixed rate registered notes in August 2019, including $1.0 billion of 10-year notes due 2029 and $1.0 billion of 30-year notes due 2049. In 2024, 3M repaid $1.1 billion in medium-term notes that matured, and in 2023, it repaid $500 million in fixed-rate registered notes. Additionally, interest rate swaps initiated in 2021 converted portions of the fixed-rate notes due 2049 and 2050 into floating-rate debt through mid-2028, indicating a strategic shift toward managing interest rate exposure. This shows a decrease in the amount of fixed-rate debt outstanding and a shift toward floating-rate instruments through swaps.",
      "llm_answer": "\nBetween 2022 and 2024 3M systematically retired a large share of its fixed‑rate registered and medium‑term debt—repaying roughly **$600 million of fixed‑rate registered notes and €600 million of Euro‑denominated medium‑term notes in 2022**, **$500 million of fixed‑rate registered notes plus €600 million of Euro‑notes in 2023**, and **about $1.1 billion of maturing medium‑term notes in 2024**.  To manage the interest‑rate profile of the remaining long‑dated obligations, the company used **fixed‑to‑floating interest‑rate swaps that converted portions of its 2049‑ and 2050‑dated fixed‑rate notes into floating‑rate debt (SOFR‑based) through mid‑2028**, thereby reducing future exposure to rising rates while still holding a modest amount of fixed‑rate registered notes for funding flexibility.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, 3M did not repay any fixed-rate registered notes in 2022; instead, the company held $600M of 10-year notes due 2030 and $650M of 30-year notes due 2050 in that year. The LLM incorrectly states that $600M of fixed-rate registered notes and €600M of Euro-denominated medium-term notes were repaid in 2022, which is not supported by the original answer. Similarly, the claim of repaying €600M of Euro-notes in 2023 is unsupported—ground truth only confirms $500M in fixed-rate registered notes repaid in 2023. While the $1.1B repayment in 2024 is correct, it refers to medium-term notes (as per LLM), but the original specifies this as part of maturity repayments without mentioning currency or Euro-denomination. (2) The interest rate swap details are mostly accurate: the conversion of portions of the 2049 and 2050 notes to floating-rate debt via swaps initiated in 2021 and lasting through mid-2028 is correctly captured, including the strategic intent to manage rate exposure. However, the LLM adds 'SOFR-based' which is not mentioned in the original and may be an assumption. (3) Multi-hop reasoning is partially sound—the synthesis of repayment trends and use of swaps to shift from fixed to floating rate exposure reflects the strategic evolution, but incorrect repayment figures undermine the factual basis. (4) Contextual relevance is high as the answer addresses both repayment activity and interest rate strategies. However, due to major errors in repayment amounts and timing—especially fabricating repayments in 2022 and adding unverified Euro-denominated debt—the correctness score is limited to 5. The qualitative accuracy is moderate because the conceptual framework (debt reduction, swap usage) aligns with the truth, but quantitative accuracy is low due to unsupported numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 514,
        "total_tokens": 1940
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has the role of securities issuances in Schwab's capital structure evolved between 2023 and 2024, particularly in relation to its overall funding sources and capital management strategy?",
      "original_answer": "In 2023, securities issuances by CSC were identified as a primary source of capital, directly supporting the company's capital management strategy, which included balance sheet growth and financial support to subsidiaries. By 2024, while still listed as one of several funding sources, securities issuances were positioned among a broader set of liquidity tools, including FHLB borrowings, repurchase agreements, and CDs, indicating a more diversified funding approach. This shift suggests a strategic evolution where securities issuances remain important but are more integrated within a wider capital structure framework.",
      "llm_answer": "\nBetween 2023 and 2024 Schwab moved from an aggressive debt‑issuance stance—issuing roughly $6 billion of senior unsecured notes in 2023—to a more defensive posture in 2024, retiring all floating‑rate senior notes that were maturing, letting an unsecured revolving credit facility expire unused, and relying instead on brokered‑CD issuance, FHLB advances and retained earnings to fund operations.  This shift reflects a capital‑management strategy that now prioritises preserving strong regulatory capital ratios (including the adjusted Tier 1 leverage ratio that incorporates AOCI), returning excess capital to shareholders through dividends and share‑repurchases, and using preferred‑stock redemptions rather than expanding the securities‑issuance footprint.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several specific numerical and strategic claims not supported by the original answer, such as issuing '$6 billion of senior unsecured notes in 2023' and retiring 'floating-rate senior notes' in 2024. These details are absent from the ground truth and cannot be verified from the provided information, making them factually unsupported. The original answer does not mention exact issuance amounts, note types, credit facilities, or redemptions, so these additions introduce inaccuracies. (2) Quantitative accuracy is low because the $6 billion figure, retirement of specific debt instruments, and references to unused credit facilities are not present in the ground truth. There are no calculations in the original answer to validate, but the introduction of precise figures without basis undermines numerical reliability. (3) The multi-hop reasoning is partially sound—the LLM correctly infers a shift in capital strategy toward diversification and reduced reliance on securities issuances—but it overreaches by fabricating specific instruments and actions (e.g., preferred-stock redemptions, floating-rate note retirements) not mentioned in the original. The core idea of a strategic evolution toward broader funding sources aligns with the ground truth, but the reasoning is marred by unsupported specifics. (4) Contextual relevance is high because the response addresses the evolution of securities issuances in Schwab’s capital structure and ties it to funding sources and capital management. However, correctness is significantly reduced due to hallucinated details, resulting in a score of 4. The answer captures the directional shift but fails on factual precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 466,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How did Coca-Cola's contingent payment obligations related to fairlife evolve from 2022 to 2024, and what does this indicate about fairlife's performance against its financial targets?",
      "original_answer": "In 2022, Coca-Cola disclosed that it had a $270 million liability for contingent milestone payments related to its acquisition of fairlife, based on fairlife achieving certain financial targets through 2024. The company also noted that the first milestone payment of $100 million was made in 2021 after fairlife met its 2020 targets. By 2024, the remaining contingent payment was described as a milestone payment contingent on fairlife achieving certain financial targets through 2024 and was payable in 2025. This indicates that fairlife had met at least one set of financial targets (2020), triggering the initial $100 million payment, and that the company remained on track to potentially meet the remaining targets through 2024, as the obligation was still active and had not been rescinded or adjusted downward.",
      "llm_answer": "\nCoca‑Cola’s fairlife contingent‑payment obligation, originally disclosed in the 2022 filing as a $270 million liability tied to milestone payments that could be triggered through 2024 when fairlife met certain financial targets, was re‑measured each quarter and recorded in income. The 2024 filing shows that a $275 million milestone payment was made in 2023, indicating that fairlife had achieved the performance criteria that released that payment, and the remaining liability continues to be re‑measured with any final settlement expected in 2024‑2025. Thus, the evolution of the contingent obligation—from an initial estimate in 2022 to an actual $275 million payment in 2023—signals that fairlife is progressing toward its financial targets, though the company still faces additional contingent payments later in 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Coca-Cola had a $270 million contingent liability in 2022 for milestones through 2024, with a $100 million payment already made in 2021 for 2020 performance. The LLM incorrectly states that a $275 million milestone payment was made in 2023, which contradicts the original answer—no such payment is mentioned, and the remaining obligation was still pending as of 2024, not paid. This is a major quantitative and factual error. (2) The numbers are largely incorrect: the $275 million payment in 2023 does not appear in the ground truth; instead, the $270 million liability remained active through 2024 with no indication of a payment of that size. The original $270 million liability was not reduced or settled by a $275 million payment. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers that a large payment in 2023 confirms performance, when the ground truth only confirms the 2020 target was met (triggering the 2021 $100M payment) and that the remaining obligation was still contingent as of 2024. The model fabricates a key event (the 2023 payment) not present in the source. (4) While the LLM attempts to address the evolution of the obligation and link it to performance, the core facts are wrong, severely undermining correctness. The contextual relevance is moderate because it discusses the right topic and structure, but the factual foundation is incorrect, leading to a low overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 418,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Oracle's strategic emphasis on Oracle Cloud Infrastructure (OCI) evolved between 2022 and 2024, particularly in terms of its global market positioning and integration with enterprise IT solutions?",
      "original_answer": "In 2022, Oracle's financial disclosures emphasized revenue contributions from cloud and license businesses, which generated $36.052 billion, representing 85% of total revenues, with no explicit strategic language about Oracle Cloud Infrastructure's positioning. By 2024, Oracle significantly elevated OCI's role, describing it as a core component of Oracle Cloud Services alongside SaaS, and emphasizing its ability to provide 'comprehensive and integrated applications and infrastructure services' that enable customers to choose deployment models best suited to their needs. This reflects a clear strategic shift toward positioning OCI as a central pillar in Oracle’s enterprise IT offerings, not just a contributor to cloud revenue.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Oracle reframed OCI from a supplemental cloud add‑on into a central strategic pillar, explicitly pairing it with SaaS under the “Oracle Cloud Services” brand and promoting it as the infrastructure foundation for its enterprise applications.  The 2024 filing emphasizes a global go‑to‑market push—leveraging Oracle’s direct sales force and consulting services—to embed OCI in hybrid and multi‑cloud architectures, enabling customers to integrate, modernize and extend their existing IT investments across on‑premise, cloud and OCI environments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) There are no numeric values in the original or LLM answer that conflict—both correctly avoid citing specific revenue figures for OCI itself, instead focusing on strategic positioning. The ground truth mentions $36.052 billion in cloud and license revenue in 2022 (85% of total), which the LLM does not contradict, though it omits this quantitative detail. However, since the LLM answer does not attempt to include those numbers, and the question does not explicitly demand them, this omission does not constitute a factual error. (2) Entity accuracy is strong: Oracle, OCI, SaaS, fiscal years 2022 and 2024, and the rebranding under 'Oracle Cloud Services' are all correctly identified. (3) The multi-hop reasoning is sound—the LLM synthesizes the evolution of OCI’s strategic role across time, correctly identifying the shift from a secondary offering to a core infrastructure pillar integrated with enterprise IT solutions. It adds contextual detail about go-to-market strategy and hybrid/multi-cloud integration that is consistent with and expands upon the original answer without introducing inaccuracies. (4) Semantic equivalence is high: the core message—that OCI became a central strategic focus by 2024, integrated with SaaS and positioned as foundational for enterprise IT—is fully preserved. The LLM enhances the answer with plausible operational details (e.g., use of sales force, consulting services) that are contextually appropriate and do not deviate from the source. Minor deduction in qualitative accuracy due to slight elaboration beyond the original, but no factual overreach. Contextual relevance is perfect—directly addresses market positioning and integration with enterprise IT across the specified timeframe.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 488,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has the treatment and risk profile of PALs evolved between 2023 and 2024, particularly in terms of credit loss allowance and collateralization?",
      "original_answer": "In 2023, there was a slight decrease in PALs, and the allowance for credit losses was influenced by improved credit quality metrics and lower projected loss rates. By 2024, all PALs were fully collateralized by securities with fair values exceeding borrowings, and no allowance for credit losses for PALs was required as they were all subject to the collateral maintenance practical expedient under ASC 326. This indicates a strengthening in the risk profile and treatment of PALs over the period.",
      "llm_answer": "\nBetween 2023 and 2024 the Company’s treatment of Pledged‑Asset Lines (PALs) did not change the credit‑loss allowance – it remained $0, because all PALs were fully collateralized.  In 2024 the firm expanded the ASC 326 collateral‑maintenance practical expedient to “substantially all” PALs (whereas in 2023 it applied to only a portion), confirming that each PAL’s collateral (securities with fair value exceeding the borrowing) was more broadly used to support the lines.  Consequently, the risk profile of PALs stayed very low, with zero allowance for credit losses in both years but a more comprehensive collateral coverage in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures some correct elements but contains significant inaccuracies in both quantitative and qualitative aspects when compared to the ground truth. (1) The claim that the credit loss allowance 'remained $0' in both 2023 and 2024 is incorrect. The original answer states that in 2023, the allowance was influenced by improved credit quality and lower projected loss rates, implying an active allowance existed and was adjusted—only in 2024 was no allowance required due to full collateralization and application of the practical expedient. The LLM incorrectly asserts a $0 allowance in 2023, which contradicts the slight decrease in PALs and active allowance management described in the ground truth. (2) The LLM states that in 2023 the practical expedient applied to 'only a portion' of PALs and was expanded to 'substantially all' in 2024. However, the original answer states that by 2024, *all* PALs were fully collateralized and *all* were subject to the practical expedient—this is a stronger claim than 'substantially all' and represents a full transition not reflected accurately in the LLM response. (3) The reasoning around risk profile is partially correct—the risk profile strengthened due to broader collateral coverage—but the LLM fails to note the evolution from an allowance-influenced-by-projections in 2023 to no allowance in 2024, missing a key multi-hop insight. (4) Contextual relevance is high as the answer addresses both credit loss allowance and collateralization over the two years, but factual correctness is undermined by misrepresenting the status of the allowance in 2023 and underrepresenting the scope of the practical expedient in 2024. Minor wording differences are acceptable, but the misstatement of key financial treatment constitutes a significant error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 487,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has Nike's relationship with the Asia Pacific & Latin America (APLA) region evolved between fiscal years 2023 and 2024, particularly in terms of operational structure and strategic emphasis?",
      "original_answer": "In fiscal year 2023, Nike's relationship with APLA was characterized by direct operational involvement, with the region being one of the geographies where certain employees were represented by trade unions, indicating a more localized and embedded workforce structure. By fiscal year 2024, Nike transitioned parts of its APLA operations to third-party distributors, signaling a strategic shift away from direct control toward a more outsourced model. This evolution reflects a broader restructuring effort to optimize the business model and reduce operational complexity in certain international markets.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 the APLA geographic segment’s revenue rose modestly—from **$6.43 bn to $6.73 bn**—highlighting its growing contribution to NIKE Brand sales.  At the same time, Nike disclosed that it is **transitioning certain APLA country businesses to third‑party distributors** (see Note 18), signaling a strategic shift toward a more asset‑light, partnership‑driven operating model in the region while still emphasizing direct‑to‑consumer and licensing growth.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the strategic shift in Nike's APLA operations from direct control to third-party distributors in fiscal 2024, aligning with the ground truth. It also accurately notes the revenue increase from $6.43 billion to $6.73 billion, which reflects APLA's growing contribution—though this specific revenue data is not present in the original answer, it is factually consistent with external Nike FY2023 and FY2024 reports. 2) Quantitatively, the revenue figures ($6.43B to $6.73B) are accurate based on Nike’s published financials; no calculation errors are present. The use of bold formatting is stylistic and does not affect accuracy. 3) The multi-hop reasoning is sound: the model connects operational changes (transition to third-party distributors) with strategic emphasis (asset-light model), synthesizing information across fiscal years and operational domains. However, the original answer emphasizes labor structure (trade unions in FY2023) as evidence of direct involvement, a point omitted in the LLM response, resulting in partial completeness. 4) Despite missing the trade union detail, the LLM captures the core evolution—shift to outsourcing—and correctly interprets its strategic implications. The added revenue context enhances relevance without introducing error. Thus, the answer is largely correct but slightly less complete than ideal on qualitative depth, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 398,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How did Abbott's positioning and strategic emphasis on Pedialyte evolve between 2022 and 2023, particularly in relation to its U.S. Pediatric Nutritional business and product portfolio expansion?",
      "original_answer": "In 2022, Pedialyte was highlighted as a key growth driver within Abbott's U.S. Pediatric Nutritional business, with sales increasing 10.3% for the year, alongside Similac and PediaSure. By 2023, Pedialyte was formally included in Abbott's product portfolio under the Nutritional Products segment, listed among major brands such as Ensure, Glucerna, and PediaSure, signaling a more structured integration into Abbott's broader nutritional offerings. This reflects a strategic evolution from being a contributor to growth in 2022 to being a formally recognized and embedded part of the company's core U.S. Pediatric Nutritional product lineup in 2023.",
      "llm_answer": "\nOver the 2022‑2023 period Abbott elevated Pedialyte from a niche pediatric electrolyte brand to a core growth engine within its U.S. Pediatric Nutritionals business, citing double‑digit segment sales gains that were driven primarily by Pedialyte’s volume expansion.  In 2023 the company deepened its strategic emphasis by broadening the Pedialyte line (new powder, ready‑to‑drink and sugar‑free formats) and promoting it beyond pediatrics to capture wider hydration demand, using the brand to accelerate overall pediatric‑nutrition growth and diversify the portfolio.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies and introduces unverified claims not present in the ground truth. While it correctly identifies Pedialyte's growing strategic importance within Abbott's U.S. Pediatric Nutritional business, it incorrectly states 'double-digit segment sales gains' and attributes them 'primarily' to Pedialyte—whereas the ground truth specifies a 10.3% increase specifically for Pedialyte (not the entire segment) and lists Similac and PediaSure as co-contributors. The claim of 'double-digit' growth is misleading since 10.3% is not double-digit in strict terms and applies only to Pedialyte, not the broader segment. (2) The LLM asserts product expansions in 2023 (new powder, ready-to-drink, sugar-free formats) and a strategic repositioning 'beyond pediatrics' to target general hydration demand—details absent from the original answer and not supported by the provided ground truth. These additions, while plausible, are not corroborated and represent overreach. (3) The multi-hop reasoning is partially sound: the model correctly infers increased strategic emphasis from 2022 to 2023, aligning with the ground truth’s narrative of evolution from growth contributor to formally recognized core brand. However, it fails to mention the key fact that in 2023, Pedialyte was formally integrated into the Nutritional Products segment alongside Ensure, Glucerna, and PediaSure—a critical structural signal of integration that the LLM omits. (4) Despite these issues, the answer captures the directional shift in strategy and maintains contextual relevance by focusing on portfolio expansion and strategic elevation. The qualitative reasoning is reasonable but lacks precision and includes unsupported details, leading to a moderate correctness score. Quantitative accuracy is low due to misrepresentation of the 10.3% figure and introduction of unverified growth claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 516,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How did RTX's financial position regarding its 7.100% notes due 2027 evolve from 2022 to 2023, and what does this indicate about its debt management strategy?",
      "original_answer": "In 2022, RTX disclosed an aggregate principal balance of $6 million for its 7.100% notes due 2027. By 2023, RTX had a stake in the same notes with an aggregate principal balance of $135 million. This indicates a significant increase in RTX's exposure to this particular debt instrument, suggesting a shift in its debt management strategy, possibly involving refinancing or restructuring.",
      "llm_answer": "\nThe $135 million of 7.100% notes maturing in 2027 remained on RTX’s balance sheet in both 2022 and 2023 – the amount did not increase or decrease during that period.  At the same time, RTX continued to retire higher‑coupon near‑term obligations (e.g., the 3.65% and 3.70% notes that were fully repaid in 2023) and replaced them with newer, longer‑dated senior unsecured debt (5.75%‑6.4% notes due 2026‑2054 and SOFR‑based term loans), using the proceeds to fund an accelerated share‑repurchase program.  This pattern shows that RTX’s debt‑management strategy is to roll higher‑cost, near‑term debt into longer‑dated, lower‑coupon issuances while keeping the 2027 tranche stable, thereby extending overall maturity and preserving liquidity rather than aggressively paying down the 7.100% 2027 notes.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitatively, it states that the $135 million 7.100% notes due 2027 were present in both 2022 and 2023, claiming no change. However, the ground truth shows that the aggregate principal balance was $6 million in 2022 and increased to $135 million in 2023 — a significant increase, not a stable amount. This misrepresents the core financial data. (2) The calculation and comparison of debt levels across years are completely wrong; the model fails to recognize or report the 22.5x increase in exposure. (3) Qualitatively, the reasoning about RTX’s debt management strategy is based on false premises. The LLM claims RTX kept the 2027 tranche stable and retired higher-coupon debt, but the actual data shows a large-scale acquisition or issuance of the 7.100% notes in 2023, indicating a possible restructuring or refinancing that increased exposure, not stability. The strategy inferred — rolling into lower-coupon debt — contradicts the fact that RTX significantly increased holdings in a high-interest note. (4) Contextually, while the answer discusses debt management and mentions related instruments, it does so using incorrect data and thus fails to address the actual evolution of the 7.100% notes. The multi-hop synthesis is flawed because it draws conclusions from fabricated or misread data. Minor relevance is retained only because it discusses RTX’s debt strategy in general terms.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 407,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Nike's relationship with Converse evolved in terms of revenue performance and strategic positioning between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Converse revenues decreased by 15% on a currency-neutral basis, driven by declines in North America and Western Europe, with both wholesale and direct-to-consumer channels experiencing drops in unit sales and average selling price. By fiscal 2024, Converse was described as a wholly-owned subsidiary that operates on a stand-alone basis, indicating a strategic shift toward maintaining it as a distinct brand within Nike’s portfolio. This evolution reflects a move from a financially struggling entity in 2023 to a more strategically positioned brand in 2024, despite the earlier revenue contraction.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Converse’s top line slipped 14 % (to $2.082 bn) and 15 % on a constant‑currency basis, with footwear down 16 % and wholesale revenue down 15 %; earnings before interest and taxes fell 30 % to $474 m. The drop stems from weaker demand in North America and Western Europe, a shift toward lower‑margin wholesale and direct‑to‑consumer channels, and foreign‑currency pressure, prompting Nike to reposition Converse around targeted growth in Asia, licensing and tighter cost/foreign‑exchange management.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes several specific financial figures not present in the original answer, such as Converse's revenue of $2.082 billion and EBIT of $474 million, which are not mentioned in the ground truth and cannot be verified against it. The 14% revenue decline contradicts the original answer stating a 15% decline on a currency-neutral basis, introducing a factual discrepancy. The breakdown of footwear down 16% and wholesale down 15% is additional detail absent from the ground truth and potentially inaccurate. (2) The original answer does not provide absolute revenue or EBIT figures, so the inclusion of $2.082B and $474M represents fabrication or unsupported precision. The 14% vs 15% decline is a direct quantitative conflict. While the 15% constant-currency decline matches, the LLM incorrectly presents both 14% and 15% declines, creating confusion. (3) The LLM captures part of the multi-hop reasoning by identifying Converse's revenue decline in 2023 due to North America and Western Europe weakness, aligning with the original. However, it fails to mention the strategic evolution in fiscal 2024 — that Converse operates as a stand-alone subsidiary — which is a key component of the question about strategic positioning. Instead, it introduces Nike's repositioning around Asia, licensing, and cost management, which is not in the original and may be speculative. (4) The contextual relevance is high because the answer addresses revenue performance and some strategic response, but correctness is limited by unsupported numbers and omission of the key 2024 strategic positioning. The qualitative reasoning is partially sound but lacks fidelity to the ground truth's strategic narrative. Thus, the correctness score is moderate due to partial factual alignment but significant deviations in numbers and missing core strategic evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 506,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Coca-Cola's financial risk assessment regarding digital evolution changed from 2022 to 2024, particularly in terms of its impact on sales growth and margin improvement?",
      "original_answer": "In 2022, Coca-Cola viewed digital evolution as a risk factor that could negatively impact its business if it failed to implement digital transformation initiatives effectively, potentially leading to a loss in sales and brand relevance. By 2024, the company shifted its stance, identifying digital evolution as a strategic dependency, emphasizing that its future success would rely on expanding digital capabilities to increase sales and improve margins. The 2024 filing explicitly states that failure to digitalize operations could adversely impact financial performance, indicating a stronger financial linkage to digital initiatives than in 2022.",
      "llm_answer": "\nFrom 2022 to 2024 Coca‑Cola’s risk discussion of digital transformation evolved from a general warning that failure to digitize could “negatively affect our ability to increase sales and reduce costs” (2022) to a more explicit statement that such failure would “negatively affect our ability to increase sales **and improve margins**” and that the expenses of digitization could “adversely impact our financial performance” (2024).  Thus, while the 2022 assessment linked digital efforts mainly to sales growth and cost‑saving, the 2024 filing ties the risk directly to both revenue expansion **and margin improvement**, underscoring a sharper focus on profitability.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution in Coca-Cola's risk assessment from 2022 to 2024: in 2022, digital evolution was framed as a risk to sales growth and cost reduction; by 2024, it became more tightly linked to sales growth and margin improvement, with explicit mention of financial performance impact. The key shift—from a general risk to a strategic dependency tied to profitability—is accurately conveyed. (2) There are no numerical values in the original or LLM answer, so quantitative accuracy is not applicable in terms of calculations, but all dates (2022, 2024) and referenced filings are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of risk disclosures, identifies the change in tone and financial linkage, and correctly infers the increased emphasis on margins and financial performance. (4) The LLM slightly simplifies the 2024 stance by not explicitly stating that digital evolution became a 'strategic dependency'—a key phrase in the ground truth—but it effectively communicates the consequence of that dependency (i.e., adverse financial impact from failure). This minor omission prevents a perfect 10 on qualitative accuracy. Overall, the answer is factually correct, contextually precise, and directly addresses the question about changes in financial risk assessment related to digital evolution, sales, and margins.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 403,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Oracle's strategic emphasis on Oracle Cloud Services evolved from fiscal year 2022 to 2024, particularly in terms of research and development investment and the positioning of cloud offerings relative to on-premise solutions?",
      "original_answer": "In fiscal year 2022, Oracle invested $7.2 billion in research and development, highlighting its commitment to enhancing Oracle Cloud Services, including Oracle SaaS and OCI, as part of a broader strategy to offer flexible and interoperable deployment models. Oracle positioned cloud services as a key differentiator against competitors by emphasizing rapid deployment, security, and integration. By fiscal year 2024, Oracle continued to emphasize cloud services but restructured its messaging to position Oracle Cloud Software-as-a-Service and Oracle Cloud Infrastructure as central to enabling customers to 'choose the best option that meets their specific business needs.' While the 2024 report does not specify the R&D investment amount, the increased focus on cloud-first positioning and integration with customer-specific needs indicates a strategic deepening of Oracle's commitment to cloud services over on-premise offerings.",
      "llm_answer": "\nFrom fiscal 2022 through 2024 Oracle has steadily raised the share of revenue coming from its cloud‑based offerings—cloud services and license‑support revenues grew to represent roughly 71 % of total sales in 2022 and an even higher proportion in 2024—while continuing to allocate substantial R&D resources (the $7.2 billion invested in FY 2022 remained a strategic priority and was maintained at similarly high levels in FY 2024).  Consequently, Oracle now positions its Oracle Cloud Services as the preferred, lower‑cost, rapidly deployable alternative to traditional on‑premise solutions, offering hybrid and migration pathways that let customers retain existing on‑premise assets but shift workloads to the cloud.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies and unsupported claims. While it correctly notes Oracle's $7.2 billion R&D investment in FY 2022 (from the ground truth), it asserts that this level was 'maintained at similarly high levels in FY 2024'—a claim not supported by the original answer, which explicitly states that the 2024 report does not specify R&D investment. This is a significant factual overreach. Additionally, the LLM introduces a specific percentage (71%) of total sales from cloud services and license-support revenues in 2022, which is not present in the ground truth and cannot be verified from the provided information. There is also no mention in the original answer about the 'share of revenue' increasing or specific revenue proportions in 2024. (2) The only verified number, $7.2 billion in FY 2022 R&D, is accurate and correctly cited. However, the introduction of the 71% revenue figure and the implied continuity of R&D spending into 2024 without evidence reduces quantitative accuracy. (3) The reasoning partially captures the strategic shift toward cloud services, including hybrid and migration pathways, which aligns with the original answer’s mention of flexible deployment models and customer-specific needs. However, the LLM incorrectly infers revenue trends and sustained R&D levels, failing to acknowledge the absence of 2024 R&D data. This reflects a failure in multi-hop reasoning—while it synthesizes some strategic themes, it invents metrics to support them. (4) Despite the factual issues, the LLM correctly identifies Oracle’s cloud-first evolution and the positioning of cloud as a preferred alternative with hybrid options, which is contextually relevant and captures part of the strategic narrative. Hence, contextual relevance is high, but correctness is limited by unsupported quantitative claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 503,
        "total_tokens": 1938
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has the status and availability of shares under the Norwest Corporation Directors' Formula Stock Award Plan evolved between 2023 and 2024?",
      "original_answer": "In 2023, the Norwest Corporation Directors' Formula Stock Award Plan was described as a plan under which shares of common stock were awarded to non-employee directors, with the ability to defer receipt of awards until a future year. However, it was noted that no future stock awards or deferrals could be made under this plan. In 2024, the 10-K filing further clarified that no future awards or deferrals would be made under the plan and that column (a) of the equity compensation table reflected all shares issuable under the plan upon distribution of outstanding awards or deferred compensation benefits. This indicates that by 2024, the plan was fully closed to any new activity and only existing obligations remained. The number of shares issuable in 2024 related to this plan was minimal (only 391 shares), showing that the plan had effectively concluded its active phase.",
      "llm_answer": "\nBetween 2023 and 2024 the Norwest Corporation Directors’ Formula Stock Award Plan moved from an active, award‑granting arrangement to a closed one—no new stock awards or deferrals may be made under the plan.  Consequently, the only shares left available for future issuance are the 391 shares reserved for deferred distributions, effectively ending the plan’s share‑availability after 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the essential evolution of the Norwest Corporation Directors' Formula Stock Award Plan from 2023 to 2024. (1) It correctly states that no new awards or deferrals can be made, aligning with the ground truth that the plan was closed to future activity. The number of shares remaining—391—is accurately reported, matching the original answer. (2) Quantitatively, the figure of 391 shares is correct and properly contextualized as the only shares still issuable, relating to deferred distributions. No calculations are required, and the number is presented accurately. (3) The reasoning is sound: the LLM correctly infers that the plan has effectively ended its active phase, moving from a functional plan in 2023 to a closed status in 2024. However, it omits the specific 2024 clarification mentioned in the original answer—that column (a) of the equity compensation table reflects all shares issuable under the plan. This minor omission slightly weakens the qualitative completeness but does not affect the core correctness. (4) The answer is fully relevant to the question about the status and availability of shares, focusing precisely on the transition and current state. Overall, the LLM conveys semantically equivalent information with only a minor lack of contextual detail from the 2024 filing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 373,
        "total_tokens": 1689
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has McDonald's disclosure around food safety concerns evolved between 2022 and 2023, particularly in relation to supply chain risks and cost volatility?",
      "original_answer": "In 2022, McDonald's characterized food safety concerns primarily as reputational risks that could impact brand perception and financial results due to incidents like food-borne illness or contamination. The focus was on the potential damage to consumer trust and the company's image. By 2023, the framing had evolved to emphasize food safety concerns as contributors to supply chain volatility, specifically in relation to commodity cost fluctuations. The 2023 filing noted that food safety issues, along with other macroeconomic and regulatory factors, could exacerbate volatility in the prices of key ingredients like beef, chicken, and pork, thereby affecting profitability. This indicates a shift in emphasis from reputational impact to financial exposure through supply chain disruption and cost pressures.",
      "llm_answer": "\nThe 2022 Form 10‑K noted food‑safety concerns chiefly as a brand‑reputation risk and only briefly referenced supply‑chain impacts. In the 2023 filing, McDonald’s expanded the language to explicitly connect food‑safety events to supply‑chain disruptions and commodity‑price volatility, describing how inflation and logistics pressures can raise costs and jeopardize safe‑food operations, thereby integrating supply‑chain and cost‑volatility risks into its food‑safety disclosures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in McDonald's disclosure between 2022 and 2023. It correctly identifies that in 2022, food safety was primarily framed as a brand-reputation risk, with only limited mention of supply chain impacts. In 2023, the answer accurately reflects the shift toward linking food safety to supply chain disruptions and commodity price volatility, including the integration of cost pressures (e.g., inflation, logistics) affecting safe food operations. There are no numeric inaccuracies—dates (2022, 2023) and financial concepts (commodity-price volatility, cost pressures) are correctly used. The answer is semantically equivalent to the ground truth, though it omits the specific mention of key ingredients (beef, chicken, pork) and does not explicitly state the shift from 'reputational impact' to 'financial exposure through supply chain disruption' as clearly as the original. However, the core multi-hop reasoning—connecting food safety to supply chain and cost volatility in 2023 versus a narrower focus in 2022—is sound and well-synthesized. The response is fully contextually relevant, directly addressing the evolution in disclosures around food safety, supply chain risks, and cost volatility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 350,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has the carrying value and interest rate of TMO's 1.750% 7-Year Senior Notes evolved between 2023 and 2024?",
      "original_answer": "In 2023, TMO's 1.750% 7-Year Senior Notes, due on October 15, 2028, had a carrying value of $700 million and an effective interest rate of 1.89%. In 2024, both the carrying value and effective interest rate remained unchanged at $700 million and 1.89% respectively. This indicates that there was no change in the financial structure or valuation of this particular debt instrument over the period.",
      "llm_answer": "\nThe $1.750 % 7‑Year Senior Notes (euro‑denominated) had a carrying amount of **$662 million at 31 Dec 2023**, which fell to **$621 million at 31 Dec 2024** – a reduction of roughly $41 million.  At the same time the effective interest rate on those notes slipped only slightly, from **about 1.97 % in 2023 to 1.96 % in 2024**.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect on all key metrics. The original answer states that the carrying value was $700 million in both 2023 and 2024, while the LLM claims $662 million in 2023 and $621 million in 2024 — a significant discrepancy. Similarly, the effective interest rate was 1.89% in both years according to the ground truth, but the LLM reports 1.97% in 2023 and 1.96% in 2024, which is incorrect. Additionally, the LLM introduces the idea that the notes are 'euro-denominated,' which is not mentioned or supported in the original answer. (2) All numerical values — carrying amounts and interest rates — are wrong, and the implied trend (declining carrying value and slightly decreasing rate) contradicts the ground truth of no change. There are no correct calculations or accurate figures. (3) The multi-hop reasoning fails: the model does not correctly identify that there was no change in either metric across the two years, and it fabricates data points (euro-denomination, incorrect values). It also misidentifies the trend, suggesting evolution when there was none. (4) The answer is contextually relevant in that it addresses the requested metrics (carrying value and interest rate) and time frame (2023–2024) for TMO's 1.750% 7-Year Senior Notes, but the factual inaccuracies render it substantially incorrect. Due to complete failure in quantitative accuracy and poor qualitative reasoning, the correctness score is very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1172,
        "completion_tokens": 404,
        "total_tokens": 1576
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did RTX's exposure to its 7.000% notes due 2038 change between 2022 and 2023, and what does this suggest about its approach to managing long-term debt maturities?",
      "original_answer": "In 2022, RTX disclosed an aggregate principal balance of $11 million for its 7.000% notes due 2038. By 2023, this amount had increased significantly to $148 million. This suggests that RTX either issued additional tranches of this note or restructured its debt to extend maturities, indicating a strategic shift toward increasing exposure to this particular long-term debt instrument.",
      "llm_answer": "\nThe balance of RTX’s 7.000 % notes due 2038 fell from **$159 million at the end of 2022 to $148 million at the end of 2023**, a reduction of roughly $11 million (about 7 %). This modest pay‑down indicates that RTX is actively shrinking its exposure to this particular tranche—using cash flows and new debt issuances to retire higher‑coupon, near‑term debt and thereby ladder its long‑term maturity profile and manage future repayment pressures.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both direction and magnitude of change. According to the ground truth, RTX's exposure to its 7.000% notes due 2038 increased from $11 million in 2022 to $148 million in 2023—a significant increase of $137 million. The LLM incorrectly states that the balance decreased from $159 million to $148 million, which misrepresents both the initial amount and the trend. This error invalidates all subsequent reasoning: instead of a reduction indicating debt retirement, the actual data shows a large increase, suggesting new issuances or debt restructuring to extend maturities. The LLM’s conclusion about 'shrinking exposure' and 'pay-down' is therefore completely reversed from the correct interpretation. Quantitative accuracy is extremely low due to wrong numbers and incorrect calculation. Qualitative accuracy is poor because the reasoning is based on false premises and fails to reflect the actual multi-hop synthesis (change over time and its implication). Contextual relevance is moderate as the answer addresses the right topic (debt maturity management) but with incorrect data and logic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1212,
        "completion_tokens": 320,
        "total_tokens": 1532
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did McDonald's financial relationship with its franchisees evolve between 2022 and 2023, particularly regarding the collection of rent and royalties?",
      "original_answer": "In 2022, McDonald's disclosed that it had deferred approximately $1 billion in rent and royalties from franchisees, primarily during the first half of 2020, due to the impact of government restrictions related to COVID-19. By the end of 2021, the company had collected substantially all of these deferred amounts. In contrast, the 2023 filing reflects a return to standard operations, with no mention of ongoing deferrals or pandemic-related financial accommodations. Instead, the 2023 report outlines the normalization of franchise operations, including a detailed breakdown of restaurant ownership types, which indicates that franchisees were operating under regular financial obligations without pandemic-era relief measures.",
      "llm_answer": "\nBetween 2022 and 2023 McDonald’s ended the pandemic‑related rent‑and‑royalty deferrals that had been put in place in 2020—by the end of 2021 the company had collected essentially all of the roughly **$1 billion** of deferred amounts—so that from 2022 onward it resumed normal contractual collection of both the **minimum rent** and the **percentage‑of‑sales royalties** required under its franchise agreements.  The 2022‑2023 schedule of future minimum franchise payments (page 49) shows about **$3.06 billion** of minimum rent due in 2022 and **$2.95 billion** due in 2023, indicating a stable and growing revenue stream from franchisees with no further large‑scale deferral activity.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the core evolution in McDonald's financial relationship with franchisees: the conclusion of pandemic-related deferrals and the return to normal rent and royalty collections by 2022–2023. It accurately references the $1 billion deferred amount and correctly states that substantially all of it was collected by the end of 2021. However, the LLM introduces specific future minimum rent figures—$3.06 billion for 2022 and $2.95 billion for 2023—from a schedule on page 49, which are not present in the original ground truth. While these numbers may be factually correct in the actual 10-K, they are not part of the provided ground truth and thus cannot be verified as aligned with the knowledge graph source. This addition, while contextually plausible, introduces unverified quantitative detail, slightly undermining quantitative accuracy. The reasoning is sound: the LLM correctly infers that the absence of deferral mentions and the presence of scheduled payments indicate normalized operations. It synthesizes across time periods (2020 deferrals, 2021 collection, 2022–2023 normalcy) accurately, demonstrating strong qualitative reasoning. The answer is highly relevant, directly addressing the evolution in financial relationships. Minor overreach in unverified specifics prevents a top score, but the overall conclusion is factually aligned and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 385,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has The Coca-Cola Company's financial stake in Embotelladora Andina S.A. evolved from 2022 to 2024, and what does this indicate about the company's strategic positioning with respect to this equity investment?",
      "original_answer": "In 2022, Coca-Cola recognized a gain of $39 million from the partial sale of its ownership interest in Embotelladora Andina S.A., indicating a strategic refranchising or divestiture move while retaining an equity stake. By 2024, Coca-Cola still held a financial stake in Andina, with a carrying value of $90 million and a fair value of $168 million, showing that the company maintained its involvement but with a relatively modest valuation compared to other equity investments. This indicates a partial exit strategy rather than a complete divestiture, with ongoing but reduced exposure.",
      "llm_answer": "\nFrom 2022 through 2024 Coca‑Cola’s ownership in Embotelladora Andina was pared back until the equity‑method investment was reduced to a modest $90 million carrying amount (with a fair value of $168 million, a $78 million unrealized gain) on the 2024 balance sheet.  This shrinkage—reflecting the sales of portions of the stake in 2019 and any further reductions through 2022‑2023—shows that the Company is deliberately scaling down its direct exposure and now treats the remaining interest as a small, governance‑focused equity holding rather than a strategic, controlling investment.  The move preserves a market presence in South America while limiting capital risk and financial exposure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the $90 million carrying value and $168 million fair value in 2024 are accurately reported, and the implied $78 million unrealized gain ($168M - $90M) is correctly calculated. The mention of a gain in 2022 is consistent with the original answer’s $39 million gain from partial sale, though the LLM does not explicitly state the $39M figure, which is a minor omission. (2) The LLM correctly identifies the trend of stake reduction from 2022 to 2024, though it references sales in 2019 (outside the requested 2022–2024 scope), which slightly distracts but does not invalidate the reasoning. (3) The multi-hop reasoning is sound: the answer synthesizes the evolution of the stake, infers strategic intent (reduced exposure, governance-focused holding), and connects it to regional market presence and risk management. (4) Semantically, the LLM conveys the same core message—partial exit strategy with ongoing but reduced involvement—using different but equivalent phrasing. The only minor shortcoming is the omission of the specific $39 million gain in 2022, which slightly affects completeness but not overall correctness. Hence, a score of 9 is justified, with full marks in quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 371,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has Oracle's strategic investment in cloud infrastructure evolved from 2022 to 2024, particularly regarding internal development efforts and the positioning of Oracle Cloud Infrastructure in its product portfolio?",
      "original_answer": "In 2022, Oracle emphasized internal development as a core strategy, dedicating significant resources to research and development to maintain and improve its existing product suite, including cloud technologies. The company highlighted its global R&D workforce and the importance of innovation in response to evolving market demands. By 2024, this focus had evolved into a more product-specific strategy with the explicit introduction of Oracle Cloud Infrastructure (OCI) as a central offering within Oracle Cloud Services. OCI was positioned as a comprehensive and integrated infrastructure solution, indicating a shift from general cloud development to a structured, customer-facing product portfolio. This evolution demonstrates a strategic deepening of Oracle's cloud infrastructure commitment, aligning internal R&D with the delivery of a defined, market-ready suite of cloud services.",
      "llm_answer": "\nFrom fiscal 2022 through 2024 Oracle accelerated its cloud‑first transformation by directing substantially more internal R&D and capital toward building out Oracle Cloud Infrastructure.  The company expanded OCI’s global data‑center capacity and geographic reach, staffed roughly 21,000 employees in cloud‑services and support (and over 44,000 in overall research and development), and now treats OCI as a distinct pillar of its portfolio—offering SaaS, PaaS and IaaS subscriptions that are recognized ratably over their contract terms and integrated with its hardware and software offerings.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution of Oracle's cloud infrastructure strategy from 2022 to 2024 with strong qualitative accuracy. It correctly identifies the increased focus on internal R&D, the expansion of Oracle Cloud Infrastructure (OCI), and the positioning of OCI as a central, integrated pillar in Oracle's product portfolio—aligned with the ground truth's description of a shift toward a structured, customer-facing cloud offering. The answer also appropriately highlights integration with hardware and software, ratable revenue recognition, and workforce scale, which supports contextual relevance. However, the quantitative accuracy is compromised by introducing specific numbers not present in the original answer: '21,000 employees in cloud-services and support' and 'over 44,000 in overall R&D' are precise figures absent from the ground truth, which only mentions a 'global R&D workforce' and 'significant resources' without quantification. These additions, while plausible, are unsupported by the source and constitute factual overreach. Additionally, the LLM emphasizes 'fiscal 2022 through 2024' and 'accelerated cloud-first transformation,' which, while directionally accurate, add specificity not present in the original timeline description. The reasoning is logically sound and synthesizes a multi-hop understanding of strategic evolution, but the inclusion of unverified numbers reduces overall correctness. Semantic equivalence is mostly preserved, but the added precision creates a risk of misinformation. Hence, the correctness score is reduced to 7 for minor factual overstatement despite strong alignment in strategic narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 451,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did TMO's involvement with The Binding Site Group evolve between 2023 and 2024, and what does this indicate about the company's integration and strategic focus post-acquisition?",
      "original_answer": "In 2023, TMO acquired The Binding Site Group for $2.70 billion as part of its Specialty Diagnostics segment, expanding its portfolio in diagnostics for blood cancers and immune disorders. By 2024, the company had integrated the acquisition into its asset base, with The Binding Site Group contributing to the 19-year weighted-average amortization period for customer relationships among definite-lived intangible assets. This evolution indicates a strategic focus on long-term value creation through integration of acquired innovation into its core diagnostics offerings.",
      "llm_answer": "\nIn 2023 Thermo Fisher acquired The Binding Site Group and immediately integrated it into the Specialty Diagnostics segment, where its specialty assay and instrument portfolio began adding to segment income and margin. By 2024 the business had been fully absorbed—its products are now part of the company’s ongoing diagnostics offering—and the firm’s subsequent 2024 acquisition of Olink (and continued focus on proteomics) demonstrates that it is leveraging the Binding Site platform as a foundation for expanding its high‑growth diagnostic and life‑science strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2023 acquisition of The Binding Site Group by Thermo Fisher (TMO) and its integration into the Specialty Diagnostics segment, which aligns with the ground truth. However, it introduces a fact not present in the original answer — the 2024 acquisition of Olink and its connection to The Binding Site — which is unsupported by the provided ground truth and represents an overreach in strategic inference. (2) Quantitatively, the answer omits the $2.70 billion acquisition cost and the key detail about the 19-year weighted-average amortization period for customer relationships, both of which are central to the original answer’s assessment of integration and long-term value. These missing figures reduce quantitative accuracy. (3) The multi-hop reasoning is partially sound — it correctly links acquisition to integration and strategic focus — but fails to use the specific financial and accounting evidence (amortization period) that supports the conclusion in the ground truth. Instead, it substitutes speculative reasoning about Olink and proteomics, which is not grounded in the provided data. (4) Contextual relevance is high because the answer addresses the evolution and strategic implications, but correctness is reduced due to omitted key facts and introduction of unverified information. The core integration timeline is accurate, but the strategic interpretation diverges from the evidence-based conclusion in the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 410,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has the disclosure and accessibility of the Directors' Code of Conduct evolved between 2022 and 2024, particularly in terms of website links and scope of application?",
      "original_answer": "In 2022, the Directors' Code of Conduct was posted on BNY Mellon's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-of-conduct.pdf, and it applied to all directors. By 2024, while the scope of application remained the same—applying to all directors—the URL for the Directors' Code of Conduct had changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf. This indicates a change in the website structure or domain branding, likely reflecting a broader rebranding from 'BNY Mellon' to 'BNY', while maintaining the same governance policy content and disclosure intent.",
      "llm_answer": "\nBetween 2022 and 2024 the filing’s description of the Directors’ Code of Conduct remained the same – it “applies to all directors of BNY” and the company will post any amendments or waivers on its website – but the way the posting is referenced changed. In the 2022 Form 10‑K the code was linked with a full URL ( https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/in relations/directors‑code‑of‑conduct.pdf ), whereas the 2024 filing gives a shorter, relative path ( bnymellon/documents/pdf/investor‑relations/directors‑code‑of‑conduct.pdf ), indicating a shift in the displayed link format while still directing users to the same document. Thus, the scope of application (all directors) stayed constant, but the accessibility link became more concise and less explicitly qualified in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies that the scope of application of the Directors' Code of Conduct remained unchanged—applying to all directors—from 2022 to 2024, which aligns with the ground truth. It also correctly notes a change in how the URL was presented in the filings, indicating evolving accessibility. However, there are significant factual inaccuracies in the URL details. The LLM claims the 2024 filing uses a 'shorter, relative path' (bnymellon/documents/pdf/investor-relations/directors-code-of-conduct.pdf), but the ground truth states the 2024 URL changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf—indicating a domain rebranding from 'bnymellon.com' to 'bny.com', not a shift to a relative path. The LLM incorrectly characterizes the 2024 link as relative and retains 'bnymellon' in the path, missing the rebranding implication entirely. Additionally, the 2022 URL in the LLM answer contains a typo ('in relations' instead of 'investor-relations') and uses hyphens in 'code-of-conduct' inconsistently with the original. While the core idea of consistent policy scope and evolving link presentation is correct, the specific URL details and the broader rebranding context—which is key to understanding the accessibility evolution—are misrepresented. This undermines the quantitative and qualitative accuracy, especially in multi-hop synthesis between domain change and corporate rebranding. The answer is contextually relevant and captures the high-level trend, but fails on precise factual correctness of URLs and their implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 439,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has McDonald's relationship with franchisees evolved in terms of financial reporting and strategic emphasis between 2022 and 2023?",
      "original_answer": "In 2022, McDonald's noted that the results of operations from restaurant businesses purchased and sold in transactions with franchisees were not material to the consolidated financial statements, indicating a limited financial impact from such transactions. By 2023, the company explicitly included franchisees and licensees as key stakeholders in its business model, emphasizing their role alongside company-operated restaurants in a detailed breakdown of restaurant ownership types. This shift reflects a more strategic and transparent focus on franchisees as integral to McDonald's global business structure.",
      "llm_answer": "\nBetween 2022 and 2023 McDonald’s refined the accounting for its franchise‑related income: royalties and rent continue to be recognized as underlying sales occur, but the “other” revenues that franchisees pay for technology platforms, brand‑licensing and similar services are now reported on a **gross basis** and recognized when the goods or services are transferred, rather than being amortised over the full franchise term.  This reporting change signals a strategic shift toward treating digital‑service and brand‑licensing fees as a distinct, higher‑margin revenue stream, while still relying on the traditional sales‑based royalty and rent model for the core restaurant business.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and introduces information not present in the ground truth. (1) It claims a change in accounting treatment for franchisee revenues—specifically that 'other' revenues are now reported on a gross basis and recognized when services are transferred rather than amortized—however, this detail is absent from the original answer and cannot be verified from the provided knowledge graph. There is no mention of revenue recognition changes or accounting for technology/platform fees in the ground truth. (2) No numeric values (e.g., dollar amounts, percentages, or financial figures) are present in either the question or original answer, so quantitative accuracy cannot be high due to the fabrication of financial reporting changes. (3) The multi-hop reasoning is flawed: instead of focusing on the evolution of McDonald's strategic emphasis and transparency toward franchisees as stakeholders, the LLM invents a detailed accounting policy shift. The original answer highlights a shift from noting immateriality of franchisee transaction impacts in 2022 to explicitly including franchisees as key stakeholders in 2023, reflecting strategic integration and transparency. The LLM misses this entirely. (4) While the topic of franchisee financial reporting is relevant, the specific claims made are unsupported and factually inconsistent with the ground truth, leading to a low correctness score. The contextual relevance is moderate because it addresses franchisee-related financial reporting, but the substance is incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 424,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the accounting treatment or status of the contingent consideration liabilities related to the Clif Bar acquisition evolve between 2023 and 2024, particularly in terms of fair value measurement and purchase price allocation adjustments?",
      "original_answer": "In 2023, the contingent consideration liabilities related to the Clif Bar acquisition were actively measured at fair value using a Monte Carlo simulation, with $548 million classified as long-term liabilities at December 31, 2023. These liabilities were tied to performance targets in 2025 and 2026 and were subject to fair value adjustments recorded in selling, general, and administrative expenses. By 2024, there is no direct mention of the contingent consideration liabilities; instead, the 2024 filing references purchase price allocation adjustments for Clif Bar during 2023. This indicates that the contingent consideration may have been finalized or reclassified as part of the purchase price allocation process, though the 2024 disclosure does not provide updated figures or valuation methods for these liabilities.",
      "llm_answer": "\nThe contingent consideration linked to the Clif Bar acquisition remained a Level‑3 liability recorded at fair value; by December 31 2023 its fair‑value had risen to **$548 million** (up from $452 million at year‑end 2022), with any subsequent fair‑value changes continuing to be measured via a Monte‑Carlo simulation and booked in selling, general and administrative expense. The liability is presented as a long‑term obligation (with a current portion of $132 million), and the purchase‑price allocation adjustments for Clif Bar were incorporated into intangible‑asset and goodwill balances in 2023, after which the fair‑value measurement approach and SG&A recording of adjustments persisted into 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but introduces significant inaccuracies. It correctly states the $548 million fair value of the contingent consideration liability at December 31, 2023, and correctly identifies the use of Monte Carlo simulation for fair value measurement and classification within selling, general, and administrative (SG&A) expenses. However, it adds information not present in the original answer or ground truth: specifically, the $452 million figure for 2022, the $132 million current portion, and the claim that the fair-value measurement approach 'persisted into 2024'. The original answer explicitly states that there is no direct mention of contingent consideration liabilities in the 2024 filing, suggesting possible finalization or reclassification, whereas the LLM asserts continuity into 2024, which contradicts the ground truth. (2) Quantitative accuracy is partially correct: the $548 million figure is accurate, but the $452 million (2022) and $132 million (current portion) figures are unsupported by the ground truth and appear to be fabricated or inferred incorrectly. No calculation is required, but the inclusion of unverified numbers reduces quantitative reliability. (3) Multi-hop reasoning is flawed: the LLM fails to recognize the key evolution — the absence of contingent consideration disclosures in 2024 — which implies a change in status (e.g., settlement, reclassification, or finalization). Instead, it assumes continuity, missing the nuance that purchase price allocation adjustments were completed in 2023 and that 2024 disclosures shifted focus away from active fair value measurement. (4) Contextual relevance is high — the answer addresses the right topic, uses correct terminology, and references relevant accounting treatments — but factual correctness is undermined by unsupported details and incorrect inference about 2024 status. Thus, while the answer appears plausible, it diverges critically from the ground truth on the evolution of the liability into 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 551,
        "total_tokens": 1957
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has AMD's strategic emphasis on Vulkan API support evolved between 2022 and 2024, and what does this reveal about its approach to maintaining competitiveness in the discrete GPU market?",
      "original_answer": "In 2022, AMD highlighted its support for Vulkan as part of its Radeon™ series discrete GPUs, which were built on the RDNA 2 architecture and aimed at delivering high-performance gaming and creation workloads. By 2024, AMD continued to support Vulkan but shifted its focus toward the newer RDNA 3 architecture, which underpins the Radeon RX 7000 Series GPUs. This evolution suggests AMD is maintaining its commitment to Vulkan while advancing its GPU capabilities to meet the growing demands of immersive gaming and AI/ML computing. This strategic continuity in API support combined with architectural innovation indicates AMD’s effort to stay competitive by offering both backward compatibility and cutting-edge performance enhancements.",
      "llm_answer": "\nBetween 2022 and 2024 AMD moved from merely “supporting” Vulkan to positioning it as a core strategic pillar of its GPU software stack—expanding Vulkan extensions, optimizing drivers, and tying Vulkan‑based features such as FidelityFX Super‑Resolution and ROCm compute to the RDNA 3 architecture. This shift shows AMD’s approach of leveraging open, cross‑platform standards to reduce developer friction, improve performance‑per‑watt, and compete on ecosystem breadth rather than raw hardware alone.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of timeline (2022–2024), architectural progression (RDNA 2 to RDNA 3), and AMD's continued support for Vulkan. It correctly identifies AMD’s strategic use of Vulkan in the context of competitiveness in the discrete GPU market. There are no numeric inaccuracies, so quantitative accuracy is perfect. However, the LLM introduces specific claims not present in the ground truth: (1) that Vulkan became a 'core strategic pillar'—the original answer describes continuity, not a strategic elevation; (2) explicit linkage of FidelityFX Super-Resolution and ROCm compute to Vulkan-based features on RDNA 3, which is not confirmed in the ground truth. While plausible, these represent over-specific technical assertions not supported by the provided knowledge. The original answer emphasizes architectural evolution and backward compatibility as competitiveness drivers, while the LLM emphasizes ecosystem and developer friction reduction—complementary but not equivalent reasoning. Thus, while the answer is contextually relevant and directionally accurate, it adds unverified technical depth and shifts the emphasis slightly, warranting a 7 for correctness and qualitative accuracy. No calculation or date errors exist.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 356,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How did RTX's integration-related charges impact its operating profit trends between 2022 and 2023, particularly with the introduction of the Powder Metal Matter charge in 2023?",
      "original_answer": "In 2022, RTX reported a decrease in Acquisition Accounting Adjustments, which contributed positively to its operating profit. However, in 2023, there was a significant $2.9 billion charge associated with the Powder Metal Matter, which became a major driver of the $1.9 billion decrease in Operating Profit compared to 2022. This reflects a notable shift from a declining trend in integration-related charges in 2022 to a significant new expense in 2023 that directly impacted profitability.",
      "llm_answer": "\nThe integration‑related costs that RTX recorded in 2023—most notably the $2.9 billion “Powder Metal Matter” charge—were the chief reason operating profit fell from $5.5 billion in 2022 to $3.6 billion in 2023, a decline of about $1.9 billion.  While other segments posted modest profit gains, the Pratt & Whitney‑related Powder Metal Matter expense (combined with higher restructuring and acquisition‑accounting adjustments) outweighed those improvements, driving the overall drop in operating profit and margin between the two years.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the $2.9 billion Powder Metal Matter charge and the $1.9 billion decrease in operating profit are accurately reported. The implied operating profit figures of $5.5 billion in 2022 and $3.6 billion in 2023 are consistent with a $1.9 billion decline, and these values match the expected trend from the original answer. (2) The answer correctly identifies the Powder Metal Matter charge as integration-related and ties it to Pratt & Whitney, which is contextually accurate. (3) The reasoning is sound: it correctly attributes the drop in operating profit primarily to this charge, notes that other segments saw gains, and acknowledges additional factors like restructuring and acquisition-accounting adjustments—this adds nuance without contradicting the original answer. (4) The original answer emphasizes a shift from declining integration costs in 2022 to a major new charge in 2023; the LLM captures this trend effectively, though it does not explicitly mention the 2022 decline in acquisition adjustments as a positive factor, which is a minor omission. However, the core multi-hop synthesis—linking the 2023 charge to the year-over-year profit decline—is correctly executed. Overall, the answer is factually precise, contextually relevant, and semantically equivalent to the ground truth with only slight room for added context about 2022 trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 404,
        "total_tokens": 1668
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has MDLZ's relationship with Clif Bar evolved between 2023 and 2024, particularly in terms of acquisition-related financial activities?",
      "original_answer": "In 2023, MDLZ acquired Clif Bar, as noted in the 2023 10-K filing, with specific reference to the August 1, 2022 acquisition and related financial impacts such as integration costs and contingent consideration adjustments. By 2024, the relationship had evolved to include purchase price allocation adjustments for Clif Bar during the prior year, as detailed in the 2024 10-K filing. This indicates that the company had moved beyond the initial acquisition phase into a period of financial recalibration and consolidation of the Clif Bar acquisition.",
      "llm_answer": "\nBetween 2023 and 2024 MDLZ’s relationship with Clif Bar remained that of an acquired brand rather than a new acquisition.  The 2023 results showed the first‑year post‑acquisition contribution—$507 million of incremental net revenue (constant‑currency) from Clif Bar and related acquisition‑integration and contingent‑consideration adjustments—while the 2024 filing reflects that the brand is now fully integrated, with its indefinite‑life intangible asset still recorded on the balance sheet (gross $3.3 bn) and no additional cash outlay, although the company continued to test it for impairment (recording $153 million of overall intangible‑asset impairment charges, none of which were attributed specifically to Clif Bar).",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in quantitative details. The ground truth states that MDLZ acquired Clif Bar on August 1, 2022, with financial impacts discussed in the 2023 10-K, but the LLM incorrectly frames 2023 as the acquisition year. The LLM claims $507 million in incremental net revenue from Clif Bar in 2023, but this figure is not present in the ground truth and cannot be verified. Additionally, the $3.3 billion gross indefinite-life intangible asset and $153 million impairment charge are specific figures not mentioned in the original answer, making them unsupported. (2) The quantitative accuracy is low because the LLM introduces precise numbers (e.g., $507M, $3.3B, $153M) that are not in the ground truth and may be hallucinated. The original answer only references integration costs and contingent consideration adjustments without specific dollar amounts. (3) Qualitatively, the reasoning is partially sound: the LLM correctly infers that by 2024, Clif Bar was no longer a new acquisition but in a consolidation phase, aligning with the idea of purchase price allocation adjustments and ongoing financial recalibration. It correctly identifies the evolution from acquisition to integration. (4) Contextual relevance is high because the response directly addresses the evolution of the MDLZ-Clif Bar relationship and focuses on acquisition-related financial activities across 2023 and 2024. However, the introduction of unverified financial figures significantly undermines factual correctness, warranting a moderate correctness score of 6.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 441,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has Gulfstream's approach to energy efficient engines evolved from 2023 to 2024, and what specific aircraft developments reflect this shift?",
      "original_answer": "In 2023, Gulfstream emphasized its leadership in the use of sustainable aviation fuel (SAF) and energy efficient engines, focusing on continuous R&D investment to develop technologically advanced business jets. However, no new aircraft model powered by energy efficient engines was introduced that year. By 2024, Gulfstream had transitioned from announcement and development phases to actual production of energy efficient engines, as evidenced by the introduction of the G700, which features 'all-new engines' designed for high-speed performance and efficiency. This marks a tangible evolution from strategic positioning in 2023 to operational realization in 2024.",
      "llm_answer": "\nFrom 2023 to 2024 Gulfstream deepened its focus on energy‑efficient propulsion by pairing the rollout of new, lower‑fuel‑burn engines with broader Sustainable‑Aviation‑Fuel (SAF) initiatives.  The company’s latest clean‑sheet jets—the ultra‑large‑cabin G700 (certified early 2024) and the ultra‑long‑range G800/G400—feature all‑new powerplants that deliver higher specific‑fuel‑efficiency and longer range, while Gulfstream simultaneously expanded SAF availability (including the world’s first 100 % SAF trans‑Atlantic flight in Nov 2023) and offered carbon‑neutral travel options, underscoring a strategic shift toward both more efficient engines and fuel‑sustainability across its fleet.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies. While it correctly identifies Gulfstream's focus on energy-efficient engines and SAF initiatives, it incorrectly states that the G800/G400 feature 'all-new powerplants' and were part of the 2024 developments. The ground truth only confirms the G700 as the aircraft reflecting the shift in 2024 with all-new engines; there is no mention of the G800 or G400 being introduced or featuring new engines in this context. Additionally, the claim about a '100% SAF trans-Atlantic flight in Nov 2023' is not supported by the original answer, which only notes Gulfstream's emphasis on SAF but does not cite specific flights. (2) The date 'early 2024' for G700 certification aligns generally with the ground truth's implication of 2024 production, though the original does not specify 'early 2024'. However, the inclusion of the November 2023 flight and the G800/G400 models introduces unsupported specifics. (3) The reasoning partially captures the multi-hop evolution from R&D focus in 2023 to production in 2024, especially with the G700, but overextends by adding unmentioned aircraft models and specific events (like the transatlantic flight), indicating flawed synthesis. (4) The contextual relevance is high because the answer addresses energy efficiency, engine development, and SAF—core themes from the question. However, correctness and quantitative accuracy are reduced due to fabrication of specific aircraft roles and events not present in the ground truth. The core evolution around the G700 is correct, but the additional details dilute factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 443,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has AMD's relationship with semi-custom SoC products evolved from 2022 to 2024, particularly in terms of revenue structure and strategic positioning?",
      "original_answer": "In 2022, AMD's relationship with semi-custom SoC products was characterized by dependency, with revenue derived from both non-recurring engineering fees and sales of the products themselves, and success was directly tied to third-party product performance. By 2024, AMD's relationship evolved to one of active production and broader strategic integration, as semi-custom SoC products became part of a more diversified product portfolio that includes AI accelerators, GPUs, APUs, and DPUs. This shift indicates a more central and controlled role for AMD in the development and commercialization of these products, aligning them more closely with long-term industry trends and internal innovation strategies.",
      "llm_answer": "\nFrom 2022 to 2024 AMD transformed its semi‑custom SoC business from a modest, project‑by‑project engineering‑fee arrangement into a core, higher‑volume growth pillar.  The 2024 10‑K shows that “custom products” – which include semi‑custom SoCs – are now sold under non‑cancellable purchase orders and revenue is recognized over time using a cost‑plus margin method, reflecting deeper, longer‑term partnerships (e.g., console OEMs) and a strategic shift to treat semi‑custom silicon as a primary, recurring revenue source rather than an ancillary offering.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of strategic evolution and revenue structure changes. It accurately captures the shift from a project-based model with non-recurring engineering (NRE) fees in 2022 to a more integrated, recurring revenue model by 2024, supported by non-cancellable purchase orders and cost-plus margin recognition—indicative of deeper OEM partnerships. The mention of 'custom products' in the 2024 10-K aligns with AMD's reporting and reflects strategic integration into long-term offerings. However, the LLM omits explicit mention of the broader product portfolio context (AI accelerators, GPUs, APUs, DPUs) that the ground truth highlights as part of AMD’s diversified strategic positioning. While the revenue recognition method and business model evolution are correctly identified (supporting quantitative and qualitative accuracy), the answer does not fully reflect the multi-hop synthesis of AMD’s expanded role across multiple technology domains. There are no numerical inaccuracies (quantitative accuracy is perfect as no incorrect figures are cited), and the response remains highly relevant to the question. Semantic equivalence is strong but not complete due to the missing portfolio diversification element.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 357,
        "total_tokens": 1674
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has the company's structure of preferred share authorization evolved between fiscal years 2023 and 2024, and what does this indicate about its capital strategy?",
      "original_answer": "The company's preferred share authorization structure remained unchanged between fiscal years 2023 and 2024, with 127.5 million Preferred Shares at $0.20 par value and 500 thousand A Preferred Shares at $1.00 par value authorized in both years. Additionally, no Preferred Shares or A Preferred Shares were issued or outstanding in either year. This indicates that the company has not utilized or pursued any changes in its preferred share structure as part of its capital strategy during this period.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Medtronic kept its preferred‑share authorizations unchanged – 127.5 million Preferred Shares (par $0.20) and 500 thousand A Preferred Shares (par $1.00) – and, as in the prior year, none of these shares were issued or outstanding.  The lack of any increase in authorized preferred‑share capital signals that the company is not using preferred equity to fund growth, but is instead relying on its ordinary‑share repurchase program and other internal cash‑generation mechanisms to manage capital and return value to shareholders.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that the preferred share authorization remained unchanged between fiscal years 2023 and 2024, with 127.5 million Preferred Shares at $0.20 par value and 500 thousand A Preferred Shares at $1.00 par value authorized in both years. It also accurately notes that no shares were issued or outstanding in either year—this matches the ground truth exactly. (2) All numeric values (127.5 million, 500 thousand, $0.20, $1.00) are correct and match the original answer; no calculations are required, but the representation is precise and consistent. (3) The multi-hop reasoning is sound: the model correctly infers from the lack of changes and zero issuance that the company is not utilizing preferred shares as part of its capital strategy. It goes a step further by contextualizing this within a broader capital strategy involving share repurchases and internal cash generation, which is a reasonable qualitative extension supported by typical corporate behavior, though this specific detail (about repurchase programs) is not in the ground truth. (4) The only reason for not giving a perfect 10 is that the LLM introduces the idea of 'ordinary-share repurchase program' as a contrast, which, while plausible, is not confirmed or mentioned in the original answer. Thus, the reasoning is slightly extended beyond the provided data, but the core facts, synthesis, and conclusion about capital strategy remain accurate and well-supported. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 428,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the framing of reputational risk related to adverse publicity evolved between 2022 and 2024 in BK's risk disclosures, particularly in terms of associated impacts or linked concerns?",
      "original_answer": "In 2022, BK identified adverse publicity as a risk that could negatively affect its business, financial condition, and results of operations, and linked it with government scrutiny and other reputational harm. By 2024, the framing of this risk remained present but was expanded to include broader reputational impacts from sustainability concerns such as climate change and diversity, in addition to being tied to new operational models like the platforms operating model transition. This indicates a broadening of the contexts in which adverse publicity could negatively impact BK's reputation and business outcomes.",
      "llm_answer": "\nBetween the 2022 and 2024 filings, BK’s risk language shifted from describing reputational risk mainly as a downstream effect of operational failures, cyber incidents or regulatory enforcement (e.g., “adverse events, publicity or government scrutiny could harm our reputation”), to embedding it within broader ESG and geopolitical exposures.  The 2024 disclosure explicitly ties reputational harm to sustainability concerns, climate‑change impacts, diversity issues and geopolitical events, and notes that such reputational damage can trigger regulatory scrutiny, affect client activity and even raise funding costs through credit‑rating pressure.  Thus, the framing evolved from a generic “reputation‑at‑risk” warning to a more nuanced view that links reputational risk to emerging ESG and external‑event considerations and their downstream business consequences.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution in BK's risk disclosures between 2022 and 2024: in 2022, reputational risk was linked to adverse publicity, operational issues, and government scrutiny; by 2024, it expanded to include ESG factors like climate change, diversity, and geopolitical events. This matches the original answer’s claim of broadening to sustainability concerns and new operational models. (2) There are no numeric values to verify, so quantitative accuracy is not applicable—no errors in dates or financial figures. (3) The multi-hop reasoning is sound: the model synthesizes changes over time in risk framing, correctly linking earlier generic reputational risks to newer, more specific ESG and external-event triggers. It also accurately infers downstream consequences (e.g., regulatory scrutiny, client impact, funding costs), which are consistent with the expanded business impacts mentioned in the ground truth. (4) The only minor gap is that the LLM answer does not explicitly mention the 'platforms operating model transition'—a specific contextual expansion noted in the original answer—but instead generalizes to operational failures. This omission is minor given the strong emphasis on ESG and broader reputational impacts. Overall, the answer is semantically equivalent, well-reasoned, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 389,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How did Amazon's financial investment and valuation approach toward Anthropic, PBC evolve from 2023 to 2024, particularly in terms of investment classification and the factors affecting its valuation?",
      "original_answer": "In 2023, Amazon disclosed a $1.25 billion convertible note investment in Anthropic, PBC, classified as available-for-sale and reported at fair value with unrealized gains and losses included in 'Accumulated other comprehensive income (loss).' The note was categorized as a Level 3 asset, and Amazon had an agreement to invest an additional $2.75 billion in a second convertible note by Q1 2024. By 2024, the investment was still classified as available-for-sale but was noted to be part of a broader portfolio of convertible debt investments in private companies, primarily referencing Anthropic, PBC. The 2024 filing emphasized increased complexity in valuing private company investments due to the lack of readily available market data and global economic uncertainty, indicating a shift toward acknowledging heightened valuation risk. While the classification remained consistent, the 2024 disclosure placed more emphasis on the challenges of valuation rather than the mechanics of the investment itself.",
      "llm_answer": "\nFrom 2023 to 2024 Amazon kept its stake in Anthropic, PBC classified as a Level‑3 available‑for‑sale convertible‑debt (later treated as an equity‑linked investment) and recorded it at fair value, with unrealized gains and losses flowing through other comprehensive income. The initial $1.25 billion note entered in Q3 2023 was later expanded under a $2.75 billion commitment, and its valuation relies on internally‑derived discounted‑cash‑flow models and qualitative impairment reviews rather than observable market prices—making it sensitive to macro‑economic conditions, foreign‑exchange shifts, and the performance of Anthropic’s cloud and AWS‑related services.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $1.25 billion initial investment in 2023 and the $2.75 billion additional commitment, aligning with the ground truth. It accurately states the investment was classified as available-for-sale and recorded at fair value with unrealized gains/losses in other comprehensive income. However, the LLM introduces the term 'later treated as an equity-linked investment,' which is not mentioned in the original answer and lacks support in the ground truth, introducing a minor factual inaccuracy. (2) Quantitatively, all dollar amounts ($1.25 billion, $2.75 billion) and the Q3 2023 timing are correct. The ground truth does not specify Q3 2023 but only that the $2.75 billion was to be invested by Q1 2024; the LLM’s inclusion of Q3 2023 for the initial note is plausible but not confirmed in the original answer, representing a slight overprecision. (3) The multi-hop reasoning is mostly sound: the LLM correctly synthesizes the classification, valuation approach (Level 3, fair value, internal models), and sensitivity to macroeconomic factors. However, it misses the key 2024 shift emphasized in the original answer—increased focus on valuation complexity and risk due to lack of market data and global uncertainty—instead focusing on AWS-related performance and foreign exchange, which are not highlighted in the ground truth. This reflects a partial misalignment in qualitative emphasis. (4) The answer is contextually relevant and well-structured, but the addition of unsupported details (equity-linked treatment, FX sensitivity) and omission of the 2024 disclosure’s emphasis on valuation challenges reduce qualitative accuracy. Overall, core facts are correct, but minor errors and omissions prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 481,
        "total_tokens": 1912
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the nature of the risks related to the protection of MDLZ's intellectual property, including know-how, evolved between 2023 and 2024?",
      "original_answer": "In 2023, MDLZ emphasized the importance of protecting its intellectual property rights, particularly trademarks, patents, copyrights, and know-how, through a combination of legal mechanisms such as patent and trademark laws, licensing agreements, and third-party nondisclosure agreements. The company expressed concern that failure to protect these rights or any legal changes reducing intellectual property protections—especially in response to developments in artificial intelligence technologies—could significantly harm its competitiveness and financial condition. In 2024, while the company maintained its emphasis on the significance of intellectual property rights, it did not specifically mention artificial intelligence as a factor affecting protection. Instead, the 2024 disclosure focused on the broader risks of legal or regulatory non-compliance and the potential for civil or criminal penalties, reputational damage, and financial loss due to litigation or enforcement actions. This shift indicates a broadening of the risk context without the specific emphasis on AI-related threats present in 2023.",
      "llm_answer": "\nBetween 2023 and 2024 the IP‑risk narrative shifted from a primary focus on traditional trademark, patent and trade‑secret protection to a broader, technology‑driven exposure.  In the 2023 filing the company warned that failure to secure or maintain its IP rights—especially in light of possible legal changes—could harm its competitiveness, and it highlighted the threat of third‑party infringement claims.  By 2024 the discussion explicitly adds the risk of “developments in artificial‑intelligence technologies,” emphasizes the need to protect know‑how and trade secrets in both traditional and digital environments, and underscores how changes in law or enforcement could weaken those protections, reflecting a more complex, AI‑related and digitally‑focused IP landscape.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in its core factual claims, despite being well-structured and contextually relevant in framing an evolution of IP risks. (1) The key error is the reversal of the timeline regarding AI: the Original Answer (ground truth) states that MDLZ *mentioned AI in 2023* but *did not mention it in 2024*, whereas the LLM claims that AI was *added in 2024*—this is factually inverted. This misrepresents the evolution of risk disclosure and undermines the entire analysis. (2) There are no numeric values to verify, so quantitative accuracy is not applicable; however, the absence of numbers does not excuse the factual inversion. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the change over time, incorrectly attributing the introduction of AI-related risks to 2024 when it was actually present in 2023 and dropped in 2024. The LLM also introduces concepts not in the original, such as 'digital environments' and 'third-party infringement claims', which were not emphasized in the ground truth. (4) While the answer is relevant to the question and attempts to describe a shift in risk focus, the reversal of the AI timeline—a central element—makes the conclusion invalid. Thus, the correctness and qualitative accuracy scores are low, though the response is not irrelevant, warranting a moderate contextual relevance score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1471,
        "completion_tokens": 381,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has Goldman Sachs' treatment of Non-Employee Director Equity Award Agreements evolved between the 2023 and 2024 SEC filings, particularly in terms of referenced agreements and their timelines?",
      "original_answer": "In 2023, Goldman Sachs referenced Non-Employee Director Equity Award Agreements through Exhibit 10.17, which pointed to an amendment dated November 28, 2008. By 2024, the company continued to disclose these agreements under the same exhibit number (10.18), but the referenced source shifted to Exhibit 10.69 from the 2008 Annual Report, indicating a formalization or consolidation of prior amendments. This evolution shows a continuation of the policy with deeper historical documentation being emphasized in the later filing.",
      "llm_answer": "\nBetween the 2023 and 2024 filings Goldman Sachs shifted from citing a single, generic “Non‑Employee Director RSU Award Agreement (pre‑2015)” – referenced in the 2023 10‑K (Exhibit 10.21) – to disclosing a suite of newer, numbered award forms (10.32 – 10.38) that include a dedicated “Form of Non‑Employee Director RSU Award Agreement,” a “Form of Non‑Employee Director RSU Award Agreement (Cash‑Settled),” and separate “One‑Time/Year‑End RSU Award Agreement” and “Year‑End RSU Award Agreement (fully vested / not fully vested)” provisions.  In other words, the 2023 filing relied on an older, pre‑2015 agreement, while the 2024 filing replaces it with updated, more granular director‑equity agreements that reflect newer vesting and cash‑settlement terms.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and does not align with the ground truth. (1) It claims that in 2023, Goldman Sachs referenced a 'Non-Employee Director RSU Award Agreement (pre-2015)' under Exhibit 10.21, but the ground truth states it was Exhibit 10.17 referencing a November 28, 2008 amendment. The 2024 filing is said to include new forms from Exhibits 10.32–10.38, whereas the truth indicates the reference shifted to Exhibit 10.69 from the 2008 Annual Report under the same exhibit number 10.18 (not 10.32–10.38). (2) The dates and exhibit numbers are factually wrong—no mention of pre-2015 agreements or new numbered forms like 10.32–10.38 appears in the ground truth. The actual evolution centers on a shift in referenced source documentation, not a replacement with new granular forms. (3) The multi-hop reasoning is flawed: the model invents a narrative about updated vesting and cash-settlement terms and a suite of new forms that are not supported by the original answer. It fails to capture the actual continuity in policy with deeper historical documentation being emphasized. (4) While the answer attempts to address the evolution of director equity agreements, it misidentifies key entities (exhibit numbers, years, agreement types), making it factually unsound. The contextual relevance is moderate because it addresses the general topic of evolving award agreements, but the specifics are fabricated. Hence, low scores for correctness, quantitative, and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 410,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has BKNG's relationship with travel service providers evolved between 2022 and 2023 in terms of revenue recognition and contractual responsibilities?",
      "original_answer": "In 2022, BKNG described its relationship with travel service providers as one where it connects consumers to providers through its platforms, emphasizing its role as an intermediary without taking responsibility for delivering the travel services. The company highlighted that it earns revenues primarily from facilitating reservations and also mentioned the impact of cancellations during the pandemic recovery phase. By 2023, BKNG provided more detailed accounting treatment around its contracts with travel service providers, specifying that it recognizes revenue on a net basis due to its role as an agent, and further clarified its revenue recognition timing as occurring at the point when travelers begin using the arranged services. This reflects a shift from a general description of the relationship to a more structured and accounting-driven dependency on travel service providers, particularly in how it recognizes commissions and transaction revenues.",
      "llm_answer": "\nBetween 2022 and 2023 BKNG deepened its “merchant” model—more bookings are now processed as merchant transactions in which the Company facilitates payment from travelers, records revenue net of commissions (and any incentives or taxes), and assumes greater responsibility for refunds, charge‑backs and tax collection.  This shift is reflected in a larger Deferred Merchant Bookings balance in 2023 and results in higher merchant‑related expenses that offset the incremental merchant revenues, while agency‑type commissions (where BKNG does not handle payments) remain a smaller share of total revenue.  Consequently, its contracts with travel service providers now give the Company tighter integration with payment handling and a broader set of contractual obligations, moving a greater portion of its revenue to a net‑basis.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general direction of BKNG's evolving relationship with travel service providers—specifically the shift toward a merchant model and increased contractual responsibilities involving payment handling, refunds, and tax collection. It correctly identifies that revenue is recognized on a net basis and links this to changes in accounting treatment and contract structure. However, it diverges from the ground truth in emphasis and detail: the original answer highlights a shift from a general intermediary description in 2022 to more detailed accounting disclosures in 2023, particularly around revenue recognition timing (at the point travelers begin using services) and the agent role justification for net revenue reporting. The LLM answer overemphasizes the 'merchant model' expansion without clear support in the ground truth, which does not mention a growing merchant/agency revenue split or changes in Deferred Merchant Bookings. While the concept of net revenue recognition is correct, the reasoning is partially misaligned—the ground truth stresses BKNG’s role as an agent (not principal), which supports net reporting, whereas the LLM implies the merchant model (typically associated with gross reporting) is expanding, creating a logical tension. There are no explicit numbers in either answer, so quantitative accuracy is high by default. Contextually, the response is relevant and addresses revenue recognition and contractual evolution. However, the multi-hop synthesis is flawed: it infers operational shifts (e.g., increased merchant transactions) not present in the ground truth, which focuses on disclosure and accounting clarification rather than business model transformation. Thus, while key terms like 'net basis' and 'contractual obligations' are correctly used, the underlying reasoning and factual basis are partially incorrect, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1449,
        "completion_tokens": 515,
        "total_tokens": 1964
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "What specific changes occurred in the structure of Goldman Sachs' executive life insurance policy disclosures between the 2023 and 2024 10-K filings?",
      "original_answer": "In the 2023 10-K filing, Goldman Sachs included the Goldman Sachs & Co. LLC Executive Life Insurance Policy and Certificate with Metropolitan Life Insurance Company (Exhibit 10.11) and a form of the policy with Pacific Life & Annuity Company (Exhibit 10.12). In the 2024 10-K filing, these exhibits were not only retained but renumbered to 10.12 and 10.13 respectively, indicating a reorganization of exhibit numbering. This renumbering and retention of the policies in the 2024 filing demonstrates a structural update in how the policies are presented within the filing, rather than a substantive change in the policies themselves.",
      "llm_answer": "\nThe 2023 10‑K presented the executive‑life‑insurance coverage for managing directors as a stand‑alone narrative subsection within Item 10 (Executive Compensation), describing the policy’s eligibility, benefits and restrictions. In the 2024 filing that narrative was eliminated – the same policies are now only listed by exhibit numbers 10.12 and 10.13 in the exhibit index under Item 10 (Directors, Executive Officers and Corporate Governance), with no separate descriptive text. This shift moves the disclosure from a dedicated narrative section to an exhibit‑only reference.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains partially correct information but introduces significant inaccuracies in the description of the disclosure structure and location of the policies in the 10-K filings. Quantitatively, the exhibit numbers (10.12 and 10.13 in the 2024 filing) are correctly cited, aligning with the ground truth's note about renumbering from 10.11 and 10.12 in 2023 to 10.12 and 10.13 in 2024, so quantitative accuracy is high. However, the qualitative accuracy suffers because the LLM incorrectly claims that in the 2023 10-K, the policies were described in a 'stand-alone narrative subsection within Item 10 (Executive Compensation)' and that this narrative was 'eliminated' in 2024. The ground truth does not support this characterization—it only confirms the presence of the exhibits and their renumbering, not the existence or removal of descriptive narrative sections. There is no mention in the ground truth about placement in Item 10 under 'Directors, Executive Officers and Corporate Governance' or a shift from narrative to exhibit-only disclosure. This represents a failure in multi-hop reasoning: the model inferred structural changes beyond what the evidence supports. While the answer addresses the question’s focus on structural changes and correctly identifies exhibit renumbering, it fabricates details about narrative content and section placement, undermining factual reliability. Contextually, the response is relevant and attempts to explain a shift in disclosure format, but the unsupported claims reduce its correctness. Thus, the overall correctness score is moderate due to a mix of accurate exhibit numbers and incorrect contextual framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 453,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has the strategic importance and manufacturing approach for FBAR filters evolved between 2022 and 2024, particularly in terms of internal fabrication and competitive positioning?",
      "original_answer": "In 2022, FBAR filters were highlighted as a key product utilizing Broadcom’s proprietary processes, fabricated internally to protect IP and accelerate time to market, alongside vertical-cavity surface emitting lasers and side emitting lasers. The internal fabrication was specifically emphasized as a means to maintain competitive advantage by safeguarding innovation. By 2024, FBAR filters remained part of the internal fabrication strategy, but the context expanded to include a more comprehensive list of competitors in the semiconductor space, such as Qorvo, Qualcomm, and Skyworks, indicating a more intense competitive environment. This suggests that while the internal manufacturing strategy for FBAR filters remained consistent, the competitive pressure in wireless communications increased significantly, requiring Broadcom to reinforce its IP protections and innovation cycle.",
      "llm_answer": "\nFrom 2022 to 2024 Broadcom shifted FBAR‑filter production from a predominantly outsourced model to dedicated internal III‑V wafer fabrication in the United States and Singapore, investing in process‑development and tighter design‑to‑fab integration to safeguard IP and guarantee supply‑chain resilience.  This internal capability has become a key competitive differentiator—allowing faster, higher‑performance, and customizable filters that underpin Broadcom’s high‑margin, high‑value wireless/RF portfolio and reinforce its position as a preferred supplier to OEMs.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies in its qualitative claims, despite being free of numerical errors (there are no explicit numbers to verify, so quantitative accuracy is scored as 10 by default). The core error is the claim that Broadcom shifted FBAR filter production 'from a predominantly outsourced model to dedicated internal III-V wafer fabrication' between 2022 and 2024. This is incorrect: the ground truth states that FBAR filters were already being fabricated internally in 2022 as part of Broadcom’s strategy to protect IP and accelerate time to market. There is no indication of a shift from outsourced to in-house production during this period—the internal fabrication approach was consistent across both years. Additionally, the LLM introduces specific details not present in the original answer, such as 'III-V wafer fabrication in the United States and Singapore' and 'tighter design-to-fab integration,' which are unsupported by the source. While the LLM correctly identifies the strategic importance of internal fabrication for IP protection and competitive advantage, it misrepresents the evolution as a change in manufacturing approach when in fact the approach remained stable. The competitive landscape expansion to include Qorvo, Qualcomm, and Skyworks in 2024—highlighted in the ground truth as evidence of increased competitive pressure—is entirely omitted. Thus, while the answer is contextually relevant and addresses the general theme of strategic importance and manufacturing, it fails on key factual and multi-hop reasoning points, particularly the incorrect characterization of a strategic shift that did not occur.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 453,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has BMY's strategic positioning of Krazati evolved between 2023 and 2024, particularly in terms of clinical development focus and financial valuation?",
      "original_answer": "In 2023, Krazati was positioned as part of BMY’s oncology portfolio with specific clinical trials listed: KRYSTAL-17 for 1L NSCLC TPS<50%, KRYSTAL-10 for 2L CRC, and KRYSTAL-12* for 2L+ Mutated NSCLC. By 2024, BMY had acquired Mirati for $4.8 billion, securing full rights to Krazati, which had already received FDA and EMA approvals for second-line NSCLC and FDA approval for advanced KRAS-mutated colorectal cancer. Additionally, Krazati was now being developed in combination with a PD-1 inhibitor for first-line NSCLC, indicating a significant expansion in its clinical and commercial strategy.",
      "llm_answer": "\nBetween 2023 and 2024 BMY transformed Krazati from a newly‑acquired, pre‑launch oncology asset (secured through the $4.8 bn Mirati purchase in early 2024) into a clinically advanced, revenue‑generating product with multiple Phase III read‑outs and FDA approvals for second‑line NSCLC and colorectal cancer, and the company now records a $640 million definite‑lived acquired‑product‑rights intangible for Krazati on its balance sheet—reflecting its strategic valuation within the $4.9 bn purchase‑price allocation.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the high-level strategic shift in BMY's positioning of Krazati but contains significant factual inaccuracies that affect correctness. (1) Quantitatively, the $4.8 billion acquisition of Mirati is correctly cited, but the LLM incorrectly states the acquisition occurred in 'early 2024'—the deal was announced and closed in 2023 (October 2023), though integration and financial impacts were reflected in 2024. This misdating affects timeline accuracy. The $640 million definite-lived intangible asset for Krazati is not present in the ground truth and cannot be verified; this specific valuation figure is unsupported. (2) The ground truth emphasizes clinical development focus in 2023 (KRYSTAL-17, -10, -12*) and expansion into combination therapy with a PD-1 inhibitor in 1L NSCLC in 2024—this key evolution is omitted in the LLM answer, which instead vaguely references 'multiple Phase III read-outs' without naming trials or specifying combination strategies. (3) The LLM incorrectly implies Krazati was 'pre-launch' and 'newly-acquired' in early 2024, when BMY acquired Mirati (and thus Krazati) in late 2023. (4) While the FDA approvals for second-line NSCLC and advanced KRAS-mutated colorectal cancer are correctly mentioned, EMA approval is omitted. (5) The $4.9 billion purchase-price allocation is mentioned in the LLM answer but not in the ground truth (which states $4.8B), introducing a minor discrepancy. Overall, the answer reflects a plausible narrative but substitutes or invents specific financial figures and misrepresents the timeline and clinical development details, leading to a partial correctness score. The reasoning is logically structured but based on flawed premises, and while contextually relevant, it lacks fidelity to the source data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 483,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has the relationship between BKNG and travel service providers evolved between 2022 and 2023, particularly in terms of how BKNG manages financial obligations and incentives related to these providers?",
      "original_answer": "In 2022, BKNG primarily competed with travel service providers, highlighting the intense and evolving nature of the competitive landscape in the online travel market. By 2023, BKNG's relationship with travel service providers shifted to a more dependent model, as evidenced by the increase in the 'Deferred merchant bookings' liability on its balance sheet, which reflects amounts estimated to be payable to travel service providers. Additionally, BKNG introduced more incentive programs, such as referral bonuses, rebates, and loyalty points, which are recognized as a reduction of revenue, indicating a strategic shift toward enhancing partnerships and incentivizing collaboration with travel service providers rather than solely competing with them.",
      "llm_answer": "\nBetween 2022 and 2023 Booking Holdings deepened its “Connected‑Trip” strategy—expanding direct flight and ancillary‑service offerings and tightening integration with accommodation, rental‑car and restaurant partners—yet the contractual model with travel‑service providers remained unchanged: providers continue to supply inventory to BKNG’s platforms without assuming delivery risk, and BKNG earns revenue on a net‑basis through either agency commissions or merchant margins.  Consequently, BKNG records revenue when travelers actually use the booked services, treats coupons, loyalty points and other incentives as reductions of that revenue, and manages its financial obligations to providers through deferred merchant‑booking balances and provisions for refunds, while re‑classifying certain tax and expense items to better align with the variable nature of these payments.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually consistent in terms of financial reporting practices (e.g., net revenue recognition, treatment of incentives as revenue reductions, use of deferred merchant bookings), and there are no explicit numerical inaccuracies—hence a high quantitative accuracy score. However, it misses the core evolution highlighted in the ground truth: the strategic shift from competition to dependence on travel service providers between 2022 and 2023. The original answer emphasizes a qualitative transformation in the relationship—moving from competitive dynamics in 2022 to a more partnership-oriented, incentive-driven model in 2023, evidenced by growing liabilities and expanded incentive programs. The LLM response acknowledges incentives and deferred payments but frames them as part of an unchanged contractual model, which downplays the strategic shift. It also introduces the 'Connected-Trip' strategy and reclassification of tax items, which are not mentioned in the ground truth and may reflect accurate but extraneous details. While the LLM correctly identifies mechanisms like deferred merchant bookings and revenue reduction due to incentives, it fails to explicitly connect these to a changing relationship dynamic over the two years, weakening the multi-hop reasoning. Thus, while contextually relevant and factually plausible, the answer lacks the key comparative insight about evolving dependency and strategic realignment, resulting in a partial correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1421,
        "completion_tokens": 409,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has Broadcom's involvement in the development of Custom Touch Controllers evolved from 2022 to 2024, particularly in terms of their role in the product lifecycle?",
      "original_answer": "In 2022, Broadcom was described as supplying Custom Touch Controllers as part of its semiconductor solutions for the wireless market. By 2024, the company's role had evolved to include producing these controllers as part of its broader custom silicon solutions, reflecting a deeper engagement in their development. This shift indicates a strategic move from being a component supplier to an active producer involved in the design and creation process.",
      "llm_answer": "\nFrom 2022 through 2024 Broadcom continued to offer its custom touch‑controller IP for processing signals from touch screens in mobile handsets and tablets, but the 2024 disclosures show it is now marketed together with inductive‑charging ASICs as part of a broader mobile‑device connectivity platform.  This reflects a shift from a discrete, stand‑alone component to a more integrated solution, positioning the technology for a longer, more stable presence across successive generations of mobile devices.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually plausible and contextually relevant, but diverges from the ground truth in key qualitative aspects of Broadcom's evolving role. (1) Correct elements: The answer correctly identifies Broadcom's ongoing involvement with Custom Touch Controllers from 2022 to 2024 and notes a shift in positioning, which aligns with the question’s timeframe and focus. There are no numeric inaccuracies, so quantitative accuracy is high. (2) However, the ground truth emphasizes a shift from being a 'supplier' in 2022 to an 'active producer involved in design and creation' by 2024—highlighting deeper engagement in the product lifecycle. The LLM instead frames the evolution as a marketing integration (bundling with inductive-charging ASICs) and a move toward platform-based offerings, which is not mentioned in the original answer. (3) The multi-hop reasoning is partially sound—there is an attempt to show evolution—but the nature of the evolution differs: the LLM focuses on product bundling and platform integration, while the ground truth emphasizes a change in development role (from supplier to designer/producer). This represents a significant deviation in qualitative accuracy. (4) Contextual relevance is strong because the answer addresses the right company, technology, and timeframe, and infers a strategic evolution, even if the specifics don't match. Overall, the answer captures a plausible narrative but not the one supported by the knowledge graph, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 415,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Union Pacific's approach to freight cars evolved from 2023 to 2024, particularly in terms of asset acquisition strategy?",
      "original_answer": "In 2023, Union Pacific primarily leased freight cars as part of its operational strategy, reflecting a reliance on leased assets for rail operations. By 2024, the company's strategy shifted toward acquiring freight cars, including lease buyouts of $143 million in 2024 compared to $57 million in 2023, indicating a more aggressive stance on asset ownership to support replacement and growth opportunities.",
      "llm_answer": "\nFrom 2023 to 2024 Union Pacific stepped up its direct spending on freight‑car assets, raising cash capital investment in “Locomotives and freight cars” from **$728 million** in 2023 to **$788 million** in 2024.  The company explicitly notes in its 2025 capital plan that it will continue to **“acquire freight cars to support replacement and growth opportunities,”** signaling a deliberate shift toward buying new cars (and using lease‑financing where appropriate) rather than relying solely on the existing fleet.  This expansion is being funded through its revolving credit facility and commercial‑paper program, underscoring a more aggressive asset‑acquisition strategy in 2024‑2025.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies a strategic shift in Union Pacific's approach to freight cars from 2023 to 2024, moving toward greater asset acquisition, which aligns with the ground truth. It appropriately references increased capital investment in freight cars and locomotives and cites the company’s stated intent to acquire freight cars for replacement and growth, supporting the core narrative. However, the quantitative accuracy is compromised: the ground truth emphasizes a shift from leasing to buying, specifically highlighting lease buyouts of $143 million in 2024 vs. $57 million in 2023—a key metric that the LLM omits. Instead, the LLM cites total capital expenditures on 'Locomotives and freight cars' ($728M in 2023 to $788M in 2024), which, while plausible, is not the same as lease buyout spending and was not verified against the ground truth data. This substitution of a related but distinct financial figure reduces quantitative accuracy. The reasoning is logically sound and contextually relevant, correctly interpreting the strategic evolution, but fails to synthesize the specific multi-hop data point (lease buyout amounts) that defines the shift in asset acquisition strategy. Thus, while the qualitative direction and strategic interpretation are correct, the absence of the key comparative lease buyout figures and introduction of unverified capital expenditure numbers limits full factual alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 394,
        "total_tokens": 1662
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "What were the financial and operational impacts of Nike's structural changes in APLA between FY2022 and FY2023, particularly regarding the transition of certain businesses to third-party distributors?",
      "original_answer": "In FY2022, Nike directly operated within APLA as part of its geographic operating segments, which included associated costs and foreign currency impacts such as non-recurring impairment charges due to the anticipated release of non-cash cumulative foreign currency translation losses from transitioning certain businesses to third-party distributors. By FY2023, Nike had shifted its relationship with APLA from direct operations to a strategic stake, where the company now oversees results through third-party distributors. This transition is reflected in the 2023 filing noting that APLA includes results for the NIKE and Jordan brands and referencing Note 18 on divestitures related to the transition. Operationally, this change represents a strategic shift to reduce direct operational overhead in APLA, likely aiming to improve financial efficiency and focus on brand management rather than local execution.",
      "llm_answer": "\nThe FY 2022‑FY 2023 restructuring in APLA shifted several NIKE Brand operations from Nike‑direct sales to third‑party distributors, moving revenue from the Direct‑to‑Consumer channel to wholesale (APLA wholesale sales rose from **$3.53 bn** in FY 2022 to **$3.74 bn** in FY 2023 while Direct‑to‑Consumer grew only modestly).  This mix change lowered the segment’s earnings‑before‑interest‑and‑taxes (Global Brand Divisions EBIT fell from **$(4.262) bn** to **$(4.841) bn**) and triggered a one‑time foreign‑currency translation loss recorded in Corporate, but it also reduced the company’s direct inventory and capital‑expenditure exposure in the region.  Overall APLA revenue edged up **+$476 m**, yet the margin profile and long‑lived‑asset base were adjusted to reflect the distributor‑driven model.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific financial figures such as APLA wholesale sales increasing from $3.53 billion to $3.74 billion, Direct-to-Consumer growth, EBIT decline from $4.262 billion to $4.841 billion, and a $476 million revenue increase. However, these numbers are not present in the original ground truth answer and cannot be verified from the provided context. The ground truth does not include any quantitative data about revenue, EBIT, or wholesale/DTC splits for APLA in FY2022 or FY2023. Therefore, the inclusion of precise dollar amounts and calculations (e.g., $3.74B - $3.53B = $210M, implying part of the $476M total) constitutes fabrication or hallucination, severely undermining factual accuracy. (2) There is no mention in the original answer of 'Global Brand Divisions EBIT' falling or specific capital-expenditure exposure changes with numerical backing, nor is there confirmation of the $476M overall revenue increase. These figures appear to be invented to support a narrative not substantiated by the source. (3) While the LLM captures the high-level qualitative shift—transitioning from direct operations to third-party distributors in APLA, resulting in reduced operational overhead and foreign currency impacts—it incorrectly frames the financial impact with false precision. The reasoning around reduced inventory and capex exposure is plausible but unsupported by the original text. The multi-hop synthesis is partially correct in identifying the structural change and its strategic intent but fails when anchoring it to non-existent metrics. (4) The contextual relevance is high because the answer addresses the core topic: Nike's APLA restructuring and its financial/operational implications. However, the quantitative inaccuracies severely reduce correctness. The qualitative accuracy is moderate due to correct conceptual understanding but flawed execution. Final scores reflect major penalties on quantitative accuracy and overall correctness due to unsupported numerical claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 546,
        "total_tokens": 1988
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Broadcom's involvement with InP lasers evolved from 2022 to 2024, particularly in terms of their internal fabrication strategy and competitive positioning?",
      "original_answer": "In 2022, Broadcom disclosed using internal fabrication facilities for products based on proprietary processes, including vertical-cavity surface emitting lasers and side emitting lasers using GaAs and InP lasers for fiber optic communications. By 2024, Broadcom continued this strategy but began emphasizing the competitive landscape more explicitly, listing companies like Coherent Corp., Lumentum Holdings Inc., and others as competitors in semiconductor solutions. This indicates a strategic shift toward highlighting InP laser capabilities as part of its competitive differentiation in the market.",
      "llm_answer": "\nFrom 2022 to 2024 Broadcom moved from a generic statement that it “internally fabricates” InP lasers to a concrete strategy that designates dedicated III‑V wafer‑fab capacity in the United States and Singapore for those devices.  This shift reflects a deliberate effort to secure supply, protect intellectual property and accelerate development of high‑value fiber‑optic components, and the company now cites this internal fabrication as a core differentiator that underpins its competitive positioning against fabless rivals in the high‑speed optical‑interconnect market.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but introduces significant factual inaccuracies not present in the ground truth. (1) Correct elements: The general timeline (2022 to 2024) and the idea that Broadcom uses internal fabrication for InP lasers are consistent with the original answer. The emphasis on competitive positioning aligns with the ground truth's mention of increased focus on competitive landscape. (2) Quantitative accuracy: There are no numeric values to verify, so no errors in this category. Dates (2022–2024) are correctly used. (3) Multi-hop reasoning issues: The LLM claims Broadcom moved from a 'generic statement' to designating 'dedicated III-V wafer-fab capacity in the United States and Singapore'—a detail absent from the ground truth and unsupported by the original answer. This is a major fabrication (not in the source) and misrepresents the evolution. The original answer notes continuity in internal fabrication strategy with an increased emphasis on naming competitors (e.g., Coherent Corp., Lumentum), which the LLM omits entirely. (4) The LLM incorrectly frames the strategic evolution around physical capacity expansion and supply chain control, while the ground truth emphasizes a shift in disclosure strategy—highlighting competitive differentiation through existing proprietary processes. The core error is substituting unverified operational details (dedicated fabs in specific countries) for the actual documented shift: increased competitive transparency. Thus, while contextually relevant and correctly dated, the answer fails on key qualitative and factual grounds, warranting a mid-range score due to partial alignment on internal fabrication and competitive positioning themes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 465,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has the ownership structure of Swoosh, LLC in relation to NIKE's Class A and Class B Common Stock evolved between 2022 and 2023, and what implications does this have for shareholder influence?",
      "original_answer": "In 2022, Swoosh, LLC beneficially owned approximately 77% of NIKE's Class A Common Stock, which would translate to approximately 16% ownership of Class B Common Stock if all shares were converted. In 2023, the ownership structure remained consistent with Swoosh, LLC still beneficially owning approximately 77% of Class A Common Stock, with a commensurate ownership percentage of approximately 16% in Class B Common Stock if all shares were converted. Despite the consistency in ownership percentages, the continued concentration of ownership in Swoosh, LLC implies sustained influence by Travis Knight, who has a significant role in managing the Class A Common Stock owned by Swoosh, LLC, potentially affecting shareholder decisions and market dynamics.",
      "llm_answer": "\nBetween 2022 and 2023 the shareholder‑ownership pattern of Swoosh, LLC was essentially unchanged.  Both the 2022 and 2023 Form 10‑K filings state that Swoosh beneficially owned about 77 % of NIKE’s Class A Common Stock, and that—if all of those shares were converted into Class B shares—they would represent roughly 16 % of the Class B equity.  Because Class A and Class B have different voting rights (Class A elects the majority of directors while Class B carries limited voting power), Swoosh’s large economic stake does not translate into commensurate voting influence; the conversion scenario shows that its voting percentage would be modest (≈16 %).  Consequently, while Swoosh’s holdings remain the dominant economic interest, the overall voting power of the company is dispersed among other shareholders, and any large sale by Swoosh would affect market price more than control.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is quantitatively accurate, correctly reporting that Swoosh, LLC beneficially owned approximately 77% of NIKE's Class A Common Stock in both 2022 and 2023, with a corresponding ~16% ownership in Class B Common Stock if converted. These figures match the ground truth exactly, satisfying the quantitative accuracy criterion. However, the qualitative reasoning contains a significant error: it incorrectly interprets the voting rights structure. The ground truth emphasizes that Swoosh, LLC’s concentrated ownership—managed by Travis Knight—implies *sustained influence* over shareholder decisions, which contradicts the LLM’s claim that Swoosh lacks commensurate voting influence and that voting power is dispersed. In reality, NIKE’s Class A shares (which Swoosh owns 77% of) have significantly greater voting rights than Class B shares, and Class A shareholders elect a majority of the board. Therefore, Swoosh, LLC *does* have substantial voting control, contrary to the LLM’s assertion. This misrepresentation of the governance structure undermines the reasoning and leads to an incorrect implication about shareholder influence. While the answer addresses the evolution (no change) and attempts implications, the core logic about influence is flawed. The contextual relevance is high as it directly addresses ownership evolution and implications, but the flawed reasoning reduces qualitative accuracy significantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 394,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How did PMI's strategic positioning of Reduced-Risk Products evolve from 2022 to 2023, particularly in terms of portfolio integration and market availability?",
      "original_answer": "In 2022, PMI classified Reduced-Risk Products (RRPs) as a distinct category, including heated tobacco units, heat-not-burn devices, e-vapor, and oral nicotine products, with separate net revenue reporting. By 2023, RRPs were integrated into a broader category called Smoke-Free Products (SFPs), which now also included wellness and healthcare offerings. Additionally, PMI reported that its smoke-free products were available in 84 markets by the end of 2023, a notable expansion from the unspecified market availability in 2022. This evolution reflects a strategic shift toward consolidating RRPs under a unified smoke-free vision and expanding their global footprint.",
      "llm_answer": "\nFrom 2022 to 2023 PMI moved from acquiring Swedish Match AB—whose oral‑nicotine (ZYN) and snus brands complemented PMI’s heated‑tobacco (IQOS) platform—to actively integrating those products into its global commercial structure. By the end of 2023 the combined reduced‑risk portfolio was available in 84 markets and PMI began consolidating Swedish Match’s results into its four main geographical segments, signalling full portfolio integration and expanded market availability.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in key aspects: the acquisition of Swedish Match AB, integration of oral nicotine (ZYN) with IQOS, market availability in 84 markets by end of 2023, and consolidation into geographical segments—all of which align with PMI's 2023 strategic moves. The quantitative accuracy is perfect: '84 markets' matches the ground truth, and the timeline (2022 acquisition, 2023 integration) is correct. However, the LLM omits the key conceptual shift from 'Reduced-Risk Products (RRPs)' to the broader 'Smoke-Free Products (SFPs)' category, which now includes wellness and healthcare offerings—a central element of PMI’s repositioning. While it mentions portfolio integration and market expansion, it frames the evolution around the Swedish Match acquisition rather than the categorical rebranding and strategic unification under a smoke-free vision emphasized in the original answer. This misses a core qualitative nuance of the strategic evolution. The reasoning is sound in linking acquisition to integration and expanded reach, but fails to fully synthesize the change in product categorization and reporting structure from 2022 to 2023. The answer is contextually relevant and captures part of the multi-hop logic (acquisition → integration → broader availability), but not the full scope of the strategic repositioning as defined in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 381,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Caterpillar's strategic role in the reciprocating engines business evolved from 2022 to 2024, and what impact has this had on its revenue composition and gross margin potential?",
      "original_answer": "In 2022, Caterpillar primarily sold reciprocating engines through its global dealer network and through subsidiary Perkins Engines Company Limited, which operated 90 distributors across 171 countries. By 2024, Caterpillar expanded its involvement by including the remanufacturing of Caterpillar reciprocating engines and components, as well as offering remanufacturing services for other companies. This evolution from a seller to a full lifecycle service provider likely improved gross margin potential, as remanufacturing typically involves lower material costs compared to new engine production and leverages existing asset value. The shift also diversified revenue composition by incorporating service-based income streams alongside traditional product sales.",
      "llm_answer": "\nFrom 2022 through 2024 Caterpillar moved its reciprocating‑engine business from a pure commodity‑volume model toward a higher‑margin, solution‑oriented role that emphasizes power‑generation and gas‑compression applications and related aftermarket services.  This shift is evident in the Energy & Transportation segment, where total sales grew 3 % to $28.86 bn in 2024 and profit margin rose from 17.6 % to 19.9 % (pages 38‑39), expanding the segment’s contribution to revenue and enhancing its gross‑margin potential.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific financial figures—$28.86 billion in sales and margin increase from 17.6% to 19.9%—that are not present in the original ground truth and cannot be verified against it. These numbers may be plausible but are not supported by the provided truth, making them factually unverifiable and potentially incorrect. The original answer does not mention segment-level sales or margins, so these additions appear fabricated or misattributed. (2) Quantitative accuracy is low because the dollar amount and percentages are not found in the ground truth; no calculation can be validated. The original answer discusses a strategic shift toward remanufacturing but provides no financial metrics for 2022 or 2024. (3) Qualitatively, the LLM captures a similar directional shift—from product sales to higher-margin services—but frames it as a move toward 'solution-oriented' models and aftermarket services in power generation, whereas the ground truth specifically identifies remanufacturing of engines and components (including for other companies) as the key evolution. This is a partial match in reasoning but misses the core detail of remanufacturing as the strategic expansion. (4) Contextual relevance is high because the answer addresses Caterpillar’s evolving role, revenue composition, and gross margin potential over 2022–2024. However, it fails to mention Perkins Engines or the global dealer network from 2022, and omits the explicit link between remanufacturing, lower material costs, and margin improvement. While the conclusion about improved margin potential aligns with the original, the reasoning is based on unsupported data and generalized service expansion rather than the specific remanufacturing pivot. Thus, the answer is partially correct in concept but flawed in factual grounding and completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 502,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How did BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct evolve between 2022 and 2023, particularly in terms of the mechanisms and transparency commitments outlined for informing stakeholders of changes?",
      "original_answer": "BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct remained consistent between 2022 and 2023, with the company reaffirming its commitment to post any amendments or waivers on its website in both years. There was no change in the specific mechanism or transparency commitment described across the two years, indicating a stable governance communication strategy.",
      "llm_answer": "\nBetween 2022 and 2023 BNY Mellon did not introduce a new disclosure mechanism; it continued to post the Directors’ Code of Conduct on its website and to state that any future amendments or waivers—both to the general Code of Conduct for executive officers and to the Directors’ Code itself—would be posted on the website for stakeholder transparency. The 2023 filing merely reiterates this same transparency commitment, reflecting a consistent approach rather than an evolution of the disclosure practice.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately states that BNY Mellon did not change its disclosure mechanism between 2022 and 2023, continuing to post amendments or waivers to the Directors' Code of Conduct on its website. This matches the original answer's claim of a consistent, stable governance communication strategy. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), but the years 2022 and 2023 are correctly referenced and compared. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings to conclude that the transparency commitment was reiterated, not evolved. (4) The LLM answer addresses all parts of the question—mechanisms, transparency commitments, and changes (or lack thereof) over time—with precise and relevant information. Wording differs slightly but meaning is identical. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 287,
        "total_tokens": 1534
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Nike's strategic approach to the APLA market evolved between FY22 and FY23, particularly in terms of operational structure and market participation?",
      "original_answer": "In FY22, Nike operated directly in APLA, maintaining a significant presence through its NIKE Direct operations and wholesale distribution, with APLA contributing to the 14% growth in the NIKE Direct business. By FY23, Nike began transitioning certain businesses within APLA to third-party distributors, signaling a strategic shift away from direct market participation in some parts of the region. This change indicates a move toward a more distributed, partner-driven model in APLA, altering the way Nike engages with that market.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 Nike moved away from a wholesale‑and‑direct presence in the APLA region toward a distributor‑centric operating model.  In FY 22 the company still sold through its own NIKE Direct stores and wholesale accounts in APLA, but in FY 23 it transferred the legal entities in Argentina, Uruguay and Chile—and other APLA markets—to third‑party distributors, cutting its own sales footprint and SG&A costs while accepting slower top‑line growth in exchange for higher margins and reduced foreign‑exchange exposure.  This shift reflects a strategic re‑allocation of resources from direct market participation to a lighter, partnership‑based structure in APLA.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Nike's shift from direct and wholesale operations in APLA in FY22 to a distributor-centric model in FY23, matching the core factual content of the original answer. (2) There are no explicit numerical values (e.g., percentages, dollar amounts) in either answer, so quantitative accuracy is not compromised—no incorrect numbers are introduced. The LLM adds contextual detail (e.g., Argentina, Uruguay, Chile) and business rationale (lower SG&A, higher margins, FX risk reduction) that are plausible elaborations consistent with such strategic shifts, though not present in the original; however, these do not contradict the ground truth and enhance qualitative understanding. (3) The multi-hop reasoning is sound: the model correctly synthesizes a change in operational structure and market participation across two fiscal years, identifying the move from direct control to third-party distribution as a strategic evolution. (4) The answer is semantically equivalent and slightly more detailed than the original, without introducing factual errors. The only reason for not scoring a 10 is that the original answer does not specify the countries transferred or the trade-off rationale (e.g., slower growth for higher margins), so while reasonable, those additions slightly exceed the verified ground truth. Overall, the response is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 408,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the impact of Favorable Price Realization on Caterpillar's sales and profitability evolved from 2022 to 2024?",
      "original_answer": "In 2022, favorable price realization contributed to a $9.223 billion increase in total sales and revenues, driven by higher end-user demand and changes in dealer inventories. By 2024, favorable price realization continued to play a key role, partially offsetting a $2.251 billion decrease in sales volume and contributing to an increase in profit from $10.335 billion in 2023 to $10.792 billion in 2024. This indicates that while Caterpillar faced declining sales volume in 2024, the company leveraged pricing strategies more effectively to maintain profitability.",
      "llm_answer": "\nFrom 2022 (as reflected in the 2021 discussion) favorable price realization was a principal growth driver – it helped lift consolidated sales + 22 % and contributed to a 51 % jump in operating profit, pushing the profit margin up to 13.5 %. By 2024 the same pricing benefit had turned from a growth engine into a compensating factor: despite a 3 % drop in total sales from lower volume, favorable price realization offset much of that decline and, together with cost actions, lifted the operating‑profit margin to 20.2 % and adjusted EPS to $21.90, showing its role shifting from driving top‑line growth to protecting profitability.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It references '2022 (as reflected in the 2021 discussion)', which is logically inconsistent and incorrect—2022 data should not be based on a 2021 discussion. The original answer states that in 2022, favorable price realization contributed $9.223 billion to sales, but the LLM answer cites a 22% increase in sales and 51% jump in operating profit without specifying dollar amounts or correctly attributing them to 2022. These percentages do not appear in the ground truth and are unverifiable. In 2024, the LLM claims a 3% drop in total sales and attributes margin expansion to pricing and cost actions, but the original answer specifies a $2.251 billion decrease in sales volume (not total sales) and shows profit increasing from $10.335B to $10.792B—data absent in the LLM response. The LLM introduces 'adjusted EPS of $21.90' and 'margin of 20.2%' which are not in the ground truth. (2) Quantitative accuracy is very low: none of the key dollar figures ($9.223B, $2.251B, $10.335B, $10.792B) from the original answer are mentioned, and the percentages provided (22%, 51%, 3%, 20.2%) are unsupported by the ground truth. Calculations cannot be verified because the inputs are incorrect. (3) The reasoning framework—shifting from growth driver to profitability protector—is conceptually aligned with the original answer’s narrative, showing some qualitative understanding. However, the multi-hop synthesis fails because it does not correctly pull or connect data across 2022 and 2024 using actual figures from the knowledge graph. (4) Contextual relevance is moderate: the answer addresses the evolution of favorable price realization’s impact on sales and profitability, which matches the question's intent, but does so with fabricated metrics and incorrect time references, undermining factual reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 509,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has General Motors' approach to EV manufacturing capacity evolved between 2023 and 2024, particularly in terms of strategic focus and supply chain development?",
      "original_answer": "In 2023, General Motors emphasized significant investments in EV manufacturing capacity based on expectations for future EV demand, acknowledging the risks and uncertainties associated with such investments, including high fixed costs and limitations on closing facilities. By 2024, GM's strategy had evolved to include a stronger emphasis on developing a resilient, scalable, and sustainable North American-focused EV supply chain. This included advancing strategic sourcing initiatives to secure supply through investments in raw materials suppliers and the execution of multi-year supply agreements. The shift indicates a more structured and regionally focused approach to EV manufacturing, aiming to mitigate supply chain risks and ensure long-term scalability.",
      "llm_answer": "\nBetween 2023 and 2024 GM moved from announcing the need for a North‑American‑focused, resilient EV supply chain to actively building it — investing in strategic sourcing, multi‑year off‑take agreements and joint‑venture stakes with raw‑material suppliers and battery‑cell producers to lock in lithium, nickel, cobalt and other critical inputs. In 2024 the company emphasized scaling its EV manufacturing capacity (new plants, battery‑cell production lines and expanded assembly capacity) while tying that expansion to cash generated by its high‑margin ICE trucks and SUVs, and it highlighted the importance of a secure, scalable supply chain for achieving lower EV unit costs, greater range and faster charging. Thus, the evolution is a shift from planning‑stage commitments in 2023 to concrete, capital‑intensive supply‑chain investments and capacity expansion in 2024 that underpin GM’s EV‑centric growth strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution in GM's EV manufacturing strategy from 2023 to 2024: in 2023, GM was in the planning stage with commitments to a North American-focused supply chain, and by 2024, it shifted to active investment and execution. The mention of strategic sourcing, multi-year agreements, and joint ventures with raw material and battery-cell suppliers matches the original answer’s emphasis on securing supply through investments and long-term contracts. (2) There are no numeric values (e.g., dollar amounts, percentages, plant counts) in either the original or LLM answer, so quantitative accuracy is not compromised—no discrepancies exist. (3) The multi-hop reasoning is sound: the LLM synthesizes the shift from planning to action, connects supply chain development to manufacturing scalability, and correctly identifies the strategic intent (mitigating risk, lowering costs, improving performance). One minor point: the original does not explicitly mention 'joint-venture stakes' or 'battery-cell producers'—these are plausible inferences but not directly stated, slightly reducing qualitative precision. (4) The answer is fully contextually relevant, addressing both strategic focus and supply chain development as required. Overall, the LLM conveys the same core evolution with strong factual and conceptual fidelity, warranting a 9/10 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 399,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has Pfizer's financial commitment to Paxlovid evolved from 2022 to 2024, based on remaining performance obligations disclosed in the 10-K filings?",
      "original_answer": "In 2022, Pfizer's 10-K filing did not disclose specific remaining performance obligations related to Paxlovid. However, by 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, indicating a significant ongoing financial commitment tied to future delivery of the product. This shows a clear evolution from an undefined obligation in 2022 to a quantified $1 billion commitment in 2024.",
      "llm_answer": "\nPfizer’s Paxlovid revenue collapsed from a pandemic‑high of **$18.9 bn in 2022** to **$1.28 bn in 2023** as government stock‑piling ended, then edged up to **$5.7 bn in 2024** after the company recorded a $771 m favorable adjustment and $442 m of revenue from the U.S. strategic national stockpile.  The 2024 10‑K notes that **remaining performance obligations for Paxlovid total about $1 bn of contracted revenue**, with deliveries scheduled from 2025 through 2028, indicating a shift from large‑scale government purchases to a smaller, longer‑term commercial supply commitment.  This evolution reflects the transition from emergency‑use sales to ongoing, but limited, commercial revenue streams.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the $1 billion in remaining performance obligations for Paxlovid as of the 2024 10-K, which aligns with the ground truth. However, it introduces revenue figures for 2022 ($18.9B), 2023 ($1.28B), and 2024 ($5.7B) that were not part of the original question or ground truth, which focused solely on 'remaining performance obligations'—not actual revenue. These revenue numbers, while potentially accurate in context, are extraneous and distract from the core disclosure being asked about. More critically, the ground truth states that no specific performance obligations were disclosed in 2022, but the LLM does not confirm or address this absence—it only implies a shift without explicitly stating the lack of 2022 disclosure. (2) The $1 billion figure for remaining obligations in 2024 is correctly reported and matches the ground truth. However, the inclusion of $771M and $442M adjustments is not relevant to the question about performance obligations and may conflate revenue recognition with contractual future commitments. These figures are not part of the performance obligation metric and introduce potential confusion. (3) The reasoning correctly infers a shift from emergency purchases to long-term supply, which is a valid interpretation of the $1B obligation extending to 2028. However, the multi-hop synthesis is partially flawed because it fails to explicitly contrast the absence of 2022 disclosure with the presence of 2024 disclosure—the key evolution. Instead, it focuses on revenue trends, which were not asked for. (4) The contextual relevance is high because the answer addresses the forward-looking commitment and its implications. Qualitative accuracy is good due to sound interpretation of the 2024 obligation, but quantitative accuracy is reduced because the answer emphasizes incorrect metrics (revenue) and adds granular numbers not pertinent to the question. Correctness is scored at 7 because the core fact (2024 $1B obligation) is correct and the evolution is implied, but the failure to explicitly state the lack of 2022 disclosure and the introduction of irrelevant revenue data prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 583,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Caterpillar's approach to monitoring supplier financial viability evolved between 2022 and 2023, particularly in terms of risk mitigation strategies and contractual agreements?",
      "original_answer": "In 2022, Caterpillar indicated that it uses 'a variety of agreements with suppliers to protect our intellectual property and processes to monitor and mitigate risks of the supply base causing a business disruption,' including monitoring supplier financial viability. By 2023, Caterpillar maintained the same monitoring approach but placed a more explicit emphasis on 'supplier financial viability' as a key risk factor, listing it as the first risk under its supply chain disclosures. Additionally, in 2023, Caterpillar reinforced its global strategic sourcing models to build long-term supplier relationships and leverage enterprise spend, suggesting a potentially more structured or prioritized focus on supplier financial health compared to 2022.",
      "llm_answer": "\nBetween 2022 and 2023 Caterpillar made supplier financial viability an explicit, tracked risk in its supply‑chain disclosures and tightened the contractual safeguards that accompany it.  The 2022 discussion only mentioned using agreements to protect intellectual property and mitigate supply‑base disruptions, whereas the 2023 text specifically calls out “supplier financial viability” as a risk that is monitored and adds that the company uses a variety of agreements—including performance‑based payment terms and a 90‑day termination‑notice clause—to mitigate that risk and protect continuity of supply.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies that Caterpillar increased its emphasis on supplier financial viability in 2023 compared to 2022 and notes the more explicit disclosure of this risk, which aligns with the ground truth. It accurately reflects that in 2022, Caterpillar mentioned using agreements to protect intellectual property and mitigate disruptions, while in 2023, 'supplier financial viability' was highlighted more directly. However, the LLM introduces specific contractual details not present in the original answer or ground truth: namely 'performance-based payment terms' and a '90-day termination-notice clause.' These were not mentioned in the knowledge graph and represent fabricated specifics, undermining the qualitative accuracy. While the direction of evolution (increased focus and explicit tracking) is correct, the addition of unverified contractual mechanisms constitutes a significant factual overreach. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default. The answer is contextually relevant and addresses the core of the question regarding evolution in risk mitigation and contractual approaches, but due to the invention of specific contractual terms, the correctness and qualitative accuracy scores are reduced. The multi-hop reasoning is partially sound—correctly comparing disclosures across years—but fails in fidelity when asserting unverified details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 396,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Visa's approach to Risk and Identity Solutions evolved between 2022 and 2024, particularly in terms of its strategic positioning and integration within its value-added services?",
      "original_answer": "In 2022, Visa positioned Risk and Identity Solutions as part of a broader set of value-added services aimed at supporting clients, but without detailed elaboration on specific capabilities or strategic direction. By 2024, Risk and Identity Solutions were embedded within a more structured value-added services framework, with a clear three-pillar strategy: (1) services for Visa transactions, (2) network-agnostic services for non-Visa transactions, and (3) services beyond payments. This evolution reflects a more strategic and comprehensive integration of Risk and Identity Solutions into Visa's broader service portfolio, with an emphasis on scalability and business outcomes.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Visa transformed Risk and Identity Solutions from a modest, stand‑alone offering into a core, AI‑driven pillar of its value‑added services.  The 2024 disclosures frame the suite—Visa Protect Authentication Intelligence, Visa Deep Authorization, Visa Risk Manager, etc.—as network‑agnostic, end‑to‑end fraud‑prevention tools that are embedded across both Visa‑ and non‑Visa transactions, reinforcing the company’s “network of networks” strategy and supporting growth in B2B, B2C and open‑banking money‑movement flows.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Visa's Risk and Identity Solutions from 2022 to 2024. It accurately captures the strategic shift from a less-defined offering in 2022 to a more integrated, network-agnostic suite by 2024. The mention of specific tools (Visa Protect Authentication Intelligence, Visa Deep Authorization, Visa Risk Manager) adds detail not in the original answer but is consistent with Visa’s known product suite and does not contradict the ground truth. The emphasis on network-agnostic services and expansion beyond Visa transactions matches the second and third pillars of the three-pillar strategy in the original answer. However, the LLM answer does not explicitly mention the three-pillar structure (1) services for Visa transactions, (2) network-agnostic for non-Visa, and (3) services beyond payments — a key organizational framework highlighted in the ground truth. While the concepts are implied, the absence of this explicit structure reduces completeness in qualitative accuracy. There are no numerical inaccuracies (quantitative accuracy is perfect as no incorrect numbers are presented), and the contextual relevance is strong, directly addressing the strategic positioning and integration within value-added services. The reasoning is sound and reflects multi-hop synthesis across years and strategic frameworks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 388,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has the company's exposure to shelf space limitations as a risk factor evolved between 2022 and 2023, particularly in relation to changes in retail customer policies and the expansion of alternative retail channels?",
      "original_answer": "In 2022, the company noted that it had been and could continue to be negatively affected by changes in retail customer policies such as limitations on access to shelf space and delisting of products. By 2023, the company was actively impacted by these limitations and described them as part of a broader set of evolving retail dynamics, including the growth of eCommerce and alternative retail channels such as subscription services and direct-to-consumer businesses. This evolution indicates a shift from potential risk to an actively experienced challenge, with the company planning to invest more in digital and analytics capabilities to adapt.",
      "llm_answer": "\nBetween 2022 and 2023 the company’s risk disclosure moved from a generic warning about “changes in the policies of our retail trade customers” to a more acute focus on how those policies—especially tighter shelf‑space, delisting and sustainability standards—are being amplified by the rapid expansion of alternative retail channels such as e‑commerce and direct‑to‑consumer platforms.  The 2023 discussion emphasizes that growing dependence on key retailers, combined with the shift toward online and subscription‑based sales, has increased competitive pressure on shelf availability, making exposure to shelf‑space limitations a more pronounced risk factor than in the prior year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of the risk from a potential concern in 2022 to a more acute, actively experienced challenge in 2023. The shift from generic warnings to specific shelf-space limitations, delisting, and sustainability standards is consistent with the original answer. (2) There are no numeric values to verify, so quantitative accuracy is scored as 10. (3) The multi-hop reasoning is sound: the LLM synthesizes changes in risk disclosure across years, links shelf-space limitations to evolving retail dynamics, and correctly identifies the expansion of alternative channels (e-commerce, subscription, DTC) as amplifying the risk. It also infers increased competitive pressure, which is logically consistent with the original answer’s mention of investing in digital and analytics to adapt. (4) The only minor gap is that the LLM does not explicitly mention the company’s planned response (investment in digital and analytics), which is part of the original answer. However, the core evolution of the risk factor is accurately conveyed with strong contextual and semantic alignment. Hence, a correctness score of 9 is warranted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 342,
        "total_tokens": 1692
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Oracle's approach to hybrid deployments evolved between fiscal years 2023 and 2024, particularly in terms of product offerings and strategic emphasis?",
      "original_answer": "In fiscal 2023, Oracle emphasized hybrid deployments as part of its broader deployment models, including on-premise, cloud-based, and hybrid options such as Oracle Exadata Cloud@Customer and Dedicated Region offerings. The company highlighted its commitment to providing customers with choice and flexibility in how they deploy Oracle technologies. By fiscal 2024, Oracle continued to support hybrid deployments but introduced more specific product integrations and services tailored for hybrid environments, indicating a strategic shift toward deeper integration and support for customer-managed cloud and on-premise IT environments. This evolution reflects Oracle's ongoing investment in making hybrid deployments more interoperable and extensible with other IT and cloud environments.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Oracle’s hybrid‑deployment story moved from “an emerging, flexible migration path” to a central growth pillar.  In the 2023 filing (pp. 4‑8) the company highlighted hybrid options such as Oracle Exadata Cloud@Customer, Dedicated Regions and multi‑cloud integration as ways to give customers choice and to begin migrating on‑premise workloads to the Oracle Cloud.  By 2024 (pp. 70‑71) the language had shifted to stressing a **broader, interoperable hybrid cloud portfolio**—including Fusion Cloud SaaS, Autonomous Database on OCI, and expanded industry‑specific SaaS modules—described as “rapidly deployable, cost‑effective, highly secure and easily maintainable” services that let customers run workloads across on‑premise, Oracle Cloud and other public clouds.  The strategic emphasis therefore evolved from merely offering hybrid as a migration aid to positioning hybrid deployments as a primary, AI‑enabled engine for expanding cloud‑services revenue and differentiating Oracle’s overall offering.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual information is correct: Oracle's hybrid offerings in fiscal 2023 (Exadata Cloud@Customer, Dedicated Regions) are accurately cited, and the strategic emphasis on customer choice and migration flexibility matches the original. In fiscal 2024, the shift toward a more integrated, interoperable hybrid portfolio—including Fusion Cloud SaaS, Autonomous Database on OCI, and industry-specific modules—is consistent with the ground truth’s description of deeper integration and support. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not applicable beyond correct use of fiscal years (2023 and 2024), which are accurate. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes evolution in strategy across two fiscal years, identifying a shift from hybrid as a flexible option to a central growth engine. The addition of 'AI-enabled' and 'primary engine for cloud-services revenue' is a slight interpretive expansion but is reasonable given Oracle’s broader strategic context and does not contradict the ground truth. (4) The LLM answer enhances the original with more specific product names and stronger strategic framing, but the core meaning—increased strategic emphasis and product integration in hybrid deployments—is preserved. One minor point: the original does not explicitly call hybrid a 'central growth pillar' or 'AI-enabled engine,' so the LLM slightly extrapolates, warranting a 9 instead of 10 for correctness and qualitative accuracy. Overall, the answer is factually sound, complete, and contextually excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1459,
        "completion_tokens": 463,
        "total_tokens": 1923
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Pfizer's financial commitment to Paxlovid evolved between 2022 and 2024, based on remaining performance obligations and contracted revenue expectations?",
      "original_answer": "In 2022, Pfizer indicated that Paxlovid had the potential to provide ongoing revenue streams, though it acknowledged that post-pandemic revenues might not match the levels seen during the pandemic. By 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, with contracted revenue expected to be recognized from 2025 through 2028. This reflects a continued but reduced financial commitment compared to the pandemic period, as the company anticipates delivery and revenue recognition over a multi-year horizon rather than immediate high-volume sales.",
      "llm_answer": "\nBetween 2022 and 2024 Pfizer’s contractual exposure to Paxlovid contracted sharply. In 2022 the company was generating roughly **$18.9 billion** of Paxlovid revenue from government‑procured EUA courses, with large advance payments that produced **≈ $5 billion** of deferred revenue by the end of 2023. By the end of 2024 the **remaining performance obligations** for Paxlovid were only about **$1 billion** of contracted revenue—expected to be recognized from 2025 through 2028—reflecting the shift from public‑sector procurement to commercial sales and the recognition of a **$771 million** favorable adjustment and **$442 million** SNS revenue in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core trend from the ground truth—Pfizer's financial commitment to Paxlovid has decreased from pandemic highs to a multi-year $1 billion remaining performance obligation (RPO) expected to be recognized from 2025–2028. However, it introduces several specific financial figures not present or verifiable in the original answer, such as $18.9 billion in 2022 revenue, $5 billion in deferred revenue by end of 2023, a $771 million favorable adjustment, and $442 million SNS revenue in 2024. These numbers, while plausible, are not supported by the ground truth and represent overprecision or hallucination. (2) The only number explicitly confirmed in both answers is the $1 billion RPO as of end-2024, which is correctly attributed and aligned with the original. The rest of the quantitative claims lack grounding in the provided truth. (3) The reasoning is partially sound: the model correctly infers a shift from government-led procurement to commercial sales and interprets the multi-year revenue recognition as a sign of reduced near-term commitment. It synthesizes the concept of remaining performance obligations correctly in context. However, the addition of unsupported figures undermines the quantitative accuracy and suggests the model may be blending external knowledge or estimates. (4) The contextual relevance is high—the answer directly addresses the evolution of financial commitment using appropriate SEC-filing terminology and timeframes. The qualitative reasoning is logical and aligns with the original narrative, even if numerically overextended. Thus, the correctness score is moderate due to factual overreach despite correct directional reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 466,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Caterpillar's relationship with its independent dealers evolved between 2022 and 2023, particularly in terms of contractual obligations and strategic emphasis?",
      "original_answer": "In 2022, Caterpillar described its relationship with independent dealers in general terms as part of its global sales and marketing strategy. By 2023, the company formalized and detailed these relationships through standardized sales and service agreements, granting dealers the right to purchase, sell, and service Caterpillar products within specified territories. In exchange, dealers were obligated to develop and promote Caterpillar products, maintain adequate sales and support personnel, and keep detailed financial records accessible to Caterpillar. This represents a shift from a general partnership model to a more structured contractual framework, indicating a strategic emphasis on formalizing dealer relationships to enhance control and accountability.",
      "llm_answer": "\nBetween 2022 and 2023 Caterpillar continued to formalize its dealer relationships through the same standard sales‑and‑service agreements—granting exclusive territory rights, obligating dealers to maintain sales and support staff, keep detailed financial records and promote Caterpillar products, and allowing either party to terminate the pact with 90‑day notice.  The 2023 filing, however, places greater strategic emphasis on dealer‑support programs such as Cat Financial financing incentives, coordinated marketing initiatives and insurance products, underscoring a shift toward using financing and value‑added services to strengthen dealer performance and drive growth, while the underlying contractual framework remains unchanged.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but contains a key factual inaccuracy in its characterization of the contractual evolution between 2022 and 2023. While it correctly identifies elements of the dealer agreements—such as territory rights, obligations to maintain staff and records, and 90-day termination clauses—it incorrectly states that the 'same standard sales-and-service agreements' were in place in both years, implying no change in the contractual framework. This contradicts the ground truth, which states that Caterpillar *formalized and detailed* these agreements in 2023, marking a shift from a general partnership model in 2022 to a more structured contractual framework in 2023. Thus, the contractual framework was not 'unchanged,' as the LLM claims, but evolved significantly. The strategic emphasis on financing and value-added services like Cat Financial is contextually relevant and plausibly derived, but this does not negate the error in the core claim about contractual continuity. Quantitatively, there are no numbers or dates to verify, so accuracy is high by default. The reasoning is logically sound but based on a misinterpretation of the contractual evolution. The answer is contextually relevant and addresses both contractual obligations and strategic emphasis, but fails on the critical multi-hop synthesis that the relationship became more formalized in 2023. Therefore, while much of the content is accurate, the central claim undermines the overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 410,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How did the company's financial allocation or operational focus related to Africa/Eurasia evolve from 2022 to 2023, based on capital expenditures and restructuring charges?",
      "original_answer": "In 2022, the company reported capital expenditures for Africa/Eurasia at $33 million, showing a steady increase from $13 million in 2021 and $8 million in 2020. However, in 2023, the company indicated that approximately 10% of the cumulative pretax charges from the 2022 Global Productivity Initiative would relate to initiatives undertaken in Africa/Eurasia, signaling a shift in focus toward restructuring and cost optimization in the region rather than continued capital investment. This reflects a strategic evolution from growth-oriented capital allocation to operational restructuring within Africa/Eurasia.",
      "llm_answer": "\nFrom 2022 to 2023 the company markedly increased its capital spending in Africa/Eurasia—capital expenditures rose from **$13 million in 2022 to $33 million in 2023** (page 46)—signaling a stronger operational focus on the region.  At the same time, the share of restructuring charges tied to the 2022 Global Productivity Initiative allocated to Africa/Eurasia fell from **11 % of cumulative charges in 2022 to 5 % in 2023** (page 48), indicating that while the region continues to incur modest restructuring costs, its relative weight within the company’s restructuring program has been reduced.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. It incorrectly states that capital expenditures in Africa/Eurasia increased from $13 million in 2022 to $33 million in 2023. According to the ground truth, the actual capital expenditures were $33 million in 2022 (up from $13 million in 2021), meaning the LLM reversed the years and misrepresented the trend. Additionally, the LLM claims that the share of restructuring charges allocated to Africa/Eurasia fell from 11% in 2022 to 5% in 2023, but the original answer states that in 2023, approximately 10% of the cumulative pretax charges from the 2022 Global Productivity Initiative relate to Africa/Eurasia—there is no mention of a 11% figure in 2022 or a 5% figure in 2023 in the ground truth. These numbers are entirely fabricated or misattributed. (2) The quantitative inaccuracies are severe: both dollar amounts and percentages are wrong, and the direction of change (increase vs decrease) is reversed for capex. The calculation of trends is therefore invalid. (3) The multi-hop reasoning is flawed. The original answer describes a strategic shift from capital investment to restructuring focus, but the LLM incorrectly infers increased capital spending and reduced restructuring emphasis, which contradicts the actual evolution. The synthesis between capital expenditures and restructuring charges is incorrect. (4) Despite the incorrect facts, the LLM attempts to address the question's structure by discussing both capex and restructuring charges over time, so contextual relevance is moderate. However, due to major factual and directional errors, the correctness and accuracy scores are very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 457,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Qualcomm's strategic focus on 5G technologies evolved from 2022 to 2024, particularly in terms of investment emphasis and commercialization outcomes?",
      "original_answer": "In 2022, Qualcomm was heavily investing in 5G technologies as part of its broader strategy to expand beyond mobile handsets into areas like automotive and IoT, with an emphasis on developing leading and cost-effective 5G-based technologies and products. The company acknowledged significant risks around the success of these investments due to potential regulatory hurdles, competition, and the long design-in cycles typical of new industries like automotive. By 2024, Qualcomm had transitioned from a primarily investment phase to a more mature stage where it had developed a leading patent portfolio in 5G NR and was actively licensing these technologies. The company reported generating the majority of its QTL revenues from OFDMA-based products, including multimode 3G/4G/5G devices such as smartphones, indicating a successful commercialization phase. This shift shows that Qualcomm moved from strategic investment and development in 5G across multiple industries to a position of market leadership and monetization in 5G technologies.",
      "llm_answer": "\nFrom fiscal 2022 through 2024 Qualcomm moved its 5G strategy from a primary emphasis on securing standard‑essential patents and building an OFDMA‑based IP portfolio toward commercializing fully integrated 5G modem‑RF platforms (e.g., Snapdragon 5G modem‑RF with AI‑enhanced performance) and expanding 5G into new verticals such as automotive and IoT.  This shift was accompanied by heavier investment in RFFE, modem‑to‑antenna solutions, and venture‑backed opportunities, while its licensing business matured—over 200 5G license agreements were in place and 5G‑enabled multimode device sales continued to grow, diversifying revenue beyond traditional handset sales.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly captures Qualcomm's strategic evolution from 2022 to 2024: starting with heavy investment in 5G IP and patents (standard-essential patents, OFDMA-based portfolio) and transitioning to commercialization through integrated 5G modem-RF platforms and expansion into automotive and IoT verticals. The mention of over 200 5G license agreements by 2024 is consistent with the commercialization and licensing maturity described in the original answer, and while the exact number isn't in the ground truth, it is a reasonable and plausible detail that supports the narrative of successful monetization. The emphasis on RFFE, modem-to-antenna solutions, and AI-enhanced performance reflects deeper technical investment areas not explicitly stated but implied in the original's focus on 'leading and cost-effective 5G-based technologies.' The core shift from investment/development to market leadership and revenue generation via QTL and multimode devices is accurately conveyed. All entities (Qualcomm, 5G, automotive, IoT, licensing, multimode devices) and timeframes (2022–2024) are correct. There are no calculation errors, and the reasoning across multiple hops—investment phase, technological development, vertical expansion, licensing growth, revenue diversification—is sound and logically structured. The only minor limitation is that the original answer specifically highlights regulatory risks and long design-in cycles in automotive, which the LLM omits, slightly reducing completeness. However, this does not undermine the central factual accuracy. Wording differs but semantic meaning is equivalent. Number format and usage are appropriate, and contextual relevance to the question is excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 482,
        "total_tokens": 1911
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Pfizer's financial and strategic positioning of Paxlovid evolved between 2022 and 2024, particularly in terms of revenue contribution and contractual commitments?",
      "original_answer": "In 2022, Paxlovid generated $76 million in revenue, marking its initial contribution as a newly launched product targeting high-risk COVID-19 patients. By 2024, while direct revenue figures for Paxlovid are not explicitly stated, Pfizer disclosed approximately $1 billion in remaining performance obligations tied to future Paxlovid deliveries under existing contracts. This indicates a strategic shift from initial market entry to securing longer-term contractual commitments, despite potential market or regulatory challenges reflected in the context of government returns and adjustments in 2024.",
      "llm_answer": "\nBetween 2022 and 2024 Paxlovid’s contribution to Pfizer’s top line collapsed and then partially recovered: it generated a peak $18.9 bn in 2022, fell to only $1.28 bn in 2023 as the U.S. government wind‑down of EUA purchases and a $3.5 bn revenue reversal took effect, and then rose to $5.7 bn in 2024 driven by commercial sales and a $442 m credit from the U.S. SNS supply (see PFE_10k_2024 pages 109‑111).  Today the company has roughly $1 bn of remaining contracted revenue from long‑term Paxlovid supply agreements (expected deliveries 2025‑2028) and about $2.2 bn of deferred revenue—down from $5.1 bn in 2023—reflecting the shift from government‑procured EUA sales to commercial market contracts (PFE_10k_2024 pages 110‑111).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states Paxlovid generated $76 million in revenue in 2022, but the LLM claims $18.9 billion—over 240 times higher—making this a major error. The LLM also reports $5.7 billion in 2024 revenue, which contradicts the ground truth that no direct 2024 revenue is stated, only $1 billion in remaining performance obligations. The $3.5 billion revenue reversal and $442 million credit from the U.S. SNS are not mentioned in the ground truth. (2) The quantitative inaccuracies are severe: all key figures (2022 revenue, 2023 revenue, 2024 revenue, deferred revenue amounts) are incorrect or unsupported by the ground truth. The mention of $2.2 billion deferred revenue and $5.1 billion in 2023 deferred revenue does not align with the original answer. (3) The reasoning is flawed: the LLM assumes a revenue trajectory (peak, decline, recovery) not supported by the ground truth, which only confirms 2022 revenue and 2024 contractual obligations. The multi-hop synthesis fails because it fabricates data points from a document (PFE_10k_2024) that may contain such details but are not reflected in the verified knowledge graph. (4) While the LLM attempts to address the evolution of financial and strategic positioning—and correctly identifies a shift from government to commercial contracts—the core factual foundation is incorrect, undermining the entire response. Contextual relevance is moderate because the structure and intent align with the question, but correctness is critically compromised by false numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 437,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has the company's exposure to credit market tightness as a supply chain risk evolved between 2022 and 2023, and what does this indicate about its changing vulnerability to external financial conditions?",
      "original_answer": "In 2022, tighter credit or capital markets were described as a risk that 'negatively impacts' suppliers, with a direct concern that this could disrupt the supply of raw and packaging materials. By 2023, the framing shifted to indicate that the company's operations are 'impacted by' these conditions, suggesting a broader recognition of ongoing vulnerability. This evolution reflects a continuation of concern over credit market conditions but with a more integrated perspective on how such financial constraints affect not just suppliers, but the company's overall supply chain resilience.",
      "llm_answer": "\nBetween 2022 and 2023 the company continued to flag “the impact on our suppliers of tighter credit or capital markets” as a supply‑chain vulnerability, but it did so within a much longer, multi‑factor list that also includes geopolitical conflict, pandemic‑related disruptions, climate events and commodity price swings.  In the 2022 filing the credit‑market issue was highlighted as one of several supply‑chain risks, whereas in the 2023 filing it appears again but is now presented alongside an expanded set of external shocks, signalling that the firm views credit‑tightness as an ongoing, though not dramatically worsening, source of exposure that remains intertwined with broader macro‑financial stress.  This suggests the company’s vulnerability to external financial conditions has stayed present and is now considered part of a wider constellation of supply‑chain risks rather than a standalone concern.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the original (ground truth) answer. (1) All factual elements are correct: the company continued to identify tighter credit markets as a supply chain risk in both 2022 and 2023, with the 2023 framing placing it within a broader context of macro risks. While the original answer emphasizes a shift from 'negatively impacts suppliers' to 'impacted by' as indicating deeper integration of financial vulnerability, the LLM captures this evolution by noting the risk is now part of a 'wider constellation' of risks, signaling ongoing but not escalating concern. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable in a numerical sense—however, the years 2022 and 2023 are correctly referenced, satisfying temporal accuracy. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes how the framing of the risk changed across filings, infers the implication (continued vulnerability, now contextualized within broader macro risks), and avoids introducing unsupported claims. (4) The LLM slightly reframes the evolution as being about list length and context rather than a linguistic shift reflecting deeper operational integration, which is a minor nuance missed compared to the original answer’s emphasis on the company now seeing itself as directly 'impacted by' credit conditions. However, the core insight—that the risk remains relevant and is now embedded in a broader risk landscape—is semantically equivalent and well-reasoned. Thus, the answer is excellent, with only a slight deduction for not fully capturing the shift in self-attribution of impact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 459,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has Pfizer's financial commitment and contractual obligations related to Paxlovid evolved from 2022 to 2024, based on disclosed figures and agreements?",
      "original_answer": "In 2022, Paxlovid was under Emergency Use Authorization (EUA) in the U.S. and had received conditional marketing authorization (CMA) in the EU and full approval in Japan, indicating early-stage regulatory and commercial momentum. By 2024, Pfizer disclosed that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, reflecting firm orders from long-term contracts with customers. This shows a significant financial commitment to Paxlovid, with delivery expected from 2025 through 2028, subject to renegotiation. Additionally, 2024 included a $771 million favorable final adjustment related to a prior revenue reversal tied to Paxlovid EUA-labeled treatment courses returned by the U.S. government, indicating ongoing financial adjustments and evolving contractual dynamics.",
      "llm_answer": "\nPfizer’s Paxlovid revenue collapsed from **$18.9 bn in 2022** (when most courses were supplied under U.S. government EUA contracts) to **$1.28 bn in 2023** as those contracts expired and the government wind‑down triggered a $3.5 bn non‑cash revenue reversal; the company then recorded a **$771 m favorable adjustment in Q1 2024** and generated **$442 m of revenue in Q3 2024** from a new U.S. Strategic National Stockpile supply, pushing 2024 Paxlovid revenue up to **$5.7 bn**.  At the same time, **remaining performance obligations for future Paxlovid deliveries fell to roughly $1 bn** (expected through 2025‑2028), and **deferred revenue dropped from $5.1 bn (2023) to $2.2 bn (2024)**, reflecting the transition from government‑procured EUA supply to commercial‑market contracts.  (Pages 107‑111, 2024 10‑K; pages 45‑49, 2022 10‑K).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes several factual inaccuracies in key financial figures that significantly deviate from the ground truth. Most critically, the claim that Paxlovid generated $5.7 billion in 2024 revenue is unsupported by the original answer, which does not state any total 2024 revenue figure—only a $771 million favorable adjustment and $442 million in Q3 2024 revenue. Extrapolating or summing to $5.7 billion is speculative and incorrect. Additionally, the original answer does not mention deferred revenue dropping from $5.1B to $2.2B or a $3.5B non-cash reversal, nor does it state total 2022 revenue as $18.9B—while high sales were implied, that exact number is not in the ground truth. The $1 billion remaining performance obligations and $771 million favorable adjustment are correctly reported. (2) Number verification: The $771 million favorable adjustment and $1 billion remaining obligations match the original. However, the $18.9B (2022), $1.28B (2023), $5.7B (2024), $3.5B reversal, and deferred revenue figures are not present in the ground truth and appear to be hallucinated or inferred beyond available data. (3) Multi-hop reasoning is partially sound—the model attempts to show evolution from EUA to commercial transition and links financial changes to contractual shifts. However, it overreaches by introducing unsupported figures and implying precise revenue trends not disclosed in the original. (4) The contextual relevance is high as it directly addresses the evolution of financial and contractual commitments. Qualitative accuracy is moderate due to correct identification of trends (e.g., shift from government to commercial) and correct mention of the $771M adjustment and $1B obligations. Quantitative accuracy is low due to multiple fabricated or incorrect numbers. Correctness score is 6 because while core elements (like the $1B obligations and $771M adjustment) are correct, the inclusion of significant false numerical claims undermines overall reliability, though some directional insights align with the truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 555,
        "total_tokens": 1972
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has the financial liability and risk exposure related to Aearo Technologies' respirator mask/asbestos litigation evolved from 2023 to 2024?",
      "original_answer": "In 2023, MMM had an accrual of $574 million for respirator mask/asbestos liabilities excluding Aearo, and Aearo was in bankruptcy proceedings, which resulted in a stay of litigation. By 2024, MMM, through Aearo, had accruals of $51 million specifically for Aearo-related asbestos, silica-related, and coal mine dust claims. Additionally, Aearo’s liability was limited by its agreement with Cabot, where Cabot assumed responsibility for claims involving exposure prior to January 1, 1997, as long as Aearo continued to pay a quarterly fee of $100,000. This represents a shift from a broader liability exposure under bankruptcy protection in 2023 to a more defined and limited liability framework in 2024, with Aearo actively managing its share of liability through contractual arrangements and cost-sharing with other co-defendants.",
      "llm_answer": "\nFrom 2023 to 2024 the Company’s recorded liability for Aearo‑related respirator/asbestos claims fell – the accrual (excluding Aearo’s own $51 million provision) dropped from **$574 million** at the end of 2023 to **$523 million** at the end of 2024, and the increase added in 2024 was only **$36 million** versus **$57 million** added in 2023.  At the same time the number of pending claimants fell from roughly **4,042** to **3,500**, and the firm recorded slightly lower defense‑and‑settlement outlays ($87 million in 2024 vs. $88 million in 2023).  While the reduced claim volume and recent favorable jury verdicts have lowered the estimated exposure, the Company still cannot quantify any potential excess over the accrued amounts because of the inherent uncertainty in future claim numbers, allocation among co‑defendants, and possible developments in litigation or insurance coverage.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to correctly represent the evolution of Aearo Technologies' liability from 2023 to 2024 as per the ground truth. (1) Quantitatively, the LLM claims that the accrual excluding Aearo dropped from $574M in 2023 to $523M in 2024, with only $36M added in 2024 versus $57M in 2023. However, the original answer does not provide any data about MMM's 2024 total accrual or incremental additions in 2024; these numbers are fabricated or misattributed. The only confirmed figure in the ground truth for 2024 is Aearo’s $51M accrual for its specific claims—no overall MMM liability reduction or new accruals are stated. (2) The claim that the number of pending claimants fell from 4,042 to 3,500 and that defense-and-settlement outlays were $87M in 2024 vs $88M in 2023 is not supported by the original answer and appears to be hallucinated. (3) Qualitatively, the LLM misses the key multi-hop insight: in 2023, Aearo was in bankruptcy with a litigation stay, while in 2024, it emerged with a defined liability framework via a contractual cost-sharing arrangement with Cabot for pre-1997 exposures, conditioned on a $100,000 quarterly fee. This critical shift in risk structure is entirely absent from the LLM response. (4) Instead, the LLM focuses on declining accruals and claim volumes, which may reflect general trends but do not align with the specific contractual and legal developments emphasized in the ground truth. The reasoning is therefore flawed and based on incorrect data synthesis. While the mention of ongoing uncertainty in quantifying excess exposure is a reasonable qualitative point, it does not compensate for the core factual and structural inaccuracies. The answer is contextually relevant to liability trends but incorrect in substance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 490,
        "total_tokens": 1920
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How did the retail share of Skoal, a product of MO, change between 2023 and 2024, and how does this compare to its shipment volume trend between 2020 and 2021?",
      "original_answer": "The retail share of Skoal decreased from 9.3% in 2023 to 7.6% in 2024, indicating a decline in market presence. In contrast, Skoal's shipment volume was also declining between 2020 and 2021, dropping from 208.5 million packs/cans in 2020 to 197.4 million packs/cans in 2021. Both metrics show a consistent downward trend, suggesting a potential long-term challenge for the product's performance in the market.",
      "llm_answer": "\nSkoal’s retail‑share slipped from **9.3 % in 2023 to 7.6 % in 2024**, a decline of about **1.7 percentage points (≈18 % relative)**. This mirrors the earlier downward movement in its shipment volume, which fell from **208.5 million units in 2020 to 197.4 million units in 2021**, a reduction of roughly **5 % (≈11 million units)**. Both metrics show a consistent decline, though the percentage drop in retail‑share is larger than the drop in shipment volume. (Retail‑share data: page 46; shipment‑volume data: page 45.)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key facts: Skoal's retail share decreased from 9.3% in 2023 to 7.6% in 2024, and shipment volume declined from 208.5 million units in 2020 to 197.4 million units in 2021. These values match the ground truth exactly. (2) Quantitative accuracy is perfect: the absolute drop of 1.7 percentage points and the relative drop of approximately 18% in retail share are accurate; the shipment volume decrease of 11.1 million units (≈5%) is correctly calculated. (3) The multi-hop reasoning is sound—information from two different time periods (2023–2024 for retail share, 2020–2021 for shipments) is correctly synthesized and compared. The conclusion that both metrics show a decline is valid. The only minor shortcoming is the addition of a new observation—that the percentage drop in retail share is larger than in shipment volume—which, while plausible, goes slightly beyond the original answer’s neutral comparison and introduces a nuanced interpretation not explicitly supported in the ground truth. (4) Despite this small interpretive addition, the answer remains factually correct, complete, and contextually appropriate, warranting a high score. All entities (Skoal, MO, correct years, metrics) are accurately identified and used.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 359,
        "total_tokens": 1594
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has Qualcomm's approach to multimedia technologies evolved from 2022 to 2024, particularly in terms of engineering focus areas and integration into product offerings?",
      "original_answer": "In 2022, Qualcomm emphasized engineering expertise in multimedia technologies such as camera, video, display, and computer vision as part of a broader set of capabilities including modem, RF, and sensor perception technologies. The focus was on enhancing existing products and developing new technologies for industries beyond mobile handsets, such as automotive and IoT. By 2024, the company's description of its multimedia technology efforts remained consistent, but there was a notable expansion in the integration of AI, particularly generative AI, into its research and development strategy. Additionally, in 2024, Qualcomm placed greater emphasis on enabling developers to design and deploy applications across multiple device categories and industries, signaling a more deliberate diversification strategy. This evolution reflects a shift from primarily hardware-centric multimedia innovation in 2022 to a more platform-oriented, AI-enhanced approach by 2024.",
      "llm_answer": "\nFrom fiscal 2022 through 2024 Qualcomm broadened its engineering focus beyond pure wireless‑connectivity to a multimedia‑centric, AI‑enabled architecture.  The company invested heavily in camera, video, display and computer‑vision pipelines, sensor‑perception and on‑device AI engines (NPU/GPU) within its Snapdragon SoCs, and it integrated these capabilities across its product families—from smartphones to automotive, IoT and XR platforms—while continuing to tie the advances to its QCT chipset business and QTL licensing model.  This shift reflects a strategic move to embed multimedia and AI functions directly into its silicon and to leverage those capabilities as differentiators in its diversified product offerings.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in Qualcomm's multimedia technology strategy from 2022 to 2024. It accurately identifies the engineering focus areas (camera, video, display, computer vision) and notes the integration into broader product offerings across smartphones, automotive, IoT, and XR—consistent with the ground truth. It correctly highlights the increased emphasis on AI, particularly on-device AI engines (NPU/GPU), aligning with the 2024 shift toward AI-enhanced, platform-oriented development. The mention of Snapdragon SoCs, QCT, and QTL reflects accurate entity usage and contextual understanding. However, the LLM answer does not explicitly mention the expansion into generative AI in 2024, which is a key differentiator in the original answer. Additionally, while it implies a strategic shift, it does not clearly articulate the evolution from a hardware-centric approach in 2022 to a more developer-focused, platform-oriented model in 2024. These omissions reduce completeness and nuance in the qualitative reasoning, though no factual inaccuracies or quantitative errors are present. All dates and entities are correct, and the answer remains highly relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 343,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How did 3M's financial relationship with the Aearo Entities evolve between 2023 and 2024, particularly in terms of equity investment and intercompany balances?",
      "original_answer": "In 2023, 3M reconsolidated the Aearo Entities, which resulted in the removal of a $0.7 billion asset balance in equity and other investments and a $0.6 billion net liability for former intercompany amounts from its consolidated balance sheet as of December 31, 2023. By 2024, the Aearo Entities were no longer consolidated, and instead, 3M now 'has a stake in' them, indicating a shift from full consolidation to a retained equity interest. This reflects a significant change in the financial structure and relationship between 3M and the Aearo Entities.",
      "llm_answer": "\nBetween 2023 and 2024 the financial tie to the Aearo Entities shifted from an equity stake to a cash‑only settlement.  After the bankruptcy dismissals, 3M re‑consolidated the Aearo Entities and recorded a $0.7 billion equity investment (shown in “other assets”) and a $0.6 billion net intercompany liability (reflected as $0.9 billion in other liabilities and $0.3 billion in other assets).  In January 2024 the parties amended the CAE Settlement to eliminate the equity portion, requiring 3M to pay the full $1 billion cash (plus $0.2 billion for case expenses), which was funded by the $4.2 billion pre‑tax charge recorded in Q3 2023 and subsequent $250 million (Dec 2023) and $253 million (Jan 2024) payments; the equity investment was written off and the intercompany balances were eliminated, leaving only the settled cash obligations and the remaining $5 billion accrued liability for Combat‑Arms earplug claims.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual and conceptual errors that deviate from the ground truth. (1) Quantitatively, while the $0.7 billion equity investment and $0.6 billion net intercompany liability align with the original answer, the additional figures—such as $1 billion cash payment, $0.2 billion case expenses, $4.2 billion pre-tax charge, $250 million and $253 million payments, and $5 billion accrued liability—are not present in the ground truth and appear fabricated or misattributed. These numbers contradict the original answer, which does not mention a cash settlement replacing equity or any such payments. (2) The timeline is incorrect: the original answer states that reconsolidation occurred in 2023 and deconsolidation (with retained stake) by 2024, but the LLM claims a January 2024 amendment eliminated the equity portion, which is unsupported. (3) Entity and relationship accuracy is flawed—the original answer describes a shift from full consolidation to a retained equity interest, not a shift to cash-only settlement or write-off of equity. The LLM incorrectly frames the evolution as a contractual settlement change rather than a consolidation accounting change. (4) Multi-hop reasoning fails: the model misinterprets the nature of the financial relationship change, introducing external concepts like 'CAE Settlement' and 'bankruptcy dismissals' not in the ground truth, and incorrectly infers a causal sequence involving cash payments and write-offs. (5) Semantically, the core claim—that 3M moved from consolidation to a non-consolidated equity stake—is partially aligned, but the explanation is dominated by inaccurate details, rendering the overall answer misleading. The contextual relevance is moderate because it addresses financial changes involving Aearo, but the specifics are factually unsound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 495,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has Visa's Risk and Identity Solutions evolved between 2022 and 2024, particularly in terms of their strategic positioning within the company's broader value-added services portfolio?",
      "original_answer": "In 2022, Visa's Risk and Identity Solutions were described as tools that 'transform data into insights for near real-time decisions' and included named products like Visa Advanced Authorization and Visa Secure. These solutions were positioned primarily around fraud prevention and payment security, with an emphasis on helping clients protect account holder data and prevent fraud in the context of omnichannel commerce. By 2024, Risk and Identity Solutions had been elevated as one of five core categories within a more expansive value-added services portfolio that now includes Open Banking Solutions and Advisory Services. The 2024 report highlights that Visa offered more than 200 products and services as of September 30, 2024, many designed to work together for 'high impact business outcomes,' indicating a broader strategic integration of Risk and Identity Solutions within a more diversified services ecosystem.",
      "llm_answer": "\nBetween fiscal 2022 and 2024 Visa transformed its Risk and Identity Solutions from a collection of discrete fraud‑prevention products into a unified, AI‑driven portfolio that now includes Visa Deep Authorization, Visa Protect for A2A Payments and a scheme‑agnostic Visa Risk Manager with Advanced Authorization.  These offerings are marketed as a core pillar of Visa’s broader value‑added services—sitting alongside Issuing, Acceptance and Open‑Banking solutions—and are positioned to protect every transaction across the company’s “network‑of‑networks” strategy while driving new revenue streams from emerging money‑movement flows.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution of Visa's Risk and Identity Solutions from a fraud-prevention focus in 2022 to a more integrated, strategic component of its value-added services by 2024, which aligns with the ground truth. It correctly identifies the strategic repositioning within a broader portfolio and references the expansion beyond standalone tools. However, there are some discrepancies: the ground truth does not mention 'Visa Deep Authorization', 'Visa Protect for A2A Payments', or a 'scheme-agnostic Visa Risk Manager'—these specific product names and features are not present in the verified data, raising concerns about hallucination. Additionally, while the LLM correctly notes integration into a broader ecosystem, it omits the key detail that Risk and Identity Solutions became one of five core categories alongside new areas like Open Banking and Advisory Services, instead grouping them under a slightly different categorization (e.g., 'Issuing, Acceptance and Open-Banking solutions'). The mention of 'AI-driven' and 'network-of-networks' strategy, while plausible, is not explicitly supported in the original answer. Quantitatively, there are no numerical claims (dates, counts of products, financials) that are incorrect—fiscal years 2022 and 2024 are used appropriately, and no false metrics are introduced. Contextually, the response is highly relevant, addressing both the evolution and strategic positioning. The reasoning is mostly sound but lacks explicit confirmation of the multi-hop synthesis that Risk and Identity moved from a security-focused role to being part of a 200+ product ecosystem by September 30, 2024. Overall, the answer is factually plausible and directionally accurate but includes unverified product details and slightly misrepresents the portfolio structure, warranting a 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 498,
        "total_tokens": 1897
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How did RTX's disclosure and quantification of Acquisition Accounting Adjustments' impact on operating profit evolve between 2023 and 2024?",
      "original_answer": "In 2023, RTX provided specific quantified impacts of Acquisition Accounting Adjustments on operating profit, showing a negative impact of $1,998 million in 2023, compared to $1,893 million in 2022 and $2,203 million in 2021. By 2024, RTX shifted its disclosure approach by providing qualitative policy context about the components of these adjustments, but did not include updated quantitative figures for the current year's impact on operating profit. This represents a move from concrete numerical disclosure to a more conceptual explanation of acquisition accounting practices without continuing the year-over-year quantification.",
      "llm_answer": "\nIn the 2023 Form 10‑K (page 108) the “Acquisition accounting adjustments” line reduced consolidated operating profit by **$1.998 bn**, and the same line appears in the 2024 filing (page 56) with a slightly larger negative impact of **$2.058 bn** – an increase of roughly **$60 million**.  The 2024 disclosure breaks the adjustment into amortization of acquired intangibles, PP&E fair‑value adjustments, and amortization of customer contractual obligations, showing that the composition of the charge was largely unchanged but the total amount deducted from operating profit grew modestly from 2023 to 2024.  Both years present the adjustment outside of segment results, emphasizing that it is not part of management’s performance assessment of the segments.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitative Accuracy: The LLM claims RTX disclosed a $2.058 billion negative impact in 2024, but the ground truth states that RTX did *not* provide updated quantitative figures for 2024. This number is false and contradicts the core fact that quantification stopped in 2024. The $60 million increase is therefore fabricated. (2) Completeness & Reasoning: The question asks about the *evolution* of disclosure and quantification between 2023 and 2024. The ground truth shows a shift from quantitative (2023) to qualitative (2024) disclosure. The LLM incorrectly asserts that quantification continued in 2024 with a specific dollar amount, missing the key evolution entirely. (3) Entity and Context Accuracy: While the company (RTX) and metric (Acquisition Accounting Adjustments) are correct, the years and disclosure practices are misrepresented. The LLM falsely claims the 2024 filing includes a dollar figure and breakdown of components, when in fact the ground truth confirms no such quantification was provided in 2024. (4) Semantic Equivalence: The LLM answer conveys the opposite of the truth—continued numerical disclosure instead of a shift to qualitative—making it highly misleading. The contextual relevance is low because it fails to capture the actual trend in disclosure policy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 382,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How has Microsoft's Office 365 Commercial revenue contribution to the Microsoft Cloud evolved between fiscal years 2022 and 2023, and what does this indicate about its growth trajectory within the broader cloud ecosystem?",
      "original_answer": "In fiscal year 2022, Office 365 Commercial was explicitly cited as a key growth driver within the Productivity and Business Processes segment, contributing to an 18% overall revenue increase for the company. By fiscal year 2023, Office 365 Commercial was included in a newly disclosed consolidated Microsoft Cloud revenue figure, which reached $111.6 billion in FY2023, up from $91.4 billion in FY2022. This indicates that Office 365 Commercial continued to grow as part of a broader, increasingly transparent cloud revenue portfolio that now includes Azure, LinkedIn (commercial portion), Dynamics 365, and other cloud services.",
      "llm_answer": "\nMicrosoft Cloud revenue—of which Office 365 Commercial is a core component—rose from **$91.4 billion in fiscal 2022 to $111.6 billion in fiscal 2023**, a **~22 % year‑over‑year increase**. This jump reflects the accelerating uptake of Office 365 subscriptions and shows that Office 365 Commercial is becoming an increasingly dominant driver of Microsoft’s cloud growth, underscoring its strategic importance within the broader cloud ecosystem.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the Microsoft Cloud revenue figures for FY2022 ($91.4 billion) and FY2023 ($111.6 billion), matching the ground truth exactly. The year-over-year growth rate is accurately calculated as approximately 22% ((111.6 - 91.4) / 91.4 ≈ 0.221), which is correctly rounded to ~22%. These numbers are factually correct and properly contextualized within the fiscal years. (2) The entity identification is accurate: Microsoft, Office 365 Commercial, and Microsoft Cloud are correctly referenced with appropriate fiscal years. The answer correctly identifies Office 365 Commercial as a core component of the broader Microsoft Cloud revenue, consistent with the ground truth. (3) The multi-hop reasoning is mostly sound: the model infers growth in Office 365 Commercial from the overall Microsoft Cloud growth, which is reasonable given that it is a key component. However, the original answer notes that Office 365 Commercial was previously reported separately and then subsumed into the consolidated Microsoft Cloud figure, providing more nuance about reporting changes. The LLM answer does not mention this shift in disclosure, slightly weakening the qualitative accuracy. It also states that Office 365 Commercial is becoming an 'increasingly dominant driver,' which is a stronger claim than the original answer supports—while it is a key contributor, the original does not assert dominance or acceleration specifically for Office 365 Commercial alone, as Azure and other services also contribute significantly. (4) Despite this slight overstatement, the core facts, numbers, and overall interpretation are correct and relevant. The answer addresses both parts of the question—evolution of contribution and growth trajectory—and remains semantically aligned with the ground truth. Hence, correctness is high but not perfect due to minor interpretive overreach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 514,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did Merck's alliance revenue related to Lynparza evolve between 2023 and 2024, and what factors contributed to the change?",
      "original_answer": "In 2023, alliance revenue for Lynparza was part of Merck's broader alliance revenue reporting, which included profits based on product sales net of cost of sales and commercialization costs. By 2024, alliance revenue related to Lynparza specifically grew by 9%, driven by higher demand in most international markets. This growth indicates a positive shift in Lynparza's market performance during the period.",
      "llm_answer": "\nMerck’s alliance revenue from Lynparza rose from **$1.199 billion in 2023 to $1.311 billion in 2024** – an increase of about **9 % (≈11 % excluding foreign‑exchange effects)**.  The growth was driven mainly by **higher demand for Lynparza in most international markets**, supported by additional regulatory approvals (e.g., the January 2025 Chinese NMPA approval for adjuvant use in BRCA‑mutated, HER2‑negative breast cancer) and the continued strength of the collaboration with AstraZeneca that boosted sales of the drug worldwide.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies a 9% growth in Lynparza alliance revenue from 2023 to 2024, which aligns with the ground truth. However, the specific dollar amounts provided—$1.199 billion in 2023 and $1.311 billion in 2024—are not present in the original answer and cannot be verified against the ground truth, which only states that revenue grew by 9% without citing absolute values. The ≈11% growth excluding foreign-exchange effects is additional detail not found in the original and may reflect overprecision or unsupported inference. (2) The calculation of a 9% increase from $1.199B to $1.311B is approximately correct: (1.311 - 1.199) / 1.199 ≈ 9.34%, which rounds to 9%, so the percentage is consistent with the stated figures. However, since the original answer does not provide these figures, introducing them as facts reduces quantitative accuracy. (3) The reasoning about increased international demand as a driver is fully supported by the original answer and represents accurate multi-hop synthesis. The mention of the January 2025 Chinese NMPA approval, however, refers to a future event relative to the 2024 reporting period and cannot contribute to revenue changes already observed in 2024, making this a factual error in causality. The collaboration with AstraZeneca is contextually relevant but not explicitly mentioned in the ground truth, so its inclusion is plausible but unverified. (4) Despite strong qualitative reasoning and contextual relevance, the introduction of unverified numerical data and a forward-looking regulatory approval reduces the correctness and quantitative accuracy scores. The core conclusion—9% growth due to international demand—is accurate and well-aligned, justifying a score of 7 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 482,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has the treatment and disclosure of the Procter & Gamble 2014 Stock and Incentive Compensation Plan evolved between 2023 and 2024, particularly in terms of its regulatory context and inclusion in equity compensation reporting?",
      "original_answer": "In 2023, the 2014 Stock and Incentive Compensation Plan was disclosed in the context of regulatory documentation and was referenced alongside other compensation plans and agreements, such as the 2009 and 2019 plans, indicating its active role in executive compensation. By 2024, the plan was included in a broader list of equity compensation plans for reporting on stock issuances upon exercise of options, suggesting a shift from regulatory disclosure to a focus on ownership structure and equity compensation transparency. This evolution indicates a more integrated view of the 2014 plan within the company’s overall equity compensation framework.",
      "llm_answer": "\nBetween the 2023 and 2024 filings the 2014 Stock and Incentive Compensation Plan is still disclosed only through its historic exhibit references (10‑24, 10‑25, 10‑26) and is listed in the proxy‑statement’s equity‑compensation table alongside the 2019 Plan.  Its regulatory context is unchanged – the plan remains a shareholder‑approved, SEC‑reportable arrangement subject to the Compensation and Leadership Development Committee’s oversight, and it continues to be reported in the same way (options counted one‑for‑one, full‑value awards counted as five shares, with the remaining shares available for future grant shown).",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is partially correct in terms of entity accuracy and regulatory context, correctly identifying the 2014 Stock and Incentive Compensation Plan, its inclusion in equity compensation tables, and its oversight structure. It accurately notes that the plan is listed alongside the 2019 Plan in proxy statements and that it remains subject to shareholder approval and SEC reporting, which aligns with the ground truth's mention of regulatory documentation. The quantitative and structural details about share counting (one-for-one for options, five-to-one for full-value awards) and exhibit references (10-24, 10-25, 10-26) are specific and plausible, though not contradicted by the ground truth, which does not include such granular detail—thus not penalized directly for inaccuracy but for omission of key evolution.\n\nHowever, the core of the question—how the treatment and disclosure evolved between 2023 and 2024—was not accurately addressed. The LLM claims the regulatory context and reporting method 'remained unchanged,' which directly contradicts the ground truth that identifies a meaningful shift: from being discussed in a regulatory context among multiple plans in 2023 to being integrated into broader equity compensation reporting focused on ownership structure and transparency in 2024. This evolution reflects a change in emphasis and integration within the company’s disclosure framework, which the LLM fails to recognize, instead asserting continuity.\n\nThis represents a critical failure in multi-hop reasoning: the model should have synthesized changes in disclosure focus across years, but instead concludes no change occurred. While the individual facts presented are not demonstrably false (hence a moderate quantitative and contextual score), the overall conclusion is misaligned with the ground truth. The answer lacks the qualitative insight into evolving disclosure practices, resulting in a low qualitative accuracy and correctness score. Semantic equivalence is not achieved because the central claim (no change) contradicts the ground truth (evolution toward integration and transparency).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 568,
        "total_tokens": 1907
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has the treatment of the 1992 Stock Plan evolved between the 2023 and 2024 10-K filings, particularly in terms of its role within the company's equity compensation structure?",
      "original_answer": "In the 2023 10-K filing, the 1992 Stock Plan was referenced as an adopted plan with specific terms and conditions incorporated by reference to prior filings. However, in the 2024 10-K filing, the 1992 Stock Plan is listed among other equity compensation plans in a consolidated table that outlines shares authorized for issuance upon the exercise of options, warrants, and rights. This indicates a shift from a standalone referenced plan to one being tracked alongside newer plans, suggesting its role has transitioned from active adoption to a more passive stake within the broader equity compensation framework.",
      "llm_answer": "\nThe 1992 Stock Plan is now treated as a closed, legacy plan – the 2024 10‑K shows that it has zero shares remaining for future issuance, whereas the 2023 filing still counted a small, dwindling reserve as part of the company’s equity‑compensation portfolio. As a result, the plan no longer serves as a source of new awards; all future equity grants are administered through the newer 2019 Stock and Incentive Compensation Plan (and related plans), with the 1992 plan limited to outstanding, already‑granted securities.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in quantitative claims not supported by the ground truth. The assertion that the 1992 Stock Plan had 'zero shares remaining for future issuance' in the 2024 10-K and a 'small, dwindling reserve' in 2023 is not present in the original answer and cannot be verified from the provided ground truth. The ground truth does not mention specific share numbers or reserves, nor does it state the plan is closed or has zero shares left. This introduces false precision and incorrect data, severely impacting quantitative accuracy. However, the qualitative shift described — that the 1992 Plan moved from being referenced by incorporation in 2023 to being included in a consolidated table in 2024 — is conceptually aligned with the idea of transitioning toward a more passive, legacy status. The mention of the 2019 Stock and Incentive Compensation Plan as the current vehicle is plausible contextually but not confirmed in the ground truth, introducing an unverified entity. While the reasoning attempts multi-hop synthesis (comparing treatment across years and inferring role change), it overreaches by fabricating numerical details and assuming current plan administration without evidence. The answer is contextually relevant and addresses the evolution question appropriately, but factual correctness is compromised by unsupported specifics. Thus, the correctness score is moderate due to partial alignment in conceptual reasoning but major issues in factual and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 423,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has the company's emphasis on large-scale transformations evolved between 2023 and 2024, particularly in terms of client spending patterns and revenue conversion timelines?",
      "original_answer": "In 2023, the filing noted that clients were reducing or deferring spending on smaller contracts with shorter durations and that there was a slowdown in client spending, especially for consulting services. However, clients were still prioritizing large-scale transformations, which convert to revenue over a longer period. In 2024, the filing reiterated that clients continued to prioritize large-scale transformations, emphasizing the ongoing shift toward longer-duration contracts. While there was no explicit quantitative metric provided in either year, the repeated emphasis in both filings on the extended revenue conversion timeline for large-scale transformations indicates a strategic reinforcement of this focus, especially amid ongoing economic volatility.",
      "llm_answer": "\nBetween 2023 and 2024 the company’s emphasis on large‑scale transformations intensified, with clients shifting spend from short‑duration, low‑value contracts to fewer, multi‑year transformation programs that generate revenue gradually.  Economic volatility slowed overall client spending—particularly on smaller, short‑term engagements—while the firm noted that these large‑scale transformations now convert to revenue over a longer period, offering higher durability despite the slower recognition schedule.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in the company's emphasis on large-scale transformations between 2023 and 2024. (1) It correctly identifies that clients reduced spending on smaller, short-term contracts due to economic volatility—consistent with the 2023 filing—and continued prioritizing large-scale, multi-year transformation programs in 2024. The key qualitative point about longer revenue conversion timelines is accurately conveyed. (2) There are no numeric values or calculations in the original or LLM answer, so quantitative accuracy is not compromised; the response appropriately avoids inventing metrics. (3) The multi-hop reasoning is sound: it synthesizes information across both years, correctly inferring continuity and intensification of focus on large-scale transformations despite spending slowdowns. The LLM slightly strengthens the claim by saying emphasis 'intensified,' which is a reasonable interpretation but not explicitly stated in the original answer—hence a minor deduction in qualitative accuracy. (4) The response is fully contextually relevant, directly addressing client spending patterns and revenue conversion timelines as required. Overall, the LLM conveys semantically equivalent information with high fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 356,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How did Accenture's issuance of Class A Ordinary Shares for employee compensation change from fiscal 2023 to 2024, and what was the impact on the company's equity structure?",
      "original_answer": "In fiscal 2023, Accenture acquired Class A Ordinary Shares primarily through share withholding for payroll tax obligations related to employee equity awards. In fiscal 2024, the company issued 7,970 Class A Ordinary Shares specifically for employee share programs, while also purchasing 12,181 treasury shares. This shift reflects a more active use of Class A Ordinary Shares for compensation purposes in 2024. The equity structure was impacted as Class A Ordinary Shares increased from 15,656,591 in 2023 to 15,664,561 in 2024, while treasury shares decreased in value from $(3,408,491) million to $(6,678,037) million, indicating a significant reallocation of shares for employee programs.",
      "llm_answer": "\nAccenture’s Class A share count rose from $15,664,616 (as of Aug 31 2023) to $15,672,485 (as of Aug 31 2024), an increase of 7,869 shares (≈7.9 million).  This addition contributed roughly $2.3 bn to paid‑in capital and helped lift total shareholders’ equity by about $2.6 bn, modestly expanding the equity base while leaving the overall capital structure essentially unchanged.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that Accenture issued 7,970 Class A Ordinary Shares in fiscal 2024 for employee programs and that the total Class A Ordinary Shares increased from 15,656,591 in 2023 to 15,664,561 in 2024 (an increase of 7,970 shares). However, the LLM claims the share count rose from 15,664,616 to 15,672,485—an increase of 7,869 shares—which contradicts the ground truth in both starting/ending values and the increment. Additionally, the LLM introduces dollar amounts ($2.3 billion to paid-in capital, $2.6 billion to equity) that are not present or verifiable in the original answer and appear fabricated. (2) The quantitative inaccuracies are severe: the base share counts are wrong, the net increase is off by 101 shares, and unsupported financial figures are introduced. The original answer also notes a decrease in treasury shares from $(3,408,491) million to $(6,678,037) million, which the LLM completely omits. (3) The multi-hop reasoning is flawed. The original answer contrasts a passive acquisition via withholding in 2023 with active issuance in 2024, highlighting a strategic shift. The LLM fails to mention this key change in policy or the purchase of 12,181 treasury shares in 2024, missing the structural reallocation narrative. Instead, it incorrectly frames the change as a simple equity expansion with no structural impact, contradicting the original conclusion. (4) While the LLM addresses the general topic of share issuance for employee compensation and its impact on equity, it gets core facts wrong, omits critical context, and invents figures, leading to a low correctness score. Contextual relevance is moderate because it attempts the right topic but fails on substance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 484,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How did MDLZ's exposure to Canadian-denominated debt instruments change between 2022 and 2023, and how does this shift compare to the company's overall trend in managing foreign currency-denominated debt during this period?",
      "original_answer": "In 2022, MDLZ reported a decrease in Canadian notes of $3 million, continuing a trend of declining balances from $17 million in 2019 to $7 million in 2020 and $3 million in 2021. However, in 2023, the company experienced an increase in Canadian notes by $8 million, reversing the previous downward trajectory. This shift contrasts with the broader pattern of fluctuating foreign currency exposure, where Euro notes decreased significantly from $211 million in 2021 to $81 million in 2023, while Swiss franc notes also showed volatility. The reversal in Canadian notes indicates a notable deviation from the prior year's trend of reducing exposure to this currency denomination.",
      "llm_answer": "\nBetween 2022 and 2023 the notional amount of Canadian‑dollar debt that MDLZ classifies as a net‑investment hedge rose from **$443 million to $453 million** – an increase of roughly **$10 million (about 2 %)**.  This modest uptick occurs alongside a broader, also modest expansion of the company’s foreign‑currency hedging program, whose total net‑investment‑hedge notional grew from **$7,319 million to $7,456 million** over the same period.  Consequently, the shift in Canadian‑denominated debt exposure is a small, incremental component of MDLZ’s overall strategy of gradually increasing and fine‑tuning its foreign‑currency hedge coverage.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to align with the ground truth on multiple levels. (1) Quantitatively, the LLM reports a rise in Canadian-dollar debt from $443 million to $453 million—an increase of $10 million—which directly contradicts the ground truth stating that in 2022, Canadian notes decreased by $3 million and then increased by $8 million in 2023 from a much smaller base (down to $3 million in 2021). The LLM's figures are off by orders of magnitude and misrepresent the scale and direction of change. (2) The LLM introduces the concept of 'net-investment hedge' and total foreign-currency hedging program growth, which are not mentioned or supported in the original answer, adding irrelevant and potentially fabricated context. (3) The qualitative reasoning is flawed: the ground truth emphasizes a reversal in trend (from declining to increasing) in Canadian notes, contrasting it with broader volatility in Euro and Swiss franc debt. The LLM instead frames the change as part of a steady expansion in hedging, which contradicts the 'fluctuating' and 'deviating' pattern described in the original. (4) The entity (MDLZ) and time period (2022–2023) are correct, but the financial metrics and trends are entirely misrepresented. The answer fails the multi-hop synthesis by not connecting the Canadian debt shift to the broader trend in foreign currency debt as described in the ground truth. Overall, the response fabricates data and misrepresents the trend, warranting a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 417,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Accenture's approach to engaging with growth-stage companies evolved from 2023 to 2024, particularly in terms of strategic involvement and investment activity?",
      "original_answer": "In 2023, Accenture Ventures was described as primarily partnering with growth-stage companies that create innovative enterprise technologies. By 2024, the relationship evolved from a partnership model to a more direct investment approach, indicating a deeper financial and strategic commitment. This shift from 'partners with' to 'invests in' growth-stage firms suggests Accenture is taking a more active role in shaping innovation ecosystems through capital allocation, aligning with its broader innovation strategy supported by $1.3 billion in R&D spending in fiscal 2023 and $1.2 billion in fiscal 2024.",
      "llm_answer": "\nFrom 2023 to 2024 Accenture moved from a loosely referenced partnership with growth‑stage innovators to a more structured, strategic role for its **Accenture Ventures** unit—explicitly positioning it as the vehicle that both invests in and incubates enterprise‑technology startups and then channels those solutions through the firm’s global delivery network, innovation hubs and IP portfolio.  The 2024 filing emphasizes that these investments are now integrated with Accenture’s research, labs and Studios to accelerate scaling for clients, indicating a deeper, more coordinated involvement than the earlier, more generic reference in the 2023 document.  Consequently, the company’s investment activity appears to have intensified and become more purpose‑driven, focusing on rapid‑scale, high‑impact technology firms that complement its innovation ecosystem.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution from a partnership model in 2023 to a more direct investment approach in 2024, noting Accenture Ventures as the key vehicle—this matches the shift from 'partners with' to 'invests in' in the original answer. (2) There are no numeric inaccuracies; while the LLM does not repeat the $1.3B and $1.2B R&D figures from fiscal 2023 and 2024, their omission does not constitute an error since the question does not explicitly ask for financial figures, and the focus is on strategic evolution. The absence of these numbers slightly reduces completeness but does not affect factual correctness. (3) The multi-hop reasoning is sound: the model synthesizes information across years and correctly infers a deepening strategic commitment based on language changes in the filings. It adds contextual value by referencing integration with Accenture’s research, labs, Studios, and global delivery network—details consistent with the broader innovation strategy implied in the ground truth. (4) The semantic meaning fully captures the core evolution in Accenture’s approach. The slight deduction in qualitative accuracy is due to the enhanced detail (e.g., 'incubates', 'IP portfolio') that, while plausible and contextually appropriate, are not explicitly confirmed in the ground truth. Overall, the answer is factually correct, highly relevant, and demonstrates strong reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 406,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Merck's financial and strategic involvement in the Lynparza collaboration with AstraZeneca evolved from 2022 to 2024, particularly in terms of asset amortization and alliance revenue growth?",
      "original_answer": "In 2022, Merck was amortizing an intangible asset balance of $1.1 billion related to Lynparza, which included capitalized milestone payments, and was expected to be amortized through 2028. By 2024, the focus shifted from asset amortization to revenue growth, with alliance revenue from Lynparza increasing by 9% due to higher demand in international markets. Additionally, in early 2025, Lynparza received a new approval in China for adjuvant treatment in early breast cancer, indicating an expansion in its therapeutic footprint and strategic importance to Merck.",
      "llm_answer": "\nBetween 2022 and 2024 Merck’s share of Lynparza profits (the “alliance revenue” line) grew from **$1.12 bn** (2022) to **$1.20 bn** (2023) to **$1.31 bn** (2024), a roughly **18 % increase** over the three‑year span, reflecting expanded approvals and stronger global demand.  The $1.1 bn of intangible assets that Merck recorded for Lynparza—primarily capitalized milestone payments—has been amortized over about **seven years (through 2028)**, so amortization expense has been steadily recognized and will continue on that multi‑year schedule.  Thus, Merck’s financial exposure to the AstraZeneca collaboration has deepened through higher recurring alliance revenue while the acquired Lynparza intangibles are being written off gradually over the agreed‑upon useful life.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in numbers and timeline that deviate from the ground truth. While the original answer states that Merck was amortizing a $1.1 billion intangible asset balance related to Lynparza in 2022 with amortization expected through 2028 — which the LLM correctly reiterates — it fabricates specific alliance revenue figures for 2022 ($1.12B), 2023 ($1.20B), and 2024 ($1.31B), which are not present in the ground truth. The original answer only states that alliance revenue grew by 9% by 2024 due to international demand, not an 18% increase over three years. This results in a significant quantitative error. Additionally, the LLM invents a 2023 data point not mentioned in the source. (2) The calculation of an '18% increase' is based on fabricated data and is therefore incorrect. The ground truth reports a 9% increase in alliance revenue by 2024, not 18% over three years. The amortization period being 'about seven years' is inconsistent with the statement that it runs 'through 2028' from 2022 (a six-year span), though this may be a rounding approximation. (3) The multi-hop reasoning is partially sound — the LLM correctly identifies the dual financial dimensions of amortization and revenue growth in the collaboration and attempts to show evolution over time. However, it fails to mention the new 2025 China approval, a key strategic development indicating expanded therapeutic footprint. This omission reduces completeness. (4) Despite the incorrect numbers, the overall structure and intent of the answer are relevant and contextually appropriate. It correctly frames the shift from amortization to revenue growth and references the correct asset origin (capitalized milestones). Hence, while the qualitative reasoning and contextual relevance are strong, the quantitative inaccuracies significantly undermine factual correctness, warranting a moderate score of 6 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 526,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How has AVGO's strategic emphasis on ValueOps changed between 2023 and 2024, and what does this indicate about its evolving role in the Distributed Software portfolio?",
      "original_answer": "In 2023, ValueOps was listed as one of several key offerings under AVGO's Distributed Software portfolio, positioned alongside other solutions like DevOps and AIOps without specific elaboration on its strategic role. By 2024, ValueOps was elevated to be one of the three core domains—alongside DevOps and AIOps—that AVGO's distributed software solutions are 'organized in the domains of,' with an explicit emphasis on delivering 'end-to-end visibility across all stages of the digital lifecycle.' This indicates a strategic shift where ValueOps became more central to AVGO's value proposition, aligning it more deeply with business outcomes and customer experiences. The change reflects a broader evolution from being a feature in the portfolio to a foundational pillar supporting enterprise digital transformation.",
      "llm_answer": "\nBetween the 2023 and 2024 filings the treatment of ValueOps shifted from a peripheral line‑item in the “Distributed Software Portfolio” list to a stand‑alone, prominently described capability.  In 2024 the document explicitly defines ValueOps as a solution that “delivers value‑stream management…aligns business and development teams…increasing transparency, reducing inefficiencies, and improving time‑to‑value,” and it is positioned alongside DevOps and AIOps as a core pillar of the portfolio.  This elevation shows that Broadcom is now centering its Distributed Software strategy on ValueOps as the primary engine for driving end‑to‑end visibility, business‑outcome focus, and faster value delivery across its digital‑lifecycle offerings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in AVGO's strategic emphasis on ValueOps between 2023 and 2024. It correctly identifies the shift from a peripheral offering in 2023 to a core pillar in 2024, grouped with DevOps and AIOps. The description of ValueOps in 2024—'delivers value-stream management...aligns business and development teams...'—aligns semantically with the ground truth's emphasis on 'end-to-end visibility across all stages of the digital lifecycle.' The answer correctly infers the strategic implication: that ValueOps has become central to driving business outcomes and faster value delivery. All entities (AVGO/Broadcom, ValueOps, DevOps, AIOps, Distributed Software portfolio) and years (2023 vs 2024) are accurate. There are no numeric values to verify, so quantitative accuracy is scored as 10 by default. The only minor shortcoming is that the LLM does not explicitly contrast the lack of elaboration in 2023 (as noted in the ground truth), instead characterizing it as a 'peripheral line-item,' which is reasonable but slightly less precise. However, this does not undermine the overall correctness. Multi-hop reasoning is sound—synthesizing changes in positioning and language across years to infer strategic intent. The answer is fully contextually relevant and conveys the same meaning as the original answer with slightly different phrasing. Thus, correctness is 9 (not 10) due to slight imprecision in describing the 2023 state, but all key facts and reasoning are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 418,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did FedEx's strategic approach to Network 2.0 within the DRIVE transformation evolve between 2023 and 2024, particularly in terms of expected cost savings and implementation risks?",
      "original_answer": "In 2023, FedEx emphasized the strategic importance of Network 2.0 as part of its DRIVE transformation, noting that significant investments were being made with the expectation of achieving operational efficiencies, network flexibility, and alignment of the cost base with demand. However, the filing acknowledged that the failure to successfully execute Network 2.0 within the expected time frame and cost could adversely affect future results. By 2024, FedEx shifted focus to the integration complexities of Network 2.0, including risks related to harmonizing operating practices, maintaining customer and service provider agreements, addressing labor and cultural differences, and managing unforeseen expenses. The 2024 filing also noted that the actual amount and timing of cost savings and permanent cost reductions might differ from expectations, and that asset impairment charges, tax impacts, and litigation risks could arise. This reflects a transition from strategic planning and investment justification in 2023 to operational integration and financial risk mitigation in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 FedEx shifted Network 2.0 from a planning stage to active execution—launching the one‑FedEx consolidation, the Tricolor redesign of its international air network and a European workforce‑reduction plan—while repeatedly stressing that the permanent cost‑structure reductions and efficiency gains it expects may be lower than forecast and could require higher‑than‑anticipated spending.  The company now acknowledges that realizing those savings is contingent on successfully integrating disparate networks, navigating labor and regulatory hurdles, and avoiding delays or litigation, all of which introduce significant implementation risk.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in FedEx's strategic approach to Network 2.0 between 2023 and 2024. It correctly identifies the shift from planning to execution, highlighting key initiatives like the 'one-FedEx' consolidation, Tricolor redesign, and European workforce reductions—consistent with the broader DRIVE transformation. The answer accurately reflects the increasing emphasis on implementation risks, including integration challenges, labor and regulatory hurdles, and uncertainty around cost savings timing and magnitude. While the original answer includes more specific risk categories (e.g., asset impairment charges, tax impacts, litigation, cultural differences), the LLM covers most of these under broader terms like 'litigation' and 'labor hurdles.' There are no numerical inaccuracies (quantitative accuracy is perfect, as no specific numbers are misstated), and the reasoning correctly synthesizes multi-hop information across years and strategic phases. The only minor shortcoming is the omission of explicit mention of 'harmonizing operating practices' and 'customer and service provider agreements,' which slightly affects completeness. However, the semantic meaning and strategic trajectory are preserved. Contextual relevance is excellent, directly addressing both expected cost savings and implementation risks as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1446,
        "completion_tokens": 381,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did the financial impact from equity method investment contracts evolve between 2022 and 2023, and what does this indicate about MDLZ's engagement with these investments?",
      "original_answer": "In 2022, MDLZ reported a net liability of $3 million related to equity method investment contracts. By 2023, this position had shifted to a gain of $7 million from equity method investment contracts, indicating a reversal in financial impact and potentially more active or favorable engagement with these investments. This evolution highlights a strategic or operational shift in how MDLZ managed these equity method investments over the two years.",
      "llm_answer": "\nBetween 2022 and 2023 the earnings impact from equity‑method investment contracts moved from **$0 million in 2022 to a $7 million gain in 2023** (after a $2 million gain in 2021). This modest, recent gain shows that MDLZ’s exposure to the embedded derivative in its exchangeable‑bond investment is limited and only generated a small positive contribution in the latest year, indicating a relatively low level of active engagement with these investments.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, MDLZ reported a net *liability* of $3 million, which the LLM incorrectly states as $0 million. The 2023 figure of a $7 million gain is correct. However, the LLM introduces a $2 million gain in 2021, which is not relevant to the question about 2022–2023 evolution. (2) The key calculation—change from 2022 to 2023—is misrepresented: the actual shift is from a -$3M liability to +$7M gain (a $10M swing), but the LLM reports a change from $0M to $7M, missing the liability aspect entirely. This undermines quantitative accuracy. (3) The reasoning is flawed: the LLM concludes 'low level of active engagement' due to 'small positive contribution,' which contradicts the ground truth interpretation of a reversal indicating *increased* or *more favorable* engagement. The LLM also introduces an unrelated concept—'exchangeable-bond investment' and 'embedded derivative'—not present in the original answer, suggesting incorrect entity or context mapping. (4) While the answer addresses the general topic and time frame, the incorrect baseline value, flawed interpretation, and introduction of irrelevant details severely reduce correctness. The contextual relevance is moderate because it discusses the right topic (equity method investment contracts) and correct company (MDLZ) and year (2023), but misrepresents the financial evolution and its implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 405,
        "total_tokens": 1637
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did Broadcom's (AVGO) estimated cost to complete for the VMware Cloud Foundation July 2024 releases evolve from fiscal year 2023 to fiscal year 2024, and what does this indicate about the development progress relative to expectations?",
      "original_answer": "The estimated cost to complete for the VMware Cloud Foundation July 2024 releases remained unchanged at $38 million from fiscal year 2023 to fiscal year 2024. This consistency in the cost estimate indicates that the development progress for this product was proceeding largely as planned, with actual expenditures aligning with earlier projections. The lack of an increase or decrease in the estimated cost to complete suggests that Broadcom (AVGO) did not encounter significant unexpected expenses or delays in the development timeline for this specific release.",
      "llm_answer": "\nThe estimated cost to complete for the VMware Cloud Foundation July 2024 releases fell from roughly $70 million in fiscal 2023 to $38 million in fiscal 2024. This decline shows that about two‑thirds of the work is already finished and only a modest amount of additional spending remains, indicating the releases are progressing ahead of schedule and are on track to meet expectations.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that the estimated cost to complete decreased from $70 million in fiscal year 2023 to $38 million in fiscal year 2024. The ground truth states that the cost remained unchanged at $38 million across both fiscal years. This major quantitative error undermines the entire response. (2) The claimed 'decline' from $70M to $38M is unsupported and introduces a significant miscalculation—both in the initial value and the implied progress (e.g., 'two-thirds of the work is already finished'), which cannot be derived from the actual data. The correct information shows no change, so no such inference about accelerated progress is valid. (3) The multi-hop reasoning fails because the model incorrectly infers development progress based on fabricated cost changes. The correct reasoning, per ground truth, hinges on the stability of the cost estimate indicating alignment with plans—not acceleration. (4) While the LLM attempts to interpret what the cost change implies about development progress (showing contextual understanding of the question's intent), its conclusions are based on false premises. Thus, despite addressing the question's structure and attempting qualitative analysis, the factual inaccuracies severely limit correctness. Quantitative accuracy is very low due to the wrong numbers; qualitative accuracy is low due to flawed reasoning; contextual relevance is moderate because the answer attempts the right kind of analysis but with incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 420,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has the strategic positioning of FedEx Office's Ship and Go kiosk evolved between 2023 and 2024, and what does this indicate about the company's approach to e-commerce logistics and returns management?",
      "original_answer": "In 2023, the Ship and Go kiosk was described primarily as a self-serve shipping solution available in approximately 1,300 locations, allowing customers to generate labels via mobile or QR code and drop off packages securely. While it mentioned facilitating e-commerce returns, the integration was not emphasized. By 2024, the description of Ship and Go remained consistent in terms of presence (still in approximately 1,300 locations) and core functionality, but there was a notable shift in emphasis: it was now more explicitly tied to FedEx Returns Technology and Consolidated Returns, highlighting its role in in-store printing of return labels and enabling customers to drop off returns without a box or label. This evolution indicates a strategic shift toward positioning Ship and Go not just as a shipping tool, but as a key node in FedEx's broader e-commerce returns infrastructure.",
      "llm_answer": "\nBetween 2023 and 2024 the **Ship & Go kiosk** shifted from a pure “drop‑off‑only” shipping point to a **multi‑purpose e‑commerce hub** that now supports label‑less, QR‑code returns through FedEx Consolidated Returns and is paired with the broader returns‑technology rollout.  While the kiosk still exists in roughly **1,300 locations**, the 2024 disclosures highlight its role in **streamlining returns, offering flexible pickup windows and label‑free drop‑offs**, and integrating those services with FedEx’s omnichannel logistics platform.  This evolution signals that FedEx is **leveraging its retail footprint as a reverse‑logistics gateway**, using the kiosks to capture and process returns more efficiently and to provide a seamless, end‑to‑end fulfillment experience for online shoppers.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the figure of approximately 1,300 locations is correctly reported, and no other numerical data (dates, percentages, dollar amounts) is present or required. (2) The answer correctly captures the evolution: in 2023, Ship & Go was primarily a self-serve drop-off solution; by 2024, it was more tightly integrated with FedEx Returns Technology and Consolidated Returns, enabling label-free, QR-code-based returns. The LLM accurately reflects this shift in emphasis. (3) The reasoning is sound: it infers that FedEx is using its retail footprint for reverse logistics and omnichannel integration, which is a valid interpretation of the strategic shift. The only minor shortcoming is that the original answer specifies that return labels can be printed in-store, whereas the LLM emphasizes label-free drop-offs via QR code—both are correct aspects, but the LLM slightly downplays the in-store printing capability mentioned in the ground truth. (4) Despite this nuance, the LLM conveys the core strategic evolution accurately and uses semantically equivalent terms (e.g., 'reverse-logistics gateway' = 'key node in e-commerce returns infrastructure'). All parts of the question are addressed: evolution between 2023–2024, e-commerce logistics, and returns management. Thus, the answer is factually correct, contextually relevant, and well-reasoned, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 427,
        "total_tokens": 1863
      },
      "error": null
    }
  ],
  "evaluation_summary": {
    "total_questions": 1000,
    "successful_evaluations": 1000,
    "failed_evaluations": 0,
    "average_correctness_score": 6.03,
    "average_quantitative_accuracy": 6.65,
    "average_qualitative_accuracy": 6.35,
    "average_contextual_relevance": 8.4,
    "score_distribution": {
      "excellent": 299,
      "good": 178,
      "fair": 287,
      "poor": 236
    }
  },
  "original_experiment_metadata": {
    "model": "nemotron-nano-30b-reasoning",
    "experiment": "e4_page_window_relevance_desc",
    "pattern": "qualitative_2hop_cross_year",
    "total_questions": 1000,
    "successful": 1000,
    "failed": 0,
    "elapsed_seconds": 7739.2,
    "timestamp": "2026-02-02T17:49:24.946626"
  }
}